7352670
D009599_D006973 NONE nitroprusside_4\NN\1740|after|sodium|prevented (r_nmod) hypertensive_1\NN\10405694|rebound|nitroprusside|.
D009599_D006973 NONE snp_2\NN\11493266| (r_compound) infusion_3\NN\14589223|during|the|snp (r_nmod) demonstrated_7\VBD\2137132|infusion|animals|increase|,|whereas|showed|. (l_dobj) increase_10\NN\13576355|a|progressive|pressure|torr (l_nmod) pressure_13\NN\11419404|in|blood
D012504_D006973 NONE saralasin_7\NN\1740|by|rats (r_nmod) prevented_5\VBN\1740|saralasin (r_acl) nitroprusside_4\NN\1740|after|sodium|prevented (r_nmod) hypertensive_1\NN\10405694|rebound|nitroprusside|.
D012504_D006973 NONE saralasin-treated_20\JJ\1740| (r_amod) animals_21\NNS\4475|the|saralasin-treated (r_nsubj) showed_22\VBD\2137132|animals|change (r_parataxis) demonstrated_7\VBD\2137132|infusion|animals|increase|,|whereas|showed|. (l_dobj) increase_10\NN\13576355|a|progressive|pressure|torr (l_nmod) pressure_13\NN\11419404|in|blood
D000809_D007022 NONE angiotensin_6\NN\4522421| (r_compound) system_7\NN\3575240|angiotensin|maintenance (r_nmod) role_1\NN\719494|the|renin|system|anesthesia (r_nsubjpass) evaluated_23\VBN\670261|role|hypotension|was|. (l_nsubjpass) hypotension_21\NN\14057371|(snp)-induced
D000809_D007022 NONE angiotensin_8\NN\4522421| (r_compound) system_9\NN\3575240|angiotensin (r_nmod) participation_3\NN\1080366|the|renin|system (r_dobj) demonstrates_1\VBZ\2137132|this|participation|antagonizing|. (l_advcl) antagonizing_11\VBG\1787955|in|effects (l_dobj) effects_15\NNS\13245626|the|combined|hypotensive|halothane (l_amod) hypotensive_14\JJ\1740|
D006221_D007022 CID halothane_15\NN\3570838| (r_compound) anesthesia_16\NN\14034177|during|halothane|and|nitroprusside (r_nmod) role_1\NN\719494|the|renin|system|anesthesia (r_nsubjpass) evaluated_23\VBN\670261|role|hypotension|was|. (l_nsubjpass) hypotension_21\NN\14057371|(snp)-induced
D006221_D007022 CID halothane_17\NN\3570838|of|and|snp (r_nmod) effects_15\NNS\13245626|the|combined|hypotensive|halothane (l_amod) hypotensive_14\JJ\1740|
D009599_D007022 CID nitroprusside_19\NN\1740|sodium (r_conj) anesthesia_16\NN\14034177|during|halothane|and|nitroprusside (r_nmod) role_1\NN\719494|the|renin|system|anesthesia (r_nsubjpass) evaluated_23\VBN\670261|role|hypotension|was|. (l_nsubjpass) hypotension_21\NN\14057371|(snp)-induced
D009599_D007022 CID (snp)-induced_20\JJ\1740| (r_amod) hypotension_21\NN\14057371|(snp)-induced
D009599_D007022 CID snp_19\NN\11493266| (r_conj) halothane_17\NN\3570838|of|and|snp (r_nmod) effects_15\NNS\13245626|the|combined|hypotensive|halothane (l_amod) hypotensive_14\JJ\1740|
15145918
D004967_D007022 NONE estrogen_3\NN\14745635|by|hypotension (l_nmod) hypotension_9\NN\14057371|alpha2-adrenergic|rats
D004967_D007022 NONE estrogen_5\NN\14745635| (r_nsubj) modulates_7\VBZ\1724459|that|estrogen|negatively|effect|and|implicates (l_dobj) effect_10\NN\34213|the|hypotensive|clonidine|rats (l_amod) hypotensive_9\JJ\1740|
D004967_D007022 NONE estrogen_4\NN\14745635| (r_nsubj) downregulates_5\VBZ\1740|that|estrogen|alpha2-|but|i1-receptor-mediated|and|highlight (l_conj) i1-receptor-mediated_9\VBN\1740|not|hypotension (l_dobj) hypotension_10\NN\14057371|
D004967_D007022 NONE alpha-methyldopa-estrogen_21\NN\1740| (r_compound) interaction_22\NN\37396|in|alpha-methyldopa-estrogen (r_nmod) role_14\NN\719494|a|control|interaction (r_dobj) highlight_12\VB\514463|role (r_conj) downregulates_5\VBZ\1740|that|estrogen|alpha2-|but|i1-receptor-mediated|and|highlight (l_conj) i1-receptor-mediated_9\VBN\1740|not|hypotension (l_dobj) hypotension_10\NN\14057371|
D048288_D007022 NONE i1-imidazoline_7\JJ\1740| (r_conj) alpha2-adrenergic_5\JJ\1740|of|and|i1-imidazoline|receptor-mediated (r_amod) hypotension_9\NN\14057371|alpha2-adrenergic|rats
D003000_D007022 NONE clonidine_12\NN\2721160|of|agonist (r_nmod) effect_10\NN\34213|the|hypotensive|clonidine|rats (l_amod) hypotensive_9\JJ\1740|
C032302_D007022 CID rilmenidine_4\NN\1740|or|alpha-methyldopa (r_appos) rats_2\NNS\2329401|in|sham-operated|,|rilmenidine|hypotension|. (l_nmod) hypotension_9\NN\14057371|elicited|similar|lasted
C032302_D007022 CID rilmenidine_15\JJ\1740| (r_amod) hypotension_16\NN\14057371|on|rilmenidine (r_nmod) effect_13\NN\34213|in|contrast|to|no|hypotension (r_nmod) enhanced_2\VBD\227165|ovx|significantly|response|,|effect|. (l_dobj) response_5\NN\11410625|the|hypotensive|alpha-methyldopa (l_amod) hypotensive_4\JJ\1740|
C032302_D007022 CID rilmenidine_15\JJ\1740| (r_amod) hypotension_16\NN\14057371|on|rilmenidine
D008750_D007022 CID alpha-methyldopa_6\JJ\1740| (r_conj) rilmenidine_4\NN\1740|or|alpha-methyldopa (r_appos) rats_2\NNS\2329401|in|sham-operated|,|rilmenidine|hypotension|. (l_nmod) hypotension_9\NN\14057371|elicited|similar|lasted
D008750_D007022 CID alpha-methyldopa_7\JJ\1740|to (r_nmod) response_5\NN\11410625|the|hypotensive|alpha-methyldopa (l_amod) hypotensive_4\JJ\1740|
D008750_D007022 CID alpha-methyldopa_7\JJ\1740|to (r_nmod) response_5\NN\11410625|the|hypotensive|alpha-methyldopa (r_dobj) enhanced_2\VBD\227165|ovx|significantly|response|,|effect|. (l_nmod) effect_13\NN\34213|in|contrast|to|no|hypotension (l_nmod) hypotension_16\NN\14057371|on|rilmenidine
D008750_D007022 CID alpha-methyldopa_2\JJ\1740| (r_amod) hypotension_3\NN\14057371|the|enhanced|alpha-methyldopa|rats
D008750_D007022 CID alpha-methyldopa-estrogen_21\NN\1740| (r_compound) interaction_22\NN\37396|in|alpha-methyldopa-estrogen (r_nmod) role_14\NN\719494|a|control|interaction (r_dobj) highlight_12\VB\514463|role (r_conj) downregulates_5\VBZ\1740|that|estrogen|alpha2-|but|i1-receptor-mediated|and|highlight (l_conj) i1-receptor-mediated_9\VBN\1740|not|hypotension (l_dobj) hypotension_10\NN\14057371|
D008750_D001523 NONE alpha-methyldopa_2\JJ\1740| (r_amod) hypotension_3\NN\14057371|the|enhanced|alpha-methyldopa|rats (r_nsubjpass) paralleled_8\VBN\2657219|hypotension|was|reduction|. (l_nmod) reduction_11\NN\351485|with|further|sdrr|and|activity (l_conj) activity_18\NN\30358|a|reduced|locomotor
11672959
D012460_D003872 CID sulphasalazine_25\NN\1740|of|oral|arthritis (r_nmod) course_22\NN\883297|of|a|sulphasalazine (r_nmod) day_19\NN\15154774|on|the|17th|course (r_nmod) beginning_15\VBG\941990|day (r_advcl) developed_3\VBD\1753788|lady|constellation|lymphadenopathy|,|beginning|. (l_dobj) constellation_5\NN\5728678|a|dermatitis|, (l_nmod) dermatitis_7\NN\14226056|of
D012460_D005334 CID sulphasalazine_25\NN\1740|of|oral|arthritis (r_nmod) course_22\NN\883297|of|a|sulphasalazine (r_nmod) day_19\NN\15154774|on|the|17th|course (r_nmod) beginning_15\VBG\941990|day (r_advcl) developed_3\VBD\1753788|lady|constellation|lymphadenopathy|,|beginning|. (l_dep) lymphadenopathy_11\NN\14204950|fever|,|and|hepatitis (l_compound) fever_9\NN\14299637|
D012460_D008206 CID sulphasalazine_25\NN\1740|of|oral|arthritis (r_nmod) course_22\NN\883297|of|a|sulphasalazine (r_nmod) day_19\NN\15154774|on|the|17th|course (r_nmod) beginning_15\VBG\941990|day (r_advcl) developed_3\VBD\1753788|lady|constellation|lymphadenopathy|,|beginning|. (l_dep) lymphadenopathy_11\NN\14204950|fever|,|and|hepatitis
D012460_D056486 CID sulphasalazine_25\NN\1740|of|oral|arthritis (r_nmod) course_22\NN\883297|of|a|sulphasalazine (r_nmod) day_19\NN\15154774|on|the|17th|course (r_nmod) beginning_15\VBG\941990|day (r_advcl) developed_3\VBD\1753788|lady|constellation|lymphadenopathy|,|beginning|. (l_dep) lymphadenopathy_11\NN\14204950|fever|,|and|hepatitis (l_conj) hepatitis_13\NN\14127211|
D012460_D001172 NONE sulphasalazine_25\NN\1740|of|oral|arthritis (l_nmod) arthritis_29\NN\14171682|for|sero-negative|rheumatoid
1664218
D000677_D002289 NONE amsacrine_5\NN\1740| (r_compound) ci-921_7\NN\1740|of|the|amsacrine|analogue (r_nmod) study_2\NN\635850|phase|ci-921|nsc|cancer|. (l_nmod) cancer_16\NN\14239425|in|non-small|cell|lung
C042315_D002289 NONE ci-921_7\NN\1740|of|the|amsacrine|analogue (r_nmod) study_2\NN\635850|phase|ci-921|nsc|cancer|. (l_nmod) cancer_16\NN\14239425|in|non-small|cell|lung
C042315_D002289 NONE 343499_10\CD\1740| (r_nummod) nsc_9\NNP\8123696|(|343499|) (r_appos) study_2\NN\635850|phase|ci-921|nsc|cancer|. (l_nmod) cancer_16\NN\14239425|in|non-small|cell|lung
6103707
D005445_D010146 CID flunitrazepam_7\NN\1740|of (r_nmod) injection_5\NN\320852|on|i.m.|flunitrazepam (r_nmod) was_1\VBD\836236|there|pain|injection|often|. (l_attr) pain_2\NN\14299637|
16787750
D014635_D001927 CID acid_1\NN\14818238|valproic (r_nsubj) induced_2\VBD\1627355|acid|cases|1994|2003|effect|. (l_dobj) cases_5\NNS\7283608|encephalopathy--19|new|germany (l_amod) encephalopathy--19_3\JJ\1740|
D014635_D001927 CID vpa-therapy_18\NN\1740|to (r_nmod) associated_16\VBN\628491|vpa-therapy|children (r_acl) effect_15\NN\34213|-|-a|side|associated (r_dobj) induced_2\VBD\1627355|acid|cases|1994|2003|effect|. (l_dobj) cases_5\NNS\7283608|encephalopathy--19|new|germany (l_amod) encephalopathy--19_3\JJ\1740|
D014635_D001927 CID vpa-induced_17\JJ\1740| (r_amod) hepatotoxicity_18\NN\1740|vpa-induced|and (r_conj) pancreatitis_11\NN\14336539|including|haemorrhagic|,|suppression|,|hepatotoxicity|vpa-induced|encephalopathy (l_conj) encephalopathy_21\JJ\1740|
D014635_D001927 CID vpa-induced_20\JJ\1740| (r_conj) pancreatitis_11\NN\14336539|including|haemorrhagic|,|suppression|,|hepatotoxicity|vpa-induced|encephalopathy (l_conj) encephalopathy_21\JJ\1740|
D014635_D001927 CID vpa-induced_4\JJ\1740| (r_amod) encephalopathy_5\NN\14084880|of|vpa-induced
D014635_D001927 CID vpa_9\NN\1740|of (r_nmod) effect_7\NN\34213|of|causative|vpa|patients (l_nmod) patients_11\NNS\9898892|in|encephalopathy (l_nmod) encephalopathy_13\JJ\1740|with
D014635_D001927 CID vpa-associated_5\JJ\1740| (r_amod) encephalopathy_6\JJ\1740|with|vpa-associated|germany
D014635_D010195 CID vpa-induced_17\JJ\1740| (r_amod) hepatotoxicity_18\NN\1740|vpa-induced|and (r_conj) pancreatitis_11\NN\14336539|including|haemorrhagic|,|suppression|,|hepatotoxicity|vpa-induced|encephalopathy
D014635_D010195 CID vpa-induced_20\JJ\1740| (r_conj) pancreatitis_11\NN\14336539|including|haemorrhagic|,|suppression|,|hepatotoxicity|vpa-induced|encephalopathy
D014635_D001855 CID vpa-induced_17\JJ\1740| (r_amod) hepatotoxicity_18\NN\1740|vpa-induced|and (r_conj) pancreatitis_11\NN\14336539|including|haemorrhagic|,|suppression|,|hepatotoxicity|vpa-induced|encephalopathy (l_conj) suppression_15\NN\13489037|bone|marrow
D014635_D001855 CID vpa-induced_20\JJ\1740| (r_conj) pancreatitis_11\NN\14336539|including|haemorrhagic|,|suppression|,|hepatotoxicity|vpa-induced|encephalopathy (l_conj) suppression_15\NN\13489037|bone|marrow
D014635_D056486 CID vpa-induced_17\JJ\1740| (r_amod) hepatotoxicity_18\NN\1740|vpa-induced|and
D014635_D056486 CID vpa-induced_20\JJ\1740| (r_conj) pancreatitis_11\NN\14336539|including|haemorrhagic|,|suppression|,|hepatotoxicity|vpa-induced|encephalopathy (l_conj) hepatotoxicity_18\NN\1740|vpa-induced|and
D014635_D003244 CID vpa-induced_4\JJ\1740| (r_amod) encephalopathy_5\NN\14084880|of|vpa-induced (r_nmod) signs_2\NNS\6643763|the|typical|encephalopathy (r_nsubj) consciousness_8\NN\5669934|signs|are|impaired|,|background|,|increased|,|hyperammonemia|.
D014635_D012640 NONE vpa-induced_4\JJ\1740| (r_amod) encephalopathy_5\NN\14084880|of|vpa-induced (r_nmod) signs_2\NNS\6643763|the|typical|encephalopathy (r_nsubj) consciousness_8\NN\5669934|signs|are|impaired|,|background|,|increased|,|hyperammonemia|. (l_conj) increased_16\VBD\169651|frequency (l_dobj) frequency_18\NN\15286249|seizure (l_amod) seizure_17\JJ\1740|
D014635_D022124 NONE vpa-induced_4\JJ\1740| (r_amod) encephalopathy_5\NN\14084880|of|vpa-induced (r_nmod) signs_2\NNS\6643763|the|typical|encephalopathy (r_nsubj) consciousness_8\NN\5669934|signs|are|impaired|,|background|,|increased|,|hyperammonemia|. (l_nmod) hyperammonemia_23\NN\1740|with|without
9931093
D016559_D006973 CID 506-induced_3\JJ\1740| (r_amod) hypertension_4\NN\14057371|of|fk|506-induced|rat
D016559_D006973 CID 506_5\CD\1740| (r_nummod) fk_4\NN\1740|of|506 (r_nmod) utility_2\NN\8186047|the|clinical|fk (r_nsubjpass) complicated_7\VBN\126264|utility|is|hypertension|. (l_nmod) hypertension_10\NN\14057371|by|substantial|and|nephrotoxicity
D016559_D006973 CID 506-induced_6\JJ\1740| (r_amod) hypertension_7\NN\14057371|of|fk|506-induced
D016559_D006973 CID 506_16\CD\1740| (r_nummod) fk_15\NN\1740|of|506 (r_nmod) effects_13\NNS\13245626|the|chronic|fk|synthesis (r_dobj) studied_10\VBD\630380|clarify|,|we|effects|,|expression|,|and|expression|. (l_advcl) clarify_1\VB\939277|to|mechanisms (l_dobj) mechanisms_3\NNS\13446390|the|hypertension (l_nmod) hypertension_7\NN\14057371|of|fk|506-induced
D016559_D006973 CID 506-induced_17\JJ\1740| (r_amod) hypertension_18\NN\14057371|on|fk|506-induced|rats
D016559_D006973 CID 506-induced_4\JJ\1740| (r_amod) hypertension_5\NN\14057371|fk|506-induced|rats
D016559_D007674 NONE 506_5\CD\1740| (r_nummod) fk_4\NN\1740|of|506 (r_nmod) utility_2\NN\8186047|the|clinical|fk (r_nsubjpass) complicated_7\VBN\126264|utility|is|hypertension|. (l_nmod) hypertension_10\NN\14057371|by|substantial|and|nephrotoxicity (l_conj) nephrotoxicity_12\NN\1740|
D009569_D006973 NONE oxide_42\NN\14818238| (r_compound) synthase_43\NN\1740|endothelial|nitric|oxide (r_compound) activity_47\NN\30358|the|synthase|enos (r_conj) expression_27\NN\4679549|the|mrna|activity (r_dobj) studied_10\VBD\630380|clarify|,|we|effects|,|expression|,|and|expression|. (l_advcl) clarify_1\VB\939277|to|mechanisms (l_dobj) mechanisms_3\NNS\13446390|the|hypertension (l_nmod) hypertension_7\NN\14057371|of|fk|506-induced
C079574_D006973 NONE 139317_14\CD\1740| (r_nummod) fr_13\NN\14625458|of|the|specific|endothelin|type|a|receptor|antagonist|139317 (r_nmod) effect_4\NN\34213|the|fr|hypertension (l_nmod) hypertension_18\NN\14057371|on|fk|506-induced|rats
230316
D006912_D020258 NONE hydroxyquinolines_3\NNS\1740|of|halogenated (r_nmod) neurotoxicity_0\NN\1740|hydroxyquinolines|:|analysis|.
D006912_D020258 NONE hydroxyquinolines_13\NNS\1740|to|halogenated|reported (r_nmod) reactions_10\NNS\13446390|of|possible|neurotoxic|hydroxyquinolines (l_amod) neurotoxic_9\JJ\1740|
D007464_D009422 NONE clioquinol_25\NN\2720201|of (r_nmod) dose_23\NN\3740161|of|a|high|clioquinol (r_nmod) ingestion_19\NN\13440063|to|the|dose|period (r_nmod) related_16\JJ\1740|usually|ingestion (r_amod) encephalopathy_14\RB\1740|of|an|acute|related (r_nmod) consisted_9\VBD\2603699|disturbance|encephalopathy (l_nsubj) disturbance_8\NN\407535|the|neurological
D007464_D001927 CID clioquinol_25\NN\2720201|of (r_nmod) dose_23\NN\3740161|of|a|high|clioquinol (r_nmod) ingestion_19\NN\13440063|to|the|dose|period (r_nmod) related_16\JJ\1740|usually|ingestion (r_amod) encephalopathy_14\RB\1740|of|an|acute|related
D007464_C538178 NONE clioquinol_13\NN\2720201| (r_dobj) received_12\VBN\2210855|many|had|clioquinol|treatment (l_nmod) treatment_15\NN\654885|as|enteropathica (l_nmod) enteropathica_18\NN\1740|for|acrodermatitis
9727773
D001067_D006976 CID suppressants_9\NNS\3247620|with|appetite|belgium (r_nmod) associated_6\VBN\628491|suppressants (r_acl) hypertension_5\NN\14057371|of|primary|pulmonary|associated
D001067_D006976 CID suppressant_21\JJ\1740| (r_amod) drugs_22\NNS\14778436|of|appetite|suppressant (r_nmod) intake_18\NN\13440063|with|the|drugs (r_nmod) associated_15\VBN\628491|which|has|been|intake (r_acl:relcl) disease_10\NN\14061805|hypertension|is|a|rare|,|associated|. (l_nsubj) hypertension_2\NN\14057371|primary|pulmonary
D001067_D006976 CID suppressants_18\NNS\3247620|appetite (r_dobj) taken_16\VBN\2367363|5|had|suppressants (r_conj) uncertain_10\JJ\1740|patients|diagnosis|was|,|taken|. (l_nsubj) diagnosis_4\NN\152018|the|hypertension (l_nmod) hypertension_8\NN\14057371|of|primary|pulmonary
D001067_D006976 CID suppressants_7\NNS\3247620|of|appetite (r_nmod) prescription_4\NN\6786629|of|unrestricted|suppressants (r_nmod) policy_1\NN\5902545|a|prescription (r_nsubj) lead_9\VB\1752884|policy|may|incidence|. (l_nmod) incidence_13\NN\13821570|to|a|high|hypertension (l_nmod) hypertension_18\NN\14057371|of|associated|primary|pulmonary
8302922
D000527_D007022 CID e1_5\NN\1740|during|prostaglandin (r_nmod) flow_2\NN\7311115|epidural|blood|e1|or|trimethaphan (r_nsubj) induced_8\VBD\1627355|flow|hypotension|. (l_dobj) hypotension_9\NN\14057371|
D000527_D007022 CID e1_6\NN\1740|of|prostaglandin|pge1|or|trimethaphan (r_nmod) effect_3\NN\34213|the|e1 (r_dobj) evaluate_1\VB\670261|to|effect (r_advcl) induced_15\VBD\1627355|evaluate|hypotension|surgery (l_dobj) hypotension_16\NN\14057371|flow
D000527_D007022 CID pge1_8\NN\1740|(|) (r_appos) e1_6\NN\1740|of|prostaglandin|pge1|or|trimethaphan (r_nmod) effect_3\NN\34213|the|e1 (r_dobj) evaluate_1\VB\670261|to|effect (r_advcl) induced_15\VBD\1627355|evaluate|hypotension|surgery (l_dobj) hypotension_16\NN\14057371|flow
D000527_D007022 CID pge1_2\NN\1740|or|tmp|,|product (r_dobj) starting_1\VBG\2009433|after|pge1 (r_advcl) decreased_14\VBD\169651|starting|compared|,|and|remained (l_conj) remained_34\VBD\2604760|degree|constant|min|discontinuation|. (l_nsubj) degree_28\NN\4916342|the|hypotension|pge1 (l_nmod) hypotension_30\NN\14057371|of
D000527_D007022 CID pge1_33\NN\1740|due (r_nmod) degree_28\NN\4916342|the|hypotension|pge1 (l_nmod) hypotension_30\NN\14057371|of
D000527_D007022 CID pge1_4\NN\1740| (r_nsubj) preferable_7\JJ\1740|that|pge1|may|be|tmp|anaesthesia|decreased (l_nmod) anaesthesia_12\NN\14034177|for|hypotensive|surgery (l_amod) hypotensive_11\JJ\1740|
D014294_D007022 CID trimethaphan_7\NN\1740| (r_conj) flow_2\NN\7311115|epidural|blood|e1|or|trimethaphan (r_nsubj) induced_8\VBD\1627355|flow|hypotension|. (l_dobj) hypotension_9\NN\14057371|
D014294_D007022 CID trimethaphan_11\NN\1740|tmp (r_conj) e1_6\NN\1740|of|prostaglandin|pge1|or|trimethaphan (r_nmod) effect_3\NN\34213|the|e1 (r_dobj) evaluate_1\VB\670261|to|effect (r_advcl) induced_15\VBD\1627355|evaluate|hypotension|surgery (l_dobj) hypotension_16\NN\14057371|flow
D014294_D007022 CID tmp_13\NN\1740|(|) (r_appos) trimethaphan_11\NN\1740|tmp (r_conj) e1_6\NN\1740|of|prostaglandin|pge1|or|trimethaphan (r_nmod) effect_3\NN\34213|the|e1 (r_dobj) evaluate_1\VB\670261|to|effect (r_advcl) induced_15\VBD\1627355|evaluate|hypotension|surgery (l_dobj) hypotension_16\NN\14057371|flow
D014294_D007022 CID tmp_4\NN\1740| (r_conj) pge1_2\NN\1740|or|tmp|,|product (r_dobj) starting_1\VBG\2009433|after|pge1 (r_advcl) decreased_14\VBD\169651|starting|compared|,|and|remained (l_conj) remained_34\VBD\2604760|degree|constant|min|discontinuation|. (l_nsubj) degree_28\NN\4916342|the|hypotension|pge1 (l_nmod) hypotension_30\NN\14057371|of
D014294_D007022 CID tmp_9\NNP\1740|to (r_nmod) preferable_7\JJ\1740|that|pge1|may|be|tmp|anaesthesia|decreased (l_nmod) anaesthesia_12\NN\14034177|for|hypotensive|surgery (l_amod) hypotensive_11\JJ\1740|
D014294_D007022 CID tmp_17\NN\1740| (r_nsubj) decreased_18\VBD\169651|because|tmp|ebf (r_advcl) preferable_7\JJ\1740|that|pge1|may|be|tmp|anaesthesia|decreased (l_nmod) anaesthesia_12\NN\14034177|for|hypotensive|surgery (l_amod) hypotensive_11\JJ\1740|
D007530_D007022 NONE isoflurane_45\NN\3570838| (r_compound) anaesthesia_46\NN\14034177|under|isoflurane (r_nmod) underwent_40\VBD\109660|who|fusion|anaesthesia (r_acl:relcl) patients_38\NNS\9898892|in|30|underwent (r_nmod) method_35\NN\5616786|the|clearance|patients (r_dobj) using_31\VBG\1156834|method (r_xcomp) measured_30\VBN\697589|induced|,|ebf|was|using|. (l_advcl) induced_15\VBD\1627355|evaluate|hypotension|surgery (l_dobj) hypotension_16\NN\14057371|flow
3437726
D013034_D064420 NONE sparteine/debrisoquine_9\NN\1740| (r_compound) polymorphism_10\NN\11418750|of|sparteine/debrisoquine|metabolism (r_nmod) phenotype_7\NN\4933544|to|the|poor-metabolizer|polymorphism|constitutes (r_nmod) belonging_3\VBG\2604760|phenotype (r_acl) patients_2\NNS\9898892|belonging (r_nsubj) experience_25\VB\2108377|therefore|,|patients|,|may|reactions|treated|. (l_dobj) reactions_28\NNS\13446390|adverse|drug
D003647_D064420 NONE sparteine/debrisoquine_9\NN\1740| (r_compound) polymorphism_10\NN\11418750|of|sparteine/debrisoquine|metabolism (r_nmod) phenotype_7\NN\4933544|to|the|poor-metabolizer|polymorphism|constitutes (r_nmod) belonging_3\VBG\2604760|phenotype (r_acl) patients_2\NNS\9898892|belonging (r_nsubj) experience_25\VB\2108377|therefore|,|patients|,|may|reactions|treated|. (l_dobj) reactions_28\NNS\13446390|adverse|drug
12789195
D008914_D004194 NONE minoxidil_7\NN\4522904|of (r_nmod) use_5\NN\407535|by|the|long-term|minoxidil (r_nmod) induced_1\VBN\1627355|use (r_acl) pseudoacromegaly_0\NNP\1740|induced|.
D008914_D004194 NONE minoxidil_13\NN\4522904|of (r_nmod) use_11\NN\407535|from|the|long-term|minoxidil (r_nmod) resulted_7\VBD\2633881|that|use|dose (r_acl:relcl) patient_3\NN\9898892|a|pseudoacromegaly|resulted (l_nmod) pseudoacromegaly_5\NN\1740|with
D008914_D004194 NONE minoxidil_13\NN\4522904| (r_compound) use_14\NN\407535|of|minoxidil (r_nmod) effect_11\NN\34213|as|a|side|use (r_nmod) report_5\NN\6470073|this|is|the|first|case|pseudoacromegaly|effect|. (l_nmod) pseudoacromegaly_7\NN\1740|of
12198388
D000109_D012640 NONE acetylcholine_4\NN\14807558| (r_compound) release_5\NN\3748886|between|hippocampal|acetylcholine|and|sensitivity|seizure-prone (l_nmod) seizure-prone_12\NN\1740|in|withdrawal|and|withdrawal|seizure-resistant
D000109_D012640 NONE acetylcholine_4\NN\14807558| (r_compound) release_5\NN\3748886|between|hippocampal|acetylcholine|and|sensitivity|seizure-prone (l_nmod) seizure-prone_12\NN\1740|in|withdrawal|and|withdrawal|seizure-resistant (l_conj) seizure-resistant_15\JJ\1740|
D000109_D012640 NONE ach_1\NN\1740|hippocampal (r_nsubjpass) measured_4\VBN\697589|ach|also|was|testing|. (l_nmod) testing_6\VBG\670261|during|convulsions (l_nmod) convulsions_9\NNS\14081375|for|handling-induced
D000109_D012640 NONE ach_2\NN\1740|hippocampal (r_nsubjpass) measured_4\VBN\697589|when|ach|was|testing (l_nmod) testing_6\VBG\670261|during|convulsions (l_nmod) convulsions_9\NNS\14081375|for|handling-induced
D000109_D012640 NONE ach_12\NN\1740|extracellular (r_nsubj) elevated_15\JJ\1740|measured|,|ach|was|significantly|%|mice|,|but|elevated|. (l_advcl) measured_4\VBN\697589|when|ach|was|testing (l_nmod) testing_6\VBG\670261|during|convulsions (l_nmod) convulsions_9\NNS\14081375|for|handling-induced
D000431_D012640 NONE alcohol-na_8\NN\1740| (r_amod) seizure-prone_11\NN\1740|in|alcohol-na|ve|withdrawal|wsp|and-resistant
D000431_D012640 NONE ethanol_20\NN\14708720| (r_compound) withdrawal_21\NN\7206096|ethanol (r_compound) severity_22\NN\5036394|with|withdrawal (r_nmod) associated_18\VBN\628491|that|differences|may|be|severity|and|implicate (l_nsubjpass) differences_6\NNS\4723816|activity (l_nmod) activity_9\NN\30358|in|cholinergic|and|sensitivity (l_conj) sensitivity_12\NN\5651971|postsynaptic|convulsants (l_nmod) convulsants_15\NNS\1740|to|cholinergic
D000431_D012640 NONE alcohol_28\NN\7881800| (r_compound) withdrawal_29\NN\7206096|in|alcohol (r_nmod) mechanisms_26\NNS\13446390|cholinergic|withdrawal (r_dobj) implicate_24\VB\2677097|mechanisms (r_conj) associated_18\VBN\628491|that|differences|may|be|severity|and|implicate (l_nsubjpass) differences_6\NNS\4723816|activity (l_nmod) activity_9\NN\30358|in|cholinergic|and|sensitivity (l_conj) sensitivity_12\NN\5651971|postsynaptic|convulsants (l_nmod) convulsants_15\NNS\1740|to|cholinergic
D009538_D014202 NONE nicotine_3\NN\14712692|,|carbachol|,|or|neostigmine (r_xcomp) administered_2\VBN\2436349|animals|were|nicotine|,|and|recorded|. (l_conj) recorded_25\VBN\2225492|latencies|were|and|converted (l_nsubjpass) latencies_17\NNS\15269513|the|onset (l_nmod) onset_19\NN\7325190|to|tremor (l_nmod) tremor_21\NN\345926|of|and|clonus
D002217_D014202 NONE carbachol_5\NN\1740| (r_conj) nicotine_3\NN\14712692|,|carbachol|,|or|neostigmine (r_xcomp) administered_2\VBN\2436349|animals|were|nicotine|,|and|recorded|. (l_conj) recorded_25\VBN\2225492|latencies|were|and|converted (l_nsubjpass) latencies_17\NNS\15269513|the|onset (l_nmod) onset_19\NN\7325190|to|tremor (l_nmod) tremor_21\NN\345926|of|and|clonus
D009388_D014202 NONE neostigmine_8\NN\2718084|infusion (r_conj) nicotine_3\NN\14712692|,|carbachol|,|or|neostigmine (r_xcomp) administered_2\VBN\2436349|animals|were|nicotine|,|and|recorded|. (l_conj) recorded_25\VBN\2225492|latencies|were|and|converted (l_nsubjpass) latencies_17\NNS\15269513|the|onset (l_nmod) onset_19\NN\7325190|to|tremor (l_nmod) tremor_21\NN\345926|of|and|clonus
D009538_D012640 CID nicotine_9\NN\14712692|by|,|carbachol|,|and|neostigmine (r_nmod) induced_7\VBN\1627355|nicotine (r_acl) endpoints_6\NNS\8566028|to|several|convulsion|induced (l_compound) convulsion_5\NN\14081375|
D002217_D012640 CID carbachol_11\NN\1740| (r_conj) nicotine_9\NN\14712692|by|,|carbachol|,|and|neostigmine (r_nmod) induced_7\VBN\1627355|nicotine (r_acl) endpoints_6\NNS\8566028|to|several|convulsion|induced (l_compound) convulsion_5\NN\14081375|
D009388_D012640 CID neostigmine_14\NN\2718084| (r_conj) nicotine_9\NN\14712692|by|,|carbachol|,|and|neostigmine (r_nmod) induced_7\VBN\1627355|nicotine (r_acl) endpoints_6\NNS\8566028|to|several|convulsion|induced (l_compound) convulsion_5\NN\14081375|
6518066
D008094_D004437 CID lithium_1\NN\14625458|maternal|and|neonatal|anomaly|:|evaluation|. (l_dep) anomaly_6\NN\14501726|ebstein
D008094_D006331 NONE lithium_7\NN\14625458|to (r_nmod) exposed_5\VBN\2110927|lithium|gestation (r_acl) newborns_4\NNS\9827683|of|exposed (r_nmod) screening_2\NN\6887726|cross-sectional|echocardiographic|newborns (r_nsubj) provide_11\VB\2199590|screening|can|accurate|assessment|. (l_dobj) assessment_16\NN\5732756|noninvasive|presence (l_nmod) presence_19\NN\13954253|of|the|or|absence|malformations (l_nmod) malformations_25\NNS\14213199|of|lithium-induced|cardiac
D008094_D006331 NONE lithium-induced_23\JJ\1740| (r_amod) malformations_25\NNS\14213199|of|lithium-induced|cardiac
10520387
D004809_D007022 NONE ephedrine_11\NN\14712692|of (r_nmod) doses_9\NNS\3740161|different|ephedrine (r_dobj) adding_7\VBG\156601|of|doses|propofol|order (l_nmod) order_15\NN\7168131|in|obtund (l_acl) obtund_17\VB\192051|to|response (l_dobj) response_20\NN\11410625|the|hypotensive (l_amod) hypotensive_19\JJ\1740|
D004809_D007022 NONE ephedrine_3\NN\14712692|of (r_nmod) addition_1\NN\3081021|the|ephedrine|propofol (r_nsubj) appears_6\VBZ\2604760|addition|method|. (l_xcomp) method_11\NN\5616786|to|be|an|effective|obtunding (l_advcl) obtunding_13\VBG\192051|of|response|doses (l_dobj) response_16\NN\11410625|the|hypotensive|propofol (l_amod) hypotensive_15\JJ\1740|
D015742_D007022 CID propofol_13\VB\1740|to (r_nmod) adding_7\VBG\156601|of|doses|propofol|order (l_nmod) order_15\NN\7168131|in|obtund (l_acl) obtund_17\VB\192051|to|response (l_dobj) response_20\NN\11410625|the|hypotensive (l_amod) hypotensive_19\JJ\1740|
D015742_D007022 CID propofol_5\NN\1740|to (r_nmod) addition_1\NN\3081021|the|ephedrine|propofol (r_nsubj) appears_6\VBZ\2604760|addition|method|. (l_xcomp) method_11\NN\5616786|to|be|an|effective|obtunding (l_advcl) obtunding_13\VBG\192051|of|response|doses (l_dobj) response_16\NN\11410625|the|hypotensive|propofol (l_amod) hypotensive_15\JJ\1740|
D015742_D007022 CID propofol_18\NN\1740|to (r_nmod) response_16\NN\11410625|the|hypotensive|propofol (l_amod) hypotensive_15\JJ\1740|
D004809_D013610 CID ephedrine_9\NN\14712692|of (r_nmod) use_7\NN\407535|with|the|ephedrine|combination (r_nmod) associated_4\VBN\628491|use (r_acl) tachycardia_3\NN\14110674|marked|associated
D004809_D013610 CID ephedrine/propofol/mixtures_24\NNS\1740|of|the (r_nmod) any_21\DT\1740|of|ephedrine/propofol/mixtures (r_nmod) patients_19\NNS\9898892|in|elderly|any|studied (r_nmod) use_16\NN\407535|the|patients (r_dobj) recommend_14\VB\875394|risk|,|we|would|not|use|. (l_nmod) risk_3\NN\14541044|due|the|tachycardia (l_nmod) tachycardia_6\NN\14110674|of|this|inducing
D015742_D013610 CID propofol_13\NN\1740|with (r_nmod) combination_11\NN\7951464|in|propofol (r_nmod) use_7\NN\407535|with|the|ephedrine|combination (r_nmod) associated_4\VBN\628491|use (r_acl) tachycardia_3\NN\14110674|marked|associated
D015742_D013610 CID ephedrine/propofol/mixtures_24\NNS\1740|of|the (r_nmod) any_21\DT\1740|of|ephedrine/propofol/mixtures (r_nmod) patients_19\NNS\9898892|in|elderly|any|studied (r_nmod) use_16\NN\407535|the|patients (r_dobj) recommend_14\VB\875394|risk|,|we|would|not|use|. (l_nmod) risk_3\NN\14541044|due|the|tachycardia (l_nmod) tachycardia_6\NN\14110674|of|this|inducing
D004809_D017202 NONE ephedrine/propofol/mixtures_24\NNS\1740|of|the (r_nmod) any_21\DT\1740|of|ephedrine/propofol/mixtures (r_nmod) patients_19\NNS\9898892|in|elderly|any|studied (r_nmod) use_16\NN\407535|the|patients (r_dobj) recommend_14\VB\875394|risk|,|we|would|not|use|. (l_nmod) risk_3\NN\14541044|due|the|tachycardia (l_nmod) tachycardia_6\NN\14110674|of|this|inducing (l_acl) inducing_7\VBG\1627355|ischemia (l_dobj) ischemia_9\NN\14195315|myocardial
D015742_D017202 NONE ephedrine/propofol/mixtures_24\NNS\1740|of|the (r_nmod) any_21\DT\1740|of|ephedrine/propofol/mixtures (r_nmod) patients_19\NNS\9898892|in|elderly|any|studied (r_nmod) use_16\NN\407535|the|patients (r_dobj) recommend_14\VB\875394|risk|,|we|would|not|use|. (l_nmod) risk_3\NN\14541044|due|the|tachycardia (l_nmod) tachycardia_6\NN\14110674|of|this|inducing (l_acl) inducing_7\VBG\1627355|ischemia (l_dobj) ischemia_9\NN\14195315|myocardial
6888657
D004967_D010911 NONE estrogen-induced_2\JJ\1740| (r_amod) tumors_4\NNS\14234074|of|estrogen-induced|adenohypophyseal
D004054_D010911 CID diethylstilbestrol_12\NN\14749794|with|des (r_nmod) treatment_10\NN\654885|by|chronic|diethylstilbestrol (r_nmod) induced_3\VBN\1627355|tumors|were|rats|treatment|implanted|. (l_nsubjpass) tumors_1\NNS\14234074|pituitary
D004054_D010911 CID des_14\NN\14749794|(|,|10|mg|) (r_dep) diethylstilbestrol_12\NN\14749794|with|des (r_nmod) treatment_10\NN\654885|by|chronic|diethylstilbestrol (r_nmod) induced_3\VBN\1627355|tumors|were|rats|treatment|implanted|. (l_nsubjpass) tumors_1\NNS\14234074|pituitary
D004054_D009369 NONE des-induced_12\JJ\1740| (r_amod) tumor_13\NN\14234074|the|des-induced
15036754
D010755_D012640 NONE organophosphate-induced_0\JJ\1740| (r_amod) convulsions_1\NNS\14081375|organophosphate-induced|and|prevention|damages|.
D010755_D004194 NONE organophosphate-induced_0\JJ\1740| (r_amod) convulsions_1\NNS\14081375|organophosphate-induced|and|prevention|damages|. (l_nmod) damages_6\NNS\13282550|of|neuropathological
D010755_D064420 NONE ops_4\NNS\1740|of (r_nmod) toxicity_2\NN\13576101|the|acute|ops
D010755_D064420 NONE op-induced_8\JJ\1740| (r_amod) signs_10\NNS\6643763|severe|typical|op-induced|toxicity (l_compound) toxicity_9\NN\13576101|
D000109_D064420 NONE acetylcholine_25\NN\14807558|ach (r_compound) levels_29\NNS\4916342|acetylcholine (r_dobj) elevates_24\VBZ\2391803|which|levels (r_acl:relcl) system_18\NN\3575240|in|the|central|nervous|cns|,|elevates (r_nmod) binding_11\NN\4688246|of|their|irreversible|aches|system (r_nmod) result_7\NN\34213|toxicity|is|the|binding|. (l_nsubj) toxicity_2\NN\13576101|the|acute|ops
D000109_D064420 NONE ach_27\NN\1740|(|) (r_appos) acetylcholine_25\NN\14807558|ach (r_compound) levels_29\NNS\4916342|acetylcholine (r_dobj) elevates_24\VBZ\2391803|which|levels (r_acl:relcl) system_18\NN\3575240|in|the|central|nervous|cns|,|elevates (r_nmod) binding_11\NN\4688246|of|their|irreversible|aches|system (r_nmod) result_7\NN\34213|toxicity|is|the|binding|. (l_nsubj) toxicity_2\NN\13576101|the|acute|ops
D007531_D064420 NONE dfp-atropine_4\NN\1740|with (r_nmod) treated_2\VBN\2376958|dfp-atropine (r_acl) rats_1\NNS\2329401|the|treated (r_nsubj) showed_5\VBD\2137132|rats|signs|. (l_dobj) signs_10\NNS\6643763|severe|typical|op-induced|toxicity (l_compound) toxicity_9\NN\13576101|
D007531_D064420 NONE dfp_8\NN\1740| (r_compound) toxicity_9\NN\13576101|against|dfp
D007531_D064420 NONE dfp_26\NN\1740|of (r_nmod) toxicity_24\NN\13576101|the|dfp|rat
D001285_D064420 NONE dfp-atropine_4\NN\1740|with (r_nmod) treated_2\VBN\2376958|dfp-atropine (r_acl) rats_1\NNS\2329401|the|treated (r_nsubj) showed_5\VBD\2137132|rats|signs|. (l_dobj) signs_10\NNS\6643763|severe|typical|op-induced|toxicity (l_compound) toxicity_9\NN\13576101|
D001285_D064420 NONE atropine-mk801_0\JJ\1740| (r_nsubj) offer_3\VB\2327200|atropine-mk801|did|not|protection|. (l_dobj) protection_6\NN\407535|any|additional|toxicity (l_nmod) toxicity_9\NN\13576101|against|dfp
D001285_D064420 NONE atropine_11\NN\14712692|with (r_nmod) combination_9\NN\7951464|in|atropine (r_nmod) diazepam_5\NN\2830852|and|2pam|combination (r_conj) cpa_3\NN\9761403|,|diazepam (r_nsubj) prevented_12\VBD\1740|conclusion|,|cpa|occurrence|and|reduced|. (l_conj) reduced_22\VBD\441445|thus|toxicity (l_dobj) toxicity_24\NN\13576101|the|dfp|rat
C048599_D011041 NONE cpa_1\NN\9761403|,|diazepam (r_nsubjpass) given_7\VBN\2327200|when|cpa|was|immediately|dfp-atropine|, (r_advcl) prevented_14\VBD\1740|given|treatments|delayed|. (l_conj) delayed_16\VBN\439958|,|or|shortened (l_conj) shortened_18\VBD\429060|occurrence (l_dobj) occurrence_20\NN\29378|the|signs (l_nmod) signs_23\NNS\6643763|of|serious|poisoning (l_nmod) poisoning_25\NN\14034177|of
C048599_D011041 NONE cpa_3\NN\9761403|,|diazepam (r_nsubj) prevented_12\VBD\1740|conclusion|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN\29378|the|signs (l_nmod) signs_17\NNS\6643763|of|serious|poisoning (l_nmod) poisoning_19\NN\14034177|of
D003975_D011041 NONE diazepam_3\NN\2830852|or|2pam (r_conj) cpa_1\NN\9761403|,|diazepam (r_nsubjpass) given_7\VBN\2327200|when|cpa|was|immediately|dfp-atropine|, (r_advcl) prevented_14\VBD\1740|given|treatments|delayed|. (l_conj) delayed_16\VBN\439958|,|or|shortened (l_conj) shortened_18\VBD\429060|occurrence (l_dobj) occurrence_20\NN\29378|the|signs (l_nmod) signs_23\NNS\6643763|of|serious|poisoning (l_nmod) poisoning_25\NN\14034177|of
D003975_D011041 NONE diazepam_5\NN\2830852|and|2pam|combination (r_conj) cpa_3\NN\9761403|,|diazepam (r_nsubj) prevented_12\VBD\1740|conclusion|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN\29378|the|signs (l_nmod) signs_17\NNS\6643763|of|serious|poisoning (l_nmod) poisoning_19\NN\14034177|of
D011220_D011041 NONE 2pam_5\NN\1740| (r_conj) diazepam_3\NN\2830852|or|2pam (r_conj) cpa_1\NN\9761403|,|diazepam (r_nsubjpass) given_7\VBN\2327200|when|cpa|was|immediately|dfp-atropine|, (r_advcl) prevented_14\VBD\1740|given|treatments|delayed|. (l_conj) delayed_16\VBN\439958|,|or|shortened (l_conj) shortened_18\VBD\429060|occurrence (l_dobj) occurrence_20\NN\29378|the|signs (l_nmod) signs_23\NNS\6643763|of|serious|poisoning (l_nmod) poisoning_25\NN\14034177|of
D011220_D011041 NONE 2pam_7\NN\1740| (r_conj) diazepam_5\NN\2830852|and|2pam|combination (r_conj) cpa_3\NN\9761403|,|diazepam (r_nsubj) prevented_12\VBD\1740|conclusion|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN\29378|the|signs (l_nmod) signs_17\NNS\6643763|of|serious|poisoning (l_nmod) poisoning_19\NN\14034177|of
D007531_D011041 NONE dfp-atropine_10\NN\1740|after (r_nmod) given_7\VBN\2327200|when|cpa|was|immediately|dfp-atropine|, (r_advcl) prevented_14\VBD\1740|given|treatments|delayed|. (l_conj) delayed_16\VBN\439958|,|or|shortened (l_conj) shortened_18\VBD\429060|occurrence (l_dobj) occurrence_20\NN\29378|the|signs (l_nmod) signs_23\NNS\6643763|of|serious|poisoning (l_nmod) poisoning_25\NN\14034177|of
D007531_D011041 NONE dfp_26\NN\1740|of (r_nmod) toxicity_24\NN\13576101|the|dfp|rat (r_dobj) reduced_22\VBD\441445|thus|toxicity (r_conj) prevented_12\VBD\1740|conclusion|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN\29378|the|signs (l_nmod) signs_17\NNS\6643763|of|serious|poisoning (l_nmod) poisoning_19\NN\14034177|of
D001285_D011041 NONE dfp-atropine_10\NN\1740|after (r_nmod) given_7\VBN\2327200|when|cpa|was|immediately|dfp-atropine|, (r_advcl) prevented_14\VBD\1740|given|treatments|delayed|. (l_conj) delayed_16\VBN\439958|,|or|shortened (l_conj) shortened_18\VBD\429060|occurrence (l_dobj) occurrence_20\NN\29378|the|signs (l_nmod) signs_23\NNS\6643763|of|serious|poisoning (l_nmod) poisoning_25\NN\14034177|of
D001285_D011041 NONE atropine_11\NN\14712692|with (r_nmod) combination_9\NN\7951464|in|atropine (r_nmod) diazepam_5\NN\2830852|and|2pam|combination (r_conj) cpa_3\NN\9761403|,|diazepam (r_nsubj) prevented_12\VBD\1740|conclusion|,|cpa|occurrence|and|reduced|. (l_dobj) occurrence_14\NN\29378|the|signs (l_nmod) signs_17\NNS\6643763|of|serious|poisoning (l_nmod) poisoning_19\NN\14034177|of
D016291_D064420 NONE atropine-mk801_0\JJ\1740| (r_nsubj) offer_3\VB\2327200|atropine-mk801|did|not|protection|. (l_dobj) protection_6\NN\407535|any|additional|toxicity (l_nmod) toxicity_9\NN\13576101|against|dfp
C048599_D064420 NONE cpa_3\NN\9761403|,|diazepam (r_nsubj) prevented_12\VBD\1740|conclusion|,|cpa|occurrence|and|reduced|. (l_conj) reduced_22\VBD\441445|thus|toxicity (l_dobj) toxicity_24\NN\13576101|the|dfp|rat
D003975_D064420 NONE diazepam_5\NN\2830852|and|2pam|combination (r_conj) cpa_3\NN\9761403|,|diazepam (r_nsubj) prevented_12\VBD\1740|conclusion|,|cpa|occurrence|and|reduced|. (l_conj) reduced_22\VBD\441445|thus|toxicity (l_dobj) toxicity_24\NN\13576101|the|dfp|rat
D011220_D064420 NONE 2pam_7\NN\1740| (r_conj) diazepam_5\NN\2830852|and|2pam|combination (r_conj) cpa_3\NN\9761403|,|diazepam (r_nsubj) prevented_12\VBD\1740|conclusion|,|cpa|occurrence|and|reduced|. (l_conj) reduced_22\VBD\441445|thus|toxicity (l_dobj) toxicity_24\NN\13576101|the|dfp|rat
2887062
D004967_D015175 CID estrogen-induced_8\JJ\1740| (r_amod) prolactinomas_10\NNS\1740|of|estrogen-induced|rat
D004967_D015175 CID estrogen-induced_21\JJ\1740| (r_amod) cells_24\NNS\3080309|to|estrogen-induced|rat|prolactinoma|h|and|h (r_nmod) applied_19\VBN\2676054|clarify|analyses|were|cells|. (l_advcl) clarify_1\VB\939277|to|effects (l_dobj) effects_3\NNS\13245626|the|bromocriptine|vivo (l_nmod) bromocriptine_5\NN\1740|of|cells (l_nmod) cells_8\NNS\3080309|on|prolactinoma (l_compound) prolactinoma_7\NN\1740|
D004967_D015175 CID estrogen-induced_21\JJ\1740| (r_amod) cells_24\NNS\3080309|to|estrogen-induced|rat|prolactinoma|h|and|h (l_compound) prolactinoma_23\NN\1740|
D001971_D015175 NONE bromocriptine_12\NN\1740| (r_compound) treatment_13\NN\654885|after|bromocriptine (r_nmod) immunohistochemical_0\JJ\1740|,|microscopic|treatment|. (l_conj) microscopic_3\JJ\1740|electron|and|morphometric|studies (l_dep) studies_6\NNS\635850|prolactinomas (l_nmod) prolactinomas_10\NNS\1740|of|estrogen-induced|rat
D001971_D015175 NONE bromocriptine_5\NN\1740|of|cells (l_nmod) cells_8\NNS\3080309|on|prolactinoma (l_compound) prolactinoma_7\NN\1740|
D001971_D015175 NONE bromocriptine_5\NN\1740|of|cells (r_nmod) effects_3\NNS\13245626|the|bromocriptine|vivo (r_dobj) clarify_1\VB\939277|to|effects (r_advcl) applied_19\VBN\2676054|clarify|analyses|were|cells|. (l_nmod) cells_24\NNS\3080309|to|estrogen-induced|rat|prolactinoma|h|and|h (l_compound) prolactinoma_23\NN\1740|
D001971_D015175 NONE bromocriptine_33\NN\1740|of|mg/kg (r_nmod) injection_31\NN\320852|after|bromocriptine (r_dep) h_29\NN\14622893|6|injection (r_conj) cells_24\NNS\3080309|to|estrogen-induced|rat|prolactinoma|h|and|h (r_nmod) applied_19\VBN\2676054|clarify|analyses|were|cells|. (l_advcl) clarify_1\VB\939277|to|effects (l_dobj) effects_3\NNS\13245626|the|bromocriptine|vivo (l_nmod) bromocriptine_5\NN\1740|of|cells (l_nmod) cells_8\NNS\3080309|on|prolactinoma (l_compound) prolactinoma_7\NN\1740|
D001971_D015175 NONE bromocriptine_33\NN\1740|of|mg/kg (r_nmod) injection_31\NN\320852|after|bromocriptine (r_dep) h_29\NN\14622893|6|injection (r_conj) cells_24\NNS\3080309|to|estrogen-induced|rat|prolactinoma|h|and|h (l_compound) prolactinoma_23\NN\1740|
D001971_D000236 NONE bromocriptine_15\NN\1740| (r_compound) treatment_16\NN\654885|after|bromocriptine|cells (l_nmod) cells_20\NNS\3080309|of|the|adenoma (l_compound) adenoma_19\NN\14236226|
10669626
D014859_D061205 CID warfarin-induced_0\JJ\1740| (r_amod) calcification_2\NN\13446390|warfarin-induced|artery
D014859_D061205 CID warfarin_22\NN\2718259|of (r_nmod) doses_20\NNS\3740161|given|sufficient|warfarin (r_nmod) extent_12\NN\13939892|the|calcification|doses|inhibit (l_nmod) calcification_15\NN\13446390|of|artery|rats
D014859_D061205 CID warfarin-treated_17\JJ\1740| (r_amod) rats_18\NNS\2329401|in|warfarin-treated (r_nmod) calcification_15\NN\13446390|on|artery|rats
D014859_D061205 CID warfarin_5\NNP\2718259|with (r_nmod) weeks_3\NNS\15113229|for|2|warfarin (r_nmod) treatment_0\NN\654885|weeks (r_nsubj) caused_6\VBD\1617192|treatment|calcification|. (l_dobj) calcification_9\NN\13446390|massive|focal|media|rats (l_nmod) media_13\NNS\3575240|of|the|artery (l_compound) artery_12\NN\5417975|
D014859_D061205 CID warfarin_18\NN\2718259| (r_compound) treatment_19\NN\654885|of|warfarin (r_nmod) weeks_16\NNS\15113229|after|4|treatment (r_nmod) detected_8\VBN\2163746|contrast|,|calcification|could|be|rats|weeks|. (l_nsubjpass) calcification_5\NN\13446390|no|artery
D014859_D061205 CID warfarin-induced_8\JJ\1740| (r_amod) calcification_10\NN\13446390|to|warfarin-induced|artery|animals
D014859_D061205 CID warfarin_7\NNP\2718259|with (r_nmod) groups_5\NNS\2137|of|both|dietary|warfarin (r_nmod) treatment_1\NN\654885|concurrent|groups (r_nsubj) produced_8\VBD\1617192|treatment|calcification|but|calcification|. (l_dobj) calcification_11\NN\13446390|massive|focal|media|rats (l_nmod) media_15\NNS\3575240|of|the|artery (l_compound) artery_14\NN\5417975|
D014859_D061205 CID warfarin_7\NNP\2718259|with (r_nmod) groups_5\NNS\2137|of|both|dietary|warfarin (r_nmod) treatment_1\NN\654885|concurrent|groups (r_nsubj) produced_8\VBD\1617192|treatment|calcification|but|calcification|. (l_conj) calcification_25\NN\13446390|no|detectable|artery|group
D014859_D061205 CID warfarin-induced_59\JJ\1740| (r_amod) calcification_61\NN\13446390|to|warfarin-induced|artery (r_nmod) resistant_57\JJ\1740|that|was|calcification (r_acl:relcl) groups_54\NNS\2137|of|the|resistant (r_nmod) either_51\DT\1740|compared|with|groups|, (r_advcl) was_22\VBD\836236|determined|,|there|relationship|,|rats|either|rats|. (l_advcl) determined_15\VBN\1645601|although|explanation|can|not|be|study (l_nsubjpass) explanation_2\NN\6722453|the|association (l_nmod) association_5\NN\8008335|for|the|calcification (l_nmod) calcification_8\NN\13446390|between|artery|and|status
D014859_D061205 CID warfarin-induced_59\JJ\1740| (r_amod) calcification_61\NN\13446390|to|warfarin-induced|artery (r_nmod) resistant_57\JJ\1740|that|was|calcification (r_acl:relcl) groups_54\NNS\2137|of|the|resistant (r_nmod) either_51\DT\1740|compared|with|groups|, (r_advcl) was_22\VBD\836236|determined|,|there|relationship|,|rats|either|rats|. (l_nsubj) relationship_24\NN\31921|a|phosphate|,|levels (l_nmod) phosphate_28\NN\15010703|between|higher|serum|and|susceptibility (l_conj) susceptibility_30\NN\13920835|calcification (l_nmod) calcification_33\NN\13446390|to|artery
D014859_D061205 CID warfarin-induced_59\JJ\1740| (r_amod) calcification_61\NN\13446390|to|warfarin-induced|artery
D014859_D061205 CID warfarin-induced_7\JJ\1740| (r_amod) calcification_9\NN\13446390|to|warfarin-induced|artery
D014859_D061205 CID warfarin_13\NN\2718259| (r_conj) d_11\NN\15089472|between|vitamin|and|warfarin|calcification (l_nmod) calcification_16\NN\13446390|in|artery
D014859_D061205 CID warfarin_7\NN\2718259|of|the|vitamin|k|antagonist (r_nmod) doses_1\NNS\3740161|high|warfarin (r_nsubjpass) known_10\VBN\2110220|doses|are|also|cause|,|but|yet|week|. (l_xcomp) cause_12\VB\1617192|to|calcification (l_dobj) calcification_13\NN\13446390|media (l_nmod) media_17\NNS\3575240|of|the|artery (l_compound) artery_16\NN\5417975|
D014859_D061205 CID warfarin_20\NN\2718259| (r_conj) d_18\NN\15089472|with|vitamin|plus|warfarin (r_nmod) treated_15\VBN\2376958|d (r_acl) rats_14\NNS\2329401|in|treated (r_nmod) calcification_12\NN\13446390|of|artery|rats
D014807_D061205 NONE d._9\NN\1740|vitamin (r_conj) growth_6\NN\13526110|by|and|d. (r_nmod) accelerated_4\VBN\226566|calcification|is|growth (l_nsubjpass) calcification_2\NN\13446390|warfarin-induced|artery
D014807_D061205 NONE d_8\NN\15089472|vitamin (r_conj) growth_5\NN\13526110|and|d|treatment (r_nsubj) enhance_10\VBP\227165|that|growth|extent (l_dobj) extent_12\NN\13939892|the|calcification|doses|inhibit (l_nmod) calcification_15\NN\13446390|of|artery|rats
D014807_D061205 NONE d_11\NN\15089472|between|vitamin|and|warfarin|calcification (l_nmod) calcification_16\NN\13446390|in|artery
D014807_D061205 NONE d_4\NN\15089472|of|vitamin (r_nmod) doses_1\NNS\3740161|high|d (r_nsubjpass) known_6\VBN\2110220|doses|are|cause|. (l_xcomp) cause_8\VB\1617192|to|calcification|days (l_dobj) calcification_9\NN\13446390|media (l_nmod) media_13\NNS\3575240|of|the|artery (l_compound) artery_12\NN\5417975|
D014807_D061205 NONE d_10\NN\15089472| (r_compound) dose_11\NN\3740161|of|vitamin|d (r_nmod) effect_7\NN\34213|between|the|dose|calcification|and|effect (l_nmod) calcification_14\NN\13446390|on|artery
D014807_D061205 NONE d_10\NN\15089472| (r_compound) dose_11\NN\3740161|of|vitamin|d (r_nmod) effect_7\NN\34213|between|the|dose|calcification|and|effect (r_nmod) parallel_4\NN\4743605|a|close|effect|suggests (l_acl:relcl) suggests_30\VBZ\1010118|which|induce (l_ccomp) induce_35\VB\1627355|that|d|may|calcification|effect (l_dobj) calcification_37\NN\13446390|artery
D014807_D061205 NONE d_20\NN\15089472| (r_compound) dose_21\NN\3740161|of|vitamin|d (r_nmod) effect_17\NN\34213|the|dose|elevation (r_conj) effect_7\NN\34213|between|the|dose|calcification|and|effect (l_nmod) calcification_14\NN\13446390|on|artery
D014807_D061205 NONE d_20\NN\15089472| (r_compound) dose_21\NN\3740161|of|vitamin|d (r_nmod) effect_17\NN\34213|the|dose|elevation (r_conj) effect_7\NN\34213|between|the|dose|calcification|and|effect (r_nmod) parallel_4\NN\4743605|a|close|effect|suggests (l_acl:relcl) suggests_30\VBZ\1010118|which|induce (l_ccomp) induce_35\VB\1627355|that|d|may|calcification|effect (l_dobj) calcification_37\NN\13446390|artery
D014807_D061205 NONE d_33\NN\15089472|vitamin (r_nsubj) induce_35\VB\1627355|that|d|may|calcification|effect (r_ccomp) suggests_30\VBZ\1010118|which|induce (r_acl:relcl) parallel_4\NN\4743605|a|close|effect|suggests (l_nmod) effect_7\NN\34213|between|the|dose|calcification|and|effect (l_nmod) calcification_14\NN\13446390|on|artery
D014807_D061205 NONE d_33\NN\15089472|vitamin (r_nsubj) induce_35\VB\1627355|that|d|may|calcification|effect (l_dobj) calcification_37\NN\13446390|artery
D014807_D061205 NONE d_18\NN\15089472|with|vitamin|plus|warfarin (r_nmod) treated_15\VBN\2376958|d (r_acl) rats_14\NNS\2329401|in|treated (r_nmod) calcification_12\NN\13446390|of|artery|rats
D014807_D002114 NONE d_8\NN\15089472|vitamin (r_conj) growth_5\NN\13526110|and|d|treatment (r_nsubj) enhance_10\VBP\227165|that|growth|extent (l_dobj) extent_12\NN\13939892|the|calcification|doses|inhibit (l_acl) inhibit_24\VB\2510337|to|gamma-carboxylation (l_dobj) gamma-carboxylation_25\NN\1740|protein (l_nmod) protein_29\NN\14944888|of|matrix|gla|,|inhibitor (l_appos) inhibitor_33\NN\20090|a|calcification|known (l_compound) calcification_32\NN\13446390|
D014807_D002114 NONE d-treated_30\JJ\1740| (r_amod) rats_31\NNS\2329401|of|vitamin|d-treated (r_nmod) media_27\NNS\3575240|in|the|rats (r_nmod) extent_22\NN\13939892|the|calcification|media|days (l_nmod) calcification_24\NN\13446390|of
D014807_D002114 NONE d_15\NN\15089472|by|vitamin (r_nmod) produced_12\VBN\1617192|d (r_acl) calcium_11\NN\14625458|in|serum|produced (r_nmod) elevation_8\NN\7445480|on|the|calcium (r_nmod) had_3\VBD\2108377|because|treatment|effect|elevation|, (r_advcl) explained_27\VBN\831651|had|best|hypothesis|. (l_nmod) hypothesis_30\NN\7162194|by|the|inhibits (l_ccomp) inhibits_33\VBZ\2510337|that|warfarin|activity|inhibitor (l_nmod) inhibitor_43\NN\20090|as|a|calcification (l_compound) calcification_42\NN\13446390|
D014807_D002114 NONE d_23\NN\15089472|vitamin (r_conj) warfarin_20\NN\2718259|between|and|d (r_nmod) synergy_18\NN\13518963|the|warfarin (r_nsubj) best_26\RBS\1740|synergy|is|probably (r_advmod) explained_27\VBN\831651|had|best|hypothesis|. (l_nmod) hypothesis_30\NN\7162194|by|the|inhibits (l_ccomp) inhibits_33\VBZ\2510337|that|warfarin|activity|inhibitor (l_nmod) inhibitor_43\NN\20090|as|a|calcification (l_compound) calcification_42\NN\13446390|
D014859_D002114 NONE warfarin_22\NN\2718259|of (r_nmod) doses_20\NNS\3740161|given|sufficient|warfarin (r_nmod) extent_12\NN\13939892|the|calcification|doses|inhibit (l_acl) inhibit_24\VB\2510337|to|gamma-carboxylation (l_dobj) gamma-carboxylation_25\NN\1740|protein (l_nmod) protein_29\NN\14944888|of|matrix|gla|,|inhibitor (l_appos) inhibitor_33\NN\20090|a|calcification|known (l_compound) calcification_32\NN\13446390|
D014859_D002114 NONE warfarin_5\NNP\2718259|with (r_nmod) weeks_3\NNS\15113229|for|2|warfarin (r_nmod) treatment_0\NN\654885|weeks (r_nsubj) caused_6\VBD\1617192|treatment|calcification|. (l_dobj) calcification_9\NN\13446390|massive|focal|media|rats (l_nmod) rats_16\NNS\2329401|in|20-day-old|and|calcification|rats (l_conj) calcification_21\NN\13446390|extensive|focal
D014859_D002114 NONE warfarin_17\NNP\2718259| (r_compound) administration_18\NN\1133281|concurrent|warfarin (r_nsubj) increased_20\VBD\169651|that|administration|dramatically|extent (l_dobj) extent_22\NN\13939892|the|calcification|media|days (l_nmod) calcification_24\NN\13446390|of
D014859_D002114 NONE warfarin_1\NN\2718259| (r_compound) treatment_2\NN\654885|warfarin (r_nsubj) had_3\VBD\2108377|because|treatment|effect|elevation|, (r_advcl) explained_27\VBN\831651|had|best|hypothesis|. (l_nmod) hypothesis_30\NN\7162194|by|the|inhibits (l_ccomp) inhibits_33\VBZ\2510337|that|warfarin|activity|inhibitor (l_nmod) inhibitor_43\NN\20090|as|a|calcification (l_compound) calcification_42\NN\13446390|
D014859_D002114 NONE warfarin_20\NN\2718259|between|and|d (r_nmod) synergy_18\NN\13518963|the|warfarin (r_nsubj) best_26\RBS\1740|synergy|is|probably (r_advmod) explained_27\VBN\831651|had|best|hypothesis|. (l_nmod) hypothesis_30\NN\7162194|by|the|inhibits (l_ccomp) inhibits_33\VBZ\2510337|that|warfarin|activity|inhibitor (l_nmod) inhibitor_43\NN\20090|as|a|calcification (l_compound) calcification_42\NN\13446390|
D014859_D002114 NONE warfarin_32\NN\2718259| (r_nsubj) inhibits_33\VBZ\2510337|that|warfarin|activity|inhibitor (l_nmod) inhibitor_43\NN\20090|as|a|calcification (l_compound) calcification_42\NN\13446390|
D010710_D061205 NONE phosphate_28\NN\15010703|between|higher|serum|and|susceptibility (r_nmod) relationship_24\NN\31921|a|phosphate|,|levels (r_nsubj) was_22\VBD\836236|determined|,|there|relationship|,|rats|either|rats|. (l_advcl) determined_15\VBN\1645601|although|explanation|can|not|be|study (l_nsubjpass) explanation_2\NN\6722453|the|association (l_nmod) association_5\NN\8008335|for|the|calcification (l_nmod) calcification_8\NN\13446390|between|artery|and|status
D010710_D061205 NONE phosphate_28\NN\15010703|between|higher|serum|and|susceptibility (l_conj) susceptibility_30\NN\13920835|calcification (l_nmod) calcification_33\NN\13446390|to|artery
D010710_D061205 NONE phosphate_28\NN\15010703|between|higher|serum|and|susceptibility (r_nmod) relationship_24\NN\31921|a|phosphate|,|levels (r_nsubj) was_22\VBD\836236|determined|,|there|relationship|,|rats|either|rats|. (l_advcl) either_51\DT\1740|compared|with|groups|, (l_nmod) groups_54\NNS\2137|of|the|resistant (l_acl:relcl) resistant_57\JJ\1740|that|was|calcification (l_nmod) calcification_61\NN\13446390|to|warfarin-induced|artery
D010710_D061205 NONE phosphate_42\NN\15010703|of|serum (r_nmod) levels_39\NNS\4916342|with|%|higher|phosphate|young (r_nmod) relationship_24\NN\31921|a|phosphate|,|levels (r_nsubj) was_22\VBD\836236|determined|,|there|relationship|,|rats|either|rats|. (l_advcl) determined_15\VBN\1645601|although|explanation|can|not|be|study (l_nsubjpass) explanation_2\NN\6722453|the|association (l_nmod) association_5\NN\8008335|for|the|calcification (l_nmod) calcification_8\NN\13446390|between|artery|and|status
D010710_D061205 NONE phosphate_42\NN\15010703|of|serum (r_nmod) levels_39\NNS\4916342|with|%|higher|phosphate|young (r_nmod) relationship_24\NN\31921|a|phosphate|,|levels (l_nmod) phosphate_28\NN\15010703|between|higher|serum|and|susceptibility (l_conj) susceptibility_30\NN\13920835|calcification (l_nmod) calcification_33\NN\13446390|to|artery
D010710_D061205 NONE phosphate_42\NN\15010703|of|serum (r_nmod) levels_39\NNS\4916342|with|%|higher|phosphate|young (r_nmod) relationship_24\NN\31921|a|phosphate|,|levels (r_nsubj) was_22\VBD\836236|determined|,|there|relationship|,|rats|either|rats|. (l_advcl) either_51\DT\1740|compared|with|groups|, (l_nmod) groups_54\NNS\2137|of|the|resistant (l_acl:relcl) resistant_57\JJ\1740|that|was|calcification (l_nmod) calcification_61\NN\13446390|to|warfarin-induced|artery
D010710_D061205 NONE phosphate_16\NN\15010703| (r_compound) levels_17\NNS\4916342|to|higher|serum|phosphate (r_nmod) related_12\JJ\1740|that|susceptibility|could|be|levels (l_nsubj) susceptibility_5\NN\13920835|increased|calcification (l_nmod) calcification_9\NN\13446390|to|warfarin-induced|artery
D014812_D061205 NONE k_5\NN\13608598| (r_compound) warfarin_7\NN\2718259|of|the|vitamin|k|antagonist (r_nmod) doses_1\NNS\3740161|high|warfarin (r_nsubjpass) known_10\VBN\2110220|doses|are|also|cause|,|but|yet|week|. (l_xcomp) cause_12\VB\1617192|to|calcification (l_dobj) calcification_13\NN\13446390|media (l_nmod) media_17\NNS\3575240|of|the|artery (l_compound) artery_16\NN\5417975|
D002118_D061205 NONE calcium_27\NN\14625458|of|serum|, (r_nmod) elevation_24\NN\7445480|on|the|calcium (r_nmod) effect_17\NN\34213|the|dose|elevation (r_conj) effect_7\NN\34213|between|the|dose|calcification|and|effect (l_nmod) calcification_14\NN\13446390|on|artery
D002118_D061205 NONE calcium_27\NN\14625458|of|serum|, (r_nmod) elevation_24\NN\7445480|on|the|calcium (r_nmod) effect_17\NN\34213|the|dose|elevation (r_conj) effect_7\NN\34213|between|the|dose|calcification|and|effect (r_nmod) parallel_4\NN\4743605|a|close|effect|suggests (l_acl:relcl) suggests_30\VBZ\1010118|which|induce (l_ccomp) induce_35\VB\1627355|that|d|may|calcification|effect (l_dobj) calcification_37\NN\13446390|artery
D002118_D061205 NONE calcium_43\NN\14625458|on|serum (r_nmod) effect_40\NN\34213|through|its|calcium (r_nmod) induce_35\VB\1627355|that|d|may|calcification|effect (r_ccomp) suggests_30\VBZ\1010118|which|induce (r_acl:relcl) parallel_4\NN\4743605|a|close|effect|suggests (l_nmod) effect_7\NN\34213|between|the|dose|calcification|and|effect (l_nmod) calcification_14\NN\13446390|on|artery
D002118_D061205 NONE calcium_43\NN\14625458|on|serum (r_nmod) effect_40\NN\34213|through|its|calcium (r_nmod) induce_35\VB\1627355|that|d|may|calcification|effect (l_dobj) calcification_37\NN\13446390|artery
D002118_D002114 NONE calcium_11\NN\14625458|in|serum|produced (r_nmod) elevation_8\NN\7445480|on|the|calcium (r_nmod) had_3\VBD\2108377|because|treatment|effect|elevation|, (r_advcl) explained_27\VBN\831651|had|best|hypothesis|. (l_nmod) hypothesis_30\NN\7162194|by|the|inhibits (l_ccomp) inhibits_33\VBZ\2510337|that|warfarin|activity|inhibitor (l_nmod) inhibitor_43\NN\20090|as|a|calcification (l_compound) calcification_42\NN\13446390|
D015055_D061205 NONE gamma-carboxylated_34\JJ\1740|that|protein|was|indeed|not (r_ccomp) showed_25\VBD\2137132|analysis|gamma-carboxylated (r_conj) found_7\VBN\2426171|levels|are|sites|,|and|showed|. (l_nmod) sites_9\NNS\8673395|at|calcification (l_nmod) calcification_12\NN\13446390|of|artery|rats
D015055_D002114 NONE gamma-carboxyglutamate_6\JJ\1740| (r_amod) residues_7\NNS\20827|the|gamma-carboxyglutamate|protein (r_nsubjpass) required_14\VBN\754942|although|residues|are|apparently|function (l_nmod) function_17\NN\13783581|for|its|inhibitor (l_nmod) inhibitor_21\NN\20090|as|a|calcification (l_compound) calcification_20\NN\13446390|
D015055_D002114 NONE gamma-carboxyglutamate_6\JJ\1740| (r_amod) residues_7\NNS\20827|the|gamma-carboxyglutamate|protein (r_nsubjpass) required_14\VBN\754942|although|residues|are|apparently|function (r_advcl) required_26\VBN\754942|that|required|,|they|are|not|accumulation (l_nmod) accumulation_29\NN\13497135|for|its|sites (l_nmod) sites_32\NNS\8673395|at|calcification (l_compound) calcification_31\NN\13446390|
18004067
D000431_D017114 NONE alcohol_8\NN\7881800| (r_compound) consumption_9\NN\13440063|with|regular|alcohol (r_nmod) patients_5\NNS\9898892|in|two|consumption|ingesting (r_nmod) failure_2\NN\66216|acute|liver|patients|.
D000082_D017114 NONE paracetamol_11\NN\1740| (r_dobj) ingesting_10\VBG\597915|paracetamol|dosage (r_acl) patients_5\NNS\9898892|in|two|consumption|ingesting (r_nmod) failure_2\NN\66216|acute|liver|patients|.
D000431_D056486 NONE alcohol_6\NN\7881800|of (r_nmod) role_4\NN\719494|the|possible|alcohol|development|acetaminophen (l_nmod) development_9\NN\248977|in|the|hepatotoxicity (l_nmod) hepatotoxicity_11\NN\1740|of|associated
D000082_D056486 CID paracetamol_17\NN\1740|of (r_nmod) doses_15\NNS\3740161|with|therapeutic|paracetamol (r_nmod) associated_12\VBN\628491|doses (r_acl) hepatotoxicity_11\NN\1740|of|associated
D000082_D056486 CID acetaminophen_19\RB\1740|(|) (r_dep) role_4\NN\719494|the|possible|alcohol|development|acetaminophen (l_nmod) development_9\NN\248977|in|the|hepatotoxicity (l_nmod) hepatotoxicity_11\NN\1740|of|associated
D000082_D056486 CID paracetamol_15\NN\1740|of (r_nmod) doses_13\NNS\3740161|with|therapeutic|paracetamol (r_nmod) treated_10\VBN\2376958|doses (r_acl) patients_9\NNS\9898892|in|treated (r_nmod) hepatotoxicity_7\NN\1740|of|patients
D000431_D017093 NONE alcohol_12\NN\7881800|of (r_nmod) consumers_10\NNS\10741590|who|were|regular|alcohol|and|developed (l_conj) developed_15\VBD\1753788|who|failure|days|hospitalization|and|stopping (l_dobj) failure_17\NN\66216|liver
D000431_D017093 NONE alcohol_27\NN\7881800| (r_compound) consumption_28\NN\13440063|alcohol (r_dobj) stopping_26\VBG\2452885|consumption|treated (r_conj) developed_15\VBD\1753788|who|failure|days|hospitalization|and|stopping (l_dobj) failure_17\NN\66216|liver
D000431_D017093 NONE alcohol_12\NN\7881800|of (r_nmod) consumption_10\NN\13440063|e.g.|regular|alcohol (r_nmod) patients_3\NNS\9898892|in|factors|consumption (r_nmod) possible_17\JJ\1740|conclusion|patients|,|failure|is|ingested|. (l_nsubj) failure_15\NN\66216|liver
D000082_D017093 CID paracetamol/day_35\NN\1740| (r_appos) g_34\NN\13717155|with|4|paracetamol/day (r_nmod) treated_31\VBN\2376958|while|being|g (r_advcl) stopping_26\VBG\2452885|consumption|treated (r_conj) developed_15\VBD\1753788|who|failure|days|hospitalization|and|stopping (l_dobj) failure_17\NN\66216|liver
17439425
D019820_D006973 NONE xanthine_2\NN\14727670| (r_compound) oxidase_3\NN\14732946|of|xanthine|hypertension (l_nmod) hypertension_6\NN\14057371|in|dexamethasone-induced|rats
D019820_D006973 NONE xanthine_7\NN\14727670| (r_compound) oxidase_8\NN\14732946|of|xanthine|xo|,|implicated (r_nmod) role_5\NN\719494|the|oxidase|,|hypertension (l_nmod) hypertension_26\NN\14057371|in|dexamethasone-induced|dex-ht
D019820_D006973 NONE xanthine_7\NN\14727670| (r_compound) oxidase_8\NN\14732946|of|xanthine|xo|,|implicated (r_nmod) role_5\NN\719494|the|oxidase|,|hypertension (l_nmod) hypertension_26\NN\14057371|in|dexamethasone-induced|dex-ht (l_appos) dex-ht_28\NNS\1740|(|)
D003907_D006973 CID dexamethasone-induced_5\JJ\1740| (r_amod) hypertension_6\NN\14057371|in|dexamethasone-induced|rats
D003907_D006973 CID dexamethasone-induced_25\JJ\1740| (r_amod) hypertension_26\NN\14057371|in|dexamethasone-induced|dex-ht
D003907_D006973 CID dexamethasone-induced_25\JJ\1740| (r_amod) hypertension_26\NN\14057371|in|dexamethasone-induced|dex-ht (l_appos) dex-ht_28\NNS\1740|(|)
D003907_D006973 CID dex-ht_28\NNS\1740|(|) (r_appos) hypertension_26\NN\14057371|in|dexamethasone-induced|dex-ht
D003907_D006973 CID dex-ht_28\NNS\1740|(|)
D003907_D006973 CID dex_0\NN\1740| (r_nsubj) increased_1\VBD\169651|dex|sbp|mmhg|and|thymus|. (l_dobj) sbp_2\NN\1740|
D003907_D006973 CID dex-ht_6\JJ\1740|
D009569_D006973 NONE oxide-redox_14\NN\1740| (r_compound) imbalance_15\NN\13934274|with|nitric|oxide-redox (r_nmod) associated_11\VBN\628491|hypertension|is|imbalance|. (l_nsubjpass) hypertension_3\NN\14057371|1|glucocorticoid-induced|gc-ht|rat
D009569_D006973 NONE oxide-redox_14\NN\1740| (r_compound) imbalance_15\NN\13934274|with|nitric|oxide-redox (r_nmod) associated_11\VBN\628491|hypertension|is|imbalance|. (l_nsubjpass) hypertension_3\NN\14057371|1|glucocorticoid-induced|gc-ht|rat (l_appos) gc-ht_5\NN\1740|(|)
D003907_D015431 CID dex_0\NN\1740| (r_nsubj) increased_1\VBD\169651|dex|sbp|mmhg|and|thymus|. (l_conj) thymus_19\NN\11579418|decreased|0.001|and|bodyweights (l_conj) bodyweights_26\NNS\1740|p
D000493_D006973 NONE allopurinol_2\NN\3740161| (r_nsubj) prevent_5\VB\1740|6|allopurinol|did|not|dex-ht|. (l_dobj) dex-ht_6\JJ\1740|
D000493_D006973 NONE allopurinol_8\NN\3740161| (r_nsubj) failed_9\VBD\1798936|that|allopurinol|prevent (l_xcomp) prevent_11\VB\1740|to|hypertension (l_dobj) hypertension_15\NN\14057371|adrenocorticotrophic|induced
D000493_D006973 NONE allopurinol_8\NN\3740161| (r_nsubj) failed_9\VBD\1798936|that|allopurinol|prevent (r_acl:relcl) findings_6\NNS\7951464|this|,|together|with|our|previous|failed (r_nsubj) suggests_17\VBZ\1010118|findings|,|determinant|. (l_ccomp) determinant_25\NN\5686481|that|activity|is|not|a|major|gc-ht|rat (l_nmod) gc-ht_27\NN\1740|of
18996674
D004837_D011317 NONE epinephrine_1\NN\14807929|intracavernous|:|treatment|. (l_dep) treatment_6\NN\654885|a|invasive|priapism|department (l_nmod) priapism_8\NN\14204950|for
D003042_D011317 CID cocaine_7\NN\3492717| (r_compound) user_8\NN\7846|an|admitted|frequent|cocaine (r_appos) man_2\NN\9605289|a|45-year-old|,|user|,|presented|. (l_acl) presented_10\VBN\2137132|department|occasions|use (l_nmod) occasions_21\NNS\5983801|on|two|separate|history (l_nmod) history_24\NN\15120823|with|a|priapism (l_nmod) priapism_26\NN\14204950|of
D003042_D011317 CID cocaine_28\NN\3492717| (r_compound) use_29\NN\407535|after|cocaine (r_nmod) presented_10\VBN\2137132|department|occasions|use (l_nmod) occasions_21\NNS\5983801|on|two|separate|history (l_nmod) history_24\NN\15120823|with|a|priapism (l_nmod) priapism_26\NN\14204950|of
9653867
D013974_D013971 CID thyroxine_0\JJ\1740| (r_amod) abuse_1\NN\418025|thyroxine|:|case|. (l_dep) case_5\NN\7283608|an|unusual|thyrotoxicosis (l_nmod) thyrotoxicosis_7\NN\14059928|of|pregnancy
D013974_D013971 CID thyroxine_28\JJ\1740| (r_amod) abuse_29\NN\418025|thyroxine (r_nsubjpass) considered_32\VBN\689344|that|remains|,|abuse|should|be|and|explored (l_advcl) remains_25\VBZ\2604760|when|cause|obscure (l_nsubj) cause_22\NN\7323922|a|thyrotoxicosis (l_nmod) thyrotoxicosis_24\NN\14059928|for
D013974_D001068 NONE thyroxine_28\JJ\1740| (r_amod) abuse_29\NN\418025|thyroxine (r_nsubjpass) considered_32\VBN\689344|that|remains|,|abuse|should|be|and|explored (r_ccomp) reminds_17\VBZ\831651|us|considered (r_conj) illustrates_3\VBZ\955601|particular|it|derangements|and|reminds|. (l_dobj) derangements_5\NNS\14395018|the|function (l_nmod) function_8\NN\13783581|of|thyroid|seen (l_acl) seen_9\VBN\2106506|women|eating (l_advcl) eating_14\VBG\1156834|with|disorders (l_dobj) disorders_15\NNS\14034177|
2348231
D010431_D006940 NONE pentoxifylline_0\NN\3247620|(|trental|) (r_nsubj) inhibit_6\VB\2510337|pentoxifylline|does|not|hyperemia|:|implications|. (l_dobj) hyperemia_9\NN\14320394|dipyridamole-induced|coronary
D010431_D006940 NONE trental_2\JJ\1740| (r_appos) pentoxifylline_0\NN\3247620|(|trental|) (r_nsubj) inhibit_6\VB\2510337|pentoxifylline|does|not|hyperemia|:|implications|. (l_dobj) hyperemia_9\NN\14320394|dipyridamole-induced|coronary
D010431_D006940 NONE pentoxifylline_1\NN\3247620| (r_nsubj) inhibits_2\VBZ\2510337|whether|pentoxifylline|hyperemia|and|stopped (l_dobj) hyperemia_5\NN\14320394|dipyridamole-induced|coronary|methylxanthines
D010431_D006940 NONE pentoxifylline_3\NN\3247620|of (r_nmod) dose_1\NN\3740161|neither|pentoxifylline (r_nsubj) decreased_5\VBD\169651|dose|significantly|hyperemia|,|lower|. (l_dobj) hyperemia_8\NN\14320394|the|dipyridamole-induced
D010431_D006940 NONE pentoxyifylline_3\NN\1740| (r_nsubj) inhibit_6\VB\2510337|that|pentoxyifylline|does|not|hyperemia|doses (l_dobj) hyperemia_9\NN\14320394|dipyridamole-induced|coronary
D004176_D006940 CID dipyridamole-induced_7\JJ\1740| (r_amod) hyperemia_9\NN\14320394|dipyridamole-induced|coronary
D004176_D006940 CID dipyridamole-thallium-201_13\JJ\1740| (r_amod) imaging_15\NN\5765159|for|dipyridamole-thallium-201|myocardial (r_nmod) implications_11\NNS\5774614|imaging (r_dep) inhibit_6\VB\2510337|pentoxifylline|does|not|hyperemia|:|implications|. (l_dobj) hyperemia_9\NN\14320394|dipyridamole-induced|coronary
D004176_D006940 CID dipyridamole-induced_3\JJ\1740| (r_amod) hyperemia_5\NN\14320394|dipyridamole-induced|coronary|methylxanthines
D004176_D006940 CID dipyridamole-thallium-201_18\NN\1740| (r_compound) imaging_19\NN\5765159|to|dipyridamole-thallium-201 (r_nmod) stopped_15\VBN\2452885|should|be|prior|imaging (r_conj) inhibits_2\VBZ\2510337|whether|pentoxifylline|hyperemia|and|stopped (l_dobj) hyperemia_5\NN\14320394|dipyridamole-induced|coronary|methylxanthines
D004176_D006940 CID dipyridamole-induced_7\JJ\1740| (r_amod) hyperemia_8\NN\14320394|the|dipyridamole-induced
D004176_D006940 CID dipyridamole-induced_7\JJ\1740| (r_amod) hyperemia_9\NN\14320394|dipyridamole-induced|coronary
D013793_D006940 NONE dipyridamole-thallium-201_13\JJ\1740| (r_amod) imaging_15\NN\5765159|for|dipyridamole-thallium-201|myocardial (r_nmod) implications_11\NNS\5774614|imaging (r_dep) inhibit_6\VB\2510337|pentoxifylline|does|not|hyperemia|:|implications|. (l_dobj) hyperemia_9\NN\14320394|dipyridamole-induced|coronary
D013793_D006940 NONE dipyridamole-thallium-201_18\NN\1740| (r_compound) imaging_19\NN\5765159|to|dipyridamole-thallium-201 (r_nmod) stopped_15\VBN\2452885|should|be|prior|imaging (r_conj) inhibits_2\VBZ\2510337|whether|pentoxifylline|hyperemia|and|stopped (l_dobj) hyperemia_5\NN\14320394|dipyridamole-induced|coronary|methylxanthines
D004176_D016491 NONE dipyridamole-thallium-201_0\NN\1740| (r_compound) imaging_1\NN\5765159|dipyridamole-thallium-201 (r_nsubjpass) performed_4\VBN\2367363|imaging|is|often|patients|disease|. (l_nmod) disease_14\NN\14061805|because|peripheral|vascular
D013793_D016491 NONE dipyridamole-thallium-201_0\NN\1740| (r_compound) imaging_1\NN\5765159|dipyridamole-thallium-201 (r_nsubjpass) performed_4\VBN\2367363|imaging|is|often|patients|disease|. (l_nmod) disease_14\NN\14061805|because|peripheral|vascular
D010431_D007383 CID pentoxifylline_6\NN\3247620|(|trental|)|,|derivative (l_appos) derivative_13\NN\5802185|a|methylxanthine|improve (l_acl:relcl) improve_16\VB\126264|which|may|claudication (l_dobj) claudication_18\NN\14548913|intermittent
D010431_D007383 CID trental_8\NNP\3247620| (r_appos) pentoxifylline_6\NN\3247620|(|trental|)|,|derivative (l_appos) derivative_13\NN\5802185|a|methylxanthine|improve (l_acl:relcl) improve_16\VB\126264|which|may|claudication (l_dobj) claudication_18\NN\14548913|intermittent
C008514_D007383 NONE methylxanthine_12\NN\1740| (r_compound) derivative_13\NN\5802185|a|methylxanthine|improve (l_acl:relcl) improve_16\VB\126264|which|may|claudication (l_dobj) claudication_18\NN\14548913|intermittent
C008514_D006940 NONE methylxanthines_8\NNS\1740|like|other|theophylline (r_nmod) hyperemia_5\NN\14320394|dipyridamole-induced|coronary|methylxanthines
D013806_D006940 NONE theophylline_11\NN\2905612|such (r_nmod) methylxanthines_8\NNS\1740|like|other|theophylline (r_nmod) hyperemia_5\NN\14320394|dipyridamole-induced|coronary|methylxanthines
D013806_D006940 NONE theophylline_19\NN\2905612|after (r_nmod) lower_17\JJR\1740|while|flow|was|significantly|theophylline|p (r_advcl) decreased_5\VBD\169651|dose|significantly|hyperemia|,|lower|. (l_dobj) hyperemia_8\NN\14320394|the|dipyridamole-induced
10807237
D003042_D000783 NONE cocaine-related_14\JJ\1740| (r_amod) aneurysms_15\NNS\14057371|with|cocaine-related
D003042_D000783 NONE cocaine-related_25\JJ\1740| (r_amod) aneurysms_26\NNS\14057371|with|cocaine-related
D003042_D000783 NONE cocaine_2\NN\3492717| (r_compound) use_3\VBP\1156834|cocaine|rupture|age (l_nmod) age_11\NN\4916342|at|a|earlier|aneurysms (l_conj) aneurysms_16\NNS\14057371|in|smaller
D003042_D017542 CID cocaine_2\NN\3492717| (r_compound) use_3\VBP\1156834|cocaine|rupture|age (l_dobj) rupture_6\NN\14285662|predisposed|aneurysmal
3865016
D005047_D054218 NONE etoposide_4\NN\1740|of|and|a (r_nmod) effect_2\NN\34213|a|synergistic|etoposide (r_nsubjpass) observed_9\VBN\2163746|effect|was|patient|. (l_nmod) patient_12\NN\9898892|in|a|leukemia|relapse (l_nmod) leukemia_16\NN\14239918|with|acute|t-lymphocytic
D016572_D054218 NONE a_7\NN\13649268|cyclosporin (r_conj) etoposide_4\NN\1740|of|and|a (r_nmod) effect_2\NN\34213|a|synergistic|etoposide (r_nsubjpass) observed_9\VBN\2163746|effect|was|patient|. (l_nmod) patient_12\NN\9898892|in|a|leukemia|relapse (l_nmod) leukemia_16\NN\14239918|with|acute|t-lymphocytic
D005047_D017254 NONE etoposide_4\NN\1740|of|and|a (r_nmod) administration_2\NN\1133281|the|concomitant|etoposide (r_nsubj) resulted_8\VBD\2633881|administration|eradication|. (l_nmod) eradication_10\NN\7334490|in|infiltration (l_nmod) infiltration_15\NN\975452|of|hitherto|refractory|leukemic|marrow
D016572_D017254 NONE a_7\NN\13649268|cyclosporin (r_conj) etoposide_4\NN\1740|of|and|a (r_nmod) administration_2\NN\1133281|the|concomitant|etoposide (r_nsubj) resulted_8\VBD\2633881|administration|eradication|. (l_nmod) eradication_10\NN\7334490|in|infiltration (l_nmod) infiltration_15\NN\975452|of|hitherto|refractory|leukemic|marrow
3192036
10791295
D001058_D010554 CID apomorphine-induced_2\JJ\1740| (r_amod) behavior_4\NN\407535|of|apomorphine-induced|aggressive
D001058_D010554 CID apomorphine-induced_3\JJ\1740|of (r_nmod) development_1\NN\248977|the|apomorphine-induced|mg/kg|daily|)|behavior (l_appos) behavior_12\NN\407535|aggressive|male|rats
D001058_D010554 CID apomorphine_5\NN\3786417| (r_compound) treatment_6\NN\654885|repeated|apomorphine (r_nsubj) induced_7\VBD\1627355|animals|,|treatment|development|evidenced|. (l_dobj) development_10\NN\248977|a|gradual|behavior (l_nmod) behavior_13\NN\407535|of|aggressive
D001058_D010554 CID apomorphine_5\NN\3786417| (r_compound) treatment_6\NN\654885|repeated|apomorphine (r_nsubj) induced_7\VBD\1627355|animals|,|treatment|development|evidenced|. (l_advcl) evidenced_15\VBN\1015244|as|intensity (l_nmod) intensity_19\NN\5090441|by|the|increased|aggressiveness|and|latency|attack (l_nmod) aggressiveness_21\NN\4835724|of
D001058_D010554 CID apomorphine-induced_14\JJ\1740| (r_amod) behavior_16\NN\407535|of|the|apomorphine-induced|aggressive
1992636
D009853_D000743 CID omeprazole_7\NN\14778019|of (r_nmod) use_5\NN\407535|with|the|omeprazole (r_nmod) associated_2\VBN\628491|use (r_acl) anemia_1\NN\14189204|hemolytic|associated|.
D009853_D000743 CID omeprazole_15\NN\14778019|of (r_nmod) use_13\NN\407535|with|the|omeprazole (r_nmod) reaction_10\NN\13446390|of|a|short-term|adverse|use (r_nmod) case_4\NN\7283608|the|first|reaction|:|anemia (l_appos) anemia_18\NN\14189204|hemolytic
D009853_D000743 CID omeprazole_4\NN\14778019|which (r_nmod) mechanism_1\NN\13446390|the|omeprazole (r_nsubj) caused_5\VBD\1617192|mechanism|uncertain|. (l_ccomp) uncertain_12\JJ\1740|anemia|is|,|but|alerted (l_nsubj) anemia_10\NN\14189204|patient|hemolytic
D009853_D053609 CID omeprazole_17\NN\14778019|with (r_nmod) therapy_15\NN\657604|omeprazole (r_dobj) starting_14\VBG\2009433|after|therapy (r_advcl) developed_2\VBD\1753788|patient|weakness|days|starting|. (l_dobj) weakness_3\NN\14462666|,|lethargy|,|and|shortness (l_conj) lethargy_5\NN\14014621|
D009853_D004417 CID omeprazole_17\NN\14778019|with (r_nmod) therapy_15\NN\657604|omeprazole (r_dobj) starting_14\VBG\2009433|after|therapy (r_advcl) developed_2\VBD\1753788|patient|weakness|days|starting|. (l_dobj) weakness_3\NN\14462666|,|lethargy|,|and|shortness (l_conj) shortness_8\NN\5129201|breath (l_nmod) breath_10\NN\13440063|of
9660111
D014299_D007035 NONE tri_4\NNP\1740| (r_appos) experiment_3\NN\641820|in|the|acute|tri|given (r_nmod) antagonize_11\VB\1787955|experiment|does|not|hypothermia|and|potentiate|. (l_dobj) hypothermia_14\NN\14034177|the|reserpine|mice
D012110_D007035 CID reserpine_13\NN\2721160| (r_compound) hypothermia_14\NN\14034177|the|reserpine|mice
D006916_D007035 NONE 5-hydroxytryptophan_22\JJ\1740| (r_amod) head_23\NN\5225090|the|5-hydroxytryptophan (r_nsubj) twitches_24\VBZ\10054|head|rats (r_dobj) potentiate_20\VB\229605|does|not|twitches (r_conj) antagonize_11\VB\1787955|experiment|does|not|hypothermia|and|potentiate|. (l_dobj) hypothermia_14\NN\14034177|the|reserpine|mice
D014299_D006948 CID tri_0\NNP\1740|given (r_nsubj) increases_5\VBZ\169651|tri|hyperactivity|)|. (l_dobj) hyperactivity_8\NN\14052403|the|locomotor|induced
D003913_D006948 CID d-amphetamine_11\NN\1740|by|,|quinpirole|and|(+)-7-hydroxy-dipropyloaminotetralin|d2 (r_nmod) induced_9\VBN\1627355|d-amphetamine|effects (r_acl) hyperactivity_8\NN\14052403|the|locomotor|induced
D019257_D006948 CID quinpirole_13\NN\1740| (r_conj) d-amphetamine_11\NN\1740|by|,|quinpirole|and|(+)-7-hydroxy-dipropyloaminotetralin|d2 (r_nmod) induced_9\VBN\1627355|d-amphetamine|effects (r_acl) hyperactivity_8\NN\14052403|the|locomotor|induced
D004298_D006948 NONE dopamine_17\NN\14807737| (r_compound) d2_18\NN\1740|(|dopamine|and|d3 (r_dep) d-amphetamine_11\NN\1740|by|,|quinpirole|and|(+)-7-hydroxy-dipropyloaminotetralin|d2 (r_nmod) induced_9\VBN\1627355|d-amphetamine|effects (r_acl) hyperactivity_8\NN\14052403|the|locomotor|induced
D010656_D010554 NONE phenylephrine_7\NN\2682038|by|intraventricularly (r_nmod) evoked_5\VBN\1617192|phenylephrine|rats (r_acl) stimulation_4\NN\242808|the|behaviour|evoked (r_dobj) increases_1\VBZ\169651|it|stimulation|,|evaluated|aggressiveness|,|mediated|. (l_dobj) aggressiveness_25\NN\4835724|the|evoked
D003000_D010554 NONE clonidine_28\NN\2721160|by (r_nmod) evoked_26\VBN\1617192|clonidine|mice (r_acl) aggressiveness_25\NN\4835724|the|evoked
19211690
D013739_D006973 NONE testosterone-dependent_0\JJ\1740| (r_amod) hypertension_1\NN\14057371|testosterone-dependent|and|upregulation|rats|.
D013739_D006973 NONE testosterone_0\NN\14747587| (r_nsubj) contributes_1\VBZ\126264|testosterone|development|possibly|upregulation|. (l_nmod) development_4\NN\248977|to|the|hypertension (l_nmod) hypertension_6\NN\14057371|of|and|injury|rats
D017673_D006973 NONE salt-sensitive_9\JJ\1740| (r_amod) rats_10\NNS\2329401|in|dahl|salt-sensitive (r_nmod) hypertension_1\NN\14057371|testosterone-dependent|and|upregulation|rats|.
D013739_D007674 NONE testosterone_22\NN\14747587|by (r_nmod) mediated_20\VBN\761713|testosterone (r_acl) angiotensinogen_19\NN\1740|of|intrarenal|mediated (r_nmod) upregulation_16\NN\1740|in|hs-induced|angiotensinogen (r_nmod) dimorphism_13\NN\11492833|a|sexual|upregulation|causes (l_acl:relcl) causes_25\VBZ\1617192|that|also|increases (l_dobj) increases_26\NNS\13576355|bp (l_nmod) bp_28\NN\1740|in|and|injury (l_conj) injury_31\NN\14052046|renal
D013739_D007674 NONE testosterone_0\NN\14747587| (r_compound) replacement_1\NN\196485|testosterone|rats (r_nsubj) increased_6\VBD\169651|replacement|bp|. (l_dobj) bp_7\NN\1740|,|injury|,|and|upregulation (l_conj) injury_10\NN\14052046|renal
D013739_D007674 NONE testosterone_0\NN\14747587| (r_nsubj) contributes_1\VBZ\126264|testosterone|development|possibly|upregulation|. (l_nmod) development_4\NN\248977|to|the|hypertension (l_nmod) hypertension_6\NN\14057371|of|and|injury|rats (l_conj) injury_9\NN\14052046|renal
D000809_D006973 NONE renin-angiotensin_23\JJ\1740| (r_amod) system_24\NN\3575240|of|the|intrarenal|renin-angiotensin (r_nmod) upregulation_19\NN\1740|through|system (r_nmod) contributes_1\VBZ\126264|testosterone|development|possibly|upregulation|. (l_nmod) development_4\NN\248977|to|the|hypertension (l_nmod) hypertension_6\NN\14057371|of|and|injury|rats
D000809_D007674 NONE renin-angiotensin_23\JJ\1740| (r_amod) system_24\NN\3575240|of|the|intrarenal|renin-angiotensin (r_nmod) upregulation_19\NN\1740|through|system (r_nmod) contributes_1\VBZ\126264|testosterone|development|possibly|upregulation|. (l_nmod) development_4\NN\248977|to|the|hypertension (l_nmod) hypertension_6\NN\14057371|of|and|injury|rats (l_conj) injury_9\NN\14052046|renal
18410508
D008694_D020258 NONE methamphetamine-induced_0\JJ\1740| (r_amod) neurotoxicity_1\NN\1740|methamphetamine-induced|and|activation
D008694_D020258 NONE meth_6\NN\2704153|by|and|mptp (r_nmod) caused_4\VBN\1617192|meth (r_acl) damage_3\NN\7296428|the|cns|caused (r_nsubj) selective_11\JJ\1740|because|damage|is|highly|system (l_nmod) system_16\NN\3575240|for|the|da|neuronal|models (l_nmod) models_19\NNS\5888929|in|mouse|neurotoxicity (l_nmod) neurotoxicity_21\NN\1740|of
D008694_D020258 NONE meth_6\NN\2704153|by|and|mptp (r_nmod) caused_4\VBN\1617192|meth (r_acl) damage_3\NN\7296428|the|cns|caused (r_nsubj) selective_11\JJ\1740|because|damage|is|highly|system (r_advcl) hypothesized_24\VBD\719734|selective|,|we|plays|. (l_ccomp) plays_28\VBZ\1072262|that|cx3cr1|role|neurotoxicity (l_nmod) neurotoxicity_33\NN\1740|in|meth-induced|and|activation
D008694_D020258 NONE meth-induced_32\JJ\1740| (r_amod) neurotoxicity_33\NN\1740|in|meth-induced|and|activation (r_nmod) plays_28\VBZ\1072262|that|cx3cr1|role|neurotoxicity (r_ccomp) hypothesized_24\VBD\719734|selective|,|we|plays|. (l_advcl) selective_11\JJ\1740|because|damage|is|highly|system (l_nmod) system_16\NN\3575240|for|the|da|neuronal|models (l_nmod) models_19\NNS\5888929|in|mouse|neurotoxicity (l_nmod) neurotoxicity_21\NN\1740|of
D008694_D020258 NONE meth-induced_32\JJ\1740| (r_amod) neurotoxicity_33\NN\1740|in|meth-induced|and|activation
D008694_D020258 NONE meth_25\NN\2704153|with (r_nmod) treated_23\VBN\2376958|mice|were|meth|and|examined|. (l_conj) examined_27\VBN\789138|neurotoxicity (l_nmod) neurotoxicity_30\NN\1740|for|striatal
D008694_D020258 NONE meth_11\NN\2704153| (r_compound) neurotoxicity_12\NN\1740|meth|or|activation
D015632_D009422 CID mptp-induced_21\JJ\1740| (r_amod) neurodegeneration_22\NN\1740|of|mptp-induced|neurons
D015632_D009422 CID mptp_8\NNP\1740| (r_conj) meth_6\NN\2704153|by|and|mptp (r_nmod) caused_4\VBN\1617192|meth (r_acl) damage_3\NN\7296428|the|cns|caused
D004298_D009422 NONE da_24\NN\10484858| (r_compound) neurons_25\NNS\5430628|of|da (r_nmod) neurodegeneration_22\NN\1740|of|mptp-induced|neurons
D004298_D009422 NONE da_14\NN\10484858| (r_compound) system_16\NN\3575240|for|the|da|neuronal|models (r_nmod) selective_11\JJ\1740|because|damage|is|highly|system (l_nsubj) damage_3\NN\7296428|the|cns|caused
D008694_D009422 CID meth_6\NN\2704153|by|and|mptp (r_nmod) caused_4\VBN\1617192|meth (r_acl) damage_3\NN\7296428|the|cns|caused
D008694_D009422 CID meth-induced_32\JJ\1740| (r_amod) neurotoxicity_33\NN\1740|in|meth-induced|and|activation (r_nmod) plays_28\VBZ\1072262|that|cx3cr1|role|neurotoxicity (r_ccomp) hypothesized_24\VBD\719734|selective|,|we|plays|. (l_advcl) selective_11\JJ\1740|because|damage|is|highly|system (l_nsubj) damage_3\NN\7296428|the|cns|caused
D015632_D020258 NONE mptp_8\NNP\1740| (r_conj) meth_6\NN\2704153|by|and|mptp (r_nmod) caused_4\VBN\1617192|meth (r_acl) damage_3\NN\7296428|the|cns|caused (r_nsubj) selective_11\JJ\1740|because|damage|is|highly|system (l_nmod) system_16\NN\3575240|for|the|da|neuronal|models (l_nmod) models_19\NNS\5888929|in|mouse|neurotoxicity (l_nmod) neurotoxicity_21\NN\1740|of
D015632_D020258 NONE mptp_8\NNP\1740| (r_conj) meth_6\NN\2704153|by|and|mptp (r_nmod) caused_4\VBN\1617192|meth (r_acl) damage_3\NN\7296428|the|cns|caused (r_nsubj) selective_11\JJ\1740|because|damage|is|highly|system (r_advcl) hypothesized_24\VBD\719734|selective|,|we|plays|. (l_ccomp) plays_28\VBZ\1072262|that|cx3cr1|role|neurotoxicity (l_nmod) neurotoxicity_33\NN\1740|in|meth-induced|and|activation
D004298_D020258 NONE da_14\NN\10484858| (r_compound) system_16\NN\3575240|for|the|da|neuronal|models (l_nmod) models_19\NNS\5888929|in|mouse|neurotoxicity (l_nmod) neurotoxicity_21\NN\1740|of
D004298_D020258 NONE da_14\NN\10484858| (r_compound) system_16\NN\3575240|for|the|da|neuronal|models (r_nmod) selective_11\JJ\1740|because|damage|is|highly|system (r_advcl) hypothesized_24\VBD\719734|selective|,|we|plays|. (l_ccomp) plays_28\VBZ\1072262|that|cx3cr1|role|neurotoxicity (l_nmod) neurotoxicity_33\NN\1740|in|meth-induced|and|activation
10743446
D007649_D006930 NONE ketamine_5\NN\3054098|of|administered|and|lidocaine (r_nmod) effects_1\NNS\13245626|differential|ketamine|dynamic|induced|. (l_nmod) dynamic_9\JJ\1740|on|and|static|hyperalgesia (l_dep) hyperalgesia_12\NN\1740|
D007649_D006930 NONE ketamine_9\NN\3054098|of|and|lidocaine (r_nmod) administration_7\NN\1133281|of|systemic|ketamine (r_nmod) effect_4\NN\34213|the|administration|pain (l_nmod) pain_17\NN\14299637|on|brush-evoked|and|hyperalgesia|induced (l_conj) hyperalgesia_23\NN\1740|punctate-evoked|static|)
D007649_D006930 NONE ketamine_0\NNP\3054098| (r_nsubj) reduced_1\VBD\441445|ketamine|area|significantly|and|tended|. (l_dobj) area_4\NN\8630985|both|the|hyperalgesia (l_nmod) hyperalgesia_9\NN\1740|of|brush-evoked
D007649_D006930 NONE ketamine_4\NN\3054098|of|and|lidocaine (r_nmod) effects_2\NNS\13245626|the|differential|ketamine|static (l_nmod) static_8\JJ\1740|on|and|dynamic|hyperalgesia (l_dep) hyperalgesia_11\NN\1740|
D007649_D006930 NONE ketamine_4\NN\3054098|of|and|lidocaine (r_nmod) effects_2\NNS\13245626|the|differential|ketamine|static (r_nsubj) suggest_12\VBP\1010118|effects|mediated|. (l_ccomp) mediated_20\VBN\761713|that|types|are|mechanisms|and|have (l_nsubjpass) types_16\NNS\5839024|the|two|hyperalgesia (l_nmod) hyperalgesia_18\NN\1740|of
D008012_D006930 NONE lidocaine_7\NN\3681148| (r_conj) ketamine_5\NN\3054098|of|administered|and|lidocaine (r_nmod) effects_1\NNS\13245626|differential|ketamine|dynamic|induced|. (l_nmod) dynamic_9\JJ\1740|on|and|static|hyperalgesia (l_dep) hyperalgesia_12\NN\1740|
D008012_D006930 NONE lidocaine_11\NN\3681148| (r_conj) ketamine_9\NN\3054098|of|and|lidocaine (r_nmod) administration_7\NN\1133281|of|systemic|ketamine (r_nmod) effect_4\NN\34213|the|administration|pain (l_nmod) pain_17\NN\14299637|on|brush-evoked|and|hyperalgesia|induced (l_conj) hyperalgesia_23\NN\1740|punctate-evoked|static|)
D008012_D006930 NONE lidocaine_0\NN\3681148| (r_nsubj) reduced_1\VBD\441445|lidocaine|area|significantly|. (l_dobj) area_3\NN\8630985|the|hyperalgesia (l_nmod) hyperalgesia_6\NN\1740|of|punctate-evoked
D008012_D006930 NONE lidocaine_6\NN\3681148| (r_conj) ketamine_4\NN\3054098|of|and|lidocaine (r_nmod) effects_2\NNS\13245626|the|differential|ketamine|static (l_nmod) static_8\JJ\1740|on|and|dynamic|hyperalgesia (l_dep) hyperalgesia_11\NN\1740|
D008012_D006930 NONE lidocaine_6\NN\3681148| (r_conj) ketamine_4\NN\3054098|of|and|lidocaine (r_nmod) effects_2\NNS\13245626|the|differential|ketamine|static (r_nsubj) suggest_12\VBP\1010118|effects|mediated|. (l_ccomp) mediated_20\VBN\761713|that|types|are|mechanisms|and|have (l_nsubjpass) types_16\NNS\5839024|the|two|hyperalgesia (l_nmod) hyperalgesia_18\NN\1740|of
D002211_D006930 CID capsaicin_16\NN\15032661|by|intradermal (r_nmod) induced_13\VBN\1627355|capsaicin|humans (r_acl) effects_1\NNS\13245626|differential|ketamine|dynamic|induced|. (l_nmod) dynamic_9\JJ\1740|on|and|static|hyperalgesia (l_dep) hyperalgesia_12\NN\1740|
D002211_D006930 CID capsaicin_26\NN\15032661|by (r_nmod) induced_24\VBN\1627355|capsaicin (r_acl) pain_17\NN\14299637|on|brush-evoked|and|hyperalgesia|induced (l_conj) hyperalgesia_23\NN\1740|punctate-evoked|static|)
D007649_D010146 NONE ketamine_9\NN\3054098|of|and|lidocaine (r_nmod) administration_7\NN\1133281|of|systemic|ketamine (r_nmod) effect_4\NN\34213|the|administration|pain (l_nmod) pain_17\NN\14299637|on|brush-evoked|and|hyperalgesia|induced
D007649_D010146 NONE ketamine_0\NNP\3054098| (r_nsubj) reduced_1\VBD\441445|ketamine|area|significantly|and|tended|. (l_conj) tended_13\VBD\2604760|it|reduce (l_xcomp) reduce_15\VB\441445|to|pain (l_dobj) pain_17\NN\14299637|brush-evoked
D008012_D010146 NONE lidocaine_11\NN\3681148| (r_conj) ketamine_9\NN\3054098|of|and|lidocaine (r_nmod) administration_7\NN\1133281|of|systemic|ketamine (r_nmod) effect_4\NN\34213|the|administration|pain (l_nmod) pain_17\NN\14299637|on|brush-evoked|and|hyperalgesia|induced
D002211_D010146 CID capsaicin_26\NN\15032661|by (r_nmod) induced_24\VBN\1627355|capsaicin (r_acl) pain_17\NN\14299637|on|brush-evoked|and|hyperalgesia|induced
18442015
D014700_D006471 NONE verapamil_3\NN\2938514|of (r_nmod) effect_1\NN\34213|protective|verapamil|ulcers|. (l_nmod) ulcers_7\NNS\14211294|on|gastric|hemorrhagic|rats (l_amod) hemorrhagic_6\JJ\1740|
D014700_D006471 NONE verapamil_13\RB\1740|by|intragastric (r_nmod) ameliorated_9\VBN\126264|ulcer|were|dose-dependently|verapamil|. (l_nsubjpass) ulcer_2\NN\14211294|this|hemorrhagic|and|parameters (l_amod) hemorrhagic_1\JJ\1740|
D014700_D006471 NONE verapamil_26\NNS\2938514|by (r_nmod) ameliorated_24\VBN\126264|that|could|be|verapamil|rats (r_acl:relcl) permeability_20\NN\4940146|microvascular|ameliorated (r_conj) aggravation_7\NN\7518261|via|back-diffusion|,|generation|,|release|and|permeability (r_nmod) produce_2\VB\1617192|atherosclerosis|could|ulcer|aggravation|. (l_dobj) ulcer_5\NN\14211294|gastric|hemorrhagic (l_amod) hemorrhagic_4\JJ\1740|
D014700_D014456 NONE verapamil_3\NN\2938514|of (r_nmod) effect_1\NN\34213|protective|verapamil|ulcers|. (l_nmod) ulcers_7\NNS\14211294|on|gastric|hemorrhagic|rats
D014700_D014456 NONE verapamil_6\NN\2938514|of (r_nmod) effect_4\NN\34213|the|protective|verapamil|model (l_nmod) model_10\NN\5888929|on|this|ulcer (l_compound) ulcer_9\NN\14211294|
D014700_D014456 NONE verapamil_13\RB\1740|by|intragastric (r_nmod) ameliorated_9\VBN\126264|ulcer|were|dose-dependently|verapamil|. (l_nsubjpass) ulcer_2\NN\14211294|this|hemorrhagic|and|parameters
D014700_D014456 NONE verapamil_26\NNS\2938514|by (r_nmod) ameliorated_24\VBN\126264|that|could|be|verapamil|rats (r_acl:relcl) permeability_20\NN\4940146|microvascular|ameliorated (r_conj) aggravation_7\NN\7518261|via|back-diffusion|,|generation|,|release|and|permeability (r_nmod) produce_2\VB\1617192|atherosclerosis|could|ulcer|aggravation|. (l_dobj) ulcer_5\NN\14211294|gastric|hemorrhagic
D014700_D050197 NONE verapamil_3\NN\2938514|of (r_nmod) effect_1\NN\34213|protective|verapamil|ulcers|. (l_nmod) ulcers_7\NNS\14211294|on|gastric|hemorrhagic|rats (l_nmod) rats_11\NNS\2329401|in|severe|atherosclerotic (l_amod) atherosclerotic_10\JJ\1740|
D014700_D050197 NONE verapamil_26\NNS\2938514|by (r_nmod) ameliorated_24\VBN\126264|that|could|be|verapamil|rats (r_acl:relcl) permeability_20\NN\4940146|microvascular|ameliorated (r_conj) aggravation_7\NN\7518261|via|back-diffusion|,|generation|,|release|and|permeability (r_nmod) produce_2\VB\1617192|atherosclerosis|could|ulcer|aggravation|. (l_nsubj) atherosclerosis_0\NN\14108324|
D006632_D006471 NONE histamine_17\NN\14739004| (r_compound) release_18\NN\3748886|mast|cell|histamine|, (r_conj) role_9\NN\719494|the|back-diffusion|,|release|generation (r_dobj) examine_7\VB\789138|to|role|modulating (l_advcl) modulating_31\VBG\1724459|in|hemorrhage (l_dobj) hemorrhage_33\NN\14285662|gastric|and|ulcer
D006632_D006471 NONE histamine_6\NN\14739004|of (r_nmod) correlation_4\NN\13841213|a|positive|histamine|hemorrhage|and|ulcer (l_nmod) hemorrhage_9\NN\14285662|to|gastric
D006632_D006471 NONE histamine_16\NN\14739004| (r_compound) release_17\NN\3748886|histamine (r_conj) aggravation_7\NN\7518261|via|back-diffusion|,|generation|,|release|and|permeability (r_nmod) produce_2\VB\1617192|atherosclerosis|could|ulcer|aggravation|. (l_dobj) ulcer_5\NN\14211294|gastric|hemorrhagic (l_amod) hemorrhagic_4\JJ\1740|
D006632_D014456 NONE histamine_17\NN\14739004| (r_compound) release_18\NN\3748886|mast|cell|histamine|, (r_conj) role_9\NN\719494|the|back-diffusion|,|release|generation (r_dobj) examine_7\VB\789138|to|role|modulating (l_advcl) modulating_31\VBG\1724459|in|hemorrhage (l_dobj) hemorrhage_33\NN\14285662|gastric|and|ulcer (l_conj) ulcer_35\NN\14211294|rats
D006632_D014456 NONE histamine_8\NN\14739004| (r_compound) concentration_9\NN\4916342|histamine (r_conj) back-diffusion_2\NN\1740|gastric|acid|,|generation|,|concentration|,|permeability (l_conj) permeability_12\NN\4940146|microvascular|,|content|areas (l_conj) areas_19\NNS\8630985|ulcer (l_compound) ulcer_18\NN\14211294|
D006632_D014456 NONE histamine_14\NN\14739004| (r_compound) release_15\NN\3748886|histamine (r_conj) back-diffusion_12\NN\1740|including|gastric|acid|,|release|,|generation|and|content (r_nmod) factors_7\NNS\7326557|with|increased|ulcerogenic|,|back-diffusion (r_nmod) accompanied_3\VBN\1835496|factors (r_acl) ulcers_2\NNS\14211294|gastric|accompanied
D006632_D014456 NONE histamine_6\NN\14739004|of (r_nmod) correlation_4\NN\13841213|a|positive|histamine|hemorrhage|and|ulcer (l_conj) ulcer_12\NN\14211294|to
D006632_D014456 NONE histamine_16\NN\14739004| (r_compound) release_17\NN\3748886|histamine (r_conj) aggravation_7\NN\7518261|via|back-diffusion|,|generation|,|release|and|permeability (r_nmod) produce_2\VB\1617192|atherosclerosis|could|ulcer|aggravation|. (l_dobj) ulcer_5\NN\14211294|gastric|hemorrhagic
D006632_D050197 NONE histamine_17\NN\14739004| (r_compound) release_18\NN\3748886|mast|cell|histamine|, (r_conj) role_9\NN\719494|the|back-diffusion|,|release|generation (r_dobj) examine_7\VB\789138|to|role|modulating (l_advcl) modulating_31\VBG\1724459|in|hemorrhage (l_dobj) hemorrhage_33\NN\14285662|gastric|and|ulcer (l_conj) ulcer_35\NN\14211294|rats (l_nmod) rats_37\NNS\2329401|in|atherosclerosis (l_nmod) atherosclerosis_39\NN\14108324|with|induced
D006632_D050197 NONE histamine_6\NN\14739004|of (r_nmod) correlation_4\NN\13841213|a|positive|histamine|hemorrhage|and|ulcer (r_nsubjpass) found_14\VBN\2426171|moreover|,|correlation|was|rats|. (l_nmod) rats_18\NNS\2329401|in|those|atherosclerotic (l_amod) atherosclerotic_17\JJ\1740|
D006632_D050197 NONE histamine_16\NN\14739004| (r_compound) release_17\NN\3748886|histamine (r_conj) aggravation_7\NN\7518261|via|back-diffusion|,|generation|,|release|and|permeability (r_nmod) produce_2\VB\1617192|atherosclerosis|could|ulcer|aggravation|. (l_nsubj) atherosclerosis_0\NN\14108324|
D004872_D006471 CID d2_45\NN\1740|of|vitamin|and|cholesterol (r_nmod) coadministration_42\NN\1740|by|d2 (r_nmod) induced_40\VBN\1627355|coadministration (r_acl) atherosclerosis_39\NN\14108324|with|induced (r_nmod) rats_37\NNS\2329401|in|atherosclerosis (r_nmod) ulcer_35\NN\14211294|rats (r_conj) hemorrhage_33\NN\14285662|gastric|and|ulcer
D004872_D014456 CID d2_45\NN\1740|of|vitamin|and|cholesterol (r_nmod) coadministration_42\NN\1740|by|d2 (r_nmod) induced_40\VBN\1627355|coadministration (r_acl) atherosclerosis_39\NN\14108324|with|induced (r_nmod) rats_37\NNS\2329401|in|atherosclerosis (r_nmod) ulcer_35\NN\14211294|rats
D004872_D050197 CID d2_45\NN\1740|of|vitamin|and|cholesterol (r_nmod) coadministration_42\NN\1740|by|d2 (r_nmod) induced_40\VBN\1627355|coadministration (r_acl) atherosclerosis_39\NN\14108324|with|induced
D004872_D050197 CID d2_19\NN\1740|vitamin|and|cholesterol (r_dobj) containing_17\VBG\2632940|d2 (r_acl) oil_16\NN\14938907|of|corn|containing (r_nmod) ml/kg_13\NN\1740|with|1.0|oil (r_nmod) days_10\NNS\15140892|for|9|ml/kg (r_nmod) challenged_4\VBN\869596|rats|were|intragastrically|daily|days|induce|. (l_xcomp) induce_23\VB\1627355|to|atherosclerosis (l_dobj) atherosclerosis_24\NN\14108324|
D002784_D006471 CID cholesterol_47\NN\15058310| (r_conj) d2_45\NN\1740|of|vitamin|and|cholesterol (r_nmod) coadministration_42\NN\1740|by|d2 (r_nmod) induced_40\VBN\1627355|coadministration (r_acl) atherosclerosis_39\NN\14108324|with|induced (r_nmod) rats_37\NNS\2329401|in|atherosclerosis (r_nmod) ulcer_35\NN\14211294|rats (r_conj) hemorrhage_33\NN\14285662|gastric|and|ulcer
D002784_D014456 CID cholesterol_47\NN\15058310| (r_conj) d2_45\NN\1740|of|vitamin|and|cholesterol (r_nmod) coadministration_42\NN\1740|by|d2 (r_nmod) induced_40\VBN\1627355|coadministration (r_acl) atherosclerosis_39\NN\14108324|with|induced (r_nmod) rats_37\NNS\2329401|in|atherosclerosis (r_nmod) ulcer_35\NN\14211294|rats
D002784_D050197 CID cholesterol_47\NN\15058310| (r_conj) d2_45\NN\1740|of|vitamin|and|cholesterol (r_nmod) coadministration_42\NN\1740|by|d2 (r_nmod) induced_40\VBN\1627355|coadministration (r_acl) atherosclerosis_39\NN\14108324|with|induced
D002784_D050197 CID cholesterol_21\NN\15058310| (r_conj) d2_19\NN\1740|vitamin|and|cholesterol (r_dobj) containing_17\VBG\2632940|d2 (r_acl) oil_16\NN\14938907|of|corn|containing (r_nmod) ml/kg_13\NN\1740|with|1.0|oil (r_nmod) days_10\NNS\15140892|for|9|ml/kg (r_nmod) challenged_4\VBN\869596|rats|were|intragastrically|daily|days|induce|. (l_xcomp) induce_23\VB\1627355|to|atherosclerosis (l_dobj) atherosclerosis_24\NN\14108324|
D002784_D050197 CID cholesterol_10\NN\15058310|total (r_conj) calcium_7\NN\14625458|such|serum|,|cholesterol|and|concentration (r_nmod) parameters_2\NNS\5858936|elevated|atherosclerotic|,|calcium (l_amod) atherosclerotic_1\JJ\1740|
D002784_D050197 CID cholesterol_10\NN\15058310|total (r_conj) calcium_7\NN\14625458|such|serum|,|cholesterol|and|concentration (r_nmod) parameters_2\NNS\5858936|elevated|atherosclerotic|,|calcium (r_nsubjpass) obtained_16\VBN\2210855|parameters|were|rats|. (l_nmod) rats_19\NNS\2329401|in|atherosclerotic (l_amod) atherosclerotic_18\JJ\1740|
D010634_D014456 NONE luminal_14\JJ\1740| (r_amod) content_16\NN\7951464|luminal|hemoglobin|and (r_conj) permeability_12\NN\4940146|microvascular|,|content|areas (l_conj) areas_19\NNS\8630985|ulcer (l_compound) ulcer_18\NN\14211294|
D010634_D014456 NONE luminal_20\JJ\1740| (r_amod) content_22\NN\7951464|luminal|hemoglobin (r_conj) back-diffusion_12\NN\1740|including|gastric|acid|,|release|,|generation|and|content (r_nmod) factors_7\NNS\7326557|with|increased|ulcerogenic|,|back-diffusion (r_nmod) accompanied_3\VBN\1835496|factors (r_acl) ulcers_2\NNS\14211294|gastric|accompanied
D002118_D050197 NONE calcium_7\NN\14625458|such|serum|,|cholesterol|and|concentration (r_nmod) parameters_2\NNS\5858936|elevated|atherosclerotic|,|calcium (l_amod) atherosclerotic_1\JJ\1740|
D002118_D050197 NONE calcium_7\NN\14625458|such|serum|,|cholesterol|and|concentration (r_nmod) parameters_2\NNS\5858936|elevated|atherosclerotic|,|calcium (r_nsubjpass) obtained_16\VBN\2210855|parameters|were|rats|. (l_nmod) rats_19\NNS\2329401|in|atherosclerotic (l_amod) atherosclerotic_18\JJ\1740|
6286738
D002762_D064420 NONE d3_1\NN\1740| (r_compound) toxicity_2\NN\13576101|vitamin|d3|cows|.
D002762_D064420 NONE d3_3\NN\1740| (r_compound) toxicity_4\NN\13576101|of|vitamin|d3
D002762_D064420 NONE d3_3\NN\1740| (r_compound) toxicity_4\NN\13576101|of|vitamin|d3 (r_nmod) signs_0\NNS\6643763|toxicity (r_nsubjpass) observed_7\VBN\2163746|signs|were|not|nonlactating|;|developed|died|. (l_parataxis) developed_18\VBD\1753788|however|,|cows|commonly|signs (l_dobj) signs_20\NNS\6643763|severe|toxicity|and (l_nmod) toxicity_24\NN\13576101|of|vitamin|d3
D002762_D064420 NONE d3_23\NN\1740| (r_compound) toxicity_24\NN\13576101|of|vitamin|d3 (r_nmod) signs_20\NNS\6643763|severe|toxicity|and (r_dobj) developed_18\VBD\1753788|however|,|cows|commonly|signs (r_parataxis) observed_7\VBN\2163746|signs|were|not|nonlactating|;|developed|died|. (l_nsubjpass) signs_0\NNS\6643763|toxicity (l_nmod) toxicity_4\NN\13576101|of|vitamin|d3
D002762_D064420 NONE d3_23\NN\1740| (r_compound) toxicity_24\NN\13576101|of|vitamin|d3
D002762_D064420 NONE d3_7\NN\1740|of|vitamin (r_nmod) toxicity_4\NN\13576101|because|the|extreme|d3|cows
D002762_D064420 NONE d3_22\NN\1740|of|vitamin (r_nmod) doses_19\NNS\3740161|between|d3|prevent (r_nmod) margin_15\NN\13903079|the|low|safety|doses (r_conj) cows_11\VBZ\1779644|jersey|and|margin (r_nmod) toxicity_4\NN\13576101|because|the|extreme|d3|cows
D002762_D064420 NONE d3_38\NN\1740|vitamin (r_nsubjpass) used_42\VBN\1156834|that|d3|can|not|be|practically|prevent (r_ccomp) concluded_35\VBD\628491|toxicity|,|we|used|prepartum|. (l_nmod) toxicity_4\NN\13576101|because|the|extreme|d3|cows
D002762_D006934 CID d3_5\NN\1740|of|vitamin (r_nmod) doses_2\NNS\3740161|large|parenteral|d3|d3 (r_nsubjpass) associated_18\VBN\628491|doses|were|hypercalcemia|cows|. (l_nmod) hypercalcemia_21\NN\14299637|with|prolonged|,|hyperphosphatemia|,|and|increases|and|metabolites
D002762_D006934 CID d3_15\NN\1740|(|17.5|)|iu|vitamin|) (r_appos) doses_2\NNS\3740161|large|parenteral|d3|d3 (r_nsubjpass) associated_18\VBN\628491|doses|were|hypercalcemia|cows|. (l_nmod) hypercalcemia_21\NN\14299637|with|prolonged|,|hyperphosphatemia|,|and|increases|and|metabolites
D002762_D006934 CID d3_30\NN\1740|of|vitamin (r_nmod) increases_27\NNS\13576355|large|d3 (r_conj) hypercalcemia_21\NN\14299637|with|prolonged|,|hyperphosphatemia|,|and|increases|and|metabolites
D002762_D054559 CID d3_5\NN\1740|of|vitamin (r_nmod) doses_2\NNS\3740161|large|parenteral|d3|d3 (r_nsubjpass) associated_18\VBN\628491|doses|were|hypercalcemia|cows|. (l_nmod) hypercalcemia_21\NN\14299637|with|prolonged|,|hyperphosphatemia|,|and|increases|and|metabolites (l_conj) hyperphosphatemia_23\NN\1740|
D002762_D054559 CID d3_15\NN\1740|(|17.5|)|iu|vitamin|) (r_appos) doses_2\NNS\3740161|large|parenteral|d3|d3 (r_nsubjpass) associated_18\VBN\628491|doses|were|hypercalcemia|cows|. (l_nmod) hypercalcemia_21\NN\14299637|with|prolonged|,|hyperphosphatemia|,|and|increases|and|metabolites (l_conj) hyperphosphatemia_23\NN\1740|
D002762_D054559 CID d3_30\NN\1740|of|vitamin (r_nmod) increases_27\NNS\13576355|large|d3 (r_conj) hypercalcemia_21\NN\14299637|with|prolonged|,|hyperphosphatemia|,|and|increases|and|metabolites (l_conj) hyperphosphatemia_23\NN\1740|
D002762_D010319 NONE d3_7\NN\1740|with|vitamin (r_nmod) treated_4\VBN\2376958|d3 (r_acl) cows_3\NNS\2402010|of|the|treated (r_nmod) none_0\NN\15228378|cows (r_nsubj) showed_8\VBD\2137132|none|signs|period|;|however (l_dobj) signs_9\NNS\6643763|fever (l_nmod) fever_12\NN\14299637|of|milk
D002762_D010319 NONE d3_7\NN\1740|with|vitamin (r_nmod) treated_4\VBN\2376958|d3 (r_acl) cows_3\NNS\2402010|of|the|treated (r_nmod) none_0\NN\15228378|cows (r_nsubj) showed_8\VBD\2137132|none|signs|period|;|however (r_ccomp) cows_25\NNS\2402010|showed|,|% (r_nsubj) developed_26\VBD\1753788|cows|signs|period|. (l_dobj) signs_28\NNS\6643763|clinical|fever (l_nmod) fever_31\NN\14299637|of|milk
D002762_D010319 NONE d3_7\NN\1740|of|vitamin (r_nmod) toxicity_4\NN\13576101|because|the|extreme|d3|cows (l_nmod) cows_11\VBZ\1779644|jersey|and|margin (l_conj) margin_15\NN\13903079|the|low|safety|doses (l_nmod) doses_19\NNS\3740161|between|d3|prevent (l_acl:relcl) prevent_24\VBP\1740|that|fever|and|doses (l_dobj) fever_26\NN\14299637|milk
D002762_D010319 NONE d3_7\NN\1740|of|vitamin (r_nmod) toxicity_4\NN\13576101|because|the|extreme|d3|cows (l_nmod) cows_11\VBZ\1779644|jersey|and|margin (l_conj) margin_15\NN\13903079|the|low|safety|doses (l_nmod) doses_19\NNS\3740161|between|d3|prevent (l_acl:relcl) prevent_24\VBP\1740|that|fever|and|doses (l_conj) doses_28\NNS\3740161|induce (l_acl:relcl) induce_30\VBP\1627355|that|fever (l_dobj) fever_32\NN\14299637|milk
D002762_D010319 NONE d3_7\NN\1740|of|vitamin (r_nmod) toxicity_4\NN\13576101|because|the|extreme|d3|cows (r_nmod) concluded_35\VBD\628491|toxicity|,|we|used|prepartum|. (l_ccomp) used_42\VBN\1156834|that|d3|can|not|be|practically|prevent (l_xcomp) prevent_45\VB\1740|to|fever (l_dobj) fever_47\NN\14299637|milk
D002762_D010319 NONE d3_22\NN\1740|of|vitamin (r_nmod) doses_19\NNS\3740161|between|d3|prevent (l_acl:relcl) prevent_24\VBP\1740|that|fever|and|doses (l_dobj) fever_26\NN\14299637|milk
D002762_D010319 NONE d3_22\NN\1740|of|vitamin (r_nmod) doses_19\NNS\3740161|between|d3|prevent (l_acl:relcl) prevent_24\VBP\1740|that|fever|and|doses (l_conj) doses_28\NNS\3740161|induce (l_acl:relcl) induce_30\VBP\1627355|that|fever (l_dobj) fever_32\NN\14299637|milk
D002762_D010319 NONE d3_22\NN\1740|of|vitamin (r_nmod) doses_19\NNS\3740161|between|d3|prevent (r_nmod) margin_15\NN\13903079|the|low|safety|doses (r_conj) cows_11\VBZ\1779644|jersey|and|margin (r_nmod) toxicity_4\NN\13576101|because|the|extreme|d3|cows (r_nmod) concluded_35\VBD\628491|toxicity|,|we|used|prepartum|. (l_ccomp) used_42\VBN\1156834|that|d3|can|not|be|practically|prevent (l_xcomp) prevent_45\VB\1740|to|fever (l_dobj) fever_47\NN\14299637|milk
D002762_D010319 NONE d3_38\NN\1740|vitamin (r_nsubjpass) used_42\VBN\1156834|that|d3|can|not|be|practically|prevent (r_ccomp) concluded_35\VBD\628491|toxicity|,|we|used|prepartum|. (l_nmod) toxicity_4\NN\13576101|because|the|extreme|d3|cows (l_nmod) cows_11\VBZ\1779644|jersey|and|margin (l_conj) margin_15\NN\13903079|the|low|safety|doses (l_nmod) doses_19\NNS\3740161|between|d3|prevent (l_acl:relcl) prevent_24\VBP\1740|that|fever|and|doses (l_dobj) fever_26\NN\14299637|milk
D002762_D010319 NONE d3_38\NN\1740|vitamin (r_nsubjpass) used_42\VBN\1156834|that|d3|can|not|be|practically|prevent (r_ccomp) concluded_35\VBD\628491|toxicity|,|we|used|prepartum|. (l_nmod) toxicity_4\NN\13576101|because|the|extreme|d3|cows (l_nmod) cows_11\VBZ\1779644|jersey|and|margin (l_conj) margin_15\NN\13903079|the|low|safety|doses (l_nmod) doses_19\NNS\3740161|between|d3|prevent (l_acl:relcl) prevent_24\VBP\1740|that|fever|and|doses (l_conj) doses_28\NNS\3740161|induce (l_acl:relcl) induce_30\VBP\1627355|that|fever (l_dobj) fever_32\NN\14299637|milk
D002762_D010319 NONE d3_38\NN\1740|vitamin (r_nsubjpass) used_42\VBN\1156834|that|d3|can|not|be|practically|prevent (l_xcomp) prevent_45\VB\1740|to|fever (l_dobj) fever_47\NN\14299637|milk
603022
D005702_D062787 NONE hydrobromide_1\NN\1740|galanthamine|,|drug|, (r_nsubjpass) used_14\VBN\1156834|hydrobromide|was|patient|. (l_nmod) patient_17\NN\9898892|in|a|demonstrating (l_acl) demonstrating_18\VBG\2137132|effects (l_dobj) effects_20\NNS\13245626|central|overdosage (l_nmod) overdosage_26\NN\1740|of|scopolamine|hyoscine|)
D012601_D062787 CID scopolamine_22\NN\14712692| (r_compound) overdosage_26\NN\1740|of|scopolamine|hyoscine|)
D012601_D062787 CID hyoscine_24\NN\14712692|( (r_compound) overdosage_26\NN\1740|of|scopolamine|hyoscine|)
1601297
D003042_D009202 NONE cocaine_8\NN\3492717| (r_compound) abusers_9\NNS\9633969|in|hospitalized|cocaine (r_nmod) injury_4\NN\14052046|of|myocardial|abusers
D003042_D009202 NONE cocaine_3\NN\3492717| (r_compound) abusers_4\NNS\9633969|of|the|cocaine (r_nmod) eleven_0\CD\13745420|abusers|and|none (r_nsubj) had_10\VBD\2108377|eleven|evidence|and|bundle|. (l_dobj) evidence_12\NN\5816287|ecg|injury (l_nmod) injury_16\NN\14052046|of|significant|myocardial|defined
D003042_D012559 NONE cocaine-abusing_7\JJ\1740| (r_amod) patients_8\NNS\9898892|of|99|cocaine-abusing (r_nmod) electrocardiograms_1\NNS\7000195|the|ecg|patients (r_nsubjpass) compared_10\VBN\644583|electrocardiograms|were|ecgs|. (l_nmod) ecgs_13\NNS\7000195|with|the|controls (l_nmod) controls_17\NNS\5190804|of|50|schizophrenic (l_amod) schizophrenic_16\JJ\1740|
D003042_D009203 CID cocaine_3\NN\3492717| (r_compound) abusers_4\NNS\9633969|of|the|cocaine (r_nmod) eleven_0\CD\13745420|abusers|and|none (r_nsubj) had_10\VBD\2108377|eleven|evidence|and|bundle|. (l_dobj) evidence_12\NN\5816287|ecg|injury (l_nmod) injury_16\NN\14052046|of|significant|myocardial|defined (l_acl) defined_17\VBN\2604760|infarction (l_nmod) infarction_20\NN\14204950|as|myocardial|,|ischemia|,
D003042_D007511 NONE cocaine_3\NN\3492717| (r_compound) abusers_4\NNS\9633969|of|the|cocaine (r_nmod) eleven_0\CD\13745420|abusers|and|none (r_nsubj) had_10\VBD\2108377|eleven|evidence|and|bundle|. (l_dobj) evidence_12\NN\5816287|ecg|injury (l_nmod) injury_16\NN\14052046|of|significant|myocardial|defined (l_acl) defined_17\VBN\2604760|infarction (l_nmod) infarction_20\NN\14204950|as|myocardial|,|ischemia|, (l_conj) ischemia_22\NN\14195315|
D003042_D002037 CID cocaine_3\NN\3492717| (r_compound) abusers_4\NNS\9633969|of|the|cocaine (r_nmod) eleven_0\CD\13745420|abusers|and|none (r_nsubj) had_10\VBD\2108377|eleven|evidence|and|bundle|. (l_conj) bundle_25\VBP\1482449|block (l_dobj) block_27\NN\21939|branch
8643971
D017239_D006258 NONE paclitaxel_5\NN\1740|of|plus|cisplatin (r_nmod) study_3\NN\635850|a|phase|i/ii|paclitaxel|therapy|:|results|. (l_nmod) therapy_10\NN\657604|as|first-line|head (l_nmod) head_12\NN\5225090|for|and|neck|cancers (l_dep) cancers_15\NNS\14239425|
D017239_D006258 NONE paclitaxel_11\NN\1740|of|single-agent (r_nmod) study_8\NN\635850|of|an|group|paclitaxel|company (r_nmod) results_1\NNS\34213|preliminary|study (r_nsubj) reported_23\VBD\831651|results|rate|,|and|used|. (l_dobj) rate_28\NN\13815152|a|%|response|patients (l_nmod) patients_30\NNS\9898892|in|head (l_nmod) head_32\NN\5225090|with|and|cancer (l_conj) cancer_35\NN\14239425|neck
D017239_D006258 NONE taxol_13\NN\1740| (r_compound) company_17\NNP\8053576|(|taxol|;|bristol-myers|squibb|,|princeton|) (r_dep) study_8\NN\635850|of|an|group|paclitaxel|company (r_nmod) results_1\NNS\34213|preliminary|study (r_nsubj) reported_23\VBD\831651|results|rate|,|and|used|. (l_dobj) rate_28\NN\13815152|a|%|response|patients (l_nmod) patients_30\NNS\9898892|in|head (l_nmod) head_32\NN\5225090|with|and|cancer (l_conj) cancer_35\NN\14239425|neck
D017239_D006258 NONE paclitaxel/cisplatin_39\NN\1740| (r_compound) combination_40\NN\7951464|the|paclitaxel/cisplatin (r_nsubjpass) used_43\VBN\1156834|combination|has|been|successfully|and|improved (r_conj) reported_23\VBD\831651|results|rate|,|and|used|. (l_dobj) rate_28\NN\13815152|a|%|response|patients (l_nmod) patients_30\NNS\9898892|in|head (l_nmod) head_32\NN\5225090|with|and|cancer (l_conj) cancer_35\NN\14239425|neck
D017239_D006258 NONE paclitaxel_14\NN\1740| (r_compound) doses_15\NNS\3740161|paclitaxel (r_dobj) escalating_13\VBG\153263|of|doses (r_advcl) response_9\NN\11410625|the|and|toxicity|escalating|combined (l_acl) combined_16\VBN\2630189|cisplatin|support (l_nmod) support_24\NN\407535|with|granulocyte|colony-stimulating|factor|patients (l_nmod) patients_26\NNS\9898892|in|head (l_nmod) head_32\NN\5225090|with|untreated|advanced|inoperable|and|carcinoma (l_conj) carcinoma_35\NN\14239918|neck
D017239_D006258 NONE paclitaxel/cisplatin_0\NN\1740| (r_nsubj) regimen_5\NN\5898568|paclitaxel/cisplatin|is|an|effective|first-line|head|warranted (l_nmod) head_9\NN\5225090|for|advanced|and|cancer (l_conj) cancer_12\NN\14239425|neck|and
D002945_D006258 NONE cisplatin_7\NN\1740| (r_conj) paclitaxel_5\NN\1740|of|plus|cisplatin (r_nmod) study_3\NN\635850|a|phase|i/ii|paclitaxel|therapy|:|results|. (l_nmod) therapy_10\NN\657604|as|first-line|head (l_nmod) head_12\NN\5225090|for|and|neck|cancers (l_dep) cancers_15\NNS\14239425|
D002945_D006258 NONE paclitaxel/cisplatin_39\NN\1740| (r_compound) combination_40\NN\7951464|the|paclitaxel/cisplatin (r_nsubjpass) used_43\VBN\1156834|combination|has|been|successfully|and|improved (r_conj) reported_23\VBD\831651|results|rate|,|and|used|. (l_dobj) rate_28\NN\13815152|a|%|response|patients (l_nmod) patients_30\NNS\9898892|in|head (l_nmod) head_32\NN\5225090|with|and|cancer (l_conj) cancer_35\NN\14239425|neck
D002945_D006258 NONE cisplatin_19\NN\1740|with|fixed-dose (r_nmod) combined_16\VBN\2630189|cisplatin|support (l_nmod) support_24\NN\407535|with|granulocyte|colony-stimulating|factor|patients (l_nmod) patients_26\NNS\9898892|in|head (l_nmod) head_32\NN\5225090|with|untreated|advanced|inoperable|and|carcinoma (l_conj) carcinoma_35\NN\14239918|neck
D002945_D006258 NONE paclitaxel/cisplatin_0\NN\1740| (r_nsubj) regimen_5\NN\5898568|paclitaxel/cisplatin|is|an|effective|first-line|head|warranted (l_nmod) head_9\NN\5225090|for|advanced|and|cancer (l_conj) cancer_12\NN\14239425|neck|and
D017239_D010051 NONE paclitaxel_11\NN\1740|of|single-agent (r_nmod) study_8\NN\635850|of|an|group|paclitaxel|company (r_nmod) results_1\NNS\34213|preliminary|study (r_nsubj) reported_23\VBD\831651|results|rate|,|and|used|. (l_conj) used_43\VBN\1156834|combination|has|been|successfully|and|improved (l_conj) improved_48\VBN\126264|has|significantly|duration (l_dobj) duration_51\NN\15113229|median|response|patients (l_nmod) patients_55\NNS\9898892|in|ovarian|cancer (l_compound) cancer_54\NN\14239425|
D017239_D010051 NONE taxol_13\NN\1740| (r_compound) company_17\NNP\8053576|(|taxol|;|bristol-myers|squibb|,|princeton|) (r_dep) study_8\NN\635850|of|an|group|paclitaxel|company (r_nmod) results_1\NNS\34213|preliminary|study (r_nsubj) reported_23\VBD\831651|results|rate|,|and|used|. (l_conj) used_43\VBN\1156834|combination|has|been|successfully|and|improved (l_conj) improved_48\VBN\126264|has|significantly|duration (l_dobj) duration_51\NN\15113229|median|response|patients (l_nmod) patients_55\NNS\9898892|in|ovarian|cancer (l_compound) cancer_54\NN\14239425|
D017239_D010051 NONE paclitaxel/cisplatin_39\NN\1740| (r_compound) combination_40\NN\7951464|the|paclitaxel/cisplatin (r_nsubjpass) used_43\VBN\1156834|combination|has|been|successfully|and|improved (l_conj) improved_48\VBN\126264|has|significantly|duration (l_dobj) duration_51\NN\15113229|median|response|patients (l_nmod) patients_55\NNS\9898892|in|ovarian|cancer (l_compound) cancer_54\NN\14239425|
D002945_D010051 NONE paclitaxel/cisplatin_39\NN\1740| (r_compound) combination_40\NN\7951464|the|paclitaxel/cisplatin (r_nsubjpass) used_43\VBN\1156834|combination|has|been|successfully|and|improved (l_conj) improved_48\VBN\126264|has|significantly|duration (l_dobj) duration_51\NN\15113229|median|response|patients (l_nmod) patients_55\NNS\9898892|in|ovarian|cancer (l_compound) cancer_54\NN\14239425|
D017239_D064420 NONE paclitaxel_14\NN\1740| (r_compound) doses_15\NNS\3740161|paclitaxel (r_dobj) escalating_13\VBG\153263|of|doses (r_advcl) response_9\NN\11410625|the|and|toxicity|escalating|combined (l_conj) toxicity_11\NN\13576101|
D017239_D064420 NONE paclitaxel_5\NN\1740| (r_compound) doses_6\NNS\3740161|paclitaxel (r_dobj) escalating_4\VBG\153263|doses (r_xcomp) incorporate_3\VBP\1461328|levels|escalating|,|and|intrapatient|permitted|. (l_conj) permitted_17\VBN\797697|are|permits (l_ccomp) permits_20\NNS\6479665|if|toxicity (l_compound) toxicity_19\NN\13576101|
D002945_D064420 NONE cisplatin_19\NN\1740|with|fixed-dose (r_nmod) combined_16\VBN\2630189|cisplatin|support (r_acl) response_9\NN\11410625|the|and|toxicity|escalating|combined (l_conj) toxicity_11\NN\13576101|
9523805
D011318_D009422 CID prilocaine_11\NN\1740|with|and|bupivacaine (r_nmod) incidence_9\NN\13821570|a|lower|prilocaine|than (r_dep) symptoms_2\NNS\5823932|neurologic|anesthesia|:|incidence|.
D011318_D009422 CID prilocaine_9\NN\1740| (r_dobj) compares_8\VBZ\644583|accordingly|,|present|prilocaine|lidocaine|and|bupivacaine|. (l_conj) bupivacaine_13\VB\1740|respect (l_nmod) respect_15\NN\5817845|with|duration (l_nmod) duration_17\NN\15113229|to|action (l_nmod) action_19\NN\30358|of|and|risk|tnss (l_nmod) tnss_24\NNS\1740|of
D011318_D009422 CID prilocaine_16\NN\1740| (r_dobj) receiving_15\VBG\2210855|prilocaine (r_acl) patients_14\NNS\9898892|30|receiving|= (r_nmod) nine_2\CD\13741022|patients|patients (l_nmod) patients_5\NNS\9898892|of|30|receiving (l_acl) receiving_6\VBG\2210855|tnss (l_dobj) tnss_9\NNS\1740|lidocaine|experienced|,
D011318_D009422 CID prilocaine_16\NN\1740| (r_dobj) receiving_15\VBG\2210855|prilocaine (r_acl) patients_14\NNS\9898892|30|receiving|= (r_nmod) nine_2\CD\13741022|patients|patients (r_nsubj) had_22\VBD\2108377|nine|them|,|and|had (l_conj) had_32\VBD\2108377|none|tnss (l_dobj) tnss_33\NNS\1740|
D011318_D009422 CID prilocaine_2\NN\1740| (r_nsubj) preferable_5\JJ\1740|prilocaine|may|be|lidocaine|has (l_advcl) has_14\VBZ\2108377|because|it|duration (l_dobj) duration_17\NN\15113229|a|similar|action|but|incidence (l_conj) incidence_23\NN\13821570|a|lower|tnss (l_nmod) tnss_25\NNS\1740|of
D002045_D009422 NONE bupivacaine_13\NN\1740| (r_conj) prilocaine_11\NN\1740|with|and|bupivacaine (r_nmod) incidence_9\NN\13821570|a|lower|prilocaine|than (r_dep) symptoms_2\NNS\5823932|neurologic|anesthesia|:|incidence|.
D002045_D009422 NONE bupivacaine_21\NN\1740|with (r_nmod) infrequent_19\JJ\1740|are|bupivacaine (r_conj) follow_13\VBP\1835496|that|symptoms|frequently|anesthesia|but|infrequent (l_nsubj) symptoms_8\NNS\5823932|transient|neurologic|tnss
D002045_D009422 NONE bupivacaine_21\NN\1740|with (r_nmod) infrequent_19\JJ\1740|are|bupivacaine (r_conj) follow_13\VBP\1835496|that|symptoms|frequently|anesthesia|but|infrequent (l_nsubj) symptoms_8\NNS\5823932|transient|neurologic|tnss (l_appos) tnss_10\NNS\1740|(|)
D002045_D009422 NONE bupivacaine_13\VB\1740|respect (l_nmod) respect_15\NN\5817845|with|duration (l_nmod) duration_17\NN\15113229|to|action (l_nmod) action_19\NN\30358|of|and|risk|tnss (l_nmod) tnss_24\NNS\1740|of
D002045_D009422 NONE bupivacaine_31\NN\1740| (r_dobj) receiving_30\VBG\2210855|bupivacaine (r_acl) patients_29\NNS\9898892|of|30|receiving (r_nmod) none_26\NN\15228378|patients (r_nsubj) had_32\VBD\2108377|none|tnss (r_conj) had_22\VBD\2108377|nine|them|,|and|had (l_nsubj) nine_2\CD\13741022|patients|patients (l_nmod) patients_5\NNS\9898892|of|30|receiving (l_acl) receiving_6\VBG\2210855|tnss (l_dobj) tnss_9\NNS\1740|lidocaine|experienced|,
D002045_D009422 NONE bupivacaine_31\NN\1740| (r_dobj) receiving_30\VBG\2210855|bupivacaine (r_acl) patients_29\NNS\9898892|of|30|receiving (r_nmod) none_26\NN\15228378|patients (r_nsubj) had_32\VBD\2108377|none|tnss (l_dobj) tnss_33\NNS\1740|
D008012_D009422 CID lidocaine_16\NN\3681148|with (r_nmod) than_14\IN\1740|lidocaine (r_prep) incidence_9\NN\13821570|a|lower|prilocaine|than (r_dep) symptoms_2\NNS\5823932|neurologic|anesthesia|:|incidence|.
D008012_D009422 CID lidocaine_14\NN\3681148| (r_compound) anesthesia_16\NN\14034177|lidocaine|spinal (r_dobj) follow_13\VBP\1835496|that|symptoms|frequently|anesthesia|but|infrequent (l_nsubj) symptoms_8\NNS\5823932|transient|neurologic|tnss
D008012_D009422 CID lidocaine_14\NN\3681148| (r_compound) anesthesia_16\NN\14034177|lidocaine|spinal (r_dobj) follow_13\VBP\1835496|that|symptoms|frequently|anesthesia|but|infrequent (l_nsubj) symptoms_8\NNS\5823932|transient|neurologic|tnss (l_appos) tnss_10\NNS\1740|(|)
D008012_D009422 CID lidocaine_11\NN\3681148|with (r_nmod) compares_8\VBZ\644583|accordingly|,|present|prilocaine|lidocaine|and|bupivacaine|. (l_conj) bupivacaine_13\VB\1740|respect (l_nmod) respect_15\NN\5817845|with|duration (l_nmod) duration_17\NN\15113229|to|action (l_nmod) action_19\NN\30358|of|and|risk|tnss (l_nmod) tnss_24\NNS\1740|of
D008012_D009422 CID lidocaine_7\NN\3681148| (r_compound) tnss_9\NNS\1740|lidocaine|experienced|,
D008012_D009422 CID lidocaine_7\NN\3681148| (r_compound) tnss_9\NNS\1740|lidocaine|experienced|, (r_dobj) receiving_6\VBG\2210855|tnss (r_acl) patients_5\NNS\9898892|of|30|receiving (r_nmod) nine_2\CD\13741022|patients|patients (r_nsubj) had_22\VBD\2108377|nine|them|,|and|had (l_conj) had_32\VBD\2108377|none|tnss (l_dobj) tnss_33\NNS\1740|
D008012_D009422 CID lidocaine_7\NN\3681148|to|procedures (r_nmod) preferable_5\JJ\1740|prilocaine|may|be|lidocaine|has (l_advcl) has_14\VBZ\2108377|because|it|duration (l_dobj) duration_17\NN\15113229|a|similar|action|but|incidence (l_conj) incidence_23\NN\13821570|a|lower|tnss (l_nmod) tnss_25\NNS\1740|of
16167916
D020849_D054556 CID raloxifene_13\NN\1740| (r_compound) treatment_14\NN\654885|due|raloxifene (r_nmod) risk_7\NN\14541044|the|increased|thromboembolism|treatment (l_nmod) thromboembolism_10\NN\14100769|of|venous
8092427
D000658_D004342 CID amoxicillin_4\NN\3910033|to (r_nmod) reactions_2\NNS\13446390|immediate|allergic|amoxicillin|.
D000658_D004342 CID amoxicillin_37\NN\3910033|to|ax (r_nmod) responses_35\NNS\11410625|selective|immediate|allergic|amoxicillin (r_dobj) had_31\VBD\2108377|whether|patients|responses|or|cross-reacting (l_nsubj) patients_26\NNS\9898892|allergic (l_amod) allergic_27\JJ\1740|antibiotics
D000658_D004342 CID amoxicillin_37\NN\3910033|to|ax (r_nmod) responses_35\NNS\11410625|selective|immediate|allergic|amoxicillin (l_amod) allergic_34\JJ\1740|
D000658_D004342 CID ax_39\NN\3265032|(|) (r_appos) amoxicillin_37\NN\3910033|to|ax (r_nmod) responses_35\NNS\11410625|selective|immediate|allergic|amoxicillin (r_dobj) had_31\VBD\2108377|whether|patients|responses|or|cross-reacting (l_nsubj) patients_26\NNS\9898892|allergic (l_amod) allergic_27\JJ\1740|antibiotics
D000658_D004342 CID ax_39\NN\3265032|(|) (r_appos) amoxicillin_37\NN\3910033|to|ax (r_nmod) responses_35\NNS\11410625|selective|immediate|allergic|amoxicillin (l_amod) allergic_34\JJ\1740|
D000658_D004342 CID ax_11\NN\3265032| (r_compound) allergy_12\NN\14533203|of|immediate|ax
D000658_D004342 CID ax_3\NN\3265032|with (r_nmod) tests_1\NNS\5798043|challenge|ax (r_nsubjpass) performed_5\VBN\2367363|tests|were|subjects|establish|,|and|cases|test|negative|. (l_xcomp) establish_14\VB\2426171|to|diagnosis (l_dobj) diagnosis_16\NN\152018|the|reaction (l_nmod) reaction_20\NN\13446390|of|immediate|allergic|ax
D000658_D004342 CID ax_22\NN\3265032|to (r_nmod) reaction_20\NN\13446390|of|immediate|allergic|ax
D000658_D004342 CID ax_38\NN\3265032|for (r_nmod) test_34\NN\5798043|both|skin|and|rast|ax (r_dep) performed_5\VBN\2367363|tests|were|subjects|establish|,|and|cases|test|negative|. (l_xcomp) establish_14\VB\2426171|to|diagnosis (l_dobj) diagnosis_16\NN\152018|the|reaction (l_nmod) reaction_20\NN\13446390|of|immediate|allergic|ax
D000658_D004342 CID ax-allergic_6\JJ\1740|
D047090_D004342 NONE beta-lactam_10\NN\1740| (r_compound) antibiotics_11\NNS\2716205|to|beta-lactam (r_nmod) reactions_8\NNS\13446390|with|suspected|allergic|antibiotics
D047090_D004342 NONE beta-lactam_29\JJ\1740| (r_amod) antibiotics_30\NNS\2716205|to|beta-lactam (r_nmod) allergic_27\JJ\1740|antibiotics
D047090_D004342 NONE beta-lactam_29\JJ\1740| (r_amod) antibiotics_30\NNS\2716205|to|beta-lactam (r_nmod) allergic_27\JJ\1740|antibiotics (r_amod) patients_26\NNS\9898892|allergic (r_nsubj) had_31\VBD\2108377|whether|patients|responses|or|cross-reacting (l_dobj) responses_35\NNS\11410625|selective|immediate|allergic|amoxicillin (l_amod) allergic_34\JJ\1740|
D047090_D004342 NONE beta-lactam_10\JJ\1740| (r_compound) antibiotics_11\NNS\2716205|to|beta-lactam (r_nmod) allergic_8\JJ\1740|as|antibiotics
D010406_D004342 NONE penicillin_46\NN\2716866| (r_compound) derivatives_47\NNS\5802185|with|other|penicillin (r_nmod) cross-reacting_43\JJ\1740|were|derivatives (r_conj) had_31\VBD\2108377|whether|patients|responses|or|cross-reacting (l_nsubj) patients_26\NNS\9898892|allergic (l_amod) allergic_27\JJ\1740|antibiotics
D010406_D004342 NONE penicillin_46\NN\2716866| (r_compound) derivatives_47\NNS\5802185|with|other|penicillin (r_nmod) cross-reacting_43\JJ\1740|were|derivatives (r_conj) had_31\VBD\2108377|whether|patients|responses|or|cross-reacting (l_dobj) responses_35\NNS\11410625|selective|immediate|allergic|amoxicillin (l_amod) allergic_34\JJ\1740|
D010400_D004342 NONE pg_17\NN\1740|of (r_nmod) tolerance_15\NN\5032565|with|good|pg (r_nmod) cases_8\NNS\7283608|the|allergy|tolerance (l_nmod) allergy_12\NN\14533203|of|immediate|ax
D010400_D004342 NONE pg_11\NN\1740| (r_dobj) tolerated_10\VBN\802318|who|have|pg (r_acl:relcl) patients_7\NNS\9898892|of|ax-allergic|tolerated (l_amod) ax-allergic_6\JJ\1740|
-1_D007645 NONE bpo_8\NN\1740|to (r_nmod) negative_6\JJ\1740|bpo (r_xcomp) test_5\NN\5798043|patients|were|skin|negative|;|51|negative|. (l_dep) negative_19\JJ\1740|were|also|mdm|,|and|46|pg (l_nmod) mdm_21\NN\1740|to
D010400_D007645 NONE pg_32\NN\1740|to (r_nmod) negative_19\JJ\1740|were|also|mdm|,|and|46|pg (l_nmod) mdm_21\NN\1740|to
11807648
D014148_D004827 NONE acid_10\NN\14818238|tranexamic (r_dobj) containing_8\VBG\2632940|acid|rats (r_acl) sealants_7\NNS\14705533|of|fibrin|containing (r_nmod) application_4\NN\947128|following|cortical|sealants (r_nmod) seizures_1\NNS\14081375|epileptic|application|.
D014148_D004827 NONE tamca_2\NN\1740| (r_nsubjpass) shown_5\VBN\2137132|however|,|tamca|has|been|cause|. (l_xcomp) cause_7\VB\1617192|to|seizures (l_dobj) seizures_9\NNS\14081375|epileptic
D014148_D012640 CID tamca_5\NN\1740| (r_nsubj) retains_6\VBZ\2700867|whether|tamca|action (l_dobj) action_9\NN\30358|its|convulsive (l_amod) convulsive_8\JJ\1740|
D014148_D012640 CID tamca_4\NN\1740| (r_dobj) containing_3\VBG\2632940|tamca (r_acl) fs_2\NN\13714184|containing (r_nsubj) caused_5\VBD\1617192|fs|activity (l_dobj) activity_8\NN\30358|paroxysmal|brain|associated (l_acl:relcl) associated_11\VBN\628491|which|was|behaviours (l_nmod) behaviours_15\NNS\14006945|with|distinct|convulsive (l_amod) convulsive_14\JJ\1740|
D014148_D012640 CID tamca_10\NN\1740|of (r_nmod) concentration_8\NN\4916342|with|increasing|tamca (r_nmod) increased_5\VBD\169651|degree|concentration|. (l_nsubj) degree_1\NN\4916342|the|seizures (l_nmod) seizures_4\NNS\14081375|of|these
D014148_D012640 CID tamca_6\NN\1740|47.5|mg/ml (r_dobj) containing_3\VBG\2632940|tamca (r_acl) fs_2\NN\13714184|containing (r_nsubj) evoked_7\VBD\1617192|thus|,|fs|seizures|rats|evoked|. (l_dobj) seizures_9\NNS\14081375|generalized
D014148_D012640 CID tamca_6\NN\1740|47.5|mg/ml (r_dobj) containing_3\VBG\2632940|tamca (r_acl) fs_2\NN\13714184|containing (r_nsubj) evoked_7\VBD\1617192|thus|,|fs|seizures|rats|evoked|. (l_advcl) evoked_28\VBD\1617192|while|concentration|only|episodes|rats (l_dobj) episodes_30\NNS\7283608|brief|potentials (l_nmod) potentials_34\NNS\14481929|of|jerk-correlated|convulsive (l_amod) convulsive_33\JJ\1740|
D014148_D012640 CID tamca_22\NN\1740|of|mg/ml (r_nmod) concentration_20\NN\4916342|the|lowest|tamca (r_nsubj) evoked_28\VBD\1617192|while|concentration|only|episodes|rats (r_advcl) evoked_7\VBD\1617192|thus|,|fs|seizures|rats|evoked|. (l_dobj) seizures_9\NNS\14081375|generalized
D014148_D012640 CID tamca_22\NN\1740|of|mg/ml (r_nmod) concentration_20\NN\4916342|the|lowest|tamca (r_nsubj) evoked_28\VBD\1617192|while|concentration|only|episodes|rats (l_dobj) episodes_30\NNS\7283608|brief|potentials (l_nmod) potentials_34\NNS\14481929|of|jerk-correlated|convulsive (l_amod) convulsive_33\JJ\1740|
D014148_D012640 CID acid_3\NN\14818238|tranexamic (r_nsubj) retains_4\VBZ\2700867|acid|action|. (l_dobj) action_7\NN\30358|its|convulsive|fs (l_amod) convulsive_6\JJ\1740|
3101906
D007654_D003643 NONE ketoconazole_9\NN\1740| (r_compound) treatment_10\NN\654885|with|ketoconazole (r_nmod) associated_7\VBN\628491|probably|treatment (r_acl) deaths_5\NNS\7296428|of|the|three|associated
D007654_D007565 CID ketoconazole_9\NN\1740| (r_compound) treatment_10\NN\654885|with|ketoconazole (r_nmod) associated_7\VBN\628491|probably|treatment (r_acl) deaths_5\NNS\7296428|of|the|three|associated (r_nmod) two_1\CD\13741022|in|deaths (r_nmod) continued_15\VBN\2367363|two|drug|had|been|onset|. (l_nmod) onset_18\NN\7325190|after|the|jaundice (l_nmod) jaundice_20\NN\14299637|of|and|symptoms
D007654_D056486 CID ketoconazole_9\NN\1740| (r_compound) treatment_10\NN\654885|with|ketoconazole (r_nmod) associated_7\VBN\628491|probably|treatment (r_acl) deaths_5\NNS\7296428|of|the|three|associated (r_nmod) two_1\CD\13741022|in|deaths (r_nmod) continued_15\VBN\2367363|two|drug|had|been|onset|. (l_nmod) onset_18\NN\7325190|after|the|jaundice (l_nmod) jaundice_20\NN\14299637|of|and|symptoms (l_conj) symptoms_23\NNS\5823932|other|hepatitis (l_nmod) hepatitis_25\NN\14127211|of
D007654_D056486 CID ketoconazole_18\NN\1740|with (r_nmod) treatment_16\NN\654885|during|long|term|ketoconazole (r_nmod) advised_12\VBN\813978|monitoring|is|treatment|prevent|. (l_nsubjpass) monitoring_3\NN\879759|clinical|intervals|evidence (l_nmod) evidence_8\NN\5816287|for|hepatitis (l_nmod) hepatitis_10\NN\14127211|of
D007654_D056486 CID ketoconazole_18\NN\1740|with (r_nmod) treatment_16\NN\654885|during|long|term|ketoconazole (r_nmod) advised_12\VBN\813978|monitoring|is|treatment|prevent|. (l_xcomp) prevent_20\VB\1740|to|injury (l_dobj) injury_24\NN\14052046|possible|serious|hepatic
17244258
D003520_D003556 CID cyclophosphamide-induced_9\JJ\1740| (r_amod) cystitis_10\NN\14566129|in|cyclophosphamide-induced
D003520_D003556 CID cyclophosphamide-induced_1\JJ\1740| (r_amod) cystitis_2\NN\14566129|in|cyclophosphamide-induced|function
26094
D008750_D003866 CID dopa_13\NN\14601829| (r_nmod:npmod) treated_14\VBN\2376958|dopa (r_amod) patients_15\NNS\9898892|in|methyl|treated|histories (r_nmod) occurring_10\VBG\2623529|patients (r_acl) depressions_9\NNS\14373582|of|occurring
D008750_D001523 NONE dopa_13\NN\14601829| (r_nmod:npmod) treated_14\VBN\2376958|dopa (r_amod) patients_15\NNS\9898892|in|methyl|treated|histories (l_nmod) histories_18\NNS\15120823|with|psychiatric (l_amod) psychiatric_17\JJ\1740|
1428568
D013999_D005901 NONE timolol_6\JJ\1740| (r_amod) 0.5%/12h_7\NN\1740|with|timolol (r_nmod) treated_4\VBN\2376958|chronically|0.5%/12h (r_acl) patients_2\NNS\9898892|eight|glaucomatous|treated|,|suffering|diagnosed|, (l_amod) glaucomatous_1\JJ\1740|
D013999_D003866 CID timolol_6\JJ\1740| (r_amod) 0.5%/12h_7\NN\1740|with|timolol (r_nmod) treated_4\VBN\2376958|chronically|0.5%/12h (r_acl) patients_2\NNS\9898892|eight|glaucomatous|treated|,|suffering|diagnosed|, (l_acl) suffering_9\VBG\2110220|depression (l_nmod) depression_11\NN\14373582|from
D013999_D003866 CID timolol_13\JJ\1740| (r_compound) treatment_14\NN\654885|under|timolol (r_nmod) patients_11\NNS\9898892|the|treatment (r_nsubj) presented_15\VBD\2137132|study|,|patients|values|(|p|)|. (l_dobj) values_18\NNS\5941423|higher|depression|measured (l_compound) depression_17\NN\14373582|
D013999_D003866 CID timolol_12\CD\2832168|than (r_nmod) less_7\JJR\1740|that|betaxolol|could|be|depression-inducer|timolol|patients (l_nmod) depression-inducer_10\NN\1740|of|a
D015784_D003866 NONE betaxolol_4\NN\1740| (r_nsubj) less_7\JJR\1740|that|betaxolol|could|be|depression-inducer|timolol|patients (l_nmod) depression-inducer_10\NN\1740|of|a
20722491
-1_D009369 NONE fluoropyrimidines_5\NNS\1740|,|5-fluorouracil|, (r_dep) importance_0\NN\5138488|field|:|fluoropyrimidines (r_nsubj) mainstay_17\NN\10677713|importance|have|been|the|treatment|>|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|colorectal|,
-1_D015179 NONE fluoropyrimidines_5\NNS\1740|,|5-fluorouracil|, (r_dep) importance_0\NN\5138488|field|:|fluoropyrimidines (r_nsubj) mainstay_17\NN\10677713|importance|have|been|the|treatment|>|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|colorectal|, (l_nmod) colorectal_26\JJ\1740|including|,|breast|head|and|neck|cancers (l_dep) cancers_33\NNS\14239425|
-1_D001943 NONE fluoropyrimidines_5\NNS\1740|,|5-fluorouracil|, (r_dep) importance_0\NN\5138488|field|:|fluoropyrimidines (r_nsubj) mainstay_17\NN\10677713|importance|have|been|the|treatment|>|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|colorectal|, (l_nmod) colorectal_26\JJ\1740|including|,|breast|head|and|neck|cancers (l_dep) cancers_33\NNS\14239425|
-1_D006258 NONE fluoropyrimidines_5\NNS\1740|,|5-fluorouracil|, (r_dep) importance_0\NN\5138488|field|:|fluoropyrimidines (r_nsubj) mainstay_17\NN\10677713|importance|have|been|the|treatment|>|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|colorectal|, (l_nmod) colorectal_26\JJ\1740|including|,|breast|head|and|neck|cancers (l_dep) cancers_33\NNS\14239425|
D005472_D009369 NONE 5-fluorouracil_9\NN\1740|in|particular|5-fu (r_nmod) fluoropyrimidines_5\NNS\1740|,|5-fluorouracil|, (r_dep) importance_0\NN\5138488|field|:|fluoropyrimidines (r_nsubj) mainstay_17\NN\10677713|importance|have|been|the|treatment|>|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|colorectal|,
D005472_D009369 NONE 5-fu_11\NN\1740|(|) (r_appos) 5-fluorouracil_9\NN\1740|in|particular|5-fu (r_nmod) fluoropyrimidines_5\NNS\1740|,|5-fluorouracil|, (r_dep) importance_0\NN\5138488|field|:|fluoropyrimidines (r_nsubj) mainstay_17\NN\10677713|importance|have|been|the|treatment|>|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|colorectal|,
D005472_D015179 NONE 5-fluorouracil_9\NN\1740|in|particular|5-fu (r_nmod) fluoropyrimidines_5\NNS\1740|,|5-fluorouracil|, (r_dep) importance_0\NN\5138488|field|:|fluoropyrimidines (r_nsubj) mainstay_17\NN\10677713|importance|have|been|the|treatment|>|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|colorectal|, (l_nmod) colorectal_26\JJ\1740|including|,|breast|head|and|neck|cancers (l_dep) cancers_33\NNS\14239425|
D005472_D015179 NONE 5-fu_11\NN\1740|(|) (r_appos) 5-fluorouracil_9\NN\1740|in|particular|5-fu (r_nmod) fluoropyrimidines_5\NNS\1740|,|5-fluorouracil|, (r_dep) importance_0\NN\5138488|field|:|fluoropyrimidines (r_nsubj) mainstay_17\NN\10677713|importance|have|been|the|treatment|>|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|colorectal|, (l_nmod) colorectal_26\JJ\1740|including|,|breast|head|and|neck|cancers (l_dep) cancers_33\NNS\14239425|
D005472_D001943 NONE 5-fluorouracil_9\NN\1740|in|particular|5-fu (r_nmod) fluoropyrimidines_5\NNS\1740|,|5-fluorouracil|, (r_dep) importance_0\NN\5138488|field|:|fluoropyrimidines (r_nsubj) mainstay_17\NN\10677713|importance|have|been|the|treatment|>|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|colorectal|, (l_nmod) colorectal_26\JJ\1740|including|,|breast|head|and|neck|cancers (l_dep) cancers_33\NNS\14239425|
D005472_D001943 NONE 5-fu_11\NN\1740|(|) (r_appos) 5-fluorouracil_9\NN\1740|in|particular|5-fu (r_nmod) fluoropyrimidines_5\NNS\1740|,|5-fluorouracil|, (r_dep) importance_0\NN\5138488|field|:|fluoropyrimidines (r_nsubj) mainstay_17\NN\10677713|importance|have|been|the|treatment|>|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|colorectal|, (l_nmod) colorectal_26\JJ\1740|including|,|breast|head|and|neck|cancers (l_dep) cancers_33\NNS\14239425|
D005472_D006258 NONE 5-fluorouracil_9\NN\1740|in|particular|5-fu (r_nmod) fluoropyrimidines_5\NNS\1740|,|5-fluorouracil|, (r_dep) importance_0\NN\5138488|field|:|fluoropyrimidines (r_nsubj) mainstay_17\NN\10677713|importance|have|been|the|treatment|>|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|colorectal|, (l_nmod) colorectal_26\JJ\1740|including|,|breast|head|and|neck|cancers (l_dep) cancers_33\NNS\14239425|
D005472_D006258 NONE 5-fu_11\NN\1740|(|) (r_appos) 5-fluorouracil_9\NN\1740|in|particular|5-fu (r_nmod) fluoropyrimidines_5\NNS\1740|,|5-fluorouracil|, (r_dep) importance_0\NN\5138488|field|:|fluoropyrimidines (r_nsubj) mainstay_17\NN\10677713|importance|have|been|the|treatment|>|. (l_nmod) treatment_19\NN\654885|of|tumors (l_nmod) tumors_23\NNS\14234074|for|several|solid|,|colorectal|, (l_nmod) colorectal_26\JJ\1740|including|,|breast|head|and|neck|cancers (l_dep) cancers_33\NNS\14239425|
C110904_D007674 NONE capecitabine_16\NN\1740|of (r_nmod) safety_14\NN\13920835|into|the|capecitabine|populations (l_nmod) populations_19\NNS\7942152|in|special|patients (l_nmod) patients_22\NNS\9898892|such|age|,|disease (l_conj) disease_30\NN\14061805|renal
C110904_D007674 NONE capecitabine_0\NNP\1740| (r_nsubj) has_1\VBZ\2108377|capecitabine|profile|and|given|. (l_conj) given_9\VBN\2327200|can|be|safely|patients (l_nmod) patients_12\NNS\9898892|to|age|dysfunctions (l_appos) dysfunctions_20\NNS\14204950|
C110904_D003967 CID capecitabine_7\NN\1740|of (r_nmod) effects_5\NNS\13245626|toxic|capecitabine (r_dobj) reported_3\VBD\831651|the|commonly|effects|diarrhea|. (l_dep) diarrhea_9\NN\14299637|are|,|nausea|syndrome
C110904_D009325 CID capecitabine_7\NN\1740|of (r_nmod) effects_5\NNS\13245626|toxic|capecitabine (r_dobj) reported_3\VBD\831651|the|commonly|effects|diarrhea|. (l_dep) diarrhea_9\NN\14299637|are|,|nausea|syndrome (l_conj) nausea_11\NN\14299637|,|vomiting
C110904_D014839 CID capecitabine_7\NN\1740|of (r_nmod) effects_5\NNS\13245626|toxic|capecitabine (r_dobj) reported_3\VBD\831651|the|commonly|effects|diarrhea|. (l_dep) diarrhea_9\NN\14299637|are|,|nausea|syndrome (l_conj) nausea_11\NN\14299637|,|vomiting (l_conj) vomiting_13\NN\116687|,|stomatitis
C110904_D013280 CID capecitabine_7\NN\1740|of (r_nmod) effects_5\NNS\13245626|toxic|capecitabine (r_dobj) reported_3\VBD\831651|the|commonly|effects|diarrhea|. (l_dep) diarrhea_9\NN\14299637|are|,|nausea|syndrome (l_conj) nausea_11\NN\14299637|,|vomiting (l_conj) vomiting_13\NN\116687|,|stomatitis (l_conj) stomatitis_15\NN\14336539|and|hand-foot
C110904_D060831 CID capecitabine_7\NN\1740|of (r_nmod) effects_5\NNS\13245626|toxic|capecitabine (r_dobj) reported_3\VBD\831651|the|commonly|effects|diarrhea|. (l_dep) diarrhea_9\NN\14299637|are|,|nausea|syndrome (l_dep) syndrome_18\NN\5870365|
C110904_D008107 NONE capecitabine_0\NNP\1740| (r_nsubj) has_1\VBZ\2108377|capecitabine|profile|and|given|. (l_conj) given_9\VBN\2327200|can|be|safely|patients (l_nmod) patients_12\NNS\9898892|to|age|dysfunctions (l_appos) dysfunctions_20\NNS\14204950|
9855119
D016559_D005922 NONE fk506_55\NN\1740| (r_compound) nephropathy_56\NN\14573196|minimal-type|chronic|fk506|n (r_conj) rejection_12\NN\30358|diagnoses|were|acute|ar|,|rejection|,|ar+cr|,|nephropathy|,|findings|,|nephropathy|,|and|nephropathy (l_conj) nephropathy_38\NN\14573196|recurrent|iga|n
D016559_D005922 NONE fk506_65\NN\1740| (r_compound) nephropathy_66\NN\14573196|mild-type|fk506|n (r_conj) rejection_12\NN\30358|diagnoses|were|acute|ar|,|rejection|,|ar+cr|,|nephropathy|,|findings|,|nephropathy|,|and|nephropathy (l_conj) nephropathy_38\NN\14573196|recurrent|iga|n
D016559_D007674 NONE fk506_55\NN\1740| (r_compound) nephropathy_56\NN\14573196|minimal-type|chronic|fk506|n
D016559_D007674 NONE fk506_55\NN\1740| (r_compound) nephropathy_56\NN\14573196|minimal-type|chronic|fk506|n (r_conj) rejection_12\NN\30358|diagnoses|were|acute|ar|,|rejection|,|ar+cr|,|nephropathy|,|findings|,|nephropathy|,|and|nephropathy (l_conj) nephropathy_66\NN\14573196|mild-type|fk506|n
D016559_D007674 NONE fk506_65\NN\1740| (r_compound) nephropathy_66\NN\14573196|mild-type|fk506|n (r_conj) rejection_12\NN\30358|diagnoses|were|acute|ar|,|rejection|,|ar+cr|,|nephropathy|,|findings|,|nephropathy|,|and|nephropathy (l_conj) nephropathy_56\NN\14573196|minimal-type|chronic|fk506|n
D016559_D007674 NONE fk506_65\NN\1740| (r_compound) nephropathy_66\NN\14573196|mild-type|fk506|n
D016559_D007674 NONE fk506_14\NN\1740| (r_compound) nephropathy_15\NN\14573196|chronic|fk506
D016559_D007674 NONE fk506_1\NN\1740| (r_compound) nephropathy_2\NN\14573196|chronic|fk506
D016559_D007674 NONE fk506_10\NN\1740| (r_compound) group_12\NN\2137|in|the|mild-type|chronic|fk506|nephropathy (l_compound) nephropathy_11\NN\14573196|
D016559_D007674 NONE fk506_10\NN\1740| (r_compound) group_12\NN\2137|in|the|mild-type|chronic|fk506|nephropathy (r_nmod) patients_5\NNS\9898892|of|group|, (r_nmod) levels_3\NNS\4916342|the|serum|creatinine|patients|included (r_nsubj) higher_22\JJR\1740|levels|,|were|statistically|those|0.001|. (l_nmod) those_24\DT\1740|than|group (l_nmod) group_30\NN\2137|in|the|minimum-type|chronic|fk506-nephropathy (l_amod) fk506-nephropathy_29\JJ\1740|
D016559_D007674 NONE fk506-nephropathy_29\JJ\1740| (r_amod) group_30\NN\2137|in|the|minimum-type|chronic|fk506-nephropathy (r_nmod) those_24\DT\1740|than|group (r_nmod) higher_22\JJR\1740|levels|,|were|statistically|those|0.001|. (l_nsubj) levels_3\NNS\4916342|the|serum|creatinine|patients|included (l_nmod) patients_5\NNS\9898892|of|group|, (l_nmod) group_12\NN\2137|in|the|mild-type|chronic|fk506|nephropathy (l_compound) nephropathy_11\NN\14573196|
D016559_D007674 NONE fk506-nephropathy_29\JJ\1740|
D016559_D007674 NONE fk506_7\NN\1740| (r_compound) nephropathy_8\NN\14573196|chronic|fk506
D016559_D007674 NONE fk506_7\NN\1740| (r_compound) nephropathy_8\NN\14573196|chronic|fk506 (r_nsubj) consists_9\VBZ\2603699|that|nephropathy|primarily (r_ccomp) demonstrates_4\VBZ\2137132|study|consists|,|and|suggests (l_conj) suggests_23\VBZ\1010118|condition (l_ccomp) condition_31\NN\24720|that|nephropathy|is|a|lead (l_nsubj) nephropathy_28\NN\14573196|mild-type|chronic|fk506
D016559_D007674 NONE fk506_27\NN\1740| (r_compound) nephropathy_28\NN\14573196|mild-type|chronic|fk506 (r_nsubj) condition_31\NN\24720|that|nephropathy|is|a|lead (r_ccomp) suggests_23\VBZ\1010118|condition (r_conj) demonstrates_4\VBZ\2137132|study|consists|,|and|suggests (l_ccomp) consists_9\VBZ\2603699|that|nephropathy|primarily (l_nsubj) nephropathy_8\NN\14573196|chronic|fk506
D016559_D007674 NONE fk506_27\NN\1740| (r_compound) nephropathy_28\NN\14573196|mild-type|chronic|fk506
D016559_D005923 CID fk506_1\NN\1740| (r_compound) nephropathy_2\NN\14573196|chronic|fk506 (r_nsubj) consisted_3\VBD\2603699|nephropathy|vacuolization|. (l_nmod) vacuolization_9\NN\13920835|of|rough|tubular|biopsies|,|arteriolopathy|,|glomerulosclerosis|and|form (l_conj) glomerulosclerosis_29\NN\1740|focal|biopsies
D016559_D005355 NONE fk506_1\NN\1740| (r_compound) nephropathy_2\NN\14573196|chronic|fk506 (r_nsubj) consisted_3\VBD\2603699|nephropathy|vacuolization|. (l_nmod) vacuolization_9\NN\13920835|of|rough|tubular|biopsies|,|arteriolopathy|,|glomerulosclerosis|and|form (l_conj) form_37\NN\6286395|the|striped|fibrosis|biopsies (l_nmod) fibrosis_40\NN\14204950|of|interstitial
D003404_D007674 NONE creatinine_2\NN\1740| (r_compound) levels_3\NNS\4916342|the|serum|creatinine|patients|included (l_nmod) patients_5\NNS\9898892|of|group|, (l_nmod) group_12\NN\2137|in|the|mild-type|chronic|fk506|nephropathy (l_compound) nephropathy_11\NN\14573196|
D003404_D007674 NONE creatinine_2\NN\1740| (r_compound) levels_3\NNS\4916342|the|serum|creatinine|patients|included (r_nsubj) higher_22\JJR\1740|levels|,|were|statistically|those|0.001|. (l_nmod) those_24\DT\1740|than|group (l_nmod) group_30\NN\2137|in|the|minimum-type|chronic|fk506-nephropathy (l_amod) fk506-nephropathy_29\JJ\1740|
16755009
D003975_D000647 CID diazepam-_0\NN\1740|,|scopolamine-|amnesia (l_dep) amnesia_5\NN\5669934|
D003975_D000647 CID diazepam_16\NN\2830852|mg/kg (r_conj) amnesia_5\NN\5669934|the|induced|mg/kg|and|diazepam
D012601_D000647 CID scopolamine-_2\NN\1740|and|ageing-induced (r_conj) diazepam-_0\NN\1740|,|scopolamine-|amnesia (l_dep) amnesia_5\NN\5669934|
D012601_D000647 CID scopolamine_8\NN\14712692|by (r_nmod) induced_6\VBN\1627355|scopolamine (r_acl) amnesia_5\NN\5669934|the|induced|mg/kg|and|diazepam
D010936_D000647 NONE dce_2\NN\1740| (r_nsubj) reversed_3\VBD\109660|furthermore|,|dce|amnesia|. (l_dobj) amnesia_5\NN\5669934|the|induced|mg/kg|and|diazepam
D010936_D003072 NONE dce_2\NN\1740| (r_nsubj) prove_4\VB\2604760|therefore|,|dce|may|remedy|. (l_xcomp) remedy_9\NN\258854|to|be|a|useful|management|activity (l_nmod) management_12\NN\1123598|for|the|dysfunctions (l_nmod) dysfunctions_15\NNS\14204950|of|cognitive|account
D002784_D003072 NONE cholesterol_30\NN\15058310|lowering (r_compound) activity_35\NN\30358|improving|cholesterol (r_nmod) remedy_9\NN\258854|to|be|a|useful|management|activity (l_nmod) management_12\NN\1123598|for|the|dysfunctions (l_nmod) dysfunctions_15\NNS\14204950|of|cognitive|account
19843802
D004837_D006973 CID epinephrine_5\NN\14807929|of (r_nmod) bolus_3\NN\13899404|a|epinephrine|injected (r_nsubj) provoked_11\VBD\1617192|however|,|bolus|crisis|. (l_dobj) crisis_14\NN\14411243|a|hypertensive (l_amod) hypertensive_13\JJ\1740|
6534871
D007545_D009203 CID isoproterenol-induced_8\JJ\1740| (r_amod) infarction_10\NN\14204950|of|isoproterenol-induced|myocardial
7449470
D004317_D066126 NONE doxorubicin_3\NN\2716866| (r_compound) cardiotoxicity_4\NN\1740|late|,|late|doxorubicin|.
D004317_D066126 NONE adriamycin_11\NN\1740|of (r_nmod) use_9\NN\407535|the|adriamycin (r_dobj) limits_7\VBZ\2510337|which|use|agent (r_acl:relcl) complication_5\NN\1073995|toxicity|is|a|major|limits|. (l_nsubj) toxicity_1\NN\13576101|cardiac
11419773
D002110_D001145 NONE caffeine-induced_0\JJ\1740| (r_amod) arrhythmia_2\NN\14103288|caffeine-induced|cardiac|:|danger|.
D002110_D008945 NONE caffeine_30\NN\14712692|of (r_nmod) concentration_28\NN\4916342|a|high|caffeine (r_dobj) containing_25\VBG\2632940|concentration (r_acl) drink_24\VBP\1156834|guarana|health|containing (r_ccomp) describe_1\VBP\1001294|we|woman|drink|. (l_dobj) woman_4\NN\9605289|a|25-year-old|prolapse (l_nmod) prolapse_9\NN\14548343|with|mitral|valve|developed
D002110_D014693 CID caffeine_30\NN\14712692|of (r_nmod) concentration_28\NN\4916342|a|high|caffeine (r_dobj) containing_25\VBG\2632940|concentration (r_acl) drink_24\VBP\1156834|guarana|health|containing (r_ccomp) describe_1\VBP\1001294|we|woman|drink|. (l_dobj) woman_4\NN\9605289|a|25-year-old|prolapse (l_nmod) prolapse_9\NN\14548343|with|mitral|valve|developed (l_acl:relcl) developed_11\VBD\1753788|who|fibrillation|consuming (l_dobj) fibrillation_14\NN\14361664|intractable|ventricular
6287825
D013831_D010523 CID thiamine_7\NN\15090742|of|and|riboflavin (r_nmod) deficiency_5\NN\14449126|due|to|nutritional|thiamine (r_nmod) neuropathy_1\NN\14204950|peripheral|deficiency
D013831_D010523 CID thiamine_7\NN\15090742|of|and|riboflavin (r_nmod) deficiency_5\NN\14449126|due|to|nutritional|thiamine (r_nmod) neuropathy_1\NN\14204950|peripheral|deficiency (r_nsubj) common_11\JJ\1740|neuropathy|was|%|and|presented|. (l_conj) presented_17\VBN\2137132|mainly|sensory (l_nmod) sensory_20\JJ\1740|as|and|sensori-motor|neuropathy (l_conj) neuropathy_23\JJ\1740|
D013831_D044342 NONE thiamine_7\NN\15090742|of|and|riboflavin (r_nmod) deficiency_5\NN\14449126|due|to|nutritional|thiamine
D012256_D010523 CID riboflavin_9\NN\15090742| (r_conj) thiamine_7\NN\15090742|of|and|riboflavin (r_nmod) deficiency_5\NN\14449126|due|to|nutritional|thiamine (r_nmod) neuropathy_1\NN\14204950|peripheral|deficiency
D012256_D010523 CID riboflavin_9\NN\15090742| (r_conj) thiamine_7\NN\15090742|of|and|riboflavin (r_nmod) deficiency_5\NN\14449126|due|to|nutritional|thiamine (r_nmod) neuropathy_1\NN\14204950|peripheral|deficiency (r_nsubj) common_11\JJ\1740|neuropathy|was|%|and|presented|. (l_conj) presented_17\VBN\2137132|mainly|sensory (l_nmod) sensory_20\JJ\1740|as|and|sensori-motor|neuropathy (l_conj) neuropathy_23\JJ\1740|
D012256_D044342 NONE riboflavin_9\NN\15090742| (r_conj) thiamine_7\NN\15090742|of|and|riboflavin (r_nmod) deficiency_5\NN\14449126|due|to|nutritional|thiamine
D007538_D009422 NONE isoniazid_0\NNP\2716205| (r_nsubj) agent_5\NN\7347|isoniazid|was|the|frequent|neuropathy|. (l_nmod) neuropathy_8\JJ\1740|in|drug-induced
19820426
C558899_D066126 NONE lopinavir/ritonavir_8\NN\1740| (r_compound) therapy_9\NN\657604|to|lopinavir/ritonavir (r_nmod) related_6\JJ\1740|therapy (r_amod) toxicity_5\NN\13576101|with|cardiac|related
C558899_D006327 CID lopinavir/ritonavir_13\NN\1740| (r_compound) therapy_14\NN\657604|to|lopinavir/ritonavir|,|agent (r_nmod) related_11\JJ\1740|cardiomyopathy|therapy (r_dobj) dilated_9\VBN\303465|related (r_conj) developed_4\VBD\1753788|one|block|and|dilated|,|developed|. (l_dobj) block_7\NN\21939|complete|heart
C558899_D002311 CID lopinavir/ritonavir_13\NN\1740| (r_compound) therapy_14\NN\657604|to|lopinavir/ritonavir|,|agent (r_nmod) related_11\JJ\1740|cardiomyopathy|therapy (l_amod) cardiomyopathy_10\DT\14103288|
C558899_D001919 CID lopinavir/ritonavir_13\NN\1740| (r_compound) therapy_14\NN\657604|to|lopinavir/ritonavir|,|agent (r_nmod) related_11\JJ\1740|cardiomyopathy|therapy (r_dobj) dilated_9\VBN\303465|related (r_conj) developed_4\VBD\1753788|one|block|and|dilated|,|developed|. (l_advcl) developed_25\VBN\1753788|while|twin|bradycardia (l_dobj) bradycardia_27\NN\14110674|mild
9766615
D003024_D001480 NONE clozapine_40\NN\3713736|(|primarily|) (r_appos) threshold_37\NN\15265518|seizure|clozapine|,|and|agranulocytosis (r_dobj) lowered_35\VBD\1850315|threshold|clozapine (r_conj) have_4\VBP\2108377|agents|risk|,|but|associated|effects|lowered|. (l_dobj) risk_7\NN\14541044|a|lower|eps (l_nmod) eps_9\NN\1740|of
D003024_D001480 NONE clozapine_46\NN\3713736|(|only|) (r_dep) lowered_35\VBD\1850315|threshold|clozapine (r_conj) have_4\VBP\2108377|agents|risk|,|but|associated|effects|lowered|. (l_dobj) risk_7\NN\14541044|a|lower|eps (l_nmod) eps_9\NN\1740|of
D003024_D015430 NONE clozapine_40\NN\3713736|(|primarily|) (r_appos) threshold_37\NN\15265518|seizure|clozapine|,|and|agranulocytosis (r_dobj) lowered_35\VBD\1850315|threshold|clozapine (r_conj) have_4\VBP\2108377|agents|risk|,|but|associated|effects|lowered|. (l_dobj) effects_21\NNS\13245626|cardiovascular|,|effects|,|dysfunction|,|effects|, (l_conj) effects_24\NNS\13245626|anticholinergic|,|gain (l_conj) gain_27\NN\13576355|weight
D003024_D015430 NONE clozapine_46\NN\3713736|(|only|) (r_dep) lowered_35\VBD\1850315|threshold|clozapine (r_conj) have_4\VBP\2108377|agents|risk|,|but|associated|effects|lowered|. (l_dobj) effects_21\NNS\13245626|cardiovascular|,|effects|,|dysfunction|,|effects|, (l_conj) effects_24\NNS\13245626|anticholinergic|,|gain (l_conj) gain_27\NN\13576355|weight
D003024_D012735 NONE clozapine_40\NN\3713736|(|primarily|) (r_appos) threshold_37\NN\15265518|seizure|clozapine|,|and|agranulocytosis (r_dobj) lowered_35\VBD\1850315|threshold|clozapine (r_conj) have_4\VBP\2108377|agents|risk|,|but|associated|effects|lowered|. (l_dobj) effects_21\NNS\13245626|cardiovascular|,|effects|,|dysfunction|,|effects|, (l_conj) dysfunction_30\NN\14204950|sexual
D003024_D012735 NONE clozapine_46\NN\3713736|(|only|) (r_dep) lowered_35\VBD\1850315|threshold|clozapine (r_conj) have_4\VBP\2108377|agents|risk|,|but|associated|effects|lowered|. (l_dobj) effects_21\NNS\13245626|cardiovascular|,|effects|,|dysfunction|,|effects|, (l_conj) dysfunction_30\NN\14204950|sexual
D003024_D012640 NONE clozapine_40\NN\3713736|(|primarily|) (r_appos) threshold_37\NN\15265518|seizure|clozapine|,|and|agranulocytosis (l_amod) seizure_36\JJ\1740|
D003024_D012640 NONE clozapine_46\NN\3713736|(|only|) (r_dep) lowered_35\VBD\1850315|threshold|clozapine (l_dobj) threshold_37\NN\15265518|seizure|clozapine|,|and|agranulocytosis (l_amod) seizure_36\JJ\1740|
D003024_D000380 CID clozapine_40\NN\3713736|(|primarily|) (r_appos) threshold_37\NN\15265518|seizure|clozapine|,|and|agranulocytosis (l_conj) agranulocytosis_44\NN\14189204|
D003024_D000380 CID clozapine_46\NN\3713736|(|only|) (r_dep) lowered_35\VBD\1850315|threshold|clozapine (l_dobj) threshold_37\NN\15265518|seizure|clozapine|,|and|agranulocytosis (l_conj) agranulocytosis_44\NN\14189204|
16330766
C040029_D009437 NONE gabapentin_11\NN\2718469|of|,|drug|, (l_appos) drug_14\NN\14778436|a|effective (l_amod) effective_15\JJ\1740|patients (l_nmod) patients_19\NNS\9898892|in|neuropathic|pain (l_compound) pain_18\NN\14299637|
C040029_D006930 NONE gabapentin-induced_15\JJ\1740| (r_amod) modulation_16\NN\7044917|the|gabapentin-induced|activity|response (l_nmod) response_21\NN\11410625|in|stimulation (l_nmod) stimulation_25\NN\242808|to|nociceptive|mechanical|skin (l_nmod) skin_28\NN\5237755|of|normal|and|hyperalgesia (l_conj) hyperalgesia_32\NN\1740|capsaicin-induced|secondary
D002211_D006930 CID capsaicin-induced_30\JJ\1740| (r_amod) hyperalgesia_32\NN\1740|capsaicin-induced|secondary
6640832
D004317_D001749 NONE adriamycin_2\NN\1740|early|adjuvant|carcinoma|. (l_nmod) carcinoma_6\NN\14239918|in|superficial|bladder
D004317_D001749 NONE adriamycin_0\NN\1740|ml (r_nsubjpass) administered_7\VBN\2436349|adriamycin|was|intravesically|h|resection|. (l_nmod) resection_14\NN\671351|after|transurethral|tumors (l_nmod) tumors_21\NNS\14234074|of|ta-t1|bladder
D004317_D002277 NONE adriamycin_2\NN\1740|early|adjuvant|carcinoma|. (l_nmod) carcinoma_6\NN\14239918|in|superficial|bladder
8421099
D015282_D042882 CID octreotide_10\NN\1740|(|) (r_appos) analog_8\NN\4743605|of|somatostatin|octreotide (r_nmod) effects_5\NNS\13245626|of|the|long-term|analog|function (l_nmod) function_14\NN\13783581|on|gallbladder|and|formation|patients (l_conj) formation_17\NN\7938773|gallstone (l_compound) gallstone_16\NN\9230768|
D015282_D042882 CID octreotide_3\NN\1740|of (r_nmod) withdrawal_1\NN\7206096|after|octreotide|patients (l_nmod) patients_6\NNS\9898892|in|10|gallstones (l_nmod) gallstones_8\NNS\9230768|without
D015282_D042882 CID octreotide_25\NN\1740| (r_compound) therapy_26\NN\657604|during|octreotide|patients (r_nmod) cholecystitis_23\NN\14336539|therapy (r_conj) sludge_18\NN\14591635|of|bile|,|gallstones|,|and|cholecystitis (l_conj) gallstones_20\NNS\9230768|
D015282_D000172 NONE octreotide_10\NN\1740|(|) (r_appos) analog_8\NN\4743605|of|somatostatin|octreotide (r_nmod) effects_5\NNS\13245626|of|the|long-term|analog|function (l_nmod) function_14\NN\13783581|on|gallbladder|and|formation|patients (l_nmod) patients_21\NNS\9898892|in|chinese|acromegalic (l_amod) acromegalic_20\JJ\1740|
D015282_D000172 NONE octreotide_26\NN\1740|of|the|analog (r_nmod) injection_21\NN\320852|with|sc|octreotide|dosages (r_nmod) treated_18\VBN\2376958|injection (r_acl) acromegaly_17\NN\14366759|with|active|treated
D015282_D000172 NONE octreotide_25\NN\1740| (r_compound) therapy_26\NN\657604|during|octreotide|patients (l_nmod) patients_30\NNS\9898892|in|chinese|acromegalic (l_amod) acromegalic_29\JJ\1740|
D015282_D000172 NONE octreotide_14\NN\1740| (r_compound) therapy_15\NN\657604|during|long-term|octreotide|patients (l_nmod) patients_18\NNS\9898892|of|acromegalic (l_amod) acromegalic_17\JJ\1740|
D015282_D002764 NONE octreotide_25\NN\1740| (r_compound) therapy_26\NN\657604|during|octreotide|patients (r_nmod) cholecystitis_23\NN\14336539|therapy
7453952
D008094_D003919 CID lithium-induced_3\JJ\1740| (r_amod) syndrome_5\NN\5870365|of|the|lithium-induced|diabetes-insipidus-like
D008094_D003919 CID lithium-induced_9\JJ\1740| (r_amod) syndrome_11\NN\5870365|of|the|lithium-induced|diabetes-insipidus-like
D008094_D003919 CID lithium_24\NN\14625458| (r_compound) concentration_25\NN\4916342|between|the|lithium|medulla (r_nmod) ratio_21\NN\13815152|of|the|concentration (r_nmod) reduction_18\NN\351485|by|a|ratio|and|levels (r_nmod) accompanied_15\VBN\1835496|experiments|,|attenuation|was|reduction|. (l_nsubjpass) attenuation_6\NN\7427337|the|syndrome|amiloride (l_nmod) syndrome_11\NN\5870365|of|the|lithium-induced|diabetes-insipidus-like
D000584_D003919 NONE amiloride_7\NN\1740|by (r_nmod) attenuation_0\NN\7427337|syndrome|amiloride|rats|. (l_nmod) syndrome_5\NN\5870365|of|the|lithium-induced|diabetes-insipidus-like
D000584_D003919 NONE amiloride_13\NN\1740|by (r_nmod) attenuation_6\NN\7427337|the|syndrome|amiloride (l_nmod) syndrome_11\NN\5870365|of|the|lithium-induced|diabetes-insipidus-like
D000584_D059606 NONE amiloride_3\NN\1740|of (r_nmod) effect_1\NN\34213|the|amiloride|polydipsia|and|concentration (l_nmod) polydipsia_6\NN\14040660|on|lithium-induced|and|polyuria
D000584_D059606 NONE amiloride_5\NN\1740| (r_compound) administration_6\NN\1133281|acute|amiloride|patients (l_nmod) patients_9\NNS\9898892|to|lithium-treated|suffering (l_acl) suffering_10\VBG\2110220|polydipsia|and|polyuria (l_nmod) polydipsia_12\NN\14040660|from
D000584_D059606 NONE amiloride_21\NN\1740| (r_compound) supplementation_22\NN\5108947|prolonged|amiloride (r_conj) patients_18\NNS\9898892|these|but|supplementation (r_dobj) relieve_16\VB\205885|that|administration|might|patients (l_nsubj) administration_6\NN\1133281|acute|amiloride|patients (l_nmod) patients_9\NNS\9898892|to|lithium-treated|suffering (l_acl) suffering_10\VBG\2110220|polydipsia|and|polyuria (l_nmod) polydipsia_12\NN\14040660|from
D000584_D011141 NONE amiloride_3\NN\1740|of (r_nmod) effect_1\NN\34213|the|amiloride|polydipsia|and|concentration (l_nmod) polydipsia_6\NN\14040660|on|lithium-induced|and|polyuria (l_conj) polyuria_8\NN\14113228|
D000584_D011141 NONE amiloride_5\NN\1740| (r_compound) administration_6\NN\1133281|acute|amiloride|patients (l_nmod) patients_9\NNS\9898892|to|lithium-treated|suffering (l_acl) suffering_10\VBG\2110220|polydipsia|and|polyuria (l_conj) polyuria_14\NN\14113228|
D000584_D011141 NONE amiloride_21\NN\1740| (r_compound) supplementation_22\NN\5108947|prolonged|amiloride (r_conj) patients_18\NNS\9898892|these|but|supplementation (r_dobj) relieve_16\VB\205885|that|administration|might|patients (l_nsubj) administration_6\NN\1133281|acute|amiloride|patients (l_nmod) patients_9\NNS\9898892|to|lithium-treated|suffering (l_acl) suffering_10\VBG\2110220|polydipsia|and|polyuria (l_conj) polyuria_14\NN\14113228|
D008094_D059606 NONE lithium-induced_5\JJ\1740| (r_amod) polydipsia_6\NN\14040660|on|lithium-induced|and|polyuria
D008094_D059606 NONE lithium_12\NN\14625458| (r_compound) concentration_13\NN\4916342|on|the|lithium|plasma (r_conj) effect_1\NN\34213|the|amiloride|polydipsia|and|concentration (l_nmod) polydipsia_6\NN\14040660|on|lithium-induced|and|polyuria
D008094_D059606 NONE lithium-treated_8\JJ\1740| (r_amod) patients_9\NNS\9898892|to|lithium-treated|suffering (l_acl) suffering_10\VBG\2110220|polydipsia|and|polyuria (l_nmod) polydipsia_12\NN\14040660|from
D008094_D059606 NONE lithium_27\NN\14625458| (r_compound) levels_28\NNS\4916342|in|elevated|lithium (r_nmod) result_24\VB\2633881|would|levels|and|hazardous (r_ccomp) concluded_2\VBN\628491|it|is|relieve|result|. (l_ccomp) relieve_16\VB\205885|that|administration|might|patients (l_nsubj) administration_6\NN\1133281|acute|amiloride|patients (l_nmod) patients_9\NNS\9898892|to|lithium-treated|suffering (l_acl) suffering_10\VBG\2110220|polydipsia|and|polyuria (l_nmod) polydipsia_12\NN\14040660|from
D008094_D011141 NONE lithium-induced_5\JJ\1740| (r_amod) polydipsia_6\NN\14040660|on|lithium-induced|and|polyuria (l_conj) polyuria_8\NN\14113228|
D008094_D011141 NONE lithium_12\NN\14625458| (r_compound) concentration_13\NN\4916342|on|the|lithium|plasma (r_conj) effect_1\NN\34213|the|amiloride|polydipsia|and|concentration (l_nmod) polydipsia_6\NN\14040660|on|lithium-induced|and|polyuria (l_conj) polyuria_8\NN\14113228|
D008094_D011141 NONE lithium-treated_8\JJ\1740| (r_amod) patients_9\NNS\9898892|to|lithium-treated|suffering (l_acl) suffering_10\VBG\2110220|polydipsia|and|polyuria (l_conj) polyuria_14\NN\14113228|
D008094_D011141 NONE lithium_27\NN\14625458| (r_compound) levels_28\NNS\4916342|in|elevated|lithium (r_nmod) result_24\VB\2633881|would|levels|and|hazardous (r_ccomp) concluded_2\VBN\628491|it|is|relieve|result|. (l_ccomp) relieve_16\VB\205885|that|administration|might|patients (l_nsubj) administration_6\NN\1133281|acute|amiloride|patients (l_nmod) patients_9\NNS\9898892|to|lithium-treated|suffering (l_acl) suffering_10\VBG\2110220|polydipsia|and|polyuria (l_conj) polyuria_14\NN\14113228|
D018021_D059606 NONE licl_35\NN\1740|with (r_nmod) treated_33\VBN\2376958|chronically|licl (r_dep) investigated_28\VBN\644583|effect|was|rats|,|treated|. (l_nsubjpass) effect_1\NN\34213|the|amiloride|polydipsia|and|concentration (l_nmod) polydipsia_6\NN\14040660|on|lithium-induced|and|polyuria
D018021_D011141 NONE licl_35\NN\1740|with (r_nmod) treated_33\VBN\2376958|chronically|licl (r_dep) investigated_28\VBN\644583|effect|was|rats|,|treated|. (l_nsubjpass) effect_1\NN\34213|the|amiloride|polydipsia|and|concentration (l_nmod) polydipsia_6\NN\14040660|on|lithium-induced|and|polyuria (l_conj) polyuria_8\NN\14113228|
D011188_D003919 NONE potassium_42\NN\14625458| (r_compound) level_43\NN\4916342|in|the|plasma|potassium (r_nmod) elevation_38\NN\7445480|an|level (r_conj) levels_32\NNS\4916342|its|blood|and|elevation (r_conj) reduction_18\NN\351485|by|a|ratio|and|levels (r_nmod) accompanied_15\VBN\1835496|experiments|,|attenuation|was|reduction|. (l_nsubjpass) attenuation_6\NN\7427337|the|syndrome|amiloride (l_nmod) syndrome_11\NN\5870365|of|the|lithium-induced|diabetes-insipidus-like
3564823
D008012_D013035 NONE lidocaine_5\NN\3681148|by (r_nmod) relieved_3\VBN\205885|lidocaine (r_acl) spasm_2\NN\14299637|drug-induced|arterial|relieved|.
D013874_D002545 NONE pentothal_10\NN\2792049|sodium (r_nsubjpass) infused_13\JJ\1740|surgery|,|pentothal|was|intravenously|minimize|. (l_xcomp) minimize_15\VB\441445|to|ischaemia (l_dobj) ischaemia_17\NN\14195315|cerebral
D008012_D020301 NONE lidocaine_11\NN\3681148| (r_nsubjpass) given_13\VBN\2327200|precluded|,|lidocaine|was|intra-arterially|,|monitoring|,|counteract|. (l_xcomp) counteract_22\VB\2367363|to|vasospasm (l_dobj) vasospasm_24\NN\1740|the
2304736
D011224_D014550 CID prazosin-induced_0\JJ\1740| (r_amod) incontinence_2\NN\13473097|prazosin-induced|stress|.
D011224_D014550 CID prazosin_8\NN\2698769|due|to (r_nmod) case_1\NN\7283608|a|incontinence|prazosin|,|drug|, (l_nmod) incontinence_5\NN\13473097|of|genuine|stress
D011224_D014550 CID prazosin_8\NN\2698769| (r_dobj) taking_7\VBG\2367363|while|prazosin (r_advcl) present_2\VBP\2137132|who|incontinence|taking (l_nmod) incontinence_5\NN\13473097|with|stress
D011224_D014549 NONE prazosin_8\NN\2698769| (r_dobj) taking_7\VBG\2367363|while|prazosin (r_advcl) present_2\VBP\2137132|who|incontinence|taking (r_acl:relcl) patients_0\NNS\9898892|present (r_nsubj) change_10\VB\46534|patients|should|medication|considering|,|resolve|. (l_advcl) resolve_22\VB\352826|because|incontinence|may|spontaneously|change (l_nsubj) incontinence_20\NN\13473097|their
4071154
D007213_D051437 NONE indomethacin-induced_0\JJ\1740| (r_amod) insufficiency_2\NN\14462946|indomethacin-induced|renal|:|recurrence|.
D007213_D051437 NONE indomethacin_24\NN\3828465| (r_compound) therapy_25\NN\657604|after|indomethacin (r_nmod) pulmonale_22\NN\1740|cor|therapy (r_conj) cirrhosis_16\NN\14116321|with|,|ascites|,|and|pulmonale (r_nmod) patient_14\NN\9898892|in|a|cirrhosis (r_nmod) failure_9\NN\66216|of|acute|oliguric|renal|hyperkalemia|patient
D007213_D006947 CID indomethacin_24\NN\3828465| (r_compound) therapy_25\NN\657604|after|indomethacin (r_nmod) pulmonale_22\NN\1740|cor|therapy (r_conj) cirrhosis_16\NN\14116321|with|,|ascites|,|and|pulmonale (r_nmod) patient_14\NN\9898892|in|a|cirrhosis (r_nmod) failure_9\NN\66216|of|acute|oliguric|renal|hyperkalemia|patient (l_nmod) hyperkalemia_11\NN\14299637|with
D007213_D005355 CID indomethacin_24\NN\3828465| (r_compound) therapy_25\NN\657604|after|indomethacin (r_nmod) pulmonale_22\NN\1740|cor|therapy (r_conj) cirrhosis_16\NN\14116321|with|,|ascites|,|and|pulmonale
D007213_D001201 CID indomethacin_24\NN\3828465| (r_compound) therapy_25\NN\657604|after|indomethacin (r_nmod) pulmonale_22\NN\1740|cor|therapy (r_conj) cirrhosis_16\NN\14116321|with|,|ascites|,|and|pulmonale (l_conj) ascites_18\NNS\14204950|
D007213_D011660 CID indomethacin_24\NN\3828465| (r_compound) therapy_25\NN\657604|after|indomethacin (r_nmod) pulmonale_22\NN\1740|cor|therapy
D007213_D009846 CID indomethacin_16\NN\3828465|of (r_nmod) dose_14\NN\3740161|to|a|single|indomethacin (r_nmod) re-exposure_10\VBP\1740|while|dose (r_advcl) followed_5\VBD\1835496|restoration|withdrawal|,|re-exposure|caused|. (l_conj) caused_17\VBD\1617192|recurrence (l_dobj) recurrence_18\NN\7342049|oliguria (l_nmod) oliguria_22\NN\14299637|of|acute|reversible
3800626
D010423_D009408 CID pentazocine-induced_8\JJ\1740| (r_amod) myopathy_10\NN\14204950|due|pentazocine-induced|fibrous (r_nmod) neuropathy_1\JJ\1740|compression|nerve|myopathy|. (l_nmod) nerve_5\NN\5475681|of|the|radial
D010423_D009408 CID pentazocine-induced_10\JJ\1740| (r_amod) myopathy_11\NN\14204950|by|pentazocine-induced (r_nmod) affected_8\VBN\126264|myopathy (r_conj) neuropathy_3\JJ\1740|however|,|compression|due|affected
D010423_D020425 CID pentazocine-induced_8\JJ\1740| (r_amod) myopathy_10\NN\14204950|due|pentazocine-induced|fibrous (r_nmod) neuropathy_1\JJ\1740|compression|nerve|myopathy|. (l_nmod) nerve_5\NN\5475681|of|the|radial
D010423_D005355 CID pentazocine-induced_8\JJ\1740| (r_amod) myopathy_10\NN\14204950|due|pentazocine-induced|fibrous
D010423_D005355 CID pentazocine_11\NN\2707683| (r_compound) injection_12\NN\320852|of|repeated|pentazocine (r_nmod) effect_8\NN\34213|myopathy|is|a|common|injection|. (l_nsubj) myopathy_1\NN\14204950|fibrous
D010423_D005355 CID pentazocine-induced_6\JJ\1740| (r_amod) myopathy_8\NN\14204950|with|documented|pentazocine-induced|fibrous|triceps
D010423_D005355 CID pentazocine-induced_6\JJ\1740| (r_amod) myopathy_8\NN\14204950|with|documented|pentazocine-induced|fibrous|triceps (r_nmod) woman_3\NN\9605289|in|a|37-year-old|myopathy|bilaterally|and|history (r_nmod) showed_26\VBD\2137132|woman|,|examination|lesion|addition|. (l_nmod) addition_46\NN\3081021|in|myopathy (l_nmod) myopathy_50\NN\14204950|to|the|fibrous
D010423_D009135 CID pentazocine-induced_8\JJ\1740| (r_amod) myopathy_10\NN\14204950|due|pentazocine-induced|fibrous
D010423_D009135 CID pentazocine_11\NN\2707683| (r_compound) injection_12\NN\320852|of|repeated|pentazocine (r_nmod) effect_8\NN\34213|myopathy|is|a|common|injection|. (l_nsubj) myopathy_1\NN\14204950|fibrous
D010423_D009135 CID pentazocine-induced_10\JJ\1740| (r_amod) myopathy_11\NN\14204950|by|pentazocine-induced
D010423_D009135 CID pentazocine-induced_6\JJ\1740| (r_amod) myopathy_8\NN\14204950|with|documented|pentazocine-induced|fibrous|triceps
D010423_D009135 CID pentazocine-induced_6\JJ\1740| (r_amod) myopathy_8\NN\14204950|with|documented|pentazocine-induced|fibrous|triceps (r_nmod) woman_3\NN\9605289|in|a|37-year-old|myopathy|bilaterally|and|history (r_nmod) showed_26\VBD\2137132|woman|,|examination|lesion|addition|. (l_nmod) addition_46\NN\3081021|in|myopathy (l_nmod) myopathy_50\NN\14204950|to|the|fibrous
15804801
D017239_D003323 CID paclitaxel-eluting_6\JJ\1740| (r_amod) stent_7\NN\4493505|of|a|paclitaxel-eluting (r_nmod) implantation_3\NN\13526110|after|stent (r_nmod) aneurysm_1\NN\14057371|coronary|implantation|.
D017239_D003323 CID paclitaxel-eluting_20\JJ\1740| (r_amod) stent_21\NN\4493505|a|paclitaxel-eluting (r_dobj) receiving_18\VBG\2210855|after|stent (r_advcl) developed_6\VBD\1753788|who|aneurysm|months|receiving (l_dobj) aneurysm_9\NN\14057371|a|coronary
11773892
D016572_D007674 CID cyclosporine_5\NN\1740|and|tacrolimus (r_dep) inhibitors_4\NNS\20090|the|calcineurin|cyclosporine (r_nsubjpass) known_10\VBN\2110220|inhibitors|are|both|nephrotoxic|. (l_xcomp) nephrotoxic_13\JJ\1740|to|be
D016559_D007674 CID tacrolimus_7\NN\1740| (r_conj) cyclosporine_5\NN\1740|and|tacrolimus (r_dep) inhibitors_4\NNS\20090|the|calcineurin|cyclosporine (r_nsubjpass) known_10\VBN\2110220|inhibitors|are|both|nephrotoxic|. (l_xcomp) nephrotoxic_13\JJ\1740|to|be
D003404_D007676 NONE creatinine_20\NN\1740|sustained|serum (r_appos) crf_16\NN\1740|,|creatinine|>|mg/dl|n=41|;|and|esrd (r_dep) divided_2\VBN\140123|patients|were|groups|n=748|;|crf|. (l_nmod) groups_5\NNS\2137|into|three|:|controls (l_appos) controls_7\NNS\5190804|,|crf|, (l_conj) crf_10\NN\1740|no|or|esrd
D003404_D007676 NONE creatinine_20\NN\1740|sustained|serum (r_appos) crf_16\NN\1740|,|creatinine|>|mg/dl|n=41|;|and|esrd (r_dep) divided_2\VBN\140123|patients|were|groups|n=748|;|crf|. (l_nmod) groups_5\NNS\2137|into|three|:|controls (l_appos) controls_7\NNS\5190804|,|crf|, (l_conj) crf_10\NN\1740|no|or|esrd (l_conj) esrd_12\NN\1740|
D003404_D007676 NONE creatinine_20\NN\1740|sustained|serum (r_appos) crf_16\NN\1740|,|creatinine|>|mg/dl|n=41|;|and|esrd
D003404_D007676 NONE creatinine_20\NN\1740|sustained|serum (r_appos) crf_16\NN\1740|,|creatinine|>|mg/dl|n=41|;|and|esrd (l_conj) esrd_28\NN\1740|,|n=45
D003404_D007676 NONE creatinine_13\NN\1740| (r_compound) levels_14\NNS\4916342|higher|preoperative|serum|creatinine|,|percentage (r_dobj) had_9\VBD\2108377|patients|patients|levels|requirement|,|and|creatinine|. (l_nsubj) patients_8\NNS\9898892|crf|esrd (l_compound) crf_5\NN\1740|and
D003404_D007676 NONE creatinine_13\NN\1740| (r_compound) levels_14\NNS\4916342|higher|preoperative|serum|creatinine|,|percentage (r_dobj) had_9\VBD\2108377|patients|patients|levels|requirement|,|and|creatinine|. (l_nsubj) patients_8\NNS\9898892|crf|esrd (l_compound) esrd_7\NN\1740|
D003404_D007676 NONE creatinine_42\NN\1740|a|higher|1-year|serum (r_conj) had_9\VBD\2108377|patients|patients|levels|requirement|,|and|creatinine|. (l_nsubj) patients_8\NNS\9898892|crf|esrd (l_compound) crf_5\NN\1740|and
D003404_D007676 NONE creatinine_42\NN\1740|a|higher|1-year|serum (r_conj) had_9\VBD\2108377|patients|patients|levels|requirement|,|and|creatinine|. (l_nsubj) patients_8\NNS\9898892|crf|esrd (l_compound) esrd_7\NN\1740|
D003404_D007676 NONE creatinine_16\NN\1740|of|serum (r_nmod) increase_13\NN\13576355|that|an|creatinine|average|year|,|months|,|and|factors|odds (l_conj) factors_34\NNS\7326557|weeks|postoperatively|were|independent|risk|development (l_nmod) development_37\NN\248977|for|the|crf (l_nmod) crf_39\NN\1740|of|or|esrd
D003404_D007676 NONE creatinine_16\NN\1740|of|serum (r_nmod) increase_13\NN\13576355|that|an|creatinine|average|year|,|months|,|and|factors|odds (l_conj) factors_34\NNS\7326557|weeks|postoperatively|were|independent|risk|development (l_nmod) development_37\NN\248977|for|the|crf (l_nmod) crf_39\NN\1740|of|or|esrd (l_conj) esrd_41\NN\1740|
D003404_D007676 NONE creatinine_11\NN\1740|a|higher|preoperative|serum (r_dobj) have_4\VBP\2108377|patients|creatinine|and|likely|. (l_nsubj) patients_0\NNS\9898892|develop (l_acl:relcl) develop_2\VBP\1753788|who|esrd (l_dobj) esrd_3\NN\1740|
D003404_D007676 NONE creatinine_6\NN\1740|of|serum (r_nmod) increase_3\NN\13576355|an|creatinine|times (r_nsubj) predictive_13\JJ\1740|however|,|increase|postoperatively|is|more|development|. (l_nmod) development_16\NN\248977|of|the|crf (l_nmod) crf_18\NN\1740|of|or|esrd
D003404_D007676 NONE creatinine_6\NN\1740|of|serum (r_nmod) increase_3\NN\13576355|an|creatinine|times (r_nsubj) predictive_13\JJ\1740|however|,|increase|postoperatively|is|more|development|. (l_nmod) development_16\NN\248977|of|the|crf (l_nmod) crf_18\NN\1740|of|or|esrd (l_conj) esrd_20\NN\1740|
D003404_D006530 NONE creatinine_13\NN\1740| (r_compound) levels_14\NNS\4916342|higher|preoperative|serum|creatinine|,|percentage (l_appos) percentage_18\NN\13815742|a|greater|patients (l_nmod) patients_20\NNS\9898892|of|syndrome (l_nmod) syndrome_23\NN\5870365|with|hepatorenal|,
D003404_D006530 NONE creatinine_42\NN\1740|a|higher|1-year|serum (r_conj) had_9\VBD\2108377|patients|patients|levels|requirement|,|and|creatinine|. (l_dobj) levels_14\NNS\4916342|higher|preoperative|serum|creatinine|,|percentage (l_appos) percentage_18\NN\13815742|a|greater|patients (l_nmod) patients_20\NNS\9898892|of|syndrome (l_nmod) syndrome_23\NN\5870365|with|hepatorenal|,
D003404_D006530 NONE creatinine_11\NN\1740|a|higher|preoperative|serum (r_dobj) have_4\VBP\2108377|patients|creatinine|and|likely|. (l_conj) likely_15\JJ\1740|are|more|have (l_xcomp) have_17\VB\2108377|to|syndrome (l_dobj) syndrome_19\NN\5870365|hepatorenal
17466854
D008775_D002386 NONE methylprednisolone_15\NN\1740|of|and|gentamicin (r_nmod) administration_13\NN\1133281|after|the|methylprednisolone|space|end (l_nmod) end_26\NN\8568978|at|the|surgery (l_nmod) surgery_30\NN\6045562|of|routine|cataract (l_amod) cataract_29\JJ\1740|
D005839_D002386 NONE gentamicin_17\NN\2716866| (r_conj) methylprednisolone_15\NN\1740|of|and|gentamicin (r_nmod) administration_13\NN\1133281|after|the|methylprednisolone|space|end (l_nmod) end_26\NN\8568978|at|the|surgery (l_nmod) surgery_30\NN\6045562|of|routine|cataract (l_amod) cataract_29\JJ\1740|
D008775_D020250 CID methylprednisolone_5\NN\1740|of|and|gentamicin (r_nmod) administration_3\NN\1133281|the|methylprednisolone|space (r_nsubj) related_15\JJ\1740|administration|was|incidence (l_nmod) incidence_19\NN\13821570|to|a|high|effects (l_nmod) effects_22\NNS\13245626|of|side|nausea (l_nmod) nausea_24\NN\14299637|including|,|vomiting|,|and|headache (l_conj) vomiting_26\NN\116687|
D008775_D006261 CID methylprednisolone_5\NN\1740|of|and|gentamicin (r_nmod) administration_3\NN\1133281|the|methylprednisolone|space (r_nsubj) related_15\JJ\1740|administration|was|incidence (l_nmod) incidence_19\NN\13821570|to|a|high|effects (l_nmod) effects_22\NNS\13245626|of|side|nausea (l_nmod) nausea_24\NN\14299637|including|,|vomiting|,|and|headache (l_conj) headache_29\VB\1740|
D005839_D020250 CID gentamicin_7\NN\2716866| (r_conj) methylprednisolone_5\NN\1740|of|and|gentamicin (r_nmod) administration_3\NN\1133281|the|methylprednisolone|space (r_nsubj) related_15\JJ\1740|administration|was|incidence (l_nmod) incidence_19\NN\13821570|to|a|high|effects (l_nmod) effects_22\NNS\13245626|of|side|nausea (l_nmod) nausea_24\NN\14299637|including|,|vomiting|,|and|headache (l_conj) vomiting_26\NN\116687|
D005839_D006261 CID gentamicin_7\NN\2716866| (r_conj) methylprednisolone_5\NN\1740|of|and|gentamicin (r_nmod) administration_3\NN\1133281|the|methylprednisolone|space (r_nsubj) related_15\JJ\1740|administration|was|incidence (l_nmod) incidence_19\NN\13821570|to|a|high|effects (l_nmod) effects_22\NNS\13245626|of|side|nausea (l_nmod) nausea_24\NN\14299637|including|,|vomiting|,|and|headache (l_conj) headache_29\VB\1740|
8590259
C016986_D015814 CID apraclonidine-treated_8\JJ\1740| (r_amod) eyes_9\NNS\5945642|for|apraclonidine-treated (r_nmod) significant_6\JJ\1740|effects|were|statistically|eyes|study|and|significant|. (l_nsubj) effects_3\NNS\13245626|the|ocular|hypotensive (l_amod) hypotensive_2\JJ\1740|
C016986_D015814 CID apraclonidine_29\NN\1740|of|% (r_nmod) administration_25\NN\1133281|after|topical|apraclonidine (r_nmod) significant_16\JJ\1740|also|statistically|eyes|hours|administration (r_conj) significant_6\JJ\1740|effects|were|statistically|eyes|study|and|significant|. (l_nsubj) effects_3\NNS\13245626|the|ocular|hypotensive (l_amod) hypotensive_2\JJ\1740|
14568327
D007980_D004409 CID levodopa-induced_2\JJ\1740| (r_amod) dyskinesias_3\NNS\14084880|of|levodopa-induced
D007980_D004409 CID levodopa-induced_0\JJ\1740| (r_amod) dyskinesias_1\NNS\14084880|levodopa-induced|lids
D007980_D004409 CID levodopa-induced_0\JJ\1740| (r_amod) dyskinesias_1\NNS\14084880|levodopa-induced|lids (l_appos) lids_3\NNS\5313679|(|)
D007980_D004409 CID levodopa_32\NN\14604959| (r_compound) therapy_33\NN\657604|of|levodopa (r_nmod) duration_30\NN\15113229|therapy (r_conj) rate_18\NN\13815152|to|which|progression|,|severity|to|and|duration (r_nmod) degree_15\NN\4916342|the|rate (r_dobj) evaluated_13\VBD\670261|using|,|study|degree|involved|. (l_ccomp) involved_36\VBN\2676054|may|be|development (l_nmod) development_39\NN\248977|in|the|lids (l_nmod) lids_41\NNS\5313679|of
D007980_D004409 CID levodopa_20\NN\14604959| (r_compound) therapy_21\NN\657604|of|levodopa (r_nmod) initiation_18\NN\7450842|therapy (r_conj) monkeys_0\NNS\2469914|exposure|,|onset|prior|initiation (r_nsubj) developed_22\VBD\1753788|monkeys|dyskinesia|. (l_dobj) dyskinesia_23\NN\14084880|days
D007980_D004409 CID levodopa_31\NN\14604959|daily (r_compound) administration_32\NN\1133281|of|levodopa (r_nmod) days_28\NNS\15140892|11|administration (r_nmod) dyskinesia_23\NN\14084880|days
D007980_D004409 CID levodopa_20\NN\14604959| (r_compound) therapy_21\NN\657604|of|levodopa (r_nmod) initiation_18\NN\7450842|therapy (r_conj) monkeys_3\NNS\2469914|exposure|,|progression|duration|prior|initiation (r_nsubj) resistant_24\JJ\1740|contrast|,|monkeys|were|more|developing|developed|. (l_advcl) developing_26\VBG\1753788|to|lids (l_dobj) lids_27\NNS\5313679|(|e.g.
D007980_D004409 CID levodopa_20\NN\14604959| (r_compound) therapy_21\NN\657604|of|levodopa (r_nmod) initiation_18\NN\7450842|therapy (r_conj) monkeys_3\NNS\2469914|exposure|,|progression|duration|prior|initiation (r_nsubj) resistant_24\JJ\1740|contrast|,|monkeys|were|more|developing|developed|. (l_advcl) developed_32\VBD\1753788|,|dyskinesia|sooner|days|) (l_nsubj) dyskinesia_31\NNP\14084880|
D007980_D004409 CID levodopa_40\NN\14604959| (r_compound) administration_41\NN\1133281|of|chronic|levodopa (r_nmod) days_37\NNS\15140892|146|administration (r_dobj) developed_32\VBD\1753788|,|dyskinesia|sooner|days|) (r_advcl) resistant_24\JJ\1740|contrast|,|monkeys|were|more|developing|developed|. (l_advcl) developing_26\VBG\1753788|to|lids (l_dobj) lids_27\NNS\5313679|(|e.g.
D007980_D004409 CID levodopa_40\NN\14604959| (r_compound) administration_41\NN\1133281|of|chronic|levodopa (r_nmod) days_37\NNS\15140892|146|administration (r_dobj) developed_32\VBD\1753788|,|dyskinesia|sooner|days|) (l_nsubj) dyskinesia_31\NNP\14084880|
D007980_D004409 CID levodopa_24\NN\14604959|to (r_nmod) prior_22\RB\1740|levodopa (r_advmod) develop_9\VB\1753788|to|lids|monkeys|prior|and|demonstrate (l_dobj) lids_10\NNS\5313679|
D007980_D004409 CID levodopa_24\NN\14604959|to (r_nmod) prior_22\RB\1740|levodopa (r_advmod) develop_9\VB\1753788|to|lids|monkeys|prior|and|demonstrate (l_conj) demonstrate_26\VBP\2137132|value|studying (l_advcl) studying_34\VBG\630380|for|further|pathophysiology (l_dobj) pathophysiology_36\NN\1740|the|lids (l_nmod) lids_38\NNS\5313679|of
D007980_D010300 NONE levodopa-induced_2\JJ\1740| (r_amod) dyskinesias_3\NNS\14084880|of|levodopa-induced (r_nmod) development_0\NN\248977|dyskinesias|monkeys (l_nmod) monkeys_6\NNS\2469914|in|parkinsonian (l_amod) parkinsonian_5\JJ\1740|
D007980_D010300 NONE levodopa-induced_0\JJ\1740| (r_amod) dyskinesias_1\NNS\14084880|levodopa-induced|lids (r_nsubj) present_5\VBP\2137132|dyskinesias|problem|. (l_dobj) problem_8\NN\14408086|a|major|management (l_nmod) management_12\NN\1123598|for|the|long-term|patients (l_nmod) patients_20\NNS\9898892|of|disease (l_compound) disease_16\NN\14061805|parkinson|pd
D007980_D010300 NONE levodopa-induced_0\JJ\1740| (r_amod) dyskinesias_1\NNS\14084880|levodopa-induced|lids (r_nsubj) present_5\VBP\2137132|dyskinesias|problem|. (l_dobj) problem_8\NN\14408086|a|major|management (l_nmod) management_12\NN\1123598|for|the|long-term|patients (l_nmod) patients_20\NNS\9898892|of|disease (l_compound) disease_16\NN\14061805|parkinson|pd (l_appos) pd_18\NN\14625458|(|)
D015632_D010302 CID mptp-induced_7\JJ\1740| (r_amod) parkinsonism_8\NN\14085708|of|mptp-induced
D015632_D004409 NONE mptp-induced_7\JJ\1740| (r_amod) parkinsonism_8\NN\14085708|of|mptp-induced (r_nmod) types_5\NNS\5839024|with|different|parkinsonism (r_nmod) using_0\VBG\1156834|monkeys|types (r_advcl) evaluated_13\VBD\670261|using|,|study|degree|involved|. (l_ccomp) involved_36\VBN\2676054|may|be|development (l_nmod) development_39\NN\248977|in|the|lids (l_nmod) lids_41\NNS\5313679|of
D015632_D004409 NONE mptp_6\NN\1740| (r_compound) exposure_7\NN\5042871|with|acute|mptp (r_nmod) monkeys_0\NNS\2469914|exposure|,|onset|prior|initiation (r_nsubj) developed_22\VBD\1753788|monkeys|dyskinesia|. (l_dobj) dyskinesia_23\NN\14084880|days
D015632_D004409 NONE mptp_6\NN\1740| (r_compound) exposure_7\NN\5042871|with|long-term|mptp (r_nmod) monkeys_3\NNS\2469914|exposure|,|progression|duration|prior|initiation (r_nsubj) resistant_24\JJ\1740|contrast|,|monkeys|were|more|developing|developed|. (l_advcl) developing_26\VBG\1753788|to|lids (l_dobj) lids_27\NNS\5313679|(|e.g.
D015632_D004409 NONE mptp_6\NN\1740| (r_compound) exposure_7\NN\5042871|with|long-term|mptp (r_nmod) monkeys_3\NNS\2469914|exposure|,|progression|duration|prior|initiation (r_nsubj) resistant_24\JJ\1740|contrast|,|monkeys|were|more|developing|developed|. (l_advcl) developed_32\VBD\1753788|,|dyskinesia|sooner|days|) (l_nsubj) dyskinesia_31\NNP\14084880|
D007980_D010302 NONE levodopa_32\NN\14604959| (r_compound) therapy_33\NN\657604|of|levodopa (r_nmod) duration_30\NN\15113229|therapy (r_conj) rate_18\NN\13815152|to|which|progression|,|severity|to|and|duration (r_nmod) degree_15\NN\4916342|the|rate (r_dobj) evaluated_13\VBD\670261|using|,|study|degree|involved|. (l_advcl) using_0\VBG\1156834|monkeys|types (l_nmod) types_5\NNS\5839024|with|different|parkinsonism (l_nmod) parkinsonism_8\NN\14085708|of|mptp-induced
9522143
D011318_D034381 CID prilocaine_2\NN\1740|given (r_nmod) patients_0\NNS\9898892|prilocaine (r_nsubj) likely_5\JJ\1740|patients|were|more|develop|22|bupivacaine|. (l_xcomp) develop_7\VB\1753788|to|loss (l_dobj) loss_9\NN\13252973|hearing|(
D011318_D034381 CID prilocaine_12\NN\1740|after|and (r_nmod) db_10\NN\14622893|loss|was|10|prilocaine|db|. (l_nsubj) loss_3\NN\13252973|the|average|hearing|frequencies
D002045_D034381 CID bupivacaine_19\NN\1740|those|given|(|22|p (r_nmod) likely_5\JJ\1740|patients|were|more|develop|22|bupivacaine|. (l_xcomp) develop_7\VB\1753788|to|loss (l_dobj) loss_9\NN\13252973|hearing|(
D002045_D034381 CID bupivacaine_17\NN\1740|after (r_nmod) db_15\NN\14622893|15|bupivacaine (r_conj) db_10\NN\14622893|loss|was|10|prilocaine|db|. (l_nsubj) loss_3\NN\13252973|the|average|hearing|frequencies
15233872
C007145_D009203 NONE crataegus_5\NN\11585340|of (r_nmod) tincture_3\NN\14984973|of|crataegus (r_nmod) effect_1\NN\34213|cardioprotective|tincture|infarction|. (l_nmod) infarction_9\NN\14204950|on|isoproterenol-induced|myocardial|rats
C007145_D009203 NONE tcr_11\NN\1740|of (r_nmod) effect_9\NN\34213|the|protective|tcr|infarction (l_nmod) infarction_16\NN\14204950|on|induced|myocardial|rats
D007545_D009203 CID isoproterenol-induced_7\JJ\1740| (r_amod) infarction_9\NN\14204950|on|isoproterenol-induced|myocardial|rats
1378968
D008094_D007676 CID lithium-induced_8\JJ\1740| (r_amod) failure_11\NN\66216|on|lithium-induced|chronic|renal|rats
D008094_D007674 NONE lithium-induced_2\JJ\1740| (r_amod) nephropathy_3\NN\14573196|with|lithium-induced
D008094_D007674 NONE li-induced_4\JJ\1740| (r_amod) nephropathy_5\NN\14573196|li-induced|,|reduced|,
D008094_D051437 NONE lithium-induced_2\JJ\1740| (r_amod) nephropathy_3\NN\14573196|with|lithium-induced (r_nmod) rats_0\NNS\2329401|nephropathy (r_nsubjpass) subjected_5\VBN\137313|rats|were|protein|feeding|,|attempt|. (l_nmod) attempt_26\NN\407535|in|an|induce (l_acl) induce_28\VB\1627355|to|hyperfiltration (l_dobj) hyperfiltration_30\NN\1740|glomerular|and|progression|failure (l_nmod) failure_36\NN\66216|of|renal
D008094_D051437 NONE lithium_21\FW\14625458| (r_compound) rats_23\NNS\2329401|in|lithium|pretreated (r_nmod) decrease_16\VB\169651|levels|rats (r_conj) increase_13\VB\169651|to|gfr|and|decrease (r_xcomp) tended_11\VBD\2604760|fact|increase (r_conj) failed_1\VBD\1798936|hp|accentuante|and|tended|. (l_xcomp) accentuante_3\VB\1740|to|progression (l_dobj) progression_4\NN\8457976|failure (l_nmod) failure_7\NN\66216|of|renal
D008094_D011507 CID lithium_0\NNP\14625458| (r_nsubj) caused_2\VBD\1617192|lithium|also|proteinuria|absence|. (l_dobj) proteinuria_3\NN\14299637|and|hypertension
D008094_D011507 CID li-induced_4\JJ\1740| (r_amod) nephropathy_5\NN\14573196|li-induced|,|reduced|, (r_nsubjpass) associated_17\VBN\628491|that|nephropathy|is|proteinuria (l_nmod) proteinuria_19\NN\14299637|with|and|hypertension
D008094_D006973 CID lithium_0\NNP\14625458| (r_nsubj) caused_2\VBD\1617192|lithium|also|proteinuria|absence|. (l_dobj) proteinuria_3\NN\14299637|and|hypertension (l_conj) hypertension_6\NN\14057371|systolic
D008094_D006973 CID li-induced_4\JJ\1740| (r_amod) nephropathy_5\NN\14573196|li-induced|,|reduced|, (r_nsubjpass) associated_17\VBN\628491|that|nephropathy|is|proteinuria (l_nmod) proteinuria_19\NN\14299637|with|and|hypertension (l_conj) hypertension_23\NN\14057371|arterial|systolic
D008094_D005921 NONE lithium_0\NNP\14625458| (r_nsubj) caused_2\VBD\1617192|lithium|also|proteinuria|absence|. (l_nmod) absence_8\NN\14449405|in|glomerulosclerosis (l_nmod) glomerulosclerosis_10\NN\1740|of
D003404_D051437 NONE creatinine_18\NN\1740| (r_compound) levels_19\NNS\4916342|plasma|creatinine (r_dobj) decrease_16\VB\169651|levels|rats (r_conj) increase_13\VB\169651|to|gfr|and|decrease (r_xcomp) tended_11\VBD\2604760|fact|increase (r_conj) failed_1\VBD\1798936|hp|accentuante|and|tended|. (l_xcomp) accentuante_3\VB\1740|to|progression (l_dobj) progression_4\NN\8457976|failure (l_nmod) failure_7\NN\66216|of|renal
3503576
D003676_D006311 NONE deferoxamine_8\NN\1740| (r_compound) therapy_9\NN\657604|deferoxamine (r_dobj) receiving_7\VBG\2210855|therapy (r_acl) patients_6\NNS\9898892|in|receiving (r_nmod) neurotoxicity_4\NN\1740|of|auditory|patients
D003676_D006311 NONE deferoxamine_24\NN\1740|with|subcutaneous (r_nmod) therapy_20\NN\657604|iron|chelation|deferoxamine (r_dobj) receiving_17\VBG\2210855|who|were|therapy (r_acl:relcl) patients_11\NNS\9898892|in|89|anemia|receiving (r_nmod) documented_6\VBN\1000214|neurotoxicity|was|previously|patients|. (l_nsubjpass) neurotoxicity_3\NN\1740|visual|auditory
D003676_D006311 NONE deferoxamine_9\NN\1740| (r_compound) doses_10\NNS\3740161|deferoxamine (r_dobj) receiving_8\VBG\2210855|18|were|initially|doses|excess (r_advcl) restarted_24\VBN\1857717|receiving|,|therapy|was|doses|degree|,|and|exception|. (l_nmod) degree_39\NN\4916342|depending|on|the|abnormality (l_nmod) abnormality_42\NN\14034177|of|auditory
D003676_D006311 NONE deferoxamine_14\NN\1740| (r_dobj) receiving_13\VBG\2210855|not|deferoxamine (r_conj) patients_9\NNS\9898892|in|individual|receiving|and|receiving (r_nmod) demonstrated_5\VBN\2137132|deterioration|serially|patients|,|respectively|,|evidence|. (l_nmod) evidence_20\NN\5816287|provided|convincing|relation (l_nmod) relation_24\NN\2137|for|a|cause-and-effect|administration (l_nmod) administration_27\NN\1133281|between|deferoxamine|and|ototoxicity (l_conj) ototoxicity_29\NN\1740|
D003676_D006311 NONE deferoxamine_26\NN\1740| (r_compound) administration_27\NN\1133281|between|deferoxamine|and|ototoxicity (l_conj) ototoxicity_29\NN\1740|
D007501_D014786 NONE iron_18\NN\14625458| (r_compound) therapy_20\NN\657604|iron|chelation|deferoxamine (r_dobj) receiving_17\VBG\2210855|who|were|therapy (r_acl:relcl) patients_11\NNS\9898892|in|89|anemia|receiving (r_nmod) documented_6\VBN\1000214|neurotoxicity|was|previously|patients|. (l_nsubjpass) neurotoxicity_3\NN\1740|visual|auditory
D007501_D006311 NONE iron_18\NN\14625458| (r_compound) therapy_20\NN\657604|iron|chelation|deferoxamine (r_dobj) receiving_17\VBG\2210855|who|were|therapy (r_acl:relcl) patients_11\NNS\9898892|in|89|anemia|receiving (r_nmod) documented_6\VBN\1000214|neurotoxicity|was|previously|patients|. (l_nsubjpass) neurotoxicity_3\NN\1740|visual|auditory
D007501_D000740 NONE iron_18\NN\14625458| (r_compound) therapy_20\NN\657604|iron|chelation|deferoxamine (r_dobj) receiving_17\VBG\2210855|who|were|therapy (r_acl:relcl) patients_11\NNS\9898892|in|89|anemia|receiving (l_nmod) anemia_14\NN\14189204|with|transfusion-dependent
D003676_D014786 NONE deferoxamine_24\NN\1740|with|subcutaneous (r_nmod) therapy_20\NN\657604|iron|chelation|deferoxamine (r_dobj) receiving_17\VBG\2210855|who|were|therapy (r_acl:relcl) patients_11\NNS\9898892|in|89|anemia|receiving (r_nmod) documented_6\VBN\1000214|neurotoxicity|was|previously|patients|. (l_nsubjpass) neurotoxicity_3\NN\1740|visual|auditory
D003676_D000740 NONE deferoxamine_24\NN\1740|with|subcutaneous (r_nmod) therapy_20\NN\657604|iron|chelation|deferoxamine (r_dobj) receiving_17\VBG\2210855|who|were|therapy (r_acl:relcl) patients_11\NNS\9898892|in|89|anemia|receiving (l_nmod) anemia_14\NN\14189204|with|transfusion-dependent
D003676_D064420 NONE deferoxamine_9\NN\1740| (r_compound) doses_10\NNS\3740161|deferoxamine (r_dobj) receiving_8\VBG\2210855|18|were|initially|doses|excess (r_advcl) restarted_24\VBN\1857717|receiving|,|therapy|was|doses|degree|,|and|exception|. (l_conj) exception_47\NN\5706954|with|the|cases (l_nmod) cases_50\NNS\7283608|of|two|demonstrated (l_acl:relcl) demonstrated_55\VBN\2137132|toxicity|was (l_nsubjpass) toxicity_53\NN\13576101|no|further
7628595
D014805_D064420 NONE b12_6\NN\1740|of|vitamin|and (r_nmod) role_3\NN\719494|of|the|b12 (r_nmod) study_0\NN\635850|role|supplementation|. (l_conj) supplementation_10\NN\5108947|folinic|acid|preventing (l_acl) preventing_12\VBG\1740|in|toxicity (l_dobj) toxicity_14\NN\13576101|hematologic|zidovudine
D002955_D064420 NONE acid_9\NN\14818238| (r_compound) supplementation_10\NN\5108947|folinic|acid|preventing (l_acl) preventing_12\VBG\1740|in|toxicity (l_dobj) toxicity_14\NN\13576101|hematologic|zidovudine
D015215_D064420 NONE zidovudine_16\NN\3834836|of (r_nmod) toxicity_14\NN\13576101|hematologic|zidovudine
D014805_D001855 NONE b12_13\NN\1740|of|vitamin|and (r_nmod) role_10\NN\719494|the|b12|supplementation (l_nmod) supplementation_17\NN\5108947|folinic|acid|preventing (l_acl) preventing_19\VBG\1740|in|suppression (l_dobj) suppression_24\NN\13489037|zidovudine|(zdv)-induced|bone|marrow
D014805_D001855 NONE b12_6\NN\1740|between|vitamin (r_nmod) correlation_3\NN\13841213|no|b12 (r_nsubj) was_1\VBD\836236|there|correlation|or|folate|. (l_conj) folate_8\VBP\1740|levels (l_dobj) levels_9\NNS\4916342|and|development (l_conj) development_11\NN\248977|myelosuppression (l_nmod) myelosuppression_13\NN\1740|of
D014805_D001855 NONE b12_1\NN\1740|vitamin|and|supplementation (r_nsubj) seem_11\VB\2604760|b12|does|not|useful|preventing|,|excluded|. (l_advcl) preventing_14\VBG\1740|in|or|reducing (l_conj) reducing_16\VBG\441445|myelotoxicity|population (l_dobj) myelotoxicity_18\NN\1740|zdv-induced
D002955_D001855 NONE acid_16\NN\14818238| (r_compound) supplementation_17\NN\5108947|folinic|acid|preventing (l_acl) preventing_19\VBG\1740|in|suppression (l_dobj) suppression_24\NN\13489037|zidovudine|(zdv)-induced|bone|marrow
D002955_D001855 NONE acid_4\NN\14818238| (r_compound) supplementation_5\NN\5108947|folinic|acid|therapy (r_conj) b12_1\NN\1740|vitamin|and|supplementation (r_nsubj) seem_11\VB\2604760|b12|does|not|useful|preventing|,|excluded|. (l_advcl) preventing_14\VBG\1740|in|or|reducing (l_conj) reducing_16\VBG\441445|myelotoxicity|population (l_dobj) myelotoxicity_18\NN\1740|zdv-induced
D015215_D001855 CID zidovudine_20\NN\3834836| (r_compound) suppression_24\NN\13489037|zidovudine|(zdv)-induced|bone|marrow
D015215_D001855 CID (zdv)-induced_21\JJ\1740| (r_amod) suppression_24\NN\13489037|zidovudine|(zdv)-induced|bone|marrow
D015215_D001855 CID zdv_7\NN\3834836| (r_compound) therapy_8\NN\657604|of|zdv (r_nmod) supplementation_5\NN\5108947|folinic|acid|therapy (r_conj) b12_1\NN\1740|vitamin|and|supplementation (r_nsubj) seem_11\VB\2604760|b12|does|not|useful|preventing|,|excluded|. (l_advcl) preventing_14\VBG\1740|in|or|reducing (l_conj) reducing_16\VBG\441445|myelotoxicity|population (l_dobj) myelotoxicity_18\NN\1740|zdv-induced
D015215_D001855 CID zdv-induced_17\JJ\1740| (r_amod) myelotoxicity_18\NN\1740|zdv-induced
D015215_D015658 NONE zdv_18\NN\3834836|either (r_dobj) receive_16\VB\2210855|to|zdv|(|daily|alone|=|or|combination (r_xcomp) randomized_14\VBN\278117|patients|were|receive|. (l_nsubjpass) patients_5\NNS\9898892|virus|(hiv)-infected|cd4|counts|<|500/mm3 (l_amod) (hiv)-infected_4\JJ\1740|
D002955_D015658 NONE acid_38\NN\14818238|with|folinic (r_nmod) combination_35\NN\7951464|in|acid|mg|and|b12 (r_conj) receive_16\VB\2210855|to|zdv|(|daily|alone|=|or|combination (r_xcomp) randomized_14\VBN\278117|patients|were|receive|. (l_nsubjpass) patients_5\NNS\9898892|virus|(hiv)-infected|cd4|counts|<|500/mm3 (l_amod) (hiv)-infected_4\JJ\1740|
D014805_D015658 NONE b12_47\NN\1740|intramascular|vitamin|micrograms|group (r_conj) combination_35\NN\7951464|in|acid|mg|and|b12 (r_conj) receive_16\VB\2210855|to|zdv|(|daily|alone|=|or|combination (r_xcomp) randomized_14\VBN\278117|patients|were|receive|. (l_nsubjpass) patients_5\NNS\9898892|virus|(hiv)-infected|cd4|counts|<|500/mm3 (l_amod) (hiv)-infected_4\JJ\1740|
D005492_D001855 NONE folate_8\VBP\1740|levels (l_dobj) levels_9\NNS\4916342|and|development (l_conj) development_11\NN\248977|myelosuppression (l_nmod) myelosuppression_13\NN\1740|of
16298782
D019331_D006311 NONE ester_2\NN\14727670|nitro-l-arginine|methyl|:|protector|. (l_dep) protector_6\NN\10466918|a|potential|ototoxicity (l_nmod) ototoxicity_9\NN\1740|against|gentamicin
D005839_D006311 NONE gentamicin_8\NN\2716866| (r_compound) ototoxicity_9\NN\1740|against|gentamicin
D009569_D006316 NONE oxide_2\NN\14818238| (r_compound) ester_9\NN\14727670|the|nitric|oxide|(|no|)|inhibitor|nitro-l-arginine|methyl|l-name (r_nsubj) act_14\VB\1619354|ester|may|otoprotectant|,|but|needed (l_nmod) otoprotectant_17\NN\1740|as|an|loss (l_nmod) loss_21\NN\13252973|against|high-frequency|hearing|caused
D009569_D006316 NONE no_4\NN\7204911| (r_compound) ester_9\NN\14727670|the|nitric|oxide|(|no|)|inhibitor|nitro-l-arginine|methyl|l-name (r_nsubj) act_14\VB\1619354|ester|may|otoprotectant|,|but|needed (l_nmod) otoprotectant_17\NN\1740|as|an|loss (l_nmod) loss_21\NN\13252973|against|high-frequency|hearing|caused
D019331_D006316 NONE ester_9\NN\14727670|the|nitric|oxide|(|no|)|inhibitor|nitro-l-arginine|methyl|l-name (r_nsubj) act_14\VB\1619354|ester|may|otoprotectant|,|but|needed (l_nmod) otoprotectant_17\NN\1740|as|an|loss (l_nmod) loss_21\NN\13252973|against|high-frequency|hearing|caused
D019331_D006316 NONE l-name_11\NN\1740|(|) (r_appos) ester_9\NN\14727670|the|nitric|oxide|(|no|)|inhibitor|nitro-l-arginine|methyl|l-name (r_nsubj) act_14\VB\1619354|ester|may|otoprotectant|,|but|needed (l_nmod) otoprotectant_17\NN\1740|as|an|loss (l_nmod) loss_21\NN\13252973|against|high-frequency|hearing|caused
D005839_D006316 NONE gentamicin_24\NN\2716866|by (r_nmod) caused_22\VBN\1617192|gentamicin (r_acl) loss_21\NN\13252973|against|high-frequency|hearing|caused
D009569_D006311 NONE no_17\NN\7204911|of (r_nmod) production_15\NN\30358|the|no (r_dobj) involves_13\VBZ\2676054|as|mechanism|production (r_advcl) problem_6\NN\14408086|ototoxicity|is|a|serious|health|and|,|involves|need (l_nsubj) ototoxicity_1\NN\1740|their
D009569_D006311 NONE no_17\NN\7204911|of (r_nmod) production_15\NN\30358|the|no (r_dobj) involves_13\VBZ\2676054|as|mechanism|production (l_nsubj) mechanism_12\NN\13446390|their|ototoxic (l_amod) ototoxic_11\JJ\1740|
D009569_D006311 NONE no_26\DT\7204911| (r_compound) inhibitors_27\NNS\20090|of|no (r_nmod) use_24\NN\407535|the|inhibitors|prevention (r_dobj) assess_22\VB\670261|to|use (r_xcomp) need_20\VBP\2604760|,|we|assess|. (r_conj) problem_6\NN\14408086|ototoxicity|is|a|serious|health|and|,|involves|need (l_nsubj) ototoxicity_1\NN\1740|their
D009569_D006311 NONE no_26\DT\7204911| (r_compound) inhibitors_27\NNS\20090|of|no (r_nmod) use_24\NN\407535|the|inhibitors|prevention (r_dobj) assess_22\VB\670261|to|use (r_xcomp) need_20\VBP\2604760|,|we|assess|. (r_conj) problem_6\NN\14408086|ototoxicity|is|a|serious|health|and|,|involves|need (l_advcl) involves_13\VBZ\2676054|as|mechanism|production (l_nsubj) mechanism_12\NN\13446390|their|ototoxic (l_amod) ototoxic_11\JJ\1740|
D009569_D006319 NONE no_17\NN\7204911|of (r_nmod) production_15\NN\30358|the|no (r_dobj) involves_13\VBZ\2676054|as|mechanism|production (r_advcl) problem_6\NN\14408086|ototoxicity|is|a|serious|health|and|,|involves|need (l_conj) need_20\VBP\2604760|,|we|assess|. (l_xcomp) assess_22\VB\670261|to|use (l_dobj) use_24\NN\407535|the|inhibitors|prevention (l_nmod) prevention_30\NN\1073995|for|the|loss (l_nmod) loss_35\NN\13252973|of|aminoglycoside-induced|sensorineural|hearing
D009569_D006319 NONE no_26\DT\7204911| (r_compound) inhibitors_27\NNS\20090|of|no (r_nmod) use_24\NN\407535|the|inhibitors|prevention (l_nmod) prevention_30\NN\1073995|for|the|loss (l_nmod) loss_35\NN\13252973|of|aminoglycoside-induced|sensorineural|hearing
D000617_D006311 NONE aminoglycoside-induced_32\JJ\1740| (r_amod) loss_35\NN\13252973|of|aminoglycoside-induced|sensorineural|hearing (r_nmod) prevention_30\NN\1073995|for|the|loss (r_nmod) use_24\NN\407535|the|inhibitors|prevention (r_dobj) assess_22\VB\670261|to|use (r_xcomp) need_20\VBP\2604760|,|we|assess|. (r_conj) problem_6\NN\14408086|ototoxicity|is|a|serious|health|and|,|involves|need (l_nsubj) ototoxicity_1\NN\1740|their
D000617_D006311 NONE aminoglycoside-induced_32\JJ\1740| (r_amod) loss_35\NN\13252973|of|aminoglycoside-induced|sensorineural|hearing (r_nmod) prevention_30\NN\1073995|for|the|loss (r_nmod) use_24\NN\407535|the|inhibitors|prevention (r_dobj) assess_22\VB\670261|to|use (r_xcomp) need_20\VBP\2604760|,|we|assess|. (r_conj) problem_6\NN\14408086|ototoxicity|is|a|serious|health|and|,|involves|need (l_advcl) involves_13\VBZ\2676054|as|mechanism|production (l_nsubj) mechanism_12\NN\13446390|their|ototoxic (l_amod) ototoxic_11\JJ\1740|
D000617_D006319 NONE aminoglycoside-induced_32\JJ\1740| (r_amod) loss_35\NN\13252973|of|aminoglycoside-induced|sensorineural|hearing
D019331_D034381 NONE l-name_0\NNP\1740| (r_nsubj) reduced_1\VBD\441445|l-name|loss|,|but|gave|. (l_dobj) loss_4\NN\13252973|gentamicin-induced|hearing|range
D005839_D034381 CID gentamicin-induced_2\JJ\1740| (r_amod) loss_4\NN\13252973|gentamicin-induced|hearing|range
6538499
D011092_D064420 NONE 400_4\CD\1740| (r_nummod) glycol_3\NN\14766364|of|polyethylene|400 (r_nmod) effect_0\NN\34213|glycol|toxicity|. (l_nmod) toxicity_7\NN\13576101|on|adriamycin|mice
D004317_D064420 NONE adriamycin_6\NN\1740| (r_compound) toxicity_7\NN\13576101|on|adriamycin|mice
D004317_D009202 CID adr-induced_8\JJ\1740| (r_amod) alterations_11\NNS\7283608|against|adr-induced|cardiac|morphological
D004317_D007939 NONE adr_6\NN\1740| (r_compound) antitumor_7\NN\1740|adr (r_compound) activity_8\NN\30358|the|antitumor|leukemia (l_nmod) leukemia_11\NN\14239918|in|l1210|and|tumor
D004317_D002286 NONE adr_6\NN\1740| (r_compound) antitumor_7\NN\1740|adr (r_compound) activity_8\NN\30358|the|antitumor|leukemia (l_nmod) leukemia_11\NN\14239918|in|l1210|and|tumor (l_conj) tumor_16\NN\14234074|ascites
12653683
D012964_D009404 NONE sodium_1\NN\14625458| (r_compound) channel_2\NN\6251781|epithelial|sodium|enac (r_compound) expression_10\NN\4679549|channel|mrna|rats|. (l_nmod) rats_12\NNS\2329401|in|syndrome (l_nmod) syndrome_17\NN\5870365|puromycin|aminonucleoside-induced|nephrotic
D012964_D009404 NONE sodium_6\NN\14625458| (r_compound) excretion_7\NN\13466586|urinary|sodium (r_nsubjpass) decreased_9\VBN\169651|syndrome|,|excretion|is|phase|. (l_nmod) syndrome_3\NN\5870365|in|experimental|nephrotic
D011692_D009404 CID aminonucleoside-induced_15\JJ\1740| (r_amod) syndrome_17\NN\5870365|puromycin|aminonucleoside-induced|nephrotic
D011692_D009404 CID aminonucleoside_12\NN\1740| (r_compound) syndrome_15\NN\5870365|in|puromycin|aminonucleoside|(pan)-induced|nephrotic
D011692_D009404 CID (pan)-induced_13\JJ\1740| (r_amod) syndrome_15\NN\5870365|in|puromycin|aminonucleoside|(pan)-induced|nephrotic
D011692_D009404 CID pan-induced_22\JJ\1740| (r_amod) syndrome_24\NN\5870365|of|pan-induced|nephrotic
D012964_D011507 NONE sodium_5\NN\14625458| (r_compound) excretion_6\NN\13466586|of|urinary|sodium (r_nmod) courses_2\NNS\883297|the|time|excretion|,|concentration (l_appos) concentration_10\NN\4916342|plasma|aldosterone|and|proteinuria (l_conj) proteinuria_12\NN\14299637|
D012964_D011507 NONE sodium_4\NN\14625458| (r_compound) excretion_5\NN\13466586|of|urinary|sodium (r_nmod) kinetics_1\NNS\6100236|the|excretion|and|appearance (l_conj) appearance_8\NN\4723816|the|proteinuria (l_nmod) proteinuria_10\NN\14299637|of
D000450_D011507 NONE aldosterone_9\NN\14751863| (r_compound) concentration_10\NN\4916342|plasma|aldosterone|and|proteinuria (l_conj) proteinuria_12\NN\14299637|
D011692_D011507 CID pan_26\NN\3101986|of|either|or|vehicle (r_nmod) dose_23\NN\3740161|with|a|single|pan (r_nmod) treated_19\VBN\2376958|dose (r_acl) rats_18\NNS\2329401|in|male|sprague-dawley|treated (r_nmod) studied_14\VBN\630380|courses|were|rats|. (l_nsubjpass) courses_2\NNS\883297|the|time|excretion|,|concentration (l_appos) concentration_10\NN\4916342|plasma|aldosterone|and|proteinuria (l_conj) proteinuria_12\NN\14299637|
D000450_D009404 NONE aldosterone_36\NN\14751863|by (r_nmod) regulation_34\NN\6652242|from|the|aldosterone (r_nmod) escape_31\VB\2075462|to|regulation|day (r_xcomp) appears_29\VBZ\2604760|escape (r_conj) increased_11\VBN\169651|conclusion|,|expression|is|phase|,|but|appears|. (l_nmod) phase_16\NN\15113229|in|the|early|model (l_nmod) model_20\NN\5888929|of|the|experimental|syndrome|rats (l_nmod) syndrome_24\NN\5870365|of|pan-induced|nephrotic
3615541
D000661_D006948 CID amphetamine-induced_6\JJ\1740| (r_amod) hyperactivity_7\NN\14052403|of|amphetamine-induced
D002116_D006948 NONE calcitonin_10\NN\5413241| (r_compound) injections_11\NNS\320852|by|intracerebral|calcitonin (r_nmod) localization_1\NN\151497|regional|antagonism|injections|. (l_nmod) antagonism_4\NN\24720|of|the|hyperactivity (l_nmod) hyperactivity_7\NN\14052403|of|amphetamine-induced
20084309
D008874_D020521 NONE mz_38\NN\1740| (r_compound) dose_39\NN\3740161|the|mz (r_conj) duration_26\NN\15113229|test|,|regurgitation|and|dose (r_appos) variables_13\NNS\2452|of|the|clinical|:|age|,|duration (l_appos) age_15\NN\4916342|,|sex|,|stroke (l_conj) stroke_19\NN\556313|,|myocardiopathy
D008874_D009202 NONE mz_38\NN\1740| (r_compound) dose_39\NN\3740161|the|mz (r_conj) duration_26\NN\15113229|test|,|regurgitation|and|dose (r_appos) variables_13\NNS\2452|of|the|clinical|:|age|,|duration (l_appos) age_15\NN\4916342|,|sex|,|stroke (l_conj) stroke_19\NN\556313|,|myocardiopathy (l_conj) myocardiopathy_21\JJ\1740|mp
D008874_D009202 NONE mz_38\NN\1740| (r_compound) dose_39\NN\3740161|the|mz (r_conj) duration_26\NN\15113229|test|,|regurgitation|and|dose (r_appos) variables_13\NNS\2452|of|the|clinical|:|age|,|duration (l_appos) age_15\NN\4916342|,|sex|,|stroke (l_conj) stroke_19\NN\556313|,|myocardiopathy (l_conj) myocardiopathy_21\JJ\1740|mp (l_appos) mp_23\NN\10249459|(|)
D008874_D009202 NONE mz_17\NN\1740|of (r_nmod) doses_15\NNS\3740161|high|mz|> (r_conj) mr_6\NN\6339416|severe|,|mp|and|doses (l_conj) mp_8\NN\10249459|%
D008874_D008944 NONE mz_38\NN\1740| (r_compound) dose_39\NN\3740161|the|mz (r_conj) duration_26\NN\15113229|test|,|regurgitation|and|dose (l_conj) regurgitation_32\NN\7406350|mitral|mr
D008874_D008944 NONE mz_38\NN\1740| (r_compound) dose_39\NN\3740161|the|mz (r_conj) duration_26\NN\15113229|test|,|regurgitation|and|dose (l_conj) regurgitation_32\NN\7406350|mitral|mr (l_appos) mr_34\NN\6339416|(|)
D008874_D008944 NONE mz_17\NN\1740|of (r_nmod) doses_15\NNS\3740161|high|mz|> (r_conj) mr_6\NN\6339416|severe|,|mp|and|doses
D008874_D000860 CID mz_44\JJ\1740| (r_amod) use_45\NN\407535|by|mz (r_nmod) caused_42\VBN\1617192|use (r_acl) hypoxia_41\NN\14035298|due|caused (r_nmod) event_10\NN\23100|hypoxia|was|the|common|patients|;|presented|8|hypoxia|. (l_nsubj) hypoxia_1\NN\14035298|mild|%
D008874_D000860 CID mz_44\JJ\1740| (r_amod) use_45\NN\407535|by|mz (r_nmod) caused_42\VBN\1617192|use (r_acl) hypoxia_41\NN\14035298|due|caused (r_nmod) event_10\NN\23100|hypoxia|was|the|common|patients|;|presented|8|hypoxia|. (l_parataxis) presented_22\VBD\2137132|patients|hypoxia|obstruction (l_dobj) hypoxia_24\NN\14035298|transient
D008874_D000860 CID mz_44\JJ\1740| (r_amod) use_45\NN\407535|by|mz (r_nmod) caused_42\VBN\1617192|use (r_acl) hypoxia_41\NN\14035298|due|caused
D008874_D000402 NONE mz_44\JJ\1740| (r_amod) use_45\NN\407535|by|mz (r_nmod) caused_42\VBN\1617192|use (r_acl) hypoxia_41\NN\14035298|due|caused (r_nmod) event_10\NN\23100|hypoxia|was|the|common|patients|;|presented|8|hypoxia|. (l_parataxis) presented_22\VBD\2137132|patients|hypoxia|obstruction (l_nmod) obstruction_29\NN\4341686|due|upper|airway|introduction
1786266
D000928_D001480 NONE antidepressant_3\JJ\1740| (r_amod) use_4\NN\407535|antidepressant (r_conj) syndrome_1\NN\5870365|rabbit|,|use|,|and|spect
15325671
D003520_D066126 NONE cyclophosphamide-based_7\JJ\1740| (r_dep) high-dose_6\JJ\1740|cyclophosphamide-based (r_amod) chemotherapy_8\NN\661091|with|high-dose|cancer (r_nmod) association_4\NN\8008335|in|chemotherapy (r_nmod) observed_2\VBN\2163746|association (r_acl) toxicity_1\NN\13576101|cardiac|observed|.
D003520_D066126 NONE cyclophosphamide-related_3\JJ\1740| (r_amod) toxicity_5\NN\13576101|of|transient|cyclophosphamide-related|cardiac
D003520_D001943 NONE cyclophosphamide-based_7\JJ\1740| (r_dep) high-dose_6\JJ\1740|cyclophosphamide-based (r_amod) chemotherapy_8\NN\661091|with|high-dose|cancer (l_nmod) cancer_12\NN\14239425|for|metastatic|breast
D003520_D001943 NONE cyclophosphamide_10\NN\1740|,|thiotepa|,|and|carboplatin (r_conj) melphalan_7\NN\2722458|and|high-dose|cyclophosphamide (r_conj) paclitaxel_5\NN\1740|,|melphalan (r_dobj) combined_4\VBD\2630189|design|we|paclitaxel|regimen|. (l_nmod) regimen_21\NN\5898568|in|a|sequential|high-dose|patients (l_nmod) patients_23\NNS\9898892|for|cancer (l_nmod) cancer_27\NN\14239425|with|metastatic|breast
D003520_D001943 NONE cyclophosphamide_14\NN\1740|96-h|infusional (r_dobj) receiving_11\VBG\2210855|cyclophosphamide (r_acl) cancer_10\NN\14239425|with|chemotherapy-responsive|metastatic|breast|receiving
D017239_D001943 NONE paclitaxel_5\NN\1740|,|melphalan (r_dobj) combined_4\VBD\2630189|design|we|paclitaxel|regimen|. (l_nmod) regimen_21\NN\5898568|in|a|sequential|high-dose|patients (l_nmod) patients_23\NNS\9898892|for|cancer (l_nmod) cancer_27\NN\14239425|with|metastatic|breast
D008558_D001943 NONE melphalan_7\NN\2722458|and|high-dose|cyclophosphamide (r_conj) paclitaxel_5\NN\1740|,|melphalan (r_dobj) combined_4\VBD\2630189|design|we|paclitaxel|regimen|. (l_nmod) regimen_21\NN\5898568|in|a|sequential|high-dose|patients (l_nmod) patients_23\NNS\9898892|for|cancer (l_nmod) cancer_27\NN\14239425|with|metastatic|breast
D013852_D001943 NONE thiotepa_12\NN\2722458| (r_conj) cyclophosphamide_10\NN\1740|,|thiotepa|,|and|carboplatin (r_conj) melphalan_7\NN\2722458|and|high-dose|cyclophosphamide (r_conj) paclitaxel_5\NN\1740|,|melphalan (r_dobj) combined_4\VBD\2630189|design|we|paclitaxel|regimen|. (l_nmod) regimen_21\NN\5898568|in|a|sequential|high-dose|patients (l_nmod) patients_23\NNS\9898892|for|cancer (l_nmod) cancer_27\NN\14239425|with|metastatic|breast
D016190_D001943 NONE carboplatin_15\NN\1740| (r_conj) cyclophosphamide_10\NN\1740|,|thiotepa|,|and|carboplatin (r_conj) melphalan_7\NN\2722458|and|high-dose|cyclophosphamide (r_conj) paclitaxel_5\NN\1740|,|melphalan (r_dobj) combined_4\VBD\2630189|design|we|paclitaxel|regimen|. (l_nmod) regimen_21\NN\5898568|in|a|sequential|high-dose|patients (l_nmod) patients_23\NNS\9898892|for|cancer (l_nmod) cancer_27\NN\14239425|with|metastatic|breast
D003520_D006333 CID cyclophosphamide_14\NN\1740|96-h|infusional (r_dobj) receiving_11\VBG\2210855|cyclophosphamide (r_acl) cancer_10\NN\14239425|with|chemotherapy-responsive|metastatic|breast|receiving (r_nmod) women_5\NNS\9605289|on|61|cancer (r_nmod) performed_2\VBN\2367363|analysis|was|women|part|:|presence|. (l_nmod) part_16\NN\31921|as|regimen|assess (l_acl) assess_24\VB\670261|to|association (l_dobj) association_25\NN\8008335|presence (l_nmod) presence_27\NN\13954253|between|failure (l_nmod) failure_32\NN\66216|of|peritransplant|congestive|heart|chf|and|characteristics
D003520_D006333 CID cyclophosphamide_14\NN\1740|96-h|infusional (r_dobj) receiving_11\VBG\2210855|cyclophosphamide (r_acl) cancer_10\NN\14239425|with|chemotherapy-responsive|metastatic|breast|receiving (r_nmod) women_5\NNS\9605289|on|61|cancer (r_nmod) performed_2\VBN\2367363|analysis|was|women|part|:|presence|. (l_nmod) part_16\NN\31921|as|regimen|assess (l_acl) assess_24\VB\670261|to|association (l_dobj) association_25\NN\8008335|presence (l_nmod) presence_27\NN\13954253|between|failure (l_nmod) failure_32\NN\66216|of|peritransplant|congestive|heart|chf|and|characteristics (l_appos) chf_34\NN\1740|(|)
D003520_D006333 CID cyclophosphamide_18\NN\1740|following|infusional|decline (r_nmod) developed_10\VBD\1753788|results|chf|cyclophosphamide|. (l_dobj) chf_15\NN\1740|reversible|grade|3
D003520_D006333 CID cyclophosphamide_5\NN\1740|during|infusional (r_nmod) monitoring_2\NN\879759|routine|ekg|cyclophosphamide (r_nsubj) predict_8\VB\916909|monitoring|did|not|development|. (l_dobj) development_10\NN\248977|chf (l_compound) chf_9\NN\1740|
D003520_D006973 NONE cyclophosphamide_14\NN\1740|96-h|infusional (r_dobj) receiving_11\VBG\2210855|cyclophosphamide (r_acl) cancer_10\NN\14239425|with|chemotherapy-responsive|metastatic|breast|receiving (r_nmod) women_5\NNS\9605289|on|61|cancer (r_nmod) performed_2\VBN\2367363|analysis|was|women|part|:|presence|. (l_dep) presence_42\NN\13954253|abnormalities|hypertension|history|use (l_conj) hypertension_52\NN\14057371|,
D003520_D003920 NONE cyclophosphamide_14\NN\1740|96-h|infusional (r_dobj) receiving_11\VBG\2210855|cyclophosphamide (r_acl) cancer_10\NN\14239425|with|chemotherapy-responsive|metastatic|breast|receiving (r_nmod) women_5\NNS\9605289|on|61|cancer (r_nmod) performed_2\VBN\2367363|analysis|was|women|part|:|presence|. (l_dep) presence_42\NN\13954253|abnormalities|hypertension|history|use (l_nmod) history_56\NN\15120823|cardiac|,|smoking (l_conj) smoking_58\NN\831191|,|mellitus (l_conj) mellitus_61\NN\1740|diabetes|,
D018943_D001943 NONE anthracyclines_66\NNS\1740|of|,|and|irradiation (r_nmod) use_64\NN\407535|prior|anthracyclines (r_appos) presence_42\NN\13954253|abnormalities|hypertension|history|use (r_dep) performed_2\VBN\2367363|analysis|was|women|part|:|presence|. (l_nmod) women_5\NNS\9605289|on|61|cancer (l_nmod) cancer_10\NN\14239425|with|chemotherapy-responsive|metastatic|breast|receiving
D018943_D006333 NONE anthracyclines_66\NNS\1740|of|,|and|irradiation (r_nmod) use_64\NN\407535|prior|anthracyclines (r_appos) presence_42\NN\13954253|abnormalities|hypertension|history|use (r_dep) performed_2\VBN\2367363|analysis|was|women|part|:|presence|. (l_nmod) part_16\NN\31921|as|regimen|assess (l_acl) assess_24\VB\670261|to|association (l_dobj) association_25\NN\8008335|presence (l_nmod) presence_27\NN\13954253|between|failure (l_nmod) failure_32\NN\66216|of|peritransplant|congestive|heart|chf|and|characteristics
D018943_D006333 NONE anthracyclines_66\NNS\1740|of|,|and|irradiation (r_nmod) use_64\NN\407535|prior|anthracyclines (r_appos) presence_42\NN\13954253|abnormalities|hypertension|history|use (r_dep) performed_2\VBN\2367363|analysis|was|women|part|:|presence|. (l_nmod) part_16\NN\31921|as|regimen|assess (l_acl) assess_24\VB\670261|to|association (l_dobj) association_25\NN\8008335|presence (l_nmod) presence_27\NN\13954253|between|failure (l_nmod) failure_32\NN\66216|of|peritransplant|congestive|heart|chf|and|characteristics (l_appos) chf_34\NN\1740|(|)
D018943_D006973 NONE anthracyclines_66\NNS\1740|of|,|and|irradiation (r_nmod) use_64\NN\407535|prior|anthracyclines (r_appos) presence_42\NN\13954253|abnormalities|hypertension|history|use (l_conj) hypertension_52\NN\14057371|,
D018943_D003920 NONE anthracyclines_66\NNS\1740|of|,|and|irradiation (r_nmod) use_64\NN\407535|prior|anthracyclines (r_appos) presence_42\NN\13954253|abnormalities|hypertension|history|use (l_nmod) history_56\NN\15120823|cardiac|,|smoking (l_conj) smoking_58\NN\831191|,|mellitus (l_conj) mellitus_61\NN\1740|diabetes|,
2802551
D012964_D007674 NONE sodium_0\NN\14625458| (r_compound) status_1\NN\24720|sodium (r_nsubj) influences_2\VBZ\137313|status|nephrotoxicity|. (l_dobj) nephrotoxicity_6\NN\1740|chronic|amphotericin|b|rats
D000666_D007674 CID b_5\NN\1355326| (r_compound) nephrotoxicity_6\NN\1740|chronic|amphotericin|b|rats
D000666_D007674 CID b_5\NN\1355326|of|amphotericin (r_nmod) potential_2\NN\14481929|the|nephrotoxic|b|mg/kg (l_amod) nephrotoxic_1\JJ\1740|
2505783
C004656_D006470 CID chloroacetaldehyde_7\NN\1740|caa (r_nsubj) metabolite_14\NN\20090|that|chloroacetaldehyde|is|an|important|cytostatics (r_ccomp) indicating_5\VBG\952524|metabolite (r_xcomp) data_3\NNS\7951464|based|on|clinical|,|indicating (r_advcl) carried_23\VBN\1850315|data|,|study|was|out|order|. (l_nmod) order_26\NN\7168131|in|elucidate (l_acl) elucidate_28\VB\939277|to|role (l_dobj) role_30\NN\719494|the|caa|development (l_nmod) development_35\NN\248977|in|the|cystitis (l_nmod) cystitis_38\NN\14566129|of|hemorrhagic
C004656_D006470 CID caa_9\NN\1740|(|) (r_appos) chloroacetaldehyde_7\NN\1740|caa (r_nsubj) metabolite_14\NN\20090|that|chloroacetaldehyde|is|an|important|cytostatics (r_ccomp) indicating_5\VBG\952524|metabolite (r_xcomp) data_3\NNS\7951464|based|on|clinical|,|indicating (r_advcl) carried_23\VBN\1850315|data|,|study|was|out|order|. (l_nmod) order_26\NN\7168131|in|elucidate (l_acl) elucidate_28\VB\939277|to|role (l_dobj) role_30\NN\719494|the|caa|development (l_nmod) development_35\NN\248977|in|the|cystitis (l_nmod) cystitis_38\NN\14566129|of|hemorrhagic
C004656_D006470 CID caa_32\NN\1740|of (r_nmod) role_30\NN\719494|the|caa|development (l_nmod) development_35\NN\248977|in|the|cystitis (l_nmod) cystitis_38\NN\14566129|of|hemorrhagic
C004656_D003556 CID chloroacetaldehyde_7\NN\1740|caa (r_nsubj) metabolite_14\NN\20090|that|chloroacetaldehyde|is|an|important|cytostatics (r_ccomp) indicating_5\VBG\952524|metabolite (r_xcomp) data_3\NNS\7951464|based|on|clinical|,|indicating (r_advcl) carried_23\VBN\1850315|data|,|study|was|out|order|. (l_nmod) order_26\NN\7168131|in|elucidate (l_acl) elucidate_28\VB\939277|to|role (l_dobj) role_30\NN\719494|the|caa|development (l_nmod) development_35\NN\248977|in|the|cystitis (l_nmod) cystitis_38\NN\14566129|of|hemorrhagic
C004656_D003556 CID caa_9\NN\1740|(|) (r_appos) chloroacetaldehyde_7\NN\1740|caa (r_nsubj) metabolite_14\NN\20090|that|chloroacetaldehyde|is|an|important|cytostatics (r_ccomp) indicating_5\VBG\952524|metabolite (r_xcomp) data_3\NNS\7951464|based|on|clinical|,|indicating (r_advcl) carried_23\VBN\1850315|data|,|study|was|out|order|. (l_nmod) order_26\NN\7168131|in|elucidate (l_acl) elucidate_28\VB\939277|to|role (l_dobj) role_30\NN\719494|the|caa|development (l_nmod) development_35\NN\248977|in|the|cystitis (l_nmod) cystitis_38\NN\14566129|of|hemorrhagic
C004656_D003556 CID caa_32\NN\1740|of (r_nmod) role_30\NN\719494|the|caa|development (l_nmod) development_35\NN\248977|in|the|cystitis (l_nmod) cystitis_38\NN\14566129|of|hemorrhagic
C004656_D001745 NONE caa_4\NNP\1740|administration (r_nsubj) contribute_10\VB\126264|that|caa|does|not|damage (l_nmod) damage_13\NN\7296428|to|bladder
11532387
D018967_D013375 CID risperidone_7\NN\1740|of (r_nmod) reduction_5\NN\351485|during|dose|risperidone (r_nmod) syndrome_2\NN\5870365|withdrawal-emergent|rabbit|reduction|.
D018967_D013375 CID risperidone_19\NN\1740|of|,|antagonist (r_nmod) profile_17\NN\6999802|to|the|pharmacological|risperidone (r_nmod) related_13\JJ\1740|mechanism|may|have|been|profile|,|suggesting|. (l_nsubj) mechanism_2\NN\13446390|the|underlying|rs|case (l_nmod) rs_5\NN\13635336|of|withdrawal-emergent
D018967_D001480 CID risperidone_7\NN\1740|of (r_nmod) reduction_5\NN\351485|during|dose|risperidone (r_nmod) syndrome_2\NN\5870365|withdrawal-emergent|rabbit|reduction|.
D018967_D001480 CID risperidone_8\NN\1740|of (r_nmod) reduction_6\NN\351485|during|dose|risperidone (r_nmod) developed_2\VBD\1753788|patient|rs|reduction|. (l_dobj) rs_3\NN\13635336|
D018967_D001480 CID risperidone_19\NN\1740|of|,|antagonist (r_nmod) profile_17\NN\6999802|to|the|pharmacological|risperidone (r_nmod) related_13\JJ\1740|mechanism|may|have|been|profile|,|suggesting|. (l_nsubj) mechanism_2\NN\13446390|the|underlying|rs|case (l_nmod) rs_5\NN\13635336|of|withdrawal-emergent
D018967_D001480 CID risperidone_19\NN\1740|of|,|antagonist (r_nmod) profile_17\NN\6999802|to|the|pharmacological|risperidone (r_nmod) related_13\JJ\1740|mechanism|may|have|been|profile|,|suggesting|. (l_xcomp) suggesting_25\VBG\1010118|influence (l_dobj) influence_28\NN\5190804|the|pathophysiologic|system|development (l_nmod) development_35\NN\248977|in|the|rs (l_nmod) rs_37\NN\13635336|of
D012701_D013375 NONE serotonin-dopamine_22\JJ\1740| (r_amod) antagonist_23\NN\7846|a|serotonin-dopamine (r_appos) risperidone_19\NN\1740|of|,|antagonist (r_nmod) profile_17\NN\6999802|to|the|pharmacological|risperidone (r_nmod) related_13\JJ\1740|mechanism|may|have|been|profile|,|suggesting|. (l_nsubj) mechanism_2\NN\13446390|the|underlying|rs|case (l_nmod) rs_5\NN\13635336|of|withdrawal-emergent
D012701_D013375 NONE serotonin_31\NN\14807737| (r_compound) system_32\NN\3575240|of|the|serotonin (r_nmod) influence_28\NN\5190804|the|pathophysiologic|system|development (r_dobj) suggesting_25\VBG\1010118|influence (r_xcomp) related_13\JJ\1740|mechanism|may|have|been|profile|,|suggesting|. (l_nsubj) mechanism_2\NN\13446390|the|underlying|rs|case (l_nmod) rs_5\NN\13635336|of|withdrawal-emergent
D012701_D001480 NONE serotonin-dopamine_22\JJ\1740| (r_amod) antagonist_23\NN\7846|a|serotonin-dopamine (r_appos) risperidone_19\NN\1740|of|,|antagonist (r_nmod) profile_17\NN\6999802|to|the|pharmacological|risperidone (r_nmod) related_13\JJ\1740|mechanism|may|have|been|profile|,|suggesting|. (l_nsubj) mechanism_2\NN\13446390|the|underlying|rs|case (l_nmod) rs_5\NN\13635336|of|withdrawal-emergent
D012701_D001480 NONE serotonin-dopamine_22\JJ\1740| (r_amod) antagonist_23\NN\7846|a|serotonin-dopamine (r_appos) risperidone_19\NN\1740|of|,|antagonist (r_nmod) profile_17\NN\6999802|to|the|pharmacological|risperidone (r_nmod) related_13\JJ\1740|mechanism|may|have|been|profile|,|suggesting|. (l_xcomp) suggesting_25\VBG\1010118|influence (l_dobj) influence_28\NN\5190804|the|pathophysiologic|system|development (l_nmod) development_35\NN\248977|in|the|rs (l_nmod) rs_37\NN\13635336|of
D012701_D001480 NONE serotonin_31\NN\14807737| (r_compound) system_32\NN\3575240|of|the|serotonin (r_nmod) influence_28\NN\5190804|the|pathophysiologic|system|development (r_dobj) suggesting_25\VBG\1010118|influence (r_xcomp) related_13\JJ\1740|mechanism|may|have|been|profile|,|suggesting|. (l_nsubj) mechanism_2\NN\13446390|the|underlying|rs|case (l_nmod) rs_5\NN\13635336|of|withdrawal-emergent
D012701_D001480 NONE serotonin_31\NN\14807737| (r_compound) system_32\NN\3575240|of|the|serotonin (r_nmod) influence_28\NN\5190804|the|pathophysiologic|system|development (l_nmod) development_35\NN\248977|in|the|rs (l_nmod) rs_37\NN\13635336|of
D004298_D013375 NONE serotonin-dopamine_22\JJ\1740| (r_amod) antagonist_23\NN\7846|a|serotonin-dopamine (r_appos) risperidone_19\NN\1740|of|,|antagonist (r_nmod) profile_17\NN\6999802|to|the|pharmacological|risperidone (r_nmod) related_13\JJ\1740|mechanism|may|have|been|profile|,|suggesting|. (l_nsubj) mechanism_2\NN\13446390|the|underlying|rs|case (l_nmod) rs_5\NN\13635336|of|withdrawal-emergent
D004298_D001480 NONE serotonin-dopamine_22\JJ\1740| (r_amod) antagonist_23\NN\7846|a|serotonin-dopamine (r_appos) risperidone_19\NN\1740|of|,|antagonist (r_nmod) profile_17\NN\6999802|to|the|pharmacological|risperidone (r_nmod) related_13\JJ\1740|mechanism|may|have|been|profile|,|suggesting|. (l_nsubj) mechanism_2\NN\13446390|the|underlying|rs|case (l_nmod) rs_5\NN\13635336|of|withdrawal-emergent
D004298_D001480 NONE serotonin-dopamine_22\JJ\1740| (r_amod) antagonist_23\NN\7846|a|serotonin-dopamine (r_appos) risperidone_19\NN\1740|of|,|antagonist (r_nmod) profile_17\NN\6999802|to|the|pharmacological|risperidone (r_nmod) related_13\JJ\1740|mechanism|may|have|been|profile|,|suggesting|. (l_xcomp) suggesting_25\VBG\1010118|influence (l_dobj) influence_28\NN\5190804|the|pathophysiologic|system|development (l_nmod) development_35\NN\248977|in|the|rs (l_nmod) rs_37\NN\13635336|of
7420681
D014031_D007674 NONE tobramycin_3\NN\2716866|of|and|gentamicin (r_nmod) nephrotoxicity_1\NN\1740|clinical|tobramycin|.
D014031_D007674 NONE sulfate_4\NN\15010703|sulfate (r_nsubj) continue_5\VBP\2367363|sulfate|demonstrate|. (l_xcomp) demonstrate_7\VB\2137132|to|ototoxicity (l_dobj) ototoxicity_8\NN\1740|and|nephrotoxicity|animal (l_conj) nephrotoxicity_10\NN\1740|
D005839_D007674 NONE gentamicin_5\NN\2716866| (r_conj) tobramycin_3\NN\2716866|of|and|gentamicin (r_nmod) nephrotoxicity_1\NN\1740|clinical|tobramycin|.
D005839_D007674 NONE sulfate_1\NN\15010703|gentamicin|and|tobramycin (r_compound) sulfate_4\NN\15010703|sulfate (r_nsubj) continue_5\VBP\2367363|sulfate|demonstrate|. (l_xcomp) demonstrate_7\VB\2137132|to|ototoxicity (l_dobj) ototoxicity_8\NN\1740|and|nephrotoxicity|animal (l_conj) nephrotoxicity_10\NN\1740|
D005839_D006311 NONE sulfate_1\NN\15010703|gentamicin|and|tobramycin (r_compound) sulfate_4\NN\15010703|sulfate (r_nsubj) continue_5\VBP\2367363|sulfate|demonstrate|. (l_xcomp) demonstrate_7\VB\2137132|to|ototoxicity (l_dobj) ototoxicity_8\NN\1740|and|nephrotoxicity|animal
D014031_D006311 NONE sulfate_4\NN\15010703|sulfate (r_nsubj) continue_5\VBP\2367363|sulfate|demonstrate|. (l_xcomp) demonstrate_7\VB\2137132|to|ototoxicity (l_dobj) ototoxicity_8\NN\1740|and|nephrotoxicity|animal
D005839_D051437 CID sulfate_21\NN\15010703|of|gentamicin|or|tobramycin (r_nmod) mg/kg/day_18\NN\1740|5|sulfate (r_nmod) treated_13\VBN\2376958|mg/kg/day (r_conj) patients_5\NNS\9898892|62|function|and|treated|sulfate (r_nsubjpass) followed_32\VBN\1835496|study|,|patients|were|up|prospectively|development|. (l_nmod) development_37\NN\248977|for|the|failure|,|defined (l_nmod) failure_41\NN\66216|of|aminoglycoside-related|renal
D005839_D051437 CID gentamicin-treated_21\JJ\1740| (r_amod) patients_22\NNS\9898892|of|the|gentamicin-treated (r_nmod) patients_10\NNS\9898892|of|the|tobramycin-treated|and|29|%|patients (r_nmod) five_0\CD\13741022|33|%|patients (r_nsubj) had_23\VBD\2108377|five|failure|. (l_dobj) failure_25\NN\66216|renal
D005839_D051437 CID gentamicin_2\NN\2716866| (r_nsubjpass) associated_4\VBN\628491|thus|,|gentamicin|was|failure|times|often|. (l_nmod) failure_7\NN\66216|with|renal
D014031_D051437 CID sulfate_24\NN\15010703|minimum (r_nmod) patients_5\NNS\9898892|62|function|and|treated|sulfate (r_nsubjpass) followed_32\VBN\1835496|study|,|patients|were|up|prospectively|development|. (l_nmod) development_37\NN\248977|for|the|failure|,|defined (l_nmod) failure_41\NN\66216|of|aminoglycoside-related|renal
D014031_D051437 CID tobramycin-treated_9\JJ\1740| (r_amod) patients_10\NNS\9898892|of|the|tobramycin-treated|and|29|%|patients (r_nmod) five_0\CD\13741022|33|%|patients (r_nsubj) had_23\VBD\2108377|five|failure|. (l_dobj) failure_25\NN\66216|renal
D014031_D051437 CID tobramycin_16\NN\2716866|as|was (r_advcl) often_13\RB\1740|as|tobramycin (r_advmod) associated_4\VBN\628491|thus|,|gentamicin|was|failure|times|often|. (l_nmod) failure_7\NN\66216|with|renal
D000617_D051437 NONE aminoglycoside-related_39\JJ\1740| (r_amod) failure_41\NN\66216|of|aminoglycoside-related|renal
12905102
D003024_D003693 CID clozapine_2\NN\3713736| (r_compound) treatment_3\NN\654885|during|clozapine (r_nmod) delirium_0\NN\14391660|treatment|:|incidence|.
D003024_D003693 CID clozapine_9\NN\3713736| (r_compound) treatment_10\NN\654885|during|clozapine (r_nmod) factors_5\NNS\7326557|incidence|delirium|treatment (l_nmod) delirium_7\NN\14391660|for
D003024_D003693 CID clozapine_15\NN\3713736|with|( (r_nmod) treated_13\VBN\2376958|clozapine (r_acl) inpatients_12\NNS\10405694|all|adult|psychiatric|treated (r_dobj) identify_8\VB\699815|to|inpatients|1995|) (r_xcomp) used_3\VBD\1156834|methods|:|we|records|identify|,|reviewed|. (l_conj) reviewed_22\VBD\644583|records|score|,|and|tested (l_advcl) score_27\VB\1111028|to|incidence (l_dobj) incidence_28\NN\13821570|and|severity (l_conj) severity_30\NN\5036394|delirium (l_nmod) delirium_32\NN\14391660|of
D003024_D003693 CID clozapine-treated_9\JJ\1740| (r_amod) inpatients_10\NNS\10405694|of|clozapine-treated (r_nmod) %_7\NN\1740|in|10|inpatients|,|patients (r_nmod) found_4\VBN\2426171|delirium|was|% (l_nsubjpass) delirium_2\NN\14391660|
D003024_D001523 NONE clozapine_15\NN\3713736|with|( (r_nmod) treated_13\VBN\2376958|clozapine (r_acl) inpatients_12\NNS\10405694|all|adult|psychiatric|treated (l_amod) psychiatric_11\JJ\1740|
8864707
D010672_D004827 NONE phenytoin_10\NN\3550533| (r_compound) overdosages_11\NNS\1740|after|phenytoin (r_nmod) volumetry_2\NN\1740|magnetic|resonance|cerebellum|patients|overdosages|. (l_nmod) patients_8\NNS\9898892|in|epileptic (l_amod) epileptic_7\JJ\1740|
D010672_D062787 CID phenytoin_10\NN\3550533| (r_compound) overdosages_11\NNS\1740|after|phenytoin
D010672_D062787 CID phenytoin_3\NN\3550533| (r_compound) overdosage_4\NN\1740|phenytoin
D010672_D062787 CID phenytoin_17\NN\3550533| (r_compound) medication_18\NN\3247620|phenytoin (r_nsubj) cause_22\NN\7323922|that|medication|was|the|only|atrophy|patients (r_ccomp) is_14\VBZ\836236|it|unlikely|cause (r_conj) conclude_1\VBP\628491|we|result|is|. (l_ccomp) result_8\VB\2633881|that|overdosage|does|not|necessarily|atrophy|and (l_nsubj) overdosage_4\NN\1740|phenytoin
D010672_D002526 NONE phenytoin_11\NN\3550533| (r_compound) medication_12\NN\3247620|between|phenytoin|and|atrophy|patients (l_conj) atrophy_15\NN\14299637|cerebellar
D010672_D002526 NONE phenytoin_3\NN\3550533| (r_compound) overdosage_4\NN\1740|phenytoin (r_nsubj) result_8\VB\2633881|that|overdosage|does|not|necessarily|atrophy|and (l_nmod) atrophy_11\NN\14299637|in|cerebellar
D010672_D002526 NONE phenytoin_3\NN\3550533| (r_compound) overdosage_4\NN\1740|phenytoin (r_nsubj) result_8\VB\2633881|that|overdosage|does|not|necessarily|atrophy|and (r_ccomp) conclude_1\VBP\628491|we|result|is|. (l_conj) is_14\VBZ\836236|it|unlikely|cause (l_ccomp) cause_22\NN\7323922|that|medication|was|the|only|atrophy|patients (l_nmod) atrophy_25\NN\14299637|of|cerebellar
D010672_D002526 NONE phenytoin_17\NN\3550533| (r_compound) medication_18\NN\3247620|phenytoin (r_nsubj) cause_22\NN\7323922|that|medication|was|the|only|atrophy|patients (r_ccomp) is_14\VBZ\836236|it|unlikely|cause (r_conj) conclude_1\VBP\628491|we|result|is|. (l_ccomp) result_8\VB\2633881|that|overdosage|does|not|necessarily|atrophy|and (l_nmod) atrophy_11\NN\14299637|in|cerebellar
D010672_D002526 NONE phenytoin_17\NN\3550533| (r_compound) medication_18\NN\3247620|phenytoin (r_nsubj) cause_22\NN\7323922|that|medication|was|the|only|atrophy|patients (l_nmod) atrophy_25\NN\14299637|of|cerebellar
D010672_D012640 NONE phenytoin_15\NN\3550533| (r_compound) levels_17\NNS\4916342|of|phenytoin|serum|and|volume (r_nmod) elevation_13\NN\7445480|levels (r_conj) duration_11\NN\15113229|between|seizure|,|elevation (l_amod) seizure_10\JJ\1740|
8372922
20003049
C031942_D013921 NONE argatroban_4\NN\1740|of|plasma (r_nmod) elevation_1\NN\7445480|prolonged|argatroban|patient|. (l_nmod) patient_9\NN\9898892|in|a|cardiac|transplant|history (l_nmod) history_13\NN\15120823|with|a|suspected|thrombocytopenia|thrombosis (l_nmod) thrombocytopenia_16\NN\14189204|of|heparin-induced
C031942_D013921 NONE argatroban_18\NN\1740| (r_acomp) administered_17\VBN\2436349|report|patient|was|argatroban|anticoagulation|transplantation|. (l_nsubjpass) patient_9\NN\9898892|a|65-year-old|ill|history (l_nmod) history_13\NN\15120823|with|a|suspected|hitt (l_nmod) hitt_15\NN\1740|of
C031942_D013927 NONE argatroban_4\NN\1740|of|plasma (r_nmod) elevation_1\NN\7445480|prolonged|argatroban|patient|. (l_nmod) patient_9\NN\9898892|in|a|cardiac|transplant|history (l_nmod) history_13\NN\15120823|with|a|suspected|thrombocytopenia|thrombosis (l_nmod) thrombosis_18\NN\14100769|with
C031942_D013927 NONE argatroban_18\NN\1740| (r_acomp) administered_17\VBN\2436349|report|patient|was|argatroban|anticoagulation|transplantation|. (l_nsubjpass) patient_9\NN\9898892|a|65-year-old|ill|history (l_nmod) history_13\NN\15120823|with|a|suspected|hitt (l_nmod) hitt_15\NN\1740|of
D006493_D013921 NONE heparin-induced_15\JJ\1740| (r_amod) thrombocytopenia_16\NN\14189204|of|heparin-induced
D006493_D013921 NONE heparin-induced_20\JJ\1740| (r_amod) thrombocytopenia_21\NN\14189204|of|heparin-induced|hit|or|hit
D006493_D013921 NONE heparin-induced_20\JJ\1740| (r_amod) thrombocytopenia_21\NN\14189204|of|heparin-induced|hit|or|hit (l_appos) hit_23\NN\36762|(|)
D006493_D013921 NONE heparin-induced_20\JJ\1740| (r_amod) thrombocytopenia_21\NN\14189204|of|heparin-induced|hit|or|hit (l_conj) hit_26\NN\36762|thrombosis
D006493_D013921 NONE heparin-induced_20\JJ\1740| (r_amod) thrombocytopenia_21\NN\14189204|of|heparin-induced|hit|or|hit (l_conj) hit_26\NN\36762|thrombosis (l_nmod) thrombosis_28\NN\14100769|with|hitt|undergoing (l_appos) hitt_30\NN\1740|(|)
D006493_D013927 NONE heparin-induced_15\JJ\1740| (r_amod) thrombocytopenia_16\NN\14189204|of|heparin-induced (r_nmod) history_13\NN\15120823|with|a|suspected|thrombocytopenia|thrombosis (l_nmod) thrombosis_18\NN\14100769|with
D006493_D013927 NONE heparin-induced_20\JJ\1740| (r_amod) thrombocytopenia_21\NN\14189204|of|heparin-induced|hit|or|hit (l_conj) hit_26\NN\36762|thrombosis (l_nmod) thrombosis_28\NN\14100769|with|hitt|undergoing
D006493_D013927 NONE heparin-induced_20\JJ\1740| (r_amod) thrombocytopenia_21\NN\14189204|of|heparin-induced|hit|or|hit (l_conj) hit_26\NN\36762|thrombosis (l_nmod) thrombosis_28\NN\14100769|with|hitt|undergoing (l_appos) hitt_30\NN\1740|(|)
C031942_D016638 NONE argatroban_18\NN\1740| (r_acomp) administered_17\VBN\2436349|report|patient|was|argatroban|anticoagulation|transplantation|. (l_nsubjpass) patient_9\NN\9898892|a|65-year-old|ill|history (l_amod) ill_8\JJ\1740|critically
C031942_D008107 NONE argatroban_6\NN\1740|of (r_nmod) concentrations_4\NNS\4916342|unexpectedly|high|argatroban (r_nsubjpass) measured_8\VBN\697589|concentrations|were|samples|microg/ml|,|and|observed (r_dep) results_0\NNS\34213|:|measured (r_nsubj) minutes_46\NNS\6502378|results|is|51|[|<|minutes|]|)|. (l_appos) minutes_52\NNS\6502378|181|impairment (l_nmod) impairment_55\NN\7296428|with|hepatic
C031942_D008107 NONE argatroban_25\NN\1740|prolonged|plasma (r_compound) life_27\NN\13954253|a|argatroban|half|t(1/2|)|minutes (r_nsubjpass) observed_36\VBN\2163746|life|was|t(1/2 (r_conj) measured_8\VBN\697589|concentrations|were|samples|microg/ml|,|and|observed (r_dep) results_0\NNS\34213|:|measured (r_nsubj) minutes_46\NNS\6502378|results|is|51|[|<|minutes|]|)|. (l_appos) minutes_52\NNS\6502378|181|impairment (l_nmod) impairment_55\NN\7296428|with|hepatic
C031942_D001778 NONE argatroban_5\NN\1740| (r_amod) concentration_6\NN\4916342|of|plasma|argatroban (r_nmod) correlation_2\NN\13841213|concentration|versus|variables (r_nsubj) suggest_16\VBP\1010118|correlation|contributed (l_ccomp) contributed_26\VBN\126264|that|levels|may|have|coagulopathy (l_nmod) coagulopathy_32\JJ\1740|to|extended
C031942_D001778 NONE argatroban_23\NN\1740|of|plasma (r_nmod) levels_20\NNS\4916342|prolonged|elevated|argatroban (r_nsubj) contributed_26\VBN\126264|that|levels|may|have|coagulopathy (l_nmod) coagulopathy_32\JJ\1740|to|extended
C031942_D001778 NONE argatroban_8\NN\1740| (r_amod) concentration_9\NN\4916342|plasma|argatroban|cpb (r_dobj) measure_6\VB\697589|to|concentration|and|extended (l_conj) extended_16\VBD\153263|coagulopathy (l_advmod) coagulopathy_17\RB\1740|
17111419
C102006_D064420 NONE citrate_1\NN\14850483| (r_compound) toxicity_2\NN\13576101|severe|citrate|complicating|.
C102006_D064420 NONE citrate_6\NN\14850483| (r_compound) toxicity_7\NN\13576101|of|severe|citrate
C102006_D064420 NONE citrate_22\NN\14850483| (r_compound) toxicity_23\NN\13576101|due|citrate
D002125_C536214 NONE gluconate_5\NN\1740|with|intravenous|calcium (r_nmod) treatment_1\NN\654885|empirical|gluconate (r_nsubjpass) initiated_7\VBN\1617192|treatment|was|,|and|subsided (l_conj) subsided_13\VBD\223500|contractions|slowly|minutes|. (l_nsubj) contractions_11\NNS\358931|muscle
D002118_D006996 NONE calcium_9\NN\14625458| (r_compound) chelation_10\NN\29677|to|calcium (r_nmod) reaction_7\NN\13446390|with|a|severe|chelation|anticoagulant|resulting (l_acl) resulting_15\VBG\2633881|hypocalcemia (l_nmod) hypocalcemia_19\NN\14299637|in|symptomatic|systemic
C102006_D006996 CID citrate_13\NN\14850483| (r_compound) anticoagulant_14\NN\3740161|by|sodium|citrate (r_nmod) reaction_7\NN\13446390|with|a|severe|chelation|anticoagulant|resulting (l_acl) resulting_15\VBG\2633881|hypocalcemia (l_nmod) hypocalcemia_19\NN\14299637|in|symptomatic|systemic
C102006_D006996 CID citrate_22\NN\14850483| (r_compound) toxicity_23\NN\13576101|due|citrate (r_nmod) prevent_17\VB\1740|reactions|toxicity (r_xcomp) help_16\VB\2556126|to|prevent (r_xcomp) recommended_14\VBN\875394|that|screening|is|help (l_nsubjpass) screening_4\NN\6887726|careful|medications (l_nmod) medications_6\NNS\3247620|for|and|underlying (l_conj) underlying_8\VBG\2604760|conditions (l_dobj) conditions_9\NNS\14512817|predisposing (l_acl) predisposing_10\VBG\680841|hypocalcemia (l_nmod) hypocalcemia_12\NN\14299637|to
D002034_D006996 NONE bumetanide_9\NN\1740| (r_nsubj) diuretic_13\NN\3247620|that|bumetanide|is|a|loop|cause (l_acl:relcl) cause_16\VB\1617192|that|may|hypocalcemia (l_dobj) hypocalcemia_18\NN\14299637|significant
D049994_D006996 NONE diuretic_13\NN\3247620|that|bumetanide|is|a|loop|cause (l_acl:relcl) cause_16\VB\1617192|that|may|hypocalcemia (l_dobj) hypocalcemia_18\NN\14299637|significant
2070391
D008012_D010146 CID lidocaine_6\NN\3681148|buffered (r_dobj) using_4\VBG\1156834|lidocaine (r_acl) reduction_0\NN\351485|pain|using|anesthetic|. (l_nmod) pain_3\NN\14299637|in|injection
D008012_D010146 CID lidocaine_11\NN\3681148|of (r_nmod) injection_9\NN\320852|with|the|lidocaine (r_nmod) associated_6\VBN\628491|injection (r_acl) pain_5\NN\14299637|associated
D008012_D010146 CID lidocaine_14\NN\3681148|of (r_nmod) ph_12\NN\5038959|the|lidocaine (r_dobj) adjust_10\VB\126264|to|ph|range (r_acl) addition_4\NN\3081021|the|solution|adjust (r_nsubj) reduce_20\VB\441445|if|addition|would|pain|injection (l_dobj) pain_21\NN\14299637|
D008012_D010146 CID lidocaine_13\NN\3681148|standard (r_dobj) receiving_11\VBG\2210855|after|lidocaine|area (r_advcl) quantify_5\VB\947077|to|severity|receiving|and|buffered (l_dobj) severity_7\NN\5036394|the|pain (l_nmod) pain_9\NN\14299637|of
D008012_D010146 CID lidocaine_20\NN\3681148| (r_dobj) buffered_19\VBD\169806|lidocaine|area (r_conj) quantify_5\VB\947077|to|severity|receiving|and|buffered (l_dobj) severity_7\NN\5036394|the|pain (l_nmod) pain_9\NN\14299637|of
D008012_D010146 CID lidocaine_6\NN\3681148|for|buffered (r_nmod) score_3\NN\5736149|the|mean|pain|lidocaine (l_compound) pain_2\NN\14299637|
D008012_D010146 CID lidocaine_16\NN\3681148|for|standard|= (r_nmod) score_13\NN\5736149|than|the|mean|lidocaine (r_nmod) lower_9\JJR\1740|score|was|significantly|score|. (l_nsubj) score_3\NN\5736149|the|mean|pain|lidocaine (l_compound) pain_2\NN\14299637|
D008012_D010146 CID lidocaine_5\NN\3681148|of|standard (r_nmod) adjustment_2\NN\7357388|the|ph|lidocaine (r_nsubjpass) accomplished_8\VBN\484166|adjustment|can|be|easily|laboratory|injection|and|results|. (l_conj) results_17\VBZ\2633881|reduction (l_nmod) reduction_20\NN\351485|in|a|pain (l_nmod) pain_23\NN\14299637|of|the|occurring
2611118
D004008_D006521 NONE sodium_6\NN\14625458| (r_compound) therapy_7\NN\657604|with|diclofenac|sodium (r_nmod) associated_3\VBN\628491|therapy (r_acl) hepatitis_2\NN\14127211|chronic|active|associated|.
D004008_D006521 NONE sodium_13\NN\14625458|with|diclofenac|progressed (r_nmod) therapy_10\NN\657604|months|sodium (r_dobj) developed_3\VBD\1753788|patient|hepatitis|therapy|,|finding|. (l_dobj) hepatitis_6\NN\14127211|chronic|active
D004008_D056486 CID diclofenac_21\VBN\1740|by (r_nmod) induced_19\VBN\1627355|diclofenac (r_acl) hepatitis_18\NN\14127211|recorded|commonly|,|severe|induced|. (l_advcl) recorded_11\VBN\2225492|although|abnormalities|have|been|and|, (l_nsubjpass) abnormalities_5\NNS\14034177|well-tolerated|function (l_nmod) function_8\NN\13783581|of|liver
D004008_D056486 CID diclofenac_21\VBN\1740|by (r_nmod) induced_19\VBN\1627355|diclofenac (r_acl) hepatitis_18\NN\14127211|recorded|commonly|,|severe|induced|.
2484011
D000547_D003866 NONE amantadine_4\NN\1740| (r_compound) activity_7\NN\30358|of|amantadine|depressed|locomotor|strains (l_amod) depressed_5\JJ\1740|
D000547_D011596 CID amantadine_2\NN\1740|of (r_nmod) readministration_0\NN\1740|amantadine|,|period|,|motility|. (l_conj) motility_11\NN\4773351|increased|control|strains (l_nmod) strains_18\NNS\7358060|in|all|exception (l_nmod) exception_20\NN\5706954|with|mice (l_nmod) mice_24\NNS\2329401|of|the|balb/c|occurred (l_acl:relcl) occurred_29\VBD\2623529|where|suppression (l_nsubj) suppression_26\NN\13489037|motility (l_nmod) motility_28\NN\4773351|of
D000547_D011596 CID amantadine_41\NN\1740|by (r_nmod) caused_39\VBN\1617192|amantadine|mice (r_acl) depression_38\NN\14373582|for|a|behavioral|caused
D000588_D011596 NONE amines_6\NNS\14951377|of|brain|biogenic|strain (r_nmod) results_2\NNS\34213|the|biochemical|amines (r_nsubj) suggest_11\VBP\1010118|results|decrease|. (l_dobj) decrease_14\NN\7296428|a|probable|rate|oxidase|and|increase (l_conj) increase_27\NN\13576355|a|resulting|o-methylation (l_nmod) o-methylation_29\NN\1740|in|norepinephrine|account (l_acl:relcl) account_34\VB\2604760|which|may|depression (l_nmod) depression_38\NN\14373582|for|a|behavioral|caused
D002395_D011596 NONE catecholamine_16\NN\5407119| (r_compound) rate_18\NN\13815152|of|catecholamine|turnover|and/or|metabolism (r_nmod) decrease_14\NN\7296428|a|probable|rate|oxidase|and|increase (l_conj) increase_27\NN\13576355|a|resulting|o-methylation (l_nmod) o-methylation_29\NN\1740|in|norepinephrine|account (l_acl:relcl) account_34\VB\2604760|which|may|depression (l_nmod) depression_38\NN\14373582|for|a|behavioral|caused
D009638_D011596 NONE norepinephrine_31\NN\14807929|of (r_nmod) o-methylation_29\NN\1740|in|norepinephrine|account (l_acl:relcl) account_34\VB\2604760|which|may|depression (l_nmod) depression_38\NN\14373582|for|a|behavioral|caused
9754849
D008691_D002819 CID methadone_7\NN\3808564|to (r_nmod) adjustment_5\NN\7357388|with|rapid|methadone (r_nmod) associated_2\VBN\628491|adjustment (r_acl) movements_1\NNS\191142|choreoathetoid|associated|.
D008691_D002819 CID methadone_22\NN\3808564|to|the|selective|mu-opioid|receptor|agonist (r_nmod) adjustment_15\NN\7357388|by|rapid|methadone (r_nmod) induced_12\VBN\1627355|both|adjustment|inpatient (r_acl) movements_9\NNS\191142|of|euphoria|induced
D003042_D002819 CID cocaine_12\NN\3492717|with|not|opiates (r_nmod) intoxications_10\NNS\14034177|during|cocaine (r_nmod) abnormalities_8\NNS\14034177|to|be|movement|intoxications (r_xcomp) known_3\VBN\2110220|hyperkinesias|are|abnormalities|. (l_nsubjpass) hyperkinesias_1\NNS\1740|choreatiform
D003042_D002819 CID cocaine_30\NN\3492717| (r_conj) heroine_28\NN\5929008|and|cocaine (r_dobj) abusing_27\VBG\2514187|previously|heroine (r_acl) inpatient_25\JJ\1740|in|an|abusing (r_nmod) induced_12\VBN\1627355|both|adjustment|inpatient (r_acl) movements_9\NNS\191142|of|euphoria|induced
D003042_D006948 CID cocaine_12\NN\3492717|with|not|opiates (r_nmod) intoxications_10\NNS\14034177|during|cocaine (r_nmod) abnormalities_8\NNS\14034177|to|be|movement|intoxications (r_xcomp) known_3\VBN\2110220|hyperkinesias|are|abnormalities|. (l_nsubjpass) hyperkinesias_1\NNS\1740|choreatiform
D003042_D020820 NONE cocaine_12\NN\3492717|with|not|opiates (r_nmod) intoxications_10\NNS\14034177|during|cocaine (r_nmod) abnormalities_8\NNS\14034177|to|be|movement|intoxications
D003932_D002819 NONE heroine_28\NN\5929008|and|cocaine (r_dobj) abusing_27\VBG\2514187|previously|heroine (r_acl) inpatient_25\JJ\1740|in|an|abusing (r_nmod) induced_12\VBN\1627355|both|adjustment|inpatient (r_acl) movements_9\NNS\191142|of|euphoria|induced
354896
D008012_D006323 CID lidocaine-induced_0\JJ\1740| (r_amod) asystole_2\NN\14204950|lidocaine-induced|cardiac|.
D008012_D003866 NONE lidocaine_8\NN\3681148|of (r_nmod) bolus_6\NN\13899404|of|a|single|50-mg|lidocaine|man (r_nmod) administration_1\NN\1133281|intravenous|bolus (r_nsubj) resulted_13\VBD\2633881|administration|depression|. (l_nmod) depression_16\NN\14373582|in|profound|activity
D008012_D001919 NONE lidocaine_29\VB\1740|to (r_nmod) idiosyncrasy_27\JJ\1740|true|lidocaine (r_dobj) represented_24\VBD\2664769|,|thus|,|this|probably|idiosyncrasy (r_conj) had_2\VBD\2108377|patient|conditions|;|and|represented|. (l_dobj) conditions_6\NNS\14512817|no|associated|predisposed (l_acl:relcl) predisposed_10\VBN\680841|which|might|have|him|development (l_nmod) development_14\NN\248977|to|the|bradyarrhythmias (l_nmod) bradyarrhythmias_16\NNS\1740|of
20619828
D002997_D001008 CID clomipramine_2\NN\4482543| (r_compound) exposure_3\NN\5042871|clomipramine|rats (r_nsubj) produced_7\VBD\1617192|exposure|changes (l_dobj) changes_12\NNS\7283608|significant|behavioral|include (l_acl:relcl) include_14\VBP\690614|that|anxiety (l_dobj) anxiety_16\NN\14373582|enhanced|elevated|burying|)
D002997_-1 NONE clomipramine_2\NN\4482543| (r_compound) exposure_3\NN\5042871|clomipramine|rats (r_nsubj) produced_7\VBD\1617192|exposure|changes (r_appos) results_0\NNS\34213|:|produced|,|inflexibility|,|impairment|. (l_appos) inflexibility_27\NN\5023741|behavioral|perseveration
D002997_-1 NONE clomipramine_2\NN\4482543| (r_compound) exposure_3\NN\5042871|clomipramine|rats (r_nsubj) produced_7\VBD\1617192|exposure|changes (r_appos) results_0\NNS\34213|:|produced|,|inflexibility|,|impairment|. (l_appos) impairment_43\NN\7296428|working|memory|(|paradigm|,|hoarding|dysfunction (l_conj) dysfunction_55\NN\14204950|corticostriatal
D002997_D008569 CID clomipramine_2\NN\4482543| (r_compound) exposure_3\NN\5042871|clomipramine|rats (r_nsubj) produced_7\VBD\1617192|exposure|changes (r_appos) results_0\NNS\34213|:|produced|,|inflexibility|,|impairment|. (l_appos) impairment_43\NN\7296428|working|memory|(|paradigm|,|hoarding|dysfunction
D002997_D060845 CID clomipramine_2\NN\4482543| (r_compound) exposure_3\NN\5042871|clomipramine|rats (r_nsubj) produced_7\VBD\1617192|exposure|changes (r_appos) results_0\NNS\34213|:|produced|,|inflexibility|,|impairment|. (l_appos) impairment_43\NN\7296428|working|memory|(|paradigm|,|hoarding|dysfunction (l_conj) hoarding_51\VBG\2265979|,|and
18329269
D006220_D002375 CID haloperidol-induced_36\JJ\1740| (r_amod) model_38\NN\5888929|in|the|rat|haloperidol-induced|catalepsy|disease (l_compound) catalepsy_37\NN\14023236|
D006220_D010300 NONE haloperidol-induced_36\JJ\1740| (r_amod) model_38\NN\5888929|in|the|rat|haloperidol-induced|catalepsy|disease (l_nmod) disease_42\NN\14061805|for|parkinson
18752389
C492458_D017093 NONE simvastatin-ezetimibe-induced_0\JJ\1740| (r_amod) transplantation_5\NN\671351|simvastatin-ezetimibe-induced|hepatic|failure|necessitating|liver|. (l_compound) failure_2\NN\66216|
C492458_D017093 NONE simvastatin-ezetimibe-induced_11\JJ\1740| (r_amod) failure_13\NN\66216|of|simvastatin-ezetimibe-induced|liver|resulted
C108606_D056486 NONE ezetimibe_10\NN\1740|with|or|agent|simvastatin-ezetimibe (r_nmod) published_8\VBN\1621555|however|,|events|have|not|been|widely|ezetimibe|. (l_nsubjpass) events_3\NNS\23100|hepatotoxic (l_amod) hepatotoxic_2\JJ\1740|
C108606_D056486 NONE ezetimibe_0\NN\1740| (r_nsubj) undergoes_1\VBZ\109660|ezetimibe|glucuronidation|glucoronosyltransferases|and|inhibited|resulting|. (l_advcl) resulting_27\VBG\2633881|exposure (l_nmod) exposure_31\NN\5042871|in|increased|simvastatin|and|hepatotoxicity (l_conj) hepatotoxicity_34\NN\1740|subsequent
C108606_D056486 NONE ezetimibe_15\JJ\1740| (r_amod) inhibition_16\NN\1068773|by|ezetimibe|enzymes (r_nmod) exposure_13\NN\5042871|that|mechanism|is|the|increased|simvastatin|inhibition (l_nsubj) mechanism_4\NN\13446390|the|hepatotoxicity (l_nmod) hepatotoxicity_8\NN\1740|of|the|simvastatinezetimibe-induced
C492458_D056486 CID simvastatin-ezetimibe_15\JJ\1740| (r_conj) ezetimibe_10\NN\1740|with|or|agent|simvastatin-ezetimibe (r_nmod) published_8\VBN\1621555|however|,|events|have|not|been|widely|ezetimibe|. (l_nsubjpass) events_3\NNS\23100|hepatotoxic (l_amod) hepatotoxic_2\JJ\1740|
C492458_D056486 CID simvastatinezetimibe_0\NN\1740|and|escitalopram|(|taking|) (r_nsubjpass) discontinued_12\VBN\2609764|simvastatinezetimibe|were|,|and|excluded (l_conj) excluded_21\VBN\471711|causes|were|. (l_nsubjpass) causes_17\NNS\7323922|other|potential|hepatotoxicity (l_nmod) hepatotoxicity_19\NN\1740|of
C492458_D056486 CID simvastatinezetimibe-induced_7\JJ\1740| (r_amod) hepatotoxicity_8\NN\1740|of|the|simvastatinezetimibe-induced
C492458_D056486 CID simvastatin-ezetimibe_8\NN\1740|with (r_nmod) hepatotoxicity_6\NN\1740|of|potential|simvastatin-ezetimibe
D019821_D017114 NONE simvastatin_19\NN\3676175|from (r_nmod) conversion_17\NN\7359599|after|simvastatin (r_nmod) developed_7\VBD\1753788|who|transplantation|weeks|conversion|mg/day|simvastatin|mg-ezetimibe|mg/day (l_dobj) transplantation_13\NN\671351|fulminant|hepatic|failure|necessitating|liver (l_compound) failure_10\NN\66216|
C492458_D017114 CID mg/day_27\NN\1740|40 (r_dobj) developed_7\VBD\1753788|who|transplantation|weeks|conversion|mg/day|simvastatin|mg-ezetimibe|mg/day (l_dobj) transplantation_13\NN\671351|fulminant|hepatic|failure|necessitating|liver (l_compound) failure_10\NN\66216|
D019821_D056486 NONE simvastatin_9\NN\3676175|with (r_nmod) maintained_7\VBN\2202928|panel|had|been|simvastatin|months|conversion|. (l_nmod) conversion_15\NN\7359599|before|the|evidence (l_nmod) evidence_17\NN\5816287|without|hepatotoxicity (l_nmod) hepatotoxicity_19\NN\1740|of
D019821_D056486 NONE simvastatin_30\NN\3676175| (r_amod) exposure_31\NN\5042871|in|increased|simvastatin|and|hepatotoxicity (l_conj) hepatotoxicity_34\NN\1740|subsequent
D019821_D056486 NONE simvastatin_12\NN\3676175| (r_amod) exposure_13\NN\5042871|that|mechanism|is|the|increased|simvastatin|inhibition (l_nsubj) mechanism_4\NN\13446390|the|hepatotoxicity (l_nmod) hepatotoxicity_8\NN\1740|of|the|simvastatinezetimibe-induced
C492458_D003866 NONE simvastatinezetimibe_0\NN\1740|and|escitalopram|(|taking|) (l_acl:relcl) taking_7\VBG\2367363|which|she|was|depression (l_nmod) depression_9\NN\14373582|for
D015283_D003866 NONE escitalopram_2\NN\1740| (r_conj) simvastatinezetimibe_0\NN\1740|and|escitalopram|(|taking|) (l_acl:relcl) taking_7\VBG\2367363|which|she|was|depression (l_nmod) depression_9\NN\14373582|for
D015283_D056486 NONE escitalopram_2\NN\1740| (r_conj) simvastatinezetimibe_0\NN\1740|and|escitalopram|(|taking|) (r_nsubjpass) discontinued_12\VBN\2609764|simvastatinezetimibe|were|,|and|excluded (l_conj) excluded_21\VBN\471711|causes|were|. (l_nsubjpass) causes_17\NNS\7323922|other|potential|hepatotoxicity (l_nmod) hepatotoxicity_19\NN\1740|of
D014530_D056486 NONE diphosphate_6\NN\1740| (r_compound) glucoronosyltransferases_7\NNS\1740|by|uridine|diphosphate|ugt|intestine (r_nmod) undergoes_1\VBZ\109660|ezetimibe|glucuronidation|glucoronosyltransferases|and|inhibited|resulting|. (l_advcl) resulting_27\VBG\2633881|exposure (l_nmod) exposure_31\NN\5042871|in|increased|simvastatin|and|hepatotoxicity (l_conj) hepatotoxicity_34\NN\1740|subsequent
C532833_D056486 NONE acid_25\NN\14818238|of|simvastatin|hydroxy (r_nmod) glucuronidation_21\NN\1740|the|acid (r_dobj) inhibited_19\VBN\2510337|may|have|glucuronidation|, (r_conj) undergoes_1\VBZ\109660|ezetimibe|glucuronidation|glucoronosyltransferases|and|inhibited|resulting|. (l_advcl) resulting_27\VBG\2633881|exposure (l_nmod) exposure_31\NN\5042871|in|increased|simvastatin|and|hepatotoxicity (l_conj) hepatotoxicity_34\NN\1740|subsequent
8996652
D000617_D006311 NONE aminoglycosides_17\NNS\1740|particularly|and|furosemide (r_dep) appeared_1\VBD\2604760|ototoxicity|related|,|aminoglycosides|. (l_nsubj) ototoxicity_0\NN\1740|
D000617_D006311 NONE aminoglycosides_17\NNS\1740|particularly|and|furosemide (r_dep) appeared_1\VBD\2604760|ototoxicity|related|,|aminoglycosides|. (l_acomp) related_3\JJ\1740|closely|administration (l_nmod) administration_7\NN\1133281|to|a|prolonged|and|dose (l_conj) dose_11\NN\3740161|higher|total|drugs (l_nmod) drugs_14\NNS\14778436|of|ototoxic (l_amod) ototoxic_13\JJ\1740|
D005665_D006311 NONE furosemide_19\NN\3214670| (r_conj) aminoglycosides_17\NNS\1740|particularly|and|furosemide (r_dep) appeared_1\VBD\2604760|ototoxicity|related|,|aminoglycosides|. (l_nsubj) ototoxicity_0\NN\1740|
D005665_D006311 NONE furosemide_19\NN\3214670| (r_conj) aminoglycosides_17\NNS\1740|particularly|and|furosemide (r_dep) appeared_1\VBD\2604760|ototoxicity|related|,|aminoglycosides|. (l_acomp) related_3\JJ\1740|closely|administration (l_nmod) administration_7\NN\1133281|to|a|prolonged|and|dose (l_conj) dose_11\NN\3740161|higher|total|drugs (l_nmod) drugs_14\NNS\14778436|of|ototoxic (l_amod) ototoxic_13\JJ\1740|
19759529
D004298_D012559 NONE dopamine_8\NN\14807737| (r_compound) neurotransmission_9\NN\1740|in|dopamine (r_nmod) dysfunction_6\NN\14204950|with|neurotransmission (r_nmod) associated_4\VBN\628491|schizophrenia|has|been|initially|dysfunction|. (l_nsubjpass) schizophrenia_0\NNP\14398067|
D018698_D012559 NONE glutamate_8\JJ\1740| (r_amod) receptor_13\NN\5225602|of|the|glutamate|n-methyl-d-aspartate|(|nmda|) (r_nmod) antagonists_5\NNS\7846|receptor (r_nsubj) produce_14\VBP\1617192|that|antagonists|symptoms|humans (l_dobj) symptoms_16\NNS\5823932|schizophrenic-like (l_amod) schizophrenic-like_15\JJ\1740|
D016202_D012559 NONE n-methyl-d-aspartate_9\NN\1740| (r_compound) receptor_13\NN\5225602|of|the|glutamate|n-methyl-d-aspartate|(|nmda|) (r_nmod) antagonists_5\NNS\7846|receptor (r_nsubj) produce_14\VBP\1617192|that|antagonists|symptoms|humans (l_dobj) symptoms_16\NNS\5823932|schizophrenic-like (l_amod) schizophrenic-like_15\JJ\1740|
D016202_D012559 NONE nmda_11\NN\1740| (r_compound) receptor_13\NN\5225602|of|the|glutamate|n-methyl-d-aspartate|(|nmda|) (r_nmod) antagonists_5\NNS\7846|receptor (r_nsubj) produce_14\VBP\1617192|that|antagonists|symptoms|humans (l_dobj) symptoms_16\NNS\5823932|schizophrenic-like (l_amod) schizophrenic-like_15\JJ\1740|
D016202_D012559 NONE nmda_33\NN\1740| (r_compound) receptor_34\NN\5225602|via|its|nmda (r_nmod) dysfunctioning_26\NN\1740|of|a|system|receptor (r_nmod) idea_23\NN\5809192|to|the|dysfunctioning (r_nmod) led_20\VBN\1752884|however|,|observation|has|idea|. (l_nsubj) observation_3\NN\996969|the|produce (l_ccomp) produce_14\VBP\1617192|that|antagonists|symptoms|humans (l_dobj) symptoms_16\NNS\5823932|schizophrenic-like (l_amod) schizophrenic-like_15\JJ\1740|
-1_D006948 NONE ssr103800_10\NN\1740|of (r_nmod) properties_8\NNS\32613|the|potential|antipsychotic-like|ssr103800 (r_dobj) investigating_4\VBG\644583|at|properties (r_advcl) aimed_2\VBN\1987160|investigating|,|focus|, (l_nmod) focus_15\NN\5704266|with|a|particular|models (l_nmod) models_17\NNS\5888929|on|hyperactivity (l_nmod) hyperactivity_19\NN\14052403|of
-1_D006948 NONE ssr103800_3\NN\1740|p.o. (r_nsubj) blocked_11\VBD\1476483|that|ssr103800|hyperactivity|hyperactivity (l_dobj) hyperactivity_12\NN\14052403|induced
-1_D006948 NONE ssr103800_3\NN\1740|p.o. (r_nsubj) blocked_11\VBD\1476483|that|ssr103800|hyperactivity|hyperactivity (l_dobj) hyperactivity_26\NN\14052403|reversed|spontaneous|nr1(neo-/-|mice
-1_D006948 NONE ssr103800_3\NN\1740| (r_nsubj) failed_4\VBD\1798936|contrast|,|ssr103800|affect|)|. (l_xcomp) affect_6\VB\126264|to|hyperactivity|or|observed (l_dobj) hyperactivity_7\NN\14052403|induced
D000661_D006948 CID amphetamine_28\NN\3248958|(|ie|,|and|mk-801|) (r_dep) challenge_24\NN\13927383|study|involving|either|drug|amphetamine|or|mice|and|dat(-/-|)|)|. (l_nsubj) study_1\NN\635850|this|aimed (l_acl) aimed_2\VBN\1987160|investigating|,|focus|, (l_nmod) focus_15\NN\5704266|with|a|particular|models (l_nmod) models_17\NNS\5888929|on|hyperactivity (l_nmod) hyperactivity_19\NN\14052403|of
D000661_D006948 CID amphetamine_10\NN\3248958|by (r_nmod) induced_8\VBN\1627355|amphetamine (r_acl) hyperactivity_7\NN\14052403|induced
D016291_D006948 CID mk-801_30\NN\1740| (r_conj) amphetamine_28\NN\3248958|(|ie|,|and|mk-801|) (r_dep) challenge_24\NN\13927383|study|involving|either|drug|amphetamine|or|mice|and|dat(-/-|)|)|. (l_nsubj) study_1\NN\635850|this|aimed (l_acl) aimed_2\VBN\1987160|investigating|,|focus|, (l_nmod) focus_15\NN\5704266|with|a|particular|models (l_nmod) models_17\NNS\5888929|on|hyperactivity (l_nmod) hyperactivity_19\NN\14052403|of
D016291_D006948 CID mk-801_21\NN\1740| (r_conj) antagonist_19\NN\7846|by|the|non-competitive|nmda|receptor|,|mk-801|and (r_nmod) induced_13\VBN\1627355|antagonist (r_acl) hyperactivity_12\NN\14052403|induced
D016291_D006948 CID mk-801_21\NN\1740| (r_conj) antagonist_19\NN\7846|by|the|non-competitive|nmda|receptor|,|mk-801|and (r_nmod) induced_13\VBN\1627355|antagonist (r_acl) hyperactivity_12\NN\14052403|induced (r_dobj) blocked_11\VBD\1476483|that|ssr103800|hyperactivity|hyperactivity (l_dobj) hyperactivity_26\NN\14052403|reversed|spontaneous|nr1(neo-/-|mice
D016202_D006948 NONE nmda_38\NN\1740| (r_compound) nr1(neo-/-_39\NN\1740|(|ie|nmda|) (r_appos) mice_34\NNS\2329401|transgenic|nr1(neo-/- (r_conj) challenge_24\NN\13927383|study|involving|either|drug|amphetamine|or|mice|and|dat(-/-|)|)|. (l_nsubj) study_1\NN\635850|this|aimed (l_acl) aimed_2\VBN\1987160|investigating|,|focus|, (l_nmod) focus_15\NN\5704266|with|a|particular|models (l_nmod) models_17\NNS\5888929|on|hyperactivity (l_nmod) hyperactivity_19\NN\14052403|of
D016202_D006948 NONE nmda_17\NN\1740| (r_compound) antagonist_19\NN\7846|by|the|non-competitive|nmda|receptor|,|mk-801|and (r_nmod) induced_13\VBN\1627355|antagonist (r_acl) hyperactivity_12\NN\14052403|induced
D016202_D006948 NONE nmda_17\NN\1740| (r_compound) antagonist_19\NN\7846|by|the|non-competitive|nmda|receptor|,|mk-801|and (r_nmod) induced_13\VBN\1627355|antagonist (r_acl) hyperactivity_12\NN\14052403|induced (r_dobj) blocked_11\VBD\1476483|that|ssr103800|hyperactivity|hyperactivity (l_dobj) hyperactivity_26\NN\14052403|reversed|spontaneous|nr1(neo-/-|mice
D016202_D006948 NONE nmda_28\NN\1740| (r_compound) nr1(neo-/-_29\NN\1740|of|nmda|) (r_nmod) hyperactivity_26\NN\14052403|reversed|spontaneous|nr1(neo-/-|mice (r_dobj) blocked_11\VBD\1476483|that|ssr103800|hyperactivity|hyperactivity (l_dobj) hyperactivity_12\NN\14052403|induced
D016202_D006948 NONE nmda_28\NN\1740| (r_compound) nr1(neo-/-_29\NN\1740|of|nmda|) (r_nmod) hyperactivity_26\NN\14052403|reversed|spontaneous|nr1(neo-/-|mice
D004298_D006948 NONE dopamine_15\NN\14807737| (r_compound) transporter_16\NN\4490091|in|dopamine|dat(-/-|)|mice (r_nmod) observed_13\VBN\2163746|naturally|transporter (r_conj) affect_6\VB\126264|to|hyperactivity|or|observed (l_dobj) hyperactivity_7\NN\14052403|induced
D006220_D006948 NONE haloperidol_5\NN\3713736|(|) (r_dep) classical_3\JJ\1740|both|haloperidol|and|atypical|olanzapine (r_compound) antipsychotics_16\NNS\4470232|classical (r_nsubj) effective_18\JJ\1740|importantly|,|antipsychotics|were|models|. (l_nmod) models_22\NNS\5888929|in|all|these|hyperactivity (l_nmod) hyperactivity_24\NN\14052403|of
C076029_D006948 NONE olanzapine_10\NN\1740|(|,|clozapine|aripiprazole|) (r_dep) classical_3\JJ\1740|both|haloperidol|and|atypical|olanzapine (r_compound) antipsychotics_16\NNS\4470232|classical (r_nsubj) effective_18\JJ\1740|importantly|,|antipsychotics|were|models|. (l_nmod) models_22\NNS\5888929|in|all|these|hyperactivity (l_nmod) hyperactivity_24\NN\14052403|of
D003024_D006948 NONE clozapine_12\NN\3713736|and (r_conj) olanzapine_10\NN\1740|(|,|clozapine|aripiprazole|) (r_dep) classical_3\JJ\1740|both|haloperidol|and|atypical|olanzapine (r_compound) antipsychotics_16\NNS\4470232|classical (r_nsubj) effective_18\JJ\1740|importantly|,|antipsychotics|were|models|. (l_nmod) models_22\NNS\5888929|in|all|these|hyperactivity (l_nmod) hyperactivity_24\NN\14052403|of
C094645_D006948 NONE aripiprazole_14\NN\1740| (r_conj) olanzapine_10\NN\1740|(|,|clozapine|aripiprazole|) (r_dep) classical_3\JJ\1740|both|haloperidol|and|atypical|olanzapine (r_compound) antipsychotics_16\NNS\4470232|classical (r_nsubj) effective_18\JJ\1740|importantly|,|antipsychotics|were|models|. (l_nmod) models_22\NNS\5888929|in|all|these|hyperactivity (l_nmod) hyperactivity_24\NN\14052403|of
-1_D002375 NONE ssr103800_6\NN\1740| (r_nsubj) produce_9\VB\1617192|however|,|latter|,|ssr103800|did|not|catalepsy|p.o.|together|show|. (l_dobj) catalepsy_10\NN\14023236|retention
-1_D002375 NONE ssr103800_32\NN\1740| (r_appos) inhibitor_30\NN\20090|the|glyt1|,|ssr103800|, (r_nsubj) produces_34\VBZ\1617192|that|inhibitor|effects|,|differ (r_ccomp) show_26\VBP\2137132|findings|produces|,|and|has (r_parataxis) produce_9\VB\1617192|however|,|latter|,|ssr103800|did|not|catalepsy|p.o.|together|show|. (l_dobj) catalepsy_10\NN\14023236|retention
8170551
D000086_D053040 NONE acetazolamide-induced_0\JJ\1740| (r_amod) nephrolithiasis_1\NN\14115914|acetazolamide-induced|:|implications|.
D000086_D053040 NONE acetazolamide_5\NN\1740|of (r_nmod) complication_3\NN\1073995|nephrolithiasis|is|a|acetazolamide|but|preclude|. (l_nsubj) nephrolithiasis_0\NN\14115914|
D000086_D009468 NONE acetazolamide-induced_0\JJ\1740| (r_amod) nephrolithiasis_1\NN\14115914|acetazolamide-induced|:|implications|. (l_dep) implications_3\NNS\5774614|treatment (l_nmod) treatment_5\NN\654885|for|disorders (l_nmod) disorders_8\NNS\14034177|of|neuromuscular
D000086_D007669 CID acetazolamide_3\NN\1740|on (r_nmod) patients_1\NNS\9898892|three|acetazolamide|% (r_nsubj) developed_8\VBD\1753788|patients|calculi|. (l_dobj) calculi_10\NNS\9416076|renal
10342929
D000806_D000799 CID inhibitors_4\NNS\20090|angioedema|due|ace|:|common|. (l_nsubj) angioedema_0\NNP\14316714|
D000806_D000799 CID inhibitor_11\NN\20090| (r_compound) treatment_12\NN\654885|enzyme|(|ace|)|inhibitor (r_nmod) incidence_2\NN\13821570|the|estimated|angioedema|treatment (l_nmod) angioedema_4\NN\14316714|of
15275829
D000109_D012640 NONE acetylcholine_5\NN\14807558| (r_compound) subunits_7\NNS\13604718|the|alpha3|nicotinic|acetylcholine|receptor (r_nsubj) necessary_9\JJ\1740|subunits|are|seizures|. (l_nmod) seizures_12\NNS\14081375|for|nicotine-induced|and|hypolocomotion|mice
D000109_D012640 NONE acetylcholine_5\NN\14807558| (r_compound) receptors_6\NNS\5225602|to|nicotinic|acetylcholine|nachrs (r_nmod) binding_0\NN\4688246|nicotine|receptors (r_nsubj) elicits_10\VBZ\1617192|binding|series|. (l_dobj) series_12\NN\8456993|a|behaviors (l_nmod) behaviors_15\NNS\407535|of|dose-dependent|go (l_acl:relcl) go_17\VBP\2367363|that|exploration|seizures (l_nmod) seizures_28\NNS\14081375|to|and|death
D000109_D006948 NONE acetylcholine_5\NN\14807558| (r_compound) subunits_7\NNS\13604718|the|alpha3|nicotinic|acetylcholine|receptor (r_nsubj) necessary_9\JJ\1740|subunits|are|seizures|. (l_nmod) seizures_12\NNS\14081375|for|nicotine-induced|and|hypolocomotion|mice (l_conj) hypolocomotion_14\NN\1740|
D009538_D012640 CID nicotine-induced_11\JJ\1740| (r_amod) seizures_12\NNS\14081375|for|nicotine-induced|and|hypolocomotion|mice
D009538_D012640 CID nicotine_2\NN\14712692|of (r_nmod) binding_0\NN\4688246|nicotine|receptors (r_nsubj) elicits_10\VBZ\1617192|binding|series|. (l_dobj) series_12\NN\8456993|a|behaviors (l_nmod) behaviors_15\NNS\407535|of|dose-dependent|go (l_acl:relcl) go_17\VBP\2367363|that|exploration|seizures (l_nmod) seizures_28\NNS\14081375|to|and|death
D009538_D012640 CID nicotine-induced_9\JJ\1740| (r_amod) seizures_10\NNS\14081375|in|nicotine-induced|and|hypolocomotion
D009538_D012640 CID nicotine_10\NN\14712692|of (r_nmod) effects_8\NNS\13245626|to|the|nicotine (r_nmod) sensitive_5\JJ\1740|mice|were|less|effects|doses|. (l_nmod) doses_14\NNS\3740161|both|at|low|,|measured|,|and|doses|,|measured (l_acl) measured_30\VBN\697589|sensitivity (l_nmod) sensitivity_32\NN\5651971|as|seizures (l_nmod) seizures_35\NNS\14081375|to|nicotine-induced
D009538_D012640 CID nicotine-induced_34\JJ\1740| (r_amod) seizures_35\NNS\14081375|to|nicotine-induced
D009538_D012640 CID nicotine-induced_7\JJ\1740| (r_amod) seizures_8\NNS\14081375|to|nicotine-induced
D009538_D012640 CID nicotine-induced_15\JJ\1740| (r_amod) seizures_16\NNS\14081375|of|nicotine-induced|and|hypolocomotion
D009538_D006948 NONE nicotine-induced_11\JJ\1740| (r_amod) seizures_12\NNS\14081375|for|nicotine-induced|and|hypolocomotion|mice (l_conj) hypolocomotion_14\NN\1740|
D009538_D006948 NONE nicotine-induced_9\JJ\1740| (r_amod) seizures_10\NNS\14081375|in|nicotine-induced|and|hypolocomotion (l_conj) hypolocomotion_12\NN\1740|
D009538_D006948 NONE nicotine-induced_15\JJ\1740| (r_amod) seizures_16\NNS\14081375|of|nicotine-induced|and|hypolocomotion (l_conj) hypolocomotion_18\NN\1740|
D009538_D014202 NONE nicotine_2\NN\14712692|of (r_nmod) binding_0\NN\4688246|nicotine|receptors (r_nsubj) elicits_10\VBZ\1617192|binding|series|. (l_dobj) series_12\NN\8456993|a|behaviors (l_nmod) behaviors_15\NNS\407535|of|dose-dependent|go (l_acl:relcl) go_17\VBP\2367363|that|exploration|seizures (l_nmod) exploration_20\NN\309647|from|altered|,|sedation|, (l_conj) sedation_22\NN\14034177|,|and|tremors (l_conj) tremors_25\NNS\345926|
D009538_D003643 NONE nicotine_2\NN\14712692|of (r_nmod) binding_0\NN\4688246|nicotine|receptors (r_nsubj) elicits_10\VBZ\1617192|binding|series|. (l_dobj) series_12\NN\8456993|a|behaviors (l_nmod) behaviors_15\NNS\407535|of|dose-dependent|go (l_acl:relcl) go_17\VBP\2367363|that|exploration|seizures (l_nmod) seizures_28\NNS\14081375|to|and|death (l_conj) death_30\NN\7296428|
D000109_D014202 NONE acetylcholine_5\NN\14807558| (r_compound) receptors_6\NNS\5225602|to|nicotinic|acetylcholine|nachrs (r_nmod) binding_0\NN\4688246|nicotine|receptors (r_nsubj) elicits_10\VBZ\1617192|binding|series|. (l_dobj) series_12\NN\8456993|a|behaviors (l_nmod) behaviors_15\NNS\407535|of|dose-dependent|go (l_acl:relcl) go_17\VBP\2367363|that|exploration|seizures (l_nmod) exploration_20\NN\309647|from|altered|,|sedation|, (l_conj) sedation_22\NN\14034177|,|and|tremors (l_conj) tremors_25\NNS\345926|
D000109_D003643 NONE acetylcholine_5\NN\14807558| (r_compound) receptors_6\NNS\5225602|to|nicotinic|acetylcholine|nachrs (r_nmod) binding_0\NN\4688246|nicotine|receptors (r_nsubj) elicits_10\VBZ\1617192|binding|series|. (l_dobj) series_12\NN\8456993|a|behaviors (l_nmod) behaviors_15\NNS\407535|of|dose-dependent|go (l_acl:relcl) go_17\VBP\2367363|that|exploration|seizures (l_nmod) seizures_28\NNS\14081375|to|and|death (l_conj) death_30\NN\7296428|
9812111
D006220_D011618 NONE haloperidol_7\NN\3713736|of (r_nmod) trial_5\NN\786195|a|randomized|,|placebo-controlled|dose-comparison|haloperidol|psychosis|. (l_nmod) psychosis_9\NN\14380140|for|and|behaviors|disease
D006220_D011618 NONE haloperidol_19\NN\3713736|of|and|placebo (r_nmod) doses_17\NNS\3740161|of|two|haloperidol (r_nmod) efficacy_11\NN\5199286|the|and|side|effects|doses|treatment (l_nmod) treatment_24\NN\654885|in|the|psychosis|patients (l_nmod) psychosis_26\NN\14380140|of|and|behaviors
D006220_D011618 NONE haloperidol_12\NN\3713736|standard-dose (r_nsubj) efficacious_14\JJ\1740|patients|haloperidol|was|and|superior (l_conj) superior_16\JJ\1740|haloperidol (l_nmod) haloperidol_20\NN\3713736|to|both|low-dose|and|placebo (l_conj) placebo_22\NN\3740161|scores (l_nmod) scores_24\NNS\13757724|for|factor (l_nmod) factor_32\NN\7326557|on|the|brief|psychiatric|rating|scale|psychosis|and|agitation (l_compound) psychosis_31\NN\14380140|
D006220_D011618 NONE haloperidol_20\NN\3713736|to|both|low-dose|and|placebo (l_conj) placebo_22\NN\3740161|scores (l_nmod) scores_24\NNS\13757724|for|factor (l_nmod) factor_32\NN\7326557|on|the|brief|psychiatric|rating|scale|psychosis|and|agitation (l_compound) psychosis_31\NN\14380140|
D006220_D011618 NONE haloperidol_6\NN\3713736|with (r_nmod) observed_4\VBN\2163746|haloperidol (r_acl) window_3\NN\3391770|the|narrow|therapeutic|observed (r_nsubj) apply_9\VB\2676054|window|may|also|neuroleptics|. (l_nmod) neuroleptics_12\NNS\4470232|to|other|used (l_acl) used_13\VBN\1156834|patients (l_nmod) patients_18\NNS\9898892|in|alzheimer|disease|psychosis (l_nmod) psychosis_20\NN\14380140|with|and|behaviors
D006220_D019958 NONE haloperidol_7\NN\3713736|of (r_nmod) trial_5\NN\786195|a|randomized|,|placebo-controlled|dose-comparison|haloperidol|psychosis|. (l_nmod) psychosis_9\NN\14380140|for|and|behaviors|disease (l_conj) behaviors_12\NNS\407535|disruptive
D006220_D019958 NONE haloperidol_19\NN\3713736|of|and|placebo (r_nmod) doses_17\NNS\3740161|of|two|haloperidol (r_nmod) efficacy_11\NN\5199286|the|and|side|effects|doses|treatment (l_nmod) treatment_24\NN\654885|in|the|psychosis|patients (l_nmod) psychosis_26\NN\14380140|of|and|behaviors (l_conj) behaviors_29\NNS\407535|disruptive
D006220_D019958 NONE haloperidol_6\NN\3713736|with (r_nmod) observed_4\VBN\2163746|haloperidol (r_acl) window_3\NN\3391770|the|narrow|therapeutic|observed (r_nsubj) apply_9\VB\2676054|window|may|also|neuroleptics|. (l_nmod) neuroleptics_12\NNS\4470232|to|other|used (l_acl) used_13\VBN\1156834|patients (l_nmod) patients_18\NNS\9898892|in|alzheimer|disease|psychosis (l_nmod) psychosis_20\NN\14380140|with|and|behaviors (l_conj) behaviors_23\NNS\407535|disruptive
D006220_D000544 NONE haloperidol_7\NN\3713736|of (r_nmod) trial_5\NN\786195|a|randomized|,|placebo-controlled|dose-comparison|haloperidol|psychosis|. (l_nmod) psychosis_9\NN\14380140|for|and|behaviors|disease (l_nmod) disease_16\NN\14061805|in|alzheimer|'s
D006220_D000544 NONE haloperidol_19\NN\3713736|of|and|placebo (r_nmod) doses_17\NNS\3740161|of|two|haloperidol (r_nmod) efficacy_11\NN\5199286|the|and|side|effects|doses|treatment (l_nmod) treatment_24\NN\654885|in|the|psychosis|patients (l_nmod) patients_31\NNS\9898892|in|disease (l_nmod) disease_35\NN\14061805|with|alzheimer|'s
D006220_D000544 NONE haloperidol_16\NN\3713736| (r_conj) random-assignment_5\JJ\1740|in|a|6-week|,|double-blind|,|trial|,|haloperidol|,|mg/day|,|and|haloperidol (r_dep) method_0\NNP\5616786|:|random-assignment|mg/day|, (r_nsubjpass) compared_40\VBN\644583|method|were|outpatients|. (l_nmod) outpatients_43\NNS\10405694|in|71|disease (l_nmod) disease_47\NN\14061805|with|alzheimer|'s
D006220_D000544 NONE haloperidol_28\VB\1740|, (r_conj) random-assignment_5\JJ\1740|in|a|6-week|,|double-blind|,|trial|,|haloperidol|,|mg/day|,|and|haloperidol (r_dep) method_0\NNP\5616786|:|random-assignment|mg/day|, (r_nsubjpass) compared_40\VBN\644583|method|were|outpatients|. (l_nmod) outpatients_43\NNS\10405694|in|71|disease (l_nmod) disease_47\NN\14061805|with|alzheimer|'s
D006220_D000544 NONE haloperidol_6\NN\3713736|with (r_nmod) observed_4\VBN\2163746|haloperidol (r_acl) window_3\NN\3391770|the|narrow|therapeutic|observed (r_nsubj) apply_9\VB\2676054|window|may|also|neuroleptics|. (l_nmod) neuroleptics_12\NNS\4470232|to|other|used (l_acl) used_13\VBN\1156834|patients (l_nmod) patients_18\NNS\9898892|in|alzheimer|disease|psychosis (l_compound) disease_17\NN\14061805|
D006220_D011595 NONE haloperidol_12\NN\3713736|standard-dose (r_nsubj) efficacious_14\JJ\1740|patients|haloperidol|was|and|superior (l_conj) superior_16\JJ\1740|haloperidol (l_nmod) haloperidol_20\NN\3713736|to|both|low-dose|and|placebo (l_conj) placebo_22\NN\3740161|scores (l_nmod) scores_24\NNS\13757724|for|factor (l_nmod) factor_32\NN\7326557|on|the|brief|psychiatric|rating|scale|psychosis|and|agitation (l_conj) agitation_36\NN\14373582|on|psychomotor
D006220_D011595 NONE haloperidol_20\NN\3713736|to|both|low-dose|and|placebo (l_conj) placebo_22\NN\3740161|scores (l_nmod) scores_24\NNS\13757724|for|factor (l_nmod) factor_32\NN\7326557|on|the|brief|psychiatric|rating|scale|psychosis|and|agitation (l_conj) agitation_36\NN\14373582|on|psychomotor
D006220_D001480 CID haloperidol_10\NN\3713736|for|doses (r_nmod) profile_8\NN\6999802|a|favorable|therapeutic|haloperidol (r_dobj) indicated_4\VBD\952524|conclusions|results|profile|,|developed|. (l_advcl) developed_22\VBD\1753788|although|subgroup|moderate (l_dobj) moderate_23\JJ\1740|signs (l_nmod) signs_27\NNS\6643763|to|severe|extrapyramidal
9351491
D018967_D011618 NONE risperidone_6\NN\1740|'s (r_nmod:poss) profile_9\NN\6999802|risperidone|pharmacologic (r_nsubj) produce_11\VB\1617192|that|profile|may|efficacy|and|decreased (l_dobj) efficacy_13\NN\5199286|improved|symptoms (l_nmod) symptoms_17\NNS\5823932|for|negative|psychotic
D018967_D010302 CID risperidone_8\NN\1740|with|%|and|haloperidol (r_nmod) treated_6\VBN\2376958|risperidone (r_acl) subjects_5\NNS\6598915|in|treated (r_nmod) observed_3\VBN\2163746|parkinsonism|was|subjects|and|observed|. (l_nsubjpass) parkinsonism_1\NN\14085708|drug-induced
D006220_D010302 CID haloperidol_14\NN\3713736|% (r_conj) risperidone_8\NN\1740|with|%|and|haloperidol (r_nmod) treated_6\VBN\2376958|risperidone (r_acl) subjects_5\NNS\6598915|in|treated (r_nmod) observed_3\VBN\2163746|parkinsonism|was|subjects|and|observed|. (l_nsubjpass) parkinsonism_1\NN\14085708|drug-induced
8829025
D016559_D006973 CID tacrolimus_5\NN\1740| (r_dobj) receiving_4\VBG\2210855|tacrolimus (r_acl) patients_3\NNS\9898892|of|receiving (r_nmod) groups_1\NNS\2137|two|patients (r_nsubjpass) compared_7\VBN\644583|groups|were|period|,|group|. (l_conj) group_16\NN\2137|one|comprising|,|and|other (l_acl) comprising_17\VBG\2604760|patients (l_dobj) patients_19\NNS\9898892|hypertensive|receiving (l_amod) hypertensive_18\JJ\1740|
D016559_D006973 CID tacrolimus_12\NN\1740|with (r_nmod) associated_10\VBN\628491|tacrolimus|recipients (r_acl) nephrotoxicity_9\NN\1740|the|associated (r_dobj) reducing_7\VBG\441445|on|nephrotoxicity (r_acl) impact_3\NN\7339329|the|observed|positive|nifedipine|reducing (r_nsubj) factor_21\NN\7326557|impact|should|be|an|important|selecting|. (l_acl) selecting_23\VBG\697589|in|agent (l_dobj) agent_25\NN\7347|an|treat (l_acl:relcl) treat_27\VB\2376958|to|hypertension|population (l_dobj) hypertension_28\NN\14057371|
D009543_D006973 NONE nifedipine_23\NN\2938514| (r_dobj) receiving_22\VBG\2210855|who|were|nifedipine (r_acl:relcl) patients_19\NNS\9898892|hypertensive|receiving (l_amod) hypertensive_18\JJ\1740|
D009543_D006973 NONE nifedipine_33\NN\2938514| (r_dobj) receiving_32\VBG\2210855|not|nifedipine (r_acl) patients_30\NNS\9898892|comprising|nonhypertensive|receiving (r_nmod) other_27\JJ\1740|the|patients (r_conj) group_16\NN\2137|one|comprising|,|and|other (l_acl) comprising_17\VBG\2604760|patients (l_dobj) patients_19\NNS\9898892|hypertensive|receiving (l_amod) hypertensive_18\JJ\1740|
D009543_D006973 NONE nifedipine_5\NN\2938514|of (r_nmod) impact_3\NN\7339329|the|observed|positive|nifedipine|reducing (r_nsubj) factor_21\NN\7326557|impact|should|be|an|important|selecting|. (l_acl) selecting_23\VBG\697589|in|agent (l_dobj) agent_25\NN\7347|an|treat (l_acl:relcl) treat_27\VB\2376958|to|hypertension|population (l_dobj) hypertension_28\NN\14057371|
D009543_D007674 NONE nifedipine_5\NN\2938514|of (r_nmod) impact_3\NN\7339329|the|observed|positive|nifedipine|reducing (l_acl) reducing_7\VBG\441445|on|nephrotoxicity (l_dobj) nephrotoxicity_9\NN\1740|the|associated
D016559_D007674 NONE tacrolimus_12\NN\1740|with (r_nmod) associated_10\VBN\628491|tacrolimus|recipients (r_acl) nephrotoxicity_9\NN\1740|the|associated
2670794
D000809_D011665 NONE angiotensin_5\NN\4522421| (r_compound) enzyme_7\NN\14723628|of|angiotensin|converting (r_nmod) inhibitor_3\NN\20090|of|an|enzyme|captopril (r_nmod) effects_0\NNS\13245626|inhibitor|insufficiency|coagulation|. (l_nmod) insufficiency_15\NN\14462946|on|pulmonary
D000809_D011665 NONE angiotensin_11\NN\4522421| (r_compound) enzyme_13\NN\14723628|of|angiotensin|converting|ace (r_nmod) inhibitor_9\NN\20090|an|enzyme (r_appos) injection_0\NN\320852|captopril|mg/kg|,|inhibitor|, (r_nsubj) reduced_18\VBD\441445|injection|insufficiency|. (l_dobj) insufficiency_23\NN\14462946|pulmonary|model
D000809_D051437 NONE angiotensin_5\NN\4522421| (r_compound) enzyme_7\NN\14723628|of|angiotensin|converting (r_nmod) inhibitor_3\NN\20090|of|an|enzyme|captopril (r_nmod) effects_0\NNS\13245626|inhibitor|insufficiency|coagulation|. (l_nmod) insufficiency_15\NN\14462946|on|pulmonary
D000809_D051437 NONE angiotensin_11\NN\4522421| (r_compound) enzyme_13\NN\14723628|of|angiotensin|converting|ace (r_nmod) inhibitor_9\NN\20090|an|enzyme (r_appos) injection_0\NN\320852|captopril|mg/kg|,|inhibitor|, (r_nsubj) reduced_18\VBD\441445|injection|insufficiency|. (l_dobj) insufficiency_23\NN\14462946|pulmonary|model
D000809_D004211 NONE angiotensin_5\NN\4522421| (r_compound) enzyme_7\NN\14723628|of|angiotensin|converting (r_nmod) inhibitor_3\NN\20090|of|an|enzyme|captopril (r_nmod) effects_0\NNS\13245626|inhibitor|insufficiency|coagulation|. (l_nmod) coagulation_19\NN\13518963|due|intravascular|rat
D002216_D011665 NONE captopril_9\NNP\2673637|(|) (r_appos) inhibitor_3\NN\20090|of|an|enzyme|captopril (r_nmod) effects_0\NNS\13245626|inhibitor|insufficiency|coagulation|. (l_nmod) insufficiency_15\NN\14462946|on|pulmonary
D002216_D011665 NONE captopril_2\NNP\2673637|of (r_nmod) injection_0\NN\320852|captopril|mg/kg|,|inhibitor|, (r_nsubj) reduced_18\VBD\441445|injection|insufficiency|. (l_dobj) insufficiency_23\NN\14462946|pulmonary|model
D002216_D051437 NONE captopril_9\NNP\2673637|(|) (r_appos) inhibitor_3\NN\20090|of|an|enzyme|captopril (r_nmod) effects_0\NNS\13245626|inhibitor|insufficiency|coagulation|. (l_nmod) insufficiency_15\NN\14462946|on|pulmonary
D002216_D051437 NONE captopril_2\NNP\2673637|of (r_nmod) injection_0\NN\320852|captopril|mg/kg|,|inhibitor|, (r_nsubj) reduced_18\VBD\441445|injection|insufficiency|. (l_dobj) insufficiency_23\NN\14462946|pulmonary|model
D002216_D004211 NONE captopril_9\NNP\2673637|(|) (r_appos) inhibitor_3\NN\20090|of|an|enzyme|captopril (r_nmod) effects_0\NNS\13245626|inhibitor|insufficiency|coagulation|. (l_nmod) coagulation_19\NN\13518963|due|intravascular|rat
D014148_D004211 CID acid_14\NN\14818238|thrombin|amca (r_nmod) injection_9\NN\320852|by|acid|rat (r_nmod) inhibition_5\NN\1068773|fibrinolysis|injection (r_conj) induction_0\NN\7450842|coagulation|and|inhibition (l_nmod) coagulation_3\NN\13518963|of|intravascular
D014148_D004211 CID amca_16\NN\1740|(|) (r_appos) acid_14\NN\14818238|thrombin|amca (r_nmod) injection_9\NN\320852|by|acid|rat (r_nmod) inhibition_5\NN\1068773|fibrinolysis|injection (r_conj) induction_0\NN\7450842|coagulation|and|inhibition (l_nmod) coagulation_3\NN\13518963|of|intravascular
D014148_D011665 NONE acid_14\NN\14818238|thrombin|amca (r_nmod) injection_9\NN\320852|by|acid|rat (r_nmod) inhibition_5\NN\1068773|fibrinolysis|injection (r_conj) induction_0\NN\7450842|coagulation|and|inhibition (r_nsubj) gives_21\VBZ\2327200|induction|rise|pulmonary|. (l_nmod) pulmonary_24\JJ\1740|to|and|renal|insufficiency|resembling|occurring (l_dep) insufficiency_27\NN\14462946|
D014148_D011665 NONE amca_16\NN\1740|(|) (r_appos) acid_14\NN\14818238|thrombin|amca (r_nmod) injection_9\NN\320852|by|acid|rat (r_nmod) inhibition_5\NN\1068773|fibrinolysis|injection (r_conj) induction_0\NN\7450842|coagulation|and|inhibition (r_nsubj) gives_21\VBZ\2327200|induction|rise|pulmonary|. (l_nmod) pulmonary_24\JJ\1740|to|and|renal|insufficiency|resembling|occurring (l_dep) insufficiency_27\NN\14462946|
D014148_D051437 NONE acid_14\NN\14818238|thrombin|amca (r_nmod) injection_9\NN\320852|by|acid|rat (r_nmod) inhibition_5\NN\1068773|fibrinolysis|injection (r_conj) induction_0\NN\7450842|coagulation|and|inhibition (r_nsubj) gives_21\VBZ\2327200|induction|rise|pulmonary|. (l_nmod) pulmonary_24\JJ\1740|to|and|renal|insufficiency|resembling|occurring (l_dep) insufficiency_27\NN\14462946|
D014148_D051437 NONE amca_16\NN\1740|(|) (r_appos) acid_14\NN\14818238|thrombin|amca (r_nmod) injection_9\NN\320852|by|acid|rat (r_nmod) inhibition_5\NN\1068773|fibrinolysis|injection (r_conj) induction_0\NN\7450842|coagulation|and|inhibition (r_nsubj) gives_21\VBZ\2327200|induction|rise|pulmonary|. (l_nmod) pulmonary_24\JJ\1740|to|and|renal|insufficiency|resembling|occurring (l_dep) insufficiency_27\NN\14462946|
D014148_D014947 NONE acid_14\NN\14818238|thrombin|amca (r_nmod) injection_9\NN\320852|by|acid|rat (r_nmod) inhibition_5\NN\1068773|fibrinolysis|injection (r_conj) induction_0\NN\7450842|coagulation|and|inhibition (r_nsubj) gives_21\VBZ\2327200|induction|rise|pulmonary|. (l_nmod) pulmonary_24\JJ\1740|to|and|renal|insufficiency|resembling|occurring (l_dep) occurring_30\VBG\2623529|that|trauma (l_nmod) trauma_32\NN\14052046|after|or|sepsis|man
D014148_D014947 NONE amca_16\NN\1740|(|) (r_appos) acid_14\NN\14818238|thrombin|amca (r_nmod) injection_9\NN\320852|by|acid|rat (r_nmod) inhibition_5\NN\1068773|fibrinolysis|injection (r_conj) induction_0\NN\7450842|coagulation|and|inhibition (r_nsubj) gives_21\VBZ\2327200|induction|rise|pulmonary|. (l_nmod) pulmonary_24\JJ\1740|to|and|renal|insufficiency|resembling|occurring (l_dep) occurring_30\VBG\2623529|that|trauma (l_nmod) trauma_32\NN\14052046|after|or|sepsis|man
D014148_D018805 NONE acid_14\NN\14818238|thrombin|amca (r_nmod) injection_9\NN\320852|by|acid|rat (r_nmod) inhibition_5\NN\1068773|fibrinolysis|injection (r_conj) induction_0\NN\7450842|coagulation|and|inhibition (r_nsubj) gives_21\VBZ\2327200|induction|rise|pulmonary|. (l_nmod) pulmonary_24\JJ\1740|to|and|renal|insufficiency|resembling|occurring (l_dep) occurring_30\VBG\2623529|that|trauma (l_nmod) trauma_32\NN\14052046|after|or|sepsis|man (l_conj) sepsis_34\NN\14174549|
D014148_D018805 NONE amca_16\NN\1740|(|) (r_appos) acid_14\NN\14818238|thrombin|amca (r_nmod) injection_9\NN\320852|by|acid|rat (r_nmod) inhibition_5\NN\1068773|fibrinolysis|injection (r_conj) induction_0\NN\7450842|coagulation|and|inhibition (r_nsubj) gives_21\VBZ\2327200|induction|rise|pulmonary|. (l_nmod) pulmonary_24\JJ\1740|to|and|renal|insufficiency|resembling|occurring (l_dep) occurring_30\VBG\2623529|that|trauma (l_nmod) trauma_32\NN\14052046|after|or|sepsis|man (l_conj) sepsis_34\NN\14174549|
D014508_D007674 NONE urea_9\NN\14727670|in|serum (r_nmod) increase_6\NN\13576355|by|an|urea (r_nmod) reflected_3\VBN\923793|as|increase|and (r_nmod) damage_1\NN\7296428|renal|reflected|weight
D002216_D007674 NONE captopril_17\NNP\2673637|by (r_nmod) prevented_15\VBN\1740|damage|was|captopril|. (l_nsubjpass) damage_1\NN\7296428|renal|reflected|weight
D002216_D007674 NONE captopril_0\NNP\2673637| (r_nsubj) reduce_8\VB\441445|captopril|may|,|mechanism|,|increase|,|diminishing|. (l_advcl) diminishing_26\VBG\169651|thereby|aggregation|,|result (l_nmod) result_38\NN\34213|with|the|deposited (l_acl) deposited_44\VBN\1340439|that|fibrin|will|be|and|thus|produced (l_conj) produced_52\VBN\1617192|less|damage|will|be (l_nsubjpass) damage_49\NN\7296428|kidney
1728522
D019980_D006099 CID acid_9\NN\14818238| (r_nmod) combination_4\NN\7951464|due|amoxicillin|acid (r_nmod) hepatitis_1\NN\14127211|granulomatous|combination|.
D019980_D006099 CID acid-induced_9\JJ\1740| (r_amod) hepatitis_10\NN\14127211|with|amoxicillin-clavulanic|acid-induced (r_nmod) patient_6\NN\9898892|of|a|hepatitis|granulomas (l_nmod) granulomas_14\NNS\14235200|with|histologic|multiple
D019980_D056486 CID acid_9\NN\14818238| (r_nmod) combination_4\NN\7951464|due|amoxicillin|acid (r_nmod) hepatitis_1\NN\14127211|granulomatous|combination|.
D019980_D056486 CID acid-induced_9\JJ\1740| (r_amod) hepatitis_10\NN\14127211|with|amoxicillin-clavulanic|acid-induced
7890216
D015282_D042882 CID octreotide_7\NN\1740|with (r_nmod) associated_5\VBN\628491|octreotide (r_acl) stones_4\NNS\19128|of|bladder|associated
D015282_D042882 CID octreotide_0\NNP\1740|,|treatment (r_nsubj) induces_8\VBZ\1627355|octreotide|,|stones|%|. (l_dobj) stones_11\NNS\19128|gall|bladder
D015282_D042882 CID octreotide_28\NN\1740| (r_dep) treated_29\VBN\2376958|octreotide (r_amod) patients_31\NNS\9898892|in|14|treated|acromegalic|stones (l_nmod) stones_34\NNS\19128|with|gall
D015282_D042882 CID octreotide_3\NN\1740| (r_compound) stones_6\NNS\19128|octreotide|induced|gall
D015282_D042882 CID octreotide_3\NN\1740| (r_compound) stones_6\NNS\19128|octreotide|induced|gall (r_nsubj) small_9\JJ\1740|conclusion|,|stones|are|generally|,|multiple|rich|,|have|. (l_conj) rich_15\JJ\1740|although (l_dep) although_16\IN\1740|,|common (l_nmod) common_19\JJ\1740|in|disease (l_nmod) disease_24\NN\14061805|with|spontaneous|gall|stone
D015282_D042882 CID octreotide_3\NN\1740| (r_compound) stones_6\NNS\19128|octreotide|induced|gall (r_nsubj) small_9\JJ\1740|conclusion|,|stones|are|generally|,|multiple|rich|,|have|. (l_conj) have_31\VB\2108377|presentation|patients|will|duct (l_dobj) duct_35\NN\5248181|a|blocked|cystic|and|stones (l_conj) stones_39\NNS\19128|some|gall|containing
D014580_D042882 NONE acid_13\NN\14818238|to|oral|ursodeoxycholic (r_nmod) response_9\NN\11410625|acid (r_dep) composition_0\NN\5075602|stones|:|response|. (l_nmod) stones_4\NNS\19128|of|bladder|associated
D015282_D000172 NONE octreotide_0\NNP\1740|,|treatment (l_appos) treatment_4\NN\654885|an|effective|acromegaly (l_nmod) acromegaly_6\NN\14366759|for
D015282_D000172 NONE octreotide_28\NN\1740| (r_dep) treated_29\VBN\2376958|octreotide (r_amod) patients_31\NNS\9898892|in|14|treated|acromegalic|stones (l_amod) acromegalic_30\JJ\1740|
D002784_D042882 NONE cholesterol_21\NN\15058310|% (r_dobj) contained_15\VBD\2632940|that|they|%|and|cholesterol|weight (r_ccomp) showed_12\VBD\2137132|contained (r_conj) retrieved_5\VBN\2210855|analysis|cholecystectomy|patients|,|showed|. (l_nsubj) analysis_1\NN\633864|chemical|stones (l_nmod) stones_4\NNS\19128|of|gall
D002784_D042882 NONE cholesterol_36\NN\15058310|that|stones|were (r_nmod:npmod) rich_37\JJ\1740|cholesterol (r_ccomp) suggesting_31\VBG\1010118|rich (r_advcl) showed_12\VBD\2137132|year|,|five|partial|gall|,|suggesting|. (l_conj) gall_27\VBP\63291|n|dissolution (l_dobj) dissolution_29\NN\13518963|stone (l_compound) stone_28\NN\19128|
D002784_D042882 NONE cholesterol_14\NN\15058310| (r_conj) multiple_11\JJ\1740|,|and|cholesterol (r_conj) small_9\JJ\1740|conclusion|,|stones|are|generally|,|multiple|rich|,|have|. (l_nsubj) stones_6\NNS\19128|octreotide|induced|gall
D002784_D042882 NONE cholesterol_14\NN\15058310| (r_conj) multiple_11\JJ\1740|,|and|cholesterol (r_conj) small_9\JJ\1740|conclusion|,|stones|are|generally|,|multiple|rich|,|have|. (l_conj) rich_15\JJ\1740|although (l_dep) although_16\IN\1740|,|common (l_nmod) common_19\JJ\1740|in|disease (l_nmod) disease_24\NN\14061805|with|spontaneous|gall|stone
D002784_D042882 NONE cholesterol_14\NN\15058310| (r_conj) multiple_11\JJ\1740|,|and|cholesterol (r_conj) small_9\JJ\1740|conclusion|,|stones|are|generally|,|multiple|rich|,|have|. (l_conj) have_31\VB\2108377|presentation|patients|will|duct (l_dobj) duct_35\NN\5248181|a|blocked|cystic|and|stones (l_conj) stones_39\NNS\19128|some|gall|containing
D002118_D042882 NONE calcium_41\NN\14625458| (r_dobj) containing_40\VBG\2632940|calcium (r_acl) stones_39\NNS\19128|some|gall|containing (r_conj) duct_35\NN\5248181|a|blocked|cystic|and|stones (r_dobj) have_31\VB\2108377|presentation|patients|will|duct (r_conj) small_9\JJ\1740|conclusion|,|stones|are|generally|,|multiple|rich|,|have|. (l_nsubj) stones_6\NNS\19128|octreotide|induced|gall
D002118_D042882 NONE calcium_41\NN\14625458| (r_dobj) containing_40\VBG\2632940|calcium (r_acl) stones_39\NNS\19128|some|gall|containing (r_conj) duct_35\NN\5248181|a|blocked|cystic|and|stones (r_dobj) have_31\VB\2108377|presentation|patients|will|duct (r_conj) small_9\JJ\1740|conclusion|,|stones|are|generally|,|multiple|rich|,|have|. (l_conj) rich_15\JJ\1740|although (l_dep) although_16\IN\1740|,|common (l_nmod) common_19\JJ\1740|in|disease (l_nmod) disease_24\NN\14061805|with|spontaneous|gall|stone
D002118_D042882 NONE calcium_41\NN\14625458| (r_dobj) containing_40\VBG\2632940|calcium (r_acl) stones_39\NNS\19128|some|gall|containing
9390208
D008942_D001943 NONE mitoxantrone_8\NN\1740|by|and|48-hour (r_nmod) treatment_0\NN\654885|cancer|mitoxantrone|infusion|benefit|. (l_nmod) cancer_6\NN\14239425|of|treated|metastatic|breast
D008942_D001943 NONE mitoxantrone_18\NN\1740|by|,|mg/m2 (r_nmod) treated_8\VBD\2376958|october|,|we|patients|mitoxantrone|,|day|,|leucovorin|,|h|. (l_dobj) patients_10\NNS\9898892|13|cancer (l_nmod) cancer_16\NN\14239425|with|chemotherapy-treated|metastatic|breast
D008942_D064420 NONE mitoxantrone_8\NN\1740|by|and|48-hour (r_nmod) treatment_0\NN\654885|cancer|mitoxantrone|infusion|benefit|. (l_nmod) benefit_23\NN\13278375|mfl|):|low|palliative|and|toxicity (l_conj) toxicity_27\NN\13576101|high|treatment-related
D005472_D001943 NONE 5-fu_15\NN\1740|of|high-dose|and|leucovorin (r_nmod) infusion_12\NN\14589223|continuous|5-fu (r_conj) treatment_0\NN\654885|cancer|mitoxantrone|infusion|benefit|. (l_nmod) cancer_6\NN\14239425|of|treated|metastatic|breast
D005472_D001943 NONE 5-fu_30\NN\1740|of (r_nmod) infusion_28\NN\14589223|continuous|5-fu|, (r_conj) day_24\NN\15154774|on|1|and|infusion|mg/m2 (r_nmod) treated_8\VBD\2376958|october|,|we|patients|mitoxantrone|,|day|,|leucovorin|,|h|. (l_dobj) patients_10\NNS\9898892|13|cancer (l_nmod) cancer_16\NN\14239425|with|chemotherapy-treated|metastatic|breast
D005472_D064420 NONE 5-fu_15\NN\1740|of|high-dose|and|leucovorin (r_nmod) infusion_12\NN\14589223|continuous|5-fu (r_conj) treatment_0\NN\654885|cancer|mitoxantrone|infusion|benefit|. (l_nmod) benefit_23\NN\13278375|mfl|):|low|palliative|and|toxicity (l_conj) toxicity_27\NN\13576101|high|treatment-related
D002955_D001943 NONE leucovorin_17\NN\1740| (r_conj) 5-fu_15\NN\1740|of|high-dose|and|leucovorin (r_nmod) infusion_12\NN\14589223|continuous|5-fu (r_conj) treatment_0\NN\654885|cancer|mitoxantrone|infusion|benefit|. (l_nmod) cancer_6\NN\14239425|of|treated|metastatic|breast
D002955_D001943 NONE leucovorin_37\NN\1740|together|with|,|mg/m2 (r_nmod) treated_8\VBD\2376958|october|,|we|patients|mitoxantrone|,|day|,|leucovorin|,|h|. (l_dobj) patients_10\NNS\9898892|13|cancer (l_nmod) cancer_16\NN\14239425|with|chemotherapy-treated|metastatic|breast
D002955_D064420 NONE leucovorin_17\NN\1740| (r_conj) 5-fu_15\NN\1740|of|high-dose|and|leucovorin (r_nmod) infusion_12\NN\14589223|continuous|5-fu (r_conj) treatment_0\NN\654885|cancer|mitoxantrone|infusion|benefit|. (l_nmod) benefit_23\NN\13278375|mfl|):|low|palliative|and|toxicity (l_conj) toxicity_27\NN\13576101|high|treatment-related
C085788_D001943 NONE mfl_19\NN\1740|( (r_compound) benefit_23\NN\13278375|mfl|):|low|palliative|and|toxicity (r_nmod) treatment_0\NN\654885|cancer|mitoxantrone|infusion|benefit|. (l_nmod) cancer_6\NN\14239425|of|treated|metastatic|breast
C085788_D064420 NONE mfl_19\NN\1740|( (r_compound) benefit_23\NN\13278375|mfl|):|low|palliative|and|toxicity (l_conj) toxicity_27\NN\13576101|high|treatment-related
C085788_D064420 NONE regimen_2\NN\5898568|the|mfl (r_nsubj) achieves_3\VBZ\2524171|regimen|benefit|and|induces|. (l_conj) induces_8\VBZ\1627355|toxicity|rate (l_dobj) toxicity_10\NN\13576101|severe
7088431
D004054_D018262 CID des-exposed_6\JJ\1740| (r_amod) offspring_7\NN\10235549|in|des-exposed|observation (r_nmod) development_0\NN\248977|adenocarcinoma|offspring|. (l_nmod) adenocarcinoma_4\NN\14242337|of|clear|cell
D004054_D018262 CID diethylstilbestrol_19\NN\14749794|to (r_nmod) exposed_15\VBN\2110927|utero|diethylstilbestrol (r_acl) women_14\NNS\9605289|in|young|exposed (r_nmod) follow-up_11\NN\4599396|at|women (r_nmod) detected_9\VBN\2163746|follow-up (r_acl) vagina_8\NN\5250659|of|the|detected
D004054_D014625 CID diethylstilbestrol_19\NN\14749794|to (r_nmod) exposed_15\VBN\2110927|utero|diethylstilbestrol (r_acl) women_14\NNS\9605289|in|young|exposed (r_nmod) follow-up_11\NN\4599396|at|women (r_nmod) detected_9\VBN\2163746|follow-up (r_acl) vagina_8\NN\5250659|of|the|detected
18417364
D009538_D009759 CID nicotine-induced_0\JJ\1740| (r_amod) nystagmus_1\NN\337486|nicotine-induced
D009538_D009759 CID nicotine-induced_3\JJ\1740| (r_amod) nystagmus_4\NN\337486|of|nicotine-induced|nin
D009538_D009759 CID nicotine-induced_3\JJ\1740| (r_amod) nystagmus_4\NN\337486|of|nicotine-induced|nin (l_appos) nin_6\NN\1740|(|)
D010100_D009759 NONE oxygen_4\NN\14622893| (r_compound) level-dependent_5\JJ\1740|with|blood|oxygen (r_amod) levels_10\NNS\4916342|level-dependent|bold|)|activity|site (r_dobj) correlated_1\VBD\2657219|nin|levels|. (l_nsubj) nin_0\NN\1740|
9869257
C087567_D000647 NONE pg-9_6\NN\1740| (r_compound) mg/kg_11\NN\1740|pg-9|(|30|,|i.p.|) (r_appos) test_4\NN\5798043|in|the|passive-avoidance|,|mg/kg|, (r_nmod) administered_16\VBN\2436349|test|min|session|,|prevented|. (l_conj) prevented_24\VBD\1740|amnesia (l_dobj) amnesia_25\NN\5669934|induced
C087567_D000647 NONE pg-9_6\NN\1740| (r_compound) microg_11\NN\1740|pg-9|(|20|mouse (r_nsubj) able_19\JJ\1740|conditions|,|microg|was|also|prevent|,|demonstrating|. (l_xcomp) prevent_21\VB\1740|to|amnesia (l_dobj) amnesia_23\NN\5669934|antimuscarine-induced
D012601_D000647 CID scopolamine_34\NN\14712692|by|both|the|non|selective|antimuscarinic|drug|and|s-(-)-et-126 (r_nmod) induced_26\VBN\1627355|scopolamine (r_acl) amnesia_25\NN\5669934|induced
C098725_D000647 CID s-(-)-et-126_39\NNS\1740|the|m1-selective|antagonist (r_conj) scopolamine_34\NN\14712692|by|both|the|non|selective|antimuscarinic|drug|and|s-(-)-et-126 (r_nmod) induced_26\VBN\1627355|scopolamine (r_acl) amnesia_25\NN\5669934|induced
3015567
D009599_D007022 CID nitroprusside-induced_0\JJ\1740| (r_amod) hypotension_1\NN\14057371|nitroprusside-induced
D009599_D007022 CID nitroprusside-induced_7\JJ\1740| (r_amod) hypotension_8\NN\14057371|to|nitroprusside-induced
D003345_D007022 NONE corticosterone_16\NN\14752057| (r_compound) level_17\NN\4916342|at|a|plasma|corticosterone|micrograms/dl (r_nmod) occurs_12\VBZ\2623529|level (r_conj) observed_10\VBN\2163746|suppression|is|and|occurs|. (l_nsubjpass) suppression_0\NN\13489037|secretion|response (l_nmod) response_5\NN\11410625|in|hypotension (l_nmod) hypotension_8\NN\14057371|to|nitroprusside-induced
8739323
D008466_D007674 NONE nitrogranulogen_8\NN\1740|such|ng (r_nmod) drugs_5\NNS\14778436|of|anticancer|nitrogranulogen (r_nmod) action_2\NN\30358|the|nephrotoxic|drugs|,|methotrexate (l_amod) nephrotoxic_1\JJ\1740|
D008466_D007674 NONE ng_10\NN\13717155|(|) (r_appos) nitrogranulogen_8\NN\1740|such|ng (r_nmod) drugs_5\NNS\14778436|of|anticancer|nitrogranulogen (r_nmod) action_2\NN\30358|the|nephrotoxic|drugs|,|methotrexate (l_amod) nephrotoxic_1\JJ\1740|
D008727_D007674 NONE methotrexate_13\VBP\1740|mtx|,|5-fluorouracil (r_amod) action_2\NN\30358|the|nephrotoxic|drugs|,|methotrexate (l_amod) nephrotoxic_1\JJ\1740|
D008727_D007674 NONE mtx_15\NN\1740|(|) (r_appos) methotrexate_13\VBP\1740|mtx|,|5-fluorouracil (r_amod) action_2\NN\30358|the|nephrotoxic|drugs|,|methotrexate (l_amod) nephrotoxic_1\JJ\1740|
D008727_D007674 NONE mtx_33\NN\1740|[|+|5-fu|+|cy|] (r_dep) 5-fluorouracil_18\NN\1740|5-fu|and|cyclophosphamide|administered|or|combination|mtx (r_conj) methotrexate_13\VBP\1740|mtx|,|5-fluorouracil (r_amod) action_2\NN\30358|the|nephrotoxic|drugs|,|methotrexate (l_amod) nephrotoxic_1\JJ\1740|
D008727_D007674 NONE mtx_6\NN\1740|of|+|5-fu|+|cy (r_nmod) nephrotoxicity_4\NN\1740|mtx|administered
D005472_D007674 NONE 5-fluorouracil_18\NN\1740|5-fu|and|cyclophosphamide|administered|or|combination|mtx (r_conj) methotrexate_13\VBP\1740|mtx|,|5-fluorouracil (r_amod) action_2\NN\30358|the|nephrotoxic|drugs|,|methotrexate (l_amod) nephrotoxic_1\JJ\1740|
D005472_D007674 NONE 5-fu_20\NN\1740|(|) (r_appos) 5-fluorouracil_18\NN\1740|5-fu|and|cyclophosphamide|administered|or|combination|mtx (r_conj) methotrexate_13\VBP\1740|mtx|,|5-fluorouracil (r_amod) action_2\NN\30358|the|nephrotoxic|drugs|,|methotrexate (l_amod) nephrotoxic_1\JJ\1740|
D005472_D007674 NONE 5-fu_35\NN\1740| (r_conj) mtx_33\NN\1740|[|+|5-fu|+|cy|] (r_dep) 5-fluorouracil_18\NN\1740|5-fu|and|cyclophosphamide|administered|or|combination|mtx (r_conj) methotrexate_13\VBP\1740|mtx|,|5-fluorouracil (r_amod) action_2\NN\30358|the|nephrotoxic|drugs|,|methotrexate (l_amod) nephrotoxic_1\JJ\1740|
D005472_D007674 NONE 5-fu_8\NN\1740| (r_conj) mtx_6\NN\1740|of|+|5-fu|+|cy (r_nmod) nephrotoxicity_4\NN\1740|mtx|administered
D003520_D007674 NONE cyclophosphamide_23\NN\1740|cy (r_conj) 5-fluorouracil_18\NN\1740|5-fu|and|cyclophosphamide|administered|or|combination|mtx (r_conj) methotrexate_13\VBP\1740|mtx|,|5-fluorouracil (r_amod) action_2\NN\30358|the|nephrotoxic|drugs|,|methotrexate (l_amod) nephrotoxic_1\JJ\1740|
D003520_D007674 NONE cy_25\NN\1740|(|) (r_appos) cyclophosphamide_23\NN\1740|cy (r_conj) 5-fluorouracil_18\NN\1740|5-fu|and|cyclophosphamide|administered|or|combination|mtx (r_conj) methotrexate_13\VBP\1740|mtx|,|5-fluorouracil (r_amod) action_2\NN\30358|the|nephrotoxic|drugs|,|methotrexate (l_amod) nephrotoxic_1\JJ\1740|
D003520_D007674 NONE cy_37\NN\1740|cmf (r_conj) mtx_33\NN\1740|[|+|5-fu|+|cy|] (r_dep) 5-fluorouracil_18\NN\1740|5-fu|and|cyclophosphamide|administered|or|combination|mtx (r_conj) methotrexate_13\VBP\1740|mtx|,|5-fluorouracil (r_amod) action_2\NN\30358|the|nephrotoxic|drugs|,|methotrexate (l_amod) nephrotoxic_1\JJ\1740|
D003520_D007674 NONE cy_10\NN\1740| (r_conj) mtx_6\NN\1740|of|+|5-fu|+|cy (r_nmod) nephrotoxicity_4\NN\1740|mtx|administered
D003520_D006470 CID cy_0\NNP\1740| (r_nsubj) caused_1\VBD\1617192|cy|cystitis|%|,|but|cause|. (l_dobj) cystitis_3\NN\14566129|hemorrhagic
D003520_D003556 CID cy_0\NNP\1740| (r_nsubj) caused_1\VBD\1617192|cy|cystitis|%|,|but|cause|. (l_dobj) cystitis_3\NN\14566129|hemorrhagic
D005472_D006470 NONE 5-fu_20\NN\1740|with|and|mtx (r_nmod) combined_18\VBN\2630189|when|5-fu (r_advcl) cause_14\VB\1617192|it|did|not|complication|combined (r_conj) caused_1\VBD\1617192|cy|cystitis|%|,|but|cause|. (l_dobj) cystitis_3\NN\14566129|hemorrhagic
D005472_D003556 NONE 5-fu_20\NN\1740|with|and|mtx (r_nmod) combined_18\VBN\2630189|when|5-fu (r_advcl) cause_14\VB\1617192|it|did|not|complication|combined (r_conj) caused_1\VBD\1617192|cy|cystitis|%|,|but|cause|. (l_dobj) cystitis_3\NN\14566129|hemorrhagic
D008727_D006470 NONE mtx_22\NN\1740| (r_conj) 5-fu_20\NN\1740|with|and|mtx (r_nmod) combined_18\VBN\2630189|when|5-fu (r_advcl) cause_14\VB\1617192|it|did|not|complication|combined (r_conj) caused_1\VBD\1617192|cy|cystitis|%|,|but|cause|. (l_dobj) cystitis_3\NN\14566129|hemorrhagic
D008727_D003556 NONE mtx_22\NN\1740| (r_conj) 5-fu_20\NN\1740|with|and|mtx (r_nmod) combined_18\VBN\2630189|when|5-fu (r_advcl) cause_14\VB\1617192|it|did|not|complication|combined (r_conj) caused_1\VBD\1617192|cy|cystitis|%|,|but|cause|. (l_dobj) cystitis_3\NN\14566129|hemorrhagic
20880751
D007980_D004409 CID levodopa-induced_0\JJ\1740| (r_amod) dyskinesias_1\NNS\14084880|levodopa-induced|patients|:|filling|.
D007980_D004409 CID levodopa-induced_17\JJ\1740| (r_amod) dyskinesias_18\NNS\14084880|levodopa-induced
D007980_D004409 CID levodopa-induced_39\JJ\1740| (r_amod) dyskinesias_40\NNS\14084880|of|levodopa-induced
D007980_D010300 NONE levodopa-induced_0\JJ\1740| (r_amod) dyskinesias_1\NNS\14084880|levodopa-induced|patients|:|filling|. (l_nmod) patients_3\NNS\9898892|in|disease (l_nmod) disease_7\NN\14061805|with|parkinson
D007980_D010300 NONE levodopa_0\NN\14604959| (r_nsubj) drug_5\NN\14778436|levodopa|is|the|effective|treatment|. (l_nmod) treatment_8\NN\654885|for|the|disease (l_nmod) disease_12\NN\14061805|of|parkinson
D004298_D004409 NONE dopamine_7\NN\14807737| (r_compound) precursor_8\NN\14580897|of|this|dopamine (r_nmod) use_4\NN\407535|the|long-term|precursor (r_nsubjpass) complicated_10\VBN\126264|however|,|use|is|fluctuations|. (l_nmod) fluctuations_14\NNS\7345593|by|disabling|and|dyskinesias (l_conj) dyskinesias_16\NNS\14084880|
D004298_D004409 NONE dopamine_21\NN\14807737| (r_compound) receptor_22\NN\5225602|dopamine (r_compound) subtypes_23\NNS\1740|receptor|, (r_conj) mechanisms_19\NNS\13446390|of|presynaptic|,|subtypes (r_nmod) role_14\NN\719494|on|the|differential|mechanisms (r_nmod) focus_10\NN\5704266|of|research|role (r_nmod) lines_7\NNS\8426461|from|promising|focus (r_nmod) data_4\NNS\7951464|recent|preclinical|lines|ionotropic|receptors|pathophysiology|. (l_nmod) pathophysiology_37\NN\1740|in|the|dyskinesias (l_nmod) dyskinesias_40\NNS\14084880|of|levodopa-induced
D018698_D004409 NONE glutamate_28\NN\15010703| (r_compound) receptors_29\NNS\5225602|glutamate|,|and|systems (r_conj) data_4\NNS\7951464|recent|preclinical|lines|ionotropic|receptors|pathophysiology|. (l_nmod) pathophysiology_37\NN\1740|in|the|dyskinesias (l_nmod) dyskinesias_40\NNS\14084880|of|levodopa-induced
20098969
D008694_D001145 NONE methamphetamine_2\NNP\2704153| (r_nsubj) addictive_6\JJ\1740|background|methamphetamine|is|a|very|,|stimulant|. (l_dep) stimulant_9\NN\5816287|powerful|increases (l_acl:relcl) increases_11\VBZ\169651|that|wakefulness|activity|and|produce (l_conj) produce_18\VB\1617192|can|effects (l_dobj) effects_20\NNS\13245626|other|dysrhythmias (l_nmod) dysrhythmias_24\NNS\1740|such|cardiac|,|hypertension|,|and|behavior
D008694_D006973 NONE methamphetamine_2\NNP\2704153| (r_nsubj) addictive_6\JJ\1740|background|methamphetamine|is|a|very|,|stimulant|. (l_dep) stimulant_9\NN\5816287|powerful|increases (l_acl:relcl) increases_11\VBZ\169651|that|wakefulness|activity|and|produce (l_conj) produce_18\VB\1617192|can|effects (l_dobj) effects_20\NNS\13245626|other|dysrhythmias (l_nmod) dysrhythmias_24\NNS\1740|such|cardiac|,|hypertension|,|and|behavior (l_conj) hypertension_26\NN\14057371|,|hallucinations
D008694_D006212 NONE methamphetamine_2\NNP\2704153| (r_nsubj) addictive_6\JJ\1740|background|methamphetamine|is|a|very|,|stimulant|. (l_dep) stimulant_9\NN\5816287|powerful|increases (l_acl:relcl) increases_11\VBZ\169651|that|wakefulness|activity|and|produce (l_conj) produce_18\VB\1617192|can|effects (l_dobj) effects_20\NNS\13245626|other|dysrhythmias (l_nmod) dysrhythmias_24\NNS\1740|such|cardiac|,|hypertension|,|and|behavior (l_conj) hypertension_26\NN\14057371|,|hallucinations (l_conj) hallucinations_28\NNS\14376855|
D008694_D001523 NONE methamphetamine_2\NNP\2704153| (r_nsubj) addictive_6\JJ\1740|background|methamphetamine|is|a|very|,|stimulant|. (l_dep) stimulant_9\NN\5816287|powerful|increases (l_acl:relcl) increases_11\VBZ\169651|that|wakefulness|activity|and|produce (l_conj) produce_18\VB\1617192|can|effects (l_dobj) effects_20\NNS\13245626|other|dysrhythmias (l_nmod) dysrhythmias_24\NNS\1740|such|cardiac|,|hypertension|,|and|behavior (l_conj) behavior_32\NN\407535|violent
D008694_D014987 NONE methamphetamine_3\NN\2704153| (r_dobj) abusing_2\VBG\2514187|methamphetamine (r_acl) patients_1\NNS\9898892|dental|abusing (r_nsubj) present_5\VB\2137132|patients|can|hygiene|. (l_nmod) hygiene_9\NN\14494893|with|poor|oral|,|xerostomia|,|caries|,|and|wear (l_conj) xerostomia_11\NN\14536438|
D008694_D003731 CID methamphetamine_3\NN\2704153| (r_dobj) abusing_2\VBG\2514187|methamphetamine (r_acl) patients_1\NNS\9898892|dental|abusing (r_nsubj) present_5\VB\2137132|patients|can|hygiene|. (l_nmod) hygiene_9\NN\14494893|with|poor|oral|,|xerostomia|,|caries|,|and|wear (l_conj) caries_14\NNS\13456715|rampant|mouth
D008694_D003731 CID methamphetamine_5\NN\2704153|of (r_nmod) use_3\NN\407535|her|methamphetamine (r_dobj) reported_1\VBD\831651|she|use|years|and|experienced|. (l_conj) experienced_12\VBN\2108377|had|not|episodes|started (l_dobj) episodes_16\NNS\7283608|any|major|carious
D008694_-1 NONE methamphetamine_3\NN\2704153| (r_dobj) abusing_2\VBG\2514187|methamphetamine (r_acl) patients_1\NNS\9898892|dental|abusing (r_nsubj) present_5\VB\2137132|patients|can|hygiene|. (l_nmod) hygiene_9\NN\14494893|with|poor|oral|,|xerostomia|,|caries|,|and|wear (l_conj) caries_14\NNS\13456715|rampant|mouth (l_appos) mouth_18\NN\5610008|(|"|meth|"|)
D008694_-1 NONE methamphetamines_26\NNS\2704153| (r_dobj) abusing_25\VBG\2514187|who|may|be|methamphetamines (r_acl:relcl) patients_21\NNS\9898892|abusing (r_dobj) manage_20\VBP\2524171|patients (r_conj) recognize_18\VBP\686447|practitioners|and|manage (r_ccomp) help_15\VB\2556126|to|recognize (r_xcomp) presented_13\VBN\2137132|case|was|help (l_nsubjpass) case_5\NN\7283608|this|clinical|showing (l_acl) showing_6\VBG\2137132|manifestations (l_dobj) manifestations_8\NNS\7321772|oral|mouth (l_nmod) mouth_11\NN\5610008|of|meth
D008694_D057085 NONE methamphetamine_3\NN\2704153| (r_dobj) abusing_2\VBG\2514187|methamphetamine (r_acl) patients_1\NNS\9898892|dental|abusing (r_nsubj) present_5\VB\2137132|patients|can|hygiene|. (l_nmod) hygiene_9\NN\14494893|with|poor|oral|,|xerostomia|,|caries|,|and|wear (l_conj) wear_25\NN\14561618|excessive|tooth
16428221
D008774_D020293 CID methylphenidate_4\NN\4320126|oral (r_compound) intake_5\NN\13440063|following|methylphenidate|adult (r_nmod) vasculitis_1\NN\14336539|cerebral|intake|:|report|.
D008774_D020293 CID methylphenidate_20\JJ\1740| (r_amod) intake_21\NN\13440063|after|methylphenidate|children (r_nmod) reported_18\VBN\831651|cases|stroke|has|been|intake|. (r_conj) documented_8\VBN\1000214|vasculitis|is|well|,|and|reported (l_nsubjpass) vasculitis_1\NN\14336539|cerebral|associated
D008774_D019969 NONE methylphenidate_20\JJ\1740| (r_amod) intake_21\NN\13440063|after|methylphenidate|children (r_nmod) reported_18\VBN\831651|cases|stroke|has|been|intake|. (r_conj) documented_8\VBN\1000214|vasculitis|is|well|,|and|reported (l_nsubjpass) vasculitis_1\NN\14336539|cerebral|associated (l_acl) associated_2\VBN\628491|abuse (l_nmod) abuse_5\NN\418025|with|amphetamine
D008774_D002544 NONE methylphenidate_20\JJ\1740| (r_amod) intake_21\NN\13440063|after|methylphenidate|children (r_nmod) reported_18\VBN\831651|cases|stroke|has|been|intake|. (l_nsubjpass) stroke_15\NN\556313|ischaemic
D008774_D002544 NONE methylphenidate_12\NN\4320126|with (r_nmod) treated_10\VBN\2376958|who|was|methylphenidate|hyperactivity|and|suffered (l_conj) suffered_17\VBN\2110220|strokes (l_nmod) strokes_21\NNS\556313|from|multiple|ischaemic
D008774_D006948 NONE methylphenidate_12\NN\4320126|with (r_nmod) treated_10\VBN\2376958|who|was|methylphenidate|hyperactivity|and|suffered (l_nmod) hyperactivity_15\NN\14052403|due
D008774_D014657 NONE methylphenidate_3\VB\1740| (r_compound) vasculitis_5\NN\14336539|methylphenidate|mediated
D008774_D014657 NONE methylphenidate_18\NN\4320126| (r_compound) therapy_19\NN\657604|of|methylphenidate (r_nmod) history_16\NN\15120823|a|therapy (r_conj) patients_10\NNS\9898892|in|symptoms|and|history (r_nmod) considered_8\VBN\689344|that|vasculitis|should|be|patients (l_nsubjpass) vasculitis_5\NN\14336539|methylphenidate|mediated
220563
C023470_D010523 CID maleate_1\NN\2718811|perhexiline|and|neuropathy|. (l_conj) neuropathy_4\NN\14204950|peripheral
C023470_D010523 CID maleate_12\NN\2718811|with|perhexiline (r_nmod) complication_7\NN\1073995|as|a|therapy|maleate|,|drug|(|trials|) (r_nmod) noted_4\VBN\1009240|neuropathy|has|been|complication|treatment|. (l_nsubjpass) neuropathy_1\NN\14204950|peripheral
C023470_D000787 NONE maleate_12\NN\2718811|with|perhexiline (r_nmod) complication_7\NN\1073995|as|a|therapy|maleate|,|drug|(|trials|) (r_nmod) noted_4\VBN\1009240|neuropathy|has|been|complication|treatment|. (l_nmod) treatment_33\NN\654885|for|the|prophylactic|pectoris (l_nmod) pectoris_36\NN\1740|of|angina
9721172
D007052_D001649 NONE ibuprofen_28\NN\3828465| (r_amod) use_29\NN\407535|with|ibuprofen (r_nmod) associated_26\VBN\628491|this|was|temporally|use (r_parataxis) described_21\VBN\1001294|child|shortly|after|syndrome|is|;|associated|. (l_nsubj) child_3\NN\9622049|a|healthy|developed (l_acl:relcl) developed_5\VBD\1753788|who|syndrome (l_dobj) syndrome_15\NN\5870365|acute|progressive|vanishing|bile|duct
D007052_D013262 CID ibuprofen_28\NN\3828465| (r_amod) use_29\NN\407535|with|ibuprofen (r_nmod) associated_26\VBN\628491|this|was|temporally|use (r_parataxis) described_21\VBN\1001294|child|shortly|after|syndrome|is|;|associated|. (l_nsubjpass) syndrome_19\NN\5870365|stevens-johnson
D014580_D002779 NONE acid_4\NN\14818238|with|ursodeoxycholic|,|prednisone|,|and|then|tacrolimus (r_nmod) therapy_1\NN\657604|despite|acid (r_nmod) unrelenting_16\VBG\1740|therapy|,|disease|was|,|cirrhosis|. (l_nsubj) disease_14\NN\14061805|her|cholestatic
D014580_D005355 NONE acid_4\NN\14818238|with|ursodeoxycholic|,|prednisone|,|and|then|tacrolimus (r_nmod) therapy_1\NN\657604|despite|acid (r_nmod) unrelenting_16\VBG\1740|therapy|,|disease|was|,|cirrhosis|. (l_nmod) cirrhosis_19\NN\14116321|with|shown
D011241_D002779 NONE prednisone_6\NN\2721538| (r_conj) acid_4\NN\14818238|with|ursodeoxycholic|,|prednisone|,|and|then|tacrolimus (r_nmod) therapy_1\NN\657604|despite|acid (r_nmod) unrelenting_16\VBG\1740|therapy|,|disease|was|,|cirrhosis|. (l_nsubj) disease_14\NN\14061805|her|cholestatic
D011241_D005355 NONE prednisone_6\NN\2721538| (r_conj) acid_4\NN\14818238|with|ursodeoxycholic|,|prednisone|,|and|then|tacrolimus (r_nmod) therapy_1\NN\657604|despite|acid (r_nmod) unrelenting_16\VBG\1740|therapy|,|disease|was|,|cirrhosis|. (l_nmod) cirrhosis_19\NN\14116321|with|shown
D016559_D002779 NONE tacrolimus_10\NN\1740| (r_conj) acid_4\NN\14818238|with|ursodeoxycholic|,|prednisone|,|and|then|tacrolimus (r_nmod) therapy_1\NN\657604|despite|acid (r_nmod) unrelenting_16\VBG\1740|therapy|,|disease|was|,|cirrhosis|. (l_nsubj) disease_14\NN\14061805|her|cholestatic
D016559_D005355 NONE tacrolimus_10\NN\1740| (r_conj) acid_4\NN\14818238|with|ursodeoxycholic|,|prednisone|,|and|then|tacrolimus (r_nmod) therapy_1\NN\657604|despite|acid (r_nmod) unrelenting_16\VBG\1740|therapy|,|disease|was|,|cirrhosis|. (l_nmod) cirrhosis_19\NN\14116321|with|shown
7919560
D000667_D004892 CID ampicillin_7\NN\3910033|by (r_nmod) caused_5\VBN\1617192|ampicillin (r_acl) myocarditis_4\NN\14338942|hypersensitivity|caused (r_conj) multiforme_1\VBD\1740|erythema|and|myocarditis|.
D000667_D004892 CID ampicillin_14\NN\3910033|by (r_nmod) caused_12\VBN\1617192|ampicillin (r_acl) myocarditis_11\NN\14338942|hypersensitivity|caused (r_nmod) case_5\NN\7283608|a|erythema|myocarditis (l_nmod) erythema_7\NN\14227218|of|multiforme (l_dep) multiforme_8\JJ\1740|and
D000667_D009205 CID ampicillin_7\NN\3910033|by (r_nmod) caused_5\VBN\1617192|ampicillin (r_acl) myocarditis_4\NN\14338942|hypersensitivity|caused
D000667_D009205 CID ampicillin_14\NN\3910033|by (r_nmod) caused_12\VBN\1617192|ampicillin (r_acl) myocarditis_11\NN\14338942|hypersensitivity|caused
D000667_D018805 NONE ampicillin_9\NN\3910033|with|and|gentamicin (r_nmod) treated_7\VBN\2376958|boy|was|ampicillin|septicemia|. (l_nmod) septicemia_15\NN\14189204|because|suspected
D005839_D018805 NONE gentamicin_11\NN\2716866| (r_conj) ampicillin_9\NN\3910033|with|and|gentamicin (r_nmod) treated_7\VBN\2376958|boy|was|ampicillin|septicemia|. (l_nmod) septicemia_15\NN\14189204|because|suspected
D010406_D009205 NONE penicillins_13\NNS\2716866|to (r_nmod) allergy_11\NN\14533203|of|penicillins (r_nmod) manifestation_9\NN\7321772|myocarditis|is|a|rare|allergy (l_nsubj) myocarditis_3\NN\14338942|hypersensitivity
D010406_D004342 NONE penicillins_13\NNS\2716866|to (r_nmod) allergy_11\NN\14533203|of|penicillins
2425813
D011239_D006529 CID prednisolone_14\NN\2721538|of (r_nmod) administration_12\NN\1133281|following|the|subcutaneous|prednisolone (r_nmod) occurred_5\VBD\2623529|enlargement|rats|administration|. (l_nsubj) enlargement_1\NN\363260|liver|and|wastage
D011239_D009133 CID prednisolone_14\NN\2721538|of (r_nmod) administration_12\NN\1133281|following|the|subcutaneous|prednisolone (r_nmod) occurred_5\VBD\2623529|enlargement|rats|administration|. (l_nsubj) enlargement_1\NN\363260|liver|and|wastage (l_conj) wastage_4\NN\13458571|muscle
12695819
D016559_D020258 NONE tacrolimus-induced_7\JJ\1740| (r_amod) neurotoxicity_8\NN\1740|of|tacrolimus-induced|patients
D016559_D020258 NONE tacrolimus-induced_13\JJ\1740| (r_amod) neurotoxicity_14\NN\1740|of|tacrolimus-induced
D016559_D009422 NONE tacrolimus_17\NN\1740|developed (l_acl:relcl) developed_19\VBD\1753788|who|complications (l_dobj) complications_21\NNS\1073995|neurologic
6133211
D012460_D015212 NONE sulphasalazine_15\NN\1740|with (r_nmod) treatment_13\NN\654885|sulphasalazine (r_dobj) received_12\VBD\2210855|who|treatment|pregnancy (r_acl:relcl) mothers_6\NNS\10399491|of|two|disease|received (l_nmod) disease_10\NN\14061805|with|inflammatory|bowel
D012460_D000013 NONE sulphasalazine_15\NN\1740|with (r_nmod) treatment_13\NN\654885|sulphasalazine (r_dobj) received_12\VBD\2210855|who|treatment|pregnancy (r_acl:relcl) mothers_6\NNS\10399491|of|two|disease|received (r_nmod) born_3\VBN\2630189|mothers (r_acl) infants_1\NNS\9918248|three|,|born|, (r_nsubjpass) found_20\VBN\2426171|infants|were|have|. (l_xcomp) have_22\VB\2108377|to|anomalies (l_dobj) anomalies_25\NNS\14501726|major|congenital
2355241
D007980_D002543 NONE levodopa_23\NN\14604959|of|and (r_nmod) effect_21\NN\34213|the|hypotensive|levodopa|mechanism (r_dobj) reflect_18\VB\923793|incidence|may|effect|. (l_nsubj) incidence_2\NN\13821570|the|low|haemorrhage|cause (l_nmod) haemorrhage_5\NN\14285662|of|cerebral
D007980_D003643 NONE levodopa_23\NN\14604959|of|and (r_nmod) effect_21\NN\34213|the|hypotensive|levodopa|mechanism (r_dobj) reflect_18\VB\923793|incidence|may|effect|. (l_nsubj) incidence_2\NN\13821570|the|low|haemorrhage|cause (l_nmod) cause_8\NN\7323922|as|a|death|patients (l_nmod) death_10\NN\7296428|of
D007980_D010300 NONE levodopa_23\NN\14604959|of|and (r_nmod) effect_21\NN\34213|the|hypotensive|levodopa|mechanism (r_dobj) reflect_18\VB\923793|incidence|may|effect|. (l_nsubj) incidence_2\NN\13821570|the|low|haemorrhage|cause (l_nmod) cause_8\NN\7323922|as|a|death|patients (l_nmod) patients_12\NNS\9898892|in|disease (l_nmod) disease_16\NN\14061805|with|parkinson
D007980_D010300 NONE levodopa_23\NN\14604959|of|and (r_nmod) effect_21\NN\34213|the|hypotensive|levodopa|mechanism (l_conj) mechanism_27\NN\13446390|a|hypotensive|levels (l_nmod) levels_32\NNS\4916342|due|reduced|noradrenaline|brain (l_nmod) brain_36\NN\5462674|in|the|parkinsonian (l_amod) parkinsonian_35\JJ\1740|
D007980_D007022 CID levodopa_23\NN\14604959|of|and (r_nmod) effect_21\NN\34213|the|hypotensive|levodopa|mechanism (l_amod) hypotensive_20\JJ\1740|
D007980_D007022 CID levodopa_23\NN\14604959|of|and (r_nmod) effect_21\NN\34213|the|hypotensive|levodopa|mechanism (l_conj) mechanism_27\NN\13446390|a|hypotensive|levels (l_amod) hypotensive_26\JJ\1740|
D009638_D002543 NONE noradrenaline_31\JJ\1740| (r_amod) levels_32\NNS\4916342|due|reduced|noradrenaline|brain (r_nmod) mechanism_27\NN\13446390|a|hypotensive|levels (r_conj) effect_21\NN\34213|the|hypotensive|levodopa|mechanism (r_dobj) reflect_18\VB\923793|incidence|may|effect|. (l_nsubj) incidence_2\NN\13821570|the|low|haemorrhage|cause (l_nmod) haemorrhage_5\NN\14285662|of|cerebral
D009638_D003643 NONE noradrenaline_31\JJ\1740| (r_amod) levels_32\NNS\4916342|due|reduced|noradrenaline|brain (r_nmod) mechanism_27\NN\13446390|a|hypotensive|levels (r_conj) effect_21\NN\34213|the|hypotensive|levodopa|mechanism (r_dobj) reflect_18\VB\923793|incidence|may|effect|. (l_nsubj) incidence_2\NN\13821570|the|low|haemorrhage|cause (l_nmod) cause_8\NN\7323922|as|a|death|patients (l_nmod) death_10\NN\7296428|of
D009638_D010300 NONE noradrenaline_31\JJ\1740| (r_amod) levels_32\NNS\4916342|due|reduced|noradrenaline|brain (r_nmod) mechanism_27\NN\13446390|a|hypotensive|levels (r_conj) effect_21\NN\34213|the|hypotensive|levodopa|mechanism (r_dobj) reflect_18\VB\923793|incidence|may|effect|. (l_nsubj) incidence_2\NN\13821570|the|low|haemorrhage|cause (l_nmod) cause_8\NN\7323922|as|a|death|patients (l_nmod) patients_12\NNS\9898892|in|disease (l_nmod) disease_16\NN\14061805|with|parkinson
D009638_D010300 NONE noradrenaline_31\JJ\1740| (r_amod) levels_32\NNS\4916342|due|reduced|noradrenaline|brain (l_nmod) brain_36\NN\5462674|in|the|parkinsonian (l_amod) parkinsonian_35\JJ\1740|
D009638_D007022 NONE noradrenaline_31\JJ\1740| (r_amod) levels_32\NNS\4916342|due|reduced|noradrenaline|brain (r_nmod) mechanism_27\NN\13446390|a|hypotensive|levels (r_conj) effect_21\NN\34213|the|hypotensive|levodopa|mechanism (l_amod) hypotensive_20\JJ\1740|
D009638_D007022 NONE noradrenaline_31\JJ\1740| (r_amod) levels_32\NNS\4916342|due|reduced|noradrenaline|brain (r_nmod) mechanism_27\NN\13446390|a|hypotensive|levels (l_amod) hypotensive_26\JJ\1740|
17608141
D008694_D020258 NONE methamphetamine-induced_2\JJ\1740| (r_amod) neurotoxicity_5\NN\1740|of|methamphetamine-induced|nigrostriatal|dopaminergic|mice
D008694_D020258 NONE methamphetamine-induced_21\JJ\1740| (r_amod) neurotoxicity_24\NN\1740|the|methamphetamine-induced|nigrostriatal|dopamine
D008694_D020258 NONE methamphetamine-induced_15\JJ\1740| (r_amod) neurotoxicity_18\NN\1740|against|methamphetamine-induced|nigrostriatal|dopamine
D008070_D020258 NONE lipopolysaccharide_9\NN\1740| (r_compound) pretreatment_10\NN\1740|by|lipopolysaccharide (r_nmod) attenuation_0\NN\7427337|neurotoxicity|pretreatment|. (l_nmod) neurotoxicity_5\NN\1740|of|methamphetamine-induced|nigrostriatal|dopaminergic|mice
D008070_D020258 NONE lipopolysaccharide_9\NN\1740|of|, (r_nmod) roles_7\NNS\719494|the|lipopolysaccharide|factor (r_dobj) examined_5\VBD\789138|study|,|we|roles|modulating|. (l_advcl) modulating_19\VBG\1724459|in|neurotoxicity (l_dobj) neurotoxicity_24\NN\1740|the|methamphetamine-induced|nigrostriatal|dopamine
D008070_D020258 NONE lipopolysaccharide_8\NN\1740| (r_compound) pretreatment_9\NN\1740|for|systemic|lipopolysaccharide (r_nmod) window_5\NN\3391770|a|critical|time|pretreatment (r_dobj) concluded_1\VBD\628491|we|window|exerting|. (l_advcl) exerting_11\VBG\1158872|in|protection (l_dobj) protection_13\NN\407535|effective|neurotoxicity (l_nmod) neurotoxicity_18\NN\1740|against|methamphetamine-induced|nigrostriatal|dopamine
D008694_D009422 NONE methamphetamine-induced_10\JJ\1740| (r_amod) damage_13\NN\7296428|in|methamphetamine-induced|dopaminergic|terminal
D004298_D020258 NONE dopamine_23\NN\14807737| (r_compound) neurotoxicity_24\NN\1740|the|methamphetamine-induced|nigrostriatal|dopamine
D004298_D020258 NONE dopamine_17\NN\14807737| (r_compound) neurotoxicity_18\NN\1740|against|methamphetamine-induced|nigrostriatal|dopamine
D008070_D005334 NONE lipopolysaccharide_0\NN\1740| (r_compound) pretreatment_1\NN\1740|lipopolysaccharide (r_nsubj) affect_4\VB\126264|pretreatment|did|not|temperature|. (l_dobj) temperature_8\NN\13575869|the|basal|body|or|hyperthermia (l_conj) hyperthermia_11\NN\14034177|methamphetamine-elicited|later
D008694_D005334 CID methamphetamine-elicited_10\JJ\1740| (r_amod) hyperthermia_11\NN\14034177|methamphetamine-elicited|later
1130930
D002512_D007674 NONE cephalothin-gentamicin_3\JJ\1740| (r_amod) regimen_4\NN\5898568|of|combined|cephalothin-gentamicin (r_nmod) nephrotoxicity_0\NN\1740|regimen|.
D005839_D007674 NONE cephalothin-gentamicin_3\JJ\1740| (r_amod) regimen_4\NN\5898568|of|combined|cephalothin-gentamicin (r_nmod) nephrotoxicity_0\NN\1740|regimen|.
D002512_D007683 CID sodium_23\NN\14625458|of|cephalothin|and|therapy (r_nmod) combination_20\NN\7951464|a|sodium (r_dobj) receiving_18\VBG\2210855|while|they|were|combination (r_advcl) developed_2\VBD\1753788|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\11444117|acute|tubular|,|characterized
D002512_D009846 NONE sodium_23\NN\14625458|of|cephalothin|and|therapy (r_nmod) combination_20\NN\7951464|a|sodium (r_dobj) receiving_18\VBG\2210855|while|they|were|combination (r_advcl) developed_2\VBD\1753788|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\11444117|acute|tubular|,|characterized (l_acl) characterized_7\VBN\609683|clinically|failure (l_nmod) failure_13\NN\66216|by|acute|oliguric|renal
D002512_D051437 NONE sodium_23\NN\14625458|of|cephalothin|and|therapy (r_nmod) combination_20\NN\7951464|a|sodium (r_dobj) receiving_18\VBG\2210855|while|they|were|combination (r_advcl) developed_2\VBD\1753788|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\11444117|acute|tubular|,|characterized (l_acl) characterized_7\VBN\609683|clinically|failure (l_nmod) failure_13\NN\66216|by|acute|oliguric|renal
D005839_D007683 CID sulfate_26\NN\15010703| (r_compound) therapy_27\NN\657604|gentamicin|sulfate (r_conj) sodium_23\NN\14625458|of|cephalothin|and|therapy (r_nmod) combination_20\NN\7951464|a|sodium (r_dobj) receiving_18\VBG\2210855|while|they|were|combination (r_advcl) developed_2\VBD\1753788|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\11444117|acute|tubular|,|characterized
D005839_D009846 NONE sulfate_26\NN\15010703| (r_compound) therapy_27\NN\657604|gentamicin|sulfate (r_conj) sodium_23\NN\14625458|of|cephalothin|and|therapy (r_nmod) combination_20\NN\7951464|a|sodium (r_dobj) receiving_18\VBG\2210855|while|they|were|combination (r_advcl) developed_2\VBD\1753788|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\11444117|acute|tubular|,|characterized (l_acl) characterized_7\VBN\609683|clinically|failure (l_nmod) failure_13\NN\66216|by|acute|oliguric|renal
D005839_D051437 NONE sulfate_26\NN\15010703| (r_compound) therapy_27\NN\657604|gentamicin|sulfate (r_conj) sodium_23\NN\14625458|of|cephalothin|and|therapy (r_nmod) combination_20\NN\7951464|a|sodium (r_dobj) receiving_18\VBG\2210855|while|they|were|combination (r_advcl) developed_2\VBD\1753788|patients|necrosis|,|receiving|. (l_dobj) necrosis_5\NN\11444117|acute|tubular|,|characterized (l_acl) characterized_7\VBN\609683|clinically|failure (l_nmod) failure_13\NN\66216|by|acute|oliguric|renal
8649546
D007980_D004409 CID levodopa-induced_2\JJ\1740| (r_amod) dyskinesia_3\NN\14084880|of|levodopa-induced
D007980_D004409 CID levodopa-induced_12\JJ\1740| (r_amod) dyskinesia_16\NN\14084880|levodopa-induced|ballistic|pd
D007980_D010300 NONE levodopa-induced_2\JJ\1740| (r_amod) dyskinesia_3\NN\14084880|of|levodopa-induced (r_nmod) improvement_0\NN\7359599|dyskinesia|propranolol|. (l_nmod) propranolol_5\NN\1740|by|disease (l_nmod) disease_9\NN\14061805|in|parkinson
D007980_D010300 NONE levodopa-induced_12\JJ\1740| (r_amod) dyskinesia_16\NN\14084880|levodopa-induced|ballistic|pd (l_nmod) pd_18\NN\14625458|in
D011433_D004409 NONE propranolol_5\NN\1740|by|disease (r_nmod) improvement_0\NN\7359599|dyskinesia|propranolol|. (l_nmod) dyskinesia_3\NN\14084880|of|levodopa-induced
D011433_D004409 NONE propranolol_16\NN\1740|low-dose (r_dobj) received_14\VBD\2210855|patients|propranolol|adjunct|. (l_nsubj) patients_1\NNS\9898892|seven|suffering (l_acl) suffering_2\VBG\2110220|disease|dyskinesia (l_nmod) dyskinesia_13\NN\14084880|with|disabling
D011433_D010300 NONE propranolol_5\NN\1740|by|disease (l_nmod) disease_9\NN\14061805|in|parkinson
D011433_D010300 NONE propranolol_16\NN\1740|low-dose (r_dobj) received_14\VBD\2210855|patients|propranolol|adjunct|. (l_nsubj) patients_1\NNS\9898892|seven|suffering (l_acl) suffering_2\VBG\2110220|disease|dyskinesia (l_nmod) disease_6\NN\14061805|from|parkinson|pd
D011433_D010300 NONE propranolol_16\NN\1740|low-dose (r_dobj) received_14\VBD\2210855|patients|propranolol|adjunct|. (l_nsubj) patients_1\NNS\9898892|seven|suffering (l_acl) suffering_2\VBG\2110220|disease|dyskinesia (l_nmod) disease_6\NN\14061805|from|parkinson|pd (l_appos) pd_8\NN\14625458|(|)
9406968
D014667_D003919 NONE vasopressin_5\NN\5407119| (r_compound) gene_6\NN\8459252|of|vasopressin (r_nmod) expression_3\NN\4679549|of|the|gene (r_nmod) upregulation_0\NN\1740|expression|paraventricular|. (l_nmod) paraventricular_9\JJ\1740|in|the|and|supraoptic|nuclei|rat (l_nmod) rat_18\NN\2329401|of|the|lithium-induced|diabetes|insipidus (l_compound) insipidus_17\NN\1740|
D008094_D003919 NONE lithium-induced_15\JJ\1740| (r_amod) rat_18\NN\2329401|of|the|lithium-induced|diabetes|insipidus (l_compound) insipidus_17\NN\1740|
D008094_D003919 NONE li-induced_35\JJ\1740| (r_amod) rat_38\NN\2329401|of|the|li-induced|diabetes|insipidus (l_compound) insipidus_37\NN\1740|
D001127_D011141 NONE vasopressin_4\NN\5407119| (r_compound) gene_8\NN\8459252|of|arginine|vasopressin|avp|) (r_nmod) expression_1\NN\4679549|the|gene|paraventricular (r_nsubjpass) investigated_22\VBN\644583|expression|was|rats|,|using|. (l_nmod) rats_24\NNS\2329401|in|polyuria (l_nmod) polyuria_28\NN\14113228|with|lithium|(li)-induced
D001127_D011141 NONE avp_6\NN\1740|( (r_compound) gene_8\NN\8459252|of|arginine|vasopressin|avp|) (r_nmod) expression_1\NN\4679549|the|gene|paraventricular (r_nsubjpass) investigated_22\VBN\644583|expression|was|rats|,|using|. (l_nmod) rats_24\NNS\2329401|in|polyuria (l_nmod) polyuria_28\NN\14113228|with|lithium|(li)-induced
D008094_D011141 NONE lithium_26\NN\14625458| (r_compound) polyuria_28\NN\14113228|with|lithium|(li)-induced
D008094_D011141 NONE (li)-induced_27\JJ\1740| (r_amod) polyuria_28\NN\14113228|with|lithium|(li)-induced
D018021_D011141 CID licl_9\NN\1740|mmol/kg (r_dobj) contained_8\VBD\2632940|that|licl|weeks (r_acl:relcl) diet_6\NN\7560652|a|contained (r_dobj) consuming_4\VBG\1168468|rats|diet|developed|. (l_conj) developed_17\VBD\1753788|polyuria (l_dobj) polyuria_19\NN\14113228|marked
D001127_D003681 NONE avp_19\NN\1740|of|plasma (r_nmod) elevation_16\NN\7445480|to|the|avp|and|upregulation (r_nmod) contribute_13\VB\126264|that|dehydration|may|elevation (l_nsubj) dehydration_4\NN\14536438|and/or|activation
D001127_D003681 NONE avp_24\NN\1740| (r_compound) expression_26\NN\4679549|of|avp|gene (r_nmod) upregulation_22\NN\1740|the|expression|pvn (r_conj) elevation_16\NN\7445480|to|the|avp|and|upregulation (r_nmod) contribute_13\VB\126264|that|dehydration|may|elevation (l_nsubj) dehydration_4\NN\14536438|and/or|activation
D001127_D003919 NONE avp_19\NN\1740|of|plasma (r_nmod) elevation_16\NN\7445480|to|the|avp|and|upregulation (l_conj) upregulation_22\NN\1740|the|expression|pvn (l_nmod) pvn_29\NN\1740|in|the|and|son|rat (l_nmod) rat_38\NN\2329401|of|the|li-induced|diabetes|insipidus (l_compound) insipidus_37\NN\1740|
D001127_D003919 NONE avp_24\NN\1740| (r_compound) expression_26\NN\4679549|of|avp|gene (r_nmod) upregulation_22\NN\1740|the|expression|pvn (l_nmod) pvn_29\NN\1740|in|the|and|son|rat (l_nmod) rat_38\NN\2329401|of|the|li-induced|diabetes|insipidus (l_compound) insipidus_37\NN\1740|
D008094_D003681 NONE li-induced_35\JJ\1740| (r_amod) rat_38\NN\2329401|of|the|li-induced|diabetes|insipidus (r_nmod) pvn_29\NN\1740|in|the|and|son|rat (r_nmod) upregulation_22\NN\1740|the|expression|pvn (r_conj) elevation_16\NN\7445480|to|the|avp|and|upregulation (r_nmod) contribute_13\VB\126264|that|dehydration|may|elevation (l_nsubj) dehydration_4\NN\14536438|and/or|activation
3187073
D005472_D002637 CID 5-fu_6\NN\1740| (r_compound) treatment_7\NN\654885|on|5-fu (r_nmod) patients_4\NNS\9898892|treatment (r_nsubj) supervision_12\NN\1133281|that|patients|should|be|under|close|and|discontinued (l_conj) discontinued_19\VBN\2609764|that|treatment|should|be|observed (l_advcl) observed_26\VBN\2163746|if|pain|is (l_nsubjpass) pain_22\NN\14299637|chest|or|tachyarrhythmia
D005472_D013610 NONE 5-fu_6\NN\1740| (r_compound) treatment_7\NN\654885|on|5-fu (r_nmod) patients_4\NNS\9898892|treatment (r_nsubj) supervision_12\NN\1133281|that|patients|should|be|under|close|and|discontinued (l_conj) discontinued_19\VBN\2609764|that|treatment|should|be|observed (l_advcl) observed_26\VBN\2163746|if|pain|is (l_nsubjpass) pain_22\NN\14299637|chest|or|tachyarrhythmia (l_conj) tachyarrhythmia_24\NN\1740|
17400887
D013726_D020078 NONE terbutaline_6\NN\1740| (r_compound) treatment_7\NN\654885|after|neonatal|terbutaline|rats (r_nmod) abnormalities_3\NNS\14034177|neuroinflammation|treatment|:|implications|. (l_amod) neuroinflammation_0\NN\1740|and|behavioral
D013726_D001523 NONE terbutaline_6\NN\1740| (r_compound) treatment_7\NN\654885|after|neonatal|terbutaline|rats (r_nmod) abnormalities_3\NNS\14034177|neuroinflammation|treatment|:|implications|.
D013726_D001321 CID terbutaline_6\NN\1740| (r_compound) treatment_7\NN\654885|after|neonatal|terbutaline|rats (r_nmod) abnormalities_3\NNS\14034177|neuroinflammation|treatment|:|implications|. (l_dep) implications_11\NNS\5774614|autism (l_nmod) autism_13\NN\14304060|for
D013726_D001321 CID terbutaline_0\NNP\1740|,|agonist|, (r_nsubjpass) associated_13\VBN\628491|terbutaline|has|been|concordance|. (l_nmod) concordance_16\NN\13968547|with|increased|autism (l_nmod) autism_18\NN\14304060|for|twins
D013726_D007752 NONE terbutaline_0\NNP\1740|,|agonist|, (l_appos) agonist_4\NN\9613191|a|beta2-adrenoceptor|used (l_acl) used_5\VBN\1156834|arrest (l_xcomp) arrest_7\VB\1212572|to|labor (l_dobj) labor_9\NN\7974025|preterm
9522152
D002045_D009461 NONE bupivacaine_11\NN\1740|of|%|hyperbaric|anaesthesia (r_nmod) injection_6\NN\320852|following|intrathecal|bupivacaine (r_nmod) deficit_3\NN\5113133|a|transient|injection|.
D002045_D009461 NONE bupivacaine_21\NN\1740|of|%|hyperbaric|injected (r_nmod) mg_16\NN\13717155|with|8|bupivacaine (r_nmod) occurred_9\VBD\2623529|that|anaesthesia|mg (r_acl:relcl) deficit_7\NN\5113133|of|transient|neurological|occurred
17562951
D007479_D051436 NONE iopamidol_16\NN\1740|of|and|iodixanol (r_nmod) comparison_14\NN\635850|double-blind|iopamidol|patients|rate (l_nmod) patients_20\NNS\9898892|in|disease (l_nmod) disease_24\NN\14061805|with|chronic|kidney
C044834_D051436 NONE iodixanol_18\NN\1740| (r_conj) iopamidol_16\NN\1740|of|and|iodixanol (r_nmod) comparison_14\NN\635850|double-blind|iopamidol|patients|rate (l_nmod) patients_20\NNS\9898892|in|disease (l_nmod) disease_24\NN\14061805|with|chronic|kidney
D000111_D003920 NONE n-acetylcysteine_14\NN\1740|of (r_nmod) use_12\NN\407535|n-acetylcysteine|, (r_appos) patients_2\NNS\9898892|in|414|,|volume|,|presence|,|use (l_appos) presence_7\NN\13954253|mellitus (l_nmod) mellitus_10\NN\1740|of|diabetes
D007479_D003920 NONE iopamidol_22\NN\1740|with|and|%|patients|iodixanol (r_nmod) increases_6\VBZ\169651|patients|,|scr|>|%|iopamidol|,|increases|. (l_nmod) patients_1\NNS\9898892|in|diabetes (l_nmod) diabetes_3\NNS\14075199|with
D007479_D003920 NONE iopamidol_7\NN\1740|with|( (r_nmod) less_5\JJR\1740|increases|were|significantly|iopamidol|patients|mg/dl|;|patients|)|. (l_dep) patients_24\NNS\9898892|diabetes|:|0.07|mg/dl|micromol/l|,|p=0.01 (l_nmod) diabetes_26\NNS\14075199|with
D007479_D003920 NONE iopamidol_23\NN\1740|of|or|iodixanol (r_nmod) administration_21\NN\1133281|after|the|intraarterial|iopamidol|patients (r_nmod) different_17\JJ\1740|rate|is|not|statistically|administration|,|mellitus (l_nmod) mellitus_34\NN\1740|with|without|diabetes
C044834_D003920 NONE iodixanol_33\NN\1740|with|p=0.11 (r_nmod) iopamidol_22\NN\1740|with|and|%|patients|iodixanol (r_nmod) increases_6\VBZ\169651|patients|,|scr|>|%|iopamidol|,|increases|. (l_nmod) patients_1\NNS\9898892|in|diabetes (l_nmod) diabetes_3\NNS\14075199|with
C044834_D003920 NONE iodixanol_25\NN\1740| (r_conj) iopamidol_23\NN\1740|of|or|iodixanol (r_nmod) administration_21\NN\1133281|after|the|intraarterial|iopamidol|patients (r_nmod) different_17\JJ\1740|rate|is|not|statistically|administration|,|mellitus (l_nmod) mellitus_34\NN\1740|with|without|diabetes
D007479_D007674 CID iopamidol_23\NN\1740|of|or|iodixanol (r_nmod) administration_21\NN\1133281|after|the|intraarterial|iopamidol|patients (r_nmod) different_17\JJ\1740|rate|is|not|statistically|administration|,|mellitus (l_nsubj) rate_3\NN\13815152|the|nephropathy|,|defined|, (l_nmod) nephropathy_6\NN\14573196|of|contrast-induced
C044834_D007674 CID iodixanol_25\NN\1740| (r_conj) iopamidol_23\NN\1740|of|or|iodixanol (r_nmod) administration_21\NN\1133281|after|the|intraarterial|iopamidol|patients (r_nmod) different_17\JJ\1740|rate|is|not|statistically|administration|,|mellitus (l_nsubj) rate_3\NN\13815152|the|nephropathy|,|defined|, (l_nmod) nephropathy_6\NN\14573196|of|contrast-induced
12574103
D003907_D006973 CID dexamethasone_1\NN\2721538| (r_compound) programs_2\NNS\5833840|prenatal|dexamethasone|hypertension|rat|. (l_dep) hypertension_3\NN\14057371|and|injury
D003907_D006973 CID dexamethasone_11\NN\2721538|prenatal (r_nsubj) programmed_12\VBD\794981|if|dexamethasone|increase (l_dobj) increase_15\NN\13576355|a|progressive|pressure (l_nmod) pressure_18\NN\11419404|in|blood|and|injury|rats
D003907_D006973 CID dexamethasone_5\NN\2721538|prenatal (r_dobj) received_3\VBD\2210855|that|dexamethasone|days|,|and|13 (r_acl:relcl) rats_1\NNS\2329401|male|received (r_nsubj) had_22\VBD\2108377|rats|pressures|months (l_dobj) pressures_25\NNS\11419404|elevated|blood
D003907_D006973 CID dexamethasone_5\NN\2721538|prenatal|rats (r_nsubj) results_8\VBZ\2633881|that|dexamethasone|reduction|administered (l_nmod) reduction_11\NN\351485|in|a|number (l_nmod) number_14\NN\5107765|in|glomerular|,|glomerulosclerosis|,|and|hypertension (l_conj) hypertension_19\NN\14057371|
D003907_D007674 CID dexamethasone_1\NN\2721538| (r_compound) programs_2\NNS\5833840|prenatal|dexamethasone|hypertension|rat|. (l_dep) hypertension_3\NN\14057371|and|injury (l_conj) injury_6\NN\14052046|renal
D003907_D007674 CID dexamethasone_11\NN\2721538|prenatal (r_nsubj) programmed_12\VBD\794981|if|dexamethasone|increase (l_dobj) increase_15\NN\13576355|a|progressive|pressure (l_nmod) pressure_18\NN\11419404|in|blood|and|injury|rats (l_conj) injury_21\NN\14052046|renal
D003907_D007674 CID dexamethasone_4\NN\2721538| (r_dobj) administered_3\VBN\2436349|offspring|dexamethasone|days|had|comparable|. (l_conj) had_11\VBD\2108377|gestation|reduction|compared (l_dobj) reduction_15\NN\351485|a|%|number (l_nmod) number_18\NN\5107765|in|glomerular
D003907_D007674 CID dexamethasone_5\NN\2721538|prenatal (r_dobj) received_3\VBD\2210855|that|dexamethasone|days|,|and|13 (r_acl:relcl) rats_1\NNS\2329401|male|received (r_nsubj) had_22\VBD\2108377|rats|pressures|months (r_ccomp) have_37\VB\2108377|had|;|group|did|not|reduction|. (l_dobj) reduction_39\NN\351485|a|number (l_nmod) number_42\NN\5107765|in|glomerular
D003907_D007674 CID dexamethasone_5\NN\2721538|prenatal|rats (r_nsubj) results_8\VBZ\2633881|that|dexamethasone|reduction|administered (l_nmod) reduction_11\NN\351485|in|a|number (l_nmod) number_14\NN\5107765|in|glomerular|,|glomerulosclerosis|,|and|hypertension
D003907_D005921 NONE dexamethasone_3\NN\2721538| (r_dobj) given_2\VBD\2327200|rats|dexamethasone|days|had|. (l_conj) had_11\VBD\2108377|glomeruli|glomerulosclerosis (l_nmod) glomerulosclerosis_15\NN\1740|with|rats
D003907_D005921 NONE dexamethasone_5\NN\2721538|prenatal|rats (r_nsubj) results_8\VBZ\2633881|that|dexamethasone|reduction|administered (l_nmod) reduction_11\NN\351485|in|a|number (l_nmod) number_14\NN\5107765|in|glomerular|,|glomerulosclerosis|,|and|hypertension (l_conj) glomerulosclerosis_16\NN\1740|
18023325
D004221_D014826 CID disulfiram_6\NN\3740161| (r_compound) intoxication_7\NN\14034177|after|acute|disulfiram (r_nmod) palsy_3\NN\14557898|acute|fold|intoxication|.
D004221_D014826 CID disulfiram_6\NN\3740161| (r_compound) overdose_7\NN\1740|by|a|disulfiram (r_nmod) caused_3\VBN\1617192|overdose (r_acl) neuropathy_2\NN\14204950|acute|peripheral|caused (r_nsubj) rare_10\JJ\1740|neuropathy|is|very|and|is|. (l_conj) is_13\VBZ\836236|there|report (l_attr) report_15\NN\6470073|no|leading (l_acl) leading_18\VBG\1752884|it|palsy (l_nmod) palsy_22\NN\14557898|to|fold
D004221_D010523 CID disulfiram_6\NN\3740161| (r_compound) overdose_7\NN\1740|by|a|disulfiram (r_nmod) caused_3\VBN\1617192|overdose (r_acl) neuropathy_2\NN\14204950|acute|peripheral|caused
D004221_D062787 NONE disulfiram_6\NN\3740161| (r_compound) overdose_7\NN\1740|by|a|disulfiram
D004221_D010243 NONE disulfiram_22\NN\3740161| (r_compound) intoxication_23\NN\14034177|by|high-dose|disulfiram (r_nmod) caused_19\VBN\1617192|intoxication (r_acl) polyneuropathy_18\NN\1740|severe|sensorimotor|axonal|caused (r_dobj) superimposed_13\VBD\1494310|polyneuropathy (r_conj) case_3\NN\7283608|this|was|a|palsy|and|superimposed|. (l_nmod) palsy_6\NN\14557898|of|acute|nerve
D004221_D011115 NONE disulfiram_22\NN\3740161| (r_compound) intoxication_23\NN\14034177|by|high-dose|disulfiram (r_nmod) caused_19\VBN\1617192|intoxication (r_acl) polyneuropathy_18\NN\1740|severe|sensorimotor|axonal|caused
12369736
D003042_D009069 CID cocaine-induced_14\JJ\1740| (r_amod) hyperactivity_16\NN\14052403|on|the|cocaine-induced|locomotor|rats
D003042_D009069 CID cocaine_34\NN\3492717|by (r_nmod) induced_32\VBN\1627355|cocaine|rats (r_acl) hyperactivity_31\NN\14052403|on|the|locomotor|induced
D003042_D009069 CID cocaine_14\NN\3492717|to (r_nmod) prior_12\JJ\1740|cocaine (r_amod) gr_0\NN\1740|55562|microg/side|,|shell|prior|, (r_nsubj) attenuated_17\VBD\224901|gr|dose-dependently|hyperactivity|. (l_dobj) hyperactivity_21\NN\14052403|the|psychostimulant-induced|locomotor
D003042_D009069 CID cocaine_4\NN\3492717| (r_nsubj) induced_5\VBD\1627355|that|cocaine (r_amod) modified_8\VBN\109660|induced|hyperlocomotion|is|ligands|core (l_nsubjpass) hyperlocomotion_6\NN\1740|
C103477_D009069 NONE 55562_1\CD\1740| (r_nummod) gr_0\NN\1740|55562|microg/side|,|shell|prior|, (r_nsubj) attenuated_17\VBD\224901|gr|dose-dependently|hyperactivity|. (l_dobj) hyperactivity_21\NN\14052403|the|psychostimulant-induced|locomotor
C103477_D009069 NONE 55562_38\CD\1740| (r_nummod) gr_37\NN\1740|(|55562|) (r_dep) antagonist_35\NN\7846|of|the|5-ht1b|receptor|gr|and|agonist (r_nmod) effects_30\NNS\13245626|antagonist (r_dep) inhibitory_27\JJ\1740|in|and|facilitatory|effects (r_nmod) consisting_25\VBG\2603699|inhibitory (r_acl) modification_24\NN\191142|this|consisting|,|respectively (r_dobj) indicate_2\VBP\952524|findings|modified|,|modification|. (l_ccomp) modified_8\VBN\109660|induced|hyperlocomotion|is|ligands|core (l_nsubjpass) hyperlocomotion_6\NN\1740|
C065046_D009069 CID 93129_44\CD\1740| (r_nummod) cp_43\NN\1740|(|93129|) (r_appos) agonist_41\NN\9613191|cp (r_conj) antagonist_35\NN\7846|of|the|5-ht1b|receptor|gr|and|agonist (r_nmod) effects_30\NNS\13245626|antagonist (r_dep) inhibitory_27\JJ\1740|in|and|facilitatory|effects (r_nmod) consisting_25\VBG\2603699|inhibitory (r_acl) modification_24\NN\191142|this|consisting|,|respectively (r_dobj) indicate_2\VBP\952524|findings|modified|,|modification|. (l_ccomp) modified_8\VBN\109660|induced|hyperlocomotion|is|ligands|core (l_nsubjpass) hyperlocomotion_6\NN\1740|
8953972
D004837_D013345 CID epinephrine_8\NN\14807929|of (r_nmod) use_6\NN\407535|with|prehospital|epinephrine (r_nmod) associated_3\VBN\628491|use (r_acl) bleeding_2\NN\14285662|fatal|intracranial|associated|.
D004837_D012128 NONE epinephrine_26\NN\14807929|subcutaneous (r_dobj) administer_24\VB\2436349|to|epinephrine (r_xcomp) led_16\VBD\1752884|onset|paramedics|administer|. (l_nsubj) onset_2\NN\7325190|the|sudden|distress|and|history (l_nmod) distress_5\NN\7494363|of|respiratory|,|rash|,
D004837_D005076 NONE epinephrine_26\NN\14807929|subcutaneous (r_dobj) administer_24\VB\2436349|to|epinephrine (r_xcomp) led_16\VBD\1752884|onset|paramedics|administer|. (l_nsubj) onset_2\NN\7325190|the|sudden|distress|and|history (l_nmod) distress_5\NN\7494363|of|respiratory|,|rash|, (l_conj) rash_7\NN\14321469|
D004837_D006323 CID epinephrine_0\NN\14807929| (r_nsubj) has_1\VBZ\2108377|epinephrine|role|; (l_dobj) role_4\NN\719494|a|proven|arrest (l_nmod) arrest_7\NN\88481|in|cardiac|care
D004837_D004342 NONE epinephrine_0\NN\14807929| (r_nsubj) has_1\VBZ\2108377|epinephrine|role|; (r_ccomp) viewed_28\VBN\689344|has|however|,|use|hypertension|should|be|caution|. (l_nsubjpass) use_14\NN\407535|paramedics (l_nmod) paramedics_16\NNS\10398624|by|patients|and (l_nmod) patients_18\NNS\9898892|in|reaction (l_nmod) reaction_22\NN\13446390|with|suspected|allergic
D004837_D006973 NONE epinephrine_0\NN\14807929| (r_nsubj) has_1\VBZ\2108377|epinephrine|role|; (r_ccomp) viewed_28\VBN\689344|has|however|,|use|hypertension|should|be|caution|. (l_nsubjpass) hypertension_25\NN\14057371|severe
20588063
D011692_D009401 CID aminonucleoside_17\NN\1740| (r_compound) nephrosis_18\NN\14304060|in|early|puromycin|aminonucleoside
D011692_D009401 CID aminonucleoside_2\NN\1740| (r_compound) nephrosis_3\NN\14304060|puromycin|aminonucleoside|pan
9293063
D003613_D001650 CID danazol_10\NN\1740|with (r_nmod) treatment_8\NN\654885|with|long-term|danazol (r_nmod) association_5\NN\8008335|in|treatment (r_nmod) occurring_3\VBG\2623529|hamartoma|association|. (l_nsubj) hamartoma_2\NN\14234074|duct
D003613_D001650 CID danazol_18\NN\1740| (r_compound) treatment_19\NN\654885|who|been|on|long-term|danazol (r_acl:relcl) patient_12\NN\9898892|in|a|treatment (r_nmod) developed_9\VBD\1753788|which|patient (r_acl:relcl) case_3\NN\7283608|a|hamartoma|developed (l_nmod) hamartoma_7\NN\14234074|of|duct
D003613_D006222 CID danazol_10\NN\1740|with (r_nmod) treatment_8\NN\654885|with|long-term|danazol (r_nmod) association_5\NN\8008335|in|treatment (r_nmod) occurring_3\VBG\2623529|hamartoma|association|. (l_nsubj) hamartoma_2\NN\14234074|duct
D003613_D006222 CID danazol_18\NN\1740| (r_compound) treatment_19\NN\654885|who|been|on|long-term|danazol (r_acl:relcl) patient_12\NN\9898892|in|a|treatment (r_nmod) developed_9\VBD\1753788|which|patient (r_acl:relcl) case_3\NN\7283608|a|hamartoma|developed (l_nmod) hamartoma_7\NN\14234074|of|duct
6634932
C002616_D017180 NONE um-272_0\NN\1740|n|,|agent|, (r_nsubjpass) administered_13\VBN\2436349|um-272|was|sublingually|dogs|. (l_nmod) dogs_16\NNS\2083346|to|tachycardias (l_nmod) tachycardias_20\NNS\14110674|with|ouabain-induced|ventricular
C002616_D017180 NONE n-dimethylpropranolol_4\NN\1740| (r_appos) n_2\NN\14622893|(|,|n-dimethylpropranolol|) (r_dep) um-272_0\NN\1740|n|,|agent|, (r_nsubjpass) administered_13\VBN\2436349|um-272|was|sublingually|dogs|. (l_nmod) dogs_16\NNS\2083346|to|tachycardias (l_nmod) tachycardias_20\NNS\14110674|with|ouabain-induced|ventricular
C002616_D017180 NONE um-272_1\NN\1740| (r_nmod:npmod) converted_2\VBD\126264|sublingual|um-272|tachycardia|dogs|. (l_dobj) tachycardia_4\NN\14110674|ventricular|rhythm
D010042_D017180 CID ouabain-induced_18\JJ\1740| (r_amod) tachycardias_20\NNS\14110674|with|ouabain-induced|ventricular
15602202
D017963_D009395 CID azithromycin_6\NN\2716205|by (r_nmod) induced_4\VBN\1627355|azithromycin (r_acl) nephritis_3\NN\14113228|recurrent|acute|interstitial|induced|.
D017963_D009395 CID azithromycin-induced_8\JJ\1740| (r_conj) recurrent_6\JJ\1740|with|,|azithromycin-induced|,|nephritis (l_appos) nephritis_12\NN\14113228|acute|interstitial
8638206
D001279_D010243 CID atracurium_6\NN\1740|of (r_nmod) use_4\NN\407535|after|prolonged|atracurium (r_nmod) paralysis_1\NN\14557898|persistent|use|absence|.
D001279_D010243 CID besylate_1\VBP\1740|atracurium|,|nmba|,|associated|. (l_conj) associated_20\VBN\628491|has|also|been|paralysis|,|but|used (l_nmod) paralysis_23\NN\14557898|with|persistent
D001279_D010243 CID atracurium-related_5\JJ\1740| (r_amod) paralysis_6\NN\14557898|of|atracurium-related|persisting
D014673_D010243 CID bromide_19\NN\14904359|such|vecuronium (r_nmod) nmbas_15\NN\1740|aminosteroid-based|bromide|, (r_dobj) involved_13\VBN\2676054|have|often|nmbas|used|. (l_aux) have_10\VBP\2108377|reports (l_nsubj) reports_0\NNS\6470073|paralysis|discontinuance (l_nmod) paralysis_3\NN\14557898|of|persistent
-1_D010243 NONE benzylisoquinolinium_5\NN\1740| (r_compound) nmba_6\NN\1740|a|short-acting|benzylisoquinolinium|eliminated (r_dobj) besylate_1\VBP\1740|atracurium|,|nmba|,|associated|. (l_conj) associated_20\VBN\628491|has|also|been|paralysis|,|but|used (l_nmod) paralysis_23\NN\14557898|with|persistent
15632880
D013148_D051437 CID spironolactone-induced_0\JJ\1740| (r_amod) insufficiency_2\NN\14462946|spironolactone-induced|renal|and|hyperkalemia|patients|.
D013148_D051437 CID spironolactone_11\NN\2721160|of (r_nmod) use_9\NN\407535|the|spironolactone|patients (r_dobj) evaluating_7\VBG\670261|use (r_acl) trial_6\NN\786195|a|randomized|controlled|evaluating (r_nsubj) reported_16\VBD\831651|trial|risk (l_dobj) risk_19\NN\14541044|a|low|hyperkalemia (l_nmod) hyperkalemia_21\NN\14299637|of|%|and|insufficiency (l_conj) insufficiency_28\NN\14462946|renal|%
D013148_D051437 CID spironolactone_21\NN\2721160|with (r_nmod) treated_19\VBN\2376958|spironolactone (r_acl) patients_18\NNS\9898892|in|heart|failure|treated (r_nmod) prevalence_6\NN\4764412|the|and|associations|patients (l_conj) associations_9\NNS\8008335|clinical|hyperkalemia (l_nmod) hyperkalemia_11\NN\14299637|of|and|insufficiency (l_conj) insufficiency_14\NN\14462946|renal
D013148_D051437 CID spironolactone_13\NN\2721160|of (r_nmod) discontinuation_11\NN\209943|required|spironolactone|hyperkalemia (l_nmod) hyperkalemia_16\NN\14299637|due|n|or|failure (l_conj) failure_24\NN\66216|renal|n
D013148_D051437 CID spironolactone-induced_2\JJ\1740| (r_amod) hyperkalemia_3\NN\14299637|spironolactone-induced|and|insufficiency (l_conj) insufficiency_6\NN\14462946|renal
D013148_D006947 CID spironolactone-induced_0\JJ\1740| (r_amod) insufficiency_2\NN\14462946|spironolactone-induced|renal|and|hyperkalemia|patients|. (l_conj) hyperkalemia_4\NN\14299637|
D013148_D006947 CID spironolactone_11\NN\2721160|of (r_nmod) use_9\NN\407535|the|spironolactone|patients (r_dobj) evaluating_7\VBG\670261|use (r_acl) trial_6\NN\786195|a|randomized|controlled|evaluating (r_nsubj) reported_16\VBD\831651|trial|risk (l_dobj) risk_19\NN\14541044|a|low|hyperkalemia (l_nmod) hyperkalemia_21\NN\14299637|of|%|and|insufficiency
D013148_D006947 CID spironolactone_21\NN\2721160|with (r_nmod) treated_19\VBN\2376958|spironolactone (r_acl) patients_18\NNS\9898892|in|heart|failure|treated (r_nmod) prevalence_6\NN\4764412|the|and|associations|patients (l_conj) associations_9\NNS\8008335|clinical|hyperkalemia (l_nmod) hyperkalemia_11\NN\14299637|of|and|insufficiency
D013148_D006947 CID spironolactone_13\NN\2721160|of (r_nmod) discontinuation_11\NN\209943|required|spironolactone|hyperkalemia (l_nmod) hyperkalemia_16\NN\14299637|due|n|or|failure
D013148_D006947 CID spironolactone-induced_2\JJ\1740| (r_amod) hyperkalemia_3\NN\14299637|spironolactone-induced|and|insufficiency
D013148_D006333 NONE spironolactone-induced_0\JJ\1740| (r_amod) insufficiency_2\NN\14462946|spironolactone-induced|renal|and|hyperkalemia|patients|. (l_nmod) patients_6\NNS\9898892|in|failure (l_nmod) failure_9\NN\66216|with|heart
D013148_D006333 NONE spironolactone_11\NN\2721160|of (r_nmod) use_9\NN\407535|the|spironolactone|patients (l_nmod) patients_15\NNS\9898892|in|heart|failure (l_compound) failure_14\NN\66216|
D013148_D006333 NONE spironolactone_11\NN\2721160|of (r_nmod) benefits_9\NNS\13278375|the|spironolactone (r_nsubjpass) reported_13\VBN\831651|since|benefits|were|, (r_advcl) changed_6\VBN\46534|because|treatments|have|reported (l_nsubj) treatments_1\NNS\654885|failure (l_nmod) failure_4\NN\66216|for|heart
D013148_D006333 NONE spironolactone_21\NN\2721160|with (r_nmod) treated_19\VBN\2376958|spironolactone (r_acl) patients_18\NNS\9898892|in|heart|failure|treated (l_compound) failure_17\NN\66216|
D013148_D006333 NONE spironolactone_14\NN\2721160|with (r_nmod) treated_12\VBN\2376958|spironolactone|practice (r_acl) patients_11\NNS\9898892|of|heart|failure|treated (l_compound) failure_10\NN\66216|
D011188_D006947 NONE k(+_7\NNS\1740|(|) (r_appos) hyperkalemia_5\NN\14299637|k(+
D011188_D006947 NONE potassium_17\NN\14625458| (r_compound) levels_18\NNS\4916342|higher|baseline|serum|potassium|and|doses (r_dobj) had_13\VBD\2108377|levels|,|and|likely (r_conj) older_5\JJR\1740|patients|were|and|likely|,|had|. (l_nsubj) patients_0\NNS\9898892|developed (l_acl:relcl) developed_2\VBD\1753788|who|hyperkalemia (l_dobj) hyperkalemia_3\NN\14299637|
D011188_D006947 NONE potassium_22\NN\14625458| (r_compound) doses_24\NNS\3740161|lower|baseline|potassium|supplement (r_conj) levels_18\NNS\4916342|higher|baseline|serum|potassium|and|doses (r_dobj) had_13\VBD\2108377|levels|,|and|likely (r_conj) older_5\JJR\1740|patients|were|and|likely|,|had|. (l_nsubj) patients_0\NNS\9898892|developed (l_acl:relcl) developed_2\VBD\1753788|who|hyperkalemia (l_dobj) hyperkalemia_3\NN\14299637|
D011188_D051437 NONE k(+_7\NNS\1740|(|) (r_appos) hyperkalemia_5\NN\14299637|k(+ (r_dobj) developed_4\VBD\1753788|who|hyperkalemia|>|) (r_acl:relcl) patients_2\NNS\9898892|cases|were|developed|or|insufficiency|or=2.5|,|and|compared|selected|. (l_conj) insufficiency_15\NN\14462946|renal
D002857_D006947 NONE cr_17\NN\14625458| (r_compound) or=2.5_19\NN\1740|(|cr|>|mg/dl|) (r_dep) patients_2\NNS\9898892|cases|were|developed|or|insufficiency|or=2.5|,|and|compared|selected|. (l_acl:relcl) developed_4\VBD\1753788|who|hyperkalemia|>|) (l_dobj) hyperkalemia_5\NN\14299637|k(+
D002857_D051437 NONE cr_17\NN\14625458| (r_compound) or=2.5_19\NN\1740|(|cr|>|mg/dl|) (r_dep) patients_2\NNS\9898892|cases|were|developed|or|insufficiency|or=2.5|,|and|compared|selected|. (l_conj) insufficiency_15\NN\14462946|renal
D011188_D003920 NONE potassium_17\NN\14625458| (r_compound) levels_18\NNS\4916342|higher|baseline|serum|potassium|and|doses (r_dobj) had_13\VBD\2108377|levels|,|and|likely (r_conj) older_5\JJR\1740|patients|were|and|likely|,|had|. (l_conj) likely_8\JJ\1740|more|have (l_xcomp) have_10\VB\2108377|to|diabetes (l_dobj) diabetes_11\NNS\14075199|
D011188_D003920 NONE potassium_22\NN\14625458| (r_compound) doses_24\NNS\3740161|lower|baseline|potassium|supplement (r_conj) levels_18\NNS\4916342|higher|baseline|serum|potassium|and|doses (r_dobj) had_13\VBD\2108377|levels|,|and|likely (r_conj) older_5\JJR\1740|patients|were|and|likely|,|had|. (l_conj) likely_8\JJ\1740|more|have (l_xcomp) have_10\VB\2108377|to|diabetes (l_dobj) diabetes_11\NNS\14075199|
D003404_D051437 NONE creatinine_14\NN\1740|higher|baseline|serum (r_conj) weight_9\NN\5009170|lower|baseline|body|and|creatinine (r_dobj) had_5\VBD\2108377|patients|weight|,|required|,|and|likely|. (l_nsubj) patients_0\NNS\9898892|developed (l_acl:relcl) developed_2\VBD\1753788|who|insufficiency (l_dobj) insufficiency_4\NN\14462946|renal
D049971_D051437 NONE thiazide_31\NN\3214670| (r_compound) diuretics_32\NNS\3247620|with|thiazide (r_nmod) treated_29\VBN\2376958|to|be|diuretics|controls (r_xcomp) likely_26\JJ\1740|were|more|treated (r_conj) had_5\VBD\2108377|patients|weight|,|required|,|and|likely|. (l_nsubj) patients_0\NNS\9898892|developed (l_acl:relcl) developed_2\VBD\1753788|who|insufficiency (l_dobj) insufficiency_4\NN\14462946|renal
6386793
D004308_D003866 NONE hydrochloride_10\NN\14817592|of|dothiepin (r_nmod) efficacy_5\NN\5199286|of|the|and|safety|hydrochloride (r_nmod) study_2\NN\635850|a|double-blind|efficacy|treatment|. (l_nmod) treatment_13\NN\654885|in|the|disorder (l_nmod) disorder_17\NN\14034177|of|major|depressive
D004308_D003866 NONE dothiepin_8\NN\1740|and|amitriptyline (r_appos) study_6\NN\635850|in|a|6-week|treatment|,|dothiepin (r_nmod) compared_12\VBN\644583|study|were|placebo|. (l_xcomp) placebo_14\VB\1740|to|treatment (l_nmod) treatment_17\NN\654885|in|the|outpatients (l_nmod) outpatients_21\NNS\10405694|of|33|depressed (l_amod) depressed_20\JJ\1740|
D004308_D003866 NONE dothiepin_0\NN\1740|and|amitriptyline (r_nsubj) effective_5\JJ\1740|dothiepin|were|equally|alleviating|,|and|superior (l_advcl) alleviating_7\VBG\205885|in|symptoms (l_dobj) symptoms_9\NNS\5823932|the|illness (l_nmod) illness_12\NN\14052046|of|depressive
D004308_D003866 NONE dothiepin_0\NNP\1740| (r_nsubjpass) found_3\VBN\2426171|dothiepin|thus|was|drug|. (l_xcomp) drug_9\NN\14778436|to|be|an|effective|antidepressant|associated (l_acl) associated_10\VBN\628491|effects (l_nmod) effects_14\NNS\13245626|with|fewer|side|amitriptyline (l_nmod) amitriptyline_16\NN\4482543|than|treatment (l_nmod) treatment_19\NN\654885|in|the|outpatients (l_nmod) outpatients_22\NNS\10405694|of|depressed (l_amod) depressed_21\JJ\1740|
D000639_D003866 NONE amitriptyline_10\NN\4482543| (r_conj) dothiepin_8\NN\1740|and|amitriptyline (r_appos) study_6\NN\635850|in|a|6-week|treatment|,|dothiepin (r_nmod) compared_12\VBN\644583|study|were|placebo|. (l_xcomp) placebo_14\VB\1740|to|treatment (l_nmod) treatment_17\NN\654885|in|the|outpatients (l_nmod) outpatients_21\NNS\10405694|of|33|depressed (l_amod) depressed_20\JJ\1740|
D000639_D003866 NONE amitriptyline_2\NN\4482543| (r_conj) dothiepin_0\NN\1740|and|amitriptyline (r_nsubj) effective_5\JJ\1740|dothiepin|were|equally|alleviating|,|and|superior (l_advcl) alleviating_7\VBG\205885|in|symptoms (l_dobj) symptoms_9\NNS\5823932|the|illness (l_nmod) illness_12\NN\14052046|of|depressive
D000639_D003866 NONE amitriptyline_16\NN\4482543|than|treatment (l_nmod) treatment_19\NN\654885|in|the|outpatients (l_nmod) outpatients_22\NNS\10405694|of|depressed (l_amod) depressed_21\JJ\1740|
D004308_D014786 NONE dothiepin_24\NN\1740|with (r_nmod) less_22\JJR\1740|incidence|were|significantly|dothiepin|amitriptyline|. (l_nsubj) incidence_2\NN\13821570|the|overall|effects|and|frequency|,|and|drowsiness (l_conj) frequency_8\NN\15286249|the|and|severity|vision (l_nmod) vision_13\NN\5767733|of|blurred|,|mouth
D004308_D014987 NONE dothiepin_24\NN\1740|with (r_nmod) less_22\JJR\1740|incidence|were|significantly|dothiepin|amitriptyline|. (l_nsubj) incidence_2\NN\13821570|the|overall|effects|and|frequency|,|and|drowsiness (l_conj) frequency_8\NN\15286249|the|and|severity|vision (l_nmod) vision_13\NN\5767733|of|blurred|,|mouth (l_conj) mouth_16\NN\5610008|dry
D000639_D014786 CID amitriptyline_27\NN\4482543|than|with (r_advcl) less_22\JJR\1740|incidence|were|significantly|dothiepin|amitriptyline|. (l_nsubj) incidence_2\NN\13821570|the|overall|effects|and|frequency|,|and|drowsiness (l_conj) frequency_8\NN\15286249|the|and|severity|vision (l_nmod) vision_13\NN\5767733|of|blurred|,|mouth
D000639_D014987 CID amitriptyline_27\NN\4482543|than|with (r_advcl) less_22\JJR\1740|incidence|were|significantly|dothiepin|amitriptyline|. (l_nsubj) incidence_2\NN\13821570|the|overall|effects|and|frequency|,|and|drowsiness (l_conj) frequency_8\NN\15286249|the|and|severity|vision (l_nmod) vision_13\NN\5767733|of|blurred|,|mouth (l_conj) mouth_16\NN\5610008|dry
D000928_D003866 NONE antidepressant_8\JJ\1740| (r_amod) drug_9\NN\14778436|to|be|an|effective|antidepressant|associated (l_acl) associated_10\VBN\628491|effects (l_nmod) effects_14\NNS\13245626|with|fewer|side|amitriptyline (l_nmod) amitriptyline_16\NN\4482543|than|treatment (l_nmod) treatment_19\NN\654885|in|the|outpatients (l_nmod) outpatients_22\NNS\10405694|of|depressed (l_amod) depressed_21\JJ\1740|
2673163
D003042_D020521 NONE cocaine_3\NN\3492717| (r_compound) use_4\NN\407535|with|cocaine (r_nmod) associated_1\VBN\628491|stroke|use|. (l_nsubj) stroke_0\NNP\556313|
D003042_D020521 NONE cocaine_6\NN\3492717| (r_compound) use_7\NN\407535|cocaine (r_nsubj) related_9\JJ\1740|whom|use|was|stroke (l_xcomp) stroke_11\VB\1206218|to|and|review
D003042_D020521 NONE cocaine_2\NN\3492717| (r_compound) use_3\NN\407535|cocaine (r_dobj) followed_1\VBD\1835496|stroke|use|inhalation|. (l_nsubj) stroke_0\NN\556313|
D003042_D020521 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|to|cocaine (r_nmod) related_12\JJ\1740|use (r_amod) stroke_11\NN\556313|of|related
D003042_D020521 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|to|cocaine (r_nmod) related_12\JJ\1740|use (r_amod) stroke_11\NN\556313|of|related (r_nmod) incidence_9\NN\13821570|the|apparent|stroke (r_nsubj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) occurs_24\VBZ\2623529|2|stroke|primarily|adults (l_nsubj) stroke_23\NN\556313|cocaine-associated
D003042_D020521 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|to|cocaine (r_nmod) related_12\JJ\1740|use (r_amod) stroke_11\NN\556313|of|related (r_nmod) incidence_9\NN\13821570|the|apparent|stroke (r_nsubj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) follow_35\VB\1835496|3|stroke|may|route (l_nsubj) stroke_33\NN\556313|
D003042_D020521 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|to|cocaine (r_nmod) related_12\JJ\1740|use (r_amod) stroke_11\NN\556313|of|related (r_nmod) incidence_9\NN\13821570|the|apparent|stroke (r_nsubj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) stroke_45\NN\556313|4|use
D003042_D020521 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|to|cocaine (r_nmod) related_12\JJ\1740|use (r_amod) stroke_11\NN\556313|of|related (r_nmod) incidence_9\NN\13821570|the|apparent|stroke (r_nsubj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) 5_61\LS\13741022|(|)|stroke|,|frequency|that (l_nmod) stroke_65\NN\556313|in|cocaine-associated
D003042_D020521 NONE cocaine-associated_22\JJ\1740| (r_amod) stroke_23\NN\556313|cocaine-associated (r_nsubj) occurs_24\VBZ\2623529|2|stroke|primarily|adults (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_nsubj) incidence_9\NN\13821570|the|apparent|stroke (l_nmod) stroke_11\NN\556313|of|related
D003042_D020521 NONE cocaine-associated_22\JJ\1740| (r_amod) stroke_23\NN\556313|cocaine-associated
D003042_D020521 NONE cocaine-associated_22\JJ\1740| (r_amod) stroke_23\NN\556313|cocaine-associated (r_nsubj) occurs_24\VBZ\2623529|2|stroke|primarily|adults (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) follow_35\VB\1835496|3|stroke|may|route (l_nsubj) stroke_33\NN\556313|
D003042_D020521 NONE cocaine-associated_22\JJ\1740| (r_amod) stroke_23\NN\556313|cocaine-associated (r_nsubj) occurs_24\VBZ\2623529|2|stroke|primarily|adults (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) stroke_45\NN\556313|4|use
D003042_D020521 NONE cocaine-associated_22\JJ\1740| (r_amod) stroke_23\NN\556313|cocaine-associated (r_nsubj) occurs_24\VBZ\2623529|2|stroke|primarily|adults (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) 5_61\LS\13741022|(|)|stroke|,|frequency|that (l_nmod) stroke_65\NN\556313|in|cocaine-associated
D003042_D020521 NONE cocaine_39\NN\3492717| (r_compound) administration_40\NN\1133281|of|cocaine (r_nmod) route_37\NN\8593262|any|administration (r_dobj) follow_35\VB\1835496|3|stroke|may|route (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_nsubj) incidence_9\NN\13821570|the|apparent|stroke (l_nmod) stroke_11\NN\556313|of|related
D003042_D020521 NONE cocaine_39\NN\3492717| (r_compound) administration_40\NN\1133281|of|cocaine (r_nmod) route_37\NN\8593262|any|administration (r_dobj) follow_35\VB\1835496|3|stroke|may|route (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) occurs_24\VBZ\2623529|2|stroke|primarily|adults (l_nsubj) stroke_23\NN\556313|cocaine-associated
D003042_D020521 NONE cocaine_39\NN\3492717| (r_compound) administration_40\NN\1133281|of|cocaine (r_nmod) route_37\NN\8593262|any|administration (r_dobj) follow_35\VB\1835496|3|stroke|may|route (l_nsubj) stroke_33\NN\556313|
D003042_D020521 NONE cocaine_39\NN\3492717| (r_compound) administration_40\NN\1133281|of|cocaine (r_nmod) route_37\NN\8593262|any|administration (r_dobj) follow_35\VB\1835496|3|stroke|may|route (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) stroke_45\NN\556313|4|use
D003042_D020521 NONE cocaine_39\NN\3492717| (r_compound) administration_40\NN\1133281|of|cocaine (r_nmod) route_37\NN\8593262|any|administration (r_dobj) follow_35\VB\1835496|3|stroke|may|route (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) 5_61\LS\13741022|(|)|stroke|,|frequency|that (l_nmod) stroke_65\NN\556313|in|cocaine-associated
D003042_D020521 NONE cocaine_47\NN\3492717| (r_compound) use_48\NN\407535|after|cocaine (r_nmod) stroke_45\NN\556313|4|use (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_nsubj) incidence_9\NN\13821570|the|apparent|stroke (l_nmod) stroke_11\NN\556313|of|related
D003042_D020521 NONE cocaine_47\NN\3492717| (r_compound) use_48\NN\407535|after|cocaine (r_nmod) stroke_45\NN\556313|4|use (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) occurs_24\VBZ\2623529|2|stroke|primarily|adults (l_nsubj) stroke_23\NN\556313|cocaine-associated
D003042_D020521 NONE cocaine_47\NN\3492717| (r_compound) use_48\NN\407535|after|cocaine (r_nmod) stroke_45\NN\556313|4|use (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) follow_35\VB\1835496|3|stroke|may|route (l_nsubj) stroke_33\NN\556313|
D003042_D020521 NONE cocaine_47\NN\3492717| (r_compound) use_48\NN\407535|after|cocaine (r_nmod) stroke_45\NN\556313|4|use
D003042_D020521 NONE cocaine_47\NN\3492717| (r_compound) use_48\NN\407535|after|cocaine (r_nmod) stroke_45\NN\556313|4|use (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) 5_61\LS\13741022|(|)|stroke|,|frequency|that (l_nmod) stroke_65\NN\556313|in|cocaine-associated
D003042_D020521 NONE cocaine-associated_64\JJ\1740| (r_amod) stroke_65\NN\556313|in|cocaine-associated (r_nmod) 5_61\LS\13741022|(|)|stroke|,|frequency|that (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_nsubj) incidence_9\NN\13821570|the|apparent|stroke (l_nmod) stroke_11\NN\556313|of|related
D003042_D020521 NONE cocaine-associated_64\JJ\1740| (r_amod) stroke_65\NN\556313|in|cocaine-associated (r_nmod) 5_61\LS\13741022|(|)|stroke|,|frequency|that (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) occurs_24\VBZ\2623529|2|stroke|primarily|adults (l_nsubj) stroke_23\NN\556313|cocaine-associated
D003042_D020521 NONE cocaine-associated_64\JJ\1740| (r_amod) stroke_65\NN\556313|in|cocaine-associated (r_nmod) 5_61\LS\13741022|(|)|stroke|,|frequency|that (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) follow_35\VB\1835496|3|stroke|may|route (l_nsubj) stroke_33\NN\556313|
D003042_D020521 NONE cocaine-associated_64\JJ\1740| (r_amod) stroke_65\NN\556313|in|cocaine-associated (r_nmod) 5_61\LS\13741022|(|)|stroke|,|frequency|that (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) stroke_45\NN\556313|4|use
D003042_D020521 NONE cocaine-associated_64\JJ\1740| (r_amod) stroke_65\NN\556313|in|cocaine-associated
D003042_D002532 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|to|cocaine (r_nmod) related_12\JJ\1740|use (r_amod) stroke_11\NN\556313|of|related (r_nmod) incidence_9\NN\13821570|the|apparent|stroke (r_nsubj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_advcl) associated_51\VBN\628491|is|frequently|aneurysms (l_nmod) aneurysms_54\NNS\14057371|with|intracranial|and|malformations
D003042_D002532 NONE cocaine-associated_22\JJ\1740| (r_amod) stroke_23\NN\556313|cocaine-associated (r_nsubj) occurs_24\VBZ\2623529|2|stroke|primarily|adults (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_advcl) associated_51\VBN\628491|is|frequently|aneurysms (l_nmod) aneurysms_54\NNS\14057371|with|intracranial|and|malformations
D003042_D002532 NONE cocaine_39\NN\3492717| (r_compound) administration_40\NN\1133281|of|cocaine (r_nmod) route_37\NN\8593262|any|administration (r_dobj) follow_35\VB\1835496|3|stroke|may|route (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_advcl) associated_51\VBN\628491|is|frequently|aneurysms (l_nmod) aneurysms_54\NNS\14057371|with|intracranial|and|malformations
D003042_D002532 NONE cocaine_47\NN\3492717| (r_compound) use_48\NN\407535|after|cocaine (r_nmod) stroke_45\NN\556313|4|use (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_advcl) associated_51\VBN\628491|is|frequently|aneurysms (l_nmod) aneurysms_54\NNS\14057371|with|intracranial|and|malformations
D003042_D002532 NONE cocaine-associated_64\JJ\1740| (r_amod) stroke_65\NN\556313|in|cocaine-associated (r_nmod) 5_61\LS\13741022|(|)|stroke|,|frequency|that (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_advcl) associated_51\VBN\628491|is|frequently|aneurysms (l_nmod) aneurysms_54\NNS\14057371|with|intracranial|and|malformations
D003042_D001165 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|to|cocaine (r_nmod) related_12\JJ\1740|use (r_amod) stroke_11\NN\556313|of|related (r_nmod) incidence_9\NN\13821570|the|apparent|stroke (r_nsubj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_advcl) associated_51\VBN\628491|is|frequently|aneurysms (l_nmod) aneurysms_54\NNS\14057371|with|intracranial|and|malformations (l_conj) malformations_57\NNS\14213199|arteriovenous
D003042_D001165 NONE cocaine-associated_22\JJ\1740| (r_amod) stroke_23\NN\556313|cocaine-associated (r_nsubj) occurs_24\VBZ\2623529|2|stroke|primarily|adults (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_advcl) associated_51\VBN\628491|is|frequently|aneurysms (l_nmod) aneurysms_54\NNS\14057371|with|intracranial|and|malformations (l_conj) malformations_57\NNS\14213199|arteriovenous
D003042_D001165 NONE cocaine_39\NN\3492717| (r_compound) administration_40\NN\1133281|of|cocaine (r_nmod) route_37\NN\8593262|any|administration (r_dobj) follow_35\VB\1835496|3|stroke|may|route (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_advcl) associated_51\VBN\628491|is|frequently|aneurysms (l_nmod) aneurysms_54\NNS\14057371|with|intracranial|and|malformations (l_conj) malformations_57\NNS\14213199|arteriovenous
D003042_D001165 NONE cocaine_47\NN\3492717| (r_compound) use_48\NN\407535|after|cocaine (r_nmod) stroke_45\NN\556313|4|use (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_advcl) associated_51\VBN\628491|is|frequently|aneurysms (l_nmod) aneurysms_54\NNS\14057371|with|intracranial|and|malformations (l_conj) malformations_57\NNS\14213199|arteriovenous
D003042_D001165 NONE cocaine-associated_64\JJ\1740| (r_amod) stroke_65\NN\556313|in|cocaine-associated (r_nmod) 5_61\LS\13741022|(|)|stroke|,|frequency|that (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_advcl) associated_51\VBN\628491|is|frequently|aneurysms (l_nmod) aneurysms_54\NNS\14057371|with|intracranial|and|malformations (l_conj) malformations_57\NNS\14213199|arteriovenous
D003042_D020300 NONE cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|to|cocaine (r_nmod) related_12\JJ\1740|use (r_amod) stroke_11\NN\556313|of|related (r_nmod) incidence_9\NN\13821570|the|apparent|stroke (r_nsubj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) 5_61\LS\13741022|(|)|stroke|,|frequency|that (l_appos) frequency_68\NN\15286249|the|exceeds (l_nmod) exceeds_72\NNS\1740|of|intracranial|hemorrhage (l_compound) hemorrhage_71\NN\14285662|
D003042_D020300 NONE cocaine-associated_22\JJ\1740| (r_amod) stroke_23\NN\556313|cocaine-associated (r_nsubj) occurs_24\VBZ\2623529|2|stroke|primarily|adults (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) 5_61\LS\13741022|(|)|stroke|,|frequency|that (l_appos) frequency_68\NN\15286249|the|exceeds (l_nmod) exceeds_72\NNS\1740|of|intracranial|hemorrhage (l_compound) hemorrhage_71\NN\14285662|
D003042_D020300 NONE cocaine_39\NN\3492717| (r_compound) administration_40\NN\1133281|of|cocaine (r_nmod) route_37\NN\8593262|any|administration (r_dobj) follow_35\VB\1835496|3|stroke|may|route (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) 5_61\LS\13741022|(|)|stroke|,|frequency|that (l_appos) frequency_68\NN\15286249|the|exceeds (l_nmod) exceeds_72\NNS\1740|of|intracranial|hemorrhage (l_compound) hemorrhage_71\NN\14285662|
D003042_D020300 NONE cocaine_47\NN\3492717| (r_compound) use_48\NN\407535|after|cocaine (r_nmod) stroke_45\NN\556313|4|use (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) 5_61\LS\13741022|(|)|stroke|,|frequency|that (l_appos) frequency_68\NN\15286249|the|exceeds (l_nmod) exceeds_72\NNS\1740|of|intracranial|hemorrhage (l_compound) hemorrhage_71\NN\14285662|
D003042_D020300 NONE cocaine-associated_64\JJ\1740| (r_amod) stroke_65\NN\556313|in|cocaine-associated (r_nmod) 5_61\LS\13741022|(|)|stroke|,|frequency|that (l_appos) frequency_68\NN\15286249|the|exceeds (l_nmod) exceeds_72\NNS\1740|of|intracranial|hemorrhage (l_compound) hemorrhage_71\NN\14285662|
D003042_D002544 CID cocaine_14\NN\3492717| (r_compound) use_15\NN\407535|to|cocaine (r_nmod) related_12\JJ\1740|use (r_amod) stroke_11\NN\556313|of|related (r_nmod) incidence_9\NN\13821570|the|apparent|stroke (r_nsubj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) 5_61\LS\13741022|(|)|stroke|,|frequency|that (l_dep) that_73\DT\1740|infarction (l_nmod) infarction_76\NN\14204950|of|cerebral
D003042_D002544 CID cocaine-associated_22\JJ\1740| (r_amod) stroke_23\NN\556313|cocaine-associated (r_nsubj) occurs_24\VBZ\2623529|2|stroke|primarily|adults (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) 5_61\LS\13741022|(|)|stroke|,|frequency|that (l_dep) that_73\DT\1740|infarction (l_nmod) infarction_76\NN\14204950|of|cerebral
D003042_D002544 CID cocaine_39\NN\3492717| (r_compound) administration_40\NN\1133281|of|cocaine (r_nmod) route_37\NN\8593262|any|administration (r_dobj) follow_35\VB\1835496|3|stroke|may|route (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) 5_61\LS\13741022|(|)|stroke|,|frequency|that (l_dep) that_73\DT\1740|infarction (l_nmod) infarction_76\NN\14204950|of|cerebral
D003042_D002544 CID cocaine_47\NN\3492717| (r_compound) use_48\NN\407535|after|cocaine (r_nmod) stroke_45\NN\556313|4|use (r_conj) increasing_17\VBG\169651|that|1|incidence|is|;|occurs|;|follow|;|stroke|associated|;|and|5 (l_conj) 5_61\LS\13741022|(|)|stroke|,|frequency|that (l_dep) that_73\DT\1740|infarction (l_nmod) infarction_76\NN\14204950|of|cerebral
D003042_D002544 CID cocaine-associated_64\JJ\1740| (r_amod) stroke_65\NN\556313|in|cocaine-associated (r_nmod) 5_61\LS\13741022|(|)|stroke|,|frequency|that (l_dep) that_73\DT\1740|infarction (l_nmod) infarction_76\NN\14204950|of|cerebral
19803309
D013390_D009224 NONE suxamethonium_27\NN\1740|of|intravenous (r_nmod) dose_24\NN\3740161|following|a|standard|suxamethonium|induction (r_nmod) developed_16\VBD\1753788|who|life|dose (r_acl:relcl) primigravida_13\NN\10144838|in|a|24-year-old|healthy|,|developed (r_nmod) case_4\NN\7283608|an|undiagnosed|congenita|primigravida (l_nmod) congenita_7\NN\1740|of|myotonia
D013390_D014313 CID suxamethonium_27\NN\1740|of|intravenous (r_nmod) dose_24\NN\3740161|following|a|standard|suxamethonium|induction (r_nmod) developed_16\VBD\1753788|who|life|dose (l_dobj) life_17\NN\13954253|threatening (l_acl) threatening_18\VBG\2603699|spasm (l_dobj) spasm_20\NN\14299637|masseter
234669
D000628_D014693 CID aminophylline_2\NN\2905612|of (r_nmod) effects_0\NNS\13245626|aminophylline|threshold|initiating|. (l_acl) initiating_7\VBG\1617192|for|fibrillation|failure (l_dobj) fibrillation_9\NN\14361664|ventricular
D000628_D014693 CID aminophylline_3\NN\2905612|of (r_nmod) effects_1\NNS\13245626|the|aminophylline|threshold|conditions (l_nmod) threshold_8\NN\15265518|on|the|ventricular|fibrillation (l_compound) fibrillation_7\NN\14361664|
D000628_D014693 CID aminophylline_4\NN\2905612|of|, (r_nmod) infusion_2\NN\14589223|during|the|aminophylline (r_nmod) reduced_11\VBN\441445|infusion|threshold|was|percent|kept|. (l_nsubjpass) threshold_9\NN\15265518|the|ventricular|fibrillation (l_compound) fibrillation_8\NN\14361664|
D000628_D014693 CID aminophylline_30\NN\2905612|of (r_nmod) infusion_28\NN\14589223|aminophylline (r_nsubj) resulted_31\VBD\2633881|produced|infusion|decrease|. (l_nmod) decrease_36\NN\7296428|in|an|greater|threshold|percent (l_nmod) threshold_40\NN\15265518|in|ventricular|fibrillation (l_compound) fibrillation_39\NN\14361664|
D000628_D012131 NONE aminophylline_2\NN\2905612|of (r_nmod) effects_0\NNS\13245626|aminophylline|threshold|initiating|. (l_acl) initiating_7\VBG\1617192|for|fibrillation|failure (l_nmod) failure_12\NN\66216|during|respiratory
D000628_D012131 NONE aminophylline_3\NN\2905612|of (r_nmod) effects_1\NNS\13245626|the|aminophylline|threshold|conditions (l_nmod) conditions_12\NNS\14512817|during|normal|acid-base|and|failure (l_conj) failure_16\NN\66216|during|respiratory
D000628_D012131 NONE aminophylline_30\NN\2905612|of (r_nmod) infusion_28\NN\14589223|aminophylline (r_nsubj) resulted_31\VBD\2633881|produced|infusion|decrease|. (l_advcl) produced_4\VBN\1617192|when|failure|was|hypoventilation (l_nsubjpass) failure_2\NN\66216|respiratory
D000628_D012131 NONE aminophylline_24\NN\2905612|particularly (r_appos) agents_21\NNS\7347|pharmacologic|,|aminophylline (r_conj) failure_18\NN\66216|in|respiratory|,|agents
D010100_D014693 NONE oxygen_26\NN\14622893|of|po2|and|dioxide (r_nmod) pressures_24\NNS\11419404|oxygen (r_conj) ph_21\NN\5038959|and|partial|pressures (r_nsubjpass) kept_37\VBN\2367363|when|ph|were|limits (r_advcl) reduced_11\VBN\441445|infusion|threshold|was|percent|kept|. (l_nsubjpass) threshold_9\NN\15265518|the|ventricular|fibrillation (l_compound) fibrillation_8\NN\14361664|
C093415_D014693 NONE po2_28\NN\1740|(|) (r_appos) oxygen_26\NN\14622893|of|po2|and|dioxide (r_nmod) pressures_24\NNS\11419404|oxygen (r_conj) ph_21\NN\5038959|and|partial|pressures (r_nsubjpass) kept_37\VBN\2367363|when|ph|were|limits (r_advcl) reduced_11\VBN\441445|infusion|threshold|was|percent|kept|. (l_nsubjpass) threshold_9\NN\15265518|the|ventricular|fibrillation (l_compound) fibrillation_8\NN\14361664|
D002245_D014693 NONE dioxide_32\NN\14971519|carbon|co2 (r_conj) oxygen_26\NN\14622893|of|po2|and|dioxide (r_nmod) pressures_24\NNS\11419404|oxygen (r_conj) ph_21\NN\5038959|and|partial|pressures (r_nsubjpass) kept_37\VBN\2367363|when|ph|were|limits (r_advcl) reduced_11\VBN\441445|infusion|threshold|was|percent|kept|. (l_nsubjpass) threshold_9\NN\15265518|the|ventricular|fibrillation (l_compound) fibrillation_8\NN\14361664|
D002245_D014693 NONE co2_34\NN\14836127|(|) (r_appos) dioxide_32\NN\14971519|carbon|co2 (r_conj) oxygen_26\NN\14622893|of|po2|and|dioxide (r_nmod) pressures_24\NNS\11419404|oxygen (r_conj) ph_21\NN\5038959|and|partial|pressures (r_nsubjpass) kept_37\VBN\2367363|when|ph|were|limits (r_advcl) reduced_11\VBN\441445|infusion|threshold|was|percent|kept|. (l_nsubjpass) threshold_9\NN\15265518|the|ventricular|fibrillation (l_compound) fibrillation_8\NN\14361664|
D000628_D007040 NONE aminophylline_30\NN\2905612|of (r_nmod) infusion_28\NN\14589223|aminophylline (r_nsubj) resulted_31\VBD\2633881|produced|infusion|decrease|. (l_advcl) produced_4\VBN\1617192|when|failure|was|hypoventilation (l_nmod) hypoventilation_6\NN\1740|by|ph|,
D000628_D001145 NONE aminophylline_24\NN\2905612|particularly (r_appos) agents_21\NNS\7347|pharmacologic|,|aminophylline (r_conj) failure_18\NN\66216|in|respiratory|,|agents (r_nmod) arrhythmias_15\NNS\14103288|of|ventricular|failure
3985451
D014859_D006470 NONE warfarin-induced_0\JJ\1740| (r_amod) hemorrhage_2\NN\14285662|warfarin-induced|iliopsoas|palsy|.
D014859_D020428 CID warfarin-induced_0\JJ\1740| (r_amod) hemorrhage_2\NN\14285662|warfarin-induced|iliopsoas|palsy|. (l_nmod) palsy_7\NN\14557898|with|subsequent|femoral|nerve
D014859_D020428 CID warfarin-induced_10\JJ\1740| (r_amod) neuropathy_12\NN\14204950|of|warfarin-induced|peripheral (r_nmod) form_8\NN\6286395|the|common|neuropathy (r_dobj) represents_4\VBZ\2664769|palsy|form (l_nsubj) palsy_3\NN\14557898|anticoagulant-induced|femoral|nerve
D014859_D009135 CID warfarin_10\NN\2718259| (r_compound) therapy_11\NN\657604|on|chronic|warfarin (r_nmod) man_7\NN\9605289|of|a|28-year-old|therapy|sustained (l_acl:relcl) sustained_13\VBD\2679899|who|tear|and|developed (l_dobj) tear_17\NN\13771404|a|minor|muscle
D014859_D010146 NONE warfarin_10\NN\2718259| (r_compound) therapy_11\NN\657604|on|chronic|warfarin (r_nmod) man_7\NN\9605289|of|a|28-year-old|therapy|sustained (l_acl:relcl) sustained_13\VBD\2679899|who|tear|and|developed (l_conj) developed_19\VBD\1753788|pain (l_dobj) pain_21\NN\14299637|increasing|and|contracture
D014859_D010146 NONE warfarin-induced_10\JJ\1740| (r_amod) neuropathy_12\NN\14204950|of|warfarin-induced|peripheral (r_nmod) form_8\NN\6286395|the|common|neuropathy (r_dobj) represents_4\VBZ\2664769|palsy|form (r_ccomp) characterized_16\VBN\609683|represents|;|it|is|pain|,|degrees|. (l_nmod) pain_19\NN\14299637|by|severe|region
D014859_D003286 NONE warfarin_10\NN\2718259| (r_compound) therapy_11\NN\657604|on|chronic|warfarin (r_nmod) man_7\NN\9605289|of|a|28-year-old|therapy|sustained (l_acl:relcl) sustained_13\VBD\2679899|who|tear|and|developed (l_conj) developed_19\VBD\1753788|pain (l_dobj) pain_21\NN\14299637|increasing|and|contracture (l_conj) contracture_25\NN\369802|a|flexure|hip
D014859_D003286 NONE warfarin-induced_10\JJ\1740| (r_amod) neuropathy_12\NN\14204950|of|warfarin-induced|peripheral (r_nmod) form_8\NN\6286395|the|common|neuropathy (r_dobj) represents_4\VBZ\2664769|palsy|form (r_ccomp) characterized_16\VBN\609683|represents|;|it|is|pain|,|degrees|. (l_nmod) degrees_26\NNS\4916342|varying|impairment|,|and|contracture (l_conj) contracture_35\NN\369802|flexure|extremity
D014859_D010523 NONE warfarin-induced_10\JJ\1740| (r_amod) neuropathy_12\NN\14204950|of|warfarin-induced|peripheral
D014859_D015417 NONE warfarin-induced_10\JJ\1740| (r_amod) neuropathy_12\NN\14204950|of|warfarin-induced|peripheral (r_nmod) form_8\NN\6286395|the|common|neuropathy (r_dobj) represents_4\VBZ\2664769|palsy|form (r_ccomp) characterized_16\VBN\609683|represents|;|it|is|pain|,|degrees|. (l_nmod) degrees_26\NNS\4916342|varying|impairment|,|and|contracture (l_nmod) impairment_31\NN\7296428|of|motor
19356053
D020123_D011507 CID sirolimus_7\NN\1740|of (r_nmod) administration_5\NN\1133281|following|the|sirolimus|recipients (r_nmod) proteinuria_2\NN\14299637|clinically|significant|administration|.
D020123_D011507 CID sirolimus_16\NN\1740|of (r_nmod) use_14\NN\407535|with|the|sirolimus (r_nmod) linked_11\VBN\628491|use (r_acl) proteinuria_10\NN\14299637|of|significant|linked
D020123_D011507 CID sirolimus_11\NN\1740| (r_compound) use_12\NN\407535|with|sirolimus (r_nmod) associated_9\VBN\628491|use (r_acl) proteinuria_8\NN\14299637|substantial|associated
D020123_D011507 CID sirolimus_12\NN\1740| (r_compound) therapy_13\NN\657604|of|sirolimus|and|proteinuria (l_conj) proteinuria_15\NN\14299637|
D020123_D011507 CID sirolimus_12\NN\1740| (r_compound) therapy_13\NN\657604|of|sirolimus|and|proteinuria (r_nmod) commencement_10\NN\15180528|between|the|therapy (r_nmod) association_7\NN\8008335|the|close|temporal|commencement (r_nsubj) implicated_16\VBD\2677097|patient|,|association|sirolimus|etiology|. (l_nmod) etiology_22\NN\7326557|as|the|likely|proteinuria (l_nmod) proteinuria_25\NN\14299637|of|the
D020123_D011507 CID sirolimus_17\NN\1740| (r_dobj) implicated_16\VBD\2677097|patient|,|association|sirolimus|etiology|. (l_nsubj) association_7\NN\8008335|the|close|temporal|commencement (l_nmod) commencement_10\NN\15180528|between|the|therapy (l_nmod) therapy_13\NN\657604|of|sirolimus|and|proteinuria (l_conj) proteinuria_15\NN\14299637|
D020123_D011507 CID sirolimus_17\NN\1740| (r_dobj) implicated_16\VBD\2677097|patient|,|association|sirolimus|etiology|. (l_nmod) etiology_22\NN\7326557|as|the|likely|proteinuria (l_nmod) proteinuria_25\NN\14299637|of|the
D020123_D011507 CID sirolimus_16\NN\1740|of (r_nmod) initiation_14\NN\7450842|between|the|sirolimus|and|development (l_conj) development_19\NN\248977|the|proteinuria (l_nmod) proteinuria_22\NN\14299637|of|nephrotic-range
D020123_D011507 CID sirolimus_5\NN\1740| (r_compound) therapy_6\NN\657604|with|sirolimus (r_nmod) correlated_1\VBD\2657219|proteinuria|strongly|therapy|compared|. (l_nsubj) proteinuria_0\NNP\14299637|
D020123_D011507 CID sirolimus_6\NN\1740|of (r_nmod) discontinuation_4\NN\209943|sirolimus (r_nsubj) resulted_7\VBD\2633881|patients|,|discontinuation|decrease|. (l_nmod) decrease_10\NN\7296428|in|a|,|resolution|,|proteinuria (l_nmod) proteinuria_17\NN\14299637|of
D020123_D011507 CID sirolimus_2\NN\1740| (r_nsubj) induces_3\VBZ\1627355|sirolimus|or|aggravates (l_conj) aggravates_5\VBZ\126264|proteinuria (l_dobj) proteinuria_7\NN\14299637|pre-existing|subset
D020123_D011507 CID sirolimus_10\NN\1740| (r_nsubjpass) withdrawn_12\VBN\1835496|,|when|sirolimus|is|. (r_conj) improve_2\VB\126264|proteinuria|may|,|but|resolve|withdrawn (l_nsubj) proteinuria_0\NNP\14299637|
D020123_D007674 NONE sirolimus_2\NN\1740| (r_nsubj) agent_7\NN\7347|background|:|sirolimus|is|the|latest|immunosuppressive|used|,|and|have|. (l_conj) have_15\VB\2108377|may|nephrotoxicity (l_dobj) nephrotoxicity_17\NN\1740|less|regimens
D003404_D011507 NONE creatinine_22\NN\1740| (r_compound) ratios_23\NNS\13815152|creatinine|,|estimate (r_dep) samples_13\NNS\5820620|on|morning|urine|measurement|:|ratios (r_nmod) assessed_9\VBN\670261|patients|,|magnitude|was|samples|. (l_nsubjpass) magnitude_5\NN\4916342|the|proteinuria (l_nmod) proteinuria_7\NN\14299637|of
D003404_D011507 NONE creatinine_22\NN\1740| (r_compound) ratios_23\NNS\13815152|creatinine|,|estimate (l_appos) estimate_26\NN\5802185|an|grams (l_nmod) grams_28\NNS\13717155|of|proteinuria/day (l_nmod) proteinuria/day_30\NN\1740|of
D020123_D009404 NONE sirolimus_16\NN\1740|of (r_nmod) initiation_14\NN\7450842|between|the|sirolimus|and|development (l_conj) development_19\NN\248977|the|proteinuria (l_nmod) proteinuria_22\NN\14299637|of|nephrotic-range (l_amod) nephrotic-range_21\JJ\1740|
7802851
D000525_D016584 NONE alprazolam_3\NNS\2830852|of|and|placebo (l_conj) placebo_5\NN\3740161|disorder|agoraphobia (l_nmod) disorder_8\NN\14034177|in|panic
D000525_D016584 NONE alprazolam_20\NNS\2830852|to|or|placebo (r_nmod) randomised_18\VBN\278117|london|were|alprazolam|. (l_nmod) london_3\NNP\1740|in|and|patients (l_conj) patients_7\NNS\9898892|toronto|154|met (l_acl:relcl) met_9\VBD\1182709|who|criteria|agoraphobia (l_dobj) criteria_11\NNS\13577171|dsm-iii|disorder (l_nmod) disorder_14\NN\14034177|for|panic
D000525_D000379 NONE alprazolam_3\NNS\2830852|of|and|placebo (l_conj) placebo_5\NN\3740161|disorder|agoraphobia (l_nmod) agoraphobia_10\NN\14381416|with
D000525_D000379 NONE alprazolam_20\NNS\2830852|to|or|placebo (r_nmod) randomised_18\VBN\278117|london|were|alprazolam|. (l_nmod) london_3\NNP\1740|in|and|patients (l_conj) patients_7\NNS\9898892|toronto|154|met (l_acl:relcl) met_9\VBD\1182709|who|criteria|agoraphobia (l_nmod) agoraphobia_16\NN\14381416|with
D000525_D003866 CID alprazolam_5\NN\2830852| (r_compound) patients_6\NNS\9898892|alprazolam (r_nsubj) developed_7\VBD\1753788|subjects|,|patients|reactions|;|and|side-effects|. (l_dobj) reactions_10\NNS\13446390|adverse|%|depression (l_nmod) depression_19\NN\14373582|of|,|enuresis|,|disinhibition
D000525_D004775 CID alprazolam_5\NN\2830852| (r_compound) patients_6\NNS\9898892|alprazolam (r_nsubj) developed_7\VBD\1753788|subjects|,|patients|reactions|;|and|side-effects|. (l_dobj) reactions_10\NNS\13446390|adverse|%|depression (l_nmod) depression_19\NN\14373582|of|,|enuresis|,|disinhibition (l_conj) enuresis_21\NN\13496972|
D000525_D001523 NONE alprazolam_5\NN\2830852| (r_compound) patients_6\NNS\9898892|alprazolam (r_nsubj) developed_7\VBD\1753788|subjects|,|patients|reactions|;|and|side-effects|. (l_dobj) reactions_10\NNS\13446390|adverse|%|depression (l_nmod) depression_19\NN\14373582|of|,|enuresis|,|disinhibition (l_conj) disinhibition_23\NN\1740|and|aggression (l_conj) aggression_25\NN\4657876|
D000525_D001523 NONE alprazolam_5\NN\2830852| (r_compound) patients_6\NNS\9898892|alprazolam (r_nsubj) developed_7\VBD\1753788|subjects|,|patients|reactions|;|and|side-effects|. (l_conj) side-effects_29\NNS\1740|more|,|sedation|,|memory|,|loss (l_appos) sedation_32\NN\14034177|particularly|,|irritability (l_conj) irritability_34\NN\7552087|
D000525_D008569 CID alprazolam_5\NN\2830852| (r_compound) patients_6\NNS\9898892|alprazolam (r_nsubj) developed_7\VBD\1753788|subjects|,|patients|reactions|;|and|side-effects|. (l_conj) side-effects_29\NNS\1740|more|,|sedation|,|memory|,|loss (l_appos) memory_37\NN\5926676|impaired
D000525_D015431 CID alprazolam_5\NN\2830852| (r_compound) patients_6\NNS\9898892|alprazolam (r_nsubj) developed_7\VBD\1753788|subjects|,|patients|reactions|;|and|side-effects|. (l_conj) side-effects_29\NNS\1740|more|,|sedation|,|memory|,|loss (l_conj) loss_40\NN\13252973|weight|and|ataxia
D000525_D001259 CID alprazolam_5\NN\2830852| (r_compound) patients_6\NNS\9898892|alprazolam (r_nsubj) developed_7\VBD\1753788|subjects|,|patients|reactions|;|and|side-effects|. (l_conj) side-effects_29\NNS\1740|more|,|sedation|,|memory|,|loss (l_conj) loss_40\NN\13252973|weight|and|ataxia (l_conj) ataxia_42\NN\14084880|
6503301
D003606_D006504 CID dacarbazine_4\NN\1740| (r_compound) therapy_5\NN\657604|after|dacarbazine|dtic|melanoma (r_nmod) disease_2\NN\14061805|veno-occlusive|liver|therapy|.
D003606_D006504 CID dtic_7\NN\8337324|(|) (r_appos) therapy_5\NN\657604|after|dacarbazine|dtic|melanoma (r_nmod) disease_2\NN\14061805|veno-occlusive|liver|therapy|.
D003606_D006504 CID dacarbazine_12\NN\1740| (r_compound) therapy_16\NN\657604|after|dacarbazine|dtic|melanoma (r_nmod) outcome_10\NN\7291312|with|fatal|therapy (r_nmod) case_1\NN\7283608|a|disease|outcome (l_nmod) disease_4\NN\14061805|of|veno-occlusive|liver (l_nmod) liver_7\NN\5298729|of|the
D003606_D006504 CID dtic_14\NN\8337324|(|) (r_amod) therapy_16\NN\657604|after|dacarbazine|dtic|melanoma (r_nmod) outcome_10\NN\7291312|with|fatal|therapy (r_nmod) case_1\NN\7283608|a|disease|outcome (l_nmod) disease_4\NN\14061805|of|veno-occlusive|liver (l_nmod) liver_7\NN\5298729|of|the
D003606_D008545 NONE dacarbazine_4\NN\1740| (r_compound) therapy_5\NN\657604|after|dacarbazine|dtic|melanoma (l_nmod) melanoma_10\NN\14252320|for
D003606_D008545 NONE dtic_7\NN\8337324|(|) (r_appos) therapy_5\NN\657604|after|dacarbazine|dtic|melanoma (l_nmod) melanoma_10\NN\14252320|for
D003606_D008545 NONE dacarbazine_12\NN\1740| (r_compound) therapy_16\NN\657604|after|dacarbazine|dtic|melanoma (l_nmod) melanoma_18\NN\14252320|for
D003606_D008545 NONE dtic_14\NN\8337324|(|) (r_amod) therapy_16\NN\657604|after|dacarbazine|dtic|melanoma (l_nmod) melanoma_18\NN\14252320|for
3714122
C005238_D020258 NONE mipafox-induced_7\JJ\1740| (r_amod) damage_9\NN\7296428|mipafox-induced|neuropathic|rats (r_conj) inhibition_5\NN\1068773|between|neurotoxic|esterase|and|damage (l_amod) neurotoxic_3\JJ\1740|
C005238_D020258 NONE mipafox_24\NNP\1740|to|(|n|,|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_nmod) exposed_22\VBN\2110927|acutely|mipafox (r_acl) rats_20\NNS\2329401|in|exposed (r_nmod) examined_18\VBN\789138|correlation|was|rats|. (l_nsubjpass) correlation_1\NN\13841213|the|damage (l_nmod) damage_4\NN\7296428|between|neuropathic|and|inhibition|esterase (l_nmod) esterase_9\NN\1740|of|neurotoxic|or|enzyme (l_amod) neurotoxic_8\JJ\1740|
C005238_D020258 NONE mipafox_24\NNP\1740|to|(|n|,|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (l_appos) organophosphate_33\NN\14919948|a|neurotoxic (l_amod) neurotoxic_32\JJ\1740|
C005238_D020258 NONE n'-diisopropylphosphorodiamidofluoridate_28\NN\1740| (r_appos) mipafox_24\NNP\1740|to|(|n|,|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_nmod) exposed_22\VBN\2110927|acutely|mipafox (r_acl) rats_20\NNS\2329401|in|exposed (r_nmod) examined_18\VBN\789138|correlation|was|rats|. (l_nsubjpass) correlation_1\NN\13841213|the|damage (l_nmod) damage_4\NN\7296428|between|neuropathic|and|inhibition|esterase (l_nmod) esterase_9\NN\1740|of|neurotoxic|or|enzyme (l_amod) neurotoxic_8\JJ\1740|
C005238_D020258 NONE n'-diisopropylphosphorodiamidofluoridate_28\NN\1740| (r_appos) mipafox_24\NNP\1740|to|(|n|,|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (l_appos) organophosphate_33\NN\14919948|a|neurotoxic (l_amod) neurotoxic_32\JJ\1740|
C005238_D009422 NONE mipafox-induced_7\JJ\1740| (r_amod) damage_9\NN\7296428|mipafox-induced|neuropathic|rats
C005238_D009422 NONE mipafox_24\NNP\1740|to|(|n|,|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_nmod) exposed_22\VBN\2110927|acutely|mipafox (r_acl) rats_20\NNS\2329401|in|exposed (r_nmod) examined_18\VBN\789138|correlation|was|rats|. (l_nsubjpass) correlation_1\NN\13841213|the|damage (l_nmod) damage_4\NN\7296428|between|neuropathic|and|inhibition|esterase
C005238_D009422 NONE mipafox_24\NNP\1740|to|(|n|,|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_nmod) exposed_22\VBN\2110927|acutely|mipafox (r_acl) rats_20\NNS\2329401|in|exposed (r_nmod) examined_18\VBN\789138|correlation|was|rats|. (l_nsubjpass) correlation_1\NN\13841213|the|damage (l_nmod) damage_4\NN\7296428|between|neuropathic|and|inhibition|esterase (l_nmod) esterase_9\NN\1740|of|neurotoxic|or|enzyme (l_conj) enzyme_13\NN\14723628|neuropathy|target|nte (l_amod) neuropathy_11\JJ\1740|
C005238_D009422 NONE n'-diisopropylphosphorodiamidofluoridate_28\NN\1740| (r_appos) mipafox_24\NNP\1740|to|(|n|,|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_nmod) exposed_22\VBN\2110927|acutely|mipafox (r_acl) rats_20\NNS\2329401|in|exposed (r_nmod) examined_18\VBN\789138|correlation|was|rats|. (l_nsubjpass) correlation_1\NN\13841213|the|damage (l_nmod) damage_4\NN\7296428|between|neuropathic|and|inhibition|esterase
C005238_D009422 NONE n'-diisopropylphosphorodiamidofluoridate_28\NN\1740| (r_appos) mipafox_24\NNP\1740|to|(|n|,|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_nmod) exposed_22\VBN\2110927|acutely|mipafox (r_acl) rats_20\NNS\2329401|in|exposed (r_nmod) examined_18\VBN\789138|correlation|was|rats|. (l_nsubjpass) correlation_1\NN\13841213|the|damage (l_nmod) damage_4\NN\7296428|between|neuropathic|and|inhibition|esterase (l_nmod) esterase_9\NN\1740|of|neurotoxic|or|enzyme (l_conj) enzyme_13\NN\14723628|neuropathy|target|nte (l_amod) neuropathy_11\JJ\1740|
C005238_D009422 NONE mipafox_18\NNP\1740| (r_compound) exposure_19\NN\5042871|mipafox (r_nsubj) predict_21\VB\916909|after|exposure|can|damage|later (l_dobj) damage_23\NN\7296428|neuropathic|rats
D010755_D009422 NONE organophosphate_33\NN\14919948|a|neurotoxic (r_appos) mipafox_24\NNP\1740|to|(|n|,|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_nmod) exposed_22\VBN\2110927|acutely|mipafox (r_acl) rats_20\NNS\2329401|in|exposed (r_nmod) examined_18\VBN\789138|correlation|was|rats|. (l_nsubjpass) correlation_1\NN\13841213|the|damage (l_nmod) damage_4\NN\7296428|between|neuropathic|and|inhibition|esterase
D010755_D009422 NONE organophosphate_33\NN\14919948|a|neurotoxic (r_appos) mipafox_24\NNP\1740|to|(|n|,|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_nmod) exposed_22\VBN\2110927|acutely|mipafox (r_acl) rats_20\NNS\2329401|in|exposed (r_nmod) examined_18\VBN\789138|correlation|was|rats|. (l_nsubjpass) correlation_1\NN\13841213|the|damage (l_nmod) damage_4\NN\7296428|between|neuropathic|and|inhibition|esterase (l_nmod) esterase_9\NN\1740|of|neurotoxic|or|enzyme (l_conj) enzyme_13\NN\14723628|neuropathy|target|nte (l_amod) neuropathy_11\JJ\1740|
D010755_D020258 NONE organophosphate_33\NN\14919948|a|neurotoxic (r_appos) mipafox_24\NNP\1740|to|(|n|,|n'-diisopropylphosphorodiamidofluoridate|)|,|organophosphate (r_nmod) exposed_22\VBN\2110927|acutely|mipafox (r_acl) rats_20\NNS\2329401|in|exposed (r_nmod) examined_18\VBN\789138|correlation|was|rats|. (l_nsubjpass) correlation_1\NN\13841213|the|damage (l_nmod) damage_4\NN\7296428|between|neuropathic|and|inhibition|esterase (l_nmod) esterase_9\NN\1740|of|neurotoxic|or|enzyme (l_amod) neurotoxic_8\JJ\1740|
D010755_D020258 NONE organophosphate_33\NN\14919948|a|neurotoxic (l_amod) neurotoxic_32\JJ\1740|
C005238_D013118 CID mipafox_5\NNP\1740|of|( (r_nmod) dosages_3\NNS\13576355|mipafox|less|)|inhibited (r_nsubj) produced_39\VBD\1617192|contrast|,|dosages|degree|%|. (l_dobj) degree_41\NN\4916342|this|damage (l_nmod) damage_44\NN\7296428|of|cord
2559236
D004317_D007674 NONE adriamycin-induced_9\JJ\1740| (r_amod) nephropathy_10\NN\14573196|of|adriamycin-induced
D004317_D007674 NONE adriamycin_24\NN\1740| (r_compound) nephrosis_25\NN\14304060|in|adriamycin (r_nmod) assess_13\VB\670261|to|effect|nephrosis (l_dobj) effect_15\NN\34213|the|enalapril (l_nmod) enalapril_17\NN\2673637|of|progression (l_nmod) progression_19\NN\8457976|on|injury (l_nmod) injury_22\NN\14052046|of|renal
D004656_D009401 NONE enalapril_10\NN\2673637| (r_nmod) effect_1\NN\34213|the|inhibitor|enalapril (r_nsubjpass) assessed_12\VBN\670261|effect|was|rats|. (l_nmod) rats_15\NNS\2329401|in|munich-wistar|nephrosis (l_nmod) nephrosis_19\NN\14304060|with|established|adriamycin
D004656_D009401 NONE enalapril_17\NN\2673637|of|progression (r_nmod) effect_15\NN\34213|the|enalapril (r_dobj) assess_13\VB\670261|to|effect|nephrosis (l_nmod) nephrosis_25\NN\14304060|in|adriamycin
D004317_D009401 CID adriamycin_18\NN\1740| (r_compound) nephrosis_19\NN\14304060|with|established|adriamycin
D004317_D009401 CID adriamycin_24\NN\1740| (r_compound) nephrosis_25\NN\14304060|in|adriamycin
D004317_D000419 CID adriamycin_7\NN\1740|of (r_nmod) dose_5\NN\3740161|a|single|adriamycin|and (r_dobj) given_2\VBN\2327200|rats|were|dose|divided|. (l_conj) divided_12\VBD\140123|month|later|groups (l_nmod) groups_15\NNS\2137|into|four|matched (l_acl) matched_16\VBN\2664769|albuminuria (l_nmod) albuminuria_18\NN\14299637|for|,|pressure|,|and|concentration
D004656_D000419 NONE enalapril_5\NN\2673637| (r_nsubj) reduced_6\VBD\441445|that|enalapril|pressure|mm|and|pressure|reducing (l_advcl) reducing_52\VBG\441445|without|albuminuria|mg/day|or|gfr (l_dobj) albuminuria_53\NN\14299637|
D004656_D000419 NONE enalapril_1\NN\2673637| (r_compound) treatment_2\NN\654885|chronic|enalapril (r_nsubj) reduced_3\VBD\441445|treatment|pressure|reducing|. (l_advcl) reducing_7\VBG\441445|without|albuminuria|group (l_dobj) albuminuria_8\NN\14299637|
D004656_D007674 NONE enalapril_17\NN\2673637|of|progression (l_nmod) progression_19\NN\8457976|on|injury (l_nmod) injury_22\NN\14052046|of|renal
10739826
D003276_D054556 CID contraceptives_5\NNS\3183080|of|newer|oral|and|risk (l_conj) risk_8\NN\14541044|the|thromboembolism (l_nmod) thromboembolism_11\NN\14100769|of|venous
D003276_D054556 CID contraceptives_17\NNS\3183080|with|newer|oc (r_nmod) associated_13\VBN\628491|contraceptives (r_acl) thromboembolism_9\NN\14100769|of|venous|vte|associated
D003276_D054556 CID contraceptives_17\NNS\3183080|with|newer|oc (r_nmod) associated_13\VBN\628491|contraceptives (r_acl) thromboembolism_9\NN\14100769|of|venous|vte|associated (l_appos) vte_11\NN\1740|(|)
D003276_D054556 CID oc_19\NNP\1740|(|) (r_appos) contraceptives_17\NNS\3183080|with|newer|oc (r_nmod) associated_13\VBN\628491|contraceptives (r_acl) thromboembolism_9\NN\14100769|of|venous|vte|associated
D003276_D054556 CID oc_19\NNP\1740|(|) (r_appos) contraceptives_17\NNS\3183080|with|newer|oc (r_nmod) associated_13\VBN\628491|contraceptives (r_acl) thromboembolism_9\NN\14100769|of|venous|vte|associated (l_appos) vte_11\NN\1740|(|)
D003276_D054556 CID oc_27\NN\1740| (r_compound) use_28\NN\407535|of|oc (r_nmod) patterns_25\NNS\5726345|between|use|,|users (r_nmod) distinguish_23\VB\618878|studies|did|not|patterns|. (l_nsubj) studies_2\NNS\635850|the|epidemiological|assessed (l_acl:relcl) assessed_4\VBD\670261|that|risk (l_dobj) risk_6\NN\14541044|the|thromboembolism (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte|associated
D003276_D054556 CID oc_27\NN\1740| (r_compound) use_28\NN\407535|of|oc (r_nmod) patterns_25\NNS\5726345|between|use|,|users (r_nmod) distinguish_23\VB\618878|studies|did|not|patterns|. (l_nsubj) studies_2\NNS\635850|the|epidemiological|assessed (l_acl:relcl) assessed_4\VBD\670261|that|risk (l_dobj) risk_6\NN\14541044|the|thromboembolism (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte|associated (l_appos) vte_11\NN\1740|(|)
D003276_D054556 CID oc_12\NNP\1740|generation (r_nmod) users_8\NNS\7846|for|repeat|oc (r_nmod) ratio_3\NN\13815152|the|adjusted|rate|vte|users (l_nmod) vte_5\NN\1740|of
12627929
C067311_D054556 CID docetaxel_9\NN\1740|of (r_nmod) combination_7\NN\7951464|with|the|docetaxel (r_nmod) thromboembolism_4\NN\14100769|of|venous|combination|and|thalidomide
C067311_D054556 CID docetaxel_24\NN\1740|with|alone (r_nmod) treated_22\VBN\2376958|who|were|docetaxel (r_acl:relcl) patients_14\NNS\9898892|in|cancer|treated (r_nmod) thromboembolism_9\NN\14100769|of|venous|vte|patients|or|combination
C067311_D054556 CID docetaxel_24\NN\1740|with|alone (r_nmod) treated_22\VBN\2376958|who|were|docetaxel (r_acl:relcl) patients_14\NNS\9898892|in|cancer|treated (r_nmod) thromboembolism_9\NN\14100769|of|venous|vte|patients|or|combination (l_appos) vte_11\NN\1740|(|)
C067311_D054556 CID docetaxel_11\NN\1740|alone (r_dobj) received_10\VBD\2210855|who|docetaxel (r_acl:relcl) patients_8\NNS\9898892|of|23|received (r_nmod) none_5\NN\15228378|patients (r_nsubj) developed_13\VBD\1753788|none|vte|,|whereas|developed (l_dobj) vte_14\NN\1740|
C067311_D054556 CID docetaxel_11\NN\1740|alone (r_dobj) received_10\VBD\2210855|who|docetaxel (r_acl:relcl) patients_8\NNS\9898892|of|23|received (r_nmod) none_5\NN\15228378|patients (r_nsubj) developed_13\VBD\1753788|none|vte|,|whereas|developed (l_conj) developed_30\VBD\1753788|9|vte|p=0.025 (l_dobj) vte_31\NN\1740|
C067311_D054556 CID docetaxel_27\NN\1740|plus|thalidomide (r_dobj) received_26\VBD\2210855|who|docetaxel (r_acl:relcl) 9_17\CD\13741022|patients|%|received (r_nsubj) developed_30\VBD\1753788|9|vte|p=0.025 (r_conj) developed_13\VBD\1753788|none|vte|,|whereas|developed (l_dobj) vte_14\NN\1740|
C067311_D054556 CID docetaxel_27\NN\1740|plus|thalidomide (r_dobj) received_26\VBD\2210855|who|docetaxel (r_acl:relcl) 9_17\CD\13741022|patients|%|received (r_nsubj) developed_30\VBD\1753788|9|vte|p=0.025 (l_dobj) vte_31\NN\1740|
C067311_D054556 CID docetaxel_7\NN\1740|to|treatment (r_nmod) addition_3\NN\3081021|the|thalidomide|docetaxel (r_nsubj) increases_15\VBZ\169651|addition|significantly|frequency (l_dobj) frequency_17\NN\15286249|the|vte (l_nmod) vte_19\NN\1740|of
C067311_D011471 NONE docetaxel_9\NN\1740|of (r_nmod) combination_7\NN\7951464|with|the|docetaxel (r_nmod) thromboembolism_4\NN\14100769|of|venous|combination|and|thalidomide (l_conj) thalidomide_11\VBP\1740|patients (l_nmod) patients_13\NNS\9898892|in|cancer (l_nmod) cancer_18\NN\14239425|with|metastatic|androgen-independent|prostate
C067311_D011471 NONE docetaxel_24\NN\1740|with|alone (r_nmod) treated_22\VBN\2376958|who|were|docetaxel (r_acl:relcl) patients_14\NNS\9898892|in|cancer|treated (l_nmod) cancer_19\NN\14239425|with|advanced|androgen-independent|prostate
C067311_D011471 NONE docetaxel_7\NN\1740|to|treatment (l_nmod) treatment_10\NN\654885|in|the|cancer (l_nmod) cancer_13\NN\14239425|of|prostate
D013792_D054556 CID thalidomide_11\VBP\1740|patients (r_conj) thromboembolism_4\NN\14100769|of|venous|combination|and|thalidomide
D013792_D054556 CID thalidomide_30\NN\4166841|with (r_nmod) combination_28\NN\7951464|in|thalidomide (r_conj) thromboembolism_9\NN\14100769|of|venous|vte|patients|or|combination
D013792_D054556 CID thalidomide_30\NN\4166841|with (r_nmod) combination_28\NN\7951464|in|thalidomide (r_conj) thromboembolism_9\NN\14100769|of|venous|vte|patients|or|combination (l_appos) vte_11\NN\1740|(|)
D013792_D054556 CID thalidomide_29\NN\4166841| (r_conj) docetaxel_27\NN\1740|plus|thalidomide (r_dobj) received_26\VBD\2210855|who|docetaxel (r_acl:relcl) 9_17\CD\13741022|patients|%|received (r_nsubj) developed_30\VBD\1753788|9|vte|p=0.025 (r_conj) developed_13\VBD\1753788|none|vte|,|whereas|developed (l_dobj) vte_14\NN\1740|
D013792_D054556 CID thalidomide_29\NN\4166841| (r_conj) docetaxel_27\NN\1740|plus|thalidomide (r_dobj) received_26\VBD\2210855|who|docetaxel (r_acl:relcl) 9_17\CD\13741022|patients|%|received (r_nsubj) developed_30\VBD\1753788|9|vte|p=0.025 (l_dobj) vte_31\NN\1740|
D013792_D054556 CID thalidomide_5\NN\4166841|of (r_nmod) addition_3\NN\3081021|the|thalidomide|docetaxel (r_nsubj) increases_15\VBZ\169651|addition|significantly|frequency (l_dobj) frequency_17\NN\15286249|the|vte (l_nmod) vte_19\NN\1740|of
D013792_D011471 NONE thalidomide_11\VBP\1740|patients (l_nmod) patients_13\NNS\9898892|in|cancer (l_nmod) cancer_18\NN\14239425|with|metastatic|androgen-independent|prostate
D013792_D011471 NONE thalidomide_30\NN\4166841|with (r_nmod) combination_28\NN\7951464|in|thalidomide (r_conj) thromboembolism_9\NN\14100769|of|venous|vte|patients|or|combination (l_nmod) patients_14\NNS\9898892|in|cancer|treated (l_nmod) cancer_19\NN\14239425|with|advanced|androgen-independent|prostate
D013792_D011471 NONE thalidomide_5\NN\4166841|of (r_nmod) addition_3\NN\3081021|the|thalidomide|docetaxel (l_nmod) docetaxel_7\NN\1740|to|treatment (l_nmod) treatment_10\NN\654885|in|the|cancer (l_nmod) cancer_13\NN\14239425|of|prostate
8919272
D014635_D001927 CID valproate_11\VBP\1740|features|rats|. (l_nsubj) features_1\NNS\5849040|morphological|encephalopathy|administration (l_nmod) encephalopathy_3\JJ\1740|of
D014635_D001927 CID valproate_8\NN\1740|of|the|antiepileptic|drug|sodium (r_nmod) application_2\NN\947128|long-term|intragastric|valproate|polfa|dose|daily|rats (r_nsubj) revealed_39\VBD\2137132|application|disorders|valproate|. (l_dep) valproate_47\VB\1740|(|"|encephalopathy|"|) (l_advmod) encephalopathy_48\RB\1740|
D014635_D001927 CID valproate_47\VB\1740|(|"|encephalopathy|"|) (l_advmod) encephalopathy_48\RB\1740|
D014635_D001927 CID valproate_15\NN\1740| (r_compound) encephalopathy_16\NN\14084880|of|valproate
D014635_D009422 NONE valproate_8\NN\1740|of|the|antiepileptic|drug|sodium (r_nmod) application_2\NN\947128|long-term|intragastric|valproate|polfa|dose|daily|rats (r_nsubj) revealed_39\VBD\2137132|application|disorders|valproate|. (l_dobj) disorders_41\NNS\14034177|neurological|indicating
D014635_D009422 NONE valproate_47\VB\1740|(|"|encephalopathy|"|) (r_dep) revealed_39\VBD\2137132|application|disorders|valproate|. (l_dobj) disorders_41\NNS\14034177|neurological|indicating
D014635_D002526 NONE valproate_8\NN\1740|of|the|antiepileptic|drug|sodium (r_nmod) application_2\NN\947128|long-term|intragastric|valproate|polfa|dose|daily|rats (r_nsubj) revealed_39\VBD\2137132|application|disorders|valproate|. (l_dobj) disorders_41\NNS\14034177|neurological|indicating (l_acl) indicating_42\VBG\952524|damage (l_dobj) damage_44\NN\7296428|cerebellum
D014635_D002526 NONE valproate_47\VB\1740|(|"|encephalopathy|"|) (r_dep) revealed_39\VBD\2137132|application|disorders|valproate|. (l_dobj) disorders_41\NNS\14034177|neurological|indicating (l_acl) indicating_42\VBG\952524|damage (l_dobj) damage_44\NN\7296428|cerebellum
D014635_D056486 NONE valproate_15\NN\1740| (r_compound) encephalopathy_16\NN\14084880|of|valproate (r_nmod) development_13\NN\248977|upon|the|encephalopathy (r_nmod) influence_2\NN\5190804|the|possible|damage|,|development (l_nmod) damage_6\NN\7296428|of|the|hepatic|,|hyperammonemia
D014635_D022124 NONE valproate_15\NN\1740| (r_compound) encephalopathy_16\NN\14084880|of|valproate (r_nmod) development_13\NN\248977|upon|the|encephalopathy (r_nmod) influence_2\NN\5190804|the|possible|damage|,|development (l_nmod) damage_6\NN\7296428|of|the|hepatic|,|hyperammonemia (l_appos) hyperammonemia_9\NN\1740|mainly
18439803
C108761_D012640 NONE n-(2-propylpentanoyl)urea_3\NN\1740|of (r_nmod) effects_1\NNS\13245626|acute|n-(2-propylpentanoyl)urea|neurotransmitters|seizure|. (l_nmod) seizure_11\NN\14081375|in|pilocarpine-induced|rats
C108761_D012640 NONE vpu_0\NNP\1740| (r_nsubj) potent_3\JJ\1740|vpu|was|more|vpa|,|exhibiting|seizure|. (l_conj) seizure_24\NN\14081375|mg/kg
C108761_D012640 NONE vpu_5\NNP\1740|and|vpa (r_nsubj) protect_9\VB\1127795|that|vpu|could|animals|seizure (l_nmod) seizure_14\JJ\1740|against|pilocarpine-induced
C108761_D012640 NONE vpu_8\NNP\1740| (r_nsubj) reduce_11\VB\441445|that|vpu|could|drastically|increases (r_ccomp) finding_6\NN\43195|the|reduce (r_nsubj) account_19\VB\2604760|therefore|,|vpa|,|finding|should|,|partly|,|activity|. (l_nmod) activity_28\NN\30358|for|its|anticonvulsant|observed (l_acl) observed_29\VBN\2163746|seizure (l_nmod) seizure_32\NN\14081375|in|pilocarpine-induced|animals
D000596_D012640 NONE acid_7\NN\14818238| (r_compound) neurotransmitters_8\NNS\14807410|on|hippocampal|amino|acid (r_nmod) effects_1\NNS\13245626|acute|n-(2-propylpentanoyl)urea|neurotransmitters|seizure|. (l_nmod) seizure_11\NN\14081375|in|pilocarpine-induced|rats
D000596_D012640 NONE acid_24\NN\14818238| (r_compound) neurotransmitters_25\NNS\14807410|of|inhibitory|amino|acid (r_nmod) reduction_20\NN\351485|the|neurotransmitters (r_nsubj) minor_28\JJ\1740|that|reduction|was|comparatively|and|offset (r_ccomp) suggested_17\VBN\1010118|based|it|is|minor|. (l_prep) based_0\VBN\2694933|finding (l_nmod) finding_3\NN\43195|on|the|protect (l_ccomp) protect_9\VB\1127795|that|vpu|could|animals|seizure (l_nmod) seizure_14\JJ\1740|against|pilocarpine-induced
D010862_D012640 CID pilocarpine-induced_10\JJ\1740| (r_amod) seizure_11\NN\14081375|in|pilocarpine-induced|rats
D010862_D012640 CID pilocarpine-induced_23\JJ\1740|against (r_nmod) rats_21\NNS\2329401|pilocarpine-induced (r_dobj) protecting_20\VBG\1127795|in|rats (r_advcl) exhibiting_7\VBG\2632167|dose|protecting (r_advcl) potent_3\JJ\1740|vpu|was|more|vpa|,|exhibiting|seizure|. (l_conj) seizure_24\NN\14081375|mg/kg
D010862_D012640 CID pilocarpine-induced_13\JJ\1740| (r_amod) seizure_14\JJ\1740|against|pilocarpine-induced
D010862_D012640 CID pilocarpine-induced_12\JJ\1740| (r_amod) increases_13\NNS\13576355|pilocarpine-induced|glutamate (r_dobj) reduce_11\VB\441445|that|vpu|could|drastically|increases (r_ccomp) finding_6\NN\43195|the|reduce (r_nsubj) account_19\VB\2604760|therefore|,|vpa|,|finding|should|,|partly|,|activity|. (l_nmod) activity_28\NN\30358|for|its|anticonvulsant|observed (l_acl) observed_29\VBN\2163746|seizure (l_nmod) seizure_32\NN\14081375|in|pilocarpine-induced|animals
D010862_D012640 CID pilocarpine-induced_31\JJ\1740| (r_amod) seizure_32\NN\14081375|in|pilocarpine-induced|animals
D014635_D012640 NONE vpa_5\NN\1740|than (r_nmod) potent_3\JJ\1740|vpu|was|more|vpa|,|exhibiting|seizure|. (l_conj) seizure_24\NN\14081375|mg/kg
D014635_D012640 NONE vpa_30\NN\1740|for (r_nmod) value_28\NN\5856066|the|corresponding|vpa (r_nsubj) mg/kg_33\NN\1740|whereas|value|was|322 (r_nmod) seizure_24\NN\14081375|mg/kg
D014635_D012640 NONE vpa_7\NN\1740| (r_conj) vpu_5\NNP\1740|and|vpa (r_nsubj) protect_9\VB\1127795|that|vpu|could|animals|seizure (l_nmod) seizure_14\JJ\1740|against|pilocarpine-induced
D014635_D012640 NONE vpa_3\NN\1740|like (r_nmod) account_19\VB\2604760|therefore|,|vpa|,|finding|should|,|partly|,|activity|. (l_nmod) activity_28\NN\30358|for|its|anticonvulsant|observed (l_acl) observed_29\VBN\2163746|seizure (l_nmod) seizure_32\NN\14081375|in|pilocarpine-induced|animals
D018698_D012640 NONE glutamate_36\NN\15010703|of|and|aspartate (r_nmod) reduction_34\NN\351485|by|a|pronounced|glutamate (r_nmod) offset_30\VB\2673134|reduction (r_conj) minor_28\JJ\1740|that|reduction|was|comparatively|and|offset (r_ccomp) suggested_17\VBN\1010118|based|it|is|minor|. (l_prep) based_0\VBN\2694933|finding (l_nmod) finding_3\NN\43195|on|the|protect (l_ccomp) protect_9\VB\1127795|that|vpu|could|animals|seizure (l_nmod) seizure_14\JJ\1740|against|pilocarpine-induced
D018698_D012640 NONE glutamate_15\NN\15010703|in|and|aspartate (r_nmod) increases_13\NNS\13576355|pilocarpine-induced|glutamate (r_dobj) reduce_11\VB\441445|that|vpu|could|drastically|increases (r_ccomp) finding_6\NN\43195|the|reduce (r_nsubj) account_19\VB\2604760|therefore|,|vpa|,|finding|should|,|partly|,|activity|. (l_nmod) activity_28\NN\30358|for|its|anticonvulsant|observed (l_acl) observed_29\VBN\2163746|seizure (l_nmod) seizure_32\NN\14081375|in|pilocarpine-induced|animals
D001224_D012640 NONE aspartate_38\VBP\1740| (r_conj) glutamate_36\NN\15010703|of|and|aspartate (r_nmod) reduction_34\NN\351485|by|a|pronounced|glutamate (r_nmod) offset_30\VB\2673134|reduction (r_conj) minor_28\JJ\1740|that|reduction|was|comparatively|and|offset (r_ccomp) suggested_17\VBN\1010118|based|it|is|minor|. (l_prep) based_0\VBN\2694933|finding (l_nmod) finding_3\NN\43195|on|the|protect (l_ccomp) protect_9\VB\1127795|that|vpu|could|animals|seizure (l_nmod) seizure_14\JJ\1740|against|pilocarpine-induced
D001224_D012640 NONE aspartate_17\NN\1740| (r_conj) glutamate_15\NN\15010703|in|and|aspartate (r_nmod) increases_13\NNS\13576355|pilocarpine-induced|glutamate (r_dobj) reduce_11\VB\441445|that|vpu|could|drastically|increases (r_ccomp) finding_6\NN\43195|the|reduce (r_nsubj) account_19\VB\2604760|therefore|,|vpa|,|finding|should|,|partly|,|activity|. (l_nmod) activity_28\NN\30358|for|its|anticonvulsant|observed (l_acl) observed_29\VBN\2163746|seizure (l_nmod) seizure_32\NN\14081375|in|pilocarpine-induced|animals
1720453
D007069_D007674 CID ifosfamide_3\NN\1740| (r_compound) toxicity_5\NN\13576101|of|ifosfamide|renal|children
D007069_C535700 NONE ifosfamide_3\NN\1740| (r_compound) toxicity_5\NN\13576101|of|ifosfamide|renal|children (l_nmod) children_7\NNS\9622049|in|treated (l_acl) treated_8\VBN\2376958|tumors (l_nmod) tumors_12\NNS\14234074|for|malignant|mesenchymal
D007069_C535700 NONE ifosfamide_19\NN\1740| (r_compound) protocol_21\NN\6652242|the|same|ifosfamide|chemotherapy|(|society (r_dobj) received_16\VBN\2210855|who|have|protocol|mmt (r_conj) function_2\NN\13783581|the|renal|children|and|received (l_nmod) children_5\NNS\9622049|of|74|tumors (l_nmod) tumors_9\NNS\14234074|with|malignant|mesenchymal|remission
D007069_C535700 NONE ifosfamide_19\NN\1740| (r_compound) protocol_21\NN\6652242|the|same|ifosfamide|chemotherapy|(|society (l_appos) society_24\NNP\7950920|international|study (l_nmod) study_31\NN\635850|of|pediatric|oncology|malignant|mesenchymal|tumor|84 (l_compound) tumor_30\NNP\14234074|
D007069_C535700 NONE ifosfamide_18\NN\1740|of (r_nmod) efficacy_16\NN\5199286|to|the|ifosfamide (r_nmod) respect_13\NN\5817845|with|efficacy|treatment (l_nmod) treatment_21\NN\654885|in|the|tumors (l_nmod) tumors_24\NNS\14234074|of|mesenchymal|children
D003404_D006030 NONE creatinine_22\NN\1740| (r_compound) clearance_23\NN\5089947|creatinine (r_conj) plasma_6\NN\5398023|and|electrolytes|,|glucosuria|ph|,|osmolarity|,|clearance (l_conj) glucosuria_11\NNS\14267841|,|proteinuria
D003404_D011507 NONE creatinine_22\NN\1740| (r_compound) clearance_23\NN\5089947|creatinine (r_conj) plasma_6\NN\5398023|and|electrolytes|,|glucosuria|ph|,|osmolarity|,|clearance (l_conj) glucosuria_11\NNS\14267841|,|proteinuria (l_conj) proteinuria_13\NN\14299637|,|aminoaciduria|,
D003404_D000608 NONE creatinine_22\NN\1740| (r_compound) clearance_23\NN\5089947|creatinine (r_conj) plasma_6\NN\5398023|and|electrolytes|,|glucosuria|ph|,|osmolarity|,|clearance (l_conj) glucosuria_11\NNS\14267841|,|proteinuria (l_conj) proteinuria_13\NN\14299637|,|aminoaciduria|, (l_conj) aminoaciduria_15\NN\14299637|
D010710_D006030 NONE phosphate_25\NN\15010703| (r_compound) reabsorption_27\NN\13526110|phosphate|tubular|,|microglobulinuria|,|and|lysozymuria (r_conj) measuring_5\VBG\697589|by|plasma|,|reabsorption (l_dobj) plasma_6\NN\5398023|and|electrolytes|,|glucosuria|ph|,|osmolarity|,|clearance (l_conj) glucosuria_11\NNS\14267841|,|proteinuria
D010710_D011507 NONE phosphate_25\NN\15010703| (r_compound) reabsorption_27\NN\13526110|phosphate|tubular|,|microglobulinuria|,|and|lysozymuria (r_conj) measuring_5\VBG\697589|by|plasma|,|reabsorption (l_dobj) plasma_6\NN\5398023|and|electrolytes|,|glucosuria|ph|,|osmolarity|,|clearance (l_conj) glucosuria_11\NNS\14267841|,|proteinuria (l_conj) proteinuria_13\NN\14299637|,|aminoaciduria|,
D010710_D000608 NONE phosphate_25\NN\15010703| (r_compound) reabsorption_27\NN\13526110|phosphate|tubular|,|microglobulinuria|,|and|lysozymuria (r_conj) measuring_5\VBG\697589|by|plasma|,|reabsorption (l_dobj) plasma_6\NN\5398023|and|electrolytes|,|glucosuria|ph|,|osmolarity|,|clearance (l_conj) glucosuria_11\NNS\14267841|,|proteinuria (l_conj) proteinuria_13\NN\14299637|,|aminoaciduria|, (l_conj) aminoaciduria_15\NN\14299637|
D010710_D064420 NONE phosphate_51\NN\15010703| (r_compound) reabsorption_52\NN\13526110|microglobulinuria|phosphate (r_nmod) patients_43\NNS\9898892|five|reabsorption (r_dobj) included_41\VBD\690614|group|patients (r_conj) identified_5\VBN\699815|subsets|were|group|:|patients|;|and|included|. (l_dep) patients_15\NNS\9898892|the|included|four|%|developed (l_acl:relcl) developed_25\VBD\1753788|who|toxicity (l_dobj) toxicity_27\NN\13576101|major|resulting
D010710_D005198 NONE phosphate_51\NN\15010703| (r_compound) reabsorption_52\NN\13526110|microglobulinuria|phosphate (r_nmod) patients_43\NNS\9898892|five|reabsorption (r_dobj) included_41\VBD\690614|group|patients (r_conj) identified_5\VBN\699815|subsets|were|group|:|patients|;|and|included|. (l_dep) patients_15\NNS\9898892|the|included|four|%|developed (l_acl:relcl) developed_25\VBD\1753788|who|toxicity (l_dobj) toxicity_27\NN\13576101|major|resulting (l_acl) resulting_28\VBG\2633881|syndrome (l_nmod) syndrome_32\NN\5870365|in|fanconi|'s|tdfs
D010710_D005198 NONE phosphate_51\NN\15010703| (r_compound) reabsorption_52\NN\13526110|microglobulinuria|phosphate (r_nmod) patients_43\NNS\9898892|five|reabsorption (r_dobj) included_41\VBD\690614|group|patients (r_conj) identified_5\VBN\699815|subsets|were|group|:|patients|;|and|included|. (l_dep) patients_15\NNS\9898892|the|included|four|%|developed (l_acl:relcl) developed_25\VBD\1753788|who|toxicity (l_dobj) toxicity_27\NN\13576101|major|resulting (l_acl) resulting_28\VBG\2633881|syndrome (l_nmod) syndrome_32\NN\5870365|in|fanconi|'s|tdfs (l_appos) tdfs_34\NN\1740|(|)
D007069_D064420 NONE ifosfamide_13\NN\1740|of (r_nmod) g/m2_11\NN\1740|of|60|ifosfamide (r_nmod) dose_8\NN\3740161|with|the|higher|cumulative|g/m2|,|age|,|and|predominance (r_nmod) correlated_3\VBN\2657219|toxicity|was|dose|. (l_nsubjpass) toxicity_1\NN\13576101|severe
D007069_D009369 NONE ifosfamide_13\NN\1740|of (r_nmod) g/m2_11\NN\1740|of|60|ifosfamide (r_nmod) dose_8\NN\3740161|with|the|higher|cumulative|g/m2|,|age|,|and|predominance (l_conj) predominance_29\NN\14441825|a|involvement (l_nmod) involvement_33\NN\1080366|of|vesicoprostatic|tumor (l_compound) tumor_32\NN\14234074|
9245658
D009538_D002318 CID nicotine_3\NN\14712692|of (r_nmod) role_1\NN\719494|the|nicotine|disease|. (l_nmod) disease_7\NN\14061805|in|smoking-related|cardiovascular
D009538_D002318 CID nicotine_0\NN\14712692| (r_nsubj) activates_1\VBZ\1641914|nicotine|system|and|contribute|. (l_conj) contribute_11\VB\126264|way|could|disease (l_nmod) disease_14\NN\14061805|to|cardiovascular
D009538_D050197 CID nicotine_7\NN\14712692| (r_nsubj) play_9\VB\1072262|that|nicotine|could|role|accelerating|,|but|inadequate (l_advcl) accelerating_13\VBG\226566|in|atherosclerosis (l_dobj) atherosclerosis_14\NN\14108324|
D009538_D013927 NONE nicotine_0\NN\14712692| (r_nsubj) appear_3\VB\2604760|nicotine|does|not|enhance|. (l_xcomp) enhance_5\VB\227165|to|thrombosis (l_dobj) thrombosis_6\NN\14100769|humans
9746003
D002220_D004832 CID carbamazepine_3\NN\1740|of|and|vigabatrin (r_nmod) use_1\NN\407535|inappropriate|carbamazepine|seizures|. (l_nmod) seizures_9\NNS\14081375|in|typical|absence
D002220_D004832 CID carbamazepine_0\NNP\1740|and|vigabatrin (r_nsubjpass) contraindicated_4\VBN\872886|carbamazepine|are|seizures|. (l_nmod) seizures_8\NNS\14081375|in|typical|absence
D020888_D004832 CID vigabatrin_5\NN\1740| (r_conj) carbamazepine_3\NN\1740|of|and|vigabatrin (r_nmod) use_1\NN\407535|inappropriate|carbamazepine|seizures|. (l_nmod) seizures_9\NNS\14081375|in|typical|absence
D020888_D004832 CID vigabatrin_2\NN\1740| (r_conj) carbamazepine_0\NNP\1740|and|vigabatrin (r_nsubjpass) contraindicated_4\VBN\872886|carbamazepine|are|seizures|. (l_nmod) seizures_8\NNS\14081375|in|typical|absence
D002220_D009207 CID carbamazepine_9\NN\1740|with (r_nmod) treated_7\VBN\2376958|carbamazepine (r_acl) children_6\NNS\9622049|in|four|treated|and|two|,|resolved (l_conj) two_11\CD\13741022|jerks (l_nmod) jerks_16\NNS\10322238|of|these|developed|myoclonic
D002220_D009207 CID carbamazepine_23\NN\1740|of (r_nmod) withdrawal_21\NN\7206096|on|carbamazepine (r_nmod) resolved_19\VBD\352826|which|withdrawal (r_acl:relcl) children_6\NNS\9622049|in|four|treated|and|two|,|resolved (l_conj) two_11\CD\13741022|jerks (l_nmod) jerks_16\NNS\10322238|of|these|developed|myoclonic
18081909
C026098_D001927 CID levetiracetam_3\NN\1740|by (r_nmod) induced_1\VBN\1627355|levetiracetam (r_acl) encephalopathy_0\NNP\14084880|induced
C026098_D001927 CID levetiracetam_9\NN\1740|of|a|(lev)-induced (l_acl) (lev)-induced_10\NN\1740|encephalopathy (l_advmod) encephalopathy_11\JJ\1740|
C026098_D001927 CID (lev)-induced_10\NN\1740|encephalopathy (l_advmod) encephalopathy_11\JJ\1740|
D014635_D001927 CID valproate_6\VB\1740|to (r_xcomp) added_4\VBN\156601|encephalopathy|valproate|. (l_nsubj) encephalopathy_0\NNP\14084880|induced
C026098_C562694 NONE lev_15\NN\13685678|with|mg|added (r_nmod) treated_13\VBN\2376958|man|was|lev (l_nsubjpass) man_4\NN\9605289|a|28-year-old|suffering (l_acl) suffering_5\VBG\2110220|epilepsy|seizures (l_nmod) epilepsy_8\NN\14085708|from|idiopathic
C026098_D012640 NONE lev_15\NN\13685678|with|mg|added (r_nmod) treated_13\VBN\2376958|man|was|lev (l_nsubjpass) man_4\NN\9605289|a|28-year-old|suffering (l_acl) suffering_5\VBG\2110220|epilepsy|seizures (l_nmod) seizures_11\NNS\14081375|with|generalized
C026098_D012640 NONE lev_5\NN\13685678|of|,|eeg|and|neuropsychological|findings (r_nmod) discontinuation_3\NN\209943|following|lev (r_nmod) improved_11\VBD\126264|outcome|discontinuation|and|seizure|decreased|. (l_conj) seizure_13\JJ\1740|frequency
D014635_C562694 NONE valproate_22\VB\1740|to|vpa|mg (r_xcomp) added_20\VBN\156601|valproate (r_acl) lev_15\NN\13685678|with|mg|added (r_nmod) treated_13\VBN\2376958|man|was|lev (l_nsubjpass) man_4\NN\9605289|a|28-year-old|suffering (l_acl) suffering_5\VBG\2110220|epilepsy|seizures (l_nmod) epilepsy_8\NN\14085708|from|idiopathic
D014635_C562694 NONE vpa_24\NN\1740|(|) (r_appos) valproate_22\VB\1740|to|vpa|mg (r_xcomp) added_20\VBN\156601|valproate (r_acl) lev_15\NN\13685678|with|mg|added (r_nmod) treated_13\VBN\2376958|man|was|lev (l_nsubjpass) man_4\NN\9605289|a|28-year-old|suffering (l_acl) suffering_5\VBG\2110220|epilepsy|seizures (l_nmod) epilepsy_8\NN\14085708|from|idiopathic
D014635_D012640 NONE valproate_22\VB\1740|to|vpa|mg (r_xcomp) added_20\VBN\156601|valproate (r_acl) lev_15\NN\13685678|with|mg|added (r_nmod) treated_13\VBN\2376958|man|was|lev (l_nsubjpass) man_4\NN\9605289|a|28-year-old|suffering (l_acl) suffering_5\VBG\2110220|epilepsy|seizures (l_nmod) seizures_11\NNS\14081375|with|generalized
D014635_D012640 NONE vpa_24\NN\1740|(|) (r_appos) valproate_22\VB\1740|to|vpa|mg (r_xcomp) added_20\VBN\156601|valproate (r_acl) lev_15\NN\13685678|with|mg|added (r_nmod) treated_13\VBN\2376958|man|was|lev (l_nsubjpass) man_4\NN\9605289|a|28-year-old|suffering (l_acl) suffering_5\VBG\2110220|epilepsy|seizures (l_nmod) seizures_11\NNS\14081375|with|generalized
20520283
C522667_D012559 NONE asenapine_4\NN\1740|of (r_nmod) efficacy_0\NNP\5199286|and|safety|asenapine|trial|. (l_nmod) trial_10\NN\786195|in|a|placebo-|patients (l_nmod) patients_12\NNS\9898892|in|exacerbation (l_nmod) exacerbation_15\NN\374224|with|acute|schizophrenia (l_nmod) schizophrenia_17\NN\14398067|of
C522667_D012559 NONE asenapine_0\NNP\1740| (r_nsubjpass) approved_2\VBN\803325|asenapine|is|administration|. (l_nmod) administration_8\NNP\1133281|by|the|food|adults (l_nmod) adults_10\NNS\7846|in|treatment (l_nmod) treatment_13\NN\654885|for|acute|schizophrenia (l_nmod) schizophrenia_15\NN\14398067|of|or|episodes
C522667_D012559 NONE asenapine_18\NN\1740|with (r_nmod) treatment_16\NN\654885|to|fixed-dose|asenapine (r_nmod) assigned_13\VBN\2475922|trial|patients|were|randomly|treatment|mg|daily|,|asenapine|. (l_nsubjpass) patients_7\NNS\9898892|458|schizophrenia (l_nmod) schizophrenia_10\NN\14398067|with|acute
C522667_D012559 NONE asenapine_28\NN\1740|bid|haloperidol (r_conj) assigned_13\VBN\2475922|trial|patients|were|randomly|treatment|mg|daily|,|asenapine|. (l_nsubjpass) patients_7\NNS\9898892|458|schizophrenia (l_nmod) schizophrenia_10\NN\14398067|with|acute
D006220_D012559 NONE haloperidol-controlled_9\JJ\1740| (r_conj) placebo-_7\NN\1740|and|haloperidol-controlled (r_amod) trial_10\NN\786195|in|a|placebo-|patients (l_nmod) patients_12\NNS\9898892|in|exacerbation (l_nmod) exacerbation_15\NN\374224|with|acute|schizophrenia (l_nmod) schizophrenia_17\NN\14398067|of
D006220_D012559 NONE haloperidol_37\VB\1740|bid (r_conj) asenapine_28\NN\1740|bid|haloperidol (r_conj) assigned_13\VBN\2475922|trial|patients|were|randomly|treatment|mg|daily|,|asenapine|. (l_nsubjpass) patients_7\NNS\9898892|458|schizophrenia (l_nmod) schizophrenia_10\NN\14398067|with|acute
C522667_D001714 NONE asenapine_0\NNP\1740| (r_nsubjpass) approved_2\VBN\803325|asenapine|is|administration|. (l_nmod) administration_8\NNP\1133281|by|the|food|adults (l_nmod) adults_10\NNS\7846|in|treatment (l_nmod) treatment_13\NN\654885|for|acute|schizophrenia (l_nmod) schizophrenia_15\NN\14398067|of|or|episodes (l_conj) episodes_21\NNS\7283608|of|manic|associated (l_amod) manic_18\JJ\1740|or|mixed
C522667_D001714 NONE asenapine_0\NNP\1740| (r_nsubjpass) approved_2\VBN\803325|asenapine|is|administration|. (l_nmod) administration_8\NNP\1133281|by|the|food|adults (l_nmod) adults_10\NNS\7846|in|treatment (l_nmod) treatment_13\NN\654885|for|acute|schizophrenia (l_nmod) schizophrenia_15\NN\14398067|of|or|episodes (l_conj) episodes_21\NNS\7283608|of|manic|associated (l_acl) associated_22\VBN\628491|disorder|features (l_nmod) disorder_26\NN\14034177|with|bipolar|i
C522667_D011618 NONE asenapine_0\NNP\1740| (r_nsubjpass) approved_2\VBN\803325|asenapine|is|administration|. (l_nmod) administration_8\NNP\1133281|by|the|food|adults (l_nmod) adults_10\NNS\7846|in|treatment (l_nmod) treatment_13\NN\654885|for|acute|schizophrenia (l_nmod) schizophrenia_15\NN\14398067|of|or|episodes (l_conj) episodes_21\NNS\7283608|of|manic|associated (l_acl) associated_22\VBN\628491|disorder|features (l_nmod) features_31\NNS\5849040|with|psychotic (l_amod) psychotic_30\JJ\1740|
C522667_D001480 CID asenapine_21\NN\1740|of|the (r_nmod) %_18\NN\1740|10|asenapine|bid|,|respectively (r_conj) reported_2\VBN\831651|symptoms|aes|occurred|%|. (l_nsubj) symptoms_1\NNS\5823932|extrapyramidal
C522667_D001480 CID asenapine_9\NN\1740|with|and|haloperidol (r_nmod) similar_7\JJ\1740|that|efficacy|was|asenapine (r_ccomp) indicated_3\VBD\952524|analyses|similar|;|seen|. (l_parataxis) seen_16\VBN\2106506|contrasts|were|aes (l_nmod) aes_18\NNS\1740|in|,|symptoms (l_appos) symptoms_22\NNS\5823932|extrapyramidal
D006220_D001480 CID haloperidol_29\VB\1740| (r_conj) bid_27\NN\7160883|at|mg|,|haloperidol|,|and|groups (r_nmod) %_18\NN\1740|10|asenapine|bid|,|respectively (r_conj) reported_2\VBN\831651|symptoms|aes|occurred|%|. (l_nsubj) symptoms_1\NNS\5823932|extrapyramidal
D006220_D001480 CID haloperidol_11\VB\1740| (r_conj) asenapine_9\NN\1740|with|and|haloperidol (r_nmod) similar_7\JJ\1740|that|efficacy|was|asenapine (r_ccomp) indicated_3\VBD\952524|analyses|similar|;|seen|. (l_parataxis) seen_16\VBN\2106506|contrasts|were|aes (l_nmod) aes_18\NNS\1740|in|,|symptoms (l_appos) symptoms_22\NNS\5823932|extrapyramidal
7504976
D002231_D056486 CID carbimazole_14\NN\1740|between|and|benzylthiouracil (r_nmod) cross-reactivity_12\NN\1740|with|carbimazole (r_nmod) one_10\CD\13741022|including|cross-reactivity (r_nmod) cases_8\NNS\7283608|four|one (r_dep) hepatitis_1\NN\14127211|toxic|induced|:|cases|.
D002231_D056486 CID carbimazole_8\NN\1740|by|omercazole (r_nmod) induced_6\VBN\1627355|carbimazole (r_acl) hepatitis_5\NN\14127211|a|cholestatic|induced
D002231_D056486 CID omercazole_11\NN\1740|(|n|) (r_appos) carbimazole_8\NN\1740|by|omercazole (r_nmod) induced_6\VBN\1627355|carbimazole (r_acl) hepatitis_5\NN\14127211|a|cholestatic|induced
D002231_D056486 CID carbimazole_12\NN\1740|following (r_nmod) had_2\VBD\2108377|others|hepatitis|carbimazole|. (l_dobj) hepatitis_10\NN\14127211|a|mixed
D002231_D056486 CID carbimazole_21\NN\1740| (r_dobj) replaced_20\VBN\1631072|had|carbimazole (r_conj) experienced_7\VBD\2108377|one|further|hepatitis|replaced|. (l_dobj) hepatitis_10\NN\14127211|a|cytolytic|appeared|)
C019269_D056486 NONE benzylthiouracil_16\NN\1740| (r_conj) carbimazole_14\NN\1740|between|and|benzylthiouracil (r_nmod) cross-reactivity_12\NN\1740|with|carbimazole (r_nmod) one_10\CD\13741022|including|cross-reactivity (r_nmod) cases_8\NNS\7283608|four|one (r_dep) hepatitis_1\NN\14127211|toxic|induced|:|cases|.
C019269_D056486 NONE benzylthiouracil_14\NNP\1740|after|(|ne (r_nmod) appeared_12\VBD\2604760|which|benzylthiouracil (r_acl:relcl) hepatitis_10\NN\14127211|a|cytolytic|appeared|)
C019269_D056486 NONE ne_17\NN\14622893|basd (r_appos) benzylthiouracil_14\NNP\1740|after|(|ne (r_nmod) appeared_12\VBD\2604760|which|benzylthiouracil (r_acl:relcl) hepatitis_10\NN\14127211|a|cytolytic|appeared|)
D002231_D002779 CID carbimazole_8\NN\1740|by|omercazole (r_nmod) induced_6\VBN\1627355|carbimazole (r_acl) hepatitis_5\NN\14127211|a|cholestatic|induced
D002231_D002779 CID omercazole_11\NN\1740|(|n|) (r_appos) carbimazole_8\NN\1740|by|omercazole (r_nmod) induced_6\VBN\1627355|carbimazole (r_acl) hepatitis_5\NN\14127211|a|cholestatic|induced
D002231_D002779 CID carbimazole_12\NN\1740|following (r_nmod) had_2\VBD\2108377|others|hepatitis|carbimazole|. (l_dobj) hepatitis_10\NN\14127211|a|mixed (l_amod) mixed_4\JJ\1740|cholestatic (l_dep) cholestatic_6\JJ\1740|(|and|cytolytic|)
11007689
D016572_D057049 CID cyclosporine_0\NN\1740|and|tacrolimus-associated (r_amod) microangiopathy_4\NN\1740|cyclosporine|thrombotic|.
D016572_D057049 CID cyclosporine_13\NN\1740|of (r_nmod) use_11\NN\407535|with|the|cyclosporine (r_nmod) associated_8\VBN\628491|use (r_acl) microangiopathy_4\NN\1740|of|thrombotic|tma|associated
D016572_D057049 CID cyclosporine_13\NN\1740|of (r_nmod) use_11\NN\407535|with|the|cyclosporine (r_nmod) associated_8\VBN\628491|use (r_acl) microangiopathy_4\NN\1740|of|thrombotic|tma|associated (l_appos) tma_6\NN\1740|(|)
D016572_D057049 CID cyclosporine-induced_20\JJ\1740| (r_amod) tma_21\NN\1740|of|cyclosporine-induced
D016572_D057049 CID cyclosporine_16\NN\1740|to|and|tacrolimus (r_nmod) exposed_13\VBN\2110927|sequentially|cyclosporine (r_acl) patients_12\NNS\9898892|in|exposed (r_nmod) recurrence_8\NN\7342049|of|the|tma|patients (l_nmod) tma_10\NN\1740|of
D016572_D057049 CID cyclosporine-induced_13\JJ\1740| (r_amod) tma_14\NN\1740|cyclosporine-induced|responded
D016572_D057049 CID cyclosporine_21\NN\1740|of (r_nmod) withdrawal_19\NN\7206096|to|the|cyclosporine (r_nmod) responded_16\VBD\2367363|that|withdrawal|conjunction (r_acl:relcl) tma_14\NN\1740|cyclosporine-induced|responded
D016572_D057049 CID cyclosporine_5\NN\1740|from (r_nmod) switched_3\VBN\138508|who|are|cyclosporine|tacrolimus (r_acl:relcl) patients_0\NNS\9898892|switched (r_nsubjpass) monitored_14\VBN\2169352|patients|versa|should|be|closely|signs|. (l_nmod) signs_17\NNS\6643763|for|the|and|symptoms|tma (l_nmod) tma_22\NN\1740|of|recurrent
D016559_D057049 CID tacrolimus-associated_2\JJ\1740| (r_conj) cyclosporine_0\NN\1740|and|tacrolimus-associated (r_amod) microangiopathy_4\NN\1740|cyclosporine|thrombotic|.
D016559_D057049 CID tacrolimus_6\NN\1740|to (r_nmod) switching_4\NN\191142|tacrolimus (r_nsubjpass) reported_9\VBN\831651|result|,|switching|has|been|option|. (l_xcomp) option_15\NN\6480506|to|be|a|viable|therapeutic|setting (l_nmod) setting_18\NN\8567235|in|the|tma (l_nmod) tma_21\NN\1740|of|cyclosporine-induced
D016559_D057049 CID tacrolimus_6\NN\1740|of (r_nmod) application_4\NN\947128|with|the|widespread|tacrolimus|transplantation (r_nmod) recognized_16\VBN\686447|application|,|tma|has|also|been|. (l_nsubjpass) tma_12\NN\1740|tacrolimus-associated
D016559_D057049 CID tacrolimus-associated_11\JJ\1740| (r_amod) tma_12\NN\1740|tacrolimus-associated
D016559_D057049 CID tacrolimus_18\NN\1740| (r_conj) cyclosporine_16\NN\1740|to|and|tacrolimus (r_nmod) exposed_13\VBN\2110927|sequentially|cyclosporine (r_acl) patients_12\NNS\9898892|in|exposed (r_nmod) recurrence_8\NN\7342049|of|the|tma|patients (l_nmod) tma_10\NN\1740|of
D016559_D057049 CID tacrolimus_2\NN\1740|of (r_nmod) introduction_0\NN\235435|tacrolimus|agent (r_nsubj) resulted_8\VBD\2633881|introduction|recurrence|. (l_nmod) recurrence_11\NN\7342049|in|the|tma|and|loss (l_nmod) tma_13\NN\1740|of
D016559_D057049 CID tacrolimus_7\NN\1740|to|or (r_nmod) switched_3\VBN\138508|who|are|cyclosporine|tacrolimus (r_acl:relcl) patients_0\NNS\9898892|switched (r_nsubjpass) monitored_14\VBN\2169352|patients|versa|should|be|closely|signs|. (l_nmod) signs_17\NNS\6643763|for|the|and|symptoms|tma (l_nmod) tma_22\NN\1740|of|recurrent
8682684
D000082_D007022 CID acetaminophen-induced_0\JJ\1740| (r_amod) hypotension_1\NN\14057371|acetaminophen-induced|.
D000082_D007022 CID acetaminophen_2\RB\1740| (r_nsubjpass) demonstrated_5\VBN\2137132|however|,|acetaminophen|has|been|produce|. (l_xcomp) produce_7\VB\1617192|to|symptoms|,|individuals (l_dobj) symptoms_8\NNS\5823932|anaphylaxis|,|hypotension (l_nmod) hypotension_13\NN\14057371|including
D000082_D007022 CID acetaminophen_18\NN\2707683|of (r_nmod) administration_16\NN\1133281|after|acetaminophen (r_nmod) developed_14\VBD\1753788|whom|episodes|reproducibly|administration (l_nsubj) episodes_10\NNS\7283608|transient|hypotension (l_nmod) hypotension_12\NN\14057371|of
D000082_D007022 CID acetaminophen_9\NN\2707683| (r_dobj) consider_8\VB\689344|for|clinicians|to|acetaminophen|patients (l_nmod) patients_11\NNS\9898892|in|hypotension (l_nmod) hypotension_13\NN\14057371|with|origin
D000082_D002318 NONE acetaminophen_3\NN\2707683|for|produce (l_acl) produce_5\VB\1617192|to|toxicities (l_dobj) toxicities_7\NNS\13576101|cardiovascular
D000082_D000707 NONE acetaminophen_2\RB\1740| (r_nsubjpass) demonstrated_5\VBN\2137132|however|,|acetaminophen|has|been|produce|. (l_xcomp) produce_7\VB\1617192|to|symptoms|,|individuals (l_dobj) symptoms_8\NNS\5823932|anaphylaxis|,|hypotension (l_nmod) anaphylaxis_10\NN\14533203|of
D000082_D016638 NONE acetaminophen_18\NN\2707683|of (r_nmod) administration_16\NN\1133281|after|acetaminophen (r_nmod) developed_14\VBD\1753788|whom|episodes|reproducibly|administration (r_acl:relcl) patients_6\NNS\9898892|two|ill|developed (l_amod) ill_5\JJ\1740|critically
15737522
D002443_D001660 CID ceftriaxone-associated_0\JJ\1740| (r_amod) pseudolithiasis_2\NN\1740|ceftriaxone-associated|biliary|patients|.
D002443_D001660 CID ceftriaxone_5\NN\2996840| (r_nsubj) leads_6\VBZ\1752884|that|ceftriaxone|pseudolithiasis (l_nmod) pseudolithiasis_8\NN\1740|to|patients
D002443_D001660 CID ceftriaxone_19\NN\2996840| (r_compound) treatment_20\NN\654885|ceftriaxone|,|had (r_dobj) receiving_18\VBG\2210855|treatment (r_acl) patients_17\NNS\9898892|in|paediatric|surgical|receiving (r_nmod) incidence_8\NN\13821570|the|and|importance|pseudolithiasis|patients (l_nmod) pseudolithiasis_13\NN\1740|of
19767176
C020972_D013226 NONE dithiocarbamate_1\NN\1740|pyrrolidine (r_nsubj) protects_2\VBZ\1127795|dithiocarbamate|cortex|model|. (l_nmod) model_11\NN\5888929|in|the|pilocarpine|status|epilepticus (l_compound) epilepticus_10\NN\1740|
C020972_D013226 NONE pdtc_3\NN\1740|of (r_nmod) effect_1\NN\34213|the|pdtc|loss|cortex (l_nmod) loss_8\NN\13252973|on|status|epilepticus-associated|cell (l_amod) epilepticus-associated_6\JJ\1740|
C020972_D013226 NONE pdtc_4\NN\1740|with|150|mg/kg (r_nmod) treatment_0\NN\654885|pdtc|before|epilepticus (l_nmod) epilepticus_9\NN\1740|following|status
C020972_D013226 NONE pdtc_4\NN\1740|of|50|mg/kg (r_nmod) administration_0\NN\1133281|pdtc|low-dose (r_nsubj) exert_10\VB\1158872|administration|did|not|effects|. (l_dobj) effects_12\NNS\13245626|major|development (l_nmod) development_15\NN\248977|on|the|epilepticus|or|rate (l_nmod) epilepticus_19\NN\1740|of|a|status
C020972_D013226 NONE pdtc-treated_16\JJ\1740| (r_conj) vehicle-_14\NN\1740|in|and|pdtc-treated|rats (r_nmod) identified_12\VBN\699815|decrease|was|vehicle-|epilepticus|. (l_nmod) epilepticus_20\NN\1740|following|status
D010862_D013226 CID pilocarpine_8\NN\14712692| (r_compound) model_11\NN\5888929|in|the|pilocarpine|status|epilepticus (l_compound) epilepticus_10\NN\1740|
D010862_D013226 CID pilocarpine_21\NN\14712692| (r_compound) model_22\NN\5888929|pilocarpine (r_dobj) fractionated_20\VBD\1458973|in|the|rat|model (r_advcl) evaluated_16\VBN\670261|effect|was|fractionated|. (l_nsubjpass) effect_1\NN\34213|the|pdtc|loss|cortex (l_nmod) loss_8\NN\13252973|on|status|epilepticus-associated|cell (l_amod) epilepticus-associated_6\JJ\1740|
D010100_D009410 NONE oxygen_5\NN\14622893| (r_compound) species_6\NNS\7992450|of|reactive|oxygen|as (r_nmod) production_2\NN\30358|species|activation (r_nsubjpass) implicated_15\VBN\2677097|both|,|production|have|been|damage|. (l_nmod) damage_19\NN\7296428|in|severe|neuronal|sub-regions|as|cortices
D010100_D009410 NONE oxygen_9\NN\14622893| (r_compound) species_10\NNS\7992450|of|reactive|oxygen|and|activation (r_nmod) generation_6\NN\7942152|the|species (r_nsubj) plays_15\VBZ\1072262|that|generation|role|damage|compared (l_nmod) damage_23\NN\7296428|in|seizure-associated|neuronal|cortex
C020972_D009410 NONE pdtc_8\NN\1740|antioxidant (r_conj) inhibitor_5\NN\20090|the|nf-kappab|and|pdtc (r_nsubj) protected_9\VBD\1127795|conclusion|,|inhibitor|cortex|,|affect|. (l_advcl) affect_18\VB\126264|whereas|it|did|not|loss (l_dobj) loss_21\NN\13252973|hilar|neuronal
D010100_D012640 NONE oxygen_9\NN\14622893| (r_compound) species_10\NNS\7992450|of|reactive|oxygen|and|activation (r_nmod) generation_6\NN\7942152|the|species (r_nsubj) plays_15\VBZ\1072262|that|generation|role|damage|compared (l_nmod) damage_23\NN\7296428|in|seizure-associated|neuronal|cortex (l_amod) seizure-associated_21\JJ\1740|
10193204
C009438_D013927 NONE tetrandrine_2\NN\1740|of|and|fangchinoline (r_nmod) effects_0\NNS\13245626|tetrandrine|thrombosis|. (l_nmod) thrombosis_7\NN\14100769|on|experimental|mice
C009438_D013927 NONE tet_10\NN\15157225|of|and|fan (r_nmod) effects_8\NNS\13245626|the|tet|thrombosis (l_nmod) thrombosis_16\NN\14100769|on|the|experimental|induced
C009438_D013927 NONE tet_15\NN\15157225|of|and|fan (r_nmod) administration_7\NN\1133281|the|mg/kg|tet|mice (r_nsubj) showed_20\VBD\2137132|study|,|administration|inhibition|,|respectively|,|showed|. (l_dobj) inhibition_22\NN\1068773|the|thrombosis|% (l_nmod) thrombosis_24\NN\14100769|of
C009438_D001791 NONE tetrandrine_2\NN\1740|of|and|fangchinoline (r_nmod) effects_0\NNS\13245626|tetrandrine|thrombosis|. (l_nmod) thrombosis_7\NN\14100769|on|experimental|mice (l_nmod) mice_9\NNS\2329401|in|and|aggregation (l_conj) aggregation_13\NN\31264|human|platelet
C009438_D001791 NONE tet_10\NN\15157225|of|and|fan (r_nmod) effects_8\NNS\13245626|the|tet|thrombosis (r_dobj) investigate_6\VB\644583|to|effects (r_xcomp) undertaken_4\VBN\1641914|study|was|investigate|,|and|aggregation|. (l_conj) aggregation_30\NN\31264|platelet|and|coagulation|vitro
C009438_D001791 NONE tet_14\NN\15157225|and|fan (r_conj) tests_12\NNS\5798043|in|,|tet (r_nmod) used_10\VBN\1156834|tests (r_acl) agonists_9\NNS\9613191|by|the|used (r_nmod) induced_6\VBN\1627355|agonists (r_acl) aggregations_5\NNS\31264|in|the|vitro|human|platelet|induced
C060802_D013927 NONE fangchinoline_4\NN\1740| (r_conj) tetrandrine_2\NN\1740|of|and|fangchinoline (r_nmod) effects_0\NNS\13245626|tetrandrine|thrombosis|. (l_nmod) thrombosis_7\NN\14100769|on|experimental|mice
C060802_D013927 NONE fan_12\NN\3183080| (r_conj) tet_10\NN\15157225|of|and|fan (r_nmod) effects_8\NNS\13245626|the|tet|thrombosis (l_nmod) thrombosis_16\NN\14100769|on|the|experimental|induced
C060802_D013927 NONE fan_17\NN\3183080| (r_conj) tet_15\NN\15157225|of|and|fan (r_nmod) administration_7\NN\1133281|the|mg/kg|tet|mice (r_nsubj) showed_20\VBD\2137132|study|,|administration|inhibition|,|respectively|,|showed|. (l_dobj) inhibition_22\NN\1068773|the|thrombosis|% (l_nmod) thrombosis_24\NN\14100769|of
C060802_D001791 NONE fangchinoline_4\NN\1740| (r_conj) tetrandrine_2\NN\1740|of|and|fangchinoline (r_nmod) effects_0\NNS\13245626|tetrandrine|thrombosis|. (l_nmod) thrombosis_7\NN\14100769|on|experimental|mice (l_nmod) mice_9\NNS\2329401|in|and|aggregation (l_conj) aggregation_13\NN\31264|human|platelet
C060802_D001791 NONE fan_12\NN\3183080| (r_conj) tet_10\NN\15157225|of|and|fan (r_nmod) effects_8\NNS\13245626|the|tet|thrombosis (r_dobj) investigate_6\VB\644583|to|effects (r_xcomp) undertaken_4\VBN\1641914|study|was|investigate|,|and|aggregation|. (l_conj) aggregation_30\NN\31264|platelet|and|coagulation|vitro
C060802_D001791 NONE fan_16\NN\3183080| (r_conj) tet_14\NN\15157225|and|fan (r_conj) tests_12\NNS\5798043|in|,|tet (r_nmod) used_10\VBN\1156834|tests (r_acl) agonists_9\NNS\9613191|by|the|used (r_nmod) induced_6\VBN\1627355|agonists (r_acl) aggregations_5\NNS\31264|in|the|vitro|human|platelet|induced
C009438_D001778 NONE tet_10\NN\15157225|of|and|fan (r_nmod) effects_8\NNS\13245626|the|tet|thrombosis (r_dobj) investigate_6\VB\644583|to|effects (r_xcomp) undertaken_4\VBN\1641914|study|was|investigate|,|and|aggregation|. (l_conj) aggregation_30\NN\31264|platelet|and|coagulation|vitro (l_conj) coagulation_33\NN\13518963|blood
C060802_D001778 NONE fan_12\NN\3183080| (r_conj) tet_10\NN\15157225|of|and|fan (r_nmod) effects_8\NNS\13245626|the|tet|thrombosis (r_dobj) investigate_6\VB\644583|to|effects (r_xcomp) undertaken_4\VBN\1641914|study|was|investigate|,|and|aggregation|. (l_conj) aggregation_30\NN\31264|platelet|and|coagulation|vitro (l_conj) coagulation_33\NN\13518963|blood
D004837_D013927 CID epinephrine_21\NN\14807929|ep (r_conj) collagen_19\NN\15026716|by|plus|epinephrine|mice (r_nmod) induced_17\VBN\1627355|collagen (r_acl) thrombosis_16\NN\14100769|on|the|experimental|induced
D004837_D013927 CID ep_23\NN\1740|(|) (r_appos) epinephrine_21\NN\14807929|ep (r_conj) collagen_19\NN\15026716|by|plus|epinephrine|mice (r_nmod) induced_17\VBN\1627355|collagen (r_acl) thrombosis_16\NN\14100769|on|the|experimental|induced
D004837_D001791 NONE epinephrine_21\NN\14807929|ep (r_conj) collagen_19\NN\15026716|by|plus|epinephrine|mice (r_nmod) induced_17\VBN\1627355|collagen (r_acl) thrombosis_16\NN\14100769|on|the|experimental|induced (r_nmod) effects_8\NNS\13245626|the|tet|thrombosis (r_dobj) investigate_6\VB\644583|to|effects (r_xcomp) undertaken_4\VBN\1641914|study|was|investigate|,|and|aggregation|. (l_conj) aggregation_30\NN\31264|platelet|and|coagulation|vitro
D004837_D001791 NONE ep_23\NN\1740|(|) (r_appos) epinephrine_21\NN\14807929|ep (r_conj) collagen_19\NN\15026716|by|plus|epinephrine|mice (r_nmod) induced_17\VBN\1627355|collagen (r_acl) thrombosis_16\NN\14100769|on|the|experimental|induced (r_nmod) effects_8\NNS\13245626|the|tet|thrombosis (r_dobj) investigate_6\VB\644583|to|effects (r_xcomp) undertaken_4\VBN\1641914|study|was|investigate|,|and|aggregation|. (l_conj) aggregation_30\NN\31264|platelet|and|coagulation|vitro
D004837_D001778 NONE epinephrine_21\NN\14807929|ep (r_conj) collagen_19\NN\15026716|by|plus|epinephrine|mice (r_nmod) induced_17\VBN\1627355|collagen (r_acl) thrombosis_16\NN\14100769|on|the|experimental|induced (r_nmod) effects_8\NNS\13245626|the|tet|thrombosis (r_dobj) investigate_6\VB\644583|to|effects (r_xcomp) undertaken_4\VBN\1641914|study|was|investigate|,|and|aggregation|. (l_conj) aggregation_30\NN\31264|platelet|and|coagulation|vitro (l_conj) coagulation_33\NN\13518963|blood
D004837_D001778 NONE ep_23\NN\1740|(|) (r_appos) epinephrine_21\NN\14807929|ep (r_conj) collagen_19\NN\15026716|by|plus|epinephrine|mice (r_nmod) induced_17\VBN\1627355|collagen (r_acl) thrombosis_16\NN\14100769|on|the|experimental|induced (r_nmod) effects_8\NNS\13245626|the|tet|thrombosis (r_dobj) investigate_6\VB\644583|to|effects (r_xcomp) undertaken_4\VBN\1641914|study|was|investigate|,|and|aggregation|. (l_conj) aggregation_30\NN\31264|platelet|and|coagulation|vitro (l_conj) coagulation_33\NN\13518963|blood
D001241_D013927 NONE acid_36\NN\14818238|acetylsalicylic|asa|,|control|, (r_nsubj) showed_50\VBD\2137132|while|acid|inhibition (r_advcl) showed_20\VBD\2137132|study|,|administration|inhibition|,|respectively|,|showed|. (l_dobj) inhibition_22\NN\1068773|the|thrombosis|% (l_nmod) thrombosis_24\NN\14100769|of
D001241_D013927 NONE asa_38\NN\1740|(|,|mg/kg|,|i.p.|) (r_dep) acid_36\NN\14818238|acetylsalicylic|asa|,|control|, (r_nsubj) showed_50\VBD\2137132|while|acid|inhibition (r_advcl) showed_20\VBD\2137132|study|,|administration|inhibition|,|respectively|,|showed|. (l_dobj) inhibition_22\NN\1068773|the|thrombosis|% (l_nmod) thrombosis_24\NN\14100769|of
7083920
D000638_D006327 CID amiodarone_11\JJ\1740| (r_amod) treatment_12\NN\654885|under|amiodarone|tachycardia (r_nmod) occurring_9\VBG\2623529|treatment (r_acl) block_8\NN\21939|of|a|reversible|intra-hisian|occurring
D000638_D013617 NONE amiodarone_11\JJ\1740| (r_amod) treatment_12\NN\654885|under|amiodarone|tachycardia (l_nmod) tachycardia_15\NN\14110674|for|atrial|patient
D000638_D006345 NONE amiodarone_11\JJ\1740| (r_amod) treatment_12\NN\654885|under|amiodarone|tachycardia (l_nmod) tachycardia_15\NN\14110674|for|atrial|patient (l_nmod) patient_18\NN\9898892|in|a|abnormalities (l_nmod) abnormalities_23\NNS\14034177|without|clear|intraventricular|conduction
D000638_D001282 NONE amiodarone_3\JJ\1740| (r_amod) discontinuation_4\NN\209943|after|amiodarone (r_nmod) days_1\NNS\15140892|thirty|discontinuation (r_nmod:tmod) showed_9\VBD\2137132|days|,|electrograms|flutter|. (l_dobj) flutter_11\NN\331950|atrial|delay
8558192
C030852_C562729 NONE vinorelbine_4\NN\1740|of (r_nmod) trial_2\NN\786195|phase|vinorelbine|carcinoma|. (l_nmod) carcinoma_10\NN\14239918|in|metastatic|squamous|cell|esophageal
C030852_C562729 NONE vinorelbine_11\NN\1740|of|vnb (r_nmod) effects_9\NNS\13245626|toxic|vinorelbine (r_conj) rate_6\NN\13815152|the|response|and|effects|administered (l_acl) administered_15\VBN\2436349|agent (l_nmod) agent_19\NN\7347|as|a|single|carcinoma (l_nmod) carcinoma_25\NN\14239918|in|metastatic|squamous|cell|esophageal
C030852_C562729 NONE vnb_13\NN\1740|(|) (r_appos) vinorelbine_11\NN\1740|of|vnb (r_nmod) effects_9\NNS\13245626|toxic|vinorelbine (r_conj) rate_6\NN\13815152|the|response|and|effects|administered (l_acl) administered_15\VBN\2436349|agent (l_nmod) agent_19\NN\7347|as|a|single|carcinoma (l_nmod) carcinoma_25\NN\14239918|in|metastatic|squamous|cell|esophageal
C030852_C562729 NONE vnb_6\NNP\1740| (r_nsubj) agent_10\NN\7347|that|vnb|is|an|active|carcinoma (l_nmod) carcinoma_16\NN\14239918|in|metastatic|esophageal|squamous|cell
D002945_D064420 NONE cisplatin-based_9\JJ\1740| (r_amod) chemotherapy_10\NN\661091|with|cisplatin-based (r_nmod) pretreated_7\JJ\1740|patients|chemotherapy (r_nsubj) assessable_12\JJ\1740|pretreated|were|toxicity|. (l_nmod) toxicity_14\NN\13576101|for|and|response
C030852_D064420 NONE vnb_0\NNP\1740| (r_nsubjpass) tolerated_3\VBN\802318|vnb|was|well|and|occurred (l_conj) occurred_13\VBD\2623529|instances|. (l_nsubj) instances_6\NNS\7283608|zero|toxicity (l_nmod) toxicity_12\NN\13576101|of|who|grade|4|nonhematologic
C030852_D064420 NONE vnb_12\NN\1740|of (r_nmod) evaluation_10\NN\874067|further|vnb|therapy (r_nsubjpass) warranted_17\VBN\1012073|profile|evaluation|is|. (l_nmod) profile_4\NN\6999802|given|its|excellent|tolerance|and|toxicity|, (l_conj) toxicity_7\NN\13576101|low
19299179
D015662_D002779 NONE co-trimoxazole_7\NN\1740| (r_compound) treatment_8\NN\654885|after|high-dose|co-trimoxazole|pneumonia (r_nmod) cholestasis_4\NN\14052403|severe|lasting|treatment|--|report|.
D015662_D011020 NONE co-trimoxazole_7\NN\1740| (r_compound) treatment_8\NN\654885|after|high-dose|co-trimoxazole|pneumonia (l_nmod) pneumonia_11\NN\14145095|for|pneumocystis|patients
D015662_D011020 NONE co-trimoxazole_21\NN\1740|of (r_nmod) doses_19\NNS\3740161|with|high|co-trimoxazole (r_nmod) treated_16\VBN\2376958|pneumonia|is|generally|doses|. (l_nsubjpass) pneumonia_1\NN\14145095|pneumocystis|pcp|,|infection|,
D015662_D011020 NONE co-trimoxazole_21\NN\1740|of (r_nmod) doses_19\NNS\3740161|with|high|co-trimoxazole (r_nmod) treated_16\VBN\2376958|pneumonia|is|generally|doses|. (l_nsubjpass) pneumonia_1\NN\14145095|pneumocystis|pcp|,|infection|, (l_appos) pcp_3\NN\10480253|(|)
D015662_D011020 NONE co-trimoxazole_31\NN\1740| (r_compound) treatment_32\NN\654885|during|co-trimoxazole|pcp (l_nmod) pcp_34\NN\10480253|for
D015662_D015658 NONE co-trimoxazole_7\NN\1740| (r_compound) treatment_8\NN\654885|after|high-dose|co-trimoxazole|pneumonia (l_nmod) pneumonia_11\NN\14145095|for|pneumocystis|patients (l_nmod) patients_14\NNS\9898892|in|hiv-infected (l_amod) hiv-infected_13\JJ\1740|
D015662_D015658 NONE co-trimoxazole_21\NN\1740|of (r_nmod) doses_19\NNS\3740161|with|high|co-trimoxazole (r_nmod) treated_16\VBN\2376958|pneumonia|is|generally|doses|. (l_nsubjpass) pneumonia_1\NN\14145095|pneumocystis|pcp|,|infection|, (l_appos) infection_9\NN\14052046|a|common|opportunistic|individuals (l_nmod) individuals_12\NNS\7347|in|hiv-infected (l_amod) hiv-infected_11\JJ\1740|
D015662_D015658 NONE co-trimoxazole_31\NN\1740| (r_compound) treatment_32\NN\654885|during|co-trimoxazole|pcp (r_nmod) lesions_21\NNS\14204950|in|one|patient|mimicking|,|treatment (r_conj) report_3\VBP\831651|here|,|we|cases|,|and|lesions|. (l_dobj) cases_5\NNS\7283608|two|patients (l_nmod) patients_10\NNS\9898892|of|immunocompromised|hiv-infected|developed (l_amod) hiv-infected_9\JJ\1740|
D015662_D009894 NONE co-trimoxazole_21\NN\1740|of (r_nmod) doses_19\NNS\3740161|with|high|co-trimoxazole (r_nmod) treated_16\VBN\2376958|pneumonia|is|generally|doses|. (l_nsubjpass) pneumonia_1\NN\14145095|pneumocystis|pcp|,|infection|, (l_appos) infection_9\NN\14052046|a|common|opportunistic|individuals
D015662_D002780 CID co-trimoxazole_31\NN\1740| (r_compound) treatment_32\NN\654885|during|co-trimoxazole|pcp (r_nmod) lesions_21\NNS\14204950|in|one|patient|mimicking|,|treatment (r_conj) report_3\VBP\831651|here|,|we|cases|,|and|lesions|. (l_dobj) cases_5\NNS\7283608|two|patients (l_nmod) patients_10\NNS\9898892|of|immunocompromised|hiv-infected|developed (l_acl:relcl) developed_12\VBD\1753788|who|cholestasis (l_dobj) cholestasis_15\NN\14052403|severe|intrahepatic
D015662_D008100 NONE co-trimoxazole_31\NN\1740| (r_compound) treatment_32\NN\654885|during|co-trimoxazole|pcp (r_nmod) lesions_21\NNS\14204950|in|one|patient|mimicking|,|treatment (l_acl) mimicking_22\VBG\1742886|formation (l_dobj) formation_25\NN\7938773|abscess|exams (l_compound) abscess_24\NN\14299637|liver
19889778
12639165
D013988_D002779 CID ticlopidine-induced_0\JJ\1740| (r_amod) hepatitis_2\NN\14127211|ticlopidine-induced|cholestatic|.
D013988_D002779 CID ticlopidine-induced_7\JJ\1740| (r_amod) hepatitis_9\NN\14127211|of|ticlopidine-induced|cholestatic
D013988_D002779 CID ticlopidine_11\NN\1740| (r_dobj) receiving_10\VBG\2210855|after|ticlopidine|angioplasty (r_advcl) developed_5\VBD\1753788|patients|hepatitis|receiving|,|remission|. (l_dobj) hepatitis_8\NN\14127211|prolonged|cholestatic
D013988_D002779 CID ticlopidine_12\NN\1740|of|the|agent (r_nmod) complication_7\NN\1073995|:|hepatitis|is|a|rare|ticlopidine|; (l_nsubj) hepatitis_3\NN\14127211|cholestatic
D013988_D002779 CID ticlopidine_7\NN\1740|with (r_nmod) treatment_5\NN\654885|following|ticlopidine (r_nmod) developed_2\VBD\1753788|patients|jaundice|treatment|and|showed|. (l_conj) showed_9\VBD\2137132|characteristics (l_dobj) characteristics_14\NNS\5849040|the|clinical|hepatitis|,|resolved (l_nmod) hepatitis_17\NN\14127211|of|cholestatic
D013988_D002779 CID ticlopidine-induced_4\JJ\1740| (r_amod) cholestasis_5\NN\14052403|of|this|ticlopidine-induced
D013988_D002779 CID ticlopidine_10\NN\1740|of|mediated (r_nmod) effect_8\NN\34213|hepatitis|is|a|rare|adverse|ticlopidine (l_nsubj) hepatitis_3\NN\14127211|cholestatic
D013988_D056486 CID ticlopidine-induced_0\JJ\1740| (r_amod) hepatitis_2\NN\14127211|ticlopidine-induced|cholestatic|.
D013988_D056486 CID ticlopidine-induced_7\JJ\1740| (r_amod) hepatitis_9\NN\14127211|of|ticlopidine-induced|cholestatic
D013988_D056486 CID ticlopidine_11\NN\1740| (r_dobj) receiving_10\VBG\2210855|after|ticlopidine|angioplasty (r_advcl) developed_5\VBD\1753788|patients|hepatitis|receiving|,|remission|. (l_dobj) hepatitis_8\NN\14127211|prolonged|cholestatic
D013988_D056486 CID ticlopidine_12\NN\1740|of|the|agent (r_nmod) complication_7\NN\1073995|:|hepatitis|is|a|rare|ticlopidine|; (l_nsubj) hepatitis_3\NN\14127211|cholestatic
D013988_D056486 CID ticlopidine_7\NN\1740|with (r_nmod) treatment_5\NN\654885|following|ticlopidine (r_nmod) developed_2\VBD\1753788|patients|jaundice|treatment|and|showed|. (l_conj) showed_9\VBD\2137132|characteristics (l_dobj) characteristics_14\NNS\5849040|the|clinical|hepatitis|,|resolved (l_nmod) hepatitis_17\NN\14127211|of|cholestatic
D013988_D056486 CID ticlopidine_10\NN\1740|of|mediated (r_nmod) effect_8\NN\34213|hepatitis|is|a|rare|adverse|ticlopidine (l_nsubj) hepatitis_3\NN\14127211|cholestatic
D013988_D007565 CID ticlopidine_7\NN\1740|with (r_nmod) treatment_5\NN\654885|following|ticlopidine (r_nmod) developed_2\VBD\1753788|patients|jaundice|treatment|and|showed|. (l_dobj) jaundice_3\NN\14299637|
12063090
D004177_D003248 NONE metamizol_0\JJ\1740| (r_nsubj) potentiates_1\VBZ\229605|metamizol|antinociception|treatment|. (l_dobj) antinociception_3\NN\1740|morphine|constipation (l_conj) constipation_6\NN\14299637|not
D004177_D003248 NONE metamizol_20\NN\1740|s.c.|acutely|once (r_dep) evaluates_2\VBZ\670261|work|effects|metamizol|rats|. (l_dobj) effects_7\NNS\13245626|the|antinociceptive|combination (l_amod) antinociceptive_4\JJ\1740|and|constipating (l_conj) constipating_6\VBG\440786|
D004177_D003248 NONE metamizol_20\NN\1740| (r_nsubj) potentiate_23\VB\229605|that|metamizol|did|not|constipation (l_dobj) constipation_25\NN\14299637|morphine-induced
D009020_D003248 CID morphine_2\JJ\1740| (r_amod) antinociception_3\NN\1740|morphine|constipation (l_conj) constipation_6\NN\14299637|not
D009020_D003248 CID morphine_15\NN\2707683|of|3.2|mg/kg|s.c. (r_nmod) combination_10\NN\7951464|of|the|morphine (r_nmod) effects_7\NNS\13245626|the|antinociceptive|combination (l_amod) antinociceptive_4\JJ\1740|and|constipating (l_conj) constipating_6\VBG\440786|
D009020_D003248 CID morphine_4\NN\2707683| (r_nsubj) inhibited_5\VBD\2510337|groups|,|morphine|transit|%|treatment|,|respectively|,|suggesting|. (l_advcl) suggesting_23\VBG\1010118|develop (l_ccomp) develop_28\VB\1753788|that|tolerance|did|not|effects (l_nmod) effects_32\NNS\13245626|to|the|constipating (l_amod) constipating_31\VBG\440786|
D009020_D003248 CID morphine_10\NN\2707683|by (r_nmod) produced_8\VBN\1617192|morphine|regardless (r_acl) that_7\DT\1740|to|produced (r_nmod) similar_5\JJ\1740|that (r_amod) transit_4\NN\4365484|intestinal|similar (r_dobj) inhibited_2\VBD\2510337|combination|transit|,|suggesting|. (l_advcl) suggesting_18\VBG\1010118|potentiate (l_ccomp) potentiate_23\VB\229605|that|metamizol|did|not|constipation (l_dobj) constipation_25\NN\14299637|morphine-induced
D009020_D003248 CID morphine-induced_24\JJ\1740| (r_amod) constipation_25\NN\14299637|morphine-induced
D002606_D010146 NONE charcoal_23\NN\14633206| (r_compound) meal_24\NN\7570720|charcoal (r_compound) test_25\NN\5798043|the|meal (r_nsubjpass) used_27\VBN\1156834|test|was|evaluate (r_conj) assessed_8\VBN\670261|day|,|effects|were|using|,|and|used|. (l_xcomp) using_9\VBG\1156834|model (l_dobj) model_11\NN\5888929|a|nociception (l_nmod) nociception_14\NN\1740|of|inflammatory|,|model (l_conj) model_19\NN\5888929|pain-induced|functional|impairment (l_amod) pain-induced_16\JJ\1740|
D009020_D059350 NONE morphine_7\NN\2707683|between|and|metamizol|rats (r_nmod) interaction_5\NN\37396|a|significant|morphine (r_dobj) show_2\VBP\2137132|findings|interaction|,|suggesting|. (l_advcl) suggesting_15\VBG\1010118|useful (l_ccomp) useful_21\JJ\1740|that|combination|could|be|treatment (l_nmod) treatment_24\NN\654885|for|the|pain (l_nmod) pain_27\NN\14299637|of|chronic
D004177_D059350 NONE metamizol_9\JJ\1740| (r_conj) morphine_7\NN\2707683|between|and|metamizol|rats (r_nmod) interaction_5\NN\37396|a|significant|morphine (r_dobj) show_2\VBP\2137132|findings|interaction|,|suggesting|. (l_advcl) suggesting_15\VBG\1010118|useful (l_ccomp) useful_21\JJ\1740|that|combination|could|be|treatment (l_nmod) treatment_24\NN\654885|for|the|pain (l_nmod) pain_27\NN\14299637|of|chronic
9672936
D008614_D012640 CID pethidine-associated_0\JJ\1740| (r_amod) seizure_1\NN\14081375|pethidine-associated|pethidine|.
D008614_D012640 CID pethidine_7\NN\1740|in|a|healthy|adolescent|receiving|control (r_nmod) seizure_1\NN\14081375|pethidine-associated|pethidine|.
D008614_D010149 NONE pethidine-associated_0\JJ\1740| (r_amod) seizure_1\NN\14081375|pethidine-associated|pethidine|. (l_nmod) pethidine_7\NN\1740|in|a|healthy|adolescent|receiving|control (l_nmod) control_11\NN\5190804|for|postoperative|pain (l_compound) pain_10\NN\14299637|
D008614_D010149 NONE pethidine_7\NN\1740|in|a|healthy|adolescent|receiving|control (l_nmod) control_11\NN\5190804|for|postoperative|pain (l_compound) pain_10\NN\14299637|
D008614_D010149 NONE pethidine_9\NN\1740|of (r_nmod) doses_7\NNS\3740161|standard|intermittent|pethidine (r_dobj) received_4\VBD\2210855|male|doses|analgesia|pump|. (l_dobj) pump_17\VBP\1224415|management (l_nmod) management_19\NN\1123598|for|control (l_nmod) control_23\NN\5190804|of|postoperative|pain (l_compound) pain_22\NN\14299637|
1749407
D003042_D009203 CID cocaine-induced_0\JJ\1740| (r_amod) infarction_2\NN\14204950|cocaine-induced|myocardial|:|observations|.
D003042_D009203 CID cocaine_13\NN\3492717| (r_nsubj) result_15\VB\2633881|which|cocaine|may|infarction (l_nmod) infarction_19\NN\14204950|in|acute|myocardial
D003042_D009203 CID cocaine-induced_24\JJ\1740| (r_amod) increase_25\NN\13576355|with|cocaine-induced|product (r_nmod) associated_22\VBN\628491|increase (r_acl) demand_21\NN\6513366|in|myocardial|oxygen|associated (r_nmod) increase_17\NN\13576355|from|an|demand (r_nmod) result_14\VB\2633881|individuals|may|increase|. (l_nmod) individuals_1\NNS\7347|in|preexisting|infarction (l_nmod) infarction_12\NN\14204950|acute|myocardial
D010100_D009203 NONE oxygen_20\NN\14622893| (r_compound) demand_21\NN\6513366|in|myocardial|oxygen|associated (r_nmod) increase_17\NN\13576355|from|an|demand (r_nmod) result_14\VB\2633881|individuals|may|increase|. (l_nmod) individuals_1\NNS\7347|in|preexisting|infarction (l_nmod) infarction_12\NN\14204950|acute|myocardial
D003042_D013035 NONE cocaine-induced_16\JJ\1740| (r_amod) vasoconstriction_17\NN\1149911|of|cocaine-induced (r_nmod) locus_14\NN\8645963|the|vasoconstriction (r_nsubj) remains_18\VBZ\2604760|locus|speculative|. (r_conj) circumstantial_10\JJ\1740|regard|,|findings|are|largely|,|and|remains (l_nmod) regard_1\NN\5817845|with|spasm (l_nmod) spasm_3\NN\14299637|to
D003042_D013927 NONE cocaine_11\NN\3492717|of (r_nmod) effect_9\NN\34213|of|a|primary|cocaine (l_amod) primary_6\JJ\1740|,|thrombotic (l_dep) thrombotic_8\JJ\1740|
4812392
D001379_D011565 NONE azathioprine_4\NN\3740161|with (r_nmod) treatment_0\NN\654885|psoriasis|azathioprine|. (l_nmod) psoriasis_2\NN\14219661|of
D001379_D011565 NONE azathioprine_0\NN\3740161| (r_compound) treatment_1\NN\654885|azathioprine (r_nsubj) benefited_2\VBD\2210855|treatment|19|%|patients|. (l_nmod) patients_11\NNS\9898892|out|29|suffering (l_acl) suffering_12\VBG\2110220|psoriasis (l_nmod) psoriasis_15\NN\14219661|from|severe
D001379_D056486 NONE azathioprine_9\NN\3740161| (r_compound) therapy_10\NN\657604|azathioprine (r_nsubjpass) continued_12\VBN\2367363|if|therapy|is|detected (l_advcl) detected_20\VBN\2163746|so|that|damage|may|be|stage (l_nsubjpass) damage_17\NN\7296428|structural|liver
18343374
D002996_D012170 CID clomiphene-induced_6\JJ\1740| (r_amod) ovulation_7\NN\13526110|with|clomiphene-induced (r_nmod) associated_4\VBN\628491|ovulation (r_acl) occlusion_3\NN\14081375|central|retinal|vein|associated|.
D002996_D012170 CID citrate_14\NN\14850483|with|clomiphene|cc (r_nmod) associated_11\VBN\628491|citrate (r_acl) occlusion_10\NN\14081375|of|central|retinal|vein|associated
D002996_D012170 CID cc_16\NN\13616054|(|) (r_appos) citrate_14\NN\14850483|with|clomiphene|cc (r_nmod) associated_11\VBN\628491|citrate (r_acl) occlusion_10\NN\14081375|of|central|retinal|vein|associated
D002996_D012170 CID cc_12\NN\13616054|with (r_nmod) induction_10\NN\7450842|after|ovulation|cc (r_nmod) occlusion_7\NN\14081375|measure(s|):|central|retinal|vein|induction|.
D002996_D012170 CID cc_15\NNP\13616054|of (r_nmod) courses_13\NNS\883297|after|eight|cc (r_nmod) developed_6\VBD\1753788|woman|occlusion|courses|. (l_dobj) occlusion_10\NN\14081375|central|retinal|vein
D002996_D012170 CID cc_16\NN\13616054|with (r_nmod) treatment_14\NN\654885|after|cc (r_nmod) case_7\NN\7283608|conclusion(s|):|this|is|the|first|reported|occlusion|treatment|. (l_nmod) occlusion_12\NN\14081375|of|central|retinal|vein
D002996_D013923 NONE cc_10\NN\13616054|of (r_nmod) complications_8\NNS\1073995|on|the|thromboembolic|cc (l_amod) thromboembolic_7\JJ\1740|
D002996_D013923 NONE cc_24\NNP\13616054| (r_compound) intake_25\NN\13440063|after|cc (r_nmod) disturbance_22\NN\407535|mild|visual|intake (r_nsubj) uncommon_28\JJ\1740|although|disturbance|is|not (r_advcl) include_13\VB\690614|search|does|not|complication|,|uncommon|. (l_nsubj) search_1\NN\407535|a|literature (l_nmod) literature_4\NN\6362953|of|the|complications (l_nmod) complications_8\NNS\1073995|on|the|thromboembolic|cc (l_amod) thromboembolic_7\JJ\1740|
D002996_D014786 CID cc_10\NN\13616054|of (r_nmod) complications_8\NNS\1073995|on|the|thromboembolic|cc (r_nmod) literature_4\NN\6362953|of|the|complications (r_nmod) search_1\NN\407535|a|literature (r_nsubj) include_13\VB\690614|search|does|not|complication|,|uncommon|. (l_advcl) uncommon_28\JJ\1740|although|disturbance|is|not (l_nsubj) disturbance_22\NN\407535|mild|visual|intake
D002996_D014786 CID cc_24\NNP\13616054| (r_compound) intake_25\NN\13440063|after|cc (r_nmod) disturbance_22\NN\407535|mild|visual|intake
D002996_D007247 NONE cc_9\NN\13616054|with (r_nmod) patients_7\NNS\9898892|infertility|cc (l_compound) infertility_6\NN\14034177|
6203452
D002945_D002277 NONE cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_nsubj) patients_1\NNS\9898892|five|carcinoma (l_nmod) carcinoma_3\NN\14239918|with
D002945_D057049 NONE cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized
D002945_D051437 NONE cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized (l_dep) characterized_8\VBN\609683|(|insufficiency|) (l_nmod) insufficiency_11\NN\14462946|by|renal|,|anemia|,|and|thrombocytopenia
D002945_D051437 NONE cisplatin_30\NN\1740| (r_compound) nephrotoxicity_31\NN\1740|to|cisplatin|and|anemia (r_nmod) ascribed_28\VBN\670261|because|failure|may|be|nephrotoxicity|suppression (l_nsubjpass) failure_25\NN\66216|renal
D002945_D000743 NONE cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized (l_dep) characterized_8\VBN\609683|(|insufficiency|) (l_nmod) insufficiency_11\NN\14462946|by|renal|,|anemia|,|and|thrombocytopenia (l_conj) anemia_15\NN\14189204|microangiopathic|hemolytic
D002945_D013921 NONE cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized (l_dep) characterized_8\VBN\609683|(|insufficiency|) (l_nmod) insufficiency_11\NN\14462946|by|renal|,|anemia|,|and|thrombocytopenia (l_conj) thrombocytopenia_19\NN\14189204|usually
D002945_D013921 NONE cisplatin_30\NN\1740| (r_compound) nephrotoxicity_31\NN\1740|to|cisplatin|and|anemia (l_conj) anemia_34\NN\14189204|the|and|thrombocytopenia (l_conj) thrombocytopenia_36\NN\14189204|
D001761_D002277 NONE bleomycin_26\NN\1740| (r_conj) cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_nsubj) patients_1\NNS\9898892|five|carcinoma (l_nmod) carcinoma_3\NN\14239918|with
D001761_D057049 NONE bleomycin_26\NN\1740| (r_conj) cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized
D001761_D051437 NONE bleomycin_26\NN\1740| (r_conj) cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized (l_dep) characterized_8\VBN\609683|(|insufficiency|) (l_nmod) insufficiency_11\NN\14462946|by|renal|,|anemia|,|and|thrombocytopenia
D001761_D000743 NONE bleomycin_26\NN\1740| (r_conj) cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized (l_dep) characterized_8\VBN\609683|(|insufficiency|) (l_nmod) insufficiency_11\NN\14462946|by|renal|,|anemia|,|and|thrombocytopenia (l_conj) anemia_15\NN\14189204|microangiopathic|hemolytic
D001761_D013921 NONE bleomycin_26\NN\1740| (r_conj) cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized (l_dep) characterized_8\VBN\609683|(|insufficiency|) (l_nmod) insufficiency_11\NN\14462946|by|renal|,|anemia|,|and|thrombocytopenia (l_conj) thrombocytopenia_19\NN\14189204|usually
D014748_D002277 NONE alkaloid_31\NN\14727670|a|vinca (r_conj) cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_nsubj) patients_1\NNS\9898892|five|carcinoma (l_nmod) carcinoma_3\NN\14239918|with
D014748_D057049 NONE alkaloid_31\NN\14727670|a|vinca (r_conj) cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized
D014748_D051437 NONE alkaloid_31\NN\14727670|a|vinca (r_conj) cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized (l_dep) characterized_8\VBN\609683|(|insufficiency|) (l_nmod) insufficiency_11\NN\14462946|by|renal|,|anemia|,|and|thrombocytopenia
D014748_D000743 NONE alkaloid_31\NN\14727670|a|vinca (r_conj) cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized (l_dep) characterized_8\VBN\609683|(|insufficiency|) (l_nmod) insufficiency_11\NN\14462946|by|renal|,|anemia|,|and|thrombocytopenia (l_conj) anemia_15\NN\14189204|microangiopathic|hemolytic
D014748_D013921 NONE alkaloid_31\NN\14727670|a|vinca (r_conj) cisplatin_24\NN\1740|with|,|bleomycin|,|and|alkaloid (r_nmod) treatment_22\NN\654885|after|cisplatin (r_nmod) developed_4\VBD\1753788|patients|microangiopathy|treatment|. (l_dobj) microangiopathy_6\NN\1740|thrombotic|characterized (l_dep) characterized_8\VBN\609683|(|insufficiency|) (l_nmod) insufficiency_11\NN\14462946|by|renal|,|anemia|,|and|thrombocytopenia (l_conj) thrombocytopenia_19\NN\14189204|usually
D002945_D007674 CID cisplatin_30\NN\1740| (r_compound) nephrotoxicity_31\NN\1740|to|cisplatin|and|anemia
D002945_D000740 NONE cisplatin_30\NN\1740| (r_compound) nephrotoxicity_31\NN\1740|to|cisplatin|and|anemia (l_conj) anemia_34\NN\14189204|the|and|thrombocytopenia
D002945_D001855 NONE cisplatin_30\NN\1740| (r_compound) nephrotoxicity_31\NN\1740|to|cisplatin|and|anemia (r_nmod) ascribed_28\VBN\670261|because|failure|may|be|nephrotoxicity|suppression (l_nmod) suppression_41\NN\13489037|to|drug-induced|bone|marrow
11279304
D018943_D066126 NONE anthracycline-induced_7\JJ\1740| (r_amod) cardiotoxicity_8\NN\1740|of|anthracycline-induced
D018943_D066126 NONE anthracyclines_0\NNS\1740| (r_nsubj) drugs_4\NNS\14778436|anthracyclines|are|effective|antineoplastic|,|but|cause (l_conj) cause_9\VBP\1617192|they|frequently|cardiotoxicity|. (l_dobj) cardiotoxicity_11\NN\1740|dose-related
D018943_D066126 NONE anthracycline_4\NN\1740| (r_compound) therapy_5\NN\657604|of|conventional|anthracycline (r_nmod) cardiotoxicity_1\NN\1740|the|therapy
D018943_D066126 NONE anthracycline-induced_24\JJ\1740| (r_amod) cardiotoxicity_25\NN\1740|of|anthracycline-induced|patients
D018943_D066126 NONE anthracycline-induced_16\JJ\1740| (r_amod) cardiotoxicity_17\NN\1740|of|anthracycline-induced
D018943_D006331 NONE anthracycline_4\NN\1740| (r_compound) therapy_5\NN\657604|of|conventional|anthracycline (r_nmod) cardiotoxicity_1\NN\1740|the|therapy (r_nsubj) highlights_6\VBZ\514463|cardiotoxicity|need|. (l_dobj) need_8\NN\13920835|a|search (l_acl) search_10\VB\2131279|to|methods (l_nmod) methods_12\NNS\5616786|for|sensitive (l_acl:relcl) sensitive_16\JJ\1740|that|are|highly|and|capable (l_conj) capable_18\JJ\1740|predicting (l_advcl) predicting_20\VBG\916909|of|dysfunction (l_dobj) dysfunction_22\NN\14204950|cardiac
D018943_D015470 NONE anthracycline-induced_24\JJ\1740| (r_amod) cardiotoxicity_25\NN\1740|of|anthracycline-induced|patients (l_nmod) patients_27\NNS\9898892|in|leukemia (l_nmod) leukemia_30\NN\14239918|with|acute|treated
D003630_D066126 NONE daunorubicin_34\NN\1740| (r_compound) regimen_36\NN\5898568|with|a|daunorubicin|(dnr)-containing (r_nmod) treated_31\VBN\2376958|regimen (r_acl) leukemia_30\NN\14239918|with|acute|treated (r_nmod) patients_27\NNS\9898892|in|leukemia (r_nmod) cardiotoxicity_25\NN\1740|of|anthracycline-induced|patients
D003630_D066126 NONE (dnr)-containing_35\NN\1740| (r_compound) regimen_36\NN\5898568|with|a|daunorubicin|(dnr)-containing (r_nmod) treated_31\VBN\2376958|regimen (r_acl) leukemia_30\NN\14239918|with|acute|treated (r_nmod) patients_27\NNS\9898892|in|leukemia (r_nmod) cardiotoxicity_25\NN\1740|of|anthracycline-induced|patients
D003630_D015470 NONE daunorubicin_34\NN\1740| (r_compound) regimen_36\NN\5898568|with|a|daunorubicin|(dnr)-containing (r_nmod) treated_31\VBN\2376958|regimen (r_acl) leukemia_30\NN\14239918|with|acute|treated
D003630_D015470 NONE (dnr)-containing_35\NN\1740| (r_compound) regimen_36\NN\5898568|with|a|daunorubicin|(dnr)-containing (r_nmod) treated_31\VBN\2376958|regimen (r_acl) leukemia_30\NN\14239918|with|acute|treated
D003630_D015470 NONE dnr-containing_9\JJ\1740| (r_amod) regimen_10\NN\5898568|with|a|dnr-containing (r_nmod) treated_6\VBN\2376958|patients|were|regimen|. (l_nsubjpass) patients_1\NNS\9898892|thirteen|leukemia (l_nmod) leukemia_4\NN\14239918|with|acute
D003630_D006333 CID dnr_16\NN\1740|given (r_nmod) failure_14\NN\66216|without|heart|dnr
20067456
D016642_D012735 NONE bupropion_5\NN\1740|of|the|adjunctive|dysfunction (l_nmod) dysfunction_9\NN\14204950|on|male|sexual|induced
D016642_D012735 NONE bupropion_10\NN\1740|adjunctive (r_compound) sustained-release_11\NN\1740|of|bupropion|sr (r_nmod) safety_5\NN\13920835|the|and|efficacy|sustained-release|dysfunction (l_nmod) dysfunction_18\NN\14204950|on|male|sexual|sd|induced
D016642_D012735 NONE bupropion_10\NN\1740|adjunctive (r_compound) sustained-release_11\NN\1740|of|bupropion|sr (r_nmod) safety_5\NN\13920835|the|and|efficacy|sustained-release|dysfunction (l_nmod) dysfunction_18\NN\14204950|on|male|sexual|sd|induced (l_appos) sd_20\NN\1740|(|)
D016642_D012735 NONE bupropion_10\NN\1740|adjunctive (r_compound) sustained-release_11\NN\1740|of|bupropion|sr (r_nmod) safety_5\NN\13920835|the|and|efficacy|sustained-release|dysfunction (r_dobj) determine_3\VB\1645601|to|safety|,|side-effect (l_advcl) side-effect_38\NN\1740|as|sd|is|a|common|ssris (l_nsubj) sd_34\NN\1740|
D016642_D012735 NONE bupropion_2\NN\1740| (r_nsubj) treatment_6\NN\654885|bupropion|is|an|effective|sd (l_nmod) sd_9\NN\1740|for|male|induced
D017367_D012735 NONE inhibitor_16\NN\20090|by|a|selective|serotonin|reuptake (r_nmod) induced_10\VBN\1627355|inhibitor (r_acl) dysfunction_9\NN\14204950|on|male|sexual|induced
D017367_D012735 NONE inhibitor_28\NN\20090|by|a|selective|serotonin|reuptake|ssri (r_nmod) induced_22\VBN\1627355|inhibitor (r_acl) dysfunction_18\NN\14204950|on|male|sexual|sd|induced
D017367_D012735 NONE inhibitor_28\NN\20090|by|a|selective|serotonin|reuptake|ssri (r_nmod) induced_22\VBN\1627355|inhibitor (r_acl) dysfunction_18\NN\14204950|on|male|sexual|sd|induced (l_appos) sd_20\NN\1740|(|)
D017367_D012735 NONE inhibitor_28\NN\20090|by|a|selective|serotonin|reuptake|ssri (r_nmod) induced_22\VBN\1627355|inhibitor (r_acl) dysfunction_18\NN\14204950|on|male|sexual|sd|induced (r_nmod) safety_5\NN\13920835|the|and|efficacy|sustained-release|dysfunction (r_dobj) determine_3\VB\1645601|to|safety|,|side-effect (l_advcl) side-effect_38\NN\1740|as|sd|is|a|common|ssris (l_nsubj) sd_34\NN\1740|
D017367_D012735 NONE ssri_30\NN\2718811|(|) (r_appos) inhibitor_28\NN\20090|by|a|selective|serotonin|reuptake|ssri (r_nmod) induced_22\VBN\1627355|inhibitor (r_acl) dysfunction_18\NN\14204950|on|male|sexual|sd|induced
D017367_D012735 NONE ssri_30\NN\2718811|(|) (r_appos) inhibitor_28\NN\20090|by|a|selective|serotonin|reuptake|ssri (r_nmod) induced_22\VBN\1627355|inhibitor (r_acl) dysfunction_18\NN\14204950|on|male|sexual|sd|induced (l_appos) sd_20\NN\1740|(|)
D017367_D012735 NONE ssri_30\NN\2718811|(|) (r_appos) inhibitor_28\NN\20090|by|a|selective|serotonin|reuptake|ssri (r_nmod) induced_22\VBN\1627355|inhibitor (r_acl) dysfunction_18\NN\14204950|on|male|sexual|sd|induced (r_nmod) safety_5\NN\13920835|the|and|efficacy|sustained-release|dysfunction (r_dobj) determine_3\VB\1645601|to|safety|,|side-effect (l_advcl) side-effect_38\NN\1740|as|sd|is|a|common|ssris (l_nsubj) sd_34\NN\1740|
D017367_D012735 NONE ssris_40\NNP\2718811|of|and|treatments (r_nmod) side-effect_38\NN\1740|as|sd|is|a|common|ssris (r_advcl) determine_3\VB\1645601|to|safety|,|side-effect (l_dobj) safety_5\NN\13920835|the|and|efficacy|sustained-release|dysfunction (l_nmod) dysfunction_18\NN\14204950|on|male|sexual|sd|induced
D017367_D012735 NONE ssris_40\NNP\2718811|of|and|treatments (r_nmod) side-effect_38\NN\1740|as|sd|is|a|common|ssris (r_advcl) determine_3\VB\1645601|to|safety|,|side-effect (l_dobj) safety_5\NN\13920835|the|and|efficacy|sustained-release|dysfunction (l_nmod) dysfunction_18\NN\14204950|on|male|sexual|sd|induced (l_appos) sd_20\NN\1740|(|)
D017367_D012735 NONE ssris_40\NNP\2718811|of|and|treatments (r_nmod) side-effect_38\NN\1740|as|sd|is|a|common|ssris (l_nsubj) sd_34\NN\1740|
D017367_D012735 NONE ssri_19\NN\2718811|of (r_nmod) type_17\NN\5839024|ssri (r_appos) sd_15\NN\1740|of|,|type|used|and|age
D017367_D012735 NONE ssris_12\NNP\2718811|by (r_nmod) induced_10\VBN\1627355|ssris (r_acl) sd_9\NN\1740|for|male|induced
8231633
D002118_D064420 NONE calcium_2\NN\14625458| (r_compound) channel_3\NN\6251781|calcium (r_compound) blockers_4\NNS\10101634|of|channel (r_nmod) effects_0\NNS\13245626|blockers|toxicity|. (l_nmod) toxicity_7\NN\13576101|on|bupivacaine-induced
D002118_D064420 NONE calcium_11\NN\14625458| (r_compound) channel_12\NN\6251781|calcium (r_compound) blockers_13\NNS\10101634|of|channel (r_nmod) influence_9\NN\5190804|the|blockers|toxicity (l_nmod) toxicity_17\NN\13576101|on|bupivacaine-induced|acute
D002045_D064420 NONE bupivacaine-induced_6\JJ\1740| (r_amod) toxicity_7\NN\13576101|on|bupivacaine-induced
D002045_D064420 NONE bupivacaine-induced_15\JJ\1740| (r_amod) toxicity_17\NN\13576101|on|bupivacaine-induced|acute
D002045_D012640 CID bupivacaine_4\NN\1740|of (r_nmod) activity_2\NN\30358|the|convulsant|bupivacaine (r_nsubjpass) modified_8\VBN\109660|activity|was|not|significantly|but|decreased|;|pronounced (l_conj) decreased_13\VBD\169651|blockers|time (l_dobj) time_15\NN\7308889|the|latency|obtain (l_acl) obtain_19\VB\2210855|to|convulsions (l_dobj) convulsions_21\NNS\14081375|bupivacaine-induced
D002045_D012640 CID bupivacaine-induced_20\JJ\1740| (r_amod) convulsions_21\NNS\14081375|bupivacaine-induced
D002118_D012640 NONE calcium_10\NN\14625458| (r_compound) channel_11\NN\6251781|calcium (r_compound) blockers_12\NNS\10101634|channel (r_nsubj) decreased_13\VBD\169651|blockers|time (l_dobj) time_15\NN\7308889|the|latency|obtain (l_acl) obtain_19\VB\2210855|to|convulsions (l_dobj) convulsions_21\NNS\14081375|bupivacaine-induced
D015764_D012640 NONE bepridil_29\NN\1740|with (r_nmod) pronounced_27\JJ\1740|effect|was|less|bepridil|. (r_parataxis) modified_8\VBN\109660|activity|was|not|significantly|but|decreased|;|pronounced (l_conj) decreased_13\VBD\169651|blockers|time (l_dobj) time_15\NN\7308889|the|latency|obtain (l_acl) obtain_19\VB\2210855|to|convulsions (l_dobj) convulsions_21\NNS\14081375|bupivacaine-induced
2549018
D005473_D017109 CID fluoxetine-induced_0\JJ\1740| (r_amod) akathisia_1\NN\1740|fluoxetine-induced|:|implications|.
D005473_D017109 CID fluoxetine_3\NN\4169152|treatment (r_dobj) receiving_2\VBG\2210855|fluoxetine (r_acl) patients_1\NNS\9898892|five|receiving (r_nsubj) developed_14\VBD\1753788|patients|akathisia|. (l_dobj) akathisia_15\NN\1740|
D005473_D017109 CID fluoxetine-induced_2\JJ\1740| (r_amod) symptoms_3\NNS\5823932|the|typical|fluoxetine-induced|restlessness|,|and|anxiety (r_nsubj) indistinguishable_22\JJ\1740|symptoms|were|those|. (l_nmod) those_24\DT\1740|from|akathisia (l_nmod) akathisia_27\NN\1740|of|neuroleptic-induced
D005473_D017109 CID fluoxetine-induced_15\JJ\1740| (r_amod) akathisia_16\NN\1740|of|fluoxetine-induced (r_nmod) symptoms_13\NNS\5823932|the|akathisia (r_nsubj) identical_18\JJ\1740|that|symptoms|were|, (r_ccomp) reported_10\VBD\831651|patients|identical|milder|. (l_nsubj) patients_1\NNS\9898892|three|experienced (l_acl:relcl) experienced_4\VBN\2108377|who|had|akathisia|past (l_dobj) akathisia_6\NN\1740|neuroleptic-induced
D005473_D017109 CID fluoxetine-induced_15\JJ\1740| (r_amod) akathisia_16\NN\1740|of|fluoxetine-induced
D005473_D017109 CID fluoxetine_9\NN\4169152|of (r_nmod) effect_7\NN\34213|to|be|a|common|side|fluoxetine (r_xcomp) appeared_1\VBD\2604760|akathisia|effect|and|responded|. (l_nsubj) akathisia_0\NNP\1740|
D005473_D017109 CID fluoxetine-induced_4\JJ\1740| (r_amod) akathisia_5\NN\1740|fluoxetine-induced
D005473_D017109 CID fluoxetine-induced_4\JJ\1740| (r_amod) akathisia_5\NN\1740|fluoxetine-induced (r_nsubjpass) caused_8\VBN\1617192|that|akathisia|may|be|inhibition (l_nmod) inhibition_12\NN\1068773|by|mediated|neurotransmission|and|identical (l_conj) identical_31\JJ\1740|that|jitteriness|may|be (l_nsubj) jitteriness_27\NN\7523905|antidepressant-induced|"|" (l_amod) antidepressant-induced_25\JJ\1740|pathophysiology (l_nsubj) pathophysiology_19\NN\1740|the|akathisia (l_nmod) akathisia_22\NN\1740|of|fluoxetine-induced|and|tricyclic
D005473_D017109 CID fluoxetine-induced_21\JJ\1740| (r_amod) akathisia_22\NN\1740|of|fluoxetine-induced|and|tricyclic (r_nmod) pathophysiology_19\NN\1740|the|akathisia (r_nsubj) antidepressant-induced_25\JJ\1740|pathophysiology (r_amod) jitteriness_27\NN\7523905|antidepressant-induced|"|" (r_nsubj) identical_31\JJ\1740|that|jitteriness|may|be (r_conj) inhibition_12\NN\1068773|by|mediated|neurotransmission|and|identical (r_nmod) caused_8\VBN\1617192|that|akathisia|may|be|inhibition (l_nsubjpass) akathisia_5\NN\1740|fluoxetine-induced
D005473_D017109 CID fluoxetine-induced_21\JJ\1740| (r_amod) akathisia_22\NN\1740|of|fluoxetine-induced|and|tricyclic
D005473_D009771 NONE fluoxetine_3\NN\4169152|treatment (l_nmod) treatment_6\NN\654885|for|the|disorder (l_nmod) disorder_10\NN\14034177|of|obsessive|compulsive|or|depression
D005473_D003865 NONE fluoxetine_3\NN\4169152|treatment (l_nmod) treatment_6\NN\654885|for|the|disorder (l_nmod) disorder_10\NN\14034177|of|obsessive|compulsive|or|depression (l_conj) depression_13\NN\14373582|major
D005473_D001008 NONE fluoxetine-induced_2\JJ\1740| (r_amod) symptoms_3\NNS\5823932|the|typical|fluoxetine-induced|restlessness|,|and|anxiety (l_conj) anxiety_20\NN\14373582|marked
D011433_D017109 NONE propranolol_20\NN\1740|with|the|beta-adrenergic|antagonist|,|reduction|,|or|both (r_nmod) treatment_15\NN\654885|to|propranolol (r_nmod) responded_12\VBD\2367363|generally|well|treatment (r_conj) appeared_1\VBD\2604760|akathisia|effect|and|responded|. (l_nsubj) akathisia_0\NNP\1740|
D000928_D017109 NONE antidepressant-induced_25\JJ\1740|pathophysiology (r_amod) jitteriness_27\NN\7523905|antidepressant-induced|"|" (r_nsubj) identical_31\JJ\1740|that|jitteriness|may|be (r_conj) inhibition_12\NN\1068773|by|mediated|neurotransmission|and|identical (r_nmod) caused_8\VBN\1617192|that|akathisia|may|be|inhibition (l_nsubjpass) akathisia_5\NN\1740|fluoxetine-induced
D000928_D017109 NONE antidepressant-induced_25\JJ\1740|pathophysiology (l_nsubj) pathophysiology_19\NN\1740|the|akathisia (l_nmod) akathisia_22\NN\1740|of|fluoxetine-induced|and|tricyclic
3997294
D000638_D010996 CID amiodarone_9\NN\2715941| (r_compound) therapy_10\NN\657604|during|amiodarone (r_nmod) neuropathy_7\JJ\1740|therapy (r_conj) effusion_5\NN\6880249|pleural|and|neuropathy
D000638_D010490 CID amiodarone_9\NN\2715941| (r_compound) therapy_10\NN\657604|during|amiodarone (r_nmod) neuropathy_7\JJ\1740|therapy (r_conj) effusion_5\NN\6880249|pleural|and|neuropathy
D000638_D009422 NONE amiodarone_9\NN\2715941| (r_compound) therapy_10\NN\657604|during|amiodarone (r_nmod) neuropathy_7\JJ\1740|therapy
D000638_D002318 NONE amiodarone_11\NN\2715941|with|dose (r_nmod) treated_9\VBN\2376958|patient|was|amiodarone|months|,|control|. (l_nsubjpass) patient_1\NN\9898892|a|disease|and|pacemaker (l_nmod) disease_4\NN\14061805|with|sinuatrial
D000638_D013617 NONE amiodarone_11\NN\2715941|with|dose (r_nmod) treated_9\VBN\2376958|patient|was|amiodarone|months|,|control|. (l_nmod) control_29\NN\5190804|for|tachyarrhythmias (l_nmod) tachyarrhythmias_32\NNS\1740|of|supraventricular
D000638_D011014 CID amiodarone_14\JJ\1740| (r_amod) pneumonitis_15\NN\14336539|of|amiodarone|,|withdrawal
D000638_D011014 CID amiodarone_20\NN\2715941|of (r_nmod) withdrawal_18\NN\7206096|immediate|amiodarone (r_appos) pneumonitis_15\NN\14336539|of|amiodarone|,|withdrawal
D013256_D011014 NONE steroid_26\NN\14727670| (r_compound) therapy_27\NN\657604|continued|steroid (r_conj) prompt_23\NN\7011209|but|therapy|ensure (r_conj) indicates_7\VBZ\952524|review|need|,|and|prompt|. (l_dobj) need_9\NN\13920835|the|diagnosis (l_nmod) diagnosis_12\NN\152018|for|early|pneumonitis (l_nmod) pneumonitis_15\NN\14336539|of|amiodarone|,|withdrawal
2265898
C009265_D004827 CID levodopa/carbidopa_4\JJ\1740| (r_amod) administration_5\NN\1133281|by|levodopa/carbidopa (r_nmod) caused_2\VBN\1617192|administration|patients (r_acl) epilepsy_1\NN\14085708|serial|caused|.
C009265_D007676 NONE carbidopa/levodopa_34\NN\1740| (r_amod) preparation_35\NN\407535|a|carbidopa/levodopa (r_dobj) receiving_32\VBG\2210855|both|had|been|preparation|; (r_parataxis) presented_7\VBN\2137132|patients|are|had|;|receiving|and|had (l_parataxis) had_11\VBD\2108377|:|patients|failure|,|hemodialysis|but|begun (l_dobj) failure_14\NN\66216|chronic|renal
C009265_D001523 NONE carbidopa/levodopa_34\NN\1740| (r_amod) preparation_35\NN\407535|a|carbidopa/levodopa (r_dobj) receiving_32\VBG\2210855|both|had|been|preparation|; (r_parataxis) presented_7\VBN\2137132|patients|are|had|;|receiving|and|had (l_conj) had_39\VBD\2108377|both|onset|. (l_dobj) onset_41\NN\7325190|the|seizures (l_nmod) seizures_46\NNS\14081375|of|hallucinosis|,|refractory (l_compound) hallucinosis_43\NN\14373582|and|recurrent
C009265_D012640 NONE carbidopa/levodopa_34\NN\1740| (r_amod) preparation_35\NN\407535|a|carbidopa/levodopa (r_dobj) receiving_32\VBG\2210855|both|had|been|preparation|; (r_parataxis) presented_7\VBN\2137132|patients|are|had|;|receiving|and|had (l_conj) had_39\VBD\2108377|both|onset|. (l_dobj) onset_41\NN\7325190|the|seizures (l_nmod) seizures_46\NNS\14081375|of|hallucinosis|,|refractory
1147734
D011441_D008107 NONE propylthiouracil_4\NN\14727670|by (r_nmod) caused_2\VBN\1617192|propylthiouracil (r_acl) disease_1\NN\14061805|liver|caused|.
D011441_D006521 CID propylthiouracil_29\NN\14727670|of (r_nmod) administration_27\NN\1133281|by|the|propylthiouracil (r_nmod) caused_24\VBN\1617192|administration (r_acl) patient_16\NN\9898892|on|a|hepatitis|caused (l_nmod) hepatitis_23\NN\14127211|with|chronic|active|aggressive|)
14659530
D009569_D008881 NONE no-induced_0\JJ\1740| (r_amod) attack_2\NN\955060|no-induced|migraine|:|increase|. (l_compound) migraine_1\NN\14326607|
D015740_D008881 NONE peptide_10\NN\14724264|in|plasma|calcitonin|gene-related|cgrp (r_nmod) increase_5\NN\13576355|strong|peptide|concentration|and|correlation (r_dep) attack_2\NN\955060|no-induced|migraine|:|increase|. (l_compound) migraine_1\NN\14326607|
D015740_D008881 NONE cgrp_12\NN\1740|(|) (r_appos) peptide_10\NN\14724264|in|plasma|calcitonin|gene-related|cgrp (r_nmod) increase_5\NN\13576355|strong|peptide|concentration|and|correlation (r_dep) attack_2\NN\955060|no-induced|migraine|:|increase|. (l_compound) migraine_1\NN\14326607|
D015740_D008881 NONE peptide_15\NN\14724264|plasma|calcitonin|gene-related (r_compound) concentration_19\NN\4916342|in|the|peptide|cgrp|)|and|serotonin (r_nmod) changes_9\NNS\7283608|concentration (r_dobj) investigate_8\VB\644583|to|changes|content (l_dobj) content_28\NN\7951464|headache|and|attack (l_conj) attack_38\NN\955060|the|delayed|genuine|migraine|provoked (l_compound) migraine_37\NN\14326607|
D015740_D008881 NONE cgrp_17\NN\1740|( (r_compound) concentration_19\NN\4916342|in|the|peptide|cgrp|)|and|serotonin (r_nmod) changes_9\NNS\7283608|concentration (r_dobj) investigate_8\VB\644583|to|changes|content (l_dobj) content_28\NN\7951464|headache|and|attack (l_conj) attack_38\NN\955060|the|delayed|genuine|migraine|provoked (l_compound) migraine_37\NN\14326607|
D015740_D008881 NONE cgrp_1\NN\1740| (r_compound) concentration_2\NN\4916342|plasma|cgrp (r_nsubj) increased_3\VBD\169651|concentration|significantly|p<0.01|attack|and|returned|. (l_nmod) attack_11\NN\955060|during|the|migraine (l_compound) migraine_10\NN\14326607|
D015740_D008881 NONE cgrp_1\NN\1740| (r_compound) concentration_2\NN\4916342|plasma|cgrp (r_nsubj) increased_3\VBD\169651|concentration|significantly|p<0.01|attack|and|returned|. (l_conj) returned_13\VBD\1835496|baseline|cessation (l_nmod) cessation_18\NN\7365849|after|the|migraine (l_nmod) migraine_21\NN\14326607|of|the
D015740_D008881 NONE cgrp_3\NN\1740| (r_compound) concentrations_4\NNS\4916342|plasma|cgrp (r_nsubj) failed_5\VBD\1798936|however|,|concentrations|change|. (l_xcomp) change_7\VB\46534|to|headache|and|subjects (l_conj) subjects_14\NNS\6598915|in|the|attack (l_nmod) attack_18\NN\955060|with|no|migraine (l_compound) migraine_17\NN\14326607|
D015740_D008881 NONE cgrp_1\NN\1740| (r_compound) concentration_2\NN\4916342|basal|cgrp (r_nsubj) higher_5\JJR\1740|concentration|was|significantly|and|tended|. (l_conj) tended_10\VBD\2604760|content|lower (l_xcomp) lower_13\JJR\1740|to|be|subjects (l_nmod) subjects_15\NNS\6598915|in|experienced (l_acl:relcl) experienced_17\VBD\2108377|who|attack (l_dobj) attack_20\NN\955060|a|migraine (l_compound) migraine_19\NN\14326607|
D015740_D008881 NONE cgrp_7\NN\1740| (r_compound) concentration_8\NN\4916342|plasma|cgrp (r_nsubj) correlates_9\VBZ\2657219|that|concentration|timing (l_nmod) timing_12\NN\5044673|with|the|and|severity (l_conj) severity_14\NN\5036394|headache (l_nmod) headache_18\NN\5829480|of|a|migraine (l_compound) migraine_17\NN\14326607|
D015740_D008881 NONE cgrp_7\NN\1740| (r_compound) concentration_8\NN\4916342|plasma|cgrp (r_nsubj) correlates_9\VBZ\2657219|that|concentration|timing (r_ccomp) fact_4\NN\5816287|the|correlates (r_nsubj) suggests_19\VBZ\1010118|conclusion|,|fact|relationship|. (l_dobj) relationship_22\NN\31921|a|direct|cgrp (l_nmod) cgrp_24\NN\1740|between|and|migraine (l_conj) migraine_26\NN\14326607|
D015740_D008881 NONE cgrp_24\NN\1740|between|and|migraine (r_nmod) relationship_22\NN\31921|a|direct|cgrp (r_dobj) suggests_19\VBZ\1010118|conclusion|,|fact|relationship|. (l_nsubj) fact_4\NN\5816287|the|correlates (l_ccomp) correlates_9\VBZ\2657219|that|concentration|timing (l_nmod) timing_12\NN\5044673|with|the|and|severity (l_conj) severity_14\NN\5036394|headache (l_nmod) headache_18\NN\5829480|of|a|migraine (l_compound) migraine_17\NN\14326607|
D015740_D008881 NONE cgrp_24\NN\1740|between|and|migraine (l_conj) migraine_26\NN\14326607|
D015740_D008881 NONE cgrp_21\NN\1740| (r_compound) release_22\NN\3748886|the|concomitant|cgrp (r_conj) headache_17\NN\5829480|the|and|release (r_dobj) counteract_15\VB\2367363|provoke|,|it|may|even|headache|model|. (l_advcl) provoke_9\VB\1617192|contrast|,|release|does|not|migraine (l_dobj) migraine_10\NN\14326607|
D012701_D008881 NONE serotonin_20\NN\14807737| (r_compound) release_21\NN\3748886|with|platelet|serotonin (r_nmod) correlation_17\NN\13841213|negative|release (r_conj) increase_5\NN\13576355|strong|peptide|concentration|and|correlation (r_dep) attack_2\NN\955060|no-induced|migraine|:|increase|. (l_compound) migraine_1\NN\14326607|
D012701_D008881 NONE serotonin_22\NN\14807737|platelet|5-hydroxytriptamine (r_conj) concentration_19\NN\4916342|in|the|peptide|cgrp|)|and|serotonin (r_nmod) changes_9\NNS\7283608|concentration (r_dobj) investigate_8\VB\644583|to|changes|content (l_dobj) content_28\NN\7951464|headache|and|attack (l_conj) attack_38\NN\955060|the|delayed|genuine|migraine|provoked (l_compound) migraine_37\NN\14326607|
D012701_D008881 NONE 5-hydroxytriptamine_24\NN\1740|(|,|5-ht|) (r_dep) serotonin_22\NN\14807737|platelet|5-hydroxytriptamine (r_conj) concentration_19\NN\4916342|in|the|peptide|cgrp|)|and|serotonin (r_nmod) changes_9\NNS\7283608|concentration (r_dobj) investigate_8\VB\644583|to|changes|content (l_dobj) content_28\NN\7951464|headache|and|attack (l_conj) attack_38\NN\955060|the|delayed|genuine|migraine|provoked (l_compound) migraine_37\NN\14326607|
D012701_D008881 NONE 5-ht_26\NN\1740| (r_appos) 5-hydroxytriptamine_24\NN\1740|(|,|5-ht|) (r_dep) serotonin_22\NN\14807737|platelet|5-hydroxytriptamine (r_conj) concentration_19\NN\4916342|in|the|peptide|cgrp|)|and|serotonin (r_nmod) changes_9\NNS\7283608|concentration (r_dobj) investigate_8\VB\644583|to|changes|content (l_dobj) content_28\NN\7951464|headache|and|attack (l_conj) attack_38\NN\955060|the|delayed|genuine|migraine|provoked (l_compound) migraine_37\NN\14326607|
D012701_D008881 NONE 5-ht_8\NN\1740| (r_compound) content_9\NN\7951464|platelet|5-ht (r_nsubj) tended_10\VBD\2604760|content|lower (l_xcomp) lower_13\JJR\1740|to|be|subjects (l_nmod) subjects_15\NNS\6598915|in|experienced (l_acl:relcl) experienced_17\VBD\2108377|who|attack (l_dobj) attack_20\NN\955060|a|migraine (l_compound) migraine_19\NN\14326607|
D012701_D008881 NONE serotonin_1\NN\14807737| (r_compound) content_2\NN\7951464|platelet|serotonin (r_nsubj) decreased_3\VBD\169651|content|significantly|p<0.01|nitroglycerin|but|observed|. (l_nmod) nitroglycerin_9\NN\15015501|after|subjects (l_nmod) subjects_11\NNS\6598915|in|attack (l_nmod) attack_15\NN\955060|with|no|migraine (l_compound) migraine_14\NN\14326607|
D012701_D008881 NONE serotonin_1\NN\14807737| (r_compound) content_2\NN\7951464|platelet|serotonin (r_nsubj) decreased_3\VBD\169651|content|significantly|p<0.01|nitroglycerin|but|observed|. (l_conj) observed_21\VBN\2163746|change|was|patients (l_nmod) patients_23\NNS\9898892|in|attack (l_nmod) attack_26\NN\955060|with|migraine (l_compound) migraine_25\NN\14326607|
D012701_D008881 NONE serotonin_3\NN\14807737| (r_compound) release_4\NN\3748886|serotonin|platelets (r_nsubj) provoke_9\VB\1617192|contrast|,|release|does|not|migraine (l_dobj) migraine_10\NN\14326607|
D015740_D006261 NONE peptide_15\NN\14724264|plasma|calcitonin|gene-related (r_compound) concentration_19\NN\4916342|in|the|peptide|cgrp|)|and|serotonin (r_nmod) changes_9\NNS\7283608|concentration (r_dobj) investigate_8\VB\644583|to|changes|content (l_dobj) content_28\NN\7951464|headache|and|attack (l_nmod) headache_32\NN\5829480|during|the|immediate
D015740_D006261 NONE cgrp_17\NN\1740|( (r_compound) concentration_19\NN\4916342|in|the|peptide|cgrp|)|and|serotonin (r_nmod) changes_9\NNS\7283608|concentration (r_dobj) investigate_8\VB\644583|to|changes|content (l_dobj) content_28\NN\7951464|headache|and|attack (l_nmod) headache_32\NN\5829480|during|the|immediate
D015740_D006261 NONE cgrp_3\NN\1740| (r_compound) concentrations_4\NNS\4916342|plasma|cgrp (r_nsubj) failed_5\VBD\1798936|however|,|concentrations|change|. (l_xcomp) change_7\VB\46534|to|headache|and|subjects (l_nmod) headache_10\NN\5829480|during|immediate
D015740_D006261 NONE cgrp_7\NN\1740| (r_compound) concentration_8\NN\4916342|plasma|cgrp (r_nsubj) correlates_9\VBZ\2657219|that|concentration|timing (l_nmod) timing_12\NN\5044673|with|the|and|severity (l_conj) severity_14\NN\5036394|headache (l_nmod) headache_18\NN\5829480|of|a|migraine
D015740_D006261 NONE cgrp_24\NN\1740|between|and|migraine (r_nmod) relationship_22\NN\31921|a|direct|cgrp (r_dobj) suggests_19\VBZ\1010118|conclusion|,|fact|relationship|. (l_nsubj) fact_4\NN\5816287|the|correlates (l_ccomp) correlates_9\VBZ\2657219|that|concentration|timing (l_nmod) timing_12\NN\5044673|with|the|and|severity (l_conj) severity_14\NN\5036394|headache (l_nmod) headache_18\NN\5829480|of|a|migraine
D015740_D006261 NONE cgrp_21\NN\1740| (r_compound) release_22\NN\3748886|the|concomitant|cgrp (r_conj) headache_17\NN\5829480|the|and|release
D012701_D006261 NONE serotonin_22\NN\14807737|platelet|5-hydroxytriptamine (r_conj) concentration_19\NN\4916342|in|the|peptide|cgrp|)|and|serotonin (r_nmod) changes_9\NNS\7283608|concentration (r_dobj) investigate_8\VB\644583|to|changes|content (l_dobj) content_28\NN\7951464|headache|and|attack (l_nmod) headache_32\NN\5829480|during|the|immediate
D012701_D006261 NONE 5-hydroxytriptamine_24\NN\1740|(|,|5-ht|) (r_dep) serotonin_22\NN\14807737|platelet|5-hydroxytriptamine (r_conj) concentration_19\NN\4916342|in|the|peptide|cgrp|)|and|serotonin (r_nmod) changes_9\NNS\7283608|concentration (r_dobj) investigate_8\VB\644583|to|changes|content (l_dobj) content_28\NN\7951464|headache|and|attack (l_nmod) headache_32\NN\5829480|during|the|immediate
D012701_D006261 NONE 5-ht_26\NN\1740| (r_appos) 5-hydroxytriptamine_24\NN\1740|(|,|5-ht|) (r_dep) serotonin_22\NN\14807737|platelet|5-hydroxytriptamine (r_conj) concentration_19\NN\4916342|in|the|peptide|cgrp|)|and|serotonin (r_nmod) changes_9\NNS\7283608|concentration (r_dobj) investigate_8\VB\644583|to|changes|content (l_dobj) content_28\NN\7951464|headache|and|attack (l_nmod) headache_32\NN\5829480|during|the|immediate
D012701_D006261 NONE serotonin_3\NN\14807737| (r_compound) release_4\NN\3748886|serotonin|platelets (r_nsubj) provoke_9\VB\1617192|contrast|,|release|does|not|migraine (r_advcl) counteract_15\VB\2367363|provoke|,|it|may|even|headache|model|. (l_dobj) headache_17\NN\5829480|the|and|release
D005996_D006261 NONE nitroglycerin_41\NN\15015501|by (r_nmod) provoked_39\VBN\1617192|nitroglycerin (r_acl) attack_38\NN\955060|the|delayed|genuine|migraine|provoked (r_conj) content_28\NN\7951464|headache|and|attack (l_nmod) headache_32\NN\5829480|during|the|immediate
D005996_D008881 NONE nitroglycerin_41\NN\15015501|by (r_nmod) provoked_39\VBN\1617192|nitroglycerin (r_acl) attack_38\NN\955060|the|delayed|genuine|migraine|provoked (l_compound) migraine_37\NN\14326607|
D005996_D008881 NONE nitroglycerin_16\NN\15015501| (r_compound) application_17\NN\947128|the|nitroglycerin|,|and|min (l_conj) min_23\NN\15154774|60|beginning|min (l_nmod) beginning_26\NN\7283608|after|the|attack (l_nmod) attack_30\NN\955060|of|the|migraine (l_compound) migraine_29\NN\14326607|
D005996_D008881 NONE nitroglycerin_9\NN\15015501|after|subjects (l_nmod) subjects_11\NNS\6598915|in|attack (l_nmod) attack_15\NN\955060|with|no|migraine (l_compound) migraine_14\NN\14326607|
D005996_D008881 NONE nitroglycerin_9\NN\15015501|after|subjects (r_nmod) decreased_3\VBD\169651|content|significantly|p<0.01|nitroglycerin|but|observed|. (l_conj) observed_21\VBN\2163746|change|was|patients (l_nmod) patients_23\NNS\9898892|in|attack (l_nmod) attack_26\NN\955060|with|migraine (l_compound) migraine_25\NN\14326607|
9034419
C047426_D012640 CID venlafaxine_4\NN\1740| (r_compound) overdose_5\NN\1740|from|a|venlafaxine (r_nmod) resulting_1\VBG\2633881|overdose (r_acl) seizure_0\NNP\14081375|resulting|.
C047426_D012640 CID venlafaxine_5\NN\1740| (r_compound) tablets_7\NNS\4233405|of|26|venlafaxine|50-mg (r_nmod) ingestion_2\NN\13440063|after|the|tablets (r_nmod) experienced_11\VBD\2108377|ingestion|,|patient|seizure|. (l_dobj) seizure_15\JJ\1740|a|generalized
C047426_D012640 CID venlafaxine_13\NN\1740| (r_compound) overdose_14\NN\1740|of|venlafaxine (r_nmod) case_11\NN\7283608|knowledge|,|this|is|the|first|reported|overdose|resulted|. (l_acl:relcl) resulted_16\VBD\2633881|that|seizure (l_nmod) seizure_20\NN\14081375|in|a|generalized
C047426_D012640 CID venlafaxine_3\NN\1740| (r_compound) overdose_4\NN\1740|the|venlafaxine|patient (r_nsubj) resulted_8\VBD\2633881|conclusions|overdose|episode|but|elicited|. (l_nmod) episode_12\NN\7283608|in|a|single|seizure (l_nmod) seizure_15\NN\14081375|of|generalized
C047426_D062787 CID venlafaxine_4\NN\1740| (r_compound) overdose_5\NN\1740|from|a|venlafaxine
C047426_D062787 CID venlafaxine_7\NN\1740| (r_compound) overdose_8\NN\1740|of|venlafaxine
C047426_D062787 CID venlafaxine_13\NN\1740|of (r_nmod) overdose_11\NN\1740|an|venlafaxine
C047426_D062787 CID venlafaxine_13\NN\1740| (r_compound) overdose_14\NN\1740|of|venlafaxine
C047426_D062787 CID venlafaxine_3\NN\1740| (r_compound) overdose_4\NN\1740|the|venlafaxine|patient
C047426_D003865 NONE venlafaxine_13\NN\1740|of (r_nmod) overdose_11\NN\1740|an|venlafaxine (r_dobj) took_9\VBD\2367363|woman|overdose|attempt (l_nsubj) woman_5\NN\9605289|a|40-year-old|depression (l_nmod) depression_8\NN\14373582|with|major
18560792
D010479_D006349 NONE pergolide_11\NN\1740|with (r_nmod) treated_9\VBN\2376958|pergolide (r_acl) patients_4\NNS\9898892|in|disease|treated (r_nmod) disease_2\NN\14061805|valvular|heart|patients|.
D010479_D006349 NONE pergolide_17\NN\1740|with (r_nmod) treated_15\VBN\2376958|pergolide (r_acl) patients_7\NNS\9898892|in|disease|treated (r_nmod) reported_5\VBN\831651|abnormalities|have|been|patients|. (l_nsubjpass) abnormalities_2\NNS\14034177|valvular|heart
D010479_D006349 NONE pergolide_12\NN\1740|of (r_nmod) role_10\NN\719494|of|the|pergolide (r_nmod) suggestive_7\JJ\1740|role (r_amod) pattern_2\NN\5726345|a|restrictive|regurgitation|,|suggestive|, (l_nmod) regurgitation_5\NN\7406350|of|valvular
D010479_D006349 NONE pergolide_0\NN\1740| (r_nsubjpass) discontinued_2\VBN\2609764|pergolide|was|patients|,|resulting|returned|. (l_nmod) patients_5\NNS\9898892|in|10|disease (l_nmod) disease_9\NN\14061805|with|valvular|heart
D010479_D006349 NONE pergolide_15\NN\1740|with (r_nmod) treated_13\VBN\2376958|pergolide (r_acl) patients_12\NNS\9898892|in|pd|treated (r_nmod) regurgitation_9\NN\7406350|of|restrictive|valve|patients
D010479_D010300 NONE pergolide_11\NN\1740|with (r_nmod) treated_9\VBN\2376958|pergolide (r_acl) patients_4\NNS\9898892|in|disease|treated (l_nmod) disease_8\NN\14061805|with|parkinson
D010479_D010300 NONE pergolide_17\NN\1740|with (r_nmod) treated_15\VBN\2376958|pergolide (r_acl) patients_7\NNS\9898892|in|disease|treated (l_nmod) disease_11\NN\14061805|with|parkinson|pd
D010479_D010300 NONE pergolide_17\NN\1740|with (r_nmod) treated_15\VBN\2376958|pergolide (r_acl) patients_7\NNS\9898892|in|disease|treated (l_nmod) disease_11\NN\14061805|with|parkinson|pd (l_appos) pd_13\NN\14625458|(|)
D010479_D010300 NONE pergolide_11\NN\1740|with (r_nmod) treated_9\VBN\2376958|pergolide (r_acl) area_8\NN\8630985|in|the|amiens|treated (r_nmod) patients_4\NNS\9898892|all|pd|area (l_compound) pd_3\NN\14625458|
D010479_D010300 NONE pergolide_15\NN\1740|with (r_nmod) treated_13\VBN\2376958|pergolide (r_acl) patients_12\NNS\9898892|in|pd|treated (l_compound) pd_11\NN\14625458|
D010479_D006333 NONE pergolide_12\NN\1740|of (r_nmod) role_10\NN\719494|of|the|pergolide (r_nmod) suggestive_7\JJ\1740|role (r_amod) pattern_2\NN\5726345|a|restrictive|regurgitation|,|suggestive|, (r_nsubjpass) observed_15\VBN\2163746|pattern|was|12/30|patients|. (l_nmod) patients_22\NNS\9898892|two (l_nmod) two_24\CD\13741022|including|failure (l_nmod) failure_27\NN\66216|with|heart
D010479_D006333 NONE pergolide_0\NN\1740| (r_nsubjpass) discontinued_2\VBN\2609764|pergolide|was|patients|,|resulting|returned|. (l_xcomp) resulting_11\VBG\2633881|grade (l_nmod) grade_16\NN\7975026|in|a|lower|regurgitation|p=0.01|echocardiography|and|patients (l_conj) patients_28\NNS\9898892|the|two|failure (l_nmod) failure_31\NN\66216|with|heart
D004298_D006349 NONE dopamine_31\NN\14807737| (r_compound) agonists_32\NNS\9613191|to|non-ergot|dopamine (r_nmod) converted_28\VBN\126264|when|treatment|is|agonists (r_advcl) usual_23\JJ\1740|that|improvement|is|converted (r_ccomp) reveals_17\VBZ\2137132|usual (r_conj) supports_2\VBZ\2199590|study|frequency|and|reveals|. (l_dobj) frequency_5\NN\15286249|the|high|regurgitation (l_nmod) regurgitation_9\NN\7406350|of|restrictive|valve|patients
D004298_D010300 NONE dopamine_31\NN\14807737| (r_compound) agonists_32\NNS\9613191|to|non-ergot|dopamine (r_nmod) converted_28\VBN\126264|when|treatment|is|agonists (r_advcl) usual_23\JJ\1740|that|improvement|is|converted (r_ccomp) reveals_17\VBZ\2137132|usual (r_conj) supports_2\VBZ\2199590|study|frequency|and|reveals|. (l_dobj) frequency_5\NN\15286249|the|high|regurgitation (l_nmod) regurgitation_9\NN\7406350|of|restrictive|valve|patients (l_nmod) patients_12\NNS\9898892|in|pd|treated (l_compound) pd_11\NN\14625458|
16181582
D014635_D001927 CID valproate-induced_0\JJ\1740|encephalopathy|. (l_advmod) encephalopathy_1\RB\1740|
D014635_D001927 CID valproate-induced_0\JJ\1740| (r_amod) encephalopathy_1\JJ\1740|valproate-induced
D014635_D001927 CID valproate-induced_3\JJ\1740| (r_amod) encephalopathy_4\JJ\1740|of|valproate-induced
D014635_D004827 NONE valproate-induced_0\JJ\1740| (r_amod) encephalopathy_1\JJ\1740|valproate-induced (r_nsubj) syndrome_5\NN\5870365|encephalopathy|is|a|rare|manifest|. (l_acl:relcl) manifest_8\VB\1015244|that|may|individuals (l_nmod) individuals_13\NNS\7347|in|otherwise|normal|epileptic (l_amod) epileptic_12\JJ\1740|
869641
D007980_D001919 NONE l-dopa_7\NN\14604959|by (r_nmod) mediation_0\NN\7148192|bradycardia|l-dopa|formation|. (l_nmod) bradycardia_5\NN\14110674|of|enhanced|reflex|vagal
D007980_D001919 NONE l-dopa_13\JJ\1740|by (r_nmod) enhanced_11\VBN\227165|addition|,|bradycardia|was|significantly|l-dopa|,|had|. (l_nsubjpass) bradycardia_4\NN\14110674|reflex|caused
D007980_D001919 NONE l-dopa_20\JJ\1740|of (r_nmod) hypotension_13\NN\14057371|on|the|,|bradycardia|or|effect|l-dopa (l_conj) bradycardia_15\NN\14110674|
D007980_D001919 NONE l-dopa_2\NN\14604959| (r_nsubj) restored_3\VBD\1631072|however|,|l-dopa|bradycardia|decreasing|. (l_dobj) bradycardia_5\NN\14110674|the|caused
D007980_D001919 NONE l-dopa_4\NN\14604959| (r_nsubj) enhances_5\VBZ\227165|that|l-dopa|bradycardia|stimulation (l_dobj) bradycardia_7\NN\14110674|reflex
D004298_D001919 NONE dopamine_10\NN\14807737| (r_compound) formation_11\NN\7938773|via|central|dopamine|dogs (r_nmod) mediation_0\NN\7148192|bradycardia|l-dopa|formation|. (l_nmod) bradycardia_5\NN\14110674|of|enhanced|reflex|vagal
D004298_D001919 NONE dopamine-beta-oxidase_3\NN\1740| (r_compound) inhibitor_4\NN\20090|a|dopamine-beta-oxidase (r_appos) fla-63_0\NN\1740|,|inhibitor|, (r_nsubj) have_8\VB\2108377|fla-63|did|not|effect|. (l_dobj) effect_10\NN\34213|any|hypotension (l_nmod) hypotension_13\NN\14057371|on|the|,|bradycardia|or|effect|l-dopa (l_conj) bradycardia_15\NN\14110674|
D009638_D001919 CID norepinephrine_8\NN\14807929|by|injected (r_nmod) caused_5\VBN\1617192|norepinephrine (r_acl) bradycardia_4\NN\14110674|reflex|caused
D009638_D001919 CID norepinephrine_29\NN\14807929|to (r_nmod) responses_27\NNS\11410625|reflex|norepinephrine (r_conj) rate_24\NN\13815152|heart|or|responses (r_conj) had_16\VBD\2108377|dl-threo-dihydroxyphenylserine|effect|pressure|,|rate (r_conj) enhanced_11\VBN\227165|addition|,|bradycardia|was|significantly|l-dopa|,|had|. (l_nsubjpass) bradycardia_4\NN\14110674|reflex|caused
D009638_D001919 CID norepinephrine_8\NN\14807929|by (r_nmod) caused_6\VBN\1617192|norepinephrine (r_acl) bradycardia_5\NN\14110674|the|caused
D009638_D001919 CID norepinephrine_18\NN\14807929|to (r_nmod) decreased_13\VBD\169651|bradycardia|norepinephrine (l_dobj) bradycardia_16\NN\14110674|the|reflex
D015103_D001919 NONE dl-threo-dihydroxyphenylserine_15\NN\1740| (r_nsubj) had_16\VBD\2108377|dl-threo-dihydroxyphenylserine|effect|pressure|,|rate (r_conj) enhanced_11\VBN\227165|addition|,|bradycardia|was|significantly|l-dopa|,|had|. (l_nsubjpass) bradycardia_4\NN\14110674|reflex|caused
D005406_D007022 NONE fla-63_0\NN\1740|,|inhibitor|, (r_nsubj) have_8\VB\2108377|fla-63|did|not|effect|. (l_dobj) effect_10\NN\34213|any|hypotension (l_nmod) hypotension_13\NN\14057371|on|the|,|bradycardia|or|effect|l-dopa
D005406_D001919 NONE fla-63_0\NN\1740|,|inhibitor|, (r_nsubj) have_8\VB\2108377|fla-63|did|not|effect|. (l_dobj) effect_10\NN\34213|any|hypotension (l_nmod) hypotension_13\NN\14057371|on|the|,|bradycardia|or|effect|l-dopa (l_conj) bradycardia_15\NN\14110674|
D004298_D007022 NONE dopamine-beta-oxidase_3\NN\1740| (r_compound) inhibitor_4\NN\20090|a|dopamine-beta-oxidase (r_appos) fla-63_0\NN\1740|,|inhibitor|, (r_nsubj) have_8\VB\2108377|fla-63|did|not|effect|. (l_dobj) effect_10\NN\34213|any|hypotension (l_nmod) hypotension_13\NN\14057371|on|the|,|bradycardia|or|effect|l-dopa
D007980_D007022 NONE l-dopa_20\JJ\1740|of (r_nmod) hypotension_13\NN\14057371|on|the|,|bradycardia|or|effect|l-dopa
D006916_D001919 NONE 5-htp_0\NN\1740|i.v. (r_nsubj) decreased_6\VBN\169651|5-htp|pressure|and|decreased|. (l_conj) decreased_13\VBD\169651|bradycardia|norepinephrine (l_dobj) bradycardia_16\NN\14110674|the|reflex
7423039
D004317_D066126 CID adriamycin_3\NN\1740| (r_compound) cardiotoxicity_4\NN\1740|in|adriamycin
D004317_D066126 CID adriamycin_4\NN\1740|of (r_nmod) effects_2\NNS\13245626|the|cardiotoxic|adriamycin (l_amod) cardiotoxic_1\JJ\1740|
8386779
D017693_D004414 NONE bicarbonate_1\NN\14798450|sodium (r_nsubj) alleviates_2\VBZ\205885|bicarbonate|penile|. (l_xcomp) penile_3\JJ\1740|pain (l_dobj) pain_4\NN\14299637|induced
D017693_D004414 NONE bicarbonate_43\NN\14798450|of|sodium (r_nmod) addition_40\NN\3081021|with|without|the|bicarbonate|total (r_nmod) injections_35\NNS\320852|following|intracorporeal|addition (r_nmod) incidence_29\NN\13821570|the|pain|injections (r_dobj) comparing_27\VBG\644583|incidence (r_acl) study_26\NN\635850|a|randomized|comparing (r_dobj) performed_23\VBD\2367363|whether|,|we|study (l_mark) whether_5\IN\1740|acidity (l_dep) acidity_17\NN\4992163|pain|could|be|due|the|medication (l_nsubj) pain_7\NN\14299637|penile|associated
D017693_D004414 NONE bicarbonate_43\NN\14798450|of|sodium (r_nmod) addition_40\NN\3081021|with|without|the|bicarbonate|total (r_nmod) injections_35\NNS\320852|following|intracorporeal|addition (r_nmod) incidence_29\NN\13821570|the|pain|injections (l_nmod) pain_32\NN\14299637|of|penile
D017693_D004414 NONE bicarbonate_6\NN\14798450|without|sodium (r_nmod) patients_3\NNS\9898892|of|the|19|bicarbonate|added (r_nsubj) complained_16\VBD\843959|patients|pain|medication|,|complained|. (l_nmod) pain_19\NN\14299637|of|penile
D017693_D004414 NONE bicarbonate_6\NN\14798450|without|sodium (r_nmod) patients_3\NNS\9898892|of|the|19|bicarbonate|added (r_nsubj) complained_16\VBD\843959|patients|pain|medication|,|complained|. (l_advcl) complained_40\VBD\843959|while|1|pain (l_nmod) pain_43\NN\14299637|of|penile
D017693_D004414 NONE bicarbonate_39\NN\14798450|sodium (r_dobj) received_37\VBD\2210855|who|bicarbonate (r_acl:relcl) 1_27\CD\13741022|only|men|%|received (r_nsubj) complained_40\VBD\843959|while|1|pain (r_advcl) complained_16\VBD\843959|patients|pain|medication|,|complained|. (l_nmod) pain_19\NN\14299637|of|penile
D017693_D004414 NONE bicarbonate_39\NN\14798450|sodium (r_dobj) received_37\VBD\2210855|who|bicarbonate (r_acl:relcl) 1_27\CD\13741022|only|men|%|received (r_nsubj) complained_40\VBD\843959|while|1|pain (l_nmod) pain_43\NN\14299637|of|penile
D017693_D007172 NONE bicarbonate_1\NN\14798450|sodium (r_nsubj) alleviates_2\VBZ\205885|bicarbonate|penile|. (l_xcomp) penile_3\JJ\1740|pain (l_dobj) pain_4\NN\14299637|induced (l_acl) induced_5\VBN\1627355|injections (l_nmod) injections_8\NNS\320852|by|intracavernous|dysfunction (l_nmod) dysfunction_11\NN\14204950|for|erectile
D017693_D007172 NONE bicarbonate_43\NN\14798450|of|sodium (r_nmod) addition_40\NN\3081021|with|without|the|bicarbonate|total (l_nmod) total_49\NN\3553|to|the|intracorporeal|a|patients (l_nmod) patients_53\NNS\9898892|of|38|consecutive|presented (l_acl:relcl) presented_55\VBD\2137132|who|clinic|impotence (l_nmod) impotence_60\NN\4723816|with
D010208_D004414 NONE papaverine_73\JJ\1740|mg.|,|micrograms (r_dep) received_61\VBD\2210855|attempt|ml.|:|papaverine|. (l_nmod) attempt_2\NN\407535|in|an|determine (l_acl) determine_4\VB\1645601|to|performed (l_ccomp) performed_23\VBD\2367363|whether|,|we|study (l_mark) whether_5\IN\1740|acidity (l_dep) acidity_17\NN\4992163|pain|could|be|due|the|medication (l_nsubj) pain_7\NN\14299637|penile|associated
D010208_D004414 NONE papaverine_73\JJ\1740|mg.|,|micrograms (r_dep) received_61\VBD\2210855|attempt|ml.|:|papaverine|. (l_nmod) attempt_2\NN\407535|in|an|determine (l_acl) determine_4\VB\1645601|to|performed (l_ccomp) performed_23\VBD\2367363|whether|,|we|study (l_dobj) study_26\NN\635850|a|randomized|comparing (l_acl) comparing_27\VBG\644583|incidence (l_dobj) incidence_29\NN\13821570|the|pain|injections (l_nmod) pain_32\NN\14299637|of|penile
D010208_D007172 NONE papaverine_73\JJ\1740|mg.|,|micrograms (r_dep) received_61\VBD\2210855|attempt|ml.|:|papaverine|. (l_nmod) attempt_2\NN\407535|in|an|determine (l_acl) determine_4\VB\1645601|to|performed (l_ccomp) performed_23\VBD\2367363|whether|,|we|study (l_dobj) study_26\NN\635850|a|randomized|comparing (l_acl) comparing_27\VBG\644583|incidence (l_dobj) incidence_29\NN\13821570|the|pain|injections (l_nmod) injections_35\NNS\320852|following|intracorporeal|addition (l_nmod) addition_40\NN\3081021|with|without|the|bicarbonate|total (l_nmod) total_49\NN\3553|to|the|intracorporeal|a|patients (l_nmod) patients_53\NNS\9898892|of|38|consecutive|presented (l_acl:relcl) presented_55\VBD\2137132|who|clinic|impotence (l_nmod) impotence_60\NN\4723816|with
11569530
D016593_D016171 CID terfenadine_17\NN\1740|e.g.|and|terodiline (r_appos) withdrawal_8\NN\7206096|to|drugs|market|(|terfenadine (r_nmod) led_6\VBN\1752884|that|has|withdrawal (r_acl:relcl) side-effect_3\NN\1740|tdp|is|a|led|)|. (l_nsubj) tdp_0\NN\1740|
D016593_D016171 CID terfenadine_13\NN\1740|,|terodiline|,|cisapride|and|e4031 (r_dep) investigated_11\VBN\644583|tdp|were|:|terfenadine (l_nsubjpass) tdp_9\NN\1740|
D016593_D016171 CID terfenadine_10\NN\1740|(|,|terodiline|,|cisapride|) (r_dep) clinic_8\NN\8053905|in|the|terfenadine (r_nmod) shown_4\VBN\2137132|that|have|tdp|clinic (l_dobj) tdp_5\NN\1740|
C010637_D016171 CID terodiline_19\NN\1740| (r_conj) terfenadine_17\NN\1740|e.g.|and|terodiline (r_appos) withdrawal_8\NN\7206096|to|drugs|market|(|terfenadine (r_nmod) led_6\VBN\1752884|that|has|withdrawal (r_acl:relcl) side-effect_3\NN\1740|tdp|is|a|led|)|. (l_nsubj) tdp_0\NN\1740|
C010637_D016171 CID terodiline_15\NN\1740| (r_conj) terfenadine_13\NN\1740|,|terodiline|,|cisapride|and|e4031 (r_dep) investigated_11\VBN\644583|tdp|were|:|terfenadine (l_nsubjpass) tdp_9\NN\1740|
C010637_D016171 CID terodiline_12\NN\1740| (r_conj) terfenadine_10\NN\1740|(|,|terodiline|,|cisapride|) (r_dep) clinic_8\NN\8053905|in|the|terfenadine (r_nmod) shown_4\VBN\2137132|that|have|tdp|clinic (l_dobj) tdp_5\NN\1740|
D020117_D016171 CID cisapride_17\NN\1740| (r_conj) terfenadine_13\NN\1740|,|terodiline|,|cisapride|and|e4031 (r_dep) investigated_11\VBN\644583|tdp|were|:|terfenadine (l_nsubjpass) tdp_9\NN\1740|
D020117_D016171 CID cisapride_14\NN\1740| (r_appos) terfenadine_10\NN\1740|(|,|terodiline|,|cisapride|) (r_dep) clinic_8\NN\8053905|in|the|terfenadine (r_nmod) shown_4\VBN\2137132|that|have|tdp|clinic (l_dobj) tdp_5\NN\1740|
C063968_D016171 NONE e4031_19\NN\1740| (r_conj) terfenadine_13\NN\1740|,|terodiline|,|cisapride|and|e4031 (r_dep) investigated_11\VBN\644583|tdp|were|:|terfenadine (l_nsubjpass) tdp_9\NN\1740|
6308277
D002110_D064420 NONE caffeine_2\NN\14712692| (r_compound) toxicity_3\NN\13576101|in|caffeine
D002110_D064420 NONE caffeine_11\NN\14712692|of (r_nmod) effects_9\NNS\13245626|the|stimulatory|caffeine|cns (r_dobj) augment_6\VB\153263|to|effects (r_xcomp) reported_4\VBN\831651|because|salicylates|have|been|augment (r_advcl) focused_18\VBN\628491|reported|,|attention|was|possibility|. (l_nmod) possibility_21\NN\5944958|on|the|reduced (l_ccomp) reduced_31\VBD\441445|that|presence|toxicity (l_dobj) toxicity_34\NN\13576101|the|cns|caffeine
D002110_D064420 NONE caffeine_36\NN\14712692|of (r_nmod) toxicity_34\NN\13576101|the|cns|caffeine
D000082_D064420 NONE acetaminophen_5\RB\1740|by (r_nmod) reduction_0\NN\351485|toxicity|acetaminophen|. (l_nmod) toxicity_3\NN\13576101|in|caffeine
D000082_D064420 NONE acetaminophen_26\NN\2707683|of (r_nmod) presence_24\NN\13954253|the|acetaminophen|micrograms/ml (r_nsubj) reduced_31\VBD\441445|that|presence|toxicity (l_dobj) toxicity_34\NN\13576101|the|cns|caffeine
D000082_D012640 NONE acetaminophen_11\NN\2707683|with (r_nmod) pretreatment_9\NN\1740|acetaminophen|mg/kg (r_nsubj) increased_16\VBD\169651|that|1|pretreatment|interval|;|and|reduced (l_dobj) interval_18\NN\33615|the|administration (l_nmod) administration_21\NN\1133281|between|the|caffeine|and|onset (l_conj) onset_33\NN\7325190|the|convulsions|factor (l_nmod) convulsions_36\NNS\14081375|of|fatal
D000082_D012640 NONE acetaminophen_11\NN\2707683|with (r_nmod) pretreatment_9\NN\1740|acetaminophen|mg/kg (r_nsubj) increased_16\VBD\169651|that|1|pretreatment|interval|;|and|reduced (l_conj) reduced_54\VBD\441445|pretreatment|incidence|) (l_dobj) incidence_56\NN\13821570|the|seizures (l_nmod) seizures_59\NNS\14081375|of|audiogenic|produced
D000082_D012640 NONE acetaminophen_49\NN\2707683|with|mg/kg (r_nmod) pretreatment_47\NN\1740|2|acetaminophen (r_nsubj) reduced_54\VBD\441445|pretreatment|incidence|) (r_conj) increased_16\VBD\169651|that|1|pretreatment|interval|;|and|reduced (l_dobj) interval_18\NN\33615|the|administration (l_nmod) administration_21\NN\1133281|between|the|caffeine|and|onset (l_conj) onset_33\NN\7325190|the|convulsions|factor (l_nmod) convulsions_36\NNS\14081375|of|fatal
D000082_D012640 NONE acetaminophen_49\NN\2707683|with|mg/kg (r_nmod) pretreatment_47\NN\1740|2|acetaminophen (r_nsubj) reduced_54\VBD\441445|pretreatment|incidence|) (l_dobj) incidence_56\NN\13821570|the|seizures (l_nmod) seizures_59\NNS\14081375|of|audiogenic|produced
D000082_D012640 NONE acetaminophen_19\RB\1740|by (r_nmod) reduced_12\VBN\441445|frequency|was|%|acetaminophen|. (l_nsubjpass) frequency_1\NN\15286249|the|seizures|caffeine (l_nmod) seizures_4\NNS\14081375|of|sound-induced
D000082_D012640 NONE acetaminophen_6\RB\1740|mg/kg (r_nsubj) modify_15\VB\109660|absence|,|acetaminophen|did|not|seizures|and|alter|tests|. (l_dobj) seizures_17\NNS\14081375|the|induced
D002110_D012640 CID caffeine_23\NN\14712692|of|ip (r_nmod) administration_21\NN\1133281|between|the|caffeine|and|onset (l_conj) onset_33\NN\7325190|the|convulsions|factor (l_nmod) convulsions_36\NNS\14081375|of|fatal
D002110_D012640 CID caffeine_23\NN\14712692|of|ip (r_nmod) administration_21\NN\1133281|between|the|caffeine|and|onset (r_nmod) interval_18\NN\33615|the|administration (r_dobj) increased_16\VBD\169651|that|1|pretreatment|interval|;|and|reduced (l_conj) reduced_54\VBD\441445|pretreatment|incidence|) (l_dobj) incidence_56\NN\13821570|the|seizures (l_nmod) seizures_59\NNS\14081375|of|audiogenic|produced
D002110_D012640 CID caffeine_65\NN\14712692|of (r_nmod) presence_63\NN\13954253|in|the|caffeine (r_nmod) produced_60\VBN\1617192|presence|ip (r_acl) seizures_59\NNS\14081375|of|audiogenic|produced (r_nmod) incidence_56\NN\13821570|the|seizures (r_dobj) reduced_54\VBD\441445|pretreatment|incidence|) (r_conj) increased_16\VBD\169651|that|1|pretreatment|interval|;|and|reduced (l_dobj) interval_18\NN\33615|the|administration (l_nmod) administration_21\NN\1133281|between|the|caffeine|and|onset (l_conj) onset_33\NN\7325190|the|convulsions|factor (l_nmod) convulsions_36\NNS\14081375|of|fatal
D002110_D012640 CID caffeine_65\NN\14712692|of (r_nmod) presence_63\NN\13954253|in|the|caffeine (r_nmod) produced_60\VBN\1617192|presence|ip (r_acl) seizures_59\NNS\14081375|of|audiogenic|produced
D002110_D012640 CID caffeine_10\NN\14712692|after|12.5|mg/kg (r_nmod) frequency_1\NN\15286249|the|seizures|caffeine (l_nmod) seizures_4\NNS\14081375|of|sound-induced
D002110_D012640 CID caffeine_4\NN\14712692|of (r_nmod) absence_2\NN\14449405|in|the|caffeine (r_nmod) modify_15\VB\109660|absence|,|acetaminophen|did|not|seizures|and|alter|tests|. (l_dobj) seizures_17\NNS\14081375|the|induced
D010433_D012640 CID pentylenetetrezol_30\NN\1740|of|mice (r_nmod) dose_28\NN\3740161|the|convulsant|pentylenetetrezol (r_dobj) alter_25\VB\126264|did|not|dose (r_conj) modify_15\VB\109660|absence|,|acetaminophen|did|not|seizures|and|alter|tests|. (l_dobj) seizures_17\NNS\14081375|the|induced
16574712
D018817_D003072 CID mdma_0\NN\3054098| (r_compound) users_2\NNS\7846|mdma|polydrug (r_nsubj) show_3\VBP\2137132|users|impairments|. (l_dobj) impairments_7\NNS\7296428|process-specific|executive|coupled (l_acl) coupled_8\VBN\1295275|processes (l_nmod) processes_15\NNS\407535|with|impaired|social
D018817_D008569 NONE mdma_12\NN\3054098|of|3,4-methylenedioxymethamphetamine (r_nmod) users_10\NNS\7846|in|mdma (r_nmod) reported_8\VBN\831651|years|have|been|users|. (l_nmod) years_2\NNS\15144371|in|recent|working (l_acl) working_3\VBG\2524171|deficits (l_dobj) deficits_5\NNS\5113133|memory
D018817_D008569 NONE 3,4-methylenedioxymethamphetamine_14\NN\1740|(|,|ecstasy|) (r_dep) mdma_12\NN\3054098|of|3,4-methylenedioxymethamphetamine (r_nmod) users_10\NNS\7846|in|mdma (r_nmod) reported_8\VBN\831651|years|have|been|users|. (l_nmod) years_2\NNS\15144371|in|recent|working (l_acl) working_3\VBG\2524171|deficits (l_dobj) deficits_5\NNS\5113133|memory
D018817_D008569 NONE ecstasy_16\NN\13985818| (r_amod) 3,4-methylenedioxymethamphetamine_14\NN\1740|(|,|ecstasy|) (r_dep) mdma_12\NN\3054098|of|3,4-methylenedioxymethamphetamine (r_nmod) users_10\NNS\7846|in|mdma (r_nmod) reported_8\VBN\831651|years|have|been|users|. (l_nmod) years_2\NNS\15144371|in|recent|working (l_acl) working_3\VBG\2524171|deficits (l_dobj) deficits_5\NNS\5113133|memory
6773726
D005996_D007022 CID nitroglycerin_5\NN\15015501|by (r_nmod) provocation_0\NN\1221611|hypotension|nitroglycerin|neuropathy|? (l_nmod) hypotension_3\NN\14057371|of|postural
D005996_D003929 NONE nitroglycerin_5\NN\15015501|by (r_nmod) provocation_0\NN\1221611|hypotension|nitroglycerin|neuropathy|? (l_nmod) neuropathy_9\JJ\1740|in|autonomic
D005996_D003920 NONE nitroglycerin_3\NN\15015501|of (r_nmod) effect_1\NN\34213|the|nitroglycerin|rate (r_nsubjpass) compared_12\VBN\644583|effect|was|subjects|neuropathy|,|and|subjects|. (l_nmod) subjects_16\NNS\6598915|in|5|normal|,|subjects (l_conj) subjects_20\NNS\6598915|12|diabetic (l_amod) diabetic_19\JJ\1740|
D005996_D003920 NONE nitroglycerin_3\NN\15015501|of (r_nmod) effect_1\NN\34213|the|nitroglycerin|rate (r_nsubjpass) compared_12\VBN\644583|effect|was|subjects|neuropathy|,|and|subjects|. (l_conj) subjects_28\NNS\6598915|5|diabetic|neuropathy (l_amod) diabetic_27\JJ\1740|
D005996_D003920 NONE nitroglycerin_19\NN\15015501|after (r_nmod) magnitude_1\NN\4916342|the|and|course|increase|and|decrease|pressure|nitroglycerin (r_nsubj) similar_21\JJ\1740|magnitude|were|subjects|neuropathy|,|whereas|occurred|. (l_nmod) subjects_27\NNS\6598915|in|the|normal (l_amod) normal_24\JJ\1740|and|diabetic (l_conj) diabetic_26\JJ\1740|
D005996_D003920 NONE nitroglycerin_19\NN\15015501|after (r_nmod) magnitude_1\NN\4916342|the|and|course|increase|and|decrease|pressure|nitroglycerin (r_nsubj) similar_21\JJ\1740|magnitude|were|subjects|neuropathy|,|whereas|occurred|. (l_parataxis) occurred_47\VBD\2623529|increase|subjects|neuropathy (l_nmod) subjects_51\NNS\6598915|in|the|diabetic (l_amod) diabetic_50\JJ\1740|
D005996_D009422 NONE nitroglycerin_3\NN\15015501|of (r_nmod) effect_1\NN\34213|the|nitroglycerin|rate (r_nsubjpass) compared_12\VBN\644583|effect|was|subjects|neuropathy|,|and|subjects|. (l_nmod) neuropathy_23\RB\1740|without|autonomic
D005996_D009422 NONE nitroglycerin_3\NN\15015501|of (r_nmod) effect_1\NN\34213|the|nitroglycerin|rate (r_nsubjpass) compared_12\VBN\644583|effect|was|subjects|neuropathy|,|and|subjects|. (l_conj) subjects_28\NNS\6598915|5|diabetic|neuropathy (l_nmod) neuropathy_31\NN\14204950|with|autonomic
D005996_D009422 NONE nitroglycerin_19\NN\15015501|after (r_nmod) magnitude_1\NN\4916342|the|and|course|increase|and|decrease|pressure|nitroglycerin (r_nsubj) similar_21\JJ\1740|magnitude|were|subjects|neuropathy|,|whereas|occurred|. (l_nmod) neuropathy_30\JJ\1740|without|autonomic
D005996_D009422 NONE nitroglycerin_19\NN\15015501|after (r_nmod) magnitude_1\NN\4916342|the|and|course|increase|and|decrease|pressure|nitroglycerin (r_nsubj) similar_21\JJ\1740|magnitude|were|subjects|neuropathy|,|whereas|occurred|. (l_parataxis) occurred_47\VBD\2623529|increase|subjects|neuropathy (l_nmod) neuropathy_54\NN\14204950|with|autonomic
15130900
D003520_D001749 CID cyclophosphamide_12\NN\1740|to (r_nmod) relation_10\NN\2137|cyclophosphamide (r_conj) risks_8\NNS\14541044|and|relation (r_dep) cancer_2\NN\14239425|bladder|granulomatosis|:|risks|.
D003520_D001749 CID cyclophosphamide_16\NN\1740|to (r_nmod) relation_14\NN\2137|its|cyclophosphamide (r_conj) assess_3\VB\670261|to|and|characterise|risk|,|and|relation|,|patients (l_dobj) risk_7\NN\14541044|the|cancer (l_nmod) cancer_10\NN\14239425|of|bladder
D003520_D001749 CID cyclophosphamide_16\NN\1740|between|and|cancer (l_conj) cancer_19\NN\14239425|bladder
D003520_D001749 CID cyclophosphamide_12\NN\1740|in (r_nmod) increment_10\NN\29677|for|every|g|cyclophosphamide|or (r_nmod) doubled_5\VBN\247390|increment (r_acl) risk_1\NN\14541044|the|cancer|doubled|interval|. (l_nmod) cancer_4\NN\14239425|of|bladder
D003520_D001749 CID cyclophosphamide_9\NN\1740|between|and|risk|risks (l_conj) risk_12\NN\14541044|the|cancer (l_nmod) cancer_15\NN\14239425|of|bladder|,
D003520_D014890 NONE cyclophosphamide_12\NN\1740|to (r_nmod) relation_10\NN\2137|cyclophosphamide (r_conj) risks_8\NNS\14541044|and|relation (r_dep) cancer_2\NN\14239425|bladder|granulomatosis|:|risks|. (l_nmod) granulomatosis_6\NN\1740|in|wegener|'s
D003520_D014890 NONE cyclophosphamide_16\NN\1740|to (r_nmod) relation_14\NN\2137|its|cyclophosphamide (r_conj) assess_3\VB\670261|to|and|characterise|risk|,|and|relation|,|patients (l_nmod) patients_19\NNS\9898892|in|granulomatosis (l_nmod) granulomatosis_23\NN\1740|with|wegener
D003520_D014890 NONE cyclophosphamide_9\NN\1740|between|and|risk|risks (r_nmod) relationship_7\NN\31921|a|dose-response|cyclophosphamide (r_dobj) indicate_4\VBP\952524|conclusion|:|results|relationship|,|and|possibility|. (l_dobj) possibility_28\NN\5944958|the|factors (l_nmod) factors_31\NNS\7326557|of|risk|operating (l_acl) operating_32\VBG\2439501|granulomatosis (l_nmod) granulomatosis_37\NN\1740|before|wegener
150790
D011736_D002653 NONE pyridoxine-dependent_1\JJ\1740| (r_amod) disorder_3\NN\14034177|a|pyridoxine-dependent|behavioral|unmasked|.
D007538_D002653 CID isoniazid_6\NNS\2716205|by (r_nmod) unmasked_4\VBN\853195|isoniazid (r_acl) disorder_3\NN\14034177|a|pyridoxine-dependent|behavioral|unmasked|.
D007538_D002653 CID isoniazid_20\NN\2716205|of (r_nmod) administration_18\NN\1133281|after|the|therapeutic|isoniazid (r_nmod) sleeping_13\VBG\14405|difficulties|administration (r_conj) had_3\VBD\2108377|girl|deterioration|and|sleeping|. (l_dobj) deterioration_5\NN\14560612|behavioral|,|hyperkinesis
D007538_D006948 CID isoniazid_20\NN\2716205|of (r_nmod) administration_18\NN\1133281|after|the|therapeutic|isoniazid (r_nmod) sleeping_13\VBG\14405|difficulties|administration (r_conj) had_3\VBD\2108377|girl|deterioration|and|sleeping|. (l_dobj) deterioration_5\NN\14560612|behavioral|,|hyperkinesis (l_nmod) hyperkinesis_8\NN\1740|with|,|irritability|,
D007538_D001523 NONE isoniazid_20\NN\2716205|of (r_nmod) administration_18\NN\1133281|after|the|therapeutic|isoniazid (r_nmod) sleeping_13\VBG\14405|difficulties|administration (r_conj) had_3\VBD\2108377|girl|deterioration|and|sleeping|. (l_dobj) deterioration_5\NN\14560612|behavioral|,|hyperkinesis (l_nmod) hyperkinesis_8\NN\1740|with|,|irritability|, (l_conj) irritability_10\NN\7552087|
D007538_D012893 NONE isoniazid_20\NN\2716205|of (r_nmod) administration_18\NN\1133281|after|the|therapeutic|isoniazid (r_nmod) sleeping_13\VBG\14405|difficulties|administration (l_dobj) difficulties_14\NNS\621627|
D011736_D006948 NONE pyridoxine_3\NN\15090742|of (r_nmod) withdrawal_1\NN\7206096|periodic|pyridoxine (r_nsubjpass) associated_5\VBN\628491|withdrawal|was|return|. (l_nmod) return_7\NN\6479665|with|hyperkinesis (l_nmod) hyperkinesis_10\NN\1740|of|the
3719553
D005472_D004342 NONE 5-fluorouracil_3\NN\1740| (r_compound) infusion_4\NN\14589223|to|5-fluorouracil (r_nmod) reaction_1\NN\13446390|allergic|infusion|.
D005472_D004342 NONE 5-fluorouracil_11\NN\1740|to|continuous|infusion (r_nmod) secondary_7\JJ\1740|5-fluorouracil (r_amod) edema_6\NN\14315192|of|angioneurotic|secondary (r_nmod) consisting_3\VBG\2603699|edema (r_acl) reaction_2\NN\13446390|an|allergic|consisting
D005472_D000799 CID 5-fluorouracil_11\NN\1740|to|continuous|infusion (r_nmod) secondary_7\JJ\1740|5-fluorouracil (r_amod) edema_6\NN\14315192|of|angioneurotic|secondary
D005472_D009062 NONE 5-fluorouracil_11\NN\1740|to|continuous|infusion (r_nmod) secondary_7\JJ\1740|5-fluorouracil (r_amod) edema_6\NN\14315192|of|angioneurotic|secondary (r_nmod) consisting_3\VBG\2603699|edema (r_acl) reaction_2\NN\13446390|an|allergic|consisting (r_nsubj) occurred_12\VBD\2623529|reaction|patient|. (l_nmod) patient_15\NN\9898892|in|a|carcinoma (l_nmod) carcinoma_18\NN\14239918|with|recurrent|cavity (l_nmod) cavity_22\NN\9304750|of|the|oral|,|cirrhosis|,|and|function
D005472_D005355 NONE 5-fluorouracil_11\NN\1740|to|continuous|infusion (r_nmod) secondary_7\JJ\1740|5-fluorouracil (r_amod) edema_6\NN\14315192|of|angioneurotic|secondary (r_nmod) consisting_3\VBG\2603699|edema (r_acl) reaction_2\NN\13446390|an|allergic|consisting (r_nsubj) occurred_12\VBD\2623529|reaction|patient|. (l_nmod) patient_15\NN\9898892|in|a|carcinoma (l_nmod) carcinoma_18\NN\14239918|with|recurrent|cavity (l_nmod) cavity_22\NN\9304750|of|the|oral|,|cirrhosis|,|and|function (l_conj) cirrhosis_24\NN\14116321|
D005472_D007674 NONE 5-fluorouracil_11\NN\1740|to|continuous|infusion (r_nmod) secondary_7\JJ\1740|5-fluorouracil (r_amod) edema_6\NN\14315192|of|angioneurotic|secondary (r_nmod) consisting_3\VBG\2603699|edema (r_acl) reaction_2\NN\13446390|an|allergic|consisting (r_nsubj) occurred_12\VBD\2623529|reaction|patient|. (l_nmod) patient_15\NN\9898892|in|a|carcinoma (l_nmod) carcinoma_18\NN\14239918|with|recurrent|cavity (l_nmod) cavity_22\NN\9304750|of|the|oral|,|cirrhosis|,|and|function (l_conj) function_30\NN\13783581|cisplatin-induced|impaired|renal
D002945_D004342 NONE cisplatin-induced_27\JJ\1740| (r_amod) function_30\NN\13783581|cisplatin-induced|impaired|renal (r_conj) cavity_22\NN\9304750|of|the|oral|,|cirrhosis|,|and|function (r_nmod) carcinoma_18\NN\14239918|with|recurrent|cavity (r_nmod) patient_15\NN\9898892|in|a|carcinoma (r_nmod) occurred_12\VBD\2623529|reaction|patient|. (l_nsubj) reaction_2\NN\13446390|an|allergic|consisting
D002945_D000799 NONE cisplatin-induced_27\JJ\1740| (r_amod) function_30\NN\13783581|cisplatin-induced|impaired|renal (r_conj) cavity_22\NN\9304750|of|the|oral|,|cirrhosis|,|and|function (r_nmod) carcinoma_18\NN\14239918|with|recurrent|cavity (r_nmod) patient_15\NN\9898892|in|a|carcinoma (r_nmod) occurred_12\VBD\2623529|reaction|patient|. (l_nsubj) reaction_2\NN\13446390|an|allergic|consisting (l_acl) consisting_3\VBG\2603699|edema (l_nmod) edema_6\NN\14315192|of|angioneurotic|secondary
D002945_D009062 NONE cisplatin-induced_27\JJ\1740| (r_amod) function_30\NN\13783581|cisplatin-induced|impaired|renal (r_conj) cavity_22\NN\9304750|of|the|oral|,|cirrhosis|,|and|function
D002945_D005355 NONE cisplatin-induced_27\JJ\1740| (r_amod) function_30\NN\13783581|cisplatin-induced|impaired|renal (r_conj) cavity_22\NN\9304750|of|the|oral|,|cirrhosis|,|and|function (l_conj) cirrhosis_24\NN\14116321|
D002945_D007674 NONE cisplatin-induced_27\JJ\1740| (r_amod) function_30\NN\13783581|cisplatin-induced|impaired|renal
D004155_D004342 NONE diphenhydramine_1\NN\2720725|oral|and|prednisone (r_nsubj) ineffective_5\JJ\1740|diphenhydramine|were|preventing|. (l_advcl) preventing_7\VBG\1740|in|recurrence (l_dobj) recurrence_9\NN\7342049|the|reaction (l_nmod) reaction_13\NN\13446390|of|the|allergic
D011241_D004342 NONE prednisone_3\NN\2721538| (r_conj) diphenhydramine_1\NN\2720725|oral|and|prednisone (r_nsubj) ineffective_5\JJ\1740|diphenhydramine|were|preventing|. (l_advcl) preventing_7\VBG\1740|in|recurrence (l_dobj) recurrence_9\NN\7342049|the|reaction (l_nmod) reaction_13\NN\13446390|of|the|allergic
12090760
D015215_D000740 CID azidothymidine-induced_9\JJ\1740| (r_amod) anemia_10\NN\14189204|with|azidothymidine-induced|and|cells
D015215_D000740 CID azidothymidine_0\NN\1740| (r_compound) anemia_2\NN\14189204|azidothymidine|(azt)-induced|mice
D015215_D000740 CID (azt)-induced_1\JJ\1740| (r_compound) anemia_2\NN\14189204|azidothymidine|(azt)-induced|mice
15120741
D010862_D013226 CID pilocarpine_5\NN\14712692| (r_compound) injection_6\NN\320852|systemic|pilocarpine (r_nsubj) causes_7\VBZ\1617192|similar|,|injection|epilepticus|,|but|identified|. (l_dobj) epilepticus_9\NN\1740|status|se|and|development|fiber
D010862_D013226 CID pilocarpine_5\NN\14712692| (r_compound) injection_6\NN\320852|systemic|pilocarpine (r_nsubj) causes_7\VBZ\1617192|similar|,|injection|epilepticus|,|but|identified|. (l_dobj) epilepticus_9\NN\1740|status|se|and|development|fiber (l_appos) se_11\NN\14724645|(|)
D010862_D013226 CID pilocarpine-treated_34\JJ\1740| (r_amod) mice_35\NNS\2329401|pilocarpine-treated (r_conj) mice_32\NNS\2329401|from|control|and|mice (r_nmod) cells_29\NNS\3080309|spike|in|granule|mice|experience (l_acl:relcl) experience_39\VB\2108377|that|did|not|se (l_dobj) se_40\NN\14724645|
D010862_D012640 CID pilocarpine_5\NN\14712692| (r_compound) injection_6\NN\320852|systemic|pilocarpine (r_nsubj) causes_7\VBZ\1617192|similar|,|injection|epilepticus|,|but|identified|. (l_dobj) epilepticus_9\NN\1740|status|se|and|development|fiber (l_conj) development_16\NN\248977|the|eventual|seizures (l_nmod) seizures_19\NNS\14081375|of|spontaneous|and
D008274_D013226 NONE mg(2+)-free_1\NN\1740| (r_compound) medium_3\NN\3575240|in|mg(2+)-free|bathing|containing|,|conditions (r_nmod) resulted_21\VBD\2633881|medium|,|stimulation|population|cells|. (l_nmod) cells_29\NNS\3080309|spike|in|granule|mice|experience (l_acl:relcl) experience_39\VB\2108377|that|did|not|se (l_dobj) se_40\NN\14724645|
D001640_D013226 NONE bicuculline_5\NN\1740| (r_dobj) containing_4\VBG\2632940|bicuculline (r_acl) medium_3\NN\3575240|in|mg(2+)-free|bathing|containing|,|conditions (r_nmod) resulted_21\VBD\2633881|medium|,|stimulation|population|cells|. (l_nmod) cells_29\NNS\3080309|spike|in|granule|mice|experience (l_acl:relcl) experience_39\VB\2108377|that|did|not|se (l_dobj) se_40\NN\14724645|
D018698_D013226 NONE glutamate_37\JJ\1740| (r_amod) antagonists_39\NNS\7846|by|ionotropic|glutamate|receptor (r_nmod) blocked_34\VBN\1476483|which|were|antagonists (r_dep) resulted_6\VBD\2633881|survivors|,|stimulation|population|,|latency|,|shifts|blocked|. (l_nmod) survivors_2\NNS\9630641|in|se (l_compound) se_1\NN\14724645|
D018698_D013226 NONE glutamate_1\JJ\1740|focal (r_amod) photostimulation_2\NN\1740|glutamate|layer (r_nsubj) resulted_15\VBD\2633881|photostimulation|responses|. (l_nmod) responses_18\NNS\11410625|in|population|duration (l_nmod) duration_24\NN\15113229|of|30|s|slices (l_nmod) slices_26\NNS\13285176|in|survivors (l_nmod) survivors_29\NNS\9630641|from|se|not|groups (l_compound) se_28\NN\14724645|
14765563
D011803_D020922 NONE quinine_23\NN\2721948| (r_nsubj) available_26\JJ\1740|banned|quinine|is|widely|beverages|. (l_advcl) banned_8\VBD\2480923|although|administration|use|lack|, (l_dobj) use_10\NN\407535|its|cramps (l_nmod) cramps_14\NNS\14299637|for|nocturnal|leg
D011803_D002493 NONE quinine_7\NN\2721948| (r_dobj) containing_6\VBG\2632940|quinine (r_acl) products_5\NNS\3076708|containing (r_nsubj) produce_9\VB\1617192|that|products|may|complications|women (l_dobj) complications_11\NNS\1073995|neurological|,|confusion|,
D011803_D003221 CID quinine_7\NN\2721948| (r_dobj) containing_6\VBG\2632940|quinine (r_acl) products_5\NNS\3076708|containing (r_nsubj) produce_9\VB\1617192|that|products|may|complications|women (l_dobj) complications_11\NNS\1073995|neurological|,|confusion|, (l_nmod) confusion_14\NN\13972797|including|,|status|,|seizures|,|and|coma
D011803_D012640 CID quinine_7\NN\2721948| (r_dobj) containing_6\VBG\2632940|quinine (r_acl) products_5\NNS\3076708|containing (r_nsubj) produce_9\VB\1617192|that|products|may|complications|women (l_dobj) complications_11\NNS\1073995|neurological|,|confusion|, (l_nmod) confusion_14\NN\13972797|including|,|status|,|seizures|,|and|coma (l_conj) seizures_20\NNS\14081375|
D011803_D003128 CID quinine_7\NN\2721948| (r_dobj) containing_6\VBG\2632940|quinine (r_acl) products_5\NNS\3076708|containing (r_nsubj) produce_9\VB\1617192|that|products|may|complications|women (l_dobj) complications_11\NNS\1073995|neurological|,|confusion|, (l_nmod) confusion_14\NN\13972797|including|,|status|,|seizures|,|and|coma (l_conj) coma_23\NN\5678932|
10835440
D009553_D020521 NONE nimodipine_3\NN\1740|of|intravenous (r_nmod) effect_0\NN\34213|nimodipine|pressure|and|outcome|. (l_conj) outcome_8\VB\1740|stroke (l_nmod) stroke_11\NN\556313|after|acute
D009553_D020521 NONE nimodipine_6\NNP\1740| (r_compound) european_8\NNP\9620078|intravenous|nimodipine|west (r_compound) trial_10\NNP\786195|the|european|stroke|inwest|) (l_compound) stroke_9\NNP\556313|
D009553_D020521 NONE nimodipine_6\NNP\1740| (r_compound) european_8\NNP\9620078|intravenous|nimodipine|west (r_compound) trial_10\NNP\786195|the|european|stroke|inwest|) (r_nsubj) found_14\VBD\2426171|trial|correlation (l_dobj) correlation_16\NN\13841213|a|reduction (l_nmod) reduction_19\NN\351485|between|nimodipine-induced|pressure|outcome (l_conj) outcome_29\NN\7291312|an|unfavorable|stroke (l_nmod) stroke_32\NN\556313|in|acute
D009553_D020521 NONE nimodipine-induced_18\JJ\1740| (r_amod) reduction_19\NN\351485|between|nimodipine-induced|pressure|outcome (r_nmod) correlation_16\NN\13841213|a|reduction (r_dobj) found_14\VBD\2426171|trial|correlation (l_nsubj) trial_10\NNP\786195|the|european|stroke|inwest|) (l_compound) stroke_9\NNP\556313|
D009553_D020521 NONE nimodipine-induced_18\JJ\1740| (r_amod) reduction_19\NN\351485|between|nimodipine-induced|pressure|outcome (l_conj) outcome_29\NN\7291312|an|unfavorable|stroke (l_nmod) stroke_32\NN\556313|in|acute
D009553_D020521 NONE nimodipine_20\NN\1740|of|high-dose (r_nmod) administration_17\NN\1133281|after|the|intravenous|nimodipine (r_nmod) worsening_13\NN\13457378|with|neurological|administration (r_nmod) associated_10\VBN\628491|dbp|was|worsening|stroke (l_nmod) stroke_23\NN\556313|after|acute
D009553_D007022 CID nimodipine_6\NNP\1740| (r_compound) european_8\NNP\9620078|intravenous|nimodipine|west (r_compound) trial_10\NNP\786195|the|european|stroke|inwest|) (r_nsubj) found_14\VBD\2426171|trial|correlation (l_dobj) correlation_16\NN\13841213|a|reduction (l_nmod) reduction_19\NN\351485|between|nimodipine-induced|pressure|outcome (l_nmod) pressure_22\NN\11419404|in|blood|bp|and
D009553_D007022 CID nimodipine-induced_18\JJ\1740| (r_amod) reduction_19\NN\351485|between|nimodipine-induced|pressure|outcome (l_nmod) pressure_22\NN\11419404|in|blood|bp|and
D009553_D007022 CID nimodipine_0\NN\1740| (r_compound) treatment_1\NN\654885|nimodipine (r_nsubj) resulted_2\VBD\2633881|treatment|reduction|placebo|. (l_nmod) reduction_7\NN\351485|in|a|significant|bp|baseline (l_nmod) bp_10\NN\1740|in|systolic|sbp|and|bp
D009553_D002544 NONE nimodipine_30\NN\1740|1|mg/h|(|low-dose|)|n=101 (r_conj) placebo_20\NN\3740161|n=100|,|nimodipine|,|or|nimodipine (r_dobj) receive_19\VB\2210855|to|placebo (r_xcomp) allocated_17\VBN\2228698|patients|were|consecutively|receive (l_nsubjpass) patients_2\NNS\9898892|diagnosis|hours (l_nmod) diagnosis_6\NN\152018|with|a|clinical|stroke (l_nmod) stroke_9\NN\556313|of|ischemic
D009553_D002544 NONE nimodipine_41\NN\1740|mg/h|(|)|n=94 (r_conj) placebo_20\NN\3740161|n=100|,|nimodipine|,|or|nimodipine (r_dobj) receive_19\VB\2210855|to|placebo (r_xcomp) allocated_17\VBN\2228698|patients|were|consecutively|receive (l_nsubjpass) patients_2\NNS\9898892|diagnosis|hours (l_nmod) diagnosis_6\NN\152018|with|a|clinical|stroke (l_nmod) stroke_9\NN\556313|of|ischemic
18464113
D019259_D006509 NONE lamivudine_0\NN\3834836|prevention|patients|. (l_nmod) prevention_3\NN\1073995|for|the|reactivation (l_nmod) reactivation_8\NN\1740|of|hepatitis|b|virus|antigen (l_compound) b_6\NN\1355326|
D019259_D006509 NONE lamivudine_20\NN\3834836|the|antiviral|agent (r_dobj) received_16\VBD\2210855|study|,|patients|lamivudine|prior|. (l_nsubj) patients_5\NNS\9898892|cancer|have (l_acl:relcl) have_7\VBP\2108377|who|malignancies (l_dobj) malignancies_11\NNS\14070360|solid|infection (l_nmod) infection_15\NN\14052046|with|chronic|hbv
D019259_D006509 NONE lamivudine_34\NN\3834836| (r_dobj) receive_33\VB\2210855|who|did|not|lamivudine (r_acl:relcl) group_29\NN\2137|with|historical|control|receive (r_nmod) compared_25\VBN\644583|group (r_acl) ct_24\NN\901316|compared (r_conj) prior_21\RB\1740|and|during|ct (r_advmod) received_16\VBD\2210855|study|,|patients|lamivudine|prior|. (l_nsubj) patients_5\NNS\9898892|cancer|have (l_acl:relcl) have_7\VBP\2108377|who|malignancies (l_dobj) malignancies_11\NNS\14070360|solid|infection (l_nmod) infection_15\NN\14052046|with|chronic|hbv
D019259_D009369 NONE lamivudine_0\NN\3834836|prevention|patients|. (l_nmod) patients_18\NNS\9898892|seropositive|cancer|undergoing (l_compound) cancer_17\NN\14239425|
D019259_D009369 NONE lamivudine_20\NN\3834836|the|antiviral|agent (r_dobj) received_16\VBD\2210855|study|,|patients|lamivudine|prior|. (l_nsubj) patients_5\NNS\9898892|cancer|have (l_compound) cancer_4\NN\14239425|
D019259_D009369 NONE lamivudine_34\NN\3834836| (r_dobj) receive_33\VB\2210855|who|did|not|lamivudine (r_acl:relcl) group_29\NN\2137|with|historical|control|receive (r_nmod) compared_25\VBN\644583|group (r_acl) ct_24\NN\901316|compared (r_conj) prior_21\RB\1740|and|during|ct (r_advmod) received_16\VBD\2210855|study|,|patients|lamivudine|prior|. (l_nsubj) patients_5\NNS\9898892|cancer|have (l_compound) cancer_4\NN\14239425|
D019259_D009369 NONE lamivudine_5\NN\3834836|prophylactic (r_nsubj) decreases_7\VBZ\169651|that|lamivudine|significantly|incidence|therapy (l_dobj) incidence_9\NN\13821570|the|reactivation|and|morbidity (l_conj) morbidity_15\NN\13826959|overall|patients (l_nmod) patients_18\NNS\9898892|in|cancer (l_compound) cancer_17\NN\14239425|
D006514_D006509 CID antigen_12\NN\20090|in|hepatitis-b|surface|hbsag (r_nmod) reactivation_8\NN\1740|of|hepatitis|b|virus|antigen (l_compound) b_6\NN\1355326|
D006514_D006509 CID hbsag_14\NN\1740|(|) (r_appos) antigen_12\NN\20090|in|hepatitis-b|surface|hbsag (r_nmod) reactivation_8\NN\1740|of|hepatitis|b|virus|antigen (l_compound) b_6\NN\1355326|
D006514_D009369 NONE antigen_12\NN\20090|in|hepatitis-b|surface|hbsag (r_nmod) reactivation_8\NN\1740|of|hepatitis|b|virus|antigen (r_nmod) prevention_3\NN\1073995|for|the|reactivation (r_nmod) lamivudine_0\NN\3834836|prevention|patients|. (l_nmod) patients_18\NNS\9898892|seropositive|cancer|undergoing (l_compound) cancer_17\NN\14239425|
D006514_D009369 NONE hbsag_14\NN\1740|(|) (r_appos) antigen_12\NN\20090|in|hepatitis-b|surface|hbsag (r_nmod) reactivation_8\NN\1740|of|hepatitis|b|virus|antigen (r_nmod) prevention_3\NN\1073995|for|the|reactivation (r_nmod) lamivudine_0\NN\3834836|prevention|patients|. (l_nmod) patients_18\NNS\9898892|seropositive|cancer|undergoing (l_compound) cancer_17\NN\14239425|
D019259_D019337 NONE lamivudine_20\NN\3834836|the|antiviral|agent (r_dobj) received_16\VBD\2210855|study|,|patients|lamivudine|prior|. (l_nsubj) patients_5\NNS\9898892|cancer|have (l_acl:relcl) have_7\VBP\2108377|who|malignancies (l_dobj) malignancies_11\NNS\14070360|solid|infection
D019259_D019337 NONE lamivudine_34\NN\3834836| (r_dobj) receive_33\VB\2210855|who|did|not|lamivudine (r_acl:relcl) group_29\NN\2137|with|historical|control|receive (r_nmod) compared_25\VBN\644583|group (r_acl) ct_24\NN\901316|compared (r_conj) prior_21\RB\1740|and|during|ct (r_advmod) received_16\VBD\2210855|study|,|patients|lamivudine|prior|. (l_nsubj) patients_5\NNS\9898892|cancer|have (l_acl:relcl) have_7\VBP\2108377|who|malignancies (l_dobj) malignancies_11\NNS\14070360|solid|infection
D019259_D056486 NONE lamivudine_3\NN\3834836| (r_compound) group_4\NN\2137|in|the|prophylactic|lamivudine (r_nmod) observed_8\VBN\2163746|group|hepatitis|were|patient|0.006|)|. (l_nsubjpass) hepatitis_6\NN\14127211|severe
2924746
D002220_D064420 NONE carbamazepine_1\NN\1740| (r_compound) treatment_2\NN\654885|chronic|carbamazepine|efficacy|concentrations|. (l_nmod) efficacy_7\NN\5199286|in|the|rat|:|,|toxicity|,|and|effect (l_conj) toxicity_9\NN\13576101|
D005492_D064420 NONE folate_17\NN\15090742| (r_compound) concentrations_18\NNS\4916342|plasma|folate (r_nmod) treatment_2\NN\654885|chronic|carbamazepine|efficacy|concentrations|. (l_nmod) efficacy_7\NN\5199286|in|the|rat|:|,|toxicity|,|and|effect (l_conj) toxicity_9\NN\13576101|
D019946_D012640 NONE glycol_13\NN\14766364|propylene (r_appos) vehicle_10\NN\3100490|a|common|,|glycol|,|itself|doses (r_appos) course_2\NN\883297|in|the|developing|,|vehicle (r_nmod) found_22\VBN\2426171|course|,|was|exhibit|. (l_xcomp) exhibit_24\VB\2632167|to|properties|and|inhibited (l_dobj) properties_26\NNS\32613|protective|seizures (l_nmod) seizures_29\NNS\14081375|against|induced
D019946_D015430 NONE glycol_13\NN\14766364|propylene (r_appos) vehicle_10\NN\3100490|a|common|,|glycol|,|itself|doses (r_appos) course_2\NN\883297|in|the|developing|,|vehicle (r_nmod) found_22\VBN\2426171|course|,|was|exhibit|. (l_xcomp) exhibit_24\VB\2632167|to|properties|and|inhibited (l_conj) inhibited_31\VBD\2510337|gain (l_dobj) gain_33\NN\13576355|weight
D005481_D012640 CID ether_4\NN\14840755|by|hexafluorodiethyl|hfde (r_nmod) induced_1\VBN\1627355|ether (r_acl) seizures_0\NNP\14081375|induced
D005481_D012640 CID ether_4\NN\14840755|by|hexafluorodiethyl|hfde (r_nmod) induced_1\VBN\1627355|ether (r_acl) seizures_0\NNP\14081375|induced (r_nsubjpass) found_10\VBN\2426171|seizures|were|also|measure|. (l_xcomp) measure_16\NN\168237|to|be|a|sensitive|protection|cbz|seizures (l_nmod) seizures_22\NNS\14081375|than|induced
D005481_D012640 CID hfde_6\NN\1740|(|) (r_appos) ether_4\NN\14840755|by|hexafluorodiethyl|hfde (r_nmod) induced_1\VBN\1627355|ether (r_acl) seizures_0\NNP\14081375|induced
D005481_D012640 CID hfde_6\NN\1740|(|) (r_appos) ether_4\NN\14840755|by|hexafluorodiethyl|hfde (r_nmod) induced_1\VBN\1627355|ether (r_acl) seizures_0\NNP\14081375|induced (r_nsubjpass) found_10\VBN\2426171|seizures|were|also|measure|. (l_xcomp) measure_16\NN\168237|to|be|a|sensitive|protection|cbz|seizures (l_nmod) seizures_22\NNS\14081375|than|induced
D005481_D012640 CID hfde-induced_21\JJ\1740| (r_amod) seizures_22\NNS\14081375|against|hfde-induced
D002220_D012640 NONE cbz_20\NN\1740|by (r_nmod) measure_16\NN\168237|to|be|a|sensitive|protection|cbz|seizures (r_xcomp) found_10\VBN\2426171|seizures|were|also|measure|. (l_nsubjpass) seizures_0\NNP\14081375|induced
D002220_D012640 NONE cbz_20\NN\1740|by (r_nmod) measure_16\NN\168237|to|be|a|sensitive|protection|cbz|seizures (l_nmod) seizures_22\NNS\14081375|than|induced
D002220_D012640 NONE cbz_3\NN\1740|of (r_nmod) administration_1\NN\1133281|oral|cbz|suspension|h (r_nsubj) protective_19\JJ\1740|administration|was|continuously|seizures|and|toxic|. (l_nmod) seizures_22\NNS\14081375|against|hfde-induced
D002220_D015430 NONE cbz_3\NN\1740|of (r_nmod) administration_1\NN\1133281|oral|cbz|suspension|h (r_nsubj) protective_19\JJ\1740|administration|was|continuously|seizures|and|toxic|. (l_conj) toxic_26\JJ\1740|was|minimally|measured (l_advcl) measured_28\VBN\697589|as|gain|weeks (l_nmod) gain_31\NN\13576355|by|weight
D005481_D015430 NONE hfde-induced_21\JJ\1740| (r_amod) seizures_22\NNS\14081375|against|hfde-induced (r_nmod) protective_19\JJ\1740|administration|was|continuously|seizures|and|toxic|. (l_conj) toxic_26\JJ\1740|was|minimally|measured (l_advcl) measured_28\VBN\697589|as|gain|weeks (l_nmod) gain_31\NN\13576355|by|weight
2224762
C027260_D009369 NONE 4'-0-tetrahydropyranyladriamycin_10\CD\1740| (r_nummod) bolus_9\NN\13899404|of|intravenous|iv|)|4'-0-tetrahydropyranyladriamycin|pirarubicin (r_nmod) study_3\NN\635850|a|phase|i|bolus (r_nsubjpass) done_15\VBN\1640855|study|was|patients|tumors|. (l_nmod) tumors_25\NNS\14234074|with|refractory
C027260_D009369 NONE pirarubicin_12\NN\1740|(|) (r_appos) bolus_9\NN\13899404|of|intravenous|iv|)|4'-0-tetrahydropyranyladriamycin|pirarubicin (r_nmod) study_3\NN\635850|a|phase|i|bolus (r_nsubjpass) done_15\VBN\1640855|study|was|patients|tumors|. (l_nmod) tumors_25\NNS\14234074|with|refractory
10721819
D007545_D013610 NONE isoproterenol_5\NN\3740161|with|tachycardia (l_nmod) tachycardia_8\NN\14110674|on|bromocriptine-induced
D007545_D013610 NONE isoproterenol_31\NN\3740161| (r_compound) pretreatment_32\NN\1740|by|5-day|isoproterenol (r_nmod) reduced_28\VBN\441445|ii|pretreatment|,|supporting (r_conj) mediated_17\VBN\761713|that|tachycardia|is|i|activation|and|reduced (l_nsubjpass) tachycardia_6\NN\14110674|bromocriptine-induced|,|persisted|,
D007545_D013610 NONE isoproterenol_10\NN\3740161|with (r_nmod) pretreatment_8\NN\1740|prolonged|isoproterenol (r_nsubj) abolish_12\VB\1740|whether|pretreatment|could|tachycardia|rats (l_dobj) tachycardia_14\NN\14110674|bromocriptine-induced
D007545_D013610 NONE isoproterenol_5\NN\3740161| (r_compound) pretreatment_6\NN\1740|by|isoproterenol (r_nmod) unaffected_3\JJ\1740|hypotension|was|pretreatment|,|reversed|effect|. (l_advcl) reversed_11\VBN\109660|while|tachycardia|was|bradycardia (l_nsubjpass) tachycardia_9\NN\14110674|
D007545_D013610 NONE isoproterenol_5\NN\3740161| (r_compound) pretreatment_6\NN\1740|15-day|isoproterenol (r_nsubj) abolished_9\VBD\1740|that|pretreatment|only|but|tachycardia|bradycardia|,|effect (l_dobj) tachycardia_13\NN\14110674|reversed|bromocriptine-induced
D001971_D013610 CID bromocriptine-induced_7\JJ\1740| (r_amod) tachycardia_8\NN\14110674|on|bromocriptine-induced
D001971_D013610 CID bromocriptine-induced_5\JJ\1740| (r_amod) tachycardia_6\NN\14110674|bromocriptine-induced|,|persisted|,
D001971_D013610 CID bromocriptine-induced_13\JJ\1740| (r_amod) tachycardia_14\NN\14110674|bromocriptine-induced
D001971_D013610 CID bromocriptine_5\NN\1740|intravenous|microg/kg (r_appos) rats_2\NNS\2329401|in|control|,|bromocriptine (r_nmod) induced_10\VBD\1627355|rats|hypotension|. (l_dobj) hypotension_12\NN\14057371|significant|and|tachycardia (l_conj) tachycardia_14\NN\14110674|
D001971_D013610 CID bromocriptine-induced_0\JJ\1740| (r_amod) hypotension_1\NN\14057371|bromocriptine-induced (r_nsubjpass) unaffected_3\JJ\1740|hypotension|was|pretreatment|,|reversed|effect|. (l_advcl) reversed_11\VBN\109660|while|tachycardia|was|bradycardia (l_nsubjpass) tachycardia_9\NN\14110674|
D001971_D013610 CID bromocriptine-induced_12\JJ\1740| (r_amod) tachycardia_13\NN\14110674|reversed|bromocriptine-induced
D001971_D013610 CID bromocriptine_13\NN\1740|of (r_nmod) tachycardia_11\NN\14110674|the|central|bromocriptine
D004298_D013610 NONE dopamine_20\NN\14807737| (r_compound) activation_23\NN\13561719|by|central|dopamine|d2|receptor (r_nmod) mediated_17\VBN\761713|that|tachycardia|is|i|activation|and|reduced (l_nsubjpass) tachycardia_6\NN\14110674|bromocriptine-induced|,|persisted|,
D004298_D013610 NONE dopamine_27\NN\14807737| (r_compound) receptors_29\NNS\5225602|at|peripheral|dopamine|d2 (r_nmod) mask_19\VB\2158587|to|bradycardia|receptors (r_conj) predominate_16\VB\2696801|to|and|mask (r_xcomp) appears_14\VBZ\2604760|that|,|rats|,|tachycardia|predominate (l_nsubj) tachycardia_11\NN\14110674|the|central|bromocriptine
D007545_D006332 CID isoproterenol_0\NN\3740161| (r_compound) pretreatment_1\NN\1740|isoproterenol|days (r_nsubj) caused_5\VBD\1617192|pretreatment|hypertrophy|affecting|. (l_dobj) hypertrophy_7\NN\14365950|cardiac
D001971_D007022 CID bromocriptine_5\NN\1740|intravenous|microg/kg (r_appos) rats_2\NNS\2329401|in|control|,|bromocriptine (r_nmod) induced_10\VBD\1627355|rats|hypotension|. (l_dobj) hypotension_12\NN\14057371|significant|and|tachycardia
D001971_D007022 CID bromocriptine-induced_0\JJ\1740| (r_amod) hypotension_1\NN\14057371|bromocriptine-induced
D001971_D001919 NONE bromocriptine-induced_0\JJ\1740| (r_amod) hypotension_1\NN\14057371|bromocriptine-induced (r_nsubjpass) unaffected_3\JJ\1740|hypotension|was|pretreatment|,|reversed|effect|. (l_advcl) reversed_11\VBN\109660|while|tachycardia|was|bradycardia (l_nmod) bradycardia_14\NN\14110674|to|significant|,
D001971_D001919 NONE bromocriptine-induced_12\JJ\1740| (r_amod) tachycardia_13\NN\14110674|reversed|bromocriptine-induced (r_dobj) abolished_9\VBD\1740|that|pretreatment|only|but|tachycardia|bradycardia|,|effect (l_nmod) bradycardia_15\NN\14110674|to
D001971_D001919 NONE bromocriptine_13\NN\1740|of (r_nmod) tachycardia_11\NN\14110674|the|central|bromocriptine (r_nsubj) appears_14\VBZ\2604760|that|,|rats|,|tachycardia|predominate (l_xcomp) predominate_16\VB\2696801|to|and|mask (l_conj) mask_19\VB\2158587|to|bradycardia|receptors (l_dobj) bradycardia_21\NN\14110674|the|agonist
D007545_D007022 NONE isoproterenol_5\NN\3740161| (r_compound) pretreatment_6\NN\1740|by|isoproterenol (r_nmod) unaffected_3\JJ\1740|hypotension|was|pretreatment|,|reversed|effect|. (l_nsubjpass) hypotension_1\NN\14057371|bromocriptine-induced
D007545_D001919 CID isoproterenol_5\NN\3740161| (r_compound) pretreatment_6\NN\1740|by|isoproterenol (r_nmod) unaffected_3\JJ\1740|hypotension|was|pretreatment|,|reversed|effect|. (l_advcl) reversed_11\VBN\109660|while|tachycardia|was|bradycardia (l_nmod) bradycardia_14\NN\14110674|to|significant|,
D007545_D001919 CID isoproterenol_5\NN\3740161| (r_compound) pretreatment_6\NN\1740|15-day|isoproterenol (r_nsubj) abolished_9\VBD\1740|that|pretreatment|only|but|tachycardia|bradycardia|,|effect (l_nmod) bradycardia_15\NN\14110674|to
D004294_D007022 NONE domperidone_24\NN\1740|by|i.v.|mg/kg (r_nmod) reduced_21\VBN\441445|that|was|partly|domperidone (r_acl:relcl) effect_17\NN\34213|an|reduced (r_dobj) unaffected_3\JJ\1740|hypotension|was|pretreatment|,|reversed|effect|. (l_nsubjpass) hypotension_1\NN\14057371|bromocriptine-induced
D004294_D013610 NONE domperidone_24\NN\1740|by|i.v.|mg/kg (r_nmod) reduced_21\VBN\441445|that|was|partly|domperidone (r_acl:relcl) effect_17\NN\34213|an|reduced (r_dobj) unaffected_3\JJ\1740|hypotension|was|pretreatment|,|reversed|effect|. (l_advcl) reversed_11\VBN\109660|while|tachycardia|was|bradycardia (l_nsubjpass) tachycardia_9\NN\14110674|
D004294_D001919 CID domperidone_24\NN\1740|by|i.v.|mg/kg (r_nmod) reduced_21\VBN\441445|that|was|partly|domperidone (r_acl:relcl) effect_17\NN\34213|an|reduced (r_dobj) unaffected_3\JJ\1740|hypotension|was|pretreatment|,|reversed|effect|. (l_advcl) reversed_11\VBN\109660|while|tachycardia|was|bradycardia (l_nmod) bradycardia_14\NN\14110674|to|significant|,
D004298_D001919 NONE dopamine_27\NN\14807737| (r_compound) receptors_29\NNS\5225602|at|peripheral|dopamine|d2 (r_nmod) mask_19\VB\2158587|to|bradycardia|receptors (l_dobj) bradycardia_21\NN\14110674|the|agonist
18754075
D004164_D011507 NONE bisphosphonate_8\NN\1740|oral (r_compound) administration_12\NN\1133281|after|bisphosphonate|(|alendronate|)|patient (r_nmod) proteinuria_1\NN\14299637|massive|and|failure|administration|.
D004164_D011507 NONE bisphosphonates_11\NNS\1740|intravenous|oral (r_nsubj) aggravate_13\VB\126264|that|bisphosphonates|can|proteinuria (l_dobj) proteinuria_14\NN\14299637|and|failure
D004164_D058186 NONE bisphosphonate_8\NN\1740|oral (r_compound) administration_12\NN\1133281|after|bisphosphonate|(|alendronate|)|patient (r_nmod) proteinuria_1\NN\14299637|massive|and|failure|administration|. (l_conj) failure_5\NN\66216|acute|renal
D004164_D058186 NONE bisphosphonate_18\NN\1740|of|the|oral|sodium (r_nmod) days_14\NNS\15140892|within|14|bisphosphonate (r_nmod) decreased_6\VBD\169651|amount|g.|days|administration|increased|. (l_conj) increased_31\VBD\169651|rapidly|g (l_dobj) g_36\NN\13717155|12.8|failure (l_nmod) failure_40\NN\66216|with|acute|renal
D004164_D058186 NONE bisphosphonates_11\NNS\1740|intravenous|oral (r_nsubj) aggravate_13\VB\126264|that|bisphosphonates|can|proteinuria (l_dobj) proteinuria_14\NN\14299637|and|failure (l_conj) failure_18\NN\66216|acute|renal
D004164_D005923 NONE bisphosphonate_8\NN\1740|oral (r_compound) administration_12\NN\1133281|after|bisphosphonate|(|alendronate|)|patient (l_nmod) patient_15\NN\9898892|in|a|glomerulosclerosis (l_nmod) glomerulosclerosis_19\NN\1740|with|focal|segmental
D019386_D011507 CID alendronate_10\NN\3740161| (r_compound) administration_12\NN\1133281|after|bisphosphonate|(|alendronate|)|patient (r_nmod) proteinuria_1\NN\14299637|massive|and|failure|administration|.
D019386_D058186 CID alendronate_10\NN\3740161| (r_compound) administration_12\NN\1133281|after|bisphosphonate|(|alendronate|)|patient (r_nmod) proteinuria_1\NN\14299637|massive|and|failure|administration|. (l_conj) failure_5\NN\66216|acute|renal
D019386_D058186 CID sodium_21\NN\14625458|(|alendronate|) (r_dep) bisphosphonate_18\NN\1740|of|the|oral|sodium (r_nmod) days_14\NNS\15140892|within|14|bisphosphonate (r_nmod) decreased_6\VBD\169651|amount|g.|days|administration|increased|. (l_conj) increased_31\VBD\169651|rapidly|g (l_dobj) g_36\NN\13717155|12.8|failure (l_nmod) failure_40\NN\66216|with|acute|renal
D019386_D005923 NONE alendronate_10\NN\3740161| (r_compound) administration_12\NN\1133281|after|bisphosphonate|(|alendronate|)|patient (l_nmod) patient_15\NN\9898892|in|a|glomerulosclerosis (l_nmod) glomerulosclerosis_19\NN\1740|with|focal|segmental
D013256_D009404 NONE steroid_17\NN\14727670| (r_compound) therapy_18\NN\657604|to|steroid (r_nmod) responding_14\VBG\2367363|man|was|initially|well|therapy|. (l_nsubj) man_3\NN\9605289|a|61-year-old|japanese|syndrome|glomerulosclerosis (l_nmod) syndrome_6\NN\5870365|with|nephrotic
D013256_D005923 NONE steroid_17\NN\14727670| (r_compound) therapy_18\NN\657604|to|steroid (r_nmod) responding_14\VBG\2367363|man|was|initially|well|therapy|. (l_nsubj) man_3\NN\9605289|a|61-year-old|japanese|syndrome|glomerulosclerosis (l_nmod) glomerulosclerosis_11\NN\1740|due|to|focal|segmental
6747681
D002330_D005910 NONE bcnu_1\NNS\1740| (r_compound) chemotherapy_2\NN\661091|intra-arterial|bcnu|treatment|. (l_nmod) treatment_4\NN\654885|for|gliomas (l_nmod) gliomas_7\NNS\14236743|of|malignant|system
D002330_D005910 NONE bcnu_7\NN\1740|of|1,3-bis-(2-chloroethyl)-1-nitrosourea (r_nmod) clearance_5\NN\5089947|because|the|rapid|systemic|bcnu (r_nmod) provide_15\VB\2199590|clearance|,|administration|should|advantage|. (l_dobj) advantage_18\NN\5154517|a|substantial|administration (l_nmod) administration_21\NN\1133281|over|intravenous|treatment (l_nmod) treatment_24\NN\654885|for|the|gliomas (l_nmod) gliomas_27\NNS\14236743|of|malignant
D002330_D005910 NONE 1,3-bis-(2-chloroethyl)-1-nitrosourea_9\NN\1740|(|) (r_appos) bcnu_7\NN\1740|of|1,3-bis-(2-chloroethyl)-1-nitrosourea (r_nmod) clearance_5\NN\5089947|because|the|rapid|systemic|bcnu (r_nmod) provide_15\VB\2199590|clearance|,|administration|should|advantage|. (l_dobj) advantage_18\NN\5154517|a|substantial|administration (l_nmod) administration_21\NN\1133281|over|intravenous|treatment (l_nmod) treatment_24\NN\654885|for|the|gliomas (l_nmod) gliomas_27\NNS\14236743|of|malignant
D002330_D001254 NONE bcnu_25\NN\1740| (r_compound) therapy_26\NN\657604|of|intra-arterial|bcnu (r_nmod) courses_22\NNS\883297|eight|therapy (r_dobj) received_18\VBD\2210855|patients|,|courses|. (l_nsubj) patients_1\NNS\9898892|twenty-four|grade|astrocytomas (l_nmod) astrocytomas_8\NNS\1740|to|iv|,|failed
D000431_D014786 NONE ethanol_11\NN\14708720| (r_compound) diluent_12\NN\14778436|of|the|ethanol (r_nmod) concentration_8\NN\4916342|after|the|diluent (r_nmod) decreased_5\VBD\169651|frequency|concentration|lowered|. (l_nsubj) frequency_1\NN\15286249|the|loss (l_nmod) loss_4\NN\13252973|of|visual
2522601
D002220_D004342 CID carbamazepine_2\VB\1740|to|presenting (r_acl) hypersensitivity_0\NN\14531772|carbamazepine|.
D002220_D004342 CID carbamazepine_8\NN\1740|to (r_nmod) hypersensitivity_6\NN\14531772|carbamazepine
D002220_D007955 CID carbamazepine_2\VB\1740|to|presenting (l_xcomp) presenting_3\NN\1740|reaction (l_nmod) reaction_7\NN\13446390|with|a|leukemoid|,|eosinophilia
D002220_D007955 CID carbamazepine_8\NN\1740|to (r_nmod) hypersensitivity_6\NN\14531772|carbamazepine (r_nsubj) presented_9\VBN\2137132|whom|hypersensitivity|erythroderma (l_nmod) erythroderma_12\NN\14219661|with|generalized|,|reaction|,|eosinophilia|,|hyponatremia|,|and|failure (l_conj) reaction_17\NN\13446390|a|severe|leukemoid
D002220_D004802 NONE carbamazepine_2\VB\1740|to|presenting (l_xcomp) presenting_3\NN\1740|reaction (l_nmod) reaction_7\NN\13446390|with|a|leukemoid|,|eosinophilia (l_conj) eosinophilia_9\NN\14299637|,|erythroderma|,|and|failure
D002220_D004802 NONE carbamazepine_8\NN\1740|to (r_nmod) hypersensitivity_6\NN\14531772|carbamazepine (r_nsubj) presented_9\VBN\2137132|whom|hypersensitivity|erythroderma (l_nmod) erythroderma_12\NN\14219661|with|generalized|,|reaction|,|eosinophilia|,|hyponatremia|,|and|failure (l_conj) eosinophilia_19\NN\14299637|
D002220_D003873 CID carbamazepine_2\VB\1740|to|presenting (l_xcomp) presenting_3\NN\1740|reaction (l_nmod) reaction_7\NN\13446390|with|a|leukemoid|,|eosinophilia (l_conj) eosinophilia_9\NN\14299637|,|erythroderma|,|and|failure (l_conj) erythroderma_11\NN\14219661|
D002220_D003873 CID carbamazepine_8\NN\1740|to (r_nmod) hypersensitivity_6\NN\14531772|carbamazepine (r_nsubj) presented_9\VBN\2137132|whom|hypersensitivity|erythroderma (l_nmod) erythroderma_12\NN\14219661|with|generalized|,|reaction|,|eosinophilia|,|hyponatremia|,|and|failure
D002220_D051437 CID carbamazepine_2\VB\1740|to|presenting (l_xcomp) presenting_3\NN\1740|reaction (l_nmod) reaction_7\NN\13446390|with|a|leukemoid|,|eosinophilia (l_conj) eosinophilia_9\NN\14299637|,|erythroderma|,|and|failure (l_conj) failure_15\NN\66216|renal
D002220_D051437 CID carbamazepine_8\NN\1740|to (r_nmod) hypersensitivity_6\NN\14531772|carbamazepine (r_nsubj) presented_9\VBN\2137132|whom|hypersensitivity|erythroderma (l_nmod) erythroderma_12\NN\14219661|with|generalized|,|reaction|,|eosinophilia|,|hyponatremia|,|and|failure (l_conj) failure_25\NN\66216|renal
D002220_D007010 CID carbamazepine_8\NN\1740|to (r_nmod) hypersensitivity_6\NN\14531772|carbamazepine (r_nsubj) presented_9\VBN\2137132|whom|hypersensitivity|erythroderma (l_nmod) erythroderma_12\NN\14219661|with|generalized|,|reaction|,|eosinophilia|,|hyponatremia|,|and|failure (l_conj) hyponatremia_21\NN\14299637|
11426838
-1_D012640 NONE bd1018_8\NN\1740|with|,|bd1063|,|or|lr132 (r_nmod) mice_6\NNS\2329401|of|bd1018 (r_nmod) pre-treatment_4\NN\1740|mice (r_nsubj) attenuated_15\VBD\224901|studies|,|pre-treatment|significantly|convulsions|. (l_dobj) convulsions_17\NNS\14081375|cocaine-induced|and|lethality
-1_D012640 NONE lr132_13\NN\1740| (r_conj) bd1018_8\NN\1740|with|,|bd1063|,|or|lr132 (r_nmod) mice_6\NNS\2329401|of|bd1018 (r_nmod) pre-treatment_4\NN\1740|mice (r_nsubj) attenuated_15\VBD\224901|studies|,|pre-treatment|significantly|convulsions|. (l_dobj) convulsions_17\NNS\14081375|cocaine-induced|and|lethality
C093337_D012640 NONE bd1063_10\NN\1740| (r_conj) bd1018_8\NN\1740|with|,|bd1063|,|or|lr132 (r_nmod) mice_6\NNS\2329401|of|bd1018 (r_nmod) pre-treatment_4\NN\1740|mice (r_nsubj) attenuated_15\VBD\224901|studies|,|pre-treatment|significantly|convulsions|. (l_dobj) convulsions_17\NNS\14081375|cocaine-induced|and|lethality
D003042_D012640 CID cocaine-induced_16\JJ\1740| (r_amod) convulsions_17\NNS\14081375|cocaine-induced|and|lethality
D003042_D012640 CID anti-cocaine_7\JJ\1740| (r_amod) effects_8\NNS\13245626|the|anti-cocaine|ligands (r_nsubj) involved_13\VBD\2676054|that|effects|antagonism (r_ccomp) hypothesis_4\NN\7162194|the|involved (r_dobj) validate_2\VB\803325|to|further|hypothesis (r_advcl) shown_27\VBN\2137132|validate|was|also|attenuate|. (l_xcomp) attenuate_30\VB\224901|to|significantly|convulsive (l_dobj) convulsive_32\JJ\1740|the|and|locomotor|effects
D003042_D012640 CID cocaine_38\NN\3492717|of (r_nmod) effects_36\NNS\13245626|stimulatory|cocaine (r_dep) convulsive_32\JJ\1740|the|and|locomotor|effects
C050232_D064420 NONE di-o-tolylguanidine_16\NN\1740|the|well-characterized|sigma|receptor|agonist|dtg|and|agonist|each (r_nsubj) worsened_31\VBD\146138|contrast|,|di-o-tolylguanidine|toxicity|. (l_dobj) toxicity_34\NN\13576101|the|behavioral|cocaine
C050232_D064420 NONE dtg_18\NN\1740|(|) (r_appos) di-o-tolylguanidine_16\NN\1740|the|well-characterized|sigma|receptor|agonist|dtg|and|agonist|each (r_nsubj) worsened_31\VBD\146138|contrast|,|di-o-tolylguanidine|toxicity|. (l_dobj) toxicity_34\NN\13576101|the|behavioral|cocaine
-1_D064420 NONE bd1031_26\NN\1740|3r-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane (r_dep) agonist_25\NN\9613191|the|receptor|bd1031 (r_conj) di-o-tolylguanidine_16\NN\1740|the|well-characterized|sigma|receptor|agonist|dtg|and|agonist|each (r_nsubj) worsened_31\VBD\146138|contrast|,|di-o-tolylguanidine|toxicity|. (l_dobj) toxicity_34\NN\13576101|the|behavioral|cocaine
-1_D064420 NONE 3r-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane_28\NN\1740|(|) (r_appos) bd1031_26\NN\1740|3r-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane (r_dep) agonist_25\NN\9613191|the|receptor|bd1031 (r_conj) di-o-tolylguanidine_16\NN\1740|the|well-characterized|sigma|receptor|agonist|dtg|and|agonist|each (r_nsubj) worsened_31\VBD\146138|contrast|,|di-o-tolylguanidine|toxicity|. (l_dobj) toxicity_34\NN\13576101|the|behavioral|cocaine
D003042_D064420 NONE cocaine_36\NN\3492717|of (r_nmod) toxicity_34\NN\13576101|the|behavioral|cocaine
D009838_D012640 NONE oligodeoxynucleotide_21\NN\1740|an|antisense|receptors (r_appos) receptors_17\NNS\5225602|of|sigma|,|oligodeoxynucleotide (r_nmod) antagonism_14\NN\24720|receptors (r_dobj) involved_13\VBD\2676054|that|effects|antagonism (r_ccomp) hypothesis_4\NN\7162194|the|involved (r_dobj) validate_2\VB\803325|to|further|hypothesis (r_advcl) shown_27\VBN\2137132|validate|was|also|attenuate|. (l_xcomp) attenuate_30\VB\224901|to|significantly|convulsive (l_dobj) convulsive_32\JJ\1740|the|and|locomotor|effects
19957053
D010656_D002534 CID phenylephrine_0\NNP\2682038|not|ephedrine (r_nsubj) reduces_4\VBZ\441445|phenylephrine|oxygenation|hypotension|. (l_dobj) oxygenation_7\NN\13518963|frontal|lobe
D010656_D007022 NONE phenylephrine_0\NNP\2682038|not|ephedrine (r_nsubj) reduces_4\VBZ\441445|phenylephrine|oxygenation|hypotension|. (l_nmod) hypotension_10\NN\14057371|following|anesthesia-induced
D010656_D007022 NONE phenylephrine_5\NN\2682038|of|and|ephedrine (r_nmod) effect_3\NN\34213|the|phenylephrine|oxygenation|hypotension (l_nmod) hypotension_18\NN\14057371|following|anesthesia-induced
D010656_D007022 NONE phenylephrine_5\NN\2682038|of (r_nmod) utilization_3\NN\407535|the|phenylephrine|correct (l_acl) correct_7\VB\138508|to|hypotension (l_dobj) hypotension_8\NN\14057371|induced
D004809_D002534 NONE ephedrine_3\NN\14712692| (r_conj) phenylephrine_0\NNP\2682038|not|ephedrine (r_nsubj) reduces_4\VBZ\441445|phenylephrine|oxygenation|hypotension|. (l_dobj) oxygenation_7\NN\13518963|frontal|lobe
D004809_D007022 NONE ephedrine_3\NN\14712692| (r_conj) phenylephrine_0\NNP\2682038|not|ephedrine (r_nsubj) reduces_4\VBZ\441445|phenylephrine|oxygenation|hypotension|. (l_nmod) hypotension_10\NN\14057371|following|anesthesia-induced
D004809_D007022 NONE ephedrine_7\NN\14712692| (r_conj) phenylephrine_5\NN\2682038|of|and|ephedrine (r_nmod) effect_3\NN\34213|the|phenylephrine|oxygenation|hypotension (l_nmod) hypotension_18\NN\14057371|following|anesthesia-induced
D004809_D007022 NONE ephedrine_20\NN\14712692| (r_nsubj) maintains_21\VBZ\2202928|while|ephedrine|frontal|oxygenation (r_advcl) has_12\VBZ\2108377|utilization|impact|)|maintains (l_nsubj) utilization_3\NN\407535|the|phenylephrine|correct (l_acl) correct_7\VB\138508|to|hypotension (l_dobj) hypotension_8\NN\14057371|induced
12684739
D020888_D019966 NONE gvg_35\NN\1740|of|sub-chronic|low|dose (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_dep) objectives_0\NNS\5980875|:|success (l_dep) success_5\NN\7283608|given|its|preclinical|treating (l_advcl) treating_7\VBG\2376958|for|abuse (l_dobj) abuse_9\NN\418025|substance|and|risk
D020888_D005128 CID gvg_35\NN\1740|of|sub-chronic|low|dose (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_dep) objectives_0\NNS\5980875|:|success (l_dep) success_5\NN\7283608|given|its|preclinical|treating (l_advcl) treating_7\VBG\2376958|for|abuse (l_dobj) abuse_9\NN\418025|substance|and|risk (l_conj) risk_13\NN\14541044|the|increased|defects (l_nmod) defects_17\NNS\14462666|of|visual|field|vfd|associated
D020888_D005128 CID gvg_35\NN\1740|of|sub-chronic|low|dose (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_dep) objectives_0\NNS\5980875|:|success (l_dep) success_5\NN\7283608|given|its|preclinical|treating (l_advcl) treating_7\VBG\2376958|for|abuse (l_dobj) abuse_9\NN\418025|substance|and|risk (l_conj) risk_13\NN\14541044|the|increased|defects (l_nmod) defects_17\NNS\14462666|of|visual|field|vfd|associated (l_appos) vfd_19\NN\1740|(|)
D003042_D019966 NONE cocaine-induced_37\JJ\1740| (r_amod) increases_38\NNS\13576355|on|cocaine-induced|accumbens|dopamine (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_dep) objectives_0\NNS\5980875|:|success (l_dep) success_5\NN\7283608|given|its|preclinical|treating (l_advcl) treating_7\VBG\2376958|for|abuse (l_dobj) abuse_9\NN\418025|substance|and|risk
D003042_D005128 NONE cocaine-induced_37\JJ\1740| (r_amod) increases_38\NNS\13576355|on|cocaine-induced|accumbens|dopamine (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_dep) objectives_0\NNS\5980875|:|success (l_dep) success_5\NN\7283608|given|its|preclinical|treating (l_advcl) treating_7\VBG\2376958|for|abuse (l_dobj) abuse_9\NN\418025|substance|and|risk (l_conj) risk_13\NN\14541044|the|increased|defects (l_nmod) defects_17\NNS\14462666|of|visual|field|vfd|associated
D003042_D005128 NONE cocaine-induced_37\JJ\1740| (r_amod) increases_38\NNS\13576355|on|cocaine-induced|accumbens|dopamine (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_dep) objectives_0\NNS\5980875|:|success (l_dep) success_5\NN\7283608|given|its|preclinical|treating (l_advcl) treating_7\VBG\2376958|for|abuse (l_dobj) abuse_9\NN\418025|substance|and|risk (l_conj) risk_13\NN\14541044|the|increased|defects (l_nmod) defects_17\NNS\14462666|of|visual|field|vfd|associated (l_appos) vfd_19\NN\1740|(|)
D004298_D019966 NONE dopamine_45\NN\14807737|nacc|da (r_nmod) increases_38\NNS\13576355|on|cocaine-induced|accumbens|dopamine (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_dep) objectives_0\NNS\5980875|:|success (l_dep) success_5\NN\7283608|given|its|preclinical|treating (l_advcl) treating_7\VBG\2376958|for|abuse (l_dobj) abuse_9\NN\418025|substance|and|risk
D004298_D019966 NONE da_47\NN\10484858|(|) (r_appos) dopamine_45\NN\14807737|nacc|da (r_nmod) increases_38\NNS\13576355|on|cocaine-induced|accumbens|dopamine (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_dep) objectives_0\NNS\5980875|:|success (l_dep) success_5\NN\7283608|given|its|preclinical|treating (l_advcl) treating_7\VBG\2376958|for|abuse (l_dobj) abuse_9\NN\418025|substance|and|risk
D004298_D005128 NONE dopamine_45\NN\14807737|nacc|da (r_nmod) increases_38\NNS\13576355|on|cocaine-induced|accumbens|dopamine (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_dep) objectives_0\NNS\5980875|:|success (l_dep) success_5\NN\7283608|given|its|preclinical|treating (l_advcl) treating_7\VBG\2376958|for|abuse (l_dobj) abuse_9\NN\418025|substance|and|risk (l_conj) risk_13\NN\14541044|the|increased|defects (l_nmod) defects_17\NNS\14462666|of|visual|field|vfd|associated
D004298_D005128 NONE dopamine_45\NN\14807737|nacc|da (r_nmod) increases_38\NNS\13576355|on|cocaine-induced|accumbens|dopamine (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_dep) objectives_0\NNS\5980875|:|success (l_dep) success_5\NN\7283608|given|its|preclinical|treating (l_advcl) treating_7\VBG\2376958|for|abuse (l_dobj) abuse_9\NN\418025|substance|and|risk (l_conj) risk_13\NN\14541044|the|increased|defects (l_nmod) defects_17\NNS\14462666|of|visual|field|vfd|associated (l_appos) vfd_19\NN\1740|(|)
D004298_D005128 NONE da_47\NN\10484858|(|) (r_appos) dopamine_45\NN\14807737|nacc|da (r_nmod) increases_38\NNS\13576355|on|cocaine-induced|accumbens|dopamine (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_dep) objectives_0\NNS\5980875|:|success (l_dep) success_5\NN\7283608|given|its|preclinical|treating (l_advcl) treating_7\VBG\2376958|for|abuse (l_dobj) abuse_9\NN\418025|substance|and|risk (l_conj) risk_13\NN\14541044|the|increased|defects (l_nmod) defects_17\NNS\14462666|of|visual|field|vfd|associated
D004298_D005128 NONE da_47\NN\10484858|(|) (r_appos) dopamine_45\NN\14807737|nacc|da (r_nmod) increases_38\NNS\13576355|on|cocaine-induced|accumbens|dopamine (r_nmod) effects_30\NNS\13245626|the|gvg|increases (r_dobj) explored_28\VBD\789138|objectives|,|we|effects|. (l_dep) objectives_0\NNS\5980875|:|success (l_dep) success_5\NN\7283608|given|its|preclinical|treating (l_advcl) treating_7\VBG\2376958|for|abuse (l_dobj) abuse_9\NN\418025|substance|and|risk (l_conj) risk_13\NN\14541044|the|increased|defects (l_nmod) defects_17\NNS\14462666|of|visual|field|vfd|associated (l_appos) vfd_19\NN\1740|(|)
17919553
C106791_D056486 CID telithromycin_6\NN\1740|to (r_nmod) exposure_4\NN\5042871|after|telithromycin (r_nmod) attack_2\NN\955060|acute|hepatitis|exposure|. (l_compound) hepatitis_1\NN\14127211|
C106791_D056486 CID telithromycin_19\NN\1740| (r_compound) usage_20\NN\407535|after|telithromycin (r_nmod) occurred_17\VBD\2623529|that|usage (r_dep) suffered_3\VBN\2110220|patient|had|episode|,|"|occurred|. (l_dobj) episode_6\NN\7283608|a|previous|hepatitis (l_nmod) hepatitis_10\NN\14127211|of|acute|origin
C106791_D056486 CID telithromycin_15\NN\1740| (r_nsubj) cause_19\NN\7323922|score|,|telithromycin|was|the|probable|hepatitis|patient|,|and|suggested (l_nmod) hepatitis_22\NN\14127211|of|acute
C106791_D056486 CID telithromycin_15\NN\1740| (r_nsubj) cause_19\NN\7323922|score|,|telithromycin|was|the|probable|hepatitis|patient|,|and|suggested (l_conj) suggested_30\VBD\1010118|findings|hepatitis|. (l_dobj) hepatitis_33\NN\14127211|drug-induced|toxic
C106791_D056486 CID telithromycin_21\NN\1740| (r_dobj) prescribed_20\VBD\748282|who|telithromycin|time (r_acl:relcl) physician_18\NN\10305802|to|the|attending|prescribed (r_nmod) communicated_14\VBN\2231661|if|incident|had|been|physician (r_ccomp) avoided_7\VBN\2452885|recurrence|might|have|been|communicated|. (l_nsubjpass) recurrence_0\NN\7342049|attack (l_nmod) attack_3\NN\955060|of|hepatitis (l_compound) hepatitis_2\NN\14127211|
C106791_D056486 CID telithromycin_16\NN\1740|of (r_nmod) administration_14\NN\1133281|with|the|telithromycin (r_nmod) associated_11\VBN\628491|probably|administration (r_acl) hepatitis_9\NN\14127211|of|acute|associated
C106791_D012141 NONE telithromycin_4\NN\1740| (r_dobj) prescribed_3\VBN\748282|he|had|been|telithromycin|po|treat|. (l_xcomp) treat_9\VB\2376958|to|infection|prior (l_dobj) infection_14\NN\14052046|an|upper|respiratory|tract
C106791_D064420 NONE telithromycin_15\NN\1740| (r_nsubj) cause_19\NN\7323922|score|,|telithromycin|was|the|probable|hepatitis|patient|,|and|suggested (l_advcl) score_3\NN\5736149|based|on|a|8|scale (l_nmod) scale_13\NN\7260623|on|the|naranjo|adverse|probability (l_compound) probability_12\NN\33615|drug|reaction (l_compound) reaction_11\NN\13446390|
7248170
D010634_D006529 CID phenobarbitone-induced_0\JJ\1740| (r_amod) enlargement_1\NN\363260|phenobarbitone-induced|liver|rat|:|relationship|. (l_nmod) liver_4\NN\5298729|of|the
D010634_D006529 CID phenobarbitone-primed_58\JJ\1740| (r_amod) rat_59\NN\2329401|in|the|phenobarbitone-primed (r_nmod) given_54\VBN\2327200|intragastrically|rat (r_acl) tetrachloride_53\NN\14818238|of|carbon|given (r_nmod) doses_50\NNS\3740161|after|12|tetrachloride (r_nmod) defined_9\VBN\2604760|yield|(|liver|,|ascites|,|albumin|,|splenomegaly|,|and|atrophy|doses|increased|. (l_conj) increased_61\VBN\169651|was|%|%|giving (l_advcl) giving_69\VBG\2327200|by|dose (l_dobj) dose_75\NN\3740161|the|initial|"|calibrating|"|tetrachloride|peak (l_nmod) peak_81\NN\13758296|at|the|enlargement (l_nmod) enlargement_85\NN\363260|of|the|phenobarbitone-induced|liver (l_nmod) liver_88\NN\5298729|of|the
D010634_D006529 CID phenobarbitone-induced_84\JJ\1740| (r_amod) enlargement_85\NN\363260|of|the|phenobarbitone-induced|liver (l_nmod) liver_88\NN\5298729|of|the
D010634_D005355 NONE phenobarbitone-induced_0\JJ\1740| (r_amod) enlargement_1\NN\363260|phenobarbitone-induced|liver|rat|:|relationship|. (l_appos) relationship_10\NN\31921|its|carbon|cirrhosis (l_nmod) cirrhosis_14\NN\14116321|tetrachloride-induced
D002251_D006529 NONE tetrachloride-induced_13\JJ\1740| (r_amod) cirrhosis_14\NN\14116321|tetrachloride-induced (r_nmod) relationship_10\NN\31921|its|carbon|cirrhosis (r_appos) enlargement_1\NN\363260|phenobarbitone-induced|liver|rat|:|relationship|. (l_nmod) liver_4\NN\5298729|of|the
D002251_D006529 NONE tetrachloride_53\NN\14818238|of|carbon|given (r_nmod) doses_50\NNS\3740161|after|12|tetrachloride (r_nmod) defined_9\VBN\2604760|yield|(|liver|,|ascites|,|albumin|,|splenomegaly|,|and|atrophy|doses|increased|. (l_conj) increased_61\VBN\169651|was|%|%|giving (l_advcl) giving_69\VBG\2327200|by|dose (l_dobj) dose_75\NN\3740161|the|initial|"|calibrating|"|tetrachloride|peak (l_nmod) peak_81\NN\13758296|at|the|enlargement (l_nmod) enlargement_85\NN\363260|of|the|phenobarbitone-induced|liver (l_nmod) liver_88\NN\5298729|of|the
D002251_D006529 NONE tetrachloride_78\NN\14818238|of|carbon (r_nmod) dose_75\NN\3740161|the|initial|"|calibrating|"|tetrachloride|peak (l_nmod) peak_81\NN\13758296|at|the|enlargement (l_nmod) enlargement_85\NN\363260|of|the|phenobarbitone-induced|liver (l_nmod) liver_88\NN\5298729|of|the
D002251_D005355 NONE tetrachloride-induced_13\JJ\1740| (r_amod) cirrhosis_14\NN\14116321|tetrachloride-induced
D002251_D008103 CID tetrachloride_53\NN\14818238|of|carbon|given (r_nmod) doses_50\NNS\3740161|after|12|tetrachloride (r_nmod) defined_9\VBN\2604760|yield|(|liver|,|ascites|,|albumin|,|splenomegaly|,|and|atrophy|doses|increased|. (l_nsubjpass) yield_1\NN\913705|the|cirrhosis (l_nmod) cirrhosis_4\NN\14116321|of|severe|liver (l_nmod) liver_7\NN\5298729|of|the
D002251_D008103 CID tetrachloride_78\NN\14818238|of|carbon (r_nmod) dose_75\NN\3740161|the|initial|"|calibrating|"|tetrachloride|peak (r_dobj) giving_69\VBG\2327200|by|dose (r_advcl) increased_61\VBN\169651|was|%|%|giving (r_conj) defined_9\VBN\2604760|yield|(|liver|,|ascites|,|albumin|,|splenomegaly|,|and|atrophy|doses|increased|. (l_nsubjpass) yield_1\NN\913705|the|cirrhosis (l_nmod) cirrhosis_4\NN\14116321|of|severe|liver (l_nmod) liver_7\NN\5298729|of|the
D002251_D001201 NONE tetrachloride_53\NN\14818238|of|carbon|given (r_nmod) doses_50\NNS\3740161|after|12|tetrachloride (r_nmod) defined_9\VBN\2604760|yield|(|liver|,|ascites|,|albumin|,|splenomegaly|,|and|atrophy|doses|increased|. (l_conj) ascites_20\NNS\14204950|greater
D002251_D001201 NONE tetrachloride_78\NN\14818238|of|carbon (r_nmod) dose_75\NN\3740161|the|initial|"|calibrating|"|tetrachloride|peak (r_dobj) giving_69\VBG\2327200|by|dose (r_advcl) increased_61\VBN\169651|was|%|%|giving (r_conj) defined_9\VBN\2604760|yield|(|liver|,|ascites|,|albumin|,|splenomegaly|,|and|atrophy|doses|increased|. (l_conj) ascites_20\NNS\14204950|greater
D002251_D013163 NONE tetrachloride_53\NN\14818238|of|carbon|given (r_nmod) doses_50\NNS\3740161|after|12|tetrachloride (r_nmod) defined_9\VBN\2604760|yield|(|liver|,|ascites|,|albumin|,|splenomegaly|,|and|atrophy|doses|increased|. (l_conj) splenomegaly_33\NN\14366759|normal
D002251_D013163 NONE tetrachloride_78\NN\14818238|of|carbon (r_nmod) dose_75\NN\3740161|the|initial|"|calibrating|"|tetrachloride|peak (r_dobj) giving_69\VBG\2327200|by|dose (r_advcl) increased_61\VBN\169651|was|%|%|giving (r_conj) defined_9\VBN\2604760|yield|(|liver|,|ascites|,|albumin|,|splenomegaly|,|and|atrophy|doses|increased|. (l_conj) splenomegaly_33\NN\14366759|normal
D002251_D001284 NONE tetrachloride_53\NN\14818238|of|carbon|given (r_nmod) doses_50\NNS\3740161|after|12|tetrachloride (r_nmod) defined_9\VBN\2604760|yield|(|liver|,|ascites|,|albumin|,|splenomegaly|,|and|atrophy|doses|increased|. (l_dep) atrophy_42\NN\14299637|testicular|weight|)
D002251_D001284 NONE tetrachloride_78\NN\14818238|of|carbon (r_nmod) dose_75\NN\3740161|the|initial|"|calibrating|"|tetrachloride|peak (r_dobj) giving_69\VBG\2327200|by|dose (r_advcl) increased_61\VBN\169651|was|%|%|giving (r_conj) defined_9\VBN\2604760|yield|(|liver|,|ascites|,|albumin|,|splenomegaly|,|and|atrophy|doses|increased|. (l_dep) atrophy_42\NN\14299637|testicular|weight|)
D010634_D008103 CID phenobarbitone-primed_58\JJ\1740| (r_amod) rat_59\NN\2329401|in|the|phenobarbitone-primed (r_nmod) given_54\VBN\2327200|intragastrically|rat (r_acl) tetrachloride_53\NN\14818238|of|carbon|given (r_nmod) doses_50\NNS\3740161|after|12|tetrachloride (r_nmod) defined_9\VBN\2604760|yield|(|liver|,|ascites|,|albumin|,|splenomegaly|,|and|atrophy|doses|increased|. (l_nsubjpass) yield_1\NN\913705|the|cirrhosis (l_nmod) cirrhosis_4\NN\14116321|of|severe|liver (l_nmod) liver_7\NN\5298729|of|the
D010634_D008103 CID phenobarbitone-induced_84\JJ\1740| (r_amod) enlargement_85\NN\363260|of|the|phenobarbitone-induced|liver (r_nmod) peak_81\NN\13758296|at|the|enlargement (r_nmod) dose_75\NN\3740161|the|initial|"|calibrating|"|tetrachloride|peak (r_dobj) giving_69\VBG\2327200|by|dose (r_advcl) increased_61\VBN\169651|was|%|%|giving (r_conj) defined_9\VBN\2604760|yield|(|liver|,|ascites|,|albumin|,|splenomegaly|,|and|atrophy|doses|increased|. (l_nsubjpass) yield_1\NN\913705|the|cirrhosis (l_nmod) cirrhosis_4\NN\14116321|of|severe|liver (l_nmod) liver_7\NN\5298729|of|the
D010634_D001201 NONE phenobarbitone-primed_58\JJ\1740| (r_amod) rat_59\NN\2329401|in|the|phenobarbitone-primed (r_nmod) given_54\VBN\2327200|intragastrically|rat (r_acl) tetrachloride_53\NN\14818238|of|carbon|given (r_nmod) doses_50\NNS\3740161|after|12|tetrachloride (r_nmod) defined_9\VBN\2604760|yield|(|liver|,|ascites|,|albumin|,|splenomegaly|,|and|atrophy|doses|increased|. (l_conj) ascites_20\NNS\14204950|greater
D010634_D001201 NONE phenobarbitone-induced_84\JJ\1740| (r_amod) enlargement_85\NN\363260|of|the|phenobarbitone-induced|liver (r_nmod) peak_81\NN\13758296|at|the|enlargement (r_nmod) dose_75\NN\3740161|the|initial|"|calibrating|"|tetrachloride|peak (r_dobj) giving_69\VBG\2327200|by|dose (r_advcl) increased_61\VBN\169651|was|%|%|giving (r_conj) defined_9\VBN\2604760|yield|(|liver|,|ascites|,|albumin|,|splenomegaly|,|and|atrophy|doses|increased|. (l_conj) ascites_20\NNS\14204950|greater
D010634_D013163 NONE phenobarbitone-primed_58\JJ\1740| (r_amod) rat_59\NN\2329401|in|the|phenobarbitone-primed (r_nmod) given_54\VBN\2327200|intragastrically|rat (r_acl) tetrachloride_53\NN\14818238|of|carbon|given (r_nmod) doses_50\NNS\3740161|after|12|tetrachloride (r_nmod) defined_9\VBN\2604760|yield|(|liver|,|ascites|,|albumin|,|splenomegaly|,|and|atrophy|doses|increased|. (l_conj) splenomegaly_33\NN\14366759|normal
D010634_D013163 NONE phenobarbitone-induced_84\JJ\1740| (r_amod) enlargement_85\NN\363260|of|the|phenobarbitone-induced|liver (r_nmod) peak_81\NN\13758296|at|the|enlargement (r_nmod) dose_75\NN\3740161|the|initial|"|calibrating|"|tetrachloride|peak (r_dobj) giving_69\VBG\2327200|by|dose (r_advcl) increased_61\VBN\169651|was|%|%|giving (r_conj) defined_9\VBN\2604760|yield|(|liver|,|ascites|,|albumin|,|splenomegaly|,|and|atrophy|doses|increased|. (l_conj) splenomegaly_33\NN\14366759|normal
D010634_D001284 NONE phenobarbitone-primed_58\JJ\1740| (r_amod) rat_59\NN\2329401|in|the|phenobarbitone-primed (r_nmod) given_54\VBN\2327200|intragastrically|rat (r_acl) tetrachloride_53\NN\14818238|of|carbon|given (r_nmod) doses_50\NNS\3740161|after|12|tetrachloride (r_nmod) defined_9\VBN\2604760|yield|(|liver|,|ascites|,|albumin|,|splenomegaly|,|and|atrophy|doses|increased|. (l_dep) atrophy_42\NN\14299637|testicular|weight|)
D010634_D001284 NONE phenobarbitone-induced_84\JJ\1740| (r_amod) enlargement_85\NN\363260|of|the|phenobarbitone-induced|liver (r_nmod) peak_81\NN\13758296|at|the|enlargement (r_nmod) dose_75\NN\3740161|the|initial|"|calibrating|"|tetrachloride|peak (r_dobj) giving_69\VBG\2327200|by|dose (r_advcl) increased_61\VBN\169651|was|%|%|giving (r_conj) defined_9\VBN\2604760|yield|(|liver|,|ascites|,|albumin|,|splenomegaly|,|and|atrophy|doses|increased|. (l_dep) atrophy_42\NN\14299637|testicular|weight|)
17242861
D010862_D012640 NONE pilocarpine-induced_4\JJ\1740| (r_amod) seizures_5\NNS\14081375|to|pilocarpine-induced|,
D010862_D012640 NONE pilocarpine-induced_4\JJ\1740| (r_amod) seizures_5\NNS\14081375|to|pilocarpine-induced|, (r_nmod) susceptibility_2\NN\13920835|for|seizures (r_nmod) qtls_0\NNS\1740|susceptibility|model|, (r_nsubjpass) reported_17\VBN\831651|qtls|have|not|been|,|and|used|. (l_conj) used_25\VBN\1156834|css|have|not|previously|been|localize (l_xcomp) localize_27\VB\2694933|to|genes (l_dobj) genes_30\NNS\8459252|seizure|susceptibility (l_amod) seizure_28\JJ\1740|
D010862_D012640 NONE pilocarpine-induced_24\JJ\1740| (r_amod) seizures_25\NNS\14081375|to|pilocarpine-induced
D010862_D012640 NONE pilocarpine-induced_19\JJ\1740| (r_amod) seizures_20\NNS\14081375|to|pilocarpine-induced
D010862_D004833 CID pilocarpine-induced_4\JJ\1740| (r_amod) seizures_5\NNS\14081375|to|pilocarpine-induced|, (r_nmod) susceptibility_2\NN\13920835|for|seizures (r_nmod) qtls_0\NNS\1740|susceptibility|model|, (l_appos) model_8\NN\5888929|a|epilepsy (l_nmod) epilepsy_12\NN\14085708|of|lobe
15278670
C009250_D012640 NONE sevoflurane_3\NN\1740|of (r_nmod) effects_1\NNS\13245626|the|sevoflurane|convulsions|. (l_nmod) convulsions_6\NNS\14081375|on|lidocaine-induced
C009250_D012640 NONE sevoflurane_3\NN\1740|of (r_nmod) influence_1\NN\5190804|the|sevoflurane|convulsions (l_nmod) convulsions_6\NNS\14081375|on|lidocaine-induced
C009250_D012640 NONE sevoflurane_38\NN\1740|of (r_nmod) concentration_36\NN\4916342|the|end-tidal|sevoflurane (r_nsubj) %_41\NN\1740|when|concentration|was|0.8 (r_advcl) increasing_24\VBG\169651|significantly|66.6|l(-1|% (r_xcomp) l(-1_13\NN\1740|threshold|was|mg.|)|infusion|,|increasing|. (l_nsubj) threshold_2\NN\15265518|the|convulsive|mean (l_amod) convulsive_1\JJ\1740|
C009250_D012640 NONE sevoflurane_10\NN\1740|between|and|enflurane (r_nmod) threshold_8\NN\15265518|in|the|convulsive|sevoflurane (l_amod) convulsive_7\JJ\1740|
C009250_D012640 NONE sevoflurane_12\NN\1740|of|or|enflurane (r_nmod) concentrations_10\NNS\4916342|higher|sevoflurane (r_nsubjpass) administered_16\VBN\2436349|when|concentrations|were|and|decreased (l_conj) decreased_23\VBD\169651|pressure|significantly|sevoflurane (l_nsubj) pressure_20\NN\11419404|the|blood|convulsions (l_nmod) convulsions_22\NNS\14081375|at
C009250_D012640 NONE sevoflurane_28\NN\1740|in|% (r_nmod) decreased_23\VBD\169651|pressure|significantly|sevoflurane (l_nsubj) pressure_20\NN\11419404|the|blood|convulsions (l_nmod) convulsions_22\NNS\14081375|at
C009250_D012640 NONE sevoflurane_4\NN\1740| (r_nsubj) reduces_5\VBZ\441445|that|sevoflurane|effect|but|carries (l_dobj) effect_8\NN\34213|the|convulsive|toxicity (l_amod) convulsive_7\JJ\1740|
D008012_D012640 CID lidocaine-induced_5\JJ\1740| (r_amod) convulsions_6\NNS\14081375|on|lidocaine-induced
D008012_D012640 CID lidocaine-induced_5\JJ\1740| (r_amod) convulsions_6\NNS\14081375|on|lidocaine-induced
D008012_D012640 CID lidocaine_16\NN\3681148| (r_compound) infusion_17\NN\14589223|with|lidocaine|mg.kg(-1).min(-1|) (r_nmod) l(-1_13\NN\1740|threshold|was|mg.|)|infusion|,|increasing|. (l_nsubj) threshold_2\NN\15265518|the|convulsive|mean (l_amod) convulsive_1\JJ\1740|
D008012_D012640 CID lidocaine_10\NN\3681148| (r_compound) toxicity_11\NN\13576101|of|lidocaine (r_nmod) effect_8\NN\34213|the|convulsive|toxicity (l_amod) convulsive_7\JJ\1740|
D004737_D012640 NONE enflurane_12\NN\3299929| (r_conj) sevoflurane_10\NN\1740|between|and|enflurane (r_nmod) threshold_8\NN\15265518|in|the|convulsive|sevoflurane (l_amod) convulsive_7\JJ\1740|
D004737_D012640 NONE enflurane_14\NN\3299929| (r_conj) sevoflurane_12\NN\1740|of|or|enflurane (r_nmod) concentrations_10\NNS\4916342|higher|sevoflurane (r_nsubjpass) administered_16\VBN\2436349|when|concentrations|were|and|decreased (l_conj) decreased_23\VBD\169651|pressure|significantly|sevoflurane (l_nsubj) pressure_20\NN\11419404|the|blood|convulsions (l_nmod) convulsions_22\NNS\14081375|at
D004737_D012640 NONE enflurane_37\NN\3299929|% (r_conj) became_5\VBD\146138|rise|marked|,|and|%|and|enflurane|. (l_acomp) marked_7\JJ\1740|less|administered (l_advcl) administered_16\VBN\2436349|when|concentrations|were|and|decreased (l_conj) decreased_23\VBD\169651|pressure|significantly|sevoflurane (l_nsubj) pressure_20\NN\11419404|the|blood|convulsions (l_nmod) convulsions_22\NNS\14081375|at
D001030_D012640 NONE apamin_0\NN\1740|ng (r_nsubj) had_5\VBD\2108377|apamin|tendency|)|but|significant (l_dobj) tendency_7\NN\6193203|a|decrease (l_acl) decrease_9\VB\169651|to|threshold (l_dobj) threshold_12\NN\15265518|the|convulsive|l(-1 (l_amod) convulsive_11\JJ\1740|
C009250_D064420 NONE sevoflurane_4\NN\1740| (r_nsubj) reduces_5\VBZ\441445|that|sevoflurane|effect|but|carries (l_dobj) effect_8\NN\34213|the|convulsive|toxicity (l_nmod) toxicity_11\NN\13576101|of|lidocaine
C009250_D003866 NONE sevoflurane_4\NN\1740| (r_nsubj) reduces_5\VBZ\441445|that|sevoflurane|effect|but|carries (l_conj) carries_13\VBZ\1850315|risk|depression (l_nmod) depression_19\NN\14373582|due|to|circulatory
D008012_D064420 NONE lidocaine_10\NN\3681148| (r_compound) toxicity_11\NN\13576101|of|lidocaine
D008012_D003866 NONE lidocaine_10\NN\3681148| (r_compound) toxicity_11\NN\13576101|of|lidocaine (r_nmod) effect_8\NN\34213|the|convulsive|toxicity (r_dobj) reduces_5\VBZ\441445|that|sevoflurane|effect|but|carries (l_conj) carries_13\VBZ\1850315|risk|depression (l_nmod) depression_19\NN\14373582|due|to|circulatory
3856631
D008727_D008577 NONE methotrexate_8\NN\2722166|with|high-dose|intravenous (r_nmod) induction_1\NN\7450842|remission|leukemia|methotrexate|. (l_nmod) leukemia_4\NN\14239918|of|meningeal
D008727_D054198 NONE methotrexate_16\VBP\1740|regimen (r_conj) treated_11\VBN\2376958|children|were|intravenous|methotrexate|. (l_nsubjpass) children_1\NNS\9622049|twenty|leukemia|developed (l_nmod) leukemia_5\NN\14239918|with|acute|lymphoblastic
D008727_D054198 NONE methotrexate_26\VBP\1740|csf (r_amod) concentrations_27\NNS\4916342|methotrexate|mol/l|need (r_dobj) maintain_24\VB\2202928|concentrations (r_conj) achieve_22\VB\2524171|to|and|maintain (r_xcomp) designed_20\VBN\1631534|that|was|achieve (r_acl:relcl) regimen_17\NN\5898568|designed (r_dobj) methotrexate_16\VBP\1740|regimen (r_conj) treated_11\VBN\2376958|children|were|intravenous|methotrexate|. (l_nsubjpass) children_1\NNS\9622049|twenty|leukemia|developed (l_nmod) leukemia_5\NN\14239918|with|acute|lymphoblastic
D008727_D054198 NONE methotrexate_2\NN\2722166|high-dose|intravenous (r_nsubj) treatment_6\NN\654885|methotrexate|is|an|effective|induction|. (l_nmod) induction_9\NN\7450842|for|the|remission|relapse (l_nmod) relapse_14\NN\66636|after|meningeal|leukemia (l_nmod) leukemia_18\NN\14239918|in|acute|lymphoblastic
D008727_D002493 NONE methotrexate_16\VBP\1740|regimen (r_conj) treated_11\VBN\2376958|children|were|intravenous|methotrexate|. (l_nsubjpass) children_1\NNS\9622049|twenty|leukemia|developed (l_acl:relcl) developed_7\VBD\1753788|who|disease (l_dobj) disease_9\NN\14061805|meningeal
D008727_D002493 NONE methotrexate_26\VBP\1740|csf (r_amod) concentrations_27\NNS\4916342|methotrexate|mol/l|need (r_dobj) maintain_24\VB\2202928|concentrations (r_conj) achieve_22\VB\2524171|to|and|maintain (r_xcomp) designed_20\VBN\1631534|that|was|achieve (r_acl:relcl) regimen_17\NN\5898568|designed (r_dobj) methotrexate_16\VBP\1740|regimen (r_conj) treated_11\VBN\2376958|children|were|intravenous|methotrexate|. (l_nsubjpass) children_1\NNS\9622049|twenty|leukemia|developed (l_acl:relcl) developed_7\VBD\1753788|who|disease (l_dobj) disease_9\NN\14061805|meningeal
D001663_D064420 NONE bilirubin_10\NN\14756039| (r_conj) transaminase_8\NN\15077571|toxicities|were|transient|serum|and|bilirubin|elevations|. (l_nsubj) toxicities_3\NNS\13576101|the|common|encountered
D001663_D009503 NONE bilirubin_10\NN\14756039| (r_conj) transaminase_8\NN\15077571|toxicities|were|transient|serum|and|bilirubin|elevations|. (l_conj) elevations_11\NNS\7445480|,|neutropenia|,|and|mucositis (l_conj) neutropenia_13\NN\14196405|
D001663_D052016 NONE bilirubin_10\NN\14756039| (r_conj) transaminase_8\NN\15077571|toxicities|were|transient|serum|and|bilirubin|elevations|. (l_conj) elevations_11\NNS\7445480|,|neutropenia|,|and|mucositis (l_conj) mucositis_16\NN\1740|
15957009
C507242_D008569 NONE ro4368554_5\NNS\1740|the|selective|5-ht6|receptor|antagonist (r_nsubj) restores_6\VBZ\1631072|ro4368554|performance|rat|. (l_dobj) performance_8\NN\6619065|memory|models (l_nmod) models_13\NNS\5888929|in|cholinergic|deficiency (l_nmod) deficiency_16\NN\14449126|of|memory
C507242_D008569 NONE ro4368554_2\NNP\1740|both|,|(|mg/kg|i.p.|)|)|and|metrifonate|mg/kg|deficits|mg/kg|i.p.|,|and|mg/kg|. (l_appos) deficits_26\NNS\5113133|reversed|memory|induced
C507242_D008569 NONE ro4368554_4\NNS\1740| (r_nsubj) improve_7\VB\126264|although|ro4368554|did|not|deficit (r_advcl) reversed_14\VBD\109660|conclusion|,|improve|,|it|cholinergic|,|suggesting|. (l_dobj) cholinergic_16\NN\1740|a|and|deficit (l_conj) deficit_21\NN\5113133|a|serotonergic|memory
C507242_D008569 NONE ro4368554_37\NNS\1740|by (r_nmod) facilitation_32\NN\13920835|in|the|memory|ro4368554|and|,|antagonists (r_nmod) involved_29\VBN\2676054|that|mechanisms|may|be|facilitation (r_ccomp) suggesting_23\VBG\1010118|involved (r_advcl) reversed_14\VBD\109660|conclusion|,|improve|,|it|cholinergic|,|suggesting|. (l_dobj) cholinergic_16\NN\1740|a|and|deficit (l_conj) deficit_21\NN\5113133|a|serotonergic|memory
D014236_D008569 NONE metrifonate_15\NN\1740| (r_conj) ro4368554_2\NNP\1740|both|,|(|mg/kg|i.p.|)|)|and|metrifonate|mg/kg|deficits|mg/kg|i.p.|,|and|mg/kg|. (l_appos) deficits_26\NNS\5113133|reversed|memory|induced
D012601_D008569 CID scopolamine_29\NN\14712692|by|and|depletion (r_nmod) induced_27\VBN\1627355|scopolamine (r_acl) deficits_26\NNS\5113133|reversed|memory|induced
D014364_D008569 NONE trp_31\NN\1740| (r_compound) depletion_32\NN\351638|trp (r_conj) scopolamine_29\NN\14712692|by|and|depletion (r_nmod) induced_27\VBN\1627355|scopolamine (r_acl) deficits_26\NNS\5113133|reversed|memory|induced
D012701_D008569 NONE 5-ht(6_43\NN\1740| (r_compound) antagonists_46\NNS\7846|possibly|,|other|5-ht(6|)|receptor (r_conj) facilitation_32\NN\13920835|in|the|memory|ro4368554|and|,|antagonists (r_nmod) involved_29\VBN\2676054|that|mechanisms|may|be|facilitation (r_ccomp) suggesting_23\VBG\1010118|involved (r_advcl) reversed_14\VBD\109660|conclusion|,|improve|,|it|cholinergic|,|suggesting|. (l_dobj) cholinergic_16\NN\1740|a|and|deficit (l_conj) deficit_21\NN\5113133|a|serotonergic|memory
15188772
D004837_D018487 NONE epinephrine_12\NN\14807929| (r_compound) overdose_13\NN\1740|due|to|accidental|iatrogenic|epinephrine (r_nmod) left_2\VBD\120316|reversible|systolic|overdose|. (l_dobj) systolic_4\NN\1740|ventricular|and|diastolic|dysfunction (l_conj) dysfunction_7\NN\14204950|
D004837_D018487 NONE epinephrine_13\NN\14807929|of (r_nmod) mg_11\NN\13717155|with|8|epinephrine (r_nmod) injected_8\VBN\81072|woman|uteri|was|inadvertently|mg|developed|,|left|,|and|markers|. (l_conj) left_30\VBD\120316|systolic (l_dobj) systolic_32\NN\1740|ventricular|and|diastolic|dysfunction (l_dep) dysfunction_35\NN\14204950|
D004837_D062787 NONE epinephrine_12\NN\14807929| (r_compound) overdose_13\NN\1740|due|to|accidental|iatrogenic|epinephrine
D002395_D009202 NONE catecholamine-induced_0\JJ\1740| (r_amod) cardiomyopathy_1\NN\14103288|catecholamine-induced|excess
D002395_D009202 NONE catecholamines_8\NNS\5407119|of|endogenous (r_nmod) excess_5\NN\5119367|due|chronic|catecholamines (r_nmod) cardiomyopathy_1\NN\14103288|catecholamine-induced|excess
D004837_D017682 CID epinephrine_13\NN\14807929|of (r_nmod) mg_11\NN\13717155|with|8|epinephrine (r_nmod) injected_8\VBN\81072|woman|uteri|was|inadvertently|mg|developed|,|left|,|and|markers|. (l_conj) developed_14\VBD\1753788|stunning|,|albeit (l_dobj) stunning_16\NN\1740|myocardial|characterized
D004837_D009202 NONE epinephrine_13\NN\14807929|of (r_nmod) mg_11\NN\13717155|with|8|epinephrine (r_nmod) injected_8\VBN\81072|woman|uteri|was|inadvertently|mg|developed|,|left|,|and|markers|. (l_conj) markers_42\NNS\21939|elevated|biochemical|necrosis (l_nmod) necrosis_45\NN\11444117|of|myocardial
17615423
D019821_D012206 CID simvastatin_11\NN\3676175|of|,|amiodarone (r_nmod) use_9\NN\407535|to|concomitant|simvastatin (r_nmod) secondary_6\JJ\1740|use (r_amod) rhabdomyolysis_1\NN\1740|severe|and|failure|secondary|.
D019821_D012206 CID simvastatin_11\NN\3676175|between|,|amiodarone|,|and|atazanavir (r_nmod) interaction_9\NN\37396|of|a|severe|simvastatin|resulting (l_acl) resulting_17\VBG\2633881|rhabdomyolysis (l_nmod) rhabdomyolysis_19\NN\1740|in|and|failure
D019821_D012206 CID simvastatin_16\NN\3676175| (r_amod) metabolism_17\NN\13526110|simvastatin (r_dobj) inhibit_15\VBP\2510337|that|metabolism (r_acl:relcl) drugs_13\NNS\14778436|of|concomitant|inhibit (r_nmod) presence_10\NN\13954253|in|the|drugs (r_nmod) increased_7\VBN\169651|risk|is|presence|. (l_nsubjpass) risk_3\NN\14541044|the|rhabdomyolysis (l_nmod) rhabdomyolysis_5\NN\1740|of
D019821_D058186 CID simvastatin_11\NN\3676175|of|,|amiodarone (r_nmod) use_9\NN\407535|to|concomitant|simvastatin (r_nmod) secondary_6\JJ\1740|use (r_amod) rhabdomyolysis_1\NN\1740|severe|and|failure|secondary|. (l_conj) failure_5\NN\66216|acute|renal
D019821_D058186 CID simvastatin_11\NN\3676175|between|,|amiodarone|,|and|atazanavir (r_nmod) interaction_9\NN\37396|of|a|severe|simvastatin|resulting (l_acl) resulting_17\VBG\2633881|rhabdomyolysis (l_nmod) rhabdomyolysis_19\NN\1740|in|and|failure (l_conj) failure_23\NN\66216|acute|renal
D000638_D012206 CID amiodarone_13\RB\1740|,|and|atazanavir (r_conj) simvastatin_11\NN\3676175|of|,|amiodarone (r_nmod) use_9\NN\407535|to|concomitant|simvastatin (r_nmod) secondary_6\JJ\1740|use (r_amod) rhabdomyolysis_1\NN\1740|severe|and|failure|secondary|.
D000638_D012206 CID amiodarone_13\RB\1740| (r_conj) simvastatin_11\NN\3676175|between|,|amiodarone|,|and|atazanavir (r_nmod) interaction_9\NN\37396|of|a|severe|simvastatin|resulting (l_acl) resulting_17\VBG\2633881|rhabdomyolysis (l_nmod) rhabdomyolysis_19\NN\1740|in|and|failure
D000638_D058186 CID amiodarone_13\RB\1740|,|and|atazanavir (r_conj) simvastatin_11\NN\3676175|of|,|amiodarone (r_nmod) use_9\NN\407535|to|concomitant|simvastatin (r_nmod) secondary_6\JJ\1740|use (r_amod) rhabdomyolysis_1\NN\1740|severe|and|failure|secondary|. (l_conj) failure_5\NN\66216|acute|renal
D000638_D058186 CID amiodarone_13\RB\1740| (r_conj) simvastatin_11\NN\3676175|between|,|amiodarone|,|and|atazanavir (r_nmod) interaction_9\NN\37396|of|a|severe|simvastatin|resulting (l_acl) resulting_17\VBG\2633881|rhabdomyolysis (l_nmod) rhabdomyolysis_19\NN\1740|in|and|failure (l_conj) failure_23\NN\66216|acute|renal
C413408_D012206 CID atazanavir_16\NN\1740| (r_conj) amiodarone_13\RB\1740|,|and|atazanavir (r_conj) simvastatin_11\NN\3676175|of|,|amiodarone (r_nmod) use_9\NN\407535|to|concomitant|simvastatin (r_nmod) secondary_6\JJ\1740|use (r_amod) rhabdomyolysis_1\NN\1740|severe|and|failure|secondary|.
C413408_D012206 CID atazanavir_16\NN\1740| (r_conj) simvastatin_11\NN\3676175|between|,|amiodarone|,|and|atazanavir (r_nmod) interaction_9\NN\37396|of|a|severe|simvastatin|resulting (l_acl) resulting_17\VBG\2633881|rhabdomyolysis (l_nmod) rhabdomyolysis_19\NN\1740|in|and|failure
C413408_D058186 CID atazanavir_16\NN\1740| (r_conj) amiodarone_13\RB\1740|,|and|atazanavir (r_conj) simvastatin_11\NN\3676175|of|,|amiodarone (r_nmod) use_9\NN\407535|to|concomitant|simvastatin (r_nmod) secondary_6\JJ\1740|use (r_amod) rhabdomyolysis_1\NN\1740|severe|and|failure|secondary|. (l_conj) failure_5\NN\66216|acute|renal
C413408_D058186 CID atazanavir_16\NN\1740| (r_conj) simvastatin_11\NN\3676175|between|,|amiodarone|,|and|atazanavir (r_nmod) interaction_9\NN\37396|of|a|severe|simvastatin|resulting (l_acl) resulting_17\VBG\2633881|rhabdomyolysis (l_nmod) rhabdomyolysis_19\NN\1740|in|and|failure (l_conj) failure_23\NN\66216|acute|renal
D019821_D015658 NONE simvastatin_0\NN\3676175|,|amiodarone|,|and|medications (l_conj) medications_11\NNS\3247620|patient|human|immunodeficiency|virus (l_compound) virus_10\NN\9312843|
D000638_D015658 NONE amiodarone_2\RB\1740| (r_conj) simvastatin_0\NN\3676175|,|amiodarone|,|and|medications (l_conj) medications_11\NNS\3247620|patient|human|immunodeficiency|virus (l_compound) virus_10\NN\9312843|
12584269
D020123_D007674 CID srl_5\NN\1740| (r_nsubj) seems_6\VBZ\2604760|srl|act|displaying|,|open|. (r_conj) nephrotoxic_2\JJ\1740|these|are|,|but|seems
D020123_D007674 CID srl_5\NN\1740| (r_nsubj) seems_6\VBZ\2604760|srl|act|displaying|,|open|. (l_xcomp) displaying_10\VBG\2137132|differently|effects (l_dobj) effects_14\NNS\13245626|minor|nephrotoxic (l_amod) nephrotoxic_13\JJ\1740|
D020123_D007674 CID srl_7\NN\1740| (r_nsubjpass) combined_9\VBN\2630189|where|srl|was|indications (l_nmod) indications_14\NNS\33020|with|a|calcineurin|inhibitor|effect (l_nmod) effect_19\NN\34213|of|a|synergistic|nephrotoxic (l_amod) nephrotoxic_18\JJ\1740|
D020123_D007674 CID srl_13\NN\1740| (r_conj) csa_11\NN\1740|of|plus|srl (r_nmod) effect_9\NN\34213|a|synergistic|nephrotoxic|csa (l_amod) nephrotoxic_8\JJ\1740|
D020123_D007674 CID srl_18\NN\1740| (r_conj) fk506_16\NN\1740|plus|srl (r_nsubjpass) tolerated_21\VBN\802318|whereas|fk506|was|better (r_advcl) demonstrated_5\VBD\2137132|conclusion|:|study|effect|,|tolerated|. (l_dobj) effect_9\NN\34213|a|synergistic|nephrotoxic|csa (l_amod) nephrotoxic_8\JJ\1740|
D016572_D005355 NONE csa_11\NN\1740|with|plus|srl|p<0.001 (r_nmod) treated_9\VBN\2376958|csa (r_acl) group_8\NN\2137|in|the|treated (r_nmod) worst_5\VBN\1101913|scoring|was|significantly|group|controls|and|showed|. (l_conj) showed_30\VBD\2137132|analysis|also|proportion|and|different (l_nsubj) analysis_22\NN\633864|the|grade (l_nmod) grade_26\NN\7975026|of|the|total|fibrosis (l_nmod) fibrosis_28\NN\14204950|of
D020123_D005355 NONE srl_13\NN\1740| (r_conj) csa_11\NN\1740|with|plus|srl|p<0.001 (r_nmod) treated_9\VBN\2376958|csa (r_acl) group_8\NN\2137|in|the|treated (r_nmod) worst_5\VBN\1101913|scoring|was|significantly|group|controls|and|showed|. (l_conj) showed_30\VBD\2137132|analysis|also|proportion|and|different (l_nsubj) analysis_22\NN\633864|the|grade (l_nmod) grade_26\NN\7975026|of|the|total|fibrosis (l_nmod) fibrosis_28\NN\14204950|of
D020123_D005355 NONE srl_3\NN\1740| (r_compound) combination_4\NN\7951464|fk506|srl (r_nsubj) showed_5\VBD\2137132|combination|degree|compared|. (l_dobj) degree_10\NN\4916342|only|a|higher|fibrosis (l_nmod) fibrosis_12\NN\14204950|of
D016559_D005355 NONE fk506_1\NN\1740|the|plus (r_compound) combination_4\NN\7951464|fk506|srl (r_nsubj) showed_5\VBD\2137132|combination|degree|compared|. (l_dobj) degree_10\NN\4916342|only|a|higher|fibrosis (l_nmod) fibrosis_12\NN\14204950|of
D016572_D007674 CID csa_11\NN\1740|of|plus|srl (r_nmod) effect_9\NN\34213|a|synergistic|nephrotoxic|csa (l_amod) nephrotoxic_8\JJ\1740|
D016559_D007674 CID fk506_16\NN\1740|plus|srl (r_nsubjpass) tolerated_21\VBN\802318|whereas|fk506|was|better (r_advcl) demonstrated_5\VBD\2137132|conclusion|:|study|effect|,|tolerated|. (l_dobj) effect_9\NN\34213|a|synergistic|nephrotoxic|csa (l_amod) nephrotoxic_8\JJ\1740|
14976857
D011405_-1 NONE propafenone_5\NN\1740| (r_compound) overdose_6\NN\1740|by|propafenone (r_nmod) induced_3\VBN\1627355|overdose|woman (r_acl) syndrome_2\NN\5870365|transient|platypnea-orthodeoxia-like|induced|.
D011405_D062787 NONE propafenone_5\NN\1740| (r_compound) overdose_6\NN\1740|by|propafenone
D011405_D062787 NONE propafenone_26\NN\1740| (r_compound) overdose_27\NN\1740|by|a|propafenone
D011405_D004437 NONE propafenone_5\NN\1740| (r_compound) overdose_6\NN\1740|by|propafenone (r_nmod) induced_3\VBN\1627355|overdose|woman (l_nmod) woman_10\NN\9605289|in|a|young|anomaly (l_nmod) anomaly_14\NN\14501726|with|ebstein
D011405_D054092 NONE propafenone_26\NN\1740| (r_compound) overdose_27\NN\1740|by|a|propafenone (r_nmod) precipitated_23\VBN\1642924|was|probably|overdose (r_conj) occurred_9\VBD\2623529|shunt|presence|,|and|precipitated|. (l_nsubj) shunt_1\NN\5248181|this|blood|ovale (l_nmod) ovale_8\NN\1740|via|a|foramen
11166519
D003042_D012640 CID cocaine-induced_1\JJ\1740|acute (r_amod) seizures_2\NNS\14081375|cocaine-induced|:|sensitivity|.
D003042_D012640 CID cocaine_22\NN\3492717|of (r_nmod) injection_20\NN\320852|by|a|single|cocaine (r_nmod) induced_16\VBN\1627355|injection (r_acl) seizures_15\NNS\14081375|to|behavioral|induced
D003042_D012640 CID cocaine-induced_14\JJ\1740| (r_amod) seizures_15\NNS\14081375|on|cocaine-induced
6209318
D008801_D001145 NONE mexiletine_1\NN\2715941|international|and|placebo|trial|: (r_compound) report_9\NNP\6470073|mexiletine|i.|arrhythmia|. (l_nmod) arrhythmia_11\NN\14103288|on|and|findings
D008801_D009203 NONE mexiletine_9\NN\2715941|of (r_nmod) form_7\NN\6286395|of|the|sustained|release|mexiletine|mexitil-perlongets (r_nmod) effects_2\NNS\13245626|the|antiarrhythmic|form (r_nsubjpass) evaluated_14\VBN\670261|effects|were|trial|. (l_nmod) trial_19\NN\786195|in|a|double-blind|placebo|patients (l_nmod) patients_22\NNS\9898892|in|630|infarction (l_nmod) infarction_27\NN\14204950|with|recent|documented|myocardial
D008801_D009203 NONE mexitil-perlongets_11\NNS\1740|(|) (r_appos) form_7\NN\6286395|of|the|sustained|release|mexiletine|mexitil-perlongets (r_nmod) effects_2\NNS\13245626|the|antiarrhythmic|form (r_nsubjpass) evaluated_14\VBN\670261|effects|were|trial|. (l_nmod) trial_19\NN\786195|in|a|double-blind|placebo|patients (l_nmod) patients_22\NNS\9898892|in|630|infarction (l_nmod) infarction_27\NN\14204950|with|recent|documented|myocardial
D008801_D003643 NONE mexiletine_6\NN\2715941| (r_compound) group_7\NN\2137|in|the|mexiletine (r_nmod) deaths_3\NNS\7296428|more|group|%
D008801_D014202 CID mexiletine_16\NN\2715941| (r_compound) group_17\NN\2137|in|the|mexiletine (r_nmod) frequent_13\JJ\1740|recognized|,|were|more|group|group|. (l_advcl) recognized_1\VBN\686447|previously|effects (l_dobj) effects_3\NNS\13245626|side|,|tremor (l_appos) tremor_6\NN\345926|particularly|and|problems
D008801_D012817 CID mexiletine_16\NN\2715941| (r_compound) group_17\NN\2137|in|the|mexiletine (r_nmod) frequent_13\JJ\1740|recognized|,|were|more|group|group|. (l_advcl) recognized_1\VBN\686447|previously|effects (l_dobj) effects_3\NNS\13245626|side|,|tremor (l_appos) tremor_6\NN\345926|particularly|and|problems (l_conj) problems_9\NNS\14408086|gastrointestinal
20196116
D000995_D017114 CID antituberculosis_0\NN\1740| (r_compound) failure_4\NN\66216|antituberculosis|therapy-induced|acute|liver|:|magnitude|.
D000995_D017114 CID antituberculosis_0\NN\1740| (r_compound) therapy_1\NN\657604|antituberculosis (r_nsubj) (att)-associated_2\VBD\1740|therapy|failure (l_dobj) failure_5\NN\66216|acute|liver|att-alf
D000995_D017114 CID antituberculosis_0\NN\1740| (r_compound) therapy_1\NN\657604|antituberculosis (r_nsubj) (att)-associated_2\VBD\1740|therapy|failure (l_dobj) failure_5\NN\66216|acute|liver|att-alf (l_appos) att-alf_7\NN\1740|(|)
D000995_D017114 CID antituberculosis_0\NN\1740| (r_compound) therapy_1\NN\657604|antituberculosis (r_nsubj) (att)-associated_2\VBD\1740|therapy|failure (r_nsubj) alf_13\NN\1740|(att)-associated|is|the|commonest|drug-induced|asia|.
D001663_D001927 NONE bilirubin_11\NN\14756039|serum|(|or=10.8|)|,|time|prolongation|,|and|iii/iv (l_conj) iii/iv_32\NN\1740|grade|encephalopathy (l_amod) encephalopathy_33\JJ\1740|presentation
20477932
D003042_D008569 CID cocaine_0\NN\3492717| (r_nsubj) causes_1\VBZ\1617192|cocaine|impairments|:|involvement|,|and|prevention|. (l_dobj) impairments_5\NNS\7296428|memory|rats
D003042_D007859 CID cocaine_0\NN\3492717| (r_nsubj) causes_1\VBZ\1617192|cocaine|impairments|:|involvement|,|and|prevention|. (l_dobj) impairments_5\NNS\7296428|memory|rats
C052342_D008569 NONE topiramate_22\NN\1740|by (r_nmod) prevention_20\NN\1073995|topiramate (r_conj) causes_1\VBZ\1617192|cocaine|impairments|:|involvement|,|and|prevention|. (l_dobj) impairments_5\NNS\7296428|memory|rats
C052342_D007859 NONE topiramate_22\NN\1740|by (r_nmod) prevention_20\NN\1073995|topiramate (r_conj) causes_1\VBZ\1617192|cocaine|impairments|:|involvement|,|and|prevention|. (l_dobj) impairments_5\NNS\7296428|memory|rats
D003042_D064420 NONE cocaine_6\NN\3492717| (r_compound) toxicity_7\NN\13576101|for|cocaine|increase|but|association
D003042_D064420 NONE cocaine_24\NN\3492717| (r_conj) brain_22\NN\5462674|and|cocaine (r_compound) induced-behaviour_25\NN\1740|in|the|brain (r_nmod) status_19\NN\24720|between|oxidative|induced-behaviour (r_nmod) association_16\NN\8008335|the|status (r_conj) toxicity_7\NN\13576101|for|cocaine|increase|but|association
D009569_D019970 NONE oxide_9\NN\14818238| (r_compound) synthase_10\NN\1740|neuronal|nitric|oxide|nnos (r_compound) activity_14\NN\30358|synthase|,|learning (r_conj) activity_2\NN\30358|therefore|nfkappab|,|stress|,|activity|as|effect|,|therapy|, (l_appos) therapy_31\NN\657604|a|proposed|addiction (l_nmod) addiction_34\NN\14034177|for|cocaine
C052342_D019970 NONE topiramate_26\NN\1740|of (r_nmod) effect_24\NN\34213|the|topiramate (r_conj) activity_2\NN\30358|therefore|nfkappab|,|stress|,|activity|as|effect|,|therapy|, (l_appos) therapy_31\NN\657604|a|proposed|addiction (l_nmod) addiction_34\NN\14034177|for|cocaine
D003042_D019970 NONE cocaine_43\NN\3492717| (r_compound) administration_44\NN\1133281|of|cocaine|rats (r_nmod) model_41\NN\5888929|in|an|experimental|administration (r_nmod) evaluated_37\VBN\670261|activity|were|model|. (l_nsubjpass) activity_2\NN\30358|therefore|nfkappab|,|stress|,|activity|as|effect|,|therapy|, (l_appos) therapy_31\NN\657604|a|proposed|addiction (l_nmod) addiction_34\NN\14034177|for|cocaine
7265370
D014223_D053040 CID triamterene_0\NN\1740| (r_compound) nephrolithiasis_1\NN\14115914|triamterene|complicating|.
D014223_D053040 CID triamterene_3\JJ\1740| (r_amod) nephrolithiasis_4\NN\14115914|of|triamterene
D014223_D053040 CID triamterene_2\JJ\1740| (r_amod) nephrolithiasis_3\NN\14115914|triamterene
C020743_D053040 NONE dyazide_3\NN\1740| (r_compound) therapy_4\NN\657604|dyazide (r_dobj) complicating_2\VBG\126264|therapy (r_acl) nephrolithiasis_1\NN\14115914|triamterene|complicating|.
C020743_D053040 NONE hydrochlorothiazide-triamterene_14\NN\1740| (r_compound) therapy_15\NN\657604|of|hydrochlorothiazide-triamterene|hypertension (r_nmod) years_12\NNS\15144371|after|4|therapy (r_nmod) reported_6\VBN\831651|case|is|man|years|. (l_nsubjpass) case_1\NN\7283608|a|nephrolithiasis (l_nmod) nephrolithiasis_4\NN\14115914|of|triamterene
D014223_D006973 NONE triamterene_3\JJ\1740| (r_amod) nephrolithiasis_4\NN\14115914|of|triamterene (r_nmod) case_1\NN\7283608|a|nephrolithiasis (r_nsubjpass) reported_6\VBN\831651|case|is|man|years|. (l_nmod) years_12\NNS\15144371|after|4|therapy (l_nmod) therapy_15\NN\657604|of|hydrochlorothiazide-triamterene|hypertension (l_nmod) hypertension_17\NN\14057371|for
C020743_D006973 NONE hydrochlorothiazide-triamterene_14\NN\1740| (r_compound) therapy_15\NN\657604|of|hydrochlorothiazide-triamterene|hypertension (l_nmod) hypertension_17\NN\14057371|for
424937
D008750_D056486 CID methyldopa_6\NN\2721160|by (r_nmod) induced_4\VBN\1627355|methyldopa (r_acl) injury_3\NN\14052046|of|hepatic|induced
D008750_D056486 CID methyldopa-induced_22\JJ\1740| (r_amod) hepatitis_23\NN\14127211|of|methyldopa-induced
D008750_D056486 CID methyldopa_14\JJ\1740|and|hepatic (r_amod) dysfunction_17\NN\14204950|between|methyldopa (r_nmod) relationship_12\NN\31921|the|causal|dysfunction (r_nsubjpass) proved_19\VBN\2604760|patient|,|relationship|was|recurrence|. (l_nmod) recurrence_22\NN\7342049|with|the|hepatitis|weeks (l_nmod) hepatitis_24\NN\14127211|of
D008750_D008107 NONE methyldopa_7\NN\2721160|to (r_nmod) related_5\JJ\1740|methyldopa (r_amod) disease_4\NN\14061805|with|liver|related
D008750_D008107 NONE methyldopa_14\JJ\1740|and|hepatic (r_amod) dysfunction_17\NN\14204950|between|methyldopa
D008750_D017093 NONE methyldopa_17\JJ\1740| (r_advmod) taking_16\VBG\2367363|who|had|been|methyldopa|years (r_acl:relcl) another_11\DT\1740|,|taking (r_conj) presented_5\VBN\2137132|having|failure|,|and|another|, (l_nmod) failure_8\NN\66216|in|hepatic
D008750_D017114 NONE methyldopa-induced_22\JJ\1740| (r_amod) hepatitis_23\NN\14127211|of|methyldopa-induced (r_nmod) episode_20\NN\7283608|after|a|prior|hepatitis (r_nmod) recommenced_14\VBN\348746|when|drug|was|accidentally|episode (r_advcl) developed_6\VBD\1753788|patient|hepatitis|recommenced|. (l_dobj) hepatitis_8\NN\14127211|fulminant
20470218
D008727_D056784 NONE methotrexate_30\VBP\1740|high-dose|toxicity|,|and|events (r_dep) included_2\VBD\690614|complications|syndrome|methotrexate|. (l_dobj) syndrome_6\NN\5870365|posterior|reversible|leukoencephalopathy|n|,|stroke|,|epilepsy (l_compound) leukoencephalopathy_5\NN\1740|
D008727_D020521 NONE methotrexate_30\VBP\1740|high-dose|toxicity|,|and|events (r_dep) included_2\VBD\690614|complications|syndrome|methotrexate|. (l_dobj) syndrome_6\NN\5870365|posterior|reversible|leukoencephalopathy|n|,|stroke|,|epilepsy (l_conj) stroke_13\NN\556313|n
D008727_D004833 NONE methotrexate_30\VBP\1740|high-dose|toxicity|,|and|events (r_dep) included_2\VBD\690614|complications|syndrome|methotrexate|. (l_dobj) syndrome_6\NN\5870365|posterior|reversible|leukoencephalopathy|n|,|stroke|,|epilepsy (l_conj) epilepsy_22\NN\14085708|lobe|n|,
D008727_D064420 NONE methotrexate_30\VBP\1740|high-dose|toxicity|,|and|events (l_dobj) toxicity_31\NN\13576101|n|,|syndrome
D008727_D007177 NONE methotrexate_30\VBP\1740|high-dose|toxicity|,|and|events (l_dobj) toxicity_31\NN\13576101|n|,|syndrome (l_conj) syndrome_38\NN\5870365|secretion|n (l_nmod) secretion_43\NN\13526110|of|inappropriate|antidiuretic|hormone
15572383
D004317_D007674 NONE adriamycin-induced_12\JJ\1740| (r_amod) damage_14\NN\7296428|to|adriamycin-induced|renal
D004317_D007674 NONE adriamycin_23\NN\1740|of (r_nmod) injection_21\NN\320852|by|a|single|adriamycin|rats (r_nmod) induced_17\VBN\1627355|injection (r_acl) damage_16\NN\7296428|of|renal|induced
D004317_D007674 NONE adriamycin_5\NN\1740| (r_nsubj) elicited_6\VBD\1617192|anticipated|,|adriamycin|proteinuria (l_dobj) proteinuria_9\NN\14299637|nephrotic|range|,|damage (l_conj) damage_13\NN\7296428|renal|interstitial|and|glomerulosclerosis
D004317_D007674 NONE adriamycin-induced_12\JJ\1740| (r_amod) damage_14\NN\7296428|of|adriamycin-induced|renal
D004317_D011507 CID adriamycin_10\NN\1740|by|n|;|controls|, (r_nmod) induced_8\VBN\1627355|week|,|proteinuria|was|adriamycin|n|]|. (l_nsubjpass) proteinuria_6\NN\14299637|
D004317_D011507 CID adriamycin_5\NN\1740| (r_nsubj) elicited_6\VBD\1617192|anticipated|,|adriamycin|proteinuria (l_dobj) proteinuria_9\NN\14299637|nephrotic|range|,|damage
D004317_D011507 CID adriamycin_12\NN\1740|after|= (r_nmod) rise_8\NN\7324673|with|the|relative|proteinuria|adriamycin|,|actin|,|influx|,|collagen (l_nmod) proteinuria_10\NN\14299637|in
D004317_D009404 NONE adriamycin_5\NN\1740| (r_nsubj) elicited_6\VBD\1617192|anticipated|,|adriamycin|proteinuria (l_dobj) proteinuria_9\NN\14299637|nephrotic|range|,|damage (l_amod) nephrotic_7\JJ\1740|
D004317_D005923 NONE adriamycin_5\NN\1740| (r_nsubj) elicited_6\VBD\1617192|anticipated|,|adriamycin|proteinuria (l_dobj) proteinuria_9\NN\14299637|nephrotic|range|,|damage (l_conj) damage_13\NN\7296428|renal|interstitial|and|glomerulosclerosis (l_conj) glomerulosclerosis_17\NN\1740|mild|focal
7582165
D000305_D004342 NONE corticosteroids_3\NNS\14745635|to (r_nmod) reactions_1\NNS\13446390|pseudo-allergic|corticosteroids|:|diagnosis|.
D010248_D004342 NONE paramethasone_3\NN\1740|from (r_nmod) different_1\JJ\1740|paramethasone (r_amod) corticosteroids_0\NNS\14745635|different (r_nsubj) produced_5\VBD\1617192|corticosteroids|also|reactions|;|however|,|tolerated|. (l_dobj) reactions_7\NNS\13446390|hypersensitivity|patients (l_compound) hypersensitivity_6\NN\14531772|
D010248_D004342 NONE paramethasone_14\NN\1740|by (r_nmod) caused_12\VBN\1617192|paramethasone (r_acl) pseudo-allergy_11\NN\1740|of|a|caused
18208574
D006493_D013927 CID heparin-induced_12\JJ\1740| (r_amod) thrombocytopenia_13\NN\14189204|with|heparin-induced (r_nmod) patients_10\NNS\9898892|in|thrombocytopenia (r_nmod) thrombosis_8\NN\14100769|patients
D006493_D013927 CID heparin-induced_12\JJ\1740| (r_amod) thrombocytopenia_13\NN\14189204|heparin-induced|hit (r_dep) two-step_11\JJ\1740|thrombocytopenia (r_amod) assay_18\NN\5733583|of|a|two-step|antigen|thrombosis (l_nmod) thrombosis_20\NN\14100769|with
D006493_D013927 CID heparin_31\NN\2718259| (r_compound) concentration_32\NN\4916342|of|a|high|heparin (r_nmod) characteristics_27\NNS\5849040|reaction|inhibition|concentration (r_dobj) utilizes_24\VBZ\161225|objectives|;|assay|characteristics|. (l_ccomp) objectives_0\NNS\5980875|:|correlate (l_acl) correlate_3\VB\2657219|to|inhibition (l_dobj) inhibition_8\NN\1068773|density|assay (l_nmod) assay_18\NN\5733583|of|a|two-step|antigen|thrombosis (l_nmod) thrombosis_20\NN\14100769|with
D006493_D013921 CID heparin-induced_12\JJ\1740| (r_amod) thrombocytopenia_13\NN\14189204|with|heparin-induced
D006493_D013921 CID heparin-induced_12\JJ\1740| (r_amod) thrombocytopenia_13\NN\14189204|heparin-induced|hit
D006493_D013921 CID heparin-induced_12\JJ\1740| (r_amod) thrombocytopenia_13\NN\14189204|heparin-induced|hit (l_appos) hit_15\NN\36762|(|)
D006493_D013921 CID heparin_31\NN\2718259| (r_compound) concentration_32\NN\4916342|of|a|high|heparin (r_nmod) characteristics_27\NNS\5849040|reaction|inhibition|concentration (r_dobj) utilizes_24\VBZ\161225|objectives|;|assay|characteristics|. (l_ccomp) objectives_0\NNS\5980875|:|correlate (l_acl) correlate_3\VB\2657219|to|inhibition (l_dobj) inhibition_8\NN\1068773|density|assay (l_nmod) assay_18\NN\5733583|of|a|two-step|antigen|thrombosis (l_amod) two-step_11\JJ\1740|thrombocytopenia (l_dep) thrombocytopenia_13\NN\14189204|heparin-induced|hit
D006493_D013921 CID heparin_31\NN\2718259| (r_compound) concentration_32\NN\4916342|of|a|high|heparin (r_nmod) characteristics_27\NNS\5849040|reaction|inhibition|concentration (r_dobj) utilizes_24\VBZ\161225|objectives|;|assay|characteristics|. (l_ccomp) objectives_0\NNS\5980875|:|correlate (l_acl) correlate_3\VB\2657219|to|inhibition (l_dobj) inhibition_8\NN\1068773|density|assay (l_nmod) assay_18\NN\5733583|of|a|two-step|antigen|thrombosis (l_amod) two-step_11\JJ\1740|thrombocytopenia (l_dep) thrombocytopenia_13\NN\14189204|heparin-induced|hit (l_appos) hit_15\NN\36762|(|)
D006493_D013921 CID heparin_25\NN\2718259|to (r_nmod) exposure_23\NN\5042871|after|heparin (r_nmod) patients_0\NNS\9898892|and|methods|:|patients|<|150|)|exposure|,|had|density (l_dep) patients_4\NNS\9898892|decrease (l_nmod) decrease_10\NN\7296428|with|%|count (l_nmod) count_13\NN\13582013|in|platelet|or|thrombocytopenia|( (l_conj) thrombocytopenia_15\NN\14189204|
D006493_D013921 CID heparin_50\NN\2718259|of (r_nmod) concentration_48\NN\4916342|with|high|heparin (r_nmod) inhibition_45\NN\1068773|>|50|concentration (r_conj) density_36\NN\4941325|[|optical|od|>|and|inhibition|] (r_dep) patients_0\NNS\9898892|and|methods|:|patients|<|150|)|exposure|,|had|density (l_dep) patients_4\NNS\9898892|decrease (l_nmod) decrease_10\NN\7296428|with|%|count (l_nmod) count_13\NN\13582013|in|platelet|or|thrombocytopenia|( (l_conj) thrombocytopenia_15\NN\14189204|
19884587
D013449_D000757 CID sulfonamides_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|sulfonamides|were|anencephaly|,|syndrome|2.7|)|,|deficiency|,|and|hernia|. (l_nmod) anencephaly_4\NN\14465048|with|aor|=|;|interval|)
D013449_D018636 CID sulfonamides_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|sulfonamides|were|anencephaly|,|syndrome|2.7|)|,|deficiency|,|and|hernia|. (l_conj) syndrome_30\NN\5870365|left|heart|aor|,|coarctation|%
D013449_D001017 CID sulfonamides_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|sulfonamides|were|anencephaly|,|syndrome|2.7|)|,|deficiency|,|and|hernia|. (l_conj) syndrome_30\NN\5870365|left|heart|aor|,|coarctation|% (l_conj) coarctation_45\NN\7313241|aorta (l_nmod) aorta_48\NN\5333777|of|the|aor|,|atresia
D013449_D002754 CID sulfonamides_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|sulfonamides|were|anencephaly|,|syndrome|2.7|)|,|deficiency|,|and|hernia|. (l_conj) syndrome_30\NN\5870365|left|heart|aor|,|coarctation|% (l_conj) coarctation_45\NN\7313241|aorta (l_nmod) aorta_48\NN\5333777|of|the|aor|,|atresia (l_conj) atresia_64\NN\14501726|choanal|aor
D013449_D017880 CID sulfonamides_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|sulfonamides|were|anencephaly|,|syndrome|2.7|)|,|deficiency|,|and|hernia|. (l_conj) deficiency_81\NN\14449126|transverse|limb|aor
D013449_D006548 CID sulfonamides_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|sulfonamides|were|anencephaly|,|syndrome|2.7|)|,|deficiency|,|and|hernia|. (l_conj) hernia_98\NN\14295248|diaphragmatic|aor
D009582_D000853 CID nitrofurantoins_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|nitrofurantoins|were|anophthalmia|syndrome|,|and|cleft|. (l_nmod) anophthalmia_4\NN\1740|with|or|microphthalmos|aor
D009582_D008850 CID nitrofurantoins_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|nitrofurantoins|were|anophthalmia|syndrome|,|and|cleft|. (l_nmod) anophthalmia_4\NN\1740|with|or|microphthalmos|aor (l_conj) microphthalmos_6\NN\1740|
D009582_D018636 CID nitrofurantoins_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|nitrofurantoins|were|anophthalmia|syndrome|,|and|cleft|. (l_conj) syndrome_24\NN\5870365|left|heart|aor|,|defects|%|1.1|)
D009582_D006344 CID nitrofurantoins_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|nitrofurantoins|were|anophthalmia|syndrome|,|and|cleft|. (l_conj) syndrome_24\NN\5870365|left|heart|aor|,|defects|%|1.1|) (l_conj) defects_41\NNS\14462666|septal|aor
D009582_D002971 CID nitrofurantoins_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|nitrofurantoins|were|anophthalmia|syndrome|,|and|cleft|. (l_conj) cleft_57\VBD\1556346|lip|palate|aor (l_dobj) lip_58\NN\5301392|
D009582_D002972 CID nitrofurantoins_0\NNS\2716205| (r_nsubjpass) associated_2\VBN\628491|nitrofurantoins|were|anophthalmia|syndrome|,|and|cleft|. (l_conj) cleft_57\VBD\1556346|lip|palate|aor (l_nmod) palate_61\NN\8660339|with|cleft
D010406_D000014 NONE penicillins_4\NNS\2716866|reassuringly|,|erythromycins (r_appos) conclusions_0\NNS\5837957|:|penicillins|,|associated|. (l_ccomp) associated_20\VBN\628491|used|,|were|not|defects (l_nmod) defects_24\NNS\14462666|with|many|birth
D004917_D000014 NONE erythromycins_6\NNS\2716866|,|and|cephalosporins (r_conj) penicillins_4\NNS\2716866|reassuringly|,|erythromycins (r_appos) conclusions_0\NNS\5837957|:|penicillins|,|associated|. (l_ccomp) associated_20\VBN\628491|used|,|were|not|defects (l_nmod) defects_24\NNS\14462666|with|many|birth
D002511_D000014 NONE cephalosporins_9\NNS\2716866| (r_conj) erythromycins_6\NNS\2716866|,|and|cephalosporins (r_conj) penicillins_4\NNS\2716866|reassuringly|,|erythromycins (r_appos) conclusions_0\NNS\5837957|:|penicillins|,|associated|. (l_ccomp) associated_20\VBN\628491|used|,|were|not|defects (l_nmod) defects_24\NNS\14462666|with|many|birth
D013449_D000014 CID sulfonamides_0\NNS\2716205|and|nitrofurantoins (r_nsubjpass) associated_4\VBN\628491|sulfonamides|were|defects|,|indicating|. (l_nmod) defects_8\NNS\14462666|with|several|birth
D009582_D000014 CID nitrofurantoins_2\NNS\2716205| (r_conj) sulfonamides_0\NNS\2716205|and|nitrofurantoins (r_nsubjpass) associated_4\VBN\628491|sulfonamides|were|defects|,|indicating|. (l_nmod) defects_8\NNS\14462666|with|several|birth
17343925
D012906_D034381 CID smoking_3\VBG\1156834|of|pregnancy|cochlea (r_nmod) influence_1\NN\5190804|the|smoking (r_nsubjpass) estimated_13\VBN\637259|influence|has|not|been|,|associated|. (l_advcl) associated_20\VBN\628491|although|smoking|has|been|positively|hearing (l_advcl) hearing_22\VBG\2106506|with|loss|adults (l_dobj) loss_23\NN\13252973|
D012906_D034381 CID smoking_16\NN\831191| (r_nsubjpass) associated_20\VBN\628491|although|smoking|has|been|positively|hearing (l_advcl) hearing_22\VBG\2106506|with|loss|adults (l_dobj) loss_23\NN\13252973|
8387218
D016049_D064420 NONE didanosine_5\NN\2725367|of|ddi (r_nmod) use_1\NN\407535|the|and|toxicity|didanosine|individuals (l_conj) toxicity_3\NN\13576101|
D016049_D064420 NONE ddi_7\NN\2725367|(|) (r_appos) didanosine_5\NN\2725367|of|ddi (r_nmod) use_1\NN\407535|the|and|toxicity|didanosine|individuals (l_conj) toxicity_3\NN\13576101|
D016049_D015658 NONE didanosine_5\NN\2725367|of|ddi (r_nmod) use_1\NN\407535|the|and|toxicity|didanosine|individuals (l_nmod) individuals_12\NNS\7347|in|hiv|antibody-positive|intolerant (l_amod) antibody-positive_11\JJ\1740|
D016049_D015658 NONE ddi_7\NN\2725367|(|) (r_appos) didanosine_5\NN\2725367|of|ddi (r_nmod) use_1\NN\407535|the|and|toxicity|didanosine|individuals (l_nmod) individuals_12\NNS\7347|in|hiv|antibody-positive|intolerant (l_amod) antibody-positive_11\JJ\1740|
D015215_D064420 NONE zidovudine_15\NN\3834836|to|azt (r_nmod) intolerant_13\JJ\1740|zidovudine (r_amod) individuals_12\NNS\7347|in|hiv|antibody-positive|intolerant (r_nmod) use_1\NN\407535|the|and|toxicity|didanosine|individuals (l_conj) toxicity_3\NN\13576101|
D015215_D064420 NONE azt_17\NN\3834836|(|) (r_appos) zidovudine_15\NN\3834836|to|azt (r_nmod) intolerant_13\JJ\1740|zidovudine (r_amod) individuals_12\NNS\7347|in|hiv|antibody-positive|intolerant (r_nmod) use_1\NN\407535|the|and|toxicity|didanosine|individuals (l_conj) toxicity_3\NN\13576101|
D015215_D015658 NONE zidovudine_15\NN\3834836|to|azt (r_nmod) intolerant_13\JJ\1740|zidovudine (r_amod) individuals_12\NNS\7347|in|hiv|antibody-positive|intolerant (l_amod) antibody-positive_11\JJ\1740|
D015215_D015658 NONE azt_17\NN\3834836|(|) (r_appos) zidovudine_15\NN\3834836|to|azt (r_nmod) intolerant_13\JJ\1740|zidovudine (r_amod) individuals_12\NNS\7347|in|hiv|antibody-positive|intolerant (l_amod) antibody-positive_11\JJ\1740|
D016049_D018149 CID didanosine_24\NN\2725367|on|ceasing (r_nmod) returned_19\VBD\1835496|normal|didanosine (r_conj) require_16\VB\754942|did|not|treatment|and|returned (r_conj) mild_12\JJ\1740|these|were|,|require (r_conj) developed_2\VBD\1753788|patients|curves|but|mild|. (l_dobj) curves_5\NNS\13863771|glucose|tolerance|characteristic
D016049_D003920 NONE didanosine_24\NN\2725367|on|ceasing (r_nmod) returned_19\VBD\1835496|normal|didanosine (r_conj) require_16\VB\754942|did|not|treatment|and|returned (r_conj) mild_12\JJ\1740|these|were|,|require (r_conj) developed_2\VBD\1753788|patients|curves|but|mild|. (l_dobj) curves_5\NNS\13863771|glucose|tolerance|characteristic (l_amod) characteristic_6\JJ\1740|diabetes (l_nmod) diabetes_8\NNS\14075199|of
1639466
D002118_D009400 NONE calcium_4\NN\14625458| (r_compound) channel_5\NN\6251781|calcium (r_compound) blocker_6\NN\10101634|the|channel (r_compound) nitrendipine_7\NN\1740|of|blocker|nephrosclerosis (l_nmod) nephrosclerosis_9\NN\14113228|on|rats
D002118_D006978 NONE calcium_4\NN\14625458| (r_compound) channel_5\NN\6251781|calcium (r_compound) blocker_6\NN\10101634|the|channel (r_compound) nitrendipine_7\NN\1740|of|blocker|nephrosclerosis (l_nmod) nephrosclerosis_9\NN\14113228|on|rats (l_nmod) rats_11\NNS\2329401|in|hypertension (l_nmod) hypertension_14\NN\14057371|with|renovascular
D002118_D006978 NONE calcium_8\NN\14625458| (r_compound) channel_9\NN\6251781|calcium (r_compound) nitrendipine_11\NN\1740|with|the|channel|blocker|or|inhibitor (r_nmod) treatment_5\NN\654885|of|a|6-week|nitrendipine (r_nmod) effect_1\NN\34213|the|treatment|enalapril (r_nsubjpass) studied_35\VBN\630380|effect|was|rats|,|clip|. (l_conj) clip_42\NN\4359335|one|hypertension (l_dobj) hypertension_44\NN\14057371|renovascular
D009568_D009400 CID nitrendipine_7\NN\1740|of|blocker|nephrosclerosis (l_nmod) nephrosclerosis_9\NN\14113228|on|rats
D009568_D006978 NONE nitrendipine_7\NN\1740|of|blocker|nephrosclerosis (l_nmod) nephrosclerosis_9\NN\14113228|on|rats (l_nmod) rats_11\NNS\2329401|in|hypertension (l_nmod) hypertension_14\NN\14057371|with|renovascular
D009568_D006978 NONE nitrendipine_11\NN\1740|with|the|channel|blocker|or|inhibitor (r_nmod) treatment_5\NN\654885|of|a|6-week|nitrendipine (r_nmod) effect_1\NN\34213|the|treatment|enalapril (r_nsubjpass) studied_35\VBN\630380|effect|was|rats|,|clip|. (l_conj) clip_42\NN\4359335|one|hypertension (l_dobj) hypertension_44\NN\14057371|renovascular
D002118_D000419 NONE calcium_8\NN\14625458| (r_compound) channel_9\NN\6251781|calcium (r_compound) nitrendipine_11\NN\1740|with|the|channel|blocker|or|inhibitor (r_nmod) treatment_5\NN\654885|of|a|6-week|nitrendipine (r_nmod) effect_1\NN\34213|the|treatment|enalapril (l_nmod) enalapril_18\NN\2673637|pressure (l_nmod) pressure_21\NN\11419404|on|blood|,|albuminuria|,|hemodynamics|and|morphology (l_conj) albuminuria_23\NN\14299637|
D009568_D000419 CID nitrendipine_11\NN\1740|with|the|channel|blocker|or|inhibitor (r_nmod) treatment_5\NN\654885|of|a|6-week|nitrendipine (r_nmod) effect_1\NN\34213|the|treatment|enalapril (l_nmod) enalapril_18\NN\2673637|pressure (l_nmod) pressure_21\NN\11419404|on|blood|,|albuminuria|,|hemodynamics|and|morphology (l_conj) albuminuria_23\NN\14299637|
D009568_D000419 CID nitrendipine-treated_5\JJ\1740| (r_amod) albuminuria_7\NN\14299637|in|the|nitrendipine-treated|group
D000809_D000419 NONE angiotensin_14\NN\4522421| (r_compound) inhibitor_17\NN\20090|the|angiotensin|converting|enzyme (r_conj) nitrendipine_11\NN\1740|with|the|channel|blocker|or|inhibitor (r_nmod) treatment_5\NN\654885|of|a|6-week|nitrendipine (r_nmod) effect_1\NN\34213|the|treatment|enalapril (l_nmod) enalapril_18\NN\2673637|pressure (l_nmod) pressure_21\NN\11419404|on|blood|,|albuminuria|,|hemodynamics|and|morphology (l_conj) albuminuria_23\NN\14299637|
D000809_D006978 NONE angiotensin_14\NN\4522421| (r_compound) inhibitor_17\NN\20090|the|angiotensin|converting|enzyme (r_conj) nitrendipine_11\NN\1740|with|the|channel|blocker|or|inhibitor (r_nmod) treatment_5\NN\654885|of|a|6-week|nitrendipine (r_nmod) effect_1\NN\34213|the|treatment|enalapril (r_nsubjpass) studied_35\VBN\630380|effect|was|rats|,|clip|. (l_conj) clip_42\NN\4359335|one|hypertension (l_dobj) hypertension_44\NN\14057371|renovascular
D004656_D000419 NONE enalapril_18\NN\2673637|pressure (l_nmod) pressure_21\NN\11419404|on|blood|,|albuminuria|,|hemodynamics|and|morphology (l_conj) albuminuria_23\NN\14299637|
D004656_D006978 NONE enalapril_18\NN\2673637|pressure (r_nmod) effect_1\NN\34213|the|treatment|enalapril (r_nsubjpass) studied_35\VBN\630380|effect|was|rats|,|clip|. (l_conj) clip_42\NN\4359335|one|hypertension (l_dobj) hypertension_44\NN\14057371|renovascular
D004656_D006973 NONE enalapril-treated_33\JJ\1740|n (r_amod) n_29\NN\14622893|(|=|,|enalapril-treated (r_dep) controls_27\NNS\5190804|untreated|hypertensive|n (r_dep) assigned_20\VBN\2475922|weeks|were|randomly|groups|:|controls|. (l_nsubjpass) weeks_1\NNS\15113229|six|clipping|mm (l_nmod) clipping_3\VBG\1552519|after|artery (l_nmod) artery_7\NN\5417975|of|one|renal|,|rats (l_appos) rats_10\NNS\2329401|hypertensive (l_amod) hypertensive_9\JJ\1740|
D004656_D006973 NONE enalapril-treated_33\JJ\1740|n (r_amod) n_29\NN\14622893|(|=|,|enalapril-treated (r_dep) controls_27\NNS\5190804|untreated|hypertensive|n (l_amod) hypertensive_26\JJ\1740|
D004656_D006973 NONE enalapril-treated_23\JJ\1740| (r_amod) group_24\NN\2137|in|the|enalapril-treated|10(-3 (r_nmod) lower_20\JJR\1740|group (r_conj) higher_6\JJR\1740|addition|,|size|was|group|mm2|)|but|lower|mm2|)|controls|. (l_nmod) controls_37\NNS\5190804|compared|with|the|hypertensive|10(-3|mm2|) (l_amod) hypertensive_36\JJ\1740|
D009568_D006973 NONE nitrendipine-treated_40\JJ\1740|n (r_conj) n_35\NN\14622893|(|=|,|or|nitrendipine-treated (r_dep) enalapril-treated_33\JJ\1740|n (r_amod) n_29\NN\14622893|(|=|,|enalapril-treated (r_dep) controls_27\NNS\5190804|untreated|hypertensive|n (r_dep) assigned_20\VBN\2475922|weeks|were|randomly|groups|:|controls|. (l_nsubjpass) weeks_1\NNS\15113229|six|clipping|mm (l_nmod) clipping_3\VBG\1552519|after|artery (l_nmod) artery_7\NN\5417975|of|one|renal|,|rats (l_appos) rats_10\NNS\2329401|hypertensive (l_amod) hypertensive_9\JJ\1740|
D009568_D006973 NONE nitrendipine-treated_40\JJ\1740|n (r_conj) n_35\NN\14622893|(|=|,|or|nitrendipine-treated (r_dep) enalapril-treated_33\JJ\1740|n (r_amod) n_29\NN\14622893|(|=|,|enalapril-treated (r_dep) controls_27\NNS\5190804|untreated|hypertensive|n (l_amod) hypertensive_26\JJ\1740|
D009568_D006973 NONE nitrendipine-treated_5\JJ\1740| (r_amod) albuminuria_7\NN\14299637|in|the|nitrendipine-treated|group (r_nmod) increased_8\VBD\169651|contrast|,|albuminuria|progressively|163|hr|. (l_advcl) hr_24\NN\15154774|compared|19.2|mg/24|controls (l_nmod) controls_28\NNS\5190804|in|the|hypertensive (l_amod) hypertensive_27\JJ\1740|
D009568_D006973 NONE nitrendipine-treated_9\JJ\1740| (r_amod) group_10\NN\2137|in|the|nitrendipine-treated (r_nmod) increased_6\VBN\169651|furthermore|,|index|was|significantly|group|controls|. (l_advcl) controls_15\NNS\5190804|compared|with|the|hypertensive|0.38 (l_amod) hypertensive_14\JJ\1740|
D009568_D006973 NONE nitrendipine-treated_9\JJ\1740| (r_amod) group_10\NN\2137|in|the|nitrendipine-treated|10(-3 (r_nmod) higher_6\JJR\1740|addition|,|size|was|group|mm2|)|but|lower|mm2|)|controls|. (l_nmod) controls_37\NNS\5190804|compared|with|the|hypertensive|10(-3|mm2|) (l_amod) hypertensive_36\JJ\1740|
D004656_D005921 NONE enalapril_14\JJ\1740| (r_amod) treatment_15\NN\654885|after|enalapril (r_nmod) change_12\VB\46534|excretion|did|not|treatment (l_nsubj) excretion_7\NN\13466586|albumin|and|glomerulosclerosis (l_conj) glomerulosclerosis_9\NN\1740|
D009568_D005921 NONE nitrendipine-treated_9\JJ\1740| (r_amod) group_10\NN\2137|in|the|nitrendipine-treated (r_nmod) increased_6\VBN\169651|furthermore|,|index|was|significantly|group|controls|. (l_nsubjpass) index_3\NN\13850304|glomerulosclerosis (l_compound) glomerulosclerosis_2\NN\1740|
16858720
D014859_D002543 CID warfarin_4\NN\2718259|by (r_nmod) induced_2\VBN\1627355|warfarin|- (r_acl) haemorrhage_1\NN\14285662|cerebral|induced|influence|.
D014859_D002543 CID warfarin-induced_11\JJ\1740| (r_amod) haemorrhages_13\NNS\14285662|of|warfarin-induced|cerebral
D014859_D002543 CID warfarin_16\NN\2718259|and|warfarin-drug (r_compound) interactions_19\NNS\37396|due|warfarin|patients (r_nmod) evaluate_3\VB\670261|to|frequency|interactions (l_dobj) frequency_5\NN\15286249|the|,|severity|haemorrhages (l_nmod) haemorrhages_13\NNS\14285662|of|warfarin-induced|cerebral
D014859_D002543 CID warfarin-drug_18\JJ\1740| (r_conj) warfarin_16\NN\2718259|and|warfarin-drug (r_compound) interactions_19\NNS\37396|due|warfarin|patients (r_nmod) evaluate_3\VB\670261|to|frequency|interactions (l_dobj) frequency_5\NN\15286249|the|,|severity|haemorrhages (l_nmod) haemorrhages_13\NNS\14285662|of|warfarin-induced|cerebral
D014859_D002543 CID warfarin_8\NN\2718259|and|warfarin-drug (r_compound) interactions_11\NNS\37396|warfarin (r_nsubj) caused_14\VBN\1617192|whether|interactions|could|have|haemorrhage (l_dobj) haemorrhage_17\NN\14285662|the|cerebral
D014859_D002543 CID warfarin-drug_10\JJ\1740| (r_conj) warfarin_8\NN\2718259|and|warfarin-drug (r_compound) interactions_11\NNS\37396|warfarin (r_nsubj) caused_14\VBN\1617192|whether|interactions|could|have|haemorrhage (l_dobj) haemorrhage_17\NN\14285662|the|cerebral
D014859_D002543 CID warfarin_19\NN\2718259| (r_compound) treatment_20\NN\654885|to|warfarin (r_nmod) related_17\JJ\1740|as|treatment (r_advcl) assessed_15\VBN\670261|patients|were|related (l_nsubjpass) patients_4\NNS\9898892|among|593|haemorrhage|,|59 (l_nmod) haemorrhage_7\NN\14285662|with|cerebral
D014859_D002543 CID warfarin-induced_2\JJ\1740| (r_amod) haemorrhages_4\NNS\14285662|warfarin-induced|cerebral
D014859_D002543 CID warfarin-related_4\JJ\1740| (r_amod) haemorrhages_6\NNS\14285662|of|warfarin-related|cerebral
D014859_D002543 CID warfarin_24\NN\2718259|with (r_nmod) interact_22\VB\2367363|to|warfarin (r_xcomp) known_20\VBN\2110220|interact (r_acl) drugs_19\NNS\14778436|when|prescribing|known (r_nmod) taken_16\VBN\2367363|if|caution|had|been|drugs (r_advcl) prevented_10\VBN\1740|proportion|might|have|been|taken|. (l_nsubjpass) proportion_2\NN\13824815|a|significant|haemorrhages (l_nmod) haemorrhages_6\NNS\14285662|of|warfarin-related|cerebral
D014859_D006470 NONE warfarin-drug_1\JJ\1740| (r_amod) interaction_2\NN\37396|a|warfarin-drug (r_nsubj) contributed_5\VBN\126264|interaction|could|have|haemorrhage|24|%|patients|considered|. (l_nmod) haemorrhage_8\NN\14285662|to|the
D014859_D006470 NONE warfarin-drug_1\JJ\1740| (r_amod) interaction_2\NN\37396|a|warfarin-drug (r_nsubj) contributed_5\VBN\126264|interaction|could|have|haemorrhage|24|%|patients|considered|. (l_conj) considered_32\VBN\689344|complication|was|possible (l_nsubjpass) complication_30\NN\1073995|the|bleeding (l_amod) bleeding_29\VBG\104868|
D014859_D006470 NONE warfarin_17\NN\2718259| (r_compound) patients_18\NNS\9898892|of|the|warfarin|and|7|these|% (r_nmod) contributed_5\VBN\126264|interaction|could|have|haemorrhage|24|%|patients|considered|. (l_nmod) haemorrhage_8\NN\14285662|to|the
D014859_D006470 NONE warfarin_17\NN\2718259| (r_compound) patients_18\NNS\9898892|of|the|warfarin|and|7|these|% (r_nmod) contributed_5\VBN\126264|interaction|could|have|haemorrhage|24|%|patients|considered|. (l_conj) considered_32\VBN\689344|complication|was|possible (l_nsubjpass) complication_30\NN\1073995|the|bleeding (l_amod) bleeding_29\VBG\104868|
3173179
D014700_D009203 CID verapamil_0\NN\2938514| (r_compound) withdrawal_1\NN\7206096|verapamil|cause|. (l_nmod) cause_5\NN\7323922|as|a|possible|infarction (l_nmod) infarction_8\NN\14204950|of|myocardial|woman
D014700_D009203 CID verapamil_18\NN\2938514|of (r_nmod) withdrawal_16\NN\7206096|the|verapamil|woman (r_conj) introduction_11\NN\235435|with|the|captopril|and|withdrawal (r_nmod) coincided_8\VBD\2604477|which|infarction|introduction (l_nsubj) infarction_7\NN\14204950|myocardial
D014700_D006973 NONE verapamil_0\NN\2938514| (r_compound) withdrawal_1\NN\7206096|verapamil|cause|. (l_nmod) cause_5\NN\7323922|as|a|possible|infarction (l_nmod) infarction_8\NN\14204950|of|myocardial|woman (l_nmod) woman_12\NN\9605289|in|a|hypertensive|angiogram (l_amod) hypertensive_11\JJ\1740|
D014700_D006973 NONE verapamil_18\NN\2938514|of (r_nmod) withdrawal_16\NN\7206096|the|verapamil|woman (l_nmod) woman_23\NN\9605289|in|a|asymptomatic|hypertension (l_nmod) hypertension_26\NN\14057371|with|severe
D002216_D009203 NONE captopril_13\NN\2673637|of (r_nmod) introduction_11\NN\235435|with|the|captopril|and|withdrawal (r_nmod) coincided_8\VBD\2604477|which|infarction|introduction (l_nsubj) infarction_7\NN\14204950|myocardial
D002216_D006973 NONE captopril_13\NN\2673637|of (r_nmod) introduction_11\NN\235435|with|the|captopril|and|withdrawal (l_conj) withdrawal_16\NN\7206096|the|verapamil|woman (l_nmod) woman_23\NN\9605289|in|a|asymptomatic|hypertension (l_nmod) hypertension_26\NN\14057371|with|severe
12202650
D002211_D063806 NONE capsaicin-induced_0\JJ\1740| (r_amod) pain_2\NN\14299637|capsaicin-induced|muscle
D002211_D010146 CID capsaicin_0\NN\15032661|g (r_nsubjpass) injected_7\VBN\81072|capsaicin|was|muscle|induce|. (l_xcomp) induce_13\VB\1627355|to|pain|volunteers (l_dobj) pain_14\NN\14299637|
1833784
D004298_D006948 NONE dopamine_8\NN\14807737| (r_compound) receptors_9\NNS\5225602|dopamine (r_nmod) involvement_3\NN\1080366|for|an|d1|receptors|mediating (l_acl) mediating_11\VBG\761713|in|hyperactivity (l_dobj) hyperactivity_13\NN\14052403|nicotine-induced|rats
D009538_D006948 CID nicotine-induced_12\JJ\1740| (r_amod) hyperactivity_13\NN\14052403|nicotine-induced|rats
D009538_D006948 CID nicotine_0\NN\14712692|mg/kg (r_nsubj) caused_5\VBD\1617192|nicotine|increase|,|but|had|. (l_dobj) increase_8\NN\13576355|a|significant|activity (l_nmod) activity_11\NN\30358|in|locomotor|rats
D009538_D006948 CID nicotine-induced_0\JJ\1740| (r_amod) hyperactivity_1\NN\14052403|nicotine-induced
D009538_D006948 CID nicotine-induced_7\JJ\1740| (r_amod) hyperactivity_8\NN\14052403|nicotine-induced
D009538_D006948 CID nicotine_5\NN\14712692| (r_compound) injection_6\NN\320852|acute|nicotine (r_nsubj) induces_7\VBZ\1627355|that|injection|hyperactivity (l_dobj) hyperactivity_10\NN\14052403|a|pronounced|rats
C534628_D006948 NONE 23390_10\CD\1740| (r_nummod) sch_9\NN\1740|by|the|selective|d1|antagonist|23390|, (r_nmod) blocked_3\VBN\1476483|hyperactivity|was|sch|raclopride|. (l_nsubjpass) hyperactivity_1\NN\14052403|nicotine-induced
D020891_D006948 NONE raclopride_16\NN\1740|the|selective|d2|antagonist|and|fluphenazine (r_nmod) blocked_3\VBN\1476483|hyperactivity|was|sch|raclopride|. (l_nsubjpass) hyperactivity_1\NN\14052403|nicotine-induced
D005476_D006948 NONE fluphenazine_21\NN\3713736|the|d1/d2|antagonist (r_conj) raclopride_16\NN\1740|the|selective|d2|antagonist|and|fluphenazine (r_nmod) blocked_3\VBN\1476483|hyperactivity|was|sch|raclopride|. (l_nsubjpass) hyperactivity_1\NN\14052403|nicotine-induced
-1_D006948 NONE phno_5\NN\1740|with|the|d2|agonist (r_nmod) pretreatment_0\NN\1740|phno (r_nsubj) enhanced_6\VBD\227165|pretreatment|hyperactivity|,|whereas|had|. (l_dobj) hyperactivity_8\NN\14052403|nicotine-induced
D015647_D006948 NONE 38393_15\CD\1740| (r_nummod) skf_14\NN\1740|the|d1|agonist|38393 (r_nsubj) had_16\VBD\2108377|skf|effect (r_parataxis) enhanced_6\VBD\227165|pretreatment|hyperactivity|,|whereas|had|. (l_dobj) hyperactivity_8\NN\14052403|nicotine-induced
3371379
D014700_D020258 CID verapamil-induced_0\JJ\1740| (r_amod) neurotoxicity_2\NN\1740|verapamil-induced|carbamazepine|.
D014700_D020258 CID verapamil_11\NNS\2938514|with (r_nmod) treatment_9\NN\654885|after|combined|verapamil (r_nmod) patients_1\NNS\9898892|two|signs|treatment (l_nmod) signs_3\NNS\6643763|with|neurotoxicity (l_nmod) neurotoxicity_6\NN\1740|of|carbamazepine
D002220_D020258 CID carbamazepine_1\NN\1740| (r_compound) neurotoxicity_2\NN\1740|verapamil-induced|carbamazepine|.
D002220_D020258 CID carbamazepine_5\NN\1740| (r_compound) neurotoxicity_6\NN\1740|of|carbamazepine
D002118_D020258 NONE calcium_19\NN\14625458| (r_compound) blocker_21\NN\10101634|of|the|calcium|entry (r_nmod) discontinuation_16\NN\209943|after|blocker (r_nmod) showed_12\VBD\2137132|patients|recovery|discontinuation|. (l_nsubj) patients_1\NNS\9898892|two|signs|treatment (l_nmod) signs_3\NNS\6643763|with|neurotoxicity (l_nmod) neurotoxicity_6\NN\1740|of|carbamazepine
20080419
D010862_D004827 CID pilocarpine_24\NN\14712692|by (r_nmod) induced_22\VBN\1627355|pilocarpine|rats (r_acl) epilepsy_21\NN\14085708|of|induced
10457883
16938416
D013739_D050197 CID testosterone_1\NN\14747587|high-dose (r_nsubjpass) associated_3\VBN\628491|testosterone|is|atherosclerosis|. (l_nmod) atherosclerosis_5\NN\14108324|with|women
D013739_D050197 CID estrogen-testosterone_26\JJ\1740| (r_amod) therapy_27\NN\657604|between|self-reported|administered|high-dose|estrogen-testosterone|estradiol-|and|atherosclerosis (l_conj) atherosclerosis_36\NN\14108324|aortic
D013739_D050197 CID testosterone_7\NN\14747587| (r_compound) therapy_8\NN\657604|high-dose|testosterone (r_nsubj) affect_11\VB\126264|that|therapy|may|adversely|atherosclerosis|and|indicate (l_dobj) atherosclerosis_12\NN\14108324|women
D004967_D050197 NONE estrogen-testosterone_26\JJ\1740| (r_amod) therapy_27\NN\657604|between|self-reported|administered|high-dose|estrogen-testosterone|estradiol-|and|atherosclerosis (l_conj) atherosclerosis_36\NN\14108324|aortic
C032109_D050197 NONE esters_32\NNS\14727670| (r_dep) estradiol-_29\NN\1740|(|and|testosterone|esters|) (r_dep) therapy_27\NN\657604|between|self-reported|administered|high-dose|estrogen-testosterone|estradiol-|and|atherosclerosis (l_conj) atherosclerosis_36\NN\14108324|aortic
D002784_D003920 NONE cholesterol_9\NN\15058310| (r_compound) level_10\NN\4916342|cholesterol (r_conj) diabetes_7\NNS\14075199|for|,|level
D000431_D003920 NONE alcohol_17\NN\7881800| (r_compound) use_18\NN\407535|alcohol (r_conj) pressure_14\NN\11419404|systolic|blood|,|or|use (r_conj) remained_2\VBD\2604760|association|adjustment|,|pressure|. (l_nmod) adjustment_5\NN\7357388|after|additional|diabetes (l_nmod) diabetes_7\NNS\14075199|for|,|level
17612891
D003024_D009205 CID clozapine_4\NN\3713736|with (r_nmod) associated_2\VBN\628491|clozapine (r_acl) myocarditis_1\NN\14338942|acute|associated|.
D003024_D009205 CID clozapine_12\NN\3713736|of (r_nmod) commencement_10\NN\15180528|with|the|clozapine (r_nmod) associated_7\VBN\628491|commencement (r_acl) myocarditis_6\NN\14338942|of|acute|associated
D003024_D009205 CID clozapine_16\NN\3713736|of (r_nmod) commencement_14\NN\15180528|after|clozapine (r_nmod) onset_10\NN\7325190|a|sudden|myocarditis|commencement (l_nmod) myocarditis_12\NN\14338942|of
D003024_D009205 CID clozapine_13\NN\3713736|of (r_nmod) use_11\NN\407535|with|the|clozapine (r_nmod) associated_8\VBN\628491|use (r_acl) complication_7\NN\1073995|myocarditis|is|an|recognized|associated (l_nsubj) myocarditis_2\NNP\14338942|
D003024_D012559 NONE clozapine_16\NN\3713736|of (r_nmod) commencement_14\NN\15180528|after|clozapine (r_nmod) onset_10\NN\7325190|a|sudden|myocarditis|commencement (r_dobj) developed_7\VBD\1753788|results|male|onset|. (l_nsubj) male_4\JJ\1740|a|20-year-old|schizophrenia (l_nmod) schizophrenia_6\NN\14398067|with
D003024_D011618 NONE clozapine_2\NN\3713736|considering|that (r_nsubj) remains_3\VBZ\2604760|clozapine|standard (l_xcomp) standard_6\JJ\1740|gold|treatment (l_nmod) treatment_8\NN\654885|in|psychosis (l_nmod) psychosis_11\NN\14380140|of|resistant
12716030
D006493_D002543 NONE heparin_7\NN\2718259| (r_nsubj) enhanced_8\VBD\227165|using|,|heparin|volume|. (l_advcl) using_3\VBG\1156834|induction|collagenase (l_nmod) induction_2\NN\7450842|in|ich (l_compound) ich_1\NN\1740|
D006493_D002543 NONE heparin_7\NN\2718259| (r_nsubj) enhanced_8\VBD\227165|using|,|heparin|volume|. (l_dobj) volume_11\NN\33615|the|hematoma|3.4-fold (l_advmod) 3.4-fold_12\RB\1740|that (l_nmod) that_14\DT\1740|over|seen (l_acl) seen_15\VBN\2106506|animals (l_nmod) animals_19\NNS\4475|in|control|ich|and|bleeding (l_compound) ich_18\NN\1740|
D006493_D006406 CID heparin_7\NN\2718259| (r_nsubj) enhanced_8\VBD\227165|using|,|heparin|volume|. (l_dobj) volume_11\NN\33615|the|hematoma|3.4-fold (l_compound) hematoma_10\NN\14317720|
D006493_D006470 NONE heparin_7\NN\2718259| (r_nsubj) enhanced_8\VBD\227165|using|,|heparin|volume|. (l_dobj) volume_11\NN\33615|the|hematoma|3.4-fold (l_advmod) 3.4-fold_12\RB\1740|that (l_nmod) that_14\DT\1740|over|seen (l_acl) seen_15\VBN\2106506|animals (l_nmod) animals_19\NNS\4475|in|control|ich|and|bleeding (l_conj) bleeding_22\NN\14285662|the|7.6-fold
16274958
D017255_D055154 CID acitretin_3\NN\1740| (r_conj) dysphonia_1\NN\14400677|recurrent|and|acitretin|.
D017255_D055154 CID acitretin_15\NN\1740|by (r_nmod) treated_13\VBN\2376958|while|she|was|acitretin (r_advcl) report_1\VBP\831651|we|case|treated|. (l_dobj) case_3\NN\7283608|the|complaining (l_nmod) complaining_7\NN\1740|of|a|woman|dysphonia (l_nmod) dysphonia_9\NN\14400677|of
D017255_D055154 CID acitretin-induced_10\JJ\1740| (r_amod) dysphonia_11\NN\14400677|of|acitretin-induced
19631624
D018817_D007859 CID ecstasy_5\NN\13985818| (r_compound) users_6\NNS\7846|in|ecstasy (r_nmod) deficits_3\NNS\5113133|learning|users|and|neural
D018817_D007859 CID ecstasy_6\NN\13985818| (r_compound) users_7\NNS\7846|ecstasy (r_nsubj) display_8\VBP\2137132|that|users|impairments|learning|performance (l_nmod) learning_11\NN\5701944|in|and|memory (l_conj) memory_13\NN\5926676|
D018817_D008569 CID ecstasy_5\NN\13985818| (r_compound) users_6\NNS\7846|in|ecstasy (r_nmod) deficits_3\NNS\5113133|learning|users|and|neural
D018817_D008569 CID ecstasy_6\NN\13985818| (r_compound) users_7\NNS\7846|ecstasy (r_nsubj) display_8\VBP\2137132|that|users|impairments|learning|performance (l_nmod) learning_11\NN\5701944|in|and|memory (l_conj) memory_13\NN\5926676|
D002188_D007859 NONE cannabis_12\NN\13112664| (r_compound) users_13\NNS\7846|in|cannabis (r_nmod) hyperactivity_7\NN\14052403|parahippocampal|and|hypoactivity|users (r_dep) deficits_0\NNS\5113133|learning|:|hyperactivity|. (l_nmod) learning_2\NN\5701944|in|and|memory (l_conj) memory_4\NN\5926676|
D002188_D008569 NONE cannabis_12\NN\13112664| (r_compound) users_13\NNS\7846|in|cannabis (r_nmod) hyperactivity_7\NN\14052403|parahippocampal|and|hypoactivity|users (r_dep) deficits_0\NNS\5113133|learning|:|hyperactivity|. (l_nmod) learning_2\NN\5701944|in|and|memory (l_conj) memory_4\NN\5926676|
D002188_D006948 NONE cannabis_12\NN\13112664| (r_compound) users_13\NNS\7846|in|cannabis (r_nmod) hyperactivity_7\NN\14052403|parahippocampal|and|hypoactivity|users
D018817_D006948 NONE ecstasy-specific_13\JJ\1740| (r_amod) hyperactivity_14\NN\14052403|ecstasy-specific|regions|,
D018817_D020258 NONE ecstasy-specific_1\JJ\1740| (r_amod) effects_2\NNS\13245626|these|ecstasy-specific (r_nsubj) related_5\JJ\1740|effects|may|be|vulnerability|. (l_nmod) vulnerability_8\NN\14540765|to|the|regions|effects (l_nmod) effects_17\NNS\13245626|to|the|neurotoxic|ecstasy (l_amod) neurotoxic_16\JJ\1740|
D018817_D020258 NONE ecstasy_19\NN\13985818|of (r_nmod) effects_17\NNS\13245626|to|the|neurotoxic|ecstasy (l_amod) neurotoxic_16\JJ\1740|
1732369
D004280_D009369 NONE dobutamine_0\JJ\1740| (r_amod) echocardiography_2\NN\177127|dobutamine|stress|:|indicator|. (l_appos) indicator_6\NN\6636259|a|sensitive|function|survivors (l_nmod) survivors_15\NNS\9630641|in|asymptomatic|doxorubicin-treated|long-term|cancer (l_nmod) cancer_18\NN\14239425|of|childhood
D004280_D009369 NONE dobutamine_21\NN\1740| (r_compound) infusion_22\NN\14589223|dobutamine (r_dobj) using_20\VBG\1156834|infusion|differentiate (l_xcomp) differentiate_24\VB\618878|to|survivors (l_dobj) survivors_27\NNS\9630641|asymptomatic|long-term|cancer (l_nmod) cancer_30\NN\14239425|of|childhood|treated
D004317_D009369 NONE doxorubicin-treated_13\JJ\1740| (r_amod) survivors_15\NNS\9630641|in|asymptomatic|doxorubicin-treated|long-term|cancer (l_nmod) cancer_18\NN\14239425|of|childhood
D004317_D009369 NONE doxorubicin_13\NN\2716866|due (r_nmod) damage_10\NN\7296428|for|cardiac|doxorubicin (r_nmod) test_7\NN\5798043|a|sensitive|echocardiographic|screening|damage (r_dobj) develop_1\VB\1753788|to|test (r_advcl) performed_19\VBN\2367363|develop|,|study|was|using|. (l_xcomp) using_20\VBG\1156834|infusion|differentiate (l_xcomp) differentiate_24\VB\618878|to|survivors (l_dobj) survivors_27\NNS\9630641|asymptomatic|long-term|cancer (l_nmod) cancer_30\NN\14239425|of|childhood|treated
D004317_D009369 NONE doxorubicin_33\NN\2716866|with|subjects (r_nmod) treated_31\VBN\2376958|doxorubicin (r_acl) cancer_30\NN\14239425|of|childhood|treated
D004317_D009202 CID doxorubicin_0\NNP\2716866| (r_nsubj) agent_6\NN\7347|doxorubicin|is|an|effective|anticancer|chemotherapeutic|known|. (l_acl) known_7\VBN\2110220|cause (l_xcomp) cause_9\VB\1617192|to|acute|cardiomyopathy (l_dobj) cardiomyopathy_13\JJ\1740|
D004317_D006331 NONE doxorubicin_13\NN\2716866|due (r_nmod) damage_10\NN\7296428|for|cardiac|doxorubicin
D004317_D006331 NONE doxorubicin_33\NN\2716866|with|subjects (r_nmod) treated_31\VBN\2376958|doxorubicin (r_acl) cancer_30\NN\14239425|of|childhood|treated (r_nmod) survivors_27\NNS\9630641|asymptomatic|long-term|cancer (r_dobj) differentiate_24\VB\618878|to|survivors (r_xcomp) using_20\VBG\1156834|infusion|differentiate (r_xcomp) performed_19\VBN\2367363|develop|,|study|was|using|. (l_advcl) develop_1\VB\1753788|to|test (l_dobj) test_7\NN\5798043|a|sensitive|echocardiographic|screening|damage (l_nmod) damage_10\NN\7296428|for|cardiac|doxorubicin
D004280_D006331 NONE dobutamine_21\NN\1740| (r_compound) infusion_22\NN\14589223|dobutamine (r_dobj) using_20\VBG\1156834|infusion|differentiate (r_xcomp) performed_19\VBN\2367363|develop|,|study|was|using|. (l_advcl) develop_1\VB\1753788|to|test (l_dobj) test_7\NN\5798043|a|sensitive|echocardiographic|screening|damage (l_nmod) damage_10\NN\7296428|for|cardiac|doxorubicin
3629586
D015790_D006402 NONE cefonicid_4\NN\1740|of|and|cefazedone (r_nmod) effects_2\NNS\13245626|the|hematologic|cefonicid|dog|:|model|. (l_dep) model_13\NN\5888929|a|potential|hematotoxicity (l_nmod) hematotoxicity_16\NN\1740|of|cephalosporin|man
D015790_D006402 NONE cefonicid_23\NN\1740|500|mg/kg|or|cefazedone (r_dobj) receiving_18\VBG\2210855|cefonicid (r_acl) %_15\NN\1740|in|50|dogs|receiving (r_nmod) occurred_11\VBD\2623529|% (r_conj) compromising_6\VBG\1035530|anemia|was|the|most|cytopenias|and|occurred|. (l_nmod) cytopenias_9\NNS\14189204|of|the
D015790_D006402 NONE cefonicid_16\NN\1740|(|not|cefazedone)-treated (r_conj) dogs_13\NNS\2083346|in|most|tested|;|cefonicid (r_nmod) reproduced_10\VBN\1621555|rechallenge|,|syndrome|was|dogs|showed|)|. (l_nsubjpass) syndrome_8\NN\5870365|the|hematologic
D015790_D006402 NONE cefonicid_9\NN\1740|of|or|cefazedone (r_nmod) doses_7\NNS\3740161|of|high|cefonicid (r_nmod) administration_4\NN\1133281|the|doses (r_nsubj) induce_15\VB\1627355|that|administration|can|hematotoxicity|and|thus|provides (l_dobj) hematotoxicity_16\NN\1740|similar
D015790_D006402 NONE cefonicid_9\NN\1740|of|or|cefazedone (r_nmod) doses_7\NNS\3740161|of|high|cefonicid (r_nmod) administration_4\NN\1133281|the|doses (r_nsubj) induce_15\VB\1627355|that|administration|can|hematotoxicity|and|thus|provides (l_dobj) hematotoxicity_16\NN\1740|similar (l_amod) similar_17\JJ\1740|dyscrasias (l_nmod) dyscrasias_22\NN\14052046|to|the|cephalosporin-induced|blood|described
C021341_D006402 NONE cefazedone_6\NN\1740| (r_conj) cefonicid_4\NN\1740|of|and|cefazedone (r_nmod) effects_2\NNS\13245626|the|hematologic|cefonicid|dog|:|model|. (l_dep) model_13\NN\5888929|a|potential|hematotoxicity (l_nmod) hematotoxicity_16\NN\1740|of|cephalosporin|man
C021341_D006402 NONE cefazedone_29\NN\1740|840|mg/kg (r_conj) cefonicid_23\NN\1740|500|mg/kg|or|cefazedone (r_dobj) receiving_18\VBG\2210855|cefonicid (r_acl) %_15\NN\1740|in|50|dogs|receiving (r_nmod) occurred_11\VBD\2623529|% (r_conj) compromising_6\VBG\1035530|anemia|was|the|most|cytopenias|and|occurred|. (l_nmod) cytopenias_9\NNS\14189204|of|the
C021341_D006402 NONE cefazedone)-treated_20\VBN\1740| (r_conj) cefonicid_16\NN\1740|(|not|cefazedone)-treated (r_conj) dogs_13\NNS\2083346|in|most|tested|;|cefonicid (r_nmod) reproduced_10\VBN\1621555|rechallenge|,|syndrome|was|dogs|showed|)|. (l_nsubjpass) syndrome_8\NN\5870365|the|hematologic
C021341_D006402 NONE cefazedone_11\NN\1740|dogs (r_conj) cefonicid_9\NN\1740|of|or|cefazedone (r_nmod) doses_7\NNS\3740161|of|high|cefonicid (r_nmod) administration_4\NN\1133281|the|doses (r_nsubj) induce_15\VB\1627355|that|administration|can|hematotoxicity|and|thus|provides (l_dobj) hematotoxicity_16\NN\1740|similar
C021341_D006402 NONE cefazedone_11\NN\1740|dogs (r_conj) cefonicid_9\NN\1740|of|or|cefazedone (r_nmod) doses_7\NNS\3740161|of|high|cefonicid (r_nmod) administration_4\NN\1133281|the|doses (r_nsubj) induce_15\VB\1627355|that|administration|can|hematotoxicity|and|thus|provides (l_dobj) hematotoxicity_16\NN\1740|similar (l_amod) similar_17\JJ\1740|dyscrasias (l_nmod) dyscrasias_22\NN\14052046|to|the|cephalosporin-induced|blood|described
D002511_D006402 NONE cephalosporin_15\NN\2716866| (r_compound) hematotoxicity_16\NN\1740|of|cephalosporin|man
D002511_D006402 NONE cephalosporin_0\NN\2716866| (r_compound) antibiotics_1\NNS\2716205|cephalosporin (r_nsubj) cause_2\VBP\1617192|antibiotics|variety|remain|. (l_dobj) variety_4\NN\7951464|a|disturbances|man|,|pathogeneses (l_nmod) disturbances_7\NNS\407535|of|hematologic
D002511_D006402 NONE cephalosporin_4\NN\2716866|with|either (r_nmod) rechallenge_1\NN\1740|upon|cephalosporin (r_nmod) reproduced_10\VBN\1621555|rechallenge|,|syndrome|was|dogs|showed|)|. (l_nsubjpass) syndrome_8\NN\5870365|the|hematologic
D002511_D006402 NONE cephalosporin-induced_20\JJ\1740| (r_amod) dyscrasias_22\NN\14052046|to|the|cephalosporin-induced|blood|described (r_nmod) similar_17\JJ\1740|dyscrasias (r_amod) hematotoxicity_16\NN\1740|similar
D002511_D006402 NONE cephalosporin-induced_20\JJ\1740| (r_amod) dyscrasias_22\NN\14052046|to|the|cephalosporin-induced|blood|described
D015790_D064420 NONE cefonicid_10\NN\1740|of|or|cefazedone (r_nmod) administration_8\NN\1133281|the|intravenous|cefonicid (r_nsubj) caused_16\VBD\1617192|studies|,|administration|incidence|months|. (l_nmod) studies_4\NNS\635850|in|four|subacute|toxicity (l_compound) toxicity_3\NN\13576101|
D015790_D000740 CID cefonicid_10\NN\1740|of|or|cefazedone (r_nmod) administration_8\NN\1133281|the|intravenous|cefonicid (r_nsubj) caused_16\VBD\1617192|studies|,|administration|incidence|months|. (l_dobj) incidence_19\NN\13821570|a|dose-dependent|anemia (l_nmod) anemia_21\NN\14189204|of|,|neutropenia|,|and|thrombocytopenia
D015790_D000740 CID cefonicid_23\NN\1740|500|mg/kg|or|cefazedone (r_dobj) receiving_18\VBG\2210855|cefonicid (r_acl) %_15\NN\1740|in|50|dogs|receiving (r_nmod) occurred_11\VBD\2623529|% (r_conj) compromising_6\VBG\1035530|anemia|was|the|most|cytopenias|and|occurred|. (l_nsubj) anemia_2\NN\14189204|a|nonregenerative
D015790_D009503 CID cefonicid_10\NN\1740|of|or|cefazedone (r_nmod) administration_8\NN\1133281|the|intravenous|cefonicid (r_nsubj) caused_16\VBD\1617192|studies|,|administration|incidence|months|. (l_dobj) incidence_19\NN\13821570|a|dose-dependent|anemia (l_nmod) anemia_21\NN\14189204|of|,|neutropenia|,|and|thrombocytopenia (l_conj) neutropenia_23\NN\14196405|
D015790_D013921 CID cefonicid_10\NN\1740|of|or|cefazedone (r_nmod) administration_8\NN\1133281|the|intravenous|cefonicid (r_nsubj) caused_16\VBD\1617192|studies|,|administration|incidence|months|. (l_dobj) incidence_19\NN\13821570|a|dose-dependent|anemia (l_nmod) anemia_21\NN\14189204|of|,|neutropenia|,|and|thrombocytopenia (l_conj) thrombocytopenia_26\NN\14189204|
C021341_D064420 NONE cefazedone_12\NN\1740|dogs (r_conj) cefonicid_10\NN\1740|of|or|cefazedone (r_nmod) administration_8\NN\1133281|the|intravenous|cefonicid (r_nsubj) caused_16\VBD\1617192|studies|,|administration|incidence|months|. (l_nmod) studies_4\NNS\635850|in|four|subacute|toxicity (l_compound) toxicity_3\NN\13576101|
C021341_D000740 CID cefazedone_12\NN\1740|dogs (r_conj) cefonicid_10\NN\1740|of|or|cefazedone (r_nmod) administration_8\NN\1133281|the|intravenous|cefonicid (r_nsubj) caused_16\VBD\1617192|studies|,|administration|incidence|months|. (l_dobj) incidence_19\NN\13821570|a|dose-dependent|anemia (l_nmod) anemia_21\NN\14189204|of|,|neutropenia|,|and|thrombocytopenia
C021341_D000740 CID cefazedone_29\NN\1740|840|mg/kg (r_conj) cefonicid_23\NN\1740|500|mg/kg|or|cefazedone (r_dobj) receiving_18\VBG\2210855|cefonicid (r_acl) %_15\NN\1740|in|50|dogs|receiving (r_nmod) occurred_11\VBD\2623529|% (r_conj) compromising_6\VBG\1035530|anemia|was|the|most|cytopenias|and|occurred|. (l_nsubj) anemia_2\NN\14189204|a|nonregenerative
C021341_D009503 CID cefazedone_12\NN\1740|dogs (r_conj) cefonicid_10\NN\1740|of|or|cefazedone (r_nmod) administration_8\NN\1133281|the|intravenous|cefonicid (r_nsubj) caused_16\VBD\1617192|studies|,|administration|incidence|months|. (l_dobj) incidence_19\NN\13821570|a|dose-dependent|anemia (l_nmod) anemia_21\NN\14189204|of|,|neutropenia|,|and|thrombocytopenia (l_conj) neutropenia_23\NN\14196405|
C021341_D013921 CID cefazedone_12\NN\1740|dogs (r_conj) cefonicid_10\NN\1740|of|or|cefazedone (r_nmod) administration_8\NN\1133281|the|intravenous|cefonicid (r_nsubj) caused_16\VBD\1617192|studies|,|administration|incidence|months|. (l_dobj) incidence_19\NN\13821570|a|dose-dependent|anemia (l_nmod) anemia_21\NN\14189204|of|,|neutropenia|,|and|thrombocytopenia (l_conj) thrombocytopenia_26\NN\14189204|
14698717
D010672_D011605 NONE phenytoin_6\NN\3550533|with (r_nmod) treatment_4\NN\654885|due|phenytoin|patient (r_nmod) psychosis_1\NN\14380140|acute|treatment|.
D010672_D011605 NONE phenytoin_10\NN\3550533| (r_compound) treatment_11\NN\654885|following|phenytoin|neuralgia (r_nmod) developed_7\VBD\1753788|who|psychosis|treatment (l_dobj) psychosis_8\NN\14380140|
D010672_D011605 NONE phenytoin_10\NN\3550533| (r_compound) treatment_11\NN\654885|following|phenytoin|patients (r_nmod) occur_8\VBP\2623529|that|treatment (r_acl:relcl) symptoms_6\NNS\5823932|the|psychotic|occur
D010672_D014277 NONE phenytoin_10\NN\3550533| (r_compound) treatment_11\NN\654885|following|phenytoin|neuralgia (l_nmod) neuralgia_14\NN\14322699|for|trigeminal
D010672_D004827 NONE phenytoin_10\NN\3550533| (r_compound) treatment_11\NN\654885|following|phenytoin|patients (l_nmod) patients_15\NNS\9898892|in|some|epileptic (l_amod) epileptic_14\JJ\1740|
D010672_D012640 NONE phenytoin_10\NN\3550533| (r_compound) treatment_11\NN\654885|following|phenytoin|patients (r_nmod) occur_8\VBP\2623529|that|treatment (r_acl:relcl) symptoms_6\NNS\5823932|the|psychotic|occur (r_nsubj) result_20\NN\34213|that|symptoms|may|be|the|direct|medication|,|unrelated (l_amod) unrelated_24\JJ\1740|seizures (l_nmod) seizures_26\NNS\14081375|to
17931375
D006493_D003288 CID heparin_10\NN\2718259| (r_compound) injection_11\NN\320852|of|subcutaneous|heparin (r_nmod) duration_7\NN\15113229|of|the|injection (r_nmod) effect_4\NN\34213|on|the|duration|bruising (l_nmod) bruising_13\NN\1740|on|and|pain
D006493_D003288 CID heparin_26\NN\2718259|of (r_nmod) injection_24\NN\320852|of|the|subcutaneous|heparin (r_nmod) administration_20\NN\1133281|following|the|injection (r_nmod) effect_10\NN\34213|the|duration|bruising|administration (l_nmod) bruising_15\NN\1740|on|and|pain
D006493_D003288 CID heparin_15\NN\2718259|of (r_nmod) injection_13\NN\320852|following|the|subcutaneous|heparin (r_nmod) prevent_6\VB\1740|although|methods|to|bruising|injection (l_dobj) bruising_7\NN\1740|and|pain
D006493_D003288 CID heparin_15\NN\2718259|of (r_nmod) injection_13\NN\320852|following|the|subcutaneous|heparin (r_nmod) prevent_6\VB\1740|although|methods|to|bruising|injection (r_advcl) studied_19\VBN\630380|prevent|have|been|widely|and|described (r_dep) background_0\NN\4921011|:|studied (r_dep) documented_37\VBN\1000214|background|,|effect|is|little|. (l_nsubjpass) effect_24\NN\34213|the|duration|occurrence (l_nmod) occurrence_30\NN\29378|on|the|bruising (l_nmod) bruising_32\NN\1740|of|and|pain
D006493_D003288 CID heparin_6\NN\2718259| (r_compound) areas_8\NNS\8630985|on|the|heparin|applied (r_nmod) bruising_3\NN\1740|of|the|areas
D006493_D003288 CID heparin_20\NN\2718259|of (r_nmod) administration_18\NN\1133281|following|the|subcutaneous|heparin (r_nmod) effect_10\NN\34213|an|bruising|administration (l_nmod) bruising_12\NN\1740|on|and|pain
D006493_D010146 CID heparin_10\NN\2718259| (r_compound) injection_11\NN\320852|of|subcutaneous|heparin (r_nmod) duration_7\NN\15113229|of|the|injection (r_nmod) effect_4\NN\34213|on|the|duration|bruising (l_nmod) bruising_13\NN\1740|on|and|pain (l_conj) pain_15\NN\14299637|
D006493_D010146 CID heparin_26\NN\2718259|of (r_nmod) injection_24\NN\320852|of|the|subcutaneous|heparin (r_nmod) administration_20\NN\1133281|following|the|injection (r_nmod) effect_10\NN\34213|the|duration|bruising|administration (l_nmod) bruising_15\NN\1740|on|and|pain (l_conj) pain_17\NN\14299637|
D006493_D010146 CID heparin_15\NN\2718259|of (r_nmod) injection_13\NN\320852|following|the|subcutaneous|heparin (r_nmod) prevent_6\VB\1740|although|methods|to|bruising|injection (l_dobj) bruising_7\NN\1740|and|pain (l_conj) pain_9\NN\14299637|
D006493_D010146 CID heparin_15\NN\2718259|of (r_nmod) injection_13\NN\320852|following|the|subcutaneous|heparin (r_nmod) prevent_6\VB\1740|although|methods|to|bruising|injection (r_advcl) studied_19\VBN\630380|prevent|have|been|widely|and|described (r_dep) background_0\NN\4921011|:|studied (r_dep) documented_37\VBN\1000214|background|,|effect|is|little|. (l_nsubjpass) effect_24\NN\34213|the|duration|occurrence (l_nmod) occurrence_30\NN\29378|on|the|bruising (l_nmod) bruising_32\NN\1740|of|and|pain (l_conj) pain_34\NN\14299637|
D006493_D010146 CID heparin_20\NN\2718259|of (r_nmod) administration_18\NN\1133281|following|the|subcutaneous|heparin (r_nmod) effect_10\NN\34213|an|bruising|administration (l_nmod) bruising_12\NN\1740|on|and|pain (l_conj) pain_14\NN\14299637|
2696505
D007741_D007022 CID labetalol_4\NN\2721160|of|and|nitroprusside (r_nmod) comparison_2\NN\635850|a|randomized|labetalol|hypotension|. (l_nmod) hypotension_9\NN\14057371|for|induced
D007741_D007022 CID labetalol-induced_5\JJ\1740| (r_amod) hypotension_6\NN\14057371|labetalol-induced|and|hypotension
D007741_D007022 CID labetalol-induced_5\JJ\1740| (r_amod) hypotension_6\NN\14057371|labetalol-induced|and|hypotension (l_conj) hypotension_9\NN\14057371|nitroprusside-induced
D009599_D007022 CID nitroprusside_6\NN\1740| (r_conj) labetalol_4\NN\2721160|of|and|nitroprusside (r_nmod) comparison_2\NN\635850|a|randomized|labetalol|hypotension|. (l_nmod) hypotension_9\NN\14057371|for|induced
D009599_D007022 CID nitroprusside-induced_8\JJ\1740| (r_amod) hypotension_9\NN\14057371|nitroprusside-induced (r_conj) hypotension_6\NN\14057371|labetalol-induced|and|hypotension
D009599_D007022 CID nitroprusside-induced_8\JJ\1740| (r_amod) hypotension_9\NN\14057371|nitroprusside-induced
D009599_D016534 CID nitroprusside_31\NN\1740|of (r_nmod) discontinuation_29\NN\209943|after|nitroprusside (r_nmod) patients_27\NNS\9898892|in|three|discontinuation (r_nmod) observed_24\VBN\2163746|hypertension|was|patients (r_parataxis) associated_3\VBN\628491|infusion|was|significant|increase|;|observed|. (l_nmod) increase_13\NN\13576355|output (l_nmod) output_19\NN\4007894|in|rate|cardiac
D009599_D006973 NONE nitroprusside_31\NN\1740|of (r_nmod) discontinuation_29\NN\209943|after|nitroprusside (r_nmod) patients_27\NNS\9898892|in|three|discontinuation (r_nmod) observed_24\VBN\2163746|hypertension|was|patients (l_nsubjpass) hypertension_22\NN\14057371|rebound
10579464
C121249_D006948 NONE nra0160_0\NN\1740|and|clozapine|hyperactivity|. (l_dep) hyperactivity_5\NN\14052403|antagonized|locomotor|induced
D003024_D006948 NONE clozapine_2\NN\3713736| (r_conj) nra0160_0\NN\1740|and|clozapine|hyperactivity|. (l_dep) hyperactivity_5\NN\14052403|antagonized|locomotor|induced
D008694_D006948 CID methamphetamine_8\NN\2704153|by|map (r_nmod) induced_6\VBN\1627355|methamphetamine|mice (r_acl) hyperactivity_5\NN\14052403|antagonized|locomotor|induced
D008694_D006948 CID map_10\NN\4076846|(|) (r_appos) methamphetamine_8\NN\2704153|by|map (r_nmod) induced_6\VBN\1627355|methamphetamine|mice (r_acl) hyperactivity_5\NN\14052403|antagonized|locomotor|induced
C121249_D002375 CID nra0160_0\NN\1740|and|clozapine (r_nsubj) induced_4\VBD\1627355|nra0160|significantly|catalepsy|,|exceed|. (l_dobj) catalepsy_5\NN\14023236|rats
D003024_D002375 CID clozapine_2\NN\3713736| (r_conj) nra0160_0\NN\1740|and|clozapine (r_nsubj) induced_4\VBD\1627355|nra0160|significantly|catalepsy|,|exceed|. (l_dobj) catalepsy_5\NN\14023236|rats
19356307
D012601_D003704 NONE scopolamine_9\NN\14712692|by (r_nmod) induced_7\VBN\1627355|scopolamine (r_acl) dementia_6\NN\14395018|of|lemon|essential|attenuate|induced
C008281_D003704 NONE s-limonene_4\NN\1740|of|and|alcohol (r_nmod) effects_2\NNS\13245626|the|anti-dementia|s-limonene (l_amod) anti-dementia_1\JJ\1740|
C032208_D003704 NONE alcohol_7\NN\7881800|s-perillyl (r_conj) s-limonene_4\NN\1740|of|and|alcohol (r_nmod) effects_2\NNS\13245626|the|anti-dementia|s-limonene (l_amod) anti-dementia_1\JJ\1740|
D012601_D008569 CID scopolamine_12\NN\14712692|by (r_nmod) impaired_10\VBN\258857|scopolamine
D012601_D008569 CID scopolamine_12\NN\14712692|by (r_nmod) impaired_10\VBN\258857|scopolamine (r_acl) memory_9\NN\5926676|impaired (r_dobj) improve_8\VB\126264|to|memory (r_acl) ability_6\NN\4723816|strong|improve (r_dobj) showed_4\VBD\2137132|oils|ability|;|relieved|. (l_parataxis) relieved_18\VBD\205885|however|,|alcohol|deficit|pa|,|and|improve (l_dobj) deficit_20\NN\5113133|the|memory (l_nmod) memory_23\NN\5926676|of|associative
C032208_D008569 NONE alcohol_17\NN\7881800|s-perillyl (r_nsubj) relieved_18\VBD\205885|however|,|alcohol|deficit|pa|,|and|improve (r_parataxis) showed_4\VBD\2137132|oils|ability|;|relieved|. (l_dobj) ability_6\NN\4723816|strong|improve (l_acl) improve_8\VB\126264|to|memory (l_dobj) memory_9\NN\5926676|impaired (l_acl) impaired_10\VBN\258857|scopolamine
C032208_D008569 NONE alcohol_17\NN\7881800|s-perillyl (r_nsubj) relieved_18\VBD\205885|however|,|alcohol|deficit|pa|,|and|improve (l_dobj) deficit_20\NN\5113133|the|memory (l_nmod) memory_23\NN\5926676|of|associative
2273650
D012601_D000647 CID scopolamine_3\NN\14712692|by|and|cycloheximide (r_nmod) produced_1\VBN\1617192|scopolamine (r_acl) amnesia_0\NNP\5669934|produced
D012601_D000647 CID scopolamine_3\NN\14712692|pre-test (r_nsubj) reversed_5\VBD\109660|similarly|,|scopolamine|partially|amnesia|,|significantly|failed (l_dobj) amnesia_8\NN\5669934|the|scopolamine-induced
D012601_D000647 CID scopolamine_3\NN\14712692|pre-test (r_nsubj) reversed_5\VBD\109660|similarly|,|scopolamine|partially|amnesia|,|significantly|failed (l_conj) failed_17\VBD\1798936|cycloheximide|reverse|. (l_xcomp) reverse_19\VB\109660|to|amnesia (l_dobj) amnesia_22\NN\5669934|the|cycloheximide-induced
D012601_D000647 CID scopolamine-induced_7\JJ\1740| (r_amod) amnesia_8\NN\5669934|the|scopolamine-induced
D012601_D000647 CID scopolamine-induced_7\JJ\1740| (r_amod) amnesia_8\NN\5669934|the|scopolamine-induced (r_dobj) reversed_5\VBD\109660|similarly|,|scopolamine|partially|amnesia|,|significantly|failed (l_conj) failed_17\VBD\1798936|cycloheximide|reverse|. (l_xcomp) reverse_19\VB\109660|to|amnesia (l_dobj) amnesia_22\NN\5669934|the|cycloheximide-induced
D003513_D000647 CID cycloheximide_5\NN\1740| (r_conj) scopolamine_3\NN\14712692|by|and|cycloheximide (r_nmod) produced_1\VBN\1617192|scopolamine (r_acl) amnesia_0\NNP\5669934|produced
D003513_D000647 CID cycloheximide_16\NN\1740|pre-test (r_nsubj) failed_17\VBD\1798936|cycloheximide|reverse|. (r_conj) reversed_5\VBD\109660|similarly|,|scopolamine|partially|amnesia|,|significantly|failed (l_dobj) amnesia_8\NN\5669934|the|scopolamine-induced
D003513_D000647 CID cycloheximide_16\NN\1740|pre-test (r_nsubj) failed_17\VBD\1798936|cycloheximide|reverse|. (l_xcomp) reverse_19\VB\109660|to|amnesia (l_dobj) amnesia_22\NN\5669934|the|cycloheximide-induced
D003513_D000647 CID cycloheximide-induced_21\JJ\1740| (r_amod) amnesia_22\NN\5669934|the|cycloheximide-induced (r_dobj) reverse_19\VB\109660|to|amnesia (r_xcomp) failed_17\VBD\1798936|cycloheximide|reverse|. (r_conj) reversed_5\VBD\109660|similarly|,|scopolamine|partially|amnesia|,|significantly|failed (l_dobj) amnesia_8\NN\5669934|the|scopolamine-induced
D003513_D000647 CID cycloheximide-induced_21\JJ\1740| (r_amod) amnesia_22\NN\5669934|the|cycloheximide-induced
D009020_D000647 NONE morphine_9\NN\2707683|by (r_nmod) reversed_7\VBN\109660|amnesia|were|morphine|min|facilitated|. (l_nsubjpass) amnesia_0\NNP\5669934|produced
D009020_D000647 NONE morphine_23\NN\2707683|pre-test (r_nsubj) facilitated_25\VBD\2547586|morphine|also|retrieval (r_conj) reversed_7\VBN\109660|amnesia|were|morphine|min|facilitated|. (l_nsubjpass) amnesia_0\NNP\5669934|produced
D009270_D000647 NONE naloxone_33\NN\3808977| (r_dobj) administered_32\VBN\2436349|naloxone|trial (r_acl) animals_31\NNS\4475|in|the|administered (r_nmod) retrieval_28\NN\13450862|the|memory|animals (r_dobj) facilitated_25\VBD\2547586|morphine|also|retrieval (r_conj) reversed_7\VBN\109660|amnesia|were|morphine|min|facilitated|. (l_nsubjpass) amnesia_0\NNP\5669934|produced
18217897
D013792_D008228 NONE thalidomide_0\NN\4166841| (r_nsubj) limited_2\VBN\2510337|thalidomide|has|activity|:|trial (l_dobj) activity_4\NN\30358|single-agent|lymphomas (l_nmod) lymphomas_11\NNS\14239918|relapsed|indolent|non-hodgkin
D013792_D009369 NONE thalidomide_0\NN\4166841| (r_nsubj) limited_2\VBN\2510337|thalidomide|has|activity|:|trial (l_dep) trial_16\NN\786195|a|phase|ii|b. (l_nmod) b._23\NNP\1740|of|group (l_compound) group_22\NNP\2137|the|cancer (l_compound) cancer_19\NN\14239425|and|leukemia
D013792_D007938 NONE thalidomide_0\NN\4166841| (r_nsubj) limited_2\VBN\2510337|thalidomide|has|activity|:|trial (l_dep) trial_16\NN\786195|a|phase|ii|b. (l_nmod) b._23\NNP\1740|of|group (l_compound) group_22\NNP\2137|the|cancer (l_compound) cancer_19\NN\14239425|and|leukemia (l_conj) leukemia_21\NNP\14239918|
D013792_D009101 NONE thalidomide_0\NN\4166841| (r_nsubj) agent_4\NN\7347|thalidomide|is|an|immunomodulatory|activity|. (l_nmod) activity_7\NN\30358|with|demonstrated|myeloma (l_nmod) myeloma_10\NN\14239425|in|multiple|,|lymphoma|and|lymphoma
D013792_D020522 NONE thalidomide_0\NN\4166841| (r_nsubj) agent_4\NN\7347|thalidomide|is|an|immunomodulatory|activity|. (l_nmod) activity_7\NN\30358|with|demonstrated|myeloma (l_nmod) myeloma_10\NN\14239425|in|multiple|,|lymphoma|and|lymphoma (l_conj) lymphoma_14\NN\14239918|mantle|cell
D013792_D008223 NONE thalidomide_0\NN\4166841| (r_nsubj) agent_4\NN\7347|thalidomide|is|an|immunomodulatory|activity|. (l_nmod) activity_7\NN\30358|with|demonstrated|myeloma (l_nmod) myeloma_10\NN\14239425|in|multiple|,|lymphoma|and|lymphoma (l_conj) lymphoma_17\NN\14239918|lymphoplasmacytic
D013792_D008223 NONE thalidomide_14\NN\4166841|mg (r_dobj) received_13\VBD\2210855|july|,|patients|thalidomide|daily|escalation|mg|tolerated|. (l_nsubj) patients_8\NNS\9898892|24|lymphomas (l_nmod) lymphomas_12\NNS\14239918|with|relapsed/refractory|indolent
D013792_D008223 NONE thalidomide_12\NN\4166841|agent|lymphomas (l_nmod) lymphomas_15\NNS\14239918|in|indolent
C467567_D008223 NONE lenalidomide_31\NN\1740| (r_appos) agent_29\NN\7347|with|the|second|generation|immunomodulatory|,|lenalidomide (r_nmod) reported_23\VBN\831651|agent (r_acl) level_22\NN\4916342|with|the|higher|activity|reported (r_nmod) contrast_17\VB\650353|level (r_conj) demonstrate_4\VB\2137132|to|rate|and|contrast (l_dobj) rate_8\NN\13815152|an|important|response|thalidomide (l_nmod) thalidomide_12\NN\4166841|agent|lymphomas (l_nmod) lymphomas_15\NNS\14239918|in|indolent
3070035
D002216_D051437 NONE captopril-induced_2\JJ\1740| (r_amod) insufficiency_4\NN\14462946|of|captopril-induced|renal
D002216_D051437 NONE captopril-induced_4\JJ\1740| (r_amod) failure_6\NN\66216|in|captopril-induced|renal
D002216_D006978 NONE captopril-induced_2\JJ\1740| (r_amod) insufficiency_4\NN\14462946|of|captopril-induced|renal (r_nmod) reversibility_0\NN\4733640|insufficiency|use|case|. (l_nmod) case_11\NN\7283608|in|an|unusual|hypertension (l_nmod) hypertension_14\NN\14057371|of|renovascular
D002216_D006973 NONE captopril_27\NN\2673637|with (r_nmod) treatment_25\NN\654885|following|captopril (r_nmod) developed_18\VBD\1753788|who|deterioration|treatment (r_acl:relcl) case_3\NN\7283608|a|hypertension|kidney|,|developed (l_nmod) hypertension_6\NN\14057371|of|severe|artery
D002216_D058186 CID captopril_27\NN\2673637|with (r_nmod) treatment_25\NN\654885|following|captopril (r_nmod) developed_18\VBD\1753788|who|deterioration|treatment (l_dobj) deterioration_20\NN\14560612|sudden|function (l_nmod) function_23\NN\13783581|of|renal
1987816
D008094_D011141 CID lithium-induced_0\JJ\1740| (r_amod) polyuria_1\NN\14113228|lithium-induced
4008111
D000638_D012848 CID amiodarone-induced_0\JJ\1740| (r_amod) block_2\NN\21939|amiodarone-induced|sinoatrial|.
D000638_D012848 CID amiodarone_7\NN\2715941| (r_amod) administration_8\NN\1133281|due|chronic|amiodarone|boy|,|syndrome (r_nmod) observed_1\VBD\2163746|we|block|administration|. (l_dobj) block_3\NN\21939|sinoatrial
D000638_D012848 CID amiodarone_5\NN\2715941|of (r_nmod) dosage_3\NN\13576355|in|the|amiodarone (r_nmod) reduction_0\NN\351485|dosage (r_nsubj) resulted_6\VBD\2633881|reduction|disappearance|. (l_nmod) disappearance_9\NN\42757|in|the|block (l_nmod) block_13\NN\21939|of|the|sinoatrial|and|persistence
D000638_D009202 NONE amiodarone_7\NN\2715941| (r_amod) administration_8\NN\1133281|due|chronic|amiodarone|boy|,|syndrome (l_nmod) boy_12\NN\9624168|in|a|5-year-old|cardiomyopathy (l_nmod) cardiomyopathy_15\JJ\1740|with|primary
D000638_D014927 NONE amiodarone_7\NN\2715941| (r_amod) administration_8\NN\1133281|due|chronic|amiodarone|boy|,|syndrome (l_conj) syndrome_18\NN\5870365|wolff-parkinson-white|and|tachycardia
D000638_D013617 NONE amiodarone_7\NN\2715941| (r_amod) administration_8\NN\1133281|due|chronic|amiodarone|boy|,|syndrome (l_conj) syndrome_18\NN\5870365|wolff-parkinson-white|and|tachycardia (l_conj) tachycardia_21\NN\14110674|supraventricular
D000638_D012804 NONE amiodarone_5\NN\2715941|of (r_nmod) dosage_3\NN\13576355|in|the|amiodarone (r_nmod) reduction_0\NN\351485|dosage (r_nsubj) resulted_6\VBD\2633881|reduction|disappearance|. (l_nmod) disappearance_9\NN\42757|in|the|block (l_nmod) block_13\NN\21939|of|the|sinoatrial|and|persistence (l_conj) persistence_16\NN\5053688|the|bradycardia (l_nmod) bradycardia_20\NN\14110674|of|asymptomatic|sinus
3425586
D003622_D000743 CID dapsone-associated_0\JJ\1740| (r_amod) anemia_4\NN\14189204|dapsone-associated|heinz|body|hemolytic|woman|.
D003622_D000743 CID dapsone_23\NN\2716205|of (r_nmod) dose_21\NN\3740161|a|dapsone (r_dobj) taking_19\VBG\2367363|while|dose|mg/day|associated (r_advcl) developed_12\VBD\1753788|woman|anemia|taking|. (l_dobj) anemia_17\NN\14189204|a|heinz|body|hemolytic
D003622_D000743 CID dapsone_21\NN\2716205| (r_nsubj) cause_24\VB\1617192|since|dapsone|does|not|anemia|dose (l_dobj) anemia_26\NN\14189204|hemolytic
D003622_D007918 NONE dapsone_23\NN\2716205|of (r_nmod) dose_21\NN\3740161|a|dapsone (r_dobj) taking_19\VBG\2367363|while|dose|mg/day|associated (r_advcl) developed_12\VBD\1753788|woman|anemia|taking|. (l_nsubj) woman_2\NN\9605289|a|cambodian|trait (l_nmod) trait_6\NN\24264|with|hemoglobin|e|ae|and|leprosy (l_conj) leprosy_11\NN\14127211|
D003622_D006461 NONE dapsone_23\NN\2716205|of (r_nmod) dose_21\NN\3740161|a|dapsone (r_dobj) taking_19\VBG\2367363|while|dose|mg/day|associated (l_dep) associated_30\VBN\628491|usually|hemolysis (l_nmod) hemolysis_33\NN\13509528|with|clinical
15338796
D000420_D014202 CID salbutamol_4\NN\1740|of (r_nmod) effects_2\NNS\13245626|tremor|side|salbutamol|,|quantified|. (l_amod) tremor_0\NN\345926|
D000420_D014202 CID salbutamol_8\JJ\1740| (r_amod) method_16\NN\5616786|of|salbutamol|an|applicable|,|quick (r_nmod) effects_6\NNS\13245626|tremor|side|method (l_compound) tremor_4\NN\345926|
D000420_D014202 CID salbutamol_19\NN\1740|of (r_nmod) doses_17\NNS\3740161|of|cumulative|salbutamol (r_nmod) administration_14\NN\1133281|after|doses (r_nmod) patients_8\NNS\9898892|in|44|disease|administration (r_nmod) assessed_4\VBD\670261|we|tremor|patients (l_dobj) tremor_5\NN\345926|
D000420_D014202 CID salbutamol_2\NN\1740| (r_nsubj) increased_4\VBD\169651|salbutamol|significantly|severity|way (l_dobj) severity_6\NN\5036394|tremor|patients (l_compound) tremor_5\NN\345926|
D000420_D008173 NONE salbutamol_19\NN\1740|of (r_nmod) doses_17\NNS\3740161|of|cumulative|salbutamol (r_nmod) administration_14\NN\1133281|after|doses (r_nmod) patients_8\NNS\9898892|in|44|disease|administration (l_nmod) disease_12\NN\14061805|with|obstructive|lung
3358181
D012312_D014693 CID ritodrine_6\NN\1740| (r_compound) therapy_7\NN\657604|after|ritodrine (r_nmod) section_4\NN\7020895|during|cesarean|therapy (r_nmod) tachyarrhythmias_1\NNS\1740|ventricular|section|:|interaction|.
D012312_D007752 NONE ritodrine_6\NN\1740| (r_dobj) receiving_5\VBG\2210855|ritodrine (r_acl) patients_4\NNS\9898892|receiving|labor (l_nmod) labor_9\NN\7974025|for|preterm
D012312_D007752 NONE ritodrine_19\NN\1740|of (r_nmod) effects_17\NNS\13245626|between|the|residual|betamimetic|ritodrine (r_nmod) interactions_12\NNS\37396|effects|and|effects (r_dobj) risk_11\VB\2530167|that|patients|may|interactions (l_nsubj) patients_4\NNS\9898892|receiving|labor (l_nmod) labor_9\NN\7974025|for|preterm
D012312_D002318 NONE ritodrine_15\NN\1740|of (r_nmod) infusion_13\NN\14589223|of|an|ritodrine (r_nmod) cessation_10\NN\7365849|after|infusion (r_nmod) result_3\VB\2633881|interactions|may|complications|cessation|. (l_nmod) complications_7\NNS\1073995|in|serious|cardiovascular
D010656_D007022 NONE phenylephrine_20\NN\2682038|such|treat (l_acl) treat_22\VB\2376958|to|patients (l_dobj) patients_24\NNS\9898892|hypotensive|tachycardia (l_amod) hypotensive_23\JJ\1740|
D010656_D013610 NONE phenylephrine_20\NN\2682038|such|treat (l_acl) treat_22\VB\2376958|to|patients (l_dobj) patients_24\NNS\9898892|hypotensive|tachycardia (l_nmod) tachycardia_26\NN\14110674|with
19581773
C417083_D009157 CID interferon_6\NN\2725367|and|ribavirin (r_compound) treatment_9\NN\654885|during|pegylated|interferon|c. (r_nmod) development_0\NN\248977|myasthenia|treatment (l_nmod) myasthenia_3\NN\14187378|of|ocular
C417083_D009157 CID alpha-2b_10\NN\1740|of|pegylated|ifn|and|ribavirin (r_nmod) therapy_6\NN\657604|with|combination|alpha-2b|chc (r_nmod) associated_3\VBN\628491|therapy (r_acl) myasthenia_2\NN\14187378|the|ocular|associated
C417083_D009157 CID ifn_35\NN\1740| (r_compound) therapy_36\NN\657604|of|ifn (r_nmod) complications_33\NNS\1073995|of|the|various|eye|therapy (r_nmod) review_28\NN\5733583|with|a|complications (r_nmod) present_23\VBP\2137132|therefore|,|we|case|review (r_parataxis) reported_18\VBN\831651|myasthenia|is|rarely|;|present|. (l_nsubjpass) myasthenia_2\NN\14187378|the|ocular|associated
C417083_D019698 NONE interferon_6\NN\2725367|and|ribavirin (r_compound) treatment_9\NN\654885|during|pegylated|interferon|c. (l_nmod) c._13\NN\1740|for|chronic|hepatitis
C417083_D019698 NONE alpha-2b_17\NN\1740|of|pegylated|interferon|and|ribavirin (l_conj) ribavirin_19\NN\2725367|c (l_nmod) c_23\NN\13714184|for|chronic|hepatitis|chc
C417083_D019698 NONE alpha-2b_17\NN\1740|of|pegylated|interferon|and|ribavirin (l_conj) ribavirin_19\NN\2725367|c (l_nmod) c_23\NN\13714184|for|chronic|hepatitis|chc (l_appos) chc_25\NN\1740|(|)
C417083_D019698 NONE alpha-2b_10\NN\1740|of|pegylated|ifn|and|ribavirin (r_nmod) therapy_6\NN\657604|with|combination|alpha-2b|chc (l_nmod) chc_14\NN\1740|for
C417083_D019698 NONE ifn_35\NN\1740| (r_compound) therapy_36\NN\657604|of|ifn (r_nmod) complications_33\NNS\1073995|of|the|various|eye|therapy (r_nmod) review_28\NN\5733583|with|a|complications (r_nmod) present_23\VBP\2137132|therefore|,|we|case|review (r_parataxis) reported_18\VBN\831651|myasthenia|is|rarely|;|present|. (l_nsubjpass) myasthenia_2\NN\14187378|the|ocular|associated (l_acl) associated_3\VBN\628491|therapy (l_nmod) therapy_6\NN\657604|with|combination|alpha-2b|chc (l_nmod) chc_14\NN\1740|for
D012254_D009157 CID ribavirin_8\NN\2725367| (r_conj) interferon_6\NN\2725367|and|ribavirin (r_compound) treatment_9\NN\654885|during|pegylated|interferon|c. (r_nmod) development_0\NN\248977|myasthenia|treatment (l_nmod) myasthenia_3\NN\14187378|of|ocular
D012254_D009157 CID ribavirin_12\NN\2725367| (r_conj) alpha-2b_10\NN\1740|of|pegylated|ifn|and|ribavirin (r_nmod) therapy_6\NN\657604|with|combination|alpha-2b|chc (r_nmod) associated_3\VBN\628491|therapy (r_acl) myasthenia_2\NN\14187378|the|ocular|associated
D012254_D019698 NONE ribavirin_8\NN\2725367| (r_conj) interferon_6\NN\2725367|and|ribavirin (r_compound) treatment_9\NN\654885|during|pegylated|interferon|c. (l_nmod) c._13\NN\1740|for|chronic|hepatitis
D012254_D019698 NONE ribavirin_19\NN\2725367|c (l_nmod) c_23\NN\13714184|for|chronic|hepatitis|chc
D012254_D019698 NONE ribavirin_19\NN\2725367|c (l_nmod) c_23\NN\13714184|for|chronic|hepatitis|chc (l_appos) chc_25\NN\1740|(|)
D012254_D019698 NONE ribavirin_12\NN\2725367| (r_conj) alpha-2b_10\NN\1740|of|pegylated|ifn|and|ribavirin (r_nmod) therapy_6\NN\657604|with|combination|alpha-2b|chc (l_nmod) chc_14\NN\1740|for
C417083_D004172 NONE alpha-2b_17\NN\1740|of|pegylated|interferon|and|ribavirin (r_nmod) administration_10\NN\1133281|of|alpha-2b (r_nmod) weeks_8\NNS\15113229|after|9|administration (r_nmod) experienced_3\VBD\2108377|male|diplopia|weeks|. (l_dobj) diplopia_5\NN\14552802|sudden
D012254_D004172 NONE ribavirin_19\NN\2725367|c (r_conj) alpha-2b_17\NN\1740|of|pegylated|interferon|and|ribavirin (r_nmod) administration_10\NN\1133281|of|alpha-2b (r_nmod) weeks_8\NNS\15113229|after|9|administration (r_nmod) experienced_3\VBD\2108377|male|diplopia|weeks|. (l_dobj) diplopia_5\NN\14552802|sudden
9088814
D000527_D007022 CID e1-induced_5\JJ\1740|prolonged|prostaglandin (r_amod) hypotension_6\NN\14057371|of|e1-induced|and|haemodilution|function
D000527_D007022 CID e1_5\NN\1740|of|prolonged|prostaglandin (r_nmod) effects_1\NNS\13245626|combined|e1 (r_nsubj) (pge1)-induced_6\VBD\1740|effects|hypotension|studied (l_dobj) hypotension_7\NN\14057371|and|haemodilution|function
D000527_D007022 CID (pge1)-induced_6\VBD\1740|effects|hypotension|studied (l_dobj) hypotension_7\NN\14057371|and|haemodilution|function
D000527_D007022 CID pge1_10\NN\1740|with (r_nmod) induced_8\VBN\1627355|hypotension|was|pge1|maintain|. (l_nsubjpass) hypotension_1\NN\14057371|controlled|groups
D000527_D007022 CID pge1-induced_13\JJ\1740| (r_amod) hypotension_14\NN\14057371|of|pge1-induced
D000527_D020141 NONE e1-induced_5\JJ\1740|prolonged|prostaglandin (r_amod) hypotension_6\NN\14057371|of|e1-induced|and|haemodilution|function (l_conj) haemodilution_8\NN\1740|
D000527_D020141 NONE e1_5\NN\1740|of|prolonged|prostaglandin (r_nmod) effects_1\NNS\13245626|combined|e1 (r_nsubj) (pge1)-induced_6\VBD\1740|effects|hypotension|studied (l_dobj) hypotension_7\NN\14057371|and|haemodilution|function (l_conj) haemodilution_9\NN\1740|
D000527_D020141 NONE (pge1)-induced_6\VBD\1740|effects|hypotension|studied (l_dobj) hypotension_7\NN\14057371|and|haemodilution|function (l_conj) haemodilution_9\NN\1740|
D000527_D020141 NONE pge1-induced_13\JJ\1740| (r_amod) hypotension_14\NN\14057371|of|pge1-induced (r_nmod) min_11\NN\15154774|of|120|hypotension|and|haemodilution (l_conj) haemodilution_17\NN\1740|moderate
D003911_D020141 NONE dextran_23\NN\1740| (r_compound) solution_24\NN\14586258|of|dextran (r_nmod) amount_21\NN\13329641|with|the|same|solution (r_nmod) replacing_16\VBG\1631072|it|amount (r_conj) withdrawing_9\VBG\1835496|by|ml|and|replacing|,|and|% (r_advcl) produced_7\VBN\1617192|haemodilution|was|withdrawing|. (l_nsubjpass) haemodilution_0\NN\1740|groups
D001663_D007022 NONE bilirubin_68\NN\14756039|total (r_conj) sgot_61\NNS\1740|,|sgpt|,|ldh|and|bilirubin (r_conj) showed_23\VBD\2137132|c|,|akbr|decrease|,|and|sgot|showed (l_dobj) decrease_26\NN\7296428|a|significant|min|and|min|start|and|min|recovery (l_nmod) start_44\NN\7290905|after|the|hypotension (l_nmod) hypotension_46\NN\14057371|of
D000527_D008107 CID pge1-induced_13\JJ\1740| (r_amod) hypotension_14\NN\14057371|of|pge1-induced (r_nmod) min_11\NN\15154774|of|120|hypotension|and|haemodilution (r_nmod) combination_6\NN\7951464|a|prolonged|min (r_nsubj) cause_19\VB\1617192|that|combination|would|impairment (l_dobj) impairment_20\NN\7296428|function (l_nmod) function_23\NN\13783581|of|hepatic
18726058
D010208_D020301 NONE hydrochloride_3\NN\14817592|papaverine (r_nsubj) vasodilator_7\NN\3198383|background|:|hydrochloride|is|a|direct-acting|used|. (l_acl) used_8\VBN\1156834|manage (l_xcomp) manage_10\VB\2524171|to|vasospasm|operations (l_dobj) vasospasm_11\NN\1740|
D010208_D020301 NONE papaverine_20\NN\3800001|topical (r_dobj) received_18\VBD\2210855|who|papaverine|vasospasm (l_nmod) vasospasm_22\NN\1740|for
D010208_D020301 NONE papaverine_1\NN\3800001|topical (r_nsubjpass) used_3\VBN\1156834|papaverine|was|action|. (l_nmod) action_8\NN\30358|as|a|direct|manage (l_acl) manage_10\VB\2524171|to|vasospasm|total (l_dobj) vasospasm_11\NN\1740|
D010208_D020301 NONE papaverine_3\NN\3800001|topical|treatment (l_nmod) treatment_6\NN\654885|for|the|vasospasm (l_nmod) vasospasm_8\NN\1740|of
D010208_D003389 NONE papaverine_13\NN\3800001|with|topical (r_nmod) cases_10\NNS\7283608|in|a|few|papaverine (r_nmod) described_6\VBN\1001294|dysfunction|has|been|cases|. (l_nsubjpass) dysfunction_3\NN\14204950|transient|cranial|nerve
D010208_D003389 NONE papaverine_8\NN\3800001|from (r_nmod) deficits_6\NNS\5113133|potential|cranial|nerve|papaverine
17639754
D014859_D006470 CID warfarin_18\NN\2718259|between|and|levofloxacin (r_nmod) interaction_16\NN\37396|of|the|warfarin (r_nmod) result_13\NN\34213|to|be|the|interaction (r_xcomp) appear_9\VBP\2604760|that|result (r_acl:relcl) cases_3\NNS\7283608|3|complications|appear (l_nmod) complications_7\NNS\1073995|of|serious|bleeding (l_amod) bleeding_6\VBG\104868|
D064704_D006470 CID levofloxacin_20\NN\1740| (r_conj) warfarin_18\NN\2718259|between|and|levofloxacin (r_nmod) interaction_16\NN\37396|of|the|warfarin (r_nmod) result_13\NN\34213|to|be|the|interaction (r_xcomp) appear_9\VBP\2604760|that|result (r_acl:relcl) cases_3\NNS\7283608|3|complications|appear (l_nmod) complications_7\NNS\1073995|of|serious|bleeding (l_amod) bleeding_6\VBG\104868|
19473225
D018698_D010523 NONE glutamate_1\JJ\1740| (r_amod) supplementation_2\NN\5108947|long-term|glutamate (r_nsubj) failed_3\VBD\1798936|supplementation|protect|. (l_xcomp) protect_5\VB\1127795|to|neurotoxicity (l_nmod) neurotoxicity_8\NN\1740|against|peripheral|paclitaxel
D018698_D010523 NONE glutamate_18\NN\15010703|and|glutamine (r_nsubjpass) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (r_advcl) factor_8\NN\7326557|neuropathy|is|still|a|significant|limiting|chemotherapy|,|claimed|. (l_nsubj) neuropathy_2\NN\14204950|toxic|peripheral
D018698_D010523 NONE glutamine_25\NN\14601829|its|related|amino|acid (r_conj) glutamate_18\NN\15010703|and|glutamine (r_nsubjpass) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (r_advcl) factor_8\NN\7326557|neuropathy|is|still|a|significant|limiting|chemotherapy|,|claimed|. (l_nsubj) neuropathy_2\NN\14204950|toxic|peripheral
D018698_D010523 NONE glutamate_9\JJ\1740| (r_amod) supplementation_10\NN\5108947|of|glutamate|preventing (l_acl) preventing_12\VBG\1740|for|neuropathy|study (l_dobj) neuropathy_15\NN\14204950|pac-induced|peripheral
D018698_D010523 NONE glutamate_8\VBP\1740|that|supplementation|fails (l_dobj) fails_14\VBZ\1798936|protect (l_xcomp) protect_16\VB\1127795|to|neurotoxicity (l_nmod) neurotoxicity_19\NN\1740|against|peripheral|pac
D017239_D010523 CID paclitaxel_10\NN\1740|of (r_nmod) neurotoxicity_8\NN\1740|against|peripheral|paclitaxel
D017239_D010523 CID paclitaxel_12\NN\1740|with|pac (r_nmod) chemotherapy_10\NN\661091|for|paclitaxel (r_nmod) factor_8\NN\7326557|neuropathy|is|still|a|significant|limiting|chemotherapy|,|claimed|. (l_nsubj) neuropathy_2\NN\14204950|toxic|peripheral
D017239_D010523 CID pac_14\NN\8324514|(|) (r_appos) paclitaxel_12\NN\1740|with|pac (r_nmod) chemotherapy_10\NN\661091|for|paclitaxel (r_nmod) factor_8\NN\7326557|neuropathy|is|still|a|significant|limiting|chemotherapy|,|claimed|. (l_nsubj) neuropathy_2\NN\14204950|toxic|peripheral
D017239_D010523 CID pac_30\NN\8324514| (r_compound) neurotoxicity_31\NN\1740|pac (r_dobj) ameliorate_29\VB\126264|to|neurotoxicity (r_xcomp) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (r_advcl) factor_8\NN\7326557|neuropathy|is|still|a|significant|limiting|chemotherapy|,|claimed|. (l_nsubj) neuropathy_2\NN\14204950|toxic|peripheral
D017239_D010523 CID pac-induced_13\JJ\1740| (r_amod) neuropathy_15\NN\14204950|pac-induced|peripheral
D017239_D010523 CID pac_21\NN\8324514|of (r_nmod) neurotoxicity_19\NN\1740|against|peripheral|pac
D017239_D020258 NONE paclitaxel_12\NN\1740|with|pac (r_nmod) chemotherapy_10\NN\661091|for|paclitaxel (r_nmod) factor_8\NN\7326557|neuropathy|is|still|a|significant|limiting|chemotherapy|,|claimed|. (l_advcl) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB\126264|to|neurotoxicity (l_dobj) neurotoxicity_31\NN\1740|pac
D017239_D020258 NONE pac_14\NN\8324514|(|) (r_appos) paclitaxel_12\NN\1740|with|pac (r_nmod) chemotherapy_10\NN\661091|for|paclitaxel (r_nmod) factor_8\NN\7326557|neuropathy|is|still|a|significant|limiting|chemotherapy|,|claimed|. (l_advcl) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB\126264|to|neurotoxicity (l_dobj) neurotoxicity_31\NN\1740|pac
D017239_D020258 NONE pac_30\NN\8324514| (r_compound) neurotoxicity_31\NN\1740|pac
D018698_D020258 NONE glutamate_18\NN\15010703|and|glutamine (r_nsubjpass) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB\126264|to|neurotoxicity (l_dobj) neurotoxicity_31\NN\1740|pac
D018698_D020258 NONE glutamine_25\NN\14601829|its|related|amino|acid (r_conj) glutamate_18\NN\15010703|and|glutamine (r_nsubjpass) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB\126264|to|neurotoxicity (l_dobj) neurotoxicity_31\NN\1740|pac
D000596_D010523 NONE acid_24\NN\14818238| (r_compound) glutamine_25\NN\14601829|its|related|amino|acid (r_conj) glutamate_18\NN\15010703|and|glutamine (r_nsubjpass) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (r_advcl) factor_8\NN\7326557|neuropathy|is|still|a|significant|limiting|chemotherapy|,|claimed|. (l_nsubj) neuropathy_2\NN\14204950|toxic|peripheral
D000596_D020258 NONE acid_24\NN\14818238| (r_compound) glutamine_25\NN\14601829|its|related|amino|acid (r_conj) glutamate_18\NN\15010703|and|glutamine (r_nsubjpass) claimed_27\VBN\1011725|although|glutamate|were|ameliorate (l_xcomp) ameliorate_29\VB\126264|to|neurotoxicity (l_dobj) neurotoxicity_31\NN\1740|pac
D017239_D010051 NONE pac-containing_14\JJ\1740| (r_amod) regimen_15\NNS\5898568|of|the|same|pac-containing (r_nmod) cycles_10\NNS\15269513|following|six|regimen (r_nmod) available_5\JJ\1740|patients|were|analysis|cycles|:|supplemented|,|and|received|. (l_nsubj) patients_3\NNS\9898892|forty-three|ovarian|cancer (l_compound) cancer_2\NN\14239425|
D018698_D010051 NONE glutamate_22\NN\15010703|by|period (r_nmod) supplemented_20\VBN\182406|23|had|been|glutamate|,|dose (r_parataxis) available_5\JJ\1740|patients|were|analysis|cycles|:|supplemented|,|and|received|. (l_nsubj) patients_3\NNS\9898892|forty-three|ovarian|cancer (l_compound) cancer_2\NN\14239425|
435349
D013390_D005207 CID suxamethonium_0\NN\1740| (r_compound) rate_2\NN\13815152|suxamethonium|infusion|and|fasciculations|. (l_conj) fasciculations_5\NNS\14361664|observed
D013390_D013746 NONE sch_20\NN\1740|120 (r_compound) mg_22\NN\13717155|sch (r_nsubjpass) exceeded_24\VBN\2673965|when|mg|was (r_advcl) discontinued_3\VBN\2609764|infusion|was|was|exceeded|. (l_advcl) was_7\VBD\836236|either|when|there|response (l_nsubj) response_10\NN\11410625|no|muscular|stimulation (l_nmod) stimulation_13\NN\242808|to|tetanic|nerve|or (l_amod) tetanic_12\JJ\1740|
3827439
D000666_D058186 CID amphotericin_6\NN\2716866|from (r_nmod) failure_4\NN\66216|recurrent|reversible|acute|renal|amphotericin|.
D000666_D058186 CID b_18\NN\1355326|of|amphotericin (r_nmod) administration_15\NN\1133281|the|b (r_dobj) following_13\VBG\1835496|immediately|administration|occasions (r_advcl) developed_8\VBD\1753788|patient|failure|following|. (l_dobj) failure_11\NN\66216|acute|renal
D000666_D058186 CID amphotericin_3\NN\2716866|,|setting|, (r_nsubj) activate_15\VB\1641914|that|amphotericin|may|feedback|,|contributing (l_advcl) contributing_20\VBG\126264|thereby|failure (l_nmod) failure_24\NN\66216|to|acute|renal
D000666_D005355 NONE b_18\NN\1355326|of|amphotericin (r_nmod) administration_15\NN\1133281|the|b (r_dobj) following_13\VBG\1835496|immediately|administration|occasions (r_advcl) developed_8\VBD\1753788|patient|failure|following|. (l_nsubj) patient_1\NN\9898892|a|cirrhosis (l_nmod) cirrhosis_4\NN\14116321|with|cryptogenic|and|sporotrichosis
D000666_D013174 NONE b_18\NN\1355326|of|amphotericin (r_nmod) administration_15\NN\1133281|the|b (r_dobj) following_13\VBG\1835496|immediately|administration|occasions (r_advcl) developed_8\VBD\1753788|patient|failure|following|. (l_nsubj) patient_1\NN\9898892|a|cirrhosis (l_nmod) cirrhosis_4\NN\14116321|with|cryptogenic|and|sporotrichosis (l_conj) sporotrichosis_7\NN\14176895|disseminated
20667451
D003474_D003072 NONE curcumin_0\NN\1740| (r_nsubj) ameliorates_1\VBZ\126264|curcumin|dysfunction|. (l_dobj) dysfunction_3\NN\14204950|cognitive|and|damage|rats
D003474_D003072 NONE curcumin_14\NN\1740| (r_compound) administration_15\NN\1133281|of|chronic|curcumin (r_nmod) effect_11\NN\34213|the|administration|phenobarbitone-|rats (l_nmod) phenobarbitone-_17\NN\1740|on|and|carbamazepine-induced|impairment|stress (l_dep) impairment_21\NN\7296428|cognitive|and
D003474_D003072 NONE curcumin_1\NN\1740| (r_compound) administration_2\NN\1133281|concomitant|curcumin (r_nsubj) prevented_3\VBD\1740|administration|impairment|and|decreased|. (l_dobj) impairment_6\NN\7296428|the|cognitive
D003474_D003072 NONE curcumin_4\NN\1740| (r_nsubj) has_5\VBZ\2108377|that|curcumin|effect|mitigating (l_advcl) mitigating_9\VBG\894738|in|deterioration (l_dobj) deterioration_11\NN\14560612|the|functions|damage (l_nmod) functions_14\NNS\13783581|of|cognitive|and
D003474_D003072 NONE curcumin_4\NN\1740| (r_nsubjpass) considered_7\VBN\689344|that|curcumin|can|be|adjuvant (l_nmod) adjuvant_14\JJ\1740|as|a|potential|safe|therapy (l_nmod) therapy_19\NN\657604|phenobarbitone|preventing (l_acl) preventing_21\VBG\1740|in|impairment (l_dobj) impairment_23\NN\7296428|cognitive|associated
D010634_D003072 CID phenobarbitone_8\NN\2792049|and|carbamazepine|administered (r_amod) rats_12\NNS\2329401|in|phenobarbitone (r_nmod) dysfunction_3\NN\14204950|cognitive|and|damage|rats
D010634_D003072 CID phenobarbitone_4\NN\2792049|and|carbamazepine (r_appos) drugs_2\NNS\14778436|the|antiepileptic|,|phenobarbitone (r_nsubjpass) known_9\VBN\2110220|drugs|are|well|cause|. (l_xcomp) cause_11\VB\1617192|to|impairment (l_dobj) impairment_13\NN\7296428|cognitive|use
D010634_D003072 CID phenobarbitone-_17\NN\1740|on|and|carbamazepine-induced|impairment|stress (l_dep) impairment_21\NN\7296428|cognitive|and
D010634_D003072 CID phenobarbitone_3\NN\2792049|of|and|carbamazepine (r_nmod) administration_1\NN\1133281|the|phenobarbitone|21days (r_nsubj) caused_8\VBD\1617192|administration|impairment|. (l_dobj) impairment_11\NN\7296428|a|significant|learning|as|stress (l_nmod) learning_13\NN\5701944|of|and|memory (l_conj) memory_15\NN\5926676|
D010634_D003072 CID phenobarbitone_22\NN\2792049|with|and|carbamazepine (r_nmod) treated_20\VBN\2376958|phenobarbitone|altering (r_acl) rats_19\NNS\2329401|in|treated (r_nmod) damage_17\NN\7296428|oxidative|rats (r_conj) deterioration_11\NN\14560612|the|functions|damage (l_nmod) functions_14\NNS\13783581|of|cognitive|and
D010634_D003072 CID phenobarbitone_16\NN\2792049|to|and|carbamazepine (r_compound) therapy_19\NN\657604|phenobarbitone|preventing (l_acl) preventing_21\VBG\1740|in|impairment (l_dobj) impairment_23\NN\7296428|cognitive|associated
D002220_D003072 CID carbamazepine_10\NN\1740| (r_conj) phenobarbitone_8\NN\2792049|and|carbamazepine|administered (r_amod) rats_12\NNS\2329401|in|phenobarbitone (r_nmod) dysfunction_3\NN\14204950|cognitive|and|damage|rats
D002220_D003072 CID carbamazepine_6\NN\1740| (r_conj) phenobarbitone_4\NN\2792049|and|carbamazepine (r_appos) drugs_2\NNS\14778436|the|antiepileptic|,|phenobarbitone (r_nsubjpass) known_9\VBN\2110220|drugs|are|well|cause|. (l_xcomp) cause_11\VB\1617192|to|impairment (l_dobj) impairment_13\NN\7296428|cognitive|use
D002220_D003072 CID carbamazepine-induced_19\JJ\1740| (r_conj) phenobarbitone-_17\NN\1740|on|and|carbamazepine-induced|impairment|stress (l_dep) impairment_21\NN\7296428|cognitive|and
D002220_D003072 CID carbamazepine_5\NN\1740| (r_conj) phenobarbitone_3\NN\2792049|of|and|carbamazepine (r_nmod) administration_1\NN\1133281|the|phenobarbitone|21days (r_nsubj) caused_8\VBD\1617192|administration|impairment|. (l_dobj) impairment_11\NN\7296428|a|significant|learning|as|stress (l_nmod) learning_13\NN\5701944|of|and|memory (l_conj) memory_15\NN\5926676|
D002220_D003072 CID carbamazepine_24\NN\1740| (r_conj) phenobarbitone_22\NN\2792049|with|and|carbamazepine (r_nmod) treated_20\VBN\2376958|phenobarbitone|altering (r_acl) rats_19\NNS\2329401|in|treated (r_nmod) damage_17\NN\7296428|oxidative|rats (r_conj) deterioration_11\NN\14560612|the|functions|damage (l_nmod) functions_14\NNS\13783581|of|cognitive|and
D002220_D003072 CID carbamazepine_18\NN\1740| (r_conj) phenobarbitone_16\NN\2792049|to|and|carbamazepine (r_compound) therapy_19\NN\657604|phenobarbitone|preventing (l_acl) preventing_21\VBG\1740|in|impairment (l_dobj) impairment_23\NN\7296428|cognitive|associated
12907309
C121465_D020258 NONE mpep_3\NN\1740|of|,|antagonist (r_nmod) action_1\NN\30358|neuroprotective|mpep|,|neurotoxicity (l_nmod) neurotoxicity_13\NN\1740|in|methamphetamine-induced|dopaminergic
C121465_D005334 NONE mpep_3\NN\1740|of|,|antagonist (r_nmod) action_1\NN\30358|neuroprotective|mpep|,|neurotoxicity (r_nsubjpass) associated_15\VBN\628491|action|is|decrease|. (l_nmod) decrease_18\NN\7296428|with|a|outflow|and|inhibition (l_conj) inhibition_23\NN\1068773|hyperthermia|rats (l_nmod) hyperthermia_25\NN\14034177|of
C121465_D005334 NONE mpep_3\NN\1740|by (r_nmod) rendered_1\VBN\120316|mpep (r_acl) neuroprotection_0\NN\1740|rendered (r_nsubjpass) associated_6\VBN\628491|neuroprotection|may|be|reduction|,|and|decrease|. (l_conj) decrease_29\NN\7296428|with|a|hyperthermia (l_nmod) hyperthermia_31\NN\14034177|in
D008694_D020258 NONE methamphetamine-induced_11\JJ\1740| (r_amod) neurotoxicity_13\NN\1740|in|methamphetamine-induced|dopaminergic
D008694_D005334 CID methamphetamine-induced_11\JJ\1740| (r_amod) neurotoxicity_13\NN\1740|in|methamphetamine-induced|dopaminergic (r_nmod) action_1\NN\30358|neuroprotective|mpep|,|neurotoxicity (r_nsubjpass) associated_15\VBN\628491|action|is|decrease|. (l_nmod) decrease_18\NN\7296428|with|a|outflow|and|inhibition (l_conj) inhibition_23\NN\1068773|hyperthermia|rats (l_nmod) hyperthermia_25\NN\14034177|of
D008694_D005334 CID methamphetamine_6\NN\2704153|the|hyperthermia (l_dep) hyperthermia_11\NN\14034177|(|10|mg/kg|sc)-induced|and|temperature
D008694_D005334 CID methamphetamine-induced_12\JJ\1740| (r_amod) efflux_14\NN\13482330|of|the|methamphetamine-induced|dopamine|striatum (r_nmod) reduction_9\NN\351485|with|the|efflux|blockade (r_nmod) associated_6\VBN\628491|neuroprotection|may|be|reduction|,|and|decrease|. (l_conj) decrease_29\NN\7296428|with|a|hyperthermia (l_nmod) hyperthermia_31\NN\14034177|in
D004298_D020258 NONE dopamine_20\NN\14807737| (r_compound) outflow_21\NN\7407777|in|dopamine (r_nmod) decrease_18\NN\7296428|with|a|outflow|and|inhibition (r_nmod) associated_15\VBN\628491|action|is|decrease|. (l_nsubjpass) action_1\NN\30358|neuroprotective|mpep|,|neurotoxicity (l_nmod) neurotoxicity_13\NN\1740|in|methamphetamine-induced|dopaminergic
D004298_D005334 NONE dopamine_20\NN\14807737| (r_compound) outflow_21\NN\7407777|in|dopamine (r_nmod) decrease_18\NN\7296428|with|a|outflow|and|inhibition (l_conj) inhibition_23\NN\1068773|hyperthermia|rats (l_nmod) hyperthermia_25\NN\14034177|of
D004298_D005334 NONE dopamine_13\NN\14807737| (r_compound) efflux_14\NN\13482330|of|the|methamphetamine-induced|dopamine|striatum (r_nmod) reduction_9\NN\351485|with|the|efflux|blockade (r_nmod) associated_6\VBN\628491|neuroprotection|may|be|reduction|,|and|decrease|. (l_conj) decrease_29\NN\7296428|with|a|hyperthermia (l_nmod) hyperthermia_31\NN\14034177|in
C121465_D064420 NONE mpep_12\NN\1740|by (r_nmod) blockade_8\NN\952963|the|mglur5|mpep (r_nsubj) protect_14\VB\1127795|that|blockade|may|neurones|toxicity (l_nmod) toxicity_19\NN\13576101|against|methamphetamine-induced
D008694_D064420 NONE methamphetamine-induced_18\JJ\1740| (r_amod) toxicity_19\NN\13576101|against|methamphetamine-induced
11391224
D003042_D006974 NONE cocaine-related_21\JJ\1740| (r_amod) failure_24\NN\66216|cocaine-related|acute|renal (r_conj) cases_3\NNS\7283608|hypertension|,|and|failure (l_nmod) hypertension_6\NN\14057371|of|malignant|,|microangiopathy|,|nephritis|,|nephritis|,|glomerulonephritis
D003042_D057049 NONE cocaine-related_21\JJ\1740| (r_amod) failure_24\NN\66216|cocaine-related|acute|renal (r_conj) cases_3\NNS\7283608|hypertension|,|and|failure (l_nmod) hypertension_6\NN\14057371|of|malignant|,|microangiopathy|,|nephritis|,|nephritis|,|glomerulonephritis (l_conj) microangiopathy_9\NN\1740|thrombotic
D003042_D008181 NONE cocaine-related_21\JJ\1740| (r_amod) failure_24\NN\66216|cocaine-related|acute|renal (r_conj) cases_3\NNS\7283608|hypertension|,|and|failure (l_nmod) hypertension_6\NN\14057371|of|malignant|,|microangiopathy|,|nephritis|,|nephritis|,|glomerulonephritis (l_conj) nephritis_12\NN\14113228|lupus
D003042_D011695 NONE cocaine-related_21\JJ\1740| (r_amod) failure_24\NN\66216|cocaine-related|acute|renal (r_conj) cases_3\NNS\7283608|hypertension|,|and|failure (l_nmod) hypertension_6\NN\14057371|of|malignant|,|microangiopathy|,|nephritis|,|nephritis|,|glomerulonephritis (l_conj) nephritis_15\NN\14113228|henoch-schonlein
D003042_D005921 NONE cocaine-related_21\JJ\1740| (r_amod) failure_24\NN\66216|cocaine-related|acute|renal (r_conj) cases_3\NNS\7283608|hypertension|,|and|failure (l_nmod) hypertension_6\NN\14057371|of|malignant|,|microangiopathy|,|nephritis|,|nephritis|,|glomerulonephritis (l_conj) glomerulonephritis_18\NN\14113798|crescentic
D003042_D058186 CID cocaine-related_21\JJ\1740| (r_amod) failure_24\NN\66216|cocaine-related|acute|renal
14596845
D000661_D019966 NONE amphetamine_13\NN\3248958|of (r_nmod) dose_11\NN\3740161|to|a|low|amphetamine (r_nmod) cross-sensitization_7\NN\1740|behavioral|dose (r_dobj) causes_5\VBZ\1617192|dependency|cross-sensitization|. (l_nsubj) dependency_4\NN\24720|a|diet|sugar
D000661_D006948 CID amphetamine_13\NN\3248958|of (r_nmod) dose_11\NN\3740161|to|a|low|amphetamine (r_nmod) cross-sensitization_7\NN\1740|behavioral|dose
D000661_D006948 CID amphetamine_22\NN\3248958|of (r_nmod) dose_20\NN\3740161|to|a|low|amphetamine (r_nmod) cross-sensitization_16\NN\1740|behavioral|dose
D000661_D006948 CID amphetamine_14\NN\3248958|response|to (r_nmod) hyperactive_10\JJ\1740|animals|were|amphetamine|groups|,|chow|.
D000661_D006948 CID amphetamine_30\NN\3248958| (r_compound) injection_31\NN\320852|by|amphetamine (r_nmod) followed_28\VBN\1835496|injection (r_acl) groups_19\NNS\2137|compared|with|four|control|libitum|followed|,|chow (r_advcl) hyperactive_10\JJ\1740|animals|were|amphetamine|groups|,|chow|.
D000661_D006948 CID amphetamine_37\NN\3248958| (r_compound) injection_38\NN\320852|by|amphetamine (r_nmod) followed_35\VBN\1835496|injection (r_acl) chow_34\NN\7971582|cyclic|followed (r_conj) groups_19\NNS\2137|compared|with|four|control|libitum|followed|,|chow (r_advcl) hyperactive_10\JJ\1740|animals|were|amphetamine|groups|,|chow|.
D000661_D006948 CID amphetamine_44\NN\3248958|with (r_nmod) chow_42\VBP\1740|libitum|amphetamine|,|or|sucrose|and|chow|) (r_conj) hyperactive_10\JJ\1740|animals|were|amphetamine|groups|,|chow|.
D013395_D006948 CID sucrose_6\NN\14836642|cyclic (r_dobj) experienced_4\VBN\2108377|that|had|sucrose|and|chow (r_acl:relcl) animals_1\NNS\4475|the|experienced (r_nsubj) hyperactive_10\JJ\1740|animals|were|amphetamine|groups|,|chow|.
D013395_D006948 CID sucrose_25\NN\14836642|% (r_appos) libitum_22\NN\1740|(|ad|sucrose|and|chow (r_dep) groups_19\NNS\2137|compared|with|four|control|libitum|followed|,|chow (r_advcl) hyperactive_10\JJ\1740|animals|were|amphetamine|groups|,|chow|.
D013395_D006948 CID sucrose_50\NN\14836642|% (r_conj) chow_42\VBP\1740|libitum|amphetamine|,|or|sucrose|and|chow|) (r_conj) hyperactive_10\JJ\1740|animals|were|amphetamine|groups|,|chow|.
19445921
C066201_D009203 NONE a_5\NN\13649268|of|salvianolic|acid (r_nmod) effect_1\NN\34213|cardioprotective|a|infarction|. (l_nmod) infarction_9\NN\14204950|on|isoproterenol-induced|myocardial|rats
C066201_D009203 NONE a_13\NN\13649268|of|salvianolic|acid|infarction (l_nmod) infarction_17\NN\14204950|on|isoproterenol-induced|myocardial|rats
C066201_D009203 NONE a_9\NN\13649268|salvianolic|acid|possessing (r_nsubj) has_13\VBZ\2108377|that|a|effect (l_dobj) effect_17\NN\34213|a|significant|protective|infarction (l_nmod) infarction_21\NN\14204950|against|isoproterenol-induced|myocardial
D007545_D009203 CID isoproterenol-induced_7\JJ\1740| (r_amod) infarction_9\NN\14204950|on|isoproterenol-induced|myocardial|rats
D007545_D009203 CID isoproterenol-induced_15\JJ\1740| (r_amod) infarction_17\NN\14204950|on|isoproterenol-induced|myocardial|rats
D007545_D009203 CID isoproterenol-induced_19\JJ\1740| (r_amod) infarction_21\NN\14204950|against|isoproterenol-induced|myocardial
D000244_D012131 NONE adp/o_13\NN\1740| (r_conj) ratio_11\NN\13815152|by|decreased|respiratory|control|and|adp/o (r_nmod) characterized_6\VBN\609683|ratio (r_acl) dysfunction_5\NN\14204950|mitochondrial|respiratory|characterized
D007545_D012131 NONE isoproterenol-treated_17\JJ\1740| (r_amod) rats_18\NNS\2329401|in|isoproterenol-treated (r_nmod) observed_15\VBN\2163746|addition|,|dysfunction|was|rats|. (l_nsubjpass) dysfunction_5\NN\14204950|mitochondrial|respiratory|characterized
C066201_D006331 NONE a_4\NN\13649268|of|salvianolic|acid (r_nmod) administration_0\NN\1133281|a|period (r_nsubj) attenuated_12\VBD\224901|administration|significantly|dysfunction|and|improved|. (l_dobj) dysfunction_15\NN\14204950|isoproterenol-induced|cardiac|and|injury
C066201_D009202 NONE a_4\NN\13649268|of|salvianolic|acid (r_nmod) administration_0\NN\1133281|a|period (r_nsubj) attenuated_12\VBD\224901|administration|significantly|dysfunction|and|improved|. (l_dobj) dysfunction_15\NN\14204950|isoproterenol-induced|cardiac|and|injury (l_conj) injury_18\NN\14052046|myocardial
C066201_D009202 NONE a_6\NN\13649268|of|salvianolic|acid (r_nmod) role_2\NN\719494|the|protective|a|damage (l_nmod) damage_10\NN\7296428|against|isoproterenol-induced|myocardial
D007545_D006331 NONE isoproterenol-induced_13\JJ\1740| (r_amod) dysfunction_15\NN\14204950|isoproterenol-induced|cardiac|and|injury
D007545_D009202 NONE isoproterenol-induced_13\JJ\1740| (r_amod) dysfunction_15\NN\14204950|isoproterenol-induced|cardiac|and|injury (l_conj) injury_18\NN\14052046|myocardial
D007545_D009202 NONE isoproterenol-induced_8\JJ\1740| (r_amod) damage_10\NN\7296428|against|isoproterenol-induced|myocardial
7930386
D002997_D012893 CID clomipramine-induced_0\JJ\1740| (r_amod) disturbance_2\NN\407535|clomipramine-induced|sleep
D002997_D012893 CID clomipramine_15\NN\4482543| (r_compound) administration_16\NN\1133281|by|clomipramine (r_nmod) induced_13\VBN\1627355|administration (r_advcl) undertaken_4\VBN\1641914|study|was|examine|induced|,|rate|. (l_xcomp) examine_6\VB\789138|to|role|, (l_dobj) role_8\NN\719494|the|disturbance (l_nmod) disturbance_11\NN\407535|of|sleep
9587734
D013390_D006323 CID suxamethonium-induced_0\JJ\1740| (r_amod) arrest_2\NN\88481|suxamethonium-induced|cardiac|and|death|days|.
D013390_D006323 CID suxamethonium_21\NN\1740|of (r_nmod) use_19\NN\407535|following|the|suxamethonium|woman (r_nmod) result_14\NN\34213|as|a|hyperkalaemia|use (r_nmod) case_5\NN\7283608|a|arrest|result (l_nmod) arrest_8\NN\88481|of|cardiac|and|death
D013390_D006323 CID suxamethonium_5\NN\1740|of|,|bradycardia|and|cardiac|arrest (l_conj) arrest_10\NN\88481|
D013390_D003643 NONE suxamethonium-induced_0\JJ\1740| (r_amod) arrest_2\NN\88481|suxamethonium-induced|cardiac|and|death|days|. (l_conj) death_4\NN\7296428|
D013390_D003643 NONE suxamethonium_21\NN\1740|of (r_nmod) use_19\NN\407535|following|the|suxamethonium|woman (r_nmod) result_14\NN\34213|as|a|hyperkalaemia|use (r_nmod) case_5\NN\7283608|a|arrest|result (l_nmod) arrest_8\NN\88481|of|cardiac|and|death (l_conj) death_11\NN\7296428|subsequent
D013390_D003643 NONE suxamethonium_11\NN\1740|to (r_nmod) hypersensitivity_9\NN\14531772|by|suxamethonium (r_nmod) caused_7\VBN\1617192|that|death|was|hypersensitivity|,|associated (l_nsubjpass) death_5\NN\7296428|her
D013390_D006947 CID suxamethonium_21\NN\1740|of (r_nmod) use_19\NN\407535|following|the|suxamethonium|woman (r_nmod) result_14\NN\34213|as|a|hyperkalaemia|use (l_nmod) hyperkalaemia_16\NN\1740|of
D013390_D006947 CID suxamethonium_35\NN\1740|of (r_nmod) administration_33\NN\1133281|following|the|suxamethonium (r_nmod) were_13\VBD\836236|apart|,|there|signs|administration|. (l_attr) signs_15\NNS\6643763|no|damage (l_nmod) damage_19\NN\7296428|of|neurone|or|any (l_conj) any_22\DT\1740|of|conditions (l_nmod) conditions_28\NNS\14512817|of|the|other|known|predisposing|hyperkalaemia (l_nmod) hyperkalaemia_30\NN\1740|for
D013390_D001919 CID suxamethonium_5\NN\1740|of|,|bradycardia|and|cardiac|arrest (l_conj) bradycardia_7\NN\14110674|
D013390_D004342 CID suxamethonium_11\NN\1740|to (r_nmod) hypersensitivity_9\NN\14531772|by|suxamethonium
11752354
D003276_D009203 CID contraceptives_1\NNS\3183080|oral|and|risk|. (l_conj) risk_4\NN\14541044|the|infarction (l_nmod) infarction_7\NN\14204950|of|myocardial
D003276_D009203 CID contraceptives_9\NNS\3183080|of|oral (r_nmod) use_6\NN\407535|between|the|contraceptives|and|risk (l_conj) risk_12\NN\14541044|the|infarction (l_nmod) infarction_15\NN\14204950|of|myocardial
D003276_D009203 CID contraceptives_29\NNS\3183080|oral (r_conj) type_8\NN\5839024|according|the|progestagen|included|contraceptives|,|dose|,|and|presence (r_nmod) investigated_1\VBD\644583|we|association|,|type|methods|:|study (r_ccomp) identified_56\VBD\699815|investigated|,|we|and|enrolled|,|year|,|and|area|. (l_conj) enrolled_58\VBD\2471690|women|years (l_nmod) years_64\NNS\15144371|through|49|age|had (l_acl:relcl) had_69\VBN\2108377|who|had|infarction (l_dobj) infarction_73\NN\14204950|a|first|myocardial|1990|women
D003276_D009203 CID contraceptives_29\NNS\3183080|oral (r_conj) type_8\NN\5839024|according|the|progestagen|included|contraceptives|,|dose|,|and|presence (r_nmod) investigated_1\VBD\644583|we|association|,|type|methods|:|study (r_ccomp) identified_56\VBD\699815|investigated|,|we|and|enrolled|,|year|,|and|area|. (l_conj) enrolled_58\VBD\2471690|women|years (l_nmod) years_64\NNS\15144371|through|49|age|had (l_acl:relcl) had_69\VBN\2108377|who|had|infarction (l_dobj) infarction_73\NN\14204950|a|first|myocardial|1990|women (l_nmod) women_81\NNS\9605289|control|had (l_acl:relcl) had_85\VBN\2108377|who|had|not|infarction|and|matched (l_dobj) infarction_88\NN\14204950|a|myocardial
D003276_D009203 CID contraceptive_39\NN\3183080|of|combined|oral (r_nmod) type_35\NN\5839024|any|contraceptive (r_dobj) used_33\VBD\1156834|who|type (r_acl:relcl) women_31\NNS\9605289|among|used (r_nmod) infarction_29\NN\14204950|for|myocardial|women
D003276_D009203 CID contraceptives_5\NNS\3183080|oral (r_dobj) used_3\VBD\1156834|who|contraceptives (r_acl:relcl) women_1\NNS\9605289|among|used|interval (r_nmod) 3.0_20\CD\1740|women|1.5|)|those|: (r_dep) increased_53\VBN\169651|3.0|risk|was|women|. (l_nsubjpass) risk_48\NN\14541044|the|infarction (l_nmod) infarction_51\NN\14204950|of|myocardial
D003276_D009203 CID contraceptives_60\NNS\3183080|second-generation|oral (r_dobj) used_57\VBD\1156834|who|contraceptives (r_acl:relcl) women_55\NNS\9605289|among|used (r_nmod) increased_53\VBN\169651|3.0|risk|was|women|. (l_nsubjpass) risk_48\NN\14541044|the|infarction (l_nmod) infarction_51\NN\14204950|of|myocardial
D003276_D009203 CID contraceptives_12\NNS\3183080|oral (r_dobj) used_10\VBD\1156834|who|contraceptives (r_acl:relcl) women_8\NNS\9605289|among|used (r_nmod) similar_6\JJ\1740|risk|was|women|had|. (l_nsubj) risk_1\NN\14541044|the|infarction (l_nmod) infarction_4\NN\14204950|of|myocardial
D011372_D009203 NONE progestagen_10\NN\1740|of (r_nmod) type_8\NN\5839024|according|the|progestagen|included|contraceptives|,|dose|,|and|presence (r_nmod) investigated_1\VBD\644583|we|association|,|type|methods|:|study (r_ccomp) identified_56\VBD\699815|investigated|,|we|and|enrolled|,|year|,|and|area|. (l_conj) enrolled_58\VBD\2471690|women|years (l_nmod) years_64\NNS\15144371|through|49|age|had (l_acl:relcl) had_69\VBN\2108377|who|had|infarction (l_dobj) infarction_73\NN\14204950|a|first|myocardial|1990|women
D011372_D009203 NONE progestagen_10\NN\1740|of (r_nmod) type_8\NN\5839024|according|the|progestagen|included|contraceptives|,|dose|,|and|presence (r_nmod) investigated_1\VBD\644583|we|association|,|type|methods|:|study (r_ccomp) identified_56\VBD\699815|investigated|,|we|and|enrolled|,|year|,|and|area|. (l_conj) enrolled_58\VBD\2471690|women|years (l_nmod) years_64\NNS\15144371|through|49|age|had (l_acl:relcl) had_69\VBN\2108377|who|had|infarction (l_dobj) infarction_73\NN\14204950|a|first|myocardial|1990|women (l_nmod) women_81\NNS\9605289|control|had (l_acl:relcl) had_85\VBN\2108377|who|had|not|infarction|and|matched (l_dobj) infarction_88\NN\14204950|a|myocardial
D017135_D009203 NONE desogestrel_17\NN\1740|(|i.e.|,|or|gestodene|) (r_dep) third-generation_13\NN\1740|in|desogestrel|and|second-generation (r_nmod) included_11\VBN\690614|third-generation (r_acl) type_8\NN\5839024|according|the|progestagen|included|contraceptives|,|dose|,|and|presence (r_nmod) investigated_1\VBD\644583|we|association|,|type|methods|:|study (r_ccomp) identified_56\VBD\699815|investigated|,|we|and|enrolled|,|year|,|and|area|. (l_conj) enrolled_58\VBD\2471690|women|years (l_nmod) years_64\NNS\15144371|through|49|age|had (l_acl:relcl) had_69\VBN\2108377|who|had|infarction (l_dobj) infarction_73\NN\14204950|a|first|myocardial|1990|women
D017135_D009203 NONE desogestrel_17\NN\1740|(|i.e.|,|or|gestodene|) (r_dep) third-generation_13\NN\1740|in|desogestrel|and|second-generation (r_nmod) included_11\VBN\690614|third-generation (r_acl) type_8\NN\5839024|according|the|progestagen|included|contraceptives|,|dose|,|and|presence (r_nmod) investigated_1\VBD\644583|we|association|,|type|methods|:|study (r_ccomp) identified_56\VBD\699815|investigated|,|we|and|enrolled|,|year|,|and|area|. (l_conj) enrolled_58\VBD\2471690|women|years (l_nmod) years_64\NNS\15144371|through|49|age|had (l_acl:relcl) had_69\VBN\2108377|who|had|infarction (l_dobj) infarction_73\NN\14204950|a|first|myocardial|1990|women (l_nmod) women_81\NNS\9605289|control|had (l_acl:relcl) had_85\VBN\2108377|who|had|not|infarction|and|matched (l_dobj) infarction_88\NN\14204950|a|myocardial
C033273_D009203 NONE gestodene_19\NN\1740| (r_conj) desogestrel_17\NN\1740|(|i.e.|,|or|gestodene|) (r_dep) third-generation_13\NN\1740|in|desogestrel|and|second-generation (r_nmod) included_11\VBN\690614|third-generation (r_acl) type_8\NN\5839024|according|the|progestagen|included|contraceptives|,|dose|,|and|presence (r_nmod) investigated_1\VBD\644583|we|association|,|type|methods|:|study (r_ccomp) identified_56\VBD\699815|investigated|,|we|and|enrolled|,|year|,|and|area|. (l_conj) enrolled_58\VBD\2471690|women|years (l_nmod) years_64\NNS\15144371|through|49|age|had (l_acl:relcl) had_69\VBN\2108377|who|had|infarction (l_dobj) infarction_73\NN\14204950|a|first|myocardial|1990|women
C033273_D009203 NONE gestodene_19\NN\1740| (r_conj) desogestrel_17\NN\1740|(|i.e.|,|or|gestodene|) (r_dep) third-generation_13\NN\1740|in|desogestrel|and|second-generation (r_nmod) included_11\VBN\690614|third-generation (r_acl) type_8\NN\5839024|according|the|progestagen|included|contraceptives|,|dose|,|and|presence (r_nmod) investigated_1\VBD\644583|we|association|,|type|methods|:|study (r_ccomp) identified_56\VBD\699815|investigated|,|we|and|enrolled|,|year|,|and|area|. (l_conj) enrolled_58\VBD\2471690|women|years (l_nmod) years_64\NNS\15144371|through|49|age|had (l_acl:relcl) had_69\VBN\2108377|who|had|infarction (l_dobj) infarction_73\NN\14204950|a|first|myocardial|1990|women (l_nmod) women_81\NNS\9605289|control|had (l_acl:relcl) had_85\VBN\2108377|who|had|not|infarction|and|matched (l_dobj) infarction_88\NN\14204950|a|myocardial
D016912_D009203 NONE levonorgestrel_26\NN\1740|(|i.e.|,|) (r_dep) second-generation_22\NN\1740|levonorgestrel (r_conj) third-generation_13\NN\1740|in|desogestrel|and|second-generation (r_nmod) included_11\VBN\690614|third-generation (r_acl) type_8\NN\5839024|according|the|progestagen|included|contraceptives|,|dose|,|and|presence (r_nmod) investigated_1\VBD\644583|we|association|,|type|methods|:|study (r_ccomp) identified_56\VBD\699815|investigated|,|we|and|enrolled|,|year|,|and|area|. (l_conj) enrolled_58\VBD\2471690|women|years (l_nmod) years_64\NNS\15144371|through|49|age|had (l_acl:relcl) had_69\VBN\2108377|who|had|infarction (l_dobj) infarction_73\NN\14204950|a|first|myocardial|1990|women
D016912_D009203 NONE levonorgestrel_26\NN\1740|(|i.e.|,|) (r_dep) second-generation_22\NN\1740|levonorgestrel (r_conj) third-generation_13\NN\1740|in|desogestrel|and|second-generation (r_nmod) included_11\VBN\690614|third-generation (r_acl) type_8\NN\5839024|according|the|progestagen|included|contraceptives|,|dose|,|and|presence (r_nmod) investigated_1\VBD\644583|we|association|,|type|methods|:|study (r_ccomp) identified_56\VBD\699815|investigated|,|we|and|enrolled|,|year|,|and|area|. (l_conj) enrolled_58\VBD\2471690|women|years (l_nmod) years_64\NNS\15144371|through|49|age|had (l_acl:relcl) had_69\VBN\2108377|who|had|infarction (l_dobj) infarction_73\NN\14204950|a|first|myocardial|1990|women (l_nmod) women_81\NNS\9605289|control|had (l_acl:relcl) had_85\VBN\2108377|who|had|not|infarction|and|matched (l_dobj) infarction_88\NN\14204950|a|myocardial
D004967_D009203 NONE estrogen_34\NN\14745635|of (r_nmod) dose_32\NN\3740161|the|estrogen (r_conj) type_8\NN\5839024|according|the|progestagen|included|contraceptives|,|dose|,|and|presence (r_nmod) investigated_1\VBD\644583|we|association|,|type|methods|:|study (r_ccomp) identified_56\VBD\699815|investigated|,|we|and|enrolled|,|year|,|and|area|. (l_conj) enrolled_58\VBD\2471690|women|years (l_nmod) years_64\NNS\15144371|through|49|age|had (l_acl:relcl) had_69\VBN\2108377|who|had|infarction (l_dobj) infarction_73\NN\14204950|a|first|myocardial|1990|women
D004967_D009203 NONE estrogen_34\NN\14745635|of (r_nmod) dose_32\NN\3740161|the|estrogen (r_conj) type_8\NN\5839024|according|the|progestagen|included|contraceptives|,|dose|,|and|presence (r_nmod) investigated_1\VBD\644583|we|association|,|type|methods|:|study (r_ccomp) identified_56\VBD\699815|investigated|,|we|and|enrolled|,|year|,|and|area|. (l_conj) enrolled_58\VBD\2471690|women|years (l_nmod) years_64\NNS\15144371|through|49|age|had (l_acl:relcl) had_69\VBN\2108377|who|had|infarction (l_dobj) infarction_73\NN\14204950|a|first|myocardial|1990|women (l_nmod) women_81\NNS\9605289|control|had (l_acl:relcl) had_85\VBN\2108377|who|had|not|infarction|and|matched (l_dobj) infarction_88\NN\14204950|a|myocardial
7444978
D013307_D020258 NONE streptomycin_9\NN\2716866|of (r_nmod) effects_7\NNS\13245626|to|neurotoxic|streptomycin (l_amod) neurotoxic_6\JJ\1740|
D013307_D004409 CID streptomycin_48\NN\2716866|to (r_nmod) sensitive_46\JJ\1740|that|cochlea|is|more|streptomycin|site (r_ccomp) indicating_40\VBG\952524|sensitive (r_xcomp) occurred_23\VBD\2623529|occurred|period|sensitivities|days|,|respectively|,|indicating|. (l_ccomp) occurred_4\VBD\2623529|movements|only|rats|; (l_nsubj) movements_1\NNS\191142|abnormal|and|deafness
D013307_D004409 CID streptomycin_48\NN\2716866|to (r_nmod) sensitive_46\JJ\1740|that|cochlea|is|more|streptomycin|site (l_nmod) site_51\NN\8673395|than|the|vestibular|responsible (l_amod) responsible_57\JJ\1740|dyskinesias (l_nmod) dyskinesias_60\NNS\14084880|for|the
D013307_D003638 CID streptomycin_48\NN\2716866|to (r_nmod) sensitive_46\JJ\1740|that|cochlea|is|more|streptomycin|site (r_ccomp) indicating_40\VBG\952524|sensitive (r_xcomp) occurred_23\VBD\2623529|occurred|period|sensitivities|days|,|respectively|,|indicating|. (l_ccomp) occurred_4\VBD\2623529|movements|only|rats|; (l_nsubj) movements_1\NNS\191142|abnormal|and|deafness (l_conj) deafness_3\VBP\1740|
18544179
D005283_D009325 NONE fentanyl_1\NN\2707683|omitting (r_nsubj) reduces_2\VBZ\441445|fentanyl|nausea|,|increasing|,|sevoflurane|. (l_dobj) nausea_3\NN\14299637|and|vomiting
D005283_D009325 NONE fentanyl_4\NN\2707683|of (r_nmod) omission_2\NN\70965|fentanyl (r_nsubj) reduce_7\VB\441445|omission|did|not|incidence|,|but|reduce (l_conj) reduce_19\VB\441445|did|incidence|prior|discharge (l_dobj) incidence_21\NN\13821570|the|vomiting (l_nmod) vomiting_23\NN\116687|of|and/or|moderate (l_conj) moderate_25\JJ\1740|nausea (l_nmod) nausea_28\NN\14299637|to|severe
D005283_D009325 NONE fentanyl_39\NN\2707683|with|and|fentanyl-dexamethasone|, (r_nmod) discharge_31\VB\1640855|to|%|fentanyl|respectively|,|% (r_advcl) reduce_19\VB\441445|did|incidence|prior|discharge (l_dobj) incidence_21\NN\13821570|the|vomiting (l_nmod) vomiting_23\NN\116687|of|and/or|moderate (l_conj) moderate_25\JJ\1740|nausea (l_nmod) nausea_28\NN\14299637|to|severe
D005283_D009325 NONE fentanyl-dexamethasone_41\NN\1740| (r_conj) fentanyl_39\NN\2707683|with|and|fentanyl-dexamethasone|, (r_nmod) discharge_31\VB\1640855|to|%|fentanyl|respectively|,|% (r_advcl) reduce_19\VB\441445|did|incidence|prior|discharge (l_dobj) incidence_21\NN\13821570|the|vomiting (l_nmod) vomiting_23\NN\116687|of|and/or|moderate (l_conj) moderate_25\JJ\1740|nausea (l_nmod) nausea_28\NN\14299637|to|severe
D005283_D009325 NONE fentanyl_3\JJ\1740| (r_amod) groups_4\NNS\2137|the|two|fentanyl (r_dobj) combining_0\VBG\2630189|groups (r_csubj) revealed_5\VBD\2137132|combining|benefits|reducing|%|decreased|. (l_advcl) reducing_15\VBG\441445|nausea|prior|discharge (l_dobj) nausea_17\NN\14299637|postoperative|and|vomiting (l_conj) vomiting_19\NN\116687|and|nausea (l_conj) nausea_21\NN\14299637|
D005283_D009325 NONE fentanyl_3\JJ\1740| (r_amod) groups_4\NNS\2137|the|two|fentanyl (r_dobj) combining_0\VBG\2630189|groups (r_csubj) revealed_5\VBD\2137132|combining|benefits|reducing|%|decreased|. (l_advcl) decreased_57\VBN\169651|while|nausea|was|%|% (l_nsubjpass) nausea_50\NN\14299637|h
D005283_D014839 NONE fentanyl_1\NN\2707683|omitting (r_nsubj) reduces_2\VBZ\441445|fentanyl|nausea|,|increasing|,|sevoflurane|. (l_dobj) nausea_3\NN\14299637|and|vomiting (l_conj) vomiting_5\NN\116687|
D005283_D014839 NONE fentanyl_4\NN\2707683|of (r_nmod) omission_2\NN\70965|fentanyl (r_nsubj) reduce_7\VB\441445|omission|did|not|incidence|,|but|reduce (l_conj) reduce_19\VB\441445|did|incidence|prior|discharge (l_dobj) incidence_21\NN\13821570|the|vomiting (l_nmod) vomiting_23\NN\116687|of|and/or|moderate
D005283_D014839 NONE fentanyl_39\NN\2707683|with|and|fentanyl-dexamethasone|, (r_nmod) discharge_31\VB\1640855|to|%|fentanyl|respectively|,|% (r_advcl) reduce_19\VB\441445|did|incidence|prior|discharge (l_dobj) incidence_21\NN\13821570|the|vomiting (l_nmod) vomiting_23\NN\116687|of|and/or|moderate
D005283_D014839 NONE fentanyl-dexamethasone_41\NN\1740| (r_conj) fentanyl_39\NN\2707683|with|and|fentanyl-dexamethasone|, (r_nmod) discharge_31\VB\1640855|to|%|fentanyl|respectively|,|% (r_advcl) reduce_19\VB\441445|did|incidence|prior|discharge (l_dobj) incidence_21\NN\13821570|the|vomiting (l_nmod) vomiting_23\NN\116687|of|and/or|moderate
D005283_D010146 NONE fentanyl_1\NN\2707683|omitting (r_nsubj) reduces_2\VBZ\441445|fentanyl|nausea|,|increasing|,|sevoflurane|. (l_advcl) increasing_8\VBG\169651|without|pain (l_dobj) pain_9\NN\14299637|
D005283_D010146 NONE fentanyl_11\NN\2707683|of (r_nmod) omission_9\NN\70965|by|the|fentanyl (r_nmod) unaffected_6\JJ\1740|severity|were|omission|. (l_nsubjpass) severity_1\NN\5036394|pain|and|requirements (l_compound) pain_0\NN\14299637|
C009250_D009325 NONE sevoflurane_12\NN\1740|after|surgery (r_nmod) reduces_2\VBZ\441445|fentanyl|nausea|,|increasing|,|sevoflurane|. (l_dobj) nausea_3\NN\14299637|and|vomiting
C009250_D014839 NONE sevoflurane_12\NN\1740|after|surgery (r_nmod) reduces_2\VBZ\441445|fentanyl|nausea|,|increasing|,|sevoflurane|. (l_dobj) nausea_3\NN\14299637|and|vomiting (l_conj) vomiting_5\NN\116687|
C009250_D010146 NONE sevoflurane_12\NN\1740|after|surgery (r_nmod) reduces_2\VBZ\441445|fentanyl|nausea|,|increasing|,|sevoflurane|. (l_advcl) increasing_8\VBG\169651|without|pain (l_dobj) pain_9\NN\14299637|
C009250_D010146 NONE sevoflurane_23\NN\1740| (r_compound) anaesthesia_24\NN\14034177|after|sevoflurane (r_nmod) h_21\NN\14622893|in|the|first|24|anaesthesia|patients (r_nmod) examined_5\VBD\789138|methods|study|incidence|h|. (l_dobj) incidence_7\NN\13821570|the|and|severity|nausea (l_nmod) nausea_12\NN\14299637|of|postoperative|and|vomiting|pain (l_conj) pain_16\NN\14299637|
C009250_D020250 NONE sevoflurane_13\NN\1740|with (r_nmod) induction_7\NN\7450842|of|and|maintenance|anaesthesia|sevoflurane (r_nmod) advantages_5\NNS\5154517|despite|induction|,|nausea (l_conj) nausea_16\NN\14299637|postoperative|and|vomiting (l_conj) vomiting_18\NN\116687|
C009250_D020250 NONE sevoflurane_23\NN\1740| (r_compound) anaesthesia_24\NN\14034177|after|sevoflurane (r_nmod) h_21\NN\14622893|in|the|first|24|anaesthesia|patients (r_nmod) examined_5\VBD\789138|methods|study|incidence|h|. (l_dobj) incidence_7\NN\13821570|the|and|severity|nausea (l_nmod) nausea_12\NN\14299637|of|postoperative|and|vomiting|pain (l_conj) vomiting_14\NN\116687|and
C009250_D020250 NONE sevoflurane_33\NN\1740|to (r_nmod) supplement_31\NN\6365467|to|be|an|unnecessary|sevoflurane|surgery (r_xcomp) appears_23\VBZ\2604760|conclusion|,|it|supplement|. (l_dep) conclusion_0\NN\5837957|:|nausea|and|had (l_dep) nausea_6\NN\14299637|as|fentanyl|exacerbated|postoperative|and|vomiting (l_conj) vomiting_8\NN\116687|improvement
D005283_D020250 CID fentanyl_4\NN\2707683|of (r_nmod) omission_2\NN\70965|fentanyl (r_nsubj) reduce_7\VB\441445|omission|did|not|incidence|,|but|reduce (l_dobj) incidence_10\NN\13821570|the|overall|nausea (l_nmod) nausea_13\NN\14299637|of|postoperative|and|vomiting (l_conj) vomiting_15\NN\116687|
D005283_D020250 CID fentanyl_39\NN\2707683|with|and|fentanyl-dexamethasone|, (r_nmod) discharge_31\VB\1640855|to|%|fentanyl|respectively|,|% (r_advcl) reduce_19\VB\441445|did|incidence|prior|discharge (r_conj) reduce_7\VB\441445|omission|did|not|incidence|,|but|reduce (l_dobj) incidence_10\NN\13821570|the|overall|nausea (l_nmod) nausea_13\NN\14299637|of|postoperative|and|vomiting (l_conj) vomiting_15\NN\116687|
D005283_D020250 CID fentanyl-dexamethasone_41\NN\1740| (r_conj) fentanyl_39\NN\2707683|with|and|fentanyl-dexamethasone|, (r_nmod) discharge_31\VB\1640855|to|%|fentanyl|respectively|,|% (r_advcl) reduce_19\VB\441445|did|incidence|prior|discharge (r_conj) reduce_7\VB\441445|omission|did|not|incidence|,|but|reduce (l_dobj) incidence_10\NN\13821570|the|overall|nausea (l_nmod) nausea_13\NN\14299637|of|postoperative|and|vomiting (l_conj) vomiting_15\NN\116687|
D005283_D020250 CID fentanyl_3\JJ\1740| (r_amod) groups_4\NNS\2137|the|two|fentanyl (r_dobj) combining_0\VBG\2630189|groups (r_csubj) revealed_5\VBD\2137132|combining|benefits|reducing|%|decreased|. (l_advcl) reducing_15\VBG\441445|nausea|prior|discharge (l_dobj) nausea_17\NN\14299637|postoperative|and|vomiting (l_conj) vomiting_19\NN\116687|and|nausea
D005283_D020250 CID fentanyl_3\JJ\1740| (r_amod) nausea_6\NN\14299637|as|fentanyl|exacerbated|postoperative|and|vomiting (l_conj) vomiting_8\NN\116687|improvement
D003907_D020250 NONE fentanyl-dexamethasone_41\NN\1740| (r_conj) fentanyl_39\NN\2707683|with|and|fentanyl-dexamethasone|, (r_nmod) discharge_31\VB\1640855|to|%|fentanyl|respectively|,|% (r_advcl) reduce_19\VB\441445|did|incidence|prior|discharge (r_conj) reduce_7\VB\441445|omission|did|not|incidence|,|but|reduce (l_dobj) incidence_10\NN\13821570|the|overall|nausea (l_nmod) nausea_13\NN\14299637|of|postoperative|and|vomiting (l_conj) vomiting_15\NN\116687|
D003907_D020250 NONE dexamethasone_0\NN\2721538| (r_nsubj) had_1\VBD\2108377|dexamethasone|effect|incidence|. (l_nmod) incidence_7\NN\13821570|on|the|or|severity|nausea (l_nmod) nausea_12\NN\14299637|of|postoperative|and|vomiting (l_conj) vomiting_14\NN\116687|
D003907_D014839 NONE fentanyl-dexamethasone_41\NN\1740| (r_conj) fentanyl_39\NN\2707683|with|and|fentanyl-dexamethasone|, (r_nmod) discharge_31\VB\1640855|to|%|fentanyl|respectively|,|% (r_advcl) reduce_19\VB\441445|did|incidence|prior|discharge (l_dobj) incidence_21\NN\13821570|the|vomiting (l_nmod) vomiting_23\NN\116687|of|and/or|moderate
D003907_D009325 NONE fentanyl-dexamethasone_41\NN\1740| (r_conj) fentanyl_39\NN\2707683|with|and|fentanyl-dexamethasone|, (r_nmod) discharge_31\VB\1640855|to|%|fentanyl|respectively|,|% (r_advcl) reduce_19\VB\441445|did|incidence|prior|discharge (l_dobj) incidence_21\NN\13821570|the|vomiting (l_nmod) vomiting_23\NN\116687|of|and/or|moderate (l_conj) moderate_25\JJ\1740|nausea (l_nmod) nausea_28\NN\14299637|to|severe
D005283_D012131 CID fentanyl_0\NNP\2707683| (r_nsubj) reduce_2\VB\441445|fentanyl|did|movement|but|had|. (l_conj) had_7\VBD\2108377|effect (l_dobj) effect_10\NN\34213|no|sevoflurane-sparing|and|depression (l_conj) depression_14\NN\14373582|increased|respiratory|,|hypotension
D005283_D007022 CID fentanyl_0\NNP\2707683| (r_nsubj) reduce_2\VB\441445|fentanyl|did|movement|but|had|. (l_conj) had_7\VBD\2108377|effect (l_dobj) effect_10\NN\34213|no|sevoflurane-sparing|and|depression (l_conj) depression_14\NN\14373582|increased|respiratory|,|hypotension (l_appos) hypotension_16\NN\14057371|and|bradycardia
D005283_D001919 CID fentanyl_0\NNP\2707683| (r_nsubj) reduce_2\VB\441445|fentanyl|did|movement|but|had|. (l_conj) had_7\VBD\2108377|effect (l_dobj) effect_10\NN\34213|no|sevoflurane-sparing|and|depression (l_conj) depression_14\NN\14373582|increased|respiratory|,|hypotension (l_appos) hypotension_16\NN\14057371|and|bradycardia (l_conj) bradycardia_18\NN\14110674|
C009250_D012131 NONE sevoflurane-sparing_9\JJ\1740| (r_amod) effect_10\NN\34213|no|sevoflurane-sparing|and|depression (l_conj) depression_14\NN\14373582|increased|respiratory|,|hypotension
C009250_D007022 NONE sevoflurane-sparing_9\JJ\1740| (r_amod) effect_10\NN\34213|no|sevoflurane-sparing|and|depression (l_conj) depression_14\NN\14373582|increased|respiratory|,|hypotension (l_appos) hypotension_16\NN\14057371|and|bradycardia
C009250_D001919 NONE sevoflurane-sparing_9\JJ\1740| (r_amod) effect_10\NN\34213|no|sevoflurane-sparing|and|depression (l_conj) depression_14\NN\14373582|increased|respiratory|,|hypotension (l_appos) hypotension_16\NN\14057371|and|bradycardia (l_conj) bradycardia_18\NN\14110674|
D005283_D010149 NONE fentanyl_3\JJ\1740| (r_amod) nausea_6\NN\14299637|as|fentanyl|exacerbated|postoperative|and|vomiting (l_conj) vomiting_8\NN\116687|improvement (l_nmod) improvement_11\NN\7359599|without|an|pain (l_nmod) pain_14\NN\14299637|in|postoperative
C009250_D010149 NONE sevoflurane_33\NN\1740|to (r_nmod) supplement_31\NN\6365467|to|be|an|unnecessary|sevoflurane|surgery (r_xcomp) appears_23\VBZ\2604760|conclusion|,|it|supplement|. (l_dep) conclusion_0\NN\5837957|:|nausea|and|had (l_dep) nausea_6\NN\14299637|as|fentanyl|exacerbated|postoperative|and|vomiting (l_conj) vomiting_8\NN\116687|improvement (l_nmod) improvement_11\NN\7359599|without|an|pain (l_nmod) pain_14\NN\14299637|in|postoperative
17241784
D019821_D009135 CID statin_8\NN\3740161| (r_compound) therapy_9\NN\657604|with|statin (r_nmod) associated_6\VBN\628491|therapy (r_acl) mhc-i_5\NN\1740|of|associated (r_nmod) up-regulation_3\NN\1740|with|mhc-i (r_nmod) myopathy_1\NN\14204950|progressive|up-regulation|.
D019821_D009135 CID statins_0\NNS\3740161| (r_nsubj) cause_2\VB\1617192|statins|can|myopathy|. (l_dobj) myopathy_5\NN\14204950|a|necrotizing|and|hyperckaemia|reversible
D019821_D009135 CID statins_9\NNS\3740161| (r_nsubj) induce_11\VB\1627355|whereby|statins|may|myopathy (l_dobj) myopathy_13\JJ\1740|a|,|persists
D019821_D009135 CID statins_4\NNS\3740161| (r_nsubj) initiate_6\VB\1617192|that|statins|may|myopathy (l_dobj) myopathy_9\NN\14204950|an|immune-mediated|persists
D019821_D009135 CID statins_13\NNS\3740161|by|response (r_nmod) induction_11\NN\7450842|the|statins (r_dobj) involve_9\VB\2676054|may|induction (r_conj) uncertain_6\JJ\1740|mechanism|is|but|involve|. (l_nsubj) mechanism_1\NN\13446390|the|myopathy (l_nmod) myopathy_4\NN\14204950|of|this
D019821_-1 NONE statins_0\NNS\3740161| (r_nsubj) cause_2\VB\1617192|statins|can|myopathy|. (l_dobj) myopathy_5\NN\14204950|a|necrotizing|and|hyperckaemia|reversible (l_conj) hyperckaemia_7\NN\1740|
19308880
D014635_D003221 CID acid_10\NN\14818238|with|valproic (r_nmod) reaction_7\NN\13446390|a|serious|adverse|drug|acid (r_appos) confusion_0\NN\13972797|,|reaction|:|review|.
D014635_D003221 CID acid_12\NN\14818238|with|valproic (r_nmod) observed_9\VBN\2163746|frequently|acid (r_acl) reaction_7\NN\13446390|confusion|is|an|adverse|drug|observed (l_nsubj) confusion_2\NN\13972797|
D014635_D003221 CID acid_19\NN\14818238|with|valproic (r_nmod) reported_14\VBN\831651|1985|acid (r_acl) cases_11\NNS\7283608|the|confusion|reported (l_nmod) confusion_13\NN\13972797|of
D014635_D003221 CID acid_10\NN\14818238|with|valproic (r_nmod) reported_7\VBN\831651|cases|were|acid|: (l_nsubjpass) cases_3\NNS\7283608|272|confusion (l_nmod) confusion_5\NN\13972797|of
D014635_D003221 CID acid_10\NN\14818238| (r_compound) exposure_11\NN\5042871|following|valproic|acid|% (r_nmod) occurred_2\VBD\2623529|confusion|mostly|weeks|exposure|. (l_nsubj) confusion_0\NN\13972797|
D014635_D003221 CID acid_9\NN\14818238|with|valproic (r_nmod) confusion_6\NN\13972797|acid
18182964
D003000_D001289 NONE clonidine_0\NN\2721160|disorder|:|ii|. (l_nmod) disorder_3\NN\14034177|for|attention-deficit/hyperactivity
D003000_D001289 NONE clonidine_9\NN\2721160|of|used (l_acl) used_10\VBN\1156834|alone|or|methylphenidate (l_conj) methylphenidate_14\NN\4320126|with|children (l_nmod) children_16\NNS\9622049|in|disorder (l_nmod) disorder_19\NN\14034177|with|attention-deficit/hyperactivity|adhd
D003000_D001289 NONE clonidine_9\NN\2721160|of|used (l_acl) used_10\VBN\1156834|alone|or|methylphenidate (l_conj) methylphenidate_14\NN\4320126|with|children (l_nmod) children_16\NNS\9622049|in|disorder (l_nmod) disorder_19\NN\14034177|with|attention-deficit/hyperactivity|adhd (l_appos) adhd_21\NN\14304060|(|)
D003000_D001289 NONE clonidine_18\NN\2721160|to|n|,|methylphenidate|,|clonidine|and|methylphenidate|n|,|or|placebo (r_nmod) assigned_16\VBN\2475922|multicenter|children|were|randomly|clonidine|. (l_nsubjpass) children_11\NNS\9622049|122|adhd (l_nmod) adhd_13\NN\14304060|with
D003000_D001289 NONE clonidine_32\NN\2721160| (r_conj) clonidine_18\NN\2721160|to|n|,|methylphenidate|,|clonidine|and|methylphenidate|n|,|or|placebo (r_nmod) assigned_16\VBN\2475922|multicenter|children|were|randomly|clonidine|. (l_nsubjpass) children_11\NNS\9622049|122|adhd (l_nmod) adhd_13\NN\14304060|with
D003000_D001289 NONE clonidine_2\NNP\2721160|,|used|, (r_nsubj) appears_10\VBZ\2604760|clonidine|safe|tolerated (l_conj) tolerated_14\VBN\802318|adhd (l_nmod) adhd_17\NN\14304060|in|childhood
D008774_D001289 NONE methylphenidate_14\NN\4320126|with|children (l_nmod) children_16\NNS\9622049|in|disorder (l_nmod) disorder_19\NN\14034177|with|attention-deficit/hyperactivity|adhd
D008774_D001289 NONE methylphenidate_14\NN\4320126|with|children (l_nmod) children_16\NNS\9622049|in|disorder (l_nmod) disorder_19\NN\14034177|with|attention-deficit/hyperactivity|adhd (l_appos) adhd_21\NN\14304060|(|)
D008774_D001289 NONE methylphenidate_25\NN\4320126|n (r_conj) clonidine_18\NN\2721160|to|n|,|methylphenidate|,|clonidine|and|methylphenidate|n|,|or|placebo (r_nmod) assigned_16\VBN\2475922|multicenter|children|were|randomly|clonidine|. (l_nsubjpass) children_11\NNS\9622049|122|adhd (l_nmod) adhd_13\NN\14304060|with
D008774_D001289 NONE methylphenidate_34\NN\4320126| (r_conj) clonidine_18\NN\2721160|to|n|,|methylphenidate|,|clonidine|and|methylphenidate|n|,|or|placebo (r_nmod) assigned_16\VBN\2475922|multicenter|children|were|randomly|clonidine|. (l_nsubjpass) children_11\NNS\9622049|122|adhd (l_nmod) adhd_13\NN\14304060|with
D008774_D001289 NONE methylphenidate_8\NN\4320126|with (r_conj) used_4\VBN\1156834|alone|or|methylphenidate (r_acl) clonidine_2\NNP\2721160|,|used|, (r_nsubj) appears_10\VBZ\2604760|clonidine|safe|tolerated (l_conj) tolerated_14\VBN\802318|adhd (l_nmod) adhd_17\NN\14304060|in|childhood
D003000_D001919 CID clonidine_12\NN\2721160|with (r_nmod) treated_10\VBN\2376958|clonidine (r_acl) subjects_9\NNS\6598915|in|treated (r_nmod) incidents_5\NNS\7283608|more|bradycardia|subjects (l_nmod) bradycardia_7\NN\14110674|of
D003000_D001919 CID clonidine_19\NN\2721160|with|= (r_nmod) treated_17\VBN\2376958|not|clonidine (r_acl) those_15\DT\1740|compared|with|treated (r_nmod) were_3\VBD\836236|results|:|there|incidents|those|,|but|differences|. (l_nsubj) incidents_5\NNS\7283608|more|bradycardia|subjects (l_nmod) bradycardia_7\NN\14110674|of
D003000_D001919 CID clonidine_2\NN\2721160|physicians|prescribing (r_nsubj) monitor_4\VB\2169352|clonidine|should|bradycardia|and|advise|. (l_nmod) bradycardia_6\NN\14110674|for
D003000_D006970 NONE clonidine_4\NN\2721160|on (r_nmod) common_2\JJ\1740|drowsiness|was|clonidine|,|but|resolved|. (l_nsubj) drowsiness_0\NNP\14015731|
D003000_D006970 NONE clonidine_2\NN\2721160|physicians|prescribing (r_nsubj) monitor_4\VB\2169352|clonidine|should|bradycardia|and|advise|. (l_conj) advise_8\VB\813978|patients (l_dobj) patients_9\NNS\9898892|likelihood (l_nmod) likelihood_13\NN\4756172|about|the|high|drowsiness (l_nmod) drowsiness_16\NN\14015731|of|initial
20528871
C104457_D015458 NONE nelarabine_3\NN\1740|with|,|etoposide|,|and|cyclophosphamide (r_nmod) therapy_1\NN\657604|salvage|nelarabine|leukaemia|. (l_nmod) leukaemia_14\NN\14239918|in|relapsed/refractory|paediatric|t-cell|lymphoblastic|and|lymphoma (l_conj) lymphoma_16\NN\14239918|
C104457_D015458 NONE nelarabine_6\NN\1740|of|arag (r_nmod) d_4\NN\15089472|of|5|nelarabine (r_nmod) combination_1\NN\7951464|a|d|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|. (l_nmod) therapy_31\NN\657604|as|salvage|children (l_nmod) children_34\NNS\9622049|in|seven|refractory (l_nmod) refractory_36\JJ\1740|with|or|relapsed|leukaemia (l_dep) leukaemia_40\NN\14239918|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
C104457_D015458 NONE arag_8\NN\1740|(|) (r_appos) nelarabine_6\NN\1740|of|arag (r_nmod) d_4\NN\15089472|of|5|nelarabine (r_nmod) combination_1\NN\7951464|a|d|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|. (l_nmod) therapy_31\NN\657604|as|salvage|children (l_nmod) children_34\NNS\9622049|in|seven|refractory (l_nmod) refractory_36\JJ\1740|with|or|relapsed|leukaemia (l_dep) leukaemia_40\NN\14239918|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
C104457_D016399 NONE nelarabine_3\NN\1740|with|,|etoposide|,|and|cyclophosphamide (r_nmod) therapy_1\NN\657604|salvage|nelarabine|leukaemia|. (l_nmod) leukaemia_14\NN\14239918|in|relapsed/refractory|paediatric|t-cell|lymphoblastic|and|lymphoma (l_conj) lymphoma_16\NN\14239918|
C104457_D016399 NONE nelarabine_6\NN\1740|of|arag (r_nmod) d_4\NN\15089472|of|5|nelarabine (r_nmod) combination_1\NN\7951464|a|d|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|. (l_nmod) therapy_31\NN\657604|as|salvage|children (l_nmod) children_34\NNS\9622049|in|seven|refractory (l_nmod) refractory_36\JJ\1740|with|or|relapsed|leukaemia (l_dep) leukaemia_40\NN\14239918|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
C104457_D016399 NONE arag_8\NN\1740|(|) (r_appos) nelarabine_6\NN\1740|of|arag (r_nmod) d_4\NN\15089472|of|5|nelarabine (r_nmod) combination_1\NN\7951464|a|d|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|. (l_nmod) therapy_31\NN\657604|as|salvage|children (l_nmod) children_34\NNS\9622049|in|seven|refractory (l_nmod) refractory_36\JJ\1740|with|or|relapsed|leukaemia (l_dep) leukaemia_40\NN\14239918|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
D005047_D015458 NONE etoposide_5\NN\1740| (r_conj) nelarabine_3\NN\1740|with|,|etoposide|,|and|cyclophosphamide (r_nmod) therapy_1\NN\657604|salvage|nelarabine|leukaemia|. (l_nmod) leukaemia_14\NN\14239918|in|relapsed/refractory|paediatric|t-cell|lymphoblastic|and|lymphoma (l_conj) lymphoma_16\NN\14239918|
D005047_D015458 NONE etoposide_14\NN\1740|of|vp|and|cyclophosphamide|chemotherapy (r_nmod) d_12\NN\15089472|with|5|etoposide (r_nmod) combination_1\NN\7951464|a|d|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|. (l_nmod) therapy_31\NN\657604|as|salvage|children (l_nmod) children_34\NNS\9622049|in|seven|refractory (l_nmod) refractory_36\JJ\1740|with|or|relapsed|leukaemia (l_dep) leukaemia_40\NN\14239918|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
D005047_D015458 NONE vp_16\NN\1740|(|) (r_appos) etoposide_14\NN\1740|of|vp|and|cyclophosphamide|chemotherapy (r_nmod) d_12\NN\15089472|with|5|etoposide (r_nmod) combination_1\NN\7951464|a|d|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|. (l_nmod) therapy_31\NN\657604|as|salvage|children (l_nmod) children_34\NNS\9622049|in|seven|refractory (l_nmod) refractory_36\JJ\1740|with|or|relapsed|leukaemia (l_dep) leukaemia_40\NN\14239918|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
D005047_D016399 NONE etoposide_5\NN\1740| (r_conj) nelarabine_3\NN\1740|with|,|etoposide|,|and|cyclophosphamide (r_nmod) therapy_1\NN\657604|salvage|nelarabine|leukaemia|. (l_nmod) leukaemia_14\NN\14239918|in|relapsed/refractory|paediatric|t-cell|lymphoblastic|and|lymphoma (l_conj) lymphoma_16\NN\14239918|
D005047_D016399 NONE etoposide_14\NN\1740|of|vp|and|cyclophosphamide|chemotherapy (r_nmod) d_12\NN\15089472|with|5|etoposide (r_nmod) combination_1\NN\7951464|a|d|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|. (l_nmod) therapy_31\NN\657604|as|salvage|children (l_nmod) children_34\NNS\9622049|in|seven|refractory (l_nmod) refractory_36\JJ\1740|with|or|relapsed|leukaemia (l_dep) leukaemia_40\NN\14239918|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
D005047_D016399 NONE vp_16\NN\1740|(|) (r_appos) etoposide_14\NN\1740|of|vp|and|cyclophosphamide|chemotherapy (r_nmod) d_12\NN\15089472|with|5|etoposide (r_nmod) combination_1\NN\7951464|a|d|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|. (l_nmod) therapy_31\NN\657604|as|salvage|children (l_nmod) children_34\NNS\9622049|in|seven|refractory (l_nmod) refractory_36\JJ\1740|with|or|relapsed|leukaemia (l_dep) leukaemia_40\NN\14239918|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
D003520_D015458 NONE cyclophosphamide_8\NN\1740| (r_conj) nelarabine_3\NN\1740|with|,|etoposide|,|and|cyclophosphamide (r_nmod) therapy_1\NN\657604|salvage|nelarabine|leukaemia|. (l_nmod) leukaemia_14\NN\14239918|in|relapsed/refractory|paediatric|t-cell|lymphoblastic|and|lymphoma (l_conj) lymphoma_16\NN\14239918|
D003520_D015458 NONE cyclophosphamide_19\NN\1740|cpm|and (r_conj) etoposide_14\NN\1740|of|vp|and|cyclophosphamide|chemotherapy (r_nmod) d_12\NN\15089472|with|5|etoposide (r_nmod) combination_1\NN\7951464|a|d|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|. (l_nmod) therapy_31\NN\657604|as|salvage|children (l_nmod) children_34\NNS\9622049|in|seven|refractory (l_nmod) refractory_36\JJ\1740|with|or|relapsed|leukaemia (l_dep) leukaemia_40\NN\14239918|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
D003520_D015458 NONE cpm_21\NN\1740|(|) (r_appos) cyclophosphamide_19\NN\1740|cpm|and (r_conj) etoposide_14\NN\1740|of|vp|and|cyclophosphamide|chemotherapy (r_nmod) d_12\NN\15089472|with|5|etoposide (r_nmod) combination_1\NN\7951464|a|d|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|. (l_nmod) therapy_31\NN\657604|as|salvage|children (l_nmod) children_34\NNS\9622049|in|seven|refractory (l_nmod) refractory_36\JJ\1740|with|or|relapsed|leukaemia (l_dep) leukaemia_40\NN\14239918|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
D003520_D016399 NONE cyclophosphamide_8\NN\1740| (r_conj) nelarabine_3\NN\1740|with|,|etoposide|,|and|cyclophosphamide (r_nmod) therapy_1\NN\657604|salvage|nelarabine|leukaemia|. (l_nmod) leukaemia_14\NN\14239918|in|relapsed/refractory|paediatric|t-cell|lymphoblastic|and|lymphoma (l_conj) lymphoma_16\NN\14239918|
D003520_D016399 NONE cyclophosphamide_19\NN\1740|cpm|and (r_conj) etoposide_14\NN\1740|of|vp|and|cyclophosphamide|chemotherapy (r_nmod) d_12\NN\15089472|with|5|etoposide (r_nmod) combination_1\NN\7951464|a|d|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|. (l_nmod) therapy_31\NN\657604|as|salvage|children (l_nmod) children_34\NNS\9622049|in|seven|refractory (l_nmod) refractory_36\JJ\1740|with|or|relapsed|leukaemia (l_dep) leukaemia_40\NN\14239918|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
D003520_D016399 NONE cpm_21\NN\1740|(|) (r_appos) cyclophosphamide_19\NN\1740|cpm|and (r_conj) etoposide_14\NN\1740|of|vp|and|cyclophosphamide|chemotherapy (r_nmod) d_12\NN\15089472|with|5|etoposide (r_nmod) combination_1\NN\7951464|a|d|d (r_nsubjpass) used_28\VBN\1156834|combination|was|therapy|. (l_nmod) therapy_31\NN\657604|as|salvage|children (l_nmod) children_34\NNS\9622049|in|seven|refractory (l_nmod) refractory_36\JJ\1740|with|or|relapsed|leukaemia (l_dep) leukaemia_40\NN\14239918|t-cell|or|lymphoma (l_conj) lymphoma_42\NN\14239918|
C104457_D009422 CID arag_8\NN\1740|to|the (r_nmod) attributable_5\JJ\1740|arag (r_amod) effects_4\NNS\13245626|the|common|side|attributable (r_nsubj) included_9\VBD\690614|effects|grade|pain|. (l_dobj) pain_20\NN\14299637|neuropathy (l_amod) neuropathy_17\JJ\1740|and|musculoskeletal
C104457_D009422 CID arag_7\NN\1740| (r_dobj) giving_6\VBG\2327200|of|arag|therapy (r_advcl) safety_4\NN\13920835|the|giving (r_dobj) supports_2\VBZ\2199590|experience|safety|,|monitored|. (l_advcl) monitored_24\VBN\2169352|although|toxicity|must|be|closely (l_nsubjpass) toxicity_20\NN\13576101|neurological
C104457_D059352 CID arag_8\NN\1740|to|the (r_nmod) attributable_5\JJ\1740|arag (r_amod) effects_4\NNS\13245626|the|common|side|attributable (r_nsubj) included_9\VBD\690614|effects|grade|pain|. (l_dobj) pain_20\NN\14299637|neuropathy
C104457_D006402 CID arag_8\NN\1740|than|alone (r_nmod) combination_6\NN\7951464|for|the|arag (r_nmod) greater_3\JJR\1740|toxicity|was|combination|,|consistent|. (l_nsubj) toxicity_1\NN\13576101|haematological
D005047_D009422 NONE etoposide_14\NN\1740|with|and|cyclophosphamide (r_nmod) synchrony_12\NN\13844690|in|etoposide (r_nmod) therapy_10\NN\657604|as|salvage|synchrony (r_nmod) giving_6\VBG\2327200|of|arag|therapy (r_advcl) safety_4\NN\13920835|the|giving (r_dobj) supports_2\VBZ\2199590|experience|safety|,|monitored|. (l_advcl) monitored_24\VBN\2169352|although|toxicity|must|be|closely (l_nsubjpass) toxicity_20\NN\13576101|neurological
D003520_D009422 NONE cyclophosphamide_16\NN\1740| (r_conj) etoposide_14\NN\1740|with|and|cyclophosphamide (r_nmod) synchrony_12\NN\13844690|in|etoposide (r_nmod) therapy_10\NN\657604|as|salvage|synchrony (r_nmod) giving_6\VBG\2327200|of|arag|therapy (r_advcl) safety_4\NN\13920835|the|giving (r_dobj) supports_2\VBZ\2199590|experience|safety|,|monitored|. (l_advcl) monitored_24\VBN\2169352|although|toxicity|must|be|closely (l_nsubjpass) toxicity_20\NN\13576101|neurological
10704919
D013629_D006461 CID tamoxifen_6\NN\2714883|by (r_nmod) induced_4\VBN\1627355|tamoxifen (r_acl) erythrocytes_3\NNS\5449268|of|human|induced (r_nmod) hemolysis_0\NN\13509528|erythrocytes
D013629_D006461 CID tam_0\NN\2954340| (r_nsubj) induces_1\VBZ\1627355|tam|hemolysis|function|. (l_dobj) hemolysis_2\NN\13509528|erythrocytes
D013629_D006461 CID tam_13\NN\2954340| (r_dep) microm_12\NN\1740|12.5|tam (r_nsubj) induces_14\VBZ\1627355|microm|hemolysis (r_conj) variable_5\JJ\1740|extension|is|samples|,|but|induces|. (l_nsubj) extension_1\NN\15272029|the|hemolysis (l_nmod) hemolysis_3\NN\13509528|of
D013629_D006461 CID tam_13\NN\2954340| (r_dep) microm_12\NN\1740|12.5|tam (r_nsubj) induces_14\VBZ\1627355|microm|hemolysis (l_dobj) hemolysis_16\NN\13509528|total|suspensions
D013629_D006461 CID tam_4\NN\2954340|of (r_nmod) effect_2\NN\34213|the|hemolytic|tam (l_amod) hemolytic_1\JJ\1740|
D013629_D006461 CID tam_4\NN\2954340|of (r_nmod) effect_2\NN\34213|the|hemolytic|tam (r_nsubjpass) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_xcomp) indicating_26\VBG\952524|related (l_ccomp) related_32\JJ\1740|that|hemolysis|is|not|damage (l_nsubj) hemolysis_29\NN\13509528|tam-induced
D013629_D006461 CID tam-induced_28\JJ\1740| (r_amod) hemolysis_29\NN\13509528|tam-induced (r_nsubj) related_32\JJ\1740|that|hemolysis|is|not|damage (r_ccomp) indicating_26\VBG\952524|related (r_xcomp) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_nsubjpass) effect_2\NN\34213|the|hemolytic|tam (l_amod) hemolytic_1\JJ\1740|
D013629_D006461 CID tam-induced_28\JJ\1740| (r_amod) hemolysis_29\NN\13509528|tam-induced
D013629_D006461 CID tam-induced_17\JJ\1740| (r_amod) hemolysis_18\NN\13509528|with|tam-induced
D013629_D006461 CID tam_3\NN\2954340|by (r_nmod) caused_1\VBN\1617192|tam (r_acl) hemolysis_0\NN\13509528|caused
D013629_D006461 CID tam_3\NN\2954340|by (r_nmod) caused_1\VBN\1617192|tam (r_acl) hemolysis_0\NN\13509528|caused (r_nsubjpass) preceded_6\VBN\2690708|hemolysis|was|not|leakage|cells|,|excluding|,|effects|. (l_xcomp) excluding_18\VBG\471711|also|mechanism (l_dobj) mechanism_22\NN\13446390|a|colloid-osmotic|type|hemolysis (l_nmod) hemolysis_24\NN\13509528|of
D013629_D006461 CID tam_15\NN\2954340| (r_compound) incorporation_16\NN\1237415|to|a|decreased|tam|membranes|damage (r_nmod) related_11\JJ\1740|that|protection|is|incorporation (l_nsubj) protection_5\NN\407535|the|hemolysis|tocopherols (l_nmod) hemolysis_7\NN\13509528|from
D013629_D006461 CID tam-induced_2\JJ\1740| (r_amod) hemolysis_3\NN\13509528|tam-induced
D013629_D001943 NONE tamoxifen_0\NN\2714883|tam|,|drug|, (l_appos) drug_7\NN\14778436|the|antiestrogenic|prescribed (l_acl) prescribed_10\VBN\748282|widely|chemotherapy (l_nmod) chemotherapy_13\NN\661091|in|the|cancer (l_nmod) cancer_16\NN\14239425|of|breast
D013629_D001943 NONE tam_2\NNP\2954340|(|) (r_appos) tamoxifen_0\NN\2714883|tam|,|drug|, (l_appos) drug_7\NN\14778436|the|antiestrogenic|prescribed (l_acl) prescribed_10\VBN\748282|widely|chemotherapy (l_nmod) chemotherapy_13\NN\661091|in|the|cancer (l_nmod) cancer_16\NN\14239425|of|breast
D013629_D000743 CID tamoxifen_0\NN\2714883|tam|,|drug|, (r_nsubj) induces_18\VBZ\1627355|tamoxifen|changes|. (l_dobj) changes_19\NNS\7283608|shape (l_nmod) shape_23\NN\5062748|in|normal|discoid|erythrocytes (l_nmod) erythrocytes_25\NNS\5449268|of|and|anemia (l_conj) anemia_28\NN\14189204|hemolytic
D013629_D000743 CID tam_2\NNP\2954340|(|) (r_appos) tamoxifen_0\NN\2714883|tam|,|drug|, (r_nsubj) induces_18\VBZ\1627355|tamoxifen|changes|. (l_dobj) changes_19\NNS\7283608|shape (l_nmod) shape_23\NN\5062748|in|normal|discoid|erythrocytes (l_nmod) erythrocytes_25\NNS\5449268|of|and|anemia (l_conj) anemia_28\NN\14189204|hemolytic
D013629_D000743 CID tam_6\NN\2954340|of (r_nmod) effects_4\NNS\13245626|the|tam|erythrocytes (r_dobj) evaluates_2\VBZ\670261|work|effects|,|attempting|. (l_advcl) attempting_12\VBG\2367363|identify (l_xcomp) identify_14\VB\699815|to|mechanisms (l_dobj) mechanisms_17\NNS\13446390|the|underlying|anemia|and|involvement (l_nmod) anemia_21\NN\14189204|on|tam-induced|hemolytic
D013629_D000743 CID tam-induced_19\JJ\1740| (r_amod) anemia_21\NN\14189204|on|tam-induced|hemolytic
D013629_D000743 CID tam_13\NN\2954340|by (r_nmod) promoted_11\VBN\2556126|tam (r_acl) stability_10\NN\4777852|mechanical|promoted (r_dobj) decreased_8\VBD\169651|stability|,|resulting (l_advcl) resulting_15\VBG\2633881|anemia (l_nmod) anemia_18\NN\14189204|in|hemolytic
D024502_D006461 NONE alpha-tocopherol_11\NN\1740|of|alpha-t|and|acetate|inactivated (r_nmod) concentrations_9\NNS\4916342|by|low|alpha-tocopherol (r_nmod) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_nsubjpass) effect_2\NN\34213|the|hemolytic|tam (l_amod) hemolytic_1\JJ\1740|
D024502_D006461 NONE alpha-tocopherol_11\NN\1740|of|alpha-t|and|acetate|inactivated (r_nmod) concentrations_9\NNS\4916342|by|low|alpha-tocopherol (r_nmod) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_xcomp) indicating_26\VBG\952524|related (l_ccomp) related_32\JJ\1740|that|hemolysis|is|not|damage (l_nsubj) hemolysis_29\NN\13509528|tam-induced
D024502_D006461 NONE alpha-t_13\NN\1740|(|) (r_appos) alpha-tocopherol_11\NN\1740|of|alpha-t|and|acetate|inactivated (r_nmod) concentrations_9\NNS\4916342|by|low|alpha-tocopherol (r_nmod) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_nsubjpass) effect_2\NN\34213|the|hemolytic|tam (l_amod) hemolytic_1\JJ\1740|
D024502_D006461 NONE alpha-t_13\NN\1740|(|) (r_appos) alpha-tocopherol_11\NN\1740|of|alpha-t|and|acetate|inactivated (r_nmod) concentrations_9\NNS\4916342|by|low|alpha-tocopherol (r_nmod) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_xcomp) indicating_26\VBG\952524|related (l_ccomp) related_32\JJ\1740|that|hemolysis|is|not|damage (l_nsubj) hemolysis_29\NN\13509528|tam-induced
D024502_D006461 NONE acetate_17\NN\15010703|alpha-tocopherol|alpha-tac (r_conj) alpha-tocopherol_11\NN\1740|of|alpha-t|and|acetate|inactivated (r_nmod) concentrations_9\NNS\4916342|by|low|alpha-tocopherol (r_nmod) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_nsubjpass) effect_2\NN\34213|the|hemolytic|tam (l_amod) hemolytic_1\JJ\1740|
D024502_D006461 NONE acetate_17\NN\15010703|alpha-tocopherol|alpha-tac (r_conj) alpha-tocopherol_11\NN\1740|of|alpha-t|and|acetate|inactivated (r_nmod) concentrations_9\NNS\4916342|by|low|alpha-tocopherol (r_nmod) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_xcomp) indicating_26\VBG\952524|related (l_ccomp) related_32\JJ\1740|that|hemolysis|is|not|damage (l_nsubj) hemolysis_29\NN\13509528|tam-induced
D024502_D006461 NONE alpha-tac_19\NN\1740|(|) (r_appos) acetate_17\NN\15010703|alpha-tocopherol|alpha-tac (r_conj) alpha-tocopherol_11\NN\1740|of|alpha-t|and|acetate|inactivated (r_nmod) concentrations_9\NNS\4916342|by|low|alpha-tocopherol (r_nmod) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_nsubjpass) effect_2\NN\34213|the|hemolytic|tam (l_amod) hemolytic_1\JJ\1740|
D024502_D006461 NONE alpha-tac_19\NN\1740|(|) (r_appos) acetate_17\NN\15010703|alpha-tocopherol|alpha-tac (r_conj) alpha-tocopherol_11\NN\1740|of|alpha-t|and|acetate|inactivated (r_nmod) concentrations_9\NNS\4916342|by|low|alpha-tocopherol (r_nmod) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_xcomp) indicating_26\VBG\952524|related (l_ccomp) related_32\JJ\1740|that|hemolysis|is|not|damage (l_nsubj) hemolysis_29\NN\13509528|tam-induced
D017665_D006461 NONE hydroxyl_24\NN\14621446|functional (r_dobj) inactivated_22\VBD\1097743|(|hydroxyl|) (r_dep) alpha-tocopherol_11\NN\1740|of|alpha-t|and|acetate|inactivated (r_nmod) concentrations_9\NNS\4916342|by|low|alpha-tocopherol (r_nmod) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_nsubjpass) effect_2\NN\34213|the|hemolytic|tam (l_amod) hemolytic_1\JJ\1740|
D017665_D006461 NONE hydroxyl_24\NN\14621446|functional (r_dobj) inactivated_22\VBD\1097743|(|hydroxyl|) (r_dep) alpha-tocopherol_11\NN\1740|of|alpha-t|and|acetate|inactivated (r_nmod) concentrations_9\NNS\4916342|by|low|alpha-tocopherol (r_nmod) prevented_6\VBN\1740|effect|is|concentrations|indicating|. (l_xcomp) indicating_26\VBG\952524|related (l_ccomp) related_32\JJ\1740|that|hemolysis|is|not|damage (l_nsubj) hemolysis_29\NN\13509528|tam-induced
D010100_D006461 NONE oxygen_7\NN\14622893| (r_compound) consumption_8\NN\13440063|of|oxygen|and|oxidation (r_nmod) absence_5\NN\14449405|by|consumption (r_nmod) evidenced_3\VBN\1015244|this|was|further|absence|determined|. (l_advcl) determined_13\VBN\1645601|both|parallel (l_nmod) parallel_15\NN\4743605|in|hemolysis (l_nmod) hemolysis_18\NN\13509528|with|tam-induced
D011188_D006461 NONE k(+_11\NN\1740|of (r_nmod) leakage_9\NN\7407777|by|the|k(+|) (r_nmod) preceded_6\VBN\2690708|hemolysis|was|not|leakage|cells|,|excluding|,|effects|. (l_nsubjpass) hemolysis_0\NN\13509528|caused
D011188_D006461 NONE k(+_11\NN\1740|of (r_nmod) leakage_9\NN\7407777|by|the|k(+|) (r_nmod) preceded_6\VBN\2690708|hemolysis|was|not|leakage|cells|,|excluding|,|effects|. (l_xcomp) excluding_18\VBG\471711|also|mechanism (l_dobj) mechanism_22\NN\13446390|a|colloid-osmotic|type|hemolysis (l_nmod) hemolysis_24\NN\13509528|of
D024505_D006461 NONE tocopherols_9\NNS\14724645|by (r_nmod) protection_5\NN\407535|the|hemolysis|tocopherols (l_nmod) hemolysis_7\NN\13509528|from
10683478
D001058_D007035 CID apomorphine_0\NNP\3786417|,|agonist|, (r_nsubjpass) selected_8\VBN\697589|apomorphine|was|effects|ability|,|and|produce|. (l_dobj) ability_17\NN\4723816|its|induce (l_acl) induce_19\VB\1627355|to|hypothermia (l_dobj) hypothermia_20\NN\14034177|
D001058_D007035 CID apomorphine_11\VB\1740|to|hypothermia (l_nmod) hypothermia_15\NN\14034177|such|drug-induced
D018491_D007035 NONE agonist_5\NN\9613191|a|nonselective|dopamine (r_appos) apomorphine_0\NNP\3786417|,|agonist|, (r_nsubjpass) selected_8\VBN\697589|apomorphine|was|effects|ability|,|and|produce|. (l_dobj) ability_17\NN\4723816|its|induce (l_acl) induce_19\VB\1627355|to|hypothermia (l_dobj) hypothermia_20\NN\14034177|
D004298_D007035 NONE dopamine_28\NN\14807737| (r_compound) turnover_29\NN\13819207|to|dopamine (r_nmod) changes_26\NNS\7283608|distinct|turnover|brain (r_dobj) produce_24\VB\1617192|to|changes (r_conj) selected_8\VBN\697589|apomorphine|was|effects|ability|,|and|produce|. (l_dobj) ability_17\NN\4723816|its|induce (l_acl) induce_19\VB\1627355|to|hypothermia (l_dobj) hypothermia_20\NN\14034177|
D001058_D006948 CID apomorphine-induced_5\JJ\1740| (r_amod) hyperactivity_6\NN\14052403|of|apomorphine-induced
12041669
D000961_D000741 NONE globulin_1\NN\14736972|antithymocyte|treatment|. (l_nmod) treatment_4\NN\654885|in|the|anemia (l_nmod) anemia_8\NN\14189204|of|d-penicillamine-induced|aplastic
D000961_D000741 NONE globulin_5\NN\14736972| (r_compound) therapy_6\NN\657604|antithymocyte|globulin|anemia (l_nmod) anemia_9\NN\14189204|for|aplastic
D000961_D000741 NONE globulin_3\NN\14736972|of|antithymocyte (r_nmod) use_0\NN\407535|globulin (r_nsubj) treatment_8\NN\654885|use|may|be|the|optimal|anemia|. (l_nmod) anemia_12\NN\14189204|of|d-penicillamine-induced|aplastic
D010396_D000741 CID d-penicillamine-induced_6\JJ\1740| (r_amod) anemia_8\NN\14189204|of|d-penicillamine-induced|aplastic
D010396_D000741 CID d-penicillamine_12\NN\1740| (r_compound) therapy_13\NN\657604|due|d-penicillamine (r_nmod) received_3\VBD\2210855|who|therapy|therapy (l_dobj) therapy_6\NN\657604|antithymocyte|globulin|anemia (l_nmod) anemia_9\NN\14189204|for|aplastic
D010396_D000741 CID d-penicillamine-induced_10\JJ\1740| (r_amod) anemia_12\NN\14189204|of|d-penicillamine-induced|aplastic
12536034
D002220_D004832 CID carbamazepine_13\NN\1740|of|and|vigabatrin (r_nmod) administration_11\NN\1133281|after|carbamazepine (r_nmod) present_2\VBP\2137132|authors|patients|administration|. (l_dobj) patients_4\NNS\9898892|three|epilepsy (l_nmod) epilepsy_9\NN\14085708|with|de|absence
D020888_D004832 CID vigabatrin_15\NN\1740| (r_conj) carbamazepine_13\NN\1740|of|and|vigabatrin (r_nmod) administration_11\NN\1133281|after|carbamazepine (r_nmod) present_2\VBP\2137132|authors|patients|administration|. (l_dobj) patients_4\NNS\9898892|three|epilepsy (l_nmod) epilepsy_9\NN\14085708|with|de|absence
D005680_D004832 NONE acid-transmitted_2\JJ\1740| (r_dep) gamma-aminobutyric_1\JJ\1740|acid-transmitted (r_amod) accounts_5\NNS\6647206|the|gamma-aminobutyric|thalamocortical|circuitry|part|. (l_nmod) part_9\NN\31921|for|a|major|neurophysiology (l_nmod) neurophysiology_13\NN\6081833|of|the|underlying|epilepsy (l_nmod) epilepsy_17\NN\14085708|of|the|absence
10365197
D003042_D019964 CID cocaine-induced_0\JJ\1740| (r_amod) disorder_2\NN\14034177|cocaine-induced|mood|:|rates|sample|.
D003042_D019964 CID cocaine-dependent_12\JJ\1740| (r_amod) sample_13\NN\5820620|in|an|outpatient|cocaine-dependent (r_nmod) disorder_2\NN\14034177|cocaine-induced|mood|:|rates|sample|.
D003042_D019964 CID cocaine-dependent_1\JJ\1740| (r_amod) outpatients_2\NNS\10405694|243|cocaine-dependent|disorder (l_nmod) disorder_6\NN\14034177|with|cocaine-induced|mood|cimd|,|disorders|,|or|disorder
D003042_D019964 CID cocaine-dependent_1\JJ\1740| (r_amod) outpatients_2\NNS\10405694|243|cocaine-dependent|disorder (l_nmod) disorder_6\NN\14034177|with|cocaine-induced|mood|cimd|,|disorders|,|or|disorder (l_conj) disorders_13\NNS\14034177|other|mood
D003042_D019964 CID cocaine-dependent_1\JJ\1740| (r_amod) outpatients_2\NNS\10405694|243|cocaine-dependent|disorder (l_nmod) disorder_6\NN\14034177|with|cocaine-induced|mood|cimd|,|disorders|,|or|disorder (l_conj) disorder_18\NN\14034177|no|mood
D003042_D019964 CID cocaine-induced_4\JJ\1740| (r_amod) disorder_6\NN\14034177|with|cocaine-induced|mood|cimd|,|disorders|,|or|disorder
D003042_D019964 CID cocaine-induced_4\JJ\1740| (r_amod) disorder_6\NN\14034177|with|cocaine-induced|mood|cimd|,|disorders|,|or|disorder (l_conj) disorders_13\NNS\14034177|other|mood
D003042_D019964 CID cocaine-induced_4\JJ\1740| (r_amod) disorder_6\NN\14034177|with|cocaine-induced|mood|cimd|,|disorders|,|or|disorder (l_conj) disorder_18\NN\14034177|no|mood
D003042_D001523 NONE cocaine-induced_0\JJ\1740| (r_amod) disorder_2\NN\14034177|cocaine-induced|mood|:|rates|sample|. (l_appos) rates_5\NNS\13308999|prevalence|and|symptoms (l_conj) symptoms_8\NNS\5823932|psychiatric (l_amod) psychiatric_7\JJ\1740|
D003042_D001523 NONE cocaine-dependent_12\JJ\1740| (r_amod) sample_13\NN\5820620|in|an|outpatient|cocaine-dependent (r_nmod) disorder_2\NN\14034177|cocaine-induced|mood|:|rates|sample|. (l_appos) rates_5\NNS\13308999|prevalence|and|symptoms (l_conj) symptoms_8\NNS\5823932|psychiatric (l_amod) psychiatric_7\JJ\1740|
D003042_D001523 NONE cocaine-dependent_1\JJ\1740| (r_amod) outpatients_2\NNS\10405694|243|cocaine-dependent|disorder (r_nsubjpass) compared_20\VBN\644583|outpatients|were|measures|. (l_nmod) measures_22\NNS\168237|on|symptoms (l_nmod) symptoms_25\NNS\5823932|of|psychiatric (l_amod) psychiatric_24\JJ\1740|
D003042_D001523 NONE cocaine-induced_4\JJ\1740| (r_amod) disorder_6\NN\14034177|with|cocaine-induced|mood|cimd|,|disorders|,|or|disorder (r_nmod) outpatients_2\NNS\10405694|243|cocaine-dependent|disorder (r_nsubjpass) compared_20\VBN\644583|outpatients|were|measures|. (l_nmod) measures_22\NNS\168237|on|symptoms (l_nmod) symptoms_25\NNS\5823932|of|psychiatric (l_amod) psychiatric_24\JJ\1740|
D003042_D019970 NONE cocaine-dependent_1\JJ\1740| (r_amod) outpatients_2\NNS\10405694|243|cocaine-dependent|disorder (l_nmod) disorder_6\NN\14034177|with|cocaine-induced|mood|cimd|,|disorders|,|or|disorder (l_appos) cimd_8\NN\1740|(|)
D003042_D019970 NONE cocaine-induced_4\JJ\1740| (r_amod) disorder_6\NN\14034177|with|cocaine-induced|mood|cimd|,|disorders|,|or|disorder (l_appos) cimd_8\NN\1740|(|)
16160878
D014579_D006973 NONE u-ii_6\NN\1740|of (r_nmod) injection_4\NN\320852|intracerebroventricular|u-ii (r_nsubj) causes_7\VBZ\1617192|injection|hypertension|and|stimulates|. (l_dobj) hypertension_8\NN\14057371|and|bradycardia
D014579_D001919 NONE u-ii_6\NN\1740|of (r_nmod) injection_4\NN\320852|intracerebroventricular|u-ii (r_nsubj) causes_7\VBZ\1617192|injection|hypertension|and|stimulates|. (l_dobj) hypertension_8\NN\14057371|and|bradycardia (l_conj) bradycardia_10\NN\14110674|
D014579_D010409 NONE u-ii_9\NN\1740|of (r_nmod) administration_7\NN\1133281|the|central|u-ii (r_nsubj) had_10\VBD\2108377|dose|administration|effect|temperature|. (l_nmod) temperature_15\NN\13575869|on|body|,|nociception|,|erection|,|and|level (l_conj) erection_21\NN\14037619|apomorphine-induced|penile|and|behavior
D001058_D010409 CID apomorphine-induced_19\JJ\1740| (r_amod) erection_21\NN\14037619|apomorphine-induced|penile|and|behavior
D003345_D010409 NONE corticosterone_29\NN\14752057| (r_compound) level_30\NN\4916342|stress-induced|plasma|corticosterone (r_conj) temperature_15\NN\13575869|on|body|,|nociception|,|erection|,|and|level (l_conj) erection_21\NN\14037619|apomorphine-induced|penile|and|behavior
D014579_D001523 NONE u-ii_4\NN\1740| (r_nsubjpass) involved_7\VBN\2676054|that|u-ii|may|be|aspects (l_nmod) aspects_10\NNS\5849789|in|some|disorders (l_nmod) disorders_13\NNS\14034177|of|psychiatric
2385256
D008274_D009157 CID magnesium_6\NN\14625458| (r_compound) administration_7\NN\1133281|after|magnesium (r_nmod) presenting_2\VBG\2137132|weakness|administration (r_acl) gravis_1\NN\1740|myasthenia|presenting|.
D008274_D009157 CID magnesium_3\NN\14625458| (r_compound) administration_4\NN\1133281|after|magnesium (r_nmod) paralysis_1\NN\14557898|administration (r_nsubjpass) described_7\VBN\1001294|although|paralysis|has|been|patients (l_nmod) patients_9\NNS\9898892|in|gravis (l_nmod) gravis_13\NN\1740|with|known|myasthenia
D008274_D009468 NONE magnesium_17\NN\14625458| (r_compound) administration_18\NN\1133281|after|parenteral|magnesium|preeclampsia (r_nmod) became_12\VBD\146138|who|quadriplegic|administration (r_acl:relcl) history_7\NN\15120823|with|no|prior|disease|became (l_nmod) disease_10\NN\14061805|of|neuromuscular
D008274_D011782 NONE magnesium_17\NN\14625458| (r_compound) administration_18\NN\1133281|after|parenteral|magnesium|preeclampsia (r_nmod) became_12\VBD\146138|who|quadriplegic|administration (l_acomp) quadriplegic_14\JJ\1740|virtually
D008274_D011225 NONE magnesium_17\NN\14625458| (r_compound) administration_18\NN\1133281|after|parenteral|magnesium|preeclampsia (l_nmod) preeclampsia_20\NN\14191037|for
D008274_D010243 NONE magnesium_3\NN\14625458| (r_compound) administration_4\NN\1133281|after|magnesium (r_nmod) paralysis_1\NN\14557898|administration
D008274_D020511 NONE magnesium_10\NN\14625458|of (r_nmod) effects_8\NNS\13245626|to|the|neuromuscular|magnesium (r_nmod) sensitive_4\JJ\1740|who|are|unusually|effects (r_acl:relcl) patients_0\NNS\9898892|sensitive (r_nsubjpass) suspected_13\VBN\916909|patients|should|be|having|. (l_advcl) having_15\VBG\2108377|of|disorder (l_dobj) disorder_18\NN\14034177|an|underlying|transmission (l_nmod) transmission_21\NN\121166|of|neuromuscular
3076126
D008148_D009135 NONE lovastatin_23\NN\3676175|with|, (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|patients|. (l_nsubjpass) myopathy_0\NNP\14204950|,|associated|,
D008148_D009212 CID lovastatin_23\NN\3676175|with|, (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|patients|. (l_nsubjpass) myopathy_0\NNP\14204950|,|associated|, (l_acl) associated_2\VBN\628491|cases|myoglobinuria|,|and|cases (l_nmod) myoglobinuria_7\NNS\14299637|with
D008148_D051437 CID lovastatin_23\NN\3676175|with|, (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|patients|. (l_nsubjpass) myopathy_0\NNP\14204950|,|associated|, (l_acl) associated_2\VBN\628491|cases|myoglobinuria|,|and|cases (l_conj) cases_12\NNS\7283608|in|2|failure (l_nmod) failure_16\NN\66216|with|transient|renal
D016572_D009135 CID cyclosporin_31\NN\1740|with (r_nmod) treated_29\VBN\2376958|concomitantly|cyclosporin (r_acl) patients_27\NNS\9898892|especially|in|treated|,|gemfibrozil (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|patients|. (l_nsubjpass) myopathy_0\NNP\14204950|,|associated|,
D016572_D009212 NONE cyclosporin_31\NN\1740|with (r_nmod) treated_29\VBN\2376958|concomitantly|cyclosporin (r_acl) patients_27\NNS\9898892|especially|in|treated|,|gemfibrozil (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|patients|. (l_nsubjpass) myopathy_0\NNP\14204950|,|associated|, (l_acl) associated_2\VBN\628491|cases|myoglobinuria|,|and|cases (l_nmod) myoglobinuria_7\NNS\14299637|with
D016572_D051437 NONE cyclosporin_31\NN\1740|with (r_nmod) treated_29\VBN\2376958|concomitantly|cyclosporin (r_acl) patients_27\NNS\9898892|especially|in|treated|,|gemfibrozil (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|patients|. (l_nsubjpass) myopathy_0\NNP\14204950|,|associated|, (l_acl) associated_2\VBN\628491|cases|myoglobinuria|,|and|cases (l_conj) cases_12\NNS\7283608|in|2|failure (l_nmod) failure_16\NN\66216|with|transient|renal
D015248_D009135 CID gemfibrozil_33\NN\3740161|or|niacin (r_conj) patients_27\NNS\9898892|especially|in|treated|,|gemfibrozil (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|patients|. (l_nsubjpass) myopathy_0\NNP\14204950|,|associated|,
D015248_D009212 NONE gemfibrozil_33\NN\3740161|or|niacin (r_conj) patients_27\NNS\9898892|especially|in|treated|,|gemfibrozil (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|patients|. (l_nsubjpass) myopathy_0\NNP\14204950|,|associated|, (l_acl) associated_2\VBN\628491|cases|myoglobinuria|,|and|cases (l_nmod) myoglobinuria_7\NNS\14299637|with
D015248_D051437 NONE gemfibrozil_33\NN\3740161|or|niacin (r_conj) patients_27\NNS\9898892|especially|in|treated|,|gemfibrozil (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|patients|. (l_nsubjpass) myopathy_0\NNP\14204950|,|associated|, (l_acl) associated_2\VBN\628491|cases|myoglobinuria|,|and|cases (l_conj) cases_12\NNS\7283608|in|2|failure (l_nmod) failure_16\NN\66216|with|transient|renal
D009525_D009135 CID niacin_35\NN\15090742| (r_conj) gemfibrozil_33\NN\3740161|or|niacin (r_conj) patients_27\NNS\9898892|especially|in|treated|,|gemfibrozil (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|patients|. (l_nsubjpass) myopathy_0\NNP\14204950|,|associated|,
D009525_D009212 NONE niacin_35\NN\15090742| (r_conj) gemfibrozil_33\NN\3740161|or|niacin (r_conj) patients_27\NNS\9898892|especially|in|treated|,|gemfibrozil (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|patients|. (l_nsubjpass) myopathy_0\NNP\14204950|,|associated|, (l_acl) associated_2\VBN\628491|cases|myoglobinuria|,|and|cases (l_nmod) myoglobinuria_7\NNS\14299637|with
D009525_D051437 NONE niacin_35\NN\15090742| (r_conj) gemfibrozil_33\NN\3740161|or|niacin (r_conj) patients_27\NNS\9898892|especially|in|treated|,|gemfibrozil (r_nmod) reported_21\VBN\831651|myopathy|has|been|rarely|lovastatin|patients|. (l_nsubjpass) myopathy_0\NNP\14204950|,|associated|, (l_acl) associated_2\VBN\628491|cases|myoglobinuria|,|and|cases (l_conj) cases_12\NNS\7283608|in|2|failure (l_nmod) failure_16\NN\66216|with|transient|renal
1592014
D003042_D012640 CID cocaine_4\NN\3492717| (r_compound) benzoylecgonine_6\NN\1740|by|the|cocaine|metabolite (r_nmod) induced_1\VBN\1627355|benzoylecgonine|rats (r_acl) seizures_0\NNP\14081375|induced|.
D003042_D012640 CID cocaine_6\NN\3492717|of (r_nmod) half-life_1\NN\15113229|the|t1/2|cocaine (r_nsubj) short_9\JJ\1740|half-life|is|relatively|,|but|occur (l_conj) occur_27\VB\2623529|some|can|hours|exposure|. (l_nsubj) some_12\DT\1740|consequences|, (l_nmod) consequences_15\NNS\34213|of|the|use|,|seizures (l_nmod) seizures_22\NNS\14081375|such|and|strokes
D003042_D012640 CID cocaine_9\NN\3492717|of|,|benzoylecgonine|, (r_nmod) metabolite_7\NN\20090|of|the|major|cocaine (r_nmod) potential_3\NN\14481929|the|metabolite (r_dobj) evaluated_1\VBD\670261|we|potential|cause|. (l_xcomp) cause_17\VB\1617192|to|seizures (l_dobj) seizures_18\NNS\14081375|
D003042_D012640 CID cocaine_17\NN\3492717|of (r_nmod) amounts_15\NNS\13329641|by|equimolar|cocaine (r_nmod) induced_12\VBN\1627355|amounts (r_acl) those_11\DT\1740|than|induced (r_nmod) latencies_9\NNS\15269513|longer|those (r_dobj) had_6\VBD\2108377|latencies (r_conj) occurred_2\VBD\2623529|seizures|frequently|and|had|. (l_nsubj) seizures_1\NNS\14081375|be-induced
D003042_D012640 CID cocaine-induced_1\JJ\1740| (r_amod) seizures_2\NNS\14081375|cocaine-induced
D003042_D012640 CID cocaine-injected_13\JJ\1740| (r_amod) animals_14\NNS\4475|than|cocaine-injected|seizures (r_nmod) activity_11\NN\30358|more|locomotor|animals (r_dobj) had_7\VBD\2108377|rats|seizures|activity|. (l_nsubj) seizures_6\NNS\14081375|
D003042_D012640 CID cocaine-injected_13\JJ\1740| (r_amod) animals_14\NNS\4475|than|cocaine-injected|seizures (l_nmod) seizures_16\NNS\14081375|without
D003042_D012640 CID cocaine-_3\NN\1740|and|be-induced|seizures (l_dep) seizures_6\NNS\14081375|
D003042_D012640 CID cocaine-_3\NN\1740|and|be-induced|seizures (r_nsubj) differ_7\VBP\1740|that|cocaine-|respects (r_ccomp) finding_1\NN\43195|the|differ (r_nsubj) suggests_11\VBZ\1010118|finding|mechanism|and|emphasizes|. (l_dobj) mechanism_15\NN\13446390|one|seizures (l_nmod) seizures_18\NNS\14081375|for|cocaine-induced
D003042_D012640 CID cocaine-induced_17\JJ\1740| (r_amod) seizures_18\NNS\14081375|for|cocaine-induced (r_nmod) mechanism_15\NN\13446390|one|seizures (r_dobj) suggests_11\VBZ\1010118|finding|mechanism|and|emphasizes|. (l_nsubj) finding_1\NN\43195|the|differ (l_ccomp) differ_7\VBP\1740|that|cocaine-|respects (l_nsubj) cocaine-_3\NN\1740|and|be-induced|seizures (l_dep) seizures_6\NNS\14081375|
D003042_D012640 CID cocaine-induced_17\JJ\1740| (r_amod) seizures_18\NNS\14081375|for|cocaine-induced
D003042_D012640 CID cocaine_25\NN\3492717| (r_compound) metabolite_26\NN\20090|of|a|cocaine|,|be (r_nmod) importance_22\NN\5138488|the|metabolite (r_dobj) emphasizes_20\VBZ\943837|importance (r_conj) suggests_11\VBZ\1010118|finding|mechanism|and|emphasizes|. (l_nsubj) finding_1\NN\43195|the|differ (l_ccomp) differ_7\VBP\1740|that|cocaine-|respects (l_nsubj) cocaine-_3\NN\1740|and|be-induced|seizures (l_dep) seizures_6\NNS\14081375|
D003042_D012640 CID cocaine_25\NN\3492717| (r_compound) metabolite_26\NN\20090|of|a|cocaine|,|be (r_nmod) importance_22\NN\5138488|the|metabolite (r_dobj) emphasizes_20\VBZ\943837|importance (r_conj) suggests_11\VBZ\1010118|finding|mechanism|and|emphasizes|. (l_dobj) mechanism_15\NN\13446390|one|seizures (l_nmod) seizures_18\NNS\14081375|for|cocaine-induced
C005618_D012640 CID benzoylecgonine_6\NN\1740|by|the|cocaine|metabolite (r_nmod) induced_1\VBN\1627355|benzoylecgonine|rats (r_acl) seizures_0\NNP\14081375|induced|.
C005618_D012640 CID benzoylecgonine_11\NN\1740|be (r_conj) cocaine_9\NN\3492717|of|,|benzoylecgonine|, (r_nmod) metabolite_7\NN\20090|of|the|major|cocaine (r_nmod) potential_3\NN\14481929|the|metabolite (r_dobj) evaluated_1\VBD\670261|we|potential|cause|. (l_xcomp) cause_17\VB\1617192|to|seizures (l_dobj) seizures_18\NNS\14081375|
C005618_D012640 CID be_13\NN\14625458|(|) (r_appos) benzoylecgonine_11\NN\1740|be (r_conj) cocaine_9\NN\3492717|of|,|benzoylecgonine|, (r_nmod) metabolite_7\NN\20090|of|the|major|cocaine (r_nmod) potential_3\NN\14481929|the|metabolite (r_dobj) evaluated_1\VBD\670261|we|potential|cause|. (l_xcomp) cause_17\VB\1617192|to|seizures (l_dobj) seizures_18\NNS\14081375|
C005618_D012640 CID be-induced_0\JJ\1740| (r_amod) seizures_1\NNS\14081375|be-induced
C005618_D012640 CID be_21\NN\14625458|by (r_nmod) induced_19\VBN\1627355|be (r_acl) those_18\DT\1740|induced (r_nsubj) prolonged_23\JJ\1740|characterized|,|those|were|,|multiple|,|and|resulted|. (l_advcl) characterized_5\VBN\609683|whereas|seizures|were|best|brief|and|resulted (l_nsubjpass) seizures_2\NNS\14081375|cocaine-induced
C005618_D012640 CID be-injected_0\JJ\1740| (r_amod) rats_1\NNS\2329401|be-injected|have (r_nsubj) had_7\VBD\2108377|rats|seizures|activity|. (l_nsubj) seizures_6\NNS\14081375|
C005618_D012640 CID be-injected_0\JJ\1740| (r_amod) rats_1\NNS\2329401|be-injected|have (r_nsubj) had_7\VBD\2108377|rats|seizures|activity|. (l_dobj) activity_11\NN\30358|more|locomotor|animals (l_nmod) animals_14\NNS\4475|than|cocaine-injected|seizures (l_nmod) seizures_16\NNS\14081375|without
C005618_D012640 CID be-induced_5\JJ\1740| (r_conj) cocaine-_3\NN\1740|and|be-induced|seizures (l_dep) seizures_6\NNS\14081375|
C005618_D012640 CID be-induced_5\JJ\1740| (r_conj) cocaine-_3\NN\1740|and|be-induced|seizures (r_nsubj) differ_7\VBP\1740|that|cocaine-|respects (r_ccomp) finding_1\NN\43195|the|differ (r_nsubj) suggests_11\VBZ\1010118|finding|mechanism|and|emphasizes|. (l_dobj) mechanism_15\NN\13446390|one|seizures (l_nmod) seizures_18\NNS\14081375|for|cocaine-induced
C005618_D012640 CID be_28\NN\14625458| (r_appos) metabolite_26\NN\20090|of|a|cocaine|,|be (r_nmod) importance_22\NN\5138488|the|metabolite (r_dobj) emphasizes_20\VBZ\943837|importance (r_conj) suggests_11\VBZ\1010118|finding|mechanism|and|emphasizes|. (l_nsubj) finding_1\NN\43195|the|differ (l_ccomp) differ_7\VBP\1740|that|cocaine-|respects (l_nsubj) cocaine-_3\NN\1740|and|be-induced|seizures (l_dep) seizures_6\NNS\14081375|
C005618_D012640 CID be_28\NN\14625458| (r_appos) metabolite_26\NN\20090|of|a|cocaine|,|be (r_nmod) importance_22\NN\5138488|the|metabolite (r_dobj) emphasizes_20\VBZ\943837|importance (r_conj) suggests_11\VBZ\1010118|finding|mechanism|and|emphasizes|. (l_dobj) mechanism_15\NN\13446390|one|seizures (l_nmod) seizures_18\NNS\14081375|for|cocaine-induced
D003042_D020521 NONE cocaine_6\NN\3492717|of (r_nmod) half-life_1\NN\15113229|the|t1/2|cocaine (r_nsubj) short_9\JJ\1740|half-life|is|relatively|,|but|occur (l_conj) occur_27\VB\2623529|some|can|hours|exposure|. (l_nsubj) some_12\DT\1740|consequences|, (l_nmod) consequences_15\NNS\34213|of|the|use|,|seizures (l_nmod) seizures_22\NNS\14081375|such|and|strokes (l_conj) strokes_24\NNS\556313|
D003042_D003643 NONE cocaine-induced_1\JJ\1740| (r_amod) seizures_2\NNS\14081375|cocaine-induced (r_nsubjpass) characterized_5\VBN\609683|whereas|seizures|were|best|brief|and|resulted (l_conj) resulted_14\VBD\2633881|death (l_nmod) death_16\NN\7296428|in
D003042_D003643 NONE cocaine-induced_1\JJ\1740| (r_amod) seizures_2\NNS\14081375|cocaine-induced (r_nsubjpass) characterized_5\VBN\609683|whereas|seizures|were|best|brief|and|resulted (r_advcl) prolonged_23\JJ\1740|characterized|,|those|were|,|multiple|,|and|resulted|. (l_conj) resulted_34\VBD\2633881|rarely|death (l_nmod) death_36\NN\7296428|in
C005618_D003643 NONE be_21\NN\14625458|by (r_nmod) induced_19\VBN\1627355|be (r_acl) those_18\DT\1740|induced (r_nsubj) prolonged_23\JJ\1740|characterized|,|those|were|,|multiple|,|and|resulted|. (l_advcl) characterized_5\VBN\609683|whereas|seizures|were|best|brief|and|resulted (l_conj) resulted_14\VBD\2633881|death (l_nmod) death_16\NN\7296428|in
C005618_D003643 NONE be_21\NN\14625458|by (r_nmod) induced_19\VBN\1627355|be (r_acl) those_18\DT\1740|induced (r_nsubj) prolonged_23\JJ\1740|characterized|,|those|were|,|multiple|,|and|resulted|. (l_conj) resulted_34\VBD\2633881|rarely|death (l_nmod) death_36\NN\7296428|in
1867351
D015767_D008288 NONE mefloquine_10\NN\2721948|with (r_nmod) treatment_8\NN\654885|mefloquine (r_conj) prophylaxis_6\NN\1077350|for|malaria|and|treatment (l_compound) malaria_5\NN\14178913|
21029050
D013390_D001049 CID succinylcholine_9\NN\3800001|after|therapy (r_nmod) patients_4\NNS\9898892|in|apnea|succinylcholine (l_nmod) apnea_7\NN\14299637|with|prolonged
D013390_D001049 CID succinylcholine_13\NN\3800001|of (r_nmod) action_11\NN\30358|of|succinylcholine (r_nmod) duration_9\NN\15113229|with|a|prolonged|action (r_nmod) patients_5\NNS\9898892|of|13|duration (r_nmod) eleven_2\CD\13745420|patients (r_nsubj) had_14\VBD\2108377|eleven|mutations|,|indicating|. (l_advcl) indicating_19\VBG\952524|reason (l_ccomp) reason_25\NN\9178821|that|this|is|the|possible|period (l_nmod) period_29\NN\13575869|for|a|prolonged|apnea (l_nmod) apnea_31\NN\14299637|of
322550
D009599_D007022 CID nitroprusside-induced_8\JJ\1740| (r_amod) hypotension_9\NN\14057371|during|nitroprusside-induced
D009599_D007022 CID nitroprusside_5\NN\1740| (r_compound) infusion_6\NN\14589223|before|nitroprusside (r_nmod) cpap_3\NN\1740|cm|h2o|infusion (r_nsubj) produced_7\VBD\1617192|cpap|decrease|and|increased|. (l_dobj) decrease_10\NN\7296428|a|further|pressure (l_nmod) pressure_14\NN\11419404|in|arterial|blood
D009599_D007022 CID nitroprusside_0\NNP\1740| (r_nsubj) caused_1\VBD\1617192|nitroprusside|decreases|and|increases|,|but|change|. (l_dobj) decreases_3\NNS\7296428|significant|pressure (l_nmod) pressure_7\NN\11419404|in|arterial|blood|and|resistance
D009599_D007022 NONE nitroprusside_1\NN\1740| (r_amod) levels_4\NNS\4916342|during|nitroprusside|infusion|low|cpap (r_nmod) alter_10\VB\126264|levels|do|not|markedly|dynamics|,|but|levels|,|decreasing|. (l_advcl) decreasing_26\VBG\169651|while|qs/qt|,|produce (l_conj) produce_29\VB\1617192|decreases (l_dobj) decreases_31\NNS\7296428|marked|pressure (l_nmod) pressure_35\NN\11419404|in|arterial|blood|and|output (l_conj) output_38\NN\4007894|cardiac
D014867_D007022 NONE h2o_2\NN\14618834| (r_compound) cpap_3\NN\1740|cm|h2o|infusion (r_nsubj) produced_7\VBD\1617192|cpap|decrease|and|increased|. (l_dobj) decrease_10\NN\7296428|a|further|pressure (l_nmod) pressure_14\NN\11419404|in|arterial|blood
D014867_D007022 NONE h2o_22\NN\14618834| (r_dep) cm_21\NNS\13649268|(|10|h2o|) (r_dep) levels_16\NNS\4916342|high|cpap|cm (r_dobj) alter_10\VB\126264|levels|do|not|markedly|dynamics|,|but|levels|,|decreasing|. (l_advcl) decreasing_26\VBG\169651|while|qs/qt|,|produce (l_conj) produce_29\VB\1617192|decreases (l_dobj) decreases_31\NNS\7296428|marked|pressure (l_nmod) pressure_35\NN\11419404|in|arterial|blood|and|output (l_conj) output_38\NN\4007894|cardiac
D014867_D002303 NONE h2o_2\NN\14618834| (r_compound) cpap_3\NN\1740|cm|h2o|infusion (r_nsubj) produced_7\VBD\1617192|cpap|decrease|and|increased|. (l_conj) increased_17\VBD\169651|significantly|rate|and|decreased (l_conj) decreased_21\VBD\169651|output (l_dobj) output_23\NN\4007894|cardiac|and|qs/qt
D014867_D002303 NONE h2o_22\NN\14618834| (r_dep) cm_21\NNS\13649268|(|10|h2o|) (r_dep) levels_16\NNS\4916342|high|cpap|cm (r_dobj) alter_10\VB\126264|levels|do|not|markedly|dynamics|,|but|levels|,|decreasing|. (l_advcl) decreasing_26\VBG\169651|while|qs/qt|,|produce (l_conj) produce_29\VB\1617192|decreases (l_dobj) decreases_31\NNS\7296428|marked|pressure (l_nmod) pressure_35\NN\11419404|in|arterial|blood|and|output (l_conj) output_38\NN\4007894|cardiac
D009599_D002303 NONE nitroprusside_5\NN\1740| (r_compound) infusion_6\NN\14589223|before|nitroprusside (r_nmod) cpap_3\NN\1740|cm|h2o|infusion (r_nsubj) produced_7\VBD\1617192|cpap|decrease|and|increased|. (l_conj) increased_17\VBD\169651|significantly|rate|and|decreased (l_conj) decreased_21\VBD\169651|output (l_dobj) output_23\NN\4007894|cardiac|and|qs/qt
D009599_D002303 NONE nitroprusside_1\NN\1740| (r_amod) levels_4\NNS\4916342|during|nitroprusside|infusion|low|cpap (r_nmod) alter_10\VB\126264|levels|do|not|markedly|dynamics|,|but|levels|,|decreasing|. (l_advcl) decreasing_26\VBG\169651|while|qs/qt|,|produce (l_conj) produce_29\VB\1617192|decreases (l_dobj) decreases_31\NNS\7296428|marked|pressure (l_nmod) pressure_35\NN\11419404|in|arterial|blood|and|output (l_conj) output_38\NN\4007894|cardiac
3031535
D013759_D002375 CID 9-tetrahydrocannabinol_7\NN\1740|delta (r_nmod) induced_4\VBN\1627355|9-tetrahydrocannabinol (r_acl) catalepsy_3\NN\14023236|in|induced
D013759_D002375 CID thc_17\NN\4017137|by (r_nmod) induced_15\VBN\1627355|thc (r_acl) catalepsy_14\NN\14023236|of|induced
D013759_D002375 CID thc_17\NN\4017137|by (r_nmod) induced_15\VBN\1627355|thc (r_acl) catalepsy_14\NN\14023236|of|induced (r_nmod) manifestation_12\NN\7321772|in|the|catalepsy (r_nmod) role_9\NN\719494|an|important|manifestation (r_dobj) have_6\VBP\2108377|that|neurons|role|,|important (l_advcl) important_23\JJ\1740|whereas|neurons|are|catalepsy (l_nmod) catalepsy_25\NN\14023236|in|induced
D006220_D002375 CID haloperidol_28\NN\3713736|by (r_nmod) induced_26\VBN\1627355|haloperidol (r_acl) catalepsy_25\NN\14023236|in|induced (r_nmod) important_23\JJ\1740|whereas|neurons|are|catalepsy (r_advcl) have_6\VBP\2108377|that|neurons|role|,|important (l_dobj) role_9\NN\719494|an|important|manifestation (l_nmod) manifestation_12\NN\7321772|in|the|catalepsy (l_nmod) catalepsy_14\NN\14023236|of|induced
D006220_D002375 CID haloperidol_28\NN\3713736|by (r_nmod) induced_26\VBN\1627355|haloperidol (r_acl) catalepsy_25\NN\14023236|in|induced
9284778
-1_D008107 NONE hydrochlorofluorocarbons_6\NNS\14603497|by|used (r_nmod) caused_4\VBN\1617192|hydrochlorofluorocarbons (r_acl) epidemic_0\NN\7435273|disease|caused|. (l_nmod) disease_3\NN\14061805|of|liver
D010126_D008107 NONE ozone-sparing_9\JJ\1740| (r_amod) substitutes_10\NNS\5695554|as|ozone-sparing|chlorofluorocarbons (r_nmod) used_7\VBN\1156834|substitutes (r_acl) hydrochlorofluorocarbons_6\NNS\14603497|by|used (r_nmod) caused_4\VBN\1617192|hydrochlorofluorocarbons (r_acl) epidemic_0\NN\7435273|disease|caused|. (l_nmod) disease_3\NN\14061805|of|liver
D017402_D008107 NONE chlorofluorocarbons_12\NNS\14871968|of (r_nmod) substitutes_10\NNS\5695554|as|ozone-sparing|chlorofluorocarbons (r_nmod) used_7\VBN\1156834|substitutes (r_acl) hydrochlorofluorocarbons_6\NNS\14603497|by|used (r_nmod) caused_4\VBN\1617192|hydrochlorofluorocarbons (r_acl) epidemic_0\NN\7435273|disease|caused|. (l_nmod) disease_3\NN\14061805|of|liver
C067411_D008107 CID 1,1-dichloro-2,2,2-trifluoroethane_21\NN\1740|of|hcfc|and|1-chloro-1,2,2,2-tetrafluoroethane (r_nmod) mixture_19\NN\19613|to|a|1,1-dichloro-2,2,2-trifluoroethane (r_nmod) exposure_16\NN\5042871|accidental|mixture (r_dobj) repeated_14\VBN\952524|who|had|had|exposure (r_acl:relcl) disease_6\NN\14061805|of|liver|workers|repeated
C067411_D008107 CID 123_24\CD\1740| (r_nummod) hcfc_23\NN\14603497|(|123|) (r_appos) 1,1-dichloro-2,2,2-trifluoroethane_21\NN\1740|of|hcfc|and|1-chloro-1,2,2,2-tetrafluoroethane (r_nmod) mixture_19\NN\19613|to|a|1,1-dichloro-2,2,2-trifluoroethane (r_nmod) exposure_16\NN\5042871|accidental|mixture (r_dobj) repeated_14\VBN\952524|who|had|had|exposure (r_acl:relcl) disease_6\NN\14061805|of|liver|workers|repeated
C067411_D008107 CID 124_8\CD\1740| (r_conj) hcfcs_5\NNS\14603497|123|and|124 (r_nsubj) result_10\VB\2633881|whether|hcfcs|can|disease (l_nmod) disease_14\NN\14061805|in|serious|liver
C072959_D008107 CID 1-chloro-1,2,2,2-tetrafluoroethane_27\NN\1740|hcfc (r_conj) 1,1-dichloro-2,2,2-trifluoroethane_21\NN\1740|of|hcfc|and|1-chloro-1,2,2,2-tetrafluoroethane (r_nmod) mixture_19\NN\19613|to|a|1,1-dichloro-2,2,2-trifluoroethane (r_nmod) exposure_16\NN\5042871|accidental|mixture (r_dobj) repeated_14\VBN\952524|who|had|had|exposure (r_acl:relcl) disease_6\NN\14061805|of|liver|workers|repeated
C072959_D008107 CID 124_30\CD\1740| (r_nummod) hcfc_29\NN\14603497|(|124|) (r_appos) 1-chloro-1,2,2,2-tetrafluoroethane_27\NN\1740|hcfc (r_conj) 1,1-dichloro-2,2,2-trifluoroethane_21\NN\1740|of|hcfc|and|1-chloro-1,2,2,2-tetrafluoroethane (r_nmod) mixture_19\NN\19613|to|a|1,1-dichloro-2,2,2-trifluoroethane (r_nmod) exposure_16\NN\5042871|accidental|mixture (r_dobj) repeated_14\VBN\952524|who|had|had|exposure (r_acl:relcl) disease_6\NN\14061805|of|liver|workers|repeated
C072959_D008107 CID 124_8\CD\1740| (r_conj) hcfcs_5\NNS\14603497|123|and|124 (r_nsubj) result_10\VB\2633881|whether|hcfcs|can|disease (l_nmod) disease_14\NN\14061805|in|serious|liver
D006221_D056486 NONE 1-bromo-1-chloro-2,2,2-trifluoroethane_9\NN\1740|as|halothane (r_nmod) way_7\NN\4916342|in|the|same|1-bromo-1-chloro-2,2,2-trifluoroethane (r_nmod) metabolised_3\VBN\1740|compounds|are|way|form|. (l_xcomp) form_14\VB\1617192|to|intermediates (l_dobj) intermediates_18\NNS\14806838|reactive|halide|,|implicated (l_acl:relcl) implicated_23\VBN\2677097|which|have|been|hepatotoxicity (l_nmod) hepatotoxicity_26\NN\1740|in|the|halothane
D006221_D056486 NONE halothane_11\NN\3570838|(|) (r_appos) 1-bromo-1-chloro-2,2,2-trifluoroethane_9\NN\1740|as|halothane (r_nmod) way_7\NN\4916342|in|the|same|1-bromo-1-chloro-2,2,2-trifluoroethane (r_nmod) metabolised_3\VBN\1740|compounds|are|way|form|. (l_xcomp) form_14\VB\1617192|to|intermediates (l_dobj) intermediates_18\NNS\14806838|reactive|halide|,|implicated (l_acl:relcl) implicated_23\VBN\2677097|which|have|been|hepatotoxicity (l_nmod) hepatotoxicity_26\NN\1740|in|the|halothane
D006221_D056486 NONE halothane_28\NN\3570838|of (r_nmod) hepatotoxicity_26\NN\1740|in|the|halothane
D014269_D056486 NONE trifluoroacetyl_16\NN\1740| (r_compound) halide_17\NN\15010703|trifluoroacetyl (r_compound) intermediates_18\NNS\14806838|reactive|halide|,|implicated (l_acl:relcl) implicated_23\VBN\2677097|which|have|been|hepatotoxicity (l_nmod) hepatotoxicity_26\NN\1740|in|the|halothane
D014269_D056486 NONE trifluoroacetyl-altered_17\JJ\1740| (r_amod) proteins_19\NNS\14944888|trifluoroacetyl-altered|liver (r_nsubjpass) involved_21\VBN\2676054|that|proteins|are (r_ccomp) suggest_15\VBP\1010118|known|,|results|involved|. (l_advcl) known_11\VBN\2110220|although|mechanism|is|not (l_nsubjpass) mechanism_3\NN\13446390|the|exact|hepatotoxicity (l_nmod) hepatotoxicity_5\NN\1740|of|agents
C067411_D056486 NONE 124_11\CD\1740| (r_conj) hcfcs_8\NNS\14603497|to|123|and|124 (r_nmod) exposure_3\NN\5042871|repeated|beings|hcfcs (r_nsubj) result_13\VB\2633881|exposure|can|injury|. (l_nmod) injury_17\NN\14052046|in|serious|liver|proportion
C072959_D056486 NONE 124_11\CD\1740| (r_conj) hcfcs_8\NNS\14603497|to|123|and|124 (r_nmod) exposure_3\NN\5042871|repeated|beings|hcfcs (r_nsubj) result_13\VB\2633881|exposure|can|injury|. (l_nmod) injury_17\NN\14052046|in|serious|liver|proportion
8752018
D008094_D003072 CID lithium-associated_0\JJ\1740| (r_amod) cognitive_1\JJ\1740|lithium-associated|and|functional|deficits|:|series|. (l_dep) deficits_4\NNS\5113133|reduced
D008094_D003072 CID lithium_15\NN\14625458|of|, (r_nmod) effects_13\NNS\13245626|of|the|common|adverse|lithium|polyuria (r_nmod) management_7\NN\1123598|about|the|effects|, (r_nmod) written_4\VBN\1697816|although|much|has|been|management (r_advcl) remain_40\VBP\2604760|written|effects|understudied|. (l_nsubj) effects_27\NNS\13245626|subtle|lithium|side|deficits (l_nmod) deficits_31\NNS\5113133|such|cognitive|,|loss|,|and|impairments
D008094_D003072 CID lithium_15\NN\14625458|of|, (r_nmod) effects_13\NNS\13245626|of|the|common|adverse|lithium|polyuria (r_nmod) management_7\NN\1123598|about|the|effects|, (r_nmod) written_4\VBN\1697816|although|much|has|been|management (r_advcl) remain_40\VBP\2604760|written|effects|understudied|. (l_nsubj) effects_27\NNS\13245626|subtle|lithium|side|deficits (l_nmod) deficits_31\NNS\5113133|such|cognitive|,|loss|,|and|impairments (l_conj) loss_33\NN\13252973|creativity (l_nmod) creativity_35\NN\5616246|of
D008094_D003072 CID lithium_15\NN\14625458|of|, (r_nmod) effects_13\NNS\13245626|of|the|common|adverse|lithium|polyuria (r_nmod) management_7\NN\1123598|about|the|effects|, (r_nmod) written_4\VBN\1697816|although|much|has|been|management (r_advcl) remain_40\VBP\2604760|written|effects|understudied|. (l_nsubj) effects_27\NNS\13245626|subtle|lithium|side|deficits (l_nmod) deficits_31\NNS\5113133|such|cognitive|,|loss|,|and|impairments (l_conj) impairments_39\NNS\7296428|functional
D008094_D003072 CID lithium_25\NN\14625458| (r_compound) effects_27\NNS\13245626|subtle|lithium|side|deficits (l_nmod) deficits_31\NNS\5113133|such|cognitive|,|loss|,|and|impairments
D008094_D003072 CID lithium_25\NN\14625458| (r_compound) effects_27\NNS\13245626|subtle|lithium|side|deficits (l_nmod) deficits_31\NNS\5113133|such|cognitive|,|loss|,|and|impairments (l_conj) loss_33\NN\13252973|creativity (l_nmod) creativity_35\NN\5616246|of
D008094_D003072 CID lithium_25\NN\14625458| (r_compound) effects_27\NNS\13245626|subtle|lithium|side|deficits (l_nmod) deficits_31\NNS\5113133|such|cognitive|,|loss|,|and|impairments (l_conj) impairments_39\NNS\7296428|functional
D008094_D003072 CID lithium_10\NN\14625458|from (r_nmod) patients_8\NNS\9898892|bipolar|lithium (r_dobj) switching_6\VBG\138508|in|patients|divalproex (r_advcl) summarizes_2\VBZ\958334|report|experience|switching|alleviate|. (l_advcl) alleviate_15\VB\205885|to|impairments (l_dobj) impairments_20\NNS\7296428|such|cognitive
D008094_D003072 CID lithium_9\NN\14625458|of (r_nmod) substitution_7\NN\7337390|where|lithium|,|fully (r_acl:relcl) cases_5\NNS\7283608|seven|substitution (r_dobj) report_3\VBP\831651|:|we|cases|,|helpful|. (l_conj) helpful_21\JJ\1740|sodium|was|extremely|reducing (l_advcl) reducing_23\VBG\441445|in|cognitive (l_dobj) cognitive_25\JJ\1740|the|,|motivational|,|or|creative|deficits (l_dep) deficits_31\NNS\5113133|attributed
D008094_D003072 CID lithium_34\NN\14625458|to (r_nmod) attributed_32\VBN\670261|lithium|patients (r_acl) deficits_31\NNS\5113133|attributed
D008094_D003072 CID lithium_14\NN\14625458|to (r_nmod) alternative_12\NN\5788149|report|,|sodium|was|a|superior|lithium|patients (l_nmod) patients_17\NNS\9898892|in|bipolar|experiencing (l_acl) experiencing_18\VBG\2108377|deficits (l_dobj) deficits_20\NNS\5113133|cognitive|,|loss|,|and|impairments
D008094_D003072 CID lithium_14\NN\14625458|to (r_nmod) alternative_12\NN\5788149|report|,|sodium|was|a|superior|lithium|patients (l_nmod) patients_17\NNS\9898892|in|bipolar|experiencing (l_acl) experiencing_18\VBG\2108377|deficits (l_dobj) deficits_20\NNS\5113133|cognitive|,|loss|,|and|impairments (l_conj) loss_22\NN\13252973|creativity (l_nmod) creativity_24\NN\5616246|of
D008094_D003072 CID lithium_14\NN\14625458|to (r_nmod) alternative_12\NN\5788149|report|,|sodium|was|a|superior|lithium|patients (l_nmod) patients_17\NNS\9898892|in|bipolar|experiencing (l_acl) experiencing_18\VBG\2108377|deficits (l_dobj) deficits_20\NNS\5113133|cognitive|,|loss|,|and|impairments (l_conj) impairments_28\NNS\7296428|functional
D014635_D003072 NONE sodium_11\NN\14625458|to|divalproex (r_nmod) switch_8\NN\3096960|by|a|sodium (r_nmod) reduced_5\VBN\441445|switch (r_acl) deficits_4\NNS\5113133|reduced
D014635_D003072 NONE sodium_13\NN\14625458| (r_dobj) divalproex_12\JJ\1740|to|sodium (r_advcl) switching_6\VBG\138508|in|patients|divalproex (r_advcl) summarizes_2\VBZ\958334|report|experience|switching|alleviate|. (l_advcl) alleviate_15\VB\205885|to|impairments (l_dobj) impairments_20\NNS\7296428|such|cognitive
D014635_D003072 NONE sodium_18\NN\14625458|with|divalproex (r_nsubj) helpful_21\JJ\1740|sodium|was|extremely|reducing (l_advcl) reducing_23\VBG\441445|in|cognitive (l_dobj) cognitive_25\JJ\1740|the|,|motivational|,|or|creative|deficits (l_dep) deficits_31\NNS\5113133|attributed
D014635_D003072 NONE sodium_8\NN\14625458|divalproex (r_nsubj) alternative_12\NN\5788149|report|,|sodium|was|a|superior|lithium|patients (l_nmod) patients_17\NNS\9898892|in|bipolar|experiencing (l_acl) experiencing_18\VBG\2108377|deficits (l_dobj) deficits_20\NNS\5113133|cognitive|,|loss|,|and|impairments
D014635_D003072 NONE sodium_8\NN\14625458|divalproex (r_nsubj) alternative_12\NN\5788149|report|,|sodium|was|a|superior|lithium|patients (l_nmod) patients_17\NNS\9898892|in|bipolar|experiencing (l_acl) experiencing_18\VBG\2108377|deficits (l_dobj) deficits_20\NNS\5113133|cognitive|,|loss|,|and|impairments (l_conj) loss_22\NN\13252973|creativity (l_nmod) creativity_24\NN\5616246|of
D014635_D003072 NONE sodium_8\NN\14625458|divalproex (r_nsubj) alternative_12\NN\5788149|report|,|sodium|was|a|superior|lithium|patients (l_nmod) patients_17\NNS\9898892|in|bipolar|experiencing (l_acl) experiencing_18\VBG\2108377|deficits (l_dobj) deficits_20\NNS\5113133|cognitive|,|loss|,|and|impairments (l_conj) impairments_28\NNS\7296428|functional
D008094_D001714 NONE lithium_2\NNP\14625458| (r_nsubj) remains_3\VBZ\2604760|background|lithium|treatment|. (l_dobj) treatment_6\NN\654885|a|first-line|treatment (l_nmod) treatment_12\NN\654885|for|the|acute|disorder (l_nmod) disorder_15\NN\14034177|of|bipolar
D008094_D001714 NONE lithium_10\NN\14625458|from (r_nmod) patients_8\NNS\9898892|bipolar|lithium (l_amod) bipolar_7\JJ\1740|
D008094_D001714 NONE lithium_9\NN\14625458|of (r_nmod) substitution_7\NN\7337390|where|lithium|,|fully (r_acl:relcl) cases_5\NNS\7283608|seven|substitution (r_dobj) report_3\VBP\831651|:|we|cases|,|helpful|. (l_conj) helpful_21\JJ\1740|sodium|was|extremely|reducing (l_advcl) reducing_23\VBG\441445|in|cognitive (l_dobj) cognitive_25\JJ\1740|the|,|motivational|,|or|creative|deficits (l_dep) deficits_31\NNS\5113133|attributed (l_acl) attributed_32\VBN\670261|lithium|patients (l_nmod) patients_38\NNS\9898892|in|our|bipolar (l_amod) bipolar_37\JJ\1740|
D008094_D001714 NONE lithium_34\NN\14625458|to (r_nmod) attributed_32\VBN\670261|lithium|patients (l_nmod) patients_38\NNS\9898892|in|our|bipolar (l_amod) bipolar_37\JJ\1740|
D008094_D001714 NONE lithium_14\NN\14625458|to (r_nmod) alternative_12\NN\5788149|report|,|sodium|was|a|superior|lithium|patients (l_nmod) patients_17\NNS\9898892|in|bipolar|experiencing (l_amod) bipolar_16\JJ\1740|
D008094_D011141 NONE lithium_15\NN\14625458|of|, (r_nmod) effects_13\NNS\13245626|of|the|common|adverse|lithium|polyuria (l_nmod) polyuria_19\NN\14113228|such|and|tremor
D008094_D011141 NONE lithium_25\NN\14625458| (r_compound) effects_27\NNS\13245626|subtle|lithium|side|deficits (r_nsubj) remain_40\VBP\2604760|written|effects|understudied|. (l_advcl) written_4\VBN\1697816|although|much|has|been|management (l_nmod) management_7\NN\1123598|about|the|effects|, (l_nmod) effects_13\NNS\13245626|of|the|common|adverse|lithium|polyuria (l_nmod) polyuria_19\NN\14113228|such|and|tremor
D008094_D014202 NONE lithium_15\NN\14625458|of|, (r_nmod) effects_13\NNS\13245626|of|the|common|adverse|lithium|polyuria (l_nmod) polyuria_19\NN\14113228|such|and|tremor (l_conj) tremor_21\NN\345926|
D008094_D014202 NONE lithium_25\NN\14625458| (r_compound) effects_27\NNS\13245626|subtle|lithium|side|deficits (r_nsubj) remain_40\VBP\2604760|written|effects|understudied|. (l_advcl) written_4\VBN\1697816|although|much|has|been|management (l_nmod) management_7\NN\1123598|about|the|effects|, (l_nmod) effects_13\NNS\13245626|of|the|common|adverse|lithium|polyuria (l_nmod) polyuria_19\NN\14113228|such|and|tremor (l_conj) tremor_21\NN\345926|
D014635_D001714 NONE sodium_13\NN\14625458| (r_dobj) divalproex_12\JJ\1740|to|sodium (r_advcl) switching_6\VBG\138508|in|patients|divalproex (l_dobj) patients_8\NNS\9898892|bipolar|lithium (l_amod) bipolar_7\JJ\1740|
D014635_D001714 NONE sodium_18\NN\14625458|with|divalproex (r_nsubj) helpful_21\JJ\1740|sodium|was|extremely|reducing (l_advcl) reducing_23\VBG\441445|in|cognitive (l_dobj) cognitive_25\JJ\1740|the|,|motivational|,|or|creative|deficits (l_dep) deficits_31\NNS\5113133|attributed (l_acl) attributed_32\VBN\670261|lithium|patients (l_nmod) patients_38\NNS\9898892|in|our|bipolar (l_amod) bipolar_37\JJ\1740|
D014635_D001714 NONE sodium_8\NN\14625458|divalproex (r_nsubj) alternative_12\NN\5788149|report|,|sodium|was|a|superior|lithium|patients (l_nmod) patients_17\NNS\9898892|in|bipolar|experiencing (l_amod) bipolar_16\JJ\1740|
7516729
D014700_D001919 CID verapamil_4\NN\2938514|by (r_nmod) induced_2\VBN\1627355|verapamil (r_acl) bradycardia_1\NN\14110674|dose-dependent|induced
6727060
D008787_D004409 CID metoclopramide_7\NN\1740|by (r_nmod) caused_5\VBN\1617192|metoclopramide (r_acl) dyskinesia_4\NN\14084880|of|tardive|caused
D008787_D004409 CID metoclopramide_21\NN\1740| (r_dobj) took_20\VBD\2367363|after|he|metoclopramide|disorder|regimen (r_advcl) appeared_3\VBD\2604760|movements|mouth|took|. (l_nsubj) movements_2\NNS\191142|abnormal
D008787_D004409 CID metoclopramide_2\NN\1740| (r_compound) administration_3\NN\1133281|the|metoclopramide (r_nsubjpass) discontinued_5\VBN\2609764|when|administration|was (r_advcl) improved_11\VBD\126264|discontinued|,|movements|gradually|extent|. (l_nsubj) movements_9\NNS\191142|the|abnormal
D008787_D005767 NONE metoclopramide_21\NN\1740| (r_dobj) took_20\VBD\2367363|after|he|metoclopramide|disorder|regimen (l_nmod) disorder_24\NN\14034177|for|gastrointestinal
983936
D001241_D009202 NONE acid_3\NN\14818238|of|acetylsalicylic|,|dipyridamole|,|and|hydrocortisone (l_conj) hydrocortisone_8\NN\14751417|injury (l_nmod) injury_12\NN\14052046|on|epinephrine-induced|myocardial|dogs
D004176_D009202 NONE dipyridamole_5\NN\1740| (r_conj) acid_3\NN\14818238|of|acetylsalicylic|,|dipyridamole|,|and|hydrocortisone (l_conj) hydrocortisone_8\NN\14751417|injury (l_nmod) injury_12\NN\14052046|on|epinephrine-induced|myocardial|dogs
D006854_D009202 NONE hydrocortisone_8\NN\14751417|injury (l_nmod) injury_12\NN\14052046|on|epinephrine-induced|myocardial|dogs
D004837_D009202 CID epinephrine-induced_10\JJ\1740| (r_amod) injury_12\NN\14052046|on|epinephrine-induced|myocardial|dogs
D004837_D009202 CID epinephrine_9\NN\14807929| (r_compound) infusion_10\NN\14589223|(|epinephrine|) (r_appos) injury_7\NN\14052046|diffuse|myocardial|infusion
D004837_D009203 NONE epinephrine_9\NN\14807929| (r_compound) infusion_10\NN\14589223|(|epinephrine|) (r_appos) injury_7\NN\14052046|diffuse|myocardial|infusion (r_dobj) producing_4\VBG\1617192|for|injury (r_acl) model_2\NN\5888929|a|reproducible|producing (r_nsubjpass) developed_14\VBN\1753788|model|has|been|study|. (l_xcomp) study_16\VB\630380|to|effects (l_dobj) effects_19\NNS\13245626|the|cardioprotective|agents (l_nmod) agents_21\NNS\7347|of|or|maneuvers|alter (l_acl:relcl) alter_26\VB\126264|which|might|evolution (l_dobj) evolution_28\NN\29677|the|infarction (l_nmod) infarction_32\NN\14204950|of|acute|myocardial
11431197
D011899_D009395 CID ranitidine-induced_0\JJ\1740| (r_amod) nephritis_3\NN\14113228|ranitidine-induced|acute|interstitial|allograft|.
D011899_D009395 CID ranitidine-induced_5\JJ\1740| (r_amod) nephritis_8\NN\14113228|of|ranitidine-induced|acute|interstitial
12757899
D004958_D012640 NONE estradiol_0\NN\14749794| (r_nsubj) reduces_1\VBZ\441445|estradiol|injury|female|. (l_dobj) injury_4\NN\14052046|seizure-induced|hippocampal (l_amod) seizure-induced_2\JJ\1740|
D004958_D012640 NONE estradiol_7\NN\14749794|of (r_nmod) effects_5\NNS\13245626|the|estradiol|threshold (l_nmod) threshold_10\NN\15265518|on|seizure|and|damage (l_amod) seizure_9\JJ\1740|
D004958_D001930 NONE estradiol_0\NN\14749794| (r_nsubj) reduces_1\VBZ\441445|estradiol|injury|female|. (l_dobj) injury_4\NN\14052046|seizure-induced|hippocampal
D007608_D001930 NONE acid-induced_10\JJ\1740|kainic (r_amod) epilepticus_12\NN\1740|by|acid-induced|status|se (r_nmod) induced_7\VBN\1627355|epilepticus (r_acl) injury_6\NN\14052046|from|hippocampal|induced
D007608_D013226 NONE acid-induced_10\JJ\1740|kainic (r_amod) epilepticus_12\NN\1740|by|acid-induced|status|se
D007608_D013226 NONE acid-induced_10\JJ\1740|kainic (r_amod) epilepticus_12\NN\1740|by|acid-induced|status|se (l_appos) se_14\NN\14724645|(|)
D004958_D013226 NONE 17beta-estradiol_5\NN\1740|of (r_nmod) effects_3\NNS\13245626|the|17beta-estradiol|rats (l_nmod) rats_12\NNS\2329401|male|female|subjected (l_acl) subjected_13\VBN\137313|se (l_nmod) se_16\NN\14724645|to|lithium-pilocarpine-induced
D008094_D013226 CID lithium-pilocarpine-induced_15\JJ\1740| (r_amod) se_16\NN\14724645|to|lithium-pilocarpine-induced
D010862_D013226 CID lithium-pilocarpine-induced_15\JJ\1740| (r_amod) se_16\NN\14724645|to|lithium-pilocarpine-induced
D012834_D013226 NONE silver-stained_3\JJ\1740| (r_amod) ca3_4\NN\1740|of|silver-stained|and|ca1 (r_compound) neurons_8\NNS\5430628|ca3|hippocampal (r_nmod) extent_1\NN\13939892|the|neurons (r_nsubjpass) evaluated_10\VBN\670261|extent|was|days|se|. (l_nmod) se_14\NNP\14724645|after
8073369
C007112_D001176 CID coniine_2\NN\1740| (r_nsubj) failed_4\VBN\1798936|however|,|coniine|has|produce|and|teratogenic|. (l_xcomp) produce_6\VB\1617192|to|arthrogryposis (l_dobj) arthrogryposis_7\NN\1740|rats
C007112_D001176 CID coniine-induced_15\JJ\1740| (r_amod) arthrogryposis_16\NN\1740|of|coniine-induced
C007112_D009140 NONE coniine_5\NN\1740|by|both|and|sulfate (r_nmod) caused_2\VBN\1617192|coniine (r_acl) deformations_1\NNS\7420770|the|caused
C007112_D009140 NONE coniine_5\NN\1740|by|both|and|sulfate (r_nmod) caused_2\VBN\1617192|coniine (r_acl) deformations_1\NNS\7420770|the|caused (r_nsubj) flexion_11\NN\14034177|deformations|were|excessive|or|extension|toes|. (l_nmod) toes_18\NNS\5566097|of|one
D009538_D009140 NONE nicotine_7\NN\14712692| (r_compound) sulfate_8\NN\15010703|nicotine (r_conj) coniine_5\NN\1740|by|both|and|sulfate (r_nmod) caused_2\VBN\1617192|coniine (r_acl) deformations_1\NNS\7420770|the|caused
D009538_D009140 NONE nicotine_7\NN\14712692| (r_compound) sulfate_8\NN\15010703|nicotine (r_conj) coniine_5\NN\1740|by|both|and|sulfate (r_nmod) caused_2\VBN\1617192|coniine (r_acl) deformations_1\NNS\7420770|the|caused (r_nsubj) flexion_11\NN\14034177|deformations|were|excessive|or|extension|toes|. (l_nmod) toes_18\NNS\5566097|of|one
D009538_D002543 CID nicotine_30\NN\14712692| (r_nmod:npmod) sulfate-treated_31\JJ\1740|nicotine (r_amod) chicks_32\NNS\1791625|in|all|sulfate-treated (r_nmod) occurred_27\VBD\2623529|seen|,|hemorrhage|chicks|. (l_nsubj) hemorrhage_26\NN\14285662|extensive|cranial
15863244
C106876_D064420 NONE dfu_15\NN\1740|and|piroxicam (r_appos) comparison_0\NN\635850|toxicity|--|dfu (l_nmod) toxicity_3\NN\13576101|of|developmental|inhibitors|rats
C106876_D064420 NONE dfu_20\NN\1740|; (r_compound) phenyl-2(5h)-furanon_24\NN\1740|(|dfu|5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl|) (r_compound) inhibitors_27\NNS\20090|of|the|non-selective|phenyl-2(5h)-furanon|)|cox-2 (r_nmod) toxicity_10\NN\13576101|the|developmental|inhibitors
C106876_D064420 NONE phenyl-2(5h)-furanon_24\NN\1740|(|dfu|5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl|) (r_compound) inhibitors_27\NNS\20090|of|the|non-selective|phenyl-2(5h)-furanon|)|cox-2 (r_nmod) toxicity_10\NN\13576101|the|developmental|inhibitors
C106876_D064420 NONE dfu_10\NN\1740| (r_compound) toxicity_12\NN\13576101|of|the|dfu|developmental|observed
D010894_D064420 NONE piroxicam_17\NN\3828465| (r_conj) dfu_15\NN\1740|and|piroxicam (r_appos) comparison_0\NN\635850|toxicity|--|dfu (l_nmod) toxicity_3\NN\13576101|of|developmental|inhibitors|rats
D010894_D064420 NONE piroxicam_15\NNS\3828465|(|) (r_dep) non-selective_13\JJ\1740|piroxicam|and|selective (r_amod) inhibitors_27\NNS\20090|of|the|non-selective|phenyl-2(5h)-furanon|)|cox-2 (r_nmod) toxicity_10\NN\13576101|the|developmental|inhibitors
D010894_D064420 NONE piroxicam_26\NN\3828465|of (r_nmod) dose_24\NN\3740161|with|the|highest|piroxicam (r_nmod) treated_20\VBN\2376958|dose (r_acl) rats_19\NNS\2329401|in|treated (r_nmod) found_17\VBN\2426171|toxicity|were|rats|. (l_nsubjpass) toxicity_3\NN\13576101|maternal|,|retardation|,|and|increase
D010894_D006345 NONE piroxicam_23\VB\1740|to|,|selective (r_nmod) exposed_21\VBN\2110927|piroxicam (r_acl) fetuses_20\NNS\1471682|for|rat|exposed|inhibitor (r_nmod) performed_17\VBN\2367363|analysis|was|fetuses|. (l_nsubjpass) analysis_3\NN\633864|the|pooled|statistical|septal (l_nmod) septal_6\NN\1740|for|ventricular|vsd|and|midline|defects (l_conj) defects_15\NNS\14462666|
D010894_D009436 NONE piroxicam_23\VB\1740|to|,|selective (r_nmod) exposed_21\VBN\2110927|piroxicam (r_acl) fetuses_20\NNS\1471682|for|rat|exposed|inhibitor (r_nmod) performed_17\VBN\2367363|analysis|was|fetuses|. (l_nsubjpass) analysis_3\NN\633864|the|pooled|statistical|septal (l_nmod) septal_6\NN\1740|for|ventricular|vsd|and|midline|defects (l_conj) defects_15\NNS\14462666|
D010894_D005317 CID piroxicam_26\NN\3828465|of (r_nmod) dose_24\NN\3740161|with|the|highest|piroxicam (r_nmod) treated_20\VBN\2376958|dose (r_acl) rats_19\NNS\2329401|in|treated (r_nmod) found_17\VBN\2426171|toxicity|were|rats|. (l_nsubjpass) toxicity_3\NN\13576101|maternal|,|retardation|,|and|increase (l_conj) retardation_7\NN\7296428|intrauterine|growth
D010894_D009139 CID piroxicam_26\NN\3828465|of (r_nmod) dose_24\NN\3740161|with|the|highest|piroxicam (r_nmod) treated_20\VBN\2376958|dose (r_acl) rats_19\NNS\2329401|in|treated (r_nmod) found_17\VBN\2426171|toxicity|were|rats|. (l_nsubjpass) toxicity_3\NN\13576101|maternal|,|retardation|,|and|increase (l_conj) increase_10\NN\13576355|variations (l_nmod) variations_15\NNS\7296428|of|external
9495837
C087567_D000647 NONE (+/-)-pg-9_0\NN\1740|kg-1 (r_nsubj) able_10\JJ\1740|(+/-)-pg-9|was|prevent|. (l_xcomp) prevent_12\VB\1740|to|amnesia|kg-1|test (l_dobj) amnesia_13\NN\5669934|induced
C087567_D000647 NONE (+/-)-pg-9_3\NN\1740|of (r_nmod) profiles_1\NNS\6999802|affinity|(+/-)-pg-9|subtypes|,|determined|, (r_nsubj) shown_42\VBN\2137132|profiles|have|ratio|. (l_dobj) ratio_46\NN\13815152|an|m4/m1|selectivity|10.2|responsible (l_acl:relcl) responsible_52\JJ\1740|that|might|be|antinociception (l_nmod) antinociception_55\NN\1740|for|the|and|effect|induced (l_conj) effect_59\NN\34213|the|anti-amnesic (l_amod) anti-amnesic_58\JJ\1740|
C087567_D000647 NONE (+/-)-pg-9_62\NN\1740|by (r_nmod) induced_60\VBN\1627355|(+/-)-pg-9|increase (r_acl) antinociception_55\NN\1740|for|the|and|effect|induced (l_conj) effect_59\NN\34213|the|anti-amnesic (l_amod) anti-amnesic_58\JJ\1740|
D012601_D000647 CID scopolamine_16\NN\14712692|by (r_nmod) induced_14\VBN\1627355|scopolamine (r_acl) amnesia_13\NN\5669934|induced
D004025_D000647 CID dicyclomine_24\NN\1740|kg-1 (r_conj) kg-1_20\NN\1740|(|mg|i.p.|)|and|dicyclomine (r_dep) prevent_12\VB\1740|to|amnesia|kg-1|test (l_dobj) amnesia_13\NN\5669934|induced
D000109_D000647 NONE acetylcholine_67\NN\14807558| (r_amod) levels_69\NNS\4916342|in|acetylcholine|extracellular (r_nmod) increase_65\NN\13576355|through|an|levels (r_nmod) induced_60\VBN\1627355|(+/-)-pg-9|increase (r_acl) antinociception_55\NN\1740|for|the|and|effect|induced (l_conj) effect_59\NN\34213|the|anti-amnesic (l_amod) anti-amnesic_58\JJ\1740|
11875660
D001374_D009436 NONE 5-azacytidine_6\NN\1740|by (r_nmod) induced_4\VBN\1627355|5-azacytidine|day (r_acl) exencephaly_3\NN\1740|the|induced
17532790
D007980_D004409 CID l-dopa-induced_10\JJ\1740| (r_amod) dyskinesia_11\NN\14084880|of|l-dopa-induced
D007980_D004409 CID l-dopa-induced_0\VBN\1740| (r_amod) dyskinesia_1\NN\14084880|l-dopa-induced|lid|is|complications|.
D007980_D004409 CID l-dopa-induced_0\VBN\1740| (r_amod) dyskinesia_1\NN\14084880|l-dopa-induced|lid|is|complications|. (l_appos) lid_3\NN\5313679|(|)
D007980_D004409 CID l-dopa_25\NN\14604959|with (r_nmod) treatment_23\NN\654885|after|a|prolonged|l-dopa (r_nmod) arise_11\VBP\2623529|that|patients|treatment (r_acl:relcl) complications_9\NNS\1073995|among|the|motor|arise (r_nmod) dyskinesia_1\NN\14084880|l-dopa-induced|lid|is|complications|.
D007980_D004409 CID l-dopa_25\NN\14604959|with (r_nmod) treatment_23\NN\654885|after|a|prolonged|l-dopa (r_nmod) arise_11\VBP\2623529|that|patients|treatment (r_acl:relcl) complications_9\NNS\1073995|among|the|motor|arise (r_nmod) dyskinesia_1\NN\14084880|l-dopa-induced|lid|is|complications|. (l_appos) lid_3\NN\5313679|(|)
D007980_D004409 CID l-dopa_3\NN\14604959|with (r_nmod) treated_1\VBN\2376958|l-dopa (r_acl) rats_0\NNS\2329401|treated (r_nsubjpass) allocated_5\VBN\2228698|rats|were|groups|. (l_nmod) groups_8\NNS\2137|to|two|based (l_acl) based_9\VBN\2694933|presence (l_nmod) presence_12\NN\13954253|on|the|or|absence|lid (l_nmod) lid_16\NN\5313679|of
D007980_D010300 NONE l-dopa-induced_0\VBN\1740| (r_amod) dyskinesia_1\NN\14084880|l-dopa-induced|lid|is|complications|. (l_nmod) complications_9\NNS\1073995|among|the|motor|arise (l_acl:relcl) arise_11\VBP\2623529|that|patients|treatment (l_nmod) patients_19\NNS\9898892|in|disease (l_compound) disease_15\NN\14061805|parkinson|pd
D007980_D010300 NONE l-dopa-induced_0\VBN\1740| (r_amod) dyskinesia_1\NN\14084880|l-dopa-induced|lid|is|complications|. (l_nmod) complications_9\NNS\1073995|among|the|motor|arise (l_acl:relcl) arise_11\VBP\2623529|that|patients|treatment (l_nmod) patients_19\NNS\9898892|in|disease (l_compound) disease_15\NN\14061805|parkinson|pd (l_appos) pd_17\NN\14625458|(|)
D007980_D010300 NONE l-dopa_25\NN\14604959|with (r_nmod) treatment_23\NN\654885|after|a|prolonged|l-dopa (r_nmod) arise_11\VBP\2623529|that|patients|treatment (l_nmod) patients_19\NNS\9898892|in|disease (l_compound) disease_15\NN\14061805|parkinson|pd
D007980_D010300 NONE l-dopa_25\NN\14604959|with (r_nmod) treatment_23\NN\654885|after|a|prolonged|l-dopa (r_nmod) arise_11\VBP\2623529|that|patients|treatment (l_nmod) patients_19\NNS\9898892|in|disease (l_compound) disease_15\NN\14061805|parkinson|pd (l_appos) pd_17\NN\14625458|(|)
D007980_D010300 NONE l-dopa_30\NN\14604959| (r_conj) saline_28\NN\14849367|with|,|l-dopa|or|bromocriptine (r_nmod) treated_26\VBN\2376958|saline (r_acl) pd_25\NN\14625458|of|treated
D016627_D010300 NONE 6-hydroxydopamine-lesion_21\NN\1740| (r_compound) model_23\NN\5888929|from|the|unilaterally|6-hydroxydopamine-lesion|rat|pd|using (l_nmod) pd_25\NN\14625458|of|treated
D001971_D010300 NONE bromocriptine_32\NN\1740| (r_conj) saline_28\NN\14849367|with|,|l-dopa|or|bromocriptine (r_nmod) treated_26\VBN\2376958|saline (r_acl) pd_25\NN\14625458|of|treated
11198499
C023754_D007022 CID tizanidine_5\NN\1740|of (r_nmod) initiation_3\NN\7450842|following|the|tizanidine|patient (r_nmod) hypotension_0\NN\14057371|initiation|.
C023754_D007022 CID tizanidine_27\NN\1740|of|,|agonist (r_nmod) addition_25\NN\3081021|following|the|tizanidine (r_nmod) developed_21\VBD\1753788|who|hypotension|addition (l_dobj) hypotension_22\NN\14057371|
C023754_D006973 NONE tizanidine_5\NN\1740|of (r_nmod) initiation_3\NN\7450842|following|the|tizanidine|patient (l_nmod) patient_8\NN\9898892|in|a|treated (l_acl) treated_9\VBN\2376958|inhibitor (l_nmod) inhibitor_15\NN\20090|with|an|angiotensin|converting|enzyme|hypertension (l_nmod) hypertension_18\NN\14057371|for|chronic
C023754_D006973 NONE tizanidine_27\NN\1740|of|,|agonist (r_nmod) addition_25\NN\3081021|following|the|tizanidine (r_nmod) developed_21\VBD\1753788|who|hypotension|addition (r_acl:relcl) hypertension_19\NN\14057371|to|control|developed
C023754_D006973 NONE tizanidine_4\NN\1740|of|and|agents (r_nmod) interaction_2\NN\37396|the|possible|tizanidine (r_nsubjpass) kept_11\VBN\2367363|interaction|should|be|mind|therapy|. (l_nmod) therapy_16\NN\657604|when|prescribing|treat (l_acl) treat_18\VB\2376958|to|hypertension (l_dobj) hypertension_20\NN\14057371|either|or|spasticity|patients
D000809_D007022 NONE angiotensin_12\NN\4522421| (r_compound) inhibitor_15\NN\20090|with|an|angiotensin|converting|enzyme|hypertension (r_nmod) treated_9\VBN\2376958|inhibitor (r_acl) patient_8\NN\9898892|in|a|treated (r_nmod) initiation_3\NN\7450842|following|the|tizanidine|patient (r_nmod) hypotension_0\NN\14057371|initiation|.
D000809_D007022 NONE angiotensin_4\NN\4522421| (r_compound) inhibitors_7\NNS\20090|with|angiotensin|converting|enzyme (r_nmod) treated_2\VBN\2376958|chronically|inhibitors (r_acl) adults_0\NNS\7846|treated (r_nsubj) have_9\VB\2108377|adults|may|ability|blocked|. (l_dobj) ability_12\NN\4723816|a|limited|respond (l_acl) respond_14\VB\2367363|to|hypotension (l_nmod) hypotension_16\NN\14057371|to
D000809_D007022 NONE angiotensin_12\NN\4522421| (r_compound) inhibitor_15\NN\20090|an|angiotensin|converting|enzyme (r_appos) boy_5\NN\9624168|a|10-year-old|treated|,|inhibitor (r_dobj) present_2\VBP\2137132|authors|boy|,|hypertension|,|treatment|. (l_nmod) hypertension_19\NN\14057371|to|control|developed (l_acl:relcl) developed_21\VBD\1753788|who|hypotension|addition (l_dobj) hypotension_22\NN\14057371|
D000809_D006973 NONE angiotensin_12\NN\4522421| (r_compound) inhibitor_15\NN\20090|with|an|angiotensin|converting|enzyme|hypertension (l_nmod) hypertension_18\NN\14057371|for|chronic
D000809_D006973 NONE angiotensin_12\NN\4522421| (r_compound) inhibitor_15\NN\20090|an|angiotensin|converting|enzyme (r_appos) boy_5\NN\9624168|a|10-year-old|treated|,|inhibitor (r_dobj) present_2\VBP\2137132|authors|boy|,|hypertension|,|treatment|. (l_nmod) hypertension_19\NN\14057371|to|control|developed
D017706_D006973 NONE lisinopril_9\NN\2673637|with (r_nmod) treated_7\VBN\2376958|chronically|lisinopril (r_acl) boy_5\NN\9624168|a|10-year-old|treated|,|inhibitor (r_dobj) present_2\VBP\2137132|authors|boy|,|hypertension|,|treatment|. (l_nmod) hypertension_19\NN\14057371|to|control|developed
D017706_D007022 CID lisinopril_9\NN\2673637|with (r_nmod) treated_7\VBN\2376958|chronically|lisinopril (r_acl) boy_5\NN\9624168|a|10-year-old|treated|,|inhibitor (r_dobj) present_2\VBP\2137132|authors|boy|,|hypertension|,|treatment|. (l_nmod) hypertension_19\NN\14057371|to|control|developed (l_acl:relcl) developed_21\VBD\1753788|who|hypotension|addition (l_dobj) hypotension_22\NN\14057371|
D017706_D009128 NONE lisinopril_9\NN\2673637|with (r_nmod) treated_7\VBN\2376958|chronically|lisinopril (r_acl) boy_5\NN\9624168|a|10-year-old|treated|,|inhibitor (r_dobj) present_2\VBP\2137132|authors|boy|,|hypertension|,|treatment|. (l_nmod) treatment_35\NN\654885|for|the|spasticity (l_nmod) spasticity_37\NN\4770535|of
D000809_D009128 NONE angiotensin_12\NN\4522421| (r_compound) inhibitor_15\NN\20090|an|angiotensin|converting|enzyme (r_appos) boy_5\NN\9624168|a|10-year-old|treated|,|inhibitor (r_dobj) present_2\VBP\2137132|authors|boy|,|hypertension|,|treatment|. (l_nmod) treatment_35\NN\654885|for|the|spasticity (l_nmod) spasticity_37\NN\4770535|of
C023754_D009128 NONE tizanidine_27\NN\1740|of|,|agonist (r_nmod) addition_25\NN\3081021|following|the|tizanidine (r_nmod) developed_21\VBD\1753788|who|hypotension|addition (r_acl:relcl) hypertension_19\NN\14057371|to|control|developed (r_nmod) present_2\VBP\2137132|authors|boy|,|hypertension|,|treatment|. (l_nmod) treatment_35\NN\654885|for|the|spasticity (l_nmod) spasticity_37\NN\4770535|of
C023754_D009128 NONE tizanidine_4\NN\1740|of|and|agents (r_nmod) interaction_2\NN\37396|the|possible|tizanidine (r_nsubjpass) kept_11\VBN\2367363|interaction|should|be|mind|therapy|. (l_nmod) therapy_16\NN\657604|when|prescribing|treat (l_acl) treat_18\VB\2376958|to|hypertension (l_dobj) hypertension_20\NN\14057371|either|or|spasticity|patients (l_conj) spasticity_22\NN\4770535|
8423889
D005473_D009069 CID fluoxetine_5\NN\4169152| (r_compound) medication_6\NN\3247620|after|fluoxetine (r_nmod) increase_0\NN\13576355|disability|medication|. (l_nmod) disability_3\NN\14547369|of|parkinson
D005473_D009069 CID fluoxetine_21\NN\4169152|to|the|antidepressant (r_nmod) exposure_17\NN\5042871|after|fluoxetine (r_nmod) amount_4\NN\13329641|the|increased|disability|exposure (l_nmod) disability_7\NN\14547369|of|motor|patients
D000928_D009069 NONE antidepressant_20\JJ\1740| (r_amod) fluoxetine_21\NN\4169152|to|the|antidepressant (r_nmod) exposure_17\NN\5042871|after|fluoxetine (r_nmod) amount_4\NN\13329641|the|increased|disability|exposure (l_nmod) disability_7\NN\14547369|of|motor|patients
D000928_D010300 NONE antidepressant_20\JJ\1740| (r_amod) fluoxetine_21\NN\4169152|to|the|antidepressant (r_nmod) exposure_17\NN\5042871|after|fluoxetine (r_nmod) amount_4\NN\13329641|the|increased|disability|exposure (l_nmod) disability_7\NN\14547369|of|motor|patients (l_nmod) patients_10\NNS\9898892|in|four|disease (l_nmod) disease_15\NN\14061805|with|idiopathic|parkinson
D005473_D010300 NONE fluoxetine_21\NN\4169152|to|the|antidepressant (r_nmod) exposure_17\NN\5042871|after|fluoxetine (r_nmod) amount_4\NN\13329641|the|increased|disability|exposure (l_nmod) disability_7\NN\14547369|of|motor|patients (l_nmod) patients_10\NNS\9898892|in|four|disease (l_nmod) disease_15\NN\14061805|with|idiopathic|parkinson
D005473_D010300 NONE fluoxetine_9\NN\4169152|of (r_nmod) capacity_7\NN\5202497|of|a|relevant|dopamine-antagonistic|fluoxetine|patients (l_nmod) patients_14\NNS\9898892|in|parkinson|disease (l_compound) disease_13\NN\14061805|
D004298_D010300 NONE dopamine-antagonistic_6\JJ\1740| (r_amod) capacity_7\NN\5202497|of|a|relevant|dopamine-antagonistic|fluoxetine|patients (l_nmod) patients_14\NNS\9898892|in|parkinson|disease (l_compound) disease_13\NN\14061805|
1420741
D005672_D003424 NONE acid_7\NN\14818238|with|fusidic|:|antibiotic (r_nmod) treatment_0\NN\654885|disease|acid|. (l_nmod) disease_4\NN\14061805|of|crohn|'s
D005672_D003424 NONE acid_28\NN\14818238| (r_compound) treatment_29\NN\654885|of|fusidic|acid (r_nmod) pharmacodynamics_23\NNS\1740|the|and|tolerability|treatment|patients (r_dobj) estimate_21\VB\637259|to|pharmacodynamics (r_xcomp) undertaken_19\VBN\1641914|need|,|study|was|estimate|. (l_nmod) need_3\NN\13920835|because|the|development (l_nmod) development_6\NN\248977|for|the|treatments (l_nmod) treatments_9\NNS\654885|of|new|disease (l_nmod) disease_13\NN\14061805|for|crohn|'s
D005672_D003424 NONE acid_9\NN\14818238|fusidic (r_nsubj) benefit_13\NN\13278375|that|acid|may|be|of|patients (l_nmod) patients_21\NNS\9898892|in|selected|chronic|active|crohn|disease|ineffective (l_compound) disease_20\NN\14061805|
D016572_D003424 NONE cyclosporin_16\NN\1740|to (r_nmod) similar_14\JJ\1740|cyclosporin (r_amod) properties_13\NNS\32613|with|immunosuppressive|similar (r_nmod) antibiotic_10\NN\2716205|an|properties (r_appos) acid_7\NN\14818238|with|fusidic|:|antibiotic (r_nmod) treatment_0\NN\654885|disease|acid|. (l_nmod) disease_4\NN\14061805|of|crohn|'s
D005672_D015212 NONE acid_13\NN\14818238|of|fusidic (r_nmod) use_10\NN\407535|for|the|acid|level (l_nmod) level_17\NN\4916342|at|the|cytokine|disease (l_nmod) disease_21\NN\14061805|in|inflammatory|bowel
18703024
D006220_D002375 CID haloperidol-induced_3\JJ\1740| (r_amod) catalepsy_4\NN\14023236|in|haloperidol-induced|or|locomotion
D016291_D002375 NONE mk-801-induced_6\JJ\1740| (r_amod) locomotion_7\NN\4773351|mk-801-induced (r_conj) catalepsy_4\NN\14023236|in|haloperidol-induced|or|locomotion
11679859
D011346_D017109 CID prochlorperazine_3\NN\2719750|of (r_nmod) administration_1\NN\1133281|intravenous|prochlorperazine|infusion (r_nsubj) affect_12\VB\126264|administration|does|not|incidence|trial|. (l_dobj) incidence_14\NN\13821570|the|akathisia|: (l_nmod) akathisia_16\NN\1740|of
D011346_D017109 CID prochlorperazine_15\NN\2719750|of|intravenous (r_nmod) administration_12\NN\1133281|after|prochlorperazine (r_nmod) rate_8\NN\13815152|the|akathisia|administration (l_nmod) akathisia_10\NN\1740|of
D011346_D017109 CID prochlorperazine_12\NN\2719750| (r_nsubjpass) administered_14\VBN\2436349|when|prochlorperazine|was|means (r_dep) conclusion_0\NN\5837957|:|reduction|administered (l_appos) reduction_5\NN\351485|a|%|incidence (l_nmod) incidence_8\NN\13821570|in|the|akathisia (l_nmod) akathisia_10\NN\1740|of
D011346_D006261 NONE prochlorperazine_8\NN\2719750|with (r_nmod) treated_6\VBN\2376958|prochlorperazine|headache (l_nmod) headache_10\NN\5829480|for|,|nausea|,|or|vomiting
D011346_D006261 NONE prochlorperazine_3\NN\2719750|of (r_nmod) efficacy_1\NN\5199286|the|prochlorperazine|treatment|likewise (l_nmod) treatment_6\NN\654885|in|the|headache (l_nmod) headache_8\NN\5829480|of|and|nausea
D011346_D009325 NONE prochlorperazine_8\NN\2719750|with (r_nmod) treated_6\VBN\2376958|prochlorperazine|headache (l_nmod) headache_10\NN\5829480|for|,|nausea|,|or|vomiting (l_conj) nausea_12\NN\14299637|
D011346_D009325 NONE prochlorperazine_3\NN\2719750|of (r_nmod) efficacy_1\NN\5199286|the|prochlorperazine|treatment|likewise (l_nmod) treatment_6\NN\654885|in|the|headache (l_nmod) headache_8\NN\5829480|of|and|nausea (l_conj) nausea_10\NN\14299637|
D011346_D014839 NONE prochlorperazine_8\NN\2719750|with (r_nmod) treated_6\VBN\2376958|prochlorperazine|headache (l_nmod) headache_10\NN\5829480|for|,|nausea|,|or|vomiting (l_conj) vomiting_15\NN\116687|
3828020
D010665_D002544 CID phenylpropanolamine_8\NN\2682038|of (r_nmod) dose_6\NN\3740161|with|a|single|oral|phenylpropanolamine (r_nmod) infarction_1\NN\14204950|cerebral|dose|.
D010665_D002544 CID ppa_20\NN\1740|of (r_nmod) dose_18\NN\3740161|a|single|oral|ppa (r_dobj) taking_14\VBG\2367363|after|dose (r_advcl) suffered_9\VBD\2110220|who|infarction|taking (l_dobj) infarction_12\NN\14204950|a|cerebral
2396046
D002794_D006528 CID choline-supplemented_13\JJ\1740| (r_amod) diet_14\NN\7560652|the|plain|choline-supplemented (r_dobj) fed_10\VBD\1182709|diet (r_conj) developed_7\VBN\1753788|nodules|rats|fed|,|developed|. (l_nsubj) nodules_3\NNS\5264913|no|hepatic|preneoplastic|or|carcinomas (l_conj) carcinomas_6\NNS\14239918|hepatocellular
D002794_D006528 CID choline-supplemented_13\JJ\1740| (r_amod) diet_14\NN\7560652|the|plain|choline-supplemented (r_dobj) fed_10\VBD\1182709|diet (r_conj) developed_7\VBN\1753788|nodules|rats|fed|,|developed|. (l_advcl) developed_24\VBD\1753788|while|nodule|rats|fed (l_nsubj) nodule_19\NN\5264913|one|preneoplastic|and|carcinoma (l_conj) carcinoma_23\NN\14239918|one|hepatocellular
D002794_D006528 CID choline-devoid_23\JJ\1740| (r_amod) diet_24\NN\7560652|the|plain|choline-devoid (r_dobj) fed_20\VBD\1182709|rats|diet|,|and|%|, (r_conj) %_11\NN\1740|incidence|was|10|and|%|,|respectively|,|fed|fed (l_nsubj) incidence_1\NN\13821570|the|nodules (l_nmod) nodules_4\NNS\5264913|of|preneoplastic|and|carcinomas (l_conj) carcinomas_8\NNS\14239918|of|hepatocellular
D002794_D006528 CID choline-devoid_38\JJ\1740| (r_amod) diet_39\NN\7560652|the|phenobarbital-containing|choline-devoid (r_dobj) fed_35\VBD\1182709|rats|diet|. (r_conj) %_11\NN\1740|incidence|was|10|and|%|,|respectively|,|fed|fed (l_nsubj) incidence_1\NN\13821570|the|nodules (l_nmod) nodules_4\NNS\5264913|of|preneoplastic|and|carcinomas (l_conj) carcinomas_8\NNS\14239918|of|hepatocellular
D010634_D006528 NONE phenobarbital_33\JJ\1740| (r_dobj) containing_32\VBG\2632940|phenobarbital (r_acl) diet_31\NN\7560652|the|same|containing (r_dobj) fed_28\VBD\1182709|diet (r_conj) developed_24\VBD\1753788|while|nodule|rats|fed (r_advcl) developed_7\VBN\1753788|nodules|rats|fed|,|developed|. (l_nsubj) nodules_3\NNS\5264913|no|hepatic|preneoplastic|or|carcinomas (l_conj) carcinomas_6\NNS\14239918|hepatocellular
D010634_D006528 NONE phenobarbital_33\JJ\1740| (r_dobj) containing_32\VBG\2632940|phenobarbital (r_acl) diet_31\NN\7560652|the|same|containing (r_dobj) fed_28\VBD\1182709|diet (r_conj) developed_24\VBD\1753788|while|nodule|rats|fed (l_nsubj) nodule_19\NN\5264913|one|preneoplastic|and|carcinoma (l_conj) carcinoma_23\NN\14239918|one|hepatocellular
D010634_D006528 NONE phenobarbital-containing_37\JJ\1740| (r_amod) diet_39\NN\7560652|the|phenobarbital-containing|choline-devoid (r_dobj) fed_35\VBD\1182709|rats|diet|. (r_conj) %_11\NN\1740|incidence|was|10|and|%|,|respectively|,|fed|fed (l_nsubj) incidence_1\NN\13821570|the|nodules (l_nmod) nodules_4\NNS\5264913|of|preneoplastic|and|carcinomas (l_conj) carcinomas_8\NNS\14239918|of|hepatocellular
9698967
D008619_D006973 CID mepivacaine_43\NN\1740|with|850|mg (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) min_36\NN\15154774|12|performance (r_nmod) observed_21\VBN\2163746|increase|was|group|,|medicated|min|,|correction|. (l_nsubjpass) increase_1\NN\13576355|an|pressure|,|accompanied|, (l_nmod) pressure_4\NN\11419404|in|blood
D008619_D001281 CID mepivacaine_43\NN\1740|with|850|mg (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) min_36\NN\15154774|12|performance (r_nmod) observed_21\VBN\2163746|increase|was|group|,|medicated|min|,|correction|. (l_nsubjpass) increase_1\NN\13576355|an|pressure|,|accompanied|, (l_acl) accompanied_6\VBN\1835496|fibrillation (l_nmod) fibrillation_9\NN\14361664|by|atrial|,|agitation
D008619_D011595 NONE mepivacaine_43\NN\1740|with|850|mg (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) min_36\NN\15154774|12|performance (r_nmod) observed_21\VBN\2163746|increase|was|group|,|medicated|min|,|correction|. (l_nsubjpass) increase_1\NN\13576355|an|pressure|,|accompanied|, (l_acl) accompanied_6\VBN\1835496|fibrillation (l_nmod) fibrillation_9\NN\14361664|by|atrial|,|agitation (l_conj) agitation_11\NN\14373582|,|shouts
D008619_D019954 NONE mepivacaine_43\NN\1740|with|850|mg (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) min_36\NN\15154774|12|performance (r_nmod) observed_21\VBN\2163746|increase|was|group|,|medicated|min|,|correction|. (l_nsubjpass) increase_1\NN\13576355|an|pressure|,|accompanied|, (l_acl) accompanied_6\VBN\1835496|fibrillation (l_nmod) fibrillation_9\NN\14361664|by|atrial|,|agitation (l_conj) agitation_11\NN\14373582|,|shouts (l_conj) shouts_14\NNS\7109847|incomprehensible|and|loss
D008619_D014474 NONE mepivacaine_43\NN\1740|with|850|mg (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) min_36\NN\15154774|12|performance (r_nmod) observed_21\VBN\2163746|increase|was|group|,|medicated|min|,|correction|. (l_nsubjpass) increase_1\NN\13576355|an|pressure|,|accompanied|, (l_acl) accompanied_6\VBN\1835496|fibrillation (l_nmod) fibrillation_9\NN\14361664|by|atrial|,|agitation (l_conj) agitation_11\NN\14373582|,|shouts (l_conj) shouts_14\NNS\7109847|incomprehensible|and|loss (l_conj) loss_16\NN\13252973|consciousness (l_nmod) consciousness_18\NN\5669934|of
D008619_D004387 NONE mepivacaine_43\NN\1740|with|850|mg (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) min_36\NN\15154774|12|performance (r_nmod) observed_21\VBN\2163746|increase|was|group|,|medicated|min|,|correction|. (l_nmod) correction_52\NN\248977|for|contracture (l_nmod) contracture_56\NN\369802|of|dupuytren
D004837_D006973 CID adrenaline_47\NN\14807929| (r_compound) mg_49\NN\13717155|adrenaline|0.225 (r_dobj) containing_46\VBG\2632940|mg (r_acl) mg_45\NN\13717155|containing (r_dep) mepivacaine_43\NN\1740|with|850|mg (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) min_36\NN\15154774|12|performance (r_nmod) observed_21\VBN\2163746|increase|was|group|,|medicated|min|,|correction|. (l_nsubjpass) increase_1\NN\13576355|an|pressure|,|accompanied|, (l_nmod) pressure_4\NN\11419404|in|blood
D004837_D001281 CID adrenaline_47\NN\14807929| (r_compound) mg_49\NN\13717155|adrenaline|0.225 (r_dobj) containing_46\VBG\2632940|mg (r_acl) mg_45\NN\13717155|containing (r_dep) mepivacaine_43\NN\1740|with|850|mg (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) min_36\NN\15154774|12|performance (r_nmod) observed_21\VBN\2163746|increase|was|group|,|medicated|min|,|correction|. (l_nsubjpass) increase_1\NN\13576355|an|pressure|,|accompanied|, (l_acl) accompanied_6\VBN\1835496|fibrillation (l_nmod) fibrillation_9\NN\14361664|by|atrial|,|agitation
D004837_D011595 NONE adrenaline_47\NN\14807929| (r_compound) mg_49\NN\13717155|adrenaline|0.225 (r_dobj) containing_46\VBG\2632940|mg (r_acl) mg_45\NN\13717155|containing (r_dep) mepivacaine_43\NN\1740|with|850|mg (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) min_36\NN\15154774|12|performance (r_nmod) observed_21\VBN\2163746|increase|was|group|,|medicated|min|,|correction|. (l_nsubjpass) increase_1\NN\13576355|an|pressure|,|accompanied|, (l_acl) accompanied_6\VBN\1835496|fibrillation (l_nmod) fibrillation_9\NN\14361664|by|atrial|,|agitation (l_conj) agitation_11\NN\14373582|,|shouts
D004837_D019954 NONE adrenaline_47\NN\14807929| (r_compound) mg_49\NN\13717155|adrenaline|0.225 (r_dobj) containing_46\VBG\2632940|mg (r_acl) mg_45\NN\13717155|containing (r_dep) mepivacaine_43\NN\1740|with|850|mg (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) min_36\NN\15154774|12|performance (r_nmod) observed_21\VBN\2163746|increase|was|group|,|medicated|min|,|correction|. (l_nsubjpass) increase_1\NN\13576355|an|pressure|,|accompanied|, (l_acl) accompanied_6\VBN\1835496|fibrillation (l_nmod) fibrillation_9\NN\14361664|by|atrial|,|agitation (l_conj) agitation_11\NN\14373582|,|shouts (l_conj) shouts_14\NNS\7109847|incomprehensible|and|loss
D004837_D014474 NONE adrenaline_47\NN\14807929| (r_compound) mg_49\NN\13717155|adrenaline|0.225 (r_dobj) containing_46\VBG\2632940|mg (r_acl) mg_45\NN\13717155|containing (r_dep) mepivacaine_43\NN\1740|with|850|mg (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) min_36\NN\15154774|12|performance (r_nmod) observed_21\VBN\2163746|increase|was|group|,|medicated|min|,|correction|. (l_nsubjpass) increase_1\NN\13576355|an|pressure|,|accompanied|, (l_acl) accompanied_6\VBN\1835496|fibrillation (l_nmod) fibrillation_9\NN\14361664|by|atrial|,|agitation (l_conj) agitation_11\NN\14373582|,|shouts (l_conj) shouts_14\NNS\7109847|incomprehensible|and|loss (l_conj) loss_16\NN\13252973|consciousness (l_nmod) consciousness_18\NN\5669934|of
D004837_D004387 NONE adrenaline_47\NN\14807929| (r_compound) mg_49\NN\13717155|adrenaline|0.225 (r_dobj) containing_46\VBG\2632940|mg (r_acl) mg_45\NN\13717155|containing (r_dep) mepivacaine_43\NN\1740|with|850|mg (r_nmod) block_41\NN\21939|of|axillary|mepivacaine (r_nmod) performance_38\NN\6619065|after|block (r_nmod) min_36\NN\15154774|12|performance (r_nmod) observed_21\VBN\2163746|increase|was|group|,|medicated|min|,|correction|. (l_nmod) correction_52\NN\248977|for|contracture (l_nmod) contracture_56\NN\369802|of|dupuytren
1616457
D010424_D000647 CID pentobarbital_7\JJ\1740|by (r_nmod) caused_5\VBN\1617192|pentobarbital|. (r_acl) learning_0\NN\5701944|rats|caused (l_nmod) rats_2\NNS\2329401|of|amnesia (l_nmod) amnesia_4\NN\5669934|under
D010424_D000647 CID pentobarbital_15\JJ\1740|by|mg/kg (r_nmod) produced_13\VBN\1617192|pentobarbital (r_acl) state_10\NN\8491826|the|amnesia|produced (l_nmod) amnesia_12\NN\5669934|of
12589964
D004317_D009202 CID doxorubicin-induced_14\JJ\1740| (r_amod) rats_16\NNS\2329401|in|doxorubicin-induced|cardiomyopathy (r_nmod) damage_12\NN\7296428|of|myocardial|rats
D004317_D009202 CID doxorubicin-induced_14\JJ\1740| (r_amod) rats_16\NNS\2329401|in|doxorubicin-induced|cardiomyopathy (l_amod) cardiomyopathy_15\JJ\1740|
D004317_D009202 CID doxorubicin_20\NN\2716866|of|(dox)-induced (r_nmod) model_18\NN\5888929|in|a|rat|doxorubicin|cardiomyopathy (r_nmod) diagnosis_11\NN\152018|for|the|damage|model (l_nmod) damage_14\NN\7296428|of|myocardial
D004317_D009202 CID doxorubicin_20\NN\2716866|of|(dox)-induced (r_nmod) model_18\NN\5888929|in|a|rat|doxorubicin|cardiomyopathy (l_amod) cardiomyopathy_22\JJ\1740|
D004317_D009202 CID (dox)-induced_21\NN\1740| (r_acl) doxorubicin_20\NN\2716866|of|(dox)-induced (r_nmod) model_18\NN\5888929|in|a|rat|doxorubicin|cardiomyopathy (r_nmod) diagnosis_11\NN\152018|for|the|damage|model (l_nmod) damage_14\NN\7296428|of|myocardial
D004317_D009202 CID (dox)-induced_21\NN\1740| (r_acl) doxorubicin_20\NN\2716866|of|(dox)-induced (r_nmod) model_18\NN\5888929|in|a|rat|doxorubicin|cardiomyopathy (l_amod) cardiomyopathy_22\JJ\1740|
D004317_D009202 CID dox_8\NN\1740|after|rats (r_nmod) injury_6\NN\14052046|of|ischemic|dox (r_nmod) markers_3\NNS\21939|among|injury (r_nmod) showed_13\VBD\2137132|conclusions|markers|,|ctnt|ability|. (l_dobj) ability_16\NN\4723816|the|greatest|detect (l_acl) detect_18\VB\2163746|to|damage (l_dobj) damage_20\NN\7296428|myocardial|assessed
D004317_D006331 NONE doxorubicin_20\NN\2716866|of|(dox)-induced (r_nmod) model_18\NN\5888929|in|a|rat|doxorubicin|cardiomyopathy (r_nmod) diagnosis_11\NN\152018|for|the|damage|model (r_nmod) value_4\NN\5856066|the|diagnostic|ctni|diagnosis (r_dobj) investigated_1\VBD\644583|we|value|,|and|examined (l_conj) examined_26\VBD\789138|we|relationship|. (l_dobj) relationship_28\NN\31921|the|ctni (l_nmod) ctni_31\NN\1740|between|serial|and|ctnt|development (l_nmod) development_36\NN\248977|with|the|disorders (l_nmod) disorders_39\NNS\14034177|of|cardiac|monitored
D004317_D006331 NONE (dox)-induced_21\NN\1740| (r_acl) doxorubicin_20\NN\2716866|of|(dox)-induced (r_nmod) model_18\NN\5888929|in|a|rat|doxorubicin|cardiomyopathy (r_nmod) diagnosis_11\NN\152018|for|the|damage|model (r_nmod) value_4\NN\5856066|the|diagnostic|ctni|diagnosis (r_dobj) investigated_1\VBD\644583|we|value|,|and|examined (l_conj) examined_26\VBD\789138|we|relationship|. (l_dobj) relationship_28\NN\31921|the|ctni (l_nmod) ctni_31\NN\1740|between|serial|and|ctnt|development (l_nmod) development_36\NN\248977|with|the|disorders (l_nmod) disorders_39\NNS\14034177|of|cardiac|monitored
D004317_D064420 NONE dox_5\NN\1740| (r_compound) rats_6\NNS\2329401|of|the|dox (r_nmod) eighteen_2\CD\13745420|rats (r_nsubj) died_7\VBD\146138|eighteen|prematurely|toxicity|period (l_nmod) toxicity_11\NN\13576101|of|general
D004317_D005355 NONE dox_8\NN\1740|given (r_nmod) rats_6\NNS\2329401|from|all|dox (r_nmod) evaluation_1\NN\874067|histological|hearts|rats (r_nsubj) revealed_9\VBD\2137132|evaluation|degrees|. (l_dobj) degrees_12\NNS\4916342|significant|slight|fibrosis (l_nmod) fibrosis_17\NN\14204950|of|perivascular
D004317_D017202 NONE dox_8\NN\1740|after|rats (r_nmod) injury_6\NN\14052046|of|ischemic|dox
D004317_D066126 NONE dox_13\NN\1740|after (r_nmod) amount_7\NN\13329641|between|the|ctni|dox (r_nmod) discrepancy_4\NN\4748836|a|amount (r_attr) was_2\VBD\836236|although|there|discrepancy|,|heterogeneity (r_advcl) is_31\VBZ\836236|was|,|it|likely|. (l_acomp) likely_32\JJ\1740|indicates (l_ccomp) indicates_39\VBZ\952524|that|ctnt|damage (l_dobj) damage_41\NN\7296428|cell|determined (l_acl) determined_42\VBN\1645601|magnitude (l_nmod) magnitude_45\NN\4916342|by|the|injury (l_nmod) injury_47\NN\14052046|of|induced (l_acl) induced_48\VBN\1627355|and|marker (l_conj) marker_56\NN\21939|that|ctnt|should|be|a|useful|prediction (l_nmod) prediction_59\NN\5772356|for|the|cardiotoxicity (l_nmod) cardiotoxicity_63\NN\1740|of|induced|and|experiments
D004317_D066126 NONE dox_38\NN\1740|after (r_nmod) rats_36\NNS\2329401|in|dox (r_nmod) ctnt_34\NN\1740|rats (r_nsubj) indicates_39\VBZ\952524|that|ctnt|damage (l_dobj) damage_41\NN\7296428|cell|determined (l_acl) determined_42\VBN\1645601|magnitude (l_nmod) magnitude_45\NN\4916342|by|the|injury (l_nmod) injury_47\NN\14052046|of|induced (l_acl) induced_48\VBN\1627355|and|marker (l_conj) marker_56\NN\21939|that|ctnt|should|be|a|useful|prediction (l_nmod) prediction_59\NN\5772356|for|the|cardiotoxicity (l_nmod) cardiotoxicity_63\NN\1740|of|induced|and|experiments
11379838
D000928_D001714 CID antidepressant-induced_0\JJ\1740| (r_amod) mania_1\NN\9180259|antidepressant-induced|patients|:|identification|.
D000928_D001714 CID antidepressant-induced_0\JJ\1740| (r_amod) mania_1\NN\9180259|antidepressant-induced|patients|:|identification|. (l_nmod) patients_4\NNS\9898892|in|bipolar (l_amod) bipolar_3\JJ\1740|
D000928_D001714 CID antidepressants_12\NNS\3740161|with (r_nmod) associated_10\VBN\628491|antidepressants (r_acl) mania_9\NN\9180259|to|associated
D000928_D001714 CID antidepressants_12\NNS\3740161|with (r_nmod) associated_10\VBN\628491|antidepressants (r_acl) mania_9\NN\9180259|to|associated (r_nmod) switching_7\NN\191142|of|mania (r_nmod) risks_5\NNS\14541044|about|possible|switching (r_nmod) concerns_2\NNS\5682950|risks (r_nsubj) continue_13\VBP\2367363|background|concerns|interfere|. (l_xcomp) interfere_15\VB\2451370|to|establishment (l_nmod) establishment_18\NN\235435|with|the|paradigm (l_nmod) paradigm_23\NN\13803782|of|an|optimal|treatment|depression (l_nmod) depression_26\NN\14373582|for|bipolar
D000928_D001714 CID antidepressant_41\JJ\1740| (r_amod) therapy_42\NN\657604|of|antidepressant (r_nmod) type_39\NN\5839024|therapy (r_conj) age_19\NN\4916342|including|,|sex|,|diagnosis|,|number|type (r_nmod) variables_17\NNS\2452|not|on|several|age (r_dobj) did_13\VBD\1640855|who|variables (r_acl:relcl) those_11\DT\1740|with|did|used|therapy|,|use (r_nmod) compared_9\VBN\644583|patients|were|those|,|and|temperament|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_acl:relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\1740|or|hypomanic
D000928_D001714 CID antidepressant_41\JJ\1740| (r_amod) therapy_42\NN\657604|of|antidepressant (r_nmod) type_39\NN\5839024|therapy (r_conj) age_19\NN\4916342|including|,|sex|,|diagnosis|,|number|type (r_nmod) variables_17\NNS\2452|not|on|several|age (r_dobj) did_13\VBD\1640855|who|variables (r_acl:relcl) those_11\DT\1740|with|did|used|therapy|,|use (r_nmod) compared_9\VBN\644583|patients|were|those|,|and|temperament|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_acl:relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\1740|or|hypomanic (l_conj) hypomanic_6\JJ\1740|
D000928_D001714 CID antidepressant_41\JJ\1740| (r_amod) therapy_42\NN\657604|of|antidepressant (r_nmod) type_39\NN\5839024|therapy (r_conj) age_19\NN\4916342|including|,|sex|,|diagnosis|,|number|type (l_conj) diagnosis_23\NN\152018|bipolar (l_appos) bipolar_26\NN\1740|(|dsm-iv|i|bipolar|) (l_dep) i_27\CD\14622893|
D000928_D001714 CID antidepressant_41\JJ\1740| (r_amod) therapy_42\NN\657604|of|antidepressant (r_nmod) type_39\NN\5839024|therapy (r_conj) age_19\NN\4916342|including|,|sex|,|diagnosis|,|number|type (l_conj) diagnosis_23\NN\152018|bipolar (l_appos) bipolar_26\NN\1740|(|dsm-iv|i|bipolar|) (l_nmod) bipolar_29\NN\1740|vs.|ii (l_nummod) ii_30\CD\13741022|
D000928_D001714 CID antidepressant_41\JJ\1740| (r_amod) therapy_42\NN\657604|of|antidepressant (r_nmod) type_39\NN\5839024|therapy (r_conj) age_19\NN\4916342|including|,|sex|,|diagnosis|,|number|type (l_conj) number_33\NN\5107765|episodes (l_nmod) episodes_37\NNS\7283608|of|previous|manic|, (l_amod) manic_36\JJ\1740|
D000928_D001714 CID antidepressant_48\JJ\1740| (r_amod) drugs_49\NNS\14778436|antidepressant (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|inhibitors|ssris|) (r_dep) those_11\DT\1740|with|did|used|therapy|,|use (r_nmod) compared_9\VBN\644583|patients|were|those|,|and|temperament|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_acl:relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\1740|or|hypomanic
D000928_D001714 CID antidepressant_48\JJ\1740| (r_amod) drugs_49\NNS\14778436|antidepressant (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|inhibitors|ssris|) (r_dep) those_11\DT\1740|with|did|used|therapy|,|use (r_nmod) compared_9\VBN\644583|patients|were|those|,|and|temperament|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_acl:relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\1740|or|hypomanic (l_conj) hypomanic_6\JJ\1740|
D000928_D001714 CID antidepressant_48\JJ\1740| (r_amod) drugs_49\NNS\14778436|antidepressant (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|inhibitors|ssris|) (r_dep) those_11\DT\1740|with|did|used|therapy|,|use (l_acl:relcl) did_13\VBD\1640855|who|variables (l_dobj) variables_17\NNS\2452|not|on|several|age (l_nmod) age_19\NN\4916342|including|,|sex|,|diagnosis|,|number|type (l_conj) diagnosis_23\NN\152018|bipolar (l_appos) bipolar_26\NN\1740|(|dsm-iv|i|bipolar|) (l_dep) i_27\CD\14622893|
D000928_D001714 CID antidepressant_48\JJ\1740| (r_amod) drugs_49\NNS\14778436|antidepressant (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|inhibitors|ssris|) (r_dep) those_11\DT\1740|with|did|used|therapy|,|use (l_acl:relcl) did_13\VBD\1640855|who|variables (l_dobj) variables_17\NNS\2452|not|on|several|age (l_nmod) age_19\NN\4916342|including|,|sex|,|diagnosis|,|number|type (l_conj) diagnosis_23\NN\152018|bipolar (l_appos) bipolar_26\NN\1740|(|dsm-iv|i|bipolar|) (l_nmod) bipolar_29\NN\1740|vs.|ii (l_nummod) ii_30\CD\13741022|
D000928_D001714 CID antidepressant_48\JJ\1740| (r_amod) drugs_49\NNS\14778436|antidepressant (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|inhibitors|ssris|) (r_dep) those_11\DT\1740|with|did|used|therapy|,|use (l_acl:relcl) did_13\VBD\1640855|who|variables (l_dobj) variables_17\NNS\2452|not|on|several|age (l_nmod) age_19\NN\4916342|including|,|sex|,|diagnosis|,|number|type (l_conj) number_33\NN\5107765|episodes (l_nmod) episodes_37\NNS\7283608|of|previous|manic|, (l_amod) manic_36\JJ\1740|
D017367_D001714 CID inhibitors_58\NNS\20090|particularly|selective|serotonin|reuptake (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|inhibitors|ssris|) (r_dep) those_11\DT\1740|with|did|used|therapy|,|use (r_nmod) compared_9\VBN\644583|patients|were|those|,|and|temperament|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_acl:relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\1740|or|hypomanic
D017367_D001714 CID inhibitors_58\NNS\20090|particularly|selective|serotonin|reuptake (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|inhibitors|ssris|) (r_dep) those_11\DT\1740|with|did|used|therapy|,|use (r_nmod) compared_9\VBN\644583|patients|were|those|,|and|temperament|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_acl:relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\1740|or|hypomanic (l_conj) hypomanic_6\JJ\1740|
D017367_D001714 CID inhibitors_58\NNS\20090|particularly|selective|serotonin|reuptake (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|inhibitors|ssris|) (r_dep) those_11\DT\1740|with|did|used|therapy|,|use (l_acl:relcl) did_13\VBD\1640855|who|variables (l_dobj) variables_17\NNS\2452|not|on|several|age (l_nmod) age_19\NN\4916342|including|,|sex|,|diagnosis|,|number|type (l_conj) diagnosis_23\NN\152018|bipolar (l_appos) bipolar_26\NN\1740|(|dsm-iv|i|bipolar|) (l_dep) i_27\CD\14622893|
D017367_D001714 CID inhibitors_58\NNS\20090|particularly|selective|serotonin|reuptake (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|inhibitors|ssris|) (r_dep) those_11\DT\1740|with|did|used|therapy|,|use (l_acl:relcl) did_13\VBD\1640855|who|variables (l_dobj) variables_17\NNS\2452|not|on|several|age (l_nmod) age_19\NN\4916342|including|,|sex|,|diagnosis|,|number|type (l_conj) diagnosis_23\NN\152018|bipolar (l_appos) bipolar_26\NN\1740|(|dsm-iv|i|bipolar|) (l_nmod) bipolar_29\NN\1740|vs.|ii (l_nummod) ii_30\CD\13741022|
D017367_D001714 CID inhibitors_58\NNS\20090|particularly|selective|serotonin|reuptake (r_conj) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|inhibitors|ssris|) (r_dep) those_11\DT\1740|with|did|used|therapy|,|use (l_acl:relcl) did_13\VBD\1640855|who|variables (l_dobj) variables_17\NNS\2452|not|on|several|age (l_nmod) age_19\NN\4916342|including|,|sex|,|diagnosis|,|number|type (l_conj) number_33\NN\5107765|episodes (l_nmod) episodes_37\NNS\7283608|of|previous|manic|, (l_amod) manic_36\JJ\1740|
D017367_D001714 CID ssris_60\NNP\2718811|[|] (r_appos) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|inhibitors|ssris|) (r_dep) those_11\DT\1740|with|did|used|therapy|,|use (r_nmod) compared_9\VBN\644583|patients|were|those|,|and|temperament|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_acl:relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\1740|or|hypomanic
D017367_D001714 CID ssris_60\NNP\2718811|[|] (r_appos) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|inhibitors|ssris|) (r_dep) those_11\DT\1740|with|did|used|therapy|,|use (r_nmod) compared_9\VBN\644583|patients|were|those|,|and|temperament|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_acl:relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\1740|or|hypomanic (l_conj) hypomanic_6\JJ\1740|
D017367_D001714 CID ssris_60\NNP\2718811|[|] (r_appos) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|inhibitors|ssris|) (r_dep) those_11\DT\1740|with|did|used|therapy|,|use (l_acl:relcl) did_13\VBD\1640855|who|variables (l_dobj) variables_17\NNS\2452|not|on|several|age (l_nmod) age_19\NN\4916342|including|,|sex|,|diagnosis|,|number|type (l_conj) diagnosis_23\NN\152018|bipolar (l_appos) bipolar_26\NN\1740|(|dsm-iv|i|bipolar|) (l_dep) i_27\CD\14622893|
D017367_D001714 CID ssris_60\NNP\2718811|[|] (r_appos) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|inhibitors|ssris|) (r_dep) those_11\DT\1740|with|did|used|therapy|,|use (l_acl:relcl) did_13\VBD\1640855|who|variables (l_dobj) variables_17\NNS\2452|not|on|several|age (l_nmod) age_19\NN\4916342|including|,|sex|,|diagnosis|,|number|type (l_conj) diagnosis_23\NN\152018|bipolar (l_appos) bipolar_26\NN\1740|(|dsm-iv|i|bipolar|) (l_nmod) bipolar_29\NN\1740|vs.|ii (l_nummod) ii_30\CD\13741022|
D017367_D001714 CID ssris_60\NNP\2718811|[|] (r_appos) therapy_46\NN\657604|(|electroconvulsive|vs.|drugs|and|,|inhibitors|ssris|) (r_dep) those_11\DT\1740|with|did|used|therapy|,|use (l_acl:relcl) did_13\VBD\1640855|who|variables (l_dobj) variables_17\NNS\2452|not|on|several|age (l_nmod) age_19\NN\4916342|including|,|sex|,|diagnosis|,|number|type (l_conj) number_33\NN\5107765|episodes (l_nmod) episodes_37\NNS\7283608|of|previous|manic|, (l_amod) manic_36\JJ\1740|
D017367_D001714 CID ssris_31\NN\2718811|with (r_nmod) treated_29\VBN\2376958|ssris (r_acl) patients_28\NNS\9898892|of|treated (r_nmod) subgroup_26\NN\31264|of|the|patients (r_nmod) %_23\NN\1740|and|in|24|subgroup (r_conj) results_0\NNS\34213|:|occurred|%|[|8/33|]|)|;|experienced|. (l_appos) occurred_7\VBD\2623529|switches|%|( (l_nsubj) switches_2\NNS\3096960|hypomania (l_nmod) hypomania_4\NN\1740|to|or|mania
D017367_D001714 CID ssris_31\NN\2718811|with (r_nmod) treated_29\VBN\2376958|ssris (r_acl) patients_28\NNS\9898892|of|treated (r_nmod) subgroup_26\NN\31264|of|the|patients (r_nmod) %_23\NN\1740|and|in|24|subgroup (r_conj) results_0\NNS\34213|:|occurred|%|[|8/33|]|)|;|experienced|. (l_appos) occurred_7\VBD\2623529|switches|%|( (l_nsubj) switches_2\NNS\3096960|hypomania (l_nmod) hypomania_4\NN\1740|to|or|mania (l_conj) mania_6\NN\9180259|
D017367_D001714 CID ssris_31\NN\2718811|with (r_nmod) treated_29\VBN\2376958|ssris (r_acl) patients_28\NNS\9898892|of|treated (r_nmod) subgroup_26\NN\31264|of|the|patients (r_nmod) %_23\NN\1740|and|in|24|subgroup (r_conj) results_0\NNS\34213|:|occurred|%|[|8/33|]|)|;|experienced|. (l_appos) experienced_44\JJ\1740|%|episodes|,|and|experienced (l_dobj) episodes_46\NNS\7283608|manic (l_amod) manic_45\JJ\1740|
D017367_D001714 CID ssris_31\NN\2718811|with (r_nmod) treated_29\VBN\2376958|ssris (r_acl) patients_28\NNS\9898892|of|treated (r_nmod) subgroup_26\NN\31264|of|the|patients (r_nmod) %_23\NN\1740|and|in|24|subgroup (r_conj) results_0\NNS\34213|:|occurred|%|[|8/33|]|)|;|experienced|. (l_appos) experienced_44\JJ\1740|%|episodes|,|and|experienced (l_conj) experienced_56\JJ\1740|%|episodes (l_dobj) episodes_58\NNS\7283608|hypomanic (l_amod) hypomanic_57\JJ\1740|
D008094_D001714 NONE lithium_71\NN\14625458|vs. (r_compound) anticonvulsants_73\NNS\3740161|(|lithium|) (r_appos) use_64\NN\407535|and|type|stabilizers|anticonvulsants (r_appos) those_11\DT\1740|with|did|used|therapy|,|use (r_nmod) compared_9\VBN\644583|patients|were|those|,|and|temperament|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_acl:relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\1740|or|hypomanic
D008094_D001714 NONE lithium_71\NN\14625458|vs. (r_compound) anticonvulsants_73\NNS\3740161|(|lithium|) (r_appos) use_64\NN\407535|and|type|stabilizers|anticonvulsants (r_appos) those_11\DT\1740|with|did|used|therapy|,|use (r_nmod) compared_9\VBN\644583|patients|were|those|,|and|temperament|. (l_nsubjpass) patients_0\NNS\9898892|experienced (l_acl:relcl) experienced_2\VBD\2108377|who|switch (l_dobj) switch_7\NN\3096960|a|manic (l_amod) manic_4\JJ\1740|or|hypomanic (l_conj) hypomanic_6\JJ\1740|
D008094_D001714 NONE lithium_71\NN\14625458|vs. (r_compound) anticonvulsants_73\NNS\3740161|(|lithium|) (r_appos) use_64\NN\407535|and|type|stabilizers|anticonvulsants (r_appos) those_11\DT\1740|with|did|used|therapy|,|use (l_acl:relcl) did_13\VBD\1640855|who|variables (l_dobj) variables_17\NNS\2452|not|on|several|age (l_nmod) age_19\NN\4916342|including|,|sex|,|diagnosis|,|number|type (l_conj) diagnosis_23\NN\152018|bipolar (l_appos) bipolar_26\NN\1740|(|dsm-iv|i|bipolar|) (l_dep) i_27\CD\14622893|
D008094_D001714 NONE lithium_71\NN\14625458|vs. (r_compound) anticonvulsants_73\NNS\3740161|(|lithium|) (r_appos) use_64\NN\407535|and|type|stabilizers|anticonvulsants (r_appos) those_11\DT\1740|with|did|used|therapy|,|use (l_acl:relcl) did_13\VBD\1640855|who|variables (l_dobj) variables_17\NNS\2452|not|on|several|age (l_nmod) age_19\NN\4916342|including|,|sex|,|diagnosis|,|number|type (l_conj) diagnosis_23\NN\152018|bipolar (l_appos) bipolar_26\NN\1740|(|dsm-iv|i|bipolar|) (l_nmod) bipolar_29\NN\1740|vs.|ii (l_nummod) ii_30\CD\13741022|
D008094_D001714 NONE lithium_71\NN\14625458|vs. (r_compound) anticonvulsants_73\NNS\3740161|(|lithium|) (r_appos) use_64\NN\407535|and|type|stabilizers|anticonvulsants (r_appos) those_11\DT\1740|with|did|used|therapy|,|use (l_acl:relcl) did_13\VBD\1640855|who|variables (l_dobj) variables_17\NNS\2452|not|on|several|age (l_nmod) age_19\NN\4916342|including|,|sex|,|diagnosis|,|number|type (l_conj) number_33\NN\5107765|episodes (l_nmod) episodes_37\NNS\7283608|of|previous|manic|, (l_amod) manic_36\JJ\1740|
7977601
11206082
C036150_D012640 CID beta-carboline-induced_8\JJ\1740| (r_amod) seizures_9\NNS\14081375|to|beta-carboline-induced
C036150_D012640 CID beta-carboline-3-carboxylate_30\NN\1740|of|methyl|beta-ccm|,|agonist (r_nmod) injection_27\NN\320852|beta-carboline-3-carboxylate (r_conj) sensitivity_9\NN\5651971|according|their|line|or|resistance|seizures|injection (l_nmod) seizures_21\NNS\14081375|to|induced
C036150_D012640 CID beta-ccm_32\NN\1740|(|) (r_appos) beta-carboline-3-carboxylate_30\NN\1740|of|methyl|beta-ccm|,|agonist (r_nmod) injection_27\NN\320852|beta-carboline-3-carboxylate (r_conj) sensitivity_9\NN\5651971|according|their|line|or|resistance|seizures|injection (l_nmod) seizures_21\NNS\14081375|to|induced
D005680_D012640 NONE gaba(a_20\NN\1740| (r_compound) ligands_23\NNS\20090|of|other|gaba(a|)|receptor (r_nmod) effects_17\NNS\13245626|to|various|pharmacological|ligands (r_nmod) sensitive_13\JJ\1740|lines|are|also|differentially|effects|. (l_nsubj) lines_2\NNS\8426461|two|mouse|selected (l_acl) selected_3\VBN\697589|sensitivities (l_nmod) sensitivities_6\NNS\5651971|for|differential|seizures (l_nmod) seizures_9\NNS\14081375|to|beta-carboline-induced
D005680_D012640 NONE gaba(a_40\NN\1740| (r_compound) site_44\NN\8673395|of|the|gaba(a|)|receptor|benzodiazepine (r_nmod) agonist_37\NN\9613191|an|inverse|site (r_appos) beta-carboline-3-carboxylate_30\NN\1740|of|methyl|beta-ccm|,|agonist (r_nmod) injection_27\NN\320852|beta-carboline-3-carboxylate (r_conj) sensitivity_9\NN\5651971|according|their|line|or|resistance|seizures|injection (l_nmod) seizures_21\NNS\14081375|to|induced
D001569_D012640 NONE benzodiazepine_43\NN\3771443| (r_compound) site_44\NN\8673395|of|the|gaba(a|)|receptor|benzodiazepine (r_nmod) agonist_37\NN\9613191|an|inverse|site (r_appos) beta-carboline-3-carboxylate_30\NN\1740|of|methyl|beta-ccm|,|agonist (r_nmod) injection_27\NN\320852|beta-carboline-3-carboxylate (r_conj) sensitivity_9\NN\5651971|according|their|line|or|resistance|seizures|injection (l_nmod) seizures_21\NNS\14081375|to|induced
D003975_D012640 NONE diazepam-induced_2\JJ\1740| (r_amod) anxiolysis_3\NN\1740|diazepam-induced|test (r_dobj) measured_1\VBD\697589|we|anxiolysis|recording|injections|. (l_advcl) recording_13\VBG\2225492|by|states (l_dobj) states_16\NNS\8491826|the|vigilance|,|and|seizures (l_conj) seizures_22\NNS\14081375|picrotoxin-
D003975_D012640 NONE diazepam-induced_10\JJ\1740| (r_amod) sedation_11\NN\14034177|diazepam-induced (r_appos) test_8\NN\5798043|with|the|elevated|plus-maze|,|sedation (r_nmod) anxiolysis_3\NN\1740|diazepam-induced|test (r_dobj) measured_1\VBD\697589|we|anxiolysis|recording|injections|. (l_advcl) recording_13\VBG\2225492|by|states (l_dobj) states_16\NNS\8491826|the|vigilance|,|and|seizures (l_conj) seizures_22\NNS\14081375|picrotoxin-
D010852_D012640 CID picrotoxin-_19\NN\1740|and|pentylenetetrazol-induced (r_amod) seizures_22\NNS\14081375|picrotoxin-
D010433_D012640 CID pentylenetetrazol-induced_21\JJ\1740| (r_conj) picrotoxin-_19\NN\1740|and|pentylenetetrazol-induced (r_amod) seizures_22\NNS\14081375|picrotoxin-
18951540
D007980_D004409 CID levodopa-induced_5\JJ\1740| (r_amod) dyskinesias_6\NNS\14084880|for|levodopa-induced|disease
D007980_D010300 NONE levodopa-induced_5\JJ\1740| (r_amod) dyskinesias_6\NNS\14084880|for|levodopa-induced|disease (l_nmod) disease_10\NN\14061805|in|parkinson
17879945
D019438_D050197 CID ritonavir_5\NN\4013993| (r_compound) treatment_6\NN\654885|ritonavir (r_nsubj) increases_7\VBZ\169651|that|treatment|formation|extent|mice (l_dobj) formation_10\NN\7938773|atherosclerotic|lesion|mice (l_compound) lesion_9\NN\14204950|
4027862
D003891_D003693 CID desipramine-induced_0\JJ\1740| (r_amod) delirium_1\NN\14391660|desipramine-induced|concentrations|:|report|.
D003891_D003693 CID desipramine_7\NN\4482543|with|low|dose (r_nmod) treated_3\VBN\2376958|desipramine (r_acl) patient_2\NN\9898892|an|elderly|treated (r_nsubj) developed_8\VBD\1753788|patient|delirium|range|. (l_dobj) delirium_10\NN\14391660|a
7862923
D002220_D012559 NONE carbamazepine_0\NNP\1740| (r_nsubjpass) switched_2\VBN\138508|carbamazepine|was|oxcarbazepine|schizophrenic|. (l_nmod) schizophrenic_11\NN\10490141|among|six|difficult-to-treat|or|patients|using
D002220_D019965 NONE carbamazepine_0\NNP\1740| (r_nsubjpass) switched_2\VBN\138508|carbamazepine|was|oxcarbazepine|schizophrenic|. (l_nmod) schizophrenic_11\NN\10490141|among|six|difficult-to-treat|or|patients|using (l_conj) patients_15\NNS\9898892|organic|psychotic (l_amod) psychotic_14\JJ\1740|
C036006_D012559 NONE oxcarbazepine_7\NN\1740|to|its|analogue (r_nmod) switched_2\VBN\138508|carbamazepine|was|oxcarbazepine|schizophrenic|. (l_nmod) schizophrenic_11\NN\10490141|among|six|difficult-to-treat|or|patients|using
C036006_D019965 NONE oxcarbazepine_7\NN\1740|to|its|analogue (r_nmod) switched_2\VBN\138508|carbamazepine|was|oxcarbazepine|schizophrenic|. (l_nmod) schizophrenic_11\NN\10490141|among|six|difficult-to-treat|or|patients|using (l_conj) patients_15\NNS\9898892|organic|psychotic (l_amod) psychotic_14\JJ\1740|
D006220_D012559 NONE haloperidol_18\JJ\1740|concomitantly|,|chlorpromazine (r_dobj) using_16\VBG\1156834|haloperidol (r_acl) schizophrenic_11\NN\10490141|among|six|difficult-to-treat|or|patients|using
D006220_D019965 NONE haloperidol_18\JJ\1740|concomitantly|,|chlorpromazine (r_dobj) using_16\VBG\1156834|haloperidol (r_acl) schizophrenic_11\NN\10490141|among|six|difficult-to-treat|or|patients|using (l_conj) patients_15\NNS\9898892|organic|psychotic (l_amod) psychotic_14\JJ\1740|
D002746_D012559 NONE chlorpromazine_20\NN\3713736|or|clozapine (r_conj) haloperidol_18\JJ\1740|concomitantly|,|chlorpromazine (r_dobj) using_16\VBG\1156834|haloperidol (r_acl) schizophrenic_11\NN\10490141|among|six|difficult-to-treat|or|patients|using
D002746_D019965 NONE chlorpromazine_20\NN\3713736|or|clozapine (r_conj) haloperidol_18\JJ\1740|concomitantly|,|chlorpromazine (r_dobj) using_16\VBG\1156834|haloperidol (r_acl) schizophrenic_11\NN\10490141|among|six|difficult-to-treat|or|patients|using (l_conj) patients_15\NNS\9898892|organic|psychotic (l_amod) psychotic_14\JJ\1740|
D003024_D012559 NONE clozapine_22\NN\3713736| (r_conj) chlorpromazine_20\NN\3713736|or|clozapine (r_conj) haloperidol_18\JJ\1740|concomitantly|,|chlorpromazine (r_dobj) using_16\VBG\1156834|haloperidol (r_acl) schizophrenic_11\NN\10490141|among|six|difficult-to-treat|or|patients|using
D003024_D019965 NONE clozapine_22\NN\3713736| (r_conj) chlorpromazine_20\NN\3713736|or|clozapine (r_conj) haloperidol_18\JJ\1740|concomitantly|,|chlorpromazine (r_dobj) using_16\VBG\1156834|haloperidol (r_acl) schizophrenic_11\NN\10490141|among|six|difficult-to-treat|or|patients|using (l_conj) patients_15\NNS\9898892|organic|psychotic (l_amod) psychotic_14\JJ\1740|
18221780
D016202_D010146 NONE nmda_3\NN\1740| (r_compound) enhancement_5\NN\248977|in|nmda|antagonist|antihyperalgesia (r_nmod) differences_1\NNS\4723816|sex|enhancement|model|:|comparisons|. (l_nmod) model_12\NN\5888929|in|a|capsaicin|pain (l_nmod) pain_15\NN\14299637|of|persistent
D016202_D010146 NONE nmda_7\NN\1740| (r_compound) antagonists_8\NNS\7846|between|nmda|and|morphine|model (l_nmod) model_15\NN\5888929|in|a|persistent|pain (l_compound) pain_14\NN\14299637|
D016202_D059787 NONE nmda_3\NN\1740| (r_compound) enhancement_5\NN\248977|in|nmda|antagonist|antihyperalgesia (r_nmod) differences_1\NNS\4723816|sex|enhancement|model|:|comparisons|. (l_dep) comparisons_17\NNS\635850|models (l_nmod) models_20\NNS\5888929|to|two|pain (l_nmod) pain_23\NN\14299637|of|acute
D016202_D059787 NONE n-methyl-d-aspartate_5\NN\1740|nmda (r_compound) antagonists_9\NNS\7846|n-methyl-d-aspartate (r_nsubj) enhance_10\VBP\227165|models|,|antagonists|effects|extent|. (l_nmod) models_3\NNS\5888929|in|acute|pain (l_compound) pain_2\NN\14299637|
D016202_D059787 NONE nmda_7\NN\1740|(|) (r_appos) n-methyl-d-aspartate_5\NN\1740|nmda (r_compound) antagonists_9\NNS\7846|n-methyl-d-aspartate (r_nsubj) enhance_10\VBP\227165|models|,|antagonists|effects|extent|. (l_nmod) models_3\NNS\5888929|in|acute|pain (l_compound) pain_2\NN\14299637|
D016202_D059787 NONE nmda_7\NN\1740| (r_compound) antagonists_8\NNS\7846|between|nmda|and|morphine|model (r_nmod) interaction_5\NN\37396|a|sexually-dimorphic|antagonists|distinguished (l_acl:relcl) distinguished_19\VBN\618878|that|can|be|those (l_nmod) those_21\DT\1740|from|observed (l_acl) observed_22\VBN\2163746|models (l_nmod) models_26\NNS\5888929|in|acute|pain (l_compound) pain_25\NN\14299637|
D009020_D010146 NONE morphine_7\NN\2707683| (r_compound) antihyperalgesia_8\NN\1740|of|morphine (r_nmod) enhancement_5\NN\248977|in|nmda|antagonist|antihyperalgesia (r_nmod) differences_1\NNS\4723816|sex|enhancement|model|:|comparisons|. (l_nmod) model_12\NN\5888929|in|a|capsaicin|pain (l_nmod) pain_15\NN\14299637|of|persistent
D009020_D010146 NONE morphine_10\NN\2707683| (r_conj) antagonists_8\NNS\7846|between|nmda|and|morphine|model (l_nmod) model_15\NN\5888929|in|a|persistent|pain (l_compound) pain_14\NN\14299637|
D009020_D059787 NONE morphine_7\NN\2707683| (r_compound) antihyperalgesia_8\NN\1740|of|morphine (r_nmod) enhancement_5\NN\248977|in|nmda|antagonist|antihyperalgesia (r_nmod) differences_1\NNS\4723816|sex|enhancement|model|:|comparisons|. (l_dep) comparisons_17\NNS\635850|models (l_nmod) models_20\NNS\5888929|to|two|pain (l_nmod) pain_23\NN\14299637|of|acute
D009020_D059787 NONE morphine_15\NN\2707683|of (r_nmod) effects_13\NNS\13245626|the|antinociceptive|morphine (r_dobj) enhance_10\VBP\227165|models|,|antagonists|effects|extent|. (l_nmod) models_3\NNS\5888929|in|acute|pain (l_compound) pain_2\NN\14299637|
D009020_D059787 NONE morphine_2\NN\2707683| (r_compound) antinociception_3\NN\1740|of|morphine (r_nmod) enhancement_0\NN\248977|antinociception|dextromethorphan (r_nsubjpass) seen_7\VBN\2106506|enhancement|was|males|,|magnitude|greater|. (l_nmod) males_10\NNS\15388|in|both|and|females|models (l_nmod) models_17\NNS\5888929|in|the|acute|pain (l_compound) pain_16\NN\14299637|
D009020_D059787 NONE morphine_10\NN\2707683| (r_conj) antagonists_8\NNS\7846|between|nmda|and|morphine|model (r_nmod) interaction_5\NN\37396|a|sexually-dimorphic|antagonists|distinguished (l_acl:relcl) distinguished_19\VBN\618878|that|can|be|those (l_nmod) those_21\DT\1740|from|observed (l_acl) observed_22\VBN\2163746|models (l_nmod) models_26\NNS\5888929|in|acute|pain (l_compound) pain_25\NN\14299637|
D002211_D010146 NONE capsaicin_11\NN\15032661| (r_compound) model_12\NN\5888929|in|a|capsaicin|pain (l_nmod) pain_15\NN\14299637|of|persistent
D002211_D059787 NONE capsaicin_11\NN\15032661| (r_compound) model_12\NN\5888929|in|a|capsaicin|pain (r_nmod) differences_1\NNS\4723816|sex|enhancement|model|:|comparisons|. (l_dep) comparisons_17\NNS\635850|models (l_nmod) models_20\NNS\5888929|to|two|pain (l_nmod) pain_23\NN\14299637|of|acute
D002211_D006930 CID capsaicin_11\NN\15032661|of (r_nmod) administration_9\NN\1133281|by|capsaicin|tail (r_nmod) induced_7\VBN\1627355|end|,|hyperalgesia|was|administration|,|immersed|,|and|measured|. (l_nsubjpass) hyperalgesia_5\NN\1740|persistent
D003915_D059787 NONE dextromethorphan_5\NN\1740|by (r_nmod) enhancement_0\NN\248977|antinociception|dextromethorphan (r_nsubjpass) seen_7\VBN\2106506|enhancement|was|males|,|magnitude|greater|. (l_nmod) males_10\NNS\15388|in|both|and|females|models (l_nmod) models_17\NNS\5888929|in|the|acute|pain (l_compound) pain_16\NN\14299637|
17261653
D003000_D001919 CID clonidine-induced_0\JJ\1740| (r_amod) bradycardia_1\NN\14110674|clonidine-induced|mice
7858459
D005472_D003221 CID 5-fluorouracil_8\NN\1740|of|and|folinic (r_nmod) infusion_6\NN\14589223|by|a|high-dose|5-fluorouracil|acid (r_nmod) induced_2\VBN\1627355|infusion (r_acl) confusion_1\NN\13972797|acute|induced|.
D005472_D003221 CID 5-fluorouracil_35\NN\1740|of|and|folinic|infusion (r_nmod) dose_29\NN\3740161|during|the|first|day|5-fluorouracil (r_nmod) lasting_21\VBG\2704349|hours|dose (r_advcl) lapsed_15\VBN\124442|then|coma|,|lasting (r_conj) developed_1\VBD\1753788|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\5823932|acute|neurologic|confusion (l_nmod) confusion_7\NN\13972797|of|mental|,|disorientation
D005472_D003221 CID 5-fluorouracil_35\NN\1740|of|and|folinic|infusion (r_nmod) dose_29\NN\3740161|during|the|first|day|5-fluorouracil (r_nmod) lasting_21\VBG\2704349|hours|dose (r_advcl) lapsed_15\VBN\124442|then|coma|,|lasting (r_conj) developed_1\VBD\1753788|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\5823932|acute|neurologic|confusion (l_nmod) confusion_7\NN\13972797|of|mental|,|disorientation (l_conj) disorientation_9\NN\5896733|and|irritability
D002955_D003221 CID acid_11\NN\14818238| (r_conj) infusion_6\NN\14589223|by|a|high-dose|5-fluorouracil|acid (r_nmod) induced_2\VBN\1627355|infusion (r_acl) confusion_1\NN\13972797|acute|induced|.
D002955_D003221 CID acid_38\NN\14818238| (r_compound) infusion_39\NN\14589223|acid (r_dep) 5-fluorouracil_35\NN\1740|of|and|folinic|infusion (r_nmod) dose_29\NN\3740161|during|the|first|day|5-fluorouracil (r_nmod) lasting_21\VBG\2704349|hours|dose (r_advcl) lapsed_15\VBN\124442|then|coma|,|lasting (r_conj) developed_1\VBD\1753788|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\5823932|acute|neurologic|confusion (l_nmod) confusion_7\NN\13972797|of|mental|,|disorientation
D002955_D003221 CID acid_38\NN\14818238| (r_compound) infusion_39\NN\14589223|acid (r_dep) 5-fluorouracil_35\NN\1740|of|and|folinic|infusion (r_nmod) dose_29\NN\3740161|during|the|first|day|5-fluorouracil (r_nmod) lasting_21\VBG\2704349|hours|dose (r_advcl) lapsed_15\VBN\124442|then|coma|,|lasting (r_conj) developed_1\VBD\1753788|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\5823932|acute|neurologic|confusion (l_nmod) confusion_7\NN\13972797|of|mental|,|disorientation (l_conj) disorientation_9\NN\5896733|and|irritability
D002945_D013274 NONE cisplatinum_9\NN\1740|,|etoposide|,|5-fluorouracil|and (r_dobj) incorporating_8\VBG\1461328|cisplatinum (r_acl) chemotherapy_7\NN\661091|with|combination|incorporating|acid (l_conj) acid_22\NN\14818238|folinic|adenocarcinoma (l_nmod) adenocarcinoma_27\NN\14242337|for|an|inoperable|gastric
D005047_D013274 NONE etoposide_11\NN\1740| (r_conj) cisplatinum_9\NN\1740|,|etoposide|,|5-fluorouracil|and (r_dobj) incorporating_8\VBG\1461328|cisplatinum (r_acl) chemotherapy_7\NN\661091|with|combination|incorporating|acid (l_conj) acid_22\NN\14818238|folinic|adenocarcinoma (l_nmod) adenocarcinoma_27\NN\14242337|for|an|inoperable|gastric
D005472_D013274 NONE 5-fluorouracil_14\NN\1740|high-dose|hours (r_conj) cisplatinum_9\NN\1740|,|etoposide|,|5-fluorouracil|and (r_dobj) incorporating_8\VBG\1461328|cisplatinum (r_acl) chemotherapy_7\NN\661091|with|combination|incorporating|acid (l_conj) acid_22\NN\14818238|folinic|adenocarcinoma (l_nmod) adenocarcinoma_27\NN\14242337|for|an|inoperable|gastric
D002955_D013274 NONE acid_22\NN\14818238|folinic|adenocarcinoma (l_nmod) adenocarcinoma_27\NN\14242337|for|an|inoperable|gastric
D005472_D001523 NONE 5-fluorouracil_35\NN\1740|of|and|folinic|infusion (r_nmod) dose_29\NN\3740161|during|the|first|day|5-fluorouracil (r_nmod) lasting_21\VBG\2704349|hours|dose (r_advcl) lapsed_15\VBN\124442|then|coma|,|lasting (r_conj) developed_1\VBD\1753788|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\5823932|acute|neurologic|confusion (l_nmod) confusion_7\NN\13972797|of|mental|,|disorientation (l_conj) disorientation_9\NN\5896733|and|irritability (l_conj) irritability_11\NN\7552087|
D005472_D003128 CID 5-fluorouracil_35\NN\1740|of|and|folinic|infusion (r_nmod) dose_29\NN\3740161|during|the|first|day|5-fluorouracil (r_nmod) lasting_21\VBG\2704349|hours|dose (r_advcl) lapsed_15\VBN\124442|then|coma|,|lasting (l_nmod) coma_19\NN\5678932|into|a|deep
D002955_D001523 NONE acid_38\NN\14818238| (r_compound) infusion_39\NN\14589223|acid (r_dep) 5-fluorouracil_35\NN\1740|of|and|folinic|infusion (r_nmod) dose_29\NN\3740161|during|the|first|day|5-fluorouracil (r_nmod) lasting_21\VBG\2704349|hours|dose (r_advcl) lapsed_15\VBN\124442|then|coma|,|lasting (r_conj) developed_1\VBD\1753788|he|symptoms|,|and|lapsed|. (l_dobj) symptoms_4\NNS\5823932|acute|neurologic|confusion (l_nmod) confusion_7\NN\13972797|of|mental|,|disorientation (l_conj) disorientation_9\NN\5896733|and|irritability (l_conj) irritability_11\NN\7552087|
D002955_D003128 CID acid_38\NN\14818238| (r_compound) infusion_39\NN\14589223|acid (r_dep) 5-fluorouracil_35\NN\1740|of|and|folinic|infusion (r_nmod) dose_29\NN\3740161|during|the|first|day|5-fluorouracil (r_nmod) lasting_21\VBG\2704349|hours|dose (r_advcl) lapsed_15\VBN\124442|then|coma|,|lasting (l_nmod) coma_19\NN\5678932|into|a|deep
D002955_D020258 NONE acid_2\NN\14818238|folinic (r_nsubj) unlikely_4\JJ\1740|because|acid|was|associated (l_xcomp) associated_7\VBN\628491|to|be|condition (l_nmod) condition_10\NN\24720|with|this|,|neurotoxicity (l_conj) neurotoxicity_12\NN\1740|5-fluorouracil
D005472_D020258 NONE 5-fluorouracil_16\NN\1740|due|high-dose (r_nmod) neurotoxicity_12\NN\1740|5-fluorouracil
D005472_D020258 NONE 5-fluorouracil_3\NN\1740| (r_compound) neurotoxicity_4\NN\1740|of|5-fluorouracil
D005463_D020258 NONE fluoroacetate_14\NN\1740|by|and|fluorocitrate|,|deficiency|,|or|deficiency (r_nmod) blockade_12\NN\952963|due|a|krebs|cycle|fluoroacetate (r_nmod) pathogenesis_1\NN\13533470|the|neurotoxicity|blockade|. (l_nmod) neurotoxicity_4\NN\1740|of|5-fluorouracil
C007744_D020258 NONE fluorocitrate_16\VB\1740| (r_conj) fluoroacetate_14\NN\1740|by|and|fluorocitrate|,|deficiency|,|or|deficiency (r_nmod) blockade_12\NN\952963|due|a|krebs|cycle|fluoroacetate (r_nmod) pathogenesis_1\NN\13533470|the|neurotoxicity|blockade|. (l_nmod) neurotoxicity_4\NN\1740|of|5-fluorouracil
D013831_D020258 NONE thiamine_18\NN\15090742| (r_compound) deficiency_19\NN\14449126|thiamine (r_conj) fluoroacetate_14\NN\1740|by|and|fluorocitrate|,|deficiency|,|or|deficiency (r_nmod) blockade_12\NN\952963|due|a|krebs|cycle|fluoroacetate (r_nmod) pathogenesis_1\NN\13533470|the|neurotoxicity|blockade|. (l_nmod) neurotoxicity_4\NN\1740|of|5-fluorouracil
C007419_D020258 NONE dihydrouracil_22\NN\1740| (r_compound) deficiency_24\NN\14449126|dihydrouracil|dehydrogenase (r_conj) fluoroacetate_14\NN\1740|by|and|fluorocitrate|,|deficiency|,|or|deficiency (r_nmod) blockade_12\NN\952963|due|a|krebs|cycle|fluoroacetate (r_nmod) pathogenesis_1\NN\13533470|the|neurotoxicity|blockade|. (l_nmod) neurotoxicity_4\NN\1740|of|5-fluorouracil
D005472_D009369 NONE 5-fluorouracil/folinic_1\NN\1740| (r_compound) therapy_4\NN\657604|high-dose|5-fluorouracil/folinic|acid|infusion (r_nsubj) become_7\VBN\146138|therapy|has|recently|regimen|. (l_attr) regimen_10\NN\5898568|a|popular|cancers (l_nmod) cancers_13\NNS\14239425|for|various
D002955_D009369 NONE acid_2\NN\14818238| (r_compound) therapy_4\NN\657604|high-dose|5-fluorouracil/folinic|acid|infusion (r_nsubj) become_7\VBN\146138|therapy|has|recently|regimen|. (l_attr) regimen_10\NN\5898568|a|popular|cancers (l_nmod) cancers_13\NNS\14239425|for|various
2234245
D003676_D014786 NONE desferrioxamine_8\NN\1740| (r_dobj) receiving_7\VBG\2210855|desferrioxamine (r_acl) patients_6\NNS\9898892|in|hemodialyzed|receiving (r_nmod) ocular_0\JJ\1740|and|auditory|toxicity|patients|. (l_dep) toxicity_3\NN\13576101|
D003676_D014786 NONE desferrioxamine_10\NN\1740| (r_dobj) receiving_9\VBG\2210855|desferrioxamine (r_acl) patients_8\NNS\9898892|period|41|hemodialyzed|receiving|times|)|time (r_nsubjpass) monitored_25\VBN\2169352|patients|were|detection|. (l_nmod) detection_27\NN\5708432|for|toxicity (l_nmod) toxicity_30\NN\13576101|of|audiovisual
D003676_D014786 NONE desferrioxamine_15\NN\1740| (r_dobj) receiving_14\VBG\2210855|desferrioxamine (r_acl) patients_13\NNS\9898892|in|hemodialyzed|receiving (r_nmod) complication_10\NN\1073995|that|toxicity|is|not|an|infrequent|patients (l_nsubj) toxicity_5\NN\13576101|audiovisual
D003676_D006311 NONE desferrioxamine_8\NN\1740| (r_dobj) receiving_7\VBG\2210855|desferrioxamine (r_acl) patients_6\NNS\9898892|in|hemodialyzed|receiving (r_nmod) ocular_0\JJ\1740|and|auditory|toxicity|patients|. (l_dep) toxicity_3\NN\13576101|
D003676_D006311 NONE desferrioxamine_10\NN\1740| (r_dobj) receiving_9\VBG\2210855|desferrioxamine (r_acl) patients_8\NNS\9898892|period|41|hemodialyzed|receiving|times|)|time (r_nsubjpass) monitored_25\VBN\2169352|patients|were|detection|. (l_nmod) detection_27\NN\5708432|for|toxicity (l_nmod) toxicity_30\NN\13576101|of|audiovisual
D003676_D006311 NONE desferrioxamine_15\NN\1740| (r_dobj) receiving_14\VBG\2210855|desferrioxamine (r_acl) patients_13\NNS\9898892|in|hemodialyzed|receiving (r_nmod) complication_10\NN\1073995|that|toxicity|is|not|an|infrequent|patients (l_nsubj) toxicity_5\NN\13576101|audiovisual
D003676_D034381 NONE desferrioxamine_0\NN\1740| (r_compound) withdrawal_1\NN\7206096|desferrioxamine (r_nsubj) resulted_2\VBD\2633881|withdrawal|recovery|,|and|reversal|. (l_conj) reversal_22\NN\199130|a|complete|hearing (l_acl) hearing_24\VBG\2106506|of|loss|patients|3 (l_dobj) loss_25\NN\13252973|
D003676_D064420 NONE desferrioxamine_10\NN\1740|of (r_nmod) doses_8\NNS\3740161|the|higher|desferrioxamine (r_dobj) receiving_5\VBG\2210855|doses (r_acl) patients_4\NNS\9898892|in|receiving (r_nmod) appeared_2\VBD\2604760|toxicity|patients|or|coincided|. (l_nsubj) toxicity_1\NN\13576101|this
-1_D064420 NONE aluminium_19\NN\14625458| (r_conj) ferritin_17\NN\14728724|of|or|aluminium (r_compound) levels_21\NNS\4916342|ferritin|serum (r_nmod) normalization_15\NN\1123598|with|the|levels (r_nmod) coincided_12\VBD\2604477|normalization (r_conj) appeared_2\VBD\2604760|toxicity|patients|or|coincided|. (l_nsubj) toxicity_1\NN\13576101|this
17437408
D010862_D012640 CID pilocarpine-induced_11\JJ\1740| (r_amod) seizures_12\NNS\14081375|after|pilocarpine-induced
18020536
D001569_D004244 CID bzds/rds_4\NN\1740|of (r_nmod) use_2\NN\407535|bzds/rds (r_nsubjpass) associated_6\VBN\628491|however|,|use|was|dizziness|. (l_nmod) dizziness_8\NN\14299637|with|,|inability
D001569_D007319 CID bzds/rds_4\NN\1740|of (r_nmod) use_2\NN\407535|bzds/rds (r_nsubjpass) associated_6\VBN\628491|however|,|use|was|dizziness|. (l_nmod) dizziness_8\NN\14299637|with|,|inability (l_conj) inability_10\NN\23271|sleep (l_acl) sleep_12\VB\14405|to|awaking
D001569_D005221 CID bzds/rds_4\NN\1740|of (r_nmod) use_2\NN\407535|bzds/rds (r_nsubjpass) associated_6\VBN\628491|however|,|use|was|dizziness|. (l_nmod) dizziness_8\NN\14299637|with|,|inability (l_conj) inability_10\NN\23271|sleep (l_acl) sleep_12\VB\14405|to|awaking (l_advcl) awaking_14\VBG\146138|after|night|and|tiredness (l_conj) tiredness_18\VB\1740|mornings|week|symptoms|stay
D001569_D003866 CID bzds/rds_4\NN\1740|of (r_nmod) use_2\NN\407535|bzds/rds (r_nsubjpass) associated_6\VBN\628491|however|,|use|was|dizziness|. (l_nmod) dizziness_8\NN\14299637|with|,|inability (l_conj) inability_10\NN\23271|sleep (l_acl) sleep_12\VB\14405|to|awaking (l_advcl) awaking_14\VBG\146138|after|night|and|tiredness (l_conj) tiredness_18\VB\1740|mornings|week|symptoms|stay (l_nmod) symptoms_32\NNS\5823932|with|depressive|measured
9625142
D002443_D056486 CID ceftriaxone_11\NN\2996840|by (r_nmod) induced_9\VBN\1627355|ceftriaxone (r_acl) erythroblastocytopenia_8\NN\1740|induced (r_conj) hepatitis_1\NN\14127211|acute|,|anemia|,|and|erythroblastocytopenia|.
D002443_D056486 CID ceftriaxone_10\NN\2996840|oral (r_dobj) ingesting_8\VBG\597915|after|ceftriaxone (r_advcl) developed_3\VBD\1753788|man|hepatitis|ingesting|. (l_dobj) hepatitis_5\NN\14127211|acute
D002443_D000744 CID ceftriaxone_11\NN\2996840|by (r_nmod) induced_9\VBN\1627355|ceftriaxone (r_acl) erythroblastocytopenia_8\NN\1740|induced (r_conj) hepatitis_1\NN\14127211|acute|,|anemia|,|and|erythroblastocytopenia|. (l_conj) anemia_5\NN\14189204|autoimmune|hemolytic
D002443_-1 NONE ceftriaxone_11\NN\2996840|by (r_nmod) induced_9\VBN\1627355|ceftriaxone (r_acl) erythroblastocytopenia_8\NN\1740|induced
D047090_D000744 NONE lactam_11\NN\1740|the|beta (r_compound) antibiotic_12\NN\2716205|lactam (r_dobj) withholding_8\VBG\2212825|after|antibiotic (r_advcl) returned_4\VBD\1835496|although|transaminases|gradually|baseline|withholding (r_advcl) was_15\VBD\836236|returned|,|there|increase|. (l_nsubj) increase_18\NN\13576355|a|gradual|bilirubin|and|decrease (l_conj) decrease_24\NN\7296428|a|concentration|caused (l_acl) caused_28\VBN\1617192|anemia (l_nmod) anemia_33\NN\14189204|by|an|autoimmune|hemolytic|and|erythroblastocytopenia
D047090_-1 NONE lactam_11\NN\1740|the|beta (r_compound) antibiotic_12\NN\2716205|lactam (r_dobj) withholding_8\VBG\2212825|after|antibiotic (r_advcl) returned_4\VBD\1835496|although|transaminases|gradually|baseline|withholding (r_advcl) was_15\VBD\836236|returned|,|there|increase|. (l_nsubj) increase_18\NN\13576355|a|gradual|bilirubin|and|decrease (l_conj) decrease_24\NN\7296428|a|concentration|caused (l_acl) caused_28\VBN\1617192|anemia (l_nmod) anemia_33\NN\14189204|by|an|autoimmune|hemolytic|and|erythroblastocytopenia (l_conj) erythroblastocytopenia_35\NN\1740|
D001663_D000744 NONE bilirubin_21\NN\14756039|in|serum (r_nmod) increase_18\NN\13576355|a|gradual|bilirubin|and|decrease (l_conj) decrease_24\NN\7296428|a|concentration|caused (l_acl) caused_28\VBN\1617192|anemia (l_nmod) anemia_33\NN\14189204|by|an|autoimmune|hemolytic|and|erythroblastocytopenia
D001663_-1 NONE bilirubin_21\NN\14756039|in|serum (r_nmod) increase_18\NN\13576355|a|gradual|bilirubin|and|decrease (l_conj) decrease_24\NN\7296428|a|concentration|caused (l_acl) caused_28\VBN\1617192|anemia (l_nmod) anemia_33\NN\14189204|by|an|autoimmune|hemolytic|and|erythroblastocytopenia (l_conj) erythroblastocytopenia_35\NN\1740|
16403073
D007654_D016171 CID ketoconazole_0\NNP\1740| (r_nsubj) induced_1\VBD\1627355|ketoconazole|torsades|use|. (l_dobj) torsades_2\NNS\1740|pointes (l_nmod) pointes_4\NNS\1740|de
D007654_D016171 CID ketoconazole_24\NN\1740| (r_dobj) taking_23\VBG\2367363|after|ketoconazole|treatment (r_advcl) developed_9\VBD\1753788|who|interval|and|torsades|taking (l_conj) torsades_16\NNS\1740|pointes (l_nmod) pointes_18\NNS\1740|de|tdp
D007654_D016171 CID ketoconazole_24\NN\1740| (r_dobj) taking_23\VBG\2367363|after|ketoconazole|treatment (r_advcl) developed_9\VBD\1753788|who|interval|and|torsades|taking (l_conj) torsades_16\NNS\1740|pointes (l_nmod) pointes_18\NNS\1740|de|tdp (l_appos) tdp_20\NN\1740|(|)
D007654_D016171 CID ketoconazole_13\NN\1740| (r_appos) ikr_11\NN\1740|on|,|ketoconazole|alone (r_nmod) action_9\NN\30358|virtue|of|its|direct|blocking|ikr (r_nsubj) prolong_16\VB\317700|that|action|may|interval|and|induce (l_conj) induce_20\VBP\1627355|tdp.|calls|attention|administered (l_dobj) tdp._21\NN\1740|
D007654_D016171 CID ketoconazole_27\NN\1740| (r_nsubjpass) administered_29\VBN\2436349|when|ketoconazole|is|patients (r_advcl) induce_20\VBP\1627355|tdp.|calls|attention|administered (l_dobj) tdp._21\NN\1740|
D007654_D003324 NONE ketoconazole_24\NN\1740| (r_dobj) taking_23\VBG\2367363|after|ketoconazole|treatment (r_advcl) developed_9\VBD\1753788|who|interval|and|torsades|taking (r_acl:relcl) disease_7\NN\14061805|with|coronary|artery|developed
D007654_D008133 CID ketoconazole_24\NN\1740| (r_dobj) taking_23\VBG\2367363|after|ketoconazole|treatment (r_advcl) developed_9\VBD\1753788|who|interval|and|torsades|taking (l_dobj) interval_14\NN\33615|a|prolonged|qt
D007654_D008133 CID ketoconazole_13\NN\1740| (r_appos) ikr_11\NN\1740|on|,|ketoconazole|alone (r_nmod) action_9\NN\30358|virtue|of|its|direct|blocking|ikr (r_nsubj) prolong_16\VB\317700|that|action|may|interval|and|induce (l_conj) induce_20\VBP\1627355|tdp.|calls|attention|administered (l_advcl) administered_29\VBN\2436349|when|ketoconazole|is|patients (l_nmod) patients_31\NNS\9898892|to|factors (l_nmod) factors_34\NNS\7326557|with|risk|syndrome (l_nmod) syndrome_39\NN\5870365|for|acquired|long|qt
D007654_D008133 CID ketoconazole_27\NN\1740| (r_nsubjpass) administered_29\VBN\2436349|when|ketoconazole|is|patients (l_nmod) patients_31\NNS\9898892|to|factors (l_nmod) factors_34\NNS\7326557|with|risk|syndrome (l_nmod) syndrome_39\NN\5870365|for|acquired|long|qt
D007654_D009181 NONE ketoconazole_24\NN\1740| (r_dobj) taking_23\VBG\2367363|after|ketoconazole|treatment (l_nmod) treatment_26\NN\654885|for|infection (l_nmod) infection_29\NN\14052046|of|fungal
3341566
D009599_D006470 NONE nitroprusside-induced_10\JJ\1740|sodium (r_amod) hypotension_11\NN\14057371|than|during|nitroprusside-induced|dogs (r_nmod) greater_4\JJR\1740|variation|is|hemorrhage|hypotension|. (l_nmod) hemorrhage_6\NN\14285662|during
D009599_D006470 NONE nitroprusside_28\NN\1740|of|sodium (r_nmod) infusion_25\NN\14589223|by|continuous|nitroprusside|snp (r_conj) hemorrhage_14\NN\14285662|either|by|hem|or|infusion
D009599_D006470 NONE nitroprusside_28\NN\1740|of|sodium (r_nmod) infusion_25\NN\14589223|by|continuous|nitroprusside|snp (r_conj) hemorrhage_14\NN\14285662|either|by|hem|or|infusion (l_dep) hem_16\NN\3264542|(|,|n|)
D009599_D006470 NONE snp_30\NN\11493266|(|,|n|) (r_dep) infusion_25\NN\14589223|by|continuous|nitroprusside|snp (r_conj) hemorrhage_14\NN\14285662|either|by|hem|or|infusion
D009599_D006470 NONE snp_30\NN\11493266|(|,|n|) (r_dep) infusion_25\NN\14589223|by|continuous|nitroprusside|snp (r_conj) hemorrhage_14\NN\14285662|either|by|hem|or|infusion (l_dep) hem_16\NN\3264542|(|,|n|)
D009599_D006470 NONE snp_19\NN\11493266| (r_compound) group_20\NN\2137|in|the|snp (r_nmod) that_16\DT\1740|with|group (r_nmod) compared_14\VBN\644583|that (r_dep) lower_8\JJR\1740|hypotension|output|was|significantly|and|systemic|resistance|compared|. (l_nmod) hypotension_2\NN\14057371|during|hem-induced (l_amod) hem-induced_1\JJ\1740|
D009599_D006470 NONE snp_24\NN\11493266| (r_compound) group_25\NN\2137|in|the|snp (r_nmod) hg_21\NNP\14625458|compared|mm|group|p (r_dep) mm_8\NN\13649268|spv|was|15.7|hg|group|,|hg|. (l_nmod) group_13\NN\2137|in|the|hem (l_compound) hem_12\NN\3264542|
D009599_D006470 NONE snp_31\NN\11493266| (r_conj) hem_29\NN\3264542|and|snp
D009599_D007022 CID nitroprusside-induced_10\JJ\1740|sodium (r_amod) hypotension_11\NN\14057371|than|during|nitroprusside-induced|dogs
D009599_D007022 CID snp_19\NN\11493266| (r_compound) group_20\NN\2137|in|the|snp (r_nmod) that_16\DT\1740|with|group (r_nmod) compared_14\VBN\644583|that (r_dep) lower_8\JJR\1740|hypotension|output|was|significantly|and|systemic|resistance|compared|. (l_nmod) hypotension_2\NN\14057371|during|hem-induced
D009599_D007022 CID snp_24\NN\11493266| (r_compound) group_25\NN\2137|in|the|snp (r_nmod) hg_21\NNP\14625458|compared|mm|group|p (r_dep) mm_8\NN\13649268|spv|was|15.7|hg|group|,|hg|. (l_nsubj) spv_1\NN\1740|the|hypotension (l_nmod) hypotension_3\NN\14057371|during
D009599_D007022 CID snp_31\NN\11493266| (r_conj) hem_29\NN\3264542|and|snp (r_compound) groups_32\NNS\2137|in|the|hem (r_nmod) hg_26\NNP\14625458|was|mm|groups|, (r_nsubj) down_2\RP\1740|delta|,|measure|,|hg|respectively|,|hypotension|. (l_nmod) hypotension_37\NN\14057371|during|p
15009014
D002211_D006940 CID capsaicin_0\NN\15032661|mm|applied (r_nsubj) induced_13\VBN\1627355|capsaicin|increases|provoked|. (l_dobj) increases_14\NNS\13576355|flow (l_nmod) flow_20\NN\7311115|in|dural|blood|and
D001285_D006940 NONE atropine_14\NN\14712692|of (r_nmod) pre-administration_12\NN\1740|by|topical|atropine (r_nmod) abolished_9\VBN\1740|increases|were|also|pre-administration|mm|and|tyr6]-vip|mater|. (l_nsubjpass) increases_2\NNS\13576355|evoked|flow (l_nmod) flow_6\NN\7311115|in|dural|blood
19058010
D010936_D009203 NONE tea_3\NN\7881800|of|green|and|combination (r_nmod) effect_0\NN\34213|tea|infarction|. (l_nmod) infarction_12\NN\14204950|in|isoproterenol|myocardial|rats
D010936_D009203 NONE tea_12\NN\7881800|of|green|and|e (r_nmod) effects_9\NNS\13245626|the|combined|tea|weight (r_dobj) investigate_6\VB\644583|to|effects (r_xcomp) aimed_4\VBN\1987160|study|was|investigate|bound|. (l_conj) bound_34\VBD\1831531|atpases|infarction (l_dobj) infarction_40\NN\14204950|isoproterenol|(iso)-induced|myocardial|rats
D010936_D009203 NONE tea_9\NN\7881800|of|green|and|e (r_nmod) effect_6\NN\34213|the|synergistic|protective|tea|infarction (l_nmod) infarction_17\NN\14204950|during|iso|myocardial|rats
D014810_D009203 NONE e_6\NN\14724645| (r_compound) combination_7\NN\7951464|vitamin|e (r_conj) tea_3\NN\7881800|of|green|and|combination (r_nmod) effect_0\NN\34213|tea|infarction|. (l_nmod) infarction_12\NN\14204950|in|isoproterenol|myocardial|rats
D014810_D009203 NONE e_15\NN\14724645|vitamin (r_conj) tea_12\NN\7881800|of|green|and|e (r_nmod) effects_9\NNS\13245626|the|combined|tea|weight (r_dobj) investigate_6\VB\644583|to|effects (r_xcomp) aimed_4\VBN\1987160|study|was|investigate|bound|. (l_conj) bound_34\VBD\1831531|atpases|infarction (l_dobj) infarction_40\NN\14204950|isoproterenol|(iso)-induced|myocardial|rats
D014810_D009203 NONE e_12\NN\14724645|vitamin (r_conj) tea_9\NN\7881800|of|green|and|e (r_nmod) effect_6\NN\34213|the|synergistic|protective|tea|infarction (l_nmod) infarction_17\NN\14204950|during|iso|myocardial|rats
D007545_D009203 CID isoproterenol_9\NN\3740161|induced (r_amod) infarction_12\NN\14204950|in|isoproterenol|myocardial|rats
D007545_D009203 CID isoproterenol_37\NN\3740161|in (r_compound) infarction_40\NN\14204950|isoproterenol|(iso)-induced|myocardial|rats
D007545_D009203 CID (iso)-induced_38\VBN\1740| (r_amod) infarction_40\NN\14204950|isoproterenol|(iso)-induced|myocardial|rats
D007545_D009203 CID iso_14\NN\1740|induced (r_amod) infarction_17\NN\14204950|during|iso|myocardial|rats
2096243
C017367_D019965 CID carmofur-induced_0\JJ\1740| (r_amod) disorders_3\NNS\14034177|carmofur-induced|organic|mental|.
C017367_D019965 CID carmofur-induced_17\JJ\1740| (r_amod) leukoencephalopathy_18\NN\1740|of|carmofur-induced (r_nmod) onset_15\NN\7325190|after|the|leukoencephalopathy (r_nmod) period_12\NN\13575869|in|the|prognostic|onset (r_nmod) female_8\NN\15388|in|a|29-year-old|period (r_nmod) observed_4\VBN\2163746|disorder|was|female|. (l_nsubjpass) disorder_2\NN\14034177|organic|mental
C017367_D056784 CID carmofur-induced_17\JJ\1740| (r_amod) leukoencephalopathy_18\NN\1740|of|carmofur-induced
C017367_D056784 CID carmofur-induced_2\JJ\1740| (r_amod) leukoencephalopathy_3\NN\1740|carmofur-induced
C017367_D010554 NONE carmofur-induced_2\JJ\1740| (r_amod) leukoencephalopathy_3\NN\1740|carmofur-induced (r_nsubj) result_6\VB\2633881|consequently|,|leukoencephalopathy|may|uncommonly|syndrome|. (l_nmod) syndrome_10\NN\5870365|in|organic|personality|state
3676049
D007530_D007022 CID isoflurane-induced_6\JJ\1740| (r_amod) hypotension_7\NN\14057371|during|isoflurane-induced|patients
D007530_D007022 CID isoflurane-induced_12\JJ\1740| (r_amod) hypotension_13\NN\14057371|during|isoflurane-induced|patients
D007530_D007022 CID isoflurane_19\NN\3570838|of (r_nmod) dose_17\NN\3740161|the|isoflurane (r_dobj) increasing_15\VBG\169651|by|dose (r_advcl) induced_13\VBN\1627355|hypotension|hg|was|increasing|,|and|maintained|. (l_nsubjpass) hypotension_1\NN\14057371|controlled|map
D007530_D002532 NONE isoflurane-induced_6\JJ\1740| (r_amod) hypotension_7\NN\14057371|during|isoflurane-induced|patients (l_nmod) patients_9\NNS\9898892|in|subjected (l_acl) subjected_10\VBN\137313|surgery|aneurysms (l_nmod) aneurysms_15\NNS\14057371|for|cerebral
D007530_D002532 NONE isoflurane-induced_12\JJ\1740| (r_amod) hypotension_13\NN\14057371|during|isoflurane-induced|patients (l_nmod) patients_16\NNS\9898892|in|10|subjected (l_acl) subjected_17\VBN\137313|craniotomy (l_advcl) craniotomy_19\VB\1740|to|clipping (l_nmod) clipping_21\VBG\1552519|for|aneurysm (l_nmod) aneurysm_25\NN\14057371|of|a|cerebral
D010100_D007022 NONE oxygen_8\NN\14622893|for (r_nmod) flow_2\NN\7311115|cerebral|blood|and|rate|oxygen (r_nsubjpass) measured_10\VBN\697589|flow|were|hypotension|. (l_nmod) hypotension_13\NN\14057371|during|isoflurane-induced|patients
D010100_D002532 NONE oxygen_8\NN\14622893|for (r_nmod) flow_2\NN\7311115|cerebral|blood|and|rate|oxygen (r_nsubjpass) measured_10\VBN\697589|flow|were|hypotension|. (l_nmod) hypotension_13\NN\14057371|during|isoflurane-induced|patients (l_nmod) patients_16\NNS\9898892|in|10|subjected (l_acl) subjected_17\VBN\137313|craniotomy (l_advcl) craniotomy_19\VB\1740|to|clipping (l_nmod) clipping_21\VBG\1552519|for|aneurysm (l_nmod) aneurysm_25\NN\14057371|of|a|cerebral
D014978_D013345 NONE xenon-133_22\NN\1740| (r_compound) anaesthesia_24\NNP\14034177|xenon-133|i.v. (r_dobj) using_21\VBG\1156834|anaesthesia (r_xcomp) measured_4\VBN\697589|flow|were|days|haemorrhage|using|maintained|. (l_nmod) haemorrhage_12\NN\14285662|after|the|subarachnoid|modification
D007530_D013345 NONE isoflurane_30\NN\3570838| (r_compound) concentration_31\NN\4916342|with|an|inspired|isoflurane|% (r_nmod) maintained_26\VBN\2202928|was|concentration|,|min-1 (r_conj) measured_4\VBN\697589|flow|were|days|haemorrhage|using|maintained|. (l_nmod) haemorrhage_12\NN\14285662|after|the|subarachnoid|modification
D009609_D013345 NONE oxide_40\NN\14818238|nitrous|oxygen (r_dep) %_38\NN\1740|67|oxide (r_conj) %_34\NN\1740|of|0.75|(|plus|%|) (r_nmod) concentration_31\NN\4916342|with|an|inspired|isoflurane|% (r_nmod) maintained_26\VBN\2202928|was|concentration|,|min-1 (r_conj) measured_4\VBN\697589|flow|were|days|haemorrhage|using|maintained|. (l_nmod) haemorrhage_12\NN\14285662|after|the|subarachnoid|modification
D010100_D013345 NONE oxygen_42\NN\14622893|in (r_nmod) oxide_40\NN\14818238|nitrous|oxygen (r_dep) %_38\NN\1740|67|oxide (r_conj) %_34\NN\1740|of|0.75|(|plus|%|) (r_nmod) concentration_31\NN\4916342|with|an|inspired|isoflurane|% (r_nmod) maintained_26\VBN\2202928|was|concentration|,|min-1 (r_conj) measured_4\VBN\697589|flow|were|days|haemorrhage|using|maintained|. (l_nmod) haemorrhage_12\NN\14285662|after|the|subarachnoid|modification
D008628_D007022 NONE hg_11\NNP\14625458| (r_nsubjpass) induced_13\VBN\1627355|hypotension|hg|was|increasing|,|and|maintained|. (l_nsubjpass) hypotension_1\NN\14057371|controlled|map
D007530_D000783 NONE isoflurane_7\NN\3570838| (r_compound) concentration_8\NN\4916342|the|isoflurane (r_nsubjpass) reduced_10\VBN\441445|clipping|concentration|was|%|. (l_nmod) clipping_2\NN\6400510|after|the|aneurysm (l_nmod) aneurysm_5\NN\14057371|of|the
10706004
D012964_D006973 NONE sodium_2\NN\14625458|and|atp (r_compound) affinities_5\NNS\11426530|of|sodium|(na (r_nmod) changes_0\NNS\7283608|affinities|during|hypertension|. (l_nmod) hypertension_18\NN\14057371|oxide|deficient
D012964_D006973 NONE (na_9\NN\1740|of|the|cardiac|,|k)-atpase (r_nmod) affinities_5\NNS\11426530|of|sodium|(na (r_nmod) changes_0\NNS\7283608|affinities|during|hypertension|. (l_nmod) hypertension_18\NN\14057371|oxide|deficient
D012964_D006973 NONE sodium_9\NN\14625458| (r_compound) level_10\NN\4916342|of|intracellular|sodium (r_nmod) elevation_6\NN\7445480|level (r_nsubjpass) documented_12\VBN\1000214|models|,|elevation|was|tissue|. (l_nmod) models_2\NNS\5888929|in|several|hypertension (l_nmod) hypertension_4\NN\14057371|of
D012964_D006973 NONE na+_11\NN\1740|of (r_nmod) transport_9\NN\3575240|in|transmembraneous|na+ (r_nmod) disturbances_6\NNS\407535|of|transport (r_nmod) basis_4\NN\13790712|the|molecular|disturbances (r_dobj) assess_1\VB\670261|to|basis (r_advcl) studied_14\VBD\630380|assess|,|we|response|weeks|. (l_dobj) response_16\NN\11410625|the|(na|hypertension (l_nmod) hypertension_24\NN\14057371|to|no-deficient|induced
D012964_D006973 NONE (na_19\NN\1740|of|cardiac|,|k)-atpase (r_nmod) response_16\NN\11410625|the|(na|hypertension (l_nmod) hypertension_24\NN\14057371|to|no-deficient|induced
D012964_D006973 NONE (na_8\NN\1740|of (r_nmod) activity_6\NN\30358|the|(na (r_nsubj) increased_11\VBD\169651|recovery|,|activity|,|k)-atpase|,|affinity|,|revealed|. (l_nmod) recovery_1\NN\7357388|after|hypertension (l_nmod) hypertension_3\NN\14057371|from
D012964_D006973 NONE na+-extrusion_10\NN\1740|by|depressed|cells (r_nmod) accompanied_7\VBN\1835496|na+-extrusion|consequence (r_acl) hypertension_6\NN\14057371|a|reversible|accompanied
D012964_D006973 NONE na+-binding_19\NN\1740| (r_compound) properties_20\NNS\32613|of|deteriorated|na+-binding|(na (r_nmod) consequence_16\NN\34213|as|a|properties (r_nmod) accompanied_7\VBN\1835496|na+-extrusion|consequence (r_acl) hypertension_6\NN\14057371|a|reversible|accompanied
D012964_D006973 NONE (na_23\NN\1740|of|the|,|k)-atpase (r_nmod) properties_20\NNS\32613|of|deteriorated|na+-binding|(na (r_nmod) consequence_16\NN\34213|as|a|properties (r_nmod) accompanied_7\VBN\1835496|na+-extrusion|consequence (r_acl) hypertension_6\NN\14057371|a|reversible|accompanied
D000255_D006973 NONE atp_4\NN\14964590| (r_conj) sodium_2\NN\14625458|and|atp (r_compound) affinities_5\NNS\11426530|of|sodium|(na (r_nmod) changes_0\NNS\7283608|affinities|during|hypertension|. (l_nmod) hypertension_18\NN\14057371|oxide|deficient
D000255_D006973 NONE atp-binding_19\JJ\1740| (r_amod) site_20\NN\8673395|of|the|atp-binding (r_nmod) affinity_16\NN\11426530|due|higher|site (r_nmod) increased_11\VBD\169651|recovery|,|activity|,|k)-atpase|,|affinity|,|revealed|. (l_nmod) recovery_1\NN\7357388|after|hypertension (l_nmod) hypertension_3\NN\14057371|from
D000255_D006973 NONE atp_30\NN\14964590|for (r_nmod) value_28\NN\5856066|from|the|lowered|km|atp (r_nmod) revealed_23\VBN\2137132|as|value (r_advcl) increased_11\VBD\169651|recovery|,|activity|,|k)-atpase|,|affinity|,|revealed|. (l_nmod) recovery_1\NN\7357388|after|hypertension (l_nmod) hypertension_3\NN\14057371|from
D011188_D006973 NONE k)-atpase_11\NN\1740| (r_conj) (na_9\NN\1740|of|the|cardiac|,|k)-atpase (r_nmod) affinities_5\NNS\11426530|of|sodium|(na (r_nmod) changes_0\NNS\7283608|affinities|during|hypertension|. (l_nmod) hypertension_18\NN\14057371|oxide|deficient
D011188_D006973 NONE k)-atpase_21\NN\1740| (r_conj) (na_19\NN\1740|of|cardiac|,|k)-atpase (r_nmod) response_16\NN\11410625|the|(na|hypertension (l_nmod) hypertension_24\NN\14057371|to|no-deficient|induced
D011188_D006973 NONE k)-atpase_10\NN\1740| (r_nsubj) increased_11\VBD\169651|recovery|,|activity|,|k)-atpase|,|affinity|,|revealed|. (l_nmod) recovery_1\NN\7357388|after|hypertension (l_nmod) hypertension_3\NN\14057371|from
D011188_D006973 NONE k)-atpase_25\NN\1740| (r_appos) (na_23\NN\1740|of|the|,|k)-atpase (r_nmod) properties_20\NNS\32613|of|deteriorated|na+-binding|(na (r_nmod) consequence_16\NN\34213|as|a|properties (r_nmod) accompanied_7\VBN\1835496|na+-extrusion|consequence (r_acl) hypertension_6\NN\14057371|a|reversible|accompanied
D009569_D006973 CID oxide_16\NN\14818238|nitric (r_compound) hypertension_18\NN\14057371|oxide|deficient
D009569_D006973 CID no_2\NN\7204911| (r_compound) synthesis_3\NN\13446390|of|no (r_nmod) inhibition_0\NN\1068773|synthesis (r_nsubj) induces_4\VBZ\1627355|inhibition|hypertension|. (l_dobj) hypertension_6\NN\14057371|sustained
D009569_D006973 CID no-deficient_23\JJ\1740| (r_amod) hypertension_24\NN\14057371|to|no-deficient|induced
D009569_D006973 CID no-synthase_29\NN\1740| (r_compound) inhibition_30\NN\1068773|by|no-synthase|ester (r_nmod) induced_25\VBN\1627355|rats|inhibition (r_acl) hypertension_24\NN\14057371|to|no-deficient|induced
D009569_D006973 CID no-synthase_2\NN\1740|of (r_nmod) inhibition_0\NN\1068773|no-synthase (r_nsubj) induced_3\VBD\1627355|inhibition|hypertension|. (l_dobj) hypertension_6\NN\14057371|a|reversible|accompanied
D019331_D006973 NONE ester_36\NN\14727670|with|mg/kg/day|n(g)-nitro-l-arginine|methyl|l-name (r_nmod) inhibition_30\NN\1068773|by|no-synthase|ester (r_nmod) induced_25\VBN\1627355|rats|inhibition (r_acl) hypertension_24\NN\14057371|to|no-deficient|induced
D019331_D006973 NONE l-name_38\NN\1740|(|) (r_appos) ester_36\NN\14727670|with|mg/kg/day|n(g)-nitro-l-arginine|methyl|l-name (r_nmod) inhibition_30\NN\1068773|by|no-synthase|ester (r_nmod) induced_25\VBN\1627355|rats|inhibition (r_acl) hypertension_24\NN\14057371|to|no-deficient|induced
D009569_D003866 NONE no-synthase_2\NN\1740|of (r_nmod) inhibition_0\NN\1068773|no-synthase (r_nsubj) induced_3\VBD\1627355|inhibition|hypertension|. (l_dobj) hypertension_6\NN\14057371|a|reversible|accompanied (l_acl) accompanied_7\VBN\1835496|na+-extrusion|consequence (l_nmod) na+-extrusion_10\NN\1740|by|depressed|cells (l_amod) depressed_9\JJ\1740|
D012964_D003866 NONE na+-extrusion_10\NN\1740|by|depressed|cells (l_amod) depressed_9\JJ\1740|
D012964_D003866 NONE na+-binding_19\NN\1740| (r_compound) properties_20\NNS\32613|of|deteriorated|na+-binding|(na (r_nmod) consequence_16\NN\34213|as|a|properties (r_nmod) accompanied_7\VBN\1835496|na+-extrusion|consequence (l_nmod) na+-extrusion_10\NN\1740|by|depressed|cells (l_amod) depressed_9\JJ\1740|
D012964_D003866 NONE (na_23\NN\1740|of|the|,|k)-atpase (r_nmod) properties_20\NNS\32613|of|deteriorated|na+-binding|(na (r_nmod) consequence_16\NN\34213|as|a|properties (r_nmod) accompanied_7\VBN\1835496|na+-extrusion|consequence (l_nmod) na+-extrusion_10\NN\1740|by|depressed|cells (l_amod) depressed_9\JJ\1740|
D011188_D003866 NONE k)-atpase_25\NN\1740| (r_appos) (na_23\NN\1740|of|the|,|k)-atpase (r_nmod) properties_20\NNS\32613|of|deteriorated|na+-binding|(na (r_nmod) consequence_16\NN\34213|as|a|properties (r_nmod) accompanied_7\VBN\1835496|na+-extrusion|consequence (l_nmod) na+-extrusion_10\NN\1740|by|depressed|cells (l_amod) depressed_9\JJ\1740|
10737864
D003000_D001919 CID clonidine_14\NN\2721160|given|that (r_nsubj) induces_15\VBZ\1627355|clonidine|withdrawal (l_dobj) withdrawal_17\NN\7206096|sympathetic|and|bradycardia (l_conj) bradycardia_19\NN\14110674|
D003000_D001919 CID clonidine_24\NN\2721160|'s (r_nmod:poss) effects_27\NNS\13245626|clonidine|developmental|rate (r_nsubj) mirror_35\VB\2136271|that|effects|would|other (r_ccomp) hypothesized_22\VBD\719734|,|we|mirror|. (r_conj) exhibits_5\VBZ\2632167|dominance|pattern|,|and|induces|hypothesized (l_conj) induces_15\VBZ\1627355|clonidine|withdrawal (l_dobj) withdrawal_17\NN\7206096|sympathetic|and|bradycardia (l_conj) bradycardia_19\NN\14110674|
D003000_D001919 CID clonidine-induced_17\JJ\1740| (r_amod) bradycardia_18\NN\14110674|clonidine-induced
12617329
D006170_D007674 NONE arabic_6\NNP\6986894|with|gum|nephrotoxicity (l_nmod) nephrotoxicity_9\NN\1740|on|gentamicin|rats
D006170_D007674 NONE arabic_14\NNP\6986894|with|gum|failure (l_nmod) failure_18\NN\66216|on|acute|renal|induced (l_acl) induced_19\VBN\1627355|nephrotoxicity (l_nmod) nephrotoxicity_25\NN\1740|gentamicin|(|gm|)
D006170_D007674 NONE arabic_6\NNP\6986894| (r_compound) treatment_7\NN\654885|gum|arabic (r_nsubj) induced_9\VBN\1627355|that|treatment|has|amelioration (l_dobj) amelioration_12\NN\248977|a|modest|some (l_nmod) some_14\DT\1740|of|indices (l_nmod) indices_20\NNS\13850304|of|the|histological|nephrotoxicity (l_nmod) nephrotoxicity_23\NN\1740|of|gm
D005839_D007674 NONE gentamicin_8\NN\2716866| (r_compound) nephrotoxicity_9\NN\1740|on|gentamicin|rats
D005839_D007674 NONE gentamicin_21\NN\2716866|by (r_compound) nephrotoxicity_25\NN\1740|gentamicin|(|gm|)
D005839_D007674 NONE gm_23\NN\13717155| (r_compound) nephrotoxicity_25\NN\1740|gentamicin|(|gm|)
D005839_D007674 NONE gm_22\NNP\13717155| (r_compound) nephrotoxicity_23\NN\1740|of|gm
D006170_D058186 CID arabic_14\NNP\6986894|with|gum|failure (l_nmod) failure_18\NN\66216|on|acute|renal|induced
D005839_D058186 CID gentamicin_21\NN\2716866|by (r_compound) nephrotoxicity_25\NN\1740|gentamicin|(|gm|) (r_nmod) induced_19\VBN\1627355|nephrotoxicity (r_acl) failure_18\NN\66216|on|acute|renal|induced
D005839_D058186 CID gm_23\NN\13717155| (r_compound) nephrotoxicity_25\NN\1740|gentamicin|(|gm|) (r_nmod) induced_19\VBN\1627355|nephrotoxicity (r_acl) failure_18\NN\66216|on|acute|renal|induced
D003404_D007674 NONE creatinine_8\NN\1740|of|and|urea (r_nmod) concentrations_6\NNS\4916342|the|creatinine|plasma|cortex (r_dobj) measuring_4\VBG\697589|by|concentrations (r_advcl) assessed_2\VBN\670261|nephrotoxicity|was|measuring|,|and|examination|. (l_nsubjpass) nephrotoxicity_0\NN\1740|
D014508_D007674 NONE urea_10\NN\14727670| (r_conj) creatinine_8\NN\1740|of|and|urea (r_nmod) concentrations_6\NNS\4916342|the|creatinine|plasma|cortex (r_dobj) measuring_4\VBG\697589|by|concentrations (r_advcl) assessed_2\VBN\670261|nephrotoxicity|was|measuring|,|and|examination|. (l_nsubjpass) nephrotoxicity_0\NN\1740|
D005978_D007674 NONE glutathione_16\NN\1740|reduced|gsh (r_conj) plasma_13\NN\5398023|in|the|and|glutathione (r_nmod) concentrations_6\NNS\4916342|the|creatinine|plasma|cortex (r_dobj) measuring_4\VBG\697589|by|concentrations (r_advcl) assessed_2\VBN\670261|nephrotoxicity|was|measuring|,|and|examination|. (l_nsubjpass) nephrotoxicity_0\NN\1740|
D005978_D007674 NONE gsh_18\NN\1740|(|) (r_appos) glutathione_16\NN\1740|reduced|gsh (r_conj) plasma_13\NN\5398023|in|the|and|glutathione (r_nmod) concentrations_6\NNS\4916342|the|creatinine|plasma|cortex (r_dobj) measuring_4\VBG\697589|by|concentrations (r_advcl) assessed_2\VBN\670261|nephrotoxicity|was|measuring|,|and|examination|. (l_nsubjpass) nephrotoxicity_0\NN\1740|
D005839_D007683 NONE gm-induced_1\JJ\1740| (r_amod) necrosis_4\NN\11444117|the|gm-induced|proximal|tubular
D005839_D007683 NONE gm_14\NNP\13717155|given (r_nmod) rats_12\NNS\2329401|in|gm (r_nmod) severe_10\JJ\1740|to|be|less|rats|arabic (r_xcomp) appeared_5\VBD\2604760|necrosis|severe|those|and|cellulose|. (l_nsubj) necrosis_4\NN\11444117|the|gm-induced|proximal|tubular
D005839_D007683 NONE gm_23\NNP\13717155|given (r_nmod) those_21\DT\1740|than|in|gm (r_nmod) appeared_5\VBD\2604760|necrosis|severe|those|and|cellulose|. (l_nsubj) necrosis_4\NN\11444117|the|gm-induced|proximal|tubular
D006170_D007683 NONE arabic_18\NNP\6986894|together|with|gum (r_nmod) severe_10\JJ\1740|to|be|less|rats|arabic (r_xcomp) appeared_5\VBD\2604760|necrosis|severe|those|and|cellulose|. (l_nsubj) necrosis_4\NN\11444117|the|gm-induced|proximal|tubular
6466532
D006024_D001919 NONE glycopyrrolate_3\NN\1740|of|i.v.|and|atropine (r_nmod) comparison_0\NN\635850|glycopyrrolate|prevention|and|arrhythmias|. (l_nmod) prevention_8\NN\1073995|in|the|bradycardia (l_nmod) bradycardia_10\NN\14110674|of
D006024_D001919 NONE glycopyrrolate_5\NN\1740|5 (r_compound) kg-1_10\NN\1740|of|glycopyrrolate|micrograms|and|atropine|kg-1 (r_nmod) administration_3\NN\1133281|of|kg-1 (r_nmod) effectiveness_1\NN\5190804|the|administration|immediately|induction|,|prevent|, (l_acl) prevent_27\VB\1740|to|arrhythmia|doses (l_dobj) arrhythmia_28\NN\14103288|and|bradycardia (l_conj) bradycardia_30\NN\14110674|
D006024_D001145 NONE glycopyrrolate_3\NN\1740|of|i.v.|and|atropine (r_nmod) comparison_0\NN\635850|glycopyrrolate|prevention|and|arrhythmias|. (l_conj) arrhythmias_12\VBZ\1740|doses
D006024_D001145 NONE glycopyrrolate_5\NN\1740|5 (r_compound) kg-1_10\NN\1740|of|glycopyrrolate|micrograms|and|atropine|kg-1 (r_nmod) administration_3\NN\1133281|of|kg-1 (r_nmod) effectiveness_1\NN\5190804|the|administration|immediately|induction|,|prevent|, (l_acl) prevent_27\VB\1740|to|arrhythmia|doses (l_dobj) arrhythmia_28\NN\14103288|and|bradycardia
D001285_D001919 NONE atropine_5\NN\14712692| (r_conj) glycopyrrolate_3\NN\1740|of|i.v.|and|atropine (r_nmod) comparison_0\NN\635850|glycopyrrolate|prevention|and|arrhythmias|. (l_nmod) prevention_8\NN\1073995|in|the|bradycardia (l_nmod) bradycardia_10\NN\14110674|of
D001285_D001919 NONE atropine_12\NN\14712692|10 (r_conj) kg-1_10\NN\1740|of|glycopyrrolate|micrograms|and|atropine|kg-1 (r_nmod) administration_3\NN\1133281|of|kg-1 (r_nmod) effectiveness_1\NN\5190804|the|administration|immediately|induction|,|prevent|, (l_acl) prevent_27\VB\1740|to|arrhythmia|doses (l_dobj) arrhythmia_28\NN\14103288|and|bradycardia (l_conj) bradycardia_30\NN\14110674|
D001285_D001145 NONE atropine_5\NN\14712692| (r_conj) glycopyrrolate_3\NN\1740|of|i.v.|and|atropine (r_nmod) comparison_0\NN\635850|glycopyrrolate|prevention|and|arrhythmias|. (l_conj) arrhythmias_12\VBZ\1740|doses
D001285_D001145 NONE atropine_12\NN\14712692|10 (r_conj) kg-1_10\NN\1740|of|glycopyrrolate|micrograms|and|atropine|kg-1 (r_nmod) administration_3\NN\1133281|of|kg-1 (r_nmod) effectiveness_1\NN\5190804|the|administration|immediately|induction|,|prevent|, (l_acl) prevent_27\VB\1740|to|arrhythmia|doses (l_dobj) arrhythmia_28\NN\14103288|and|bradycardia
D013390_D001919 CID suxamethonium_17\NN\1740|of (r_nmod) doses_15\NNS\3740161|following|repeated|suxamethonium|children (r_nmod) arrhythmias_12\VBZ\1740|doses (r_conj) comparison_0\NN\635850|glycopyrrolate|prevention|and|arrhythmias|. (l_nmod) prevention_8\NN\1073995|in|the|bradycardia (l_nmod) bradycardia_10\NN\14110674|of
D013390_D001919 CID suxamethonium_35\NN\1740|of (r_nmod) doses_33\NNS\3740161|following|repeated|suxamethonium|children (r_nmod) prevent_27\VB\1740|to|arrhythmia|doses (l_dobj) arrhythmia_28\NN\14103288|and|bradycardia (l_conj) bradycardia_30\NN\14110674|
D013390_D001145 NONE suxamethonium_17\NN\1740|of (r_nmod) doses_15\NNS\3740161|following|repeated|suxamethonium|children (r_nmod) arrhythmias_12\VBZ\1740|doses
D013390_D001145 NONE suxamethonium_35\NN\1740|of (r_nmod) doses_33\NNS\3740161|following|repeated|suxamethonium|children (r_nmod) prevent_27\VB\1740|to|arrhythmia|doses (l_dobj) arrhythmia_28\NN\14103288|and|bradycardia
9199746
D000583_D064420 NONE amikacin_4\NN\1740|after|intravitreal (r_nmod) toxicity_1\NN\13576101|macula|amikacin|.
D000617_D009877 NONE aminoglycosides_4\NNS\1740| (r_nsubj) improved_7\VBN\126264|although|intravitreal|aminoglycosides|have|substantially|prognosis (l_dobj) prognosis_9\NN\6748969|visual|endophthalmitis (l_nmod) endophthalmitis_11\NN\1740|in
D000617_D007238 NONE aminoglycosides_4\NNS\1740| (r_nsubj) improved_7\VBN\126264|although|intravitreal|aminoglycosides|have|substantially|prognosis (r_advcl) impair_16\VB\258857|background|:|improved|,|infarction|may|recovery|. (l_nsubj) infarction_14\NN\14204950|macular
D000583_D012164 CID amikacin_8\NN\1740| (r_compound) toxicity_10\NN\13576101|of|presumed|amikacin|retinal
D000583_D012164 CID amikacin_14\NN\1740|with|and|vancomycin (r_nmod) treatment_12\NN\654885|following|amikacin|endophthalmitis (r_nmod) case_5\NN\7283608|a|toxicity|treatment (l_nmod) toxicity_10\NN\13576101|of|presumed|amikacin|retinal
D000583_D013290 NONE amikacin_8\NN\1740| (r_compound) toxicity_10\NN\13576101|of|presumed|amikacin|retinal (r_nmod) case_5\NN\7283608|a|toxicity|treatment (l_nmod) treatment_12\NN\654885|following|amikacin|endophthalmitis (l_nmod) endophthalmitis_20\NN\1740|for|alpha-haemolytic|streptococcal
D000583_D013290 NONE amikacin_14\NN\1740|with|and|vancomycin (r_nmod) treatment_12\NN\654885|following|amikacin|endophthalmitis (l_nmod) endophthalmitis_20\NN\1740|for|alpha-haemolytic|streptococcal
D014640_D012164 NONE vancomycin_16\NN\2716866| (r_conj) amikacin_14\NN\1740|with|and|vancomycin (r_nmod) treatment_12\NN\654885|following|amikacin|endophthalmitis (r_nmod) case_5\NN\7283608|a|toxicity|treatment (l_nmod) toxicity_10\NN\13576101|of|presumed|amikacin|retinal
D014640_D013290 NONE vancomycin_16\NN\2716866| (r_conj) amikacin_14\NN\1740|with|and|vancomycin (r_nmod) treatment_12\NN\654885|following|amikacin|endophthalmitis (l_nmod) endophthalmitis_20\NN\1740|for|alpha-haemolytic|streptococcal
D019793_D013684 NONE fluorescein_1\NN\14598383| (r_compound) angiography_2\NN\904623|fundus|fluorescein (r_nsubj) confirmed_3\VBD\1011725|angiography|closure|. (l_dobj) closure_6\NN\280853|macular|capillary|and|telangiectasis (l_conj) telangiectasis_8\NN\1740|
17175308
D020123_D011507 CID sirolimus_4\NN\1740|to (r_nmod) conversion_2\NN\7359599|after|sirolimus|recipients (r_nmod) proteinuria_0\NNP\14299637|conversion|.
D020123_D011507 CID sirolimus_11\NN\1740| (r_compound) therapy_12\NN\657604|of|sirolimus (r_nmod) consequence_9\NN\34213|as|a|therapy (r_nmod) reported_6\VBN\831651|recently|,|proteinuria|has|been|consequence|,|remained|. (l_nsubjpass) proteinuria_3\NN\14299637|
D020123_D011507 CID srl_18\NN\1740| (r_compound) conversion_19\NN\7359599|after|srl (r_nmod) displayed_14\VBD\2137132|proteinuria|conversion (l_dobj) proteinuria_16\NN\14299637|increased
D020123_D011507 CID srl_8\NN\1740|of (r_nmod) use_6\NN\407535|after|the|srl|therapy (r_nmod) common_3\JJ\1740|proteinuria|was|use|. (l_nsubj) proteinuria_1\NN\14299637|heavy
D020123_D051436 NONE srl_13\NN\1740|with (r_nmod) treated_11\VBN\2376958|cohort|was|srl|therapy|,|nephropathy|. (l_nmod) nephropathy_22\NN\14573196|due|chronic|allograft|can|neoplasia|or|nephropathy
D020123_D007674 NONE srl_13\NN\1740|with (r_nmod) treated_11\VBN\2376958|cohort|was|srl|therapy|,|nephropathy|. (l_nmod) nephropathy_22\NN\14573196|due|chronic|allograft|can|neoplasia|or|nephropathy (l_appos) can_24\NN\3094503|(|)
D020123_D007674 NONE srl_13\NN\1740|with (r_nmod) treated_11\VBN\2376958|cohort|was|srl|therapy|,|nephropathy|. (l_nmod) nephropathy_22\NN\14573196|due|chronic|allograft|can|neoplasia|or|nephropathy (l_conj) nephropathy_57\NN\14573196|bk|virus|n
D020123_D009369 NONE srl_13\NN\1740|with (r_nmod) treated_11\VBN\2376958|cohort|was|srl|therapy|,|nephropathy|. (l_nmod) nephropathy_22\NN\14573196|due|chronic|allograft|can|neoplasia|or|nephropathy (l_conj) neoplasia_31\NN\13533470|n|n|,|carsinom|)
D020123_D012514 NONE srl_13\NN\1740|with (r_nmod) treated_11\VBN\2376958|cohort|was|srl|therapy|,|nephropathy|. (l_nmod) nephropathy_22\NN\14573196|due|chronic|allograft|can|neoplasia|or|nephropathy (l_conj) neoplasia_31\NN\13533470|n|n|,|carsinom|) (l_dep) n_33\NN\14622893|(|=|;|sarcoma|,|tumors (l_conj) sarcoma_39\NN\14239918|kaposi|,|cancers
D020123_D012878 NONE srl_13\NN\1740|with (r_nmod) treated_11\VBN\2376958|cohort|was|srl|therapy|,|nephropathy|. (l_nmod) nephropathy_22\NN\14573196|due|chronic|allograft|can|neoplasia|or|nephropathy (l_conj) neoplasia_31\NN\13533470|n|n|,|carsinom|) (l_dep) n_33\NN\14622893|(|=|;|sarcoma|,|tumors (l_conj) sarcoma_39\NN\14239918|kaposi|,|cancers (l_conj) cancers_43\NNS\14239425|four|skin
D020123_D007414 NONE srl_13\NN\1740|with (r_nmod) treated_11\VBN\2376958|cohort|was|srl|therapy|,|nephropathy|. (l_nmod) nephropathy_22\NN\14573196|due|chronic|allograft|can|neoplasia|or|nephropathy (l_conj) neoplasia_31\NN\13533470|n|n|,|carsinom|) (l_dep) n_33\NN\14622893|(|=|;|sarcoma|,|tumors (l_conj) tumors_47\NNS\14234074|one|intestinal
D020123_D002292 NONE srl_13\NN\1740|with (r_nmod) treated_11\VBN\2376958|cohort|was|srl|therapy|,|nephropathy|. (l_nmod) nephropathy_22\NN\14573196|due|chronic|allograft|can|neoplasia|or|nephropathy (l_conj) neoplasia_31\NN\13533470|n|n|,|carsinom|) (l_conj) carsinom_52\NN\1740|one|renal|cell
3750012
D010396_D009157 CID penicillamine_4\NN\3740161|by|and|therapy (r_nmod) caused_2\VBN\1617192|penicillamine|arthritis (r_acl) gravis_1\NN\1740|myasthenia|caused|.
D010396_D009157 CID penicillamine_14\NN\3740161|after|and|therapy (r_nmod) had_7\VBD\2108377|who|reversible|gravis|penicillamine|arthritis (l_dobj) gravis_12\NN\1740|myasthenia
D010396_D001172 NONE penicillamine_4\NN\3740161|by|and|therapy (r_nmod) caused_2\VBN\1617192|penicillamine|arthritis (l_nmod) arthritis_10\NN\14171682|for|rheumatoid
D010396_D001172 NONE penicillamine_14\NN\3740161|after|and|therapy (r_nmod) had_7\VBD\2108377|who|reversible|gravis|penicillamine|arthritis (l_nmod) arthritis_20\NN\14171682|for|rheumatoid
D002738_D009157 CID chloroquine_6\NN\2721948| (r_compound) therapy_7\NN\657604|chloroquine (r_conj) penicillamine_4\NN\3740161|by|and|therapy (r_nmod) caused_2\VBN\1617192|penicillamine|arthritis (r_acl) gravis_1\NN\1740|myasthenia|caused|.
D002738_D009157 CID chloroquine_16\NN\2721948| (r_compound) therapy_17\NN\657604|chloroquine (r_conj) penicillamine_14\NN\3740161|after|and|therapy (r_nmod) had_7\VBD\2108377|who|reversible|gravis|penicillamine|arthritis (l_dobj) gravis_12\NN\1740|myasthenia
D002738_D001172 NONE chloroquine_6\NN\2721948| (r_compound) therapy_7\NN\657604|chloroquine (r_conj) penicillamine_4\NN\3740161|by|and|therapy (r_nmod) caused_2\VBN\1617192|penicillamine|arthritis (l_nmod) arthritis_10\NN\14171682|for|rheumatoid
D002738_D001172 NONE chloroquine_16\NN\2721948| (r_compound) therapy_17\NN\657604|chloroquine (r_conj) penicillamine_14\NN\3740161|after|and|therapy (r_nmod) had_7\VBD\2108377|who|reversible|gravis|penicillamine|arthritis (l_nmod) arthritis_20\NN\14171682|for|rheumatoid
18186898
D019259_D006509 NONE lamivudine_0\NNP\3834836| (r_nsubjpass) added_2\VBN\156601|lamivudine|was|infection|. (l_nmod) infection_9\NN\14052046|because|de|hepatitis|b|follow-up
D016559_D000138 NONE tacrolimus_1\NN\1740| (r_nsubjpass) suspected_3\VBN\916909|although|tacrolimus|was|cause|and|replaced (l_xcomp) cause_7\NN\7323922|to|be|the|acidosis (l_nmod) acidosis_12\NN\14204950|of|late|post-transplant|renal
D016559_D000138 NONE tacrolimus_1\NN\1740| (r_nsubjpass) suspected_3\VBN\916909|although|tacrolimus|was|cause|and|replaced (l_conj) replaced_15\VBN\1631072|was|sirolimus (l_nmod) sirolimus_17\NN\1740|by|,|acidosis|,|and (l_conj) acidosis_19\NN\14204950|
D020123_D000138 NONE sirolimus_17\NN\1740|by|,|acidosis|,|and (r_nmod) replaced_15\VBN\1631072|was|sirolimus (r_conj) suspected_3\VBN\916909|although|tacrolimus|was|cause|and|replaced (l_xcomp) cause_7\NN\7323922|to|be|the|acidosis (l_nmod) acidosis_12\NN\14204950|of|late|post-transplant|renal
D020123_D000138 NONE sirolimus_17\NN\1740|by|,|acidosis|,|and (l_conj) acidosis_19\NN\14204950|
D016559_D005198 CID tacrolimus_20\NN\1740|by (r_nmod) triggered_18\VBN\1641914|which|is|tacrolimus|and|augmented (r_acl:relcl) dysfunction_15\NN\14204950|from|mitochondrial|triggered (r_nmod) resulted_12\VBN\2633881|may|have|dysfunction (r_ccomp) suggest_1\VBP\1010118|we|dysfunction|resulted|. (l_ccomp) dysfunction_7\NN\14204950|that|patient|tubular|and|myopathy
D016559_D009135 CID tacrolimus_20\NN\1740|by (r_nmod) triggered_18\VBN\1641914|which|is|tacrolimus|and|augmented (r_acl:relcl) dysfunction_15\NN\14204950|from|mitochondrial|triggered (r_nmod) resulted_12\VBN\2633881|may|have|dysfunction (r_ccomp) suggest_1\VBP\1010118|we|dysfunction|resulted|. (l_ccomp) dysfunction_7\NN\14204950|that|patient|tubular|and|myopathy (l_conj) myopathy_9\NN\14204950|
D016559_D028361 NONE tacrolimus_20\NN\1740|by (r_nmod) triggered_18\VBN\1641914|which|is|tacrolimus|and|augmented (r_acl:relcl) dysfunction_15\NN\14204950|from|mitochondrial|triggered
D019259_D005198 CID lamivudine_24\NN\3834836|by (r_nmod) augmented_22\VBN\153263|lamivudine (r_conj) triggered_18\VBN\1641914|which|is|tacrolimus|and|augmented (r_acl:relcl) dysfunction_15\NN\14204950|from|mitochondrial|triggered (r_nmod) resulted_12\VBN\2633881|may|have|dysfunction (r_ccomp) suggest_1\VBP\1010118|we|dysfunction|resulted|. (l_ccomp) dysfunction_7\NN\14204950|that|patient|tubular|and|myopathy
D019259_D009135 CID lamivudine_24\NN\3834836|by (r_nmod) augmented_22\VBN\153263|lamivudine (r_conj) triggered_18\VBN\1641914|which|is|tacrolimus|and|augmented (r_acl:relcl) dysfunction_15\NN\14204950|from|mitochondrial|triggered (r_nmod) resulted_12\VBN\2633881|may|have|dysfunction (r_ccomp) suggest_1\VBP\1010118|we|dysfunction|resulted|. (l_ccomp) dysfunction_7\NN\14204950|that|patient|tubular|and|myopathy (l_conj) myopathy_9\NN\14204950|
D019259_D028361 NONE lamivudine_24\NN\3834836|by (r_nmod) augmented_22\VBN\153263|lamivudine (r_conj) triggered_18\VBN\1641914|which|is|tacrolimus|and|augmented (r_acl:relcl) dysfunction_15\NN\14204950|from|mitochondrial|triggered
16330293
12084448
D007069_D001927 CID ifosfamide_0\NN\1740| (r_compound) encephalopathy_1\JJ\1740|ifosfamide
D007069_D020820 NONE ifosfamide_0\NN\1740| (r_compound) encephalopathy_1\JJ\1740|ifosfamide (r_amod) presenting_2\VBG\2137132|encephalopathy|asterixis|. (l_nmod) asterixis_4\NN\1740|with
D007069_D020820 NONE ifosfamide_3\NN\1740|of (r_nmod) administration_1\NN\1133281|the|ifosfamide (r_nsubjpass) discontinued_5\VBN\2609764|administration|was|and|resolved|. (l_conj) resolved_12\VBN\352826|h|asterixis|completely (l_nsubj) asterixis_11\NN\1740|the
D007069_D020820 NONE ifosfamide_12\NN\1740|of (r_nmod) infusion_10\NN\14589223|during|ifosfamide (r_nmod) presence_6\NN\13954253|the|asterixis|infusion (l_nmod) asterixis_8\NN\1740|of
D007069_D020820 NONE ifx_41\NN\1740|of (r_nmod) use_39\NN\407535|with|the|ifx (r_nmod) associated_36\VBN\628491|that|myoclonus|is|use (r_ccomp) suggest_31\VBP\1010118|patient|,|findings|associated|. (l_nmod) patient_2\NN\9898892|in|the|described|,|presence (l_appos) presence_6\NN\13954253|the|asterixis|infusion (l_nmod) asterixis_8\NN\1740|of
D007069_D009207 CID ifosfamide_25\NN\1740|of|plasmacytoma (r_nmod) infusion_23\NN\14589223|after|the|ifosfamide (r_nmod) myoclonus_14\NN\14360459|negative|extremities|infusion
D007069_D009207 CID ifosfamide_12\NN\1740|of (r_nmod) infusion_10\NN\14589223|during|ifosfamide (r_nmod) presence_6\NN\13954253|the|asterixis|infusion (r_appos) patient_2\NN\9898892|in|the|described|,|presence (r_nmod) suggest_31\VBP\1010118|patient|,|findings|associated|. (l_ccomp) associated_36\VBN\628491|that|myoclonus|is|use (l_nsubjpass) myoclonus_34\NN\14360459|negative
D007069_D009207 CID ifx_41\NN\1740|of (r_nmod) use_39\NN\407535|with|the|ifx (r_nmod) associated_36\VBN\628491|that|myoclonus|is|use (l_nsubjpass) myoclonus_34\NN\14360459|negative
D007069_D010954 NONE ifosfamide_25\NN\1740|of|plasmacytoma (l_nmod) plasmacytoma_27\NN\14235200|for
15458908
D020849_D010024 NONE raloxifene_6\NNP\1740| (r_compound) evaluation_7\NNP\874067|of|raloxifene|, (r_nmod) outcomes_4\NNPS\7291312|the|multiple|evaluation|multicenter|, (r_nsubj) enrolled_17\VBD\2471690|methods|outcomes|women|osteoporosis|. (l_nmod) osteoporosis_22\NN\14204950|with
D020849_D054556 CID raloxifene_10\NN\1740| (r_nsubjpass) associated_12\VBN\628491|results|follow-up|,|raloxifene|was|risk|. (l_nmod) risk_16\NN\14541044|with|an|increased|thromboembolism (l_nmod) thromboembolism_19\NN\14100769|for|venous|risk
D020849_D054556 CID raloxifene_2\NNP\1740| (r_nsubjpass) associated_4\VBN\628491|raloxifene|was|risk|,|but|was (l_nmod) risk_8\NN\14541044|with|an|increased|thromboembolism (l_nmod) thromboembolism_11\NN\14100769|for|venous
D020849_D002386 NONE raloxifene_0\NN\1740| (r_nsubj) increase_3\VB\169651|raloxifene|did|not|risk|. (l_dobj) risk_4\NN\14541044|cataracts (l_nmod) cataracts_6\NNS\14252864|for|rr|,|disease|,|hyperplasia|,|or|cancer
D020849_D002386 NONE raloxifene_2\NNP\1740| (r_nsubjpass) associated_4\VBN\628491|raloxifene|was|risk|,|but|was (l_conj) was_15\VBD\836236|there|risk (l_attr) risk_18\NN\14541044|no|increased|cataracts (l_nmod) cataracts_20\NNS\14252864|for|,|disease|,|or|cancer
D020849_D005705 NONE raloxifene_0\NN\1740| (r_nsubj) increase_3\VB\169651|raloxifene|did|not|risk|. (l_dobj) risk_4\NN\14541044|cataracts (l_nmod) cataracts_6\NNS\14252864|for|rr|,|disease|,|hyperplasia|,|or|cancer (l_conj) disease_20\NN\14061805|gallbladder|rr
D020849_D005705 NONE raloxifene_2\NNP\1740| (r_nsubjpass) associated_4\VBN\628491|raloxifene|was|risk|,|but|was (l_conj) was_15\VBD\836236|there|risk (l_attr) risk_18\NN\14541044|no|increased|cataracts (l_nmod) cataracts_20\NNS\14252864|for|,|disease|,|or|cancer (l_conj) disease_23\NN\14061805|gallbladder|,|hyperplasia
D020849_D004714 NONE raloxifene_0\NN\1740| (r_nsubj) increase_3\VB\169651|raloxifene|did|not|risk|. (l_dobj) risk_4\NN\14541044|cataracts (l_nmod) cataracts_6\NNS\14252864|for|rr|,|disease|,|hyperplasia|,|or|cancer (l_conj) hyperplasia_34\NN\14365950|endometrial|rr
D020849_D004714 NONE raloxifene_2\NNP\1740| (r_nsubjpass) associated_4\VBN\628491|raloxifene|was|risk|,|but|was (l_conj) was_15\VBD\836236|there|risk (l_attr) risk_18\NN\14541044|no|increased|cataracts (l_nmod) cataracts_20\NNS\14252864|for|,|disease|,|or|cancer (l_conj) disease_23\NN\14061805|gallbladder|,|hyperplasia (l_conj) hyperplasia_26\NN\14365950|endometrial
D020849_D016889 NONE raloxifene_0\NN\1740| (r_nsubj) increase_3\VB\169651|raloxifene|did|not|risk|. (l_dobj) risk_4\NN\14541044|cataracts (l_nmod) cataracts_6\NNS\14252864|for|rr|,|disease|,|hyperplasia|,|or|cancer (l_conj) cancer_49\NN\14239425|endometrial|rr
D020849_D016889 NONE raloxifene_2\NNP\1740| (r_nsubjpass) associated_4\VBN\628491|raloxifene|was|risk|,|but|was (l_conj) was_15\VBD\836236|there|risk (l_attr) risk_18\NN\14541044|no|increased|cataracts (l_nmod) cataracts_20\NNS\14252864|for|,|disease|,|or|cancer (l_conj) cancer_30\NN\14239425|endometrial
17491223
D004280_D017202 CID dobutamine-induced_12\JJ\1740| (r_amod) ischemia_14\NN\14195315|of|dobutamine-induced|myocardial
D004280_D017202 CID dobutamine-induced_10\JJ\1740| (r_amod) ischemia_12\NN\14195315|dobutamine-induced|myocardial
D004280_D017202 CID dobutamine-induced_35\JJ\1740| (r_amod) ischemia_37\NN\14195315|dobutamine-induced|myocardial
D004280_D007511 NONE dobutamine-induced_35\JJ\1740| (r_amod) ischemia_37\NN\14195315|dobutamine-induced|myocardial (r_dobj) detecting_34\VBG\2163746|for|ischemia (r_advcl) assess_3\VB\670261|to|value|changes|,|compared|,|detecting|,|using (l_advcl) using_39\VBG\1156834|tomography|standard (l_nmod) standard_48\NN\13577171|as|the|gold|comparison (l_nmod) comparison_50\NN\635850|of|assess (l_acl) assess_52\VB\670261|to|presence (l_dobj) presence_54\NN\13954253|the|or|absence|ischemia (l_nmod) ischemia_58\NN\14195315|of
D017256_D017202 NONE tc99m-sestamibi_40\NN\1740| (r_compound) emission_42\NN\44455|tc99m-sestamibi|single-photon (r_compound) tomography_44\NN\900375|emission|computed (r_dobj) using_39\VBG\1156834|tomography|standard (r_advcl) assess_3\VB\670261|to|value|changes|,|compared|,|detecting|,|using (l_advcl) detecting_34\VBG\2163746|for|ischemia (l_dobj) ischemia_37\NN\14195315|dobutamine-induced|myocardial
D017256_D007511 NONE tc99m-sestamibi_40\NN\1740| (r_compound) emission_42\NN\44455|tc99m-sestamibi|single-photon (r_compound) tomography_44\NN\900375|emission|computed (r_dobj) using_39\VBG\1156834|tomography|standard (l_nmod) standard_48\NN\13577171|as|the|gold|comparison (l_nmod) comparison_50\NN\635850|of|assess (l_acl) assess_52\VB\670261|to|presence (l_dobj) presence_54\NN\13954253|the|or|absence|ischemia (l_nmod) ischemia_58\NN\14195315|of
10091617
D012642_D007024 CID selegiline-induced_0\JJ\1740| (r_amod) hypotension_2\NN\14057371|selegiline-induced|postural|disease|:|study|.
D012642_D007024 CID selegiline_7\NN\1740|with|and|l-dopa (r_nmod) therapy_5\NN\657604|selegiline (r_nsubjpass) associated_11\VBN\628491|that|therapy|was|hypotension (l_nmod) hypotension_16\NN\14057371|with|selective|systolic|orthostatic|abolished
D012642_D007024 CID selegiline_23\NN\1740|of (r_nmod) withdrawal_21\NN\7206096|by|selegiline (r_nmod) abolished_19\VBN\1740|which|was|withdrawal (r_acl:relcl) hypotension_16\NN\14057371|with|selective|systolic|orthostatic|abolished
D012642_D007024 CID selegiline_29\NN\1740| (r_dobj) stopping_28\VBG\2452885|of|selegiline|expectation (r_advcl) consequences_26\NNS\34213|of|the|cardiovascular|stopping (r_nmod) course_22\NN\883297|the|time|consequences|shed (l_acl) shed_36\VB\173338|that|this|might|light|mechanisms (l_nmod) mechanisms_40\NNS\13446390|on|the|causes (l_acl:relcl) causes_45\VBZ\1617192|which|drug|hypotension (l_dobj) hypotension_47\NN\14057371|orthostatic
D012642_D007024 CID selegiline_18\NN\1740|on|, (r_nmod) patients_16\NNS\9898892|in|20|pd|selegiline (r_nmod) marked_10\VBN\1296462|which|was|patients (r_acl:relcl) hypotension_7\NN\14057371|systolic|orthostatic|marked
D012642_D007024 CID selegiline_9\NN\1740|of (r_nmod) withdrawal_7\NN\7206096|after|selegiline (r_nmod) ameliorated_3\VBN\126264|hypotension|was|days|withdrawal|and|abolished|. (l_nsubjpass) hypotension_1\NN\14057371|orthostatic
D012642_D007024 CID selegiline_1\NN\1740| (r_dobj) stopping_0\VBG\2452885|selegiline (r_csubj) reduced_4\VBD\441445|stopping|also|significantly|systolic|. (l_dobj) systolic_7\NN\1740|the|supine|and|diastolic|pressures (l_conj) pressures_11\NNS\11419404|blood|consistent
D012642_D007024 CID selegiline_9\NN\1740|combination (r_nsubjpass) associated_15\VBN\628491|that|selegiline|is|hypotension (l_nmod) hypotension_19\NN\14057371|with|selective|orthostatic
D012642_D010300 NONE selegiline-induced_0\JJ\1740| (r_amod) hypotension_2\NN\14057371|selegiline-induced|postural|disease|:|study|. (l_nmod) disease_6\NN\14061805|in|parkinson
D012642_D010300 NONE selegiline_32\NN\1740|mg (r_dobj) receive_29\VB\2210855|to|selegiline|day (r_xcomp) randomized_27\VBD\278117|receive|those (r_ccomp) found_14\VBD\2426171|objectives|trial|mortality|randomized|. (l_nsubj) trial_13\NN\786195|the|group (l_compound) group_9\NNP\2137|parkinson|disease|research|ukpdrg (l_compound) disease_7\NNP\14061805|
D012642_D010300 NONE selegiline_32\NN\1740|mg (r_dobj) receive_29\VB\2210855|to|selegiline|day (r_xcomp) randomized_27\VBD\278117|receive|those (r_ccomp) found_14\VBD\2426171|objectives|trial|mortality|randomized|. (l_dobj) mortality_17\NN\5054863|an|increased|patients (l_nmod) patients_19\NNS\9898892|in|disease (l_nmod) disease_23\NN\14061805|with|parkinson|pd
D012642_D010300 NONE selegiline_32\NN\1740|mg (r_dobj) receive_29\VB\2210855|to|selegiline|day (r_xcomp) randomized_27\VBD\278117|receive|those (r_ccomp) found_14\VBD\2426171|objectives|trial|mortality|randomized|. (l_dobj) mortality_17\NN\5054863|an|increased|patients (l_nmod) patients_19\NNS\9898892|in|disease (l_nmod) disease_23\NN\14061805|with|parkinson|pd (l_appos) pd_25\NN\14625458|(|)
D012642_D010300 NONE selegiline_17\NN\1740| (r_dobj) receiving_16\VBG\2210855|selegiline (r_acl) patients_15\NNS\9898892|in|pd|receiving (l_compound) pd_14\NN\14625458|
D012642_D010300 NONE selegiline_18\NN\1740|on|, (r_nmod) patients_16\NNS\9898892|in|20|pd|selegiline (l_compound) pd_15\NN\14625458|
D007980_D010300 NONE l-dopa_36\JJ\1740| (r_conj) day_34\NN\15154774|per|and|l-dopa (r_nmod) receive_29\VB\2210855|to|selegiline|day (r_xcomp) randomized_27\VBD\278117|receive|those (r_ccomp) found_14\VBD\2426171|objectives|trial|mortality|randomized|. (l_nsubj) trial_13\NN\786195|the|group (l_compound) group_9\NNP\2137|parkinson|disease|research|ukpdrg (l_compound) disease_7\NNP\14061805|
D007980_D010300 NONE l-dopa_36\JJ\1740| (r_conj) day_34\NN\15154774|per|and|l-dopa (r_nmod) receive_29\VB\2210855|to|selegiline|day (r_xcomp) randomized_27\VBD\278117|receive|those (r_ccomp) found_14\VBD\2426171|objectives|trial|mortality|randomized|. (l_dobj) mortality_17\NN\5054863|an|increased|patients (l_nmod) patients_19\NNS\9898892|in|disease (l_nmod) disease_23\NN\14061805|with|parkinson|pd
D007980_D010300 NONE l-dopa_36\JJ\1740| (r_conj) day_34\NN\15154774|per|and|l-dopa (r_nmod) receive_29\VB\2210855|to|selegiline|day (r_xcomp) randomized_27\VBD\278117|receive|those (r_ccomp) found_14\VBD\2426171|objectives|trial|mortality|randomized|. (l_dobj) mortality_17\NN\5054863|an|increased|patients (l_nmod) patients_19\NNS\9898892|in|disease (l_nmod) disease_23\NN\14061805|with|parkinson|pd (l_appos) pd_25\NN\14625458|(|)
D007980_D010300 NONE l-dopa_41\NN\14604959| (r_dobj) taking_40\VBG\2367363|l-dopa|alone (r_acl) those_39\DT\1740|compared|with|taking (r_advcl) randomized_27\VBD\278117|receive|those (r_ccomp) found_14\VBD\2426171|objectives|trial|mortality|randomized|. (l_nsubj) trial_13\NN\786195|the|group (l_compound) group_9\NNP\2137|parkinson|disease|research|ukpdrg (l_compound) disease_7\NNP\14061805|
D007980_D010300 NONE l-dopa_41\NN\14604959| (r_dobj) taking_40\VBG\2367363|l-dopa|alone (r_acl) those_39\DT\1740|compared|with|taking (r_advcl) randomized_27\VBD\278117|receive|those (r_ccomp) found_14\VBD\2426171|objectives|trial|mortality|randomized|. (l_dobj) mortality_17\NN\5054863|an|increased|patients (l_nmod) patients_19\NNS\9898892|in|disease (l_nmod) disease_23\NN\14061805|with|parkinson|pd
D007980_D010300 NONE l-dopa_41\NN\14604959| (r_dobj) taking_40\VBG\2367363|l-dopa|alone (r_acl) those_39\DT\1740|compared|with|taking (r_advcl) randomized_27\VBD\278117|receive|those (r_ccomp) found_14\VBD\2426171|objectives|trial|mortality|randomized|. (l_dobj) mortality_17\NN\5054863|an|increased|patients (l_nmod) patients_19\NNS\9898892|in|disease (l_nmod) disease_23\NN\14061805|with|parkinson|pd (l_appos) pd_25\NN\14625458|(|)
D007980_D007024 NONE l-dopa_9\NN\14604959| (r_conj) selegiline_7\NN\1740|with|and|l-dopa (r_nmod) therapy_5\NN\657604|selegiline (r_nsubjpass) associated_11\VBN\628491|that|therapy|was|hypotension (l_nmod) hypotension_16\NN\14057371|with|selective|systolic|orthostatic|abolished
D007980_D007024 NONE l-dopa_13\NN\14604959|with (r_nmod) combination_11\NN\7951464|in|l-dopa (r_nmod) selegiline_9\NN\1740|combination (r_nsubjpass) associated_15\VBN\628491|that|selegiline|is|hypotension (l_nmod) hypotension_19\NN\14057371|with|selective|orthostatic
2951327
D009638_D013610 NONE norepinephrine_72\NN\14807929| (r_compound) rate_74\NN\13815152|of|the|norepinephrine|release (r_nmod) tachycardia_66\NN\14110674|no|and|augmentation|rate|(|0.3|microgram/kg/min|)
D009638_D007022 NONE norepinephrine_72\NN\14807929| (r_compound) rate_74\NN\13815152|of|the|norepinephrine|release (r_nmod) tachycardia_66\NN\14110674|no|and|augmentation|rate|(|0.3|microgram/kg/min|) (r_conj) 99_26\CD\1740|mean|infusions|was|+/-|1|,|95|p|,|93|p|,|or|79|%|,|respectively|,|but|tachycardia (r_nsubjpass) observed_82\VBN\2163746|99|were|,|hypotension|. (l_dep) hypotension_90\NN\14057371|which|is|contrast|to|comparable|induced
D006830_D013610 NONE hydralazine_93\NN\2721160|by|or|nitroglycerin (r_nmod) induced_91\VBN\1627355|hydralazine (r_acl) hypotension_90\NN\14057371|which|is|contrast|to|comparable|induced (r_dep) observed_82\VBN\2163746|99|were|,|hypotension|. (l_nsubjpass) 99_26\CD\1740|mean|infusions|was|+/-|1|,|95|p|,|93|p|,|or|79|%|,|respectively|,|but|tachycardia (l_conj) tachycardia_66\NN\14110674|no|and|augmentation|rate|(|0.3|microgram/kg/min|)
D006830_D007022 CID hydralazine_93\NN\2721160|by|or|nitroglycerin (r_nmod) induced_91\VBN\1627355|hydralazine (r_acl) hypotension_90\NN\14057371|which|is|contrast|to|comparable|induced
D005996_D013610 NONE nitroglycerin_95\NN\15015501| (r_conj) hydralazine_93\NN\2721160|by|or|nitroglycerin (r_nmod) induced_91\VBN\1627355|hydralazine (r_acl) hypotension_90\NN\14057371|which|is|contrast|to|comparable|induced (r_dep) observed_82\VBN\2163746|99|were|,|hypotension|. (l_nsubjpass) 99_26\CD\1740|mean|infusions|was|+/-|1|,|95|p|,|93|p|,|or|79|%|,|respectively|,|but|tachycardia (l_conj) tachycardia_66\NN\14110674|no|and|augmentation|rate|(|0.3|microgram/kg/min|)
D005996_D007022 CID nitroglycerin_95\NN\15015501| (r_conj) hydralazine_93\NN\2721160|by|or|nitroglycerin (r_nmod) induced_91\VBN\1627355|hydralazine (r_acl) hypotension_90\NN\14057371|which|is|contrast|to|comparable|induced
19657887
D000431_D005483 CID alcohol_9\NN\7881800|of (r_nmod) ingestion_7\NN\13440063|after|the|alcohol (r_nmod) hour_4\NN\15154774|in|1|ingestion (r_nmod) developed_12\VBD\1753788|hour|,|he|malaise|flushing|. (l_advcl) flushing_15\NN\1740|with|face (l_nmod) face_18\NN\5225090|of|the|,|tachycardia
D000431_D013610 CID alcohol_9\NN\7881800|of (r_nmod) ingestion_7\NN\13440063|after|the|alcohol (r_nmod) hour_4\NN\15154774|in|1|ingestion (r_nmod) developed_12\VBD\1753788|hour|,|he|malaise|flushing|. (l_advcl) flushing_15\NN\1740|with|face (l_nmod) face_18\NN\5225090|of|the|,|tachycardia (l_conj) tachycardia_20\NN\14110674|,|and|dyspnea
D000431_D004417 CID alcohol_9\NN\7881800|of (r_nmod) ingestion_7\NN\13440063|after|the|alcohol (r_nmod) hour_4\NN\15154774|in|1|ingestion (r_nmod) developed_12\VBD\1753788|hour|,|he|malaise|flushing|. (l_advcl) flushing_15\NN\1740|with|face (l_nmod) face_18\NN\5225090|of|the|,|tachycardia (l_conj) tachycardia_20\NN\14110674|,|and|dyspnea (l_conj) dyspnea_23\VB\1740|
D004221_D005483 NONE disulfiram-like_7\JJ\1740| (r_amod) syndrome_8\NN\5870365|disulfiram-like (r_dobj) developed_6\VBD\1753788|hours|,|he|syndrome|flushing|consuming|. (l_advcl) flushing_10\NN\1740|with|,|tachycardia|,|and|hypotension
D004221_D013610 NONE disulfiram-like_7\JJ\1740| (r_amod) syndrome_8\NN\5870365|disulfiram-like (r_dobj) developed_6\VBD\1753788|hours|,|he|syndrome|flushing|consuming|. (l_advcl) flushing_10\NN\1740|with|,|tachycardia|,|and|hypotension (l_conj) tachycardia_12\NN\14110674|
D004221_D007022 NONE disulfiram-like_7\JJ\1740| (r_amod) syndrome_8\NN\5870365|disulfiram-like (r_dobj) developed_6\VBD\1753788|hours|,|he|syndrome|flushing|consuming|. (l_advcl) flushing_10\NN\1740|with|,|tachycardia|,|and|hypotension (l_conj) hypotension_16\NN\14057371|arterial
2071257
D005997_D000647 NONE l-alpha-glyceryl-phosphorylcholine_2\NN\1740|of (r_nmod) effect_0\NN\34213|l-alpha-glyceryl-phosphorylcholine|amnesia|caused|. (l_nmod) amnesia_4\NN\5669934|on
D012601_D000647 NONE scopolamine_7\NN\14712692|by (r_nmod) caused_5\VBN\1617192|scopolamine (r_acl) effect_0\NN\34213|l-alpha-glyceryl-phosphorylcholine|amnesia|caused|. (l_nmod) amnesia_4\NN\5669934|on
D005997_D008569 NONE l-alpha-glycerylphosphorylcholine_11\NN\1740|of|l-alpha-gfc (r_nmod) effects_9\NNS\13245626|the|l-alpha-glycerylphosphorylcholine|impairment (l_nmod) impairment_17\NN\7296428|on|memory|induced
D005997_D008569 NONE l-alpha-gfc_13\NN\1740|(|) (r_appos) l-alpha-glycerylphosphorylcholine_11\NN\1740|of|l-alpha-gfc (r_nmod) effects_9\NNS\13245626|the|l-alpha-glycerylphosphorylcholine|impairment (l_nmod) impairment_17\NN\7296428|on|memory|induced
D012601_D008569 CID scopolamine_20\NN\14712692|by (r_nmod) induced_18\VBN\1627355|scopolamine|man (r_acl) impairment_17\NN\7296428|on|memory|induced
D012601_D008569 CID scopolamine_20\NN\14712692|by (r_nmod) induced_18\VBN\1627355|scopolamine (r_acl) attention_15\NN\5701944|of|and|memory|induced (l_conj) memory_17\NN\5926676|
2375138
D008874_D006323 CID midazolam-associated_2\JJ\1740| (r_amod) cardiorespiratory_3\JJ\1740|intramuscular|midazolam-associated (r_amod) arrest_4\NN\88481|possible|cardiorespiratory|and|death|.
D008874_D006323 CID midazolam_17\NN\2830852|of (r_nmod) administration_15\NN\1133281|with|intramuscular|midazolam (r_nmod) associated_12\VBN\628491|administration (r_acl) arrest_9\NN\88481|of|cardiorespiratory|and|death|associated
D008874_D003643 NONE midazolam-associated_2\JJ\1740| (r_amod) cardiorespiratory_3\JJ\1740|intramuscular|midazolam-associated (r_amod) arrest_4\NN\88481|possible|cardiorespiratory|and|death|. (l_conj) death_6\NN\7296428|
D008874_D003643 NONE midazolam_17\NN\2830852|of (r_nmod) administration_15\NN\1133281|with|intramuscular|midazolam (r_nmod) associated_12\VBN\628491|administration (r_acl) arrest_9\NN\88481|of|cardiorespiratory|and|death|associated (l_conj) death_11\NN\7296428|
1436384
D000661_D020258 CID amphetamine-induced_2\JJ\1740| (r_amod) neurotoxicity_3\NN\1740|against|amphetamine-induced|neurons
D000661_D020258 CID amphetamine_10\NN\3248958|of|and|related|compounds (r_nmod) effect_8\NN\34213|the|neurotoxic|amphetamine|neurons (l_amod) neurotoxic_7\JJ\1740|
D004298_D020258 NONE dopamine_6\NN\14807737| (r_compound) neurons_7\NNS\5430628|toward|striatal|dopamine|rodents (r_nmod) neurotoxicity_3\NN\1740|against|amphetamine-induced|neurons
D004298_D020258 NONE dopamine_16\NN\14807737| (r_compound) neurons_17\NNS\5430628|toward|nigrostriatal|dopamine (r_nmod) effect_8\NN\34213|the|neurotoxic|amphetamine|neurons (l_amod) neurotoxic_7\JJ\1740|
C070935_D020258 NONE ly274614_11\NN\1740|by|,|antagonist (r_nmod) rodents_9\NNS\1886756|in|ly274614 (r_nmod) neurons_7\NNS\5430628|toward|striatal|dopamine|rodents (r_nmod) neurotoxicity_3\NN\1740|against|amphetamine-induced|neurons
C070935_D020258 NONE ly274614_23\NN\1740| (r_nsubj) antagonist_28\NN\7846|that|ly274614|is|an|nmda|receptor|effects (r_conj) involves_18\VBZ\2676054|that|effect|receptors|and|antagonist (l_nsubj) effect_8\NN\34213|the|neurotoxic|amphetamine|neurons (l_amod) neurotoxic_7\JJ\1740|
D000596_D020258 NONE acid_16\NN\14818238| (r_compound) antagonist_17\NN\7846|an|excitatory|amino|acid (r_appos) ly274614_11\NN\1740|by|,|antagonist (r_nmod) rodents_9\NNS\1886756|in|ly274614 (r_nmod) neurons_7\NNS\5430628|toward|striatal|dopamine|rodents (r_nmod) neurotoxicity_3\NN\1740|against|amphetamine-induced|neurons
D016202_D020258 NONE nmda_19\NN\1740| (r_compound) receptors_20\NNS\5225602|nmda (r_dobj) involves_18\VBZ\2676054|that|effect|receptors|and|antagonist (l_nsubj) effect_8\NN\34213|the|neurotoxic|amphetamine|neurons (l_amod) neurotoxic_7\JJ\1740|
D016202_D020258 NONE nmda_26\NN\1740| (r_compound) antagonist_28\NN\7846|that|ly274614|is|an|nmda|receptor|effects (r_conj) involves_18\VBZ\2676054|that|effect|receptors|and|antagonist (l_nsubj) effect_8\NN\34213|the|neurotoxic|amphetamine|neurons (l_amod) neurotoxic_7\JJ\1740|
12443032
D003042_D002637 CID cocaine_0\NN\3492717| (r_nmod:npmod) related_1\JJ\1740|cocaine (r_amod) pain_3\NN\14299637|related|chest
D003042_D002637 CID cocaine_6\NN\3492717|of (r_nmod) tendency_4\NN\6193203|the|cocaine|produce (l_acl) produce_8\VB\1617192|to|pain (l_dobj) pain_10\NN\14299637|chest
D003042_D002637 CID cocaine_6\NN\3492717|of (r_nmod) tendency_4\NN\6193203|the|cocaine|produce (r_nsubj) ought_11\MD\1740|in|,|tendency|to|faced|. (l_advcl) faced_22\VBN\2439281|when|victim (l_nmod) victim_26\NN\9630641|with|a|young|pain|otherwise (l_nmod) pain_29\NN\14299637|of|chest
D003042_D002637 CID cocaine_7\NN\3492717| (r_compound) use_8\NN\407535|to|cocaine (r_nmod) related_5\JJ\1740|use (r_amod) pain_4\NN\14299637|of|chest|related
11135224
D017239_D002289 NONE paclitaxel_0\NNP\1740|,|cisplatin|,|and|chemotherapy|. (l_conj) chemotherapy_7\NN\661091|combination|approach (l_nmod) approach_12\NN\940842|within|a|therapeutic|carcinoma (l_nmod) carcinoma_18\NN\14239918|in|metastatic|nonsmall|cell|lung
D017239_D002289 NONE paclitaxel_20\NN\1740|of|a|,|cisplatin|,|and (r_nmod) feasibility_11\NN\5152150|the|,|rate|,|and|toxicity|paclitaxel|combination|treat (l_acl) treat_28\VB\2376958|to|nsclc (l_dobj) nsclc_30\NN\1740|metastatic
D017239_D002289 NONE paclitaxel_26\NN\1740|of (r_nmod) combination_24\NN\7951464|with|a|paclitaxel|mg/m(2|given|day|days|, (r_nmod) treated_21\VBN\2376958|patients|were|combination|weeks|. (l_nsubjpass) patients_3\NNS\9898892|thirty-five|consecutive|nsclc (l_nmod) nsclc_7\NN\1740|with|stage|iv|and|status
D017239_D002289 NONE paclitaxel_5\NN\1740|of|,|cisplatin|,|and|gemcitabine (r_nmod) combination_3\NN\7951464|the|paclitaxel (r_nsubjpass) tolerated_13\VBN\802318|combination|is|well|and|shows (l_conj) shows_15\VBZ\2137132|activity (l_dobj) activity_17\NN\30358|high|nsclc (l_nmod) nsclc_20\NN\1740|in|metastatic
D002945_D002289 NONE cisplatin_2\NN\1740| (r_conj) paclitaxel_0\NNP\1740|,|cisplatin|,|and|chemotherapy|. (l_conj) chemotherapy_7\NN\661091|combination|approach (l_nmod) approach_12\NN\940842|within|a|therapeutic|carcinoma (l_nmod) carcinoma_18\NN\14239918|in|metastatic|nonsmall|cell|lung
D002945_D002289 NONE cisplatin-based_2\JJ\1740| (r_amod) combinations_4\NNS\7951464|cisplatin-based|chemotherapy (r_nsubj) improve_5\VBP\126264|background|:|combinations|quality|. (l_dobj) quality_6\NN\24264|life (l_nmod) life_8\NN\13954253|of|and|survival|carcinoma (l_nmod) carcinoma_16\NN\14239918|in|advanced|nonsmall|cell|lung|nsclc
D002945_D002289 NONE cisplatin-based_2\JJ\1740| (r_amod) combinations_4\NNS\7951464|cisplatin-based|chemotherapy (r_nsubj) improve_5\VBP\126264|background|:|combinations|quality|. (l_dobj) quality_6\NN\24264|life (l_nmod) life_8\NN\13954253|of|and|survival|carcinoma (l_nmod) carcinoma_16\NN\14239918|in|advanced|nonsmall|cell|lung|nsclc (l_appos) nsclc_18\NN\1740|(|)
D002945_D002289 NONE cisplatin_22\NN\1740| (r_conj) paclitaxel_20\NN\1740|of|a|,|cisplatin|,|and (r_nmod) feasibility_11\NN\5152150|the|,|rate|,|and|toxicity|paclitaxel|combination|treat (l_acl) treat_28\VB\2376958|to|nsclc (l_dobj) nsclc_30\NN\1740|metastatic
D002945_D002289 NONE cisplatin_41\NN\1740|mg/m(2|given (r_appos) day_38\NN\15154774|on|1|,|cisplatin|) (r_nmod) given_31\VBN\2327200|intravenously|hours|day (r_acl) combination_24\NN\7951464|with|a|paclitaxel|mg/m(2|given|day|days|, (r_nmod) treated_21\VBN\2376958|patients|were|combination|weeks|. (l_nsubjpass) patients_3\NNS\9898892|thirty-five|consecutive|nsclc (l_nmod) nsclc_7\NN\1740|with|stage|iv|and|status
D002945_D002289 NONE cisplatin_7\NN\1740| (r_conj) paclitaxel_5\NN\1740|of|,|cisplatin|,|and|gemcitabine (r_nmod) combination_3\NN\7951464|the|paclitaxel (r_nsubjpass) tolerated_13\VBN\802318|combination|is|well|and|shows (l_conj) shows_15\VBZ\2137132|activity (l_dobj) activity_17\NN\30358|high|nsclc (l_nmod) nsclc_20\NN\1740|in|metastatic
C056507_D002289 NONE gemcitabine_5\NN\1740| (r_compound) combination_6\NN\7951464|gemcitabine (r_compound) chemotherapy_7\NN\661091|combination|approach (l_nmod) approach_12\NN\940842|within|a|therapeutic|carcinoma (l_nmod) carcinoma_18\NN\14239918|in|metastatic|nonsmall|cell|lung
C056507_D002289 NONE gemcitabine_25\NN\1740| (r_compound) combination_26\NN\7951464|gemcitabine (r_conj) feasibility_11\NN\5152150|the|,|rate|,|and|toxicity|paclitaxel|combination|treat (l_acl) treat_28\VB\2376958|to|nsclc (l_dobj) nsclc_30\NN\1740|metastatic
C056507_D002289 NONE gemcitabine_57\NN\1740|mg/m(2 (r_conj) day_53\NN\15154774|on|1|,|and|gemcitabine|given|) (r_nmod) combination_24\NN\7951464|with|a|paclitaxel|mg/m(2|given|day|days|, (r_nmod) treated_21\VBN\2376958|patients|were|combination|weeks|. (l_nsubjpass) patients_3\NNS\9898892|thirty-five|consecutive|nsclc (l_nmod) nsclc_7\NN\1740|with|stage|iv|and|status
C056507_D002289 NONE gemcitabine_10\NN\1740| (r_conj) paclitaxel_5\NN\1740|of|,|cisplatin|,|and|gemcitabine (r_nmod) combination_3\NN\7951464|the|paclitaxel (r_nsubjpass) tolerated_13\VBN\802318|combination|is|well|and|shows (l_conj) shows_15\VBZ\2137132|activity (l_dobj) activity_17\NN\30358|high|nsclc (l_nmod) nsclc_20\NN\1740|in|metastatic
D017239_D064420 NONE paclitaxel_20\NN\1740|of|a|,|cisplatin|,|and (r_nmod) feasibility_11\NN\5152150|the|,|rate|,|and|toxicity|paclitaxel|combination|treat (l_conj) toxicity_17\NN\13576101|
D002945_D064420 NONE cisplatin_22\NN\1740| (r_conj) paclitaxel_20\NN\1740|of|a|,|cisplatin|,|and (r_nmod) feasibility_11\NN\5152150|the|,|rate|,|and|toxicity|paclitaxel|combination|treat (l_conj) toxicity_17\NN\13576101|
C056507_D064420 NONE gemcitabine_25\NN\1740| (r_compound) combination_26\NN\7951464|gemcitabine (r_conj) feasibility_11\NN\5152150|the|,|rate|,|and|toxicity|paclitaxel|combination|treat (l_conj) toxicity_17\NN\13576101|
3403780
D000082_D003128 NONE paracetamol-associated_0\JJ\1740| (r_amod) coma_1\NN\5678932|paracetamol-associated|,|acidosis|,|failure|.
D000082_D000138 CID paracetamol-associated_0\JJ\1740| (r_amod) coma_1\NN\5678932|paracetamol-associated|,|acidosis|,|failure|. (l_conj) acidosis_4\NN\14204950|metabolic
D000082_D000138 CID paracetamol_13\NN\1740| (r_compound) ingestion_14\NN\13440063|following|paracetamol (r_nmod) failure_8\NN\66216|acute|renal|and|failure|ingestion (r_conj) acidosis_4\NN\14204950|of|metabolic|,|failure
D000082_D058186 CID paracetamol_13\NN\1740| (r_compound) ingestion_14\NN\13440063|following|paracetamol (r_nmod) failure_8\NN\66216|acute|renal|and|failure|ingestion (l_conj) failure_11\NN\66216|hepatic
D000082_D058186 NONE paracetamol-associated_0\JJ\1740| (r_amod) coma_1\NN\5678932|paracetamol-associated|,|acidosis|,|failure|. (l_appos) failure_9\NN\66216|renal
D000082_D017093 NONE paracetamol-associated_0\JJ\1740| (r_amod) coma_1\NN\5678932|paracetamol-associated|,|acidosis|,|failure|. (l_appos) failure_9\NN\66216|renal
D000082_D017114 CID paracetamol_13\NN\1740| (r_compound) ingestion_14\NN\13440063|following|paracetamol (r_nmod) failure_8\NN\66216|acute|renal|and|failure|ingestion (l_conj) failure_11\NN\66216|hepatic
2632720
D007654_D006973 CID ketoconazole_7\NN\1740| (r_compound) treatment_8\NN\654885|of|prolonged|ketoconazole (r_nmod) complication_4\NN\1073995|as|a|treatment (r_nmod) hypertension_1\NN\14057371|arterial|complication|.
D007654_D006973 CID ketoconazole_14\NN\1740|with (r_nmod) basis_12\NN\13790712|on|a|long-term|ketoconazole (r_nmod) treated_8\VBN\2376958|basis (r_acl) patients_3\NNS\9898892|14|syndrome|treated (r_nsubj) developed_15\VBD\1753788|patients|hypertension|. (l_dobj) hypertension_17\NN\14057371|sustained
D007654_D006973 CID ketoconazole_14\NN\1740| (r_compound) therapy_15\NN\657604|following|ketoconazole (r_nmod) achieved_12\VBN\2524171|cases|levels|had|been|therapy|,|yet|demonstrated|. (l_conj) demonstrated_22\VBD\2137132|monitoring|hypertension|treatment (l_dobj) hypertension_23\NN\14057371|31|patient|and|weeks
D007654_D006973 CID ketoconazole_10\NN\1740|of (r_nmod) doses_8\NNS\3740161|with|high|ketoconazole (r_nmod) treatment_5\NN\654885|long-term|doses (r_nsubj) induce_12\VB\1627355|that|treatment|may|blockade (l_dobj) blockade_14\NN\952963|enzyme|leading (l_acl) leading_15\VBG\1752884|hypertension (l_nmod) hypertension_18\NN\14057371|to|mineralocorticoid-related
D007654_D003480 NONE ketoconazole_14\NN\1740|with (r_nmod) basis_12\NN\13790712|on|a|long-term|ketoconazole (r_nmod) treated_8\VBN\2376958|basis (r_acl) patients_3\NNS\9898892|14|syndrome|treated (l_nmod) syndrome_7\NN\5870365|with|cushing|'s
D006854_D006973 NONE cortisol_8\NN\14751417| (r_compound) levels_9\NNS\4916342|plasma|cortisol (r_nsubjpass) achieved_12\VBN\2524171|cases|levels|had|been|therapy|,|yet|demonstrated|. (l_conj) demonstrated_22\VBD\2137132|monitoring|hypertension|treatment (l_dobj) hypertension_23\NN\14057371|31|patient|and|weeks
17042910
C065179_D006973 NONE atorvastatin_3\NN\3676175|of (r_nmod) effects_1\NNS\13245626|anti-oxidant|atorvastatin|hypertension|. (l_nmod) hypertension_6\NN\14057371|in|dexamethasone-induced|rat
C065179_D006973 NONE atorvastatin_0\NN\3676175|ato (r_nsubj) possesses_4\VBZ\2630189|atorvastatin|properties|reduced|. (l_conj) reduced_21\VBD\441445|production (l_dobj) production_23\NN\30358|o2-|forms (l_nmod) forms_26\NNS\6286395|in|various|hypertension (l_nmod) hypertension_28\NN\14057371|of
C065179_D006973 NONE ato_2\NN\1740|(|) (r_appos) atorvastatin_0\NN\3676175|ato (r_nsubj) possesses_4\VBZ\2630189|atorvastatin|properties|reduced|. (l_conj) reduced_21\VBD\441445|production (l_dobj) production_23\NN\30358|o2-|forms (l_nmod) forms_26\NNS\6286395|in|various|hypertension (l_nmod) hypertension_28\NN\14057371|of
D003907_D006973 CID dexamethasone-induced_5\JJ\1740| (r_amod) hypertension_6\NN\14057371|in|dexamethasone-induced|rat
D003907_D006973 CID dexamethasone_2\NN\2721538| (r_nsubj) (dex)-induced_3\VBD\1740|1|dexamethasone (r_amod) hypertension_4\NN\14057371|(dex)-induced
D003907_D006973 CID (dex)-induced_3\VBD\1740|1|dexamethasone (r_amod) hypertension_4\NN\14057371|(dex)-induced
D009569_D006973 NONE oxide_13\NN\14818238|nitric (r_compound) deficiency_17\NN\14449126|with|oxide|(|no|) (r_nmod) associated_10\VBN\628491|deficiency (r_acl) dysfunction_9\NN\14204950|by|endothelial|associated|and|production (r_nmod) characterized_6\VBN\609683|hypertension|is|dysfunction|. (l_nsubjpass) hypertension_4\NN\14057371|(dex)-induced
D009569_D006973 NONE no_15\NN\7204911| (r_compound) deficiency_17\NN\14449126|with|oxide|(|no|) (r_nmod) associated_10\VBN\628491|deficiency (r_acl) dysfunction_9\NN\14204950|by|endothelial|associated|and|production (r_nmod) characterized_6\VBN\609683|hypertension|is|dysfunction|. (l_nsubjpass) hypertension_4\NN\14057371|(dex)-induced
D009569_D006973 NONE no_19\NN\7204911|of (r_nmod) availability_17\NN\4718563|through|increased|no (r_nmod) improve_12\VB\126264|to|function|availability|and (r_xcomp) reported_10\VBN\831651|that|have|been|improve (r_acl:relcl) properties_6\NNS\32613|pleiotropic|reported (r_dobj) possesses_4\VBZ\2630189|atorvastatin|properties|reduced|. (l_conj) reduced_21\VBD\441445|production (l_dobj) production_23\NN\30358|o2-|forms (l_nmod) forms_26\NNS\6286395|in|various|hypertension (l_nmod) hypertension_28\NN\14057371|of
D013481_D006973 NONE superoxide_20\NN\14971519|o2- (r_compound) production_24\NN\30358|increased|superoxide (r_conj) dysfunction_9\NN\14204950|by|endothelial|associated|and|production (r_nmod) characterized_6\VBN\609683|hypertension|is|dysfunction|. (l_nsubjpass) hypertension_4\NN\14057371|(dex)-induced
D013481_D006973 NONE o2-_22\NN\1740|(|) (r_appos) superoxide_20\NN\14971519|o2- (r_compound) production_24\NN\30358|increased|superoxide (r_conj) dysfunction_9\NN\14204950|by|endothelial|associated|and|production (r_nmod) characterized_6\VBN\609683|hypertension|is|dysfunction|. (l_nsubjpass) hypertension_4\NN\14057371|(dex)-induced
D013481_D006973 NONE o2-_22\NN\1740| (r_amod) production_23\NN\30358|o2-|forms (l_nmod) forms_26\NNS\6286395|in|various|hypertension (l_nmod) hypertension_28\NN\14057371|of
3780846
D009020_D009127 CID morphine_14\NN\2707683|by|rats (r_nmod) produced_12\VBN\1617192|morphine (r_acl) rigidity_11\NN\5023233|to|the|muscular|produced
D009020_D009127 CID morphine_10\NN\2707683|by (r_nmod) produced_8\VBN\1617192|morphine (r_acl) rigidity_7\NN\5023233|to|the|muscular|produced
D009020_D009127 CID morphine_7\NN\2707683|of (r_nmod) dose_5\NN\3740161|given|a|test|morphine|mg/kg (r_nmod) controls_1\NNS\5190804|saline-pretreated|dose (r_nsubj) showed_13\VBD\2137132|controls|rigidity|. (l_dobj) rigidity_16\NN\5023233|a|pronounced|recorded
D009020_D009127 CID morphine_6\NN\2707683|with (r_nmod) days_4\NNS\15140892|for|11|morphine (r_nmod) treated_1\VBN\2376958|days|and|withdrawn (r_acl) rats_0\NNS\2329401|treated (r_nsubj) showed_14\VBD\2137132|rats|differences|showed|. (l_conj) showed_27\VBD\2137132|rigidity (l_dobj) rigidity_29\NN\5023233|a|dose
D009020_D009127 CID morphine_35\NN\2707683|of (r_nmod) dose_33\NN\3740161|after|the|test|morphine|less (r_nmod) rigidity_29\NN\5023233|a|dose
D009020_D009127 CID morphine_16\NN\2707683|of (r_nmod) action_14\NN\30358|to|be|due|an|morphine|striatum (r_xcomp) assumed_8\VBN\719734|which|is|action (r_acl:relcl) rigidity_4\NN\5023233|,|assumed|,
D009020_D018476 CID morphine_6\NN\2707683|with (r_nmod) days_4\NNS\15140892|for|11|morphine (r_nmod) treated_1\VBN\2376958|days|and|withdrawn (r_acl) rats_0\NNS\2329401|treated (r_nsubj) showed_14\VBD\2137132|rats|differences|showed|. (l_conj) showed_27\VBD\2137132|rigidity (l_dobj) rigidity_29\NN\5023233|a|dose (l_nmod) dose_33\NN\3740161|after|the|test|morphine|less (l_acl:relcl) less_40\JJR\1740|that|was|not|significantly|controls|and|akinetic (l_conj) akinetic_47\JJ\1740|were|group
D009020_D018476 CID morphine_35\NN\2707683|of (r_nmod) dose_33\NN\3740161|after|the|test|morphine|less (l_acl:relcl) less_40\JJR\1740|that|was|not|significantly|controls|and|akinetic (l_conj) akinetic_47\JJ\1740|were|group
D006220_D009127 CID haloperidol_7\NN\3713736|mg/kg (r_appos) series_3\NN\8456993|in|a|further|experiments|,|haloperidol (r_nmod) used_14\VBN\1156834|series|was|order|. (l_nmod) order_16\NN\7168131|in|block (l_acl) block_18\VB\1476483|to|activation|and|estimate (l_conj) estimate_24\VB\637259|to|degree|interference (l_dobj) degree_27\NN\4916342|the|real|tolerance (l_nmod) tolerance_30\NN\5032565|of|the|rigidity (l_nmod) rigidity_33\NN\5023233|to|the
D006220_D009127 CID haloperidol_0\NNP\3713736| (r_nsubj) enhanced_1\VBD\227165|haloperidol|rigidity|. (l_dobj) rigidity_3\NN\5023233|the|group
3693336
D014229_D001714 CID triazolam-induced_0\JJ\1740| (r_amod) episodes_2\NNS\7283608|triazolam-induced|brief|mania|patient|. (l_nmod) mania_5\NN\9180259|of|secondary
D014229_D001714 CID triazolam_3\NNS\2830852|of (r_nmod) doses_1\NNS\3740161|large|triazolam (r_nsubj) induced_5\VBD\1627355|doses|repeatedly|episodes|woman|. (l_dobj) episodes_7\NNS\7283608|brief|mania (l_nmod) mania_9\NN\9180259|of
D014229_D001714 CID triazolam_10\NNS\2830852|of (r_nmod) action_8\NN\30358|of|triazolam (r_nmod) duration_6\NN\15113229|with|the|action (r_nmod) coincident_3\JJ\1740|excitement|was|duration|. (l_nsubj) excitement_1\NN\7527352|manic (l_amod) manic_0\JJ\1740|
D014229_D003866 NONE triazolam-induced_0\JJ\1740| (r_amod) episodes_2\NNS\7283608|triazolam-induced|brief|mania|patient|. (l_nmod) patient_9\NN\9898892|in|a|depressed (l_amod) depressed_8\JJ\1740|
D014229_D003866 NONE triazolam_3\NNS\2830852|of (r_nmod) doses_1\NNS\3740161|large|triazolam (r_nsubj) induced_5\VBD\1627355|doses|repeatedly|episodes|woman|. (l_nmod) woman_14\NN\9605289|in|a|depressed|elderly (l_amod) depressed_12\JJ\1740|
12523465
C022189_D006212 CID zonisamide_4\NN\1740|with (r_nmod) associated_2\VBN\628491|zonisamide (r_acl) hallucinations_1\NNS\14376855|visual|associated|.
C022189_D006212 CID zonisamide_29\NN\1740| (r_compound) treatment_30\NN\654885|after|zonisamide (r_nmod) experienced_20\VBD\2108377|who|hallucinations|treatment (r_acl:relcl) patients_18\NNS\9898892|three|experienced (r_dobj) describe_16\VBP\1001294|reported|,|we|patients|begun|. (l_advcl) reported_6\VBN\831651|although|hallucinations|have|not|been|effect (l_nsubjpass) hallucinations_2\NNS\14376855|visual
C022189_D006212 CID zonisamide_29\NN\1740| (r_compound) treatment_30\NN\654885|after|zonisamide (r_nmod) experienced_20\VBD\2108377|who|hallucinations|treatment (l_dobj) hallucinations_23\NNS\14376855|complex|visual|and|status
C022189_D012640 NONE zonisamide_0\NNP\1740| (r_nsubj) drug_5\NN\14778436|zonisamide|is|a|broad-spectrum|antiepileptic|used|. (l_acl) used_6\VBN\1156834|treat (l_xcomp) treat_8\VB\2376958|to|types (l_dobj) types_10\NNS\5839024|various|seizures (l_nmod) seizures_12\NNS\14081375|of
15649445
D012110_D004409 CID reserpine_1\NN\2721160|acute|and|subchronic (r_nsubj) change_6\VBP\46534|reserpine|glutamate|. (l_dobj) glutamate_9\NN\15010703|synaptosomal|brain|uptake|and|elicit (l_conj) elicit_12\VB\1617192|dyskinesia (l_dobj) dyskinesia_14\NN\14084880|orofacial|rats
D012110_D004409 CID reserpine-_0\NN\1740|and|dyskinesia (l_conj) dyskinesia_4\NN\14084880|haloperidol-induced|orofacial
D012110_D004409 CID reserpine-_0\NN\1740|and|dyskinesia (r_nsubj) models_8\NNS\5888929|reserpine-|are|putative|animal|dyskinesia|. (l_nmod) dyskinesia_11\NN\14084880|of|tardive|td|related
D012110_D004409 CID reserpine-_0\NN\1740|and|dyskinesia (r_nsubj) models_8\NNS\5888929|reserpine-|are|putative|animal|dyskinesia|. (l_nmod) dyskinesia_11\NN\14084880|of|tardive|td|related (l_appos) td_13\NN\1740|(|)
D012110_D004409 CID reserpine_12\NN\2721160|by|acute (r_nmod) induced_7\VBD\1627355|study|,|authors|dyskinesia|reserpine|and|subchronic|. (l_dobj) dyskinesia_9\NN\14084880|orofacial
D006220_D004409 CID haloperidol_4\NN\3713736| (r_compound) treatments_5\NNS\654885|haloperidol (r_dobj) subchronic_3\JJ\1740|treatments (r_conj) reserpine_1\NN\2721160|acute|and|subchronic (r_nsubj) change_6\VBP\46534|reserpine|glutamate|. (l_dobj) glutamate_9\NN\15010703|synaptosomal|brain|uptake|and|elicit (l_conj) elicit_12\VB\1617192|dyskinesia (l_dobj) dyskinesia_14\NN\14084880|orofacial|rats
D006220_D004409 CID haloperidol-induced_2\JJ\1740| (r_amod) dyskinesia_4\NN\14084880|haloperidol-induced|orofacial
D006220_D004409 CID haloperidol-induced_2\JJ\1740| (r_amod) dyskinesia_4\NN\14084880|haloperidol-induced|orofacial (r_conj) reserpine-_0\NN\1740|and|dyskinesia (r_nsubj) models_8\NNS\5888929|reserpine-|are|putative|animal|dyskinesia|. (l_nmod) dyskinesia_11\NN\14084880|of|tardive|td|related
D006220_D004409 CID haloperidol-induced_2\JJ\1740| (r_amod) dyskinesia_4\NN\14084880|haloperidol-induced|orofacial (r_conj) reserpine-_0\NN\1740|and|dyskinesia (r_nsubj) models_8\NNS\5888929|reserpine-|are|putative|animal|dyskinesia|. (l_nmod) dyskinesia_11\NN\14084880|of|tardive|td|related (l_appos) td_13\NN\1740|(|)
D006220_D004409 CID haloperidol_15\NN\3713736|administration (r_dep) subchronic_14\JJ\1740|haloperidol|rats (r_conj) induced_7\VBD\1627355|study|,|authors|dyskinesia|reserpine|and|subchronic|. (l_dobj) dyskinesia_9\NN\14084880|orofacial
D018698_D004409 NONE glutamate_9\NN\15010703|synaptosomal|brain|uptake|and|elicit (l_conj) elicit_12\VB\1617192|dyskinesia (l_dobj) dyskinesia_14\NN\14084880|orofacial|rats
D018698_D004409 NONE glutamate_5\JJ\1740| (r_amod) uptake_6\NN\13440063|in|glutamate (r_nmod) decrease_3\NN\7296428|a|uptake (r_nsubj) correlates_7\VBZ\2657219|importantly|,|decrease|negatively|increase|. (l_nmod) increase_11\NN\13576355|with|an|incidence (l_nmod) incidence_14\NN\13821570|in|the|diskinesia (l_nmod) diskinesia_17\NN\1740|of|orofacial
18631865
D020123_D051436 NONE rapamycin_16\NN\1740|of|mtor (r_compound) inhibitors_20\NNS\20090|rapamycin|,|sirolimus (r_nmod) target_14\NN\7258332|to|mammalian|inhibitors (r_nmod) conversion_8\NN\7359599|after|inhibitors|target (r_nmod) observed_6\VBN\2163746|excretion|has|been|conversion|,|recipients|nephropathy|. (l_advmod) nephropathy_32\NN\14573196|
D020123_D051436 NONE sirolimus_23\NN\1740|especially (r_appos) inhibitors_20\NNS\20090|rapamycin|,|sirolimus (r_nmod) target_14\NN\7258332|to|mammalian|inhibitors (r_nmod) conversion_8\NN\7359599|after|inhibitors|target (r_nmod) observed_6\VBN\2163746|excretion|has|been|conversion|,|recipients|nephropathy|. (l_advmod) nephropathy_32\NN\14573196|
D020123_D011507 CID sirolimus_5\NN\1740|to|or|consequence (r_nmod) due_3\JJ\1740|proteinuria|was|sirolimus|remained|. (l_nsubj) proteinuria_1\NN\14299637|whether
D020123_D011507 CID sirolimus_5\NN\1740|to|or|consequence (r_nmod) due_3\JJ\1740|proteinuria|was|sirolimus|remained|. (l_conj) remained_14\VBD\2604760|unsolved|observed (l_advcl) observed_22\VBN\2163746|until|proteinuria|has|been|therapy (l_nsubjpass) proteinuria_19\NN\14299637|high|range
D020123_D011507 CID sirolimus_24\NN\1740| (r_compound) therapy_25\NN\657604|during|sirolimus|transplantation (r_nmod) observed_22\VBN\2163746|until|proteinuria|has|been|therapy (r_advcl) remained_14\VBD\2604760|unsolved|observed (r_conj) due_3\JJ\1740|proteinuria|was|sirolimus|remained|. (l_nsubj) proteinuria_1\NN\14299637|whether
D020123_D011507 CID sirolimus_24\NN\1740| (r_compound) therapy_25\NN\657604|during|sirolimus|transplantation (r_nmod) observed_22\VBN\2163746|until|proteinuria|has|been|therapy (l_nsubjpass) proteinuria_19\NN\14299637|high|range
D020123_D011507 CID sirolimus_34\NN\1740| (r_dobj) received_33\VBD\2210855|who|sirolimus|novo (r_acl:relcl) transplantation_28\NN\671351|in|islet|and|patients|received (r_nmod) therapy_25\NN\657604|during|sirolimus|transplantation (r_nmod) observed_22\VBN\2163746|until|proteinuria|has|been|therapy (r_advcl) remained_14\VBD\2604760|unsolved|observed (r_conj) due_3\JJ\1740|proteinuria|was|sirolimus|remained|. (l_nsubj) proteinuria_1\NN\14299637|whether
D020123_D011507 CID sirolimus_34\NN\1740| (r_dobj) received_33\VBD\2210855|who|sirolimus|novo (r_acl:relcl) transplantation_28\NN\671351|in|islet|and|patients|received (r_nmod) therapy_25\NN\657604|during|sirolimus|transplantation (r_nmod) observed_22\VBN\2163746|until|proteinuria|has|been|therapy (l_nsubjpass) proteinuria_19\NN\14299637|high|range
1085609
D011736_D012640 NONE pyridoxine_1\NN\15090742| (r_compound) convulsions_3\NNS\14081375|neonatal|pyridoxine|responsive|therapy|.
D011736_D012640 NONE pyridoxine_9\NN\15090742|intramuscular (r_dobj) administering_7\VBG\2436349|of|pyridoxine (r_advcl) hours_5\NNS\15118228|within|4|administering (r_nmod) ceased_2\VBD\1740|fits|hours|,|suggesting|. (l_nsubj) fits_1\NNS\7518132|the
D011736_D012640 NONE pyridoxine_15\NN\15090742| (r_amod) deficiency_16\NN\14449126|of|pyridoxine|secondary (r_nmod) aetiology_13\NN\7326557|an|deficiency (r_dobj) suggesting_11\VBG\1010118|aetiology (r_advcl) ceased_2\VBD\1740|fits|hours|,|suggesting|. (l_nsubj) fits_1\NNS\7518132|the
D007538_D012640 CID isoniazid_6\NN\2716205| (r_compound) therapy_7\NN\657604|due|isoniazid (r_nmod) convulsions_3\NNS\14081375|neonatal|pyridoxine|responsive|therapy|.
D007538_D012640 CID isoniazid_4\NN\2716205| (r_compound) therapy_5\NN\657604|on|isoniazid (r_compound) mg/kg_7\NN\1740|therapy|13 (r_nmod) infant_2\NN\9918248|a|17-day-old|mg/kg|daily|birth|tuberculosis (r_nsubjpass) admitted_16\VBN\822367|infant|was|days|. (l_nmod) days_19\NNS\15140892|after|4|fits (l_nmod) fits_22\NNS\7518132|of|clonic
D007538_D012640 CID isoniazid_19\NN\2716205|to|medication (r_nmod) secondary_17\JJ\1740|isoniazid (r_amod) deficiency_16\NN\14449126|of|pyridoxine|secondary (r_nmod) aetiology_13\NN\7326557|an|deficiency (r_dobj) suggesting_11\VBG\1010118|aetiology (r_advcl) ceased_2\VBD\1740|fits|hours|,|suggesting|. (l_nsubj) fits_1\NNS\7518132|the
D007538_D014376 NONE isoniazid_4\NN\2716205| (r_compound) therapy_5\NN\657604|on|isoniazid (r_compound) mg/kg_7\NN\1740|therapy|13 (r_nmod) infant_2\NN\9918248|a|17-day-old|mg/kg|daily|birth|tuberculosis (l_nmod) tuberculosis_14\NN\14127211|because|maternal
891050
D003276_D006463 CID contraceptives_17\NNS\3183080|oral (r_dobj) taking_15\VBG\2367363|contraceptives (r_acl) woman_14\NN\9605289|in|a|taking (r_nmod) syndrome_8\NN\5870365|of|the|hemolytic|uremic|hus|woman
D003276_D006463 CID contraceptives_17\NNS\3183080|oral (r_dobj) taking_15\VBG\2367363|contraceptives (r_acl) woman_14\NN\9605289|in|a|taking (r_nmod) syndrome_8\NN\5870365|of|the|hemolytic|uremic|hus|woman (l_appos) hus_10\NN\1740|(|)
D006493_D001002 NONE heparin_4\NN\2718259|with|,|dipyridamole (r_nmod) treated_2\VBN\2376958|she|was|heparin|;|and|rose (l_conj) rose_20\VBD\1835496|months|,|output|ml|;|and|onset (l_nmod) onset_30\NN\7325190|after|the|anuria (l_nmod) anuria_32\NN\14061805|of
D004176_D001002 NONE dipyridamole_6\NN\1740|and|hemodialysis (r_conj) heparin_4\NN\2718259|with|,|dipyridamole (r_nmod) treated_2\VBN\2376958|she|was|heparin|;|and|rose (l_conj) rose_20\VBD\1835496|months|,|output|ml|;|and|onset (l_nmod) onset_30\NN\7325190|after|the|anuria (l_nmod) anuria_32\NN\14061805|of
7199841
C004616_D010243 CID 2-chloroprocaine-ce_9\CD\1740| (r_compound) seven_10\CD\13741022|of|2-chloroprocaine-ce|% (r_nmod) injection_7\NN\320852|subarachnoid|seven (r_dobj) received_5\VBD\2210855|that|injection (r_acl:relcl) animals_3\NNS\4475|of|the|20|received (r_nsubj) developed_15\VBD\1753788|animals|paralysis|. (l_dobj) paralysis_17\NN\14557898|hind-limb
D002045_D010243 NONE bupivacaine_6\NN\1740|,|saline|,|or|saline|titrated (r_dobj) received_5\VBD\2210855|that|bupivacaine (r_acl:relcl) animals_3\NNS\4475|of|the|received (r_nmod) none_0\NN\15228378|animals (r_nsubj) developed_19\VBD\1753788|none|paralysis|. (l_dobj) paralysis_21\NN\14557898|hind-limb
C004616_D013118 CID 2-chloroprocaine-ce_10\CD\1740| (r_dobj) received_9\VBD\2210855|that|2-chloroprocaine-ce (r_acl:relcl) animals_7\NNS\4475|of|the|received (r_nmod) cords_4\NNS\4489008|of|the|15|spinal|animals (r_nmod) showed_13\VBD\2137132|cords|,|13|necrosis|;|normal|. (l_dobj) necrosis_15\NN\11444117|subpial
11256525
D019808_D001002 CID losartan_4\JJ\1740| (r_amod) administration_5\NN\1133281|following|losartan|patient (r_nmod) anuria_2\NN\14061805|repeated|transient|administration|.
D019808_D001002 CID losartan_25\JJ\1740| (r_amod) administration_26\NN\1133281|after|losartan (r_nmod) developed_18\VBD\1753788|who|episodes|administration (l_dobj) episodes_20\NNS\7283608|two|anuria (l_nmod) anuria_23\NN\14061805|of|transient
D019808_D001002 CID losartan_9\NN\1740|of (r_nmod) mg_7\NN\13717155|of|50|losartan (r_nmod) dose_4\NN\3740161|the|first|mg (r_nsubj) resulted_10\VBD\2633881|surprisingly|,|dose|anuria|. (l_nmod) anuria_14\NN\14061805|in|a|sudden|,|lasted
D019808_D001002 CID losartan_7\NN\1740| (r_nsubjpass) prescribed_9\VBN\748282|later|,|mistake|,|losartan|was|again|and|dose|developed|. (l_conj) developed_22\VBD\1753788|,|patient|episode (l_dobj) episode_25\NN\7283608|a|second|anuria (l_nmod) anuria_28\NN\14061805|of|transient|lasting
D019808_D006973 NONE losartan_25\JJ\1740| (r_amod) administration_26\NN\1133281|after|losartan (r_nmod) developed_18\VBD\1753788|who|episodes|administration (r_acl:relcl) kidney_12\NN\5333259|with|a|solitary|and|insufficiency|developed (r_nmod) man_8\NN\9605289|of|a|70-year-old|hypertensive|kidney (l_amod) hypertensive_7\JJ\1740|
D019808_D051436 NONE losartan_25\JJ\1740| (r_amod) administration_26\NN\1133281|after|losartan (r_nmod) developed_18\VBD\1753788|who|episodes|administration (r_acl:relcl) kidney_12\NN\5333259|with|a|solitary|and|insufficiency|developed (l_conj) insufficiency_16\NN\14462946|chronic|renal
D019808_D006331 NONE losartan_5\NN\1740|due|severe|systolic|dysfunction (l_compound) dysfunction_4\NN\14204950|
D005665_D001002 NONE furosemide_22\NN\3214670|despite|high-dose|and|infusion (r_nmod) lasted_17\VBD\2704349|which|hours|furosemide (r_acl:relcl) anuria_14\NN\14061805|in|a|sudden|,|lasted
D000588_D001002 NONE amine_24\NN\14951377| (r_compound) infusion_25\NN\14589223|amine (r_conj) furosemide_22\NN\3214670|despite|high-dose|and|infusion (r_nmod) lasted_17\VBD\2704349|which|hours|furosemide (r_acl:relcl) anuria_14\NN\14061805|in|a|sudden|,|lasted
D000809_D012078 NONE renin-angiotensin_22\JJ\1740| (r_amod) system_23\NN\3575240|of|the|renin-angiotensin|ras (r_nmod) activation_19\NN\13561719|in|a|strong|system (r_nmod) resulted_15\VBD\2633881|patient|,|stenosis|certainly|activation|. (l_nsubj) stenosis_6\NN\14204950|renal|artery|combined
D000809_D006333 NONE renin-angiotensin_22\JJ\1740| (r_amod) system_23\NN\3575240|of|the|renin-angiotensin|ras (r_nmod) activation_19\NN\13561719|in|a|strong|system (r_nmod) resulted_15\VBD\2633881|patient|,|stenosis|certainly|activation|. (l_nsubj) stenosis_6\NN\14204950|renal|artery|combined (l_acl) combined_7\VBN\2630189|failure (l_nmod) failure_10\NN\66216|with|heart|and|therapy
D000804_D014652 NONE ii_9\CD\13741022| (r_nummod) losartan_12\NN\1740|the|angiotensin|ii|receptor|antagonist (r_nsubj) cause_14\VB\1617192|that|losartan|can|complications|and|used (l_dobj) complications_17\NNS\1073995|serious|unexpected|patients (l_nmod) patients_19\NNS\9898892|in|disease (l_nmod) disease_22\NN\14061805|with|renovascular
D019808_D014652 NONE losartan_12\NN\1740|the|angiotensin|ii|receptor|antagonist (r_nsubj) cause_14\VB\1617192|that|losartan|can|complications|and|used (l_dobj) complications_17\NNS\1073995|serious|unexpected|patients (l_nmod) patients_19\NNS\9898892|in|disease (l_nmod) disease_22\NN\14061805|with|renovascular
3412544
D000082_D014523 NONE paracetamol_1\NN\1740| (r_nsubj) cause_2\VB\1617192|does|paracetamol|cancer|? (l_dobj) cancer_4\NN\14239425|urothelial|or|necrosis
D000082_D007681 NONE paracetamol_1\NN\1740| (r_nsubj) cause_2\VB\1617192|does|paracetamol|cancer|? (l_dobj) cancer_4\NN\14239425|urothelial|or|necrosis (l_conj) necrosis_8\NN\11444117|renal|papillary
D000082_D007681 NONE paracetamol_24\NN\1740| (r_conj) phenacetin_22\NN\2707683|of|either|or|paracetamol (r_nmod) consumption_19\NN\13440063|with|phenacetin (r_nmod) associated_17\VBN\628491|consumption (r_acl) risk_1\NN\14541044|the|developing|associated (l_advcl) developing_3\VBG\1753788|of|necrosis (l_dobj) necrosis_6\NN\11444117|renal|papillary|or|cancer|pelvis
D000082_D007681 NONE paracetamol_12\NN\1740| (r_amod) consumption_13\NN\13440063|from|paracetamol|necrosis (l_nmod) necrosis_17\NN\11444117|for|renal|papillary|or|any
D010615_D007681 CID phenacetin_22\NN\2707683|of|either|or|paracetamol (r_nmod) consumption_19\NN\13440063|with|phenacetin (r_nmod) associated_17\VBN\628491|consumption (r_acl) risk_1\NN\14541044|the|developing|associated (l_advcl) developing_3\VBG\1753788|of|necrosis (l_dobj) necrosis_6\NN\11444117|renal|papillary|or|cancer|pelvis
D010615_D007681 CID phenacetin_13\NN\2707683|of (r_nmod) consumption_11\NN\13440063|by|phenacetin|,|increased (r_nmod) increased_7\VBN\169651|risk|was|20-fold|consumption|. (l_nsubjpass) risk_1\NN\14541044|the|necrosis (l_nmod) necrosis_5\NN\11444117|of|renal|papillary
D010615_D007680 CID phenacetin_13\NN\2707683|of (r_nmod) consumption_11\NN\13440063|by|phenacetin|,|increased (l_acl:relcl) increased_17\VBD\169651|which|also|risk (l_dobj) risk_19\NN\14541044|the|cancer (l_nmod) cancer_21\NN\14239425|for|pelvis|but|cancer (l_nmod) pelvis_25\NN\5578911|of|the|renal|and|bladder (l_conj) bladder_27\NN\5515670|
D010615_D007680 NONE phenacetin_22\NN\2707683|of|either|or|paracetamol (r_nmod) consumption_19\NN\13440063|with|phenacetin (r_nmod) associated_17\VBN\628491|consumption (r_acl) risk_1\NN\14541044|the|developing|associated (l_advcl) developing_3\VBG\1753788|of|necrosis (l_dobj) necrosis_6\NN\11444117|renal|papillary|or|cancer|pelvis (l_nmod) pelvis_12\NNS\5578911|of|the|renal|,|ureter|or|bladder (l_conj) bladder_16\NN\5515670|
D010615_D014516 NONE phenacetin_22\NN\2707683|of|either|or|paracetamol (r_nmod) consumption_19\NN\13440063|with|phenacetin (r_nmod) associated_17\VBN\628491|consumption (r_acl) risk_1\NN\14541044|the|developing|associated (l_advcl) developing_3\VBG\1753788|of|necrosis (l_dobj) necrosis_6\NN\11444117|renal|papillary|or|cancer|pelvis (l_nmod) pelvis_12\NNS\5578911|of|the|renal|,|ureter|or|bladder (l_conj) bladder_16\NN\5515670|
D010615_D014516 NONE phenacetin_13\NN\2707683|of (r_nmod) consumption_11\NN\13440063|by|phenacetin|,|increased (l_acl:relcl) increased_17\VBD\169651|which|also|risk (l_dobj) risk_19\NN\14541044|the|cancer (l_nmod) cancer_21\NN\14239425|for|pelvis|but|cancer (l_conj) cancer_32\NN\14239425|not|for|ureteric
D010615_D001749 CID phenacetin_13\NN\2707683|of (r_nmod) consumption_11\NN\13440063|by|phenacetin|,|increased (l_acl:relcl) increased_17\VBD\169651|which|also|risk (l_dobj) risk_19\NN\14541044|the|cancer (l_nmod) cancer_21\NN\14239425|for|pelvis|but|cancer (l_nmod) pelvis_25\NN\5578911|of|the|renal|and|bladder (l_conj) bladder_27\NN\5515670|
D010615_D001749 NONE phenacetin_22\NN\2707683|of|either|or|paracetamol (r_nmod) consumption_19\NN\13440063|with|phenacetin (r_nmod) associated_17\VBN\628491|consumption (r_acl) risk_1\NN\14541044|the|developing|associated (l_advcl) developing_3\VBG\1753788|of|necrosis (l_dobj) necrosis_6\NN\11444117|renal|papillary|or|cancer|pelvis (l_nmod) pelvis_12\NNS\5578911|of|the|renal|,|ureter|or|bladder (l_conj) bladder_16\NN\5515670|
D000082_D007680 NONE paracetamol_24\NN\1740| (r_conj) phenacetin_22\NN\2707683|of|either|or|paracetamol (r_nmod) consumption_19\NN\13440063|with|phenacetin (r_nmod) associated_17\VBN\628491|consumption (r_acl) risk_1\NN\14541044|the|developing|associated (l_advcl) developing_3\VBG\1753788|of|necrosis (l_dobj) necrosis_6\NN\11444117|renal|papillary|or|cancer|pelvis (l_nmod) pelvis_12\NNS\5578911|of|the|renal|,|ureter|or|bladder (l_conj) bladder_16\NN\5515670|
D000082_D014516 NONE paracetamol_24\NN\1740| (r_conj) phenacetin_22\NN\2707683|of|either|or|paracetamol (r_nmod) consumption_19\NN\13440063|with|phenacetin (r_nmod) associated_17\VBN\628491|consumption (r_acl) risk_1\NN\14541044|the|developing|associated (l_advcl) developing_3\VBG\1753788|of|necrosis (l_dobj) necrosis_6\NN\11444117|renal|papillary|or|cancer|pelvis (l_nmod) pelvis_12\NNS\5578911|of|the|renal|,|ureter|or|bladder (l_conj) bladder_16\NN\5515670|
D000082_D014516 NONE paracetamol_12\NN\1740| (r_amod) consumption_13\NN\13440063|from|paracetamol|necrosis (r_nmod) risk_10\NN\14541044|an|increased|consumption (r_dobj) substantiate_7\VB\2604760|to|risk (r_xcomp) unable_5\JJ\1740|contrast|,|we|were|substantiate|was|. (l_advcl) was_25\VBD\836236|although|there|suggestion (l_attr) suggestion_27\NN\5833840|a|association (l_nmod) association_30\NN\8008335|of|an|cancer (l_nmod) cancer_32\NN\14239425|with|ureter (l_nmod) ureter_35\NN\5250659|of|the
D000082_D001749 NONE paracetamol_24\NN\1740| (r_conj) phenacetin_22\NN\2707683|of|either|or|paracetamol (r_nmod) consumption_19\NN\13440063|with|phenacetin (r_nmod) associated_17\VBN\628491|consumption (r_acl) risk_1\NN\14541044|the|developing|associated (l_advcl) developing_3\VBG\1753788|of|necrosis (l_dobj) necrosis_6\NN\11444117|renal|papillary|or|cancer|pelvis (l_nmod) pelvis_12\NNS\5578911|of|the|renal|,|ureter|or|bladder (l_conj) bladder_16\NN\5515670|
D000082_D009369 NONE paracetamol_12\NN\1740| (r_amod) consumption_13\NN\13440063|from|paracetamol|necrosis (l_nmod) necrosis_17\NN\11444117|for|renal|papillary|or|any (l_conj) any_19\DT\1740|cancers (l_nmod) cancers_22\NNS\14239425|of|these
9862868
D004997_D002780 CID estradiol_9\NN\14749794|ee (r_compound) treatment_13\NN\654885|by|ethinyl|estradiol|and|cholestasis (r_nmod) used_1\VBD\1156834|we|models|treatment|ligation|determine|. (l_dobj) models_3\NNS\5888929|rat|cholestasis (l_nmod) cholestasis_6\NN\14052403|of|intrahepatic
D004997_D002780 CID ee_11\NN\6125041|(|) (r_appos) estradiol_9\NN\14749794|ee (r_compound) treatment_13\NN\654885|by|ethinyl|estradiol|and|cholestasis (r_nmod) used_1\VBD\1156834|we|models|treatment|ligation|determine|. (l_dobj) models_3\NNS\5888929|rat|cholestasis (l_nmod) cholestasis_6\NN\14052403|of|intrahepatic
D004997_D001651 NONE estradiol_9\NN\14749794|ee (r_compound) treatment_13\NN\654885|by|ethinyl|estradiol|and|cholestasis (l_conj) cholestasis_16\NN\14052403|extrahepatic
D004997_D001651 NONE ee_11\NN\6125041|(|) (r_appos) estradiol_9\NN\14749794|ee (r_compound) treatment_13\NN\654885|by|ethinyl|estradiol|and|cholestasis (l_conj) cholestasis_16\NN\14052403|extrahepatic
2008831
D008755_D000788 NONE methylergonovine_6\NN\1740|of (r_nmod) administration_4\NN\1133281|of|direct|intracoronary|methylergonovine|patients (l_nmod) patients_8\NNS\9898892|in|angina (l_nmod) angina_13\NN\14171682|with|without|variant
D008755_D000788 NONE methylergonovine_6\NN\1740|of (r_nmod) administration_4\NN\1133281|of|intracoronary|methylergonovine (r_nmod) effects_1\NNS\13245626|the|administration (r_nsubjpass) studied_8\VBN\630380|effects|were|patients|. (l_nmod) patients_11\NNS\9898892|in|21|angina|and|others (l_nmod) angina_14\NN\14171682|with|variant|and|patients
D008755_D000788 NONE methylergonovine_19\NN\1740|of (r_nmod) dose_17\NN\3740161|of|a|low|methylergonovine (r_nmod) injection_12\NN\320852|an|intracoronary|dose (r_dobj) use_9\VBP\1156834|which|injection (r_acl:relcl) tests_6\NNS\5798043|spasm|provocation|,|use|, (r_nsubj) have_21\VBP\2108377|that|tests|sensitivity|greater (l_dobj) sensitivity_24\NN\5651971|a|high|angina|and|vasoreactivity (l_nmod) angina_27\NN\14171682|in|variant
D008755_D002637 NONE methylergonovine_6\NN\1740|of (r_nmod) administration_4\NN\1133281|of|intracoronary|methylergonovine (r_nmod) effects_1\NNS\13245626|the|administration (r_nsubjpass) studied_8\VBN\630380|effects|were|patients|. (l_nmod) patients_11\NNS\9898892|in|21|angina|and|others (l_nmod) angina_14\NN\14171682|with|variant|and|patients (l_conj) patients_17\NNS\9898892|22|pain (l_nmod) pain_21\NN\14299637|with|atypical|chest
D008755_D000787 NONE methylergonovine_6\NN\1740|of (r_nmod) administration_4\NN\1133281|of|intracoronary|methylergonovine (r_nmod) effects_1\NNS\13245626|the|administration (r_nsubjpass) studied_8\VBN\630380|effects|were|patients|. (l_nmod) patients_11\NNS\9898892|in|21|angina|and|others (l_conj) others_24\NNS\1740|in|pectoris|group (l_nmod) pectoris_27\NN\1740|without|angina
D008755_D013035 NONE methylergonovine_19\NN\1740|of (r_nmod) dose_17\NN\3740161|of|a|low|methylergonovine (r_nmod) injection_12\NN\320852|an|intracoronary|dose (r_dobj) use_9\VBP\1156834|which|injection (r_acl:relcl) tests_6\NNS\5798043|spasm|provocation|,|use|, (l_compound) spasm_4\NN\14299637|
17020434
D014859_D020521 NONE warfarin_12\NN\2718259| (r_nsubj) reduces_13\VBZ\441445|that|warfarin|risk|%|,|and|reduces (l_dobj) risk_15\NN\14541044|the|stroke (l_nmod) stroke_17\NN\556313|of
D014859_D020521 NONE warfarin_6\NN\2718259| (r_nsubj) superior_8\JJ\1740|overall|,|patients|,|warfarin|is|aspirin|preventing|,|reduction|. (l_advcl) preventing_12\VBG\1740|in|strokes (l_dobj) strokes_13\NNS\556313|
D001241_D020521 NONE aspirin_24\NN\2707683|alone (r_nsubj) reduces_26\VBZ\441445|that|aspirin|risk|% (r_conj) reduces_13\VBZ\441445|that|warfarin|risk|%|,|and|reduces (l_dobj) risk_15\NN\14541044|the|stroke (l_nmod) stroke_17\NN\556313|of
D001241_D020521 NONE aspirin_10\NN\2707683|to (r_nmod) superior_8\JJ\1740|overall|,|patients|,|warfarin|is|aspirin|preventing|,|reduction|. (l_advcl) preventing_12\VBG\1740|in|strokes (l_dobj) strokes_13\NNS\556313|
C426686_D004617 NONE ximelagatran_0\NNP\1740|,|inhibitor|, (r_nsubjpass) found_9\VBN\2426171|ximelagatran|was|efficient|,|but|withdrawn|. (l_xcomp) efficient_13\JJ\1740|to|be|as|drugs|prevention (l_nmod) prevention_21\NN\1073995|in|the|events (l_nmod) events_24\NNS\23100|of|embolic
C426686_D056486 CID ximelagatran_0\NNP\1740|,|inhibitor|, (r_nsubjpass) found_9\VBN\2426171|ximelagatran|was|efficient|,|but|withdrawn|. (l_conj) withdrawn_30\VBN\1835496|has|been|recently|tests (l_nmod) tests_36\NNS\5798043|because|abnormal|function (l_compound) function_35\NN\13783581|liver
D014812_D004617 NONE k_16\NN\13608598| (r_compound) drugs_18\NNS\14778436|as|vitamin|k|antagonist (r_nmod) efficient_13\JJ\1740|to|be|as|drugs|prevention (l_nmod) prevention_21\NN\1073995|in|the|events (l_nmod) events_24\NNS\23100|of|embolic
D014812_D056486 NONE k_16\NN\13608598| (r_compound) drugs_18\NNS\14778436|as|vitamin|k|antagonist (r_nmod) efficient_13\JJ\1740|to|be|as|drugs|prevention (r_xcomp) found_9\VBN\2426171|ximelagatran|was|efficient|,|but|withdrawn|. (l_conj) withdrawn_30\VBN\1835496|has|been|recently|tests (l_nmod) tests_36\NNS\5798043|because|abnormal|function (l_compound) function_35\NN\13783581|liver
C055162_D001281 NONE clopidogrel_5\NNP\1740|fibrillation (l_compound) fibrillation_4\NNP\14361664|
C055162_D001281 NONE clopidogrel_26\NN\1740|(|plus|aspirin|) (r_dep) therapy_24\NN\657604|to|platelet|clopidogrel (r_nmod) superior_21\JJ\1740|that|warfarin|is|therapy|prevention (r_ccomp) demonstrated_17\VBN\2137132|study|has|superior|. (l_nsubj) study_15\NN\635850|active-w (l_compound) active-w_1\NN\1740|the|(|trial|prevention (l_appos) trial_6\NNP\786195|atrial|clopidogrel|irbesartan (l_compound) clopidogrel_5\NNP\1740|fibrillation (l_compound) fibrillation_4\NNP\14361664|
C055162_D004617 NONE clopidogrel_5\NNP\1740|fibrillation (r_compound) trial_6\NNP\786195|atrial|clopidogrel|irbesartan (r_appos) active-w_1\NN\1740|the|(|trial|prevention (r_compound) study_15\NN\635850|active-w (r_nsubj) demonstrated_17\VBN\2137132|study|has|superior|. (l_ccomp) superior_21\JJ\1740|that|warfarin|is|therapy|prevention (l_nmod) prevention_32\NN\1073995|in|the|events (l_nmod) events_35\NNS\23100|af|embolic
C055162_D004617 NONE clopidogrel_26\NN\1740|(|plus|aspirin|) (r_dep) therapy_24\NN\657604|to|platelet|clopidogrel (r_nmod) superior_21\JJ\1740|that|warfarin|is|therapy|prevention (l_nmod) prevention_32\NN\1073995|in|the|events (l_nmod) events_35\NNS\23100|af|embolic
C081309_D001281 NONE irbesartan_8\NNP\1740|with (r_nmod) trial_6\NNP\786195|atrial|clopidogrel|irbesartan (l_compound) clopidogrel_5\NNP\1740|fibrillation (l_compound) fibrillation_4\NNP\14361664|
C081309_D004617 NONE irbesartan_8\NNP\1740|with (r_nmod) trial_6\NNP\786195|atrial|clopidogrel|irbesartan (r_appos) active-w_1\NN\1740|the|(|trial|prevention (r_compound) study_15\NN\635850|active-w (r_nsubj) demonstrated_17\VBN\2137132|study|has|superior|. (l_ccomp) superior_21\JJ\1740|that|warfarin|is|therapy|prevention (l_nmod) prevention_32\NN\1073995|in|the|events (l_nmod) events_35\NNS\23100|af|embolic
D014859_D001281 NONE warfarin_19\NN\2718259| (r_nsubj) superior_21\JJ\1740|that|warfarin|is|therapy|prevention (r_ccomp) demonstrated_17\VBN\2137132|study|has|superior|. (l_nsubj) study_15\NN\635850|active-w (l_compound) active-w_1\NN\1740|the|(|trial|prevention (l_appos) trial_6\NNP\786195|atrial|clopidogrel|irbesartan (l_compound) clopidogrel_5\NNP\1740|fibrillation (l_compound) fibrillation_4\NNP\14361664|
D014859_D004617 NONE warfarin_19\NN\2718259| (r_nsubj) superior_21\JJ\1740|that|warfarin|is|therapy|prevention (l_nmod) prevention_32\NN\1073995|in|the|events (l_nmod) events_35\NNS\23100|af|embolic
D001241_D001281 NONE aspirin_28\NN\2707683| (r_conj) clopidogrel_26\NN\1740|(|plus|aspirin|) (r_dep) therapy_24\NN\657604|to|platelet|clopidogrel (r_nmod) superior_21\JJ\1740|that|warfarin|is|therapy|prevention (r_ccomp) demonstrated_17\VBN\2137132|study|has|superior|. (l_nsubj) study_15\NN\635850|active-w (l_compound) active-w_1\NN\1740|the|(|trial|prevention (l_appos) trial_6\NNP\786195|atrial|clopidogrel|irbesartan (l_compound) clopidogrel_5\NNP\1740|fibrillation (l_compound) fibrillation_4\NNP\14361664|
D001241_D004617 NONE aspirin_28\NN\2707683| (r_conj) clopidogrel_26\NN\1740|(|plus|aspirin|) (r_dep) therapy_24\NN\657604|to|platelet|clopidogrel (r_nmod) superior_21\JJ\1740|that|warfarin|is|therapy|prevention (l_nmod) prevention_32\NN\1073995|in|the|events (l_nmod) events_35\NNS\23100|af|embolic
C479958_D001281 NONE idraparinux_0\NNP\1740|,|inhibitor|, (r_nsubjpass) evaluated_9\VBN\670261|idraparinux|is|being|patients|. (l_nmod) patients_11\NNS\9898892|in|fibrillation (l_nmod) fibrillation_14\NN\14361664|with|atrial
D000809_D001281 NONE angiotensin-converting_0\JJ\1740| (r_amod) inhibitors_2\NNS\20090|angiotensin-converting|enzyme|and|drugs (r_nsubj) hold_8\VBP\2439501|inhibitors|promise|fibrillation|remodelling|. (l_nmod) fibrillation_12\NN\14361664|in|atrial
D000809_D020257 NONE angiotensin-converting_0\JJ\1740| (r_amod) inhibitors_2\NNS\20090|angiotensin-converting|enzyme|and|drugs (r_nsubj) hold_8\VBP\2439501|inhibitors|promise|fibrillation|remodelling|. (l_nmod) remodelling_15\NN\1740|through|cardiac
D000804_D001281 NONE ii_5\CD\13741022| (r_nummod) drugs_7\NNS\14778436|angiotensin|ii|receptor-blocking (r_conj) inhibitors_2\NNS\20090|angiotensin-converting|enzyme|and|drugs (r_nsubj) hold_8\VBP\2439501|inhibitors|promise|fibrillation|remodelling|. (l_nmod) fibrillation_12\NN\14361664|in|atrial
D000804_D020257 NONE ii_5\CD\13741022| (r_nummod) drugs_7\NNS\14778436|angiotensin|ii|receptor-blocking (r_conj) inhibitors_2\NNS\20090|angiotensin-converting|enzyme|and|drugs (r_nsubj) hold_8\VBP\2439501|inhibitors|promise|fibrillation|remodelling|. (l_nmod) remodelling_15\NN\1740|through|cardiac
11745184
D002945_D001943 NONE cisplatin_5\NN\1740|of|plus|wr-2721|carcinoma (l_nmod) carcinoma_14\NN\14239918|for|metastatic|breast
D002945_D001943 NONE cisplatin_2\NNP\1740| (r_nsubj) has_3\VBZ\2108377|background|:|cisplatin|activity|used|. (l_advcl) used_8\VBN\1156834|when|treatment (l_nmod) treatment_13\NN\654885|as|second-|carcinoma (l_nmod) carcinoma_17\NN\14239918|of|metastatic|breast
D002945_D001943 NONE cisplatin_8\NN\1740|with|,|toxicities (r_nmod) observed_6\VBN\2163746|although|effect|has|been|cisplatin (r_advcl) limited_27\VBN\2510337|observed|have|use|treatment|. (l_nmod) treatment_32\NN\654885|as|a|carcinoma (l_nmod) carcinoma_35\NN\14239918|for|breast
D002945_D001943 NONE cisplatin_15\NN\1740|with|e.g. (r_nmod) associated_13\VBN\628491|cisplatin (r_acl) toxicities_12\NNS\13576101|the|dose-limiting|associated (r_appos) cisplatin_8\NN\1740|with|,|toxicities (r_nmod) observed_6\VBN\2163746|although|effect|has|been|cisplatin (r_advcl) limited_27\VBN\2510337|observed|have|use|treatment|. (l_nmod) treatment_32\NN\654885|as|a|carcinoma (l_nmod) carcinoma_35\NN\14239918|for|breast
D002945_D001943 NONE cisplatin_10\NN\1740|of|plus|amifostine (r_nmod) combination_8\NN\7951464|of|the|cisplatin (r_nmod) study_5\NN\635850|a|phase|ii|combination (r_nsubjpass) conducted_14\VBN\2436349|study|was|patients|,|regimen (l_nmod) patients_16\NNS\9898892|in|carcinoma (l_nmod) carcinoma_21\NN\14239918|with|progressive|metastatic|breast|received
D004999_D001943 NONE wr-2721_7\JJ\1740|amifostine (r_conj) cisplatin_5\NN\1740|of|plus|wr-2721|carcinoma (l_nmod) carcinoma_14\NN\14239918|for|metastatic|breast
D004999_D001943 NONE amifostine_9\NN\1740|(|) (r_appos) wr-2721_7\JJ\1740|amifostine (r_conj) cisplatin_5\NN\1740|of|plus|wr-2721|carcinoma (l_nmod) carcinoma_14\NN\14239918|for|metastatic|breast
D004999_D001943 NONE amifostine_12\NN\1740| (r_conj) cisplatin_10\NN\1740|of|plus|amifostine (r_nmod) combination_8\NN\7951464|of|the|cisplatin (r_nmod) study_5\NN\635850|a|phase|ii|combination (r_nsubjpass) conducted_14\VBN\2436349|study|was|patients|,|regimen (l_nmod) patients_16\NNS\9898892|in|carcinoma (l_nmod) carcinoma_21\NN\14239918|with|progressive|metastatic|breast|received
D002945_D064420 NONE cisplatin_8\NN\1740|with|,|toxicities (l_appos) toxicities_12\NNS\13576101|the|dose-limiting|associated
D002945_D064420 NONE cisplatin_15\NN\1740|with|e.g. (r_nmod) associated_13\VBN\628491|cisplatin (r_acl) toxicities_12\NNS\13576101|the|dose-limiting|associated
D002945_D064420 NONE cisplatin_18\NN\1740|to (r_nmod) addition_14\NN\3081021|with|the|amifostine|cisplatin|trial (r_nmod) observed_11\VBN\2163746|effect|was|addition|. (l_nsubjpass) effect_3\NN\34213|neither|a|tumor-protective|nor|toxicity (l_conj) toxicity_6\NN\13576101|reduced|tissues
D002945_D007674 CID cisplatin_8\NN\1740|with|,|toxicities (l_appos) toxicities_12\NNS\13576101|the|dose-limiting|associated (l_acl) associated_13\VBN\628491|cisplatin (l_nmod) cisplatin_15\NN\1740|with|e.g. (l_dep) e.g._17\FW\1740|(|,|nephrotoxicity|) (l_conj) nephrotoxicity_19\NN\1740|,|ototoxicity|,|and|neurotoxicity
D002945_D007674 CID cisplatin_15\NN\1740|with|e.g. (l_dep) e.g._17\FW\1740|(|,|nephrotoxicity|) (l_conj) nephrotoxicity_19\NN\1740|,|ototoxicity|,|and|neurotoxicity
D002945_D007674 CID cisplatin_3\NN\1740|of|and|amifostine (r_nmod) trials_1\NNS\786195|early|cisplatin (r_nsubj) suggested_7\VBD\1010118|trials|also|reduced|. (l_ccomp) reduced_22\VBN\441445|that|incidence|were (l_nsubjpass) incidence_10\NN\13821570|the|and|severity|nephrotoxicity (l_nmod) nephrotoxicity_15\NN\1740|of|cisplatin-induced|,|ototoxicity|,|and|neuropathy
D002945_D007674 CID cisplatin-induced_14\JJ\1740| (r_amod) nephrotoxicity_15\NN\1740|of|cisplatin-induced|,|ototoxicity|,|and|neuropathy
D002945_D006311 CID cisplatin_8\NN\1740|with|,|toxicities (l_appos) toxicities_12\NNS\13576101|the|dose-limiting|associated (l_acl) associated_13\VBN\628491|cisplatin (l_nmod) cisplatin_15\NN\1740|with|e.g. (l_dep) e.g._17\FW\1740|(|,|nephrotoxicity|) (l_conj) nephrotoxicity_19\NN\1740|,|ototoxicity|,|and|neurotoxicity (l_conj) ototoxicity_21\NN\1740|
D002945_D006311 CID cisplatin_15\NN\1740|with|e.g. (l_dep) e.g._17\FW\1740|(|,|nephrotoxicity|) (l_conj) nephrotoxicity_19\NN\1740|,|ototoxicity|,|and|neurotoxicity (l_conj) ototoxicity_21\NN\1740|
D002945_D006311 CID cisplatin_3\NN\1740|of|and|amifostine (r_nmod) trials_1\NNS\786195|early|cisplatin (r_nsubj) suggested_7\VBD\1010118|trials|also|reduced|. (l_ccomp) reduced_22\VBN\441445|that|incidence|were (l_nsubjpass) incidence_10\NN\13821570|the|and|severity|nephrotoxicity (l_nmod) nephrotoxicity_15\NN\1740|of|cisplatin-induced|,|ototoxicity|,|and|neuropathy (l_conj) ototoxicity_17\NN\1740|
D002945_D006311 CID cisplatin-induced_14\JJ\1740| (r_amod) nephrotoxicity_15\NN\1740|of|cisplatin-induced|,|ototoxicity|,|and|neuropathy (l_conj) ototoxicity_17\NN\1740|
D002945_D020258 NONE cisplatin_8\NN\1740|with|,|toxicities (l_appos) toxicities_12\NNS\13576101|the|dose-limiting|associated (l_acl) associated_13\VBN\628491|cisplatin (l_nmod) cisplatin_15\NN\1740|with|e.g. (l_dep) e.g._17\FW\1740|(|,|nephrotoxicity|) (l_conj) nephrotoxicity_19\NN\1740|,|ototoxicity|,|and|neurotoxicity (l_conj) neurotoxicity_24\NN\1740|
D002945_D020258 NONE cisplatin_15\NN\1740|with|e.g. (l_dep) e.g._17\FW\1740|(|,|nephrotoxicity|) (l_conj) nephrotoxicity_19\NN\1740|,|ototoxicity|,|and|neurotoxicity (l_conj) neurotoxicity_24\NN\1740|
D002945_D009422 CID cisplatin_3\NN\1740|of|and|amifostine (r_nmod) trials_1\NNS\786195|early|cisplatin (r_nsubj) suggested_7\VBD\1010118|trials|also|reduced|. (l_ccomp) reduced_22\VBN\441445|that|incidence|were (l_nsubjpass) incidence_10\NN\13821570|the|and|severity|nephrotoxicity (l_nmod) nephrotoxicity_15\NN\1740|of|cisplatin-induced|,|ototoxicity|,|and|neuropathy (l_conj) neuropathy_20\RB\1740|
D002945_D009422 CID cisplatin-induced_14\JJ\1740| (r_amod) nephrotoxicity_15\NN\1740|of|cisplatin-induced|,|ototoxicity|,|and|neuropathy (l_conj) neuropathy_20\RB\1740|
D004999_D007674 NONE amifostine_5\NN\1740| (r_conj) cisplatin_3\NN\1740|of|and|amifostine (r_nmod) trials_1\NNS\786195|early|cisplatin (r_nsubj) suggested_7\VBD\1010118|trials|also|reduced|. (l_ccomp) reduced_22\VBN\441445|that|incidence|were (l_nsubjpass) incidence_10\NN\13821570|the|and|severity|nephrotoxicity (l_nmod) nephrotoxicity_15\NN\1740|of|cisplatin-induced|,|ototoxicity|,|and|neuropathy
D004999_D006311 NONE amifostine_5\NN\1740| (r_conj) cisplatin_3\NN\1740|of|and|amifostine (r_nmod) trials_1\NNS\786195|early|cisplatin (r_nsubj) suggested_7\VBD\1010118|trials|also|reduced|. (l_ccomp) reduced_22\VBN\441445|that|incidence|were (l_nsubjpass) incidence_10\NN\13821570|the|and|severity|nephrotoxicity (l_nmod) nephrotoxicity_15\NN\1740|of|cisplatin-induced|,|ototoxicity|,|and|neuropathy (l_conj) ototoxicity_17\NN\1740|
D004999_D009422 NONE amifostine_5\NN\1740| (r_conj) cisplatin_3\NN\1740|of|and|amifostine (r_nmod) trials_1\NNS\786195|early|cisplatin (r_nsubj) suggested_7\VBD\1010118|trials|also|reduced|. (l_ccomp) reduced_22\VBN\441445|that|incidence|were (l_nsubjpass) incidence_10\NN\13821570|the|and|severity|nephrotoxicity (l_nmod) nephrotoxicity_15\NN\1740|of|cisplatin-induced|,|ototoxicity|,|and|neuropathy (l_conj) neuropathy_20\RB\1740|
D004999_D009369 NONE amifostine_16\NN\1740|of (r_nmod) addition_14\NN\3081021|with|the|amifostine|cisplatin|trial (r_nmod) observed_11\VBN\2163746|effect|was|addition|. (l_nsubjpass) effect_3\NN\34213|neither|a|tumor-protective|nor|toxicity (l_amod) tumor-protective_2\JJ\1740|
D004999_D064420 NONE amifostine_16\NN\1740|of (r_nmod) addition_14\NN\3081021|with|the|amifostine|cisplatin|trial (r_nmod) observed_11\VBN\2163746|effect|was|addition|. (l_nsubjpass) effect_3\NN\34213|neither|a|tumor-protective|nor|toxicity (l_conj) toxicity_6\NN\13576101|reduced|tissues
D002945_D009369 NONE cisplatin_18\NN\1740|to (r_nmod) addition_14\NN\3081021|with|the|amifostine|cisplatin|trial (r_nmod) observed_11\VBN\2163746|effect|was|addition|. (l_nsubjpass) effect_3\NN\34213|neither|a|tumor-protective|nor|toxicity (l_amod) tumor-protective_2\JJ\1740|
8410052
D019344_D001480 NONE lactate_10\NN\14850483|of (r_nmod) infusion_8\NN\14589223|by|lactate|ph|or|stab (r_nmod) produced_6\VBN\1617192|injury|was|infusion|. (l_nsubjpass) injury_1\NN\14052046|focal|cortex (l_nmod) cortex_4\NN\5462674|in|the
D010862_D002544 CID pilocarpine-induced_10\JJ\1740| (r_amod) epilepticus_12\NN\1740|by|prolonged|pilocarpine-induced|status (r_nmod) evoked_7\VBN\1617192|infarcts|were|epilepticus|. (l_nsubjpass) infarcts_0\NNS\14204950|reticulata (l_nmod) reticulata_5\NNS\1740|in|substantia|nigra|pars
D010862_D013226 CID pilocarpine-induced_10\JJ\1740| (r_amod) epilepticus_12\NN\1740|by|prolonged|pilocarpine-induced|status
14657095
D000666_D002311 CID b_6\NN\1355326| (r_compound) therapy_7\NN\657604|to|amphotericin|b (r_nmod) related_3\JJ\1740|therapy (r_amod) dilated_1\VBD\303465|reversible|cardiomyopathy|related|. (l_dobj) cardiomyopathy_2\DT\14103288|
D000666_D002311 CID b_20\NN\1355326|with|amphotericin|amb (r_nmod) therapy_17\NN\657604|of|b (r_nmod) months_15\NNS\15113229|after|2|therapy (r_nmod) developed_5\VBD\1753788|who|failure|months|coccidioidomycosis (l_dobj) failure_12\NN\66216|dilated|cardiomyopathy|congestive|heart (l_amod) cardiomyopathy_7\JJ\1740|and|clinical
D000666_D002311 CID amb_22\NN\1740|(|) (r_appos) b_20\NN\1355326|with|amphotericin|amb (r_nmod) therapy_17\NN\657604|of|b (r_nmod) months_15\NNS\15113229|after|2|therapy (r_nmod) developed_5\VBD\1753788|who|failure|months|coccidioidomycosis (l_dobj) failure_12\NN\66216|dilated|cardiomyopathy|congestive|heart (l_amod) cardiomyopathy_7\JJ\1740|and|clinical
D000666_D006333 CID b_20\NN\1355326|with|amphotericin|amb (r_nmod) therapy_17\NN\657604|of|b (r_nmod) months_15\NNS\15113229|after|2|therapy (r_nmod) developed_5\VBD\1753788|who|failure|months|coccidioidomycosis (l_dobj) failure_12\NN\66216|dilated|cardiomyopathy|congestive|heart
D000666_D006333 CID amb_22\NN\1740|(|) (r_appos) b_20\NN\1355326|with|amphotericin|amb (r_nmod) therapy_17\NN\657604|of|b (r_nmod) months_15\NNS\15113229|after|2|therapy (r_nmod) developed_5\VBD\1753788|who|failure|months|coccidioidomycosis (l_dobj) failure_12\NN\66216|dilated|cardiomyopathy|congestive|heart
D000666_D006333 CID amb._12\NN\1740|for (r_nmod) substituted_10\VBN\126264|abnormalities|was|amb.|important (l_nsubjpass) abnormalities_2\NNS\14034177|his|echocardiographic|and|failure|resolved (l_conj) failure_5\NN\66216|heart
D000666_D006333 CID amb._25\NN\1740|of (r_nmod) toxicity_23\NN\13576101|rare|amb. (r_dobj) recognize_17\VB\686447|to|toxicity (r_xcomp) important_15\JJ\1740|it|is|recognize (r_advcl) substituted_10\VBN\126264|abnormalities|was|amb.|important (l_nsubjpass) abnormalities_2\NNS\14034177|his|echocardiographic|and|failure|resolved (l_conj) failure_5\NN\66216|heart
D000666_D003047 NONE b_20\NN\1355326|with|amphotericin|amb (r_nmod) therapy_17\NN\657604|of|b (r_nmod) months_15\NNS\15113229|after|2|therapy (r_nmod) developed_5\VBD\1753788|who|failure|months|coccidioidomycosis (l_nmod) coccidioidomycosis_26\NN\14176895|for|disseminated
D000666_D003047 NONE amb_22\NN\1740|(|) (r_appos) b_20\NN\1355326|with|amphotericin|amb (r_nmod) therapy_17\NN\657604|of|b (r_nmod) months_15\NNS\15113229|after|2|therapy (r_nmod) developed_5\VBD\1753788|who|failure|months|coccidioidomycosis (l_nmod) coccidioidomycosis_26\NN\14176895|for|disseminated
C101425_D006333 NONE posaconazole_8\NN\1740|after (r_nmod) resolved_6\VBN\352826|posaconazole (r_acl) abnormalities_2\NNS\14034177|his|echocardiographic|and|failure|resolved (l_conj) failure_5\NN\66216|heart
C101425_D064420 NONE posaconazole_8\NN\1740|after (r_nmod) resolved_6\VBN\352826|posaconazole (r_acl) abnormalities_2\NNS\14034177|his|echocardiographic|and|failure|resolved (r_nsubjpass) substituted_10\VBN\126264|abnormalities|was|amb.|important (l_advcl) important_15\JJ\1740|it|is|recognize (l_xcomp) recognize_17\VB\686447|to|toxicity (l_dobj) toxicity_23\NN\13576101|rare|amb.
D000666_D064420 NONE amb._12\NN\1740|for (r_nmod) substituted_10\VBN\126264|abnormalities|was|amb.|important (l_advcl) important_15\JJ\1740|it|is|recognize (l_xcomp) recognize_17\VB\686447|to|toxicity (l_dobj) toxicity_23\NN\13576101|rare|amb.
D000666_D064420 NONE amb._25\NN\1740|of (r_nmod) toxicity_23\NN\13576101|rare|amb.
2334618
D009020_D001049 NONE morphine_17\NN\2707683|of (r_nmod) infusion_15\NN\14589223|a|continuous|i.v.|morphine|mg|and|patients (r_dobj) receiving_11\VBG\2210855|infusion (r_acl) patients_10\NNS\9898892|between|five|receiving (r_nmod) compared_7\VBN\644583|incidence|was|patients|period|. (l_nsubjpass) incidence_1\NN\13821570|the|apnoea (l_nmod) apnoea_5\NN\1740|of|postoperative|respiratory
D002045_D001049 NONE bupivacaine_34\NN\1740|of|%|(|mg|) (r_nmod) infusion_30\NN\14589223|a|continuous|extradural|bupivacaine (r_dobj) receiving_26\VBG\2210855|infusion (r_acl) patients_25\NNS\9898892|five|receiving (r_conj) infusion_15\NN\14589223|a|continuous|i.v.|morphine|mg|and|patients (r_dobj) receiving_11\VBG\2210855|infusion (r_acl) patients_10\NNS\9898892|between|five|receiving (r_nmod) compared_7\VBN\644583|incidence|was|patients|period|. (l_nsubjpass) incidence_1\NN\13821570|the|apnoea (l_nmod) apnoea_5\NN\1740|of|postoperative|respiratory
D009020_D020181 CID morphine_25\NN\2707683| (r_compound) infusion_26\NN\14589223|a|morphine (r_dobj) had_23\VBD\2108377|who|infusion (r_acl:relcl) patients_21\NNS\9898892|in|had (r_nmod) frequently_19\RB\1740|more|patients (r_advmod) occurred_17\VBD\2623529|obstructive|frequently|. (l_nsubj) obstructive_1\JJ\1740|both|p|and|apnoea (l_conj) apnoea_10\NN\1740|central|p
D009020_D020182 CID morphine_25\NN\2707683| (r_compound) infusion_26\NN\14589223|a|morphine (r_dobj) had_23\VBD\2108377|who|infusion (r_acl:relcl) patients_21\NNS\9898892|in|had (r_nmod) frequently_19\RB\1740|more|patients (r_advmod) occurred_17\VBD\2623529|obstructive|frequently|. (l_nsubj) obstructive_1\JJ\1740|both|p|and|apnoea (l_conj) apnoea_10\NN\1740|central|p
D009020_D013610 NONE morphine_26\NN\2707683| (r_compound) group_28\NN\2137|in|the|morphine|infusion (r_nmod) incidence_5\NN\13821570|a|higher|tachyarrhythmias|p|and|beats|group (l_nmod) tachyarrhythmias_7\NNS\1740|of
D009020_D018879 CID morphine_26\NN\2707683| (r_compound) group_28\NN\2137|in|the|morphine|infusion (r_nmod) incidence_5\NN\13821570|a|higher|tachyarrhythmias|p|and|beats|group (l_conj) beats_17\NNS\8289449|ventricular|ectopic|p
8437969
D002927_D054138 CID cimetidine_5\NN\14778019|with|continuous-infusion (r_nmod) associated_2\VBN\628491|cimetidine (r_acl) arrest_1\NN\88481|sinus|associated|.
D002927_D054138 CID cimetidine_23\NN\14778019|continuous-infusion|mg/hour (r_dobj) receiving_21\VBG\2210855|while|cimetidine (r_advcl) developed_11\VBD\1753788|man|recurrent|,|episodes|receiving|. (l_dobj) episodes_15\NNS\7283608|brief|arrest (l_nmod) arrest_19\NN\88481|of|apparent|sinus
D002927_D054138 CID cimetidine_12\NN\14778019|with|continuous-infusion (r_nmod) associated_9\VBN\628491|cimetidine (r_acl) arrest_8\NN\88481|of|sinus|associated
D002927_D001919 CID cimetidine_7\NN\14778019|of (r_nmod) infusions_5\NNS\14589223|of|intermittent|intravenous|cimetidine (r_nmod) administration_1\NN\1133281|the|infusions (r_nsubjpass) associated_10\VBN\628491|administration|is|infrequently|development|. (l_nmod) development_13\NN\248977|with|the|bradyarrhythmias (l_nmod) bradyarrhythmias_15\NNS\1740|of
D002927_D007938 NONE cimetidine_23\NN\14778019|continuous-infusion|mg/hour (r_dobj) receiving_21\VBG\2210855|while|cimetidine (r_advcl) developed_11\VBD\1753788|man|recurrent|,|episodes|receiving|. (l_nsubj) man_2\NN\9605289|a|40-year-old|leukemia|and|history (l_nmod) leukemia_4\NN\14239918|with
D002927_D006331 NONE cimetidine_23\NN\14778019|continuous-infusion|mg/hour (r_dobj) receiving_21\VBG\2210855|while|cimetidine (r_advcl) developed_11\VBD\1753788|man|recurrent|,|episodes|receiving|. (l_nsubj) man_2\NN\9605289|a|40-year-old|leukemia|and|history (l_conj) history_7\NN\15120823|no|disease (l_nmod) disease_10\NN\14061805|of|cardiac
D002927_D001145 NONE cimetidine_6\NN\14778019| (r_compound) administration_7\NN\1133281|to|cimetidine (r_nmod) related_4\JJ\1740|arrhythmias|were|temporally|administration|,|disappeared|. (l_nsubj) arrhythmias_1\NNS\14103288|the
D011899_D001145 NONE ranitidine_18\NN\14778019| (r_compound) treatment_19\NN\654885|during|ranitidine (r_nmod) recur_16\VB\339934|did|not|treatment (r_conj) disappeared_9\VBD\2609764|dechallenge|,|and|recur (r_conj) related_4\JJ\1740|arrhythmias|were|temporally|administration|,|disappeared|. (l_nsubj) arrhythmias_1\NNS\14103288|the
2870085
C047847_D013610 NONE flestolol_0\NNP\1740| (r_nsubj) produced_1\VBD\1617192|flestolol|attenuation|. (l_dobj) attenuation_4\NN\7427337|a|dose-dependent|tachycardia (l_nmod) tachycardia_7\NN\14110674|of|isoproterenol-induced
D007545_D013610 CID isoproterenol-induced_6\JJ\1740| (r_amod) tachycardia_7\NN\14110674|of|isoproterenol-induced
C047847_D013617 NONE flestolol_0\NNP\1740| (r_nsubj) reduced_2\VBD\441445|flestolol|effectively|rate|. (l_dobj) rate_4\NN\13815152|heart|patients (l_nmod) patients_6\NNS\9898892|in|tachyarrhythmia (l_nmod) tachyarrhythmia_9\NN\1740|with|supraventricular
C047847_D000789 NONE flestolol_6\NN\1740| (r_compound) infusion_7\NN\14589223|flestolol (r_nsubjpass) found_9\VBN\2426171|patients|,|infusion|was|safe|. (l_nmod) patients_1\NNS\9898892|in|angina (l_nmod) angina_4\NN\14171682|with|unstable
C047847_D002637 NONE flestolol_6\NN\1740| (r_compound) infusion_7\NN\14589223|flestolol (r_nsubjpass) found_9\VBN\2426171|patients|,|infusion|was|safe|. (l_xcomp) safe_12\JJ\1740|to|be|and|effective (l_conj) effective_14\JJ\1740|controlling (l_advcl) controlling_16\VBG\2422663|in|pain (l_dobj) pain_18\NN\14299637|chest
7053303
D002927_D003704 CID cimetidine_10\NN\14778019|due|to|(|level (r_nmod) case_4\NN\7283608|one|dementia|possibly|cimetidine (l_nmod) dementia_6\NN\14395018|of
D002927_D003704 CID cimetidine_38\NN\14778019| (r_compound) levels_39\NNS\4916342|cimetidine (r_dobj) had_37\VBD\2108377|who|levels|microgram/ml (r_acl:relcl) group_27\NN\2137|in|a|patients|liver|had (r_nmod) was_1\VBD\836236|there|case|hr|dose|)|group|. (l_attr) case_4\NN\7283608|one|dementia|possibly|cimetidine (l_nmod) dementia_6\NN\14395018|of
D002927_D003704 CID cimetidine_3\NN\14778019| (r_compound) levels_4\NNS\4916342|high|cimetidine|alone (r_nsubj) induce_9\VB\1627355|thus|,|levels|do|not|always|dementia|. (l_dobj) dementia_10\NN\14395018|
D002927_D008107 NONE cimetidine_10\NN\14778019|due|to|(|level (r_nmod) case_4\NN\7283608|one|dementia|possibly|cimetidine (r_attr) was_1\VBD\836236|there|case|hr|dose|)|group|. (l_nmod) group_27\NN\2137|in|a|patients|liver|had (l_nmod) liver_32\NN\5298729|without|or|disease (l_conj) disease_35\NN\14061805|kidney
D002927_D008107 NONE cimetidine_38\NN\14778019| (r_compound) levels_39\NNS\4916342|cimetidine (r_dobj) had_37\VBD\2108377|who|levels|microgram/ml (r_acl:relcl) group_27\NN\2137|in|a|patients|liver|had (l_nmod) liver_32\NN\5298729|without|or|disease (l_conj) disease_35\NN\14061805|kidney
D002927_D007674 NONE cimetidine_10\NN\14778019|due|to|(|level (r_nmod) case_4\NN\7283608|one|dementia|possibly|cimetidine (r_attr) was_1\VBD\836236|there|case|hr|dose|)|group|. (l_nmod) group_27\NN\2137|in|a|patients|liver|had (l_nmod) liver_32\NN\5298729|without|or|disease (l_conj) disease_35\NN\14061805|kidney
D002927_D007674 NONE cimetidine_38\NN\14778019| (r_compound) levels_39\NNS\4916342|cimetidine (r_dobj) had_37\VBD\2108377|who|levels|microgram/ml (r_acl:relcl) group_27\NN\2137|in|a|patients|liver|had (l_nmod) liver_32\NN\5298729|without|or|disease (l_conj) disease_35\NN\14061805|kidney
12921865
D013256_D012640 NONE steroids_4\NNS\14727670|of|neuroactive|kindled-seizures (l_nmod) kindled-seizures_7\NN\1740|against|cocaine
D013256_D012640 NONE steroid_13\NN\14727670|two|endogenous|synthetic|modulate|receptor (l_dep) receptor_24\NN\5225602|)|increase (l_nmod) increase_27\NN\13576355|against|the|sensitivity (l_nmod) sensitivity_29\NN\5651971|in|effects (l_nmod) effects_33\NNS\13245626|to|the|convulsant|cocaine (l_nmod) cocaine_35\NN\3492717|of|engendered (l_acl) engendered_36\VBN\1645601|administration (l_nmod) administration_40\NN\1133281|by|repeated|cocaine|(|kindling (l_appos) kindling_43\NN\15101361|seizure (l_amod) seizure_42\JJ\1740|
D003042_D012640 CID cocaine_6\NN\3492717| (r_compound) kindled-seizures_7\NN\1740|against|cocaine
D003042_D012640 CID cocaine_35\NN\3492717|of|engendered (l_acl) engendered_36\VBN\1645601|administration (l_nmod) administration_40\NN\1133281|by|repeated|cocaine|(|kindling (l_appos) kindling_43\NN\15101361|seizure (l_amod) seizure_42\JJ\1740|
D003042_D012640 CID cocaine_39\NN\3492717| (r_compound) administration_40\NN\1133281|by|repeated|cocaine|(|kindling (l_appos) kindling_43\NN\15101361|seizure (l_amod) seizure_42\JJ\1740|
D003042_D012640 CID cocaine-kindled_39\JJ\1740| (r_amod) seizures_40\NNS\14081375|of|cocaine-kindled
D003042_D012640 CID cocaine_10\NN\3492717|of|60|mg/kg (r_nmod) administration_6\NN\1133281|by|daily|cocaine (r_nmod) induced_3\VBN\1627355|seizures|were|administration|days|. (l_nsubjpass) seizures_1\NNS\14081375|kindled
D013256_D009422 NONE steroids_1\NNS\14727670|neuroactive (r_nsubj) demonstrate_2\VBP\2137132|steroids|actions|. (l_dobj) actions_4\NNS\30358|pharmacological|have (l_acl:relcl) have_6\VBP\2108377|that|relevance (l_dobj) relevance_7\NN\13791389|host (l_nmod) host_10\NN\9605289|for|a|neurological|disorders (l_nmod) disorders_15\NNS\14034177|
D013256_D001523 NONE steroids_1\NNS\14727670|neuroactive (r_nsubj) demonstrate_2\VBP\2137132|steroids|actions|. (l_dobj) actions_4\NNS\30358|pharmacological|have (l_acl:relcl) have_6\VBP\2108377|that|relevance (l_dobj) relevance_7\NN\13791389|host (l_nmod) host_10\NN\9605289|for|a|neurological|disorders (l_nmod) disorders_15\NNS\14034177|
D005680_D012640 NONE acid_19\NN\14818238|the|gamma-aminobutyric|gaba(a (r_dobj) modulate_16\VBP\1724459|that|positively|acid (r_acl:relcl) steroid_13\NN\14727670|two|endogenous|synthetic|modulate|receptor (l_dep) receptor_24\NN\5225602|)|increase (l_nmod) increase_27\NN\13576355|against|the|sensitivity (l_nmod) sensitivity_29\NN\5651971|in|effects (l_nmod) effects_33\NNS\13245626|to|the|convulsant|cocaine (l_nmod) cocaine_35\NN\3492717|of|engendered (l_acl) engendered_36\VBN\1645601|administration (l_nmod) administration_40\NN\1133281|by|repeated|cocaine|(|kindling (l_appos) kindling_43\NN\15101361|seizure (l_amod) seizure_42\JJ\1740|
D005680_D012640 NONE gaba(a_21\NN\1740|(|) (r_appos) acid_19\NN\14818238|the|gamma-aminobutyric|gaba(a (r_dobj) modulate_16\VBP\1724459|that|positively|acid (r_acl:relcl) steroid_13\NN\14727670|two|endogenous|synthetic|modulate|receptor (l_dep) receptor_24\NN\5225602|)|increase (l_nmod) increase_27\NN\13576355|against|the|sensitivity (l_nmod) sensitivity_29\NN\5651971|in|effects (l_nmod) effects_33\NNS\13245626|to|the|convulsant|cocaine (l_nmod) cocaine_35\NN\3492717|of|engendered (l_acl) engendered_36\VBN\1645601|administration (l_nmod) administration_40\NN\1133281|by|repeated|cocaine|(|kindling (l_appos) kindling_43\NN\15101361|seizure (l_amod) seizure_42\JJ\1740|
D005680_D012640 NONE gaba(a_4\NN\1740| (r_compound) modulators_6\NNS\1740|of|these|positive|gaba(a|) (r_nmod) all_0\DT\1740|modulators (r_nsubj) suppressed_7\VBD\2510337|all|expression|,|inhibited|. (l_dobj) expression_9\NN\4679549|the|seizures (l_nmod) seizures_12\NNS\14081375|of|kindled
D011280_D012640 NONE allopregnanolone_0\NN\1740|3alpha-hydroxy-5alpha-pregnan-20-one|,|pregnanolone|and|ganaxolone (r_nsubjpass) tested_20\VBN\670261|allopregnanolone|were|ability|. (l_nmod) ability_23\NN\4723816|for|their|suppress (l_acl) suppress_25\VB\2510337|to|expression (l_dobj) expression_27\NN\4679549|the|effect|and|development|seizures|male|,|mice (l_nmod) seizures_40\NNS\14081375|of|cocaine-kindled
D011280_D012640 NONE 3alpha-hydroxy-5alpha-pregnan-20-one_2\NN\1740|(|) (r_appos) allopregnanolone_0\NN\1740|3alpha-hydroxy-5alpha-pregnan-20-one|,|pregnanolone|and|ganaxolone (r_nsubjpass) tested_20\VBN\670261|allopregnanolone|were|ability|. (l_nmod) ability_23\NN\4723816|for|their|suppress (l_acl) suppress_25\VB\2510337|to|expression (l_dobj) expression_27\NN\4679549|the|effect|and|development|seizures|male|,|mice (l_nmod) seizures_40\NNS\14081375|of|cocaine-kindled
D011280_D012640 NONE pregnanolone_5\NN\1740|3alpha-hydroxy-5beta-pregnan-20-one (r_appos) allopregnanolone_0\NN\1740|3alpha-hydroxy-5alpha-pregnan-20-one|,|pregnanolone|and|ganaxolone (r_nsubjpass) tested_20\VBN\670261|allopregnanolone|were|ability|. (l_nmod) ability_23\NN\4723816|for|their|suppress (l_acl) suppress_25\VB\2510337|to|expression (l_dobj) expression_27\NN\4679549|the|effect|and|development|seizures|male|,|mice (l_nmod) seizures_40\NNS\14081375|of|cocaine-kindled
D011280_D012640 NONE 3alpha-hydroxy-5beta-pregnan-20-one_7\NN\1740|(|) (r_appos) pregnanolone_5\NN\1740|3alpha-hydroxy-5beta-pregnan-20-one (r_appos) allopregnanolone_0\NN\1740|3alpha-hydroxy-5alpha-pregnan-20-one|,|pregnanolone|and|ganaxolone (r_nsubjpass) tested_20\VBN\670261|allopregnanolone|were|ability|. (l_nmod) ability_23\NN\4723816|for|their|suppress (l_acl) suppress_25\VB\2510337|to|expression (l_dobj) expression_27\NN\4679549|the|effect|and|development|seizures|male|,|mice (l_nmod) seizures_40\NNS\14081375|of|cocaine-kindled
D011280_D012640 NONE allopregnanolone_16\NN\1740|of|3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one (r_nmod) derivative_14\NN\5802185|a|synthetic|allopregnanolone (r_appos) ganaxolone_10\NN\1740|(|derivative|) (r_conj) allopregnanolone_0\NN\1740|3alpha-hydroxy-5alpha-pregnan-20-one|,|pregnanolone|and|ganaxolone (r_nsubjpass) tested_20\VBN\670261|allopregnanolone|were|ability|. (l_nmod) ability_23\NN\4723816|for|their|suppress (l_acl) suppress_25\VB\2510337|to|expression (l_dobj) expression_27\NN\4679549|the|effect|and|development|seizures|male|,|mice (l_nmod) seizures_40\NNS\14081375|of|cocaine-kindled
D011280_D012640 NONE allopregnanolone_16\NN\1740|only|and|ganaxolone (r_nsubj) inhibited_19\VBD\2510337|whereas|allopregnanolone|development (r_advcl) suppressed_7\VBD\2510337|all|expression|,|inhibited|. (l_dobj) expression_9\NN\4679549|the|seizures (l_nmod) seizures_12\NNS\14081375|of|kindled
C105051_D012640 NONE ganaxolone_10\NN\1740|(|derivative|) (r_conj) allopregnanolone_0\NN\1740|3alpha-hydroxy-5alpha-pregnan-20-one|,|pregnanolone|and|ganaxolone (r_nsubjpass) tested_20\VBN\670261|allopregnanolone|were|ability|. (l_nmod) ability_23\NN\4723816|for|their|suppress (l_acl) suppress_25\VB\2510337|to|expression (l_dobj) expression_27\NN\4679549|the|effect|and|development|seizures|male|,|mice (l_nmod) seizures_40\NNS\14081375|of|cocaine-kindled
C105051_D012640 NONE 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one_17\CD\1740| (r_nummod) allopregnanolone_16\NN\1740|of|3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one (r_nmod) derivative_14\NN\5802185|a|synthetic|allopregnanolone (r_appos) ganaxolone_10\NN\1740|(|derivative|) (r_conj) allopregnanolone_0\NN\1740|3alpha-hydroxy-5alpha-pregnan-20-one|,|pregnanolone|and|ganaxolone (r_nsubjpass) tested_20\VBN\670261|allopregnanolone|were|ability|. (l_nmod) ability_23\NN\4723816|for|their|suppress (l_acl) suppress_25\VB\2510337|to|expression (l_dobj) expression_27\NN\4679549|the|effect|and|development|seizures|male|,|mice (l_nmod) seizures_40\NNS\14081375|of|cocaine-kindled
C105051_D012640 NONE ganaxolone_18\NN\1740| (r_conj) allopregnanolone_16\NN\1740|only|and|ganaxolone (r_nsubj) inhibited_19\VBD\2510337|whereas|allopregnanolone|development (r_advcl) suppressed_7\VBD\2510337|all|expression|,|inhibited|. (l_dobj) expression_9\NN\4679549|the|seizures (l_nmod) seizures_12\NNS\14081375|of|kindled
16904497
D013256_D011128 NONE steroid_5\NN\14727670| (r_compound) injection_6\NN\320852|after|epidural|steroid (r_nmod) syndrome_2\NN\5870365|cauda|equina|injection|:|report|.
D013256_D011843 NONE steroid_13\NN\14727670| (r_compound) injections_14\NNS\320852|epidural|steroid (r_conj) therapy_10\NN\657604|methods|are|physical|,|injections|,|medications|,|and|therapy (l_nsubj) methods_4\NNS\5616786|conventional|treatment|radiculopathy (l_nmod) radiculopathy_7\NN\1740|of|lumbusacral
D014221_D011128 NONE triamcinolone_16\NN\14751417|of (r_nmod) injection_14\NN\320852|by|epidural|triamcinolone|and|bupivacaine (r_nmod) caused_11\VBN\1617192|possibly|injection (r_acl) syndrome_9\NN\5870365|of|cauda|equina|caused
D002045_D011128 CID bupivacaine_18\NN\1740| (r_conj) injection_14\NN\320852|by|epidural|triamcinolone|and|bupivacaine (r_nmod) caused_11\VBN\1617192|possibly|injection (r_acl) syndrome_9\NN\5870365|of|cauda|equina|caused
D013256_D017116 NONE steroid_17\NN\14727670| (r_compound) injection_18\NN\320852|for|epidural|steroid (r_nmod) scheduled_14\VBN\704690|was|injection|. (r_acl:relcl) features_1\NN\5849040|clinical|:|woman|scheduled (l_dep) woman_5\NN\9605289|a|50-year-old|back|pain (l_nmod) pain_12\NN\14299637|leg
D013256_D010146 NONE steroid_17\NN\14727670| (r_compound) injection_18\NN\320852|for|epidural|steroid (r_nmod) scheduled_14\VBN\704690|was|injection|. (r_acl:relcl) features_1\NN\5849040|clinical|:|woman|scheduled (l_dep) woman_5\NN\9605289|a|50-year-old|back|pain (l_nmod) pain_12\NN\14299637|leg
D013256_D009422 NONE steroid_10\NN\14727670| (r_compound) injections_11\NNS\320852|after|epidural|steroid (r_nmod) examination_1\NN\633864|clinical|and|vigilance|injections (l_conj) vigilance_4\NN\5650579|continued|deterioration (l_nmod) deterioration_7\NN\14560612|for|neurologic
12596116
D015282_D000860 NONE octreotide-induced_0\JJ\1740| (r_amod) hypoxemia_1\NN\1740|octreotide-induced|and|hypertension|neonates|.
D015282_D006976 CID octreotide-induced_0\JJ\1740| (r_amod) hypoxemia_1\NN\1740|octreotide-induced|and|hypertension|neonates|. (l_conj) hypertension_4\NN\14057371|pulmonary
D015282_D006976 CID octreotide_10\NN\1740| (r_advmod) developed_2\VBD\1753788|hypertension|administration|,|octreotide|,|enhance|. (l_nsubj) hypertension_1\NN\14057371|pulmonary
D015282_D005402 NONE octreotide_10\NN\1740| (r_advmod) developed_2\VBD\1753788|hypertension|administration|,|octreotide|,|enhance|. (l_xcomp) enhance_13\VB\227165|to|resolution (l_dobj) resolution_14\NN\6470073|fistula (l_nmod) fistula_17\NN\14253124|of|the
16337777
D010862_D004827 NONE pilocarpine_12\NN\14712692|by (r_nmod) induced_10\VBN\1627355|pilocarpine (r_acl) epilepsy_9\NN\14085708|of|induced
D010862_D013226 NONE pilocarpine_49\NN\14712692| (r_compound) model_50\NN\5888929|of|the|pilocarpine|epilepsy (r_nmod) phase_46\NN\15113229|in|the|chronic|model (r_nmod) sufficient_16\JJ\1740|whether|generation|would|be|provoke|expression|,|phase (l_nsubj) generation_8\NN\7942152|increased|fr|epilepticus (l_nmod) epilepticus_13\NN\1740|during|status
D010862_D004833 CID pilocarpine_49\NN\14712692| (r_compound) model_50\NN\5888929|of|the|pilocarpine|epilepsy (l_nmod) epilepsy_54\NN\14085708|of|temporal|lobe
18503483
D016559_D020968 CID tacrolimus-associated_2\JJ\1740| (r_amod) neuritis_4\NN\14336539|of|tacrolimus-associated|brachial
C107135_D020968 NONE everolimus_8\NN\1740|to (r_nmod) conversion_6\NN\7359599|after|everolimus|recipient (r_nmod) recovery_0\NN\7357388|neuritis|conversion (l_nmod) neuritis_4\NN\14336539|of|tacrolimus-associated|brachial
11334364
D000082_D009336 CID acetaminophen-induced_13\JJ\1740| (r_amod) nephrotoxicity_14\NN\1740|during|acetaminophen-induced|,|toxicity|and|cardiotoxicity (r_nmod) deaths_11\NNS\7296428|of|associated|apoptotic|cell|nephrotoxicity (l_amod) apoptotic_7\JJ\1740|and|necrotic (l_conj) necrotic_9\JJ\1740|
D000082_D009336 CID aap_9\NNP\1740|such|,|ami|and|dox (r_nmod) drugs_4\NNS\14778436|all|the|,|aap (r_nsubj) induced_14\VBD\1627355|interestingly|,|drugs|death|addition|. (l_nmod) addition_18\NN\3081021|in|necrosis (l_nmod) necrosis_20\NN\11444117|to|organs
D000082_D007674 CID acetaminophen-induced_13\JJ\1740| (r_amod) nephrotoxicity_14\NN\1740|during|acetaminophen-induced|,|toxicity|and|cardiotoxicity
D000082_D007674 CID acetaminophen_16\RB\1740| (r_advmod) prevent_15\VB\1740|to|acetaminophen|nephrotoxicity (l_dobj) nephrotoxicity_18\NN\1740|(aap)-induced|,|toxicity|,|and|cardiotoxicity|mice
D000082_D007674 CID (aap)-induced_17\VBN\1740| (r_amod) nephrotoxicity_18\NN\1740|(aap)-induced|,|toxicity|,|and|cardiotoxicity|mice
D000082_D008171 NONE acetaminophen-induced_13\JJ\1740| (r_amod) nephrotoxicity_14\NN\1740|during|acetaminophen-induced|,|toxicity|and|cardiotoxicity (l_conj) toxicity_18\NN\13576101|amiodarone-induced|lung
D000082_D008171 NONE acetaminophen_16\RB\1740| (r_advmod) prevent_15\VB\1740|to|acetaminophen|nephrotoxicity (l_dobj) nephrotoxicity_18\NN\1740|(aap)-induced|,|toxicity|,|and|cardiotoxicity|mice (l_conj) toxicity_23\NN\13576101|(ami)-induced|lung
D000082_D008171 NONE (aap)-induced_17\VBN\1740| (r_amod) nephrotoxicity_18\NN\1740|(aap)-induced|,|toxicity|,|and|cardiotoxicity|mice (l_conj) toxicity_23\NN\13576101|(ami)-induced|lung
D000082_D066126 NONE acetaminophen-induced_13\JJ\1740| (r_amod) nephrotoxicity_14\NN\1740|during|acetaminophen-induced|,|toxicity|and|cardiotoxicity (l_conj) cardiotoxicity_21\NN\1740|doxorubicin-induced
D000082_D066126 NONE acetaminophen_16\RB\1740| (r_advmod) prevent_15\VB\1740|to|acetaminophen|nephrotoxicity (l_dobj) nephrotoxicity_18\NN\1740|(aap)-induced|,|toxicity|,|and|cardiotoxicity|mice (l_conj) cardiotoxicity_28\NN\1740|doxorubicin|(dox)-induced
D000082_D066126 NONE (aap)-induced_17\VBN\1740| (r_amod) nephrotoxicity_18\NN\1740|(aap)-induced|,|toxicity|,|and|cardiotoxicity|mice (l_conj) cardiotoxicity_28\NN\1740|doxorubicin|(dox)-induced
D000638_D009336 CID amiodarone-induced_16\JJ\1740| (r_amod) toxicity_18\NN\13576101|amiodarone-induced|lung (r_conj) nephrotoxicity_14\NN\1740|during|acetaminophen-induced|,|toxicity|and|cardiotoxicity (r_nmod) deaths_11\NNS\7296428|of|associated|apoptotic|cell|nephrotoxicity (l_amod) apoptotic_7\JJ\1740|and|necrotic (l_conj) necrotic_9\JJ\1740|
D000638_D009336 CID ami_11\NN\1740| (r_conj) aap_9\NNP\1740|such|,|ami|and|dox (r_nmod) drugs_4\NNS\14778436|all|the|,|aap (r_nsubj) induced_14\VBD\1627355|interestingly|,|drugs|death|addition|. (l_nmod) addition_18\NN\3081021|in|necrosis (l_nmod) necrosis_20\NN\11444117|to|organs
D000638_D007674 NONE amiodarone-induced_16\JJ\1740| (r_amod) toxicity_18\NN\13576101|amiodarone-induced|lung (r_conj) nephrotoxicity_14\NN\1740|during|acetaminophen-induced|,|toxicity|and|cardiotoxicity
D000638_D007674 NONE amiodarone_20\JJ\1740| (r_amod) (ami)-induced_21\VBN\1740|amiodarone (r_amod) toxicity_23\NN\13576101|(ami)-induced|lung (r_conj) nephrotoxicity_18\NN\1740|(aap)-induced|,|toxicity|,|and|cardiotoxicity|mice
D000638_D007674 NONE (ami)-induced_21\VBN\1740|amiodarone (r_amod) toxicity_23\NN\13576101|(ami)-induced|lung (r_conj) nephrotoxicity_18\NN\1740|(aap)-induced|,|toxicity|,|and|cardiotoxicity|mice
D000638_D008171 CID amiodarone-induced_16\JJ\1740| (r_amod) toxicity_18\NN\13576101|amiodarone-induced|lung
D000638_D008171 CID amiodarone_20\JJ\1740| (r_amod) (ami)-induced_21\VBN\1740|amiodarone (r_amod) toxicity_23\NN\13576101|(ami)-induced|lung
D000638_D008171 CID (ami)-induced_21\VBN\1740|amiodarone (r_amod) toxicity_23\NN\13576101|(ami)-induced|lung
D000638_D066126 NONE amiodarone-induced_16\JJ\1740| (r_amod) toxicity_18\NN\13576101|amiodarone-induced|lung (r_conj) nephrotoxicity_14\NN\1740|during|acetaminophen-induced|,|toxicity|and|cardiotoxicity (l_conj) cardiotoxicity_21\NN\1740|doxorubicin-induced
D000638_D066126 NONE amiodarone_20\JJ\1740| (r_amod) (ami)-induced_21\VBN\1740|amiodarone (r_amod) toxicity_23\NN\13576101|(ami)-induced|lung (r_conj) nephrotoxicity_18\NN\1740|(aap)-induced|,|toxicity|,|and|cardiotoxicity|mice (l_conj) cardiotoxicity_28\NN\1740|doxorubicin|(dox)-induced
D000638_D066126 NONE (ami)-induced_21\VBN\1740|amiodarone (r_amod) toxicity_23\NN\13576101|(ami)-induced|lung (r_conj) nephrotoxicity_18\NN\1740|(aap)-induced|,|toxicity|,|and|cardiotoxicity|mice (l_conj) cardiotoxicity_28\NN\1740|doxorubicin|(dox)-induced
D004317_D009336 CID doxorubicin-induced_20\JJ\1740| (r_amod) cardiotoxicity_21\NN\1740|doxorubicin-induced (r_conj) nephrotoxicity_14\NN\1740|during|acetaminophen-induced|,|toxicity|and|cardiotoxicity (r_nmod) deaths_11\NNS\7296428|of|associated|apoptotic|cell|nephrotoxicity (l_amod) apoptotic_7\JJ\1740|and|necrotic (l_conj) necrotic_9\JJ\1740|
D004317_D009336 CID dox_13\NN\1740| (r_conj) aap_9\NNP\1740|such|,|ami|and|dox (r_nmod) drugs_4\NNS\14778436|all|the|,|aap (r_nsubj) induced_14\VBD\1627355|interestingly|,|drugs|death|addition|. (l_nmod) addition_18\NN\3081021|in|necrosis (l_nmod) necrosis_20\NN\11444117|to|organs
D004317_D007674 NONE doxorubicin-induced_20\JJ\1740| (r_amod) cardiotoxicity_21\NN\1740|doxorubicin-induced (r_conj) nephrotoxicity_14\NN\1740|during|acetaminophen-induced|,|toxicity|and|cardiotoxicity
D004317_D007674 NONE doxorubicin_26\NN\2716866| (r_compound) cardiotoxicity_28\NN\1740|doxorubicin|(dox)-induced (r_conj) nephrotoxicity_18\NN\1740|(aap)-induced|,|toxicity|,|and|cardiotoxicity|mice
D004317_D007674 NONE (dox)-induced_27\JJ\1740| (r_amod) cardiotoxicity_28\NN\1740|doxorubicin|(dox)-induced (r_conj) nephrotoxicity_18\NN\1740|(aap)-induced|,|toxicity|,|and|cardiotoxicity|mice
D004317_D008171 NONE doxorubicin-induced_20\JJ\1740| (r_amod) cardiotoxicity_21\NN\1740|doxorubicin-induced (r_conj) nephrotoxicity_14\NN\1740|during|acetaminophen-induced|,|toxicity|and|cardiotoxicity (l_conj) toxicity_18\NN\13576101|amiodarone-induced|lung
D004317_D008171 NONE doxorubicin_26\NN\2716866| (r_compound) cardiotoxicity_28\NN\1740|doxorubicin|(dox)-induced (r_conj) nephrotoxicity_18\NN\1740|(aap)-induced|,|toxicity|,|and|cardiotoxicity|mice (l_conj) toxicity_23\NN\13576101|(ami)-induced|lung
D004317_D008171 NONE (dox)-induced_27\JJ\1740| (r_amod) cardiotoxicity_28\NN\1740|doxorubicin|(dox)-induced (r_conj) nephrotoxicity_18\NN\1740|(aap)-induced|,|toxicity|,|and|cardiotoxicity|mice (l_conj) toxicity_23\NN\13576101|(ami)-induced|lung
D004317_D066126 CID doxorubicin-induced_20\JJ\1740| (r_amod) cardiotoxicity_21\NN\1740|doxorubicin-induced
D004317_D066126 CID doxorubicin_26\NN\2716866| (r_compound) cardiotoxicity_28\NN\1740|doxorubicin|(dox)-induced
D004317_D066126 CID (dox)-induced_27\JJ\1740| (r_amod) cardiotoxicity_28\NN\1740|doxorubicin|(dox)-induced
C511402_D009336 NONE extract_29\NN\14589223|by|a|novel|proanthocyanidin (r_nmod) protection_2\NN\407535|in|deaths|extract|. (l_nmod) deaths_11\NNS\7296428|of|associated|apoptotic|cell|nephrotoxicity (l_amod) apoptotic_7\JJ\1740|and|necrotic (l_conj) necrotic_9\JJ\1740|
C511402_D009336 NONE gspe_31\NN\1740|by (r_nmod) blocked_29\VBN\1476483|which|was|effectively|gspe (r_acl:relcl) organs_24\NNS\7649854|in|the|respective|blocked (r_nmod) necrosis_20\NN\11444117|to|organs
C511402_D007674 NONE extract_29\NN\14589223|by|a|novel|proanthocyanidin (r_nmod) protection_2\NN\407535|in|deaths|extract|. (l_nmod) deaths_11\NNS\7296428|of|associated|apoptotic|cell|nephrotoxicity (l_nmod) nephrotoxicity_14\NN\1740|during|acetaminophen-induced|,|toxicity|and|cardiotoxicity
C511402_D007674 NONE extract_10\NN\14589223|of|ih636|grape|seed|proanthocyanidin|gspe (r_nmod) ability_4\NN\4723816|the|extract|prevent (l_acl) prevent_15\VB\1740|to|acetaminophen|nephrotoxicity (l_dobj) nephrotoxicity_18\NN\1740|(aap)-induced|,|toxicity|,|and|cardiotoxicity|mice
C511402_D007674 NONE gspe_12\NN\1740|(|) (r_appos) extract_10\NN\14589223|of|ih636|grape|seed|proanthocyanidin|gspe (r_nmod) ability_4\NN\4723816|the|extract|prevent (l_acl) prevent_15\VB\1740|to|acetaminophen|nephrotoxicity (l_dobj) nephrotoxicity_18\NN\1740|(aap)-induced|,|toxicity|,|and|cardiotoxicity|mice
C511402_D008171 NONE extract_29\NN\14589223|by|a|novel|proanthocyanidin (r_nmod) protection_2\NN\407535|in|deaths|extract|. (l_nmod) deaths_11\NNS\7296428|of|associated|apoptotic|cell|nephrotoxicity (l_nmod) nephrotoxicity_14\NN\1740|during|acetaminophen-induced|,|toxicity|and|cardiotoxicity (l_conj) toxicity_18\NN\13576101|amiodarone-induced|lung
C511402_D008171 NONE extract_10\NN\14589223|of|ih636|grape|seed|proanthocyanidin|gspe (r_nmod) ability_4\NN\4723816|the|extract|prevent (l_acl) prevent_15\VB\1740|to|acetaminophen|nephrotoxicity (l_dobj) nephrotoxicity_18\NN\1740|(aap)-induced|,|toxicity|,|and|cardiotoxicity|mice (l_conj) toxicity_23\NN\13576101|(ami)-induced|lung
C511402_D008171 NONE gspe_12\NN\1740|(|) (r_appos) extract_10\NN\14589223|of|ih636|grape|seed|proanthocyanidin|gspe (r_nmod) ability_4\NN\4723816|the|extract|prevent (l_acl) prevent_15\VB\1740|to|acetaminophen|nephrotoxicity (l_dobj) nephrotoxicity_18\NN\1740|(aap)-induced|,|toxicity|,|and|cardiotoxicity|mice (l_conj) toxicity_23\NN\13576101|(ami)-induced|lung
C511402_D066126 NONE extract_29\NN\14589223|by|a|novel|proanthocyanidin (r_nmod) protection_2\NN\407535|in|deaths|extract|. (l_nmod) deaths_11\NNS\7296428|of|associated|apoptotic|cell|nephrotoxicity (l_nmod) nephrotoxicity_14\NN\1740|during|acetaminophen-induced|,|toxicity|and|cardiotoxicity (l_conj) cardiotoxicity_21\NN\1740|doxorubicin-induced
C511402_D066126 NONE extract_10\NN\14589223|of|ih636|grape|seed|proanthocyanidin|gspe (r_nmod) ability_4\NN\4723816|the|extract|prevent (l_acl) prevent_15\VB\1740|to|acetaminophen|nephrotoxicity (l_dobj) nephrotoxicity_18\NN\1740|(aap)-induced|,|toxicity|,|and|cardiotoxicity|mice (l_conj) cardiotoxicity_28\NN\1740|doxorubicin|(dox)-induced
C511402_D066126 NONE gspe_12\NN\1740|(|) (r_appos) extract_10\NN\14589223|of|ih636|grape|seed|proanthocyanidin|gspe (r_nmod) ability_4\NN\4723816|the|extract|prevent (l_acl) prevent_15\VB\1740|to|acetaminophen|nephrotoxicity (l_dobj) nephrotoxicity_18\NN\1740|(aap)-induced|,|toxicity|,|and|cardiotoxicity|mice (l_conj) cardiotoxicity_28\NN\1740|doxorubicin|(dox)-induced
C511402_D017695 NONE gspe_30\NN\1740| (r_compound) preexposure_31\NN\1740|absence|of|gspe (r_advcl) revealed_9\VBD\2137132|examination|sections|moderate|drugs|preexposure|presence|. (l_xcomp) moderate_10\JJ\1740|damage (l_nmod) damage_14\NN\7296428|to|massive|tissue|variety
19346865
D008795_D001927 CID metronidazole-induced_5\JJ\1740| (r_amod) encephalopathy_6\JJ\1740|in|metronidazole-induced (r_nmod) lesion_3\NN\14204950|reversible|inferior|colliculus|encephalopathy|:|findings|.
D008795_D001927 CID metronidazole-induced_5\JJ\1740| (r_amod) encephalopathy_6\JJ\1740|in|metronidazole-induced
D008795_D001927 CID metronidazole-induced_11\JJ\1740| (r_amod) encephalopathy_12\JJ\1740|in|metronidazole-induced (r_nmod) lesions_9\NNS\14204950|reversible|inferior|colliculus|encephalopathy
D008795_D001927 CID metronidazole-induced_11\JJ\1740| (r_amod) encephalopathy_12\JJ\1740|in|metronidazole-induced
D008795_D001927 CID metronidazole-induced_24\JJ\1740| (r_amod) encephalopathy_25\JJ\1740|metronidazole-induced|range
D008795_D001927 CID metronidazole-induced_13\JJ\1740| (r_amod) encephalopathy_14\JJ\1740|for|metronidazole-induced (r_nmod) characteristic_11\NN\5849040|as|the|encephalopathy (r_nmod) considered_8\VBN\689344|conclusions|lesions|could|be|characteristic|,|next|. (l_nsubjpass) lesions_5\NNS\14204950|reversible|inferior|colliculus
D008795_D001927 CID metronidazole-induced_13\JJ\1740| (r_amod) encephalopathy_14\JJ\1740|for|metronidazole-induced
D008795_D007239 NONE metronidazole_4\NN\2723292|(|dosage (r_dobj) taking_3\VBG\2367363|they|had|been|metronidazole|duration|months|)|treat|. (l_advcl) treat_23\VB\2376958|to|infection (l_dobj) infection_25\NN\14052046|the|organs
3970039
D000477_D015470 CID agents_4\NNS\7347|with|alkylating (r_nmod) treated_1\VBN\2376958|agents (r_acl) patients_0\NNS\9898892|treated (r_nsubj) have_5\VBP\2108377|patients|risk|,|and|associated|. (l_dobj) risk_8\NN\14541044|an|increased|development (l_nmod) development_10\NN\248977|of|leukemia (l_nmod) leukemia_14\NN\14239918|of|acute|nonlymphocytic
D000477_D015470 CID agents_19\NNS\7347|both|alkylating|and|azathioprine (r_nsubjpass) associated_23\VBN\628491|agents|are|development (r_conj) have_5\VBP\2108377|patients|risk|,|and|associated|. (l_dobj) risk_8\NN\14541044|an|increased|development (l_nmod) development_10\NN\248977|of|leukemia (l_nmod) leukemia_14\NN\14239918|of|acute|nonlymphocytic
D000477_D008228 CID agents_4\NNS\7347|with|alkylating (r_nmod) treated_1\VBN\2376958|agents (r_acl) patients_0\NNS\9898892|treated (r_nsubj) have_5\VBP\2108377|patients|risk|,|and|associated|. (l_conj) associated_23\VBN\628491|agents|are|development (l_nmod) development_26\NN\248977|with|the|lymphoma (l_nmod) lymphoma_30\NN\14239918|of|non-hodgkin
D000477_D008228 CID agents_19\NNS\7347|both|alkylating|and|azathioprine (r_nsubjpass) associated_23\VBN\628491|agents|are|development (l_nmod) development_26\NN\248977|with|the|lymphoma (l_nmod) lymphoma_30\NN\14239918|of|non-hodgkin
D001379_D015470 NONE azathioprine_21\NN\3740161| (r_conj) agents_19\NNS\7347|both|alkylating|and|azathioprine (r_nsubjpass) associated_23\VBN\628491|agents|are|development (r_conj) have_5\VBP\2108377|patients|risk|,|and|associated|. (l_dobj) risk_8\NN\14541044|an|increased|development (l_nmod) development_10\NN\248977|of|leukemia (l_nmod) leukemia_14\NN\14239918|of|acute|nonlymphocytic
D001379_D008228 CID azathioprine_21\NN\3740161| (r_conj) agents_19\NNS\7347|both|alkylating|and|azathioprine (r_nsubjpass) associated_23\VBN\628491|agents|are|development (l_nmod) development_26\NN\248977|with|the|lymphoma (l_nmod) lymphoma_30\NN\14239918|of|non-hodgkin
D003520_D001749 CID cyclophosphamide_0\NN\1740| (r_compound) therapy_1\NN\657604|cyclophosphamide (r_nsubj) increases_2\VBZ\169651|therapy|risk|. (l_dobj) risk_4\NN\14541044|the|carcinoma (l_nmod) carcinoma_6\NN\14239918|of|bladder (l_nmod) bladder_9\NN\5515670|of|the
D003520_D002277 CID cyclophosphamide_0\NN\1740| (r_compound) therapy_1\NN\657604|cyclophosphamide (r_nsubj) increases_2\VBZ\169651|therapy|risk|. (l_dobj) risk_4\NN\14541044|the|carcinoma (l_nmod) carcinoma_6\NN\14239918|of|bladder (l_nmod) bladder_9\NN\5515670|of|the
D001379_D001172 NONE azathioprine_13\NN\3740161|with|and|cyclophosphamide (r_nmod) treated_11\VBN\2376958|azathioprine (r_acl) patients_7\NNS\9898892|of|arthritis|treated (l_nmod) arthritis_10\NN\14171682|with|rheumatoid
D001379_D009369 NONE azathioprine_13\NN\3740161|with|and|cyclophosphamide (r_nmod) treated_11\VBN\2376958|azathioprine (r_acl) patients_7\NNS\9898892|of|arthritis|treated (r_nmod) studies_5\NNS\635850|several|long-term|patients|and|incidence (l_conj) incidence_18\NN\13821570|the|most (l_nmod) most_20\JJS\1740|of|cancers (l_nmod) cancers_24\NNS\14239425|of|the|common
D003520_D001172 NONE cyclophosphamide_15\NN\1740| (r_conj) azathioprine_13\NN\3740161|with|and|cyclophosphamide (r_nmod) treated_11\VBN\2376958|azathioprine (r_acl) patients_7\NNS\9898892|of|arthritis|treated (l_nmod) arthritis_10\NN\14171682|with|rheumatoid
D003520_D009369 NONE cyclophosphamide_15\NN\1740| (r_conj) azathioprine_13\NN\3740161|with|and|cyclophosphamide (r_nmod) treated_11\VBN\2376958|azathioprine (r_acl) patients_7\NNS\9898892|of|arthritis|treated (r_nmod) studies_5\NNS\635850|several|long-term|patients|and|incidence (l_conj) incidence_18\NN\13821570|the|most (l_nmod) most_20\JJS\1740|of|cancers (l_nmod) cancers_24\NNS\14239425|of|the|common
D000477_D009369 NONE agents_31\NNS\7347|alkylating (r_appos) drugs_27\NNS\14778436|of|immunosuppressive|,|agents (r_nmod) use_24\NN\407535|the|drugs|,|treatment (r_nsubjpass) reserved_41\VBN\2213690|use|should|be|patients|. (r_conj) collected_14\VBN\2281093|data|are|still|being|,|and|available|reserved (l_nsubjpass) data_0\NNS\7951464|risk (l_nmod) risk_5\NN\14541044|on|the|possible|increased|malignancy|arthritis (l_nmod) malignancy_7\NN\14070360|of
D000477_D001172 NONE agents_31\NNS\7347|alkylating (r_appos) drugs_27\NNS\14778436|of|immunosuppressive|,|agents (r_nmod) use_24\NN\407535|the|drugs|,|treatment (r_nsubjpass) reserved_41\VBN\2213690|use|should|be|patients|. (r_conj) collected_14\VBN\2281093|data|are|still|being|,|and|available|reserved (l_nsubjpass) data_0\NNS\7951464|risk (l_nmod) risk_5\NN\14541044|on|the|possible|increased|malignancy|arthritis (l_nmod) arthritis_10\NN\14171682|in|rheumatoid
D000477_D001172 NONE agents_31\NNS\7347|alkylating (r_appos) drugs_27\NNS\14778436|of|immunosuppressive|,|agents (r_nmod) use_24\NN\407535|the|drugs|,|treatment (l_nmod) treatment_35\NN\654885|in|the|arthritis (l_nmod) arthritis_38\NN\14171682|of|rheumatoid
2266990
D008454_D020388 NONE mazindol_5\NN\1740|of (r_nmod) trial_3\NN\786195|randomized|mazindol|dystrophy|. (l_nmod) dystrophy_8\NN\14151139|in|duchenne
D008454_D020388 NONE mazindol_7\NN\1740|of|,|inhibitor (r_nmod) trial_5\NN\786195|a|controlled|mazindol (r_dobj) conducted_1\VBD\2436349|we|trial|,|boys|. (l_nmod) boys_18\NNS\9624168|in|83|dystrophy (l_nmod) dystrophy_21\NN\14151139|with|duchenne
D008454_D020388 NONE mazindol_0\NN\1740| (r_compound) doses_1\NNS\3740161|mazindol (r_nsubj) slow_3\VB\151689|doses|not|progression|. (l_dobj) progression_5\NN\8457976|the|weakness (l_nmod) weakness_7\NN\14462666|of|dystrophy (l_nmod) dystrophy_10\NN\14151139|in|duchenne
D008454_D001068 CID mazindol_4\NN\1740|to (r_nmod) attributable_2\JJ\1740|mazindol (r_amod) effects_1\NNS\13245626|side|attributable (r_nsubj) included_5\VBN\690614|effects|appetite|;|reduced (l_dobj) appetite_7\NN\7485475|decreased|%|,|mouth|,|change|,|and|symptoms
D008454_D001068 CID mazindol_35\NN\1740| (r_compound) dosage_36\NN\13576355|mazindol (r_nsubjpass) reduced_38\VBN\441445|dosage|was|%|. (r_conj) included_5\VBN\690614|effects|appetite|;|reduced (l_dobj) appetite_7\NN\7485475|decreased|%|,|mouth|,|change|,|and|symptoms
D008454_D014987 CID mazindol_4\NN\1740|to (r_nmod) attributable_2\JJ\1740|mazindol (r_amod) effects_1\NNS\13245626|side|attributable (r_nsubj) included_5\VBN\690614|effects|appetite|;|reduced (l_dobj) appetite_7\NN\7485475|decreased|%|,|mouth|,|change|,|and|symptoms (l_conj) mouth_14\NN\5610008|dry|%
D008454_D014987 CID mazindol_35\NN\1740| (r_compound) dosage_36\NN\13576355|mazindol (r_nsubjpass) reduced_38\VBN\441445|dosage|was|%|. (r_conj) included_5\VBN\690614|effects|appetite|;|reduced (l_dobj) appetite_7\NN\7485475|decreased|%|,|mouth|,|change|,|and|symptoms (l_conj) mouth_14\NN\5610008|dry|%
D008454_D012817 CID mazindol_4\NN\1740|to (r_nmod) attributable_2\JJ\1740|mazindol (r_amod) effects_1\NNS\13245626|side|attributable (r_nsubj) included_5\VBN\690614|effects|appetite|;|reduced (l_dobj) appetite_7\NN\7485475|decreased|%|,|mouth|,|change|,|and|symptoms (l_conj) symptoms_29\NNS\5823932|gastrointestinal|%
D008454_D012817 CID mazindol_35\NN\1740| (r_compound) dosage_36\NN\13576355|mazindol (r_nsubjpass) reduced_38\VBN\441445|dosage|was|%|. (r_conj) included_5\VBN\690614|effects|appetite|;|reduced (l_dobj) appetite_7\NN\7485475|decreased|%|,|mouth|,|change|,|and|symptoms (l_conj) symptoms_29\NNS\5823932|gastrointestinal|%
D008454_D018908 NONE mazindol_0\NN\1740| (r_compound) doses_1\NNS\3740161|mazindol (r_nsubj) slow_3\VB\151689|doses|not|progression|. (l_dobj) progression_5\NN\8457976|the|weakness (l_nmod) weakness_7\NN\14462666|of|dystrophy
6861444
D009638_D006973 CID noradrenaline_3\NN\14807929|of (r_nmod) infusion_1\NN\14589223|intrarenal|noradrenaline (r_nsubj) caused_4\VBD\1617192|infusion|hypertension|. (l_dobj) hypertension_5\NN\14057371|doses
D009638_D006973 CID noradrenaline_8\NN\14807929| (r_compound) infusion_9\NN\14589223|after|chronic|intrarenal|noradrenaline (r_nmod) hypertension_4\NN\14057371|infusion
D009638_D006973 CID noradrenaline_18\NN\14807929|of|circulating|and|triggering (r_nmod) levels_15\NNS\4916342|by|higher|noradrenaline (r_nmod) produced_11\VBN\1617192|that|hypertension|is|levels (l_nsubjpass) hypertension_4\NN\14057371|infusion
137340
D009020_D006948 CID morphine-induced_5\JJ\1740| (r_amod) increase_6\NN\13576355|of|morphine-induced|activity (l_nmod) activity_9\NN\30358|in|locomotor|mice
D009020_D006948 CID morphine-induced_7\JJ\1740| (r_amod) increase_8\NN\13576355|on|the|morphine-induced|activity (l_nmod) activity_11\NN\30358|in|locomotor|mice
D009020_D006948 CID morphine-hc1_7\NN\1740|of (r_nmod) mg/kg_5\NN\1740|of|10|morphine-hc1 (r_nmod) administration_2\NN\1133281|the|subcutaneous|mg/kg (r_nsubj) produced_8\VBD\1617192|administration|increase|. (l_dobj) increase_11\NN\13576355|a|marked|activity (l_nmod) activity_14\NN\30358|in|locomotor|mice
D009020_D006948 CID morphine-induced_1\JJ\1740| (r_amod) hyperactivity_2\NN\14052403|the|morphine-induced
D009020_D006948 CID morphine_24\NN\2707683|by (r_nmod) produced_22\VBN\1617192|morphine (r_acl) hyperactivity_21\NN\14052403|on|the|produced
D012601_D006948 CID scopolamine_6\NN\14712692|by (r_nmod) potentiated_4\VBN\229605|hyperactivity|was|scopolamine|and|attenuated|. (l_nsubjpass) hyperactivity_2\NN\14052403|the|morphine-induced
D010830_D006948 NONE physostigmine_10\NN\14712692|by (r_nmod) attenuated_8\VBN\224901|physostigmine (r_conj) potentiated_4\VBN\229605|hyperactivity|was|scopolamine|and|attenuated|. (l_nsubjpass) hyperactivity_2\NN\14052403|the|morphine-induced
D019832_D006948 NONE methscopolamine_4\NN\1740|both|and|neostigmine|,|penetrate|, (r_nsubj) had_16\VBD\2108377|contrast|,|methscopolamine|effect|. (l_dobj) effect_18\NN\34213|no|hyperactivity (l_nmod) hyperactivity_21\NN\14052403|on|the|produced
D009388_D006948 NONE neostigmine_6\NN\2718084| (r_conj) methscopolamine_4\NN\1740|both|and|neostigmine|,|penetrate|, (r_nsubj) had_16\VBD\2108377|contrast|,|methscopolamine|effect|. (l_dobj) effect_18\NN\34213|no|hyperactivity (l_nmod) hyperactivity_21\NN\14052403|on|the|produced
D010134_D006948 NONE p-chlorophenylalamine_7\NN\1740|with (r_nmod) pretreatment_5\NN\1740|p-chlorophenylalamine|mg/kg|,|depletor|, (r_nsubj) caused_23\VBD\1617192|hand|,|pretreatment|change|. (l_dobj) change_26\NN\7283608|no|significant|hyperactivity (l_nmod) hyperactivity_29\NN\14052403|in|the
D012701_D006948 NONE serotonin_20\NN\14807737| (r_compound) depletor_21\NN\1740|a|serotonin (r_appos) pretreatment_5\NN\1740|p-chlorophenylalamine|mg/kg|,|depletor|, (r_nsubj) caused_23\VBD\1617192|hand|,|pretreatment|change|. (l_dobj) change_26\NN\7283608|no|significant|hyperactivity (l_nmod) hyperactivity_29\NN\14052403|in|the
227508
D003000_D006973 NONE clonidine_17\NN\2721160|by|intravenous|,|micrograms/kg (r_nmod) produced_14\VBN\1617192|clonidine (r_acl) pressure_10\NN\11419404|in|blood|and|rate|produced (r_nmod) decrease_7\NN\7296428|the|pressure (r_dobj) rats_5\VBZ\2584097|in|unanesthetized|,|hypertensive|decrease|, (l_amod) hypertensive_4\JJ\1740|spontaneously
D003000_D006973 NONE clonidine_7\NN\2721160| (r_dep) rats_6\NNS\2329401|from|spontaneously|hypertensive|clonidine (l_amod) hypertensive_5\JJ\1740|
D003000_D006973 NONE clonidine-suppressible_41\JJ\1740| (r_amod) binding_42\NN\4688246|clonidine-suppressible|[3h]-dihydroergocryptine (r_dobj) influence_40\VB\137313|did|not|binding (r_conj) influence_18\VB\137313|membranes|did|not|binding|10(-8|10(-4|,|influence|. (l_nmod) membranes_2\NNS\4188643|in|brain|rats|,|10(-8|10(-5|m|, (l_nmod) rats_6\NNS\2329401|from|spontaneously|hypertensive|clonidine (l_amod) hypertensive_5\JJ\1740|
-1_D006973 NONE nalozone_29\NN\1740|by|,|mg/kg (r_nmod) reversed_27\VBN\109660|nalozone (r_conj) inhibited_25\VBN\2510337|rats|was|or|reversed|. (l_nmod) rats_5\VBZ\2584097|in|unanesthetized|,|hypertensive|decrease|, (l_amod) hypertensive_4\JJ\1740|spontaneously
-1_D006973 NONE [3h]-naloxone_22\XX\1740|of|nm (r_nmod) binding_20\NN\4688246|stereoselective|[3h]-naloxone|,|and|naloxone (r_dobj) influence_18\VB\137313|membranes|did|not|binding|10(-8|10(-4|,|influence|. (l_nmod) membranes_2\NNS\4188643|in|brain|rats|,|10(-8|10(-5|m|, (l_nmod) rats_6\NNS\2329401|from|spontaneously|hypertensive|clonidine (l_amod) hypertensive_5\JJ\1740|
-1_D006973 NONE [3h]-dihydroergocryptine_44\XX\1740|of|nm (r_nmod) binding_42\NN\4688246|clonidine-suppressible|[3h]-dihydroergocryptine (r_dobj) influence_40\VB\137313|did|not|binding (r_conj) influence_18\VB\137313|membranes|did|not|binding|10(-8|10(-4|,|influence|. (l_nmod) membranes_2\NNS\4188643|in|brain|rats|,|10(-8|10(-5|m|, (l_nmod) rats_6\NNS\2329401|from|spontaneously|hypertensive|clonidine (l_amod) hypertensive_5\JJ\1740|
D008750_D007022 CID alpha-methyldopa_6\NN\1740|of|100|mg/kg (r_nmod) effect_2\NN\34213|the|hypotensive|alpha-methyldopa (l_amod) hypotensive_1\JJ\1740|
D009270_D007022 NONE naloxone_12\NN\3808977|by (r_nmod) reversed_10\VBN\109660|effect|was|partially|naloxone|. (l_nsubjpass) effect_2\NN\34213|the|hypotensive|alpha-methyldopa (l_amod) hypotensive_1\JJ\1740|
D009270_D006973 NONE naloxone_29\NN\3808977| (r_conj) binding_20\NN\4688246|stereoselective|[3h]-naloxone|,|and|naloxone (r_dobj) influence_18\VB\137313|membranes|did|not|binding|10(-8|10(-4|,|influence|. (l_nmod) membranes_2\NNS\4188643|in|brain|rats|,|10(-8|10(-5|m|, (l_nmod) rats_6\NNS\2329401|from|spontaneously|hypertensive|clonidine (l_amod) hypertensive_5\JJ\1740|
16680561
D003891_D009325 CID desipramine_8\NN\4482543|with|alone (r_nmod) treatment_6\NN\654885|following|desipramine (r_nmod) events_4\NNS\23100|adverse|treatment (r_dobj) reported_2\VBD\831651|subjects|events|receiving|%|,|frequent|. (l_dep) frequent_25\JJ\1740|the|most|which|reported (l_nmod) which_27\WDT\1740|of|nausea (l_dep) nausea_29\NN\14299637|(|and|headache|)
D003891_D009325 CID desipramine_13\NN\4482543|cinacalcet (r_dobj) receiving_12\VBG\2210855|when|desipramine (r_advcl) reported_2\VBD\831651|subjects|events|receiving|%|,|frequent|. (l_dep) frequent_25\JJ\1740|the|most|which|reported (l_nmod) which_27\WDT\1740|of|nausea (l_dep) nausea_29\NN\14299637|(|and|headache|)
D003891_D009325 CID desipramine_41\NN\4482543|with|either|or|cinacalcet (r_nmod) treated_38\VBN\2376958|desipramine (r_acl) patients_37\NNS\9898892|for|treated (r_nmod) reported_35\VBN\831651|have|been|patients (r_acl:relcl) frequent_25\JJ\1740|the|most|which|reported (l_nmod) which_27\WDT\1740|of|nausea (l_dep) nausea_29\NN\14299637|(|and|headache|)
D003891_D006261 CID desipramine_8\NN\4482543|with|alone (r_nmod) treatment_6\NN\654885|following|desipramine (r_nmod) events_4\NNS\23100|adverse|treatment (r_dobj) reported_2\VBD\831651|subjects|events|receiving|%|,|frequent|. (l_dep) frequent_25\JJ\1740|the|most|which|reported (l_nmod) which_27\WDT\1740|of|nausea (l_dep) nausea_29\NN\14299637|(|and|headache|) (l_conj) headache_31\NN\5829480|
D003891_D006261 CID desipramine_13\NN\4482543|cinacalcet (r_dobj) receiving_12\VBG\2210855|when|desipramine (r_advcl) reported_2\VBD\831651|subjects|events|receiving|%|,|frequent|. (l_dep) frequent_25\JJ\1740|the|most|which|reported (l_nmod) which_27\WDT\1740|of|nausea (l_dep) nausea_29\NN\14299637|(|and|headache|) (l_conj) headache_31\NN\5829480|
D003891_D006261 CID desipramine_41\NN\4482543|with|either|or|cinacalcet (r_nmod) treated_38\VBN\2376958|desipramine (r_acl) patients_37\NNS\9898892|for|treated (r_nmod) reported_35\VBN\831651|have|been|patients (r_acl:relcl) frequent_25\JJ\1740|the|most|which|reported (l_nmod) which_27\WDT\1740|of|nausea (l_dep) nausea_29\NN\14299637|(|and|headache|) (l_conj) headache_31\NN\5829480|
C476217_D009325 CID cinacalcet_15\NN\1740|with (r_nmod) desipramine_13\NN\4482543|cinacalcet (r_dobj) receiving_12\VBG\2210855|when|desipramine (r_advcl) reported_2\VBD\831651|subjects|events|receiving|%|,|frequent|. (l_dep) frequent_25\JJ\1740|the|most|which|reported (l_nmod) which_27\WDT\1740|of|nausea (l_dep) nausea_29\NN\14299637|(|and|headache|)
C476217_D009325 CID cinacalcet_43\NN\1740| (r_conj) desipramine_41\NN\4482543|with|either|or|cinacalcet (r_nmod) treated_38\VBN\2376958|desipramine (r_acl) patients_37\NNS\9898892|for|treated (r_nmod) reported_35\VBN\831651|have|been|patients (r_acl:relcl) frequent_25\JJ\1740|the|most|which|reported (l_nmod) which_27\WDT\1740|of|nausea (l_dep) nausea_29\NN\14299637|(|and|headache|)
C476217_D006261 CID cinacalcet_15\NN\1740|with (r_nmod) desipramine_13\NN\4482543|cinacalcet (r_dobj) receiving_12\VBG\2210855|when|desipramine (r_advcl) reported_2\VBD\831651|subjects|events|receiving|%|,|frequent|. (l_dep) frequent_25\JJ\1740|the|most|which|reported (l_nmod) which_27\WDT\1740|of|nausea (l_dep) nausea_29\NN\14299637|(|and|headache|) (l_conj) headache_31\NN\5829480|
C476217_D006261 CID cinacalcet_43\NN\1740| (r_conj) desipramine_41\NN\4482543|with|either|or|cinacalcet (r_nmod) treated_38\VBN\2376958|desipramine (r_acl) patients_37\NNS\9898892|for|treated (r_nmod) reported_35\VBN\831651|have|been|patients (r_acl:relcl) frequent_25\JJ\1740|the|most|which|reported (l_nmod) which_27\WDT\1740|of|nausea (l_dep) nausea_29\NN\14299637|(|and|headache|) (l_conj) headache_31\NN\5829480|
7881871
D011692_D007674 CID aminonucleoside-induced_7\JJ\1740| (r_amod) nephropathy_8\NN\14573196|aminonucleoside-induced
D011692_D007674 CID aminonucleoside_12\NN\1740|of|acute|puromycin (r_nmod) pathogenesis_8\NN\13533470|in|the|aminonucleoside (r_nmod) implicated_5\VBN\2677097|species|have|been|pathogenesis|(pan)-induced|nephropathy|,|reducing|. (l_advmod) nephropathy_14\NN\14573196|
D011692_D007674 CID (pan)-induced_13\VBN\1740| (r_punct) implicated_5\VBN\2677097|species|have|been|pathogenesis|(pan)-induced|nephropathy|,|reducing|. (l_advmod) nephropathy_14\NN\14573196|
D011692_D007674 CID pan_14\NN\3101986| (r_compound) nephropathy_15\NN\14573196|in|pan
D010100_D007674 NONE oxygen_1\NN\14622893| (r_compound) species_2\NNS\7992450|reactive|oxygen (r_nsubjpass) implicated_5\VBN\2677097|species|have|been|pathogenesis|(pan)-induced|nephropathy|,|reducing|. (l_advmod) nephropathy_14\NN\14573196|
D010100_D011507 NONE oxygen_1\NN\14622893| (r_compound) species_2\NNS\7992450|reactive|oxygen (r_nsubjpass) implicated_5\VBN\2677097|species|have|been|pathogenesis|(pan)-induced|nephropathy|,|reducing|. (l_advcl) reducing_19\VBG\441445|antioxidants|significantly|proteinuria (l_dobj) proteinuria_21\NN\14299637|the
D011692_D011507 CID aminonucleoside_12\NN\1740|of|acute|puromycin (r_nmod) pathogenesis_8\NN\13533470|in|the|aminonucleoside (r_nmod) implicated_5\VBN\2677097|species|have|been|pathogenesis|(pan)-induced|nephropathy|,|reducing|. (l_advcl) reducing_19\VBG\441445|antioxidants|significantly|proteinuria (l_dobj) proteinuria_21\NN\14299637|the
D011692_D011507 CID (pan)-induced_13\VBN\1740| (r_punct) implicated_5\VBN\2677097|species|have|been|pathogenesis|(pan)-induced|nephropathy|,|reducing|. (l_advcl) reducing_19\VBG\441445|antioxidants|significantly|proteinuria (l_dobj) proteinuria_21\NN\14299637|the
D011692_D011507 CID pan_14\NN\3101986| (r_compound) nephropathy_15\NN\14573196|in|pan (r_nmod) mediating_9\VBG\761713|in|injury|nephropathy (l_dobj) injury_12\NN\14052046|the|proteinuric
16740173
6666578
D010396_D001018 CID d-penicillamine-induced_0\JJ\1740| (r_amod) angiopathy_1\NN\14204950|d-penicillamine-induced|rats|.
9249847
D014700_D013611 CID verapamil_7\NN\2938514|and|catheter (r_compound) ablation_10\NN\671351|after|verapamil|patient (r_nmod) tachycardia_5\NN\14110674|induced|intractable|atrioventricular|reentrant|ablation|.
D014700_D013611 CID verapamil_10\NN\2938514|after|or|antegrade (r_compound) block_14\NN\21939|verapamil|pathway (r_nmod) beats_8\VBZ\1108148|by|junctional|escape|block (r_nmod) caused_4\VBN\1617192|beats|ablation (l_nmod) ablation_20\NN\671351|after|catheter|,|attack (l_conj) attack_25\NN\955060|established|frequent|avrt (l_compound) avrt_24\NN\1740|
D014700_D014927 NONE verapamil_7\NN\2938514|and|catheter (r_compound) ablation_10\NN\671351|after|verapamil|patient (l_nmod) patient_13\NN\9898892|in|a|syndrome (l_nmod) syndrome_16\NN\5870365|with|wolff-parkinson-white|and|dilated|cardiomyopathy
D014700_D002311 NONE verapamil_7\NN\2938514|and|catheter (r_compound) ablation_10\NN\671351|after|verapamil|patient (l_nmod) patient_13\NN\9898892|in|a|syndrome (l_nmod) syndrome_16\NN\5870365|with|wolff-parkinson-white|and|dilated|cardiomyopathy (l_amod) cardiomyopathy_20\JJ\1740|
3107448
D005905_D056486 CID glyburide-induced_0\JJ\1740| (r_amod) hepatitis_1\NN\14127211|glyburide-induced|.
D005905_D056486 CID glyburide_1\VB\1740|for|,|sulfonylurea (r_nmod) reports_10\NNS\6470073|glyburide|,|two|brief|exist|. (l_nmod) exist_13\NN\1740|of|hepatotoxicity (l_compound) hepatotoxicity_12\NN\1740|
D005905_D056486 CID glyburide_16\NN\2719105| (r_compound) therapy_17\NN\657604|of|glyburide (r_nmod) initiation_14\NN\7450842|after|therapy (r_nmod) developed_7\VBD\1753788|patients|syndrome|soon|initiation|. (l_dobj) syndrome_11\NN\5870365|an|acute|hepatitis-like
D005905_D056486 CID glyburide_0\NNP\2719105| (r_nsubj) produce_2\VB\1617192|glyburide|can|illness|persons|. (l_dobj) illness_6\NN\14052046|an|hepatitis-like
D013453_D056486 NONE sulfonylureas_12\NNS\2719105|with (r_nmod) reported_8\VBN\831651|although|,|has|been|infrequently|sulfonylureas (r_advcl) hepatotoxicity_1\NN\1740|drug-induced|,|reported|.
D013453_D056486 NONE sulfonylurea_5\NN\2719105|second-generation (r_conj) glyburide_1\VB\1740|for|,|sulfonylurea (r_nmod) reports_10\NNS\6470073|glyburide|,|two|brief|exist|. (l_nmod) exist_13\NN\1740|of|hepatotoxicity (l_compound) hepatotoxicity_12\NN\1740|
D005905_D003924 NONE glyburide_16\NN\2719105| (r_compound) therapy_17\NN\657604|of|glyburide (r_nmod) initiation_14\NN\7450842|after|therapy (r_nmod) developed_7\VBD\1753788|patients|syndrome|soon|initiation|. (l_nsubj) patients_1\NNS\9898892|two|mellitus (l_nmod) mellitus_6\NN\1740|with|type|ii|diabetes
6387529
D003975_D016584 NONE diazepam_3\NN\2830852|of|and|propranolol|patients (l_nmod) patients_7\NNS\9898892|in|disorder (l_nmod) disorder_10\NN\14034177|with|panic|and|agoraphobia
D003975_D016584 NONE diazepam_6\NN\2830852|of (r_nmod) doses_4\NNS\3740161|of|oral|diazepam (r_nmod) effects_1\NNS\13245626|the|doses|dose|and|propranolol|performance (l_nmod) performance_45\NN\6619065|on|psychological|patients (l_nmod) patients_47\NNS\9898892|of|disorders (l_nmod) disorders_50\NNS\14034177|with|panic|and|agoraphobia
D003975_D000379 NONE diazepam_3\NN\2830852|of|and|propranolol|patients (l_nmod) patients_7\NNS\9898892|in|disorder (l_nmod) disorder_10\NN\14034177|with|panic|and|agoraphobia (l_conj) agoraphobia_12\NN\14381416|
D003975_D000379 NONE diazepam_6\NN\2830852|of (r_nmod) doses_4\NNS\3740161|of|oral|diazepam (r_nmod) effects_1\NNS\13245626|the|doses|dose|and|propranolol|performance (l_nmod) performance_45\NN\6619065|on|psychological|patients (l_nmod) patients_47\NNS\9898892|of|disorders (l_nmod) disorders_50\NNS\14034177|with|panic|and|agoraphobia (l_conj) agoraphobia_52\NN\14381416|
D011433_D016584 NONE propranolol_5\NN\1740| (r_conj) diazepam_3\NN\2830852|of|and|propranolol|patients (l_nmod) patients_7\NNS\9898892|in|disorder (l_nmod) disorder_10\NN\14034177|with|panic|and|agoraphobia
D011433_D016584 NONE propranolol_25\NN\1740|dose (r_conj) effects_1\NNS\13245626|the|doses|dose|and|propranolol|performance (l_nmod) performance_45\NN\6619065|on|psychological|patients (l_nmod) patients_47\NNS\9898892|of|disorders (l_nmod) disorders_50\NNS\14034177|with|panic|and|agoraphobia
D011433_D000379 NONE propranolol_5\NN\1740| (r_conj) diazepam_3\NN\2830852|of|and|propranolol|patients (l_nmod) patients_7\NNS\9898892|in|disorder (l_nmod) disorder_10\NN\14034177|with|panic|and|agoraphobia (l_conj) agoraphobia_12\NN\14381416|
D011433_D000379 NONE propranolol_25\NN\1740|dose (r_conj) effects_1\NNS\13245626|the|doses|dose|and|propranolol|performance (l_nmod) performance_45\NN\6619065|on|psychological|patients (l_nmod) patients_47\NNS\9898892|of|disorders (l_nmod) disorders_50\NNS\14034177|with|panic|and|agoraphobia (l_conj) agoraphobia_52\NN\14381416|
D003975_D008569 CID diazepam_12\NN\2830852|for|propranolol (r_nmod) greater_10\JJR\1740|decrease|was|diazepam|. (r_conj) impaired_2\VBD\258857|drugs|recall|but|greater (l_dobj) recall_5\NN\7185325|immediate|free
D011433_D008569 CID propranolol_14\NN\1740|than (r_nmod) diazepam_12\NN\2830852|for|propranolol (r_nmod) greater_10\JJR\1740|decrease|was|diazepam|. (r_conj) impaired_2\VBD\258857|drugs|recall|but|greater (l_dobj) recall_5\NN\7185325|immediate|free
18083142
D009638_D001008 NONE norepinephrine_0\NN\14807929| (r_compound) signaling_1\NN\33020|norepinephrine|receptors (r_nsubj) critical_6\JJ\1740|signaling|is|expression|. (l_nmod) expression_8\NN\4679549|for|anxiety (l_nmod) anxiety_11\NN\14373582|of|cocaine-induced
D009638_D001008 NONE norepinephrine_22\NN\14807929|ne (r_dobj) lack_21\VBP\1740|which|norepinephrine (r_acl:relcl) mice_18\NNS\2329401|,|lack (r_nmod) performance_9\NN\6619065|the|knockout|mice (r_dobj) evaluated_7\VBD\670261|study|,|we|performance|, (r_appos) methods_0\NNS\5616786|:|evaluated|maze|examine|. (l_advcl) examine_36\VB\789138|to|contribution (l_dobj) contribution_38\NN\786195|the|signaling|anxiety (l_nmod) anxiety_44\NN\14373582|to|cocaine-induced
D009638_D001008 NONE ne_24\NN\14622893|(|) (r_appos) norepinephrine_22\NN\14807929|ne (r_dobj) lack_21\VBP\1740|which|norepinephrine (r_acl:relcl) mice_18\NNS\2329401|,|lack (r_nmod) performance_9\NN\6619065|the|knockout|mice (r_dobj) evaluated_7\VBD\670261|study|,|we|performance|, (r_appos) methods_0\NNS\5616786|:|evaluated|maze|examine|. (l_advcl) examine_36\VB\789138|to|contribution (l_dobj) contribution_38\NN\786195|the|signaling|anxiety (l_nmod) anxiety_44\NN\14373582|to|cocaine-induced
D003042_D001008 CID cocaine-induced_10\JJ\1740| (r_amod) anxiety_11\NN\14373582|of|cocaine-induced
D003042_D001008 CID cocaine_4\NN\3492717|'s (r_nmod:poss) effects_7\NNS\13245626|cocaine|rewarding (r_dobj) underlying_3\VBG\2604760|effects (r_acl) mechanisms_2\NNS\13446390|the|underlying (r_nsubjpass) studied_10\VBN\630380|while|mechanisms|have|been|extensively (r_advcl) paid_17\VBN\2199590|studied|,|attention|has|been|states|. (l_nmod) states_22\NNS\8491826|to|the|unpleasant|behavioral|induced (l_acl) induced_23\VBN\1627355|cocaine (l_nmod) cocaine_25\NN\3492717|by|,|anxiety (l_nmod) anxiety_29\NN\14373582|such
D003042_D001008 CID cocaine_25\NN\3492717|by|,|anxiety (l_nmod) anxiety_29\NN\14373582|such
D003042_D001008 CID cocaine-induced_43\JJ\1740| (r_amod) anxiety_44\NN\14373582|to|cocaine-induced
D003042_D001008 CID cocaine_5\NN\3492717| (r_nsubj) increased_7\VBD\169651|that|cocaine|dose-dependently|behavior|mice|,|measured (l_dobj) behavior_9\NN\407535|anxiety-like|control (l_amod) anxiety-like_8\JJ\1740|
D003042_D001008 CID cocaine-induced_0\JJ\1740| (r_amod) anxiety_1\NN\14373582|cocaine-induced
D003042_D001008 CID cocaine-induced_18\JJ\1740| (r_amod) behavior_20\NN\407535|cocaine-induced|anxiety-like (l_amod) anxiety-like_19\JJ\1740|
D003042_D001008 CID cocaine-induced_14\JJ\1740| (r_amod) anxiety_15\NN\14373582|for|cocaine-induced|mice
D004298_D001008 NONE dopamine_11\NN\14807737| (r_compound) knockout_13\NN\10787470|of|dopamine|beta-hydroxylase|-/- (r_nmod) performance_9\NN\6619065|the|knockout|mice (r_dobj) evaluated_7\VBD\670261|study|,|we|performance|, (r_appos) methods_0\NNS\5616786|:|evaluated|maze|examine|. (l_advcl) examine_36\VB\789138|to|contribution (l_dobj) contribution_38\NN\786195|the|signaling|anxiety (l_nmod) anxiety_44\NN\14373582|to|cocaine-induced
D004298_D001008 NONE dopamine_15\NN\14807737| (r_compound) beta-hydroxylase_16\NN\1740|dopamine|dbh (r_compound) inhibitor_20\NN\20090|a|beta-hydroxylase|) (r_appos) disulfiram_12\NN\3740161|of|,|inhibitor (r_nmod) administration_10\NN\1133281|following|disulfiram (r_nmod) attenuated_4\VBN\224901|anxiety|was|also|dbh|administration|. (l_nsubjpass) anxiety_1\NN\14373582|cocaine-induced
D004221_D001008 NONE disulfiram_12\NN\3740161|of|,|inhibitor (r_nmod) administration_10\NN\1133281|following|disulfiram (r_nmod) attenuated_4\VBN\224901|anxiety|was|also|dbh|administration|. (l_nsubjpass) anxiety_1\NN\14373582|cocaine-induced
D011433_D001008 NONE propranolol_16\NN\1740|with|the|beta-adrenergic|receptor|antagonist (r_nmod) pretreatment_10\NN\1740|propranolol (r_nsubj) blocked_17\VBD\1476483|that|pretreatment|behavior|dbh|,|prazosin|had (l_dobj) behavior_20\NN\407535|cocaine-induced|anxiety-like (l_amod) anxiety-like_19\JJ\1740|
D011224_D001008 NONE prazosin_34\NN\2698769|while|alpha(1|antagonist|and|alpha(2|)|yohimbine (r_advcl) blocked_17\VBD\1476483|that|pretreatment|behavior|dbh|,|prazosin|had (l_dobj) behavior_20\NN\407535|cocaine-induced|anxiety-like (l_amod) anxiety-like_19\JJ\1740|
D015016_D001008 NONE yohimbine_40\NN\1740|antagonist (r_conj) prazosin_34\NN\2698769|while|alpha(1|antagonist|and|alpha(2|)|yohimbine (r_advcl) blocked_17\VBD\1476483|that|pretreatment|behavior|dbh|,|prazosin|had (l_dobj) behavior_20\NN\407535|cocaine-induced|anxiety-like (l_amod) anxiety-like_19\JJ\1740|
3173180
D008795_D006463 CID metronidazole_5\NN\2723292|with (r_nmod) treatment_3\NN\654885|after|metronidazole (r_nmod) syndrome_1\NN\5870365|haemolytic-uraemic|treatment|.
D008795_D006463 CID metronidazole_17\NN\2723292|with (r_nmod) treatment_15\NN\654885|after|metronidazole (r_nmod) developed_10\VBD\1753788|who|syndrome|treatment (l_dobj) syndrome_13\NN\5870365|the|haemolytic-uraemic
D008795_D006463 CID metronidazole_4\NN\2723292|of (r_nmod) involvement_2\NN\1080366|the|metronidazole|aetiology (l_nmod) aetiology_7\NN\7326557|in|the|syndrome (l_nmod) syndrome_11\NN\5870365|of|the|haemolytic-uraemic
D008795_D006463 CID metronidazole_4\NN\2723292|of (r_nmod) involvement_2\NN\1080366|the|metronidazole|aetiology (r_nsubjpass) established_14\VBN\2426171|while|involvement|is|not|firmly (r_advcl) suggest_39\VBP\1010118|established|,|action|link|. (l_nsubj) action_18\NN\30358|the|drug|sensitizing|and|evidence (l_conj) evidence_31\NN\5816287|the|reported|changes (l_nmod) changes_34\NNS\7283608|of|oxidation|syndrome (l_nmod) syndrome_38\NN\5870365|in|the|haemolytic-uraemic
D008795_D006463 CID metronidazole_4\NN\2723292|of (r_nmod) involvement_2\NN\1080366|the|metronidazole|aetiology (r_nsubjpass) established_14\VBN\2426171|while|involvement|is|not|firmly (r_advcl) suggest_39\VBP\1010118|established|,|action|link|. (l_dobj) link_42\NN\13792579|a|possible|treatment (l_nmod) treatment_45\NN\654885|between|metronidazole|and|cases (l_conj) cases_48\NNS\7283608|some|syndrome (l_nmod) syndrome_52\NN\5870365|of|the|haemolytic-uraemic
D008795_D006463 CID metronidazole_44\NN\2723292| (r_compound) treatment_45\NN\654885|between|metronidazole|and|cases (r_nmod) link_42\NN\13792579|a|possible|treatment (r_dobj) suggest_39\VBP\1010118|established|,|action|link|. (l_advcl) established_14\VBN\2426171|while|involvement|is|not|firmly (l_nsubjpass) involvement_2\NN\1080366|the|metronidazole|aetiology (l_nmod) aetiology_7\NN\7326557|in|the|syndrome (l_nmod) syndrome_11\NN\5870365|of|the|haemolytic-uraemic
D008795_D006463 CID metronidazole_44\NN\2723292| (r_compound) treatment_45\NN\654885|between|metronidazole|and|cases (r_nmod) link_42\NN\13792579|a|possible|treatment (r_dobj) suggest_39\VBP\1010118|established|,|action|link|. (l_nsubj) action_18\NN\30358|the|drug|sensitizing|and|evidence (l_conj) evidence_31\NN\5816287|the|reported|changes (l_nmod) changes_34\NNS\7283608|of|oxidation|syndrome (l_nmod) syndrome_38\NN\5870365|in|the|haemolytic-uraemic
D008795_D006463 CID metronidazole_44\NN\2723292| (r_compound) treatment_45\NN\654885|between|metronidazole|and|cases (l_conj) cases_48\NNS\7283608|some|syndrome (l_nmod) syndrome_52\NN\5870365|of|the|haemolytic-uraemic
2578334
D001374_D011230 CID 5-azacytidine_0\NN\1740| (r_nsubj) potentiates_1\VBZ\229605|5-azacytidine|initiation|. (l_dobj) initiation_2\NN\7450842|induced (l_acl) induced_3\VBN\1627355|carcinogens (l_nmod) carcinogens_5\NNS\20090|by|liver
D001374_D011230 CID 5-azacytidine_22\NN\1740|5-azc|mg/kg (r_conj) process_20\NN\407535|of|carcinogenic|,|5-azacytidine|,|inhibitor
D001374_D011230 CID 5-azc_24\NN\1740|(|) (r_appos) 5-azacytidine_22\NN\1740|5-azc|mg/kg (r_conj) process_20\NN\407535|of|carcinogenic|,|5-azacytidine|,|inhibitor
D001564_D011230 CID benzo[a]-pyrene_53\NN\1740|mg/kg (r_appos) carcinogens_51\NNS\20090|by|the|three|,|benzo[a]-pyrene|,|n-methyl-n-nitrosourea|and|1,2-dimethylhydrazine (r_nmod) induced_47\VBN\1627355|carcinogens (r_acl) synthesis_46\NN\13446390|of|repair|induced (r_nmod) phase_43\NN\15113229|during|the|synthesis (r_nmod) rats_40\NNS\2329401|to|phase (r_nmod) given_38\VBN\2327200|test|was|rats|. (l_advcl) test_1\VB\670261|to|validity|, (l_dobj) validity_3\NN\4782878|the|hypothesis (l_nmod) hypothesis_6\NN\7162194|of|the|plays (l_ccomp) plays_11\VBZ\1072262|that|hypomethylation|role|initiation (l_nmod) initiation_17\NN\7450842|in|the|process (l_nmod) process_20\NN\407535|of|carcinogenic|,|5-azacytidine|,|inhibitor
D008770_D011230 CID n-methyl-n-nitrosourea_59\NN\1740|mg/kg (r_conj) carcinogens_51\NNS\20090|by|the|three|,|benzo[a]-pyrene|,|n-methyl-n-nitrosourea|and|1,2-dimethylhydrazine (r_nmod) induced_47\VBN\1627355|carcinogens (r_acl) synthesis_46\NN\13446390|of|repair|induced (r_nmod) phase_43\NN\15113229|during|the|synthesis (r_nmod) rats_40\NNS\2329401|to|phase (r_nmod) given_38\VBN\2327200|test|was|rats|. (l_advcl) test_1\VB\670261|to|validity|, (l_dobj) validity_3\NN\4782878|the|hypothesis (l_nmod) hypothesis_6\NN\7162194|of|the|plays (l_ccomp) plays_11\VBZ\1072262|that|hypomethylation|role|initiation (l_nmod) initiation_17\NN\7450842|in|the|process (l_nmod) process_20\NN\407535|of|carcinogenic|,|5-azacytidine|,|inhibitor
D019813_D011230 CID 1,2-dimethylhydrazine_65\NN\1740|1,2-dmh|mg/kg (r_conj) carcinogens_51\NNS\20090|by|the|three|,|benzo[a]-pyrene|,|n-methyl-n-nitrosourea|and|1,2-dimethylhydrazine (r_nmod) induced_47\VBN\1627355|carcinogens (r_acl) synthesis_46\NN\13446390|of|repair|induced (r_nmod) phase_43\NN\15113229|during|the|synthesis (r_nmod) rats_40\NNS\2329401|to|phase (r_nmod) given_38\VBN\2327200|test|was|rats|. (l_advcl) test_1\VB\670261|to|validity|, (l_dobj) validity_3\NN\4782878|the|hypothesis (l_nmod) hypothesis_6\NN\7162194|of|the|plays (l_ccomp) plays_11\VBZ\1072262|that|hypomethylation|role|initiation (l_nmod) initiation_17\NN\7450842|in|the|process (l_nmod) process_20\NN\407535|of|carcinogenic|,|5-azacytidine|,|inhibitor
D019813_D011230 CID 1,2-dmh_67\CD\1740|(|) (r_appos) 1,2-dimethylhydrazine_65\NN\1740|1,2-dmh|mg/kg (r_conj) carcinogens_51\NNS\20090|by|the|three|,|benzo[a]-pyrene|,|n-methyl-n-nitrosourea|and|1,2-dimethylhydrazine (r_nmod) induced_47\VBN\1627355|carcinogens (r_acl) synthesis_46\NN\13446390|of|repair|induced (r_nmod) phase_43\NN\15113229|during|the|synthesis (r_nmod) rats_40\NNS\2329401|to|phase (r_nmod) given_38\VBN\2327200|test|was|rats|. (l_advcl) test_1\VB\670261|to|validity|, (l_dobj) validity_3\NN\4782878|the|hypothesis (l_nmod) hypothesis_6\NN\7162194|of|the|plays (l_ccomp) plays_11\VBZ\1072262|that|hypomethylation|role|initiation (l_nmod) initiation_17\NN\7450842|in|the|process (l_nmod) process_20\NN\407535|of|carcinogenic|,|5-azacytidine|,|inhibitor
8669433
D000082_D007676 NONE acetaminophen_3\NN\2707683|of (r_nmod) use_1\NN\407535|habitual|acetaminophen|factor|:|comparison|. (l_nmod) factor_7\NN\7326557|as|a|risk|failure (l_nmod) failure_11\NN\66216|for|chronic|renal
D000082_D007676 NONE acetaminophen_27\NN\2707683|of (r_nmod) use_25\NN\407535|habitual|acetaminophen (r_nsubjpass) associated_30\VBN\628491|that|use|is|also|failure|,|risk (l_nmod) failure_34\NN\66216|with|chronic|renal|and|esrd
D000082_D007676 NONE acetaminophen_27\NN\2707683|of (r_nmod) use_25\NN\407535|habitual|acetaminophen (r_nsubjpass) associated_30\VBN\628491|that|use|is|also|failure|,|risk (l_nmod) failure_34\NN\66216|with|chronic|renal|and|esrd (l_conj) esrd_36\NN\1740|
D000082_D007676 NONE acetaminophen_7\NN\2707683| (r_conj) phenacetin_5\NN\2707683|both|and|acetaminophen (r_nsubj) contribute_9\VB\126264|that|phenacetin|may|burden|,|risk|less (l_nmod) burden_12\NN\5832264|to|the|esrd (l_nmod) esrd_14\NN\1740|of
D000082_D007676 NONE acetaminophen_6\NN\2707683|of (r_nmod) use_4\NN\407535|habitual|acetaminophen|alone (r_nsubj) increases_8\VBZ\169651|that|use|risk (l_dobj) risk_10\NN\14541044|the|esrd (l_nmod) esrd_12\NN\1740|of
D010615_D007676 CID phenacetin_16\NN\2707683|with (r_nmod) comparison_14\NN\635850|a|phenacetin (r_dep) use_1\NN\407535|habitual|acetaminophen|factor|:|comparison|. (l_nmod) factor_7\NN\7326557|as|a|risk|failure (l_nmod) failure_11\NN\66216|for|chronic|renal
D010615_D007676 CID phenacetin_14\NN\2707683|of (r_nmod) use_12\NN\407535|habitual|phenacetin (r_nsubjpass) associated_16\VBN\628491|that|use|is|development|,|risk (l_nmod) development_19\NN\248977|with|the|failure (l_nmod) failure_23\NN\66216|of|chronic|renal|and|disease
D010615_D007676 CID phenacetin_14\NN\2707683|of (r_nmod) use_12\NN\407535|habitual|phenacetin (r_nsubjpass) associated_16\VBN\628491|that|use|is|development|,|risk (l_nmod) development_19\NN\248977|with|the|failure (l_nmod) failure_23\NN\66216|of|chronic|renal|and|disease (l_conj) disease_27\NN\14061805|end-stage|renal|esrd
D010615_D007676 CID phenacetin_14\NN\2707683|of (r_nmod) use_12\NN\407535|habitual|phenacetin (r_nsubjpass) associated_16\VBN\628491|that|use|is|development|,|risk (l_nmod) development_19\NN\248977|with|the|failure (l_nmod) failure_23\NN\66216|of|chronic|renal|and|disease (l_conj) disease_27\NN\14061805|end-stage|renal|esrd (l_appos) esrd_29\NN\1740|(|)
D010615_D007676 CID phenacetin_5\NN\2707683|both|and|acetaminophen (r_nsubj) contribute_9\VB\126264|that|phenacetin|may|burden|,|risk|less (l_nmod) burden_12\NN\5832264|to|the|esrd (l_nmod) esrd_14\NN\1740|of
8741744
D009538_D009069 NONE nicotine_25\NN\14712692|by|kg(-1 (r_nmod) caused_23\VBN\1617192|nicotine (r_acl) hypoactivity_22\NN\1740|early|min|)|free-field|locomotor|caused
D009538_D009069 NONE nicotine-induced_44\JJ\1740| (r_amod) hyperactivity_45\NN\14052403|the|nicotine-induced (r_dobj) enhanced_35\VBD\227165|hyperactivity|,|and|raised (r_conj) blunted_12\VBD\224901|controls|,|lesions|hypoactivity|,|i.m.|,|enhanced|. (l_dobj) hypoactivity_22\NN\1740|early|min|)|free-field|locomotor|caused
D009538_D006948 CID nicotine_25\NN\14712692|by|kg(-1 (r_nmod) caused_23\VBN\1617192|nicotine (r_acl) hypoactivity_22\NN\1740|early|min|)|free-field|locomotor|caused (r_dobj) blunted_12\VBD\224901|controls|,|lesions|hypoactivity|,|i.m.|,|enhanced|. (l_conj) enhanced_35\VBD\227165|hyperactivity|,|and|raised (l_dobj) hyperactivity_45\NN\14052403|the|nicotine-induced
D009538_D006948 CID nicotine-induced_44\JJ\1740| (r_amod) hyperactivity_45\NN\14052403|the|nicotine-induced
2894766
D012460_D008180 CID sulfasalazine-induced_0\JJ\1740| (r_amod) erythematosus_2\NN\1740|sulfasalazine-induced|lupus|.
D012460_D008180 CID sulfasalazine-induced_7\JJ\1740| (r_amod) lupus_8\NN\14219661|sulfasalazine-induced
D012460_D008180 CID sulfasalazine_3\NN\1740| (r_dobj) use_2\VBP\1156834|who|sulfasalazine|treat (r_acl:relcl) physicians_0\NNS\10305802|use (r_nsubj) aware_13\JJ\1740|physicians|should|be|signs|. (l_nmod) signs_16\NNS\6643763|of|the|syndrome (l_nmod) syndrome_20\NN\5870365|of|sulfasalazine-induced|lupus
D012460_D008180 CID sulfasalazine-induced_18\JJ\1740| (r_amod) syndrome_20\NN\5870365|of|sulfasalazine-induced|lupus
D012460_D011014 CID sulfasalazine_25\NN\1740| (r_compound) therapy_26\NN\657604|long-term|sulfasalazine|colitis (r_dobj) receiving_23\VBG\2210855|who|was|therapy (r_acl:relcl) man_19\NN\9605289|in|a|43-year-old|,|receiving (r_nmod) developed_15\VBD\1753788|pneumonitis|man|. (l_nsubj) pneumonitis_0\NN\14336539|,|effusions|,|evidence|,|and|autoantibodies
D012460_D010996 CID sulfasalazine_25\NN\1740| (r_compound) therapy_26\NN\657604|long-term|sulfasalazine|colitis (r_dobj) receiving_23\VBG\2210855|who|was|therapy (r_acl:relcl) man_19\NN\9605289|in|a|43-year-old|,|receiving (r_nmod) developed_15\VBD\1753788|pneumonitis|man|. (l_nsubj) pneumonitis_0\NN\14336539|,|effusions|,|evidence|,|and|autoantibodies (l_appos) effusions_4\NNS\6880249|bilateral|pleural
D012460_D002305 CID sulfasalazine_25\NN\1740| (r_compound) therapy_26\NN\657604|long-term|sulfasalazine|colitis (r_dobj) receiving_23\VBG\2210855|who|was|therapy (r_acl:relcl) man_19\NN\9605289|in|a|43-year-old|,|receiving (r_nmod) developed_15\VBD\1753788|pneumonitis|man|. (l_nsubj) pneumonitis_0\NN\14336539|,|effusions|,|evidence|,|and|autoantibodies (l_appos) evidence_7\NN\5816287|echocardiographic|tamponade (l_nmod) tamponade_10\NN\14507951|of|cardiac
D012460_D003093 NONE sulfasalazine_25\NN\1740| (r_compound) therapy_26\NN\657604|long-term|sulfasalazine|colitis (l_nmod) colitis_30\NN\14336539|for|chronic|ulcerative
D012460_D012700 NONE sulfasalazine-induced_7\JJ\1740| (r_amod) lupus_8\NN\14219661|sulfasalazine-induced (r_dobj) had_6\VBD\2108377|that|patient|lupus|,|manifested (l_advcl) manifested_11\VBD\1015244|which|serositis|absence (l_nmod) serositis_13\NN\1740|with|and|pulmonary|involvement
D012460_D015212 NONE sulfasalazine_3\NN\1740| (r_dobj) use_2\VBP\1156834|who|sulfasalazine|treat (l_xcomp) treat_5\VB\2376958|to|patients (l_dobj) patients_6\NNS\9898892|disease (l_nmod) disease_10\NN\14061805|with|inflammatory|bowel
D012460_D015212 NONE sulfasalazine-induced_18\JJ\1740| (r_amod) syndrome_20\NN\5870365|of|sulfasalazine-induced|lupus (r_nmod) signs_16\NNS\6643763|of|the|syndrome (r_nmod) aware_13\JJ\1740|physicians|should|be|signs|. (l_nsubj) physicians_0\NNS\10305802|use (l_acl:relcl) use_2\VBP\1156834|who|sulfasalazine|treat (l_xcomp) treat_5\VB\2376958|to|patients (l_dobj) patients_6\NNS\9898892|disease (l_nmod) disease_10\NN\14061805|with|inflammatory|bowel
19729346
D010098_D010146 NONE oxycodone_16\NN\1740|of|immediate-release (r_nmod) dose_13\NN\3740161|of|a|single|10-mg|oxycodone (r_nmod) effects_8\NNS\13245626|dose (r_dep) objective_4\JJ\1740|the|and|subjective|effects (r_dobj) measured_2\VBD\697589|study|objective|pain|. (l_dobj) pain_45\NN\14299637|healthy|chronic
D010098_D059350 NONE oxycodone_28\NN\1740|of|immediate-release (r_nmod) dose_25\NN\3740161|to|a|10-mg|oxycodone (r_nmod) response_21\NN\11410625|in|dose (r_nmod) adults_7\NNS\7846|for|healthy|older|suffering|neurocognitive|response (l_acl:relcl) suffering_11\VBG\2110220|who|are|not|pain|, (l_nmod) pain_14\NN\14299637|from|chronic
14513889
D007654_D009422 NONE ketoconazole-induced_0\JJ\1740| (r_amod) sequelae_2\NN\14501726|ketoconazole-induced|neurologic|.
D007654_D018908 CID ketoconazole_21\NN\1740|of|mg (r_nmod) ingestion_17\NN\13440063|after|ketoconazole|time (r_nmod) developed_3\VBD\1753788|patient|weakness|h|ingestion|. (l_dobj) weakness_4\NN\14462666|extremities (l_nmod) extremities_6\NNS\5225090|of|,|paralysis
D007654_D010243 CID ketoconazole_21\NN\1740|of|mg (r_nmod) ingestion_17\NN\13440063|after|ketoconazole|time (r_nmod) developed_3\VBD\1753788|patient|weakness|h|ingestion|. (l_dobj) weakness_4\NN\14462666|extremities (l_nmod) extremities_6\NNS\5225090|of|,|paralysis (l_conj) paralysis_9\NN\14557898|legs|,|dysarthria
D007654_D004401 CID ketoconazole_21\NN\1740|of|mg (r_nmod) ingestion_17\NN\13440063|after|ketoconazole|time (r_nmod) developed_3\VBD\1753788|patient|weakness|h|ingestion|. (l_dobj) weakness_4\NN\14462666|extremities (l_nmod) extremities_6\NNS\5225090|of|,|paralysis (l_conj) paralysis_9\NN\14557898|legs|,|dysarthria (l_conj) dysarthria_11\NN\14400677|and|tremor
D007654_D014202 CID ketoconazole_21\NN\1740|of|mg (r_nmod) ingestion_17\NN\13440063|after|ketoconazole|time (r_nmod) developed_3\VBD\1753788|patient|weakness|h|ingestion|. (l_dobj) weakness_4\NN\14462666|extremities (l_nmod) extremities_6\NNS\5225090|of|,|paralysis (l_conj) paralysis_9\NN\14557898|legs|,|dysarthria (l_conj) dysarthria_11\NN\14400677|and|tremor (l_conj) tremor_13\NN\345926|1
20633755
D013390_D001049 CID suxamethonium_0\NNP\1740| (r_nsubj) induced_1\VBD\1627355|suxamethonium|apnea|patient|. (l_dobj) apnea_3\NN\14299637|prolonged
D013390_D001049 CID suxamethonium_0\NNP\1740| (r_nsubj) causes_1\VBZ\1617192|suxamethonium|apnea|. (l_dobj) apnea_3\NN\14299637|prolonged|patients|gets
D009943_D001049 CID poisons_17\NNS\20090| (r_nmod) deactivated_11\VBN\1097743|organophosphorus|poisons (r_xcomp) gets_10\VBZ\146138|whom|enzyme|deactivated (r_acl:relcl) apnea_3\NN\14299637|prolonged|patients|gets
D009943_D001049 CID compound_14\NN\5869584|by|op (r_nmod) attempt_11\NN\407535|about|suicidal|compound (r_nmod) information_8\NN\6598915|the|attempt (r_nsubjpass) concealed_16\VBN\1740|because|information|was|team (r_advcl) ensued_5\VBN\2633881|apnea|concealed|. (l_nsubj) apnea_1\NN\14299637|prolonged|case
8319760
D019808_D009401 NONE 753_1\CD\1740| (r_nummod) dup_0\NN\1740|753 (r_nsubj) prevents_2\VBZ\1740|dup|development|. (l_dobj) development_4\NN\248977|the|nephrosis (l_nmod) nephrosis_8\NN\14304060|of|puromycin|aminonucleoside-induced
D011692_D009401 NONE aminonucleoside-induced_7\JJ\1740| (r_amod) nephrosis_8\NN\14304060|of|puromycin|aminonucleoside-induced
D011692_D009401 NONE aminonucleoside-induced_15\JJ\1740| (r_amod) nephrosis_16\NN\14304060|of|puromycin|aminonucleoside-induced
D001806_D009404 NONE urea_17\NN\14727670|in|blood|nitrogen (r_nmod) increase_13\VB\169651|urea (r_conj) appearance_1\NN\4723816|the|syndromes|,|hypercholesterolemia|and|increase|,|induced (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria
D001806_D011507 NONE urea_17\NN\14727670|in|blood|nitrogen (r_nmod) increase_13\VB\169651|urea (r_conj) appearance_1\NN\4723816|the|syndromes|,|hypercholesterolemia|and|increase|,|induced (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria (l_nmod) proteinuria_7\NN\14299637|such|,|hypoalbuminemia
D001806_D034141 NONE urea_17\NN\14727670|in|blood|nitrogen (r_nmod) increase_13\VB\169651|urea (r_conj) appearance_1\NN\4723816|the|syndromes|,|hypercholesterolemia|and|increase|,|induced (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria (l_nmod) proteinuria_7\NN\14299637|such|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN\1740|
D001806_D006937 NONE urea_17\NN\14727670|in|blood|nitrogen (r_nmod) increase_13\VB\169651|urea (r_conj) appearance_1\NN\4723816|the|syndromes|,|hypercholesterolemia|and|increase|,|induced (l_appos) hypercholesterolemia_11\NN\14299637|
D011692_D009404 CID aminonucleoside_26\NN\1740|of|puromycin (r_nmod) injection_23\NN\320852|by|aminonucleoside (r_nmod) induced_19\VBN\1627355|rats|injection (r_acl) appearance_1\NN\4723816|the|syndromes|,|hypercholesterolemia|and|increase|,|induced (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria
D011692_D011507 CID aminonucleoside_26\NN\1740|of|puromycin (r_nmod) injection_23\NN\320852|by|aminonucleoside (r_nmod) induced_19\VBN\1627355|rats|injection (r_acl) appearance_1\NN\4723816|the|syndromes|,|hypercholesterolemia|and|increase|,|induced (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria (l_nmod) proteinuria_7\NN\14299637|such|,|hypoalbuminemia
D011692_D034141 CID aminonucleoside_26\NN\1740|of|puromycin (r_nmod) injection_23\NN\320852|by|aminonucleoside (r_nmod) induced_19\VBN\1627355|rats|injection (r_acl) appearance_1\NN\4723816|the|syndromes|,|hypercholesterolemia|and|increase|,|induced (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria (l_nmod) proteinuria_7\NN\14299637|such|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN\1740|
D011692_D006937 CID aminonucleoside_26\NN\1740|of|puromycin (r_nmod) injection_23\NN\320852|by|aminonucleoside (r_nmod) induced_19\VBN\1627355|rats|injection (r_acl) appearance_1\NN\4723816|the|syndromes|,|hypercholesterolemia|and|increase|,|induced (l_appos) hypercholesterolemia_11\NN\14299637|
D019808_D009404 NONE 753_35\CD\1740| (r_nummod) dup_34\NN\1740|of|753|losartan|, (r_nmod) administration_32\NN\1133281|by|oral|dup|antagonist (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|,|dose|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes|,|hypercholesterolemia|and|increase|,|induced (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria
D019808_D009404 NONE losartan_37\NN\1740|(|) (r_appos) dup_34\NN\1740|of|753|losartan|, (r_nmod) administration_32\NN\1133281|by|oral|dup|antagonist (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|,|dose|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes|,|hypercholesterolemia|and|increase|,|induced (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria
D019808_D011507 NONE 753_35\CD\1740| (r_nummod) dup_34\NN\1740|of|753|losartan|, (r_nmod) administration_32\NN\1133281|by|oral|dup|antagonist (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|,|dose|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes|,|hypercholesterolemia|and|increase|,|induced (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria (l_nmod) proteinuria_7\NN\14299637|such|,|hypoalbuminemia
D019808_D011507 NONE losartan_37\NN\1740|(|) (r_appos) dup_34\NN\1740|of|753|losartan|, (r_nmod) administration_32\NN\1133281|by|oral|dup|antagonist (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|,|dose|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes|,|hypercholesterolemia|and|increase|,|induced (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria (l_nmod) proteinuria_7\NN\14299637|such|,|hypoalbuminemia
D019808_D034141 NONE 753_35\CD\1740| (r_nummod) dup_34\NN\1740|of|753|losartan|, (r_nmod) administration_32\NN\1133281|by|oral|dup|antagonist (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|,|dose|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes|,|hypercholesterolemia|and|increase|,|induced (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria (l_nmod) proteinuria_7\NN\14299637|such|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN\1740|
D019808_D034141 NONE losartan_37\NN\1740|(|) (r_appos) dup_34\NN\1740|of|753|losartan|, (r_nmod) administration_32\NN\1133281|by|oral|dup|antagonist (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|,|dose|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes|,|hypercholesterolemia|and|increase|,|induced (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria (l_nmod) proteinuria_7\NN\14299637|such|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN\1740|
D019808_D006937 NONE 753_35\CD\1740| (r_nummod) dup_34\NN\1740|of|753|losartan|, (r_nmod) administration_32\NN\1133281|by|oral|dup|antagonist (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|,|dose|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes|,|hypercholesterolemia|and|increase|,|induced (l_appos) hypercholesterolemia_11\NN\14299637|
D019808_D006937 NONE losartan_37\NN\1740|(|) (r_appos) dup_34\NN\1740|of|753|losartan|, (r_nmod) administration_32\NN\1133281|by|oral|dup|antagonist (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|,|dose|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes|,|hypercholesterolemia|and|increase|,|induced (l_appos) hypercholesterolemia_11\NN\14299637|
D000804_D009404 NONE ii_43\CD\13741022| (r_nummod) antagonist_45\NN\7846|a|novel|angiotensin|ii|receptor (r_dep) administration_32\NN\1133281|by|oral|dup|antagonist (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|,|dose|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes|,|hypercholesterolemia|and|increase|,|induced (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria
D000804_D011507 NONE ii_43\CD\13741022| (r_nummod) antagonist_45\NN\7846|a|novel|angiotensin|ii|receptor (r_dep) administration_32\NN\1133281|by|oral|dup|antagonist (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|,|dose|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes|,|hypercholesterolemia|and|increase|,|induced (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria (l_nmod) proteinuria_7\NN\14299637|such|,|hypoalbuminemia
D000804_D034141 NONE ii_43\CD\13741022| (r_nummod) antagonist_45\NN\7846|a|novel|angiotensin|ii|receptor (r_dep) administration_32\NN\1133281|by|oral|dup|antagonist (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|,|dose|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes|,|hypercholesterolemia|and|increase|,|induced (l_nmod) syndromes_4\NNS\5870365|of|nephrotic|proteinuria (l_nmod) proteinuria_7\NN\14299637|such|,|hypoalbuminemia (l_conj) hypoalbuminemia_9\NN\1740|
D000804_D006937 NONE ii_43\CD\13741022| (r_nummod) antagonist_45\NN\7846|a|novel|angiotensin|ii|receptor (r_dep) administration_32\NN\1133281|by|oral|dup|antagonist (r_nmod) inhibited_29\VBN\2510337|appearance|was|markedly|administration|,|dose|. (l_nsubjpass) appearance_1\NN\4723816|the|syndromes|,|hypercholesterolemia|and|increase|,|induced (l_appos) hypercholesterolemia_11\NN\14299637|
D000809_D009401 NONE renin-angiotensin_8\JJ\1740| (r_amod) system_9\NN\3575240|of|the|renin-angiotensin (r_nmod) involvement_5\NN\1080366|a|possible|system|development (l_nmod) development_12\NN\248977|in|the|nephrosis (l_nmod) nephrosis_16\NN\14304060|of|puromycin|aminonucleoside-induced
11147747
D018490_D014549 CID antidepressants_1\NNS\3740161|serotonergic|and|incontinence|. (l_conj) incontinence_4\NN\13473097|urinary
D018490_D014549 CID antidepressants_8\NNS\3740161|to|serotonergic (r_nmod) secondary_5\JJ\1740|antidepressants (r_amod) incontinence_4\NN\13473097|secondary
C047426_D014549 CID venlafaxine_10\NN\1740| (r_dobj) taking_9\VBG\2367363|while|venlafaxine (r_advcl) experienced_6\VBD\2108377|who|incontinence|taking (l_dobj) incontinence_7\NN\13473097|
C047426_D014549 CID venlafaxine_35\NN\1740|on (r_nmod) developed_30\VBD\1753788|who|effect|venlafaxine (r_acl:relcl) third_28\NN\13732295|a|developed (r_conj) describe_6\VBP\1001294|paper|authors|patients|,|as|third|. (l_dobj) patients_9\NNS\9898892|2|female|developed|paroxetine (l_acl:relcl) developed_11\VBD\1753788|who|incontinence (l_dobj) incontinence_12\NN\13473097|secondary
D012701_D014549 NONE serotonin_17\NN\14807737| (r_compound) inhibitors_19\NNS\20090|to|the|selective|serotonin|reuptake (r_nmod) secondary_13\JJ\1740|inhibitors (r_amod) incontinence_12\NN\13473097|secondary
D017374_D014549 CID paroxetine_20\NN\1740|and|sertraline (r_dep) patients_9\NNS\9898892|2|female|developed|paroxetine (l_acl:relcl) developed_11\VBD\1753788|who|incontinence (l_dobj) incontinence_12\NN\13473097|secondary
D020280_D014549 CID sertraline_22\NN\4169152| (r_conj) paroxetine_20\NN\1740|and|sertraline (r_dep) patients_9\NNS\9898892|2|female|developed|paroxetine (l_acl:relcl) developed_11\VBD\1753788|who|incontinence (l_dobj) incontinence_12\NN\13473097|secondary
D016651_D014549 CID carbonate_12\NN\15010703|lithium|and|beta-blockers (r_dobj) taking_10\VBG\2367363|patients|were|also|carbonate|, (r_acl:relcl) cases_5\NNS\7283608|of|the|3|taking (r_nmod) 2_1\CD\13741022|in|cases (r_nmod) contributed_21\VBN\126264|2|both|could|have|incontinence|. (l_nmod) incontinence_24\NN\13473097|to|the
20882060
D009496_D002375 NONE neurotensin_3\NN\1740|of|pallidal (r_nmod) effects_0\NNS\13245626|neurotensin|catalepsy|. (l_nmod) catalepsy_7\NN\14023236|on|haloperidol-induced|parkinsonian|:|studies
D009496_D002375 NONE neurotensin_5\NN\1740|of (r_nmod) infusions_3\NNS\14589223|bilateral|neurotensin|catalepsy (l_nmod) catalepsy_13\NN\14023236|into|the|globus|pallidus|reversed|haloperidol-induced|parkinsonian|rats
D006220_D002375 CID haloperidol-induced_5\JJ\1740| (r_amod) catalepsy_7\NN\14023236|on|haloperidol-induced|parkinsonian|:|studies
D006220_D002375 CID haloperidol-induced_11\JJ\1740| (r_amod) catalepsy_13\NN\14023236|into|the|globus|pallidus|reversed|haloperidol-induced|parkinsonian|rats
D009496_D010302 NONE neurotensin_10\NN\1740|of|pallidal (r_nmod) effects_7\NNS\13245626|the|neurotensin|symptoms (l_nmod) symptoms_14\NNS\5823932|on|haloperidol-induced|parkinsonian
D006220_D010302 NONE haloperidol-induced_12\JJ\1740| (r_amod) symptoms_14\NNS\5823932|on|haloperidol-induced|parkinsonian
3496378
D014217_D002779 CID troleandomycin-induced_3\JJ\1740| (r_amod) hepatitis_5\NN\14127211|after|troleandomycin-induced|acute (r_nmod) cholestasis_1\NN\14052403|prolonged|hepatitis|.
D014217_D002779 CID troleandomycin-induced_9\JJ\1740| (r_amod) hepatitis_10\NN\14127211|troleandomycin-induced (r_nsubjpass) followed_12\VBN\1835496|whom|hepatitis|was|cholestasis (l_nmod) cholestasis_16\NN\14052403|by|prolonged|anicteric
D014217_D002779 CID troleandomycin-induced_8\JJ\1740| (r_amod) hepatitis_10\NN\14127211|troleandomycin-induced|acute (r_dobj) follow_7\VB\1835496|that|cholestasis|can|hepatitis (l_nsubj) cholestasis_5\NN\14052403|prolonged
D014217_D056486 CID troleandomycin-induced_3\JJ\1740| (r_amod) hepatitis_5\NN\14127211|after|troleandomycin-induced|acute
D014217_D056486 CID troleandomycin-induced_9\JJ\1740| (r_amod) hepatitis_10\NN\14127211|troleandomycin-induced
D014217_D056486 CID troleandomycin-induced_8\JJ\1740| (r_amod) hepatitis_10\NN\14127211|troleandomycin-induced|acute
D014217_D007565 CID troleandomycin_5\NN\1740|of (r_nmod) administration_3\NN\1133281|after|troleandomycin (r_nmod) occurred_1\VBD\2623529|jaundice|administration|days|and|associated|. (l_nsubj) jaundice_0\NNP\14299637|
D014217_D004802 CID troleandomycin_5\NN\1740|of (r_nmod) administration_3\NN\1133281|after|troleandomycin (r_nmod) occurred_1\VBD\2623529|jaundice|administration|days|and|associated|. (l_conj) associated_11\VBN\628491|was|hypereosinophilia (l_nmod) hypereosinophilia_13\NN\1740|with
16005948
-1_D062787 NONE gnc92h2_6\NN\1740|of|the|antibody (r_nmod) evaluation_0\NN\874067|gnc92h2|immunotherapy|. (l_nmod) immunotherapy_9\NN\661091|as|an|overdose (l_nmod) overdose_12\NN\1740|for|cocaine
-1_D062787 NONE gnc92h2_7\NN\1740|of|the|anticocaine|antibody (r_nmod) potential_2\NN\14481929|the|therapeutic|gnc92h2 (r_nsubjpass) examined_9\VBN\789138|potential|was|using|. (l_xcomp) using_10\VBG\1156834|model (l_dobj) model_12\NN\5888929|a|overdose (l_nmod) overdose_15\NN\1740|of|cocaine
-1_D062787 NONE gnc92h2_7\NN\1740|of (r_nmod) potential_5\NN\14481929|the|important|gnc92h2 (r_dobj) support_2\VBP\2199590|results|potential|tool|. (l_nmod) tool_11\NN\3563967|as|a|therapeutic|overdose (l_nmod) overdose_14\NN\1740|against|cocaine
D003042_D062787 NONE cocaine_4\NN\3492717|of (r_nmod) use_2\NN\407535|the|illicit|cocaine (r_nsubj) continues_5\VBZ\2367363|use|proportions|remains|. (l_nmod) proportions_8\NNS\13824815|in|epidemic|and|treatment (l_conj) treatment_10\NN\654885|overdose (l_nmod) overdose_13\NN\1740|for|cocaine
D003042_D064420 NONE cocaine_3\NN\3492717| (r_compound) toxicity_4\NN\13576101|of|cocaine
D003042_D012640 CID cocaine_3\NN\3492717| (r_compound) toxicity_4\NN\13576101|of|cocaine (r_nmod) blockade_1\NN\952963|significant|toxicity (r_nsubjpass) observed_6\VBN\2163746|blockade|was|dose|,|seizures|. (l_conj) seizures_28\VBZ\1740|%|%
D003042_D003643 NONE cocaine_3\NN\3492717| (r_compound) toxicity_4\NN\13576101|of|cocaine (r_nmod) blockade_1\NN\952963|significant|toxicity (r_nsubjpass) observed_6\VBN\2163746|blockade|was|dose|,|seizures|. (l_conj) seizures_28\VBZ\1740|%|% (l_dobj) %_32\NN\1740|77|and|death (l_conj) death_34\NN\7296428|
D003042_D003643 NONE post-cocaine_6\JJ\1740| (r_amod) injection_7\NN\320852|even|post-cocaine (r_dobj) prevented_3\VBD\1740|importantly|,|gnc92h2|death|injection|. (l_dobj) death_4\NN\7296428|
-1_D064420 NONE gnc92h2_12\NN\1740|of|mg/kg|,|reduced (r_nmod) dose_10\NN\3740161|with|the|higher|gnc92h2 (r_nmod) observed_6\VBN\2163746|blockade|was|dose|,|seizures|. (l_nsubjpass) blockade_1\NN\952963|significant|toxicity (l_nmod) toxicity_4\NN\13576101|of|cocaine
-1_D012640 NONE gnc92h2_12\NN\1740|of|mg/kg|,|reduced (r_nmod) dose_10\NN\3740161|with|the|higher|gnc92h2 (r_nmod) observed_6\VBN\2163746|blockade|was|dose|,|seizures|. (l_conj) seizures_28\VBZ\1740|%|%
-1_D003643 NONE gnc92h2_12\NN\1740|of|mg/kg|,|reduced (r_nmod) dose_10\NN\3740161|with|the|higher|gnc92h2 (r_nmod) observed_6\VBN\2163746|blockade|was|dose|,|seizures|. (l_conj) seizures_28\VBZ\1740|%|% (l_dobj) %_32\NN\1740|77|and|death (l_conj) death_34\NN\7296428|
-1_D003643 NONE gnc92h2_2\NNP\1740| (r_nsubj) prevented_3\VBD\1740|importantly|,|gnc92h2|death|injection|. (l_dobj) death_4\NN\7296428|
11897407
C067171_D009203 NONE 99mtc-glucarate_0\NN\1740|detection|. (l_nmod) detection_2\NN\5708432|for|infarction (l_nmod) infarction_6\NN\14204950|of|isoproterenol-induced|myocardial|rats
C067171_D009203 NONE 99mtc-glucarate_0\NN\1740| (r_nsubj) easy_2\JJ\1740|99mtc-glucarate|was|prepare|and|used|. (l_conj) used_12\VBN\1156834|was|study (l_xcomp) study_14\VB\630380|to|biodistribution (l_dobj) biodistribution_16\NN\1740|its|rats (l_nmod) rats_18\NNS\2329401|in|infarction (l_nmod) infarction_23\NN\14204950|with|isoproterenol-induced|acute|myocardial
D007545_D009203 CID isoproterenol-induced_4\JJ\1740| (r_amod) infarction_6\NN\14204950|of|isoproterenol-induced|myocardial|rats
D007545_D009203 CID isoproterenol-induced_20\JJ\1740| (r_amod) infarction_23\NN\14204950|with|isoproterenol-induced|acute|myocardial
D007545_D007238 NONE isoproterenol_18\NN\3740161|with (r_nmod) obtained_16\VBN\2210855|induction|can|be|easily|isoproterenol (r_conj) implies_7\VBZ\943837|model|ligation|obtained|. (l_nsubj) model_2\NN\5888929|the|animal|used (l_acl) used_3\VBN\1156834|produce (l_xcomp) produce_5\VB\1617192|to|infarction (l_dobj) infarction_6\NN\14204950|
D007545_D007238 NONE isoproterenol_12\JJ\1740| (r_compound) administration_13\NN\1133281|after|isoproterenol (r_nmod) developed_6\VBD\1753788|that|rats|h|administration (l_dobj) h_10\NN\14622893|an|infarct|18 (l_compound) infarct_8\NN\14204950|
D005937_D007238 NONE acid_7\NN\14818238|on|glucaric (r_nmod) based_4\VBN\2694933|acid (r_acl) radiopharmaceutical_3\JJ\1740|a|new|based (l_amod) new_1\JJ\1740|infarct-avid (l_dep) infarct-avid_2\JJ\1740|
567256
D004054_D006394 CID diethylstilbestrol_6\NN\14749794|with (r_nmod) associated_4\VBN\628491|diethylstilbestrol (r_acl) liver_3\NN\5298729|of|the|associated
D004054_D006394 CID diethylstilbestrol_21\NN\14749794|with|years (r_nmod) adenocarcinoma_16\NN\14242337|for|a|well-differentiated|liver|diethylstilbestrol (r_nmod) treated_12\VBN\2376958|who|had|been|adenocarcinoma (r_acl:relcl) man_8\NN\9605289|in|a|76-year-old|treated (r_nmod) occurred_4\VBD\2623529|angiosarcoma|man|. (l_nsubj) angiosarcoma_0\NN\14239425|liver (l_nmod) liver_3\NN\5298729|of|the
D004054_D008113 CID diethylstilbestrol_6\NN\14749794|with (r_nmod) associated_4\VBN\628491|diethylstilbestrol (r_acl) liver_3\NN\5298729|of|the|associated
D004054_D008113 CID diethylstilbestrol_21\NN\14749794|with|years (r_nmod) adenocarcinoma_16\NN\14242337|for|a|well-differentiated|liver|diethylstilbestrol (r_nmod) treated_12\VBN\2376958|who|had|been|adenocarcinoma (r_acl:relcl) man_8\NN\9605289|in|a|76-year-old|treated (r_nmod) occurred_4\VBD\2623529|angiosarcoma|man|. (l_nsubj) angiosarcoma_0\NN\14239425|liver (l_nmod) liver_3\NN\5298729|of|the
D004054_D008113 NONE diethylstilbestrol_21\NN\14749794|with|years (r_nmod) adenocarcinoma_16\NN\14242337|for|a|well-differentiated|liver|diethylstilbestrol (l_nmod) liver_19\NN\5298729|of|the
D004054_D000230 NONE diethylstilbestrol_21\NN\14749794|with|years (r_nmod) adenocarcinoma_16\NN\14242337|for|a|well-differentiated|liver|diethylstilbestrol (l_nmod) liver_19\NN\5298729|of|the
15515654
D003676_D006311 NONE dfo_6\NNP\1740|than (r_nmod) other_4\JJ\1740|dfo (r_amod) factor_2\NN\7326557|no|ototoxic|,|other|, (l_amod) ototoxic_1\JJ\1740|
D003676_D006319 CID dfo_6\NN\1740| (r_compound) reduction_7\NN\351485|to|dfo|or|withdrawal (r_nmod) submitted_4\VBN\1952898|subjects|were|reduction|. (l_nsubjpass) subjects_0\NNS\6598915|snhl (l_nmod) snhl_2\NN\1740|with
D003676_D034381 NONE dfo_7\NN\1740|'s (r_nmod:poss) role_10\NN\719494|of|dfo|contributing|development (l_nmod) development_13\NN\248977|in|the|impairment (l_nmod) impairment_16\NN\7296428|of|hearing
18162529
D012313_D006966 NONE acid_5\NN\14818238| (r_compound) levels_6\NNS\4916342|hypothalamic|prolactin|receptor|messenger|ribonucleic|acid|,|signaling|,|and|inhibition (l_conj) inhibition_13\NN\1068773|hyperprolactinemic|secretion (l_amod) hyperprolactinemic_12\JJ\1740|
D004958_D006966 NONE estradiol_22\NN\14749794|on (r_nmod) dependent_20\JJ\1740|levels|are|estradiol|. (l_nsubj) levels_6\NNS\4916342|hypothalamic|prolactin|receptor|messenger|ribonucleic|acid|,|signaling|,|and|inhibition (l_conj) inhibition_13\NN\1068773|hyperprolactinemic|secretion (l_amod) hyperprolactinemic_12\JJ\1740|
D004958_D006966 NONE estradiol_30\NN\14749794|of (r_nmod) levels_28\NNS\4916342|of|chronic|low|estradiol (r_nmod) presence_24\NN\13954253|only|in|the|levels (r_conj) caused_8\VBD\1617192|hyperprolactinemia|frequency|,|but|presence|. (l_nsubj) hyperprolactinemia_1\NN\1740|chronic|induced
D004967_D006966 NONE estrogen-induced_20\JJ\1740| (r_amod) lh_21\NN\5410315|the|estrogen-induced (r_conj) secretion_17\NN\13526110|lh|and|lh (r_dobj) pulsatile_15\VB\1740|secretion (r_dep) inhibited_6\VBD\2510337|whether|hyperprolactinemia|parameters|:|pulsatile|surge (l_nsubj) hyperprolactinemia_5\NN\1740|chronic
D004298_D006966 NONE dopamine_5\NN\14807737| (r_compound) sulpiride_7\NN\1740|by|the|dopamine|antagonist (r_nmod) induced_2\VBN\1627355|sulpiride (r_acl) hyperprolactinemia_1\NN\1740|chronic|induced
D013469_D006966 CID sulpiride_7\NN\1740|by|the|dopamine|antagonist (r_nmod) induced_2\VBN\1627355|sulpiride (r_acl) hyperprolactinemia_1\NN\1740|chronic|induced
D013256_D006966 NONE steroid-dependent_14\JJ\1740| (r_amod) manner_15\NN\4916342|in|a|steroid-dependent (r_nmod) inhibited_8\VBN\2510337|that|frequency|is|hyperprolactinemia|manner (l_nmod) hyperprolactinemia_11\NN\1740|by|chronic
11587867
D014750_D001927 NONE vincristin_6\NN\1740| (r_compound) administration_7\NN\1133281|due|to|accidental|intrathecal|vincristin|: (r_nmod) myeloencephalopathy_1\NN\1740|fatal|administration|report|.
D014750_D054198 NONE vincristine_9\NN\3917455| (r_compound) instillation_10\NN\320852|of|accidental|intrathecal|vincristine|girl (l_nmod) girl_15\NN\10787470|in|a|5-year|old|leucemia|and|man (l_nmod) leucemia_20\NN\1740|with|recurrent|acute|lymphoblastic
D014750_D054198 NONE vincristine_9\NN\3917455| (r_compound) instillation_10\NN\320852|of|accidental|intrathecal|vincristine|girl (l_nmod) girl_15\NN\10787470|in|a|5-year|old|leucemia|and|man (l_conj) man_25\NN\9605289|a|57-year|lymphoma (l_nmod) lymphoma_28\NN\14239918|with|lymphoblastic
D014750_D003711 CID vincristine_26\NN\3917455|to (r_nmod) exposed_24\VBN\2110927|vincristine (r_acl) areas_23\NNS\8630985|in|exposed (r_nmod) transformation_21\NN\7296428|pseudocystic|areas (r_conj) degeneration_12\NN\29677|myelin|transformation (l_nmod) myelin_14\NN\14864360|of|and|axons|as (l_conj) axons_16\NNS\5464104|
D014750_D009410 CID vincristine_26\NN\3917455|to (r_nmod) exposed_24\VBN\2110927|vincristine (r_acl) areas_23\NNS\8630985|in|exposed (r_nmod) transformation_21\NN\7296428|pseudocystic|areas (r_conj) degeneration_12\NN\29677|myelin|transformation (l_nmod) myelin_14\NN\14864360|of|and|axons|as (l_conj) axons_16\NNS\5464104|
D014750_-1 NONE vincristine_26\NN\3917455|to (r_nmod) exposed_24\VBN\2110927|vincristine (r_acl) areas_23\NNS\8630985|in|exposed (r_nmod) transformation_21\NN\7296428|pseudocystic|areas
2312209
D007548_D009203 CID dinitrate_7\NN\1740|of|isosorbide (r_nmod) administration_4\NN\1133281|following|sublingual|dinitrate (r_nmod) infarction_1\NN\14204950|myocardial|administration|.
D007548_D009203 CID dinitrate_20\NN\1740|of|isosorbide (r_nmod) administration_17\NN\1133281|following|the|dinitrate (r_nmod) infarction_10\NN\14204950|a|recurrent|myocardial|wall|administration
D007548_D009336 NONE dinitrate_20\NN\1740|of|isosorbide (r_nmod) administration_17\NN\1133281|following|the|dinitrate (r_nmod) infarction_10\NN\14204950|a|recurrent|myocardial|wall|administration (r_dobj) suffered_6\VBD\2110220|78-year-old|infarction|mg|. (l_nsubj) 78-year-old_1\RB\1740|a|necrosis (l_nmod) necrosis_5\NN\11444117|with|healed|septal
6229975
D013999_D009203 NONE timolol_6\NN\2832168| (r_dep) long-term_5\JJ\1740|timolol (r_amod) treatment_7\NN\654885|during|long-term (r_nmod) changes_0\NNS\7283608|size|treatment|infarction|. (l_nmod) infarction_10\NN\14204950|after|myocardial
D013999_D009203 NONE timolol_4\CD\2832168| (r_dep) long-term_3\JJ\1740|timolol (r_amod) treatment_5\NN\654885|of|long-term (r_nmod) effect_1\NN\34213|the|treatment|size|infarction (l_nmod) infarction_11\NN\14204950|after|myocardial
D013999_D009203 NONE timolol_27\NN\2832168|115 (r_conj) placebo_24\NN\3740161|(|126|,|timolol|) (r_dep) patients_22\NNS\9898892|including|241|placebo (r_nmod) study_19\NN\635850|in|a|double-blind|patients (r_nmod) evaluated_13\VBN\670261|effect|was|x-ray|study|. (l_nsubjpass) effect_1\NN\34213|the|treatment|size|infarction (l_nmod) infarction_11\NN\14204950|after|myocardial
D013999_D001919 NONE timolol-induced_6\JJ\1740| (r_amod) bradycardia_7\NN\14110674|by|timolol-induced|and|increase
D013999_D007238 NONE timolol_15\CD\2832168| (r_compound) group_16\NN\2137|in|the|timolol (r_nmod) remained_11\VBD\2604760|unchanged|group (r_conj) increased_5\VBD\169651|re-infarction|,|size|group|and|remained|. (l_nmod) re-infarction_1\NN\1740|after
10901305
D007649_D050723 NONE ketamine_0\NNP\3054098| (r_compound) sedation_1\NN\14034177|ketamine|reduction|. (l_nmod) reduction_4\NN\351485|for|the|fractures (l_nmod) fractures_8\NNS\14285662|of|children|department
D007649_D050723 NONE ketamine_14\NN\3054098|of (r_nmod) safety_10\NN\13920835|the|and|efficacy|ketamine|sedation|treatment (l_nmod) treatment_19\NN\654885|in|the|fractures (l_nmod) fractures_23\NNS\14285662|of|children|department
D007649_D050723 NONE ketamine_9\NN\3054098|of (r_nmod) administration_7\NN\1133281|from|intravenous|ketamine|manipulation (l_nmod) manipulation_11\NN\157081|to|fracture (l_nmod) fracture_14\NN\14285662|of|the|or|dislocation
D007649_D050723 NONE ketamine_2\NNP\3054098|reliably|,|safely|,|and (r_nsubj) provided_9\VBD\2199590|ketamine|quickly|sedation|facilitate (l_advcl) facilitate_14\VB\2547586|to|effectively|reduction (l_dobj) reduction_16\NN\351485|the|fractures|institution (l_nmod) fractures_20\NNS\14285662|of|children|department
D007649_D004204 NONE ketamine_9\NN\3054098|of (r_nmod) administration_7\NN\1133281|from|intravenous|ketamine|manipulation (l_nmod) manipulation_11\NN\157081|to|fracture (l_nmod) fracture_14\NN\14285662|of|the|or|dislocation (l_conj) dislocation_16\NN\7367812|
7988234
D008790_D000799 CID metoprolol_6\NN\2832168|of (r_nmod) administration_4\NN\1133281|following|the|intravenous|metoprolol (r_nmod) angioedema_0\NNP\14316714|administration|.
D008790_D000799 CID metoprolol_12\NN\2832168|intravenous (r_nsubjpass) given_14\VBN\2327200|day|,|metoprolol|was|,|resulting|. (l_xcomp) resulting_16\VBG\2633881|angioedema (l_nmod) angioedema_19\NN\14316714|in|severe
D017706_D000799 CID lisinopril_6\NN\2673637| (r_compound) therapy_7\NN\657604|to|lisinopril (r_nmod) secondary_4\JJ\1740|therapy (r_amod) angioedema_3\NN\14316714|of|secondary
D013256_D000799 NONE steroids_7\NNS\14727670|with|intravenous|and|hydrochloride (r_nmod) therapy_4\NN\657604|after|steroids (r_nmod) resolved_2\VBN\352826|therapy (r_acl) angioedema_1\NN\14316714|the|resolved|.
D004155_D000799 NONE diphenhydramine_9\NN\2720725| (r_compound) hydrochloride_10\NN\14817592|diphenhydramine (r_conj) steroids_7\NNS\14727670|with|intravenous|and|hydrochloride (r_nmod) therapy_4\NN\657604|after|steroids (r_nmod) resolved_2\VBN\352826|therapy (r_acl) angioedema_1\NN\14316714|the|resolved|.
2054792
D004317_D005334 NONE adriamycin_2\NN\1740|of|combined (l_acl) combined_3\VBN\2630189|hyperthermia (l_nmod) hyperthermia_7\NN\14034177|with|whole|body|tumor
D004317_D005334 NONE adriamycin-mediated_3\JJ\1740| (r_amod) activity_5\NN\30358|of|adriamycin-mediated|antitumor (r_nmod) enhancement_1\NN\248977|thermal|activity|and|toxicities|hyperthermia (l_nmod) hyperthermia_13\NN\14034177|by|whole|body
D004317_D005334 NONE adriamycin-mediated_13\JJ\1740| (r_amod) activity_15\NN\30358|both|adriamycin-mediated|antitumor|and|effects (r_dobj) enhanced_11\VBD\227165|hyperthermia|activity|. (l_nsubj) hyperthermia_2\NN\14034177|whole|body|min
D004317_D005334 NONE adriamycin-mediated_7\JJ\1740| (r_amod) effect_9\NN\34213|adriamycin-mediated|antitumor (r_dobj) enhances_6\VBZ\227165|while|hyperthermia|effect (l_nsubj) hyperthermia_5\NN\14034177|whole|body
D004317_D009369 NONE adriamycin_2\NN\1740|of|combined (l_acl) combined_3\VBN\2630189|hyperthermia (l_nmod) hyperthermia_7\NN\14034177|with|whole|body|tumor (l_nmod) tumor_9\NN\14234074|on|and|normal|tissues
D004317_D064420 NONE adriamycin-mediated_3\JJ\1740| (r_amod) activity_5\NN\30358|of|adriamycin-mediated|antitumor (r_nmod) enhancement_1\NN\248977|thermal|activity|and|toxicities|hyperthermia (l_conj) toxicities_9\NNS\13576101|tissue
D004317_D064420 NONE adriamycin-mediated_7\JJ\1740| (r_amod) effect_9\NN\34213|adriamycin-mediated|antitumor (r_dobj) enhances_6\VBZ\227165|while|hyperthermia|effect (r_advcl) increased_16\VBN\169651|thus|,|enhances|,|toxicity|is|also|,|and|eroded|. (l_nsubjpass) toxicity_13\NN\13576101|normal|tissue
20621845
D002122_D017545 CID cacl2-induced_14\JJ\1740| (r_amod) aneurysm_17\NN\14057371|cacl2-induced|thoracic|aortic|model
D002122_D017545 CID chloride_20\NN\14818238|by|calcium|injury (r_nmod) establish_7\VB\2426171|to|model|chloride (l_dobj) model_10\NN\5888929|a|rat|aneurysm (l_nmod) aneurysm_14\NN\14057371|of|thoracic|aortic|taa
D002122_D017545 CID chloride_20\NN\14818238|by|calcium|injury (r_nmod) establish_7\VB\2426171|to|model|chloride (l_dobj) model_10\NN\5888929|a|rat|aneurysm (l_nmod) aneurysm_14\NN\14057371|of|thoracic|aortic|taa (l_appos) taa_16\NN\1740|(|)
D002122_D017545 CID chloride_20\NN\14818238|by|calcium|injury (l_appos) injury_24\NN\14052046|(|cacl(2))-induced|arterial|and|explore (l_conj) explore_27\VB\789138|to|role (l_dobj) role_30\NN\719494|the|potential|disintegrin|inhibitors|formation (l_nmod) formation_54\NN\7938773|in|taa (l_compound) taa_53\NN\1740|
D002122_D017545 CID cacl(2))-induced_22\JJ\1740| (r_amod) injury_24\NN\14052046|(|cacl(2))-induced|arterial|and|explore (r_appos) chloride_20\NN\14818238|by|calcium|injury (r_nmod) establish_7\VB\2426171|to|model|chloride (l_dobj) model_10\NN\5888929|a|rat|aneurysm (l_nmod) aneurysm_14\NN\14057371|of|thoracic|aortic|taa
D002122_D017545 CID cacl(2))-induced_22\JJ\1740| (r_amod) injury_24\NN\14052046|(|cacl(2))-induced|arterial|and|explore (r_appos) chloride_20\NN\14818238|by|calcium|injury (r_nmod) establish_7\VB\2426171|to|model|chloride (l_dobj) model_10\NN\5888929|a|rat|aneurysm (l_nmod) aneurysm_14\NN\14057371|of|thoracic|aortic|taa (l_appos) taa_16\NN\1740|(|)
D002122_D017545 CID cacl(2))-induced_22\JJ\1740| (r_amod) injury_24\NN\14052046|(|cacl(2))-induced|arterial|and|explore (l_conj) explore_27\VB\789138|to|role (l_dobj) role_30\NN\719494|the|potential|disintegrin|inhibitors|formation (l_nmod) formation_54\NN\7938773|in|taa (l_compound) taa_53\NN\1740|
D002122_D017545 CID )_11\-RRB-\1740| (r_punct) establishes_4\VBZ\2426171|study|model|)|exposure|,|and|demonstrates (l_dobj) model_7\NN\5888929|a|taa|cacl(2 (l_compound) taa_6\NN\1740|
D002122_D014652 NONE chloride_20\NN\14818238|by|calcium|injury (l_appos) injury_24\NN\14052046|(|cacl(2))-induced|arterial|and|explore
D002122_D014652 NONE cacl(2))-induced_22\JJ\1740| (r_amod) injury_24\NN\14052046|(|cacl(2))-induced|arterial|and|explore
1835291
D009241_D029424 NONE bromide_5\NN\14904359|of|ipratropium|and|theophylline (r_nmod) effects_2\NNS\13245626|acute|bronchodilating|bromide|disease|. (l_nmod) disease_12\NN\14061805|in|chronic|obstructive|pulmonary
D009241_D029424 NONE bromide_9\NN\14904359|of|ipratropium (r_nmod) dose_6\NN\3740161|of|a|single|bromide (r_nmod) effects_2\NNS\13245626|the|bronchodilator|dose|aerosol|tablets (r_nsubjpass) compared_33\VBN\644583|effects|were|study|. (l_nmod) study_40\VBP\630380|in|a|double-blind|,|crossover|patients (l_nmod) patients_43\NNS\9898892|in|21|stable|disease (l_nmod) disease_50\NN\14061805|chronic|obstructive|pulmonary
D009241_D029424 NONE ipratropium_4\NN\1740| (r_nsubj) bronchodilator_9\NN\3740161|that|ipratropium|is|a|potent|theophylline (l_nmod) theophylline_12\NN\2905612|than|oral|patients (l_nmod) patients_14\NNS\9898892|in|obstruction (l_nmod) obstruction_18\NN\4341686|with|chronic|airflow
D013806_D029424 NONE theophylline_7\NN\2905612| (r_conj) bromide_5\NN\14904359|of|ipratropium|and|theophylline (r_nmod) effects_2\NNS\13245626|acute|bronchodilating|bromide|disease|. (l_nmod) disease_12\NN\14061805|in|chronic|obstructive|pulmonary
D013806_D029424 NONE theophylline_17\NN\2905612| (r_compound) tablets_18\NNS\4233405|short-acting|theophylline|dose (r_conj) effects_2\NNS\13245626|the|bronchodilator|dose|aerosol|tablets (r_nsubjpass) compared_33\VBN\644583|effects|were|study|. (l_nmod) study_40\VBP\630380|in|a|double-blind|,|crossover|patients (l_nmod) patients_43\NNS\9898892|in|21|stable|disease (l_nmod) disease_50\NN\14061805|chronic|obstructive|pulmonary
D013806_D029424 NONE theophylline_12\NN\2905612|than|oral|patients (l_nmod) patients_14\NNS\9898892|in|obstruction (l_nmod) obstruction_18\NN\4341686|with|chronic|airflow
D013806_D002318 CID theophylline_9\NN\2905612| (r_compound) use_10\NN\407535|after|theophylline (r_nmod) experienced_7\VBN\2108377|use (r_acl) those_6\DT\1740|experienced (r_nsubj) involve_12\VB\2676054|rare|those|did|systems|. (l_dobj) systems_17\NNS\3575240|the|cardiovascular
D013806_D005767 CID theophylline_9\NN\2905612| (r_compound) use_10\NN\407535|after|theophylline (r_nmod) experienced_7\VBN\2108377|use (r_acl) those_6\DT\1740|experienced (r_nsubj) involve_12\VB\2676054|rare|those|did|systems|. (l_dobj) systems_17\NNS\3575240|the|cardiovascular
347884
D006220_D019967 NONE haloperidol_6\NN\3713736|with (r_nmod) study_4\NN\635850|in|the|blind|haloperidol (r_nmod) found_11\VBN\2426171|study|,|substances|were|effective|. (l_xcomp) effective_15\JJ\1740|to|be|highly|treatment (l_nmod) treatment_18\NN\654885|in|the|syndromes|belonging (l_acl) belonging_22\VBG\2604760|predominantly|group (l_nmod) group_27\NN\2137|to|the|schizophrenia
2445283
D012254_D006478 NONE ribavirin_5\NN\2725367|of (r_nmod) tolerance_0\NN\5032565|and|effect|ribavirin|patients|. (l_nmod) patients_7\NNS\9898892|in|fever (l_nmod) fever_11\NN\14299637|with|argentine|hemorrhagic
D012254_D006478 NONE ribavirin_5\NN\2725367|of (r_nmod) tolerance_0\NN\5032565|and|effect|ribavirin (r_nsubjpass) studied_7\VBN\630380|tolerance|was|patients|. (l_nmod) patients_10\NNS\9898892|in|6|fever (l_nmod) fever_14\NN\14299637|with|argentine|hemorrhagic|ahf|days
D012254_D006478 NONE ribavirin_5\NN\2725367|of (r_nmod) tolerance_0\NN\5032565|and|effect|ribavirin (r_nsubjpass) studied_7\VBN\630380|tolerance|was|patients|. (l_nmod) patients_10\NNS\9898892|in|6|fever (l_nmod) fever_14\NN\14299637|with|argentine|hemorrhagic|ahf|days (l_appos) ahf_16\NN\1740|(|)
D012254_D006478 NONE ribavirin_7\NN\2725367| (r_nsubj) has_8\VBZ\2108377|that|ribavirin|effect|,|and|managed (l_dobj) effect_11\NN\34213|an|antiviral|cases (l_nmod) cases_14\NNS\7283608|in|advanced|ahf (l_nmod) ahf_16\NN\1740|of
D012254_D006478 NONE ribavirin_5\NN\2725367|of (r_nmod) effect_3\NN\34213|the|possible|beneficial|ribavirin|days (l_nmod) days_9\NNS\15140892|during|the|initial|ahf (l_nmod) ahf_11\NN\1740|of
D012254_D014766 NONE ribavirin_2\NN\2725367|of (r_nmod) administration_0\NN\1133281|ribavirin (r_nsubj) resulted_3\VBD\2633881|administration|neutralization|. (l_nmod) neutralization_6\NN\231567|in|a|viremia|drop (l_nmod) viremia_8\NN\14204950|of|and
D012254_D000740 CID ribavirin_7\NN\2725367| (r_nsubj) has_8\VBZ\2108377|that|ribavirin|effect|,|and|managed (l_conj) managed_31\VBN\2524171|anemia|can|be|easily (l_nsubjpass) anemia_20\NN\14189204|that|,|reaction|,
17854040
D019259_D006509 NONE lamivudine-resistance_3\NN\1740|with|therapy-na|patients (l_nmod) patients_14\NNS\9898892|virus|infected|co-infection (l_amod) infected_13\JJ\1740|
D019259_D006509 NONE lamivudine-resistance_3\NN\1740|with|therapy-na|patients (r_nmod) associated_1\VBN\628491|lamivudine-resistance (r_acl) mutations_0\NNS\4475|associated|:|implications (r_nsubj) co-infected_29\VBD\1740|mutations|patients|.
D019259_D006509 NONE lamivudine-resistant_7\JJ\1740| (r_amod) virus_10\NN\9312843|lamivudine-resistant|hepatitis|b|hbv (l_compound) b_9\NN\1355326|
D019259_D006509 NONE lamivudine-na_17\JJ\1740|in|selected (r_amod) carriers_20\NNS\9629752|lamivudine-na|ve|hbv (r_nmod) strains_14\NNS\7358060|carriers|co-infection (r_dobj) investigate_6\VB\644583|to|virus|strains (l_dobj) virus_10\NN\9312843|lamivudine-resistant|hepatitis|b|hbv (l_compound) b_9\NN\1355326|
D019259_D006509 NONE lamivudine-na_1\NN\1740|thirty-five (r_amod) patients_5\NNS\9898892|lamivudine-na|ve|hbv|infected|co-infection (l_amod) infected_4\JJ\1740|
D019259_D006509 NONE lamivudine-na_1\NN\1740|thirty-five (r_amod) patients_5\NNS\9898892|lamivudine-na|ve|hbv|infected|co-infection (r_nsubjpass) studied_12\VBN\630380|patients|were|:|patients|. (l_dep) patients_18\NNS\9898892|15|chronic|hbv|mono-infected|and|patients (l_amod) mono-infected_17\JJ\1740|
D019259_D006509 NONE lamivudine-na_1\NN\1740|thirty-five (r_amod) patients_5\NNS\9898892|lamivudine-na|ve|hbv|infected|co-infection (r_nsubjpass) studied_12\VBN\630380|patients|were|:|patients|. (l_dep) patients_18\NNS\9898892|15|chronic|hbv|mono-infected|and|patients (l_conj) patients_23\NNS\9898892|20|hbv-hiv|co-infected (l_amod) co-infected_22\VBD\1740|
D019259_D006509 NONE lamivudine-resistant_1\JJ\1740| (r_amod) strains_2\NNS\7358060|hbv|lamivudine-resistant (r_nsubjpass) detected_4\VBN\2163746|strains|were|patients|. (l_nmod) patients_13\NNS\9898892|in|15|mono-infected|chronic|hepatitis|b|and|patients (l_compound) b_12\NN\1355326|
D019259_D006509 NONE lamivudine-resistant_1\JJ\1740| (r_amod) strains_2\NNS\7358060|hbv|lamivudine-resistant (r_nsubjpass) detected_4\VBN\2163746|strains|were|patients|. (l_nmod) patients_13\NNS\9898892|in|15|mono-infected|chronic|hepatitis|b|and|patients (l_conj) patients_20\NNS\9898892|20|hbv-hiv|co-infected (l_amod) co-infected_19\VBD\1740|
D019259_D006509 NONE lamivudine-resistant_14\JJ\1740| (r_amod) strains_15\NNS\7358060|of|hbv|lamivudine-resistant|therapy-na|patients (l_nmod) patients_21\NNS\9898892|hbv-hiv|co-infected (l_amod) co-infected_20\VBD\1740|
D019259_D006509 NONE lamivudine-containing_20\JJ\1740| (r_amod) active_22\JJ\1740|when|lamivudine-containing|highly (r_amod) treatment_27\NN\654885|active|antiretroviral|arv|haart (r_dobj) result_11\VB\2633881|whether|mutations|could|emergence|treatment (r_ccomp) seen_4\VBN\2106506|to|be|result (r_xcomp) remains_1\VBZ\2604760|it|seen|become|,|likely|. (l_advcl) likely_42\JJ\1740|as|this|is|have (l_xcomp) have_44\VB\2108377|to|implications (l_dobj) implications_46\NNS\5774614|potential|management (l_nmod) management_49\NN\1123598|in|the|patients (l_nmod) patients_53\NNS\9898892|of|hbv-hiv|co-infected (l_amod) co-infected_52\VBD\1740|
D019259_D015658 NONE lamivudine-resistance_3\NN\1740|with|therapy-na|patients (l_nmod) patients_14\NNS\9898892|virus|infected|co-infection (l_nmod) co-infection_19\NN\1740|with|without|hiv
D019259_D015658 NONE lamivudine-resistance_3\NN\1740|with|therapy-na|patients (r_nmod) associated_1\VBN\628491|lamivudine-resistance (r_acl) mutations_0\NNS\4475|associated|:|implications (r_nsubj) co-infected_29\VBD\1740|mutations|patients|.
D019259_D015658 NONE lamivudine-resistant_7\JJ\1740| (r_amod) virus_10\NN\9312843|lamivudine-resistant|hepatitis|b|hbv (r_dobj) investigate_6\VB\644583|to|virus|strains (l_dobj) strains_14\NNS\7358060|carriers|co-infection (l_nmod) co-infection_30\NN\1740|with|virus|patients
D019259_D015658 NONE lamivudine-na_17\JJ\1740|in|selected (r_amod) carriers_20\NNS\9629752|lamivudine-na|ve|hbv (r_nmod) strains_14\NNS\7358060|carriers|co-infection (l_nmod) co-infection_30\NN\1740|with|virus|patients
D019259_D015658 NONE lamivudine-na_1\NN\1740|thirty-five (r_amod) patients_5\NNS\9898892|lamivudine-na|ve|hbv|infected|co-infection (l_nmod) co-infection_10\NN\1740|with|hiv
D019259_D015658 NONE lamivudine-na_1\NN\1740|thirty-five (r_amod) patients_5\NNS\9898892|lamivudine-na|ve|hbv|infected|co-infection (r_nsubjpass) studied_12\VBN\630380|patients|were|:|patients|. (l_dep) patients_18\NNS\9898892|15|chronic|hbv|mono-infected|and|patients (l_conj) patients_23\NNS\9898892|20|hbv-hiv|co-infected (l_amod) co-infected_22\VBD\1740|
D019259_D015658 NONE lamivudine-resistant_1\JJ\1740| (r_amod) strains_2\NNS\7358060|hbv|lamivudine-resistant (r_nsubjpass) detected_4\VBN\2163746|strains|were|patients|. (l_nmod) patients_13\NNS\9898892|in|15|mono-infected|chronic|hepatitis|b|and|patients (l_conj) patients_20\NNS\9898892|20|hbv-hiv|co-infected (l_amod) co-infected_19\VBD\1740|
D019259_D015658 NONE lamivudine-resistant_14\JJ\1740| (r_amod) strains_15\NNS\7358060|of|hbv|lamivudine-resistant|therapy-na|patients (l_nmod) patients_21\NNS\9898892|hbv-hiv|co-infected (l_amod) co-infected_20\VBD\1740|
D019259_D015658 NONE lamivudine-containing_20\JJ\1740| (r_amod) active_22\JJ\1740|when|lamivudine-containing|highly (r_amod) treatment_27\NN\654885|active|antiretroviral|arv|haart (r_dobj) result_11\VB\2633881|whether|mutations|could|emergence|treatment (r_ccomp) seen_4\VBN\2106506|to|be|result (r_xcomp) remains_1\VBZ\2604760|it|seen|become|,|likely|. (l_advcl) likely_42\JJ\1740|as|this|is|have (l_xcomp) have_44\VB\2108377|to|implications (l_dobj) implications_46\NNS\5774614|potential|management (l_nmod) management_49\NN\1123598|in|the|patients (l_nmod) patients_53\NNS\9898892|of|hbv-hiv|co-infected (l_amod) co-infected_52\VBD\1740|
D012964_D006509 NONE therapy-na_5\JJ\1740|in (r_nmod) lamivudine-resistance_3\NN\1740|with|therapy-na|patients (l_nmod) patients_14\NNS\9898892|virus|infected|co-infection (l_amod) infected_13\JJ\1740|
D012964_D006509 NONE therapy-na_5\JJ\1740|in (r_nmod) lamivudine-resistance_3\NN\1740|with|therapy-na|patients (r_nmod) associated_1\VBN\628491|lamivudine-resistance (r_acl) mutations_0\NNS\4475|associated|:|implications (r_nsubj) co-infected_29\VBD\1740|mutations|patients|.
D012964_D006509 NONE lamivudine-na_17\JJ\1740|in|selected (r_amod) carriers_20\NNS\9629752|lamivudine-na|ve|hbv (r_nmod) strains_14\NNS\7358060|carriers|co-infection (r_dobj) investigate_6\VB\644583|to|virus|strains (l_dobj) virus_10\NN\9312843|lamivudine-resistant|hepatitis|b|hbv (l_compound) b_9\NN\1355326|
D012964_D006509 NONE lamivudine-na_1\NN\1740|thirty-five (r_amod) patients_5\NNS\9898892|lamivudine-na|ve|hbv|infected|co-infection (l_amod) infected_4\JJ\1740|
D012964_D006509 NONE lamivudine-na_1\NN\1740|thirty-five (r_amod) patients_5\NNS\9898892|lamivudine-na|ve|hbv|infected|co-infection (r_nsubjpass) studied_12\VBN\630380|patients|were|:|patients|. (l_dep) patients_18\NNS\9898892|15|chronic|hbv|mono-infected|and|patients (l_amod) mono-infected_17\JJ\1740|
D012964_D006509 NONE lamivudine-na_1\NN\1740|thirty-five (r_amod) patients_5\NNS\9898892|lamivudine-na|ve|hbv|infected|co-infection (r_nsubjpass) studied_12\VBN\630380|patients|were|:|patients|. (l_dep) patients_18\NNS\9898892|15|chronic|hbv|mono-infected|and|patients (l_conj) patients_23\NNS\9898892|20|hbv-hiv|co-infected (l_amod) co-infected_22\VBD\1740|
D012964_D006509 NONE therapy-na_17\NN\1740|in|ve (r_nmod) strains_15\NNS\7358060|of|hbv|lamivudine-resistant|therapy-na|patients (l_nmod) patients_21\NNS\9898892|hbv-hiv|co-infected (l_amod) co-infected_20\VBD\1740|
D012964_D015658 NONE therapy-na_5\JJ\1740|in (r_nmod) lamivudine-resistance_3\NN\1740|with|therapy-na|patients (l_nmod) patients_14\NNS\9898892|virus|infected|co-infection (l_nmod) co-infection_19\NN\1740|with|without|hiv
D012964_D015658 NONE therapy-na_5\JJ\1740|in (r_nmod) lamivudine-resistance_3\NN\1740|with|therapy-na|patients (r_nmod) associated_1\VBN\628491|lamivudine-resistance (r_acl) mutations_0\NNS\4475|associated|:|implications (r_nsubj) co-infected_29\VBD\1740|mutations|patients|.
D012964_D015658 NONE lamivudine-na_17\JJ\1740|in|selected (r_amod) carriers_20\NNS\9629752|lamivudine-na|ve|hbv (r_nmod) strains_14\NNS\7358060|carriers|co-infection (l_nmod) co-infection_30\NN\1740|with|virus|patients
D012964_D015658 NONE lamivudine-na_1\NN\1740|thirty-five (r_amod) patients_5\NNS\9898892|lamivudine-na|ve|hbv|infected|co-infection (l_nmod) co-infection_10\NN\1740|with|hiv
D012964_D015658 NONE lamivudine-na_1\NN\1740|thirty-five (r_amod) patients_5\NNS\9898892|lamivudine-na|ve|hbv|infected|co-infection (r_nsubjpass) studied_12\VBN\630380|patients|were|:|patients|. (l_dep) patients_18\NNS\9898892|15|chronic|hbv|mono-infected|and|patients (l_conj) patients_23\NNS\9898892|20|hbv-hiv|co-infected (l_amod) co-infected_22\VBD\1740|
D012964_D015658 NONE therapy-na_17\NN\1740|in|ve (r_nmod) strains_15\NNS\7358060|of|hbv|lamivudine-resistant|therapy-na|patients (l_nmod) patients_21\NNS\9898892|hbv-hiv|co-infected (l_amod) co-infected_20\VBD\1740|
7468724
D013726_D002318 CID terbutaline_4\NN\1740| (r_compound) treatment_5\NN\654885|with|terbutaline|labor (r_nmod) associated_2\VBN\628491|treatment (r_acl) complications_1\NNS\1073995|cardiovascular|associated|.
D013726_D002318 CID terbutaline_11\NN\1740|with (r_nmod) treated_9\VBN\2376958|terbutaline|labor (r_acl) patients_8\NNS\9898892|in|eight|of|160|treated (r_nmod) occurred_3\VBD\2623529|complications|patients|. (l_nsubj) complications_2\NNS\1073995|severe|cardiovascular
D013726_D007752 NONE terbutaline_4\NN\1740| (r_compound) treatment_5\NN\654885|with|terbutaline|labor (l_nmod) labor_8\NN\7974025|for|preterm
D013726_D007752 NONE terbutaline_11\NN\1740|with (r_nmod) treated_9\VBN\2376958|terbutaline|labor (l_nmod) labor_14\NN\7974025|for|preterm
7269015
D002066_D006470 CID busulfan-induced_0\JJ\1740| (r_amod) cystitis_2\NN\14566129|busulfan-induced|hemorrhagic|.
D002066_D006470 CID busulfan-induced_4\JJ\1740| (r_amod) cystitis_6\NN\14566129|of|a|busulfan-induced|hemorrhage
D002066_D003556 CID busulfan-induced_0\JJ\1740| (r_amod) cystitis_2\NN\14566129|busulfan-induced|hemorrhagic|.
D002066_D003556 CID busulfan-induced_4\JJ\1740| (r_amod) cystitis_6\NN\14566129|of|a|busulfan-induced|hemorrhage
D002066_D003556 CID busulfan_7\NNS\1740|of|cystitis (l_dep) cystitis_8\NN\14566129|
D002066_D003556 CID busulfan_7\NNS\1740|of|cystitis (r_nmod) appearances_5\NNS\4723816|between|the|histologic|busulfan|and|radiation (l_conj) radiation_11\NN\11452218|both|and|cystitis (l_conj) cystitis_14\NN\14566129|cyclophosphamide-induced
D003520_D003556 NONE cyclophosphamide-induced_13\JJ\1740| (r_amod) cystitis_14\NN\14566129|cyclophosphamide-induced (r_conj) radiation_11\NN\11452218|both|and|cystitis (r_conj) appearances_5\NNS\4723816|between|the|histologic|busulfan|and|radiation (l_nmod) busulfan_7\NNS\1740|of|cystitis (l_dep) cystitis_8\NN\14566129|
D003520_D003556 NONE cyclophosphamide-induced_13\JJ\1740| (r_amod) cystitis_14\NN\14566129|cyclophosphamide-induced
D002066_D002277 NONE busulfan_7\NNS\1740|of (r_nmod) tendency_5\NN\6193203|of|the|known|busulfan|induce (l_acl) induce_9\VB\1627355|to|atypia (l_dobj) atypia_11\NN\1740|cellular|and|carcinoma|sites (l_conj) carcinoma_13\NN\14239918|
15899738
D003401_D001281 CID creatine_5\NN\14601829| (r_compound) supplementation_7\NN\5108947|with|creatine|monohydrate (r_nmod) associated_3\VBN\628491|supplementation (r_acl) fibrillation_2\NN\14361664|lone|atrial|associated|.
D003401_D001145 NONE creatine_5\NN\14601829| (r_dobj) linked_4\VBN\628491|reports|have|creatine|development|. (l_nmod) development_8\NN\248977|to|the|arrhythmia (l_nmod) arrhythmia_10\NN\14103288|of
12615818
D017373_D054556 CID acetate_9\NN\15010703|cyproterone (r_dobj) prescribed_7\VBD\748282|risk|acetate|combination|:|analysis|. (l_nsubj) risk_1\NN\14541044|the|thromboembolism (l_nmod) thromboembolism_4\NN\14100769|of|venous|women
D017373_D054556 CID cpa/ee_15\NN\1740|with (r_nmod) associated_13\VBN\628491|cpa/ee (r_acl) thromboembolism_9\NN\14100769|of|venous|vte|associated
D017373_D054556 CID cpa/ee_15\NN\1740|with (r_nmod) associated_13\VBN\628491|cpa/ee (r_acl) thromboembolism_9\NN\14100769|of|venous|vte|associated (l_appos) vte_11\NN\1740|(|)
D017373_D054556 CID cpa/ee_42\NN\1740|with (r_nmod) associated_40\VBN\628491|cpa/ee (r_acl) vte_39\NN\1740|of|associated
D017373_D054556 CID cpa/ee_15\NN\1740|of|women (r_nmod) use_13\NN\407535|with|the|cpa/ee (r_nmod) associated_10\VBN\628491|use (r_acl) vte_9\NN\1740|of|associated
D004997_D054556 CID estradiol_14\NN\14749794|with|ethinyl (r_nmod) combination_11\NN\7951464|in|estradiol (r_nmod) prescribed_7\VBD\748282|risk|acetate|combination|:|analysis|. (l_nsubj) risk_1\NN\14541044|the|thromboembolism (l_nmod) thromboembolism_4\NN\14100769|of|venous|women
D004997_D054556 CID cpa/ee_15\NN\1740|with (r_nmod) associated_13\VBN\628491|cpa/ee (r_acl) thromboembolism_9\NN\14100769|of|venous|vte|associated
D004997_D054556 CID cpa/ee_15\NN\1740|with (r_nmod) associated_13\VBN\628491|cpa/ee (r_acl) thromboembolism_9\NN\14100769|of|venous|vte|associated (l_appos) vte_11\NN\1740|(|)
D004997_D054556 CID cpa/ee_42\NN\1740|with (r_nmod) associated_40\VBN\628491|cpa/ee (r_acl) vte_39\NN\1740|of|associated
D004997_D054556 CID cpa/ee_15\NN\1740|of|women (r_nmod) use_13\NN\407535|with|the|cpa/ee (r_nmod) associated_10\VBN\628491|use (r_acl) vte_9\NN\1740|of|associated
D017373_D000152 NONE acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\VBN\803325|background|acetate|is|uk|treatment|and|option|. (l_nmod) treatment_18\NN\654885|for|the|women (l_nmod) women_20\NNS\9605289|of|acne (l_nmod) acne_22\NN\14171682|with|and|hirsutism
D017373_D000152 NONE cpa/ee_9\NN\1740|(|) (r_appos) estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\VBN\803325|background|acetate|is|uk|treatment|and|option|. (l_nmod) treatment_18\NN\654885|for|the|women (l_nmod) women_20\NNS\9605289|of|acne (l_nmod) acne_22\NN\14171682|with|and|hirsutism
D017373_D000152 NONE cpa/ee_42\NN\1740|with (r_nmod) associated_40\VBN\628491|cpa/ee (r_acl) vte_39\NN\1740|of|associated (r_nmod) risk_37\NN\14541044|the|vte (r_dobj) estimate_35\VB\637259|to|risk (r_advcl) conducted_9\VBD\2436349|methods|we|analysis|estimate|. (l_dobj) analysis_12\NN\633864|a|cohort|and|study|nested|years (l_conj) years_27\NNS\15144371|acne (l_nmod) acne_29\NN\14171682|with|,|hirsutism
D017373_D000152 NONE cpa/ee_15\NN\1740|of|women (l_nmod) women_17\NNS\9605289|in|acne (l_nmod) acne_19\NN\14171682|with|,|hirsutism
D017373_D006628 NONE acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\VBN\803325|background|acetate|is|uk|treatment|and|option|. (l_nmod) treatment_18\NN\654885|for|the|women (l_nmod) women_20\NNS\9605289|of|acne (l_nmod) acne_22\NN\14171682|with|and|hirsutism (l_conj) hirsutism_24\NN\4683453|
D017373_D006628 NONE cpa/ee_9\NN\1740|(|) (r_appos) estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\VBN\803325|background|acetate|is|uk|treatment|and|option|. (l_nmod) treatment_18\NN\654885|for|the|women (l_nmod) women_20\NNS\9605289|of|acne (l_nmod) acne_22\NN\14171682|with|and|hirsutism (l_conj) hirsutism_24\NN\4683453|
D017373_D006628 NONE cpa/ee_42\NN\1740|with (r_nmod) associated_40\VBN\628491|cpa/ee (r_acl) vte_39\NN\1740|of|associated (r_nmod) risk_37\NN\14541044|the|vte (r_dobj) estimate_35\VB\637259|to|risk (r_advcl) conducted_9\VBD\2436349|methods|we|analysis|estimate|. (l_dobj) analysis_12\NN\633864|a|cohort|and|study|nested|years (l_conj) years_27\NNS\15144371|acne (l_nmod) acne_29\NN\14171682|with|,|hirsutism (l_conj) hirsutism_31\NN\4683453|or|pcos
D017373_D006628 NONE cpa/ee_15\NN\1740|of|women (l_nmod) women_17\NNS\9605289|in|acne (l_nmod) acne_19\NN\14171682|with|,|hirsutism (l_conj) hirsutism_21\NN\4683453|or|pcos
D017373_D011085 NONE acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\VBN\803325|background|acetate|is|uk|treatment|and|option|. (l_conj) option_30\NN\6480506|is|also|a|treatment|syndrome (l_nmod) syndrome_34\NN\5870365|for|polycystic|ovary|pcos
D017373_D011085 NONE acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\VBN\803325|background|acetate|is|uk|treatment|and|option|. (l_conj) option_30\NN\6480506|is|also|a|treatment|syndrome (l_nmod) syndrome_34\NN\5870365|for|polycystic|ovary|pcos (l_appos) pcos_36\NN\1740|(|)
D017373_D011085 NONE cpa/ee_9\NN\1740|(|) (r_appos) estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\VBN\803325|background|acetate|is|uk|treatment|and|option|. (l_conj) option_30\NN\6480506|is|also|a|treatment|syndrome (l_nmod) syndrome_34\NN\5870365|for|polycystic|ovary|pcos
D017373_D011085 NONE cpa/ee_9\NN\1740|(|) (r_appos) estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\VBN\803325|background|acetate|is|uk|treatment|and|option|. (l_conj) option_30\NN\6480506|is|also|a|treatment|syndrome (l_nmod) syndrome_34\NN\5870365|for|polycystic|ovary|pcos (l_appos) pcos_36\NN\1740|(|)
D017373_D011085 NONE cpa/ee_42\NN\1740|with (r_nmod) associated_40\VBN\628491|cpa/ee (r_acl) vte_39\NN\1740|of|associated (r_nmod) risk_37\NN\14541044|the|vte (r_dobj) estimate_35\VB\637259|to|risk (r_advcl) conducted_9\VBD\2436349|methods|we|analysis|estimate|. (l_dobj) analysis_12\NN\633864|a|cohort|and|study|nested|years (l_conj) years_27\NNS\15144371|acne (l_nmod) acne_29\NN\14171682|with|,|hirsutism (l_conj) hirsutism_31\NN\4683453|or|pcos (l_conj) pcos_33\NN\1740|
D017373_D011085 NONE cpa/ee_15\NN\1740|of|women (l_nmod) women_17\NNS\9605289|in|acne (l_nmod) acne_19\NN\14171682|with|,|hirsutism (l_conj) hirsutism_21\NN\4683453|or|pcos (l_conj) pcos_23\NN\1740|
D004997_D000152 NONE estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\VBN\803325|background|acetate|is|uk|treatment|and|option|. (l_nmod) treatment_18\NN\654885|for|the|women (l_nmod) women_20\NNS\9605289|of|acne (l_nmod) acne_22\NN\14171682|with|and|hirsutism
D004997_D000152 NONE cpa/ee_9\NN\1740|(|) (r_appos) estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\VBN\803325|background|acetate|is|uk|treatment|and|option|. (l_nmod) treatment_18\NN\654885|for|the|women (l_nmod) women_20\NNS\9605289|of|acne (l_nmod) acne_22\NN\14171682|with|and|hirsutism
D004997_D000152 NONE cpa/ee_42\NN\1740|with (r_nmod) associated_40\VBN\628491|cpa/ee (r_acl) vte_39\NN\1740|of|associated (r_nmod) risk_37\NN\14541044|the|vte (r_dobj) estimate_35\VB\637259|to|risk (r_advcl) conducted_9\VBD\2436349|methods|we|analysis|estimate|. (l_dobj) analysis_12\NN\633864|a|cohort|and|study|nested|years (l_conj) years_27\NNS\15144371|acne (l_nmod) acne_29\NN\14171682|with|,|hirsutism
D004997_D000152 NONE cpa/ee_15\NN\1740|of|women (l_nmod) women_17\NNS\9605289|in|acne (l_nmod) acne_19\NN\14171682|with|,|hirsutism
D004997_D006628 NONE estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\VBN\803325|background|acetate|is|uk|treatment|and|option|. (l_nmod) treatment_18\NN\654885|for|the|women (l_nmod) women_20\NNS\9605289|of|acne (l_nmod) acne_22\NN\14171682|with|and|hirsutism (l_conj) hirsutism_24\NN\4683453|
D004997_D006628 NONE cpa/ee_9\NN\1740|(|) (r_appos) estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\VBN\803325|background|acetate|is|uk|treatment|and|option|. (l_nmod) treatment_18\NN\654885|for|the|women (l_nmod) women_20\NNS\9605289|of|acne (l_nmod) acne_22\NN\14171682|with|and|hirsutism (l_conj) hirsutism_24\NN\4683453|
D004997_D006628 NONE cpa/ee_42\NN\1740|with (r_nmod) associated_40\VBN\628491|cpa/ee (r_acl) vte_39\NN\1740|of|associated (r_nmod) risk_37\NN\14541044|the|vte (r_dobj) estimate_35\VB\637259|to|risk (r_advcl) conducted_9\VBD\2436349|methods|we|analysis|estimate|. (l_dobj) analysis_12\NN\633864|a|cohort|and|study|nested|years (l_conj) years_27\NNS\15144371|acne (l_nmod) acne_29\NN\14171682|with|,|hirsutism (l_conj) hirsutism_31\NN\4683453|or|pcos
D004997_D006628 NONE cpa/ee_15\NN\1740|of|women (l_nmod) women_17\NNS\9605289|in|acne (l_nmod) acne_19\NN\14171682|with|,|hirsutism (l_conj) hirsutism_21\NN\4683453|or|pcos
D004997_D011085 NONE estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\VBN\803325|background|acetate|is|uk|treatment|and|option|. (l_conj) option_30\NN\6480506|is|also|a|treatment|syndrome (l_nmod) syndrome_34\NN\5870365|for|polycystic|ovary|pcos
D004997_D011085 NONE estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\VBN\803325|background|acetate|is|uk|treatment|and|option|. (l_conj) option_30\NN\6480506|is|also|a|treatment|syndrome (l_nmod) syndrome_34\NN\5870365|for|polycystic|ovary|pcos (l_appos) pcos_36\NN\1740|(|)
D004997_D011085 NONE cpa/ee_9\NN\1740|(|) (r_appos) estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\VBN\803325|background|acetate|is|uk|treatment|and|option|. (l_conj) option_30\NN\6480506|is|also|a|treatment|syndrome (l_nmod) syndrome_34\NN\5870365|for|polycystic|ovary|pcos
D004997_D011085 NONE cpa/ee_9\NN\1740|(|) (r_appos) estradiol_7\NN\14749794|with|ethinyl|cpa/ee (r_nmod) combined_4\VBN\2630189|estradiol (r_acl) acetate_3\NN\15010703|cyproterone|combined (r_nsubjpass) licensed_12\VBN\803325|background|acetate|is|uk|treatment|and|option|. (l_conj) option_30\NN\6480506|is|also|a|treatment|syndrome (l_nmod) syndrome_34\NN\5870365|for|polycystic|ovary|pcos (l_appos) pcos_36\NN\1740|(|)
D004997_D011085 NONE cpa/ee_42\NN\1740|with (r_nmod) associated_40\VBN\628491|cpa/ee (r_acl) vte_39\NN\1740|of|associated (r_nmod) risk_37\NN\14541044|the|vte (r_dobj) estimate_35\VB\637259|to|risk (r_advcl) conducted_9\VBD\2436349|methods|we|analysis|estimate|. (l_dobj) analysis_12\NN\633864|a|cohort|and|study|nested|years (l_conj) years_27\NNS\15144371|acne (l_nmod) acne_29\NN\14171682|with|,|hirsutism (l_conj) hirsutism_31\NN\4683453|or|pcos (l_conj) pcos_33\NN\1740|
D004997_D011085 NONE cpa/ee_15\NN\1740|of|women (l_nmod) women_17\NNS\9605289|in|acne (l_nmod) acne_19\NN\14171682|with|,|hirsutism (l_conj) hirsutism_21\NN\4683453|or|pcos (l_conj) pcos_23\NN\1740|
D003276_D054556 NONE contraceptives_21\NNS\3183080|compared|with|conventional|combined|oral|cocs (r_nmod) risk_6\NN\14541044|an|increased|thromboembolism|contraceptives (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte|associated
D003276_D054556 NONE contraceptives_21\NNS\3183080|compared|with|conventional|combined|oral|cocs (r_nmod) risk_6\NN\14541044|an|increased|thromboembolism|contraceptives (l_nmod) thromboembolism_9\NN\14100769|of|venous|vte|associated (l_appos) vte_11\NN\1740|(|)
12483326
D016190_D005128 NONE carboplatin_9\NN\1740|of (r_nmod) injection_7\NN\320852|after|intracarotid|carboplatin|glioblastomas (r_nmod) toxicity_4\NN\13576101|severe|ocular|injection|.
D016190_D005128 NONE carboplatin_2\NN\1740| (r_nsubjpass) said_4\VBN\940384|generally|,|carboplatin|is|have|known|. (l_ccomp) known_20\JJ\1740|toxicity|are|well (l_nsubjpass) toxicity_17\NN\13576101|whose|ocular
D016190_D005128 NONE carboplatin_16\NN\1740|of (r_nmod) injection_14\NN\320852|after|intracarotid|carboplatin (r_nmod) case_5\NN\7283608|a|toxicity|injection|,|reported (l_nmod) toxicity_11\NN\13576101|of|severe|ocular
D016190_D005128 NONE carboplatin_7\NN\1740|of (r_nmod) injection_5\NN\320852|intracarotid|carboplatin (r_dobj) performing_3\VBG\2367363|when|injection (r_advcl) aware_12\JJ\1740|performing|,|we|must|be|toxicity (l_nmod) toxicity_18\NN\13576101|of|its|blinding|ocular
D016190_D009916 NONE carboplatin_9\NN\1740|of (r_nmod) injection_7\NN\320852|after|intracarotid|carboplatin|glioblastomas (r_nmod) toxicity_4\NN\13576101|severe|ocular|injection|.
D016190_D009916 NONE carboplatin_2\NN\1740| (r_nsubjpass) said_4\VBN\940384|generally|,|carboplatin|is|have|known|. (l_ccomp) known_20\JJ\1740|toxicity|are|well (l_nsubjpass) toxicity_17\NN\13576101|whose|ocular
D016190_D009916 NONE carboplatin_16\NN\1740|of (r_nmod) injection_14\NN\320852|after|intracarotid|carboplatin (r_nmod) case_5\NN\7283608|a|toxicity|injection|,|reported (l_nmod) toxicity_11\NN\13576101|of|severe|ocular
D016190_D005909 NONE carboplatin_9\NN\1740|of (r_nmod) injection_7\NN\320852|after|intracarotid|carboplatin|glioblastomas (l_nmod) glioblastomas_12\NNS\14236743|for|recurrent
D016190_D005909 NONE carboplatin_10\NN\1740|of (r_nmod) injection_8\NN\320852|an|intracarotid|carboplatin|glioblastomas (l_nmod) glioblastomas_13\NNS\14236743|for|recurrent
D002945_D005128 NONE cisplatin_11\NN\1740|than|, (r_nmod) effects_9\NNS\13245626|milder|side|cisplatin (r_dobj) have_6\VB\2108377|to|effects (r_xcomp) said_4\VBN\940384|generally|,|carboplatin|is|have|known|. (l_ccomp) known_20\JJ\1740|toxicity|are|well (l_nsubjpass) toxicity_17\NN\13576101|whose|ocular
D002945_D009916 NONE cisplatin_11\NN\1740|than|, (r_nmod) effects_9\NNS\13245626|milder|side|cisplatin (r_dobj) have_6\VB\2108377|to|effects (r_xcomp) said_4\VBN\940384|generally|,|carboplatin|is|have|known|. (l_ccomp) known_20\JJ\1740|toxicity|are|well (l_nsubjpass) toxicity_17\NN\13576101|whose|ocular
D016190_D064420 NONE carboplatin_7\NN\1740| (r_compound) toxicity_8\NN\13576101|by|carboplatin
7292072
D003891_D017180 CID desipramine_4\NN\4482543| (r_compound) toxicity_5\NN\13576101|in|desipramine (r_nmod) tachycardia_2\NN\14110674|variant|ventricular|toxicity|.
D003891_D017180 CID desipramine_10\NN\4482543| (r_compound) toxicity_11\NN\13576101|by|desipramine (r_nmod) induced_8\VBN\1627355|toxicity (r_acl) tachycardia_7\NN\14110674|of|variant|ventricular|induced
D003891_D064420 NONE desipramine_4\NN\4482543| (r_compound) toxicity_5\NN\13576101|in|desipramine
D003891_D064420 NONE desipramine_10\NN\4482543| (r_compound) toxicity_11\NN\13576101|by|desipramine
9401499
D013988_D000741 CID ticlopidine-induced_0\JJ\1740| (r_amod) anemia_2\NN\14189204|ticlopidine-induced|aplastic|:|report|.
D013988_D000741 CID ticlopidine-induced_8\JJ\1740| (r_amod) anemia_10\NN\14189204|with|ticlopidine-induced|aplastic
D013988_D000741 CID ticlopidine-induced_2\JJ\1740| (r_amod) anemia_4\NN\14189204|for|ticlopidine-induced|aplastic|factors
D013988_D000380 CID ticlopidine_9\NN\1740|of (r_nmod) initiation_7\NN\7450842|after|ticlopidine (r_dep) weeks_5\NNS\15113229|3|initiation|,|examination (r_dobj) occurred_1\VBD\2623529|agranulocytosis|weeks|recommended|. (l_nsubj) agranulocytosis_0\NN\14189204|
9195768
D018170_D010292 CID sumatriptan_7\NN\1740|of|subcutaneous (r_nmod) use_4\NN\407535|following|the|sumatriptan (r_nmod) sensations_1\NNS\5708432|atypical|use
17147461
D020123_D011507 CID sirolimus-associated_0\JJ\1740| (r_amod) proteinuria_1\NN\14299637|sirolimus-associated|and|dysfunction|.
D020123_D011507 CID sirolimus_11\NN\1740| (r_nsubjpass) associated_13\VBN\628491|that|,|circumstances|,|sirolimus|is|proteinuria (l_nmod) proteinuria_15\NN\14299637|with|and|dysfunction
D020123_D011507 CID sirolimus-associated_3\JJ\1740| (r_amod) proteinuria_4\NN\14299637|of|sirolimus-associated
D020123_D011507 CID sirolimus_21\NN\1740|of (r_nmod) effects_19\NNS\13245626|of|the|molecular|sirolimus|kidney (r_nmod) knowledge_15\NN\23100|by|effects (r_nmod) minimised_13\VBN\831651|occur|,|occurrence|could|be|knowledge|,|use|. (l_dep) use_27\NN\407535|the|sirolimus|populations|,|monitoring|,|use|occurs (l_conj) monitoring_36\NN\879759|close|proteinuria (l_nmod) proteinuria_38\NN\14299637|of|and|function
D020123_D011507 CID sirolimus_21\NN\1740|of (r_nmod) effects_19\NNS\13245626|of|the|molecular|sirolimus|kidney (r_nmod) knowledge_15\NN\23100|by|effects (r_nmod) minimised_13\VBN\831651|occur|,|occurrence|could|be|knowledge|,|use|. (l_dep) use_27\NN\407535|the|sirolimus|populations|,|monitoring|,|use|occurs (l_advcl) occurs_55\VBZ\2623529|if|proteinuria|and|withdrawal|needed (l_nsubj) proteinuria_54\NN\14299637|
D020123_D011507 CID sirolimus_29\NN\1740|of (r_nmod) use_27\NN\407535|the|sirolimus|populations|,|monitoring|,|use|occurs (l_conj) monitoring_36\NN\879759|close|proteinuria (l_nmod) proteinuria_38\NN\14299637|of|and|function
D020123_D011507 CID sirolimus_29\NN\1740|of (r_nmod) use_27\NN\407535|the|sirolimus|populations|,|monitoring|,|use|occurs (l_advcl) occurs_55\VBZ\2623529|if|proteinuria|and|withdrawal|needed (l_nsubj) proteinuria_54\NN\14299637|
D020123_D007674 CID sirolimus-associated_0\JJ\1740| (r_amod) proteinuria_1\NN\14299637|sirolimus-associated|and|dysfunction|. (l_conj) dysfunction_4\NN\14204950|renal
D020123_D007674 CID sirolimus_0\NN\1740| (r_nsubj) represents_1\VBZ\2664769|sirolimus|advance|nephropathy|. (l_advmod) nephropathy_17\RB\1740|
D020123_D007674 CID sirolimus_1\NN\1740| (r_nsubj) share_4\VB\2660631|because|sirolimus|does|not|effects (r_advcl) designated_18\VBN\2475922|share|,|it|has|been|drug|. (l_xcomp) drug_22\NN\14778436|a|'|non-nephrotoxic|' (l_amod) non-nephrotoxic_21\JJ\1740|
D020123_D058186 NONE sirolimus_11\NN\1740| (r_nsubjpass) associated_13\VBN\628491|that|,|circumstances|,|sirolimus|is|proteinuria (l_nmod) proteinuria_15\NN\14299637|with|and|dysfunction (l_conj) dysfunction_19\NN\14204950|acute|renal
D020123_D058186 NONE sirolimus_6\NN\1740|with|(|function (r_nmod) associated_4\VBN\628491|sirolimus|) (r_acl) dysfunction_3\NN\14204950|the|acute|renal|associated
D000809_D011507 NONE angiotensin-converting_45\JJ\1740| (r_amod) inhibitors_47\NNS\20090|of|angiotensin-converting|enzyme|or|blockers (r_nmod) use_43\NN\407535|inhibitors (r_conj) use_27\NN\407535|the|sirolimus|populations|,|monitoring|,|use|occurs (l_conj) monitoring_36\NN\879759|close|proteinuria (l_nmod) proteinuria_38\NN\14299637|of|and|function
D000809_D011507 NONE angiotensin-converting_45\JJ\1740| (r_amod) inhibitors_47\NNS\20090|of|angiotensin-converting|enzyme|or|blockers (r_nmod) use_43\NN\407535|inhibitors (r_conj) use_27\NN\407535|the|sirolimus|populations|,|monitoring|,|use|occurs (l_advcl) occurs_55\VBZ\2623529|if|proteinuria|and|withdrawal|needed (l_nsubj) proteinuria_54\NN\14299637|
D000804_D011507 NONE ii_50\CD\13741022| (r_compound) receptor_51\NN\5225602|angiotensin|ii (r_compound) blockers_52\NNS\10101634|receptor (r_conj) inhibitors_47\NNS\20090|of|angiotensin-converting|enzyme|or|blockers (r_nmod) use_43\NN\407535|inhibitors (r_conj) use_27\NN\407535|the|sirolimus|populations|,|monitoring|,|use|occurs (l_conj) monitoring_36\NN\879759|close|proteinuria (l_nmod) proteinuria_38\NN\14299637|of|and|function
D000804_D011507 NONE ii_50\CD\13741022| (r_compound) receptor_51\NN\5225602|angiotensin|ii (r_compound) blockers_52\NNS\10101634|receptor (r_conj) inhibitors_47\NNS\20090|of|angiotensin-converting|enzyme|or|blockers (r_nmod) use_43\NN\407535|inhibitors (r_conj) use_27\NN\407535|the|sirolimus|populations|,|monitoring|,|use|occurs (l_advcl) occurs_55\VBZ\2623529|if|proteinuria|and|withdrawal|needed (l_nsubj) proteinuria_54\NN\14299637|
12464714
C093622_D008881 NONE rizatriptan_7\JJ\1740| (r_amod) mg_9\NN\13717155|for|rizatriptan|10|versus|ergotamine/caffeine (l_conj) ergotamine/caffeine_11\NN\1740|migraine (l_nmod) migraine_13\NN\14326607|in
C093622_D008881 NONE rizatriptan_0\NNP\1740| (r_nsubj) agonist_7\NN\9613191|rizatriptan|is|a|selective|5-ht(1b/1d|)|receptor|absorption|. (l_nmod) absorption_11\NN\13558490|with|rapid|oral|and|onset|treatment (l_nmod) treatment_20\NN\654885|in|the|acute|migraine (l_nmod) migraine_22\NN\14326607|of
C093622_D008881 NONE rizatriptan_12\JJ\1740| (r_amod) mg_14\NN\13717155|1|rizatriptan|10 (r_compound) tablet_15\NN\4233405|for|mg|ergotamine|tablets|patients (l_nmod) patients_26\NNS\9898892|in|439|treating (l_acl) treating_27\VBG\2376958|attack (l_dobj) attack_31\NN\955060|a|single|migraine|therapy (l_compound) migraine_30\NN\14326607|
D004878_D008881 NONE ergotamine/caffeine_11\NN\1740|migraine (l_nmod) migraine_13\NN\14326607|in
D004878_D008881 NONE ergotamine_18\NN\14712692|to|2|mg/caffeine (r_nmod) tablet_15\NN\4233405|for|mg|ergotamine|tablets|patients (l_nmod) patients_26\NNS\9898892|in|439|treating (l_acl) treating_27\VBG\2376958|attack (l_dobj) attack_31\NN\955060|a|single|migraine|therapy (l_compound) migraine_30\NN\14326607|
D002110_D008881 NONE ergotamine/caffeine_11\NN\1740|migraine (l_nmod) migraine_13\NN\14326607|in
D002110_D008881 NONE mg/caffeine_20\NN\1740|1 (r_dep) ergotamine_18\NN\14712692|to|2|mg/caffeine (r_nmod) tablet_15\NN\4233405|for|mg|ergotamine|tablets|patients (l_nmod) patients_26\NNS\9898892|in|439|treating (l_acl) treating_27\VBG\2376958|attack (l_dobj) attack_31\NN\955060|a|single|migraine|therapy (l_compound) migraine_30\NN\14326607|
D012701_D008881 NONE 5-ht(1b/1d_4\NN\1740| (r_compound) agonist_7\NN\9613191|rizatriptan|is|a|selective|5-ht(1b/1d|)|receptor|absorption|. (l_nmod) absorption_11\NN\13558490|with|rapid|oral|and|onset|treatment (l_nmod) treatment_20\NN\654885|in|the|acute|migraine (l_nmod) migraine_22\NN\14326607|of
C093622_D006261 NONE rizatriptan_19\JJ\1740| (r_dobj) preferring_18\VBG\1777210|rizatriptan (r_acl) patients_17\NNS\9898892|of|preferring (r_nmod) %_15\NN\1740|by|67.3|patients|and|% (r_nmod) cited_12\VBN\730052|% (r_acl) reason_8\NN\9178821|relief|was|the|important|preference|,|cited|. (l_nsubj) relief_1\NN\7492516|faster|headache (l_nmod) headache_3\NN\5829480|of
C093622_D006261 NONE rizatriptan_9\NN\1740|for (r_nmod) %_7\NN\1740|relief|was|75.9|rizatriptan|and|%|,|superior|. (l_nsubj) relief_1\NN\7492516|headache|h (l_compound) headache_0\NNP\5829480|
C093622_D006261 NONE rizatriptan_24\NN\1740| (r_nsubj) superior_26\JJ\1740|with|rizatriptan|being|ergotamine/caffeine|min (r_advcl) %_7\NN\1740|relief|was|75.9|rizatriptan|and|%|,|superior|. (l_nsubj) relief_1\NN\7492516|headache|h (l_compound) headache_0\NNP\5829480|
D004878_D006261 NONE ergotamine/caffeine_27\NN\1740| (r_dobj) preferred_26\VBD\1777210|who|ergotamine/caffeine (r_acl:relcl) patients_24\NNS\9898892|of|preferred (r_nmod) %_22\NN\1740|54.2|patients (r_conj) %_15\NN\1740|by|67.3|patients|and|% (r_nmod) cited_12\VBN\730052|% (r_acl) reason_8\NN\9178821|relief|was|the|important|preference|,|cited|. (l_nsubj) relief_1\NN\7492516|faster|headache (l_nmod) headache_3\NN\5829480|of
D004878_D006261 NONE ergotamine/caffeine_14\NN\1740|for|< (r_nmod) %_12\NN\1740|47.3|ergotamine/caffeine (r_conj) %_7\NN\1740|relief|was|75.9|rizatriptan|and|%|,|superior|. (l_nsubj) relief_1\NN\7492516|headache|h (l_compound) headache_0\NNP\5829480|
D004878_D006261 NONE ergotamine/caffeine_28\NN\1740|to (r_nmod) superior_26\JJ\1740|with|rizatriptan|being|ergotamine/caffeine|min (r_advcl) %_7\NN\1740|relief|was|75.9|rizatriptan|and|%|,|superior|. (l_nsubj) relief_1\NN\7492516|headache|h (l_compound) headache_0\NNP\5829480|
D002110_D006261 NONE ergotamine/caffeine_27\NN\1740| (r_dobj) preferred_26\VBD\1777210|who|ergotamine/caffeine (r_acl:relcl) patients_24\NNS\9898892|of|preferred (r_nmod) %_22\NN\1740|54.2|patients (r_conj) %_15\NN\1740|by|67.3|patients|and|% (r_nmod) cited_12\VBN\730052|% (r_acl) reason_8\NN\9178821|relief|was|the|important|preference|,|cited|. (l_nsubj) relief_1\NN\7492516|faster|headache (l_nmod) headache_3\NN\5829480|of
D002110_D006261 NONE ergotamine/caffeine_14\NN\1740|for|< (r_nmod) %_12\NN\1740|47.3|ergotamine/caffeine (r_conj) %_7\NN\1740|relief|was|75.9|rizatriptan|and|%|,|superior|. (l_nsubj) relief_1\NN\7492516|headache|h (l_compound) headache_0\NNP\5829480|
D002110_D006261 NONE ergotamine/caffeine_28\NN\1740|to (r_nmod) superior_26\JJ\1740|with|rizatriptan|being|ergotamine/caffeine|min (r_advcl) %_7\NN\1740|relief|was|75.9|rizatriptan|and|%|,|superior|. (l_nsubj) relief_1\NN\7492516|headache|h (l_compound) headache_0\NNP\5829480|
C093622_D010146 NONE rizatriptan_15\NN\1740|of (r_nmod) favor_13\NN\34574|in|rizatriptan (r_nmod) also_11\RB\1740|endpoint|was|favor|. (l_nsubj) endpoint_2\NN\8566028|the|co-primary|being (l_advcl) being_4\VBG\836236|of|pain|free (l_acomp) pain_5\NN\14299637|
C093622_D010146 NONE rizatriptan_10\NN\1740|after (r_dep) h_8\NN\14622893|2|rizatriptan (r_nmod) free_6\JJ\1740|percent|were|pain|h|,|compared|,|superior|. (l_advmod) pain_5\NN\14299637|
C093622_D010146 NONE rizatriptan_27\NN\1740| (r_nsubj) superior_29\JJ\1740|rizatriptan|being|h (r_conj) free_6\JJ\1740|percent|were|pain|h|,|compared|,|superior|. (l_advmod) pain_5\NN\14299637|
C093622_D010146 NONE rizatriptan_6\NN\1740| (r_dobj) taking_5\VBG\2367363|rizatriptan (r_acl) patients_4\NNS\9898892|of|taking (r_nmod) %_2\NN\1740|36|patients (r_nsubj) free_9\JJ\1740|%|were|pain|h|and|had|. (l_advmod) pain_8\NN\14299637|
D004878_D010146 NONE ergotamine/caffeine_18\NN\1740|with|0.001 (r_nmod) treated_16\VBN\2376958|ergotamine/caffeine (r_acl) %_15\NN\1740|with|24.3|treated (r_nmod) compared_12\VBN\644583|% (r_dep) free_6\JJ\1740|percent|were|pain|h|,|compared|,|superior|. (l_advmod) pain_5\NN\14299637|
D004878_D010146 NONE ergotamine/caffeine_33\NN\1740|on|< (r_nmod) patients_31\NNS\9898892|of|ergotamine/caffeine (r_nmod) %_29\NN\1740|to|20|patients (r_nmod) compared_26\VBN\644583|% (r_prep) had_14\VBD\2108377|recurrence|or|need|,|compared (r_conj) free_9\JJ\1740|%|were|pain|h|and|had|. (l_advmod) pain_8\NN\14299637|
D002110_D010146 NONE ergotamine/caffeine_18\NN\1740|with|0.001 (r_nmod) treated_16\VBN\2376958|ergotamine/caffeine (r_acl) %_15\NN\1740|with|24.3|treated (r_nmod) compared_12\VBN\644583|% (r_dep) free_6\JJ\1740|percent|were|pain|h|,|compared|,|superior|. (l_advmod) pain_5\NN\14299637|
D002110_D010146 NONE ergotamine/caffeine_33\NN\1740|on|< (r_nmod) patients_31\NNS\9898892|of|ergotamine/caffeine (r_nmod) %_29\NN\1740|to|20|patients (r_nmod) compared_26\VBN\644583|% (r_prep) had_14\VBD\2108377|recurrence|or|need|,|compared (r_conj) free_9\JJ\1740|%|were|pain|h|and|had|. (l_advmod) pain_8\NN\14299637|
C093622_D009325 CID rizatriptan_0\NNP\1740| (r_nsubj) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|h|intake|p|. (l_nmod) proportions_8\NNS\13824815|in|the|patients|and|patients (l_nmod) patients_10\NNS\9898892|of|nausea (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting
C093622_D009325 CID rizatriptan_17\JJ\1740|after|and|ergotamine/caffeine (r_nmod) events_4\NNS\23100|the|common|adverse|incidence|rizatriptan|,|respectively (r_nsubj) dizziness_24\JJ\1740|events|,|were|%|,|nausea|%|and|somnolence|. (l_conj) nausea_32\NN\14299637|4.2
C093622_D014839 NONE rizatriptan_0\NNP\1740| (r_nsubj) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|h|intake|p|. (l_nmod) proportions_8\NNS\13824815|in|the|patients|and|patients (l_nmod) patients_10\NNS\9898892|of|nausea (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting (l_conj) vomiting_15\NN\116687|,|phonophobia
C093622_D012001 NONE rizatriptan_0\NNP\1740| (r_nsubj) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|h|intake|p|. (l_nmod) proportions_8\NNS\13824815|in|the|patients|and|patients (l_nmod) patients_10\NNS\9898892|of|nausea (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting (l_conj) vomiting_15\NN\116687|,|phonophobia (l_conj) phonophobia_17\NN\14382238|or|photophobia
C093622_D020795 NONE rizatriptan_0\NNP\1740| (r_nsubj) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|h|intake|p|. (l_nmod) proportions_8\NNS\13824815|in|the|patients|and|patients (l_nmod) patients_10\NNS\9898892|of|nausea (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting (l_conj) vomiting_15\NN\116687|,|phonophobia (l_conj) phonophobia_17\NN\14382238|or|photophobia (l_conj) photophobia_19\NN\14382238|
D004878_D009325 NONE ergotamine/caffeine_5\NN\1740|to (r_nmod) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|h|intake|p|. (l_nmod) proportions_8\NNS\13824815|in|the|patients|and|patients (l_nmod) patients_10\NNS\9898892|of|nausea (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting
D004878_D009325 NONE ergotamine/caffeine_19\NN\1740| (r_conj) rizatriptan_17\JJ\1740|after|and|ergotamine/caffeine (r_nmod) events_4\NNS\23100|the|common|adverse|incidence|rizatriptan|,|respectively (r_nsubj) dizziness_24\JJ\1740|events|,|were|%|,|nausea|%|and|somnolence|. (l_conj) nausea_32\NN\14299637|4.2
D004878_D014839 NONE ergotamine/caffeine_5\NN\1740|to (r_nmod) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|h|intake|p|. (l_nmod) proportions_8\NNS\13824815|in|the|patients|and|patients (l_nmod) patients_10\NNS\9898892|of|nausea (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting (l_conj) vomiting_15\NN\116687|,|phonophobia
D004878_D012001 NONE ergotamine/caffeine_5\NN\1740|to (r_nmod) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|h|intake|p|. (l_nmod) proportions_8\NNS\13824815|in|the|patients|and|patients (l_nmod) patients_10\NNS\9898892|of|nausea (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting (l_conj) vomiting_15\NN\116687|,|phonophobia (l_conj) phonophobia_17\NN\14382238|or|photophobia
D004878_D020795 NONE ergotamine/caffeine_5\NN\1740|to (r_nmod) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|h|intake|p|. (l_nmod) proportions_8\NNS\13824815|in|the|patients|and|patients (l_nmod) patients_10\NNS\9898892|of|nausea (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting (l_conj) vomiting_15\NN\116687|,|phonophobia (l_conj) phonophobia_17\NN\14382238|or|photophobia (l_conj) photophobia_19\NN\14382238|
D002110_D009325 NONE ergotamine/caffeine_5\NN\1740|to (r_nmod) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|h|intake|p|. (l_nmod) proportions_8\NNS\13824815|in|the|patients|and|patients (l_nmod) patients_10\NNS\9898892|of|nausea (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting
D002110_D009325 NONE ergotamine/caffeine_19\NN\1740| (r_conj) rizatriptan_17\JJ\1740|after|and|ergotamine/caffeine (r_nmod) events_4\NNS\23100|the|common|adverse|incidence|rizatriptan|,|respectively (r_nsubj) dizziness_24\JJ\1740|events|,|were|%|,|nausea|%|and|somnolence|. (l_conj) nausea_32\NN\14299637|4.2
D002110_D014839 NONE ergotamine/caffeine_5\NN\1740|to (r_nmod) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|h|intake|p|. (l_nmod) proportions_8\NNS\13824815|in|the|patients|and|patients (l_nmod) patients_10\NNS\9898892|of|nausea (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting (l_conj) vomiting_15\NN\116687|,|phonophobia
D002110_D012001 NONE ergotamine/caffeine_5\NN\1740|to (r_nmod) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|h|intake|p|. (l_nmod) proportions_8\NNS\13824815|in|the|patients|and|patients (l_nmod) patients_10\NNS\9898892|of|nausea (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting (l_conj) vomiting_15\NN\116687|,|phonophobia (l_conj) phonophobia_17\NN\14382238|or|photophobia
D002110_D020795 NONE ergotamine/caffeine_5\NN\1740|to (r_nmod) superior_3\JJ\1740|rizatriptan|was|also|ergotamine/caffeine|proportions|h|intake|p|. (l_nmod) proportions_8\NNS\13824815|in|the|patients|and|patients (l_nmod) patients_10\NNS\9898892|of|nausea (l_nmod) nausea_13\NN\14299637|with|no|,|vomiting (l_conj) vomiting_15\NN\116687|,|phonophobia (l_conj) phonophobia_17\NN\14382238|or|photophobia (l_conj) photophobia_19\NN\14382238|
C093622_D004244 CID rizatriptan_17\JJ\1740|after|and|ergotamine/caffeine (r_nmod) events_4\NNS\23100|the|common|adverse|incidence|rizatriptan|,|respectively (r_nsubj) dizziness_24\JJ\1740|events|,|were|%|,|nausea|%|and|somnolence|.
C093622_D006970 NONE rizatriptan_17\JJ\1740|after|and|ergotamine/caffeine (r_nmod) events_4\NNS\23100|the|common|adverse|incidence|rizatriptan|,|respectively (r_nsubj) dizziness_24\JJ\1740|events|,|were|%|,|nausea|%|and|somnolence|. (l_conj) somnolence_40\NN\14015731|%
D004878_D004244 NONE ergotamine/caffeine_19\NN\1740| (r_conj) rizatriptan_17\JJ\1740|after|and|ergotamine/caffeine (r_nmod) events_4\NNS\23100|the|common|adverse|incidence|rizatriptan|,|respectively (r_nsubj) dizziness_24\JJ\1740|events|,|were|%|,|nausea|%|and|somnolence|.
D004878_D006970 NONE ergotamine/caffeine_19\NN\1740| (r_conj) rizatriptan_17\JJ\1740|after|and|ergotamine/caffeine (r_nmod) events_4\NNS\23100|the|common|adverse|incidence|rizatriptan|,|respectively (r_nsubj) dizziness_24\JJ\1740|events|,|were|%|,|nausea|%|and|somnolence|. (l_conj) somnolence_40\NN\14015731|%
D002110_D004244 NONE ergotamine/caffeine_19\NN\1740| (r_conj) rizatriptan_17\JJ\1740|after|and|ergotamine/caffeine (r_nmod) events_4\NNS\23100|the|common|adverse|incidence|rizatriptan|,|respectively (r_nsubj) dizziness_24\JJ\1740|events|,|were|%|,|nausea|%|and|somnolence|.
D002110_D006970 NONE ergotamine/caffeine_19\NN\1740| (r_conj) rizatriptan_17\JJ\1740|after|and|ergotamine/caffeine (r_nmod) events_4\NNS\23100|the|common|adverse|incidence|rizatriptan|,|respectively (r_nsubj) dizziness_24\JJ\1740|events|,|were|%|,|nausea|%|and|somnolence|. (l_conj) somnolence_40\NN\14015731|%
18619688
D004317_D003643 NONE adriamycin-induced_0\JJ\1740| (r_amod) death_3\NN\7296428|adriamycin-induced|autophagic|cardiomyocyte
D004317_D003643 NONE adriamycin_19\NN\1740|by (r_nmod) induced_17\VBN\1627355|adriamycin (r_acl) rats_16\NNS\2329401|in|induced (r_nmod) failure_14\NN\66216|of|heart|rats (r_nmod) pathogenesis_11\NN\13533470|in|the|failure (r_nmod) plays_5\VBZ\1072262|death|role|pathogenesis|. (l_nsubj) death_4\NN\7296428|autophagic|cardiomyocyte
D004317_D006333 CID adriamycin-induced_0\JJ\1740| (r_amod) death_3\NN\7296428|adriamycin-induced|autophagic|cardiomyocyte (r_nsubj) plays_4\VBZ\1072262|death|role|model|. (l_nmod) model_11\NN\5888929|in|a|rat|failure (l_nmod) failure_14\NN\66216|of|heart
D004317_D006333 CID adriamycin_9\NN\1740|by (r_nmod) induced_7\VBN\1627355|adriamycin (r_acl) failure_6\NN\66216|heart|induced
D004317_D006333 CID adriamycin_20\NN\1740|by (r_nmod) induced_18\VBN\1627355|adriamycin (r_acl) failure_17\NN\66216|of|heart|induced
D004317_D006333 CID adriamycin_20\NN\1740|by (r_nmod) induced_18\VBN\1627355|adriamycin (r_acl) failure_17\NN\66216|of|heart|induced (r_nmod) progression_14\NN\8457976|in|the|failure (r_nmod) involved_11\VBN\2676054|whether|autophagy|was|progression (r_ccomp) investigate_7\VB\644583|to|involved|,|develop (l_advcl) develop_26\VB\1753788|so|that|we|can|strategy (l_dobj) strategy_30\NN\5902545|a|novel|treatment|failure (l_nmod) failure_33\NN\66216|for|heart
D004317_D006333 CID adriamycin_23\NN\1740|by (r_nmod) induced_21\VBN\1627355|adriamycin (r_acl) rats_20\NNS\2329401|of|induced (r_nmod) model_18\NN\5888929|in|a|heart|failure|rats (l_compound) failure_17\NN\66216|
D004317_D006333 CID adriamycin_19\NN\1740|by (r_nmod) induced_17\VBN\1627355|adriamycin (r_acl) rats_16\NNS\2329401|in|induced (r_nmod) failure_14\NN\66216|of|heart|rats
D004317_D006333 CID adriamycin_13\NN\1740|by (r_nmod) caused_11\VBN\1617192|adriamycin|pathway (r_acl) failure_10\NN\66216|of|heart|caused
C025946_D006333 NONE 3-methyladenine_2\NN\1740|3ma|,|inhibitor (r_appos) methods_0\NNS\5616786|:|3-methyladenine (r_nsubjpass) used_13\VBN\1156834|methods|was|model|. (l_nmod) model_18\NN\5888929|in|a|heart|failure|rats (l_compound) failure_17\NN\66216|
C025946_D006333 NONE 3ma_4\NN\1740|(|) (r_appos) 3-methyladenine_2\NN\1740|3ma|,|inhibitor (r_appos) methods_0\NNS\5616786|:|3-methyladenine (r_nsubjpass) used_13\VBN\1156834|methods|was|model|. (l_nmod) model_18\NN\5888929|in|a|heart|failure|rats (l_compound) failure_17\NN\66216|
11250767
D011441_D014657 NONE propylthiouracil-induced_0\JJ\1740| (r_amod) vasculitis_5\NN\14336539|propylthiouracil-induced|perinuclear-staining|antineutrophil|cytoplasmic|autoantibody-positive|conjunction|.
D011441_D014657 NONE propylthiouracil-induced_7\JJ\1740| (r_amod) manifesting_9\NN\1740|of|propylthiouracil-induced|vasculitis|pericarditis (l_compound) vasculitis_8\NN\14336539|
D011441_D014657 NONE uracil_16\NN\14964590| (r_compound) therapy_17\NN\657604|with|propylthio-|uracil (r_nmod) associated_13\VBN\628491|therapy (r_acl) vasculitis_12\NN\14336539|in|anti-mpo|panca-positive|associated
D011441_D014657 NONE uracil_14\NN\14964590| (r_compound) therapy_15\NN\657604|to|propylthio-|uracil (r_nmod) attributable_11\JJ\1740|therapy (r_amod) vasculitis_10\NN\14336539|of|drug-induced|attributable
D011441_D010493 CID propylthiouracil-induced_0\JJ\1740| (r_amod) vasculitis_5\NN\14336539|propylthiouracil-induced|perinuclear-staining|antineutrophil|cytoplasmic|autoantibody-positive|conjunction|. (l_nmod) conjunction_7\NN\5048123|in|pericarditis (l_nmod) pericarditis_9\NN\14338942|with
D011441_D010493 CID propylthiouracil-induced_7\JJ\1740| (r_amod) manifesting_9\NN\1740|of|propylthiouracil-induced|vasculitis|pericarditis (l_nmod) pericarditis_11\NN\14338942|with
D011441_D010493 CID propylthiouracil_15\NN\14727670|with|developed (l_acl:relcl) developed_27\VBD\1753788|whom|syndrome (l_nsubj) syndrome_19\NN\5870365|a|pericarditis (l_nmod) pericarditis_21\NN\14338942|of|,|fever|,|and|glomerulonephritis
D011441_D010493 CID uracil_16\NN\14964590| (r_compound) therapy_17\NN\657604|with|propylthio-|uracil (r_nmod) associated_13\VBN\628491|therapy (r_acl) vasculitis_12\NN\14336539|in|anti-mpo|panca-positive|associated (r_nmod) reports_6\NNS\6470073|no|prior|pericarditis|vasculitis (l_nmod) pericarditis_8\NN\14338942|of
D011441_D010493 CID uracil_14\NN\14964590| (r_compound) therapy_15\NN\657604|to|propylthio-|uracil (r_nmod) attributable_11\JJ\1740|therapy (r_amod) vasculitis_10\NN\14336539|of|drug-induced|attributable (r_nmod) manifestation_7\NN\7321772|pericarditis|may|be|the|initial|vasculitis (l_nsubj) pericarditis_2\NNP\14338942|
D011441_D006980 NONE propylthiouracil_15\NN\14727670|with|developed (r_nmod) treated_13\VBN\2376958|propylthiouracil (r_acl) hyperthyroidism_12\NN\14059928|with|treated
D011441_D005334 CID propylthiouracil_15\NN\14727670|with|developed (l_acl:relcl) developed_27\VBD\1753788|whom|syndrome (l_nsubj) syndrome_19\NN\5870365|a|pericarditis (l_nmod) pericarditis_21\NN\14338942|of|,|fever|,|and|glomerulonephritis (l_conj) fever_23\NN\14299637|
D011441_D005921 CID propylthiouracil_15\NN\14727670|with|developed (l_acl:relcl) developed_27\VBD\1753788|whom|syndrome (l_nsubj) syndrome_19\NN\5870365|a|pericarditis (l_nmod) pericarditis_21\NN\14338942|of|,|fever|,|and|glomerulonephritis (l_conj) glomerulonephritis_26\NN\14113798|
11706060
D019344_D009202 NONE lactate_8\NN\14850483|plasma (r_dobj) elevates_6\VBZ\2391803|lactate|mice (r_conj) causes_3\VBZ\1617192|therapy|cardiomyopathy|and|elevates|. (l_dobj) cardiomyopathy_4\JJ\1740|
D019344_D009202 NONE lactate_18\NN\14850483|in|elevated|plasma|la|aids (r_conj) cardiomyopathy_10\JJ\1740|in|cm|and|lactate
D019344_D009202 NONE lactate_18\NN\14850483|in|elevated|plasma|la|aids (r_conj) cardiomyopathy_10\JJ\1740|in|cm|and|lactate (l_appos) cm_12\NN\13649268|(|)
D019344_D009202 NONE la_20\NN\14625458|(|) (r_appos) lactate_18\NN\14850483|in|elevated|plasma|la|aids (r_conj) cardiomyopathy_10\JJ\1740|in|cm|and|lactate
D019344_D009202 NONE la_20\NN\14625458|(|) (r_appos) lactate_18\NN\14850483|in|elevated|plasma|la|aids (r_conj) cardiomyopathy_10\JJ\1740|in|cm|and|lactate (l_appos) cm_12\NN\13649268|(|)
D019344_D009202 NONE la_41\NNP\14625458|of|plasma (r_nmod) determination_38\NN\43195|la (r_conj) mrna_20\NN\14832193|(|ventricular|encoding|,|and|determination (r_nmod) underwent_7\VBD\109660|termination|,|mice|echocardiography|mrna|. (l_dobj) echocardiography_8\NN\177127|,|quantitation (l_conj) quantitation_10\NN\1740|abundance (l_nmod) abundance_12\NN\5108740|of|markers (l_nmod) markers_15\NNS\21939|of|molecular|cm (l_nmod) cm_17\NN\13649268|of
D019344_D009202 NONE la_10\NN\14625458|with|elevated|mice (r_nmod) cm_7\NN\13649268|mitochondrial|la
D019344_D000163 NONE lactate_8\NN\14850483|plasma (r_dobj) elevates_6\VBZ\2391803|lactate|mice (l_nmod) mice_12\NNS\2329401|in|transgenic|aids (l_compound) aids_11\NN\13974317|
D019344_D000163 NONE lactate_18\NN\14850483|in|elevated|plasma|la|aids (l_nmod) aids_23\NN\13974317|in
D019344_D000163 NONE la_20\NN\14625458|(|) (r_appos) lactate_18\NN\14850483|in|elevated|plasma|la|aids (l_nmod) aids_23\NN\13974317|in
D019344_D000163 NONE la_10\NN\14625458|with|elevated|mice (l_nmod) mice_14\NNS\2329401|in|aids|transgenic (l_compound) aids_12\NN\13974317|
D019344_D028361 NONE lactate_18\NN\14850483|in|elevated|plasma|la|aids (r_conj) cardiomyopathy_10\JJ\1740|in|cm|and|lactate (r_nmod) implicated_8\VBN\2677097|therapy|is|cardiomyopathy|mechanisms|. (l_nmod) mechanisms_25\NNS\13446390|through|dysfunction (l_nmod) dysfunction_28\NN\14204950|of|mitochondrial
D019344_D028361 NONE la_20\NN\14625458|(|) (r_appos) lactate_18\NN\14850483|in|elevated|plasma|la|aids (r_conj) cardiomyopathy_10\JJ\1740|in|cm|and|lactate (r_nmod) implicated_8\VBN\2677097|therapy|is|cardiomyopathy|mechanisms|. (l_nmod) mechanisms_25\NNS\13446390|through|dysfunction (l_nmod) dysfunction_28\NN\14204950|of|mitochondrial
D015215_D000163 NONE zidovudine_33\NN\3834836|of|,|lamivudine|,|and|indinavir|or|control (r_nmod) combination_31\NN\7951464|with|the|haart|zidovudine|days|or|days (r_nmod) treated_27\VBN\2376958|determine|mice|littermates|were|combination|. (l_nsubjpass) mice_13\NNS\2329401|8-week-old|transgenic|aids|3delta (l_compound) aids_12\NN\13974317|
D019259_D000163 NONE lamivudine_35\NN\3834836| (r_conj) zidovudine_33\NN\3834836|of|,|lamivudine|,|and|indinavir|or|control (r_nmod) combination_31\NN\7951464|with|the|haart|zidovudine|days|or|days (r_nmod) treated_27\VBN\2376958|determine|mice|littermates|were|combination|. (l_nsubjpass) mice_13\NNS\2329401|8-week-old|transgenic|aids|3delta (l_compound) aids_12\NN\13974317|
D019469_D000163 NONE indinavir_38\NN\4013993| (r_conj) zidovudine_33\NN\3834836|of|,|lamivudine|,|and|indinavir|or|control (r_nmod) combination_31\NN\7951464|with|the|haart|zidovudine|days|or|days (r_nmod) treated_27\VBN\2376958|determine|mice|littermates|were|combination|. (l_nsubjpass) mice_13\NNS\2329401|8-week-old|transgenic|aids|3delta (l_compound) aids_12\NN\13974317|
D002118_D009202 NONE calcium_30\NN\14625458| (r_compound) atpase_31\NN\1740|sarcoplasmic|calcium|serca2 (r_conj) factor_24\NN\7326557|atrial|natriuretic|anf|and|atpase|) (r_dobj) encoding_21\VBG\115157|factor (r_acl) mrna_20\NN\14832193|(|ventricular|encoding|,|and|determination (r_nmod) underwent_7\VBD\109660|termination|,|mice|echocardiography|mrna|. (l_dobj) echocardiography_8\NN\177127|,|quantitation (l_conj) quantitation_10\NN\1740|abundance (l_nmod) abundance_12\NN\5108740|of|markers (l_nmod) markers_15\NNS\21939|of|molecular|cm (l_nmod) cm_17\NN\13649268|of
9100294
D002118_D018376 NONE calcium_7\NN\14625458| (r_compound) channel_8\NN\6251781|calcium (r_compound) blockers_9\NNS\10101634|to|channel (r_nmod) exposed_5\VBN\2110927|blockers (r_acl) fetuses_4\NNS\1471682|in|rat|exposed (r_nmod) alterations_1\NNS\7283608|cardiovascular|fetuses|.
D002118_D018376 NONE calcium_7\NN\14625458| (r_compound) channel_8\NN\6251781|calcium (r_compound) blocker_9\NN\10101634|that|a|new|channel|,|ro|alterations (l_conj) alterations_18\NNS\7283608|induced|cardiovascular|fetuses
D002118_D018376 NONE calcium_10\NN\14625458| (r_compound) channel_11\NN\6251781|calcium (r_compound) blockers_12\NNS\10101634|channel|general (r_nsubj) induce_15\VBP\1627355|that|blockers|malformations (l_dobj) malformations_17\NNS\14213199|cardiovascular
D002118_D018376 NONE calcium_7\NN\14625458| (r_compound) channel_8\NN\6251781|calcium (r_compound) blockers_9\NNS\10101634|of|these|channel (r_nmod) one_4\CD\13741022|blockers (r_xcomp) administered_3\VBN\2436349|rats|were|one|period|and|offspring|. (l_conj) offspring_18\NN\10235549|the|examined (l_acl) examined_19\VBN\789138|day (l_nmod) day_21\NN\15154774|on|20|gestation (l_nmod) gestation_24\NN\15116532|of|malformations (l_nmod) malformations_27\NNS\14213199|for|cardiovascular
D002118_D018376 NONE calcium_15\NN\14625458| (r_compound) channel_16\NN\6251781|calcium (r_compound) blockers_17\NNS\10101634|of|the|four|channel (r_nmod) each_11\DT\1740|to|blockers (r_nmod) exposure_9\NN\5042871|after|each (r_nmod) observed_7\VBN\2163746|incidence|was|exposure|,|but|significant (l_nsubjpass) incidence_2\NN\13821570|a|low|malformations (l_nmod) malformations_5\NNS\14213199|of|cardiovascular
D020748_D018376 CID 5967_14\CD\1740|- (r_prep) 40_12\CD\13745420|5967 (r_nummod) ro_11\NN\6894544|40 (r_appos) blocker_9\NN\10101634|that|a|new|channel|,|ro|alterations (l_conj) alterations_18\NNS\7283608|induced|cardiovascular|fetuses
D014700_D018376 CID verapamil_27\NN\2938514|only|for|and|nifedipine (r_nmod) significant_24\JJ\1740|incidence|was|statistically|verapamil|. (r_conj) observed_7\VBN\2163746|incidence|was|exposure|,|but|significant (l_nsubjpass) incidence_2\NN\13821570|a|low|malformations (l_nmod) malformations_5\NNS\14213199|of|cardiovascular
D009543_D018376 CID nifedipine_29\NN\2938514| (r_conj) verapamil_27\NN\2938514|only|for|and|nifedipine (r_nmod) significant_24\JJ\1740|incidence|was|statistically|verapamil|. (r_conj) observed_7\VBN\2163746|incidence|was|exposure|,|but|significant (l_nsubjpass) incidence_2\NN\13821570|a|low|malformations (l_nmod) malformations_5\NNS\14213199|of|cardiovascular
16867021
D006632_D002375 NONE histamine_10\NN\14739004| (r_compound) ligands_12\NNS\20090|of|histamine|h(3)-receptor (r_nmod) effect_8\NN\34213|the|ligands|catalepsy (l_nmod) catalepsy_15\NN\14023236|on|neuroleptic-induced|,|behavior|mice
D001058_D002375 NONE apomorphine-induced_17\JJ\1740| (r_amod) behavior_19\NN\407535|apomorphine-induced|climbing|and|activities (r_conj) catalepsy_15\NN\14023236|on|neuroleptic-induced|,|behavior|mice
D001058_D002375 NONE apomorphine_12\NN\3786417|s.c.|and|amphetamine|s.c. (r_nsubjpass) used_26\VBN\1156834|while|apomorphine|were|studying (r_advcl) induced_2\VBN\1627355|catalepsy|was|haloperidol|,|used|. (l_nsubjpass) catalepsy_0\NNP\14023236|
D001058_D002375 NONE apomorphine-induced_15\JJ\1740| (r_amod) climbing_16\NN\7445480|apomorphine-induced|mice (r_dobj) reducing_14\VBG\441445|climbing (r_conj) reducing_10\VBG\441445|hyperactivity|and|reducing (r_conj) potentiating_6\VBG\229605|by|catalepsy|,|reducing (l_dobj) catalepsy_8\NN\14023236|haloperidol-induced
D000661_D002375 NONE amphetamine-induced_21\JJ\1740| (r_amod) activities_23\NNS\30358|amphetamine-induced|locomotor (r_conj) behavior_19\NN\407535|apomorphine-induced|climbing|and|activities (r_conj) catalepsy_15\NN\14023236|on|neuroleptic-induced|,|behavior|mice
D000661_D002375 NONE amphetamine_19\NN\3248958| (r_conj) apomorphine_12\NN\3786417|s.c.|and|amphetamine|s.c. (r_nsubjpass) used_26\VBN\1156834|while|apomorphine|were|studying (r_advcl) induced_2\VBN\1627355|catalepsy|was|haloperidol|,|used|. (l_nsubjpass) catalepsy_0\NNP\14023236|
D000661_D002375 NONE amphetamine-induced_11\JJ\1740| (r_amod) hyperactivity_12\NN\14052403|amphetamine-induced (r_dobj) reducing_10\VBG\441445|hyperactivity|and|reducing (r_conj) potentiating_6\VBG\229605|by|catalepsy|,|reducing (l_dobj) catalepsy_8\NN\14023236|haloperidol-induced
D006220_D002375 CID haloperidol_4\NN\3713736|by|p.o. (r_nmod) induced_2\VBN\1627355|catalepsy|was|haloperidol|,|used|. (l_nsubjpass) catalepsy_0\NNP\14023236|
D006220_D002375 CID haloperidol_16\NN\3713736|to (r_nmod) prior_14\RB\1740|haloperidol (r_amod) administration_0\NN\1133281|thp|mg/kg|h|prior (r_nsubj) resulted_17\VBD\2633881|administration|increase|. (l_nmod) increase_21\NN\13576355|in|a|dose-dependent|times|p (l_nmod) times_25\NNS\15113229|in|the|catalepsy (l_compound) catalepsy_24\NN\14023236|
D006220_D002375 CID haloperidol-induced_7\JJ\1740| (r_amod) catalepsy_8\NN\14023236|haloperidol-induced
C069357_D002375 NONE (r)-alpha-methylhistamine_0\NN\1740|ramh|i.c.v.|and|thioperamide|mg/kg (r_nsubj) cause_24\VB\1617192|(r)-alpha-methylhistamine|,|se|did|not|catalepsy|. (l_dobj) catalepsy_25\NN\14023236|
C069357_D002375 NONE ramh_2\NN\1740|(|) (r_appos) (r)-alpha-methylhistamine_0\NN\1740|ramh|i.c.v.|and|thioperamide|mg/kg (r_nsubj) cause_24\VB\1617192|(r)-alpha-methylhistamine|,|se|did|not|catalepsy|. (l_dobj) catalepsy_25\NN\14023236|
C052075_D002375 CID thioperamide_10\NN\1740|thp (r_conj) (r)-alpha-methylhistamine_0\NN\1740|ramh|i.c.v.|and|thioperamide|mg/kg (r_nsubj) cause_24\VB\1617192|(r)-alpha-methylhistamine|,|se|did|not|catalepsy|. (l_dobj) catalepsy_25\NN\14023236|
C052075_D002375 CID thp_12\NN\1740|(|) (r_appos) thioperamide_10\NN\1740|thp (r_conj) (r)-alpha-methylhistamine_0\NN\1740|ramh|i.c.v.|and|thioperamide|mg/kg (r_nsubj) cause_24\VB\1617192|(r)-alpha-methylhistamine|,|se|did|not|catalepsy|. (l_dobj) catalepsy_25\NN\14023236|
C052075_D002375 CID thp_2\NN\1740|of (r_nmod) administration_0\NN\1133281|thp|mg/kg|h|prior (r_nsubj) resulted_17\VBD\2633881|administration|increase|. (l_nmod) increase_21\NN\13576355|in|a|dose-dependent|times|p (l_nmod) times_25\NNS\15113229|in|the|catalepsy (l_compound) catalepsy_24\NN\14023236|
C052075_D002375 CID thp_0\NN\1740| (r_nsubj) exhibited_1\VBD\2632167|thp|profile|potentiating|. (l_advcl) potentiating_6\VBG\229605|by|catalepsy|,|reducing (l_dobj) catalepsy_8\NN\14023236|haloperidol-induced
D000661_D006948 CID amphetamine-induced_1\JJ\1740| (r_amod) hyperactivity_2\NN\14052403|on|amphetamine-induced|,|thp|time|,|distance|.
D000661_D006948 CID amphetamine-induced_11\JJ\1740| (r_amod) hyperactivity_12\NN\14052403|amphetamine-induced
C052075_D006948 NONE thp_4\NN\1740|mg/kg (r_conj) hyperactivity_2\NN\14052403|on|amphetamine-induced|,|thp|time|,|distance|.
C052075_D006948 NONE thp_0\NN\1740| (r_nsubj) exhibited_1\VBD\2632167|thp|profile|potentiating|. (l_advcl) potentiating_6\VBG\229605|by|catalepsy|,|reducing (l_conj) reducing_10\VBG\441445|hyperactivity|and|reducing (l_dobj) hyperactivity_12\NN\14052403|amphetamine-induced
D006220_D006948 NONE haloperidol-induced_7\JJ\1740| (r_amod) catalepsy_8\NN\14023236|haloperidol-induced (r_dobj) potentiating_6\VBG\229605|by|catalepsy|,|reducing (l_conj) reducing_10\VBG\441445|hyperactivity|and|reducing (l_dobj) hyperactivity_12\NN\14052403|amphetamine-induced
D001058_D006948 NONE apomorphine-induced_15\JJ\1740| (r_amod) climbing_16\NN\7445480|apomorphine-induced|mice (r_dobj) reducing_14\VBG\441445|climbing (r_conj) reducing_10\VBG\441445|hyperactivity|and|reducing (l_dobj) hyperactivity_12\NN\14052403|amphetamine-induced
19269743
D002211_D010146 CID capsaicin-induced_7\JJ\1740| (r_amod) pain_8\NN\14299637|of|capsaicin-induced
D002211_D010146 CID capsaicin_19\NN\15032661|of (r_nmod) doses_17\NNS\3740161|of|three|capsaicin|0.05|microg|,|separated|) (r_nmod) injections_14\NNS\320852|intradermal|doses (r_dobj) received_12\VBD\2210855|order|,|volunteers|injections|,|times|. (l_nmod) order_1\NN\7168131|in|address (l_acl) address_3\VB\740577|to|memory (l_dobj) memory_6\NN\5926676|long-term|pain (l_compound) pain_5\NN\14299637|
D002211_D010146 CID capsaicin_11\NN\15032661| (r_compound) doses_12\NNS\3740161|across|capsaicin|p<0.001 (r_nmod) discriminate_5\VB\650353|to|reliably|magnitude|doses (l_dobj) magnitude_7\NN\4916342|pain|and|duration (l_compound) pain_6\NN\14299637|
84204
D002927_D003221 CID cimetidine-associated_7\JJ\1740| (r_amod) confusion_9\NN\13972797|with|cimetidine-associated|mental
D002927_D003221 CID cimetidine-associated_3\JJ\1740| (r_amod) confusion_5\NN\13972797|of|cimetidine-associated|mental
D002927_D051437 NONE cimetidine_19\NN\14778019| (r_compound) trough-concentrations_20\NNS\1740|cimetidine|microgram/ml (r_conj) had_3\VBD\2108377|patients|dysfunction|,|as|trough-concentrations|. (l_dobj) dysfunction_8\NN\14204950|renal|liver|p
D002927_D008107 NONE cimetidine_19\NN\14778019| (r_compound) trough-concentrations_20\NNS\1740|cimetidine|microgram/ml (r_conj) had_3\VBD\2108377|patients|dysfunction|,|as|trough-concentrations|. (l_dobj) dysfunction_8\NN\14204950|renal|liver|p
11027905
D007649_D009369 NONE ketamine_4\NN\3054098|of|intravenous (r_nmod) effect_1\NN\34213|analgesic|ketamine|patients|:|crossover|. (l_nmod) patients_7\NNS\9898892|in|cancer|therapy (l_compound) cancer_6\NN\14239425|
D007649_D009369 NONE ketamine_7\NN\3054098|of (r_nmod) doses_5\NNS\3740161|of|subhypnotic|ketamine (r_nmod) bolus_2\NN\13899404|a|slow|doses|mg/kg (r_nsubjpass) given_16\VBN\2327200|bolus|was|patients|. (l_nmod) patients_20\NNS\9898892|to|10|cancer|unrelieved (l_compound) cancer_19\NN\14239425|
D009020_D009369 NONE morphine_9\NN\2707683| (r_compound) therapy_10\NN\657604|on|morphine (r_nmod) patients_7\NNS\9898892|in|cancer|therapy (l_compound) cancer_6\NN\14239425|
D009020_D009369 NONE morphine_26\NN\2707683|by (r_nmod) unrelieved_24\VBN\1740|pain|was|morphine|crossover (r_acl:relcl) patients_20\NNS\9898892|to|10|cancer|unrelieved (l_compound) cancer_19\NN\14239425|
D009020_D010146 NONE morphine_4\NN\2707683|to (r_nmod) responsive_2\JJ\1740|pain|not|morphine (l_nsubj) pain_0\NN\14299637|
D009020_D010146 NONE morphine_26\NN\2707683|by (r_nmod) unrelieved_24\VBN\1740|pain|was|morphine|crossover (l_nsubjpass) pain_22\NN\14299637|whose
D009020_D010146 NONE morphine_3\NN\2707683| (r_amod) analgesia_4\NN\14034177|morphine (r_dobj) improve_2\VB\126264|ketamine|can|analgesia|syndromes|. (l_nmod) syndromes_8\NNS\5870365|in|difficult|pain|,|pain (l_compound) pain_7\NN\14299637|
D016202_D010146 NONE n-methyl-d-aspartate_7\NN\1740|nmda (r_compound) antagonists_11\NNS\7846|n-methyl-d-aspartate|,|ketamine|, (r_nsubj) effective_19\JJ\1740|that|antagonists|may|be|improving (l_advcl) improving_21\VBG\126264|in|analgesia|syndromes (l_nmod) syndromes_27\NNS\5870365|in|difficult|pain|,|pain (l_compound) pain_26\NN\14299637|
D016202_D010146 NONE nmda_9\NN\1740|(|) (r_appos) n-methyl-d-aspartate_7\NN\1740|nmda (r_compound) antagonists_11\NNS\7846|n-methyl-d-aspartate|,|ketamine|, (r_nsubj) effective_19\JJ\1740|that|antagonists|may|be|improving (l_advcl) improving_21\VBG\126264|in|analgesia|syndromes (l_nmod) syndromes_27\NNS\5870365|in|difficult|pain|,|pain (l_compound) pain_26\NN\14299637|
D016202_D009437 NONE n-methyl-d-aspartate_7\NN\1740|nmda (r_compound) antagonists_11\NNS\7846|n-methyl-d-aspartate|,|ketamine|, (r_nsubj) effective_19\JJ\1740|that|antagonists|may|be|improving (l_advcl) improving_21\VBG\126264|in|analgesia|syndromes (l_nmod) syndromes_27\NNS\5870365|in|difficult|pain|,|pain (l_nmod) pain_32\NN\14299637|such|neuropathic
D016202_D009437 NONE nmda_9\NN\1740|(|) (r_appos) n-methyl-d-aspartate_7\NN\1740|nmda (r_compound) antagonists_11\NNS\7846|n-methyl-d-aspartate|,|ketamine|, (r_nsubj) effective_19\JJ\1740|that|antagonists|may|be|improving (l_advcl) improving_21\VBG\126264|in|analgesia|syndromes (l_nmod) syndromes_27\NNS\5870365|in|difficult|pain|,|pain (l_nmod) pain_32\NN\14299637|such|neuropathic
D007649_D010146 NONE ketamine_15\NN\3054098|such (r_nmod) antagonists_11\NNS\7846|n-methyl-d-aspartate|,|ketamine|, (r_nsubj) effective_19\JJ\1740|that|antagonists|may|be|improving (l_advcl) improving_21\VBG\126264|in|analgesia|syndromes (l_nmod) syndromes_27\NNS\5870365|in|difficult|pain|,|pain (l_compound) pain_26\NN\14299637|
D007649_D010146 NONE ketamine_7\NN\3054098|of (r_nmod) doses_5\NNS\3740161|of|subhypnotic|ketamine (r_nmod) bolus_2\NN\13899404|a|slow|doses|mg/kg (r_nsubjpass) given_16\VBN\2327200|bolus|was|patients|. (l_nmod) patients_20\NNS\9898892|to|10|cancer|unrelieved (l_acl:relcl) unrelieved_24\VBN\1740|pain|was|morphine|crossover (l_nsubjpass) pain_22\NN\14299637|whose
D007649_D010146 NONE ketamine_0\NNP\3054098|,|not|solution|, (r_nsubj) reduced_8\VBD\441445|ketamine|significantly|intensity|. (l_dobj) intensity_11\NN\5090441|the|pain|patients (l_compound) pain_10\NN\14299637|
D007649_D010146 NONE ketamine_0\NNP\3054098| (r_nsubj) improve_2\VB\126264|ketamine|can|analgesia|syndromes|. (l_nmod) syndromes_8\NNS\5870365|in|difficult|pain|,|pain (l_compound) pain_7\NN\14299637|
D007649_D009437 NONE ketamine_15\NN\3054098|such (r_nmod) antagonists_11\NNS\7846|n-methyl-d-aspartate|,|ketamine|, (r_nsubj) effective_19\JJ\1740|that|antagonists|may|be|improving (l_advcl) improving_21\VBG\126264|in|analgesia|syndromes (l_nmod) syndromes_27\NNS\5870365|in|difficult|pain|,|pain (l_nmod) pain_32\NN\14299637|such|neuropathic
D007649_D009437 NONE ketamine_0\NNP\3054098| (r_nsubj) improve_2\VB\126264|ketamine|can|analgesia|syndromes|. (l_nmod) syndromes_8\NNS\5870365|in|difficult|pain|,|pain (l_nmod) pain_13\NN\14299637|such|neuropathic
D009020_D009437 NONE morphine_3\NN\2707683| (r_amod) analgesia_4\NN\14034177|morphine (r_dobj) improve_2\VB\126264|ketamine|can|analgesia|syndromes|. (l_nmod) syndromes_8\NNS\5870365|in|difficult|pain|,|pain (l_nmod) pain_13\NN\14299637|such|neuropathic
3409645
D008727_D007172 CID methotrexate_21\NN\2722166|of (r_nmod) taking_19\NN\37396|the|methotrexate (r_conj) co-morbidity_16\NN\1740|with|and|taking (r_nmod) associated_14\VBN\628491|to|be|co-morbidity (r_xcomp) found_11\VBN\2426171|was|associated (r_conj) common_3\JJ\1740|impotence|was|more|patients|and|found|. (l_nsubj) impotence_0\NN\4723816|
7234705
D011342_D017180 CID procainamide-induced_0\JJ\1740| (r_amod) tachycardia_3\NN\14110674|procainamide-induced|polymorphous|ventricular|.
D011342_D017180 CID procainamide-induced_3\JJ\1740| (r_amod) tachycardia_6\NN\14110674|of|procainamide-induced|polymorphous|ventricular
D011342_D017180 CID procainamide_17\NN\1740|of (r_nmod) mg_15\NN\13717155|of|400|procainamide (r_nmod) administration_10\NN\1133281|after|intravenous|mg|treatment (r_nmod) appeared_7\VBD\2604760|patients|,|tachycardia|administration|. (l_nsubj) tachycardia_6\NN\14110674|polymorphous|ventricular
D011342_D017180 CID procainamide_17\NN\1740|of (r_nmod) mg_15\NN\13717155|of|400|procainamide (r_nmod) administration_10\NN\1133281|after|intravenous|mg|treatment (l_nmod) treatment_20\NN\654885|for|the|tachycardia (l_nmod) tachycardia_24\NN\14110674|of|sustained|ventricular
D011342_D017180 CID procainamide_16\NN\1740| (r_compound) therapy_17\NN\657604|of|procainamide|, (r_nmod) continuation_14\NN\407535|despite|therapy (r_nmod) inserted_10\VBN\1296462|patient|,|pacemaker|was|and|,|continuation|reoccur|. (l_conj) reoccur_24\VB\1740|tachycardia|did|not (l_nsubj) tachycardia_21\NN\14110674|polymorphous|ventricular
D011342_D017180 CID procainamide_5\NN\1740| (r_nsubj) produce_7\VB\1617192|that|procainamide|can|syndrome|tachycardia (l_nmod) tachycardia_16\NN\14110674|with|polymorphous|ventricular
D011342_D018879 NONE procainamide_6\NN\1740| (r_nsubjpass) administered_8\VBN\2436349|patients|,|procainamide|was|orally|treatment|. (l_nmod) treatment_11\NN\654885|for|contractions (l_nmod) contractions_16\NNS\358931|of|chronic|premature|ventricular|or|flutter
D011342_D001282 NONE procainamide_6\NN\1740| (r_nsubjpass) administered_8\VBN\2436349|patients|,|procainamide|was|orally|treatment|. (l_nmod) treatment_11\NN\654885|for|contractions (l_nmod) contractions_16\NNS\358931|of|chronic|premature|ventricular|or|flutter (l_conj) flutter_19\NN\331950|atrial
D011342_D008133 NONE procainamide_5\NN\1740| (r_nsubj) produce_7\VB\1617192|that|procainamide|can|syndrome|tachycardia (l_dobj) syndrome_12\NN\5870365|an|acquired|prolonged|q-t
1549199
D007980_D064420 NONE levodopa_9\NN\14604959| (r_compound) therapy_10\NN\657604|for|levodopa (r_nmod) dose_7\NN\3740161|starting|therapy (r_nmod) correct_5\JJ\1740|no|single|dose (r_nsubj) is_2\VBZ\836236|while|there|correct (r_advcl) started_16\VBN\2009433|is|,|individuals|can|be|25/100|,|attempt|. (l_xcomp) attempt_31\VB\2367363|rule|not|to|titrate (l_xcomp) titrate_33\VB\489837|to|carbidopa-levodopa (l_advmod) carbidopa-levodopa_34\JJ\1740|point (l_nmod) point_37\NN\5868954|to|the|normality (l_nmod) normality_40\NN\13920835|of|"|,|"|lead (l_acl:relcl) lead_45\VB\1752884|which|can|toxicity (l_nmod) toxicity_47\NN\13576101|to
D007980_D064420 NONE carbidopa-levodopa_34\JJ\1740|point (l_nmod) point_37\NN\5868954|to|the|normality (l_nmod) normality_40\NN\13920835|of|"|,|"|lead (l_acl:relcl) lead_45\VB\1752884|which|can|toxicity (l_nmod) toxicity_47\NN\13576101|to
D002230_D064420 NONE carbidopa-levodopa_34\JJ\1740|point (l_nmod) point_37\NN\5868954|to|the|normality (l_nmod) normality_40\NN\13920835|of|"|,|"|lead (l_acl:relcl) lead_45\VB\1752884|which|can|toxicity (l_nmod) toxicity_47\NN\13576101|to
D007980_D005767 CID levodopa-induced_13\JJ\1740| (r_amod) psychosis_14\NN\14380140|levodopa-induced (r_conj) hypotension_11\NN\14057371|orthostatic|,|psychosis (r_conj) disorders_8\NNS\14034177|such|gastrointestinal|,|hypotension|,|disturbances|,|or|interactions
D007980_D007024 CID levodopa-induced_13\JJ\1740| (r_amod) psychosis_14\NN\14380140|levodopa-induced (r_conj) hypotension_11\NN\14057371|orthostatic|,|psychosis
D007980_D011618 NONE levodopa-induced_13\JJ\1740| (r_amod) psychosis_14\NN\14380140|levodopa-induced
D007980_D012893 NONE levodopa-induced_13\JJ\1740| (r_amod) psychosis_14\NN\14380140|levodopa-induced (r_conj) hypotension_11\NN\14057371|orthostatic|,|psychosis (r_conj) disorders_8\NNS\14034177|such|gastrointestinal|,|hypotension|,|disturbances|,|or|interactions (l_conj) disturbances_17\NNS\407535|sleep|or|parasomnias
D007980_D020447 CID levodopa-induced_13\JJ\1740| (r_amod) psychosis_14\NN\14380140|levodopa-induced (r_conj) hypotension_11\NN\14057371|orthostatic|,|psychosis (r_conj) disorders_8\NNS\14034177|such|gastrointestinal|,|hypotension|,|disturbances|,|or|interactions (l_conj) disturbances_17\NNS\407535|sleep|or|parasomnias (l_conj) parasomnias_19\NNS\1740|
18308784
C035054_D007859 NONE rg1_1\NN\1740|ginsenoside (r_nsubj) restores_2\VBZ\1631072|rg1|impairment|. (l_dobj) impairment_4\NN\7296428|the|learning (l_nmod) learning_6\NN\5701944|of|induced
C035054_D007859 NONE rg1_0\NN\1740|,|ginsenoside|, (r_nsubj) ameliorate_11\VB\126264|rg1|could|impairment|. (l_dobj) impairment_14\NN\7296428|spatial|learning
C035054_D007859 NONE rg1_11\NN\1740|of (r_nmod) effect_9\NN\34213|the|rg1|impairment|administration (l_nmod) impairment_14\NN\7296428|on|learning
D009020_D007859 CID morphine_10\NN\2707683| (r_amod) administration_11\NN\1133281|by|chronic|morphine|rats (r_nmod) induced_7\VBN\1627355|administration (r_acl) learning_6\NN\5701944|of|induced
D009020_D007859 CID morphine_17\NN\2707683| (r_compound) administration_18\NN\1133281|by|chronic|morphine|and|mechanism (r_nmod) effect_9\NN\34213|the|rg1|impairment|administration (l_nmod) impairment_14\NN\7296428|on|learning
D036145_D007859 NONE ginsenoside_4\NN\1740|as|a|extracted (r_nmod) rg1_0\NN\1740|,|ginsenoside|, (r_nsubj) ameliorate_11\VB\126264|rg1|could|impairment|. (l_dobj) impairment_14\NN\7296428|spatial|learning
18768591
D004317_D009404 CID doxorubicin-induced_6\JJ\1740| (r_amod) syndrome_8\NN\5870365|in|doxorubicin-induced|nephrotic
D004317_D009404 CID doxorubicin_0\NN\2716866| (r_compound) treatment_1\NN\654885|doxorubicin (r_nsubj) resulted_2\VBD\2633881|treatment|proteinuria|15/44|mice|. (l_nmod) mice_23\NNS\2329401|leading (l_acl) leading_24\VBG\1752884|syndrome (l_nmod) syndrome_28\NN\5870365|to|severe|nephrotic|ascites
D004317_D007674 NONE doxorubicin-induced_0\JJ\1740| (r_amod) nephropathy_1\NN\14573196|doxorubicin-induced
D004317_D016055 NONE doxorubicin-induced_0\JJ\1740| (r_amod) nephropathy_1\NN\14573196|doxorubicin-induced (r_nsubj) leads_2\VBZ\1752884|nephropathy|retention|. (l_dobj) retention_9\NN\809465|channel|(enac)-dependent|volume|and|fibrosis
D004317_D005355 NONE doxorubicin-induced_0\JJ\1740| (r_amod) nephropathy_1\NN\14573196|doxorubicin-induced (r_nsubj) leads_2\VBZ\1752884|nephropathy|retention|. (l_dobj) retention_9\NN\809465|channel|(enac)-dependent|volume|and|fibrosis (l_conj) fibrosis_12\NN\14204950|renal
D012964_D007674 NONE sodium_5\NN\14625458| (r_compound) channel_6\NN\6251781|to|epithelial|sodium (r_compound) retention_9\NN\809465|channel|(enac)-dependent|volume|and|fibrosis (r_dobj) leads_2\VBZ\1752884|nephropathy|retention|. (l_nsubj) nephropathy_1\NN\14573196|doxorubicin-induced
D012964_D016055 NONE sodium_5\NN\14625458| (r_compound) channel_6\NN\6251781|to|epithelial|sodium (r_compound) retention_9\NN\809465|channel|(enac)-dependent|volume|and|fibrosis
D012964_D005355 NONE sodium_5\NN\14625458| (r_compound) channel_6\NN\6251781|to|epithelial|sodium (r_compound) retention_9\NN\809465|channel|(enac)-dependent|volume|and|fibrosis (l_conj) fibrosis_12\NN\14204950|renal
D000450_D005355 NONE aldosterone-sensitive_1\JJ\1740| (r_amod) serum-_2\NN\1740|the|aldosterone-sensitive|and|glucocorticoid-inducible|kinase|sgk1 (r_nsubjpass) shown_9\VBN\2137132|serum-|has|been|participate|. (l_xcomp) participate_11\VB\2367363|to|stimulation|and|mediate (l_conj) mediate_19\VB\761713|to|fibrosis|excess (l_dobj) fibrosis_21\NN\14204950|renal|mineralocorticoid
D004317_D011507 CID doxorubicin_0\NN\2716866| (r_compound) treatment_1\NN\654885|doxorubicin (r_nsubj) resulted_2\VBD\2633881|treatment|proteinuria|15/44|mice|. (l_nmod) proteinuria_5\NN\14299637|in|heavy|(|crea|)
D004317_D001201 CID doxorubicin_0\NN\2716866| (r_compound) treatment_1\NN\654885|doxorubicin (r_nsubj) resulted_2\VBD\2633881|treatment|proteinuria|15/44|mice|. (l_nmod) mice_23\NNS\2329401|leading (l_acl) leading_24\VBG\1752884|syndrome (l_nmod) syndrome_28\NN\5870365|to|severe|nephrotic|ascites (l_nmod) ascites_30\NNS\14204950|with|,|lipidemia|,|and|hypoalbuminemia
D004317_D006949 CID doxorubicin_0\NN\2716866| (r_compound) treatment_1\NN\654885|doxorubicin (r_nsubj) resulted_2\VBD\2633881|treatment|proteinuria|15/44|mice|. (l_nmod) mice_23\NNS\2329401|leading (l_acl) leading_24\VBG\1752884|syndrome (l_nmod) syndrome_28\NN\5870365|to|severe|nephrotic|ascites (l_nmod) ascites_30\NNS\14204950|with|,|lipidemia|,|and|hypoalbuminemia (l_conj) lipidemia_32\NN\14299637|
D004317_D034141 CID doxorubicin_0\NN\2716866| (r_compound) treatment_1\NN\654885|doxorubicin (r_nsubj) resulted_2\VBD\2633881|treatment|proteinuria|15/44|mice|. (l_nmod) mice_23\NNS\2329401|leading (l_acl) leading_24\VBG\1752884|syndrome (l_nmod) syndrome_28\NN\5870365|to|severe|nephrotic|ascites (l_nmod) ascites_30\NNS\14204950|with|,|lipidemia|,|and|hypoalbuminemia (l_conj) hypoalbuminemia_35\NN\1740|genotypes
D000450_D009404 NONE aldosterone_1\NN\14751863| (r_compound) levels_2\NNS\4916342|plasma|aldosterone (r_nsubj) increased_3\VBD\169651|levels|mice|and|followed|. (l_nmod) mice_6\NNS\2329401|in|nephrotic|genotypes (l_amod) nephrotic_5\JJ\1740|
D012964_D015430 NONE sodium_1\NN\14625458| (r_compound) excretion_2\NN\13466586|urinary|sodium (r_nsubj) reached_3\VBD\2005948|excretion|values|mice|and|associated|)|mice|(|+|vs.|)|. (l_conj) associated_32\VBN\628491|was|gain|sgk1(+/+ (l_nmod) gain_39\NN\13576355|with|a|higher|body|weight
D014508_D009404 NONE urea_8\NN\14727670| (r_compound) concentrations_9\NNS\4916342|serum|urea (r_nsubj) increased_10\VBD\169651|course|,|concentrations|significantly|faster|sgk1(-/-|mice|mice|)|mice|days|in|sgk1(+/+|)|mice|)|. (l_nmod) course_2\NN\883297|during|the|syndrome (l_nmod) syndrome_5\NN\5870365|of|nephrotic
D014508_D014511 NONE urea_8\NN\14727670| (r_compound) concentrations_9\NNS\4916342|serum|urea (r_nsubj) increased_10\VBD\169651|course|,|concentrations|significantly|faster|sgk1(-/-|mice|mice|)|mice|days|in|sgk1(+/+|)|mice|)|. (l_nmod) mice_21\NNS\2329401|than|in|leading (l_acl) leading_22\VBG\1752884|uremia (l_nmod) uremia_24\NN\14204950|to|and|survival
1967484
D013469_D004421 CID sulpiride-induced_0\JJ\1740| (r_amod) dystonia_2\NN\1740|sulpiride-induced|tardive|.
D013469_D004421 CID sulpiride_15\NN\1740| (r_compound) therapy_16\NN\657604|sulpiride (r_dobj) starting_14\VBG\2009433|after|therapy (r_advcl) developed_6\VBD\1753788|who|dystonia|months|starting (l_dobj) dystonia_9\NN\1740|persistent|segmental
D013469_D004421 CID sulpiride-induced_8\JJ\1740| (r_amod) dystonia_10\NN\1740|of|sulpiride-induced|tardive
D013469_D004409 NONE sulpiride-induced_11\JJ\1740|dyskinesia (l_dobj) dyskinesia_13\NN\14084880|tardive|and|parkinsonism
D013469_D010302 NONE sulpiride-induced_11\JJ\1740|dyskinesia (l_dobj) dyskinesia_13\NN\14084880|tardive|and|parkinsonism (l_conj) parkinsonism_15\NN\14085708|
12707296
D001120_D006973 NONE l-arginine_0\NN\1740| (r_compound) transport_1\NN\3575240|l-arginine|humans|. (l_nmod) humans_3\NNS\31264|in|hypertension (l_nmod) hypertension_6\NN\14057371|with|cortisol-induced
D001120_D006973 NONE l-arginine-nitric_2\JJ\1740| (r_amod) system_4\NN\3575240|a|deficient|l-arginine-nitric|oxide (r_nsubjpass) implicated_6\VBN\2677097|system|is|hypertension|. (l_nmod) hypertension_9\NN\14057371|in|cortisol-induced
D001120_D006973 NONE l-arginine_15\NN\1740| (r_compound) system_17\NN\3575240|in|the|l-arginine|transport (r_nmod) abnormalities_12\NNS\14034177|with|system (r_nmod) associated_10\VBN\628491|that|increases|are|not|abnormalities (l_nsubjpass) increases_4\NNS\13576355|cortisol-induced|pressure (l_nmod) pressure_7\NN\11419404|in|blood
D006854_D006973 NONE cortisol-induced_5\JJ\1740| (r_amod) hypertension_6\NN\14057371|with|cortisol-induced
D006854_D006973 NONE cortisol-induced_8\JJ\1740| (r_amod) hypertension_9\NN\14057371|in|cortisol-induced
D006854_D006973 NONE cortisol-induced_3\JJ\1740| (r_amod) increases_4\NNS\13576355|cortisol-induced|pressure (l_nmod) pressure_7\NN\11419404|in|blood
D009569_D006973 NONE oxide_3\NN\14818238| (r_compound) system_4\NN\3575240|a|deficient|l-arginine-nitric|oxide (r_nsubjpass) implicated_6\VBN\2677097|system|is|hypertension|. (l_nmod) hypertension_9\NN\14057371|in|cortisol-induced
2440413
D001556_D012640 NONE gamma-hexachlorocyclohexane_3\JJ\1740|of|lindane (r_nmod) effects_1\NNS\13245626|differential|gamma-hexachlorocyclohexane|seizures|. (l_nmod) seizures_9\NNS\14081375|on|pharmacologically-induced
D001556_D012640 NONE lindane_5\NN\14919948|(|) (r_appos) gamma-hexachlorocyclohexane_3\JJ\1740|of|lindane (r_nmod) effects_1\NNS\13245626|differential|gamma-hexachlorocyclohexane|seizures|. (l_nmod) seizures_9\NNS\14081375|on|pharmacologically-induced
D001556_D012640 NONE gamma-hexachlorocyclohexane_0\JJ\1740|gamma-hch|,|ingredient|, (r_nsubjpass) shown_15\VBN\2137132|gamma-hexachlorocyclohexane|has|been|decrease|vohland|. (l_xcomp) decrease_17\VB\169651|to|seizure|h|exposure|and|increase|h|exposure (l_xcomp) seizure_18\JJ\1740|threshold|pentylenetrazol
D001556_D012640 NONE gamma-hexachlorocyclohexane_0\JJ\1740|gamma-hch|,|ingredient|, (r_nsubjpass) shown_15\VBN\2137132|gamma-hexachlorocyclohexane|has|been|decrease|vohland|. (l_xcomp) decrease_17\VB\169651|to|seizure|h|exposure|and|increase|h|exposure (l_conj) increase_33\VB\169651|conversely|threshold|seizures (l_nmod) seizures_37\NNS\14081375|to|ptz-induced
D001556_D012640 NONE gamma-hch_2\NN\1740|(|) (r_appos) gamma-hexachlorocyclohexane_0\JJ\1740|gamma-hch|,|ingredient|, (r_nsubjpass) shown_15\VBN\2137132|gamma-hexachlorocyclohexane|has|been|decrease|vohland|. (l_xcomp) decrease_17\VB\169651|to|seizure|h|exposure|and|increase|h|exposure (l_xcomp) seizure_18\JJ\1740|threshold|pentylenetrazol
D001556_D012640 NONE gamma-hch_2\NN\1740|(|) (r_appos) gamma-hexachlorocyclohexane_0\JJ\1740|gamma-hch|,|ingredient|, (r_nsubjpass) shown_15\VBN\2137132|gamma-hexachlorocyclohexane|has|been|decrease|vohland|. (l_xcomp) decrease_17\VB\169651|to|seizure|h|exposure|and|increase|h|exposure (l_conj) increase_33\VB\169651|conversely|threshold|seizures (l_nmod) seizures_37\NNS\14081375|to|ptz-induced
D001556_D012640 NONE lindane_11\NN\14919948|of|the|insecticide (r_nmod) ingredient_7\NN\3081021|the|active|lindane (r_appos) gamma-hexachlorocyclohexane_0\JJ\1740|gamma-hch|,|ingredient|, (r_nsubjpass) shown_15\VBN\2137132|gamma-hexachlorocyclohexane|has|been|decrease|vohland|. (l_xcomp) decrease_17\VB\169651|to|seizure|h|exposure|and|increase|h|exposure (l_xcomp) seizure_18\JJ\1740|threshold|pentylenetrazol
D001556_D012640 NONE lindane_11\NN\14919948|of|the|insecticide (r_nmod) ingredient_7\NN\3081021|the|active|lindane (r_appos) gamma-hexachlorocyclohexane_0\JJ\1740|gamma-hch|,|ingredient|, (r_nsubjpass) shown_15\VBN\2137132|gamma-hexachlorocyclohexane|has|been|decrease|vohland|. (l_xcomp) decrease_17\VB\169651|to|seizure|h|exposure|and|increase|h|exposure (l_conj) increase_33\VB\169651|conversely|threshold|seizures (l_nmod) seizures_37\NNS\14081375|to|ptz-induced
D001556_D012640 NONE gamma-hch_30\NN\1740|to (r_nmod) exposure_28\NN\5042871|after|gamma-hch (r_nmod) decrease_17\VB\169651|to|seizure|h|exposure|and|increase|h|exposure (l_xcomp) seizure_18\JJ\1740|threshold|pentylenetrazol
D001556_D012640 NONE gamma-hch_30\NN\1740|to (r_nmod) exposure_28\NN\5042871|after|gamma-hch (r_nmod) decrease_17\VB\169651|to|seizure|h|exposure|and|increase|h|exposure (l_conj) increase_33\VB\169651|conversely|threshold|seizures (l_nmod) seizures_37\NNS\14081375|to|ptz-induced
D001556_D012640 NONE gamma-hch_43\NN\1740|to (r_nmod) exposure_41\NN\5042871|after|gamma-hch (r_nmod) decrease_17\VB\169651|to|seizure|h|exposure|and|increase|h|exposure (l_xcomp) seizure_18\JJ\1740|threshold|pentylenetrazol
D001556_D012640 NONE gamma-hch_43\NN\1740|to (r_nmod) exposure_41\NN\5042871|after|gamma-hch (r_nmod) decrease_17\VB\169651|to|seizure|h|exposure|and|increase|h|exposure (l_conj) increase_33\VB\169651|conversely|threshold|seizures (l_nmod) seizures_37\NNS\14081375|to|ptz-induced
D001556_D012640 NONE gamma-hch_26\NN\1740|of|80|mg/kg (r_nmod) administration_22\NN\1133281|after|intraperitoneal|gamma-hch (r_nmod) h_19\NN\14622893|administration (r_nmod) tested_13\VBN\670261|study|,|severity|was|mice|h|. (l_nsubjpass) severity_5\NN\5036394|the|response (l_nmod) response_7\NN\11410625|of|agents (l_nmod) agents_11\NNS\7347|to|other|seizure-inducing (l_amod) seizure-inducing_10\JJ\1740|
D001556_D012640 NONE gamma-hch_6\NN\1740|of (r_nmod) administration_4\NN\1133281|after|the|gamma-hch (r_nmod) hour_1\NN\15154774|one|administration (r_nmod:tmod) increased_14\VBN\169651|hour|,|activity|was|,|regardless|,|observed|. (l_nsubjpass) activity_9\NN\30358|the|agents (l_nmod) agents_12\NNS\7347|of|seizure-inducing (l_amod) seizure-inducing_11\JJ\1740|
D001556_D012640 NONE gamma-hch_25\NN\1740| (r_compound) response_28\NN\11410625|after|gamma-hch|a|differential (r_dep) h_23\NN\14622893|24|response (r_nsubjpass) observed_30\VBN\2163746|while|h|was (r_advcl) increased_14\VBN\169651|hour|,|activity|was|,|regardless|,|observed|. (l_nsubjpass) activity_9\NN\30358|the|agents (l_nmod) agents_12\NNS\7347|of|seizure-inducing (l_amod) seizure-inducing_11\JJ\1740|
D001556_D012640 NONE gamma-hch_20\NN\1740|after (r_nmod) induced_12\VBN\1627355|ptz|h|gamma-hch (r_acl) activity_11\NN\30358|induced (r_dobj) seizure_10\VB\1740|to|activity
D001556_D012640 NONE gamma-hch_20\NN\1740|after (r_nmod) induced_12\VBN\1627355|ptz|h|gamma-hch (r_acl) activity_11\NN\30358|induced (r_dobj) seizure_10\VB\1740|to|activity (r_xcomp) occur_8\VB\2623529|that|tolerance|may|seizure|,|decreased (l_advcl) decreased_32\VBN\169651|since|response|agents|is (l_nsubjpass) agents_30\NNS\7347|only|these|two|seizure-inducing (l_amod) seizure-inducing_29\JJ\1740|
D001556_D012640 NONE gamma-hch_18\NN\1740|after (r_dep) h_16\NN\14622893|24|gamma-hch (r_dep) site_7\NN\8673395|the|responsible|h (l_amod) responsible_8\JJ\1740|decrease (l_nmod) decrease_11\NN\7296428|for|the|activity (l_nmod) activity_14\NN\30358|in|seizure (l_amod) seizure_13\JJ\1740|
D010433_D012640 CID ptz_23\NN\1740|(|) (r_appos) pentylenetrazol_21\JJ\1740|to|ptz (r_nmod) seizure_18\JJ\1740|threshold|pentylenetrazol
D010433_D012640 CID ptz_23\NN\1740|(|) (r_appos) pentylenetrazol_21\JJ\1740|to|ptz (r_nmod) seizure_18\JJ\1740|threshold|pentylenetrazol (r_xcomp) decrease_17\VB\169651|to|seizure|h|exposure|and|increase|h|exposure (l_conj) increase_33\VB\169651|conversely|threshold|seizures (l_nmod) seizures_37\NNS\14081375|to|ptz-induced
D010433_D012640 CID ptz-induced_36\JJ\1740| (r_amod) seizures_37\NNS\14081375|to|ptz-induced (r_nmod) increase_33\VB\169651|conversely|threshold|seizures (r_conj) decrease_17\VB\169651|to|seizure|h|exposure|and|increase|h|exposure (l_xcomp) seizure_18\JJ\1740|threshold|pentylenetrazol
D010433_D012640 CID ptz-induced_36\JJ\1740| (r_amod) seizures_37\NNS\14081375|to|ptz-induced
D010433_D012640 CID ptz_4\NN\1740|due|and|picrotoxin (r_nmod) activity_1\NN\30358|seizure|ptz (l_compound) seizure_0\NN\14081375|
D010433_D012640 CID ptz_4\NN\1740|due|and|picrotoxin (r_nmod) activity_1\NN\30358|seizure|ptz (r_nsubjpass) decreased_12\VBN\169651|activity|was|significantly|;|however|activity|different|. (l_dobj) activity_17\NN\30358|seizure|acid (l_amod) seizure_16\JJ\1740|
D010433_D012640 CID ptz_14\NN\1740|by|and|ptx (r_nmod) induced_12\VBN\1627355|ptz|h|gamma-hch (r_acl) activity_11\NN\30358|induced (r_dobj) seizure_10\VB\1740|to|activity
D010433_D012640 CID ptz_14\NN\1740|by|and|ptx (r_nmod) induced_12\VBN\1627355|ptz|h|gamma-hch (r_acl) activity_11\NN\30358|induced (r_dobj) seizure_10\VB\1740|to|activity (r_xcomp) occur_8\VB\2623529|that|tolerance|may|seizure|,|decreased (l_advcl) decreased_32\VBN\169651|since|response|agents|is (l_nsubjpass) agents_30\NNS\7347|only|these|two|seizure-inducing (l_amod) seizure-inducing_29\JJ\1740|
D010852_D012640 CID picrotoxin_6\NN\1740|ptx (r_conj) ptz_4\NN\1740|due|and|picrotoxin (r_nmod) activity_1\NN\30358|seizure|ptz (l_compound) seizure_0\NN\14081375|
D010852_D012640 CID picrotoxin_6\NN\1740|ptx (r_conj) ptz_4\NN\1740|due|and|picrotoxin (r_nmod) activity_1\NN\30358|seizure|ptz (r_nsubjpass) decreased_12\VBN\169651|activity|was|significantly|;|however|activity|different|. (l_dobj) activity_17\NN\30358|seizure|acid (l_amod) seizure_16\JJ\1740|
D010852_D012640 CID ptx_8\NN\1740|(|) (r_appos) picrotoxin_6\NN\1740|ptx (r_conj) ptz_4\NN\1740|due|and|picrotoxin (r_nmod) activity_1\NN\30358|seizure|ptz (l_compound) seizure_0\NN\14081375|
D010852_D012640 CID ptx_8\NN\1740|(|) (r_appos) picrotoxin_6\NN\1740|ptx (r_conj) ptz_4\NN\1740|due|and|picrotoxin (r_nmod) activity_1\NN\30358|seizure|ptz (r_nsubjpass) decreased_12\VBN\169651|activity|was|significantly|;|however|activity|different|. (l_dobj) activity_17\NN\30358|seizure|acid (l_amod) seizure_16\JJ\1740|
D010852_D012640 CID ptx_16\NN\1740|24 (r_conj) ptz_14\NN\1740|by|and|ptx (r_nmod) induced_12\VBN\1627355|ptz|h|gamma-hch (r_acl) activity_11\NN\30358|induced (r_dobj) seizure_10\VB\1740|to|activity
D010852_D012640 CID ptx_16\NN\1740|24 (r_conj) ptz_14\NN\1740|by|and|ptx (r_nmod) induced_12\VBN\1627355|ptz|h|gamma-hch (r_acl) activity_11\NN\30358|induced (r_dobj) seizure_10\VB\1740|to|activity (r_xcomp) occur_8\VB\2623529|that|tolerance|may|seizure|,|decreased (l_advcl) decreased_32\VBN\169651|since|response|agents|is (l_nsubjpass) agents_30\NNS\7347|only|these|two|seizure-inducing (l_amod) seizure-inducing_29\JJ\1740|
D015097_D012640 CID acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (r_dobj) decreased_12\VBN\169651|activity|was|significantly|;|however|activity|different|. (l_nsubjpass) activity_1\NN\30358|seizure|ptz (l_compound) seizure_0\NN\14081375|
D015097_D012640 CID acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (l_amod) seizure_16\JJ\1740|
D015097_D012640 CID mpa_23\NN\1740|(|) (r_appos) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (r_dobj) decreased_12\VBN\169651|activity|was|significantly|;|however|activity|different|. (l_nsubjpass) activity_1\NN\30358|seizure|ptz (l_compound) seizure_0\NN\14081375|
D015097_D012640 CID mpa_23\NN\1740|(|) (r_appos) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (l_amod) seizure_16\JJ\1740|
D001640_D012640 CID bicuculline_26\NN\1740|bcc (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (r_dobj) decreased_12\VBN\169651|activity|was|significantly|;|however|activity|different|. (l_nsubjpass) activity_1\NN\30358|seizure|ptz (l_compound) seizure_0\NN\14081375|
D001640_D012640 CID bicuculline_26\NN\1740|bcc (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (l_amod) seizure_16\JJ\1740|
D001640_D012640 CID bcc_28\NN\1740|(|) (r_appos) bicuculline_26\NN\1740|bcc (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (r_dobj) decreased_12\VBN\169651|activity|was|significantly|;|however|activity|different|. (l_nsubjpass) activity_1\NN\30358|seizure|ptz (l_compound) seizure_0\NN\14081375|
D001640_D012640 CID bcc_28\NN\1740|(|) (r_appos) bicuculline_26\NN\1740|bcc (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (l_amod) seizure_16\JJ\1740|
C034818_D012640 CID 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740|methyl|dmcm (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (r_dobj) decreased_12\VBN\169651|activity|was|significantly|;|however|activity|different|. (l_nsubjpass) activity_1\NN\30358|seizure|ptz (l_compound) seizure_0\NN\14081375|
C034818_D012640 CID 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740|methyl|dmcm (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (l_amod) seizure_16\JJ\1740|
C034818_D012640 CID dmcm_34\NN\1740|(|) (r_appos) 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740|methyl|dmcm (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (r_dobj) decreased_12\VBN\169651|activity|was|significantly|;|however|activity|different|. (l_nsubjpass) activity_1\NN\30358|seizure|ptz (l_compound) seizure_0\NN\14081375|
C034818_D012640 CID dmcm_34\NN\1740|(|) (r_appos) 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate_32\NN\1740|methyl|dmcm (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (l_amod) seizure_16\JJ\1740|
D013331_D012640 CID strychnine_38\NN\14712692|str (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (r_dobj) decreased_12\VBN\169651|activity|was|significantly|;|however|activity|different|. (l_nsubjpass) activity_1\NN\30358|seizure|ptz (l_compound) seizure_0\NN\14081375|
D013331_D012640 CID strychnine_38\NN\14712692|str (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (l_amod) seizure_16\JJ\1740|
D013331_D012640 CID str_40\NN\1740|(|) (r_appos) strychnine_38\NN\14712692|str (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (r_dobj) decreased_12\VBN\169651|activity|was|significantly|;|however|activity|different|. (l_nsubjpass) activity_1\NN\30358|seizure|ptz (l_compound) seizure_0\NN\14081375|
D013331_D012640 CID str_40\NN\1740|(|) (r_appos) strychnine_38\NN\14712692|str (r_conj) acid_21\NN\14818238|due|3-mercaptopropionic|mpa|,|bicuculline|,|6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate|,|or|strychnine (r_nmod) activity_17\NN\30358|seizure|acid (l_amod) seizure_16\JJ\1740|
D005680_D012640 NONE gaba-a_22\NN\1740| (r_nmod:npmod) receptor-linked_23\JJ\1740|gaba-a (r_amod) channel_25\NN\6251781|that|site|may|be|the|receptor-linked|chloride (l_nsubj) site_7\NN\8673395|the|responsible|h (l_amod) responsible_8\JJ\1740|decrease (l_nmod) decrease_11\NN\7296428|for|the|activity (l_nmod) activity_14\NN\30358|in|seizure (l_amod) seizure_13\JJ\1740|
1527456
D008012_D014012 NONE lignocaine_7\NN\1740|of|lidocaine|2 (r_nmod) instillation_5\NN\320852|by|intratympanic|lignocaine|cent (r_nmod) treatment_0\NN\654885|tinnitus|instillation|. (l_nmod) tinnitus_2\NN\14299637|of
D008012_D014012 NONE lidocaine_9\NN\3681148|(|) (r_appos) lignocaine_7\NN\1740|of|lidocaine|2 (r_nmod) instillation_5\NN\320852|by|intratympanic|lignocaine|cent (r_nmod) treatment_0\NN\654885|tinnitus|instillation|. (l_nmod) tinnitus_2\NN\14299637|of
D008012_D014012 NONE lignocaine_12\NN\1740|of|lidocaine|2 (r_nmod) instillation_10\NN\320852|by|intratympanic|lignocaine|cent (r_nmod) treating_6\VBG\2376958|of|ist|instillation|grommet (l_dobj) ist_7\NN\1740|
D008012_D014012 NONE lidocaine_14\NN\3681148|(|) (r_appos) lignocaine_12\NN\1740|of|lidocaine|2 (r_nmod) instillation_10\NN\320852|by|intratympanic|lignocaine|cent (r_nmod) treating_6\VBG\2376958|of|ist|instillation|grommet (l_dobj) ist_7\NN\1740|
2515254
D005996_D008881 CID nitroglycerin_11\NN\15015501|of (r_nmod) application_9\NN\947128|frontotemporal|nitroglycerin|patients (r_dobj) sided_7\VBD\733632|application|or (r_acl) one_6\CD\13741022|a|sided (r_dobj) received_4\VBD\2210855|patients|one|ointment|study|. (l_nsubj) patients_3\NNS\9898892|twenty|common|migraine (l_compound) migraine_2\NN\14326607|
D005996_D008881 CID nitroglycerin_7\NN\15015501|by (r_nmod) induced_5\VBN\1627355|attacks|were|nitroglycerin|patients|. (l_nsubjpass) attacks_3\NNS\955060|onset|migraine (l_compound) migraine_2\NN\14326607|
D005996_D008881 CID nitroglycerin_13\NN\15015501|with|frontotemporal (r_nmod) attack_10\NN\955060|an|early|onset|nitroglycerin (r_dobj) developed_6\VBD\1753788|who|attack (r_acl:relcl) patients_3\NNS\9898892|subsequently|20|migraine|,|developed|, (l_compound) migraine_2\NN\14326607|
D005996_D008881 CID nitroglycerin_5\NN\15015501|of (r_nmod) effect_3\NN\34213|the|migraine-inducing|nitroglycerin (l_amod) migraine-inducing_2\JJ\1740|
D005996_D008881 CID nitroglycerin_5\NN\15015501|of (r_nmod) effect_3\NN\34213|the|migraine-inducing|nitroglycerin (r_nsubj) seems_6\VBZ\2604760|thus|effect|depend|,|suggesting|. (l_xcomp) suggesting_19\VBG\1010118|importance (l_ccomp) importance_27\NN\5138488|that|region|is|of|crucial|development (l_nmod) development_30\NN\248977|in|the|crisis (l_nmod) crisis_34\NN\14411243|of|a|migraine (l_compound) migraine_33\NN\14326607|
D005996_D010146 NONE nitroglycerin_5\NN\15015501|of (r_nmod) effect_3\NN\34213|the|migraine-inducing|nitroglycerin (r_nsubj) seems_6\VBZ\2604760|thus|effect|depend|,|suggesting|. (l_xcomp) depend_8\VB\2604760|to|stimulation (l_nmod) stimulation_11\NN\242808|on|direct|site (l_nmod) site_15\NN\8673395|of|the|habitual|pain (l_nmod) pain_17\NN\14299637|of
20080983
C048833_D012893 NONE modafinil_15\NN\1740|of|morning-dosed (r_nmod) effect_12\NN\34213|the|modafinil|sleep|sleepiness (l_nmod) sleepiness_20\NN\14015731|users
C048833_D012893 NONE modafinil_0\NNP\1740| (r_nsubjpass) associated_2\VBN\628491|modafinil|was|latency|,|measured|,|and|decrease|. (l_conj) decrease_22\NN\7296428|a|significant|sleepiness (l_nmod) sleepiness_26\NN\14015731|in|subjective|daytime
C048833_D012893 NONE modafinil_3\NN\1740|morning-dosed (r_nsubj) promotes_4\VBZ\2556126|modafinil|architecture|,|and|decreases (l_conj) decreases_13\VBZ\169651|sleepiness (l_dobj) sleepiness_15\NN\14015731|daytime|users
D003042_D012893 CID cocaine_23\NN\3492717| (r_compound) users_24\NNS\7846|in|chronic|cocaine (r_nmod) sleepiness_20\NN\14015731|users
D003042_D012893 CID cocaine_18\NN\3492717| (r_compound) users_19\NNS\7846|in|abstinent|cocaine (r_nmod) sleepiness_15\NN\14015731|daytime|users
3125768
D015760_D009127 CID alfentanil-induced_4\JJ\1740| (r_amod) rigidity_5\NN\5023233|during|alfentanil-induced
D015760_D009127 CID alfentanil-induced_8\JJ\1740| (r_amod) rigidity_9\NN\5023233|during|alfentanil-induced|rats
D015760_D009127 CID alfentanil_9\JJ\1740|when (r_advcl) prevented_7\VBN\1740|that|rigidity|should|be|alfentanil|,|and|,|presumably|opiates|used (l_nsubjpass) rigidity_4\NN\5023233|
C032943_D009127 NONE metocurine_10\NN\1740|with (r_nmod) abolished_8\VBN\1740|when|rigidity|was|metocurine (l_nsubjpass) rigidity_6\NN\5023233|
20698227
D012254_D000743 NONE ribavirin_8\NN\2725367| (r_compound) anemia_11\NN\14189204|for|ribavirin|associated|hemolytic
D012254_D006461 NONE ribavirin_3\NN\2725367|recently (r_nsubjpass) found_6\VBN\2426171|background/aims|:|ribavirin|has|been|inhibit|found|. (l_conj) found_23\VBN\2426171|have|been|cause (l_xcomp) cause_25\VB\1617192|to|hemolysis (l_dobj) hemolysis_27\NN\13509528|acute
C473478_D006461 CID sunitinib_18\NN\1740|such|and|sorafenib (r_nmod) inhibitors_15\NNS\20090|of|angiogenesis|sunitinib (r_nmod) number_12\NN\5107765|a|inhibitors (r_conj) angiogenesis_9\NN\13489037|and|number (r_dobj) inhibit_8\VB\2510337|to|angiogenesis (r_xcomp) found_6\VBN\2426171|background/aims|:|ribavirin|has|been|inhibit|found|. (l_conj) found_23\VBN\2426171|have|been|cause (l_xcomp) cause_25\VB\1617192|to|hemolysis (l_dobj) hemolysis_27\NN\13509528|acute
C471405_D006461 CID sorafenib_20\NN\1740| (r_conj) sunitinib_18\NN\1740|such|and|sorafenib (r_nmod) inhibitors_15\NNS\20090|of|angiogenesis|sunitinib (r_nmod) number_12\NN\5107765|a|inhibitors (r_conj) angiogenesis_9\NN\13489037|and|number (r_dobj) inhibit_8\VB\2510337|to|angiogenesis (r_xcomp) found_6\VBN\2426171|background/aims|:|ribavirin|has|been|inhibit|found|. (l_conj) found_23\VBN\2426171|have|been|cause (l_xcomp) cause_25\VB\1617192|to|hemolysis (l_dobj) hemolysis_27\NN\13509528|acute
C100416_D019698 NONE 2a_16\NN\1740|by|pegylated|interferon|alpha|and|ribavirin (r_nmod) treated_11\VBN\2376958|patients|were|2a|. (l_nsubjpass) patients_3\NNS\9898892|fourteen|infected (l_acl) infected_5\VBN\2316868|chronically|virus (l_nmod) virus_9\NN\9312843|with|hepatitis|c
D012254_D019698 NONE ribavirin_18\NN\2725367| (r_conj) 2a_16\NN\1740|by|pegylated|interferon|alpha|and|ribavirin (r_nmod) treated_11\VBN\2376958|patients|were|2a|. (l_nsubjpass) patients_3\NNS\9898892|fourteen|infected (l_acl) infected_5\VBN\2316868|chronically|virus (l_nmod) virus_9\NN\9312843|with|hepatitis|c
D012254_D019698 NONE ribavirin_18\NN\2725367| (r_compound) anemia_20\NN\14189204|ribavirin|induced|patients (l_nmod) patients_22\NNS\9898892|in|c (l_nmod) c_25\NN\13714184|with|hepatitis
D012254_D000740 NONE ribavirin_18\NN\2725367| (r_compound) anemia_20\NN\14189204|ribavirin|induced|patients
18261172
D020123_D011507 CID sirolimus-based_6\JJ\1740| (r_amod) immunosuppression_7\NN\13973990|to|sirolimus-based|patients (r_nmod) switch_4\NN\3096960|after|immunosuppression (r_nmod) development_0\NN\248977|proteinuria|switch|. (l_nmod) proteinuria_2\NN\14299637|of
D020123_D011507 CID sirolmus_7\NN\1740|the|novel|is|)|drug|srl (r_nsubj) lacks_11\VBZ\1740|sirolmus|effects|;|however|,|reported|. (l_parataxis) reported_23\VBN\831651|proteinuria|has|been|transplantation (l_nsubjpass) proteinuria_17\NN\14299637|associated
D020123_D011507 CID srl_9\NN\1740|(|) (r_appos) sirolmus_7\NN\1740|the|novel|is|)|drug|srl (r_nsubj) lacks_11\VBZ\1740|sirolmus|effects|;|however|,|reported|. (l_parataxis) reported_23\VBN\831651|proteinuria|has|been|transplantation (l_nsubjpass) proteinuria_17\NN\14299637|associated
D020123_D011507 CID srl_20\NNP\1740|with (r_nmod) associated_18\VBN\628491|srl (r_acl) proteinuria_17\NN\14299637|associated
D020123_D011507 CID srl_10\NN\1740|with (r_nmod) associated_8\VBN\628491|srl (r_acl) proteinuria_7\NN\14299637|of|associated
D020123_D011507 CID srl_12\NNP\1740|to (r_nmod) switch_10\NN\3096960|after|srl|, (r_nmod) develop_4\VB\1753788|thus|,|proteinuria|may|patients|switch|have|. (l_nsubj) proteinuria_2\NN\14299637|
D020123_D011507 CID srl_0\NN\1740| (r_nsubjpass) used_3\VBN\1156834|srl|should|be|therapy|and|increased|. (l_nmod) therapy_6\NN\657604|with|acei/arb|and|patients|monitored (l_acl) monitored_9\VBN\2169352|proteinuria (l_nmod) proteinuria_11\NN\14299637|for
D020123_D007674 NONE sirolmus_7\NN\1740|the|novel|is|)|drug|srl (r_nsubj) lacks_11\VBZ\1740|sirolmus|effects|;|however|,|reported|. (l_dobj) effects_13\NNS\13245626|nephrotoxic (l_amod) nephrotoxic_12\JJ\1740|
D020123_D007674 NONE srl_9\NN\1740|(|) (r_appos) sirolmus_7\NN\1740|the|novel|is|)|drug|srl (r_nsubj) lacks_11\VBZ\1740|sirolmus|effects|;|however|,|reported|. (l_dobj) effects_13\NNS\13245626|nephrotoxic (l_amod) nephrotoxic_12\JJ\1740|
D020123_D007674 NONE srl_20\NNP\1740|with (r_nmod) associated_18\VBN\628491|srl (r_acl) proteinuria_17\NN\14299637|associated (r_nsubjpass) reported_23\VBN\831651|proteinuria|has|been|transplantation (r_parataxis) lacks_11\VBZ\1740|sirolmus|effects|;|however|,|reported|. (l_dobj) effects_13\NNS\13245626|nephrotoxic (l_amod) nephrotoxic_12\JJ\1740|
D020123_D007674 NONE srl_0\NN\1740| (r_nsubjpass) used_3\VBN\1156834|srl|should|be|therapy|and|increased|. (l_conj) increased_13\VBD\169651|dysfunction (l_dobj) dysfunction_15\NN\14204950|renal
D000806_D011507 NONE inhibitor_1\NN\20090|ace|and|therapy (r_nsubj) reduced_9\VBD\441445|inhibitor|development|. (l_dobj) development_11\NN\248977|proteinuria (l_compound) proteinuria_10\NN\14299637|
D000806_D011507 NONE acei/arb_5\NN\1740| (r_compound) therapy_6\NN\657604|with|acei/arb|and|patients|monitored (l_acl) monitored_9\VBN\2169352|proteinuria (l_nmod) proteinuria_11\NN\14299637|for
D057911_D011507 NONE blocker_4\NN\10101634|angiotensin-releasing|arb (r_compound) therapy_8\NN\657604|blocker (r_conj) inhibitor_1\NN\20090|ace|and|therapy (r_nsubj) reduced_9\VBD\441445|inhibitor|development|. (l_dobj) development_11\NN\248977|proteinuria (l_compound) proteinuria_10\NN\14299637|
D057911_D011507 NONE arb_6\NN\9882007|(|) (r_appos) blocker_4\NN\10101634|angiotensin-releasing|arb (r_compound) therapy_8\NN\657604|blocker (r_conj) inhibitor_1\NN\20090|ace|and|therapy (r_nsubj) reduced_9\VBD\441445|inhibitor|development|. (l_dobj) development_11\NN\248977|proteinuria (l_compound) proteinuria_10\NN\14299637|
D057911_D011507 NONE acei/arb_5\NN\1740| (r_compound) therapy_6\NN\657604|with|acei/arb|and|patients|monitored (l_acl) monitored_9\VBN\2169352|proteinuria (l_nmod) proteinuria_11\NN\14299637|for
D000806_D007674 NONE acei/arb_5\NN\1740| (r_compound) therapy_6\NN\657604|with|acei/arb|and|patients|monitored (r_nmod) used_3\VBN\1156834|srl|should|be|therapy|and|increased|. (l_conj) increased_13\VBD\169651|dysfunction (l_dobj) dysfunction_15\NN\14204950|renal
D057911_D007674 NONE acei/arb_5\NN\1740| (r_compound) therapy_6\NN\657604|with|acei/arb|and|patients|monitored (r_nmod) used_3\VBN\1156834|srl|should|be|therapy|and|increased|. (l_conj) increased_13\VBD\169651|dysfunction (l_dobj) dysfunction_15\NN\14204950|renal
7834920
D012293_D005921 CID rifampin_6\NN\2716205| (r_compound) therapy_7\NN\657604|with|intermittent|rifampin|tuberculosis (r_nmod) associated_3\VBN\628491|therapy (r_acl) glomerulonephritis_2\NN\14113798|crescentic|fibrillary|associated|.
D012293_D005921 CID rifampin_17\NN\2716205|with (r_nmod) treated_15\VBN\2376958|rifampin (r_acl) patient_14\NN\9898892|in|a|treated (r_nmod) glomerulonephritis_11\NN\14113798|of|proliferative|crescentic|patient|had
D012293_D005921 CID rifampin_20\NN\2716205|with (r_nmod) treated_18\VBN\2376958|rifampin (r_acl) patient_17\NN\9898892|in|a|treated (r_nmod) crescents_11\NNS\13867641|with|and|glomerulonephritis|patient (r_nmod) documents_2\VBZ\1000214|report|occurrence|crescents|. (l_dobj) occurrence_5\NN\29378|the|unusual|glomerulonephritis (l_nmod) glomerulonephritis_9\NN\14113798|of|progressive
D012293_D005921 CID rifampin_20\NN\2716205|with (r_nmod) treated_18\VBN\2376958|rifampin (r_acl) patient_17\NN\9898892|in|a|treated (r_nmod) crescents_11\NNS\13867641|with|and|glomerulonephritis|patient (l_conj) glomerulonephritis_14\NN\14113798|fibrillar
D012293_D014397 NONE rifampin_6\NN\2716205| (r_compound) therapy_7\NN\657604|with|intermittent|rifampin|tuberculosis (l_nmod) tuberculosis_10\NN\14127211|for|pulmonary
D012293_D014397 NONE rifampin_7\NN\2716205|of|and|isoniazid (r_nmod) regimen_5\NN\5898568|a|10-month|rifampin|tuberculosis (l_nmod) tuberculosis_12\NN\14127211|for|pulmonary
D012293_D051437 CID rifampin_7\NN\2716205|of|and|isoniazid (r_nmod) regimen_5\NN\5898568|a|10-month|rifampin|tuberculosis (r_dobj) underwent_2\VBD\109660|patient|regimen|and|discovered|. (l_conj) discovered_15\VBN\2163746|was|developed (l_xcomp) developed_18\VBN\1753788|to|have|signs|weeks|completion (l_dobj) signs_19\NNS\6643763|failure (l_nmod) failure_23\NN\66216|of|severe|renal
D007538_D014397 NONE isoniazid_9\NNS\2716205| (r_conj) rifampin_7\NN\2716205|of|and|isoniazid (r_nmod) regimen_5\NN\5898568|a|10-month|rifampin|tuberculosis (l_nmod) tuberculosis_12\NN\14127211|for|pulmonary
D007538_D051437 NONE isoniazid_9\NNS\2716205| (r_conj) rifampin_7\NN\2716205|of|and|isoniazid (r_nmod) regimen_5\NN\5898568|a|10-month|rifampin|tuberculosis (r_dobj) underwent_2\VBD\109660|patient|regimen|and|discovered|. (l_conj) discovered_15\VBN\2163746|was|developed (l_xcomp) developed_18\VBN\1753788|to|have|signs|weeks|completion (l_dobj) signs_19\NNS\6643763|failure (l_nmod) failure_23\NN\66216|of|severe|renal
11928786
D016642_D064420 NONE bupropion_0\NN\1740|zyban (r_compound) toxicity_4\NN\13576101|bupropion|.
D016642_D064420 NONE zyban_2\NN\1740|(|) (r_appos) bupropion_0\NN\1740|zyban (r_compound) toxicity_4\NN\13576101|bupropion|.
D003975_D012640 NONE diazepam_5\NN\2830852|with|and (r_nmod) treated_3\VBN\2376958|seizures|were|diazepam|treated|. (l_nsubjpass) seizures_1\NNS\14081375|recurrent
D003975_D013610 NONE diazepam_5\NN\2830852|with|and (r_nmod) treated_3\VBN\2376958|seizures|were|diazepam|treated|. (l_conj) treated_12\VBN\2376958|tachycardia|was|successfully|adenosine (l_nsubjpass) tachycardia_9\NN\14110674|complex
D000241_D012640 NONE adenosine_14\NN\14964367|with (r_nmod) treated_12\VBN\2376958|tachycardia|was|successfully|adenosine (r_conj) treated_3\VBN\2376958|seizures|were|diazepam|treated|. (l_nsubjpass) seizures_1\NNS\14081375|recurrent
D000241_D013610 NONE adenosine_14\NN\14964367|with (r_nmod) treated_12\VBN\2376958|tachycardia|was|successfully|adenosine (l_nsubjpass) tachycardia_9\NN\14110674|complex
D016642_D020258 NONE zyban_0\NNP\1740| (r_nsubj) caused_1\VBD\1617192|zyban|neurological|overdose|. (l_dobj) neurological_3\JJ\1740|significant|and|cardiovascular|toxicity (l_dep) toxicity_6\NN\13576101|
D016642_D002318 NONE zyban_0\NNP\1740| (r_nsubj) caused_1\VBD\1617192|zyban|neurological|overdose|. (l_dobj) neurological_3\JJ\1740|significant|and|cardiovascular|toxicity (l_dep) toxicity_6\NN\13576101|
D016642_D062787 NONE zyban_0\NNP\1740| (r_nsubj) caused_1\VBD\1617192|zyban|neurological|overdose|. (l_nmod) overdose_8\NN\1740|in
3560095
D005480_D001171 NONE flurbiprofen_0\NN\3828465|treatment|. (l_nmod) treatment_3\NN\654885|in|the|arthritis (l_nmod) arthritis_7\NN\14171682|of|juvenile|rheumatoid
D005480_D001171 NONE flurbiprofen_11\NN\3828465|with (r_nmod) treated_9\VBN\2376958|who|were|flurbiprofen|dose|mg/kg/day (r_acl:relcl) patients_1\NNS\9898892|thirty-four|arthritis|,|treated|, (l_nmod) arthritis_5\NN\14171682|with|juvenile|rheumatoid
D005480_D001168 NONE flurbiprofen_11\NN\3828465|with (r_nmod) treated_9\VBN\2376958|who|were|flurbiprofen|dose|mg/kg/day (r_acl:relcl) patients_1\NNS\9898892|thirty-four|arthritis|,|treated|, (r_nsubj) had_20\VBD\2108377|patients|decreases|weeks|. (l_dobj) decreases_23\NNS\7296428|significant|baseline|indices (l_nmod) indices_29\NNS\13850304|in|6|arthritis (l_compound) arthritis_28\NN\14171682|
8701950
D016559_D000743 CID fk506_4\NN\1740| (r_compound) therapy_8\NN\657604|fk506|tacrolimus|) (r_dobj) complicating_3\VBG\126264|therapy (r_acl) anemia_2\NN\14189204|microangiopathic|hemolytic|complicating|.
D016559_D000743 CID tacrolimus_6\NN\1740|( (r_compound) therapy_8\NN\657604|fk506|tacrolimus|) (r_dobj) complicating_3\VBG\126264|therapy (r_acl) anemia_2\NN\14189204|microangiopathic|hemolytic|complicating|.
D016559_D000743 CID fk506_17\NN\1740| (r_compound) therapy_21\NN\657604|under|fk506|tacrolimus|) (r_nmod) recipients_15\NNS\9764201|in|2|solid|organ|therapy (r_nmod) episodes_3\NNS\7283608|3|anemia|recipients (l_nmod) anemia_7\NN\14189204|of|microangiopathic|hemolytic|maha
D016559_D000743 CID fk506_17\NN\1740| (r_compound) therapy_21\NN\657604|under|fk506|tacrolimus|) (r_nmod) recipients_15\NNS\9764201|in|2|solid|organ|therapy (r_nmod) episodes_3\NNS\7283608|3|anemia|recipients (l_nmod) anemia_7\NN\14189204|of|microangiopathic|hemolytic|maha (l_appos) maha_9\NN\9654687|(|)
D016559_D000743 CID tacrolimus_19\NN\1740|( (r_compound) therapy_21\NN\657604|under|fk506|tacrolimus|) (r_nmod) recipients_15\NNS\9764201|in|2|solid|organ|therapy (r_nmod) episodes_3\NNS\7283608|3|anemia|recipients (l_nmod) anemia_7\NN\14189204|of|microangiopathic|hemolytic|maha
D016559_D000743 CID tacrolimus_19\NN\1740|( (r_compound) therapy_21\NN\657604|under|fk506|tacrolimus|) (r_nmod) recipients_15\NNS\9764201|in|2|solid|organ|therapy (r_nmod) episodes_3\NNS\7283608|3|anemia|recipients (l_nmod) anemia_7\NN\14189204|of|microangiopathic|hemolytic|maha (l_appos) maha_9\NN\9654687|(|)
D016559_D000743 CID fk506_6\NN\1740|of (r_nmod) discontinuation_4\NN\209943|fk506|and|treatment|,|replacement (r_nsubj) led_24\VBD\1752884|cases|,|discontinuation|resolution|. (l_nmod) resolution_26\NN\6470073|to|maha (l_nmod) maha_28\NN\9654687|of
D016559_D000743 CID fk506_6\NN\1740|of (r_nmod) reintroduction_4\NN\7217349|fk506 (r_nsubj) led_7\VBD\1752884|patient|,|reintroduction|recurrence|. (l_nmod) recurrence_10\NN\7342049|to|rapid|maha (l_nmod) maha_12\NN\9654687|of
D016559_D000743 CID fk506-associated_0\JJ\1740| (r_amod) maha_1\NN\9654687|fk506-associated
D016559_D000743 CID fk506_9\NN\1740| (r_nsubj) seem_12\VB\2604760|experience|literature|,|fk506|does|not|cross-react|. (l_xcomp) cross-react_14\VB\1740|to|a (l_nmod) a_17\NN\13649268|with|cyclosporin|cya|,|drug (l_appos) drug_24\NN\14778436|an|immuno-suppressive|known (l_acl) known_26\VBN\2110220|already|induce (l_xcomp) induce_28\VB\1627355|to|maha (l_dobj) maha_29\NN\9654687|
D000305_D000743 NONE corticosteroids_18\NNS\14745635|,|aspirin (r_conj) replacement_16\NN\196485|fresh|frozen|plasma|,|corticosteroids|,|and|dipyridamole (r_conj) discontinuation_4\NN\209943|fk506|and|treatment|,|replacement (r_nsubj) led_24\VBD\1752884|cases|,|discontinuation|resolution|. (l_nmod) resolution_26\NN\6470073|to|maha (l_nmod) maha_28\NN\9654687|of
D001241_D000743 NONE aspirin_20\NN\2707683| (r_conj) corticosteroids_18\NNS\14745635|,|aspirin (r_conj) replacement_16\NN\196485|fresh|frozen|plasma|,|corticosteroids|,|and|dipyridamole (r_conj) discontinuation_4\NN\209943|fk506|and|treatment|,|replacement (r_nsubj) led_24\VBD\1752884|cases|,|discontinuation|resolution|. (l_nmod) resolution_26\NN\6470073|to|maha (l_nmod) maha_28\NN\9654687|of
D004176_D000743 NONE dipyridamole_23\NN\1740| (r_conj) replacement_16\NN\196485|fresh|frozen|plasma|,|corticosteroids|,|and|dipyridamole (r_conj) discontinuation_4\NN\209943|fk506|and|treatment|,|replacement (r_nsubj) led_24\VBD\1752884|cases|,|discontinuation|resolution|. (l_nmod) resolution_26\NN\6470073|to|maha (l_nmod) maha_28\NN\9654687|of
D016572_D000743 NONE a_17\NN\13649268|with|cyclosporin|cya|,|drug (l_appos) drug_24\NN\14778436|an|immuno-suppressive|known (l_acl) known_26\VBN\2110220|already|induce (l_xcomp) induce_28\VB\1627355|to|maha (l_dobj) maha_29\NN\9654687|
D016572_D000743 NONE cya_19\NN\1740|(|) (r_appos) a_17\NN\13649268|with|cyclosporin|cya|,|drug (l_appos) drug_24\NN\14778436|an|immuno-suppressive|known (l_acl) known_26\VBN\2110220|already|induce (l_xcomp) induce_28\VB\1627355|to|maha (l_dobj) maha_29\NN\9654687|
18809400
D008063_D028361 NONE acid_1\NN\14818238|alpha-lipoic (r_nsubj) prevents_2\VBZ\1740|acid|damage|. (l_dobj) damage_4\NN\7296428|mitochondrial|and|neurotoxicity|neuropathy
D008063_D028361 NONE acid_5\NN\14818238|alpha-lipoic (r_nsubj) neuroprotective_7\JJ\1740|if|acid|is|neurotoxicity|, (r_ccomp) investigates_2\VBZ\644583|study|neuroprotective|plays|. (l_advcl) plays_16\VBZ\1072262|if|damage|role|cascade|,|and|depend (l_nsubj) damage_15\NN\7296428|mitochondrial
D008063_D028361 NONE acid_31\NN\14818238|of|alpha-lipoic (r_nmod) effects_28\NNS\13245626|neuroprotective|acid (r_nsubj) depend_32\NN\1740|if|effects|protection (r_conj) plays_16\VBZ\1072262|if|damage|role|cascade|,|and|depend (l_nsubj) damage_15\NN\7296428|mitochondrial
D008063_D028361 NONE acid_1\NN\14818238|alpha-lipoic (r_nsubj) exerts_2\VBZ\1158872|acid|effects|rescues (l_parataxis) rescues_14\VBZ\2551832|:|it|toxicity|and|induces|. (l_dobj) toxicity_17\NN\13576101|the|mitochondrial
D008063_D020258 NONE acid_1\NN\14818238|alpha-lipoic (r_nsubj) prevents_2\VBZ\1740|acid|damage|. (l_dobj) damage_4\NN\7296428|mitochondrial|and|neurotoxicity|neuropathy (l_conj) neurotoxicity_6\NN\1740|
D008063_D020258 NONE acid_5\NN\14818238|alpha-lipoic (r_nsubj) neuroprotective_7\JJ\1740|if|acid|is|neurotoxicity|, (l_nmod) neurotoxicity_11\NN\1740|against|induced
D008063_D020258 NONE acid_31\NN\14818238|of|alpha-lipoic (r_nmod) effects_28\NNS\13245626|neuroprotective|acid (r_nsubj) depend_32\NN\1740|if|effects|protection (r_conj) plays_16\VBZ\1072262|if|damage|role|cascade|,|and|depend (r_advcl) investigates_2\VBZ\644583|study|neuroprotective|plays|. (l_ccomp) neuroprotective_7\JJ\1740|if|acid|is|neurotoxicity|, (l_nmod) neurotoxicity_11\NN\1740|against|induced
D008063_D020258 NONE acid_1\NN\14818238|alpha-lipoic (r_nsubj) exerts_2\VBZ\1158872|acid|effects|rescues (l_dobj) effects_4\NNS\13245626|neuroprotective|neurotoxicity (l_nmod) neurotoxicity_8\NN\1740|against|induced|neurons
D008063_D009422 NONE acid_1\NN\14818238|alpha-lipoic (r_nsubj) prevents_2\VBZ\1740|acid|damage|. (l_dobj) damage_4\NN\7296428|mitochondrial|and|neurotoxicity|neuropathy (l_nmod) neuropathy_10\JJ\1740|in|chemotherapy
D008063_D009410 NONE acid_5\NN\14818238|alpha-lipoic (r_nsubj) neuroprotective_7\JJ\1740|if|acid|is|neurotoxicity|, (r_ccomp) investigates_2\VBZ\644583|study|neuroprotective|plays|. (l_advcl) plays_16\VBZ\1072262|if|damage|role|cascade|,|and|depend (l_nmod) cascade_23\NN\9475292|in|toxic|neurodegenerative
D008063_D009410 NONE acid_31\NN\14818238|of|alpha-lipoic (r_nmod) effects_28\NNS\13245626|neuroprotective|acid (r_nsubj) depend_32\NN\1740|if|effects|protection (r_conj) plays_16\VBZ\1072262|if|damage|role|cascade|,|and|depend (l_nmod) cascade_23\NN\9475292|in|toxic|neurodegenerative
D017239_D010523 CID paclitaxel_32\NN\1740|to|and|cisplatin (r_nmod) neurons_30\NNS\5430628|sensory|paclitaxel (r_nmod) cultures_21\NNS\7966140|primary|ganglion|neurons (r_dobj) exposing_19\VBG\2110927|by|cultures (r_advcl) mimic_13\VBP\1742886|that|closely|condition|exposing (r_acl:relcl) neuropathy_10\NN\14204950|of|induced|peripheral|mimic
D002945_D010523 CID cisplatin_34\NN\1740| (r_conj) paclitaxel_32\NN\1740|to|and|cisplatin (r_nmod) neurons_30\NNS\5430628|sensory|paclitaxel (r_nmod) cultures_21\NNS\7966140|primary|ganglion|neurons (r_dobj) exposing_19\VBG\2110927|by|cultures (r_advcl) mimic_13\VBP\1742886|that|closely|condition|exposing (r_acl:relcl) neuropathy_10\NN\14204950|of|induced|peripheral|mimic
D008063_D001480 NONE acid_8\NN\14818238|of|alpha-lipoic (r_nmod) efficacy_5\NN\5199286|the|acid (r_dobj) investigating_3\VBG\644583|efficacy|preventing (l_advcl) preventing_10\VBG\1740|in|damage (l_dobj) damage_12\NN\7296428|axonal|and|apoptosis|and|function
D008063_D001480 NONE acid_30\NN\14818238|alpha-lipoic (r_conj) agents_27\NNS\7347|to|toxic|and|acid (r_nmod) exposure_24\NN\5042871|after|agents (r_nmod) function_17\NN\13783581|the|and|morphology|mitochondria|exposure (r_conj) damage_12\NN\7296428|axonal|and|apoptosis|and|function
D002945_D028361 NONE cisplatin_5\NN\1740|both|and|paclitaxel (r_nsubj) cause_8\VBP\1617192|that|cisplatin|impairment (l_dobj) impairment_11\NN\7296428|early|mitochondrial|loss|and|induction
D002945_D028361 NONE cisplatin_13\NN\1740| (r_nmod:npmod) induced_14\VBN\1627355|cisplatin (r_amod) neurotoxicity_15\NN\1740|induced (r_conj) event_8\NN\23100|toxicity|is|an|early|common|both|neurotoxicity|. (l_nmod) toxicity_3\NN\13576101|in|conclusion|mitochondrial
D017239_D028361 NONE paclitaxel_7\NN\1740| (r_conj) cisplatin_5\NN\1740|both|and|paclitaxel (r_nsubj) cause_8\VBP\1617192|that|cisplatin|impairment (l_dobj) impairment_11\NN\7296428|early|mitochondrial|loss|and|induction
D017239_D028361 NONE paclitaxel_11\NN\1740|in|and (r_nmod) both_9\CC\1740|paclitaxel (r_nmod:npmod) event_8\NN\23100|toxicity|is|an|early|common|both|neurotoxicity|. (l_nmod) toxicity_3\NN\13576101|in|conclusion|mitochondrial
D017239_D020258 NONE paclitaxel_11\NN\1740|in|and (r_nmod) both_9\CC\1740|paclitaxel (r_nmod:npmod) event_8\NN\23100|toxicity|is|an|early|common|both|neurotoxicity|. (l_conj) neurotoxicity_15\NN\1740|induced
D002945_D020258 NONE cisplatin_13\NN\1740| (r_nmod:npmod) induced_14\VBN\1627355|cisplatin (r_amod) neurotoxicity_15\NN\1740|induced
D008063_D010523 NONE acid_5\NN\14818238|alpha-lipoic (r_nsubj) reduce_7\VB\441445|that|acid|might|risk|and|encourage (l_dobj) risk_9\NN\14541044|the|developing (l_advcl) developing_11\VBG\1753788|of|toxicity (l_dobj) toxicity_14\NN\13576101|peripheral|nerve|patients
11961407
D014443_D009401 NONE tyrosine_2\NN\14601829| (r_compound) phosphatase_3\NN\14732946|glepp1|receptor|tyrosine|ptpro|nephrosis|. (l_nmod) nephrosis_10\NN\14304060|in|rat|pan
D011692_D009401 CID pan_9\NN\3101986| (r_compound) nephrosis_10\NN\14304060|in|rat|pan
D011692_D009401 CID aminonucleoside_1\NN\1740| (r_compound) nephrosis_2\NN\14304060|puromycin|aminonucleoside
D011692_D009401 CID aminonucleoside_11\NN\1740|of|puromycin (r_nmod) injection_8\NN\320852|by|intraperitoneal|aminonucleoside|pan (r_nmod) induced_4\VBN\1627355|nephrosis|was|injection|. (l_nsubjpass) nephrosis_2\NN\14304060|puromycin|aminonucleoside
D011692_D009401 CID pan_13\NN\3101986|(|,|mg/100|bw|) (r_dep) injection_8\NN\320852|by|intraperitoneal|aminonucleoside|pan (r_nmod) induced_4\VBN\1627355|nephrosis|was|injection|. (l_nsubjpass) nephrosis_2\NN\14304060|puromycin|aminonucleoside
D011692_D011507 CID pan_21\NN\3101986| (r_compound) injection_22\NN\320852|after|pan (r_nmod) days_19\NNS\15140892|0|injection (r_nmod) analyzed_2\VBN\78760|tissues|were|days|include|. (l_advcl) include_26\VB\690614|so|as|to|phase (l_dobj) phase_30\NN\15113229|both|the|acute|proteinuria|days|and|phase (l_nmod) proteinuria_32\NN\14299637|of|associated
D011692_D011507 CID pan_21\NN\3101986| (r_compound) injection_22\NN\320852|after|pan (r_nmod) days_19\NNS\15140892|0|injection (r_nmod) analyzed_2\VBN\78760|tissues|were|days|include|. (l_advcl) include_26\VB\690614|so|as|to|phase (l_dobj) phase_30\NN\15113229|both|the|acute|proteinuria|days|and|phase (l_conj) phase_47\NN\15113229|the|chronic|proteinuria|days (l_nmod) proteinuria_49\NN\14299637|of|associated
D011692_D005921 NONE pan_21\NN\3101986| (r_compound) injection_22\NN\320852|after|pan (r_nmod) days_19\NNS\15140892|0|injection (r_nmod) analyzed_2\VBN\78760|tissues|were|days|include|. (l_advcl) include_26\VB\690614|so|as|to|phase (l_dobj) phase_30\NN\15113229|both|the|acute|proteinuria|days|and|phase (l_conj) phase_47\NN\15113229|the|chronic|proteinuria|days (l_nmod) proteinuria_49\NN\14299637|of|associated (l_acl) associated_50\VBN\628491|glomerulosclerosis (l_nmod) glomerulosclerosis_52\NN\1740|with
11581460
D005283_D016055 CID fentanyl_12\NN\2707683|: (r_amod) reports_16\NNS\6470073|of|fentanyl|case (r_nmod) infusion_10\NN\14589223|of|continuous|intravenous|reports (r_nmod) result_6\NN\34213|as|a|infusion (r_nmod) retention_1\NN\809465|bladder|urine|result|. (l_nmod) urine_3\NN\14853947|of
D005283_D009127 NONE fentanyl_5\JJ\1740| (r_amod) administration_6\NN\1133281|of|fentanyl (r_nmod) effects_3\NNS\13245626|side|administration (r_dobj) reported_1\VBD\831651|various|effects|include|. (l_conj) include_7\VBP\690614|rigidity (l_dobj) rigidity_10\NN\5023233|chest|wall|,|hypotension|,|and|bradycardia
D005283_D007022 CID fentanyl_5\JJ\1740| (r_amod) administration_6\NN\1133281|of|fentanyl (r_nmod) effects_3\NNS\13245626|side|administration (r_dobj) reported_1\VBD\831651|various|effects|include|. (l_conj) include_7\VBP\690614|rigidity (l_dobj) rigidity_10\NN\5023233|chest|wall|,|hypotension|,|and|bradycardia (l_conj) hypotension_12\NN\14057371|,|depression
D005283_D012131 CID fentanyl_5\JJ\1740| (r_amod) administration_6\NN\1133281|of|fentanyl (r_nmod) effects_3\NNS\13245626|side|administration (r_dobj) reported_1\VBD\831651|various|effects|include|. (l_conj) include_7\VBP\690614|rigidity (l_dobj) rigidity_10\NN\5023233|chest|wall|,|hypotension|,|and|bradycardia (l_conj) hypotension_12\NN\14057371|,|depression (l_conj) depression_15\NN\14373582|respiratory
D005283_D001919 CID fentanyl_5\JJ\1740| (r_amod) administration_6\NN\1133281|of|fentanyl (r_nmod) effects_3\NNS\13245626|side|administration (r_dobj) reported_1\VBD\831651|various|effects|include|. (l_conj) include_7\VBP\690614|rigidity (l_dobj) rigidity_10\NN\5023233|chest|wall|,|hypotension|,|and|bradycardia (l_conj) bradycardia_18\NN\14110674|
D005283_D001745 CID fentanyl_22\NN\2707683|of (r_nmod) infusion_20\NN\14589223|of|continuous|fentanyl (r_nmod) result_17\NN\34213|as|a|infusion (r_nmod) leading_8\VBG\1752884|dilatation|mimicking|result (r_acl) cases_3\NNS\7283608|2|retention|leading (l_nmod) retention_7\NN\809465|of|urinary|bladder
D005283_D006869 NONE fentanyl_22\NN\2707683|of (r_nmod) infusion_20\NN\14589223|of|continuous|fentanyl (r_nmod) result_17\NN\34213|as|a|infusion (r_nmod) leading_8\VBG\1752884|dilatation|mimicking|result (l_advcl) mimicking_13\VBG\1742886|hydronephrosis (l_dobj) hydronephrosis_14\NN\14204950|
2024540
D004656_D006333 NONE enalapril_9\NN\2673637|of|and|prazosin (r_nmod) safety_7\NN\13920835|enalapril|phase (l_nmod) phase_16\NN\15113229|in|the|initial|treatment|patients (l_nmod) patients_18\NNS\9898892|of|failure (l_nmod) failure_22\NN\66216|with|congestive|heart
D011224_D006333 NONE prazosin_11\NN\2698769| (r_conj) enalapril_9\NN\2673637|of|and|prazosin (r_nmod) safety_7\NN\13920835|enalapril|phase (l_nmod) phase_16\NN\15113229|in|the|initial|treatment|patients (l_nmod) patients_18\NNS\9898892|of|failure (l_nmod) failure_22\NN\66216|with|congestive|heart
D000806_D006333 NONE inhibitors_10\NNS\20090|since|introduction|enzyme|(|ace|)|treatment|,|cases|,|day|, (l_nmod) treatment_14\NN\654885|into|the|adjunctive|patients (l_nmod) patients_16\NNS\9898892|of|failure (l_nmod) failure_20\NN\66216|with|congestive|heart
D000806_D007022 CID inhibitors_10\NNS\20090|since|introduction|enzyme|(|ace|)|treatment|,|cases|,|day|, (l_appos) cases_22\NNS\7283608|hypotension (l_nmod) hypotension_25\NN\14057371|of|severe
D000806_D007022 CID inhibitor_7\NN\20090|of|the|ace (r_nmod) safety_3\NN\13920835|the|inhibitor (r_dobj) assess_1\VB\670261|to|safety|enalapril|multicenter (r_advcl) designed_17\VBN\1631534|assess|,|trial|was|incidence|. (l_ccomp) incidence_21\NN\13821570|that|compared|the|and|severity|day (l_conj) severity_23\NN\5036394|hypotension (l_nmod) hypotension_26\NN\14057371|of|symptomatic
D004656_D007022 NONE enalapril_8\NN\2673637| (r_dep) assess_1\VB\670261|to|safety|enalapril|multicenter (r_advcl) designed_17\VBN\1631534|assess|,|trial|was|incidence|. (l_ccomp) incidence_21\NN\13821570|that|compared|the|and|severity|day (l_conj) severity_23\NN\5036394|hypotension (l_nmod) hypotension_26\NN\14057371|of|symptomatic
D004656_D007022 NONE enalapril_3\NN\2673637| (r_dobj) received_2\VBD\2210855|who|enalapril (r_acl:relcl) patients_0\NNS\9898892|received (r_nsubj) experienced_4\VBN\2108377|patients|hypotension|. (l_dobj) hypotension_11\NN\14057371|symptomatic|%|patients|)
D011224_D007022 CID prazosin-controlled_14\JJ\1740| (r_amod) trial_15\NN\786195|prazosin-controlled (r_nsubjpass) designed_17\VBN\1631534|assess|,|trial|was|incidence|. (l_ccomp) incidence_21\NN\13821570|that|compared|the|and|severity|day (l_conj) severity_23\NN\5036394|hypotension (l_nmod) hypotension_26\NN\14057371|of|symptomatic
D011224_D007022 CID prazosin_21\NN\2698769|(|% (r_dobj) received_20\VBD\2210855|who|prazosin (r_acl:relcl) patients_18\NNS\9898892|than|the|received (r_nmod) hypotension_11\NN\14057371|symptomatic|%|patients|)
19300402
D001920_D006930 NONE bradykinin_0\NNP\1740| (r_compound) receptors_1\NNS\5225602|bradykinin (r_compound) antagonists_2\NNS\7846|receptors|and|inhibitors|vincristine (r_nsubj) induced_12\VBD\1627355|antagonists|hyperalgesia|chemotherapy|model|. (l_dobj) hyperalgesia_13\NN\1740|
D001920_D006930 NONE bradykinin_11\NN\1740| (r_compound) receptors_12\NNS\5225602|of|bradykinin (r_nmod) inhibition_9\NN\1068773|receptors|and|synthase|activity (r_nsubj) reduces_23\VBZ\441445|that|inhibition|hyperalgesia (l_dobj) hyperalgesia_25\NN\1740|diabetic
D001920_D006930 NONE bradykinin_19\NN\1740| (r_conj) products_6\NNS\3076708|both|synthase|as|bradykinin (r_nsubjpass) involved_21\VBN\2676054|that|products|are|hyperalgesia (l_nmod) hyperalgesia_23\NN\1740|in|produced
D001920_D006930 NONE bradykinin_12\NN\1740|of (r_nmod) activity_10\NN\30358|in|pronociceptive|bradykinin (r_nmod) participates_7\VBZ\2367363|hyperalgesia|,|synthase|activity|,|seemed|. (l_nmod) hyperalgesia_2\NN\1740|in|streptozotocin-induced
D001920_D006930 NONE bradykinin_12\NN\1740|of (r_nmod) activity_10\NN\30358|in|pronociceptive|bradykinin (r_nmod) participates_7\VBZ\2367363|hyperalgesia|,|synthase|activity|,|seemed|. (l_advcl) seemed_19\VBD\2604760|whereas|bradykinin|activate (l_nsubj) bradykinin_18\NN\1740|in|vincristine-induced|hyperalgesia (l_compound) hyperalgesia_17\NN\1740|
D001920_D006930 NONE bradykinin_18\NN\1740|in|vincristine-induced|hyperalgesia (r_nsubj) seemed_19\VBD\2604760|whereas|bradykinin|activate (r_advcl) participates_7\VBZ\2367363|hyperalgesia|,|synthase|activity|,|seemed|. (l_nmod) hyperalgesia_2\NN\1740|in|streptozotocin-induced
D001920_D006930 NONE bradykinin_18\NN\1740|in|vincristine-induced|hyperalgesia (l_compound) hyperalgesia_17\NN\1740|
D001920_D003929 NONE bradykinin_0\NNP\1740| (r_compound) receptors_1\NNS\5225602|bradykinin (r_compound) antagonists_2\NNS\7846|receptors|and|inhibitors|vincristine (r_nsubj) induced_12\VBD\1627355|antagonists|hyperalgesia|chemotherapy|model|. (l_dobj) model_20\NN\5888929|neuropathy|rat (l_amod) neuropathy_18\JJ\1740|
D001920_D003929 NONE bradykinin_66\NN\1740|d-arg-[hyp3,thi5,d-tic7,oic8|]|hoe|or|des (r_nmod) influence_3\NN\5190804|the|inhibitor|action|bradykinin|ip|respectively|,|model (l_nmod) model_88\NN\5888929|in|diabetic (l_nmod) diabetic_90\JJ\1740|of|streptozotocin-induced|and|toxic|neuropathy (l_dep) neuropathy_99\RB\1740|
D009569_D006930 NONE oxide_5\NN\14818238| (r_compound) synthase_6\NN\1740|nitric|oxide (r_compound) inhibitors_7\NNS\20090|synthase (r_conj) antagonists_2\NNS\7846|receptors|and|inhibitors|vincristine (r_nsubj) induced_12\VBD\1627355|antagonists|hyperalgesia|chemotherapy|model|. (l_dobj) hyperalgesia_13\NN\1740|
D009569_D006930 NONE no_15\NN\7204911| (r_compound) synthase_16\NN\1740|inducible|no (r_conj) inhibition_9\NN\1068773|receptors|and|synthase|activity (r_nsubj) reduces_23\VBZ\441445|that|inhibition|hyperalgesia (l_dobj) hyperalgesia_25\NN\1740|diabetic
D009569_D006930 NONE no_20\NN\7204911| (r_compound) activity_22\NN\30358|neuronal|no|synthase (r_dep) inhibition_9\NN\1068773|receptors|and|synthase|activity (r_nsubj) reduces_23\VBZ\441445|that|inhibition|hyperalgesia (l_dobj) hyperalgesia_25\NN\1740|diabetic
D009569_D006930 NONE no_9\NN\7204911| (r_compound) synthase_10\NN\1740|of|inducible|no|and|activation (r_nmod) products_6\NNS\3076708|both|synthase|as|bradykinin (r_nsubjpass) involved_21\VBN\2676054|that|products|are|hyperalgesia (l_nmod) hyperalgesia_23\NN\1740|in|produced
D009569_D006930 NONE no_13\NN\7204911| (r_compound) activation_15\NN\13561719|neuronal|no|synthase (r_conj) synthase_10\NN\1740|of|inducible|no|and|activation (r_nmod) products_6\NNS\3076708|both|synthase|as|bradykinin (r_nsubjpass) involved_21\VBN\2676054|that|products|are|hyperalgesia (l_nmod) hyperalgesia_23\NN\1740|in|produced
D009569_D006930 NONE no_5\NN\7204911| (r_compound) synthase_6\NN\1740|inducible|no (r_nsubj) participates_7\VBZ\2367363|hyperalgesia|,|synthase|activity|,|seemed|. (l_nmod) hyperalgesia_2\NN\1740|in|streptozotocin-induced
D009569_D006930 NONE no_5\NN\7204911| (r_compound) synthase_6\NN\1740|inducible|no (r_nsubj) participates_7\VBZ\2367363|hyperalgesia|,|synthase|activity|,|seemed|. (l_advcl) seemed_19\VBD\2604760|whereas|bradykinin|activate (l_nsubj) bradykinin_18\NN\1740|in|vincristine-induced|hyperalgesia (l_compound) hyperalgesia_17\NN\1740|
D009569_D006930 NONE no_23\NN\7204911| (r_compound) pathway_25\NN\5483677|neuronal|no|synthase (r_dobj) activate_21\VB\1641914|to|pathway (r_xcomp) seemed_19\VBD\2604760|whereas|bradykinin|activate (r_advcl) participates_7\VBZ\2367363|hyperalgesia|,|synthase|activity|,|seemed|. (l_nmod) hyperalgesia_2\NN\1740|in|streptozotocin-induced
D009569_D006930 NONE no_23\NN\7204911| (r_compound) pathway_25\NN\5483677|neuronal|no|synthase (r_dobj) activate_21\VB\1641914|to|pathway (r_xcomp) seemed_19\VBD\2604760|whereas|bradykinin|activate (l_nsubj) bradykinin_18\NN\1740|in|vincristine-induced|hyperalgesia (l_compound) hyperalgesia_17\NN\1740|
D009569_D003929 NONE oxide_5\NN\14818238| (r_compound) synthase_6\NN\1740|nitric|oxide (r_compound) inhibitors_7\NNS\20090|synthase (r_conj) antagonists_2\NNS\7846|receptors|and|inhibitors|vincristine (r_nsubj) induced_12\VBD\1627355|antagonists|hyperalgesia|chemotherapy|model|. (l_dobj) model_20\NN\5888929|neuropathy|rat (l_amod) neuropathy_18\JJ\1740|
D009569_D003929 NONE no_10\NN\7204911| (r_compound) synthase_11\NN\1740|of|constitutive|no (r_nmod) inhibitor_7\NN\20090|of|an|irreversible|synthase|l-noarg|,|inhibitor|, (r_nmod) influence_3\NN\5190804|the|inhibitor|action|bradykinin|ip|respectively|,|model (l_nmod) model_88\NN\5888929|in|diabetic (l_nmod) diabetic_90\JJ\1740|of|streptozotocin-induced|and|toxic|neuropathy (l_dep) neuropathy_99\RB\1740|
D009569_D003929 NONE no_26\NN\7204911| (r_compound) synthase_27\NN\1740|of|inducible|no (r_nmod) inhibitor_23\NN\20090|a|selective|synthase|l-nil|and|inhibitor (r_appos) inhibitor_7\NN\20090|of|an|irreversible|synthase|l-noarg|,|inhibitor|, (r_nmod) influence_3\NN\5190804|the|inhibitor|action|bradykinin|ip|respectively|,|model (l_nmod) model_88\NN\5888929|in|diabetic (l_nmod) diabetic_90\JJ\1740|of|streptozotocin-induced|and|toxic|neuropathy (l_dep) neuropathy_99\RB\1740|
D009569_D003929 NONE no_42\NN\7204911| (r_compound) synthase_43\NN\1740|of|neuronal|no (r_nmod) inhibitor_39\NN\20090|a|specific|synthase|7-ni (r_conj) inhibitor_23\NN\20090|a|selective|synthase|l-nil|and|inhibitor (r_appos) inhibitor_7\NN\20090|of|an|irreversible|synthase|l-noarg|,|inhibitor|, (r_nmod) influence_3\NN\5190804|the|inhibitor|action|bradykinin|ip|respectively|,|model (l_nmod) model_88\NN\5888929|in|diabetic (l_nmod) diabetic_90\JJ\1740|of|streptozotocin-induced|and|toxic|neuropathy (l_dep) neuropathy_99\RB\1740|
D014750_D006930 CID vincristine_9\NN\3917455|in|and|streptozotocin (r_nmod) antagonists_2\NNS\7846|receptors|and|inhibitors|vincristine (r_nsubj) induced_12\VBD\1627355|antagonists|hyperalgesia|chemotherapy|model|. (l_dobj) hyperalgesia_13\NN\1740|
D014750_D006930 CID vincristine_26\NN\3917455|by (r_nmod) produced_24\VBN\1617192|vincristine (r_acl) hyperalgesia_23\NN\1740|in|produced
D014750_D006930 CID vincristine-induced_16\JJ\1740| (r_amod) bradykinin_18\NN\1740|in|vincristine-induced|hyperalgesia (r_nsubj) seemed_19\VBD\2604760|whereas|bradykinin|activate (r_advcl) participates_7\VBZ\2367363|hyperalgesia|,|synthase|activity|,|seemed|. (l_nmod) hyperalgesia_2\NN\1740|in|streptozotocin-induced
D014750_D006930 CID vincristine-induced_16\JJ\1740| (r_amod) bradykinin_18\NN\1740|in|vincristine-induced|hyperalgesia (l_compound) hyperalgesia_17\NN\1740|
D014750_D003929 NONE vincristine_9\NN\3917455|in|and|streptozotocin (r_nmod) antagonists_2\NNS\7846|receptors|and|inhibitors|vincristine (r_nsubj) induced_12\VBD\1627355|antagonists|hyperalgesia|chemotherapy|model|. (l_dobj) model_20\NN\5888929|neuropathy|rat (l_amod) neuropathy_18\JJ\1740|
D013311_D006930 CID streptozotocin_11\NN\1740| (r_conj) vincristine_9\NN\3917455|in|and|streptozotocin (r_nmod) antagonists_2\NNS\7846|receptors|and|inhibitors|vincristine (r_nsubj) induced_12\VBD\1627355|antagonists|hyperalgesia|chemotherapy|model|. (l_dobj) hyperalgesia_13\NN\1740|
D013311_D006930 CID streptozotocin-induced_1\JJ\1740| (r_amod) hyperalgesia_2\NN\1740|in|streptozotocin-induced
D013311_D006930 CID streptozotocin-induced_1\JJ\1740| (r_amod) hyperalgesia_2\NN\1740|in|streptozotocin-induced (r_nmod) participates_7\VBZ\2367363|hyperalgesia|,|synthase|activity|,|seemed|. (l_advcl) seemed_19\VBD\2604760|whereas|bradykinin|activate (l_nsubj) bradykinin_18\NN\1740|in|vincristine-induced|hyperalgesia (l_compound) hyperalgesia_17\NN\1740|
D013311_D003929 CID streptozotocin_11\NN\1740| (r_conj) vincristine_9\NN\3917455|in|and|streptozotocin (r_nmod) antagonists_2\NNS\7846|receptors|and|inhibitors|vincristine (r_nsubj) induced_12\VBD\1627355|antagonists|hyperalgesia|chemotherapy|model|. (l_dobj) model_20\NN\5888929|neuropathy|rat (l_amod) neuropathy_18\JJ\1740|
D009569_D010523 NONE no_10\NN\7204911| (r_compound) synthase_11\NN\1740|of|constitutive|no (r_nmod) inhibitor_7\NN\20090|of|an|irreversible|synthase|l-noarg|,|inhibitor|, (r_nmod) influence_3\NN\5190804|the|inhibitor|action|bradykinin|ip|respectively|,|model (l_nmod) model_88\NN\5888929|in|diabetic (l_nmod) diabetic_90\JJ\1740|of|streptozotocin-induced|and|toxic|neuropathy (l_dep) neuropathy_99\RB\1740|
D009569_D010523 NONE no_26\NN\7204911| (r_compound) synthase_27\NN\1740|of|inducible|no (r_nmod) inhibitor_23\NN\20090|a|selective|synthase|l-nil|and|inhibitor (r_appos) inhibitor_7\NN\20090|of|an|irreversible|synthase|l-noarg|,|inhibitor|, (r_nmod) influence_3\NN\5190804|the|inhibitor|action|bradykinin|ip|respectively|,|model (l_nmod) model_88\NN\5888929|in|diabetic (l_nmod) diabetic_90\JJ\1740|of|streptozotocin-induced|and|toxic|neuropathy (l_dep) neuropathy_99\RB\1740|
D009569_D010523 NONE no_42\NN\7204911| (r_compound) synthase_43\NN\1740|of|neuronal|no (r_nmod) inhibitor_39\NN\20090|a|specific|synthase|7-ni (r_conj) inhibitor_23\NN\20090|a|selective|synthase|l-nil|and|inhibitor (r_appos) inhibitor_7\NN\20090|of|an|irreversible|synthase|l-noarg|,|inhibitor|, (r_nmod) influence_3\NN\5190804|the|inhibitor|action|bradykinin|ip|respectively|,|model (l_nmod) model_88\NN\5888929|in|diabetic (l_nmod) diabetic_90\JJ\1740|of|streptozotocin-induced|and|toxic|neuropathy (l_dep) neuropathy_99\RB\1740|
D001920_D010523 NONE bradykinin_66\NN\1740|d-arg-[hyp3,thi5,d-tic7,oic8|]|hoe|or|des (r_nmod) influence_3\NN\5190804|the|inhibitor|action|bradykinin|ip|respectively|,|model (l_nmod) model_88\NN\5888929|in|diabetic (l_nmod) diabetic_90\JJ\1740|of|streptozotocin-induced|and|toxic|neuropathy (l_dep) neuropathy_99\RB\1740|
C065679_D003929 NONE 140_69\CD\1740| (r_nummod) hoe_68\NN\4451818|(|140|;|70|ip|) (r_dep) bradykinin_66\NN\1740|d-arg-[hyp3,thi5,d-tic7,oic8|]|hoe|or|des (r_nmod) influence_3\NN\5190804|the|inhibitor|action|bradykinin|ip|respectively|,|model (l_nmod) model_88\NN\5888929|in|diabetic (l_nmod) diabetic_90\JJ\1740|of|streptozotocin-induced|and|toxic|neuropathy (l_dep) neuropathy_99\RB\1740|
C065679_D010523 NONE 140_69\CD\1740| (r_nummod) hoe_68\NN\4451818|(|140|;|70|ip|) (r_dep) bradykinin_66\NN\1740|d-arg-[hyp3,thi5,d-tic7,oic8|]|hoe|or|des (r_nmod) influence_3\NN\5190804|the|inhibitor|action|bradykinin|ip|respectively|,|model (l_nmod) model_88\NN\5888929|in|diabetic (l_nmod) diabetic_90\JJ\1740|of|streptozotocin-induced|and|toxic|neuropathy (l_dep) neuropathy_99\RB\1740|
C065679_D010523 NONE 140_13\CD\1740| (r_nummod) hoe_12\NN\4451818|of|140|or|des-arg10hoe (l_conj) des-arg10hoe_15\NN\1740|140|neuropathy (l_nmod) neuropathy_19\NN\14204950|in|toxic
C078665_D003929 NONE 140_79\CD\1740| (r_nummod) hoe_78\NN\4451818|arg10|140 (r_compound) ip_83\NN\5999797|hoe|nmol/kg|) (r_nmod) influence_3\NN\5190804|the|inhibitor|action|bradykinin|ip|respectively|,|model (l_nmod) model_88\NN\5888929|in|diabetic (l_nmod) diabetic_90\JJ\1740|of|streptozotocin-induced|and|toxic|neuropathy (l_dep) neuropathy_99\RB\1740|
C078665_D010523 NONE 140_79\CD\1740| (r_nummod) hoe_78\NN\4451818|arg10|140 (r_compound) ip_83\NN\5999797|hoe|nmol/kg|) (r_nmod) influence_3\NN\5190804|the|inhibitor|action|bradykinin|ip|respectively|,|model (l_nmod) model_88\NN\5888929|in|diabetic (l_nmod) diabetic_90\JJ\1740|of|streptozotocin-induced|and|toxic|neuropathy (l_dep) neuropathy_99\RB\1740|
C078665_D010523 NONE 140_16\CD\1740| (r_nummod) des-arg10hoe_15\NN\1740|140|neuropathy (l_nmod) neuropathy_19\NN\14204950|in|toxic
D001920_D009437 NONE bradykinin_8\NN\1740| (r_compound) antagonists_10\NNS\7846|of|bradykinin|receptor (r_nmod) doses_6\NNS\3740161|of|small|antagonists|and|inhibitors (r_nmod) administration_3\NN\1133281|concomitant|doses (r_nsubj) effective_17\JJ\1740|therefore|,|administration|can|be|alleviation|,|care|. (l_nmod) alleviation_19\NN\7492516|in|pain (l_nmod) pain_22\NN\14299637|of|neuropathic
D009569_D009437 NONE no_12\NN\7204911| (r_compound) inhibitors_14\NNS\20090|no|synthase (r_conj) doses_6\NNS\3740161|of|small|antagonists|and|inhibitors (r_nmod) administration_3\NN\1133281|concomitant|doses (r_nsubj) effective_17\JJ\1740|therefore|,|administration|can|be|alleviation|,|care|. (l_nmod) alleviation_19\NN\7492516|in|pain (l_nmod) pain_22\NN\14299637|of|neuropathic
11642480
D015283_D004409 CID citalopram_7\NN\1740|on (r_nmod) adolescent_5\JJ\1740|in|a|depressed|citalopram (r_nmod) twitching_1\VBG\10054|palpebral|adolescent|.
D015283_D004409 CID citalopram_8\NN\1740|with (r_nmod) treatment_6\NN\654885|to|citalopram (r_nmod) response_4\NN\11410625|a|favorable|treatment|boy (l_nmod) boy_12\NN\9624168|by|a|15-year-old|depression|exhibited (l_acl:relcl) exhibited_17\VBD\2632167|who|twitching|weeks (l_dobj) twitching_19\NN\14360459|palpebral
D015283_D003866 NONE citalopram_7\NN\1740|on (r_nmod) adolescent_5\JJ\1740|in|a|depressed|citalopram (l_amod) depressed_4\JJ\1740|
D015283_D003865 NONE citalopram_8\NN\1740|with (r_nmod) treatment_6\NN\654885|to|citalopram (r_nmod) response_4\NN\11410625|a|favorable|treatment|boy (l_nmod) boy_12\NN\9624168|by|a|15-year-old|depression|exhibited (l_nmod) depression_15\NN\14373582|with|major
15859940
D016572_D064420 NONE cyclosporine_5\NN\1740|(|,|tacrolimus|) (r_dep) drug-related_3\JJ\1740|cyclosporine (r_amod) toxicity_9\NN\13576101|drug-related|,|status|,|and|rejection
D016559_D064420 NONE tacrolimus_7\NN\1740| (r_appos) cyclosporine_5\NN\1740|(|,|tacrolimus|) (r_dep) drug-related_3\JJ\1740|cyclosporine (r_amod) toxicity_9\NN\13576101|drug-related|,|status|,|and|rejection
D016572_D057049 CID cyclosporine_16\NN\1740|to (r_nmod) secondary_13\JJ\1740|mainly|cyclosporine (r_conj) related_11\JJ\1740|drug|,|secondary (l_nmod:npmod) drug_10\NN\14778436|that|cause|was (l_nsubj) cause_5\NN\7323922|the|most-frequent|microangiopathy (l_nmod) microangiopathy_8\NN\1740|of|thrombotic
8595686
D013874_D010146 NONE thiopentone_0\NN\1740| (r_compound) pretreatment_1\NN\1740|thiopentone|pain|. (l_nmod) pain_5\NN\14299637|for|propofol|injection|patients
D013874_D010146 NONE thiopentone_17\NN\1740| (r_nsubj) reduces_19\VBZ\441445|whereas|thiopentone|only|severity (r_advcl) reduces_4\VBZ\441445|that|lidocaine|incidence|reduces (l_dobj) incidence_6\NN\13821570|the|and|severity|pain|patients (l_nmod) pain_12\NN\14299637|of|injection
D015742_D010146 CID propofol_3\NN\1740| (r_compound) pain_5\NN\14299637|for|propofol|injection|patients
D015742_D010146 CID propofol_3\NN\1740| (r_compound) pain_5\NN\14299637|propofol|injection|patients
D015742_D010146 CID propofol_10\NN\1740| (r_compound) injection_11\NN\320852|propofol (r_compound) pain_12\NN\14299637|of|injection
D008012_D010146 NONE lidocaine_3\NN\3681148| (r_nsubj) reduces_4\VBZ\441445|that|lidocaine|incidence|reduces (l_dobj) incidence_6\NN\13821570|the|and|severity|pain|patients (l_nmod) pain_12\NN\14299637|of|injection
11263551
D016572_D010146 CID cyclosporine-_3\NN\1740|or|trough (r_compound) levels_7\NNS\4916342|of|cyclosporine- (r_nmod) reduction_1\NN\351485|the|levels|and|administration (r_nsubj) led_15\VBD\1752884|reduction|relief|. (l_nmod) relief_17\NN\7492516|to|pain (l_nmod) pain_19\NN\14299637|of
D016572_D010146 CID cyclosporine_16\NN\1740|of|or|tacrolimus (r_nmod) effect_14\NN\34213|rare|side|cyclosporine|and (l_amod) rare_10\JJ\1740|syndrome|is|a|but|severe (l_nsubj) syndrome_4\NN\5870365|induced|pain|cips (l_compound) pain_3\NN\14299637|
D016559_D010146 CID tacrolimus_5\NN\1740| (r_compound) trough_6\NN\9366017|tacrolimus (r_conj) cyclosporine-_3\NN\1740|or|trough (r_compound) levels_7\NNS\4916342|of|cyclosporine- (r_nmod) reduction_1\NN\351485|the|levels|and|administration (r_nsubj) led_15\VBD\1752884|reduction|relief|. (l_nmod) relief_17\NN\7492516|to|pain (l_nmod) pain_19\NN\14299637|of
D016559_D010146 CID tacrolimus_18\NN\1740| (r_conj) cyclosporine_16\NN\1740|of|or|tacrolimus (r_nmod) effect_14\NN\34213|rare|side|cyclosporine|and (l_amod) rare_10\JJ\1740|syndrome|is|a|but|severe (l_nsubj) syndrome_4\NN\5870365|induced|pain|cips (l_compound) pain_3\NN\14299637|
D002118_D010146 NONE calcium_12\NN\14625458| (r_compound) channel_13\NN\6251781|calcium (r_compound) blockers_14\NNS\10101634|of|channel (r_nmod) administration_10\NN\1133281|the|blockers (r_conj) reduction_1\NN\351485|the|levels|and|administration (r_nsubj) led_15\VBD\1752884|reduction|relief|. (l_nmod) relief_17\NN\7492516|to|pain (l_nmod) pain_19\NN\14299637|of
D016572_-1 NONE cyclosporine_16\NN\1740|of|or|tacrolimus (r_nmod) effect_14\NN\34213|rare|side|cyclosporine|and (l_amod) rare_10\JJ\1740|syndrome|is|a|but|severe (l_nsubj) syndrome_4\NN\5870365|induced|pain|cips (l_appos) cips_6\NN\1740|(|)
D016559_-1 NONE tacrolimus_18\NN\1740| (r_conj) cyclosporine_16\NN\1740|of|or|tacrolimus (r_nmod) effect_14\NN\34213|rare|side|cyclosporine|and (l_amod) rare_10\JJ\1740|syndrome|is|a|but|severe (l_nsubj) syndrome_4\NN\5870365|induced|pain|cips (l_appos) cips_6\NN\1740|(|)
2572625
C084599_D056486 CID clotiazepam-induced_0\JJ\1740| (r_amod) hepatitis_2\NN\14127211|clotiazepam-induced|acute|.
C084599_D056486 CID clotiazepam_24\NN\1740|of|, (r_nmod) administration_22\NN\1133281|of|clotiazepam (r_nmod) onset_20\NN\7325190|after|the|administration (r_nmod) necrosis_14\NN\11444117|with|extensive|hepatocellular|,|onset (r_nmod) developed_8\VBD\1753788|who|hepatitis|necrosis (l_dobj) hepatitis_10\NN\14127211|acute
C084599_D056486 CID clotiazepam_9\VB\1740|to (r_nmod) related_7\JJ\1740|chemically|clotiazepam (r_amod) administration_1\NN\1133281|the|benzodiazepines|,|related (r_nsubj) interfere_13\VB\2451370|administration|,|did|not|recovery|and|induce|. (l_conj) induce_19\VB\1627355|did|not|relapse (l_dobj) relapse_21\NN\66636|any|hepatitis (l_nmod) hepatitis_23\NN\14127211|of
C084599_D056486 CID clotiazepam_4\NN\1740| (r_nsubj) induce_6\VB\1627355|that|clotiazepam|can|hepatitis|and|suggests (l_dobj) hepatitis_8\NN\14127211|acute
C084599_D056486 CID clotiazepam_4\NN\1740| (r_nsubj) induce_6\VB\1627355|that|clotiazepam|can|hepatitis|and|suggests (l_conj) suggests_10\VBZ\1010118|is (l_ccomp) is_13\VBZ\836236|that|there|hepatotoxicity (l_nsubj) hepatotoxicity_16\NN\1740|no|cross|clotiazepam
C084599_D056486 CID clotiazepam_18\NN\1740|between|and|benzodiazepines (r_nmod) hepatotoxicity_16\NN\1740|no|cross|clotiazepam (r_nsubj) is_13\VBZ\836236|that|there|hepatotoxicity (r_ccomp) suggests_10\VBZ\1010118|is (r_conj) induce_6\VB\1627355|that|clotiazepam|can|hepatitis|and|suggests (l_dobj) hepatitis_8\NN\14127211|acute
C084599_D056486 CID clotiazepam_18\NN\1740|between|and|benzodiazepines (r_nmod) hepatotoxicity_16\NN\1740|no|cross|clotiazepam
C084599_D047508 NONE clotiazepam_24\NN\1740|of|, (r_nmod) administration_22\NN\1133281|of|clotiazepam (r_nmod) onset_20\NN\7325190|after|the|administration (r_nmod) necrosis_14\NN\11444117|with|extensive|hepatocellular|,|onset
C013295_D056486 NONE thienodiazepine_27\NN\1740|a (r_compound) derivative_28\NN\5802185|thienodiazepine (r_conj) patient_6\NN\9898892|of|a|developed|derivative (l_acl:relcl) developed_8\VBD\1753788|who|hepatitis|necrosis (l_dobj) hepatitis_10\NN\14127211|acute
C013295_D047508 NONE thienodiazepine_27\NN\1740|a (r_compound) derivative_28\NN\5802185|thienodiazepine (r_conj) patient_6\NN\9898892|of|a|developed|derivative (l_acl:relcl) developed_8\VBD\1753788|who|hepatitis|necrosis (l_nmod) necrosis_14\NN\11444117|with|extensive|hepatocellular|,|onset
D001569_D056486 NONE benzodiazepines_4\NNS\3771443|of|several (r_nmod) administration_1\NN\1133281|the|benzodiazepines|,|related (r_nsubj) interfere_13\VB\2451370|administration|,|did|not|recovery|and|induce|. (l_conj) induce_19\VB\1627355|did|not|relapse (l_dobj) relapse_21\NN\66636|any|hepatitis (l_nmod) hepatitis_23\NN\14127211|of
D001569_D056486 NONE benzodiazepines_21\NNS\3771443|several (r_conj) clotiazepam_18\NN\1740|between|and|benzodiazepines (r_nmod) hepatotoxicity_16\NN\1740|no|cross|clotiazepam (r_nsubj) is_13\VBZ\836236|that|there|hepatotoxicity (r_ccomp) suggests_10\VBZ\1010118|is (r_conj) induce_6\VB\1627355|that|clotiazepam|can|hepatitis|and|suggests (l_dobj) hepatitis_8\NN\14127211|acute
D001569_D056486 NONE benzodiazepines_21\NNS\3771443|several (r_conj) clotiazepam_18\NN\1740|between|and|benzodiazepines (r_nmod) hepatotoxicity_16\NN\1740|no|cross|clotiazepam
10406016
C007789_D002543 NONE fucoidan_2\JJ\1740| (r_amod) treatment_3\NN\654885|of|fucoidan|hemorrhage (l_nmod) hemorrhage_7\NN\14285662|on|collagenase-induced|intracerebral
C007789_D002543 NONE fucoidan_5\JJ\1740| (r_advmod) tested_1\VBD\670261|we|polysaccharide|fucoidan|,|reported|,|model|. (l_nmod) model_20\NN\5888929|in|a|rat|hemorrhage (l_nmod) hemorrhage_23\NN\14285662|of|intracerebral|induced
C007789_D001925 NONE fucoidan_5\JJ\1740| (r_advmod) tested_1\VBD\670261|we|polysaccharide|fucoidan|,|reported|,|model|. (l_dep) reported_10\VBN\831651|which|has|been|reduce (l_xcomp) reduce_12\VB\441445|to|damage (l_dobj) damage_15\NN\7296428|inflammatory|brain
C007789_D020141 CID fucoidan-treated_0\JJ\1740| (r_amod) rats_1\NNS\2329401|fucoidan-treated (r_nsubj) exhibited_2\VBD\2632167|rats|evidence|,|had|. (l_dobj) evidence_3\NN\5816287|clotting (l_nmod) clotting_7\NN\13518963|of|impaired|blood|and|hemodilution
C007789_D020141 CID fucoidan-treated_0\JJ\1740| (r_amod) rats_1\NNS\2329401|fucoidan-treated (r_nsubj) exhibited_2\VBD\2632167|rats|evidence|,|had|. (l_dobj) evidence_3\NN\5816287|clotting (l_nmod) clotting_7\NN\13518963|of|impaired|blood|and|hemodilution (l_conj) hemodilution_9\NN\1740|
C007789_D006406 NONE fucoidan-treated_0\JJ\1740| (r_amod) rats_1\NNS\2329401|fucoidan-treated (r_nsubj) exhibited_2\VBD\2632167|rats|evidence|,|had|. (l_conj) had_11\VBD\2108377|hematomas|,|and|tended (l_dobj) hematomas_13\NNS\14317720|larger
C007789_D006406 NONE fucoidan-treated_0\JJ\1740| (r_amod) rats_1\NNS\2329401|fucoidan-treated (r_nsubj) exhibited_2\VBD\2632167|rats|evidence|,|had|. (l_conj) had_11\VBD\2108377|hematomas|,|and|tended (l_conj) tended_16\VBD\2604760|have|days (l_xcomp) have_18\VB\2108377|to|inflammation (l_dobj) inflammation_20\NN\14299637|less|vicinity (l_nmod) vicinity_23\NN\8648322|in|the|hematoma (l_nmod) hematoma_26\NN\14317720|of|the
C007789_D007249 NONE fucoidan-treated_0\JJ\1740| (r_amod) rats_1\NNS\2329401|fucoidan-treated (r_nsubj) exhibited_2\VBD\2632167|rats|evidence|,|had|. (l_conj) had_11\VBD\2108377|hematomas|,|and|tended (l_conj) tended_16\VBD\2604760|have|days (l_xcomp) have_18\VB\2108377|to|inflammation (l_dobj) inflammation_20\NN\14299637|less|vicinity
12820454
D016729_D000740 CID acetate_6\NN\15010703|[|leuprolide|lhrh-a (r_dep) cab_3\NN\3079741|acetate|mg (r_dobj) received_2\VBD\2210855|patients|cab|,|intramuscularly|,|days|os|]|and|evaluated|. (l_conj) evaluated_30\VBN\670261|were|anemia|examination|and|intervals (l_nmod) anemia_32\NN\14189204|for
D016729_D000740 CID lhrh-a_8\NN\1740|(|) (r_appos) acetate_6\NN\15010703|[|leuprolide|lhrh-a (r_dep) cab_3\NN\3079741|acetate|mg (r_dobj) received_2\VBD\2210855|patients|cab|,|intramuscularly|,|days|os|]|and|evaluated|. (l_conj) evaluated_30\VBN\670261|were|anemia|examination|and|intervals (l_nmod) anemia_32\NN\14189204|for
D005485_D000740 CID flutamide_21\NN\1740|mg|,|tid|, (r_conj) days_17\NNS\15140892|every|28|plus|flutamide (r_dobj) received_2\VBD\2210855|patients|cab|,|intramuscularly|,|days|os|]|and|evaluated|. (l_conj) evaluated_30\VBN\670261|were|anemia|examination|and|intervals (l_nmod) anemia_32\NN\14189204|for
2476560
D001556_D012532 NONE lindane_12\NN\14919948|hexachloride (r_xcomp) consider_11\VB\689344|most|lindane|treatment (r_parataxis) initiated_5\VBN\1617192|treatment|is|usually|practitioners|;|consider|. (l_nsubjpass) treatment_0\NN\654885|scabies (l_nmod) scabies_2\NNS\14174549|for
D001556_D012532 NONE hexachloride_16\NN\1740|(|gamma|benzene|) (r_appos) lindane_12\NN\14919948|hexachloride (r_xcomp) consider_11\VB\689344|most|lindane|treatment (r_parataxis) initiated_5\VBN\1617192|treatment|is|usually|practitioners|;|consider|. (l_nsubjpass) treatment_0\NN\654885|scabies (l_nmod) scabies_2\NNS\14174549|for
D001556_D002493 CID lindane_4\NN\14919948|that (r_nsubj) toxic_7\JJ\1740|lindane|can|be|system|and|associated (l_nmod) system_12\NN\3575240|to|the|central|nervous
D001556_D000741 CID lindane_4\NN\14919948|that (r_nsubj) toxic_7\JJ\1740|lindane|can|be|system|and|associated (l_conj) associated_16\VBN\628491|may|be|anaemia (l_nmod) anaemia_19\NN\14299637|with|aplastic
3560096
D013467_D006947 CID sulindac_3\NN\3828465| (r_compound) therapy_4\NN\657604|with|sulindac (r_nmod) associated_1\VBN\628491|therapy (r_acl) hyperkalemia_0\NN\14299637|associated|.
D013467_D006947 CID sulindac_20\NN\3828465| (r_compound) administration_21\NN\1133281|of|sulindac (r_nmod) days_18\NNS\15140892|within|8|administration (r_nmod) developed_13\VBD\1753788|days (r_conj) describe_1\VBP\1001294|we|patients|developed|. (l_dobj) patients_3\NNS\9898892|4|ranging (l_acl:relcl) ranging_7\VBG\2604760|whom|hyperkalemia|meq/l (l_nsubj) hyperkalemia_6\NN\14299637|
D013467_D006947 CID sulindac_25\NN\3828465|between|and|hyperkalemia (l_conj) hyperkalemia_27\NN\14299637|
D007213_D006947 CID indomethacin_17\NN\3828465|such (r_nmod) agents_11\NNS\7347|of|nonsteroidal|antiinflammatory|nsaid|indomethacin (r_nmod) complication_7\NN\1073995|as|a|agents (r_nmod) recognized_4\VBN\686447|hyperkalemia|has|recently|been|complication|. (l_nsubjpass) hyperkalemia_0\NN\14299637|
D011188_D006947 NONE potassium_8\NN\14625458|serum (r_dobj) effect_6\NN\34213|to|potassium (r_xcomp) known_4\VBN\2110220|effect (r_acl) medications_3\NNS\3247620|as|no|other|known (r_nsubjpass) given_11\VBN\2327200|medications|had|been|concomitantly|, (r_advcl) suggestive_19\JJ\1740|given|course|is|relationship|. (l_nmod) relationship_23\NN\31921|of|a|cause-and-effect|sulindac (l_nmod) sulindac_25\NN\3828465|between|and|hyperkalemia (l_conj) hyperkalemia_27\NN\14299637|
1009330
C004658_D003556 NONE p-choloroaniline_8\NN\1740|the|product (r_nsubj) factor_13\NN\7326557|that|p-choloroaniline|is|not|a|significant|cystitis (l_nmod) cystitis_18\NN\14566129|in|chlorhexidine-digluconate|erosive
C010882_D003556 CID chlorhexidine-digluconate_15\JJ\1740|associated (r_amod) cystitis_18\NN\14566129|in|chlorhexidine-digluconate|erosive
D007612_D003556 CID kanamycin-colistin_4\JJ\1740|and|povidone-iodine (r_amod) irrigations_7\NNS\1057200|of|kanamycin-colistin (r_nmod) percentage_2\NN\13815742|a|high|irrigations (r_nsubjpass) associated_9\VBN\628491|percentage|were|cystitis|and|suggested|. (l_nmod) cystitis_12\NN\14566129|with|erosive
D003091_D003556 CID kanamycin-colistin_4\JJ\1740|and|povidone-iodine (r_amod) irrigations_7\NNS\1057200|of|kanamycin-colistin (r_nmod) percentage_2\NN\13815742|a|high|irrigations (r_nsubjpass) associated_9\VBN\628491|percentage|were|cystitis|and|suggested|. (l_nmod) cystitis_12\NN\14566129|with|erosive
D011206_D003556 CID povidone-iodine_6\JJ\1740| (r_conj) kanamycin-colistin_4\JJ\1740|and|povidone-iodine (r_amod) irrigations_7\NNS\1057200|of|kanamycin-colistin (r_nmod) percentage_2\NN\13815742|a|high|irrigations (r_nsubjpass) associated_9\VBN\628491|percentage|were|cystitis|and|suggested|. (l_nmod) cystitis_12\NN\14566129|with|erosive
C005253_D003556 NONE picloxydine_0\NN\1740| (r_compound) irrigations_1\NNS\1057200|picloxydine (r_nsubj) appeared_2\VBD\2604760|irrigations|have|but|have|. (l_xcomp) have_4\VB\2108377|to|incidence (l_dobj) incidence_7\NN\13821570|a|lower|cystitis (l_nmod) cystitis_10\NN\14566129|of|erosive
19387625
D002211_D010146 NONE capsaicin-induced_7\JJ\1740| (r_amod) hyperalgesia_9\NN\1740|in|capsaicin-induced|secondary (r_nmod) modulation_1\NN\7044917|attentional|intensity|hyperalgesia|. (l_nmod) intensity_5\NN\5090441|of|perceived|pain (l_compound) pain_4\NN\14299637|
D002211_D010146 NONE capsaicin-induced_16\JJ\1740| (r_amod) hyperalgesia_18\NN\1740|in|capsaicin-induced|secondary (r_nmod) attention_14\NN\5701944|by|hyperalgesia (r_nmod) affected_12\VBN\126264|that|how|ratings|are|attention (l_nsubjpass) ratings_10\NNS\5733583|pain|intensity (l_compound) pain_8\NN\14299637|
D002211_D010146 NONE capsaicin_7\NN\15032661| (r_compound) treatment_8\NN\654885|between|capsaicin|and|modulation (r_nmod) interaction_5\NN\37396|no|treatment (r_dobj) showing_3\VBG\2137132|interaction (r_acl) findings_1\NNS\7951464|our|,|showing (r_nsubj) suggest_12\VBP\1010118|findings|affect|. (l_ccomp) affect_20\VB\126264|that|hyperalgesia|might|pain|mechanisms (l_dobj) pain_22\NN\14299637|mechanical
D002211_D010146 NONE capsaicin-induced_14\JJ\1740| (r_amod) hyperalgesia_16\NN\1740|capsaicin-induced|secondary|and|attention (r_nsubj) affect_20\VB\126264|that|hyperalgesia|might|pain|mechanisms (l_dobj) pain_22\NN\14299637|mechanical
D002211_D006930 CID capsaicin-induced_7\JJ\1740| (r_amod) hyperalgesia_9\NN\1740|in|capsaicin-induced|secondary
D002211_D006930 CID capsaicin-induced_16\JJ\1740| (r_amod) hyperalgesia_18\NN\1740|in|capsaicin-induced|secondary
D002211_D006930 CID capsaicin-untreated_20\JJ\1740|,|control (r_amod) condition_23\NN\24720|of|capsaicin-untreated (r_nmod) that_18\DT\1740|to|condition (r_nmod) similar_16\JJ\1740|that|magnitude|is|very|that (l_nsubj) magnitude_7\NN\4916342|the|modulation (l_nmod) modulation_10\NN\7044917|of|attentional|hyperalgesia (l_nmod) hyperalgesia_13\NN\1740|in|secondary
D002211_D006930 CID capsaicin_7\NN\15032661| (r_compound) treatment_8\NN\654885|between|capsaicin|and|modulation (r_nmod) interaction_5\NN\37396|no|treatment (r_dobj) showing_3\VBG\2137132|interaction (r_acl) findings_1\NNS\7951464|our|,|showing (r_nsubj) suggest_12\VBP\1010118|findings|affect|. (l_ccomp) affect_20\VB\126264|that|hyperalgesia|might|pain|mechanisms (l_nsubj) hyperalgesia_16\NN\1740|capsaicin-induced|secondary|and|attention
D002211_D006930 CID capsaicin-induced_14\JJ\1740| (r_amod) hyperalgesia_16\NN\1740|capsaicin-induced|secondary|and|attention
18821488
C080436_D064420 NONE 8-aminoquinoline_8\NN\1740| (r_compound) 5-(l-hexyloxy)-6-methoxy-4-methylquinoline_10\NN\1740|of|the|8-aminoquinoline|8-[(4-amino-l-methylbutyl)amino]-|wr242511 (r_nmod) administration_5\NN\1133281|following|5-(l-hexyloxy)-6-methoxy-4-methylquinoline (r_nmod) toxicity_0\NN\13576101|monkeys|administration|.
C068820_D064420 NONE 5-(l-hexyloxy)-6-methoxy-4-methylquinoline_10\NN\1740|of|the|8-aminoquinoline|8-[(4-amino-l-methylbutyl)amino]-|wr242511 (r_nmod) administration_5\NN\1133281|following|5-(l-hexyloxy)-6-methoxy-4-methylquinoline (r_nmod) toxicity_0\NN\13576101|monkeys|administration|.
C068820_D064420 NONE wr242511_12\NN\1740|(|) (r_appos) 5-(l-hexyloxy)-6-methoxy-4-methylquinoline_10\NN\1740|of|the|8-aminoquinoline|8-[(4-amino-l-methylbutyl)amino]-|wr242511 (r_nmod) administration_5\NN\1133281|following|5-(l-hexyloxy)-6-methoxy-4-methylquinoline (r_nmod) toxicity_0\NN\13576101|monkeys|administration|.
C068820_D064420 NONE wr242511_4\NN\1740| (r_nsubjpass) pursued_8\VBN\2367363|that|wr242511|should|not|be|pretreatment|dissociated (l_advcl) dissociated_25\VBN\2431320|unless|characteristics|can|be|successfully|toxicity (l_nmod) toxicity_30\NN\13576101|from|those|producing|undesirable
C068820_D008708 NONE wr242511_6\NN\1740|of (r_nmod) doses_4\NNS\3740161|the|selected|wr242511|,|produced|, (l_acl:relcl) produced_9\VBD\1617192|which|methemoglobinemia|studies (l_dobj) methemoglobinemia_11\NN\1740|significant|dogs
C068820_D006456 CID wr242511_11\NN\1740|of (r_nmod) postinjection_9\NN\1740|minutes|wr242511|mg/kg (r_dobj) noted_5\VBN\1009240|furthermore|,|hemoglobinuria|was|postinjection|,|and|occurred (l_nsubjpass) hemoglobinuria_3\NN\14299637|transient
C068820_D011041 NONE wr242511_4\NN\1740| (r_nsubjpass) pursued_8\VBN\2367363|that|wr242511|should|not|be|pretreatment|dissociated (l_nmod) pretreatment_11\NN\1740|as|a|poisoning (l_nmod) poisoning_14\NN\14034177|for|cn
3782049
D008972_D012206 CID molindone_6\NN\3713736| (r_compound) administration_7\NN\1133281|following|molindone (r_nmod) rhabdomyolysis_4\NN\1740|of|massive|administration
D008972_D012206 CID molindone_18\NN\3713736| (r_compound) administration_19\NN\1133281|following|molindone (r_nmod) rhabdomyolysis_11\NN\1740|massive|and|failure|administration
D008972_D012559 NONE molindone_18\NN\3713736| (r_compound) administration_19\NN\1133281|following|molindone (r_nmod) rhabdomyolysis_11\NN\1740|massive|and|failure|administration (r_dobj) illustrate_9\VB\955601|to|rhabdomyolysis (r_xcomp) reported_7\VBN\831651|case|is|illustrate|. (l_nsubjpass) case_1\NN\7283608|the|patient (l_nmod) patient_5\NN\9898892|of|a|schizophrenic (l_amod) schizophrenic_4\JJ\1740|
D008972_D058186 CID molindone_18\NN\3713736| (r_compound) administration_19\NN\1133281|following|molindone (r_nmod) rhabdomyolysis_11\NN\1740|massive|and|failure|administration (l_conj) failure_16\NN\66216|subsequent|acute|renal
8690168
D006497_D003928 NONE sulphate-associated_3\JJ\1740| (r_amod) sites_5\NNS\8673395|of|heparan|sulphate-associated|anionic|membrane (l_nmod) membrane_10\NN\4188643|in|the|glomerular|basement|rats (l_nmod) rats_12\NNS\2329401|of|nephropathy (l_nmod) nephropathy_16\NN\14573196|with|streptozotocin-induced
D013311_D003928 CID streptozotocin-induced_14\JJ\1740|diabetic (r_amod) nephropathy_16\NN\14573196|with|streptozotocin-induced
D006497_D003920 NONE sulphate-associated_1\JJ\1740| (r_amod) sites_3\NNS\8673395|heparan|sulphate-associated|anionic|membrane (r_nsubjpass) studied_10\VBN\630380|sites|were|rats|months|induction|,|employing|. (l_nmod) induction_16\NN\7450842|after|diabetes|streptozotocin (l_nmod) diabetes_18\NNS\14075199|of
D006497_D003920 NONE sulphate_16\NN\15010703|heparan (r_compound) charge_17\NN\972621|sulphate (r_compound) barrier/density_18\NN\1740|a|reduced|charge (r_nsubjpass) found_20\VBN\2426171|that|rats|,|barrier/density|is|rara|externa (l_nmod) rats_5\NNS\2329401|in|streptozotocin-diabetic|excretion (l_amod) streptozotocin-diabetic_4\JJ\1740|
D013311_D003920 NONE streptozotocin_20\NN\1740|by|and|rats (r_nmod) induction_16\NN\7450842|after|diabetes|streptozotocin (l_nmod) diabetes_18\NNS\14075199|of
D013311_D003920 NONE streptozotocin-diabetic_4\JJ\1740|
C015445_D003920 NONE blue_34\JJ\1740|dye|cuprolinic (r_dobj) employing_29\VBG\1740|blue (r_advcl) studied_10\VBN\630380|sites|were|rats|months|induction|,|employing|. (l_nmod) induction_16\NN\7450842|after|diabetes|streptozotocin (l_nmod) diabetes_18\NNS\14075199|of
1468485
D010100_D006470 NONE oxygen_1\NN\14622893| (r_compound) therapy_2\NN\657604|hyperbaric|oxygen|control|. (l_nmod) control_4\NN\5190804|for|cystitis (l_nmod) cystitis_9\NN\14566129|of|intractable|cyclophosphamide-induced|hemorrhagic
D010100_D003556 NONE oxygen_1\NN\14622893| (r_compound) therapy_2\NN\657604|hyperbaric|oxygen|control|. (l_nmod) control_4\NN\5190804|for|cystitis (l_nmod) cystitis_9\NN\14566129|of|intractable|cyclophosphamide-induced|hemorrhagic
D003520_D006470 CID cyclophosphamide-induced_7\JJ\1740| (r_amod) cystitis_9\NN\14566129|of|intractable|cyclophosphamide-induced|hemorrhagic
D003520_D006470 CID cyclophosphamide_10\NN\1740| (r_compound) therapy_11\NN\657604|due|to|cyclophosphamide|granulomatosis (r_nmod) case_3\NN\7283608|a|cystitis|therapy (l_nmod) cystitis_7\NN\14566129|of|intractable|hemorrhagic
D003520_D006470 CID cyclophosphamide-induced_16\JJ\1740| (r_amod) cystitis_18\NN\14566129|of|cyclophosphamide-induced|hemorrhagic
D003520_D003556 CID cyclophosphamide-induced_7\JJ\1740| (r_amod) cystitis_9\NN\14566129|of|intractable|cyclophosphamide-induced|hemorrhagic
D003520_D003556 CID cyclophosphamide_10\NN\1740| (r_compound) therapy_11\NN\657604|due|to|cyclophosphamide|granulomatosis (r_nmod) case_3\NN\7283608|a|cystitis|therapy (l_nmod) cystitis_7\NN\14566129|of|intractable|hemorrhagic
D003520_D003556 CID cyclophosphamide-induced_16\JJ\1740| (r_amod) cystitis_18\NN\14566129|of|cyclophosphamide-induced|hemorrhagic
D003520_D014890 NONE cyclophosphamide_10\NN\1740| (r_compound) therapy_11\NN\657604|due|to|cyclophosphamide|granulomatosis (l_nmod) granulomatosis_15\NN\1740|for|wegener
D015237_D006470 NONE alpha_14\NN\6828818|of|prostaglandin|f2 (r_nmod) saline_8\NN\14849367|with|physiological|and|instillation|alpha (r_nmod) irrigation_5\NN\1057200|including|bladder|saline (r_nmod) treatment_1\NN\654885|conservative|,|irrigation|, (r_nsubj) failed_16\VBD\1798936|treatment|control|. (l_xcomp) control_19\VB\2422663|to|totally|hemorrhage (l_dobj) hemorrhage_20\NN\14285662|
88336
D002719_D013375 NONE chlormethiazole_6\NN\1740|of|symptoms (l_nmod) symptoms_10\NNS\5823932|for|withdrawal
D002719_D062787 NONE chlormethiazole_6\NN\1740|of|symptoms (r_nmod) doses_4\NNS\3740161|high|chlormethiazole (r_dobj) received_2\VBD\2210855|patients|doses|,|and|took (l_conj) took_14\VBD\2367363|one|overdose|. (l_dobj) overdose_17\NN\1740|a|suicidal|nitrazepam
D002719_D062787 NONE chlormethiazole_10\NN\1740| (r_compound) intoxication_11\NN\14034177|with|chlormethiazole|conformed (r_nmod) those_8\DT\1740|of|intoxication (r_nmod) two_6\CD\13741022|those (r_conj) overdose_4\NN\1740|patient|and|two|,|showing|.
D000431_D013375 NONE alcohol_8\NN\7881800| (r_compound) withdrawal_9\NN\7206096|alcohol (r_compound) symptoms_10\NNS\5823932|for|withdrawal
D000431_D062787 NONE alcohol_8\NN\7881800| (r_compound) withdrawal_9\NN\7206096|alcohol (r_compound) symptoms_10\NNS\5823932|for|withdrawal (r_nmod) chlormethiazole_6\NN\1740|of|symptoms (r_nmod) doses_4\NNS\3740161|high|chlormethiazole (r_dobj) received_2\VBD\2210855|patients|doses|,|and|took (l_conj) took_14\VBD\2367363|one|overdose|. (l_dobj) overdose_17\NN\1740|a|suicidal|nitrazepam
D009567_D013375 NONE nitrazepam_19\NN\2830852|of (r_nmod) overdose_17\NN\1740|a|suicidal|nitrazepam (r_dobj) took_14\VBD\2367363|one|overdose|. (r_conj) received_2\VBD\2210855|patients|doses|,|and|took (l_dobj) doses_4\NNS\3740161|high|chlormethiazole (l_nmod) chlormethiazole_6\NN\1740|of|symptoms (l_nmod) symptoms_10\NNS\5823932|for|withdrawal
D009567_D062787 CID nitrazepam_19\NN\2830852|of (r_nmod) overdose_17\NN\1740|a|suicidal|nitrazepam
D009567_D062787 CID nitrazepam_3\NN\2830852|with (r_nmod) patient_1\NN\9898892|the|nitrazepam (r_nsubj) overdose_4\NN\1740|patient|and|two|,|showing|.
D009567_D003128 CID nitrazepam_3\NN\2830852|with (r_nmod) patient_1\NN\9898892|the|nitrazepam (r_nsubj) overdose_4\NN\1740|patient|and|two|,|showing|. (l_conj) two_6\CD\13741022|those (l_nmod) those_8\DT\1740|of|intoxication (l_nmod) intoxication_11\NN\14034177|with|chlormethiazole|conformed (l_acl) conformed_12\VBN\109660|criteria (l_nmod) criteria_15\NNS\13577171|to|the|coma|' (l_nmod) coma_19\NN\5678932|of|'|alpha
D002719_D003128 CID chlormethiazole_10\NN\1740| (r_compound) intoxication_11\NN\14034177|with|chlormethiazole|conformed (l_acl) conformed_12\VBN\109660|criteria (l_nmod) criteria_15\NNS\13577171|to|the|coma|' (l_nmod) coma_19\NN\5678932|of|'|alpha
9334596
D013739_D007172 NONE testosterone_8\NN\14747587|of|serum|and|determination|patients (l_nmod) patients_14\NNS\9898892|in|1,022|referred (l_acl) referred_15\VBN\730052|dysfunction (l_nmod) dysfunction_19\NN\14204950|because|erectile
D013739_D007172 NONE testosterone_5\NN\14747587| (r_compound) levels_6\NNS\4916342|of|the|other|low|testosterone (r_nmod) most_0\JJS\1740|levels (r_nsubj) seemed_7\VBD\2604760|most|result|hormone|and|have|. (l_conj) have_24\VB\2108377|to|role|%|therapy|%|) (l_dobj) role_28\NN\719494|only|a|small|dysfunction (l_nmod) dysfunction_31\NN\14204950|in|erectile
D013739_D007172 NONE testosterone_8\NN\14747587|of|low|and|prolactin (r_nmod) prevalences_3\NNS\4764412|low|and|effects|testosterone|dysfunction (l_nmod) dysfunction_14\NN\14204950|in|erectile
D013739_D020018 CID testosterone_5\NN\14747587|for|and|451 (r_nmod) screened_3\VBN\2533282|patient|was|testosterone|screened|. (l_conj) screened_9\VBN\2533282|were|prolactin|basis|ng./ml (l_nmod) basis_14\NN\13790712|on|the|desire (l_nmod) desire_18\NN\26192|of|low|sexual|,|gynecomastia
D013739_D020018 CID testosterone_22\NN\14747587| (r_conj) gynecomastia_20\NN\14501726|or|testosterone (r_conj) desire_18\NN\26192|of|low|sexual|,|gynecomastia
D013739_D020018 CID testosterone_1\NN\14747587| (r_dobj) determining_0\VBG\1645601|testosterone|cases (l_nmod) cases_4\NNS\7283608|only|in|desire (l_nmod) desire_8\NN\26192|of|low|sexual|or|examination
D013739_D020018 CID testosterone_23\NN\14747587|with|low (r_nmod) cases_20\NNS\7283608|of|the|testosterone (r_nmod) %_17\NN\1740|40|cases (r_dobj) missed_15\VBN\1825237|determining|would|have|%|,|%|. (l_csubj) determining_0\VBG\1645601|testosterone|cases (l_nmod) cases_4\NNS\7283608|only|in|desire (l_nmod) desire_8\NN\26192|of|low|sexual|or|examination
D013739_D020018 CID testosterone_8\NN\14747587|years (r_nsubjpass) determined_10\VBN\1645601|that|age|testosterone|be|only|cases|but|measured (l_nmod) cases_13\NNS\7283608|in|desire|and|examination (l_nmod) desire_17\NN\26192|of|low|sexual
D013739_D020018 CID testosterone_14\NN\14747587| (r_conj) gynecomastia_12\NN\14501726|and/or|testosterone (r_conj) desire_10\NN\26192|of|low|sexual|,|gynecomastia|ng./ml
D013739_D006177 NONE testosterone_5\NN\14747587|for|and|451 (r_nmod) screened_3\VBN\2533282|patient|was|testosterone|screened|. (l_conj) screened_9\VBN\2533282|were|prolactin|basis|ng./ml (l_nmod) basis_14\NN\13790712|on|the|desire (l_nmod) desire_18\NN\26192|of|low|sexual|,|gynecomastia (l_conj) gynecomastia_20\NN\14501726|or|testosterone
D013739_D006177 NONE testosterone_22\NN\14747587| (r_conj) gynecomastia_20\NN\14501726|or|testosterone
D013739_D006177 NONE testosterone_14\NN\14747587| (r_conj) gynecomastia_12\NN\14501726|and/or|testosterone
C004648_D007006 NONE heptylate_5\NN\1740|of|testosterone|or|gonadotropin (r_nmod) consisted_2\VBD\2603699|heptylate|hypogonadism (l_nmod) hypogonadism_11\NN\14076126|for|and|bromocriptine
C004648_D006966 NONE heptylate_5\NN\1740|of|testosterone|or|gonadotropin (r_nmod) consisted_2\VBD\2603699|heptylate|hypogonadism (l_nmod) hypogonadism_11\NN\14076126|for|and|bromocriptine (l_conj) bromocriptine_13\NN\1740|hyperprolactinemia (l_nmod) hyperprolactinemia_15\NN\1740|for
D001971_D007006 NONE bromocriptine_13\NN\1740|hyperprolactinemia (r_conj) hypogonadism_11\NN\14076126|for|and|bromocriptine
D001971_D006966 NONE bromocriptine_13\NN\1740|hyperprolactinemia (l_nmod) hyperprolactinemia_15\NN\1740|for
D013739_D010911 NONE testosterone_6\NN\14747587| (r_compound) determination_7\NN\43195|after|testosterone (r_nmod) discovered_4\VBN\2163746|tumors|were|determination|. (l_nsubjpass) tumors_2\NNS\14234074|two|pituitary
D013739_D007027 NONE testosterone_5\NN\14747587| (r_compound) levels_6\NNS\4916342|of|the|other|low|testosterone (r_nmod) most_0\JJS\1740|levels (r_nsubj) seemed_7\VBD\2604760|most|result|hormone|and|have|. (l_xcomp) result_9\VB\2633881|to|dysfunction (l_nmod) dysfunction_13\NN\14204950|from|nonorganic|hypothalamic
1919871
D001241_D007681 CID aspirin_18\NN\2707683|with (r_nmod) treatment_16\NN\654885|during|continuous|long-term|aspirin|and|paracetamol (r_nmod) developed_12\VBN\1753788|necrosis|treatment|. (l_nsubj) necrosis_2\NN\11444117|renal|papillary|rpn|and|ability
D001241_D007681 CID aspirin_18\NN\2707683|with (r_nmod) treatment_16\NN\654885|during|continuous|long-term|aspirin|and|paracetamol (r_nmod) developed_12\VBN\1753788|necrosis|treatment|. (l_nsubj) necrosis_2\NN\11444117|renal|papillary|rpn|and|ability (l_appos) rpn_4\NN\1740|(|)
D000082_D007681 CID paracetamol_20\NN\1740|rats (r_conj) treatment_16\NN\654885|during|continuous|long-term|aspirin|and|paracetamol (r_nmod) developed_12\VBN\1753788|necrosis|treatment|. (l_nsubj) necrosis_2\NN\11444117|renal|papillary|rpn|and|ability
D000082_D007681 CID paracetamol_20\NN\1740|rats (r_conj) treatment_16\NN\654885|during|continuous|long-term|aspirin|and|paracetamol (r_nmod) developed_12\VBN\1753788|necrosis|treatment|. (l_nsubj) necrosis_2\NN\11444117|renal|papillary|rpn|and|ability (l_appos) rpn_4\NN\1740|(|)
8955532
D001920_D006973 NONE bradykinin_4\NN\1740| (r_compound) receptors_6\NNS\5225602|of|bradykinin|b2 (r_nmod) activation_2\NN\13561719|of|receptors (r_nmod) role_0\NN\719494|activation|disruption|hypertension|. (l_nmod) hypertension_15\NN\14057371|during|acute
D001920_D006973 NONE bradykinin_13\NN\1740|of (r_nmod) synthesis/release_11\NN\1740|of|bradykinin (r_nmod) role_9\NN\719494|the|synthesis/release|activate (l_acl) activate_15\VB\1641914|to|receptors|disruption (l_nmod) disruption_19\NN\1066163|in|barrier|hypertension (l_nmod) hypertension_26\NN\14057371|during|acute
D001920_D006973 NONE bradykinin_19\NN\1740|of (r_nmod) synthesis/release_17\NN\1740|to|the|bradykinin|activate (r_nmod) related_14\JJ\1740|that|disruption|is|not|synthesis/release (l_nsubj) disruption_4\NN\1066163|barrier|hypertension (l_nmod) hypertension_11\NN\14057371|during|acute
D003911_D006973 NONE dextran_11\NN\1740|of|fluorescent-labeled (r_nmod) clearance_8\NN\5089947|by|dextran (r_nmod) quantitated_6\VBN\1740|permeability|was|clearance|hypertension|. (l_nmod) hypertension_17\NN\14057371|before|during|phenylephrine-induced|acute|rats
D010656_D006973 CID phenylephrine-induced_15\JJ\1740| (r_amod) hypertension_17\NN\14057371|before|during|phenylephrine-induced|acute|rats
C065679_D006973 NONE hoe-140_24\NN\1740|microm (r_conj) vehicle_22\NN\3100490|with|and|hoe-140 (r_nmod) treated_20\VBN\2376958|vehicle (r_acl) rats_19\NNS\2329401|in|treated (r_nmod) hypertension_17\NN\14057371|before|during|phenylephrine-induced|acute|rats
19037603
D019259_D012216 NONE lamivudine_3\NN\3834836|of|therapy (l_nmod) therapy_7\NN\657604|with|chronic|immunosuppressive|disorders (l_nmod) disorders_10\NNS\14034177|for|rheumatologic
D019259_D012216 NONE lamivudine_18\NN\3834836|of (r_nmod) administration_16\NN\1133281|of|the|prophylactic|lamivudine|antigen|patients (l_nmod) patients_30\NNS\9898892|positive|disease (l_nmod) disease_33\NN\14061805|with|rheumatologic
D019259_D012216 NONE lamivudine_23\NN\3834836| (r_compound) therapies_24\NNS\657604|lamivudine (r_dep) immunosuppressive_20\JJ\1740|who|were|on|both|and|prophylactic|therapies (r_acl:relcl) diseases_14\NNS\14061805|with|rheumatologic|,|immunosuppressive
D006514_D012216 NONE antigen_24\NN\20090|in|hepatitis|b|virus|surface|ag (r_nmod) administration_16\NN\1133281|of|the|prophylactic|lamivudine|antigen|patients (l_nmod) patients_30\NNS\9898892|positive|disease (l_nmod) disease_33\NN\14061805|with|rheumatologic
D006514_D012216 NONE ag_27\NN\14821043|(|hbs|) (r_appos) antigen_24\NN\20090|in|hepatitis|b|virus|surface|ag (r_nmod) administration_16\NN\1133281|of|the|prophylactic|lamivudine|antigen|patients (l_nmod) patients_30\NNS\9898892|positive|disease (l_nmod) disease_33\NN\14061805|with|rheumatologic
D006514_D012216 NONE ag_9\NN\14821043| (r_compound) patients_11\NNS\9898892|11|hbs|ag|positive|diseases|, (l_nmod) diseases_14\NNS\14061805|with|rheumatologic|,|immunosuppressive
809711
D010656_D009203 NONE phenylephrine_2\NN\2682038|by|effects (l_nmod) effects_6\NNS\13245626|of|the|beneficial|nitroglycerin|patients (l_nmod) patients_11\NNS\9898892|in|infarction (l_nmod) infarction_15\NN\14204950|with|acute|myocardial
D010656_D009203 NONE phenylephrine_6\NN\2682038|of (r_nmod) addition_4\NN\3081021|phenylephrine|nitroglycerin (r_nsubj) beneficial_11\JJ\1740|that|addition|is|not|treatment (l_nmod) treatment_14\NN\654885|in|the|patients (l_nmod) patients_16\NNS\9898892|of|infarction (l_nmod) infarction_20\NN\14204950|with|acute|myocardial
D005996_D009203 NONE nitroglycerin_9\NN\15015501|of|intravenous (r_nmod) effects_6\NNS\13245626|of|the|beneficial|nitroglycerin|patients (l_nmod) patients_11\NNS\9898892|in|infarction (l_nmod) infarction_15\NN\14204950|with|acute|myocardial
D005996_D009203 NONE nitroglycerin_0\NNP\15015501| (r_nsubjpass) shown_3\VBN\2137132|nitroglycerin|has|been|reduce|potentiated (l_xcomp) reduce_5\VB\441445|to|elevation|infarction (l_nmod) infarction_11\NN\14204950|during|acute|myocardial
D005996_D009203 NONE nitroglycerin-induced_23\JJ\1740| (r_amod) hypotension_24\NN\14057371|nitroglycerin-induced (r_dobj) reverse_22\VBP\109660|that|hypotension (r_acl:relcl) agents_20\NNS\7347|by|reverse (r_nmod) dog_18\NN\2083346|in|the|agents (r_nmod) potentiated_15\VBD\229605|,|effect|dog|. (r_conj) shown_3\VBN\2137132|nitroglycerin|has|been|reduce|potentiated (l_xcomp) reduce_5\VB\441445|to|elevation|infarction (l_nmod) infarction_11\NN\14204950|during|acute|myocardial
D005996_D009203 NONE nitroglycerin_9\NN\15015501|intravenous (r_dobj) received_7\VBD\2210855|patients|nitroglycerin|,|sufficient|,|minutes|. (l_nsubj) patients_1\NNS\9898892|ten|infarctions (l_nmod) infarctions_6\NNS\14204950|with|acute|transmural|myocardial
D005996_D009203 NONE nitroglycerin_8\NN\15015501|to (r_nmod) addition_4\NN\3081021|phenylephrine|nitroglycerin (r_nsubj) beneficial_11\JJ\1740|that|addition|is|not|treatment (l_nmod) treatment_14\NN\654885|in|the|patients (l_nmod) patients_16\NNS\9898892|of|infarction (l_nmod) infarction_20\NN\14204950|with|acute|myocardial
D005996_D007022 CID nitroglycerin_0\NNP\15015501| (r_nsubjpass) shown_3\VBN\2137132|nitroglycerin|has|been|reduce|potentiated (l_conj) potentiated_15\VBD\229605|,|effect|dog|. (l_nmod) dog_18\NN\2083346|in|the|agents (l_nmod) agents_20\NNS\7347|by|reverse (l_acl:relcl) reverse_22\VBP\109660|that|hypotension (l_dobj) hypotension_24\NN\14057371|nitroglycerin-induced
D005996_D007022 CID nitroglycerin-induced_23\JJ\1740| (r_amod) hypotension_24\NN\14057371|nitroglycerin-induced
17600377
C524754_D003072 NONE p-coumarate_5\NN\1740|maltolyl (r_appos) compound_2\NN\5869584|a|novel|,|p-coumarate|, (r_nsubj) attenuates_7\VBZ\224901|compound|deficits|and|shows|. (l_dobj) deficits_9\NNS\5113133|cognitive
C524754_D003072 NONE p-coumarate_9\NN\1740|maltolyl (r_nsubj) improve_11\VB\126264|whether|p-coumarate|could|decline|and|rats (l_dobj) decline_13\NN\13458571|cognitive|rats
C524754_D003072 NONE p-coumarate_1\NN\1740|maltolyl (r_nsubjpass) found_3\VBN\2426171|p-coumarate|was|attenuate|using|. (l_xcomp) attenuate_5\VB\224901|to|deficits|models (l_dobj) deficits_7\NNS\5113133|cognitive
C524754_D003072 NONE p-coumarate_15\NN\1740|maltolyl (r_nsubj) candidate_20\NN\10450303|that|p-coumarate|is|a|effective|disease|characterized (l_acl:relcl) characterized_27\VBN\609683|that|is|death (l_nmod) death_32\NN\7296428|by|wide|neuronal|and|decline (l_conj) decline_35\NN\13458571|progressive|function (l_nmod) function_38\NN\13783581|of|cognitive
C524754_D003704 NONE p-coumarate_5\NN\1740|maltolyl (r_appos) compound_2\NN\5869584|a|novel|,|p-coumarate|, (r_nsubj) attenuates_7\VBZ\224901|compound|deficits|and|shows|. (l_conj) shows_11\VBZ\2137132|effects|and|models (l_dobj) models_20\NNS\5888929|in|dementia (l_compound) dementia_19\NN\14395018|
D012601_D003072 CID scopolamine-injected_15\JJ\1740| (r_amod) rats_16\NNS\2329401|in|scopolamine-injected (r_nmod) decline_13\NN\13458571|cognitive|rats
C544092_D003072 NONE 42)-infused_23\JJ\1740|peptide(1|- (r_amod) rats_24\NNS\2329401|in|beta|42)-infused (r_nmod) improve_11\VB\126264|whether|p-coumarate|could|decline|and|rats (l_dobj) decline_13\NN\13458571|cognitive|rats
C544092_D003072 NONE 42)-infused_32\JJ\1740|peptide(1|- (r_amod) rats_33\NNS\2329401|of|the|beta|42)-infused (r_nmod) hippocampus_25\NN\5462674|in|the|rats (r_nmod) observed_22\VBN\2163746|hippocampus (r_acl) death_21\NN\7296428|apoptotic|cell|observed (r_dobj) reduce_18\VB\441445|to|death (r_conj) using_12\VBG\1156834|test|and|reduce (r_xcomp) found_3\VBN\2426171|p-coumarate|was|attenuate|using|. (l_xcomp) attenuate_5\VB\224901|to|deficits|models (l_dobj) deficits_7\NNS\5113133|cognitive
C524754_D000544 NONE p-coumarate_15\NN\1740|maltolyl (r_nsubj) candidate_20\NN\10450303|that|p-coumarate|is|a|effective|disease|characterized (l_nmod) disease_24\NN\14061805|against|alzheimer|'s
C524754_D009410 NONE p-coumarate_15\NN\1740|maltolyl (r_nsubj) candidate_20\NN\10450303|that|p-coumarate|is|a|effective|disease|characterized (l_acl:relcl) characterized_27\VBN\609683|that|is|death (l_nmod) death_32\NN\7296428|by|wide|neuronal|and|decline
10526274
C056507_D002289 NONE gemcitabine_0\NN\1740|plus|vinorelbine|patients|age|years|older|patients|receive|. (l_nmod) patients_8\NNS\9898892|in|nonsmall|cell|lung|carcinoma (l_compound) carcinoma_7\NN\14239918|
C056507_D002289 NONE gem_12\NN\2743547|of|and|vnb (r_nmod) combination_10\NN\7951464|of|the|gem|patients (l_nmod) patients_17\NNS\9898892|in|elderly|nsclc (l_nmod) nsclc_20\NN\1740|with|advanced|or|those
C030852_D002289 NONE vinorelbine_2\NN\1740| (r_conj) gemcitabine_0\NN\1740|plus|vinorelbine|patients|age|years|older|patients|receive|. (l_nmod) patients_8\NNS\9898892|in|nonsmall|cell|lung|carcinoma (l_compound) carcinoma_7\NN\14239918|
C030852_D002289 NONE vnb_14\NN\1740| (r_conj) gem_12\NN\2743547|of|and|vnb (r_nmod) combination_10\NN\7951464|of|the|gem|patients (l_nmod) patients_17\NNS\9898892|in|elderly|nsclc (l_nmod) nsclc_20\NN\1740|with|advanced|or|those
D002945_D002289 NONE cisplatin_20\NN\1740| (r_dobj) receive_19\VB\2210855|who|can|not|cisplatin (r_acl:relcl) gemcitabine_0\NN\1740|plus|vinorelbine|patients|age|years|older|patients|receive|. (l_nmod) patients_8\NNS\9898892|in|nonsmall|cell|lung|carcinoma (l_compound) carcinoma_7\NN\14239918|
D002945_D002289 NONE cisplatin_28\NN\1740| (r_dobj) receiving_27\VBG\2210855|to|cisplatin (r_advcl) contraindication_25\NN\5819149|with|some|receiving (r_nmod) those_22\DT\1740|contraindication (r_conj) nsclc_20\NN\1740|with|advanced|or|those
D002945_D002289 NONE cisplatin_33\NN\1740| (r_dobj) receiving_32\VBG\2210855|to|cisplatin (r_advcl) had_28\VBD\2108377|who|contraindication|receiving (r_conj) age_22\NN\4916342|age|were|years|but|had (r_conj) included_8\VBN\690614|methods|patients|were|,|age|. (l_nsubjpass) patients_3\NNS\9898892|forty-nine|nsclc (l_nmod) nsclc_6\NN\1740|with|advanced
C030852_D064420 NONE vinorelbine_8\NN\1740|with|vnb|or|gemcitabine (r_nmod) therapy_6\NN\657604|single|agent|vinorelbine (r_nsubj) obtain_18\VB\2210855|that|therapy|may|rate|,|toxicity (l_nmod) toxicity_33\NN\13576101|with|acceptable|and|improvement|symptoms
C030852_D064420 NONE vnb_10\NN\1740|(|) (r_appos) vinorelbine_8\NN\1740|with|vnb|or|gemcitabine (r_nmod) therapy_6\NN\657604|single|agent|vinorelbine (r_nsubj) obtain_18\VB\2210855|that|therapy|may|rate|,|toxicity (l_nmod) toxicity_33\NN\13576101|with|acceptable|and|improvement|symptoms
C030852_D064420 NONE vnb_14\NN\1740| (r_conj) gem_12\NN\2743547|of|and|vnb (r_nmod) combination_10\NN\7951464|of|the|gem|patients (r_nmod) efficacy_5\NN\5199286|the|and|toxicity|combination (l_conj) toxicity_7\NN\13576101|
C056507_D064420 NONE gemcitabine_13\NN\1740|gem (r_conj) vinorelbine_8\NN\1740|with|vnb|or|gemcitabine (r_nmod) therapy_6\NN\657604|single|agent|vinorelbine (r_nsubj) obtain_18\VB\2210855|that|therapy|may|rate|,|toxicity (l_nmod) toxicity_33\NN\13576101|with|acceptable|and|improvement|symptoms
C056507_D064420 NONE gem_15\NN\2743547|(|) (r_appos) gemcitabine_13\NN\1740|gem (r_conj) vinorelbine_8\NN\1740|with|vnb|or|gemcitabine (r_nmod) therapy_6\NN\657604|single|agent|vinorelbine (r_nsubj) obtain_18\VB\2210855|that|therapy|may|rate|,|toxicity (l_nmod) toxicity_33\NN\13576101|with|acceptable|and|improvement|symptoms
C056507_D064420 NONE gem_12\NN\2743547|of|and|vnb (r_nmod) combination_10\NN\7951464|of|the|gem|patients (r_nmod) efficacy_5\NN\5199286|the|and|toxicity|combination (l_conj) toxicity_7\NN\13576101|
D002945_D064420 NONE cisplatin_28\NN\1740| (r_dobj) receiving_27\VBG\2210855|to|cisplatin (r_advcl) contraindication_25\NN\5819149|with|some|receiving (r_nmod) those_22\DT\1740|contraindication (r_conj) nsclc_20\NN\1740|with|advanced|or|those (r_nmod) patients_17\NNS\9898892|in|elderly|nsclc (r_nmod) combination_10\NN\7951464|of|the|gem|patients (r_nmod) efficacy_5\NN\5199286|the|and|toxicity|combination (l_conj) toxicity_7\NN\13576101|
6692345
D001241_D001749 NONE aspirin_3\NN\2707683|of (r_nmod) co-administration_1\NN\1740|the|aspirin|n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide|rats (r_nsubj) resulted_11\VBD\2633881|co-administration|incidence|. (l_nmod) incidence_15\NN\13821570|in|a|reduced|carcinomas|but|induction (l_nmod) carcinomas_19\NNS\14239918|of|fanft-induced|bladder
D001241_D013274 NONE aspirin_3\NN\2707683|of (r_nmod) co-administration_1\NN\1740|the|aspirin|n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide|rats (r_nsubj) resulted_11\VBD\2633881|co-administration|incidence|. (l_nmod) incidence_15\NN\13821570|in|a|reduced|carcinomas|but|induction (l_conj) induction_23\NN\7450842|a|concomitant|tumors (l_nmod) tumors_26\NNS\14234074|of|forestomach
D005200_D001749 CID n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_5\NN\1740|with|fanft (r_nmod) co-administration_1\NN\1740|the|aspirin|n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide|rats (r_nsubj) resulted_11\VBD\2633881|co-administration|incidence|. (l_nmod) incidence_15\NN\13821570|in|a|reduced|carcinomas|but|induction (l_nmod) carcinomas_19\NNS\14239918|of|fanft-induced|bladder
D005200_D001749 CID fanft_7\NN\1740|(|) (r_appos) n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_5\NN\1740|with|fanft (r_nmod) co-administration_1\NN\1740|the|aspirin|n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide|rats (r_nsubj) resulted_11\VBD\2633881|co-administration|incidence|. (l_nmod) incidence_15\NN\13821570|in|a|reduced|carcinomas|but|induction (l_nmod) carcinomas_19\NNS\14239918|of|fanft-induced|bladder
D005200_D001749 CID fanft-induced_17\JJ\1740| (r_amod) carcinomas_19\NNS\14239918|of|fanft-induced|bladder
D005200_D013274 CID n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_5\NN\1740|with|fanft (r_nmod) co-administration_1\NN\1740|the|aspirin|n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide|rats (r_nsubj) resulted_11\VBD\2633881|co-administration|incidence|. (l_nmod) incidence_15\NN\13821570|in|a|reduced|carcinomas|but|induction (l_conj) induction_23\NN\7450842|a|concomitant|tumors (l_nmod) tumors_26\NNS\14234074|of|forestomach
D005200_D013274 CID fanft_7\NN\1740|(|) (r_appos) n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_5\NN\1740|with|fanft (r_nmod) co-administration_1\NN\1740|the|aspirin|n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide|rats (r_nsubj) resulted_11\VBD\2633881|co-administration|incidence|. (l_nmod) incidence_15\NN\13821570|in|a|reduced|carcinomas|but|induction (l_conj) induction_23\NN\7450842|a|concomitant|tumors (l_nmod) tumors_26\NNS\14234074|of|forestomach
D005200_D013274 CID fanft-induced_17\JJ\1740| (r_amod) carcinomas_19\NNS\14239918|of|fanft-induced|bladder (r_nmod) incidence_15\NN\13821570|in|a|reduced|carcinomas|but|induction (l_conj) induction_23\NN\7450842|a|concomitant|tumors (l_nmod) tumors_26\NNS\14234074|of|forestomach
D005200_D063646 NONE fanft_16\NN\1740| (r_compound) carcinogenesis_17\NN\1740|in|fanft|bladder
D005200_D063646 NONE fanft_30\NN\1740|on (r_nmod) effect_28\NN\34213|that|aspirin|fanft|forestomach|effect (r_conj) involved_14\VBN\2676054|that|mechanisms|are|carcinogenesis|,|and|effect (l_nmod) carcinogenesis_17\NN\1740|in|fanft|bladder
D001241_D063646 NONE aspirin_26\NN\2707683|'s (r_nmod:poss) effect_28\NN\34213|that|aspirin|fanft|forestomach|effect (r_conj) involved_14\VBN\2676054|that|mechanisms|are|carcinogenesis|,|and|effect (l_nmod) carcinogenesis_17\NN\1740|in|fanft|bladder
2950248
D004176_D017202 NONE dipyridamole-induced_0\JJ\1740| (r_amod) ischemia_2\NN\14195315|dipyridamole-induced|myocardial|.
D004176_D017202 NONE dipyridamole_16\NN\1740| (r_compound) therapy_17\NN\657604|of|preoperative|dipyridamole (r_nmod) effect_13\NN\34213|as|a|side|therapy (r_nmod) reported_9\VBN\831651|knowledge|,|this|has|not|previously|been|effect|,|demonstrated|. (l_advcl) demonstrated_25\VBN\2137132|although|ischemia|has|been|occur (l_nsubjpass) ischemia_22\NN\14195315|dipyridamole-induced|myocardial
D004176_D017202 NONE dipyridamole-induced_20\JJ\1740| (r_amod) ischemia_22\NN\14195315|dipyridamole-induced|myocardial
D004176_D000787 CID dipyridamole_10\NN\1740|of|oral (r_nmod) administration_7\NN\1133281|after|dipyridamole|patients (r_nmod) occurred_5\VBD\2623529|changes|administration|. (l_nsubj) changes_4\NNS\7283608|angina|electrocardiographic (l_amod) angina_0\JJ\1740|and|ischemic
D004176_D003324 NONE dipyridamole_16\NN\1740| (r_compound) therapy_17\NN\657604|of|preoperative|dipyridamole (r_nmod) effect_13\NN\34213|as|a|side|therapy (r_nmod) reported_9\VBN\831651|knowledge|,|this|has|not|previously|been|effect|,|demonstrated|. (l_advcl) demonstrated_25\VBN\2137132|although|ischemia|has|been|occur (l_xcomp) occur_27\VB\2623529|to|animals|disease (l_nmod) disease_35\NN\14061805|with|coronary|artery
D004176_D003324 NONE dipyridamole-induced_20\JJ\1740| (r_amod) ischemia_22\NN\14195315|dipyridamole-induced|myocardial (r_nsubjpass) demonstrated_25\VBN\2137132|although|ischemia|has|been|occur (l_xcomp) occur_27\VB\2623529|to|animals|disease (l_nmod) disease_35\NN\14061805|with|coronary|artery
D004176_D007511 NONE dipyridamole-induced_23\JJ\1740| (r_amod) ischemia_24\NN\14195315|of|the|dipyridamole-induced|observed
18791946
D002939_D013921 CID ciprofloxacin_7\NN\2716866|with (r_nmod) associated_5\VBN\628491|ciprofloxacin (r_acl) thrombocytopenia_1\NN\14189204|severe|and|anaemia|associated|:|report|.
D002939_D013921 CID ciprofloxacin_5\NN\2716866| (r_nsubj) precipitate_7\VB\1642924|that|ciprofloxacin|may|thrombocytopenia|,|phases (l_dobj) thrombocytopenia_9\NN\14189204|life-threatening|and|anaemia
D002939_D000743 CID ciprofloxacin_7\NN\2716866|with (r_nmod) associated_5\VBN\628491|ciprofloxacin (r_acl) thrombocytopenia_1\NN\14189204|severe|and|anaemia|associated|:|report|. (l_conj) anaemia_4\NN\14299637|haemolytic
D002939_D000743 CID ciprofloxacin_5\NN\2716866| (r_nsubj) precipitate_7\VB\1642924|that|ciprofloxacin|may|thrombocytopenia|,|phases (l_dobj) thrombocytopenia_9\NN\14189204|life-threatening|and|anaemia (l_conj) anaemia_12\NN\14299637|haemolytic
D002939_D015746 CID ciprofloxacin_16\NN\2716866|of|oral (r_nmod) administration_13\NN\1133281|after|3-day|ciprofloxacin|suspect (r_nmod) reported_5\VBN\831651|pain|administration (l_nmod) pain_8\NN\14299637|with|abdominal|and|jaundice
D002939_D007565 CID ciprofloxacin_16\NN\2716866|of|oral (r_nmod) administration_13\NN\1133281|after|3-day|ciprofloxacin|suspect (r_nmod) reported_5\VBN\831651|pain|administration (l_nmod) pain_8\NN\14299637|with|abdominal|and|jaundice (l_conj) jaundice_10\NN\14299637|
D002939_D014552 NONE ciprofloxacin_16\NN\2716866|of|oral (r_nmod) administration_13\NN\1133281|after|3-day|ciprofloxacin|suspect (l_nmod) suspect_19\NN\7846|for|a|infection (l_nmod) infection_23\NN\14052046|of|tract
17344566
D019821_D003161 CID simvastatin-induced_0\JJ\1740| (r_amod) syndrome_4\NN\5870365|simvastatin-induced|bilateral|leg|compartment|and|myonecrosis|associated|.
D019821_D003161 CID simvastatin_7\NN\3676175| (r_conj) thyroxine_5\NN\5413241|and|simvastatin (r_dobj) taking_4\VBG\2367363|thyroxine (r_acl) male_3\JJ\1740|a|54-year-old|hypothyroid|taking (r_nsubj) presented_8\VBN\2137132|male|syndrome|. (l_nmod) syndrome_13\NN\5870365|with|bilateral|leg|compartment|and|myonecrosis
D019821_D009135 NONE simvastatin-induced_0\JJ\1740| (r_amod) syndrome_4\NN\5870365|simvastatin-induced|bilateral|leg|compartment|and|myonecrosis|associated|. (l_conj) myonecrosis_6\NN\11486708|
D019821_D009135 NONE simvastatin_7\NN\3676175| (r_conj) thyroxine_5\NN\5413241|and|simvastatin (r_dobj) taking_4\VBG\2367363|thyroxine (r_acl) male_3\JJ\1740|a|54-year-old|hypothyroid|taking (r_nsubj) presented_8\VBN\2137132|male|syndrome|. (l_nmod) syndrome_13\NN\5870365|with|bilateral|leg|compartment|and|myonecrosis (l_conj) myonecrosis_15\NN\11486708|
D019821_D007037 NONE simvastatin-induced_0\JJ\1740| (r_amod) syndrome_4\NN\5870365|simvastatin-induced|bilateral|leg|compartment|and|myonecrosis|associated|. (l_acl) associated_7\VBN\628491|hypothyroidism (l_nmod) hypothyroidism_9\NN\14059928|with
D019821_D007037 NONE simvastatin_7\NN\3676175| (r_conj) thyroxine_5\NN\5413241|and|simvastatin (r_dobj) taking_4\VBG\2367363|thyroxine (r_acl) male_3\JJ\1740|a|54-year-old|hypothyroid|taking (l_amod) hypothyroid_2\JJ\1740|
D013974_D007037 NONE thyroxine_5\NN\5413241|and|simvastatin (r_dobj) taking_4\VBG\2367363|thyroxine (r_acl) male_3\JJ\1740|a|54-year-old|hypothyroid|taking (l_amod) hypothyroid_2\JJ\1740|
D013974_D003161 NONE thyroxine_5\NN\5413241|and|simvastatin (r_dobj) taking_4\VBG\2367363|thyroxine (r_acl) male_3\JJ\1740|a|54-year-old|hypothyroid|taking (r_nsubj) presented_8\VBN\2137132|male|syndrome|. (l_nmod) syndrome_13\NN\5870365|with|bilateral|leg|compartment|and|myonecrosis
D013974_D009135 NONE thyroxine_5\NN\5413241|and|simvastatin (r_dobj) taking_4\VBG\2367363|thyroxine (r_acl) male_3\JJ\1740|a|54-year-old|hypothyroid|taking (r_nsubj) presented_8\VBN\2137132|male|syndrome|. (l_nmod) syndrome_13\NN\5870365|with|bilateral|leg|compartment|and|myonecrosis (l_conj) myonecrosis_15\NN\11486708|
